-DOCSTART- -X- -X- O

a NN O O
common NN O O
human NN O O
skin NN B-DiseaseClass B-MSH:D012878
tumour NN I-DiseaseClass I-MSH:D012878
is NN O O
caused NN O O
by NN O O
activating NN O O
mutations NN O O
in NN O O
beta-catenin NN O O
. NN O O

wnt NN O O
signalling NN O O
orchestrates NN O O
a NN O O
number NN O O
of NN O O
developmental NN O O
programs. NN O O
in NN O O
response NN O O
to NN O O
this NN O O
stimulus, NN O O
cytoplasmic NN O O
beta-catenin NN O O
(encoded NN O O
by NN O O
ctnnb NN O O
1) NN O O
is NN O O
stabilized, NN O O
enabling NN O O
downstream NN O O
transcriptional NN O O
activation NN O O
by NN O O
members NN O O
of NN O O
the NN O O
lef/tcf NN O O
family. NN O O
one NN O O
of NN O O
the NN O O
target NN O O
genes NN O O
for NN O O
beta-catenin/tcf NN O O
encodes NN O O
c-myc, NN O O
explaining NN O O
why NN O O
constitutive NN O O
activation NN O O
of NN O O
the NN O O
wnt NN O O
pathway NN O O
can NN O O
lead NN O O
to NN O O
cancer NN B-DiseaseClass B-MSH:D009369
, NN O O
particularly NN O O
in NN O O
the NN O O
colon. NN O O
most NN O O
colon NN B-DiseaseClass B-MSH:D003110
cancers NN I-DiseaseClass I-MSH:D003110
arise NN O O
from NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
( NN O O
APC NN B-SpecificDisease B-MSH:D011125
), NN O O
a NN O O
protein NN O O
required NN O O
for NN O O
ubiquitin-mediated NN O O
degradation NN O O
of NN O O
beta-catenin, NN O O
but NN O O
a NN O O
small NN O O
percentage NN O O
of NN O O
colon NN B-CompositeMention B-MSH:D003110
and NN I-CompositeMention I-MSH:D003110
some NN I-CompositeMention I-MSH:D003110
other NN I-CompositeMention I-MSH:D003110
cancers NN I-CompositeMention I-MSH:D003110
harbour NN O O
beta-catenin-stabilizing NN O O
mutations. NN O O
recently, NN O O
we NN O O
discovered NN O O
that NN O O
transgenic NN O O
mice NN O O
expressing NN O O
an NN O O
activated NN O O
beta-catenin NN O O
are NN O O
predisposed NN O O
to NN O O
developin NN O O
. NN O O

skin NN O O
tumours NN O O
resembling NN O O
pilomatricomas NN B-SpecificDisease B-MSH:D018296
. NN O O
given NN O O
that NN O O
the NN O O
skin NN O O
of NN O O
these NN O O
adult NN O O
mice NN O O
also NN O O
exhibits NN O O
signs NN O O
of NN O O
de NN O O
novo NN O O
hair-follicle NN O O
morphogenesis, NN O O
we NN O O
wondered NN O O
whether NN O O
human NN O O
pilomatricomas NN B-SpecificDisease B-MSH:D018296
might NN O O
originate NN O O
from NN O O
hair NN O O
matrix NN O O
cells NN O O
and NN O O
whether NN O O
they NN O O
might NN O O
possess NN O O
beta-catenin-stabilizing NN O O
mutations. NN O O
here, NN O O
we NN O O
explore NN O O
the NN O O
cell NN O O
origin NN O O
and NN O O
aetiology NN O O
of NN O O
this NN O O
common NN O O
human NN O O
skin NN B-DiseaseClass B-MSH:D012878
tumour NN I-DiseaseClass I-MSH:D012878
. NN O O
we NN O O
found NN O O
nuclear NN O O
lef-1 NN O O
in NN O O
the NN O O
dividing NN O O
tumour NN B-Modifier B-MSH:D009369
cells, NN O O
providing NN O O
biochemical NN O O
evidence NN O O
that NN O O
pilomatricomas NN B-SpecificDisease B-MSH:D018296
are NN O O
derived NN O O
from NN O O
hair NN O O
matrix NN O O
cells. NN O O
at NN O O
least NN O O
75% NN O O
of NN O O
these NN O O
tumours NN B-DiseaseClass B-MSH:D009369
possess NN O O
mutations NN O O
affecting NN O O
the NN O O
amino-terminal NN O O
segment, NN O O
normally NN O O
involved NN O O
in NN O O
phosphorylation-dependent, NN O O
ubiquitin-mediated NN O O
degradation NN O O
of NN O O
the NN O O
protein. NN O O
this NN O O
percentage NN O O
of NN O O
ctnnb NN O O
1 NN O O
mutations NN O O
is NN O O
greater NN O O
than NN O O
in NN O O
all NN O O
other NN O O
human NN O O
tumours NN B-DiseaseClass B-MSH:D009369
examined NN O O
thus NN O O
far, NN O O
and NN O O
directly NN O O
implicates NN O O
bet NN O O
. NN O O

-catenin/lef NN O O
misregulation NN O O
as NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
hair NN O O
matrix NN O O
cell NN O O
tumorigenesis NN O O
in NN O O
humans. NN O O
. NN O O

hfe NN O O
mutations NN O O
analysis NN O O
in NN O O
711 NN O O
hemochromatosis NN B-Modifier B-MSH:D016399
probands: NN O O
evidence NN O O
for NN O O
s NN O O
65 NN O O
c NN O O
implication NN O O
in NN O O
mild NN O O
form NN O O
of NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
. NN O O

hereditary NN O O
hemochromatosis NN O O
( NN O O
HH NN B-SpecificDisease B-MSH:D006432
) NN O O
is NN O O
a NN O O
common NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
genetic NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
of NN O O
iron NN O O
metabolism. NN O O
the NN O O
hfe NN O O
candidate NN O O
gene NN O O
encoding NN O O
an NN O O
hla NN O O
class NN O O
i-like NN O O
protein NN O O
involved NN O O
in NN O O
HH NN B-SpecificDisease B-MSH:D006432
was NN O O
identified NN O O
in NN O O
1996. NN O O
two NN O O
missense NN O O
mutations NN O O
have NN O O
been NN O O
described NN O O
c NN O O
282 NN O O
y, NN O O
accounting NN O O
for NN O O
80% NN O O
to NN O O
90% NN O O
of NN O O
HH NN B-Modifier B-MSH:D006432
chromosomes, NN O O
and NN O O
h NN O O
63 NN O O
d, NN O O
which NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
representing NN O O
40% NN O O
to NN O O
70% NN O O
of NN O O
non-c NN O O
282 NN O O
y NN O O
HH NN B-Modifier B-MSH:D006432
chromosomes. NN O O
we NN O O
report NN O O
here NN O O
on NN O O
the NN O O
analysis NN O O
of NN O O
c NN O O
282 NN O O
y, NN O O
h NN O O
63 NN O O
d, NN O O
and NN O O
the NN O O
193 NN O O
a-- NN O O
> NN O O
t NN O O
substitution NN O O
leading NN O O
to NN O O
the NN O O
s NN O O
65 NN O O
c NN O O
missense NN O O
substitution NN O O
in NN O O
a NN O O
large NN O O
series NN O O
of NN O O
probands NN O O
and NN O O
controls. NN O O
the NN O O
results NN O O
confirm NN O O
that NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
substitution NN O O
was NN O O
the NN O O
mai NN O O
. NN O O

mutation NN O O
involved NN O O
in NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
, NN O O
accounting NN O O
for NN O O
85% NN O O
of NN O O
carrier NN O O
chromosomes, NN O O
whereas NN O O
the NN O O
h NN O O
63 NN O O
d NN O O
substitution NN O O
represented NN O O
39% NN O O
of NN O O
the NN O O
HH NN B-Modifier B-MSH:D006432
chromosomes NN O O
that NN O O
did NN O O
not NN O O
carry NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation. NN O O
in NN O O
addition, NN O O
our NN O O
screening NN O O
showed NN O O
that NN O O
the NN O O
s NN O O
65 NN O O
c NN O O
substitution NN O O
was NN O O
significantly NN O O
enriched NN O O
in NN O O
probands NN O O
with NN O O
at NN O O
least NN O O
one NN O O
chromosome NN O O
without NN O O
an NN O O
assigned NN O O
mutation. NN O O
this NN O O
substitution NN O O
accounted NN O O
for NN O O
7. NN O O
8% NN O O
of NN O O
HH NN B-Modifier B-MSH:D006432
chromosomes NN O O
that NN O O
were NN O O
neither NN O O
c NN O O
282 NN O O
y NN O O
nor NN O O
h NN O O
63 NN O O
d. NN O O
this NN O O
enrichment NN O O
of NN O O
s NN O O
65 NN O O
c NN O O
among NN O O
HH NN B-Modifier B-MSH:D006432
chromosomes NN O O
suggests NN O O
that NN O O
the NN O O
s NN O O
65 NN O O
c NN O O
substitution NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
mild NN O O
form NN O O
of NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
. NN O O

germline NN O O
brca NN O O
1 NN O O
alterations NN O O
in NN O O
a NN O O
population-based NN O O
series NN O O
of NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
cases NN O O
. NN O O

the NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
provide NN O O
more NN O O
accurate NN O O
frequency NN O O
estimates NN O O
of NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
susceptibility NN O O
gene NN O O
1 NN O O
(brca NN O O
1) NN O O
germline NN O O
alterations NN O O
in NN O O
the NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
population. NN O O
to NN O O
achieve NN O O
this, NN O O
we NN O O
determined NN O O
the NN O O
prevalence NN O O
of NN O O
brca NN O O
1 NN O O
alterations NN O O
in NN O O
a NN O O
population-based NN O O
series NN O O
of NN O O
consecutive NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
cases. NN O O
this NN O O
is NN O O
the NN O O
first NN O O
population-based NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
study NN O O
reporting NN O O
brca NN O O
1 NN O O
alterations NN O O
derived NN O O
from NN O O
a NN O O
comprehensive NN O O
screen NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region. NN O O
one NN O O
hundred NN O O
and NN O O
seven NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
cases NN O O
were NN O O
analyzed NN O O
for NN O O
brca NN O O
1 NN O O
alterations NN O O
using NN O O
the NN O O
rnase NN O O
mismatch NN O O
cleavage NN O O
assay NN O O
followed NN O O
by NN O O
direct NN O O
sequencing. NN O O
two NN O O
truncating NN O O
mutations, NN O O
962 NN O O
del NN O O
4 NN O O
and NN O O
3600 NN O O
del NN O O
11, NN O O
were NN O O
identified. NN O O
both NN O O
patients NN O O
had NN O O
a NN O O
family NN O O
history NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
. NN O O
several NN O O
novel NN O O
as NN O O
well NN O O
as NN O O
previously NN O O
reported NN O O
uncharacterized NN O O
variants NN O O
wer NN O O
. NN O O

also NN O O
identified, NN O O
some NN O O
of NN O O
which NN O O
were NN O O
associated NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
. NN O O
the NN O O
frequency NN O O
distribution NN O O
of NN O O
common NN O O
polymorphisms NN O O
was NN O O
determined NN O O
in NN O O
the NN O O
91 NN O O
caucasian NN O O
cancer NN B-Modifier B-MSH:D009369
cases NN O O
in NN O O
this NN O O
series NN O O
and NN O O
24 NN O O
sister NN O O
controls NN O O
using NN O O
allele-specific NN O O
amplification. NN O O
the NN O O
rare NN O O
form NN O O
of NN O O
the NN O O
q NN O O
356 NN O O
r NN O O
polymorphism NN O O
was NN O O
significantly NN O O
(p NN O O
= NN O O
0. NN O O
03) NN O O
associated NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
, NN O O
suggesting NN O O
that NN O O
this NN O O
polymorphism NN O O
may NN O O
influence NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
risk. NN O O
in NN O O
summary, NN O O
our NN O O
data NN O O
suggest NN O O
a NN O O
role NN O O
for NN O O
some NN O O
uncharacterized NN O O
variants NN O O
and NN O O
rare NN O O
forms NN O O
of NN O O
polymorphisms NN O O
in NN O O
determining NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
risk, NN O O
and NN O O
highlight NN O O
the NN O O
necessity NN O O
to NN O O
screen NN O O
for NN O O
missense NN O O
alterations NN O O
as NN O O
well NN O O
as NN O O
truncating NN O O
mutations NN O O
in NN O O
this NN O O
population NN O O
. NN O O

identification NN O O
of NN O O
apc NN O O
2, NN O O
a NN O O
homologue NN O O
of NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
tumour NN I-Modifier I-MSH:D011125
suppressor NN O O
. NN O O

the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
(APC) NN I-Modifier I-MSH:D011125
tumour NN I-Modifier I-MSH:D011125
-suppressor NN O O
protein NN O O
controls NN O O
the NN O O
wnt NN O O
signalling NN O O
pathway NN O O
by NN O O
forming NN O O
a NN O O
complex NN O O
with NN O O
glycogen NN O O
synthase NN O O
kinase NN O O
3 NN O O
beta NN O O
(gsk-3 NN O O
beta), NN O O
axin/conductin NN O O
and NN O O
betacatenin. NN O O
complex NN O O
formation NN O O
induces NN O O
the NN O O
rapid NN O O
degradation NN O O
of NN O O
betacatenin. NN O O
in NN O O
colon NN B-Modifier B-MSH:D003110
carcinoma NN I-Modifier I-MSH:D003110
cells, NN O O
loss NN O O
of NN O O
apc NN O O
leads NN O O
to NN O O
the NN O O
accumulation NN O O
of NN O O
betacatenin NN O O
in NN O O
the NN O O
nucleus, NN O O
where NN O O
it NN O O
binds NN O O
to NN O O
and NN O O
activates NN O O
the NN O O
tcf-4 NN O O
transcription NN O O
factor NN O O
(reviewed NN O O
in NN O O
[1] NN O O
[2]). NN O O
here, NN O O
we NN O O
report NN O O
the NN O O
identification NN O O
and NN O O
genomic NN O O
structure NN O O
of NN O O
apc NN O O
homologues. NN O O
mammalian NN O O
apc NN O O
2, NN O O
which NN O O
closely NN O O
resembles NN O O
apc NN O O
in NN O O
overall NN O O
domain NN O O
structure, NN O O
was NN O O
functionally NN O O
analyzed NN O O
and NN O O
shown NN O O
to NN O O
contain NN O O
two NN O O
samp NN O O
domains, NN O O
both NN O O
of NN O O
which NN O O
are NN O O
required NN O O
for NN O O
binding NN O O
to NN O O
conductin. NN O O
like NN O O
apc, NN O O
ap NN O O
. NN O O

2 NN O O
regulates NN O O
the NN O O
formation NN O O
of NN O O
active NN O O
betacatenin-tcf NN O O
complexes, NN O O
as NN O O
demonstrated NN O O
using NN O O
transient NN O O
transcriptional NN O O
activation NN O O
assays NN O O
in NN O O
apc NN O O
-/- NN O O
colon NN B-Modifier B-MSH:D003110
carcinoma NN I-Modifier I-MSH:D003110
cells. NN O O
human NN O O
apc NN O O
2 NN O O
maps NN O O
to NN O O
chromosome NN O O
19 NN O O
p NN O O
13. NN O O
3. NN O O
apc NN O O
and NN O O
apc NN O O
2 NN O O
may NN O O
therefore NN O O
have NN O O
comparable NN O O
functions NN O O
in NN O O
development NN O O
and NN O O
cancer NN B-SpecificDisease B-MSH:D009369
. NN O O

familial NN O O
deficiency NN O O
of NN O O
the NN O O
seventh NN O O
component NN O O
of NN O O
complement NN O O
associated NN O O
with NN O O
recurrent NN O O
bacteremic NN B-DiseaseClass B-MSH:D016870
infections NN I-DiseaseClass I-MSH:D016870
due NN I-DiseaseClass I-MSH:D016870
to NN I-DiseaseClass I-MSH:D016870
Neisseria NN I-DiseaseClass I-MSH:D016870
. NN O O

the NN O O
serum NN O O
of NN O O
a NN O O
29-year NN O O
old NN O O
woman NN O O
with NN O O
a NN O O
recent NN O O
episode NN O O
of NN O O
disseminated NN B-SpecificDisease B-MSH:D004673
gonococcal NN I-SpecificDisease I-MSH:D004673
infection NN I-SpecificDisease I-MSH:D004673
and NN O O
a NN O O
history NN O O
of NN O O
meningococcal NN B-SpecificDisease B-MSH:D008585
meningitis NN I-SpecificDisease I-MSH:D008585
and NN O O
arthritis NN B-DiseaseClass B-MSH:D001168
as NN O O
a NN O O
child NN O O
was NN O O
found NN O O
to NN O O
lack NN O O
serum NN O O
hemolytic NN O O
complement NN O O
activity. NN O O
the NN O O
seventh NN O O
component NN O O
of NN O O
complement NN O O
(c NN O O
7) NN O O
was NN O O
not NN O O
detected NN O O
by NN O O
functional NN O O
or NN O O
immunochemical NN O O
assays, NN O O
whereas NN O O
other NN O O
components NN O O
were NN O O
normal NN O O
by NN O O
hemolytic NN O O
and NN O O
immunochemical NN O O
assessment. NN O O
her NN O O
fresh NN O O
serum NN O O
lacked NN O O
complement-mediated NN O O
bactericidal NN O O
activity NN O O
against NN O O
neisseria NN O O
gonorrhoeae, NN O O
but NN O O
the NN O O
addition NN O O
of NN O O
fresh NN O O
normal NN O O
serum NN O O
or NN O O
purified NN O O
c NN O O
7 NN O O
restored NN O O
bactericidal NN O O
activity NN O O
as NN O O
well NN O O
as NN O O
hemolytic NN O O
activity. NN O O
the NN O O
absence NN B-Modifier B-OMIM:610102
of NN I-Modifier I-OMIM:610102
functional NN I-Modifier I-OMIM:610102
C7 NN I-Modifier I-OMIM:610102
activity NN O O
could NN O O
not NN O O
be NN O O
accounted NN O O
for NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
an NN O O
inhibitor. NN O O
opsonization NN O O
and NN O O
generation NN O O
of NN O O
chemotactic NN O O
activity NN O O
functioned NN O O
normally. NN O O
Complete NN B-SpecificDisease B-OMIM:610102
absence NN I-SpecificDisease I-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
C7 NN I-SpecificDisease I-OMIM:610102
was NN O O
also NN O O
found NN O O
in NN O O
one NN O O
sibling NN O O
who NN O O
ha NN O O
. NN O O

the NN O O
clinical NN O O
syndrome NN O O
of NN O O
meningococcal NN B-SpecificDisease B-MSH:D008585
meningitis NN I-SpecificDisease I-MSH:D008585
and NN O O
arthritis NN B-DiseaseClass B-MSH:D001168
as NN O O
a NN O O
child NN O O
and NN O O
in NN O O
this NN O O
siblings NN O O
clinically NN O O
well NN O O
eight-year-old NN O O
son. NN O O
hla NN O O
histocompatibility NN O O
typing NN O O
of NN O O
the NN O O
family NN O O
members NN O O
did NN O O
not NN O O
demonstrate NN O O
evidence NN O O
for NN O O
genetic NN O O
linkage NN O O
of NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficiency NN I-SpecificDisease I-OMIM:610102
with NN O O
the NN O O
major NN O O
histocompatibility NN O O
loci. NN O O
this NN O O
report NN O O
represents NN O O
the NN O O
first NN O O
cases NN O O
of NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficiency NN I-SpecificDisease I-OMIM:610102
associated NN O O
with NN O O
infectious NN O O
complications NN O O
and NN O O
suggests NN O O
that NN O O
bactericidal NN O O
activity NN O O
may NN O O
be NN O O
important NN O O
in NN O O
host NN O O
defense NN O O
against NN O O
bacteremic NN B-SpecificDisease B-MSH:D016870
neisseria NN I-SpecificDisease I-MSH:D016870
infections NN I-SpecificDisease I-MSH:D016870
. NN O O

gch NN O O
1 NN O O
mutation NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
adult-onset NN O O
oromandibular NN B-SpecificDisease B-MSH:D008538
dystonia NN I-SpecificDisease I-MSH:D008538
. NN O O

the NN O O
authors NN O O
report NN O O
a NN O O
mutation NN O O
in NN O O
exon NN O O
5 NN O O
of NN O O
gch NN O O
1 NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
adult-onset NN O O
oromandibular NN B-SpecificDisease B-MSH:D008538
dystonia NN I-SpecificDisease I-MSH:D008538
and NN O O
no NN O O
obvious NN O O
family NN O O
history NN O O
of NN O O
dystonia NN B-DiseaseClass B-MSH:D004421
. NN O O
the NN O O
patient NN O O
responded NN O O
positively NN O O
to NN O O
treatment NN O O
with NN O O
l-dopa. NN O O
these NN O O
findings NN O O
demonstrate NN O O
that NN O O
gch NN O O
1 NN O O
mutations NN O O
must NN O O
be NN O O
considered NN O O
even NN O O
in NN O O
patients NN O O
with NN O O
dystonic NN B-Modifier B-MSH:D004421
symptoms NN O O
not NN O O
typical NN O O
of NN O O
dopa-responsive NN B-SpecificDisease B-MSH:C538007
dystonia NN I-SpecificDisease I-MSH:C538007
. NN O O

the NN O O
hereditary NN B-Modifier B-MSH:D006432
hemochromatosis NN I-Modifier I-MSH:D006432
protein, NN O O
hfe, NN O O
specifically NN O O
regulates NN O O
transferrin-mediated NN O O
iron NN O O
uptake NN O O
in NN O O
hela NN O O
cells NN O O
. NN O O

hfe NN O O
is NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
the NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
hereditary NN B-SpecificDisease B-MSH:D006432
hemochromatosis NN I-SpecificDisease I-MSH:D006432
(feder, NN O O
j. NN O O
n., NN O O
gnirke, NN O O
a., NN O O
thomas, NN O O
w., NN O O
tsuchihashi, NN O O
z., NN O O
ruddy, NN O O
d. NN O O
a., NN O O
basava, NN O O
a., NN O O
dormishian, NN O O
f., NN O O
domingo, NN O O
r. NN O O
j., NN O O
ellis, NN O O
m. NN O O
c., NN O O
fullan, NN O O
a., NN O O
hinton, NN O O
l. NN O O
m., NN O O
jones, NN O O
n. NN O O
l., NN O O
kimmel, NN O O
b. NN O O
e., NN O O
kronmal, NN O O
g. NN O O
s., NN O O
lauer, NN O O
p., NN O O
lee, NN O O
v. NN O O
k., NN O O
loeb, NN O O
d. NN O O
b., NN O O
mapa, NN O O
f. NN O O
a., NN O O
mcclelland, NN O O
e., NN O O
meyer, NN O O
n. NN O O
c NN O O
. NN O O

, NN O O
mintier, NN O O
g. NN O O
a., NN O O
moeller, NN O O
n., NN O O
moore, NN O O
t., NN O O
morikang, NN O O
e., NN O O
prasss, NN O O
c. NN O O
e NN O O
., NN O O
quintana, NN O O
l., NN O O
starnes, NN O O
s. NN O O
m NN O O
., NN O O
schatzman, NN O O
r. NN O O
c NN O O
., NN O O
brunke, NN O O
k. NN O O
j NN O O
., NN O O
drayna, NN O O
d. NN O O
t., NN O O
risch, NN O O
n. NN O O
j NN O O
., NN O O
bacon, NN O O
b. NN O O
r NN O O
., NN O O
and NN O O
wolff, NN O O
r. NN O O
r NN O O
. NN O O
(1996) NN O O
nat. NN O O
genet. NN O O
13, NN O O
399-408). NN O O
at NN O O
the NN O O
cell NN O O
surface, NN O O
hfe NN O O
complexes NN O O
with NN O O
transferrin NN O O
receptor NN O O
(tfr), NN O O
increasing NN O O
the NN O O
dissociation NN O O
constant NN O O
of NN O O
transferrin NN O O
(tf) NN O O
for NN O O
its NN O O
receptor NN O O
10-fold NN O O
(gross, NN O O
c. NN O O
n NN O O
., NN O O
irrinki, NN O O
a. NN O O
. NN O O
zman, NN O O
r. NN O O
c NN O O
., NN O O
brunke, NN O O
k. NN O O
j NN O O
., NN O O
drayna, NN O O
d. NN O O
t., NN O O
risch, NN O O
n. NN O O
j NN O O
., NN O O
bacon, NN O O
b. NN O O
r NN O O
., NN O O
and NN O O
wolff, NN O O
r. NN O O
r NN O O
. NN O O
(1996) NN O O
nat. NN O O
genet. NN O O
13, NN O O
399-408). NN O O
at NN O O
the NN O O
cell NN O O
surface, NN O O
hfe NN O O
complexes NN O O
with NN O O
transferrin NN O O
receptor NN O O
(tfr), NN O O
increasing NN O O
the NN O O
dissociation NN O O
constant NN O O
of NN O O
transferrin NN O O
(tf) NN O O
for NN O O
its NN O O
receptor NN O O
10-fold NN O O
(gross, NN O O
c. NN O O
n NN O O
., NN O O
irrinki, NN O O
a. NN O O
. NN O O

feder, NN O O
j. NN O O
n NN O O
., NN O O
and NN O O
enns, NN O O
c. NN O O
a NN O O
. NN O O
(1998) NN O O
j. NN O O
biol. NN O O
chem. NN O O
273, NN O O
22068-22074; NN O O
feder, NN O O
j. NN O O
n., NN O O
penny, NN O O
d. NN O O
m., NN O O
irrinki, NN O O
a., NN O O
lee, NN O O
v. NN O O
k., NN O O
lebron, NN O O
j. NN O O
a., NN O O
watson, NN O O
n., NN O O
tsuchihashi, NN O O
z., NN O O
sigal, NN O O
e., NN O O
bjorkman, NN O O
p. NN O O
j., NN O O
and NN O O
schatzman, NN O O
r. NN O O
c. NN O O
(1998) NN O O
proc. NN O O
natl NN O O
. NN O O
acad. NN O O
sci. NN O O
u NN O O
s NN O O
a NN O O
95, NN O O
1472-1477). NN O O
hfe NN O O
does NN O O
not NN O O
remain NN O O
at NN O O
the NN O O
cell NN O O
surface, NN O O
but NN O O
traffics NN O O
with NN O O
tfr NN O O
to NN O O
tf-positive NN O O
internal NN O O
compartments NN O O
(gross NN O O
et NN O O
al., NN O O
1998) NN O O
. NN O O
a., NN O O
lee, NN O O
v. NN O O
k., NN O O
lebron, NN O O
j. NN O O
a., NN O O
watson, NN O O
n., NN O O
tsuchihashi, NN O O
z., NN O O
sigal, NN O O
e., NN O O
bjorkman, NN O O
p. NN O O
j., NN O O
and NN O O
schatzman, NN O O
r. NN O O
c. NN O O
(1998) NN O O
proc. NN O O
natl NN O O
. NN O O
acad. NN O O
sci. NN O O
u NN O O
s NN O O
a NN O O
95, NN O O
1472-1477). NN O O
hfe NN O O
does NN O O
not NN O O
remain NN O O
at NN O O
the NN O O
cell NN O O
surface, NN O O
but NN O O
traffics NN O O
with NN O O
tfr NN O O
to NN O O
tf-positive NN O O
internal NN O O
compartments NN O O
(gross NN O O
et NN O O
al., NN O O
1998) NN O O
. NN O O

using NN O O
a NN O O
hela NN O O
cell NN O O
line NN O O
in NN O O
which NN O O
the NN O O
expression NN O O
of NN O O
hfe NN O O
is NN O O
controlled NN O O
by NN O O
tetracycline, NN O O
we NN O O
show NN O O
that NN O O
the NN O O
expression NN O O
of NN O O
hfe NN O O
reduces NN O O
55 NN O O
fe NN O O
uptake NN O O
from NN O O
tf NN O O
by NN O O
33% NN O O
but NN O O
does NN O O
not NN O O
affect NN O O
the NN O O
endocytic NN O O
or NN O O
exocytic NN O O
rates NN O O
of NN O O
tfr NN O O
cycling. NN O O
therefore, NN O O
hfe NN O O
appears NN O O
to NN O O
reduce NN O O
cellular NN O O
acquisition NN O O
of NN O O
iron NN O O
from NN O O
tf NN O O
within NN O O
endocytic NN O O
compartments. NN O O
hfe NN O O
specifically NN O O
reduces NN O O
iron NN O O
uptake NN O O
from NN O O
tf, NN O O
as NN O O
non-tf-mediated NN O O
iron NN O O
uptake NN O O
from NN O O
fe-nitrilotriacetic NN O O
acid NN O O
is NN O O
not NN O O
altered. NN O O
these NN O O
results NN O O
explain NN O O
the NN O O
decreased NN O O
ferritin NN O O
levels NN O O
seen NN O O
in NN O O
our NN O O
hela NN O O
cell NN O O
system NN O O
and NN O O
demonstrate NN O O
the NN O O
specific NN O O
control NN O O
of NN O O
hfe NN O O
over NN O O
the NN O O
tf-mediated NN O O
pathway NN O O
of NN O O
iron NN O O
uptake. NN O O
these NN O O
results NN O O
also NN O O
have NN O O
implications NN O O
for NN O O
the NN O O
understanding NN O O
of NN O O
cellular NN O O
iron NN O O
homeostasis NN O O
in NN O O
organs NN O O
such NN O O
as NN O O
the NN O O
liver, NN O O
pancreas, NN O O
heart, NN O O
an NN O O
. NN O O
sion NN O O
of NN O O
hfe NN O O
reduces NN O O
55 NN O O
fe NN O O
uptake NN O O
from NN O O
tf NN O O
by NN O O
33% NN O O
but NN O O
does NN O O
not NN O O
affect NN O O
the NN O O
endocytic NN O O
or NN O O
exocytic NN O O
rates NN O O
of NN O O
tfr NN O O
cycling. NN O O
therefore, NN O O
hfe NN O O
appears NN O O
to NN O O
reduce NN O O
cellular NN O O
acquisition NN O O
of NN O O
iron NN O O
from NN O O
tf NN O O
within NN O O
endocytic NN O O
compartments. NN O O
hfe NN O O
specifically NN O O
reduces NN O O
iron NN O O
uptake NN O O
from NN O O
tf, NN O O
as NN O O
non-tf-mediated NN O O
iron NN O O
uptake NN O O
from NN O O
fe-nitrilotriacetic NN O O
acid NN O O
is NN O O
not NN O O
altered. NN O O
these NN O O
results NN O O
explain NN O O
the NN O O
decreased NN O O
ferritin NN O O
levels NN O O
seen NN O O
in NN O O
our NN O O
hela NN O O
cell NN O O
system NN O O
and NN O O
demonstrate NN O O
the NN O O
specific NN O O
control NN O O
of NN O O
hfe NN O O
over NN O O
the NN O O
tf-mediated NN O O
pathway NN O O
of NN O O
iron NN O O
uptake. NN O O
these NN O O
results NN O O
also NN O O
have NN O O
implications NN O O
for NN O O
the NN O O
understanding NN O O
of NN O O
cellular NN O O
iron NN O O
homeostasis NN O O
in NN O O
organs NN O O
such NN O O
as NN O O
the NN O O
liver, NN O O
pancreas, NN O O
heart, NN O O
an NN O O
. NN O O

spleen NN O O
that NN O O
are NN O O
iron NN O O
loaded NN O O
in NN O O
hereditary NN B-Modifier B-MSH:D006432
hemochromatotic NN I-Modifier I-MSH:D006432
individuals NN O O
lacking NN O O
functional NN O O
hfe NN O O
. NN O O

mutation NN O O
and NN O O
haplotype NN O O
studies NN O O
of NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
reveal NN O O
new NN O O
ancestral NN O O
relationships NN O O
and NN O O
evidence NN O O
for NN O O
a NN O O
high NN O O
carrier NN O O
frequency NN O O
with NN O O
reduced NN O O
penetrance NN O O
in NN O O
the NN O O
ashkenazi NN O O
jewish NN O O
population NN O O
. NN O O

familial NN O O
mediterranean NN O O
fever NN O O
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
) NN O O
is NN O O
a NN O O
recessive NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
episodes NN O O
of NN O O
fever NN O O
with NN O O
serositis NN B-DiseaseClass B-MSH:D012700
or NN O O
synovitis NN B-DiseaseClass B-MSH:D013585
. NN O O
the NN O O
FMF NN B-Modifier B-MSH:D010505
gene NN O O
(mefv) NN O O
was NN O O
cloned NN O O
recently, NN O O
and NN O O
four NN O O
missense NN O O
mutations NN O O
were NN O O
identified. NN O O
here NN O O
we NN O O
present NN O O
data NN O O
from NN O O
non-ashkenazi NN O O
jewish NN O O
and NN O O
arab NN O O
patients NN O O
in NN O O
whom NN O O
we NN O O
had NN O O
not NN O O
originally NN O O
found NN O O
mutations NN O O
and NN O O
from NN O O
a NN O O
new, NN O O
more NN O O
ethnically NN O O
diverse NN O O
panel. NN O O
among NN O O
90 NN O O
symptomatic NN O O
mutation-positive NN O O
individuals, NN O O
11 NN O O
mutations NN O O
accounted NN O O
for NN O O
79% NN O O
of NN O O
carrier NN O O
chromosomes. NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
that NN O O
are NN O O
novel, NN O O
one NN O O
alters NN O O
the NN O O
same NN O O
residue NN O O
(680) NN O O
as NN O O
a NN O O
previously NN O O
known NN O O
mutation, NN O O
and NN O O
the NN O O
other NN O O
(p NN O O
369 NN O O
s) NN O O
is NN O O
located NN O O
in NN O O
exon NN O O
3. NN O O
consistent NN O O
with NN O O
another NN O O
recent NN O O
report, NN O O
the NN O O
e NN O O
148 NN O O
q NN O O
mutation NN O O
was NN O O
observed NN O O
in NN O O
patients NN O O
of NN O O
several NN O O
ethnicities NN O O
an NN O O
. NN O O

on NN O O
multiple NN O O
microsatellite NN O O
haplotypes, NN O O
but NN O O
haplotype NN O O
data NN O O
indicate NN O O
an NN O O
ancestral NN O O
relationships NN O O
between NN O O
non-jewish NN O O
italian NN O O
and NN O O
ashkenazi NN O O
jewish NN O O
patients NN O O
with NN O O
FMF NN B-SpecificDisease B-MSH:D010505
and NN O O
other NN O O
affected NN O O
populations. NN O O
among NN O O
approximately NN O O
200 NN O O
anonymous NN O O
ashkenazi NN O O
jewish NN O O
dna NN O O
samples, NN O O
the NN O O
mefv NN O O
carrier NN O O
frequency NN O O
was NN O O
21%, NN O O
with NN O O
e NN O O
148 NN O O
q NN O O
the NN O O
most NN O O
common NN O O
mutation. NN O O
several NN O O
lines NN O O
of NN O O
evidence NN O O
indicate NN O O
reduced NN O O
penetrance NN O O
among NN O O
ashkenazi NN O O
jews, NN O O
especially NN O O
for NN O O
e NN O O
148 NN O O
q, NN O O
p NN O O
369 NN O O
s, NN O O
and NN O O
k NN O O
695 NN O O
r. NN O O
nevertheless, NN O O
e NN O O
148 NN O O
q NN O O
helps NN O O
account NN O O
for NN O O
recessive NN O O
inheritance NN O O
in NN O O
an NN O O
ashkenazi NN O O
family NN O O
previously NN O O
reported NN O O
as NN O O
an NN O O
unusual NN O O
case NN O O
of NN O O
dominantly NN O O
inherited NN O O
FMF NN B-SpecificDisease B-MSH:D010505
. NN O O
the NN O O
presence NN O O
of NN O O
three NN O O
frequent NN O O
mefv NN O O
mutations NN O O
in NN O O
multiple NN O O
mediterranean NN O O
populations NN O O
strongly NN O O
suggests NN O O
a NN O O
heterozygote NN O O
advantage NN O O
in NN O O
this NN O O
geographic NN O O
region NN O O
. NN O O

autoimmune NN O O
lymphoproliferative NN O O
syndrome NN O O
with NN O O
defective NN O O
fas: NN O O
genotype NN O O
influences NN O O
penetrance NN O O
. NN O O

autoimmune NN O O
lymphoproliferative NN O O
syndrome NN O O
( NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
) NN O O
is NN O O
a NN O O
disorder NN B-CompositeMention B-MSH:D008232
of NN I-CompositeMention I-MSH:D008232
lymphocyte NN I-CompositeMention I-MSH:D008232
homeostasis NN I-CompositeMention I-MSH:D008232
and NN I-CompositeMention I-MSH:D008232
immunological NN I-CompositeMention I-MSH:D008232
tolerance NN I-CompositeMention I-MSH:D008232
. NN O O
most NN O O
patients NN O O
have NN O O
a NN O O
heterozygous NN O O
mutation NN O O
in NN O O
the NN O O
apt NN O O
1 NN O O
gene, NN O O
which NN O O
encodes NN O O
fas NN O O
(cd NN O O
95, NN O O
apo-1), NN O O
mediator NN O O
of NN O O
an NN O O
apoptotic NN O O
pathway NN O O
crucial NN O O
to NN O O
lymphocyte NN O O
homeostasis. NN O O
of NN O O
17 NN O O
unique NN O O
apt NN O O
1 NN O O
mutations NN O O
in NN O O
unrelated NN O O
ALPS NN B-Modifier B-MSH:D056735
probands, NN O O
12 NN O O
(71%) NN O O
occurred NN O O
in NN O O
exons NN O O
7-9, NN O O
which NN O O
encode NN O O
the NN O O
intracellular NN O O
portion NN O O
of NN O O
fas. NN O O
in NN O O
vitro, NN O O
activated NN O O
lymphocytes NN O O
from NN O O
all NN O O
17 NN O O
patients NN O O
showed NN O O
apoptotic NN O O
defects NN O O
when NN O O
exposed NN O O
to NN O O
an NN O O
anti-fas NN O O
agonist NN O O
monoclonal NN O O
antibody. NN O O
similar NN O O
defects NN O O
were NN O O
found NN O O
in NN O O
a NN O O
fas-negative NN O O
cell NN O O
line NN O O
transfected NN O O
with NN O O
cdnas NN O O
bearing NN O O
each NN O O
of NN O O
the NN O O
mutations. NN O O
in NN O O
cotransfection NN O O
experiments, NN O O
fas NN O O
constructs NN O O
with NN O O
either NN O O
intra- NN O O
or NN O O
extracellular NN O O
mutations NN O O
caused NN O O
dominant NN O O
inhibitio NN O O
. NN O O

of NN O O
apoptosis NN O O
mediated NN O O
by NN O O
wild-type NN O O
fas. NN O O
two NN O O
missense NN O O
fas NN O O
variants, NN O O
not NN O O
restricted NN O O
to NN O O
patients NN O O
with NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
, NN O O
were NN O O
identified. NN O O
variant NN O O
a NN O O
(-1) NN O O
t NN O O
at NN O O
the NN O O
fas NN O O
signal-sequence NN O O
cleavage NN O O
site, NN O O
which NN O O
mediates NN O O
apoptosis NN O O
less NN O O
well NN O O
than NN O O
wild-type NN O O
fas NN O O
and NN O O
is NN O O
partially NN O O
inhibitory, NN O O
was NN O O
present NN O O
in NN O O
13% NN O O
of NN O O
african NN O O
american NN O O
alleles. NN O O
among NN O O
the NN O O
ALPS NN B-Modifier B-MSH:D056735
-associated NN O O
fas NN O O
mutants, NN O O
dominant NN O O
inhibition NN O O
of NN O O
apoptosis NN O O
was NN O O
much NN O O
more NN O O
pronounced NN O O
in NN O O
mutants NN O O
affecting NN O O
the NN O O
intracellular, NN O O
versus NN O O
extracellular, NN O O
portion NN O O
of NN O O
the NN O O
fas NN O O
receptor. NN O O
mutations NN O O
causing NN O O
disruption NN O O
of NN O O
the NN O O
intracellular NN O O
fas NN O O
death NN O O
domain NN O O
also NN O O
showed NN O O
a NN O O
higher NN O O
penetrance NN O O
of NN O O
ALPS NN B-Modifier B-MSH:D056735
phenotype NN O O
features NN O O
in NN O O
mutation-bearing NN O O
relatives. NN O O
significant NN O O
ALPS NN B-Modifier B-MSH:D056735
-related NN O O
morbidity NN O O
occurred NN O O
in NN O O
44% NN O O
of NN O O
relatives NN O O
with NN O O
intracellular NN O O
mutations, NN O O
versus NN O O
0% NN O O
of NN O O
relative NN O O
. NN O O

with NN O O
extracellular NN O O
mutations. NN O O
thus, NN O O
the NN O O
location NN O O
of NN O O
mutations NN O O
within NN O O
apt NN O O
1 NN O O
strongly NN O O
influences NN O O
the NN O O
development NN O O
and NN O O
the NN O O
severity NN O O
of NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
. NN O O

mutational NN O O
analysis NN O O
and NN O O
genotype-phenotype NN O O
correlation NN O O
of NN O O
29 NN O O
unrelated NN O O
japanese NN O O
patients NN O O
with NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
. NN O O

background NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
is NN O O
an NN O O
inherited NN B-DiseaseClass B-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
progressive NN O O
neurologic NN B-SpecificDisease B-MSH:D009461
dysfunction NN I-SpecificDisease I-MSH:D009461
, NN O O
occasionally NN O O
associated NN O O
with NN O O
adrenal NN B-DiseaseClass B-MSH:D000309
insufficiency NN I-DiseaseClass I-MSH:D000309
. NN O O
the NN O O
classic NN O O
form NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
usually NN O O
has NN O O
onset NN O O
in NN O O
childhood NN O O
( NN O O
childhood NN B-SpecificDisease B-MSH:D000326
cerebral NN I-SpecificDisease I-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
), NN O O
with NN O O
rapid NN O O
neurologic NN B-DiseaseClass B-MSH:D009461
deterioration NN I-DiseaseClass I-MSH:D009461
leading NN O O
to NN O O
a NN O O
vegetative NN O O
state. NN O O
adult-onset NN O O
cerebral NN B-SpecificDisease B-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
also NN O O
presents NN O O
with NN O O
rapidly NN O O
progressive NN O O
neurologic NN B-DiseaseClass B-MSH:D009461
dysfunction NN I-DiseaseClass I-MSH:D009461
. NN O O
milder NN O O
phenotypes NN O O
such NN O O
as NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
and NN O O
Addison NN B-SpecificDisease B-MSH:D000224
disease NN I-SpecificDisease I-MSH:D000224
only NN O O
also NN O O
have NN O O
been NN O O
recognized. NN O O
despite NN O O
discovery NN O O
of NN O O
the NN O O
causative NN O O
gene, NN O O
a NN O O
molecular NN O O
basis NN O O
for NN O O
the NN O O
diverse NN O O
clinical NN O O
presentations NN O O
remains NN O O
to NN O O
be NN O O
elucidated. NN O O
objectives NN O O
to NN O O
conduct NN O O
mutational NN O O
analyses NN O O
in NN O O
29 NN O O
japanese NN O O
patients NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
from NN O O
29 NN O O
unrelated NN O O
families, NN O O
to NN O O
obtain NN O O
knowledge NN O O
of NN O O
the NN O O
spectrum NN O O
of NN O O
mutations NN O O
in NN O O
this NN O O
gene, NN O O
and NN O O
to NN O O
study NN O O
genotype-phenotype NN O O
correlations NN O O
in NN O O
japanese NN O O
patients. NN O O
methods NN O O
the NN O O
29 NN O O
patient NN O O
. NN O O

comprised NN O O
13 NN O O
patients NN O O
with NN O O
childhood NN B-SpecificDisease B-MSH:D000326
cerebral NN I-SpecificDisease I-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
, NN O O
11 NN O O
patients NN O O
with NN O O
adult-onset NN O O
cerebral NN B-SpecificDisease B-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
, NN O O
and NN O O
5 NN O O
patients NN O O
with NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
. NN O O
we NN O O
conducted NN O O
detailed NN O O
mutational NN O O
analyses NN O O
of NN O O
29 NN O O
unrelated NN O O
japanese NN O O
patients NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
by NN O O
genomic NN O O
southern NN O O
blot NN O O
analysis NN O O
and NN O O
direct NN O O
nucleotide NN O O
sequence NN O O
analysis NN O O
of NN O O
reverse NN O O
transcriptase-polymerase NN O O
chain NN O O
reaction NN O O
products NN O O
derived NN O O
from NN O O
total NN O O
rna NN O O
that NN O O
was NN O O
extracted NN O O
from NN O O
cultured NN O O
skin NN O O
fibroblasts, NN O O
lymphoblastoid NN O O
cells, NN O O
or NN O O
peripheral NN O O
blood NN O O
leukocytes. NN O O
results NN O O
three NN O O
patients NN O O
with NN O O
adult-onset NN O O
cerebral NN B-SpecificDisease B-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
were NN O O
identified NN O O
as NN O O
having NN O O
large NN O O
genomic NN O O
rearrangements. NN O O
the NN O O
remaining NN O O
26 NN O O
patients NN O O
were NN O O
identified NN O O
as NN O O
having NN O O
21 NN O O
independent NN O O
mutations, NN O O
including NN O O
12 NN O O
novel NN O O
mutations NN O O
resulting NN O O
in NN O O
small NN O O
nucleotide NN O O
alterations NN O O
in NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene. NN O O
eighteen NN O O
(69%) NN O O
of NN O O
26 NN O O
mutations NN O O
were NN O O
missense NN O O
mutations. NN O O
most NN O O
missense NN O O
mutations NN O O
involved NN O O
amino NN O O
acids NN O O
conserved NN O O
in NN O O
homologous NN O O
gene NN O O
products NN O O
. NN O O

including NN O O
pmp NN O O
70, NN O O
maldrp, NN O O
and NN O O
pxa NN O O
1 NN O O
p. NN O O
the NN O O
ag NN O O
dinucleotide NN O O
deletion NN O O
at NN O O
position NN O O
1081-1082, NN O O
which NN O O
has NN O O
been NN O O
reported NN O O
previously NN O O
to NN O O
be NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
white NN O O
patients NN O O
(12% NN O O
-17%), NN O O
was NN O O
also NN O O
identified NN O O
as NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
japanese NN O O
patients NN O O
(12%). NN O O
all NN O O
phenotypes NN O O
were NN O O
associated NN O O
with NN O O
mutations NN O O
resulting NN O O
in NN O O
protein NN O O
truncation NN O O
or NN O O
subtle NN O O
amino NN O O
acid NN O O
changes. NN O O
there NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
phenotypic NN O O
expressions NN O O
between NN O O
missense NN O O
mutations NN O O
involving NN O O
conserved NN O O
amino NN O O
acids NN O O
and NN O O
those NN O O
involving NN O O
nonconserved NN O O
amino NN O O
acids. NN O O
conclusions NN O O
there NN O O
are NN O O
no NN O O
obvious NN O O
correlations NN O O
between NN O O
the NN O O
phenotypes NN O O
of NN O O
patients NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
their NN O O
genotypes, NN O O
suggesting NN O O
that NN O O
other NN O O
genetic NN O O
or NN O O
environmental NN O O
factors NN O O
modify NN O O
the NN O O
phenotypic NN O O
expressions NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
. NN O O

absence NN O O
of NN O O
the NN O O
seventh NN O O
component NN O O
of NN O O
complement NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
chronic NN B-SpecificDisease B-MSH:D008589
meningococcemia NN I-SpecificDisease I-MSH:D008589
presenting NN O O
as NN O O
vasculitis NN B-SpecificDisease B-MSH:D014657
. NN O O

a NN O O
previously NN O O
healthy NN O O
40-year-old NN O O
man NN O O
presenting NN O O
with NN O O
fever NN B-SpecificDisease B-MSH:D005334
, NN O O
arthritis NN B-SpecificDisease B-MSH:D001168
, NN O O
and NN O O
cutaneous NN B-SpecificDisease B-MSH:D018366
vasculitis NN I-SpecificDisease I-MSH:D018366
was NN O O
found NN O O
to NN O O
have NN O O
chronic NN B-SpecificDisease B-MSH:D008589
meningococcemia NN I-SpecificDisease I-MSH:D008589
. NN O O
evaluation NN O O
of NN O O
his NN O O
complement NN O O
system NN O O
showed NN O O
an NN O O
absence NN O O
of NN O O
functional NN O O
and NN O O
antigenic NN O O
c NN O O
7, NN O O
compatible NN O O
with NN O O
a NN O O
complete NN O O
deficiency NN B-SpecificDisease B-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
the NN I-SpecificDisease I-OMIM:610102
seventh NN I-SpecificDisease I-OMIM:610102
component NN I-SpecificDisease I-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
complement NN I-SpecificDisease I-OMIM:610102
. NN O O
study NN O O
of NN O O
the NN O O
patients NN O O
family NN O O
spanning NN O O
four NN O O
generations NN O O
showed NN O O
heterozygous NN O O
deficiency NN B-SpecificDisease B-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
C7 NN I-SpecificDisease I-OMIM:610102
in NN O O
five NN O O
members. NN O O
Chronic NN B-SpecificDisease B-MSH:D016870
neisserial NN I-SpecificDisease I-MSH:D016870
infection NN I-SpecificDisease I-MSH:D016870
can NN O O
be NN O O
associated NN O O
with NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficiency NN I-SpecificDisease I-OMIM:610102
and NN O O
must NN O O
be NN O O
distinguished NN O O
from NN O O
other NN O O
causes NN O O
of NN O O
cutaneous NN B-SpecificDisease B-MSH:D018366
vasculitis NN I-SpecificDisease I-MSH:D018366
. NN O O
. NN O O

genotype NN O O
and NN O O
phenotype NN O O
in NN O O
patients NN O O
with NN O O
dihydropyrimidine NN B-SpecificDisease B-MSH:D054067
dehydrogenase NN I-SpecificDisease I-MSH:D054067
deficiency NN I-SpecificDisease I-MSH:D054067
. NN O O

dihydropyrimidine NN O O
dehydrogenase NN O O
(dpd) NN O O
deficiency NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
characterised NN O O
by NN O O
thymine-uraciluria NN O O
in NN O O
homozygous NN O O
deficient NN O O
patients NN O O
and NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
a NN O O
variable NN O O
clinical NN O O
phenotype. NN O O
in NN O O
order NN O O
to NN O O
understand NN O O
the NN O O
genetic NN O O
and NN O O
phenotypic NN O O
basis NN O O
for NN O O
DPD NN B-SpecificDisease B-MSH:D054067
deficiency NN I-SpecificDisease I-MSH:D054067
, NN O O
we NN O O
have NN O O
reviewed NN O O
17 NN O O
families NN O O
presenting NN O O
22 NN O O
patients NN O O
with NN O O
complete NN O O
deficiency NN B-SpecificDisease B-MSH:D054067
of NN I-SpecificDisease I-MSH:D054067
DPD NN I-SpecificDisease I-MSH:D054067
. NN O O
in NN O O
this NN O O
group NN O O
of NN O O
patients, NN O O
7 NN O O
different NN O O
mutations NN O O
have NN O O
been NN O O
identified, NN O O
including NN O O
2 NN O O
deletions NN O O
[295-298 NN O O
deltcat, NN O O
1897 NN O O
delc], NN O O
1 NN O O
splice-site NN O O
mutation NN O O
[ivs NN O O
14 NN O O
+ NN O O
1 NN O O
g NN O O
> NN O O
a)] NN O O
and NN O O
4 NN O O
missense NN O O
mutations NN O O
(85 NN O O
t NN O O
> NN O O
c, NN O O
703 NN O O
c NN O O
> NN O O
t, NN O O
2658 NN O O
g NN O O
> NN O O
a, NN O O
2983 NN O O
g NN O O
> NN O O
t). NN O O
analysis NN O O
of NN O O
the NN O O
prevalence NN O O
of NN O O
the NN O O
various NN O O
mutations NN O O
among NN O O
DPD NN B-Modifier B-MSH:D054067
patients NN O O
has NN O O
shown NN O O
that NN O O
the NN O O
. NN O O

-- NN O O
> NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
the NN O O
invariant NN O O
splice NN O O
donor NN O O
site NN O O
is NN O O
by NN O O
far NN O O
the NN O O
most NN O O
common NN O O
(52%), NN O O
whereas NN O O
the NN O O
other NN O O
six NN O O
mutations NN O O
are NN O O
less NN O O
frequently NN O O
observed. NN O O
a NN O O
large NN O O
phenotypic NN O O
variability NN O O
has NN O O
been NN O O
observed, NN O O
with NN O O
convulsive NN B-DiseaseClass B-MSH:D004829
disorders NN I-DiseaseClass I-MSH:D004829
, NN O O
motor NN B-DiseaseClass B-MSH:D019957
retardation NN I-DiseaseClass I-MSH:D019957
and NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
being NN O O
the NN O O
most NN O O
abundant NN O O
manifestations. NN O O
a NN O O
clear NN O O
correlation NN O O
between NN O O
the NN O O
genotype NN O O
and NN O O
phenotype NN O O
has NN O O
not NN O O
been NN O O
established. NN O O
an NN O O
altered NN O O
beta-alanine, NN O O
uracil NN O O
and NN O O
thymine NN O O
homeostasis NN O O
might NN O O
underlie NN O O
the NN O O
various NN O O
clinical NN B-DiseaseClass B-MSH:D013568
abnormalities NN I-DiseaseClass I-MSH:D013568
encountered NN O O
in NN O O
patients NN O O
with NN O O
DPD NN B-SpecificDisease B-MSH:D054067
deficiency NN I-SpecificDisease I-MSH:D054067
. NN O O

molecular NN O O
characterization NN O O
of NN O O
glucose-6-phosphate NN B-SpecificDisease B-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
by NN O O
natural NN O O
and NN O O
amplification NN O O
created NN O O
restriction NN O O
sites: NN O O
five NN O O
mutations NN O O
account NN O O
for NN O O
most NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
cases NN O O
in NN O O
taiwan NN O O
. NN O O

we NN O O
have NN O O
developed NN O O
a NN O O
rapid NN O O
and NN O O
simple NN O O
method NN O O
to NN O O
diagnose NN O O
the NN O O
molecular NN O O
defects NN O O
of NN O O
glucose-6-phosphate NN B-SpecificDisease B-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
chinese NN O O
in NN O O
taiwan. NN O O
this NN O O
method NN O O
involves NN O O
the NN O O
selective NN O O
amplification NN O O
of NN O O
a NN O O
dna NN O O
fragment NN O O
from NN O O
human NN O O
g NN O O
6 NN O O
pd NN O O
gene NN O O
with NN O O
specific NN O O
oligonucleotide NN O O
primers NN O O
followed NN O O
by NN O O
digestion NN O O
with NN O O
restriction NN O O
enzymes NN O O
that NN O O
recognize NN O O
artificially NN O O
created NN O O
or NN O O
naturally NN O O
occurring NN O O
restriction NN O O
sites. NN O O
ninety-four NN O O
chinese NN O O
males NN O O
with NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
were NN O O
studied. NN O O
the NN O O
results NN O O
show NN O O
that NN O O
50% NN O O
(47 NN O O
of NN O O
94) NN O O
were NN O O
g NN O O
to NN O O
t NN O O
mutation NN O O
at NN O O
nucleotide NN O O
(nt) NN O O
1376, NN O O
21. NN O O
3% NN O O
(20 NN O O
of NN O O
94) NN O O
were NN O O
g NN O O
to NN O O
a NN O O
mutation NN O O
at NN O O
nt NN O O
1388, NN O O
7. NN O O
4% NN O O
(7 NN O O
of NN O O
94) NN O O
were NN O O
a NN O O
to NN O O
g NN O O
mutation NN O O
at NN O O
nt NN O O
493, NN O O
. NN O O

. NN O O
4% NN O O
(7 NN O O
of NN O O
94) NN O O
were NN O O
a NN O O
to NN O O
g NN O O
mutation NN O O
at NN O O
nt NN O O
95, NN O O
4. NN O O
2% NN O O
(4 NN O O
of NN O O
94) NN O O
were NN O O
c NN O O
to NN O O
t NN O O
mutation NN O O
at NN O O
nt NN O O
1024, NN O O
1. NN O O
1% NN O O
(1 NN O O
of NN O O
94) NN O O
was NN O O
g NN O O
to NN O O
t NN O O
mutation NN O O
at NN O O
nt NN O O
392, NN O O
and NN O O
1. NN O O
1% NN O O
(1 NN O O
of NN O O
94) NN O O
was NN O O
g NN O O
to NN O O
a NN O O
mutation NN O O
at NN O O
nt NN O O
487. NN O O
these NN O O
results NN O O
show NN O O
that NN O O
the NN O O
former NN O O
five NN O O
mutations NN O O
account NN O O
for NN O O
more NN O O
than NN O O
90% NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
cases NN O O
in NN O O
taiwan. NN O O
aside NN O O
from NN O O
showing NN O O
that NN O O
g NN O O
to NN O O
t NN O O
change NN O O
at NN O O
nt NN O O
1376 NN O O
is NN O O
the NN O O
most NN O O
common NN O O
mutation, NN O O
our NN O O
research NN O O
indicates NN O O
that NN O O
nt NN O O
493 NN O O
mutation NN O O
is NN O O
a NN O O
frequent NN O O
mutation NN O O
among NN O O
chinese NN O O
in NN O O
taiwan. NN O O
we NN O O
compared NN O O
g NN O O
6 NN O O
pd NN O O
activity NN O O
among NN O O
different NN O O
mutations, NN O O
without NN O O
discoverin NN O O
. NN O O

significant NN O O
differences NN O O
between NN O O
them NN O O
. NN O O

homozygous NN O O
hypobetalipoproteinemia: NN O O
a NN O O
disease NN O O
distinct NN O O
from NN O O
abetalipoproproteinemia NN B-SpecificDisease B-MSH:D000012
at NN O O
the NN O O
molecular NN O O
level NN O O
. NN O O

apob NN O O
dna, NN O O
rna, NN O O
and NN O O
protein NN O O
from NN O O
two NN O O
patients NN O O
with NN O O
homozygous NN B-SpecificDisease B-MSH:D006995
hypobetalipoproteinemia NN I-SpecificDisease I-MSH:D006995
( NN O O
HBL NN B-SpecificDisease B-MSH:D006995
) NN O O
were NN O O
evaluated NN O O
and NN O O
compared NN O O
with NN O O
normal NN O O
individuals. NN O O
southern NN O O
blot NN O O
analysis NN O O
with NN O O
10 NN O O
different NN O O
cdna NN O O
probes NN O O
revealed NN O O
a NN O O
normal NN O O
gene NN O O
without NN O O
major NN O O
insertions, NN O O
deletions, NN O O
or NN O O
rearrangements. NN O O
northern NN O O
and NN O O
slot NN O O
blot NN O O
analyses NN O O
of NN O O
total NN O O
liver NN O O
mrna NN O O
from NN O O
HBL NN B-Modifier B-MSH:D006995
patients NN O O
documented NN O O
a NN O O
normal NN O O
size NN O O
apob NN O O
mrna NN O O
that NN O O
was NN O O
present NN O O
in NN O O
greatly NN O O
reduced NN O O
quantities. NN O O
apob NN O O
protein NN O O
was NN O O
detected NN O O
within NN O O
HBL NN B-Modifier B-MSH:D006995
hepatocytes NN O O
utilizing NN O O
immunohistochemical NN O O
techniques; NN O O
however, NN O O
it NN O O
was NN O O
markedly NN O O
reduced NN O O
in NN O O
quantity NN O O
when NN O O
compared NN O O
with NN O O
control NN O O
samples. NN O O
no NN O O
apob NN O O
was NN O O
detectable NN O O
in NN O O
the NN O O
plasma NN O O
of NN O O
HBL NN B-Modifier B-MSH:D006995
individuals NN O O
with NN O O
an NN O O
elisa NN O O
assay. NN O O
these NN O O
data NN O O
are NN O O
most NN O O
consistent NN O O
with NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
portion NN O O
of NN O O
the NN O O
apob NN O O
gene NN O O
in NN O O
HBL NN B-Modifier B-MSH:D006995
patients, NN O O
leading NN O O
to NN O O
an NN O O
abnormal NN O O
apob NN O O
protein NN O O
and NN O O
apob NN O O
mrn NN O O
. NN O O

instability. NN O O
these NN O O
results NN O O
are NN O O
distinct NN O O
from NN O O
those NN O O
previously NN O O
noted NN O O
in NN O O
abetalipoproteinemia NN B-SpecificDisease B-MSH:D000012
, NN O O
which NN O O
was NN O O
characterized NN O O
by NN O O
an NN O O
elevated NN O O
level NN O O
of NN O O
hepatic NN O O
apob NN O O
mrna NN O O
and NN O O
accumulation NN O O
of NN O O
intracellular NN O O
hepatic NN O O
apob NN O O
protein. NN O O
. NN O O

a NN O O
population-based NN O O
study NN O O
of NN O O
the NN O O
clinical NN O O
expression NN O O
of NN O O
the NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
gene NN O O
. NN O O

background NN O O
and NN O O
methods NN O O
Hereditary NN B-SpecificDisease B-MSH:D006432
hemochromatosis NN I-SpecificDisease I-MSH:D006432
is NN O O
associated NN O O
with NN O O
homozygosity NN O O
for NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
in NN O O
the NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
(hfe) NN O O
gene NN O O
on NN O O
chromosome NN O O
6, NN O O
elevated NN O O
serum NN O O
transferrin NN O O
saturation, NN O O
and NN O O
excess NN B-DiseaseClass B-MSH:D019190
iron NN I-DiseaseClass I-MSH:D019190
deposits NN I-DiseaseClass I-MSH:D019190
throughout NN O O
the NN O O
body. NN O O
to NN O O
assess NN O O
the NN O O
prevalence NN O O
and NN O O
clinical NN O O
expression NN O O
of NN O O
the NN O O
hfe NN O O
gene, NN O O
we NN O O
conducted NN O O
a NN O O
population-based NN O O
study NN O O
in NN O O
busselton, NN O O
australia. NN O O
in NN O O
1994, NN O O
we NN O O
obtained NN O O
blood NN O O
samples NN O O
for NN O O
the NN O O
determination NN O O
of NN O O
serum NN O O
transferrin NN O O
saturation NN O O
and NN O O
ferritin NN O O
levels NN O O
and NN O O
the NN O O
presence NN O O
or NN O O
absence NN O O
of NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
and NN O O
the NN O O
h NN O O
63 NN O O
d NN O O
mutation NN O O
(which NN O O
may NN O O
contribute NN O O
to NN O O
increased NN O O
hepatic NN O O
iron NN O O
levels) NN O O
in NN O O
3011 NN O O
unrelated NN O O
white NN O O
adults. NN O O
we NN O O
evaluated NN O O
all NN O O
subjects NN O O
who NN O O
had NN O O
persistently NN O O
elevated NN O O
transferrin-saturation NN O O
values NN O O
(45 NN O O
percent NN O O
or NN O O
higher) NN O O
or NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutatio NN O O
. NN O O

. NN O O
we NN O O
recommended NN O O
liver NN O O
biopsy NN O O
for NN O O
subjects NN O O
with NN O O
serum NN O O
ferritin NN O O
levels NN O O
of NN O O
300 NN O O
ng NN O O
per NN O O
milliliter NN O O
or NN O O
higher. NN O O
the NN O O
subjects NN O O
were NN O O
followed NN O O
for NN O O
up NN O O
to NN O O
four NN O O
years. NN O O
results NN O O
sixteen NN O O
of NN O O
the NN O O
subjects NN O O
(0. NN O O
5 NN O O
percent) NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation, NN O O
and NN O O
424 NN O O
(14. NN O O
1 NN O O
percent) NN O O
were NN O O
heterozygous. NN O O
the NN O O
serum NN O O
transferrin NN O O
saturation NN O O
was NN O O
45 NN O O
percent NN O O
or NN O O
higher NN O O
in NN O O
15 NN O O
of NN O O
the NN O O
16 NN O O
who NN O O
were NN O O
homozygous; NN O O
in NN O O
1 NN O O
subject NN O O
it NN O O
was NN O O
43 NN O O
percent. NN O O
four NN O O
of NN O O
the NN O O
homozygous NN O O
subjects NN O O
had NN O O
previously NN O O
been NN O O
given NN O O
a NN O O
diagnosis NN O O
of NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
, NN O O
and NN O O
12 NN O O
had NN O O
not. NN O O
seven NN O O
of NN O O
these NN O O
12 NN O O
patients NN O O
had NN O O
elevated NN O O
serum NN O O
ferritin NN O O
levels NN O O
in NN O O
1994; NN O O
6 NN O O
of NN O O
the NN O O
7 NN O O
had NN O O
further NN O O
increases NN O O
in NN O O
1998, NN O O
and NN O O
1 NN O O
had NN O O
a NN O O
decrease, NN O O
although NN O O
the NN O O
value NN O O
remained NN O O
elevated NN O O
. NN O O

the NN O O
serum NN O O
ferritin NN O O
levels NN O O
in NN O O
the NN O O
four NN O O
other NN O O
homozygous NN O O
patients NN O O
remained NN O O
in NN O O
the NN O O
normal NN O O
range. NN O O
eleven NN O O
of NN O O
the NN O O
16 NN O O
homozygous NN O O
subjects NN O O
underwent NN O O
liver NN O O
biopsy; NN O O
3 NN O O
had NN O O
hepatic NN B-DiseaseClass B-MSH:D008103
fibrosis NN I-DiseaseClass I-MSH:D008103
, NN O O
and NN O O
1, NN O O
who NN O O
had NN O O
a NN O O
history NN O O
of NN O O
excessive NN B-SpecificDisease B-MSH:D000435
alcohol NN I-SpecificDisease I-MSH:D000435
consumption NN I-SpecificDisease I-MSH:D000435
, NN O O
had NN O O
cirrhosis NN B-DiseaseClass B-MSH:D008103
and NN O O
mild NN O O
microvesicular NN B-SpecificDisease B-MSH:D005234
steatosis NN I-SpecificDisease I-MSH:D005234
. NN O O
eight NN O O
of NN O O
the NN O O
16 NN O O
homozygous NN O O
subjects NN O O
had NN O O
clinical NN O O
findings NN O O
that NN O O
were NN O O
consistent NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
hereditary NN B-SpecificDisease B-MSH:D006432
hemochromatosis NN I-SpecificDisease I-MSH:D006432
, NN O O
such NN O O
as NN O O
hepatomegaly NN B-DiseaseClass B-MSH:D006529
, NN O O
skin NN B-DiseaseClass B-MSH:D010859
pigmentation NN I-DiseaseClass I-MSH:D010859
, NN O O
and NN O O
arthritis NN B-DiseaseClass B-MSH:D001168
. NN O O
conclusions NN O O
in NN O O
a NN O O
population NN O O
of NN O O
white NN O O
adults NN O O
of NN O O
northern NN O O
european NN O O
ancestry, NN O O
0. NN O O
5 NN O O
percent NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
in NN O O
the NN O O
hfe NN O O
gene. NN O O
however, NN O O
only NN O O
half NN O O
of NN O O
those NN O O
who NN O O
were NN O O
homozygous NN O O
had NN O O
clinical NN O O
features NN O O
of NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
, NN O O
and NN O O
one NN O O
quarter NN O O
had NN O O
serum NN O O
ferritin NN O O
levels NN O O
that NN O O
remained NN O O
normal NN O O
over NN O O
a NN O O
four-year NN O O
period NN O O
. NN O O

overexpression NN O O
of NN O O
dm NN O O
20 NN O O
messenger NN O O
rna NN O O
in NN O O
two NN O O
brothers NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
. NN O O

pelizaeus-merzbacher NN O O
disease NN O O
is NN O O
a NN O O
rare, NN B-DiseaseClass B-MSH:D020279
sex-linked NN I-DiseaseClass I-MSH:D020279
recessive, NN I-DiseaseClass I-MSH:D020279
dysmyelinating NN I-DiseaseClass I-MSH:D020279
disease NN I-DiseaseClass I-MSH:D020279
of NN I-DiseaseClass I-MSH:D020279
the NN I-DiseaseClass I-MSH:D020279
central NN I-DiseaseClass I-MSH:D020279
nervous NN I-DiseaseClass I-MSH:D020279
system NN I-DiseaseClass I-MSH:D020279
that NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
mutations NN O O
in NN O O
the NN O O
myelin NN O O
proteolipid NN O O
protein NN O O
(plp) NN O O
gene. NN O O
only NN O O
25% NN O O
of NN O O
patients NN O O
studied NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
have NN O O
exonic NN O O
mutations NN O O
in NN O O
this NN O O
gene, NN O O
the NN O O
underlying NN O O
cause NN O O
of NN O O
the NN O O
disease NN O O
in NN O O
the NN O O
remaining NN O O
patients NN O O
is NN O O
unknown. NN O O
the NN O O
plp NN O O
gene NN O O
encodes NN O O
two NN O O
major NN O O
alternatively NN O O
spliced NN O O
transcripts NN O O
called NN O O
plp NN O O
and NN O O
dm NN O O
20. NN O O
plp NN O O
messenger NN O O
rna NN O O
is NN O O
specifically NN O O
expressed NN O O
in NN O O
central NN O O
nervous NN O O
system NN O O
tissue, NN O O
whereas NN O O
dm NN O O
20 NN O O
messenger NN O O
rna NN O O
is NN O O
found NN O O
in NN O O
central NN O O
nervous NN O O
system, NN O O
cardiac, NN O O
and NN O O
other NN O O
tissues. NN O O
we NN O O
studied NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
2 NN O O
brothers NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
who NN O O
exhibited NN O O
no NN O O
detectable NN O O
exonic NN O O
mutation NN O O
of NN O O
the NN O O
plp NN O O
gene. NN O O
examination NN O O
of NN O O
rna NN O O
fro NN O O
. NN O O

these NN O O
cells NN O O
showed NN O O
that NN O O
the NN O O
level NN O O
of NN O O
dm NN O O
20 NN O O
messenger NN O O
rna NN O O
is NN O O
elevated NN O O
sixfold NN O O
relative NN O O
to NN O O
male NN O O
control NN O O
skin NN O O
fibroblasts. NN O O
an NN O O
unrelated NN O O
female NN O O
carrier, NN O O
also NN O O
with NN O O
no NN O O
detectable NN O O
exonic NN O O
mutation, NN O O
showed NN O O
a NN O O
threefold NN O O
increase NN O O
in NN O O
dm NN O O
20 NN O O
messenger NN O O
rna NN O O
in NN O O
cultured NN O O
skin NN O O
fibroblasts. NN O O
our NN O O
findings NN O O
suggest NN O O
that NN O O
in NN O O
some NN O O
patients, NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
is NN O O
caused NN O O
by NN O O
overexpression NN O O
of NN O O
plp NN O O
gene NN O O
transcripts, NN O O
and NN O O
that NN O O
in NN O O
these NN O O
families NN O O
a NN O O
50% NN O O
increase NN O O
of NN O O
dm NN O O
20 NN O O
messenger NN O O
rna NN O O
in NN O O
females, NN O O
relative NN O O
to NN O O
the NN O O
increase NN O O
in NN O O
affected NN O O
males, NN O O
can NN O O
identify NN O O
a NN O O
female NN O O
carrier. NN O O
. NN O O

homozygosity NN O O
for NN O O
a NN O O
novel NN O O
dtdst NN O O
mutation NN O O
in NN O O
a NN O O
child NN O O
with NN O O
a NN O O
'broad NN O O
bone-platyspondylic' NN O O
variant NN O O
of NN O O
diastrophic NN B-SpecificDisease B-MSH:C536170
dysplasia NN I-SpecificDisease I-MSH:C536170
. NN O O

atypical NN O O
or NN O O
variant NN O O
forms NN O O
of NN O O
well-known NN O O
chondrodysplasias NN B-DiseaseClass B-MSH:D010009
may NN O O
pose NN O O
diagnostic NN O O
problems. NN O O
we NN O O
report NN O O
on NN O O
a NN O O
girl NN O O
with NN O O
clinical NN O O
features NN O O
suggesting NN O O
diastrophic NN B-SpecificDisease B-MSH:C536170
dysplasia NN I-SpecificDisease I-MSH:C536170
but NN O O
with NN O O
unusual NN O O
radiographic NN O O
features NN O O
including NN O O
severe NN O O
platyspondyly NN B-DiseaseClass B-MSH:D013122
, NN O O
wide NN O O
metaphyses, NN O O
and NN O O
fibular NN O O
overgrowth, NN O O
which NN O O
are NN O O
partially NN O O
reminiscent NN O O
of NN O O
metatropic NN B-SpecificDisease B-MSH:C537356
dysplasia NN I-SpecificDisease I-MSH:C537356
. NN O O
the NN O O
diagnosis NN O O
was NN O O
clarified NN O O
by NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
dtdst NN O O
gene, NN O O
which NN O O
revealed NN O O
homozygosity NN O O
for NN O O
a NN O O
previously NN O O
undescribed NN O O
mutation NN O O
leading NN O O
to NN O O
a NN O O
q NN O O
454 NN O O
p NN O O
substitution NN O O
in NN O O
the NN O O
10 NN O O
th NN O O
transmembrane NN O O
domain NN O O
of NN O O
the NN O O
dtdst NN O O
sulfate NN O O
transporter. NN O O
molecular NN O O
analysis NN O O
may NN O O
be NN O O
of NN O O
particular NN O O
value NN O O
in NN O O
such NN O O
atypical NN O O
cases. NN O O
. NN O O

carrier NN O O
detection NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
of NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
using NN O O
a NN O O
combination NN O O
of NN O O
anonymous NN O O
dna NN O O
polymorphisms NN O O
and NN O O
the NN O O
proteolipid NN O O
protein NN O O
(plp) NN O O
gene NN O O
cdna NN O O
. NN O O

we NN O O
report NN O O
carrier NN O O
identification NN O O
and NN O O
a NN O O
prenatal NN O O
diagnosis NN O O
using NN O O
dna NN O O
polymorphisms NN O O
in NN O O
2 NN O O
families NN O O
with NN O O
X-linked NN B-SpecificDisease B-OMIM:312080
Pelizaeus-Merzbacher NN I-SpecificDisease I-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
( NN O O
PMD NN B-SpecificDisease B-OMIM:312080
). NN O O
in NN O O
both NN O O
families, NN O O
the NN O O
proteolipid NN O O
protein NN O O
(plp) NN O O
gene NN O O
in NN O O
the NN O O
single NN O O
affected NN O O
male NN O O
could NN O O
be NN O O
traced NN O O
back NN O O
to NN O O
his NN O O
unaffected NN O O
maternal NN O O
grandfather. NN O O
therefore, NN O O
each NN O O
family NN O O
contains NN O O
a NN O O
new NN O O
mutation. NN O O
in NN O O
the NN O O
case NN O O
of NN O O
the NN O O
prenatal NN O O
diagnosis, NN O O
the NN O O
fetus NN O O
was NN O O
shown NN O O
by NN O O
cytogenetic NN O O
analysis NN O O
to NN O O
be NN O O
a NN O O
female, NN O O
who NN O O
we NN O O
predict NN O O
will NN O O
be NN O O
a NN O O
noncarrier NN O O
of NN O O
PMD NN B-SpecificDisease B-OMIM:312080
based NN O O
on NN O O
her NN O O
genotype NN O O
with NN O O
the NN O O
plp NN O O
intragenic NN O O
polymorphism. NN O O
. NN O O

gardner NN O O
syndrome NN O O
in NN O O
a NN O O
boy NN O O
with NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5 NN O O
. NN O O

we NN O O
described NN O O
a NN O O
15-year-old NN O O
boy NN O O
with NN O O
Gardner NN B-SpecificDisease B-MSH:D005736
syndrome NN I-SpecificDisease I-MSH:D005736
( NN O O
GS NN B-SpecificDisease B-MSH:D005736
), NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
and NN O O
craniofacial NN B-DiseaseClass B-MSH:D019465
abnormalities NN I-DiseaseClass I-MSH:D019465
. NN O O
high-resolution NN O O
banding NN O O
analysis NN O O
showed NN O O
an NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5 NN O O
(q NN O O
22. NN O O
1----q NN O O
31 NN O O
1----q NN O O
31. NN O O
1). NN O O
the NN O O
breakpoints NN O O
in NN O O
the NN O O
present NN O O
case NN O O
and NN O O
in NN O O
3 NN O O
previously NN O O
reported NN O O
5 NN O O
q- NN O O
patients NN O O
with NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
suggest NN O O
that NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
GS NN B-SpecificDisease B-MSH:D005736
/or NN O O
familial NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
( NN O O
FPC NN B-SpecificDisease B-MSH:D011125
) NN O O
is NN O O
in NN O O
the NN O O
5 NN O O
q NN O O
22 NN O O
region, NN O O
a NN O O
result NN O O
consistent NN O O
with NN O O
the NN O O
findings NN O O
of NN O O
linkage NN O O
studie NN O O
. NN O O

type NN O O
i NN O O
human NN O O
complement NN O O
c NN O O
2 NN O O
deficiency. NN O O
a NN O O
28-base NN O O
pair NN O O
gene NN O O
deletion NN O O
causes NN O O
skipping NN O O
of NN O O
exon NN O O
6 NN O O
during NN O O
rna NN O O
splicing NN O O
. NN O O

two NN O O
variants NN O O
of NN O O
a NN O O
genetic NN O O
deficiency NN B-SpecificDisease B-OMIM:217000
of NN I-SpecificDisease I-OMIM:217000
complement NN I-SpecificDisease I-OMIM:217000
protein NN I-SpecificDisease I-OMIM:217000
C2 NN I-SpecificDisease I-OMIM:217000
(c NN O O
2 NN O O
d) NN O O
have NN O O
been NN O O
previously NN O O
identified. NN O O
no NN O O
c NN O O
2 NN O O
protein NN O O
translation NN O O
is NN O O
detected NN O O
in NN O O
type NN O O
i NN O O
deficiency, NN O O
while NN O O
type NN O O
ii NN O O
deficiency NN O O
is NN O O
characterized NN O O
by NN O O
a NN O O
selective NN O O
block NN O O
in NN O O
c NN O O
2 NN O O
secretion. NN O O
Type NN B-SpecificDisease B-OMIM:217000
I NN I-SpecificDisease I-OMIM:217000
C2 NN I-SpecificDisease I-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
was NN O O
described NN O O
in NN O O
a NN O O
family NN O O
in NN O O
which NN O O
the NN O O
c NN O O
2 NN O O
null NN O O
allele NN O O
(c NN O O
2 NN O O
q NN O O
0) NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
major NN O O
histocompatibility NN O O
haplotype/complotype NN O O
hla-a NN O O
25, NN O O
b NN O O
18, NN O O
c NN O O
2 NN O O
q NN O O
0, NN O O
bfs, NN O O
c NN O O
4 NN O O
a NN O O
4, NN O O
c NN O O
4 NN O O
b NN O O
2, NN O O
drw NN O O
2; NN O O
this NN O O
extended NN O O
haplotype NN O O
occurs NN O O
in NN O O
over NN O O
90% NN O O
of NN O O
C2-deficient NN B-Modifier B-OMIM:217000
individuals NN O O
(common NN O O
complotype/haplotype). NN O O
to NN O O
determine NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
type NN B-SpecificDisease B-OMIM:217000
I NN I-SpecificDisease I-OMIM:217000
C2 NN I-SpecificDisease I-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
. NN O O

, NN O O
the NN O O
c NN O O
2 NN O O
gene NN O O
and NN O O
cdna NN O O
were NN O O
characterized NN O O
from NN O O
a NN O O
homozygous NN O O
type NN B-Modifier B-OMIM:217000
I NN I-Modifier I-OMIM:217000
C2-deficient NN I-Modifier I-OMIM:217000
individual NN O O
with NN O O
the NN O O
common NN O O
associated NN O O
haplotype/complotype. NN O O
we NN O O
found NN O O
a NN O O
28-base NN O O
pair NN O O
deletion NN O O
in NN O O
the NN O O
type NN O O
i NN O O
c NN O O
2 NN O O
q NN O O
0 NN O O
gene, NN O O
beginning NN O O
9 NN O O
base NN O O
pairs NN O O
upstream NN O O
of NN O O
the NN O O
3-end NN O O
of NN O O
exon NN O O
6, NN O O
that NN O O
generates NN O O
a NN O O
c NN O O
2 NN O O
transcript NN O O
with NN O O
a NN O O
complete NN O O
deletion NN O O
of NN O O
exon NN O O
6 NN O O
(134 NN O O
base NN O O
pair) NN O O
and NN O O
a NN O O
premature NN O O
termination NN O O
codon. NN O O
in NN O O
studies NN O O
of NN O O
eight NN O O
kindred, NN O O
the NN O O
28-base NN O O
pair NN O O
deletion NN O O
was NN O O
observed NN O O
in NN O O
all NN O O
c NN O O
2 NN O O
q NN O O
0 NN O O
alleles NN O O
associated NN O O
with NN O O
the NN O O
common NN O O
type NN O O
i NN O O
deficient NN O O
complotype/haplotype; NN O O
this NN O O
deletion NN O O
was NN O O
not NN O O
present NN O O
in NN O O
normal NN O O
c NN O O
2 NN O O
nor NN O O
in NN O O
type NN B-Modifier B-OMIM:217000
II NN I-Modifier I-OMIM:217000
C2-deficient NN I-Modifier I-OMIM:217000
genes. NN O O
these NN O O
data NN O O
demonstrate NN O O
that NN O O
1 NN O O
. NN O O

type NN O O
i NN O O
human NN O O
complement NN O O
c NN O O
2 NN O O
deficiency NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
28-base NN O O
pair NN O O
genomic NN O O
deletion NN O O
that NN O O
causes NN O O
skipping NN O O
of NN O O
exon NN O O
6 NN O O
during NN O O
rna NN O O
splicing, NN O O
resulting NN O O
in NN O O
generation NN O O
of NN O O
a NN O O
premature NN O O
termination NN O O
codo NN O O
. NN O O

, NN O O
2) NN O O
the NN O O
28-base NN O O
pair NN O O
deletion NN O O
in NN O O
the NN O O
type NN O O
i NN O O
c NN O O
2 NN O O
q NN O O
0 NN O O
gene NN O O
is NN O O
strongly NN O O
associated NN O O
with NN O O
the NN O O
hla NN O O
haplotype/complotype NN O O
a NN O O
25, NN O O
b NN O O
18, NN O O
c NN O O
2 NN O O
q NN O O
0, NN O O
bfs, NN O O
c NN O O
4 NN O O
a NN O O
4, NN O O
c NN O O
4 NN O O
b NN O O
2, NN O O
drw NN O O
2, NN O O
suggesting NN O O
that NN O O
all NN O O
C2-deficient NN B-Modifier B-OMIM:217000
individuals NN O O
with NN O O
this NN O O
haplotype/complotype NN O O
will NN O O
harbor NN O O
the NN O O
28-base NN O O
pair NN O O
c NN O O
2 NN O O
gene NN O O
deletion, NN O O
and NN O O
3) NN O O
type NN B-SpecificDisease B-OMIM:217000
II NN I-SpecificDisease I-OMIM:217000
C2 NN I-SpecificDisease I-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
is NN O O
caused NN O O
by NN O O
a NN O O
different, NN O O
as NN O O
yet NN O O
uncharacterized, NN O O
molecular NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
. NN O O
. NN O O

(over)correction NN O O
of NN O O
FMR1 NN B-SpecificDisease B-OMIM:300624
deficiency NN I-SpecificDisease I-OMIM:300624
with NN O O
yac NN O O
transgenics: NN O O
behavioral NN O O
and NN O O
physical NN O O
features NN O O
. NN O O

fragile NN O O
x NN O O
syndrome NN O O
is NN O O
a NN O O
common NN O O
cause NN O O
of NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
involving NN O O
loss NN O O
of NN O O
expression NN O O
of NN O O
the NN O O
fmr NN O O
1 NN O O
gene. NN O O
the NN O O
role NN O O
of NN O O
fmr NN O O
1 NN O O
remains NN O O
undetermined NN O O
but NN O O
the NN O O
protein NN O O
appears NN O O
to NN O O
be NN O O
involved NN O O
in NN O O
rna NN O O
metabolism. NN O O
fmr NN O O
1 NN O O
knockout NN O O
mice NN O O
exhibit NN O O
a NN O O
phenotype NN O O
with NN O O
some NN O O
similarities NN O O
to NN O O
humans, NN O O
such NN O O
as NN O O
macroorchidism NN B-SpecificDisease B-MSH:D005600
and NN O O
behavioral NN O O
abnormalities. NN O O
as NN O O
a NN O O
step NN O O
toward NN O O
understanding NN O O
the NN O O
function NN O O
of NN O O
fmr NN O O
1 NN O O
and NN O O
the NN O O
determination NN O O
of NN O O
the NN O O
potential NN O O
for NN O O
therapeutic NN O O
approaches NN O O
to NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
, NN O O
yeast NN O O
artificial NN O O
chromosome NN O O
(yac) NN O O
transgenic NN O O
mice NN O O
were NN O O
generated NN O O
in NN O O
order NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
fmr NN O O
1 NN O O
knockout NN O O
mouse NN O O
phenotype NN O O
could NN O O
be NN O O
rescued. NN O O
several NN O O
transgenic NN O O
lines NN O O
were NN O O
generated NN O O
that NN O O
carried NN O O
the NN O O
entire NN O O
fmr NN O O
1 NN O O
locus NN O O
with NN O O
extensive NN O O
amounts NN O O
of NN O O
flanking NN O O
sequence. NN O O
we NN O O
observed NN O O
that NN O O
the NN O O
yac NN O O
transgene NN O O
supported NN O O
production NN O O
of NN O O
the NN O O
human NN O O
protein NN O O
(fmr NN O O
. NN O O

) NN O O
which NN O O
was NN O O
present NN O O
at NN O O
levels NN O O
10 NN O O
to NN O O
15 NN O O
times NN O O
that NN O O
of NN O O
endogenous NN O O
protein NN O O
and NN O O
was NN O O
expressed NN O O
in NN O O
a NN O O
cell- NN O O
and NN O O
tissue-specific NN O O
manner. NN O O
macro-orchidism NN O O
was NN O O
absent NN O O
in NN O O
knockout NN O O
mice NN O O
carrying NN O O
the NN O O
yac NN O O
transgene NN O O
indicating NN O O
functional NN O O
rescue NN O O
by NN O O
the NN O O
human NN O O
protein. NN O O
given NN O O
the NN O O
complex NN O O
behavioral NN O O
phenotype NN O O
in NN O O
fragile NN B-Modifier B-MSH:D005600
X NN I-Modifier I-MSH:D005600
patients NN O O
and NN O O
the NN O O
mild NN O O
phenotype NN O O
previously NN O O
reported NN O O
for NN O O
the NN O O
fmr NN O O
1 NN O O
knockout NN O O
mouse, NN O O
we NN O O
performed NN O O
a NN O O
more NN O O
thorough NN O O
evaluation NN O O
of NN O O
the NN O O
fmr NN O O
1 NN O O
knockout NN O O
phenotype NN O O
using NN O O
additional NN O O
behavioral NN O O
assays NN O O
that NN O O
had NN O O
not NN O O
previously NN O O
been NN O O
reported NN O O
for NN O O
this NN O O
animal NN O O
model. NN O O
the NN O O
mouse NN O O
displayed NN O O
reduced NN O O
anxiety NN B-Modifier B-MSH:D001008
-related NN O O
responses NN O O
with NN O O
increased NN O O
exploratory NN O O
behavior. NN O O
fmr NN O O
1 NN O O
yac NN O O
transgenic NN O O
mice NN O O
overexpressing NN O O
the NN O O
human NN O O
protein NN O O
did NN O O
produce NN O O
opposing NN O O
behavioral NN O O
responses NN O O
and NN O O
additional NN O O
abnormal NN O O
behaviors NN O O
were NN O O
also NN O O
observed. NN O O
these NN O O
findings NN O O
have NN O O
significant NN O O
implications NN O O
for NN O O
gene NN O O
therapy NN O O
fo NN O O
. NN O O

fragile NN O O
x NN O O
syndrome NN O O
since NN O O
overexpression NN O O
of NN O O
the NN O O
gene NN O O
may NN O O
harbor NN O O
its NN O O
own NN O O
phenotype. NN O O
. NN O O

fabry NN O O
disease: NN O O
identification NN O O
of NN O O
novel NN O O
alpha-galactosidase NN O O
a NN O O
mutations NN O O
and NN O O
molecular NN O O
carrier NN O O
detection NN O O
by NN O O
use NN O O
of NN O O
fluorescent NN O O
chemical NN O O
cleavage NN O O
of NN O O
mismatches NN O O
. NN O O

fabry NN O O
disease NN O O
( NN O O
FD NN B-SpecificDisease B-MSH:D000795
) NN O O
( NN O O
angiokeratoma NN B-SpecificDisease B-MSH:D000795
corporis NN I-SpecificDisease I-MSH:D000795
diffusum NN I-SpecificDisease I-MSH:D000795
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D008052
inborn NN I-DiseaseClass I-MSH:D008052
error NN I-DiseaseClass I-MSH:D008052
of NN I-DiseaseClass I-MSH:D008052
glycosphingolipid NN I-DiseaseClass I-MSH:D008052
metabolism NN I-DiseaseClass I-MSH:D008052
caused NN O O
by NN O O
defects NN O O
in NN O O
the NN O O
lysosomal NN O O
alpha-galactosidase NN O O
a NN O O
gene NN O O
(gla). NN O O
the NN O O
enzymatic NN O O
defect NN O O
leads NN O O
to NN O O
the NN O O
systemic NN O O
accumulation NN O O
of NN O O
neutral NN O O
glycosphingolipids NN O O
with NN O O
terminal NN O O
alpha-galactosyl NN O O
moieties. NN O O
clinically, NN O O
affected NN O O
hemizygous NN O O
males NN O O
have NN O O
angiokeratoma NN B-SpecificDisease B-MSH:D000794
, NN O O
severe NN B-SpecificDisease B-MSH:D010292
acroparesthesia NN I-SpecificDisease I-MSH:D010292
, NN O O
renal NN B-SpecificDisease B-MSH:D051437
failure NN I-SpecificDisease I-MSH:D051437
, NN O O
and NN O O
vasculopathy NN B-CompositeMention B-MSH:D014652
of NN I-CompositeMention I-MSH:D014652
the NN I-CompositeMention I-MSH:D014652
heart NN I-CompositeMention I-MSH:D014652
and NN I-CompositeMention I-MSH:D014652
brain NN I-CompositeMention I-MSH:D014652
. NN O O
while NN O O
demonstration NN O O
of NN O O
alpha-galactosidase NN B-SpecificDisease B-MSH:D000795
deficiency NN I-SpecificDisease I-MSH:D000795
in NN O O
leukocytes NN O O
is NN O O
diagnostic NN O O
in NN O O
affected NN O O
males, NN O O
enzymatic NN O O
detection NN O O
of NN O O
female NN O O
carriers NN O O
is NN O O
often NN O O
inconclusive, NN O O
due NN O O
to NN O O
random NN O O
x-chromosomal NN O O
inactivation, NN O O
underlining NN O O
the NN O O
need NN O O
of NN O O
molecular NN O O
investigations NN O O
for NN O O
accurate NN O O
genetic NN O O
counseling. NN O O
by NN O O
use NN O O
of NN O O
chemical NN O O
cleavage NN O O
of NN O O
mismatches NN O O
adapted NN O O
to NN O O
fluorescence-based NN O O
detection NN O O
systems, NN O O
we NN O O
have NN O O
characterized NN O O
the NN O O
mutations NN O O
underlying NN O O
alpha-Gal NN B-SpecificDisease B-MSH:D000795
A NN I-SpecificDisease I-MSH:D000795
deficiency NN I-SpecificDisease I-MSH:D000795

-gal NN O O
a NN O O
deficiency NN O O
in NN O O
16 NN O O
individuals NN O O
from NN O O
six NN O O
unrelated NN O O
families NN O O
with NN O O
FD NN B-SpecificDisease B-MSH:D000795
. NN O O
the NN O O
mutational NN O O
spectrum NN O O
included NN O O
five NN O O
missense NN O O
mutations NN O O
(c NN O O
202 NN O O
w, NN O O
c NN O O
223 NN O O
g, NN O O
n NN O O
224 NN O O
d, NN O O
r NN O O
301 NN O O
q, NN O O
and NN O O
q NN O O
327 NN O O
k) NN O O
and NN O O
one NN O O
splice-site NN O O
mutation NN O O
[ivs NN O O
3 NN O O
g NN O O
(-1) NN O O
-- NN O O
> NN O O
c]. NN O O
studies NN O O
at NN O O
the NN O O
mrna NN O O
level NN O O
showed NN O O
that NN O O
the NN O O
latter NN O O
led NN O O
to NN O O
altered NN O O
pre-mrna NN O O
splicing NN O O
with NN O O
consequent NN O O
alteration NN O O
of NN O O
the NN O O
mrna NN O O
translational NN O O
reading NN O O
frame NN O O
and NN O O
generation NN O O
of NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
of NN O O
translation. NN O O
by NN O O
use NN O O
of NN O O
this NN O O
strategy, NN O O
carrier NN O O
status NN O O
was NN O O
accurately NN O O
assessed NN O O
in NN O O
all NN O O
seven NN O O
at-risk NN O O
females NN O O
tested, NN O O
whereas NN O O
enzymatic NN O O
dosages NN O O
failed NN O O
to NN O O
diagnose NN O O
or NN O O
exclude NN O O
heterozygosity. NN O O
. NN O O

evidence NN O O
for NN O O
linkage NN O O
of NN O O
bipolar NN B-SpecificDisease B-MSH:D001714
disorder NN I-SpecificDisease I-MSH:D001714
to NN O O
chromosome NN O O
18 NN O O
with NN O O
a NN O O
parent-of-origin NN O O
effect NN O O
. NN O O

a NN O O
susceptibility NN O O
gene NN O O
on NN O O
chromosome NN O O
18 NN O O
and NN O O
a NN O O
parent-of-origin NN O O
effect NN O O
have NN O O
been NN O O
suggested NN O O
for NN O O
bipolar NN B-SpecificDisease B-MSH:D001714
affective NN I-SpecificDisease I-MSH:D001714
disorder NN I-SpecificDisease I-MSH:D001714
( NN O O
BPAD NN B-SpecificDisease B-MSH:D001714
). NN O O
we NN O O
have NN O O
studied NN O O
28 NN O O
nuclear NN O O
families NN O O
selected NN O O
for NN O O
apparent NN O O
unilineal NN O O
transmission NN O O
of NN O O
the NN O O
BPAD NN B-Modifier B-MSH:D001714
phenotype, NN O O
by NN O O
using NN O O
31 NN O O
polymorphic NN O O
markers NN O O
spanning NN O O
chromosome NN O O
18. NN O O
evidence NN O O
for NN O O
linkage NN O O
was NN O O
tested NN O O
with NN O O
affected-sib-pair NN O O
and NN O O
lod NN O O
score NN O O
methods NN O O
under NN O O
two NN O O
definitions NN O O
of NN O O
the NN O O
affected NN O O
phenotype. NN O O
the NN O O
affected-sibpair NN O O
analyses NN O O
indicated NN O O
excess NN O O
allele NN O O
sharing NN O O
for NN O O
markers NN O O
on NN O O
18 NN O O
p NN O O
within NN O O
the NN O O
region NN O O
reported NN O O
previously. NN O O
the NN O O
greatest NN O O
sharing NN O O
was NN O O
at NN O O
d NN O O
18 NN O O
s NN O O
37 NN O O
64% NN O O
in NN O O
bipolar NN O O
and NN O O
recurrent NN O O
unipolar NN O O
(rup) NN O O
sib NN O O
pairs NN O O
(p NN O O
=. NN O O
0006). NN O O
in NN O O
addition, NN O O
excess NN O O
sharing NN O O
of NN O O
the NN O O
paternally, NN O O
but NN O O
not NN O O
maternally, NN O O
transmitted NN O O
alleles NN O O
was NN O O
observed NN O O
at NN O O
thre NN O O
. NN O O

markers NN O O
on NN O O
18 NN O O
q NN O O
at NN O O
d NN O O
18 NN O O
s NN O O
41, NN O O
51 NN O O
bipolar NN O O
and NN O O
rup NN O O
sib NN O O
pairs NN O O
were NN O O
concordant NN O O
for NN O O
paternally NN O O
transmitted NN O O
alleles, NN O O
and NN O O
21 NN O O
pairs NN O O
were NN O O
discordant NN O O
(p NN O O
= NN O O
0004). NN O O
the NN O O
evidence NN O O
for NN O O
linkage NN O O
to NN O O
loci NN O O
on NN O O
both NN O O
18 NN O O
p NN O O
and NN O O
18 NN O O
q NN O O
was NN O O
strongest NN O O
in NN O O
the NN O O
11 NN O O
paternal NN O O
pedigrees, NN O O
i. NN O O
e NN O O
e., NN O O
those NN O O
in NN O O
which NN O O
the NN O O
father NN O O
or NN O O
one NN O O
of NN O O
the NN O O
fathers NN O O
sibs NN O O
is NN O O
affected. NN O O
in NN O O
these NN O O
pedigrees, NN O O
the NN O O
greatest NN O O
allele NN O O
sharing NN O O
(81%; NN O O
p NN O O
=. NN O O
00002) NN O O
and NN O O
the NN O O
highest NN O O
lod NN O O
score NN O O
(3. NN O O
51; NN O O
phi NN O O
= NN O O
0. NN O O
0) NN O O
were NN O O
observed NN O O
at NN O O
d NN O O
18 NN O O
s NN O O
41. NN O O
our NN O O
results NN O O
provide NN O O
further NN O O
support NN O O
for NN O O
linkage NN O O
of NN O O
BPAD NN B-SpecificDisease B-MSH:D001714
to NN O O
chromosome NN O O
18 NN O O
and NN O O
the NN O O
first NN O O
molecular NN O O
evidence NN O O
for NN O O
a NN O O
parent-of-origi NN O O
. NN O O

effect NN O O
operating NN O O
in NN O O
this NN O O
disorder. NN O O
the NN O O
number NN O O
of NN O O
loci NN O O
involved, NN O O
and NN O O
their NN O O
precise NN O O
location, NN O O
require NN O O
further NN O O
stud NN O O
. NN O O

brca NN O O
1 NN O O
mutations NN O O
in NN O O
a NN O O
population-based NN O O
sample NN O O
of NN O O
young NN O O
women NN O O
with NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O

background. NN O O
inherited NN O O
mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
in NN O O
some NN O O
families. NN O O
however, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
contribution NN O O
of NN O O
brca NN O O
1 NN O O
mutations NN O O
to NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
in NN O O
the NN O O
general NN O O
population. NN O O
we NN O O
analyzed NN O O
dna NN O O
samples NN O O
from NN O O
women NN O O
enrolled NN O O
in NN O O
a NN O O
population-based NN O O
study NN O O
of NN O O
early-onset NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
to NN O O
assess NN O O
the NN O O
spectrum NN O O
and NN O O
frequency NN O O
of NN O O
germ-line NN O O
brca NN O O
1 NN O O
mutations NN O O
in NN O O
young NN O O
women NN O O
with NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O
methods. NN O O
we NN O O
studied NN O O
80 NN O O
women NN O O
in NN O O
whom NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
was NN O O
diagnosed NN O O
before NN O O
the NN O O
age NN O O
of NN O O
35, NN O O
and NN O O
who NN O O
were NN O O
not NN O O
selected NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
family NN O O
history. NN O O
genomic NN O O
dna NN O O
was NN O O
studied NN O O
for NN O O
brca NN O O
1 NN O O
mutations NN O O
by NN O O
analysis NN O O
involving NN O O
single-strand NN O O
conformation NN O O
polymorphisms NN O O
and NN O O
with NN O O
allele-specific NN O O
assays. NN O O
alterations NN O O
were NN O O
defined NN O O
b NN O O
. NN O O

dna NN O O
sequencing. NN O O
results. NN O O
germ-line NN O O
brca NN O O
1 NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
6 NN O O
of NN O O
the NN O O
80 NN O O
women. NN O O
four NN O O
additional NN O O
rare NN O O
sequence NN O O
variants NN O O
of NN O O
unknown NN O O
functional NN O O
importance NN O O
were NN O O
also NN O O
identified. NN O O
two NN O O
of NN O O
the NN O O
mutations NN O O
and NN O O
three NN O O
of NN O O
the NN O O
rare NN O O
sequence NN O O
variants NN O O
were NN O O
found NN O O
among NN O O
the NN O O
39 NN O O
women NN O O
who NN O O
reported NN O O
no NN O O
family NN O O
history NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
. NN O O
none NN O O
of NN O O
the NN O O
mutations NN O O
and NN O O
only NN O O
one NN O O
of NN O O
the NN O O
rare NN O O
variants NN O O
was NN O O
identified NN O O
in NN O O
a NN O O
reference NN O O
population NN O O
of NN O O
73 NN O O
unrelated NN O O
subjects. NN O O
conclusions. NN O O
alterations NN O O
in NN O O
brca NN O O
1 NN O O
were NN O O
identified NN O O
in NN O O
approximately NN O O
10 NN O O
percent NN O O
of NN O O
this NN O O
cohort NN O O
of NN O O
young NN O O
women NN O O
with NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O
the NN O O
risk NN O O
of NN O O
harboring NN O O
a NN O O
mutation NN O O
was NN O O
not NN O O
limited NN O O
to NN O O
women NN O O
with NN O O
family NN O O
histories NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
. NN O O
these NN O O
results NN O O
represent NN O O
a NN O O
minimal NN O O
estimate NN O O
of NN O O
the NN O O
frequency NN O O
of NN O O
brca NN O O
1 NN O O
mutations NN O O
in NN O O
thi NN O O
. NN O O

population. NN O O
comprehensive NN O O
methods NN O O
of NN O O
identifying NN O O
brca NN O O
1 NN O O
mutations NN O O
and NN O O
understanding NN O O
their NN O O
importance NN O O
will NN O O
be NN O O
needed NN O O
before NN O O
testing NN O O
of NN O O
women NN O O
in NN O O
the NN O O
general NN O O
population NN O O
can NN O O
be NN O O
undertaken. NN O O
. NN O O

retinoschisin, NN O O
the NN O O
X-linked NN B-Modifier B-MSH:D041441
retinoschisis NN I-Modifier I-MSH:D041441
protein, NN O O
is NN O O
a NN O O
secreted NN O O
photoreceptor NN O O
protein, NN O O
and NN O O
is NN O O
expressed NN O O
and NN O O
released NN O O
by NN O O
weri-rb NN O O
1 NN O O
cells NN O O
. NN O O

x-linked NN O O
retinoschisis NN O O
is NN O O
characterized NN O O
by NN O O
microcystic-like NN O O
changes NN O O
of NN O O
the NN O O
macular NN O O
region NN O O
and NN O O
schisis NN O O
within NN O O
the NN O O
inner NN O O
retinal NN O O
layers, NN O O
leading NN O O
to NN O O
visual NN B-DiseaseClass B-MSH:C531604
deterioration NN I-DiseaseClass I-MSH:C531604
in NN O O
males. NN O O
many NN O O
missense NN O O
and NN O O
protein-truncating NN O O
mutations NN O O
of NN O O
the NN O O
causative NN O O
gene NN O O
rs NN O O
1 NN O O
have NN O O
now NN O O
been NN O O
identified NN O O
and NN O O
are NN O O
thought NN O O
to NN O O
be NN O O
inactivating. NN O O
rs NN O O
1 NN O O
encodes NN O O
a NN O O
224 NN O O
amino NN O O
acid NN O O
protein, NN O O
retinoschisin, NN O O
which NN O O
contains NN O O
a NN O O
discoidin NN O O
domain NN O O
but NN O O
is NN O O
of NN O O
unknown NN O O
function. NN O O
we NN O O
have NN O O
generated NN O O
a NN O O
polyclonal NN O O
antibody NN O O
against NN O O
a NN O O
peptide NN O O
from NN O O
a NN O O
unique NN O O
region NN O O
within NN O O
retinoschisin, NN O O
which NN O O
detects NN O O
a NN O O
protein NN O O
of NN O O
approximately NN O O
28 NN O O
kda NN O O
in NN O O
retinal NN O O
samples NN O O
reduced NN O O
with NN O O
dithiothreitol, NN O O
but NN O O
multimers NN O O
sized NN O O
> NN O O
40 NN O O
kda NN O O
under NN O O
non-reducing NN O O
conditions. NN O O
a NN O O
screen NN O O
of NN O O
human NN O O
tissues NN O O
with NN O O
this NN O O
antibody NN O O
reveals NN O O
retinoschisin NN O O
to NN O O
be NN O O
retina NN O O
specific NN O O
and NN O O
the NN O O
antibody NN O O
detects NN O O
a NN O O
protein NN O O
o NN O O
. NN O O

similar NN O O
size NN O O
in NN O O
bovine NN O O
and NN O O
murine NN O O
retinae. NN O O
we NN O O
investigated NN O O
the NN O O
expression NN O O
pattern NN O O
in NN O O
the NN O O
retina NN O O
of NN O O
both NN O O
rs NN O O
1 NN O O
mrna NN O O
(using NN O O
in NN O O
situ NN O O
hybridization NN O O
with NN O O
riboprobes) NN O O
and NN O O
retinoschisin NN O O
(using NN O O
immunohistochemistry). NN O O
the NN O O
antisense NN O O
riboprobe NN O O
detected NN O O
rs NN O O
1 NN O O
mrna NN O O
only NN O O
in NN O O
the NN O O
photoreceptor NN O O
layer NN O O
but NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene NN O O
was NN O O
present NN O O
both NN O O
in NN O O
the NN O O
photoreceptors NN O O
and NN O O
within NN O O
the NN O O
inner NN O O
portions NN O O
of NN O O
the NN O O
retina. NN O O
furthermore, NN O O
differentiated NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
cells NN O O
(weri-rb NN O O
1 NN O O
cells) NN O O
were NN O O
found NN O O
to NN O O
express NN O O
rs NN O O
1 NN O O
mrna NN O O
and NN O O
to NN O O
release NN O O
retinoschisin. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
retinoschisin NN O O
is NN O O
released NN O O
by NN O O
photo-receptors NN O O
and NN O O
has NN O O
functions NN O O
within NN O O
the NN O O
inner NN O O
retinal NN O O
layers. NN O O
thus, NN O O
X-linked NN B-SpecificDisease B-MSH:D041441
retinoschisis NN I-SpecificDisease I-MSH:D041441
is NN O O
caused NN O O
by NN O O
abnormalities NN O O
in NN O O
a NN O O
putative NN O O
secreted NN O O
photoreceptor NN O O
protein NN O O
and NN O O
is NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
secreted NN O O
photo NN O O
. NN O O

receptor NN O O
protein NN O O
associated NN O O
with NN O O
a NN O O
retinal NN B-DiseaseClass B-MSH:D058499
dystrophy NN I-DiseaseClass I-MSH:D058499
. NN O O
. NN O O

aberrant NN O O
splicing NN O O
of NN O O
the NN O O
CHM NN B-Modifier B-MSH:D015794
gene NN O O
is NN O O
a NN O O
significant NN O O
cause NN O O
of NN O O
choroideremia NN B-SpecificDisease B-MSH:D015794
. NN O O

choroideremia NN O O
( NN O O
CHM NN B-SpecificDisease B-MSH:D015794
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D015785
progressive NN I-DiseaseClass I-MSH:D015785
degeneration NN I-DiseaseClass I-MSH:D015785
of NN I-DiseaseClass I-MSH:D015785
the NN I-DiseaseClass I-MSH:D015785
choroid NN I-DiseaseClass I-MSH:D015785
and NN I-DiseaseClass I-MSH:D015785
retina NN I-DiseaseClass I-MSH:D015785
. NN O O
12% NN O O
of NN O O
unrelated NN O O
male NN O O
patients NN O O
carry NN O O
deletions NN O O
of NN O O
the NN O O
partially NN O O
cloned NN O O
CHM NN B-Modifier B-MSH:D015794
gene. NN O O
in NN O O
finland, NN O O
there NN O O
are NN O O
more NN O O
than NN O O
120 NN O O
living NN O O
CHM NN B-Modifier B-MSH:D015794
patients NN O O
belonging NN O O
to NN O O
eight NN O O
apparently NN O O
unrelated NN O O
pedigrees. NN O O
molecular NN O O
deletions NN O O
involving NN O O
the NN O O
CHM NN B-Modifier B-MSH:D015794
gene NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
three NN O O
families. NN O O
we NN O O
have NN O O
screened NN O O
the NN O O
remaining NN O O
five NN O O
families NN O O
for NN O O
point NN O O
mutations. NN O O
in NN O O
one NN O O
large NN O O
family NN O O
a NN O O
single NN O O
nucleotide NN O O
(t) NN O O
insertion NN O O
into NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
exon NN O O
c NN O O
leads NN O O
to NN O O
two NN O O
aberrantly NN O O
spliced NN O O
mrnas NN O O
both NN O O
producing NN O O
a NN O O
premature NN O O
stop NN O O
codon. NN O O
the NN O O
mutation NN O O
can NN O O
be NN O O
assayed NN O O
easily NN O O
by NN O O
amplification NN O O
and NN O O
digestion NN O O
with NN O O
msel. NN O O
our NN O O
findings NN O O
provide NN O O
additional NN O O
evidence NN O O
for NN O O
the NN O O
pathogenetic NN O O
role NN O O
of NN O O
CHM NN B-Modifier B-MSH:D015794
mutations NN O O
and NN O O
provide NN O O
a NN O O
diagnostic NN O O
tool NN O O
for NN O O
one NN O O
fifth NN O O
o NN O O
. NN O O

the NN O O
worlds NN O O
known NN O O
CHM NN B-Modifier B-MSH:D015794
patients. NN O O
. NN O O

x-linked NN O O
adrenoleukodystrophy NN O O
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
): NN O O
a NN O O
novel NN O O
mutation NN O O
of NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
in NN O O
6 NN O O
members NN O O
of NN O O
a NN O O
family NN O O
presenting NN O O
with NN O O
5 NN O O
different NN O O
phenotypes NN O O
. NN O O

fragments NN O O
of NN O O
the NN O O
adrenoleukodystrophy NN B-Modifier B-MSH:D000326
( NN O O
ALD NN B-Modifier B-MSH:D000326
) NN O O
cdna NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
adolescent NN B-SpecificDisease B-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
were NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
and NN O O
subcloned. NN O O
bidirectional NN O O
sequencing NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
disclosed NN O O
a NN O O
cytosine NN O O
to NN O O
guanine NN O O
transversion NN O O
at NN O O
nucleotide NN O O
1451 NN O O
in NN O O
exon NN O O
five, NN O O
resulting NN O O
in NN O O
substitution NN O O
of NN O O
proline NN O O
484 NN O O
by NN O O
arginine. NN O O
five NN O O
of NN O O
nine NN O O
siblings NN O O
of NN O O
the NN O O
patient, NN O O
comprising NN O O
two NN O O
cerebral NN B-SpecificDisease B-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
, NN O O
one NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
, NN O O
one NN O O
Addison NN B-SpecificDisease B-MSH:D000224
only NN I-SpecificDisease I-MSH:D000224
as NN O O
well NN O O
as NN O O
the NN O O
symptomatic NN O O
mother NN O O
(all NN O O
accumulating NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids) NN O O
carried NN O O
this NN O O
mutation, NN O O
which NN O O
was NN O O
not NN O O
found NN O O
in NN O O
the NN O O
unaffected NN O O
persons, NN O O
in NN O O
five NN O O
unrelated NN O O
ALD NN B-Modifier B-MSH:D000326
patients, NN O O
and NN O O
in NN O O
twenty NN O O
controls. NN O O
we NN O O
propose NN O O
that NN O O
this NN O O
missense NN O O
mutation NN O O
generated NN O O
the NN O O
disease NN O O
per NN O O
se NN O O
as NN O O
well NN O O
as NN O O
the NN O O
metabolic NN O O
defect; NN O O
the NN O O
different NN O O
phenotypes, NN O O
however, NN O O
must NN O O
have NN O O
originated NN O O
by NN O O
mean NN O O
. NN O O

of NN O O
additional NN O O
pathogenetic NN O O
factors. NN O O
. NN O O

statistical NN O O
analysis NN O O
of NN O O
the NN O O
two NN O O
stage NN O O
mutation NN O O
model NN O O
in NN O O
von NN B-SpecificDisease B-MSH:D006623
Hippel-Lindau NN I-SpecificDisease I-MSH:D006623
disease NN I-SpecificDisease I-MSH:D006623
, NN O O
and NN O O
in NN O O
sporadic NN B-SpecificDisease B-MSH:D018325
cerebellar NN I-SpecificDisease I-MSH:D018325
haemangioblastoma NN I-SpecificDisease I-MSH:D018325
and NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
. NN O O

analysis NN O O
of NN O O
the NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
unilateral NN B-CompositeMention B-MSH:D012175
and NN I-CompositeMention I-MSH:D012175
bilateral NN I-CompositeMention I-MSH:D012175
retinoblastoma NN I-CompositeMention I-MSH:D012175
led NN O O
knudson NN O O
to NN O O
propose NN O O
that NN O O
hereditary NN B-DiseaseClass B-MSH:D009386
tumours NN I-DiseaseClass I-MSH:D009386
may NN O O
arise NN O O
by NN O O
a NN O O
single NN O O
event NN O O
and NN O O
sporadic NN B-DiseaseClass B-MSH:D009369
tumours NN I-DiseaseClass I-MSH:D009369
by NN O O
a NN O O
two NN O O
stage NN O O
mutation NN O O
process. NN O O
it NN O O
has NN O O
been NN O O
suggested NN O O
recently NN O O
that NN O O
sporadic NN B-SpecificDisease B-MSH:D002292
renal NN I-SpecificDisease I-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
may NN O O
arise NN O O
from NN O O
a NN O O
two NN O O
stage NN O O
mutation NN O O
process. NN O O
we NN O O
analysed NN O O
the NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
symptomatic NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
(n NN O O
= NN O O
26) NN O O
and NN O O
cerebellar NN B-SpecificDisease B-MSH:D018325
haemangioblastoma NN I-SpecificDisease I-MSH:D018325
(n NN O O
= NN O O
68) NN O O
in NN O O
109 NN O O
patients NN O O
with NN O O
von NN B-SpecificDisease B-MSH:D006623
Hippel-Lindau NN I-SpecificDisease I-MSH:D006623
(VHL) NN I-SpecificDisease I-MSH:D006623
disease NN I-SpecificDisease I-MSH:D006623
, NN O O
and NN O O
compared NN O O
them NN O O
to NN O O
104 NN O O
patients NN O O
with NN O O
sporadic NN B-SpecificDisease B-MSH:D002292
renal NN I-SpecificDisease I-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
and NN O O
43 NN O O
patients NN O O
with NN O O
sporadic NN B-SpecificDisease B-MSH:D018325
cerebellar NN I-SpecificDisease I-MSH:D018325
haemangioblastoma NN I-SpecificDisease I-MSH:D018325
. NN O O
the NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
and NN O O
cerebellar NN B-SpecificDisease B-MSH:D018325
haemangioblastoma NN I-SpecificDisease I-MSH:D018325
in NN O O
VHL NN B-SpecificDisease B-MSH:D006623
disease NN I-SpecificDisease I-MSH:D006623
were NN O O
compatible NN O O
with NN O O
a NN O O
single NN O O
mutation NN O O
model, NN O O
whereas NN O O
the NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
sporadic NN B-SpecificDisease B-MSH:D002292
renal NN I-SpecificDisease I-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292

carcinoma NN O O
and NN O O
cerebellar NN B-SpecificDisease B-MSH:D018325
haemangioblastoma NN I-SpecificDisease I-MSH:D018325
suggested NN O O
a NN O O
two NN O O
stage NN O O
mutation NN O O
process. NN O O
these NN O O
data NN O O
are NN O O
compatible NN O O
with NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
functioning NN O O
as NN O O
a NN O O
recessive NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
gene. NN O O
Sporadic NN B-SpecificDisease B-MSH:D018325
cerebellar NN I-SpecificDisease I-MSH:D018325
haemangioblastoma NN I-SpecificDisease I-MSH:D018325
and NN O O
some NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
may NN O O
arise NN O O
from NN O O
somatic NN O O
mutations NN O O
inactivating NN O O
both NN O O
alleles NN O O
at NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
locus. NN O O
. NN O O

characterization NN O O
of NN O O
a NN O O
germline NN O O
mosaicism NN O O
in NN O O
families NN O O
with NN O O
Lowe NN B-SpecificDisease B-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
, NN O O
and NN O O
identification NN O O
of NN O O
seven NN O O
novel NN O O
mutations NN O O
in NN O O
the NN O O
ocrl NN O O
1 NN O O
gene NN O O
. NN O O

the NN O O
oculocerebrorenal NN B-SpecificDisease B-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
of NN I-SpecificDisease I-MSH:D009800
Lowe NN I-SpecificDisease I-MSH:D009800
( NN O O
OCRL NN B-SpecificDisease B-MSH:D009800
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
characterized NN O O
by NN O O
major NN O O
abnormalities NN B-CompositeMention B-MSH:D000015
of NN I-CompositeMention I-MSH:D000015
eyes, NN I-CompositeMention I-MSH:D000015
nervous NN I-CompositeMention I-MSH:D000015
system, NN I-CompositeMention I-MSH:D000015
and NN I-CompositeMention I-MSH:D000015
kidneys NN I-CompositeMention I-MSH:D000015
. NN O O
mutations NN O O
in NN O O
the NN O O
ocrl NN O O
1 NN O O
gene NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
disease. NN O O
ocrl NN O O
1 NN O O
encodes NN O O
a NN O O
phosphatidylinositol NN O O
4, NN O O
5-biphosphate NN O O
(ptdins NN O O
[4, NN O O
5] NN O O
p NN O O
2) NN O O
5-phosphatase. NN O O
we NN O O
have NN O O
examined NN O O
the NN O O
ocrl NN O O
1 NN O O
gene NN O O
in NN O O
eight NN O O
unrelated NN O O
patients NN O O
with NN O O
OCRL NN B-SpecificDisease B-MSH:D009800
and NN O O
have NN O O
found NN O O
seven NN O O
new NN O O
mutations NN O O
and NN O O
one NN O O
recurrent NN O O
in-frame NN O O
deletion. NN O O
among NN O O
the NN O O
new NN O O
mutations, NN O O
two NN O O
nonsense NN O O
mutations NN O O
(r NN O O
317 NN O O
x NN O O
and NN O O
e NN O O
558 NN O O
x) NN O O
and NN O O
three NN O O
other NN O O
frameshift NN O O
mutations NN O O
caused NN O O
premature NN O O
termination NN O O
of NN O O
the NN O O
protein. NN O O
a NN O O
missense NN O O
mutation, NN O O
r NN O O
483 NN O O
g, NN O O
was NN O O
located NN O O
in NN O O
the NN O O
highly NN O O
conserved NN O O
ptdins NN O O
( NN O O
. NN O O

, NN O O
5) NN O O
p NN O O
2 NN O O
5-phosphatase NN O O
domain. NN O O
finally, NN O O
one NN O O
frameshift NN O O
mutation, NN O O
2799 NN O O
delc, NN O O
modifies NN O O
the NN O O
c-terminal NN O O
part NN O O
of NN O O
ocrl NN O O
1, NN O O
with NN O O
an NN O O
extension NN O O
of NN O O
six NN O O
amino NN O O
acids. NN O O
altogether, NN O O
70% NN O O
of NN O O
missense NN O O
mutations NN O O
are NN O O
located NN O O
in NN O O
exon NN O O
15, NN O O
and NN O O
52% NN O O
of NN O O
all NN O O
mutations NN O O
cluster NN O O
in NN O O
exons NN O O
11-15. NN O O
we NN O O
also NN O O
identified NN O O
two NN O O
new NN O O
microsatellite NN O O
markers NN O O
for NN O O
the NN O O
ocrl NN O O
1 NN O O
locus, NN O O
and NN O O
we NN O O
detected NN O O
a NN O O
germline NN O O
mosaicism NN O O
in NN O O
one NN O O
family. NN O O
this NN O O
observation NN O O
has NN O O
direct NN O O
implications NN O O
for NN O O
genetic NN O O
counseling NN O O
of NN O O
Lowe NN B-Modifier B-MSH:D009800
syndrome NN I-Modifier I-MSH:D009800
families. NN O O
. NN O O

aminoglycoside NN O O
antibiotics NN O O
restore NN O O
dystrophin NN O O
function NN O O
to NN O O
skeletal NN O O
muscles NN O O
of NN O O
mdx NN O O
mice NN O O
. NN O O

duchenne NN O O
muscular NN O O
dystrophy NN O O
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
dystrophin NN O O
gene, NN O O
leading NN O O
to NN O O
the NN O O
absence NN O O
of NN O O
the NN O O
dystrophin NN O O
protein NN O O
in NN O O
striated NN O O
muscle. NN O O
a NN O O
significant NN O O
number NN O O
of NN O O
these NN O O
mutations NN O O
are NN O O
premature NN O O
stop NN O O
codons. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
observation NN O O
that NN O O
aminoglycoside NN O O
treatment NN O O
can NN O O
suppress NN O O
stop NN O O
codons NN O O
in NN O O
cultured NN O O
cells, NN O O
we NN O O
tested NN O O
the NN O O
effect NN O O
of NN O O
gentamicin NN O O
on NN O O
cultured NN O O
muscle NN O O
cells NN O O
from NN O O
the NN O O
mdx NN O O
mouse NN O O
- NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
DMD NN B-SpecificDisease B-MSH:D020388
that NN O O
possesses NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
in NN O O
the NN O O
dystrophin NN O O
gene. NN O O
exposure NN O O
of NN O O
mdx NN O O
myotubes NN O O
to NN O O
gentamicin NN O O
led NN O O
to NN O O
the NN O O
expression NN O O
and NN O O
localization NN O O
of NN O O
dystrophin NN O O
to NN O O
the NN O O
cell NN O O
membrane. NN O O
we NN O O
then NN O O
evaluated NN O O
the NN O O
effects NN O O
of NN O O
differing NN O O
dosages NN O O
of NN O O
gentamicin NN O O
on NN O O
expression NN O O
and NN O O
functional NN O O
protection NN O O
of NN O O
the NN O O
muscles NN O O
of NN O O
mdx NN O O
mice. NN O O
we NN O O
identified NN O O
a NN O O
treatment NN O O
regimen NN O O
that NN O O
resulted NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
dystrophin NN O O
i NN O O
. NN O O

the NN O O
cell NN O O
membrane NN O O
in NN O O
all NN O O
striated NN O O
muscles NN O O
examined NN O O
and NN O O
that NN O O
provided NN O O
functional NN O O
protection NN O O
against NN O O
muscular NN B-DiseaseClass B-MSH:D014947
injury NN I-DiseaseClass I-MSH:D014947
. NN O O
to NN O O
our NN O O
knowledge, NN O O
our NN O O
results NN O O
are NN O O
the NN O O
first NN O O
to NN O O
demonstrate NN O O
that NN O O
aminoglycosides NN O O
can NN O O
suppress NN O O
stop NN O O
codons NN O O
not NN O O
only NN O O
in NN O O
vitro NN O O
but NN O O
also NN O O
in NN O O
vivo. NN O O
furthermore, NN O O
these NN O O
results NN O O
raise NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
novel NN O O
treatment NN O O
regimen NN O O
for NN O O
muscular NN B-SpecificDisease B-MSH:D009136
dystrophy NN I-SpecificDisease I-MSH:D009136
and NN O O
other NN O O
diseases NN O O
caused NN O O
by NN O O
premature NN O O
stop NN O O
codon NN O O
mutations. NN O O
this NN O O
treatment NN O O
could NN O O
prove NN O O
effective NN O O
in NN O O
up NN O O
to NN O O
15% NN O O
of NN O O
patients NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
. NN O O

molecular NN O O
and NN O O
metabolic NN O O
basis NN O O
for NN O O
the NN O O
metabolic NN B-DiseaseClass B-MSH:D008659
disorder NN I-DiseaseClass I-MSH:D008659
normotriglyceridemic NN B-SpecificDisease B-MSH:D000012
abetalipoproteinemia NN I-SpecificDisease I-MSH:D000012
. NN O O

we NN O O
have NN O O
previously NN O O
described NN O O
a NN O O
disorder, NN O O
normotriglyceridemic NN B-SpecificDisease B-MSH:D000012
abetalipoproteinemia NN I-SpecificDisease I-MSH:D000012
, NN O O
that NN O O
is NN O O
characterized NN O O
by NN O O
the NN O O
virtual NN O O
absence NN O O
of NN O O
plasma NN O O
low NN O O
density NN O O
lipoproteins NN O O
and NN O O
complete NN O O
absence NN O O
of NN O O
apob-100, NN O O
but NN O O
with NN O O
apparently NN O O
normal NN O O
secretion NN O O
of NN O O
triglyceride-rich NN O O
lipoproteins NN O O
containing NN O O
apob-48. NN O O
the NN O O
patients NN O O
plasma NN O O
lipoproteins NN O O
were NN O O
shown NN O O
on NN O O
polyacrylamide NN O O
gels NN O O
and NN O O
by NN O O
antibody NN O O
mapping NN O O
to NN O O
have NN O O
a NN O O
new NN O O
truncated NN O O
apob NN O O
variant, NN O O
apob-50, NN O O
circulating NN O O
along NN O O
with NN O O
her NN O O
apob-48. NN O O
we NN O O
have NN O O
found NN O O
this NN O O
individual NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
single NN O O
c-to-t NN O O
nucleotide NN O O
substitution NN O O
at NN O O
apob NN O O
codon NN O O
2252, NN O O
which NN O O
produces NN O O
a NN O O
premature NN O O
in-frame NN O O
stop NN O O
codon. NN O O
thus, NN O O
this NN O O
is NN O O
a NN O O
rare NN O O
example NN O O
of NN O O
homozygous NN B-SpecificDisease B-MSH:D006995
hypobetalipoproteinemia NN I-SpecificDisease I-MSH:D006995
. NN O O
electron NN O O
photomicrographs NN O O
revealed NN O O
that NN O O
the NN O O
diameters NN O O
of NN O O
particles NN O O
in NN O O
the NN O O
d NN O O
less NN O O
than NN O O
1. NN O O
006 NN O O
g NN O O
. NN O O

ml NN O O
lipoprotein NN O O
fraction, NN O O
in NN O O
both NN O O
the NN O O
postprandial NN O O
and NN O O
postabsorptive NN O O
state, NN O O
are NN O O
bimodally NN O O
distributed. NN O O
the NN O O
molar NN O O
ratio NN O O
of NN O O
apoe NN O O
to NN O O
apob NN O O
in NN O O
these NN O O
particles NN O O
is NN O O
3. NN O O
5 NN O O
1, NN O O
similar NN O O
to NN O O
normal NN O O
vldl. NN O O
the NN O O
plasma NN O O
ldl NN O O
interval NN O O
contains NN O O
both NN O O
spherical NN O O
and NN O O
cuboidal NN O O
particles. NN O O
autologous NN O O
reinfusion NN O O
of NN O O
labeled NN O O
d NN O O
less NN O O
than NN O O
1. NN O O
006 NN O O
g/ml NN O O
lipoproteins NN O O
showed NN O O
exponential NN O O
disappearance NN O O
from NN O O
plasma, NN O O
with NN O O
an NN O O
apparent NN O O
half-removal NN O O
time NN O O
of NN O O
50 NN O O
min, NN O O
somewhat NN O O
slower NN O O
than NN O O
for NN O O
normal NN O O
chylomicrons NN O O
but NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
for NN O O
vldl. NN O O
the NN O O
calculated NN O O
production NN O O
rate NN O O
for NN O O
apob NN O O
was NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
in NN O O
this NN O O
subject NN O O
. NN O O

von NN O O
willebrand NN O O
disease NN O O
type NN O O
b: NN O O
a NN O O
missense NN O O
mutation NN O O
selectively NN O O
abolishes NN O O
ristocetin-induced NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
binding NN O O
to NN O O
platelet NN O O
glycoprotein NN O O
ib NN O O
. NN O O

von NN O O
willebrand NN O O
factor NN O O
(vwf) NN O O
is NN O O
a NN O O
multimeric NN O O
glycoprotein NN O O
that NN O O
mediates NN O O
the NN O O
adhesion NN O O
of NN O O
platelets NN O O
to NN O O
the NN O O
subendothelium NN O O
by NN O O
binding NN O O
to NN O O
platelet NN O O
glycoprotein NN O O
ib. NN O O
for NN O O
human NN O O
vwf, NN O O
this NN O O
interaction NN O O
can NN O O
be NN O O
induced NN O O
in NN O O
vitro NN O O
by NN O O
the NN O O
antibiotic NN O O
ristocetin NN O O
or NN O O
the NN O O
snake NN O O
venom NN O O
protein NN O O
botrocetin. NN O O
a NN O O
missense NN O O
mutation, NN O O
gly-561-- NN O O
> NN O O
ser, NN O O
was NN O O
identified NN O O
within NN O O
the NN O O
proposed NN O O
glycoprotein NN O O
ib NN O O
binding NN O O
domain NN O O
of NN O O
vwf NN O O
in NN O O
the NN O O
proband NN O O
with NN O O
von NN B-SpecificDisease B-MSH:D014842
Willebrand NN I-SpecificDisease I-MSH:D014842
disease NN I-SpecificDisease I-MSH:D014842
type NN I-SpecificDisease I-MSH:D014842
B NN I-SpecificDisease I-MSH:D014842
, NN O O
a NN O O
unique NN O O
variant NN O O
characterized NN O O
by NN O O
no NN O O
ristocetin-induced, NN O O
but NN O O
normal NN O O
botrocetin-induced, NN O O
binding NN O O
to NN O O
glycoprotein NN O O
ib. NN O O
the NN O O
corresponding NN O O
mutant NN O O
recombinant NN O O
protein, NN O O
rvwf NN O O
(g NN O O
561 NN O O
s), NN O O
formed NN O O
normal NN O O
multimers NN O O
and NN O O
exhibited NN O O
the NN O O
same NN O O
functional NN O O
defect NN O O
as NN O O
the NN O O
patients NN O O
plasma NN O O
vwf, NN O O
confirming NN O O
that NN O O
this NN O O
mutation NN O O
causes NN O O
von NN B-SpecificDisease B-MSH:D014842
Willebrand NN I-SpecificDisease I-MSH:D014842
disease NN I-SpecificDisease I-MSH:D014842
type NN I-SpecificDisease I-MSH:D014842
B NN I-SpecificDisease I-MSH:D014842
. NN O O

. NN O O
these NN O O
data NN O O
show NN O O
that NN O O
botrocetin NN O O
and NN O O
ristocetin NN O O
cofactor NN O O
activities NN O O
of NN O O
vwf NN O O
can NN O O
be NN O O
dissociated NN O O
by NN O O
a NN O O
point NN O O
mutation NN O O
and NN O O
confirm NN O O
that NN O O
these NN O O
mediators NN O O
promote NN O O
vwf NN O O
binding NN O O
to NN O O
platelets NN O O
by NN O O
different NN O O
mechanisms. NN O O
the NN O O
normal NN O O
botrocetin-induced NN O O
binding NN O O
and NN O O
the NN O O
defective NN O O
ristocetin-induced NN O O
binding NN O O
of NN O O
rvwf NN O O
(g NN O O
561 NN O O
s) NN O O
suggest NN O O
that NN O O
the NN O O
primary NN O O
defect NN O O
in NN O O
von NN B-SpecificDisease B-MSH:D014842
Willebrand NN I-SpecificDisease I-MSH:D014842
disease NN I-SpecificDisease I-MSH:D014842
type NN I-SpecificDisease I-MSH:D014842
B NN I-SpecificDisease I-MSH:D014842
may NN O O
be NN O O
a NN O O
failure NN O O
of NN O O
normal NN O O
allosteric NN O O
regulation NN O O
of NN O O
the NN O O
glycoprotein NN O O
ib NN O O
binding NN O O
function NN O O
of NN O O
vwf. NN O O
. NN O O

a NN O O
high NN O O
incidence NN O O
of NN O O
brca NN O O
1 NN O O
mutations NN O O
in NN O O
20 NN O O
breast-ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families NN O O
. NN O O

we NN O O
have NN O O
analyzed NN O O
20 NN O O
breast-ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families, NN O O
the NN O O
majority NN O O
of NN O O
which NN O O
show NN O O
positive NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
chromosome NN O O
17 NN O O
q NN O O
12 NN O O
for NN O O
germ-line NN O O
mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene. NN O O
brca NN O O
1 NN O O
mutations NN O O
cosegregating NN O O
with NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
susceptibility NN O O
were NN O O
identified NN O O
in NN O O
16 NN O O
families, NN O O
including NN O O
1 NN O O
family NN O O
with NN O O
a NN O O
case NN O O
of NN O O
male NN B-SpecificDisease B-MSH:D018567
breast NN I-SpecificDisease I-MSH:D018567
cancer NN I-SpecificDisease I-MSH:D018567
. NN O O
nine NN O O
of NN O O
these NN O O
mutations NN O O
have NN O O
not NN O O
been NN O O
reported NN O O
previously. NN O O
the NN O O
majority NN O O
of NN O O
mutations NN O O
were NN O O
found NN O O
to NN O O
generate NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
leading NN O O
to NN O O
the NN O O
formation NN O O
of NN O O
a NN O O
truncated NN O O
brca NN O O
1 NN O O
protein NN O O
of NN O O
2% NN O O
-88% NN O O
of NN O O
the NN O O
expected NN O O
normal NN O O
length. NN O O
two NN O O
mutations NN O O
altered NN O O
the NN O O
ring NN O O
finger NN O O
domain. NN O O
sequencing NN O O
of NN O O
genomic NN O O
dna NN O O
led NN O O
to NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
12 NN O O
families, NN O O
and NN O O
cdna NN O O
analysis NN O O
reveale NN O O
. NN O O

an NN O O
abnormal NN O O
or NN O O
missing NN O O
brca NN O O
1 NN O O
transcript NN O O
in NN O O
4 NN O O
of NN O O
the NN O O
8 NN O O
remaining NN O O
families. NN O O
a NN O O
total NN O O
of NN O O
eight NN O O
mutations NN O O
were NN O O
associated NN O O
with NN O O
a NN O O
reduced NN O O
quantity NN O O
of NN O O
brca NN O O
1 NN O O
transcript. NN O O
we NN O O
were NN O O
unable NN O O
to NN O O
detect NN O O
brca NN O O
1 NN O O
mutations NN O O
in NN O O
4 NN O O
of NN O O
the NN O O
20 NN O O
families, NN O O
but NN O O
only NN O O
1 NN O O
of NN O O
these NN O O
was NN O O
clearly NN O O
linked NN O O
to NN O O
brca NN O O
1. NN O O
it NN O O
is NN O O
expected NN O O
that NN O O
the NN O O
majority NN O O
of NN O O
clear NN O O
examples NN O O
of NN O O
the NN O O
breast-ovarian NN B-SpecificDisease B-MSH:D061325
syndrome NN I-SpecificDisease I-MSH:D061325
will NN O O
be NN O O
associated NN O O
with NN O O
germ-line NN O O
mutations NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
brca NN O O
1. NN O O
. NN O O

assignment NN O O
of NN O O
the NN O O
human NN O O
na+/glucose NN O O
cotransporter NN O O
gene NN O O
sglt NN O O
1 NN O O
to NN O O
chromosome NN O O
22 NN O O
q NN O O
13.1 NN O O
. NN O O

the NN O O
na NN O O
+/glucose NN O O
cotransporter NN O O
gene NN O O
sglt NN O O
1 NN O O
encodes NN O O
the NN O O
primary NN O O
carrier NN O O
protein NN O O
responsible NN O O
for NN O O
the NN O O
uptake NN O O
of NN O O
the NN O O
dietary NN O O
sugars NN O O
glucose NN O O
and NN O O
galactose NN O O
from NN O O
the NN O O
intestinal NN O O
lumen. NN O O
sglt NN O O
1 NN O O
transport NN O O
activity NN O O
is NN O O
currently NN O O
exploited NN O O
in NN O O
oral NN O O
rehydration NN O O
therapy. NN O O
the NN O O
75-kda NN O O
glycoprotein NN O O
is NN O O
localized NN O O
in NN O O
the NN O O
brush NN O O
border NN O O
of NN O O
the NN O O
intestinal NN O O
epithelium NN O O
and NN O O
is NN O O
predicted NN O O
to NN O O
comprise NN O O
12 NN O O
membrane NN O O
spans. NN O O
in NN O O
two NN O O
patients NN O O
with NN O O
the NN O O
autosomal NN B-SpecificDisease B-OMIM:606824
recessive NN I-SpecificDisease I-OMIM:606824
disease NN I-SpecificDisease I-OMIM:606824
glucose/galactose NN I-SpecificDisease I-OMIM:606824
malabsorption NN I-SpecificDisease I-OMIM:606824
, NN O O
the NN O O
underlying NN O O
cause NN O O
was NN O O
found NN O O
to NN O O
be NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
sglt NN O O
1, NN O O
and NN O O
the NN O O
asp NN O O
28-- NN O O
> NN O O
asn NN O O
change NN O O
was NN O O
demonstrated NN O O
in NN O O
vitro NN O O
to NN O O
eliminate NN O O
sglt NN O O
1 NN O O
transport NN O O
activity. NN O O
the NN O O
sglt NN O O
1 NN O O
gene NN O O
was NN O O
previously NN O O
shown NN O O
to NN O O
reside NN O O
on NN O O
the NN O O
distal NN O O
q NN O O
arm NN O O
of NN O O
chromosome NN O O
22 NN O O
(11. NN O O
2-- NN O O
> NN O O
qter) NN O O
. NN O O

we NN O O
have NN O O
used NN O O
a NN O O
cosmid NN O O
probe NN O O
for NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization, NN O O
which NN O O
refines NN O O
the NN O O
localization NN O O
to NN O O
22 NN O O
q NN O O
13. NN O O
1, NN O O
and NN O O
provide NN O O
an NN O O
example NN O O
of NN O O
the NN O O
utility NN O O
of NN O O
the NN O O
sglt NN O O
1 NN O O
probe NN O O
as NN O O
a NN O O
diagnostic NN O O
for NN O O
genetic NN B-DiseaseClass B-MSH:D030342
diseases NN I-DiseaseClass I-MSH:D030342
associated NN O O
with NN O O
translocations NN O O
of NN O O
chromosome NN O O
22 NN O O
. NN O O

a NN O O
pseudodeficiency NN O O
allele NN O O
common NN O O
in NN O O
non-jewish NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
carriers: NN O O
implications NN O O
for NN O O
carrier NN O O
screening NN O O
. NN O O

deficiency NN O O
of NN O O
beta-hexosaminidase NN O O
a NN O O
(hex NN O O
a) NN O O
activity NN O O
typically NN O O
results NN O O
in NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
. NN O O
however, NN O O
healthy NN O O
subjects NN O O
found NN O O
to NN O O
be NN O O
deficient NN B-SpecificDisease B-MSH:D013661
in NN I-SpecificDisease I-MSH:D013661
Hex NN I-SpecificDisease I-MSH:D013661
A NN I-SpecificDisease I-MSH:D013661
activity NN O O
(i. NN O O
e., NN O O
pseudodeficient) NN O O
by NN O O
means NN O O
of NN O O
in NN O O
vitro NN O O
biochemical NN O O
tests NN O O
have NN O O
been NN O O
described. NN O O
we NN O O
analyzed NN O O
the NN O O
hexa NN O O
gene NN O O
of NN O O
one NN O O
pseudodeficient NN O O
subject NN O O
and NN O O
identified NN O O
both NN O O
a NN O O
c NN O O
739-to-t NN O O
substitution NN O O
that NN O O
changes NN O O
arg NN O O
247----trp NN O O
on NN O O
one NN O O
allele NN O O
and NN O O
a NN O O
previously NN O O
identified NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
mutation NN O O
on NN O O
the NN O O
second NN O O
allele. NN O O
six NN O O
additional NN O O
pseudodeficient NN O O
subjects NN O O
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
c NN O O
739-to-t NN O O
mutation. NN O O
this NN O O
allele NN O O
accounted NN O O
for NN O O
32% NN O O
(20/62) NN O O
of NN O O
non-jewish NN O O
enzyme-defined NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
carriers NN O O
but NN O O
for NN O O
none NN O O
o NN O O
. NN O O

36 NN O O
jewish NN O O
enzyme-defined NN O O
carriers NN O O
who NN O O
did NN O O
not NN O O
have NN O O
one NN O O
of NN O O
three NN O O
known NN O O
mutations NN O O
common NN O O
to NN O O
this NN O O
group. NN O O
the NN O O
c NN O O
739-to-t NN O O
allele, NN O O
together NN O O
with NN O O
a NN O O
" NN O O
true NN O O
" NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
allele, NN O O
causes NN O O
hex NN O O
a NN O O
pseudodeficiency. NN O O
given NN O O
both NN O O
the NN O O
large NN O O
proportion NN O O
of NN O O
non-jewish NN O O
carriers NN O O
with NN O O
this NN O O
allele NN O O
and NN O O
that NN O O
standard NN O O
biochemical NN O O
screening NN O O
cannot NN O O
differentiate NN O O
between NN O O
heterozygotes NN O O
for NN O O
the NN O O
c NN O O
739-to-t NN O O
mutations NN O O
and NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
carriers, NN O O
dna NN O O
testing NN O O
for NN O O
this NN O O
mutation NN O O
in NN O O
at-risk NN O O
couples NN O O
is NN O O
essential NN O O
. NN O O

the NN O O
presence NN O O
of NN O O
two NN O O
different NN O O
infantile NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
mutations NN O O
in NN O O
a NN O O
cajun NN O O
population NN O O
. NN O O

a NN O O
study NN O O
was NN O O
undertaken NN O O
to NN O O
characterize NN O O
the NN O O
mutation NN O O
(s) NN O O
responsible NN O O
for NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
) NN O O
in NN O O
a NN O O
cajun NN O O
population NN O O
in NN O O
southwest NN O O
louisiana NN O O
and NN O O
to NN O O
identify NN O O
the NN O O
origins NN O O
of NN O O
these NN O O
mutations. NN O O
eleven NN O O
of NN O O
12 NN O O
infantile NN O O
TSD NN B-Modifier B-MSH:D013661
alleles NN O O
examined NN O O
in NN O O
six NN O O
families NN O O
had NN O O
the NN O O
beta-hexosaminidase NN O O
a NN O O
(hex NN O O
a) NN O O
alpha-subunit NN O O
exon NN O O
11 NN O O
insertion NN O O
mutation NN O O
that NN O O
is NN O O
present NN O O
in NN O O
approximately NN O O
70% NN O O
of NN O O
ashkenazi NN O O
jewish NN O O
TSD NN B-Modifier B-MSH:D013661
heterozygotes. NN O O
the NN O O
mutation NN O O
in NN O O
the NN O O
remaining NN O O
allele NN O O
was NN O O
a NN O O
single-base NN O O
transition NN O O
in NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
the NN O O
alpha-subunit NN O O
intron NN O O
9. NN O O
to NN O O
determine NN O O
the NN O O
origins NN O O
of NN O O
these NN O O
two NN O O
mutations NN O O
in NN O O
the NN O O
cajun NN O O
population, NN O O
the NN O O
TSD NN B-Modifier B-MSH:D013661
carrier NN O O
status NN O O
was NN O O
enzymatically NN O O
determined NN O O
for NN O O
90 NN O O
members NN O O
of NN O O
four NN O O
of NN O O
the NN O O
six NN O O
families, NN O O
and NN O O
extensive NN O O
pedigrees NN O O
were NN O O
constructed NN O O
for NN O O
all NN O O
carriers NN O O
. NN O O

a NN O O
single NN O O
ancestral NN O O
couple NN O O
from NN O O
france NN O O
was NN O O
found NN O O
to NN O O
be NN O O
common NN O O
to NN O O
most NN O O
of NN O O
the NN O O
carriers NN O O
of NN O O
the NN O O
exon NN O O
11 NN O O
insertion. NN O O
pedigree NN O O
data NN O O
suggest NN O O
that NN O O
this NN O O
mutation NN O O
has NN O O
been NN O O
in NN O O
the NN O O
cajun NN O O
population NN O O
since NN O O
its NN O O
founding NN O O
over NN O O
2 NN O O
centuries NN O O
ago NN O O
and NN O O
that NN O O
it NN O O
may NN O O
be NN O O
widely NN O O
distributed NN O O
within NN O O
the NN O O
population. NN O O
in NN O O
contrast, NN O O
the NN O O
intron NN O O
9 NN O O
mutation NN O O
apparently NN O O
was NN O O
introduced NN O O
within NN O O
the NN O O
last NN O O
century NN O O
and NN O O
probably NN O O
is NN O O
limited NN O O
to NN O O
a NN O O
few NN O O
louisiana NN O O
families. NN O O
. NN O O

canavan NN O O
disease: NN O O
genomic NN O O
organization NN O O
and NN O O
localization NN O O
of NN O O
human NN O O
aspa NN O O
to NN O O
17 NN O O
p NN O O
13-ter NN O O
and NN O O
conservation NN O O
of NN O O
the NN O O
aspa NN O O
gene NN O O
during NN O O
evolution NN O O
. NN O O

canavan NN O O
disease, NN O O
or NN O O
spongy NN B-SpecificDisease B-MSH:D017825
degeneration NN I-SpecificDisease I-MSH:D017825
of NN I-SpecificDisease I-MSH:D017825
the NN I-SpecificDisease I-MSH:D017825
brain NN I-SpecificDisease I-MSH:D017825
, NN O O
is NN O O
a NN O O
severe NN O O
leukodystrophy NN B-SpecificDisease B-MSH:D007966
caused NN O O
by NN O O
the NN O O
deficiency NN B-SpecificDisease B-MSH:D017825
of NN I-SpecificDisease I-MSH:D017825
aspartoacylase NN I-SpecificDisease I-MSH:D017825
(aspa). NN O O
recently, NN O O
a NN O O
missense NN O O
mutation NN O O
was NN O O
identified NN O O
in NN O O
human NN O O
aspa NN O O
coding NN O O
sequence NN O O
from NN O O
patients NN O O
with NN O O
Canavan NN B-SpecificDisease B-MSH:D017825
disease NN I-SpecificDisease I-MSH:D017825
. NN O O
the NN O O
human NN O O
aspa NN O O
gene NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
found NN O O
to NN O O
span NN O O
29 NN O O
kb NN O O
of NN O O
the NN O O
genome. NN O O
human NN O O
aspartoacylase NN O O
is NN O O
coded NN O O
by NN O O
six NN O O
exons NN O O
intervened NN O O
by NN O O
five NN O O
introns. NN O O
the NN O O
exons NN O O
vary NN O O
from NN O O
94 NN O O
(exon NN O O
iii) NN O O
to NN O O
514 NN O O
(exon NN O O
vi) NN O O
bases. NN O O
the NN O O
exon/intron NN O O
splice NN O O
junction NN O O
sites NN O O
follow NN O O
the NN O O
gt/ag NN O O
consensus NN O O
sequence NN O O
rule. NN O O
southern NN O O
blot NN O O
analysis NN O O
of NN O O
genomic NN O O
dna NN O O
from NN O O
human/mouse NN O O
somatic NN O O
cell NN O O
hybrid NN O O
cell NN O O
lines NN O O
localized NN O O
aspa NN O O
to NN O O
human NN O O
chromosome NN O O
17. NN O O
the NN O O
human NN O O
aspa NN O O
locus NN O O
was NN O O
further NN O O
mapped NN O O
in NN O O
the NN O O
17 NN O O
p NN O O
13-te NN O O
. NN O O

region NN O O
by NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization. NN O O
the NN O O
bovine NN O O
aspa NN O O
gene NN O O
has NN O O
also NN O O
been NN O O
cloned, NN O O
and NN O O
its NN O O
exon/intron NN O O
organization NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
of NN O O
the NN O O
human NN O O
gene. NN O O
the NN O O
500-base NN O O
sequence NN O O
upstream NN O O
of NN O O
the NN O O
initiator NN O O
atg NN O O
codon NN O O
in NN O O
the NN O O
human NN O O
gene NN O O
and NN O O
that NN O O
in NN O O
the NN O O
bovine NN O O
gene NN O O
are NN O O
77% NN O O
identical. NN O O
human NN O O
aspa NN O O
coding NN O O
sequences NN O O
cross-hybridize NN O O
with NN O O
genomic NN O O
dna NN O O
from NN O O
yeast, NN O O
chicken, NN O O
rabbit, NN O O
cow, NN O O
dog, NN O O
mouse, NN O O
rat, NN O O
and NN O O
monkey. NN O O
the NN O O
specificity NN O O
of NN O O
cross-species NN O O
hybridization NN O O
of NN O O
coding NN O O
sequences NN O O
suggests NN O O
that NN O O
aspartoacylase NN O O
has NN O O
been NN O O
conserved NN O O
during NN O O
evolution. NN O O
it NN O O
should NN O O
now NN O O
be NN O O
possible NN O O
to NN O O
identify NN O O
mutations NN O O
in NN O O
the NN O O
noncoding NN O O
genomic NN O O
sequences NN O O
that NN O O
lead NN O O
to NN O O
Canavan NN B-SpecificDisease B-MSH:D017825
disease NN I-SpecificDisease I-MSH:D017825
and NN O O
to NN O O
study NN O O
the NN O O
regulation NN O O
of NN O O
aspa. NN O O
. NN O O

adrenoleukodystrophy: NN O O
survey NN O O
of NN O O
303 NN O O
cases: NN O O
biochemistry, NN O O
diagnosis, NN O O
and NN O O
therapy NN O O
. NN O O

adrenoleukodystrophy NN O O
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
is NN O O
a NN O O
genetically NN O O
determined NN O O
disorder NN O O
associated NN O O
with NN O O
progressive NN B-DiseaseClass B-MSH:D003711
central NN I-DiseaseClass I-MSH:D003711
demyelination NN I-DiseaseClass I-MSH:D003711
and NN O O
adrenal NN B-DiseaseClass B-MSH:D000309
cortical NN I-DiseaseClass I-MSH:D000309
insufficiency NN I-DiseaseClass I-MSH:D000309
. NN O O
all NN O O
affected NN O O
persons NN O O
show NN O O
increased NN O O
levels NN O O
of NN O O
saturated NN O O
unbranched NN O O
very-long-chain NN O O
fatty NN O O
acids, NN O O
particularly NN O O
hexacosanoate NN O O
(c NN O O
26 NN O O
0), NN O O
because NN O O
of NN O O
impaired NN O O
capacity NN O O
to NN O O
degrade NN O O
these NN O O
acids. NN O O
this NN O O
degradation NN O O
normally NN O O
takes NN O O
place NN O O
in NN O O
a NN O O
subcellular NN O O
organelle NN O O
called NN O O
the NN O O
peroxisome, NN O O
and NN O O
ALD NN B-SpecificDisease B-MSH:D000326
, NN O O
together NN O O
with NN O O
Zellwegers NN B-SpecificDisease B-MSH:D015211
cerebrohepatorenal NN I-SpecificDisease I-MSH:D015211
syndrome NN I-SpecificDisease I-MSH:D015211
, NN O O
is NN O O
now NN O O
considered NN O O
to NN O O
belong NN O O
to NN O O
the NN O O
newly NN O O
formed NN O O
category NN O O
of NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
disorders NN I-DiseaseClass I-MSH:D018901
. NN O O
biochemical NN O O
assays NN O O
permit NN O O
prenatal NN O O
diagnosis, NN O O
as NN O O
well NN O O
as NN O O
identification NN O O
of NN O O
most NN O O
heterozygotes. NN O O
we NN O O
have NN O O
identified NN O O
303 NN O O
patients NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
in NN O O
217 NN O O
kindreds. NN O O
these NN O O
patients NN O O
show NN O O
a NN O O
wide NN O O
phenotypic NN O O
variation. NN O O
sixty NN O O
percent NN O O
of NN O O
patients NN O O
had NN O O
childhood NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
17% NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
, NN O O
both NN O O
of NN O O
which NN O O
are NN O O
x NN O O
. NN O O

linked, NN O O
with NN O O
the NN O O
gene NN O O
mapped NN O O
to NN O O
xq NN O O
28. NN O O
Neonatal NN B-SpecificDisease B-OMIM:202370
ALD NN I-SpecificDisease I-OMIM:202370
, NN O O
a NN O O
distinct NN O O
entity NN O O
with NN O O
autosomal NN O O
recessive NN O O
inheritance NN O O
and NN O O
points NN O O
of NN O O
resemblance NN O O
to NN O O
Zellwegers NN B-SpecificDisease B-MSH:D015211
syndrome NN I-SpecificDisease I-MSH:D015211
, NN O O
accounted NN O O
for NN O O
7% NN O O
of NN O O
the NN O O
cases. NN O O
although NN O O
excess NN O O
c NN O O
26 NN O O
0 NN O O
in NN O O
the NN O O
brain NN O O
of NN O O
patients NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
is NN O O
partially NN O O
of NN O O
dietary NN O O
origin, NN O O
dietary NN O O
c NN O O
26 NN O O
0 NN O O
restriction NN O O
did NN O O
not NN O O
produce NN O O
clear NN O O
benefit. NN O O
bone NN O O
marrow NN O O
transplant NN O O
lowered NN O O
the NN O O
plasma NN O O
c NN O O
26 NN O O
0 NN O O
level NN O O
but NN O O
failed NN O O
to NN O O
arrest NN O O
neurological NN O O
progression. NN O O
. NN O O

french NN O O
Machado-Joseph NN B-Modifier B-MSH:D017827
disease NN I-Modifier I-MSH:D017827
patients NN O O
do NN O O
not NN O O
exhibit NN O O
gametic NN O O
segregation NN O O
distortion: NN O O
a NN O O
sperm NN O O
typing NN O O
analysis NN O O
. NN O O

segregation NN O O
distortion NN O O
has NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
in NN O O
a NN O O
number NN O O
of NN O O
the NN O O
trinucleotide NN B-DiseaseClass B-MSH:D030342
repeat NN I-DiseaseClass I-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
a NN O O
sperm NN O O
typing NN O O
study NN O O
performed NN O O
in NN O O
patients NN O O
of NN O O
japanese NN O O
descent NN O O
with NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
( NN O O
MJD NN B-SpecificDisease B-MSH:D017827
), NN O O
it NN O O
was NN O O
reported NN O O
that NN O O
disease NN O O
alleles NN O O
are NN O O
preferentially NN O O
transmitted NN O O
during NN O O
meiosis. NN O O
we NN O O
performed NN O O
a NN O O
sperm NN O O
typing NN O O
study NN O O
of NN O O
five NN O O
MJD NN B-Modifier B-MSH:D017827
patients NN O O
of NN O O
french NN O O
descent NN O O
and NN O O
analysis NN O O
of NN O O
the NN O O
pooled NN O O
data NN O O
shows NN O O
a NN O O
ratio NN O O
of NN O O
mutant NN O O
to NN O O
normal NN O O
alleles NN O O
of NN O O
379 NN O O
436 NN O O
(46. NN O O
5 NN O O
53. NN O O
5%), NN O O
which NN O O
does NN O O
not NN O O
support NN O O
meiotic NN O O
segregation NN O O
distortion. NN O O
to NN O O
confirm NN O O
these NN O O
results, NN O O
sperm NN O O
typing NN O O
analysis NN O O
was NN O O
also NN O O
performed NN O O
using NN O O
a NN O O
polymorphic NN O O
marker, NN O O
d NN O O
14 NN O O
s NN O O
1050, NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
mjd NN O O
1 NN O O
gene. NN O O
among NN O O
910 NN O O
sperm NN O O
analyzed, NN O O
the NN O O
allele NN O O
linked NN O O
to NN O O
the NN O O
disease NN O O
chromosom NN O O
. NN O O

was NN O O
detected NN O O
in NN O O
50. NN O O
3% NN O O
of NN O O
the NN O O
samples NN O O
and NN O O
the NN O O
allele NN O O
linked NN O O
to NN O O
the NN O O
normal NN O O
chromosome NN O O
was NN O O
found NN O O
in NN O O
49. NN O O
6% NN O O
of NN O O
the NN O O
sperm. NN O O
the NN O O
difference NN O O
in NN O O
frequency NN O O
of NN O O
these NN O O
two NN O O
alleles NN O O
is NN O O
not NN O O
significant NN O O
(p NN O O
= NN O O
0. NN O O
8423). NN O O
likelihood-based NN O O
analysis NN O O
of NN O O
segregation NN O O
distortion NN O O
in NN O O
the NN O O
single NN O O
sperm NN O O
data NN O O
using NN O O
the NN O O
spermseg NN O O
program NN O O
also NN O O
showed NN O O
no NN O O
support NN O O
for NN O O
segregation NN O O
distortion NN O O
at NN O O
the NN O O
gamete NN O O
level NN O O
in NN O O
this NN O O
patient NN O O
population. NN O O
the NN O O
previous NN O O
report NN O O
on NN O O
the NN O O
japanese NN O O
patients NN O O
also NN O O
suggested NN O O
that NN O O
disease NN O O
allele NN O O
stability NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
a NN O O
trans NN O O
effect NN O O
of NN O O
an NN O O
intragenic NN O O
polymorphism NN O O
(987 NN O O
g/c) NN O O
in NN O O
the NN O O
wild-type NN O O
allele. NN O O
all NN O O
of NN O O
the NN O O
french NN O O
patients NN O O
were NN O O
heterozygous NN O O
for NN O O
this NN O O
polymorphism. NN O O
however, NN O O
analysis NN O O
of NN O O
the NN O O
variance NN O O
in NN O O
repeat NN O O
number NN O O
in NN O O
sperm NN O O
fro NN O O
. NN O O
distortion NN O O
at NN O O
the NN O O
gamete NN O O
level NN O O
in NN O O
this NN O O
patient NN O O
population. NN O O
the NN O O
previous NN O O
report NN O O
on NN O O
the NN O O
japanese NN O O
patients NN O O
also NN O O
suggested NN O O
that NN O O
disease NN O O
allele NN O O
stability NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
a NN O O
trans NN O O
effect NN O O
of NN O O
an NN O O
intragenic NN O O
polymorphism NN O O
(987 NN O O
g/c) NN O O
in NN O O
the NN O O
wild-type NN O O
allele. NN O O
all NN O O
of NN O O
the NN O O
french NN O O
patients NN O O
were NN O O
heterozygous NN O O
for NN O O
this NN O O
polymorphism. NN O O
however, NN O O
analysis NN O O
of NN O O
the NN O O
variance NN O O
in NN O O
repeat NN O O
number NN O O
in NN O O
sperm NN O O
fro NN O O
. NN O O

the NN O O
french NN O O
MJD NN B-Modifier B-MSH:D017827
patients NN O O
overlapped NN O O
significantly NN O O
with NN O O
the NN O O
variance NN O O
in NN O O
repeat NN O O
number NN O O
observed NN O O
in NN O O
the NN O O
c/c NN O O
homozygous NN O O
japanese NN O O
patients NN O O
. NN O O

nebulin NN O O
seen NN O O
in NN O O
DMD NN B-Modifier B-MSH:D020388
males NN O O
including NN O O
one NN O O
patient NN O O
with NN O O
a NN O O
large NN O O
dna NN O O
deletion NN O O
encompassing NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
. NN O O

the NN O O
presence NN O O
of NN O O
nebulin NN O O
in NN O O
a NN O O
muscle NN O O
specimen NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
due NN O O
to NN O O
a NN O O
large NN O O
deletion NN O O
precludes NN O O
the NN O O
possibility NN O O
that NN O O
this NN O O
protein NN O O
is NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
product. NN O O
. NN O O

the NN O O
human NN O O
gene NN O O
for NN O O
alkaptonuria NN B-SpecificDisease B-MSH:D000474
( NN O O
AKU NN B-SpecificDisease B-MSH:D000474
) NN O O
maps NN O O
to NN O O
chromosome NN O O
3 NN O O
q NN O O
. NN O O

alkaptonuria NN O O
( NN O O
AKU NN B-SpecificDisease B-MSH:D000474
; NN O O
mckusick NN O O
no. NN O O
203500) NN O O
is NN O O
a NN O O
rare NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
the NN O O
lack NN O O
of NN O O
homogentisic NN O O
acid NN O O
oxidase NN O O
activity. NN O O
patients NN O O
excrete NN O O
large NN O O
amounts NN O O
of NN O O
homogentisic NN O O
acid NN O O
in NN O O
their NN O O
urine NN O O
and NN O O
a NN O O
black NN O O
ochronotic NN O O
pigment NN O O
is NN O O
deposited NN O O
in NN O O
their NN O O
cartilage NN O O
and NN O O
collagenous NN O O
tissues. NN O O
Ochronosis NN B-SpecificDisease B-MSH:D009794
is NN O O
the NN O O
predominant NN O O
clinical NN O O
complication NN O O
of NN O O
the NN O O
disease NN O O
leading NN O O
to NN O O
ochronotic NN B-SpecificDisease B-MSH:D009794
arthropathy NN I-SpecificDisease I-MSH:D009794
, NN O O
dark NN O O
urine, NN O O
pigment NN O O
changes NN O O
of NN O O
the NN O O
skin, NN O O
and NN O O
other NN O O
clinical NN O O
features. NN O O
a NN O O
mutation NN O O
causing NN O O
alkaptonuria NN B-SpecificDisease B-MSH:D000474
in NN O O
the NN O O
mouse NN O O
has NN O O
mapped NN O O
to NN O O
chromosome NN O O
16. NN O O
considering NN O O
conserved NN O O
synteny, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
map NN O O
the NN O O
human NN O O
gene NN O O
to NN O O
chromosome NN O O
3 NN O O
q NN O O
in NN O O
six NN O O
alkaptonuria NN B-Modifier B-MSH:D000474
pedigrees NN O O
of NN O O
slovak NN O O
origin. NN O O
. NN O O

the NN O O
APC NN B-Modifier B-MSH:D011125
gene, NN O O
responsible NN O O
for NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
, NN O O
is NN O O
mutated NN O O
in NN O O
human NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
. NN O O

although NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
is NN O O
the NN O O
most NN O O
common NN O O
cancer NN B-DiseaseClass B-MSH:D009369
in NN O O
the NN O O
world, NN O O
genetic NN O O
changes NN O O
during NN O O
its NN O O
carcinogenesis NN O O
are NN O O
not NN O O
well NN O O
understood. NN O O
since NN O O
some NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancers NN I-SpecificDisease I-MSH:D013274
are NN O O
considered NN O O
to NN O O
originate NN O O
from NN O O
the NN O O
intestinal NN O O
metaplasia, NN O O
it NN O O
is NN O O
likely NN O O
that NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
( NN O O
APC NN B-Modifier B-MSH:D011125
) NN O O
gene, NN O O
the NN O O
mutation NN O O
of NN O O
which NN O O
causes NN O O
adenomatous NN B-SpecificDisease B-MSH:D018256
polyps NN I-SpecificDisease I-MSH:D018256
in NN I-SpecificDisease I-MSH:D018256
the NN I-SpecificDisease I-MSH:D018256
colon NN I-SpecificDisease I-MSH:D018256
, NN O O
is NN O O
associated NN O O
with NN O O
carcinogenesis NN O O
of NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
. NN O O
based NN O O
on NN O O
this NN O O
idea, NN O O
dnas NN O O
isolated NN O O
from NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancers NN I-SpecificDisease I-MSH:D013274
were NN O O
examined NN O O
by NN O O
means NN O O
of NN O O
a NN O O
rnase NN O O
protection NN O O
analysis NN O O
coupled NN O O
with NN O O
polymerase NN O O
chain NN O O
reaction NN O O
followed NN O O
by NN O O
sequencing NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
products. NN O O
by NN O O
screening NN O O
nearly NN O O
one-half NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
in NN O O
44 NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
somatic NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
three NN O O
tumors NN B-DiseaseClass B-MSH:D009369
a NN O O
missense NN O O
mutation, NN O O
a NN O O
nonsense NN O O
mutation, NN O O
and NN O O
a NN O O
5-base NN O O
pai NN O O
. NN O O

deletion NN O O
resulting NN O O
in NN O O
a NN O O
frame NN O O
shift NN O O
which NN O O
causes NN O O
truncation NN O O
of NN O O
the NN O O
gene NN O O
product. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
mutation NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
also NN O O
plays NN O O
an NN O O
important NN O O
role NN O O
during NN O O
the NN O O
carcinogenesis NN O O
of NN O O
at NN O O
least NN O O
some NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancers NN I-SpecificDisease I-MSH:D013274
. NN O O
. NN O O

molecular NN O O
epidemiology NN O O
of NN O O
C9 NN B-Modifier B-OMIM:613825
deficiency NN I-Modifier I-OMIM:613825
heterozygotes NN O O
with NN O O
an NN O O
arg NN O O
95 NN O O
stop NN O O
mutation NN O O
of NN O O
the NN O O
c NN O O
9 NN O O
gene NN O O
in NN O O
japan NN O O
. NN O O

deficiency NN O O
of NN O O
the NN O O
ninth NN O O
component NN O O
of NN O O
human NN O O
complement NN O O
(c NN O O
9) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
complement NN B-DiseaseClass B-MSH:D007153
deficiency NN I-DiseaseClass I-MSH:D007153
in NN O O
japan, NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
approximately NN O O
one NN O O
homozygote NN O O
in NN O O
1000, NN O O
but NN O O
is NN O O
very NN O O
rare NN O O
in NN O O
other NN O O
countries. NN O O
genetic NN O O
analyses NN O O
of NN O O
japanese NN O O
C9 NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
have NN O O
shown NN O O
that NN O O
a NN O O
c-to-t NN O O
transition NN O O
leading NN O O
to NN O O
tga NN O O
stop NN O O
codon NN O O
for NN O O
arg NN O O
95 NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
the NN O O
c NN O O
9 NN O O
gene NN O O
(arg NN O O
95 NN O O
stop) NN O O
is NN O O
common NN O O
in NN O O
japanese NN O O
C9 NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
. NN O O
to NN O O
determine NN O O
the NN O O
prevalence NN O O
of NN O O
heterozygous NN O O
carriers NN O O
of NN O O
the NN O O
arg NN O O
95 NN O O
stop NN O O
mutation NN O O
in NN O O
a NN O O
japanese NN O O
population, NN O O
we NN O O
collected NN O O
dna NN O O
samples NN O O
from NN O O
300 NN O O
individuals NN O O
in NN O O
two NN O O
of NN O O
the NN O O
four NN O O
main NN O O
islands NN O O
of NN O O
japan. NN O O
heterozygote NN O O
detection NN O O
was NN O O
performed NN O O
with NN O O
an NN O O
allele-specific NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
system NN O O
designed NN O O
to NN O O
detect NN O O
exclusivel NN O O
. NN O O

only NN O O
one NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
mutant NN O O
alleles, NN O O
followed NN O O
by NN O O
confirmation NN O O
with NN O O
pcr/single-strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing. NN O O
twenty NN O O
individuals NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
arg NN O O
95 NN O O
stop NN O O
mutation. NN O O
none NN O O
was NN O O
homozygous. NN O O
the NN O O
prevalence NN O O
of NN O O
carriers NN O O
of NN O O
the NN O O
arg NN O O
95 NN O O
stop NN O O
mutation NN O O
was NN O O
6. NN O O
7% NN O O
(20/300). NN O O
an NN O O
estimated NN O O
frequency NN O O
(0. NN O O
12%) NN O O
of NN O O
complete NN O O
C9 NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
due NN O O
to NN O O
homozygous NN O O
arg NN O O
95 NN O O
stop NN O O
mutation NN O O
was NN O O
consistent NN O O
with NN O O
frequencies NN O O
determined NN O O
by NN O O
serological NN O O
studie NN O O
. NN O O

molecular NN O O
analysis NN O O
of NN O O
a NN O O
female NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
patient NN O O
. NN O O

we NN O O
report NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
female NN O O
patient NN O O
with NN O O
the NN O O
x-linked NN O O
recessive NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
( NN O O
hypoxanthine NN B-SpecificDisease B-MSH:D007926
phosphoribosyltransferase NN I-SpecificDisease I-MSH:D007926
[HPRT] NN I-SpecificDisease I-MSH:D007926
deficiency NN I-SpecificDisease I-MSH:D007926
). NN O O
cytogenetic NN O O
and NN O O
carrier NN O O
studies NN O O
revealed NN O O
structurally NN O O
normal NN O O
chromosomes NN O O
for NN O O
this NN O O
patient NN O O
and NN O O
her NN O O
parents NN O O
and NN O O
demonstrated NN O O
that NN O O
this NN O O
mutation NN O O
arose NN O O
through NN O O
a NN O O
de NN O O
novo NN O O
gametic NN O O
event. NN O O
comparison NN O O
of NN O O
this NN O O
patients NN O O
dna NN O O
with NN O O
the NN O O
dna NN O O
of NN O O
her NN O O
parents NN O O
revealed NN O O
that NN O O
a NN O O
microdeletion, NN O O
which NN O O
occurred NN O O
within NN O O
a NN O O
maternal NN O O
gamete NN O O
and NN O O
involved NN O O
the NN O O
entire NN O O
hprt NN O O
gene, NN O O
was NN O O
partially NN O O
responsible NN O O
for NN O O
the NN O O
disease NN O O
in NN O O
this NN O O
patient. NN O O
somatic NN O O
cell NN O O
hybrids, NN O O
generated NN O O
to NN O O
separate NN O O
maternal NN O O
and NN O O
paternal NN O O
x NN O O
chromosomes, NN O O
showed NN O O
that NN O O
expression NN O O
of NN O O
two NN O O
additional NN O O
x-linked NN O O
enzymes, NN O O
phosphoglycerate NN O O
kinase NN O O
and NN O O
glucose-6-phosphate NN O O
dehydrogenase, NN O O
were NN O O
expressed NN O O
only NN O O
in NN O O
cells NN O O
that NN O O
contained NN O O
the NN O O
maternal NN O O
x NN O O
chromosome, NN O O
suggestin NN O O
. NN O O

the NN O O
presence NN O O
of NN O O
a NN O O
functionally NN O O
inactive NN O O
paternal NN O O
x NN O O
chromosome. NN O O
furthermore, NN O O
comparison NN O O
of NN O O
methylation NN O O
patterns NN O O
within NN O O
a NN O O
region NN O O
of NN O O
the NN O O
hprt NN O O
gene NN O O
known NN O O
to NN O O
be NN O O
important NN O O
in NN O O
gene NN O O
regulation NN O O
revealed NN O O
differences NN O O
between NN O O
dna NN O O
from NN O O
the NN O O
father NN O O
and NN O O
the NN O O
patient, NN O O
in NN O O
keeping NN O O
with NN O O
an NN O O
active NN O O
hprt NN O O
locus NN O O
in NN O O
the NN O O
father NN O O
and NN O O
an NN O O
inactive NN O O
hprt NN O O
locus NN O O
in NN O O
the NN O O
patient. NN O O
together NN O O
these NN O O
data NN O O
indicate NN O O
that NN O O
nonrandom NN O O
inactivation NN O O
of NN O O
the NN O O
cytogenetically NN O O
normal NN O O
paternal NN O O
x NN O O
chromosome NN O O
and NN O O
a NN O O
microdeletion NN O O
of NN O O
the NN O O
hprt NN O O
gene NN O O
on NN O O
an NN O O
active NN O O
maternal NN O O
x NN O O
chromosome NN O O
were NN O O
responsible NN O O
for NN O O
the NN O O
absence NN O O
of NN O O
hprt NN O O
in NN O O
this NN O O
patient. NN O O
. NN O O
important NN O O
in NN O O
gene NN O O
regulation NN O O
revealed NN O O
differences NN O O
between NN O O
dna NN O O
from NN O O
the NN O O
father NN O O
and NN O O
the NN O O
patient, NN O O
in NN O O
keeping NN O O
with NN O O
an NN O O
active NN O O
hprt NN O O
locus NN O O
in NN O O
the NN O O
father NN O O
and NN O O
an NN O O
inactive NN O O
hprt NN O O
locus NN O O
in NN O O
the NN O O
patient. NN O O
together NN O O
these NN O O
data NN O O
indicate NN O O
that NN O O
nonrandom NN O O
inactivation NN O O
of NN O O
the NN O O
cytogenetically NN O O
normal NN O O
paternal NN O O
x NN O O
chromosome NN O O
and NN O O
a NN O O
microdeletion NN O O
of NN O O
the NN O O
hprt NN O O
gene NN O O
on NN O O
an NN O O
active NN O O
maternal NN O O
x NN O O
chromosome NN O O
were NN O O
responsible NN O O
for NN O O
the NN O O
absence NN O O
of NN O O
hprt NN O O
in NN O O
this NN O O
patient. NN O O
. NN O O

changes NN O O
at NN O O
p NN O O
183 NN O O
of NN O O
emerin NN O O
weaken NN O O
its NN O O
protein-protein NN O O
interactions NN O O
resulting NN O O
in NN O O
X-linked NN B-SpecificDisease B-MSH:D020389
Emery-Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
. NN O O

emery-dreifuss NN O O
muscular NN O O
dystrophy NN O O
( NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
recessive NN I-DiseaseClass I-MSH:D040181
muscular NN I-DiseaseClass I-MSH:D040181
dystrophy NN I-DiseaseClass I-MSH:D040181
characterized NN O O
by NN O O
early NN O O
contractures NN B-CompositeMention B-MSH:D003286
of NN I-CompositeMention I-MSH:D003286
the NN I-CompositeMention I-MSH:D003286
elbows, NN I-CompositeMention I-MSH:D003286
Achilles NN I-CompositeMention I-MSH:D003286
tendons NN I-CompositeMention I-MSH:D003286
and NN I-CompositeMention I-MSH:D003286
spine NN I-CompositeMention I-MSH:D003286
, NN O O
slowly NN O O
progressive NN O O
muscle NN B-DiseaseClass B-MSH:D009133
wasting NN I-DiseaseClass I-MSH:D009133
and NN O O
weakness NN B-DiseaseClass B-MSH:D018908
, NN O O
and NN O O
cardiomyopathy NN B-SpecificDisease B-MSH:D009202
associated NN O O
with NN O O
cardiac NN B-SpecificDisease B-OMIM:115080
conduction NN I-SpecificDisease I-OMIM:115080
defects NN I-SpecificDisease I-OMIM:115080
. NN O O
the NN O O
emerin NN O O
gene NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
xq NN O O
28 NN O O
and NN O O
encodes NN O O
a NN O O
34-kda NN O O
serine-rich NN O O
protein, NN O O
emerin, NN O O
which NN O O
has NN O O
been NN O O
localized NN O O
to NN O O
the NN O O
nuclear NN O O
envelope NN O O
in NN O O
a NN O O
wide NN O O
variety NN O O
of NN O O
tissues, NN O O
including NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle. NN O O
mutations NN O O
spanning NN O O
the NN O O
emerin NN O O
gene NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
. NN O O
we NN O O
present NN O O
here NN O O
the NN O O
effect, NN O O
on NN O O
emerin NN O O
protein NN O O
expression, NN O O
of NN O O
two NN O O
missense NN O O
mutations NN O O
identified NN O O
in NN O O
unrelated NN O O
EDMD NN B-Modifier B-MSH:D020389
patients. NN O O
these NN O O
alterations NN O O
predict NN O O
the NN O O
replacement NN O O
of NN O O
a NN O O
proline NN O O
residue NN O O
at NN O O
position NN O O
183 NN O O
with NN O O
either NN O O
a NN O O
histidine NN O O
or NN O O
a NN O O
threonin NN O O
. NN O O

. NN O O
biochemical NN O O
analysis NN O O
has NN O O
demonstrated NN O O
that NN O O
the NN O O
mobility NN O O
and NN O O
expression NN O O
levels NN O O
of NN O O
the NN O O
mutant NN O O
forms NN O O
of NN O O
emerin NN O O
are NN O O
indistinguishable NN O O
from NN O O
that NN O O
of NN O O
wild-type NN O O
emerin, NN O O
but NN O O
that NN O O
they NN O O
have NN O O
weakened NN O O
interactions NN O O
with NN O O
nuclear NN O O
lamina NN O O
components. NN O O
in NN O O
comparison NN O O
with NN O O
the NN O O
usual NN O O
EDMD NN B-Modifier B-MSH:D020389
phenotype, NN O O
patients NN O O
with NN O O
p NN O O
183 NN O O
missense NN O O
mutations NN O O
have NN O O
a NN O O
later NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
first NN O O
symptoms, NN O O
elbow NN B-SpecificDisease B-MSH:D003286
contractures NN I-SpecificDisease I-MSH:D003286
, NN O O
ankle NN B-SpecificDisease B-MSH:D003286
contractures NN I-SpecificDisease I-MSH:D003286
, NN O O
upper NN B-SpecificDisease B-MSH:D018908
limb NN I-SpecificDisease I-MSH:D018908
weakness NN I-SpecificDisease I-MSH:D018908
and NN O O
lower NN B-SpecificDisease B-MSH:D018908
limb NN I-SpecificDisease I-MSH:D018908
weakness NN I-SpecificDisease I-MSH:D018908
, NN O O
but NN O O
there NN O O
is NN O O
no NN O O
difference NN O O
for NN O O
the NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
cardiac NN B-DiseaseClass B-MSH:D006331
involvement NN I-DiseaseClass I-MSH:D006331
. NN O O
this NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
protein NN O O
studies NN O O
on NN O O
patients NN O O
with NN O O
missense NN O O
mutations NN O O
resulting NN O O
in NN O O
the NN O O
clinical NN O O
features NN O O
of NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
. NN O O
these NN O O
studies NN O O
demonstrate NN O O
the NN O O
importance NN O O
of NN O O
proline NN O O
183 NN O O
for NN O O
the NN O O
proper NN O O
structure/function NN O O
of NN O O
emerin. NN O O
. NN O O

decreased NN O O
expression NN O O
of NN O O
brca NN O O
1 NN O O
accelerates NN O O
growth NN O O
and NN O O
is NN O O
often NN O O
present NN O O
during NN O O
sporadic NN B-Modifier B-MSH:D001943
breast NN I-Modifier I-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
progression NN O O
. NN O O

we NN O O
have NN O O
characterized NN O O
expression NN O O
of NN O O
the NN O O
familial NN B-Modifier B-MSH:D061325
breast NN I-Modifier I-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
gene, NN O O
brca NN O O
1, NN O O
in NN O O
cases NN O O
of NN O O
non-hereditary NN B-SpecificDisease B-MSH:D001943
(sporadic) NN I-SpecificDisease I-MSH:D001943
breast NN I-SpecificDisease I-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
and NN O O
analyzed NN O O
the NN O O
effect NN O O
of NN O O
antisense NN O O
inhibition NN O O
of NN O O
brca NN O O
1 NN O O
on NN O O
the NN O O
proliferative NN O O
rate NN O O
of NN O O
mammary NN O O
epithelial NN O O
cells. NN O O
brca NN O O
1 NN O O
mrna NN O O
levels NN O O
are NN O O
markedly NN O O
decreased NN O O
during NN O O
the NN O O
transition NN O O
from NN O O
carcinoma NN B-DiseaseClass B-MSH:D002278
in NN I-DiseaseClass I-MSH:D002278
situ NN I-DiseaseClass I-MSH:D002278
to NN O O
invasive NN B-DiseaseClass B-MSH:D009362
cancer NN I-DiseaseClass I-MSH:D009362
. NN O O
experimental NN O O
inhibition NN O O
of NN O O
brca NN O O
1 NN O O
expression NN O O
with NN O O
antisense NN O O
oligonucleotides NN O O
produced NN O O
accelerated NN O O
growth NN O O
of NN O O
normal NN O O
and NN O O
malignant NN O O
mammary NN O O
cells, NN O O
but NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
non-mammary NN O O
epithelial NN O O
cells. NN O O
these NN O O
studies NN O O
suggest NN O O
that NN O O
brca NN O O
1 NN O O
may NN O O
normally NN O O
serve NN O O
as NN O O
a NN O O
negative NN O O
regulator NN O O
of NN O O
mammary NN O O
epithelial NN O O
cell NN O O
growth NN O O
whose NN O O
function NN O O
is NN O O
compromised NN O O
in NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
either NN O O
by NN O O
direct NN O O
mutation NN O O
or NN O O
alterations NN O O
in NN O O
gene NN O O
expression. NN O O
. NN O O

additional NN O O
copies NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
causing NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
arise NN O O
by NN O O
separate NN O O
integration NN O O
into NN O O
the NN O O
x NN O O
chromosome NN O O
. NN O O

the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
(plp) NN O O
is NN O O
normally NN O O
present NN O O
at NN O O
chromosome NN O O
xq NN O O
22. NN O O
mutations NN O O
and NN O O
duplications NN O O
of NN O O
this NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
( NN O O
PMD NN B-SpecificDisease B-OMIM:312080
). NN O O
here NN O O
we NN O O
describe NN O O
two NN O O
new NN O O
families NN O O
in NN O O
which NN O O
males NN O O
affected NN O O
with NN O O
PMD NN B-SpecificDisease B-OMIM:312080
were NN O O
found NN O O
to NN O O
have NN O O
a NN O O
copy NN O O
of NN O O
plp NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome, NN O O
in NN O O
addition NN O O
to NN O O
a NN O O
normal NN O O
copy NN O O
on NN O O
xq NN O O
22. NN O O
in NN O O
the NN O O
first NN O O
family, NN O O
the NN O O
extra NN O O
copy NN O O
was NN O O
first NN O O
detected NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
heterozygosity NN O O
of NN O O
the NN O O
ahaii NN O O
dimorphism NN O O
within NN O O
the NN O O
plp NN O O
gene. NN O O
the NN O O
results NN O O
of NN O O
fish NN O O
analysis NN O O
showed NN O O
an NN O O
additional NN O O
copy NN O O
of NN O O
plp NN O O
in NN O O
xp NN O O
22. NN O O
1, NN O O
although NN O O
no NN O O
chromosomal NN O O
rearrangements NN O O
could NN O O
be NN O O
detected NN O O
by NN O O
standard NN O O
karyotype NN O O
analysis. NN O O
another NN O O
three NN O O
affected NN O O
males NN O O
from NN O O
the NN O O
family NN O O
had NN O O
similar NN O O
findings. NN O O
in NN O O
a NN O O
second NN O O
unrelate NN O O
. NN O O

family NN O O
with NN O O
signs NN O O
of NN O O
PMD NN B-SpecificDisease B-OMIM:312080
, NN O O
cytogenetic NN O O
analysis NN O O
showed NN O O
a NN O O
pericentric NN O O
inversion NN O O
of NN O O
the NN O O
x NN O O
chromosome. NN O O
in NN O O
the NN O O
inv NN O O
(x) NN O O
carried NN O O
by NN O O
several NN O O
affected NN O O
family NN O O
members, NN O O
fish NN O O
showed NN O O
plp NN O O
signals NN O O
at NN O O
xp NN O O
11. NN O O
4 NN O O
and NN O O
xq NN O O
22. NN O O
a NN O O
third NN O O
family NN O O
has NN O O
previously NN O O
been NN O O
reported, NN O O
in NN O O
which NN O O
affected NN O O
members NN O O
had NN O O
an NN O O
extra NN O O
copy NN O O
of NN O O
the NN O O
plp NN O O
gene NN O O
detected NN O O
at NN O O
xq NN O O
26 NN O O
in NN O O
a NN O O
chromosome NN O O
with NN O O
an NN O O
otherwise NN O O
normal NN O O
banding NN O O
pattern. NN O O
the NN O O
identification NN O O
of NN O O
three NN O O
separate NN O O
families NN O O
in NN O O
which NN O O
plp NN O O
is NN O O
duplicated NN O O
at NN O O
a NN O O
noncontiguous NN O O
site NN O O
suggests NN O O
that NN O O
such NN O O
duplications NN O O
could NN O O
be NN O O
a NN O O
relatively NN O O
common NN O O
but NN O O
previously NN O O
undetected NN O O
cause NN O O
of NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
. NN O O

linkage NN O O
relationships NN O O
of NN O O
the NN O O
apolipoprotein NN O O
c NN O O
1 NN O O
gene NN O O
and NN O O
a NN O O
cytochrome NN O O
p NN O O
450 NN O O
gene NN O O
(cyp NN O O
2 NN O O
a) NN O O
to NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
. NN O O

we NN O O
have NN O O
studied NN O O
the NN O O
genetic NN O O
linkage NN O O
of NN O O
two NN O O
markers, NN O O
the NN O O
apolipoprotein NN O O
c NN O O
1 NN O O
(apoc NN O O
1) NN O O
gene NN O O
and NN O O
a NN O O
cytochrome NN O O
p NN O O
450 NN O O
(cyp NN O O
2 NN O O
a) NN O O
gene, NN O O
in NN O O
relation NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
). NN O O
a NN O O
peak NN O O
lod NN O O
score NN O O
of NN O O
9. NN O O
29 NN O O
at NN O O
2 NN O O
cm NN O O
was NN O O
observed NN O O
for NN O O
apoc NN O O
1-dm, NN O O
with NN O O
a NN O O
lod NN O O
score NN O O
of NN O O
8. NN O O
55 NN O O
at NN O O
4 NN O O
cm NN O O
for NN O O
cyp NN O O
2 NN O O
a-dm. NN O O
these NN O O
two NN O O
markers NN O O
also NN O O
show NN O O
close NN O O
linkage NN O O
to NN O O
each NN O O
other NN O O
(theta NN O O
max NN O O
= NN O O
0. NN O O
05, NN O O
zmax NN O O
= NN O O
9. NN O O
09). NN O O
from NN O O
examination NN O O
of NN O O
the NN O O
genotypes NN O O
of NN O O
the NN O O
recombinant NN O O
individuals, NN O O
cyp NN O O
2 NN O O
a NN O O
appears NN O O
to NN O O
map NN O O
proximal NN O O
to NN O O
dm NN O O
because NN O O
in NN O O
one NN O O
recombinant NN O O
individual NN O O
cyp NN O O
2 NN O O
a, NN O O
apoc NN O O
2 NN O O
and NN O O
ckmm NN O O
had NN O O
all NN O O
recombine NN O O
. NN O O

with NN O O
dm. NN O O
evidence NN O O
from NN O O
another NN O O
cyp NN O O
2 NN O O
a-dm NN O O
recombinant NN O O
individual NN O O
places NN O O
cyp NN O O
2 NN O O
a NN O O
proximal NN O O
to NN O O
apoc NN O O
2 NN O O
and NN O O
ckmm. NN O O
localisation NN O O
of NN O O
cyp NN O O
2 NN O O
a NN O O
on NN O O
a NN O O
panel NN O O
of NN O O
somatic NN O O
cell NN O O
hybrids NN O O
also NN O O
suggests NN O O
that NN O O
it NN O O
is NN O O
proximal NN O O
to NN O O
dm NN O O
and NN O O
apoc NN O O
2/c NN O O
1/e NN O O
gene NN O O
cluster NN O O
. NN O O
sts NN O O
that NN O O
it NN O O
is NN O O
proximal NN O O
to NN O O
dm NN O O
and NN O O
apoc NN O O
2/c NN O O
1/e NN O O
gene NN O O
cluster NN O O
. NN O O

beta-galactosidase NN O O
gene NN O O
mutations NN O O
affecting NN O O
the NN O O
lysosomal NN O O
enzyme NN O O
and NN O O
the NN O O
elastin-binding NN O O
protein NN O O
in NN O O
GM1-gangliosidosis NN B-Modifier B-MSH:D016537
patients NN O O
with NN O O
cardiac NN B-SpecificDisease B-MSH:D006331
involvement NN I-SpecificDisease I-MSH:D006331
. NN O O

gm NN O O
1-gangliosidosis NN O O
is NN O O
a NN O O
lysosomal NN B-DiseaseClass B-MSH:D016464
storage NN I-DiseaseClass I-MSH:D016464
disorder NN I-DiseaseClass I-MSH:D016464
caused NN O O
by NN O O
deficiency NN B-SpecificDisease B-MSH:D016537
of NN I-SpecificDisease I-MSH:D016537
acid NN I-SpecificDisease I-MSH:D016537
beta-galactosidase NN I-SpecificDisease I-MSH:D016537
(glb NN O O
1). NN O O
we NN O O
report NN O O
five NN O O
new NN O O
beta-galactosidase NN O O
gene NN O O
mutations NN O O
in NN O O
nine NN O O
italian NN O O
patients NN O O
and NN O O
one NN O O
fetus, NN O O
segregating NN O O
in NN O O
seven NN O O
unrelated NN O O
families. NN O O
six NN O O
of NN O O
the NN O O
eight NN O O
patients NN O O
with NN O O
the NN O O
infantile, NN O O
severe NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
presented NN O O
cardiac NN B-DiseaseClass B-MSH:D006331
involvement NN I-DiseaseClass I-MSH:D006331
, NN O O
a NN O O
feature NN O O
rarely NN O O
associated NN O O
with NN O O
GM1-gangliosidosis NN B-SpecificDisease B-MSH:D016537
. NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
patients NN O O
rna NN O O
and NN O O
dna NN O O
identified NN O O
two NN O O
new NN O O
rna NN O O
splicing NN O O
defects, NN O O
three NN O O
new NN O O
and NN O O
three NN O O
previously NN O O
described NN O O
amino NN O O
acid NN O O
substitutions. NN O O
interestingly, NN O O
all NN O O
patients NN O O
with NN O O
cardiac NN B-DiseaseClass B-MSH:D006331
involvement NN I-DiseaseClass I-MSH:D006331
were NN O O
homozygous NN O O
for NN O O
one NN O O
of NN O O
these NN O O
mutations NN O O
r NN O O
59 NN O O
h, NN O O
y NN O O
591 NN O O
c, NN O O
y NN O O
591 NN O O
n, NN O O
or NN O O
ivs NN O O
14-2 NN O O
a NN O O
> NN O O
g. NN O O
in NN O O
contrast, NN O O
all NN O O
other NN O O
patients NN O O
wer NN O O
. NN O O

compound NN O O
heterozygous NN O O
for NN O O
one NN O O
of NN O O
the NN O O
following NN O O
mutations NN O O
r NN O O
201 NN O O
h, NN O O
r NN O O
482 NN O O
h, NN O O
g NN O O
579 NN O O
d, NN O O
ivs NN O O
8 NN O O
+ NN O O
2 NN O O
t NN O O
> NN O O
c. NN O O
although NN O O
we NN O O
could NN O O
not NN O O
directly NN O O
correlate NN O O
the NN O O
presence NN O O
of NN O O
cardiac NN B-DiseaseClass B-MSH:D018376
abnormalities NN I-DiseaseClass I-MSH:D018376
with NN O O
specific NN O O
genetic NN B-DiseaseClass B-MSH:D020022
lesions NN I-DiseaseClass I-MSH:D020022
, NN O O
the NN O O
mutations NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O
cardiomyopathy NN B-DiseaseClass B-MSH:D009202
fell NN O O
in NN O O
the NN O O
glb NN O O
1 NN O O
cdna NN O O
region NN O O
common NN O O
to NN O O
the NN O O
lysosomal NN O O
enzyme NN O O
and NN O O
the NN O O
hbeta-gal-related NN O O
protein, NN O O
also NN O O
known NN O O
as NN O O
the NN O O
elastin NN O O
binding NN O O
protein NN O O
(ebp). NN O O
consequently, NN O O
both NN O O
molecules NN O O
are NN O O
affected NN O O
by NN O O
the NN O O
mutations, NN O O
and NN O O
they NN O O
may NN O O
contribute NN O O
differently NN O O
to NN O O
the NN O O
occurrence NN O O
of NN O O
specific NN O O
clinical NN O O
manifestations. NN O O
. NN O O

exclusion NN O O
of NN O O
linkage NN O O
between NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
and NN O O
the NN O O
human NN O O
serum NN O O
amyloid NN O O
a NN O O
(saa) NN O O
gene NN O O
cluster NN O O
. NN O O

we NN O O
studied NN O O
the NN O O
relationship NN O O
between NN O O
the NN O O
autosomal NN O O
recessive NN O O
trait NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
) NN O O
and NN O O
the NN O O
serum NN O O
amyloid NN O O
a NN O O
(saa) NN O O
genes NN O O
by NN O O
comparing NN O O
alleles NN O O
of NN O O
a NN O O
highly NN O O
polymorphic NN O O
dinucleotide NN O O
repeat NN O O
and NN O O
a NN O O
conventional NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
(rflp) NN O O
in NN O O
the NN O O
saa NN O O
gene NN O O
cluster NN O O
in NN O O
israeli NN O O
FMF NN B-Modifier B-MSH:D010505
kindreds. NN O O
by NN O O
haplotype NN O O
analysis, NN O O
our NN O O
data NN O O
indicate NN O O
a NN O O
minimum NN O O
crossover NN O O
frequency NN O O
of NN O O
22% NN O O
between NN O O
the NN O O
saa NN O O
gene NN O O
marker NN O O
and NN O O
FMF NN B-SpecificDisease B-MSH:D010505
. NN O O
by NN O O
conventional NN O O
linkage NN O O
analysis NN O O
this NN O O
eliminates NN O O
a NN O O
minimum NN O O
of NN O O
10. NN O O
4 NN O O
cm NN O O
including NN O O
and NN O O
surrounding NN O O
the NN O O
saa NN O O
gene NN O O
cluster NN O O
as NN O O
the NN O O
site NN O O
of NN O O
the NN O O
FMF NN B-Modifier B-MSH:D010505
mutation NN O O
although NN O O
saa NN O O
proteins NN O O
are NN O O
prominent NN O O
physiologic NN O O
markers NN O O
of NN O O
the NN O O
acute NN O O
attacks NN O O
. NN O O

mice NN O O
deficient NN B-SpecificDisease B-MSH:D030342
in NN I-SpecificDisease I-MSH:D030342
Six5 NN I-SpecificDisease I-MSH:D030342
develop NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
: NN O O
implications NN O O
for NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
. NN O O

expansion NN O O
of NN O O
a NN O O
ctg NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
3 NN O O
utr NN O O
of NN O O
the NN O O
gene NN O O
dmpk NN O O
at NN O O
the NN O O
dm NN O O
1 NN O O
locus NN O O
on NN O O
chromosome NN O O
19 NN O O
causes NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
, NN O O
a NN O O
dominantly NN B-DiseaseClass B-MSH:D030342
inherited NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
skeletal NN O O
muscle NN B-SpecificDisease B-MSH:D009136
dystrophy NN I-SpecificDisease I-MSH:D009136
and NN O O
myotonia NN B-DiseaseClass B-MSH:D009222
, NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
and NN O O
cardiac NN B-DiseaseClass B-OMIM:115080
conduction NN I-DiseaseClass I-OMIM:115080
defects NN I-DiseaseClass I-OMIM:115080
. NN O O
targeted NN O O
deletion NN O O
of NN O O
dm NN O O
15, NN O O
the NN O O
mouse NN O O
orthologue NN O O
of NN O O
human NN O O
dmpk, NN O O
produced NN O O
mice NN O O
with NN O O
a NN O O
mild NN O O
myopathy NN B-DiseaseClass B-MSH:D009135
and NN O O
cardiac NN B-DiseaseClass B-MSH:D006327
conduction NN I-DiseaseClass I-MSH:D006327
abnormalities NN I-DiseaseClass I-MSH:D006327
, NN O O
but NN O O
without NN O O
other NN O O
features NN O O
of NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
, NN O O
such NN O O
as NN O O
myotonia NN B-DiseaseClass B-MSH:D009222
and NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
. NN O O
we, NN O O
and NN O O
others, NN O O
have NN O O
demonstrated NN O O
that NN O O
repeat NN O O
expansion NN O O
decreases NN O O
expression NN O O
of NN O O
the NN O O
adjacent NN O O
gene NN O O
six NN O O
5 NN O O
(refs NN O O
. NN O O

, NN O O
8), NN O O
which NN O O
encodes NN O O
a NN O O
homeodomain NN O O
transcription NN O O
factor. NN O O
to NN O O
determine NN O O
whether NN O O
SIX5 NN B-SpecificDisease B-MSH:D030342
deficiency NN I-SpecificDisease I-MSH:D030342
contributes NN O O
to NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
phenotype, NN O O
we NN O O
disrupted NN O O
mouse NN O O
six NN O O
5 NN O O
by NN O O
replacing NN O O
the NN O O
first NN O O
exon NN O O
with NN O O
a NN O O
beta-galactosidase NN O O
reporter. NN O O
six NN O O
5-mutant NN O O
mice NN O O
showed NN O O
reporter NN O O
expression NN O O
in NN O O
multiple NN O O
tissues, NN O O
including NN O O
the NN O O
developing NN O O
lens. NN O O
homozygous NN O O
mutant NN O O
mice NN O O
had NN O O
no NN O O
apparent NN O O
abnormalities NN B-DiseaseClass B-MSH:D009139
of NN I-DiseaseClass I-MSH:D009139
skeletal NN I-DiseaseClass I-MSH:D009139
muscle NN I-DiseaseClass I-MSH:D009139
function NN I-DiseaseClass I-MSH:D009139
, NN O O
but NN O O
developed NN O O
lenticular NN B-SpecificDisease B-MSH:D002386
opacities NN I-SpecificDisease I-MSH:D002386
at NN O O
a NN O O
higher NN O O
rate NN O O
than NN O O
controls. NN O O
our NN O O
results NN O O
suggest NN O O
that NN O O
SIX5 NN B-SpecificDisease B-MSH:D030342
deficiency NN I-SpecificDisease I-MSH:D030342
contributes NN O O
to NN O O
the NN O O
cataract NN B-Modifier B-MSH:D002386
phenotype NN O O
in NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
, NN O O
and NN O O
that NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
represents NN O O
a NN O O
multigenic NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
. NN O O
. NN O O

screening NN O O
for NN O O
germ-line NN O O
mutations NN O O
in NN O O
familial NN B-Modifier B-MSH:D011125
adenomatous NN I-Modifier I-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
patients: NN O O
61 NN O O
new NN O O
patients NN O O
and NN O O
a NN O O
summary NN O O
of NN O O
150 NN O O
unrelated NN O O
patients NN O O
. NN O O

we NN O O
report NN O O
here NN O O
the NN O O
result NN O O
of NN O O
a NN O O
screening NN O O
for NN O O
germ-line NN O O
mutations NN O O
in NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
( NN O O
APC NN B-Modifier B-MSH:D011125
) NN O O
gene NN O O
in NN O O
61 NN O O
new NN O O
familial NN B-Modifier B-MSH:D011125
adenomatous NN I-Modifier I-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
( NN O O
FAP NN B-Modifier B-MSH:D011125
) NN O O
patients NN O O
as NN O O
well NN O O
as NN O O
a NN O O
summary NN O O
of NN O O
the NN O O
results NN O O
of NN O O
150 NN O O
patients. NN O O
examination NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene, NN O O
based NN O O
on NN O O
a NN O O
ribonuclease NN O O
protection NN O O
assay NN O O
coupled NN O O
with NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr), NN O O
disclosed NN O O
mutations NN O O
that NN O O
were NN O O
considered NN O O
to NN O O
cause NN O O
significant NN O O
defects NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
product NN O O
in NN O O
97 NN O O
of NN O O
150 NN O O
unrelated NN O O
FAP NN B-Modifier B-MSH:D011125
patients. NN O O
our NN O O
findings NN O O
revealed NN O O
the NN O O
following NN O O
characteristics NN O O
of NN O O
the NN O O
germ-line NN O O
mutations NN O O
of NN O O
apc NN O O
1) NN O O
the NN O O
great NN O O
majority NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
found NN O O
to NN O O
truncate NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
product; NN O O
2) NN O O
almost NN O O
all NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
located NN O O
within NN O O
the NN O O
first NN O O
half NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
. NN O O

3) NN O O
no NN O O
correlation NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
locations NN O O
of NN O O
germ-line NN O O
mutations NN O O
and NN O O
extracolonic NN O O
manifestations NN O O
in NN O O
FAP NN B-Modifier B-MSH:D011125
patients; NN O O
4) NN O O
more NN O O
than NN O O
80% NN O O
of NN O O
base NN O O
substitutions NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
were NN O O
from NN O O
cytosine NN O O
to NN O O
other NN O O
nucleotides, NN O O
nearly NN O O
one-third NN O O
of NN O O
which NN O O
occurred NN O O
at NN O O
the NN O O
gpg NN O O
site. NN O O
our NN O O
results NN O O
provide NN O O
information NN O O
helpful NN O O
to NN O O
an NN O O
understanding NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
and NN O O
will NN O O
also NN O O
contribute NN O O
to NN O O
presymptomatic NN O O
diagnosis NN O O
of NN O O
members NN O O
in NN O O
FAP NN B-Modifier B-MSH:D011125
families. NN O O
. NN O O

hereditary NN O O
deficiency NN B-SpecificDisease B-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
C5 NN I-SpecificDisease I-OMIM:609536
in NN O O
association NN O O
with NN O O
discoid NN B-SpecificDisease B-MSH:D008179
lupus NN I-SpecificDisease I-MSH:D008179
erythematosus NN I-SpecificDisease I-MSH:D008179
. NN O O

a NN O O
29-year-old NN O O
woman NN O O
with NN O O
discoid NN B-SpecificDisease B-MSH:D008179
lupus NN I-SpecificDisease I-MSH:D008179
erythematosus NN I-SpecificDisease I-MSH:D008179
had NN O O
undetectable NN O O
classic NN O O
pathway NN O O
complement NN O O
activity. NN O O
Hypocomplementemia NN B-DiseaseClass B-MSH:D007153
was NN O O
due NN O O
to NN O O
selective NN O O
deficiency NN B-SpecificDisease B-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
C5 NN I-SpecificDisease I-OMIM:609536
. NN O O
one NN O O
of NN O O
her NN O O
children NN O O
was NN O O
also NN O O
deficient. NN O O
to NN O O
our NN O O
knowledge NN O O
this NN O O
is NN O O
the NN O O
first NN O O
documented NN O O
case NN O O
of NN O O
an NN O O
association NN O O
between NN O O
discoid NN B-SpecificDisease B-MSH:D008179
lupus NN I-SpecificDisease I-MSH:D008179
erythematosus NN I-SpecificDisease I-MSH:D008179
and NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
. NN O O
. NN O O

isolation, NN O O
genomic NN O O
organization, NN O O
and NN O O
expression NN O O
analysis NN O O
of NN O O
the NN O O
mouse NN O O
and NN O O
rat NN O O
homologs NN O O
of NN O O
mefv, NN O O
the NN O O
gene NN O O
for NN O O
familial NN B-SpecificDisease B-MSH:D010505
mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
. NN O O

familial NN O O
mediterranean NN O O
fever NN O O
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
) NN O O
is NN O O
a NN O O
recessive NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
episodes NN O O
of NN O O
fever NN B-DiseaseClass B-MSH:D005334
with NN O O
serositis NN B-SpecificDisease B-MSH:D012700
or NN O O
synovitis NN B-SpecificDisease B-MSH:D013585
. NN O O
recently NN O O
the NN O O
FMF NN B-Modifier B-MSH:D010505
gene NN O O
(mefv) NN O O
was NN O O
cloned; NN O O
the NN O O
protein NN O O
product, NN O O
pyrin/marenostrin, NN O O
is NN O O
thought NN O O
to NN O O
regulate NN O O
inflammation NN O O
in NN O O
myeloid NN O O
cells. NN O O
in NN O O
this NN O O
manuscript NN O O
we NN O O
report NN O O
the NN O O
mouse NN O O
and NN O O
rat NN O O
homologs NN O O
of NN O O
mefv. NN O O
the NN O O
murine NN O O
gene NN O O
contains NN O O
ten NN O O
exons NN O O
with NN O O
a NN O O
coding NN O O
sequence NN O O
of NN O O
2304 NN O O
bp, NN O O
while NN O O
the NN O O
rat NN O O
homolog NN O O
has NN O O
nine NN O O
exons NN O O
with NN O O
a NN O O
coding NN O O
sequence NN O O
of NN O O
2253 NN O O
bp. NN O O
a NN O O
considerable NN O O
amino NN O O
acid NN O O
sequence NN O O
homology NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
mouse NN O O
and NN O O
human NN O O
(47. NN O O
6% NN O O
identity NN O O
and NN O O
65. NN O O
5% NN O O
similarity) NN O O
and NN O O
between NN O O
the NN O O
mouse NN O O
and NN O O
rat NN O O
genes NN O O
(73. NN O O
5% NN O O
identity NN O O
and NN O O
82. NN O O
1% NN O O
similarity). NN O O
the NN O O
predicted NN O O
rodent NN O O
protein NN O O
. NN O O

have NN O O
several NN O O
important NN O O
domains NN O O
and NN O O
signals NN O O
found NN O O
in NN O O
human NN O O
pyrin, NN O O
including NN O O
a NN O O
b-box NN O O
zinc NN O O
finger NN O O
domain, NN O O
robbins-dingwall NN O O
nuclear NN O O
localization NN O O
signal, NN O O
and NN O O
coiled-coil NN O O
domain. NN O O
however, NN O O
perhaps NN O O
because NN O O
of NN O O
an NN O O
ancient NN O O
frame-shift NN O O
mutation, NN O O
neither NN O O
the NN O O
mouse NN O O
nor NN O O
the NN O O
rat NN O O
protein NN O O
has NN O O
an NN O O
intact NN O O
c-terminal NN O O
b NN O O
30. NN O O
2 NN O O
domain, NN O O
in NN O O
which NN O O
most NN O O
FMF NN B-Modifier B-MSH:D010505
-associated NN O O
mutations NN O O
have NN O O
been NN O O
found NN O O
in NN O O
human NN O O
mefv. NN O O
nevertheless, NN O O
like NN O O
the NN O O
human NN O O
gene, NN O O
mouse NN O O
mefv NN O O
is NN O O
expressed NN O O
in NN O O
peripheral NN O O
blood NN O O
granulocytes NN O O
but NN O O
not NN O O
lymphocytes. NN O O
consistent NN O O
with NN O O
its NN O O
expression NN O O
in NN O O
granulocytes, NN O O
mefv NN O O
was NN O O
detected NN O O
at NN O O
high NN O O
levels NN O O
in NN O O
the NN O O
primary NN O O
follicles NN O O
and NN O O
marginal NN O O
zones NN O O
of NN O O
the NN O O
splenic NN O O
white NN O O
pulp. NN O O
mefv NN O O
is NN O O
localized NN O O
on NN O O
mouse NN O O
chromosome NN O O
(chr) NN O O
16, NN O O
region NN O O
a NN O O
3-b NN O O
. NN O O

, NN O O
extending NN O O
a NN O O
region NN O O
of NN O O
synteny NN O O
with NN O O
human NN O O
chr NN O O
16 NN O O
p NN O O
13. NN O O
3. NN O O
development NN O O
of NN O O
knockout NN O O
and NN O O
knockin NN O O
mouse NN O O
models NN O O
may NN O O
provide NN O O
further NN O O
insights NN O O
into NN O O
the NN O O
functional NN O O
evolution NN O O
of NN O O
this NN O O
gene NN O O
. NN O O

analysis NN O O
of NN O O
x-chromosome NN O O
inactivation NN O O
and NN O O
presumptive NN O O
expression NN O O
of NN O O
the NN O O
Wiskott-Aldrich NN B-Modifier B-MSH:D014923
syndrome NN I-Modifier I-MSH:D014923
( NN O O
WAS NN B-Modifier B-MSH:D014923
) NN O O
gene NN O O
in NN O O
hematopoietic NN O O
cell NN O O
lineages NN O O
of NN O O
a NN O O
thrombocytopenic NN O O
carrier NN O O
female NN O O
of NN O O
WAS NN B-SpecificDisease B-MSH:D014923
. NN O O

we NN O O
report NN O O
on NN O O
a NN O O
thrombocytopenic NN B-Modifier B-MSH:D013921
female NN O O
belonging NN O O
to NN O O
a NN O O
pedigree NN O O
with NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
). NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
(rflp) NN O O
analysis NN O O
with NN O O
probe NN O O
m NN O O
27 NN O O
beta, NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
gene, NN O O
demonstrated NN O O
that NN O O
she NN O O
is NN O O
a NN O O
carrier NN O O
of NN O O
WAS NN B-SpecificDisease B-MSH:D014923
. NN O O
both NN O O
small-sized NN O O
and NN O O
normal-sized NN O O
platelets NN O O
were NN O O
present, NN O O
suggesting NN O O
that, NN O O
unlike NN O O
the NN O O
vast NN O O
majority NN O O
of NN O O
WAS NN B-Modifier B-MSH:D014923
carriers, NN O O
she NN O O
does NN O O
not NN O O
manifest NN O O
nonrandom NN O O
x-chromosome NN O O
inactivation NN O O
in NN O O
the NN O O
thrombopoietic NN O O
cell NN O O
lineage. NN O O
study NN O O
of NN O O
x-chromosome NN O O
inactivation NN O O
by NN O O
means NN O O
of NN O O
rflp NN O O
and NN O O
methylation NN O O
analysis NN O O
demonstrated NN O O
that NN O O
the NN O O
pattern NN O O
of NN O O
x-chromosome NN O O
inactivation NN O O
was NN O O
nonrandom NN O O
in NN O O
t NN O O
lymphocytes, NN O O
but NN O O
random NN O O
in NN O O
granulocytes. NN O O
while NN O O
this NN O O
is NN O O
the NN O O
first NN O O
complete NN O O
report NN O O
on NN O O
the NN O O
occurrence NN O O
of NN O O
thrombocytopenia NN B-SpecificDisease B-MSH:D013921
in NN O O
a NN O O
carrier NN O O
female NN O O
of NN O O
WAS NN B-SpecificDisease B-MSH:D014923
a NN O O
. NN O O

the NN O O
result NN O O
of NN O O
atypical NN O O
lyonization, NN O O
it NN O O
also NN O O
suggests NN O O
that NN O O
expression NN O O
of NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
gene NN O O
occurs NN O O
at NN O O
(or NN O O
extends NN O O
up NN O O
to) NN O O
a NN O O
later NN O O
stage NN O O
than NN O O
the NN O O
multipotent NN O O
stem NN O O
cell NN O O
along NN O O
the NN O O
hematopoietic NN O O
differentiation NN O O
pathway. NN O O
. NN O O

hcds NN O O
1-mediated NN O O
phosphorylation NN O O
of NN O O
brca NN O O
1 NN O O
regulates NN O O
the NN O O
dna NN O O
damage NN O O
response NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
(ref. NN O O
1) NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
gene NN O O
are NN O O
found NN O O
in NN O O
almost NN O O
all NN O O
of NN O O
the NN O O
families NN O O
with NN O O
inherited NN B-CompositeMention B-MSH:D061325
breast NN I-CompositeMention I-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancers NN I-CompositeMention I-MSH:D061325
and NN O O
about NN O O
half NN O O
of NN O O
the NN O O
families NN O O
with NN O O
only NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O
although NN O O
the NN O O
biochemical NN O O
function NN O O
of NN O O
brca NN O O
1 NN O O
is NN O O
not NN O O
well NN O O
understood, NN O O
it NN O O
is NN O O
important NN O O
for NN O O
dna NN O O
damage NN O O
repair NN O O
and NN O O
cell-cycle NN O O
checkpoint. NN O O
brca NN O O
1 NN O O
exists NN O O
in NN O O
nuclear NN O O
foci NN O O
but NN O O
is NN O O
hyperphosphorylated NN O O
and NN O O
disperses NN O O
after NN O O
dna NN O O
damage. NN O O
it NN O O
is NN O O
not NN O O
known NN O O
whether NN O O
brca NN O O
1 NN O O
phosphorylation NN O O
and NN O O
dispersion NN O O
and NN O O
its NN O O
function NN O O
in NN O O
dna NN O O
damage NN O O
response NN O O
are NN O O
related. NN O O
in NN O O
yeast NN O O
the NN O O
dna NN O O
damage NN O O
response NN O O
and NN O O
the NN O O
replication-block NN O O
checkpoint NN O O
are NN O O
mediated NN O O
partly NN O O
through NN O O
the NN O O
cds NN O O
1 NN O O
kinase NN O O
family. NN O O
here NN O O
we NN O O
report NN O O
that NN O O
the NN O O
human NN O O
cds NN O O
1 NN O O
kinase NN O O
(hcds NN O O
1/chk NN O O
2) NN O O
regulates NN O O
brca NN O O
1 NN O O
functio NN O O
. NN O O

after NN O O
dna NN O O
damage NN O O
by NN O O
phosphorylating NN O O
serine NN O O
988 NN O O
of NN O O
brca NN O O
1. NN O O
we NN O O
show NN O O
that NN O O
hcds NN O O
1 NN O O
and NN O O
brca NN O O
1 NN O O
interact NN O O
and NN O O
co-localize NN O O
within NN O O
discrete NN O O
nuclear NN O O
foci NN O O
but NN O O
separate NN O O
after NN O O
gamma NN O O
irradiation. NN O O
phosphorylation NN O O
of NN O O
brca NN O O
1 NN O O
at NN O O
serine NN O O
988 NN O O
is NN O O
required NN O O
for NN O O
the NN O O
release NN O O
of NN O O
brca NN O O
1 NN O O
from NN O O
hcds NN O O
1. NN O O
this NN O O
phosphorylation NN O O
is NN O O
also NN O O
important NN O O
for NN O O
the NN O O
ability NN O O
of NN O O
brca NN O O
1 NN O O
to NN O O
restore NN O O
survival NN O O
after NN O O
dna NN O O
damage NN O O
in NN O O
the NN O O
brca NN O O
1-mutated NN O O
cell NN O O
line NN O O
hcc NN O O
1937. NN O O
. NN O O
tion NN O O
of NN O O
brca NN O O
1 NN O O
at NN O O
serine NN O O
988 NN O O
is NN O O
required NN O O
for NN O O
the NN O O
release NN O O
of NN O O
brca NN O O
1 NN O O
from NN O O
hcds NN O O
1. NN O O
this NN O O
phosphorylation NN O O
is NN O O
also NN O O
important NN O O
for NN O O
the NN O O
ability NN O O
of NN O O
brca NN O O
1 NN O O
to NN O O
restore NN O O
survival NN O O
after NN O O
dna NN O O
damage NN O O
in NN O O
the NN O O
brca NN O O
1-mutated NN O O
cell NN O O
line NN O O
hcc NN O O
1937. NN O O
. NN O O

ataxin-3 NN O O
with NN O O
an NN O O
altered NN O O
conformation NN O O
that NN O O
exposes NN O O
the NN O O
polyglutamine NN O O
domain NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
nuclear NN O O
matrix NN O O
. NN O O

spinocerebellar NN O O
ataxia NN O O
type-3 NN O O
or NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
( NN O O
SCA3 NN B-SpecificDisease B-MSH:D017827
/ NN O O
MJD NN B-SpecificDisease B-MSH:D017827
) NN O O
is NN O O
a NN O O
member NN O O
of NN O O
the NN O O
CAG/polyglutamine NN B-DiseaseClass B-MSH:D030342
repeat NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
family. NN O O
in NN O O
this NN O O
family NN O O
of NN O O
disorders, NN O O
a NN O O
normally NN O O
polymorphic NN O O
cag NN O O
repeat NN O O
becomes NN O O
expanded, NN O O
resulting NN O O
in NN O O
expression NN O O
of NN O O
an NN O O
expanded NN O O
polyglutamine NN O O
domain NN O O
in NN O O
the NN O O
disease NN O O
gene NN O O
product. NN O O
experimental NN O O
models NN O O
of NN O O
polyglutamine NN B-DiseaseClass B-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
implicate NN O O
the NN O O
nucleus NN O O
in NN O O
pathogenesis; NN O O
however, NN O O
the NN O O
link NN O O
between NN O O
intranuclear NN O O
expression NN O O
of NN O O
expanded NN O O
polyglutamine NN O O
and NN O O
neuronal NN B-DiseaseClass B-MSH:D009461
dysfunction NN I-DiseaseClass I-MSH:D009461
remains NN O O
unclear. NN O O
here NN O O
we NN O O
demonstrate NN O O
that NN O O
ataxin-3, NN O O
the NN O O
disease NN O O
protein NN O O
in NN O O
SCA3 NN B-SpecificDisease B-MSH:D017827
/ NN O O
MJD NN B-SpecificDisease B-MSH:D017827
, NN O O
adopts NN O O
a NN O O
unique NN O O
conformation NN O O
when NN O O
expressed NN O O
within NN O O
the NN O O
nucleus NN O O
of NN O O
transfected NN O O
cells. NN O O
the NN O O
monoclonal NN O O
antibody NN O O
1 NN O O
c NN O O
2 NN O O
is NN O O
known NN O O
preferentially NN O O
to NN O O
bind NN O O
expanded NN O O
polyglutamine, NN O O
but NN O O
we NN O O
find NN O O
that NN O O
it NN O O
also NN O O
binds NN O O
a NN O O
fragment NN O O
of NN O O
ataxin- NN O O
. NN O O

containing NN O O
a NN O O
normal NN O O
glutamine NN O O
repeat. NN O O
in NN O O
addition, NN O O
expression NN O O
of NN O O
ataxin-3 NN O O
within NN O O
the NN O O
nucleus NN O O
exposes NN O O
the NN O O
glutamine NN O O
domain NN O O
of NN O O
the NN O O
full-length NN O O
non-pathological NN O O
protein, NN O O
allowing NN O O
it NN O O
to NN O O
bind NN O O
the NN O O
monoclonal NN O O
antibody NN O O
1 NN O O
c NN O O
2. NN O O
fractionation NN O O
and NN O O
immunochemical NN O O
experiments NN O O
indicate NN O O
that NN O O
this NN O O
novel NN O O
conformation NN O O
of NN O O
intranuclear NN O O
ataxin-3 NN O O
is NN O O
not NN O O
due NN O O
to NN O O
proteolysis, NN O O
suggesting NN O O
instead NN O O
that NN O O
association NN O O
with NN O O
nuclear NN O O
protein NN O O
(s) NN O O
alters NN O O
the NN O O
structure NN O O
of NN O O
full-length NN O O
ataxin-3 NN O O
which NN O O
exposes NN O O
the NN O O
polyglutamine NN O O
domain. NN O O
this NN O O
conformationally NN O O
altered NN O O
ataxin-3 NN O O
is NN O O
bound NN O O
to NN O O
the NN O O
nuclear NN O O
matrix. NN O O
the NN O O
pathological NN O O
form NN O O
of NN O O
ataxin-3 NN O O
with NN O O
an NN O O
expanded NN O O
polyglutamine NN O O
domain NN O O
also NN O O
associates NN O O
with NN O O
the NN O O
nuclear NN O O
matrix. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
an NN O O
early NN O O
event NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
SCA3 NN B-SpecificDisease B-MSH:D017827
/ NN O O
MJD NN B-SpecificDisease B-MSH:D017827
may NN O O
be NN O O
an NN O O
altered NN O O
conformatio NN O O
. NN O O

of NN O O
ataxin-3 NN O O
within NN O O
the NN O O
nucleus NN O O
that NN O O
exposes NN O O
the NN O O
polyglutamine NN O O
domain. NN O O
. NN O O

a NN O O
zinc NN O O
finger NN O O
truncation NN O O
of NN O O
murine NN O O
wt NN O O
1 NN O O
results NN O O
in NN O O
the NN O O
characteristic NN O O
urogenital NN B-DiseaseClass B-MSH:D014564
abnormalities NN I-DiseaseClass I-MSH:D014564
of NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
. NN O O

the NN O O
Wilms NN B-Modifier B-MSH:D009396
tumor NN I-Modifier I-MSH:D009396
-suppressor NN O O
gene, NN O O
wt NN O O
1, NN O O
plays NN O O
a NN O O
key NN O O
role NN O O
in NN O O
urogenital NN O O
development, NN O O
and NN O O
WT1 NN B-SpecificDisease B-MSH:D030342
dysfunction NN I-SpecificDisease I-MSH:D030342
is NN O O
implicated NN O O
in NN O O
both NN O O
neoplastic NN B-Modifier B-MSH:D009369
( NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
, NN O O
mesothelioma NN B-SpecificDisease B-MSH:D008654
, NN O O
leukemias NN B-SpecificDisease B-MSH:D007938
, NN O O
and NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
) NN O O
and NN O O
nonneoplastic NN B-Modifier B-MSH:D004194
( NN O O
glomerulosclerosis NN B-SpecificDisease B-MSH:D005921
) NN O O
disease. NN O O
the NN O O
analysis NN O O
of NN O O
diseases NN O O
linked NN O O
specifically NN O O
with NN O O
wt NN O O
1 NN O O
mutations, NN O O
such NN O O
as NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
( NN O O
DDS NN B-SpecificDisease B-MSH:D030321
), NN O O
can NN O O
provide NN O O
valuable NN O O
insight NN O O
concerning NN O O
the NN O O
role NN O O
of NN O O
wt NN O O
1 NN O O
in NN O O
development NN O O
and NN O O
disease. NN O O
DDS NN B-SpecificDisease B-MSH:D030321
is NN O O
a NN O O
rare NN O O
childhood NN O O
disease NN O O
characterized NN O O
by NN O O
a NN O O
nephropathy NN B-SpecificDisease B-MSH:D007674
involving NN O O
mesangial NN B-SpecificDisease B-MSH:C537346
sclerosis NN I-SpecificDisease I-MSH:C537346
, NN O O
xy NN O O
pseudohermaphroditism NN B-SpecificDisease B-MSH:D012734
, NN O O
and/or NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
( NN O O
WT NN B-SpecificDisease B-MSH:D009396
). NN O O
DDS NN B-Modifier B-MSH:D030321
patients NN O O
are NN O O
constitutionally NN O O
heterozygous NN O O
for NN O O
exonic NN O O
point NN O O
mutations NN O O
in NN O O
wt NN O O
1, NN O O
which NN O O
include NN O O
mutations NN O O
predicted NN O O
to NN O O
truncate NN O O
the NN O O
protein NN O O
within NN O O
the NN O O
c-terminal NN O O
zinc NN O O
finger NN O O
(zf) NN O O
regio NN O O
. NN O O

. NN O O
we NN O O
report NN O O
that NN O O
heterozygosity NN O O
for NN O O
a NN O O
targeted NN O O
murine NN O O
wt NN O O
1 NN O O
allele, NN O O
wt NN O O
1 NN O O
(tmt NN O O
396), NN O O
which NN O O
truncates NN O O
zf NN O O
3 NN O O
at NN O O
codon NN O O
396, NN O O
induces NN O O
mesangial NN B-SpecificDisease B-MSH:C537346
sclerosis NN I-SpecificDisease I-MSH:C537346
characteristic NN O O
of NN O O
DDS NN B-SpecificDisease B-MSH:D030321
in NN O O
adult NN O O
heterozygous NN O O
and NN O O
chimeric NN O O
mice. NN O O
Male NN B-DiseaseClass B-MSH:D005832
genital NN I-DiseaseClass I-MSH:D005832
defects NN I-DiseaseClass I-MSH:D005832
also NN O O
were NN O O
evident NN O O
and NN O O
there NN O O
was NN O O
a NN O O
single NN O O
case NN O O
of NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
in NN O O
which NN O O
the NN O O
transcript NN O O
of NN O O
the NN O O
nontargeted NN O O
allele NN O O
showed NN O O
an NN O O
exon NN O O
9 NN O O
skipping NN O O
event, NN O O
implying NN O O
a NN O O
causal NN O O
link NN O O
between NN O O
Wt1 NN B-SpecificDisease B-MSH:D030342
dysfunction NN I-SpecificDisease I-MSH:D030342
and NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumorigenesis NN I-SpecificDisease I-MSH:D009396
in NN O O
mice. NN O O
however, NN O O
the NN O O
mutant NN O O
wt NN O O
1 NN O O
(tmt NN O O
396) NN O O
protein NN O O
accounted NN O O
for NN O O
only NN O O
5% NN O O
of NN O O
wt NN O O
1 NN O O
in NN O O
both NN O O
heterozygous NN O O
embryonic NN O O
stem NN O O
cells NN O O
and NN O O
the NN O O
WT NN B-SpecificDisease B-MSH:D009396
. NN O O
this NN O O
has NN O O
implications NN O O
regarding NN O O
the NN O O
mechanism NN O O
by NN O O
which NN O O
the NN O O
mutant NN O O
allele NN O O
exerts NN O O
its NN O O
effect NN O O
. NN O O

heterogeneity NN O O
of NN O O
"mediterranean NN O O
type" NN O O
glucose-6-phosphate NN B-SpecificDisease B-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
spain NN O O
and NN O O
description NN O O
of NN O O
two NN O O
new NN O O
variants NN O O
associated NN O O
with NN O O
favism NN B-SpecificDisease B-MSH:D005236
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd); NN O O
ec NN O O
1. NN O O
1. NN O O
1. NN O O
49 NN O O
from NN O O
thirty-six NN O O
unrelated NN O O
spanish NN O O
males NN O O
was NN O O
partially NN O O
purified NN O O
from NN O O
blood, NN O O
and NN O O
the NN O O
variants NN O O
were NN O O
characterized NN O O
biochemically NN O O
and NN O O
electrophoretically NN O O
according NN O O
to NN O O
the NN O O
methods NN O O
recommended NN O O
by NN O O
the NN O O
world NN O O
health NN O O
organization. NN O O
subjects NN O O
were NN O O
from NN O O
multiple NN O O
geographic NN O O
regions NN O O
within NN O O
spain, NN O O
and NN O O
all NN O O
suffered NN O O
from NN O O
hemolytic NN B-SpecificDisease B-MSH:D000743
anemia NN I-SpecificDisease I-MSH:D000743
, NN O O
either NN O O
acute NN O O
(34 NN O O
cases) NN O O
or NN O O
chronic NN O O
nonspherocytic NN O O
(2 NN O O
cases). NN O O
almost NN O O
all NN O O
the NN O O
variants NN O O
studied NN O O
presented NN O O
residual NN O O
erythrocyte NN O O
g NN O O
6 NN O O
pd NN O O
activity NN O O
ranging NN O O
from NN O O
0 NN O O
to NN O O
10% NN O O
of NN O O
normal, NN O O
and NN O O
five NN O O
different NN O O
mutants NN O O
were NN O O
responsible NN O O
for NN O O
the NN O O
deficient NN O O
phenotype. NN O O
three NN O O
variants NN O O
were NN O O
similar NN O O
to NN O O
others NN O O
previously NN O O
described NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
(11 NN O O
cases), NN O O
g NN O O
6 NN O O
pd NN O O
athens-like NN O O
(3 NN O O
case NN O O
. NN O O

), NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
union NN O O
(2 NN O O
cases). NN O O
the NN O O
remaining NN O O
variants NN O O
were NN O O
different NN O O
from NN O O
the NN O O
numerous NN O O
variants NN O O
already NN O O
reported NN O O
and NN O O
have NN O O
been NN O O
considered NN O O
as NN O O
new NN O O
mutants. NN O O
provisionally NN O O
they NN O O
are NN O O
called NN O O
g NN O O
6 NN O O
pd NN O O
betica NN O O
(19 NN O O
cases) NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
menorca NN O O
(1 NN O O
case). NN O O
the NN O O
present NN O O
study NN O O
constitutes NN O O
the NN O O
first NN O O
attempt NN O O
to NN O O
characterize NN O O
the NN O O
deficient NN B-Modifier B-MSH:D005955
G6PD NN I-Modifier I-MSH:D005955
variants NN O O
found NN O O
in NN O O
spain NN O O
and NN O O
supplies NN O O
new NN O O
data NN O O
on NN O O
the NN O O
relationship NN O O
between NN O O
molecular NN O O
characteristics NN O O
of NN O O
deficient NN O O
variants NN O O
and NN O O
their NN O O
clinical NN O O
manifestations. NN O O
the NN O O
most NN O O
important NN O O
findings NN O O
can NN O O
be NN O O
summarized NN O O
as NN O O
follows NN O O
(1) NN O O
the NN O O
spanish NN O O
population NN O O
is NN O O
characterized NN O O
by NN O O
an NN O O
important NN O O
heterogeneity NN O O
in NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
. NN O O
(2) NN O O
although NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
is NN O O
very NN O O
frequent, NN O O
it NN O O
presents NN O O
a NN O O
relatively NN O O
high NN O O
degree NN O O
of NN O O
polymorphism. NN O O
(3 NN O O
. NN O O

favism NN O O
has NN O O
been NN O O
observed NN O O
associated NN O O
with NN O O
all NN O O
kinds NN O O
of NN O O
variants NN O O
described NN O O
here. NN O O
(4) NN O O
g NN O O
6 NN O O
pd NN O O
betica, NN O O
which NN O O
is NN O O
the NN O O
most NN O O
frequent NN O O
variant NN O O
found NN O O
in NN O O
subjects NN O O
of NN O O
southern NN O O
spanish NN O O
origin, NN O O
has NN O O
been NN O O
observed NN O O
associated NN O O
with NN O O
favism NN B-SpecificDisease B-MSH:D005236
in NN O O
all NN O O
cases NN O O
except NN O O
one NN O O
. NN O O

early NN O O
onset NN O O
of NN O O
X-linked NN B-SpecificDisease B-MSH:D020389
Emery-Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
in NN O O
a NN O O
boy NN O O
with NN O O
emerin NN O O
gene NN O O
deletion NN O O
. NN O O

a NN O O
boy NN O O
developed NN O O
contractures NN B-DiseaseClass B-MSH:D003286
of NN I-DiseaseClass I-MSH:D003286
the NN I-DiseaseClass I-MSH:D003286
Achilles NN I-DiseaseClass I-MSH:D003286
tendons NN I-DiseaseClass I-MSH:D003286
at NN O O
3 NN O O
years NN O O
and NN O O
of NN O O
the NN O O
postcervical NN O O
muscles NN O O
at NN O O
7 NN O O
years, NN O O
although NN O O
neither NN O O
contractures NN B-DiseaseClass B-MSH:D003286
of NN I-DiseaseClass I-MSH:D003286
the NN I-DiseaseClass I-MSH:D003286
elbows NN I-DiseaseClass I-MSH:D003286
nor NN O O
cardiac NN B-DiseaseClass B-MSH:D018376
abnormality NN I-DiseaseClass I-MSH:D018376
were NN O O
recognized NN O O
by NN O O
the NN O O
age NN O O
of NN O O
9 NN O O
years. NN O O
muscle NN O O
computed NN O O
tomography NN O O
scanning NN O O
revealed NN O O
changes NN O O
characteristic NN O O
of NN O O
muscle NN O O
involvement. NN O O
emerin NN O O
was NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
biopsied NN O O
muscle, NN O O
and NN O O
rt-pcr NN O O
and NN O O
pcr-based NN O O
genomic NN O O
dna NN O O
analyses NN O O
of NN O O
the NN O O
emerin NN O O
gene NN O O
demonstrated NN O O
no NN O O
amplification NN O O
product NN O O
in NN O O
the NN O O
patient. NN O O
these NN O O
results NN O O
confirmed NN O O
the NN O O
diagnosis NN O O
of NN O O
X-linked NN B-SpecificDisease B-MSH:D020389
Emery-Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
( NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
), NN O O
and NN O O
reinforce NN O O
the NN O O
necessity NN O O
of NN O O
molecular NN O O
genetic NN O O
diagnosis NN O O
of NN O O
the NN O O
membrane NN O O
protein NN O O
emerin NN O O
in NN O O
younger NN O O
patients NN O O
with NN O O
possible NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
before NN O O
appearance NN O O
of NN O O
the NN O O
typical NN O O
symptoms, NN O O
to NN O O
avoid NN O O
sudden NN B-SpecificDisease B-MSH:D016757
cardiac NN I-SpecificDisease I-MSH:D016757
death NN I-SpecificDisease I-MSH:D016757
. NN O O
. NN O O

prad NN O O
1, NN O O
a NN O O
candidate NN O O
bcl NN O O
1 NN O O
oncogene: NN O O
mapping NN O O
and NN O O
expression NN O O
in NN O O
centrocytic NN B-DiseaseClass B-MSH:D008223
lymphoma NN I-DiseaseClass I-MSH:D008223
. NN O O

rearrangement NN O O
of NN O O
the NN O O
bcl NN O O
1 NN O O
(b-cell NN O O
lymphoma NN O O
1) NN O O
region NN O O
on NN O O
chromosome NN O O
11 NN O O
q NN O O
13 NN O O
appears NN O O
to NN O O
be NN O O
highly NN O O
characteristic NN O O
of NN O O
centrocytic NN B-DiseaseClass B-MSH:D008223
lymphoma NN I-DiseaseClass I-MSH:D008223
and NN O O
also NN O O
is NN O O
found NN O O
infrequently NN O O
in NN O O
other NN O O
B-cell NN B-SpecificDisease B-MSH:D016393
neoplasms NN I-SpecificDisease I-MSH:D016393
. NN O O
rearrangement NN O O
is NN O O
thought NN O O
to NN O O
deregulate NN O O
a NN O O
nearby NN O O
protooncogene, NN O O
but NN O O
transcribed NN O O
sequences NN O O
in NN O O
the NN O O
immediate NN O O
vicinity NN O O
of NN O O
bcl NN O O
1 NN O O
breakpoints NN O O
had NN O O
not NN O O
been NN O O
identified. NN O O
prad NN O O
1, NN O O
previously NN O O
designated NN O O
d NN O O
11 NN O O
s NN O O
287 NN O O
e, NN O O
was NN O O
identified NN O O
on NN O O
11 NN O O
q NN O O
13 NN O O
as NN O O
a NN O O
chromosomal NN O O
breakpoint NN O O
region NN O O
rearranged NN O O
with NN O O
the NN O O
parathyroid NN O O
hormone NN O O
gene NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
parathyroid NN B-DiseaseClass B-MSH:D010282
adenomas NN I-DiseaseClass I-MSH:D010282
; NN O O
this NN O O
highly NN O O
conserved NN O O
putative NN O O
oncogene, NN O O
which NN O O
encodes NN O O
a NN O O
novel NN O O
cyclin, NN O O
has NN O O
been NN O O
linked NN O O
to NN O O
bcl NN O O
1 NN O O
and NN O O
implicated NN O O
also NN O O
in NN O O
subsets NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
squamous NN I-CompositeMention I-MSH:D001943
cell NN I-CompositeMention I-MSH:D001943
neoplasms NN I-CompositeMention I-MSH:D001943
with NN O O
11 NN O O
q NN O O
13 NN O O
amplification. NN O O
we NN O O
report NN O O
pulsed-field NN O O
gel NN O O
electrophoresi NN O O
. NN O O

data NN O O
showing NN O O
bcl NN O O
1 NN O O
and NN O O
prad NN O O
1 NN O O
to NN O O
be NN O O
no NN O O
more NN O O
than NN O O
130 NN O O
kilobases NN O O
apart. NN O O
prad NN O O
1 NN O O
mrna NN O O
is NN O O
abundantly NN O O
expressed NN O O
in NN O O
seven NN O O
of NN O O
seven NN O O
centrocytic NN B-DiseaseClass B-MSH:D008223
lymphomas NN I-DiseaseClass I-MSH:D008223
(kiel NN O O
classification), NN O O
in NN O O
contrast NN O O
to NN O O
13 NN O O
closely NN O O
related NN O O
but NN O O
noncentrocytic NN B-DiseaseClass B-MSH:D008223
lymphomas NN I-DiseaseClass I-MSH:D008223
. NN O O
three NN O O
of NN O O
the NN O O
seven NN O O
centrocytic NN B-DiseaseClass B-MSH:D008223
lymphomas NN I-DiseaseClass I-MSH:D008223
had NN O O
detectable NN O O
bcl NN O O
1 NN O O
dna NN O O
rearrangement. NN O O
also, NN O O
two NN O O
unusual NN O O
cases NN O O
of NN O O
cll NN O O
with NN O O
bcl NN O O
1 NN O O
rearrangement NN O O
overexpressed NN O O
prad NN O O
1, NN O O
in NN O O
contrast NN O O
to NN O O
five NN O O
cll NN O O
controls. NN O O
thus, NN O O
prad NN O O
1 NN O O
is NN O O
an NN O O
excellent NN O O
candidate NN O O
" NN O O
bcl NN O O
1 NN O O
oncogene. NN O O
" NN O O
its NN O O
overexpression NN O O
may NN O O
be NN O O
a NN O O
key NN O O
consequence NN O O
of NN O O
rearrangement NN O O
of NN O O
the NN O O
bcl NN O O
1 NN O O
vicinity NN O O
in NN O O
B-cell NN B-SpecificDisease B-MSH:D016393
neoplasms NN I-SpecificDisease I-MSH:D016393
and NN O O
a NN O O
unifying NN O O
pathogenetic NN O O
feature NN O O
in NN O O
centrocytic NN B-DiseaseClass B-MSH:D008223
lymphoma NN I-DiseaseClass I-MSH:D008223
. NN O O

adrenoleukodystrophy: NN O O
increased NN O O
plasma NN O O
content NN O O
of NN O O
saturated NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
. NN O O

with NN O O
a NN O O
new NN O O
method NN O O
we NN O O
measured NN O O
the NN O O
saturated NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
in NN O O
the NN O O
plasma NN O O
of NN O O
adrenoleukodystrophy NN B-Modifier B-MSH:D000326
( NN O O
ALD NN B-Modifier B-MSH:D000326
) NN O O
hemizygotes, NN O O
ALD NN B-Modifier B-MSH:D000326
heterozygotes, NN O O
and NN O O
controls. NN O O
ALD NN B-Modifier B-MSH:D000326
hemizygotes NN O O
showed NN O O
increased NN O O
levels NN O O
of NN O O
hexacosanoate NN O O
(c NN O O
26 NN O O
fatty NN O O
acid) NN O O
which NN O O
represented NN O O
0. NN O O
081 NN O O
+/- NN O O
0. NN O O
0066% NN O O
(sem) NN O O
of NN O O
total NN O O
fatty NN O O
acids, NN O O
compared NN O O
to NN O O
0. NN O O
015 NN O O
+/- NN O O
0. NN O O
0032% NN O O
in NN O O
the NN O O
controls. NN O O
c NN O O
25, NN O O
c NN O O
24, NN O O
and NN O O
c NN O O
23 NN O O
fatty NN O O
acids NN O O
were NN O O
also NN O O
increased, NN O O
but NN O O
the NN O O
c NN O O
22 NN O O
and NN O O
c NN O O
20 NN O O
fatty NN O O
acids NN O O
were NN O O
normal. NN O O
c NN O O
26 NN O O
levels NN O O
were NN O O
also NN O O
increased NN O O
in NN O O
most NN O O
ALD NN B-Modifier B-MSH:D000326
heterozygotes, NN O O
with NN O O
a NN O O
mean NN O O
level NN O O
0. NN O O
057 NN O O
+/- NN O O
0. NN O O
0063% NN O O
of NN O O
total NN O O
fatty NN O O
acids. NN O O
the NN O O
technique NN O O
can NN O O
be NN O O
use NN O O
. NN O O

for NN O O
diagnosis NN O O
and NN O O
carrier NN O O
identification, NN O O
and NN O O
in NN O O
the NN O O
evaluation NN O O
of NN O O
therapy NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
deficiency NN O O
inhibits NN O O
in NN O O
vitro NN O O
growth NN O O
of NN O O
plasmodium NN O O
falciparum NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd; NN O O
ec NN O O
1. NN O O
1. NN O O
1. NN O O
49) NN O O
-deficient NN O O
red NN O O
blood NN O O
cells NN O O
from NN O O
male NN O O
hemizygotes NN O O
and NN O O
female NN O O
heterozygotes NN O O
from NN O O
the NN O O
island NN O O
of NN O O
sardinia NN O O
were NN O O
studied NN O O
for NN O O
their NN O O
ability NN O O
to NN O O
support NN O O
growth NN O O
in NN O O
vitro NN O O
of NN O O
the NN O O
malaria NN B-Modifier B-MSH:D008288
-causing NN O O
organism NN O O
plasmodium NN O O
falciparum. NN O O
parasite NN O O
growth NN O O
was NN O O
approximately NN O O
one-third NN O O
of NN O O
normal NN O O
in NN O O
both NN O O
hemi- NN O O
and NN O O
heterozygotes NN O O
for NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
. NN O O
in NN O O
sardinians NN O O
with NN O O
the NN O O
beta NN O O
0-thalassemia NN O O
trait, NN O O
parasite NN O O
growth NN O O
was NN O O
normal NN O O
except NN O O
when NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
occurred NN O O
together NN O O
with NN O O
the NN O O
thalassemia NN B-Modifier B-MSH:D013789
trait. NN O O
the NN O O
data NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
may NN O O
confer NN O O
a NN O O
selective NN O O
advantage NN O O
in NN O O
a NN O O
malarious NN B-Modifier B-MSH:D008288
area; NN O O
the NN O O
female NN O O
heterozygote NN O O
may NN O O
be NN O O
at NN O O
a NN O O
particular NN O O
advantage NN O O
because NN O O
resistance NN O O
to NN O O
malaria NN B-SpecificDisease B-MSH:D008288
equals NN O O
that NN O O
of NN O O
mal NN O O
. NN O O

hemizygotes, NN O O
but NN O O
the NN O O
risk NN O O
of NN O O
fatal NN B-SpecificDisease B-MSH:D006461
hemolysis NN I-SpecificDisease I-MSH:D006461
may NN O O
be NN O O
less. NN O O
however, NN O O
more NN O O
female NN O O
heterozygotes NN O O
must NN O O
be NN O O
studied NN O O
to NN O O
confirm NN O O
this NN O O
hypothesis. NN O O
no NN O O
protective NN O O
effect NN O O
of NN O O
beta NN O O
0-thalassemia NN O O
trait NN O O
could NN O O
be NN O O
demonstrated NN O O
in NN O O
vitro NN O O
. NN O O

heterozygous NN O O
c NN O O
2 NN O O
deficiency NN O O
associated NN O O
with NN O O
angioedema NN B-SpecificDisease B-MSH:D000799
, NN O O
myasthenia NN B-SpecificDisease B-MSH:D009157
gravis NN I-SpecificDisease I-MSH:D009157
, NN O O
and NN O O
systemic NN B-SpecificDisease B-MSH:D008180
lupus NN I-SpecificDisease I-MSH:D008180
erythematosus NN I-SpecificDisease I-MSH:D008180
. NN O O

we NN O O
describe NN O O
a NN O O
patient NN O O
with NN O O
myasthenia NN B-SpecificDisease B-MSH:D009157
gravis NN I-SpecificDisease I-MSH:D009157
, NN O O
systemic NN B-SpecificDisease B-MSH:D008180
lupus NN I-SpecificDisease I-MSH:D008180
erythematosus NN I-SpecificDisease I-MSH:D008180
, NN O O
and NN O O
angioedema NN B-SpecificDisease B-MSH:D000799
associated NN O O
with NN O O
heterozygous NN O O
complement NN B-SpecificDisease B-OMIM:217000
factor NN I-SpecificDisease I-OMIM:217000
2 NN I-SpecificDisease I-OMIM:217000
(C2) NN I-SpecificDisease I-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
. NN O O
the NN O O
significance NN O O
of NN O O
this NN O O
association NN O O
is NN O O
controversial, NN O O
though NN O O
the NN O O
association NN O O
of NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
with NN O O
certain NN O O
histocompatibility NN O O
antigens NN O O
suggests NN O O
possible NN O O
linkage NN O O
to NN O O
immune NN O O
response NN O O
genes. NN O O
to NN O O
our NN O O
knowledge NN O O
this NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
heterozygous NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
in NN O O
association NN O O
with NN O O
this NN O O
combination NN O O
of NN O O
autoimmune NN B-DiseaseClass B-MSH:D001327
disorders NN I-DiseaseClass I-MSH:D001327
, NN O O
and NN O O
we NN O O
discuss NN O O
the NN O O
aetiological NN O O
implications. NN O O
. NN O O

inherited NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
with NN O O
recurrent NN O O
infections NN O O
and NN O O
glomerulonephritis NN B-SpecificDisease B-MSH:D005921
. NN O O

a NN O O
10-year-old NN O O
laotian NN O O
boy NN O O
had NN O O
homozygous NN O O
deficiency NN B-SpecificDisease B-OMIM:613779
of NN I-SpecificDisease I-OMIM:613779
the NN I-SpecificDisease I-OMIM:613779
third NN I-SpecificDisease I-OMIM:613779
component NN I-SpecificDisease I-OMIM:613779
of NN I-SpecificDisease I-OMIM:613779
complement NN I-SpecificDisease I-OMIM:613779
and NN O O
recurrent NN O O
bacterial NN B-DiseaseClass B-MSH:D001424
infections NN I-DiseaseClass I-MSH:D001424
beginning NN O O
at NN O O
age NN O O
5 NN O O
months. NN O O
cellular NN O O
and NN O O
humoral NN O O
immunity NN O O
were NN O O
normal, NN O O
as NN O O
were NN O O
polymorphonuclear NN O O
leukocyte NN O O
chemotaxis NN O O
and NN O O
bactericidal NN O O
activities. NN O O
serum NN O O
complement-mediated NN O O
hemolytic, NN O O
chemotactic, NN O O
and NN O O
opsonic NN O O
activities NN O O
were NN O O
deficient. NN O O
in NN O O
vitro NN O O
addition NN O O
of NN O O
purified NN O O
c NN O O
3 NN O O
to NN O O
patient NN O O
serum NN O O
restored NN O O
hemolytic NN O O
complement NN O O
to NN O O
normal NN O O
levels, NN O O
and NN O O
plasma NN O O
infusion NN O O
during NN O O
each NN O O
of NN O O
four NN O O
episodes NN O O
of NN O O
pneumonia NN B-SpecificDisease B-MSH:D011014
significantly NN O O
enhanced NN O O
serum NN O O
opsonic NN O O
activity NN O O
for NN O O
as NN O O
long NN O O
as NN O O
36 NN O O
hours. NN O O
a NN O O
renal NN O O
biopsy NN O O
specimen NN O O
revealed NN O O
mesangiopathic NN B-SpecificDisease B-MSH:D005921
glomerulonephritis NN I-SpecificDisease I-MSH:D005921
, NN O O
although NN O O
significant NN O O
levels NN O O
of NN O O
circulating NN O O
igg NN O O
immune NN O O
complexes NN O O
were NN O O
not NN O O
detected. NN O O
these NN O O
findings NN O O
further NN O O
support NN O O
the NN O O
association NN O O
of NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
with NN O O
immune-complex NN B-DiseaseClass B-MSH:D007105
disease NN I-DiseaseClass I-MSH:D007105
and NN O O
suggest NN O O
that NN O O
plasma NN O O
infusion NN O O
may NN O O
be NN O O
an NN O O
adjunc NN O O
. NN O O

to NN O O
antibiotic NN O O
therapy NN O O
in NN O O
the NN O O
management NN O O
of NN O O
severe NN O O
pyogenic NN B-DiseaseClass B-MSH:D007239
infections NN I-DiseaseClass I-MSH:D007239
in NN O O
patients NN O O
with NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
. NN O O
. NN O O

southern NN O O
analysis NN O O
reveals NN O O
a NN O O
large NN O O
deletion NN O O
at NN O O
the NN O O
hypoxanthine NN O O
phosphoribosyltransferase NN O O
locus NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O

whole NN O O
genomic NN O O
hprt NN O O
clones NN O O
were NN O O
used NN O O
in NN O O
southern NN O O
analysis NN O O
to NN O O
screen NN O O
the NN O O
integrity NN O O
of NN O O
the NN O O
hprt NN O O
gene NN O O
in NN O O
a NN O O
family NN O O
that NN O O
includes NN O O
a NN O O
patient NN O O
with NN O O
HPRT NN B-SpecificDisease B-MSH:D007926
enzyme NN I-SpecificDisease I-MSH:D007926
deficiency NN I-SpecificDisease I-MSH:D007926
causal NN O O
to NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O
a NN O O
5 NN O O
kb NN O O
dna NN O O
sequence NN O O
deletion NN O O
was NN O O
found NN O O
to NN O O
have NN O O
its NN O O
endpoints NN O O
in NN O O
the NN O O
first NN O O
and NN O O
third NN O O
introns. NN O O
the NN O O
probes NN O O
identified NN O O
the NN O O
carrier NN O O
status NN O O
of NN O O
female NN O O
family NN O O
members, NN O O
aided NN O O
by NN O O
an NN O O
rflp NN O O
carried NN O O
by NN O O
the NN O O
mothers NN O O
normal NN O O
x-chromosome. NN O O
. NN O O

association NN O O
of NN O O
brca NN O O
1 NN O O
with NN O O
the NN O O
hrad NN O O
50-hmre NN O O
11-p NN O O
95 NN O O
complex NN O O
and NN O O
the NN O O
dna NN O O
damage NN O O
response NN O O
. NN O O

brca NN O O
1 NN O O
encodes NN O O
a NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
that NN O O
is NN O O
mutated NN O O
in NN O O
familial NN B-CompositeMention B-MSH:D061325
breast NN I-CompositeMention I-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancers NN I-CompositeMention I-MSH:D061325
. NN O O
here, NN O O
it NN O O
is NN O O
shown NN O O
that NN O O
brca NN O O
1 NN O O
interacts NN O O
in NN O O
vitro NN O O
and NN O O
in NN O O
vivo NN O O
with NN O O
hrad NN O O
50, NN O O
which NN O O
forms NN O O
a NN O O
complex NN O O
with NN O O
hmre NN O O
11 NN O O
and NN O O
p NN O O
95/nibrin. NN O O
upon NN O O
irradiation, NN O O
brca NN O O
1 NN O O
was NN O O
detected NN O O
in NN O O
discrete NN O O
foci NN O O
in NN O O
the NN O O
nucleus, NN O O
which NN O O
colocalize NN O O
with NN O O
hrad NN O O
50. NN O O
formation NN O O
of NN O O
irradiation-induced NN O O
foci NN O O
positive NN O O
for NN O O
brca NN O O
1, NN O O
hrad NN O O
50, NN O O
hmre NN O O
11, NN O O
or NN O O
p NN O O
95 NN O O
was NN O O
dramatically NN O O
reduced NN O O
in NN O O
hcc/1937 NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
cells NN O O
carrying NN O O
a NN O O
homozygous NN O O
mutation NN O O
in NN O O
brca NN O O
1 NN O O
but NN O O
was NN O O
restored NN O O
by NN O O
transfection NN O O
of NN O O
wild-type NN O O
brca NN O O
1. NN O O
ectopic NN O O
expression NN O O
of NN O O
wild-type, NN O O
but NN O O
not NN O O
mutated, NN O O
brca NN O O
1 NN O O
in NN O O
these NN O O
cells NN O O
rendered NN O O
them NN O O
less NN O O
sensitive NN O O
to NN O O
the NN O O
dna NN O O
damag NN O O
. NN O O

agent, NN O O
methyl NN O O
methanesulfonate. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
brca NN O O
1 NN O O
is NN O O
important NN O O
for NN O O
the NN O O
cellular NN O O
responses NN O O
to NN O O
dna NN O O
damage NN O O
that NN O O
are NN O O
mediated NN O O
by NN O O
the NN O O
hrad NN O O
50-hmre NN O O
11-p NN O O
95 NN O O
complex. NN O O
. NN O O

nebulin NN O O
and NN O O
titin NN O O
expression NN O O
in NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
appears NN O O
normal NN O O
. NN O O

monoclonal NN O O
antibodies NN O O
which NN O O
recognize NN O O
different NN O O
epitopes NN O O
on NN O O
either NN O O
titin NN O O
or NN O O
nebulin NN O O
show NN O O
normal NN O O
staining NN O O
patterns NN O O
on NN O O
frozen NN O O
sections NN O O
of NN O O
three NN O O
muscle NN O O
biopsies NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
gel NN O O
electrophoresis NN O O
and NN O O
immunoblotting NN O O
performed NN O O
on NN O O
two NN O O
of NN O O
these NN O O
muscle NN O O
biopsies NN O O
show NN O O
the NN O O
normal NN O O
pattern NN O O
of NN O O
titin NN O O
and NN O O
nebulin NN O O
polypeptides. NN O O
since NN O O
the NN O O
donor NN O O
of NN O O
one NN O O
of NN O O
these NN O O
biopsies NN O O
has NN O O
a NN O O
large NN O O
deletion NN O O
of NN O O
the NN O O
5-region NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene, NN O O
our NN O O
results NN O O
argue NN O O
against NN O O
the NN O O
recent NN O O
proposal NN O O
that NN O O
nebulin NN O O
is NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
kinase NN O O
is NN O O
a NN O O
component NN O O
of NN O O
neuromuscular NN O O
junctions NN O O
. NN O O

the NN O O
clinical NN O O
manifestation NN O O
of NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
correlated NN O O
to NN O O
the NN O O
extent NN O O
of NN O O
expansion NN O O
of NN O O
an NN O O
unstable NN O O
[ctg] NN O O
n NN O O
dna NN O O
motif. NN O O
recent NN O O
studies NN O O
have NN O O
demonstrated NN O O
that NN O O
this NN O O
trinucleotide NN O O
motif NN O O
forms NN O O
part NN O O
of NN O O
the NN O O
last, NN O O
3 NN O O
untranslated NN O O
exon NN O O
of NN O O
a NN O O
gene NN O O
which NN O O
potentially NN O O
encodes NN O O
multiple NN O O
protein NN O O
isoforms NN O O
of NN O O
a NN O O
serine/threonine NN O O
protein NN O O
kinase NN O O
( NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
protein NN O O
kinase, NN O O
dm-pk). NN O O
we NN O O
report NN O O
here NN O O
on NN O O
the NN O O
development NN O O
of NN O O
antisera NN O O
against NN O O
synthetic NN O O
dm-pk NN O O
peptide NN O O
antigens NN O O
and NN O O
their NN O O
use NN O O
in NN O O
biochemical NN O O
and NN O O
histochemical NN O O
studies. NN O O
immunoreactive NN O O
dm-kinase NN O O
protein NN O O
of NN O O
53 NN O O
kd NN O O
is NN O O
present NN O O
at NN O O
low NN O O
levels NN O O
in NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle NN O O
extracts NN O O
of NN O O
DM NN B-Modifier B-MSH:D009223
patients NN O O
and NN O O
normal NN O O
controls. NN O O
immunohistochemical NN O O
staining NN O O
revealed NN O O
that NN O O
dm-pk NN O O
is NN O O
localised NN O O
prominently NN O O
at NN O O
sites NN O O
of NN O O
neuromuscular NN O O
and NN O O
myotendinous NN O O
junctions NN O O
(nmjs NN O O
an NN O O
. NN O O

mtjs) NN O O
of NN O O
human NN O O
and NN O O
rodent NN O O
skeletal NN O O
muscles. NN O O
furthermore, NN O O
very NN O O
low NN O O
levels NN O O
of NN O O
immunoreactive NN O O
dm-pk NN O O
protein NN O O
are NN O O
present NN O O
in NN O O
the NN O O
sarcoplasm NN O O
of NN O O
predominantly NN O O
type NN O O
i NN O O
fibres NN O O
in NN O O
various NN O O
muscles. NN O O
strikingly, NN O O
presence NN O O
of NN O O
the NN O O
protein NN O O
can NN O O
also NN O O
be NN O O
demonstrated NN O O
for NN O O
nmjs NN O O
of NN O O
muscular NN O O
tissues NN O O
of NN O O
adult NN O O
and NN O O
congenital NN O O
cases NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
, NN O O
with NN O O
no NN O O
gross NN O O
changes NN O O
in NN O O
structural NN O O
organisation. NN O O
our NN O O
findings NN O O
provide NN O O
a NN O O
basis NN O O
for NN O O
further NN O O
characterisation NN O O
of NN O O
the NN O O
role NN O O
of NN O O
the NN O O
kinase NN O O
in NN O O
protein NN O O
assembly NN O O
processes NN O O
or NN O O
signal NN O O
mediation NN O O
at NN O O
synaptic NN O O
sites NN O O
and NN O O
ultimately NN O O
for NN O O
the NN O O
understanding NN O O
of NN O O
the NN O O
complex NN O O
pathophysiology NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O
. NN O O

new NN O O
genetic NN O O
variants NN O O
of NN O O
glucose NN O O
6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
in NN O O
italy NN O O
. NN O O

six NN O O
new NN O O
variants NN O O
of NN O O
human NN O O
erythrocyte NN O O
g NN O O
6 NN O O
pd NN O O
have NN O O
been NN O O
characterized. NN O O
all NN O O
of NN O O
them NN O O
were NN O O
found NN O O
in NN O O
italian NN O O
males NN O O
and NN O O
all NN O O
were NN O O
associated NN O O
with NN O O
enzyme NN B-DiseaseClass B-MSH:D008661
deficiency NN I-DiseaseClass I-MSH:D008661
, NN O O
but NN O O
only NN O O
two NN O O
with NN O O
signs NN O O
of NN O O
haemolysis NN B-SpecificDisease B-MSH:D006461
. NN O O
these NN O O
and NN O O
other NN O O
variants NN O O
reported NN O O
in NN O O
the NN O O
literature, NN O O
which NN O O
must NN O O
thus NN O O
far NN O O
be NN O O
regarded NN O O
as NN O O
sporadic, NN O O
are NN O O
found NN O O
to NN O O
map NN O O
in NN O O
parts NN O O
of NN O O
italy NN O O
where NN O O
common NN O O
types NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
are NN O O
also NN O O
prevalent. NN O O
. NN O O

atm-heterozygous NN O O
germline NN O O
mutations NN O O
contribute NN O O
to NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
-susceptibility NN O O
. NN O O

approximately NN O O
0. NN O O
5% NN O O
-1% NN O O
of NN O O
the NN O O
general NN O O
population NN O O
has NN O O
been NN O O
estimated NN O O
to NN O O
be NN O O
heterozygous NN O O
for NN O O
a NN O O
germline NN O O
mutation NN O O
in NN O O
the NN O O
atm NN O O
gene. NN O O
mutations NN O O
in NN O O
the NN O O
atm NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
the NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
( NN O O
A-T NN B-SpecificDisease B-MSH:D001260
) NN O O
(mim NN O O
208900). NN O O
the NN O O
finding NN O O
that NN O O
atm-heterozygotes NN O O
have NN O O
an NN O O
increased NN O O
relative NN O O
risk NN O O
for NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
was NN O O
supported NN O O
by NN O O
some NN O O
studies NN O O
but NN O O
not NN O O
confirmed NN O O
by NN O O
others. NN O O
in NN O O
view NN O O
of NN O O
this NN O O
discrepancy, NN O O
we NN O O
examined NN O O
the NN O O
frequency NN O O
of NN O O
atm NN O O
germline NN O O
mutations NN O O
in NN O O
a NN O O
selected NN O O
group NN O O
of NN O O
dutch NN O O
patients NN O O
with NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O
we NN O O
have NN O O
analyzed NN O O
atm NN O O
germline NN O O
mutations NN O O
in NN O O
normal NN O O
blood NN O O
lymphocytes, NN O O
using NN O O
the NN O O
protein-truncation NN O O
test NN O O
followed NN O O
by NN O O
genomic-sequence NN O O
analysis. NN O O
a NN O O
high NN O O
percentage NN O O
of NN O O
atm NN O O
germline NN O O
mutations NN O O
was NN O O
demonstrated NN O O
among NN O O
patients NN O O
with NN O O
sporadic NN B-SpecificDisease B-MSH:D001943
breast NN I-SpecificDisease I-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943

cancer. NN O O
the NN O O
82 NN O O
patients NN O O
included NN O O
in NN O O
this NN O O
study NN O O
had NN O O
developed NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
at NN O O
age NN O O
< NN O O
45 NN O O
and NN O O
had NN O O
survived NN O O
>/= NN O O
5 NN O O
years NN O O
(mean NN O O
15 NN O O
years), NN O O
and NN O O
in NN O O
33 NN O O
(40%) NN O O
of NN O O
the NN O O
patients NN O O
a NN O O
contralateral NN O O
breast NN O O
tumor NN O O
had NN O O
been NN O O
diagnosed. NN O O
among NN O O
these NN O O
patients NN O O
we NN O O
identified NN O O
seven NN O O
(8. NN O O
5%) NN O O
atm NN O O
germline NN O O
mutations, NN O O
of NN O O
which NN O O
five NN O O
are NN O O
distinct. NN O O
one NN O O
splice-site NN O O
mutation NN O O
(ivs NN O O
10-6 NN O O
t-- NN O O
> NN O O
g) NN O O
was NN O O
detected NN O O
three NN O O
times NN O O
in NN O O
our NN O O
series. NN O O
four NN O O
heterozygous NN O O
carriers NN O O
were NN O O
patients NN O O
with NN O O
bilateral NN O O
breast NN O O
cancer. NN O O
our NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
mutations NN O O
identified NN O O
in NN O O
this NN O O
study NN O O
are NN O O
" NN O O
a-t NN O O
disease-causing NN O O
" NN O O
mutations NN O O
that NN O O
might NN O O
be NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
breast NN O O
cancer NN O O
in NN O O
heterozygotes. NN O O
w NN O O
. NN O O

conclude NN O O
that NN O O
atm NN O O
heterozygotes NN O O
have NN O O
an NN O O
approximately NN O O
ninefold-increased NN O O
risk NN O O
of NN O O
developing NN O O
a NN O O
type NN O O
of NN O O
breast NN O O
cancer NN O O
characterized NN O O
by NN O O
frequent NN O O
bilateral NN O O
occurrence, NN O O
early NN O O
age NN O O
at NN O O
onset, NN O O
and NN O O
long-term NN O O
survival. NN O O
the NN O O
specific NN O O
characteristics NN O O
of NN O O
our NN O O
population NN O O
of NN O O
patients NN O O
may NN O O
explain NN O O
why NN O O
such NN O O
a NN O O
high NN O O
frequency NN O O
was NN O O
not NN O O
found NN O O
in NN O O
other NN O O
series NN O O
. NN O O
isk NN O O
of NN O O
developing NN O O
a NN O O
type NN O O
of NN O O
breast NN O O
cancer NN O O
characterized NN O O
by NN O O
frequent NN O O
bilateral NN O O
occurrence, NN O O
early NN O O
age NN O O
at NN O O
onset, NN O O
and NN O O
long-term NN O O
survival. NN O O
the NN O O
specific NN O O
characteristics NN O O
of NN O O
our NN O O
population NN O O
of NN O O
patients NN O O
may NN O O
explain NN O O
why NN O O
such NN O O
a NN O O
high NN O O
frequency NN O O
was NN O O
not NN O O
found NN O O
in NN O O
other NN O O
series NN O O
. NN O O

autoimmune NN O O
lymphoproliferative NN O O
syndrome NN O O
( NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
) NN O O
in NN O O
a NN O O
child NN O O
from NN O O
consanguineous NN O O
parents: NN O O
a NN O O
dominant NN O O
or NN O O
recessive NN O O
disease? NN O O
Autoimmune NN B-SpecificDisease B-MSH:D056735
lymphoproliferative NN I-SpecificDisease I-MSH:D056735
syndrome NN I-SpecificDisease I-MSH:D056735
( NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
) NN O O
is NN O O
characterized NN O O
by NN O O
autoimmune NN O O
features NN O O
and NN O O
lymphoproliferations NN O O
and NN O O
is NN O O
generally NN O O
caused NN O O
by NN O O
defective NN O O
fas-mediated NN O O
apoptosis. NN O O
this NN O O
report NN O O
describes NN O O
a NN O O
child NN O O
with NN O O
clinical NN O O
features NN O O
of NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
without NN O O
detectable NN O O
fas NN O O
expression NN O O
on NN O O
freshly NN O O
isolated NN O O
blood NN O O
leukocytes. NN O O
detection NN O O
of NN O O
fas NN O O
transcripts NN O O
via NN O O
real-time NN O O
quantitative NN O O
pcr NN O O
made NN O O
a NN O O
severe NN O O
transcriptional NN O O
defect NN O O
unlikely. NN O O
sequencing NN O O
of NN O O
the NN O O
fas NN O O
gene NN O O
revealed NN O O
a NN O O
20-nucleotide NN O O
duplication NN O O
in NN O O
the NN O O
last NN O O
exon NN O O
affecting NN O O
the NN O O
cytoplasmic NN O O
signaling NN O O
domain. NN O O
the NN O O
patient NN O O
was NN O O
homozygous NN O O
for NN O O
this NN O O
mutation, NN O O
whereas NN O O
the NN O O
consanguineous NN O O
parents NN O O
and NN O O
the NN O O
siblings NN O O
were NN O O
heterozygous. NN O O
the NN O O
patient NN O O
reported NN O O
here NN O O
is NN O O
a NN O O
human NN O O
homologue NN O O
of NN O O
the NN O O
fas-null NN O O
mouse, NN O O
inasmuch NN O O
as NN O O
she NN O O
carries NN O O
an NN O O
autosoma NN O O
. NN O O

homozygous NN O O
mutation NN O O
in NN O O
the NN O O
fas NN O O
gene NN O O
and NN O O
she NN O O
shows NN O O
the NN O O
severe NN O O
and NN O O
accelerated NN O O
ALPS NN B-Modifier B-MSH:D056735
phenotype. NN O O
the NN O O
heterozygous NN O O
family NN O O
members NN O O
did NN O O
not NN O O
have NN O O
the NN O O
ALPS NN B-Modifier B-MSH:D056735
phenotype, NN O O
indicating NN O O
that NN O O
the NN O O
disease-causing NN O O
fas NN O O
mutation NN O O
in NN O O
this NN O O
family NN O O
is NN O O
autosomal NN O O
recessive. NN O O
. NN O O

a NN O O
prevalent NN O O
mutation NN O O
for NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
among NN O O
black NN O O
americans NN O O
. NN O O

objective NN O O
to NN O O
define NN O O
the NN O O
mutation NN O O
causing NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
in NN O O
patients NN O O
of NN O O
black NN O O
american NN O O
origin NN O O
who NN O O
have NN O O
no NN O O
galactose-1-phosphate NN O O
uridyltransferase NN O O
(galt) NN O O
activity NN O O
in NN O O
erythrocytes NN O O
but NN O O
good NN O O
clinical NN O O
outcome. NN O O
methods NN O O
we NN O O
discovered NN O O
a NN O O
mutation NN O O
caused NN O O
by NN O O
a NN O O
c-- NN O O
> NN O O
t NN O O
transition NN O O
at NN O O
base-pair NN O O
1158 NN O O
of NN O O
the NN O O
galt NN O O
gene NN O O
that NN O O
results NN O O
in NN O O
a NN O O
serine-to-leucine NN O O
substitution NN O O
at NN O O
codon NN O O
135 NN O O
(s NN O O
135 NN O O
l). NN O O
we NN O O
developed NN O O
a NN O O
method NN O O
with NN O O
which NN O O
to NN O O
screen NN O O
populations NN O O
for NN O O
its NN O O
prevalence. NN O O
we NN O O
compared NN O O
galactose-1-phosphate NN O O
uridyltransferase NN O O
among NN O O
erythrocytes, NN O O
leukocytes, NN O O
and NN O O
transformed NN O O
lymphoblasts, NN O O
as NN O O
well NN O O
as NN O O
total NN O O
body NN O O
oxidation NN O O
of NN O O
d- NN O O
(13 NN O O
c) NN O O
-galactose NN O O
to NN O O
13 NN O O
co NN O O
2 NN O O
among NN O O
three NN O O
genotypes NN O O
for NN O O
galt NN O O
(s NN O O
135 NN O O
l/s NN O O
135 NN O O
l, NN O O
q NN O O
18 NN O O
. NN O O

r/q NN O O
188 NN O O
r, NN O O
and NN O O
normal/normal). NN O O
results NN O O
we NN O O
found NN O O
a NN O O
48% NN O O
prevalence NN O O
of NN O O
the NN O O
s NN O O
135 NN O O
l NN O O
mutation NN O O
among NN O O
17 NN O O
black NN O O
american NN O O
patients NN O O
with NN O O
classic NN B-SpecificDisease B-MSH:D005693
galactosemia NN I-SpecificDisease I-MSH:D005693
and NN O O
a NN O O
1% NN O O
prevalence NN O O
in NN O O
a NN O O
population NN O O
of NN O O
50 NN O O
black NN O O
americans NN O O
without NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
. NN O O
the NN O O
s NN O O
135 NN O O
l NN O O
mutation NN O O
was NN O O
not NN O O
found NN O O
in NN O O
84 NN O O
white NN O O
patients NN O O
with NN O O
g/g NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
nor NN O O
in NN O O
87 NN O O
white NN O O
control NN O O
subjects NN O O
without NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
. NN O O
we NN O O
found NN O O
normal NN O O
whole NN O O
body NN O O
oxidation NN O O
of NN O O
d- NN O O
(13 NN O O
c) NN O O
-galactose NN O O
by NN O O
the NN O O
patient NN O O
homozygous NN O O
for NN O O
s NN O O
135 NN O O
l NN O O
and NN O O
various NN O O
degrees NN O O
of NN O O
enzyme NN O O
impairment NN O O
among NN O O
different NN O O
tissues. NN O O
conclusions NN O O
the NN O O
s NN O O
135 NN O O
l NN O O
mutation NN O O
in NN O O
the NN O O
galt NN O O
gene NN O O
is NN O O
a NN O O
prevalent NN O O
cause NN O O
of NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
among NN O O
black NN O O
patients. NN O O
because NN O O
galt NN O O
activity NN O O
varies NN O O
in NN O O
different NN O O
tissues NN O O
of NN O O
patients NN O O
homozygous NN O O
for NN O O
s NN O O
13 NN O O
. NN O O

l, NN O O
they NN O O
may NN O O
have NN O O
a NN O O
better NN O O
clinical NN O O
outcome NN O O
than NN O O
patients NN O O
who NN O O
are NN O O
homozygous NN O O
for NN O O
q NN O O
188 NN O O
r NN O O
when NN O O
both NN O O
are NN O O
treated NN O O
from NN O O
infancy. NN O O
. NN O O

constitutive NN O O
and NN O O
regulated NN O O
modes NN O O
of NN O O
splicing NN O O
produce NN O O
six NN O O
major NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
protein NN O O
kinase NN O O
(dmpk) NN O O
isoforms NN O O
with NN O O
distinct NN O O
properties NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
the NN O O
most NN O O
prevalent NN O O
inherited NN B-DiseaseClass B-MSH:D009468
neuromuscular NN I-DiseaseClass I-MSH:D009468
disease NN I-DiseaseClass I-MSH:D009468
in NN O O
adults. NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
is NN O O
a NN O O
ctg NN O O
triplet NN O O
repeat NN O O
expansion NN O O
in NN O O
the NN O O
3-untranslated NN O O
region NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
protein NN O O
kinase NN O O
(dmpk) NN O O
gene, NN O O
consisting NN O O
of NN O O
15 NN O O
exons. NN O O
using NN O O
a NN O O
transgenic NN O O
dmpk-overexpressor NN O O
mouse NN O O
model, NN O O
we NN O O
demonstrate NN O O
here NN O O
that NN O O
the NN O O
endogenous NN O O
mouse NN O O
dmpk NN O O
gene NN O O
and NN O O
the NN O O
human NN O O
dmpk NN O O
transgene NN O O
produce NN O O
six NN O O
major NN O O
alternatively NN O O
spliced NN O O
mrnas NN O O
which NN O O
have NN O O
almost NN O O
identical NN O O
cell NN O O
type-dependent NN O O
distribution NN O O
frequencies NN O O
and NN O O
expression NN O O
patterns. NN O O
use NN O O
of NN O O
a NN O O
cryptic NN O O
5 NN O O
splice NN O O
site NN O O
in NN O O
exon NN O O
8, NN O O
which NN O O
results NN O O
in NN O O
absence NN O O
or NN O O
presence NN O O
of NN O O
15 NN O O
nucleotides NN O O
specifying NN O O
a NN O O
vsggg NN O O
peptide NN O O
motif, NN O O
and/or NN O O
use NN O O
of NN O O
a NN O O
cryptic NN O O
3 NN O O
splice NN O O
site NN O O
in NN O O
exon NN O O
14, NN O O
which NN O O
leads NN O O
to NN O O
a NN O O
frameshift NN O O
in NN O O
the NN O O
mrna NN O O
reading NN O O
frame NN O O
. NN O O

occur NN O O
as NN O O
independent NN O O
stochastic NN O O
events NN O O
in NN O O
all NN O O
tissues NN O O
examined. NN O O
in NN O O
contrast, NN O O
the NN O O
excision NN O O
of NN O O
exons NN O O
13/14 NN O O
that NN O O
causes NN O O
a NN O O
frameshift NN O O
and NN O O
creates NN O O
a NN O O
c-terminally NN O O
truncated NN O O
protein NN O O
is NN O O
clearly NN O O
cell NN O O
type NN O O
dependent NN O O
and NN O O
occurs NN O O
predominantly NN O O
in NN O O
smooth NN O O
muscle. NN O O
we NN O O
generated NN O O
all NN O O
six NN O O
full-length NN O O
mouse NN O O
cdnas NN O O
that NN O O
result NN O O
from NN O O
combinations NN O O
of NN O O
these NN O O
three NN O O
major NN O O
splicing NN O O
events NN O O
and NN O O
show NN O O
that NN O O
their NN O O
transfection NN O O
into NN O O
cells NN O O
in NN O O
culture NN O O
leads NN O O
to NN O O
production NN O O
of NN O O
four NN O O
different NN O O
approximately NN O O
74 NN O O
kda NN O O
full-length NN O O
(heart-, NN O O
skeletal NN O O
muscle- NN O O
or NN O O
brain-specific) NN O O
and NN O O
two NN O O
c-terminally NN O O
truncated NN O O
approximately NN O O
68 NN O O
kda NN O O
(smooth NN O O
muscle-specific) NN O O
isoforms. NN O O
information NN O O
on NN O O
dmpk NN O O
mrna NN O O
and NN O O
protein NN O O
isoform NN O O
expression NN O O
patterns NN O O
will NN O O
be NN O O
useful NN O O
for NN O O
recognizing NN O O
differential NN O O
effects NN O O
of NN O O
(ctg) NN O O
(n) NN O O
expansion NN O O
in NN O O
DM NN B-Modifier B-MSH:D009223
manifestatio NN O O
. NN O O

. NN O O
. NN O O

linkage NN O O
analysis NN O O
in NN O O
a NN O O
large NN O O
brazilian NN O O
family NN O O
with NN O O
van NN B-SpecificDisease B-MSH:C536528
der NN I-SpecificDisease I-MSH:C536528
Woude NN I-SpecificDisease I-MSH:C536528
syndrome NN I-SpecificDisease I-MSH:C536528
suggests NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
susceptibility NN O O
locus NN O O
for NN O O
cleft NN B-SpecificDisease B-MSH:D002972
palate NN I-SpecificDisease I-MSH:D002972
at NN O O
17 NN O O
p NN O O
11.2-11.1 NN O O
. NN O O

van NN O O
der NN O O
woude NN O O
syndrome NN O O
( NN O O
VWS NN B-SpecificDisease B-MSH:C536528
), NN O O
which NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
1 NN O O
q NN O O
32-41, NN O O
is NN O O
characterized NN O O
by NN O O
pits NN B-CompositeMention B-MSH:D008047
and/or NN I-CompositeMention I-MSH:D008047
sinuses NN I-CompositeMention I-MSH:D008047
of NN I-CompositeMention I-MSH:D008047
the NN I-CompositeMention I-MSH:D008047
lower NN I-CompositeMention I-MSH:D008047
lip NN I-CompositeMention I-MSH:D008047
, NN O O
cleft NN B-SpecificDisease B-MSH:D002971
lip/palate NN I-SpecificDisease I-MSH:D002971
( NN O O
CL/P NN B-SpecificDisease B-MSH:D002971
), NN O O
cleft NN B-SpecificDisease B-MSH:D002972
palate NN I-SpecificDisease I-MSH:D002972
( NN O O
CP NN B-SpecificDisease B-MSH:D002972
), NN O O
bifid NN B-SpecificDisease B-MSH:C531732
uvula NN I-SpecificDisease I-MSH:C531732
, NN O O
and NN O O
hypodontia NN B-SpecificDisease B-MSH:D000848
( NN O O
H NN B-SpecificDisease B-MSH:D000848
). NN O O
the NN O O
expression NN O O
of NN O O
VWS NN B-SpecificDisease B-MSH:C536528
, NN O O
which NN O O
has NN O O
incomplete NN O O
penetrance, NN O O
is NN O O
highly NN O O
variable. NN O O
both NN O O
the NN O O
occurrence NN O O
of NN O O
CL/P NN B-SpecificDisease B-MSH:D002971
and NN O O
CP NN B-SpecificDisease B-MSH:D002972
within NN O O
the NN O O
same NN O O
genealogy NN O O
and NN O O
a NN O O
recurrence NN O O
risk NN O O
< NN O O
40% NN O O
for NN O O
CP NN B-SpecificDisease B-MSH:D002972
among NN O O
descendants NN O O
with NN O O
VWS NN B-SpecificDisease B-MSH:C536528
have NN O O
suggested NN O O
that NN O O
the NN O O
development NN O O
of NN O O
clefts NN B-DiseaseClass B-MSH:D002971
in NN O O
this NN O O
syndrome NN O O
is NN O O
influenced NN O O
by NN O O
modifying NN O O
genes NN O O
at NN O O
other NN O O
loci. NN O O
to NN O O
test NN O O
this NN O O
hypothesis, NN O O
we NN O O
have NN O O
conducted NN O O
linkage NN O O
analysis NN O O
in NN O O
a NN O O
large NN O O
brazilian NN O O
kindred NN O O
with NN O O
VWS NN B-SpecificDisease B-MSH:C536528
, NN O O
considering NN O O
as NN O O
affected NN O O
the NN O O
individuals NN O O
wit NN O O
. NN O O

cp, NN O O
regardless NN O O
of NN O O
whether NN O O
it NN O O
is NN O O
associated NN O O
with NN O O
other NN O O
clinical NN O O
signs NN O O
of NN O O
VWS NN B-SpecificDisease B-MSH:C536528
. NN O O
our NN O O
results NN O O
suggest NN O O
that NN O O
a NN O O
gene NN O O
at NN O O
17 NN O O
p NN O O
11. NN O O
2-11 NN O O
2-11. NN O O
1, NN O O
together NN O O
with NN O O
the NN O O
VWS NN B-Modifier B-MSH:C536528
gene NN O O
at NN O O
1 NN O O
p NN O O
32-41, NN O O
enhances NN O O
the NN O O
probability NN O O
of NN O O
CP NN B-SpecificDisease B-MSH:D002972
in NN O O
an NN O O
individual NN O O
carrying NN O O
the NN O O
two NN O O
at-risk NN O O
genes. NN O O
if NN O O
this NN O O
hypothesis NN O O
is NN O O
confirmed NN O O
in NN O O
other NN O O
VWS NN B-Modifier B-MSH:C536528
pedigrees, NN O O
it NN O O
will NN O O
represent NN O O
one NN O O
of NN O O
the NN O O
first NN O O
examples NN O O
of NN O O
a NN O O
gene, NN O O
mapped NN O O
through NN O O
linkage NN O O
analysis, NN O O
which NN O O
modifies NN O O
the NN O O
expression NN O O
of NN O O
a NN O O
major NN O O
gene NN O O
. NN O O

diverse NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
gene NN O O
cause NN O O
enzyme NN B-DiseaseClass B-MSH:D008661
deficiency NN I-DiseaseClass I-MSH:D008661
and NN O O
mild NN O O
or NN O O
severe NN O O
hemolytic NN B-SpecificDisease B-MSH:D000743
anemia NN I-SpecificDisease I-MSH:D000743
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd; NN O O
ec NN O O
1. NN O O
1. NN O O
1. NN O O
49) NN O O
deficiency NN O O
is NN O O
a NN O O
common NN O O
genetic NN B-DiseaseClass B-MSH:D030342
abnormality NN I-DiseaseClass I-MSH:D030342
affecting NN O O
an NN O O
estimated NN O O
400 NN O O
million NN O O
people NN O O
worldwide. NN O O
clinical NN O O
and NN O O
biochemical NN O O
analyses NN O O
have NN O O
identified NN O O
many NN O O
variants NN O O
exhibiting NN O O
a NN O O
range NN O O
of NN O O
phenotypes, NN O O
which NN O O
have NN O O
been NN O O
well NN O O
characterized NN O O
from NN O O
the NN O O
hematological NN O O
point NN O O
of NN O O
view. NN O O
however, NN O O
until NN O O
now, NN O O
their NN O O
precise NN O O
molecular NN O O
basis NN O O
has NN O O
remained NN O O
unknown. NN O O
we NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
seven NN O O
mutant NN O O
g NN O O
6 NN O O
pd NN O O
alleles. NN O O
in NN O O
the NN O O
nondeficient NN O O
polymorphic NN O O
african NN O O
variant NN O O
g NN O O
6 NN O O
pd NN O O
a NN O O
we NN O O
have NN O O
found NN O O
a NN O O
single NN O O
point NN O O
mutation. NN O O
the NN O O
other NN O O
six NN O O
mutants NN O O
investigated NN O O
were NN O O
all NN O O
associated NN O O
with NN O O
enzyme NN B-DiseaseClass B-MSH:D008661
deficiency NN I-DiseaseClass I-MSH:D008661
. NN O O
in NN O O
one NN O O
of NN O O
the NN O O
commonest, NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean, NN O O
which NN O O
is NN O O
associated NN O O
with NN O O
favism NN B-DiseaseClass B-MSH:D005236
among NN O O
other NN O O
clinical NN O O
manifestations, NN O O
a NN O O
single NN O O
amino NN O O
aci NN O O
. NN O O

replacement NN O O
was NN O O
found NN O O
(serine----phenylalanine) NN O O
it NN O O
must NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
decreased NN O O
stability NN O O
and NN O O
the NN O O
reduced NN O O
catalytic NN O O
efficiency NN O O
of NN O O
this NN O O
enzyme. NN O O
single NN O O
point NN O O
mutations NN O O
were NN O O
also NN O O
found NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
metaponto NN O O
(southern NN O O
italy) NN O O
and NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
ilesha NN O O
(nigeria), NN O O
which NN O O
are NN O O
asymptomatic, NN O O
and NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
chatham, NN O O
which NN O O
was NN O O
observed NN O O
in NN O O
an NN O O
indian NN O O
boy NN O O
with NN O O
neonatal NN B-DiseaseClass B-MSH:D007567
jaundice NN I-DiseaseClass I-MSH:D007567
. NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
" NN O O
matera, NN O O
" NN O O
which NN O O
is NN O O
now NN O O
known NN O O
to NN O O
be NN O O
the NN O O
same NN O O
as NN O O
g NN O O
6 NN O O
pd NN O O
a-, NN O O
two NN O O
separate NN O O
point NN O O
mutations NN O O
were NN O O
found, NN O O
one NN O O
of NN O O
which NN O O
is NN O O
the NN O O
same NN O O
as NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
a. NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
santiago, NN O O
a NN O O
de NN O O
novo NN O O
mutation NN O O
(glycine----arginine) NN O O
is NN O O
associated NN O O
with NN O O
sever NN O O
. NN O O

chronic NN O O
hemolytic NN B-SpecificDisease B-MSH:D000743
anemia NN I-SpecificDisease I-MSH:D000743
. NN O O
the NN O O
mutations NN O O
observed NN O O
show NN O O
a NN O O
striking NN O O
predominance NN O O
of NN O O
c----t NN O O
transitions, NN O O
with NN O O
cg NN O O
doublets NN O O
involved NN O O
in NN O O
four NN O O
of NN O O
seven NN O O
cases. NN O O
thus, NN O O
diverse NN O O
point NN O O
mutations NN O O
may NN O O
account NN O O
largely NN O O
for NN O O
the NN O O
phenotypic NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
. NN O O

increased NN O O
high-density NN O O
lipoprotein NN O O
levels NN O O
caused NN O O
by NN O O
a NN O O
common NN O O
cholesteryl-ester NN O O
transfer NN O O
protein NN O O
gene NN O O
mutation NN O O
. NN O O

background NN O O
and NN O O
methods. NN O O
the NN O O
plasma NN O O
cholesteryl-ester NN O O
transfer NN O O
protein NN O O
(cetp) NN O O
catalyzes NN O O
the NN O O
transfer NN O O
of NN O O
cholesteryl NN O O
esters NN O O
from NN O O
high-density NN O O
lipoprotein NN O O
(hdl) NN O O
to NN O O
other NN O O
lipoproteins. NN O O
we NN O O
recently NN O O
described NN O O
a NN O O
japanese NN O O
family NN O O
with NN O O
increased NN O O
hdl NN O O
levels NN O O
and NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
due NN O O
to NN O O
a NN O O
splicing NN O O
defect NN O O
of NN O O
the NN O O
cetp NN O O
gene. NN O O
to NN O O
assess NN O O
the NN O O
frequency NN O O
and NN O O
phenotype NN O O
of NN O O
this NN O O
condition, NN O O
we NN O O
screened NN O O
11 NN O O
additional NN O O
families NN O O
with NN O O
high NN O O
hdl NN O O
levels NN O O
by NN O O
means NN O O
of NN O O
a NN O O
radioimmunoassay NN O O
for NN O O
cetp NN O O
and NN O O
dna NN O O
analysis. NN O O
results. NN O O
we NN O O
found NN O O
the NN O O
same NN O O
cetp NN O O
gene NN O O
mutation NN O O
in NN O O
four NN O O
families NN O O
from NN O O
three NN O O
different NN O O
regions NN O O
of NN O O
japan. NN O O
analysis NN O O
of NN O O
restriction-fragment-length NN O O
polymorphisms NN O O
of NN O O
the NN O O
mutant NN O O
cetp NN O O
allele NN O O
showed NN O O
that NN O O
all NN O O
probands NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
identical NN O O
haplotype. NN O O
family NN O O
members NN O O
homozygous NN O O
for NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
(n NN O O
= NN O O
10) NN O O
ha NN O O
. NN O O

moderate NN O O
hypercholesterolemia NN B-SpecificDisease B-MSH:D006937
(mean NN O O
total NN O O
cholesterol NN O O
level NN O O
[+/- NN O O
sd], NN O O
7. NN O O
01 NN O O
+/- NN O O
0. NN O O
83 NN O O
mmol NN O O
per NN O O
liter), NN O O
markedly NN O O
increased NN O O
levels NN O O
of NN O O
hdl NN O O
cholesterol NN O O
(4. NN O O
24 NN O O
+/- NN O O
1. NN O O
01 NN O O
mmol NN O O
per NN O O
liter) NN O O
and NN O O
apolipoprotein NN O O
a-i, NN O O
and NN O O
decreased NN O O
levels NN O O
of NN O O
low-density NN O O
lipoprotein NN O O
cholesterol NN O O
(1. NN O O
99 NN O O
+/- NN O O
0. NN O O
80 NN O O
mmol NN O O
per NN O O
liter) NN O O
and NN O O
apolipoprotein NN O O
b. NN O O
members NN O O
heterozygous NN O O
for NN O O
the NN O O
deficiency NN O O
(n NN O O
= NN O O
20), NN O O
whose NN O O
cetp NN O O
levels NN O O
were NN O O
in NN O O
the NN O O
lower NN O O
part NN O O
of NN O O
the NN O O
normal NN O O
range, NN O O
had NN O O
moderately NN O O
increased NN O O
levels NN O O
of NN O O
hdl NN O O
cholesterol NN O O
and NN O O
apolipoprotein NN O O
a-i NN O O
and NN O O
an NN O O
increased NN O O
ratio NN O O
of NN O O
hdl NN O O
subclass NN O O
2 NN O O
to NN O O
hdl NN O O
subclass NN O O
3, NN O O
as NN O O
compared NN O O
with NN O O
unaffected NN O O
family NN O O
members NN O O
(1. NN O O
. NN O O

+/- NN O O
0. NN O O
8 NN O O
vs. NN O O
0. NN O O
7 NN O O
+/- NN O O
0. NN O O
4). NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
was NN O O
not NN O O
found NN O O
in NN O O
six NN O O
unrelated NN O O
subjects NN O O
with NN O O
elevated NN O O
hdl NN O O
cholesterol NN O O
levels NN O O
who NN O O
were NN O O
from NN O O
different NN O O
parts NN O O
of NN O O
the NN O O
united NN O O
states. NN O O
conclusions. NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
appears NN O O
to NN O O
be NN O O
a NN O O
frequent NN O O
cause NN O O
of NN O O
increased NN O O
hdl NN O O
levels NN O O
in NN O O
the NN O O
population NN O O
of NN O O
japan, NN O O
possibly NN O O
because NN O O
of NN O O
a NN O O
founder NN O O
effect. NN O O
the NN O O
results NN O O
that NN O O
we NN O O
observed NN O O
in NN O O
heterozygotes NN O O
suggest NN O O
that NN O O
cetp NN O O
normally NN O O
plays NN O O
a NN O O
part NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
levels NN O O
of NN O O
hdl NN O O
subclass NN O O
2. NN O O
there NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
premature NN B-SpecificDisease B-MSH:D050197
atherosclerosis NN I-SpecificDisease I-MSH:D050197
in NN O O
the NN O O
families NN O O
with NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
. NN O O
in NN O O
fact, NN O O
the NN O O
lipoprotein NN O O
profile NN O O
of NN O O
persons NN O O
with NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
is NN O O
potentially NN O O
antiatherogenic NN O O
and NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
life NN O O
span NN O O
. NN O O

hereditary NN O O
deficiency NN B-SpecificDisease B-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
the NN I-SpecificDisease I-OMIM:610102
seventh NN I-SpecificDisease I-OMIM:610102
component NN I-SpecificDisease I-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
complement NN I-SpecificDisease I-OMIM:610102
and NN O O
recurrent NN O O
meningococcal NN B-SpecificDisease B-MSH:D008589
infection NN I-SpecificDisease I-MSH:D008589
: NN O O
investigations NN O O
of NN O O
an NN O O
irish NN O O
family NN O O
using NN O O
a NN O O
novel NN O O
haemolytic NN O O
screening NN O O
assay NN O O
for NN O O
complement NN O O
activity NN O O
and NN O O
c NN O O
7 NN O O
m/n NN O O
allotyping NN O O
. NN O O

terminal NN O O
complement NN O O
component NN O O
deficiency NN O O
predisposes NN O O
to NN O O
meningococcal NN B-SpecificDisease B-MSH:D008589
infection NN I-SpecificDisease I-MSH:D008589
and NN O O
is NN O O
inherited NN O O
in NN O O
an NN O O
autosomal NN O O
co-dominant NN O O
manner. NN O O
an NN O O
irish NN O O
family NN O O
is NN O O
described, NN O O
in NN O O
which NN O O
2 NN O O
of NN O O
3 NN O O
brothers NN O O
had NN O O
recurrent NN O O
meningococcal NN B-SpecificDisease B-MSH:D008589
infection NN I-SpecificDisease I-MSH:D008589
. NN O O
a NN O O
novel NN O O
screening NN O O
assay NN O O
was NN O O
used NN O O
to NN O O
investigate NN O O
for NN O O
terminal NN B-SpecificDisease B-MSH:D007153
complement NN I-SpecificDisease I-MSH:D007153
deficiency NN I-SpecificDisease I-MSH:D007153
and NN O O
the NN O O
2 NN O O
affected NN O O
brothers NN O O
were NN O O
found NN O O
to NN O O
be NN O O
completely NN B-SpecificDisease B-OMIM:610102
deficient NN I-SpecificDisease I-OMIM:610102
in NN I-SpecificDisease I-OMIM:610102
the NN I-SpecificDisease I-OMIM:610102
seventh NN I-SpecificDisease I-OMIM:610102
component NN I-SpecificDisease I-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
complement NN I-SpecificDisease I-OMIM:610102
(c NN O O
7). NN O O
enzyme-linked NN O O
immunosorbent NN O O
assay NN O O
for NN O O
c NN O O
7 NN O O
revealed NN O O
lower NN O O
than NN O O
normal NN O O
levels NN O O
in NN O O
the NN O O
remaining NN O O
brother NN O O
and NN O O
parents. NN O O
c NN O O
7 NN O O
m/n NN O O
protein NN O O
polymorphism NN O O
allotyping, NN O O
used NN O O
to NN O O
investigate NN O O
the NN O O
segregation NN O O
of NN O O
the NN O O
C7 NN B-Modifier B-OMIM:610102
deficiency NN I-Modifier I-OMIM:610102
genes, NN O O
showed NN O O
that NN O O
the NN O O
apparently NN O O
complement NN O O
sufficient NN O O
brother NN O O
was NN O O
heterozygous NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficient NN I-SpecificDisease I-OMIM:610102
and NN O O
a NN O O
carrier NN O O
of NN O O
one NN O O
of NN O O
the NN O O
deficiency NN O O
genes. NN O O
complement NN O O
screening NN O O
should NN O O
be NN O O
carried NN O O
out NN O O
i NN O O
. NN O O

any NN O O
individual NN O O
suffering NN O O
recurrent NN O O
meningococcal NN B-SpecificDisease B-MSH:D008589
infection NN I-SpecificDisease I-MSH:D008589
or NN O O
infection NN O O
with NN O O
an NN O O
uncommon NN O O
meningococcal NN B-Modifier B-MSH:D008589
serogroup. NN O O
identification NN O O
of NN O O
complement NN B-Modifier B-MSH:D007153
deficient NN I-Modifier I-MSH:D007153
patients NN O O
allows NN O O
the NN O O
implementation NN O O
of NN O O
strategies NN O O
to NN O O
prevent NN O O
recurrent NN O O
infection. NN O O
. NN O O

mild NN O O
and NN O O
severe NN O O
muscular NN B-DiseaseClass B-MSH:D009136
dystrophy NN I-DiseaseClass I-MSH:D009136
associated NN O O
with NN O O
deletions NN O O
in NN O O
xp NN O O
21 NN O O
of NN O O
the NN O O
human NN O O
x NN O O
chromosome NN O O
. NN O O

we NN O O
have NN O O
analysed NN O O
over NN O O
300 NN O O
patients NN O O
suffering NN O O
from NN O O
Duchenne NN B-CompositeMention B-MSH:D020388
or NN I-CompositeMention I-MSH:D020388
Becker NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
or NN O O
BMD NN B-SpecificDisease B-MSH:C537666
). NN O O
deletions NN O O
have NN O O
been NN O O
characterised NN O O
which NN O O
encompass NN O O
either NN O O
the NN O O
pert NN O O
87 NN O O
(dxs NN O O
164) NN O O
locus NN O O
only, NN O O
the NN O O
xj NN O O
1. NN O O
1 NN O O
(dxs NN O O
206) NN O O
and NN O O
hip NN O O
25 NN O O
loci NN O O
only, NN O O
or NN O O
all NN O O
three NN O O
loci. NN O O
these NN O O
loci NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
lie NN O O
within NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
region NN O O
covering NN O O
several NN O O
hundred NN O O
kilobases NN O O
(kb) NN O O
of NN O O
dna. NN O O
one NN O O
mildly NN O O
affected NN O O
BMD NN B-Modifier B-MSH:C537666
patient NN O O
possesses NN O O
a NN O O
deletion NN O O
of NN O O
at NN O O
least NN O O
110 NN O O
kb NN O O
including NN O O
exons NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene. NN O O
other NN O O
patients NN O O
with NN O O
similar NN O O
exon NN O O
deletions, NN O O
or NN O O
smaller NN O O
deletions, NN O O
show NN O O
the NN O O
more NN O O
severe NN O O
phenotype NN O O
typical NN O O
of NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
we NN O O
conclude NN O O
from NN O O
these NN O O
studies NN O O
that NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
clinical NN O O
phenotype NN O O
cannot NN O O
be NN O O
explained NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
size NN O O
of NN O O
th NN O O
. NN O O

deletion. NN O O
we NN O O
discuss NN O O
this NN O O
in NN O O
the NN O O
context NN O O
of NN O O
candidate NN O O
gene NN O O
sequences NN O O
. NN O O

meiotic NN O O
segregation NN O O
analysis NN O O
of NN O O
rb NN O O
1 NN O O
alleles NN O O
in NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
pedigrees NN O O
by NN O O
use NN O O
of NN O O
single-sperm NN O O
typing NN O O
. NN O O

in NN O O
hereditary NN B-SpecificDisease B-MSH:D012175
retinoblastoma NN I-SpecificDisease I-MSH:D012175
, NN O O
different NN O O
epidemiological NN O O
studies NN O O
have NN O O
indicated NN O O
a NN O O
preferential NN O O
paternal NN O O
transmission NN O O
of NN O O
mutant NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
alleles NN O O
to NN O O
offspring, NN O O
suggesting NN O O
the NN O O
occurrence NN O O
of NN O O
a NN O O
meiotic NN O O
drive. NN O O
to NN O O
investigate NN O O
this NN O O
mechanism, NN O O
we NN O O
analyzed NN O O
sperm NN O O
samples NN O O
from NN O O
six NN O O
individuals NN O O
from NN O O
five NN O O
unrelated NN O O
families NN O O
affected NN O O
with NN O O
hereditary NN B-SpecificDisease B-MSH:D012175
retinoblastoma NN I-SpecificDisease I-MSH:D012175
. NN O O
single-sperm NN O O
typing NN O O
techniques NN O O
were NN O O
performed NN O O
for NN O O
each NN O O
sample NN O O
by NN O O
study NN O O
of NN O O
two NN O O
informative NN O O
short NN O O
tandem NN O O
repeats NN O O
located NN O O
either NN O O
in NN O O
or NN O O
close NN O O
to NN O O
the NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
gene NN O O
(rb NN O O
1). NN O O
the NN O O
segregation NN O O
probability NN O O
of NN O O
mutant NN O O
rb NN O O
1 NN O O
alleles NN O O
in NN O O
sperm NN O O
samples NN O O
was NN O O
assessed NN O O
by NN O O
use NN O O
of NN O O
the NN O O
spermseg NN O O
program, NN O O
which NN O O
includes NN O O
experimental NN O O
parameters, NN O O
recombination NN O O
fractions NN O O
between NN O O
the NN O O
markers, NN O O
and NN O O
segregation NN O O
parameters. NN O O
a NN O O
total NN O O
of NN O O
2, NN O O
952 NN O O
single NN O O
sperm NN O O
from NN O O
the NN O O
six NN O O
donors NN O O
were NN O O
analyzed. NN O O
we NN O O
detected NN O O
a NN O O
significant NN O O
segregation NN O O
distortion NN O O
in NN O O
the NN O O
dat NN O O
. NN O O

as NN O O
a NN O O
whole NN O O
(p NN O O
=. NN O O
0099) NN O O
and NN O O
a NN O O
significant NN O O
heterogeneity NN O O
in NN O O
the NN O O
segregation NN O O
rate NN O O
across NN O O
donors NN O O
(. NN O O
0092). NN O O
further NN O O
analysis NN O O
shows NN O O
that NN O O
this NN O O
result NN O O
can NN O O
be NN O O
explained NN O O
by NN O O
segregation NN O O
distortion NN O O
in NN O O
favor NN O O
of NN O O
the NN O O
normal NN O O
allele NN O O
in NN O O
one NN O O
donor NN O O
only NN O O
and NN O O
that NN O O
it NN O O
does NN O O
not NN O O
provide NN O O
evidence NN O O
of NN O O
a NN O O
significant NN O O
segregation NN O O
distortion NN O O
in NN O O
the NN O O
other NN O O
donors. NN O O
the NN O O
segregation NN O O
distortion NN O O
favoring NN O O
the NN O O
mutant NN O O
rb NN O O
1 NN O O
allele NN O O
does NN O O
not NN O O
seem NN O O
to NN O O
occur NN O O
during NN O O
spermatogenesis, NN O O
and, NN O O
thus, NN O O
meiotic NN O O
drive NN O O
may NN O O
result NN O O
either NN O O
from NN O O
various NN O O
mechanisms, NN O O
including NN O O
a NN O O
fertilization NN O O
advantage NN O O
or NN O O
a NN O O
better NN O O
mobility NN O O
in NN O O
sperm NN O O
bearing NN O O
a NN O O
mutant NN O O
rb NN O O
1 NN O O
gene, NN O O
or NN O O
from NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
defectively NN O O
imprinted NN O O
gene NN O O
located NN O O
on NN O O
the NN O O
human NN O O
x NN O O
chromosome NN O O
. NN O O
a NN O O
fertilization NN O O
advantage NN O O
or NN O O
a NN O O
better NN O O
mobility NN O O
in NN O O
sperm NN O O
bearing NN O O
a NN O O
mutant NN O O
rb NN O O
1 NN O O
gene, NN O O
or NN O O
from NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
defectively NN O O
imprinted NN O O
gene NN O O
located NN O O
on NN O O
the NN O O
human NN O O
x NN O O
chromosome NN O O
. NN O O

functional NN O O
differences NN O O
of NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
product NN O O
are NN O O
associated NN O O
with NN O O
phenotypic NN O O
variation NN O O
in NN O O
patients NN O O
with NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
and NN O O
non-syndromic NN B-SpecificDisease B-MSH:C537845
hearing NN I-SpecificDisease I-MSH:C537845
loss NN I-SpecificDisease I-MSH:C537845
( NN O O
DFNB4 NN B-SpecificDisease B-OMIM:600791
) NN O O
. NN O O

the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
encodes NN O O
a NN O O
transmembrane NN O O
protein, NN O O
known NN O O
as NN O O
pendrin, NN O O
which NN O O
functions NN O O
as NN O O
a NN O O
transporter NN O O
of NN O O
iodide NN O O
and NN O O
chloride. NN O O
mutations NN O O
in NN O O
this NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
and NN O O
autosomal NN B-SpecificDisease B-OMIM:600791
recessive NN I-SpecificDisease I-OMIM:600791
non-syndromic NN I-SpecificDisease I-OMIM:600791
hearing NN I-SpecificDisease I-OMIM:600791
loss NN I-SpecificDisease I-OMIM:600791
at NN O O
the NN O O
DFNB4 NN B-Modifier B-OMIM:600791
locus NN O O
on NN O O
chromosome NN O O
7 NN O O
q NN O O
31. NN O O
a NN O O
screen NN O O
of NN O O
20 NN O O
individuals NN O O
from NN O O
the NN O O
midwestern NN O O
usa NN O O
with NN O O
non-syndromic NN B-SpecificDisease B-MSH:C537845
hearing NN I-SpecificDisease I-MSH:C537845
loss NN I-SpecificDisease I-MSH:C537845
and NN O O
dilated NN O O
vestibular NN O O
aqueducts NN O O
identified NN O O
three NN O O
people NN O O
(15%) NN O O
with NN O O
PDS NN B-Modifier B-MSH:C536648
mutations. NN O O
to NN O O
determine NN O O
whether NN O O
PDS NN B-Modifier B-MSH:C536648
mutations NN O O
in NN O O
individuals NN O O
with NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
differ NN O O
functionally NN O O
from NN O O
PDS NN B-Modifier B-MSH:C536648
mutations NN O O
in NN O O
individuals NN O O
with NN O O
non-syndromic NN B-SpecificDisease B-MSH:C537845
hearing NN I-SpecificDisease I-MSH:C537845
loss NN I-SpecificDisease I-MSH:C537845
, NN O O
we NN O O
compared NN O O
three NN O O
common NN O O
Pendred NN B-Modifier B-MSH:C536648
syndrome NN I-Modifier I-MSH:C536648
allele NN O O
variants NN O O
(l NN O O
236 NN O O
p, NN O O
t NN O O
416 NN O O
p NN O O
and NN O O
e NN O O
384 NN O O
g), NN O O
with NN O O
three NN O O
PDS NN B-Modifier B-MSH:C536648
mutations NN O O
reported NN O O
only NN O O
in NN O O
individuals NN O O
with NN O O
non-syndromic NN B-SpecificDisease B-MSH:C537845
hearing NN I-SpecificDisease I-MSH:C537845
loss NN I-SpecificDisease I-MSH:C537845
. NN O O

(v NN O O
480 NN O O
d, NN O O
v NN O O
653 NN O O
a NN O O
and NN O O
i NN O O
490 NN O O
l/g NN O O
497 NN O O
s). NN O O
the NN O O
mutations NN O O
associated NN O O
with NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
have NN O O
complete NN O O
loss NN O O
of NN O O
pendrin-induced NN O O
chloride NN O O
and NN O O
iodide NN O O
transport, NN O O
while NN O O
alleles NN O O
unique NN O O
to NN O O
people NN O O
with NN O O
DFNB4 NN B-SpecificDisease B-OMIM:600791
are NN O O
able NN O O
to NN O O
transport NN O O
both NN O O
iodide NN O O
and NN O O
chloride, NN O O
albeit NN O O
at NN O O
a NN O O
much NN O O
lower NN O O
level NN O O
than NN O O
wild-type NN O O
pendrin. NN O O
we NN O O
hypothesize NN O O
that NN O O
this NN O O
residual NN O O
level NN O O
of NN O O
anion NN O O
transport NN O O
is NN O O
sufficient NN O O
to NN O O
eliminate NN O O
or NN O O
postpone NN O O
the NN O O
onset NN O O
of NN O O
goiter NN B-DiseaseClass B-MSH:D006042
in NN O O
individuals NN O O
with NN O O
DFNB4 NN B-SpecificDisease B-OMIM:600791
. NN O O
we NN O O
propose NN O O
a NN O O
model NN O O
for NN O O
pendrin NN O O
function NN O O
in NN O O
the NN O O
thyroid NN O O
in NN O O
which NN O O
pendrin NN O O
transports NN O O
iodide NN O O
across NN O O
the NN O O
apical NN O O
membrane NN O O
of NN O O
the NN O O
thyrocyte NN O O
into NN O O
the NN O O
colloid NN O O
space. NN O O
. NN O O

late-onset NN O O
metachromatic NN B-SpecificDisease B-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
: NN O O
molecular NN O O
pathology NN O O
in NN O O
two NN O O
siblings NN O O
. NN O O

we NN O O
report NN O O
on NN O O
a NN O O
new NN O O
allele NN O O
at NN O O
the NN O O
arylsulfatase NN O O
a NN O O
(arsa) NN O O
locus NN O O
causing NN O O
late-onset NN O O
metachromatic NN B-SpecificDisease B-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
( NN O O
MLD NN B-SpecificDisease B-MSH:D007966
). NN O O
in NN O O
that NN O O
allele NN O O
arginine NN O O
84, NN O O
a NN O O
residue NN O O
that NN O O
is NN O O
highly NN O O
conserved NN O O
in NN O O
the NN O O
arylsulfatase NN O O
gene NN O O
family, NN O O
is NN O O
replaced NN O O
by NN O O
glutamine. NN O O
in NN O O
contrast NN O O
to NN O O
alleles NN O O
that NN O O
cause NN O O
early-onset NN O O
MLD NN B-SpecificDisease B-MSH:D007966
, NN O O
the NN O O
arginine NN O O
84 NN O O
to NN O O
glutamine NN O O
substitution NN O O
is NN O O
associated NN O O
with NN O O
some NN O O
residual NN O O
arsa NN O O
activity. NN O O
a NN O O
comparison NN O O
of NN O O
genotypes, NN O O
arsa NN O O
activities, NN O O
and NN O O
clinical NN O O
data NN O O
on NN O O
4 NN O O
individuals NN O O
carrying NN O O
the NN O O
allele NN O O
of NN O O
81 NN O O
patients NN O O
with NN O O
MLD NN B-Modifier B-MSH:D007966
examined, NN O O
further NN O O
validates NN O O
the NN O O
concept NN O O
that NN O O
different NN O O
degrees NN O O
of NN O O
residual NN O O
arsa NN O O
activity NN O O
are NN O O
the NN O O
basis NN O O
of NN O O
phenotypical NN O O
variation NN O O
in NN O O
MLD NN B-SpecificDisease B-MSH:D007966
. NN O O
. NN O O

defective NN O O
cd NN O O
95/apo-1/fas NN O O
signal NN O O
complex NN O O
formation NN O O
in NN O O
the NN O O
human NN O O
autoimmune NN B-SpecificDisease B-MSH:D056735
lymphoproliferative NN I-SpecificDisease I-MSH:D056735
syndrome, NN I-SpecificDisease I-MSH:D056735
type NN I-SpecificDisease I-MSH:D056735
Ia NN I-SpecificDisease I-MSH:D056735
. NN O O

heterozygous NN O O
mutations NN O O
in NN O O
the NN O O
cd NN O O
95 NN O O
(apo-1/fas) NN O O
receptor NN O O
occur NN O O
in NN O O
most NN O O
individuals NN O O
with NN O O
autoimmune NN B-SpecificDisease B-MSH:D056735
lymphoproliferative NN I-SpecificDisease I-MSH:D056735
syndrome NN I-SpecificDisease I-MSH:D056735
( NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
) NN O O
and NN O O
dominantly NN O O
interfere NN O O
with NN O O
apoptosis NN O O
by NN O O
an NN O O
unknown NN O O
mechanism. NN O O
we NN O O
show NN O O
that NN O O
local NN O O
or NN O O
global NN O O
alterations NN O O
in NN O O
the NN O O
structure NN O O
of NN O O
the NN O O
cytoplasmic NN O O
death NN O O
domain NN O O
from NN O O
nine NN O O
independent NN O O
ALPS NN B-Modifier B-MSH:D056735
cd NN O O
95 NN O O
death-domain NN O O
mutations NN O O
result NN O O
in NN O O
a NN O O
failure NN O O
to NN O O
bind NN O O
the NN O O
fadd/mort NN O O
1 NN O O
signaling NN O O
protein. NN O O
despite NN O O
heterozygosity NN O O
for NN O O
the NN O O
abnormal NN O O
allele, NN O O
lymphocytes NN O O
from NN O O
ALPS NN B-Modifier B-MSH:D056735
patients NN O O
showed NN O O
markedly NN O O
decreased NN O O
fadd NN O O
association NN O O
and NN O O
a NN O O
loss NN O O
of NN O O
caspase NN O O
recruitment NN O O
and NN O O
activation NN O O
after NN O O
cd NN O O
95 NN O O
crosslinking. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
intracytoplasmic NN O O
cd NN O O
95 NN O O
mutations NN O O
in NN O O
ALPS NN B-SpecificDisease B-MSH:D056735
impair NN O O
apoptosis NN O O
chiefly NN O O
by NN O O
disrupting NN O O
death-domain NN O O
interactions NN O O
with NN O O
the NN O O
signaling NN O O
protein NN O O
fadd/mort NN O O
1. NN O O
. NN O O

classical NN O O
galactosemia NN O O
and NN O O
mutations NN O O
at NN O O
the NN O O
galactose-1-phosphate NN O O
uridyl NN O O
transferase NN O O
(galt) NN O O
gene NN O O
. NN O O

classical NN O O
galactosemia NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
deficiency NN O O
in NN O O
activity NN O O
of NN O O
the NN O O
enzyme NN O O
galactose-1-phosphate NN O O
uridyl NN O O
transferase NN O O
(galt), NN O O
which, NN O O
in NN O O
turn, NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
at NN O O
the NN O O
galt NN O O
gene. NN O O
the NN O O
disorder NN O O
exhibits NN O O
considerable NN O O
allelic NN O O
heterogeneity NN O O
and, NN O O
at NN O O
the NN O O
end NN O O
of NN O O
1998, NN O O
more NN O O
than NN O O
150 NN O O
different NN O O
base NN O O
changes NN O O
were NN O O
recorded NN O O
in NN O O
24 NN O O
different NN O O
populations NN O O
and NN O O
ethnic NN O O
groups NN O O
in NN O O
15 NN O O
countries NN O O
worldwide. NN O O
the NN O O
mutations NN O O
most NN O O
frequently NN O O
cited NN O O
are NN O O
q NN O O
188 NN O O
r, NN O O
k NN O O
285 NN O O
n, NN O O
s NN O O
135 NN O O
l, NN O O
and NN O O
n NN O O
314 NN O O
d. NN O O
q NN O O
188 NN O O
r NN O O
is NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
european NN O O
populations NN O O
or NN O O
in NN O O
those NN O O
predominantly NN O O
of NN O O
european NN O O
descent. NN O O
overall, NN O O
it NN O O
accounts NN O O
for NN O O
60-70% NN O O
of NN O O
mutant NN O O
chromosomes, NN O O
but NN O O
there NN O O
are NN O O
significant NN O O
differences NN O O
in NN O O
its NN O O
relative NN O O
frequency NN O O
in NN O O
individual NN O O
populations. NN O O
individual NN O O
. NN O O
its NN O O
relative NN O O
frequency NN O O
in NN O O
individual NN O O
populations. NN O O
individual NN O O
. NN O O

homoallelic NN O O
for NN O O
q NN O O
188 NN O O
r NN O O
tend NN O O
to NN O O
have NN O O
a NN O O
severe NN O O
phenotype NN O O
and NN O O
this NN O O
is NN O O
in NN O O
keeping NN O O
with NN O O
the NN O O
virtually NN O O
complete NN O O
loss NN O O
of NN O O
enzyme NN O O
activity NN O O
observed NN O O
in NN O O
in NN O O
vitro NN O O
expression NN O O
systems. NN O O
globally, NN O O
k NN O O
285 NN O O
n NN O O
is NN O O
rarer, NN O O
but NN O O
in NN O O
many NN O O
european NN O O
populations NN O O
it NN O O
can NN O O
be NN O O
found NN O O
on NN O O
25-40% NN O O
of NN O O
mutant NN O O
chromosomes. NN O O
it NN O O
is NN O O
invariably NN O O
associated NN O O
with NN O O
a NN O O
severe NN O O
phenotype. NN O O
s NN O O
135 NN O O
l NN O O
is NN O O
found NN O O
almost NN O O
exclusively NN O O
in NN O O
african NN O O
americans. NN O O
in NN O O
vitro NN O O
expression NN O O
results NN O O
are NN O O
discrepant, NN O O
but NN O O
some NN O O
individuals NN O O
carrying NN O O
s NN O O
135 NN O O
l NN O O
appear NN O O
to NN O O
exhibit NN O O
galt NN O O
activity NN O O
in NN O O
some NN O O
tissues. NN O O
duarte NN O O
1 NN O O
(or NN O O
los NN O O
angeles) NN O O
and NN O O
duarte NN O O
2 NN O O
(or NN O O
duarte) NN O O
variants NN O O
carry NN O O
the NN O O
same NN O O
amino NN O O
acid NN O O
substitution, NN O O
n NN O O
314 NN O O
d, NN O O
even NN O O
though NN O O
d NN O O
1 NN O O
is NN O O
associated NN O O
with NN O O
increased NN O O
erythrocyte NN O O
galt NN O O
activity NN O O
and NN O O
d NN O O
. NN O O
creased NN O O
erythrocyte NN O O
galt NN O O
activity NN O O
and NN O O
d NN O O
. NN O O

with NN O O
reduced NN O O
activity. NN O O
n NN O O
314 NN O O
d NN O O
is NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
other NN O O
base NN O O
changes NN O O
that NN O O
differ NN O O
on NN O O
the NN O O
d NN O O
1 NN O O
and NN O O
d NN O O
2 NN O O
alleles. NN O O
n NN O O
314 NN O O
d NN O O
does NN O O
not NN O O
impair NN O O
galt NN O O
activity NN O O
in NN O O
in NN O O
vitro NN O O
expression NN O O
systems. NN O O
however, NN O O
there NN O O
are NN O O
differences NN O O
in NN O O
the NN O O
abundance NN O O
of NN O O
galt NN O O
protein NN O O
in NN O O
lymphoblastoid NN O O
cells NN O O
lines NN O O
from NN O O
d NN O O
2 NN O O
and NN O O
d NN O O
1 NN O O
individuals. NN O O
it NN O O
is NN O O
unclear NN O O
whether NN O O
the NN O O
specific NN O O
molecular NN O O
changes NN O O
that NN O O
distinguish NN O O
the NN O O
d NN O O
1 NN O O
and NN O O
d NN O O
2 NN O O
alleles NN O O
account NN O O
for NN O O
the NN O O
different NN O O
activities. NN O O
the NN O O
considerable NN O O
genetic NN O O
heterogeneity NN O O
documented NN O O
to NN O O
date NN O O
undoubtedly NN O O
contributes NN O O
to NN O O
the NN O O
phenotypic NN O O
heterogeneity NN O O
that NN O O
is NN O O
observed NN O O
in NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
. NN O O
the NN O O
additional NN O O
effects NN O O
of NN O O
nonallelic NN O O
variation NN O O
and NN O O
other NN O O
constitutional NN O O
factors NN O O
on NN O O
phenotypic NN O O
variability NN O O
remain NN O O
to NN O O
be NN O O
elucidated. NN O O
. NN O O

x-linked NN O O
retinoschisis NN O O
with NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
xlrs NN O O
1 NN O O
gene NN O O
. NN O O

background NN O O
X-linked NN B-SpecificDisease B-MSH:D041441
retinoschisis NN I-SpecificDisease I-MSH:D041441
( NN O O
XLRS NN B-SpecificDisease B-MSH:D041441
) NN O O
is NN O O
a NN O O
relatively NN O O
rare NN O O
vitreoretinal NN B-DiseaseClass B-MSH:D058499
dystrophy NN I-DiseaseClass I-MSH:D058499
that NN O O
causes NN O O
visual NN B-SpecificDisease B-MSH:C531604
loss NN I-SpecificDisease I-MSH:C531604
in NN O O
young NN O O
men. NN O O
recently, NN O O
a NN O O
gene NN O O
responsible NN O O
for NN O O
this NN O O
disease, NN O O
designated NN O O
xlrs NN O O
1, NN O O
was NN O O
identified, NN O O
and NN O O
several NN O O
deleterious NN O O
gene NN O O
mutations NN O O
were NN O O
reported. NN O O
objective NN O O
to NN O O
analyze NN O O
japanese NN O O
patients NN O O
clinically NN O O
diagnosed NN O O
as NN O O
having NN O O
XLRS NN B-Modifier B-MSH:D041441
formutational NN O O
changes NN O O
in NN O O
the NN O O
xlrs NN O O
1 NN O O
gene. NN O O
methods NN O O
ten NN O O
patients NN O O
with NN O O
XLRS NN B-SpecificDisease B-MSH:D041441
underwent NN O O
full NN O O
ophthalmologic NN O O
examination, NN O O
including NN O O
slitlamp NN O O
biomicroscopy NN O O
and NN O O
dilated NN O O
funduscopy. NN O O
genomic NN O O
dna NN O O
was NN O O
isolated NN O O
from NN O O
leukocytes, NN O O
and NN O O
all NN O O
exons NN O O
of NN O O
the NN O O
xlrs NN O O
1 NN O O
gene NN O O
were NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
and NN O O
analyzed NN O O
using NN O O
a NN O O
direct NN O O
sequencing NN O O
method. NN O O
results NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
xlrs NN O O
1 NN O O
gene NN O O
were NN O O
identified NN O O
in NN O O
all NN O O
10 NN O O
patients. NN O O
the NN O O
mutations NN O O
were NN O O
identical NN O O
in NN O O
each NN O O
of NN O O
2 NN O O
pairs NN O O
of NN O O
brothers. NN O O
six NN O O
of NN O O
th NN O O
. NN O O

point NN O O
mutations NN O O
represented NN O O
missense NN O O
mutations, NN O O
1 NN O O
was NN O O
a NN O O
nonsense NN O O
mutation, NN O O
and NN O O
1 NN O O
was NN O O
a NN O O
frameshift NN O O
mutation. NN O O
five NN O O
of NN O O
the NN O O
mutations NN O O
are NN O O
newly NN O O
reported NN O O
herein. NN O O
conclusions NN O O
the NN O O
discovery NN O O
of NN O O
new NN O O
point NN O O
mutations NN O O
in NN O O
this NN O O
study NN O O
increases NN O O
the NN O O
available NN O O
information NN O O
regarding NN O O
the NN O O
spectrum NN O O
of NN O O
genetic NN B-DiseaseClass B-MSH:D030342
abnormalities NN I-DiseaseClass I-MSH:D030342
and NN O O
clinical NN O O
manifestations NN O O
of NN O O
XLRS NN B-SpecificDisease B-MSH:D041441
. NN O O
however, NN O O
the NN O O
limited NN O O
data NN O O
failed NN O O
to NN O O
reveal NN O O
a NN O O
correlation NN O O
between NN O O
mutation NN O O
and NN O O
disease NN O O
phenotype. NN O O
clinical NN O O
relevance NN O O
identification NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
xlrs NN O O
1 NN O O
gene NN O O
and NN O O
expanded NN O O
information NN O O
on NN O O
clinical NN O O
manifestations NN O O
will NN O O
facilitate NN O O
early NN O O
diagnosis, NN O O
appropriate NN O O
early NN O O
therapy, NN O O
and NN O O
genetic NN O O
counseling NN O O
regarding NN O O
the NN O O
prognosis NN O O
of NN O O
XLRS NN B-SpecificDisease B-MSH:D041441
. NN O O
. NN O O

relationship NN O O
among NN O O
genotype, NN O O
biochemical NN O O
phenotype, NN O O
and NN O O
cognitive NN O O
performance NN O O
in NN O O
females NN O O
with NN O O
phenylalanine NN B-SpecificDisease B-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
deficiency NN I-SpecificDisease I-OMIM:261600
: NN O O
report NN O O
from NN O O
the NN O O
Maternal NN B-Modifier B-MSH:D017042
Phenylketonuria NN I-Modifier I-MSH:D017042
collaborative NN O O
study NN O O
. NN O O

objective NN O O
to NN O O
examine NN O O
the NN O O
relationship NN O O
of NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
genotypes NN O O
to NN O O
biochemical NN O O
phenotype NN O O
and NN O O
cognitive NN O O
development NN O O
in NN O O
maternal NN B-SpecificDisease B-MSH:D017042
phenylketonuria NN I-SpecificDisease I-MSH:D017042
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
). NN O O
methodology NN O O
pah NN O O
gene NN O O
mutations NN O O
were NN O O
examined NN O O
in NN O O
222 NN O O
hyperphenylalaninemic NN B-Modifier B-MSH:D010661
females NN O O
enrolled NN O O
in NN O O
the NN O O
Maternal NN B-Modifier B-MSH:D017042
PKU NN I-Modifier I-MSH:D017042
collaborative NN O O
study NN O O
(mpkucs). NN O O
a NN O O
total NN O O
of NN O O
84 NN O O
different NN O O
mutations NN O O
were NN O O
detected, NN O O
and NN O O
complete NN O O
genotype NN O O
was NN O O
obtained NN O O
in NN O O
199 NN O O
individuals. NN O O
based NN O O
on NN O O
previous NN O O
knowledge NN O O
about NN O O
mutation-phenotype NN O O
associations, NN O O
78 NN O O
of NN O O
the NN O O
mutations NN O O
could NN O O
be NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
four NN O O
classes NN O O
of NN O O
severity NN O O
(severe NN O O
PKU NN B-SpecificDisease B-MSH:D010661
, NN O O
moderate NN O O
PKU NN B-SpecificDisease B-MSH:D010661
, NN O O
mild NN O O
PKU NN B-SpecificDisease B-MSH:D010661
, NN O O
and NN O O
mild NN B-SpecificDisease B-MSH:D010661
hyperphenylalaninemia NN I-SpecificDisease I-MSH:D010661
[ NN O O
MHP NN B-SpecificDisease B-MSH:D010661
]). NN O O
then, NN O O
189 NN O O
mpkucs NN O O
subjects NN O O
were NN O O
grouped NN O O
according NN O O
to NN O O
the NN O O
various NN O O
combinations NN O O
of NN O O
mutation NN O O
classifications. NN O O
the NN O O
sample NN O O
sizes NN O O
were NN O O
large NN O O
enough NN O O
for NN O O
statistical NN O O
testing NN O O
in NN O O
four NN O O
groups NN O O
with NN O O
at NN O O
least NN O O
one NN O O
mutation NN O O
tha NN O O
. NN O O

completely NN O O
abolishes NN O O
enzyme NN O O
activity. NN O O
these NN O O
patients NN O O
are NN O O
considered NN O O
functionally NN O O
hemizygous. NN O O
results NN O O
the NN O O
biochemical NN O O
phenotype NN O O
predicted NN O O
from NN O O
the NN O O
genotype NN O O
in NN O O
functionally NN O O
hemizygous NN O O
patients NN O O
was NN O O
related NN O O
significantly NN O O
to NN O O
the NN O O
assigned NN O O
phenylalanine NN O O
level. NN O O
cognitive NN O O
performance NN O O
(iq) NN O O
was NN O O
also NN O O
significantly NN O O
related NN O O
to NN O O
genotype. NN O O
the NN O O
iq NN O O
of NN O O
PAH-deficient NN B-Modifier B-OMIM:261600
mothers NN O O
with NN O O
a NN O O
severe NN O O
PKU NN B-Modifier B-MSH:D010661
mutation NN O O
in NN O O
combination NN O O
with NN O O
a NN O O
MHP NN B-Modifier B-MSH:D010661
mutation NN O O
or NN O O
a NN O O
mild NN O O
PKU NN B-Modifier B-MSH:D010661
mutation NN O O
was NN O O
99 NN O O
and NN O O
96, NN O O
respectively, NN O O
whereas NN O O
the NN O O
iq NN O O
of NN O O
PKU NN B-Modifier B-MSH:D010661
mothers NN O O
with NN O O
two NN O O
severe NN O O
PKU NN B-Modifier B-MSH:D010661
mutations NN O O
or NN O O
with NN O O
one NN O O
severe NN O O
and NN O O
one NN O O
moderate NN O O
PKU NN B-Modifier B-MSH:D010661
mutation NN O O
was NN O O
83 NN O O
and NN O O
84, NN O O
respectively. NN O O
of NN O O
the NN O O
patients NN O O
with NN O O
PKU NN B-SpecificDisease B-MSH:D010661
, NN O O
92% NN O O
had NN O O
been NN O O
treated NN O O
during NN O O
childhood. NN O O
those NN O O
who NN O O
were NN O O
untreated NN O O
or NN O O
treated NN O O
late NN O O
had NN O O
lower NN O O
than NN O O
average NN O O
iq NN O O
scores NN O O
for NN O O
their NN O O
group NN O O
of NN O O
mutation NN O O
combinations. NN O O
females NN O O
with NN O O
moderate NN O O
o NN O O
. NN O O

mild NN O O
PKU NN B-SpecificDisease B-MSH:D010661
who NN O O
were NN O O
treated NN O O
early NN O O
and NN O O
treated NN O O
for NN O O
> NN O O
6 NN O O
years NN O O
showed NN O O
iq NN O O
scores NN O O
10 NN O O
points NN O O
above NN O O
average NN O O
for NN O O
their NN O O
group. NN O O
conclusions NN O O
the NN O O
reproductive NN O O
outcome NN O O
in NN O O
maternal NN B-SpecificDisease B-MSH:D017042
phenylketonuria NN I-SpecificDisease I-MSH:D017042
is NN O O
dependent NN O O
on NN O O
prenatal NN O O
metabolic NN O O
control NN O O
and NN O O
postnatal NN O O
environmental NN O O
circumstances. NN O O
both NN O O
factors NN O O
depend NN O O
on NN O O
the NN O O
intellectual NN O O
resources NN O O
of NN O O
the NN O O
mother NN O O
with NN O O
PKU NN B-SpecificDisease B-MSH:D010661
. NN O O
the NN O O
significant NN O O
relationship NN O O
among NN O O
genotype, NN O O
biochemical NN O O
phenotype, NN O O
and NN O O
cognitive NN O O
performance NN O O
observed NN O O
in NN O O
the NN O O
present NN O O
study NN O O
is NN O O
of NN O O
importance NN O O
for NN O O
the NN O O
development NN O O
of NN O O
an NN O O
optimal NN O O
strategy NN O O
for NN O O
future NN O O
treatment NN O O
of NN O O
females NN O O
with NN O O
PKU NN B-SpecificDisease B-MSH:D010661
who NN O O
plan NN O O
pregnancy. NN O O
. NN O O

uncoupling NN O O
of NN O O
hypomyelination NN B-SpecificDisease B-MSH:D003711
and NN O O
glial NN B-SpecificDisease B-MSH:D004194
cell NN I-SpecificDisease I-MSH:D004194
death NN I-SpecificDisease I-MSH:D004194
by NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
. NN O O

proteolipid NN O O
protein NN O O
(plp; NN O O
m NN O O
(r) NN O O
30, NN O O
000) NN O O
is NN O O
a NN O O
highly NN O O
conserved NN O O
major NN O O
polytopic NN O O
membrane NN O O
protein NN O O
in NN O O
myelin NN O O
but NN O O
its NN O O
cellular NN O O
function NN O O
remains NN O O
obscure. NN O O
neurological NN O O
mutant NN O O
mice NN O O
can NN O O
often NN O O
provide NN O O
model NN O O
systems NN O O
for NN O O
human NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
. NN O O
mutations NN O O
of NN O O
the NN O O
x-chromosome-linked NN O O
plp NN O O
gene NN O O
are NN O O
lethal, NN O O
identified NN O O
first NN O O
in NN O O
the NN O O
jimpy NN O O
mouse NN O O
and NN O O
subsequently NN O O
in NN O O
patients NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
. NN O O
the NN O O
unexplained NN O O
phenotype NN O O
of NN O O
these NN O O
mutations NN O O
includes NN O O
degeneration NN B-CompositeMention B-MSH:D056784
and NN I-CompositeMention I-MSH:D056784
premature NN I-CompositeMention I-MSH:D056784
cell NN I-CompositeMention I-MSH:D056784
death NN I-CompositeMention I-MSH:D056784
of NN I-CompositeMention I-MSH:D056784
oligodendrocytes NN I-CompositeMention I-MSH:D056784
with NN O O
associated NN O O
hypomyelination NN B-SpecificDisease B-MSH:D003711
. NN O O
here NN O O
we NN O O
show NN O O
that NN O O
a NN O O
new NN O O
mouse NN O O
mutant NN O O
rumpshaker NN O O
is NN O O
defined NN O O
by NN O O
the NN O O
amino-acid NN O O
substitution NN O O
ile-to-thr NN O O
at NN O O
residue NN O O
186 NN O O
in NN O O
a NN O O
membrane-embedded NN O O
domain NN O O
of NN O O
plp. NN O O
surprisingly, NN O O
rumpshaker NN O O
mice, NN O O
although NN O O
myelin-deficient NN B-SpecificDisease B-MSH:D003711
, NN O O
have NN O O
normal NN O O
longevity NN O O
and NN O O
a NN O O
ful NN O O
. NN O O

complement NN O O
of NN O O
morphologically NN O O
normal NN O O
oligodendrocytes. NN O O
Hypomyelination NN B-SpecificDisease B-MSH:D003711
can NN O O
thus NN O O
be NN O O
genetically NN O O
separated NN O O
from NN O O
the NN O O
plp-dependent NN O O
oligodendrocyte NN B-SpecificDisease B-MSH:D056784
degeneration NN I-SpecificDisease I-MSH:D056784
. NN O O
we NN O O
suggest NN O O
that NN O O
plp NN O O
has NN O O
a NN O O
vital NN O O
function NN O O
in NN O O
glial NN O O
cell NN O O
development, NN O O
distinct NN O O
from NN O O
its NN O O
later NN O O
role NN O O
in NN O O
myelin NN O O
assembly, NN O O
and NN O O
that NN O O
this NN O O
dichotomy NN O O
of NN O O
action NN O O
may NN O O
explain NN O O
the NN O O
clinical NN O O
spectrum NN O O
of NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
. NN O O
. NN O O

mutational NN O O
analysis NN O O
of NN O O
the NN O O
hgo NN O O
gene NN O O
in NN O O
finnish NN O O
alkaptonuria NN B-Modifier B-MSH:D000474
patients NN O O
. NN O O

alkaptonuria NN O O
( NN O O
AKU NN B-SpecificDisease B-MSH:D000474
), NN O O
the NN O O
prototypic NN O O
inborn NN B-DiseaseClass B-MSH:D008661
error NN I-DiseaseClass I-MSH:D008661
of NN I-DiseaseClass I-MSH:D008661
metabolism NN I-DiseaseClass I-MSH:D008661
, NN O O
has NN O O
recently NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
loss NN O O
of NN O O
function NN O O
mutations NN O O
in NN O O
the NN O O
homogentisate-1, NN O O
2-dioxygenase NN O O
gene NN O O
(hgo). NN O O
so NN O O
far NN O O
17 NN O O
mutations NN O O
have NN O O
been NN O O
characterised NN O O
in NN O O
AKU NN B-Modifier B-MSH:D000474
patients NN O O
of NN O O
different NN O O
ethnic NN O O
origin. NN O O
we NN O O
describe NN O O
three NN O O
novel NN O O
mutations NN O O
(r NN O O
58 NN O O
fs, NN O O
r NN O O
330 NN O O
s, NN O O
and NN O O
h NN O O
371 NN O O
r) NN O O
and NN O O
one NN O O
common NN O O
AKU NN B-Modifier B-MSH:D000474
mutation NN O O
(m NN O O
368 NN O O
v), NN O O
detected NN O O
by NN O O
mutational NN O O
and NN O O
polymorphism NN O O
analysis NN O O
of NN O O
the NN O O
hgo NN O O
gene NN O O
in NN O O
five NN O O
finnish NN O O
AKU NN B-Modifier B-MSH:D000474
pedigrees. NN O O
the NN O O
three NN O O
novel NN O O
AKU NN B-Modifier B-MSH:D000474
mutations NN O O
are NN O O
most NN O O
likely NN O O
specific NN O O
for NN O O
the NN O O
finnish NN O O
population NN O O
and NN O O
have NN O O
originated NN O O
recently. NN O O
. NN O O

putative NN O O
X-linked NN B-Modifier B-MSH:D000326
adrenoleukodystrophy NN I-Modifier I-MSH:D000326
gene NN O O
shares NN O O
unexpected NN O O
homology NN O O
with NN O O
abc NN O O
transporters NN O O
. NN O O

adrenoleukodystrophy NN O O
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
disease NN I-DiseaseClass I-MSH:D040181
affecting NN O O
1/20, NN O O
000 NN O O
males NN O O
either NN O O
as NN O O
cerebral NN B-SpecificDisease B-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
in NN O O
childhood NN O O
or NN O O
as NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
AMN NN B-SpecificDisease B-MSH:D000326
) NN O O
in NN O O
adults. NN O O
childhood NN O O
ALD NN B-SpecificDisease B-MSH:D000326
is NN O O
the NN O O
more NN O O
severe NN O O
form, NN O O
with NN O O
onset NN O O
of NN O O
neurological NN O O
symptoms NN O O
between NN O O
5-12 NN O O
years NN O O
of NN O O
age. NN O O
Central NN B-DiseaseClass B-MSH:D003711
nervous NN I-DiseaseClass I-MSH:D003711
system NN I-DiseaseClass I-MSH:D003711
demyelination NN I-DiseaseClass I-MSH:D003711
progresses NN O O
rapidly NN O O
and NN O O
death NN O O
occurs NN O O
within NN O O
a NN O O
few NN O O
years. NN O O
AMN NN B-SpecificDisease B-MSH:D000326
is NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
with NN O O
onset NN O O
at NN O O
15-30 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
a NN O O
more NN O O
progressive NN O O
course. NN O O
Adrenal NN B-DiseaseClass B-MSH:D000309
insufficiency NN I-DiseaseClass I-MSH:D000309
( NN O O
Addisons NN B-SpecificDisease B-MSH:D000224
disease NN I-SpecificDisease I-MSH:D000224
) NN O O
may NN O O
remain NN O O
the NN O O
only NN O O
clinical NN O O
manifestation NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
the NN O O
principal NN O O
biochemical NN O O
abnormality NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
is NN O O
the NN O O
accumulation NN O O
of NN O O
very-long-chain NN O O
fatty NN O O
acids NN O O
(vlcfa) NN O O
because NN O O
of NN O O
impaired NN O O
beta-oxidation NN O O
in NN O O
peroxisomes. NN O O
the NN O O
normal NN O O
oxidation NN O O
of NN O O
vlcfa NN O O
. NN O O

coa NN O O
in NN O O
patients NN O O
fibroblasts NN O O
suggested NN O O
that NN O O
the NN O O
gene NN O O
coding NN O O
for NN O O
the NN O O
vlcfa-coa NN O O
synthetase NN O O
could NN O O
be NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
here NN O O
we NN O O
use NN O O
positional NN O O
cloning NN O O
to NN O O
identify NN O O
a NN O O
gene NN O O
partially NN O O
deleted NN O O
in NN O O
6 NN O O
of NN O O
85 NN O O
independent NN O O
patients NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
in NN O O
familial NN O O
cases, NN O O
the NN O O
deletions NN O O
segregated NN O O
with NN O O
the NN O O
disease. NN O O
an NN O O
identical NN O O
deletion NN O O
was NN O O
detected NN O O
in NN O O
two NN O O
brothers NN O O
presenting NN O O
with NN O O
different NN O O
clinical NN O O
ALD NN B-Modifier B-MSH:D000326
phenotypes. NN O O
candidate NN O O
exons NN O O
were NN O O
identified NN O O
by NN O O
computer NN O O
analysis NN O O
of NN O O
genomic NN O O
sequences NN O O
and NN O O
used NN O O
to NN O O
isolate NN O O
complementary NN O O
dnas NN O O
by NN O O
exon NN O O
connection NN O O
and NN O O
screening NN O O
of NN O O
cdna NN O O
libraries. NN O O
the NN O O
deduced NN O O
protein NN O O
sequence NN O O
shows NN O O
significant NN O O
sequence NN O O
identity NN O O
to NN O O
a NN O O
peroxisomal NN O O
membrane NN O O
protein NN O O
of NN O O
m NN O O
(r) NN O O
70 NN O O
k NN O O
that NN O O
is NN O O
involved NN O O
in NN O O
peroxisome NN O O
biogenesis NN O O
and NN O O
belongs NN O O
to NN O O
the NN O O
atp-binding NN O O
cassette NN O O
superfamily NN O O
of NN O O
transporters. NN O O
. NN O O

cardiac NN O O
na(+) NN O O
channel NN O O
dysfunction NN O O
in NN O O
Brugada NN B-SpecificDisease B-MSH:D053840
syndrome NN I-SpecificDisease I-MSH:D053840
is NN O O
aggravated NN O O
by NN O O
beta(1)-subunit NN O O
. NN O O

background NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
human NN O O
cardiac NN O O
na NN O O
(+) NN O O
channel NN O O
alpha-subunit NN O O
(hh NN O O
1) NN O O
are NN O O
responsible NN O O
for NN O O
chromosome NN O O
3-linked NN O O
congenital NN B-SpecificDisease B-MSH:D008133
long-QT NN I-SpecificDisease I-MSH:D008133
syndrome NN I-SpecificDisease I-MSH:D008133
( NN O O
LQT3 NN B-SpecificDisease B-MSH:C537034
) NN O O
and NN O O
idiopathic NN B-SpecificDisease B-MSH:C537182
ventricular NN I-SpecificDisease I-MSH:C537182
fibrillation NN I-SpecificDisease I-MSH:C537182
( NN O O
IVF NN B-SpecificDisease B-MSH:C537182
). NN O O
an NN O O
auxiliary NN O O
beta NN O O
(1) NN O O
-subunit, NN O O
widely NN O O
expressed NN O O
in NN O O
excitable NN O O
tissues, NN O O
shifts NN O O
the NN O O
voltage NN O O
dependence NN O O
of NN O O
steady-state NN O O
inactivation NN O O
toward NN O O
more NN O O
negative NN O O
potentials NN O O
and NN O O
restores NN O O
normal NN O O
gating NN O O
kinetics NN O O
of NN O O
brain NN O O
and NN O O
skeletal NN O O
muscle NN O O
na NN O O
(+) NN O O
channels NN O O
expressed NN O O
in NN O O
xenopus NN O O
oocytes NN O O
but NN O O
has NN O O
little NN O O
if NN O O
any NN O O
functional NN O O
effect NN O O
on NN O O
the NN O O
cardiac NN O O
isoform. NN O O
here, NN O O
we NN O O
characterize NN O O
the NN O O
altered NN O O
effects NN O O
of NN O O
a NN O O
human NN O O
beta NN O O
(1) NN O O
-subunit NN O O
(hbeta NN O O
(1)) NN O O
on NN O O
the NN O O
heterologously NN O O
expressed NN O O
hh NN O O
1 NN O O
mutation NN O O
(t NN O O
1620 NN O O
m) NN O O
previously NN O O
associate NN O O
. NN O O

with NN O O
IVF NN B-SpecificDisease B-MSH:C537182
. NN O O
methods NN O O
and NN O O
results NN O O
when NN O O
expressed NN O O
alone NN O O
in NN O O
xenopus NN O O
oocytes, NN O O
t NN O O
1620 NN O O
m NN O O
exhibited NN O O
no NN O O
persistent NN O O
currents, NN O O
in NN O O
contrast NN O O
to NN O O
the NN O O
LQT3 NN B-Modifier B-MSH:C537034
mutant NN O O
channels, NN O O
but NN O O
the NN O O
midpoint NN O O
of NN O O
steady-state NN O O
inactivation NN O O
(v NN O O
(1/2)) NN O O
was NN O O
significantly NN O O
shifted NN O O
toward NN O O
more NN O O
positive NN O O
potentials NN O O
than NN O O
for NN O O
wild-type NN O O
hh NN O O
1. NN O O
coexpression NN O O
of NN O O
hbeta NN O O
(1) NN O O
did NN O O
not NN O O
significantly NN O O
alter NN O O
current NN O O
decay NN O O
or NN O O
recovery NN O O
from NN O O
inactivation NN O O
of NN O O
wild-type NN O O
hh NN O O
1; NN O O
however, NN O O
it NN O O
further NN O O
shifted NN O O
the NN O O
v NN O O
(1/2) NN O O
and NN O O
accelerated NN O O
the NN O O
recovery NN O O
from NN O O
inactivation NN O O
of NN O O
t NN O O
1620 NN O O
m. NN O O
oocyte NN O O
macropatch NN O O
analysis NN O O
revealed NN O O
that NN O O
the NN O O
activation NN O O
kinetics NN O O
of NN O O
t NN O O
1620 NN O O
m NN O O
were NN O O
normal. NN O O
conclusions NN O O
it NN O O
is NN O O
suggested NN O O
that NN O O
coexpression NN O O
of NN O O
hbeta NN O O
(1) NN O O
exposes NN O O
a NN O O
more NN O O
severe NN O O
functional NN O O
defect NN O O
tha NN O O
. NN O O

results NN O O
in NN O O
a NN O O
greater NN O O
overlap NN O O
in NN O O
the NN O O
relationship NN O O
between NN O O
channel NN O O
inactivation NN O O
and NN O O
activation NN O O
(window NN O O
current) NN O O
in NN O O
t NN O O
1620 NN O O
m, NN O O
which NN O O
is NN O O
proposed NN O O
to NN O O
be NN O O
a NN O O
potential NN O O
pathophysiological NN O O
mechanism NN O O
of NN O O
IVF NN B-SpecificDisease B-MSH:C537182
in NN O O
vivo. NN O O
one NN O O
possible NN O O
explanation NN O O
for NN O O
our NN O O
finding NN O O
is NN O O
an NN O O
altered NN O O
alpha-/beta NN O O
(1) NN O O
-subunit NN O O
association NN O O
in NN O O
the NN O O
mutant. NN O O
. NN O O

autosomal NN O O
recessive NN O O
familial NN O O
neurohypophyseal NN O O
diabetes NN O O
insipidus NN O O
with NN O O
continued NN O O
secretion NN O O
of NN O O
mutant NN O O
weakly NN O O
active NN O O
vasopressin NN O O
. NN O O

familial NN O O
neurohypophyseal NN O O
diabetes NN O O
insipidus NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
post-natal NN O O
development NN O O
of NN O O
arginine NN B-SpecificDisease B-OMIM:125700
vasopressin NN I-SpecificDisease I-OMIM:125700
(AVP) NN I-SpecificDisease I-OMIM:125700
deficiency NN I-SpecificDisease I-OMIM:125700
due NN O O
to NN O O
mutations NN O O
in NN O O
the NN O O
avp NN O O
gene. NN O O
all NN O O
published NN O O
mutations NN O O
affect NN O O
the NN O O
signal NN O O
peptide NN O O
or NN O O
the NN O O
neurophysin-ii NN O O
carrier NN O O
protein NN O O
and NN O O
are NN O O
presumed NN O O
to NN O O
interfere NN O O
with NN O O
processing NN O O
of NN O O
the NN O O
preprohormone, NN O O
leading NN O O
to NN O O
neuronal NN B-DiseaseClass B-MSH:D009410
damage NN I-DiseaseClass I-MSH:D009410
. NN O O
we NN O O
studied NN O O
an NN O O
unusual NN O O
palestinian NN O O
family NN O O
consisting NN O O
of NN O O
asymptomatic NN O O
first NN O O
cousin NN O O
parents NN O O
and NN O O
three NN O O
children NN O O
affected NN O O
with NN O O
neurohypophyseal NN B-SpecificDisease B-MSH:D020790
diabetes NN I-SpecificDisease I-MSH:D020790
insipidus NN I-SpecificDisease I-MSH:D020790
, NN O O
suggesting NN O O
autosomal NN O O
recessive NN O O
inheritance. NN O O
all NN O O
three NN O O
affected NN O O
children NN O O
were NN O O
homozygous NN O O
and NN O O
the NN O O
parents NN O O
heterozygous NN O O
for NN O O
a NN O O
single NN O O
novel NN O O
mutation NN O O
(c NN O O
301- NN O O
> NN O O
t) NN O O
in NN O O
exon NN O O
1, NN O O
replacing NN O O
pro NN O O
7 NN O O
of NN O O
mature NN O O
avp NN O O
with NN O O
leu NN O O
(leu-avp). NN O O
leu-avp NN O O
was NN O O
a NN O O
weak NN O O
agonist NN O O
with NN O O
approximately NN O O
30-fold NN O O
reduced NN O O
bindin NN O O
. NN O O

to NN O O
the NN O O
human NN O O
v NN O O
2 NN O O
receptor. NN O O
measured NN O O
by NN O O
radioimmunoassay NN O O
with NN O O
a NN O O
synthetic NN O O
leu-avp NN O O
standard, NN O O
serum NN O O
leu-avp NN O O
levels NN O O
were NN O O
elevated NN O O
in NN O O
all NN O O
three NN O O
children NN O O
and NN O O
further NN O O
increased NN O O
during NN O O
water NN O O
deprivation NN O O
to NN O O
as NN O O
high NN O O
as NN O O
30 NN O O
times NN O O
normal. NN O O
the NN O O
youngest NN O O
child NN O O
(2 NN O O
years NN O O
old) NN O O
was NN O O
only NN O O
mildly NN O O
affected NN O O
but NN O O
had NN O O
leu-avp NN O O
levels NN O O
similar NN O O
to NN O O
her NN O O
severely NN O O
affected NN O O
8-year-old NN O O
brother, NN O O
suggesting NN O O
that NN O O
unknown NN O O
mechanisms NN O O
may NN O O
partially NN O O
compensate NN O O
for NN O O
a NN O O
deficiency NN B-DiseaseClass B-OMIM:125700
of NN I-DiseaseClass I-OMIM:125700
active NN I-DiseaseClass I-OMIM:125700
AVP NN I-DiseaseClass I-OMIM:125700
in NN O O
very NN O O
young NN O O
children. NN O O
. NN O O

autosomal NN O O
dominant NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
linked NN O O
to NN O O
the NN O O
chromosome NN O O
11 NN O O
p NN O O
13 NN O O
markers NN O O
catalase NN O O
and NN O O
d NN O O
11 NN O O
s NN O O
151 NN O O
in NN O O
a NN O O
large NN O O
dutch NN O O
family NN O O
. NN O O

in NN O O
a NN O O
large NN O O
pedigree NN O O
with NN O O
autosomal NN O O
dominant NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
we NN O O
found NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
aniridia NN B-Modifier B-MSH:D015783
locus NN O O
an NN O O
2 NN O O
and NN O O
the NN O O
markers NN O O
catalase NN O O
(cat) NN O O
(zeta NN O O
= NN O O
7. NN O O
27 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
00) NN O O
and NN O O
d NN O O
11 NN O O
s NN O O
151 NN O O
(zeta NN O O
= NN O O
3. NN O O
86 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
10) NN O O
flanking NN O O
the NN O O
an NN O O
2 NN O O
locus NN O O
on NN O O
11 NN O O
p NN O O
13. NN O O
positive NN O O
lod NN O O
scores NN O O
were NN O O
also NN O O
obtained NN O O
for NN O O
the NN O O
11 NN O O
p NN O O
13----11 NN O O
p NN O O
14 NN O O
markers NN O O
d NN O O
11 NN O O
s NN O O
16 NN O O
and NN O O
fshb NN O O
with NN O O
the NN O O
linkage NN O O
group NN O O
cat/an NN O O
2/d NN O O
11 NN O O
s NN O O
151. NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
autosomal NN O O
dominant NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
in NN O O
this NN O O
family NN O O
is NN O O
due NN O O
to NN O O
a NN O O
mutation NN O O
at NN O O
the NN O O
an NN O O
2 NN O O
locus NN O O
on NN O O
11 NN O O
p NN O O
13. NN O O
we NN O O
have NN O O
excluded NN O O
linkage NN O O
(zeta NN O O
less NN O O
than NN O O
. NN O O

2 NN O O
at NN O O
theta NN O O
less NN O O
than NN O O
0. NN O O
18) NN O O
between NN O O
the NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
and NN O O
the NN O O
chromosome NN O O
2 NN O O
p NN O O
25 NN O O
marker NN O O
d NN O O
2 NN O O
s NN O O
1 NN O O
(linked NN O O
to NN O O
acp NN O O
1) NN O O
. NN O O

knobloch NN O O
syndrome NN O O
involving NN O O
midline NN B-DiseaseClass B-MSH:C538225
scalp NN I-DiseaseClass I-MSH:C538225
defect NN I-DiseaseClass I-MSH:C538225
of NN I-DiseaseClass I-MSH:C538225
the NN I-DiseaseClass I-MSH:C538225
frontal NN I-DiseaseClass I-MSH:C538225
region NN I-DiseaseClass I-MSH:C538225
. NN O O

we NN O O
report NN O O
on NN O O
a NN O O
4-year-old NN O O
boy NN O O
with NN O O
Knobloch NN B-SpecificDisease B-MSH:C537209
syndrome NN I-SpecificDisease I-MSH:C537209
. NN O O
he NN O O
has NN O O
vitreoretinal NN B-SpecificDisease B-MSH:D012162
degeneration NN I-SpecificDisease I-MSH:D012162
, NN O O
high NN B-SpecificDisease B-MSH:D009216
myopia NN I-SpecificDisease I-MSH:D009216
, NN O O
cataract NN B-SpecificDisease B-MSH:D002386
, NN O O
telecanthus NN B-SpecificDisease B-MSH:D030342
, NN O O
hypertelorism NN B-SpecificDisease B-MSH:D006972
, NN O O
and NN O O
a NN O O
high-arched NN B-SpecificDisease B-MSH:D007569
palate NN I-SpecificDisease I-MSH:D007569
. NN O O
he NN O O
also NN O O
has NN O O
a NN O O
defect NN B-DiseaseClass B-MSH:C538225
of NN I-DiseaseClass I-MSH:C538225
the NN I-DiseaseClass I-MSH:C538225
anterior NN I-DiseaseClass I-MSH:C538225
midline NN I-DiseaseClass I-MSH:C538225
scalp NN I-DiseaseClass I-MSH:C538225
with NN O O
involvement NN O O
of NN O O
the NN O O
frontal NN O O
bone NN O O
as NN O O
documented NN O O
by NN O O
a NN O O
computed NN O O
tomography NN O O
(ct) NN O O
scan. NN O O
the NN O O
brain NN O O
was NN O O
normal NN O O
on NN O O
ct NN O O
scan NN O O
and NN O O
magnetic NN O O
resonance NN O O
imaging. NN O O
we NN O O
present NN O O
a NN O O
review NN O O
of NN O O
the NN O O
23 NN O O
published NN O O
cases NN O O
with NN O O
this NN O O
syndrome. NN O O
our NN O O
patient NN O O
illustrates NN O O
the NN O O
importance NN O O
of NN O O
investigating NN O O
for NN O O
underlying NN O O
ocular NN O O
and NN O O
central NN O O
nervous NN O O
system NN O O
pathology NN O O
whenever NN O O
midline NN B-DiseaseClass B-MSH:C538225
scalp NN I-DiseaseClass I-MSH:C538225
defects NN I-DiseaseClass I-MSH:C538225
are NN O O
present. NN O O
. NN O O

pendred NN O O
syndrome: NN O O
phenotypic NN O O
variability NN O O
in NN O O
two NN O O
families NN O O
carrying NN O O
the NN O O
same NN O O
PDS NN B-Modifier B-MSH:C536648
missense NN O O
mutation NN O O
. NN O O

pendred NN O O
syndrome NN O O
comprises NN O O
congenital NN B-SpecificDisease B-MSH:D006319
sensorineural NN I-SpecificDisease I-MSH:D006319
hearing NN I-SpecificDisease I-MSH:D006319
loss NN I-SpecificDisease I-MSH:D006319
, NN O O
thyroid NN B-SpecificDisease B-MSH:D006042
goiter NN I-SpecificDisease I-MSH:D006042
, NN O O
and NN O O
positive NN O O
perchlorate NN O O
discharge NN O O
test. NN O O
recently, NN O O
this NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
was NN O O
shown NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene, NN O O
which NN O O
encodes NN O O
an NN O O
anion NN O O
transporter NN O O
called NN O O
pendrin. NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
was NN O O
performed NN O O
in NN O O
two NN O O
consanguineous NN O O
large NN O O
families NN O O
from NN O O
southern NN O O
tunisia NN O O
comprising NN O O
a NN O O
total NN O O
of NN O O
23 NN O O
individuals NN O O
affected NN O O
with NN O O
profound NN O O
congenital NN B-SpecificDisease B-MSH:D003638
deafness NN I-SpecificDisease I-MSH:D003638
; NN O O
the NN O O
same NN O O
missense NN O O
mutation, NN O O
l NN O O
445 NN O O
w, NN O O
was NN O O
identified NN O O
in NN O O
all NN O O
affected NN O O
individuals. NN O O
a NN O O
widened NN B-SpecificDisease B-OMIM:600791
vestibular NN I-SpecificDisease I-OMIM:600791
aqueduct NN I-SpecificDisease I-OMIM:600791
was NN O O
found NN O O
in NN O O
all NN O O
patients NN O O
who NN O O
underwent NN O O
computed NN O O
tomography NN O O
(ct) NN O O
scan NN O O
exploration NN O O
of NN O O
the NN O O
inner NN O O
ear. NN O O
in NN O O
contrast, NN O O
goiter NN B-SpecificDisease B-MSH:D006042
was NN O O
present NN O O
in NN O O
only NN O O
11 NN O O
affected NN O O
individuals, NN O O
who NN O O
interestingly NN O O
had NN O O
a NN O O
normal NN O O
result NN O O
of NN O O
the NN O O
perchlorate NN O O
discharge NN O O
test NN O O
whenever NN O O
performed. NN O O
the NN O O
present NN O O
results NN O O
questio NN O O
. NN O O

the NN O O
sensitivity NN O O
of NN O O
the NN O O
perchlorate NN O O
test NN O O
for NN O O
the NN O O
diagnosis NN O O
of NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
and NN O O
support NN O O
the NN O O
use NN O O
of NN O O
a NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
in NN O O
the NN O O
assessment NN O O
of NN O O
individuals NN O O
with NN O O
severe NN O O
to NN O O
profound NN O O
congenital NN B-SpecificDisease B-MSH:D003638
hearing NN I-SpecificDisease I-MSH:D003638
loss NN I-SpecificDisease I-MSH:D003638
associated NN O O
with NN O O
inner NN B-SpecificDisease B-MSH:D007759
ear NN I-SpecificDisease I-MSH:D007759
morphological NN I-SpecificDisease I-MSH:D007759
anomaly NN I-SpecificDisease I-MSH:D007759
even NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
thyroid NN B-SpecificDisease B-MSH:D006042
goiter NN I-SpecificDisease I-MSH:D006042
. NN O O
. NN O O

the NN O O
type NN O O
of NN O O
somatic NN O O
mutation NN O O
at NN O O
apc NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
is NN O O
determined NN O O
by NN O O
the NN O O
site NN O O
of NN O O
the NN O O
germline NN O O
mutation: NN O O
a NN O O
new NN O O
facet NN O O
to NN O O
knudson's NN O O
'two-hit' NN O O
hypothesis NN O O
. NN O O

apc NN O O
is NN O O
often NN O O
cited NN O O
as NN O O
a NN O O
prime NN O O
example NN O O
of NN O O
a NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
gene. NN O O
truncating NN O O
germline NN O O
and NN O O
somatic NN O O
mutations NN O O
(or, NN O O
infrequently, NN O O
allelic NN O O
loss) NN O O
occur NN O O
in NN O O
tumors NN B-DiseaseClass B-MSH:D009369
in NN O O
FAP NN B-SpecificDisease B-MSH:D011125
( NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
). NN O O
most NN O O
sporadic NN B-SpecificDisease B-MSH:D015179
colorectal NN I-SpecificDisease I-MSH:D015179
cancers NN I-SpecificDisease I-MSH:D015179
also NN O O
have NN O O
two NN O O
APC NN B-Modifier B-MSH:D011125
mutations. NN O O
clues NN O O
from NN O O
attenuated NN B-Modifier B-MSH:C538265
polyposis NN I-Modifier I-MSH:C538265
, NN O O
missense NN O O
germline NN O O
variants NN O O
with NN O O
mild NN O O
disease NN O O
and NN O O
the NN O O
somatic NN O O
mutation NN O O
cluster NN O O
region NN O O
(codons NN O O
1, NN O O
250-1, NN O O
450) NN O O
indicate, NN O O
however, NN O O
that NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
might NN O O
not NN O O
result NN O O
in NN O O
simple NN O O
loss NN O O
of NN O O
protein NN O O
function. NN O O
we NN O O
have NN O O
found NN O O
that NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
with NN O O
germline NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
within NN O O
a NN O O
small NN O O
region NN O O
(codons NN O O
1, NN O O
194-1, NN O O
392 NN O O
at NN O O
most) NN O O
mainly NN O O
show NN O O
allelic NN O O
loss NN O O
in NN O O
their NN O O
colorectal NN B-SpecificDisease B-MSH:D000236
adenomas NN I-SpecificDisease I-MSH:D000236
, NN O O
in NN O O
contrast NN O O
to NN O O
other NN O O
FAP NN B-Modifier B-MSH:D011125
patients, NN O O
whose NN O O
second NN O O
hits NN O O
tend NN O O
to NN O O
occu NN O O
. NN O O

by NN O O
truncating NN O O
mutations NN O O
in NN O O
the NN O O
mutation NN O O
cluster NN O O
region. NN O O
our NN O O
results NN O O
indicate NN O O
that NN O O
different NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
provide NN O O
cells NN O O
with NN O O
different NN O O
selective NN O O
advantages, NN O O
with NN O O
mutations NN O O
close NN O O
to NN O O
codon NN O O
1, NN O O
300 NN O O
providing NN O O
the NN O O
greatest NN O O
advantage. NN O O
allelic NN O O
loss NN O O
is NN O O
selected NN O O
strongly NN O O
in NN O O
cells NN O O
with NN O O
one NN O O
mutation NN O O
near NN O O
codon NN O O
1, NN O O
300. NN O O
a NN O O
different NN O O
germline-somatic NN O O
APC NN B-Modifier B-MSH:D011125
mutation NN O O
association NN O O
exists NN O O
in NN O O
FAP NN B-SpecificDisease B-MSH:D018222
desmoids NN I-SpecificDisease I-MSH:D018222
. NN O O
apc NN O O
is NN O O
not, NN O O
therefore, NN O O
a NN O O
classical NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor. NN O O
our NN O O
findings NN O O
also NN O O
indicate NN O O
a NN O O
new NN O O
mechanism NN O O
for NN O O
disease NN O O
severity NN O O
if NN O O
a NN O O
broader NN O O
spectrum NN O O
of NN O O
mutations NN O O
is NN O O
selected NN O O
in NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
the NN O O
somatic NN O O
mutation NN O O
rate NN O O
is NN O O
effectively NN O O
higher NN O O
and NN O O
more NN O O
tumors NN B-DiseaseClass B-MSH:D009369
grow. NN O O
. NN O O

purification NN O O
of NN O O
human NN O O
very-long-chain NN O O
acyl-coenzyme NN O O
a NN O O
dehydrogenase NN O O
and NN O O
characterization NN O O
of NN O O
its NN O O
deficiency NN O O
in NN O O
seven NN O O
patients NN O O
. NN O O

mitochondrial NN O O
very-long-chain NN O O
acyl-coenzyme NN O O
a NN O O
dehydrogenase NN O O
(vlcad) NN O O
was NN O O
purified NN O O
from NN O O
human NN O O
liver. NN O O
the NN O O
molecular NN O O
masses NN O O
of NN O O
the NN O O
native NN O O
enzyme NN O O
and NN O O
the NN O O
subunit NN O O
were NN O O
estimated NN O O
to NN O O
be NN O O
154 NN O O
and NN O O
70 NN O O
kd, NN O O
respectively. NN O O
the NN O O
enzyme NN O O
was NN O O
found NN O O
to NN O O
catalyze NN O O
the NN O O
major NN O O
part NN O O
of NN O O
mitochondrial NN O O
palmitoylcoenzyme NN O O
a NN O O
dehydrogenation NN O O
in NN O O
liver, NN O O
heart, NN O O
skeletal NN O O
muscle, NN O O
and NN O O
skin NN O O
fibroblasts NN O O
(89-97, NN O O
86-99, NN O O
96-99, NN O O
and NN O O
78-87%, NN O O
respectively). NN O O
skin NN O O
fibroblasts NN O O
from NN O O
26 NN O O
patients NN O O
suspected NN O O
of NN O O
having NN O O
a NN O O
disorder NN O O
of NN O O
mitochondrial NN O O
beta-oxidation NN O O
were NN O O
analyzed NN O O
for NN O O
vlcad NN O O
protein NN O O
using NN O O
immunoblotting, NN O O
and NN O O
7 NN O O
of NN O O
them NN O O
contained NN O O
undetectable NN O O
or NN O O
trace NN O O
levels NN O O
of NN O O
the NN O O
enzyme. NN O O
the NN O O
seven NN O O
deficient NN O O
fibroblast NN O O
lines NN O O
were NN O O
characterized NN O O
by NN O O
measuring NN O O
acyl-coenzyme NN O O
a NN O O
dehydrogenation NN O O
activities NN O O
. NN O O
zyme. NN O O
the NN O O
seven NN O O
deficient NN O O
fibroblast NN O O
lines NN O O
were NN O O
characterized NN O O
by NN O O
measuring NN O O
acyl-coenzyme NN O O
a NN O O
dehydrogenation NN O O
activities NN O O
. NN O O

overall NN O O
palmitic NN O O
acid NN O O
oxidation, NN O O
and NN O O
vlcad NN O O
protein NN O O
synthesis NN O O
using NN O O
pulse-chase, NN O O
further NN O O
confirming NN O O
the NN O O
diagnosis NN O O
of NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
. NN O O
these NN O O
results NN O O
suggested NN O O
the NN O O
heterogenous NN O O
nature NN O O
of NN O O
the NN O O
mutations NN O O
causing NN O O
the NN O O
deficiency NN O O
in NN O O
the NN O O
seven NN O O
patients. NN O O
clinically, NN O O
all NN O O
patients NN O O
with NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
exhibited NN O O
cardiac NN B-DiseaseClass B-MSH:D006331
disease NN I-DiseaseClass I-MSH:D006331
. NN O O
at NN O O
least NN O O
four NN O O
of NN O O
them NN O O
presented NN O O
with NN O O
hypertrophic NN B-SpecificDisease B-MSH:D002312
cardiomyopathy NN I-SpecificDisease I-MSH:D002312
. NN O O
this NN O O
frequency NN O O
(> NN O O
57%) NN O O
was NN O O
much NN O O
higher NN O O
than NN O O
that NN O O
observed NN O O
in NN O O
patients NN O O
with NN O O
other NN O O
disorders NN O O
of NN O O
mitochondrial NN O O
long-chain NN O O
fatty NN O O
acid NN O O
oxidation NN O O
that NN O O
may NN O O
be NN O O
accompanied NN O O
by NN O O
cardiac NN B-DiseaseClass B-MSH:D006331
disease NN I-DiseaseClass I-MSH:D006331
in NN O O
infants. NN O O
. NN O O

a NN O O
germ NN O O
line NN O O
mutation NN O O
within NN O O
the NN O O
coding NN O O
sequence NN O O
for NN O O
the NN O O
putative NN O O
5-phosphoribosyl-1-pyrophosphate NN O O
binding NN O O
site NN O O
of NN O O
hypoxanthine-guanine NN O O
phosphoribosyltransferase NN O O
(hprt) NN O O
in NN O O
a NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
patient: NN O O
missense NN O O
mutations NN O O
within NN O O
a NN O O
functionally NN O O
important NN O O
region NN O O
probably NN O O
cause NN O O
disease NN O O
. NN O O

lesch-nyhan NN O O
syndrome NN O O
caused NN O O
by NN O O
a NN O O
complete NN B-SpecificDisease B-MSH:D007926
deficiency NN I-SpecificDisease I-MSH:D007926
of NN I-SpecificDisease I-MSH:D007926
hypoxanthine NN I-SpecificDisease I-MSH:D007926
guanine NN I-SpecificDisease I-MSH:D007926
phosphoribosyltransferase NN I-SpecificDisease I-MSH:D007926
(hprt) NN O O
is NN O O
the NN O O
result NN O O
of NN O O
a NN O O
heterogeneous NN O O
group NN O O
of NN O O
germ NN O O
line NN O O
mutations. NN O O
identification NN O O
of NN O O
each NN O O
mutant NN O O
gene NN O O
provides NN O O
valuable NN O O
information NN O O
as NN O O
to NN O O
the NN O O
type NN O O
of NN O O
mutation NN O O
that NN O O
occurs NN O O
spontaneously. NN O O
we NN O O
report NN O O
here NN O O
a NN O O
newly NN O O
identified NN O O
hprt NN O O
mutation NN O O
in NN O O
a NN O O
japanese NN O O
patient NN O O
with NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O
this NN O O
gene, NN O O
designated NN O O
hprt NN O O
tokyo, NN O O
had NN O O
a NN O O
single NN O O
nucleotide NN O O
change NN O O
from NN O O
g NN O O
to NN O O
a, NN O O
as NN O O
identified NN O O
by NN O O
sequencing NN O O
cdna NN O O
amplified NN O O
by NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction. NN O O
allele NN O O
specific NN O O
oligonucleotide NN O O
hybridization NN O O
analysis NN O O
using NN O O
amplified NN O O
genomic NN O O
dna NN O O
showed NN O O
that NN O O
the NN O O
mutant NN O O
gene NN O O
was NN O O
transmitted NN O O
from NN O O
the NN O O
maternal NN O O
germ NN O O
line. NN O O
this NN O O
mutation NN O O
would NN O O
lead NN O O
to NN O O
an NN O O
amino NN O O
acid NN O O
substitution NN O O
of NN O O
asp NN O O
for NN O O
gly NN O O
at NN O O
the NN O O
amino NN O O
acid NN O O
position NN O O
140 NN O O
located NN O O
within NN O O
the NN O O
putative NN O O
5 NN O O
. NN O O

phosphoribosyl-1-pyrophosphate NN O O
(prpp) NN O O
binding NN O O
region. NN O O
missense NN O O
mutations NN O O
in NN O O
human NN O O
HPRT NN B-Modifier B-MSH:D007926
deficient NN I-Modifier I-MSH:D007926
patients NN O O
thus NN O O
far NN O O
reported NN O O
tend NN O O
to NN O O
accumulate NN O O
in NN O O
this NN O O
functionally NN O O
active NN O O
region. NN O O
however, NN O O
a NN O O
comparison NN O O
of NN O O
the NN O O
data NN O O
suggested NN O O
that NN O O
both NN O O
missense NN O O
and NN O O
synonymous NN O O
mutations NN O O
can NN O O
occur NN O O
at NN O O
any NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
human NN O O
germ NN O O
line NN O O
hprt NN O O
gene, NN O O
but NN O O
that NN O O
a NN O O
limited NN O O
percentage NN O O
of NN O O
all NN O O
the NN O O
missense NN O O
mutations NN O O
cause NN O O
disease. NN O O
the NN O O
probability NN O O
that NN O O
a NN O O
mutation NN O O
will NN O O
cause NN O O
disease NN O O
tends NN O O
to NN O O
be NN O O
higher NN O O
when NN O O
the NN O O
missense NN O O
mutation NN O O
is NN O O
within NN O O
a NN O O
functionally NN O O
important NN O O
sequence. NN O O
. NN O O

in NN O O
vitro NN O O
and NN O O
in NN O O
vivo NN O O
correlations NN O O
for NN O O
i NN O O
65 NN O O
t NN O O
and NN O O
m NN O O
1 NN O O
v NN O O
mutations NN O O
at NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
locus NN O O
. NN O O
e NN O O
locus NN O O
. NN O O

mutations NN O O
at NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
locus NN O O
are NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
hyperphenylalaninemia NN B-DiseaseClass B-MSH:D010661
. NN O O
we NN O O
have NN O O
previously NN O O
described NN O O
four NN O O
mutations NN O O
(m NN O O
1 NN O O
v, NN O O
ivs NN O O
12 NN O O
nt NN O O
1, NN O O
r NN O O
408 NN O O
w, NN O O
and NN O O
s NN O O
349 NN O O
p) NN O O
at NN O O
the NN O O
pah NN O O
locus NN O O
in NN O O
french NN O O
canadians NN O O
with NN O O
ancestry NN O O
in NN O O
eastern NN O O
quebec. NN O O
here NN O O
we NN O O
report NN O O
(1) NN O O
identification NN O O
of NN O O
another NN O O
mutation, NN O O
on NN O O
a NN O O
haplotype NN O O
9 NN O O
chromosome, NN O O
which NN O O
converts NN O O
codon NN O O
65 NN O O
from NN O O
isoleucine NN O O
(att) NN O O
to NN O O
threonine NN O O
(act), NN O O
(2) NN O O
expression NN O O
analysis NN O O
of NN O O
the NN O O
i NN O O
65 NN O O
t NN O O
mutation NN O O
in NN O O
cos NN O O
cells NN O O
demonstrating NN O O
75% NN O O
loss NN O O
of NN O O
both NN O O
immunoreactive NN O O
protein NN O O
and NN O O
enzyme NN O O
activity, NN O O
and NN O O
(3) NN O O
expression NN O O
analysis NN O O
of NN O O
the NN O O
most NN O O
prevalent NN O O
PKU NN B-Modifier B-MSH:D010661
allele NN O O
(m NN O O
1 NN O O
v) NN O O
in NN O O
eastern NN O O
quebec, NN O O
showing NN O O
nondetectable NN O O
levels NN O O
of NN O O
pah NN O O
protein NN O O
an NN O O
. NN O O

activity, NN O O
a NN O O
finding NN O O
compatible NN O O
with NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
translation NN O O
initiation NN O O
codon. NN O O
homozygosity NN O O
for NN O O
m NN O O
1 NN O O
v NN O O
and NN O O
codominant NN O O
inheritance NN O O
of NN O O
i NN O O
65 NN O O
t/r NN O O
408 NN O O
w NN O O
were NN O O
both NN O O
associated NN O O
with NN O O
classical NN B-SpecificDisease B-MSH:D010661
phenylketonuria NN I-SpecificDisease I-MSH:D010661
. NN O O
. NN O O

experimental NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
due NN O O
to NN O O
mhc NN O O
class NN O O
i NN O O
HFE NN B-SpecificDisease B-MSH:D006432
deficiency NN I-SpecificDisease I-MSH:D006432
: NN O O
immune NN O O
status NN O O
and NN O O
iron NN O O
metabolism NN O O
. NN O O

the NN O O
puzzling NN O O
linkage NN O O
between NN O O
genetic NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
and NN O O
histocompatibility NN O O
loci NN O O
became NN O O
even NN O O
more NN O O
so NN O O
when NN O O
the NN O O
gene NN O O
involved, NN O O
hfe, NN O O
was NN O O
identified. NN O O
indeed, NN O O
within NN O O
the NN O O
well NN O O
defined, NN O O
mainly NN O O
peptide-binding, NN O O
mhc NN O O
class NN O O
i NN O O
family NN O O
of NN O O
molecules, NN O O
hfe NN O O
seems NN O O
to NN O O
perform NN O O
an NN O O
unusual NN O O
yet NN O O
essential NN O O
function. NN O O
as NN O O
yet, NN O O
our NN O O
understanding NN O O
of NN O O
hfe NN O O
function NN O O
in NN O O
iron NN O O
homeostasis NN O O
is NN O O
only NN O O
partial; NN O O
an NN O O
even NN O O
more NN O O
open NN O O
question NN O O
is NN O O
its NN O O
possible NN O O
role NN O O
in NN O O
the NN O O
immune NN O O
system. NN O O
to NN O O
advance NN O O
on NN O O
both NN O O
of NN O O
these NN O O
avenues, NN O O
we NN O O
report NN O O
the NN O O
deletion NN O O
of NN O O
hfe NN O O
alpha NN O O
1 NN O O
and NN O O
alpha NN O O
2 NN O O
putative NN O O
ligand NN O O
binding NN O O
domains NN O O
in NN O O
vivo. NN O O
HFE-deficient NN B-Modifier B-MSH:D006432
animals NN O O
were NN O O
analyzed NN O O
for NN O O
a NN O O
comprehensive NN O O
set NN O O
of NN O O
metabolic NN O O
and NN O O
immune NN O O
parameters. NN O O
faithfully NN O O
mimicking NN O O
human NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
, NN O O
mice NN O O
homozygous NN O O
for NN O O
this NN O O
deletion NN O O
develop NN O O
iron NN O O
overload, NN O O
characterized NN O O
by NN O O
. NN O O

higher NN O O
plasma NN O O
iron NN O O
content NN O O
and NN O O
a NN O O
raised NN O O
transferrin NN O O
saturation NN O O
as NN O O
well NN O O
as NN O O
an NN O O
elevated NN O O
hepatic NN O O
iron NN O O
load. NN O O
the NN O O
primary NN O O
defect NN O O
could, NN O O
indeed, NN O O
be NN O O
traced NN O O
to NN O O
an NN O O
augmented NN O O
duodenal NN O O
iron NN O O
absorption. NN O O
in NN O O
parallel, NN O O
measurement NN O O
of NN O O
the NN O O
gut NN O O
mucosal NN O O
iron NN O O
content NN O O
as NN O O
well NN O O
as NN O O
iron NN O O
regulatory NN O O
proteins NN O O
allows NN O O
a NN O O
more NN O O
informed NN O O
evaluation NN O O
of NN O O
various NN O O
hypotheses NN O O
regarding NN O O
the NN O O
precise NN O O
role NN O O
of NN O O
hfe NN O O
in NN O O
iron NN O O
homeostasis. NN O O
finally, NN O O
an NN O O
extensive NN O O
phenotyping NN O O
of NN O O
primary NN O O
and NN O O
secondary NN O O
lymphoid NN O O
organs NN O O
including NN O O
the NN O O
gut NN O O
provides NN O O
no NN O O
compelling NN O O
evidence NN O O
for NN O O
an NN O O
obvious NN O O
immune-linked NN O O
function NN O O
for NN O O
hfe. NN O O
. NN O O

[genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
: NN O O
mutant NN O O
alleles NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
in NN O O
the NN O O
shekii NN O O
district NN O O
of NN O O
azerbaijan] NN O O
examination NN O O
on NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
349 NN O O
patients NN O O
of NN O O
shekii NN O O
district NN O O
hospital NN O O
(azerbaijan) NN O O
revealed NN O O
16 NN O O
hemi-, NN O O
4 NN O O
homo- NN O O
and NN O O
9 NN O O
heterozygotic NN O O
carriers NN O O
of NN O O
the NN O O
defect. NN O O
gd- NN O O
frequency, NN O O
calculated NN O O
from NN O O
the NN O O
data NN O O
obtained NN O O
(7. NN O O
7%), NN O O
may NN O O
be NN O O
compared NN O O
to NN O O
neighbouring NN O O
regions NN O O
frequencies NN O O
(6-30%). NN O O
carriers NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
are NN O O
residents NN O O
of NN O O
11 NN O O
villages NN O O
located NN O O
in NN O O
alasani-aphtalan NN O O
valley, NN O O
highly NN O O
endemic NN O O
with NN O O
malaria NN B-SpecificDisease B-MSH:D008288
in NN O O
the NN O O
past; NN O O
nearly NN O O
all NN O O
marriages NN O O
are NN O O
endogamic. NN O O
physico-chemical NN O O
and NN O O
kinetic NN O O
study NN O O
of NN O O
10 NN O O
mutant NN O O
forms NN O O
of NN O O
g NN O O
6 NN O O
pd, NN O O
according NN O O
to NN O O
who NN O O
program, NN O O
led NN O O
to NN O O
identification NN O O
o NN O O
. NN O O

5 NN O O
variants NN O O
of NN O O
the NN O O
ii NN O O
class NN O O
(shekii, NN O O
bideiz, NN O O
shirin-bulakh, NN O O
okhut NN O O
i NN O O
and NN O O
zakataly) NN O O
and NN O O
2 NN O O
variants NN O O
of NN O O
the NN O O
iii NN O O
class NN O O
(okhut NN O O
ii NN O O
and NN O O
martinique-like). NN O O
resemblance NN O O
of NN O O
the NN O O
majority NN O O
of NN O O
variants NN O O
in NN O O
electrophoretic NN O O
mobility NN O O
and NN O O
the NN O O
level NN O O
of NN O O
erythrocyte NN O O
enzyme NN O O
activity NN O O
permit NN O O
to NN O O
suggest NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
common NN O O
parental NN O O
mutant NN O O
g NN O O
6 NN O O
pd NN O O
allele NN O O
distributed NN O O
in NN O O
this NN O O
area NN O O
. NN O O

[gd- NN O O
allele NN O O
distribution NN O O
patterns NN O O
in NN O O
azerbaijan. NN O O
iii. NN O O
the NN O O
identification NN O O
of NN O O
mutant NN O O
forms NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase] NN O O
in NN O O
28 NN O O
families NN O O
with NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
living NN O O
in NN O O
3 NN O O
settlements NN O O
of NN O O
shekii NN O O
district NN O O
of NN O O
azerbaijan NN O O
11 NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
of NN O O
ii NN O O
and NN O O
iii NN O O
classes NN O O
differing NN O O
by NN O O
kinetic NN O O
properties NN O O
were NN O O
identified NN O O
according NN O O
who NN O O
program. NN O O
9 NN O O
of NN O O
them NN O O
are NN O O
characterized NN O O
with NN O O
the NN O O
same NN O O
electrophoretic NN O O
mobility. NN O O
comparison NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
spectra NN O O
in NN O O
two NN O O
subpopulations NN O O
and NN O O
in NN O O
a NN O O
mixed NN O O
group NN O O
permits NN O O
to NN O O
make NN O O
a NN O O
conclusion NN O O
about NN O O
existence NN O O
of NN O O
common NN O O
and NN O O
rare NN O O
g NN O O
6 NN O O
pd NN O O
alleles NN O O
in NN O O
examined NN O O
population. NN O O
they NN O O
distribute NN O O
by NN O O
gene NN O O
drift NN O O
supported NN O O
by NN O O
natural NN O O
selection. NN O O
among NN O O
7 NN O O
samples NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
with NN O O
normal NN O O
and NN O O
increased NN O O
activity NN O O
two NN O O
new NN O O
variants NN O O
of NN O O
iv NN O O
class NN O O
-- NN O O
nukha NN O O
and NN O O
bash-kungu NN O O
. NN O O

-- NN O O
were NN O O
found. NN O O
. NN O O

determination NN O O
of NN O O
carrier NN O O
status NN O O
for NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
by NN O O
flow NN O O
cytometric NN O O
analysis NN O O
of NN O O
Wiskott-Aldrich NN B-Modifier B-MSH:D014923
syndrome NN I-Modifier I-MSH:D014923
protein NN O O
expression NN O O
in NN O O
peripheral NN O O
blood NN O O
mononuclear NN O O
cells NN O O
. NN O O

the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
) NN O O
is NN O O
caused NN O O
by NN O O
defects NN O O
in NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
protein NN O O
(wasp) NN O O
gene NN O O
on NN O O
the NN O O
x NN O O
chromosome. NN O O
previous NN O O
study NN O O
disclosed NN O O
that NN O O
flow NN O O
cytometric NN O O
analysis NN O O
of NN O O
intracellular NN O O
wasp NN O O
expression NN O O
(fcm-wasp NN O O
analysis) NN O O
in NN O O
lymphocytes NN O O
was NN O O
useful NN O O
for NN O O
the NN O O
diagnosis NN O O
of NN O O
WAS NN B-Modifier B-MSH:D014923
patients. NN O O
lymphocytes NN O O
from NN O O
all NN O O
WAS NN B-Modifier B-MSH:D014923
patients NN O O
showed NN O O
waspdim NN O O
instead NN O O
of NN O O
waspbright. NN O O
here NN O O
we NN O O
report NN O O
that NN O O
fcm-wasp NN O O
analysis NN O O
in NN O O
monocytes NN O O
could NN O O
be NN O O
a NN O O
useful NN O O
tool NN O O
for NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
carrier NN O O
diagnosis. NN O O
monocytes NN O O
from NN O O
all NN O O
nine NN O O
WAS NN B-Modifier B-MSH:D014923
carriers NN O O
showed NN O O
varied NN O O
population NN O O
of NN O O
waspdim NN O O
together NN O O
with NN O O
waspbright. NN O O
none NN O O
of NN O O
control NN O O
individuals NN O O
possessed NN O O
the NN O O
waspdim NN O O
population. NN O O
in NN O O
contrast, NN O O
lymphocytes NN O O
from NN O O
all NN O O
the NN O O
carriers NN O O
except NN O O
two NN O O
lacked NN O O
the NN O O
waspdim NN O O
population. NN O O
the NN O O
difference NN O O
of NN O O
the NN O O
waspdim NN O O
population NN O O
in NN O O
monocytes NN O O
and NN O O
lymphocytes NN O O
observed NN O O
in NN O O
WAS NN B-Modifier B-MSH:D014923
carriers NN O O
suggests NN O O
tha NN O O
. NN O O

wasp NN O O
plays NN O O
a NN O O
more NN O O
critical NN O O
role NN O O
in NN O O
the NN O O
development NN O O
of NN O O
lymphocytes NN O O
than NN O O
in NN O O
that NN O O
of NN O O
monocytes. NN O O
the NN O O
present NN O O
studies NN O O
suggest NN O O
that NN O O
a NN O O
skewed NN O O
x-chromosomal NN O O
inactivation NN O O
pattern NN O O
observed NN O O
in NN O O
WAS NN B-Modifier B-MSH:D014923
carrier NN O O
peripheral NN O O
blood NN O O
cells NN O O
is NN O O
not NN O O
fixed NN O O
at NN O O
the NN O O
hemopoietic NN O O
stem NN O O
cell NN O O
level NN O O
but NN O O
progresses NN O O
after NN O O
the NN O O
lineage NN O O
commitment. NN O O
. NN O O

linkage NN O O
of NN O O
dna NN O O
markers NN O O
at NN O O
xq NN O O
28 NN O O
to NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
and NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
present NN O O
within NN O O
the NN O O
same NN O O
family NN O O
. NN O O

we NN O O
present NN O O
a NN O O
large NN O O
kindred NN O O
that NN O O
contained NN O O
patients NN O O
with NN O O
either NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
or NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
AMN NN B-SpecificDisease B-MSH:D000326
). NN O O
the NN O O
pedigree NN O O
clearly NN O O
supported NN O O
the NN O O
x-linked NN O O
mode NN O O
of NN O O
inheritance NN O O
of NN O O
the NN O O
nonneonatal NN O O
form NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
/ NN O O
AMN NN B-SpecificDisease B-MSH:D000326
. NN O O
analysis NN O O
with NN O O
dna NN O O
markers NN O O
at NN O O
xq NN O O
28 NN O O
suggested NN O O
segregation NN O O
of NN O O
both NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
AMN NN B-SpecificDisease B-MSH:D000326
with NN O O
an NN O O
identical NN O O
haplotype. NN O O
this NN O O
indicated NN O O
that NN O O
nonneonatal NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
AMN NN B-SpecificDisease B-MSH:D000326
are NN O O
caused NN O O
by NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
same NN O O
gene NN O O
at NN O O
xq NN O O
28. NN O O
it NN O O
showed, NN O O
furthermore, NN O O
that NN O O
phenotypic NN O O
differences NN O O
between NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
AMN NN B-SpecificDisease B-MSH:D000326
are NN O O
not NN O O
necessarily NN O O
the NN O O
consequence NN O O
of NN O O
allelic NN O O
heterogeneity NN O O
due NN O O
to NN O O
different NN O O
mutations NN O O
within NN O O
the NN O O
same NN O O
gene. NN O O
the NN O O
maximal NN O O
lod NN O O
score NN O O
for NN O O
linkage NN O O
of NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
/ NN O O
AMN NN B-Modifier B-MSH:D000326
gene NN O O
and NN O O
the NN O O
multiallelic NN O O
anonymous NN O O
dna NN O O
marker NN O O
at NN O O
dxs NN O O
52 NN O O
was NN O O
3. NN O O
0 NN O O
at NN O O
a NN O O
recombination NN O O
fraction NN O O
of NN O O
0 NN O O
. NN O O

00. NN O O
this NN O O
made NN O O
a NN O O
prenatal NN O O
or NN O O
presymptomatic NN O O
diagnosis NN O O
and NN O O
heterozygote NN O O
detection NN O O
by NN O O
dna NN O O
analysis NN O O
with NN O O
this NN O O
marker NN O O
reliable NN O O
. NN O O

further NN O O
investigation NN O O
of NN O O
the NN O O
hexa NN O O
gene NN O O
intron NN O O
9 NN O O
donor NN O O
splice NN O O
site NN O O
mutation NN O O
frequently NN O O
found NN O O
in NN O O
non-jewish NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
patients NN O O
from NN O O
the NN O O
british NN O O
isles NN O O
. NN O O

in NN O O
a NN O O
previous NN O O
study NN O O
we NN O O
found NN O O
that NN O O
a NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
) NN O O
causing NN O O
mutation NN O O
in NN O O
the NN O O
intron NN O O
9 NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
the NN O O
hexa NN O O
gene NN O O
occurs NN O O
at NN O O
high NN O O
frequency NN O O
in NN O O
non-jewish NN O O
patients NN O O
and NN O O
carriers NN O O
from NN O O
the NN O O
british NN O O
isles. NN O O
it NN O O
was NN O O
found NN O O
more NN O O
frequently NN O O
in NN O O
subjects NN O O
of NN O O
irish, NN O O
scottish, NN O O
and NN O O
welsh NN O O
origin NN O O
compared NN O O
with NN O O
english NN O O
origin NN O O
(63% NN O O
and NN O O
31% NN O O
respectively). NN O O
we NN O O
have NN O O
now NN O O
tested, NN O O
in NN O O
a NN O O
blind NN O O
study, NN O O
26 NN O O
american NN O O
TSD NN B-Modifier B-MSH:D013661
carriers NN O O
and NN O O
28 NN O O
non-carriers NN O O
who NN O O
have NN O O
british NN O O
ancestry NN O O
for NN O O
the NN O O
intron NN O O
9 NN O O
splice NN O O
site NN O O
mutation. NN O O
six NN O O
of NN O O
the NN O O
carriers NN O O
and NN O O
none NN O O
of NN O O
the NN O O
controls NN O O
were NN O O
positive NN O O
for NN O O
the NN O O
mutation. NN O O
all NN O O
six NN O O
had NN O O
irish NN O O
ancestry, NN O O
compared NN O O
with NN O O
nine NN O O
of NN O O
the NN O O
20 NN O O
other NN O O
(intron NN O O
9 NN O O
mutation NN O O
negative) NN O O
TSD NN B-Modifier B-MSH:D013661
carriers NN O O
. NN O O

p NN O O
< NN O O
0. NN O O
05). NN O O
these NN O O
results NN O O
confirm NN O O
the NN O O
previously NN O O
found NN O O
high NN O O
frequency NN O O
of NN O O
the NN O O
intron NN O O
9 NN O O
mutation NN O O
in NN O O
non-jewish NN O O
TSD NN B-Modifier B-MSH:D013661
families NN O O
of NN O O
british NN O O
isles, NN O O
particularly NN O O
irish, NN O O
origin, NN O O
and NN O O
reinforce NN O O
the NN O O
need NN O O
to NN O O
screen NN O O
such NN O O
families NN O O
for NN O O
this NN O O
mutation NN O O
. NN O O

the NN O O
murine NN O O
homologues NN O O
of NN O O
the NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
gene NN O O
(hdh) NN O O
and NN O O
the NN O O
alpha-adducin NN O O
gene NN O O
(add NN O O
1) NN O O
map NN O O
to NN O O
mouse NN O O
chromosome NN O O
5 NN O O
within NN O O
a NN O O
region NN O O
of NN O O
conserved NN O O
synteny NN O O
with NN O O
human NN O O
chromosome NN O O
4 NN O O
p NN O O
16.3 NN O O
. NN O O

huntington NN O O
disease NN O O
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
is NN O O
a NN O O
severe NN O O
autosomal NN B-DiseaseClass B-MSH:D019636
dominant NN I-DiseaseClass I-MSH:D019636
neurodegenerative NN I-DiseaseClass I-MSH:D019636
disorder NN I-DiseaseClass I-MSH:D019636
associated NN O O
with NN O O
a NN O O
novel NN O O
gene NN O O
(it NN O O
15). NN O O
recently, NN O O
we NN O O
reported NN O O
the NN O O
cloning NN O O
of NN O O
hdh, NN O O
the NN O O
murine NN O O
homologue NN O O
of NN O O
it NN O O
15. NN O O
here, NN O O
using NN O O
an NN O O
interspecific NN O O
backcross, NN O O
we NN O O
have NN O O
mapped NN O O
both NN O O
hdh NN O O
and NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
human NN O O
alpha-adducin NN O O
(add NN O O
1), NN O O
a NN O O
membrane-associated NN O O
cytoskeletal NN O O
protein NN O O
gene. NN O O
both NN O O
of NN O O
these NN O O
genes NN O O
map NN O O
in NN O O
the NN O O
same NN O O
position NN O O
on NN O O
mouse NN O O
chromosome NN O O
5 NN O O
in NN O O
a NN O O
region NN O O
associated NN O O
with NN O O
ancestral NN O O
chromosomal NN O O
rearrangements NN O O
and NN O O
show NN O O
no NN O O
recombination NN O O
with NN O O
d NN O O
5 NN O O
h NN O O
4 NN O O
s NN O O
43, NN O O
d NN O O
5 NN O O
h NN O O
4 NN O O
s NN O O
115, NN O O
and NN O O
d NN O O
5 NN O O
h NN O O
4 NN O O
s NN O O
62, NN O O
the NN O O
murine NN O O
homologues NN O O
of NN O O
d NN O O
4 NN O O
s NN O O
43, NN O O
d NN O O
4 NN O O
s NN O O
115, NN O O
and NN O O
d NN O O
4 NN O O
s NN O O
62 NN O O
. NN O O

respectively. NN O O
further NN O O
mapping NN O O
studies NN O O
of NN O O
humans, NN O O
mice, NN O O
and NN O O
other NN O O
mammalian NN O O
species NN O O
should NN O O
reveal NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
rearrangements NN O O
affecting NN O O
this NN O O
chromosomal NN O O
segment NN O O
during NN O O
mammalian NN O O
evolution. NN O O
. NN O O
s NN O O
should NN O O
reveal NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
rearrangements NN O O
affecting NN O O
this NN O O
chromosomal NN O O
segment NN O O
during NN O O
mammalian NN O O
evolution. NN O O
. NN O O

linkage NN O O
analysis NN O O
of NN O O
the NN O O
apolipoprotein NN O O
c NN O O
2 NN O O
gene NN O O
and NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
on NN O O
human NN O O
chromosome NN O O
19 NN O O
reveals NN O O
linkage NN O O
disequilibrium NN O O
in NN O O
a NN O O
french-canadian NN O O
population NN O O
. NN O O

the NN O O
gene NN O O
for NN O O
human NN O O
apolipoprotein NN O O
c NN O O
2 NN O O
(apoc NN O O
2), NN O O
situated NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
19, NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
adult NN O O
muscular NN B-DiseaseClass B-MSH:D009136
dystrophy NN I-DiseaseClass I-MSH:D009136
, NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
). NN O O
six NN O O
apoc NN O O
2 NN O O
rflps NN O O
(taqi, NN O O
bgli, NN O O
bani, NN O O
bamhi, NN O O
ncoi, NN O O
and NN O O
avaii) NN O O
have NN O O
been NN O O
identified NN O O
to NN O O
date. NN O O
we NN O O
have NN O O
conducted NN O O
a NN O O
comprehensive NN O O
DM NN B-Modifier B-MSH:D009223
linkage NN O O
study NN O O
utilizing NN O O
all NN O O
six NN O O
rflps NN O O
and NN O O
involving NN O O
50 NN O O
families NN O O
and NN O O
372 NN O O
individuals. NN O O
the NN O O
most NN O O
informative NN O O
rflps NN O O
are, NN O O
in NN O O
descending NN O O
order, NN O O
ncoi NN O O
(lod NN O O
= NN O O
6. NN O O
64, NN O O
theta NN O O
= NN O O
0. NN O O
05), NN O O
bgli NN O O
(lod NN O O
= NN O O
6. NN O O
12, NN O O
theta NN O O
= NN O O
0. NN O O
05), NN O O
avaii NN O O
(lod NN O O
= NN O O
6. NN O O
02, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

03), NN O O
bani NN O O
(lod NN O O
= NN O O
5. NN O O
76, NN O O
theta NN O O
= NN O O
0. NN O O
04), NN O O
taqi NN O O
(lod NN O O
= NN O O
4. NN O O
29, NN O O
theta NN O O
= NN O O
0. NN O O
06), NN O O
and NN O O
bamhi NN O O
(lod NN O O
= NN O O
1. NN O O
75, NN O O
theta NN O O
= NN O O
0. NN O O
01). NN O O
a NN O O
substantial NN O O
increase NN O O
in NN O O
the NN O O
lod NN O O
scores NN O O
over NN O O
those NN O O
seen NN O O
with NN O O
the NN O O
individual NN O O
rflps NN O O
was NN O O
obtained NN O O
when NN O O
the NN O O
linkage NN O O
of NN O O
the NN O O
entire NN O O
apoc NN O O
2 NN O O
haplotype NN O O
(composed NN O O
of NN O O
the NN O O
six NN O O
rflps) NN O O
was NN O O
studied NN O O
(lod NN O O
= NN O O
17. NN O O
87, NN O O
theta NN O O
= NN O O
0. NN O O
04). NN O O
we NN O O
have NN O O
observed NN O O
significant NN O O
inter-apoc NN O O
2 NN O O
rflp NN O O
linkage NN O O
disequilibrium. NN O O
consequently, NN O O
the NN O O
three NN O O
most NN O O
informative NN O O
rflps NN O O
have NN O O
been NN O O
found NN O O
to NN O O
be NN O O
bani, NN O O
taqi, NN O O
and NN O O
either NN O O
bgli, NN O O
avaii, NN O O
or NN O O
ncoi NN O O
polymorphisms. NN O O
we NN O O
also NN O O
demonstrate NN O O
linkage NN O O
disequilibriu NN O O
. NN O O
ve NN O O
observed NN O O
significant NN O O
inter-apoc NN O O
2 NN O O
rflp NN O O
linkage NN O O
disequilibrium. NN O O
consequently, NN O O
the NN O O
three NN O O
most NN O O
informative NN O O
rflps NN O O
have NN O O
been NN O O
found NN O O
to NN O O
be NN O O
bani, NN O O
taqi, NN O O
and NN O O
either NN O O
bgli, NN O O
avaii, NN O O
or NN O O
ncoi NN O O
polymorphisms. NN O O
we NN O O
also NN O O
demonstrate NN O O
linkage NN O O
disequilibriu NN O O
. NN O O

between NN O O
dm NN O O
and NN O O
apoc NN O O
2 NN O O
in NN O O
our NN O O
french-canadian NN O O
population NN O O
(standardized NN O O
disequilibrium NN O O
constant NN O O
phi NN O O
=. NN O O
22, NN O O
chi NN O O
2 NN O O
= NN O O
5. NN O O
12, NN O O
df NN O O
= NN O O
1, NN O O
p NN O O
less NN O O
than NN O O
0. NN O O
04). NN O O
this NN O O
represents NN O O
the NN O O
first NN O O
evidence NN O O
of NN O O
linkage NN O O
disequilibrium NN O O
between NN O O
apoc NN O O
2 NN O O
and NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
locus NN O O
. NN O O

a NN O O
retrospective NN O O
anonymous NN O O
pilot NN O O
study NN O O
in NN O O
screening NN O O
newborns NN O O
for NN O O
hfe NN O O
mutations NN O O
in NN O O
scandinavian NN O O
populations NN O O
. NN O O

we NN O O
have NN O O
retrospectively NN O O
analyzed NN O O
837 NN O O
random NN O O
anonymized NN O O
dried NN O O
blood NN O O
spot NN O O
(dbs) NN O O
samples NN O O
from NN O O
neonatal NN O O
screening NN O O
programs NN O O
in NN O O
scandinavia NN O O
for NN O O
mutations NN O O
in NN O O
hfe, NN O O
the NN O O
candidate NN O O
gene NN O O
for NN O O
hemochromatosis NN B-SpecificDisease B-MSH:D006432
. NN O O
we NN O O
have NN O O
found NN O O
c NN O O
282 NN O O
y NN O O
allele NN O O
frequencies NN O O
of NN O O
2. NN O O
3% NN O O
(+ NN O O
2. NN O O
0%) NN O O
(-1. NN O O
3%) NN O O
in NN O O
greenland, NN O O
4. NN O O
5% NN O O
+/-1. NN O O
9% NN O O
in NN O O
iceland, NN O O
5. NN O O
1% NN O O
+/-2. NN O O
3% NN O O
in NN O O
the NN O O
faeroe NN O O
islands, NN O O
and NN O O
8. NN O O
2% NN O O
+/-2. NN O O
7% NN O O
in NN O O
denmark. NN O O
the NN O O
high NN O O
prevalence NN O O
of NN O O
hfe NN O O
mutations NN O O
in NN O O
denmark NN O O
suggests NN O O
that NN O O
population NN O O
screening NN O O
for NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
could NN O O
be NN O O
highly NN O O
advantageous NN O O
in NN O O
terms NN O O
of NN O O
preventive NN O O
health NN O O
care. NN O O
long-term NN O O
follow NN O O
. NN O O

up NN O O
evaluation NN O O
of NN O O
c NN O O
282 NN O O
y NN O O
homozygotes NN O O
and NN O O
h NN O O
63 NN O O
d/c NN O O
282 NN O O
y NN O O
compound NN O O
heterozygotes NN O O
will NN O O
give NN O O
an NN O O
indication NN O O
of NN O O
the NN O O
penetrance NN O O
of NN O O
the NN O O
mutations NN O O
. NN O O

hereditary NN O O
tp NN O O
53 NN O O
codon NN O O
292 NN O O
and NN O O
somatic NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a NN O O
codon NN O O
94 NN O O
mutations NN O O
in NN O O
a NN O O
Li-Fraumeni NN B-Modifier B-MSH:D016864
syndrome NN I-Modifier I-MSH:D016864
family NN O O
. NN O O

li-fraumeni NN O O
syndrome NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
that NN O O
is NN O O
characterized NN O O
by NN O O
various NN O O
types NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
in NN O O
childhood NN O O
and NN O O
adult NN O O
cases. NN O O
although NN O O
hereditary NN O O
tp NN O O
53 NN O O
mutation NN O O
is NN O O
very NN O O
rare NN O O
in NN O O
different NN O O
human NN O O
cancers NN B-DiseaseClass B-MSH:D009369
, NN O O
it NN O O
has NN O O
been NN O O
frequently NN O O
reported NN O O
in NN O O
Li-Fraumeni NN B-SpecificDisease B-MSH:D016864
syndrome NN I-SpecificDisease I-MSH:D016864
. NN O O
on NN O O
the NN O O
other NN O O
hand, NN O O
hereditary NN O O
mutations NN O O
of NN O O
tp NN O O
57 NN O O
kip NN O O
2, NN O O
p NN O O
15 NN O O
ink NN O O
4 NN O O
b, NN O O
and NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a, NN O O
which NN O O
affect NN O O
the NN O O
cell NN O O
cycle NN O O
similar NN O O
to NN O O
tp NN O O
53, NN O O
were NN O O
observed NN O O
in NN O O
some NN O O
types NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
. NN O O
in NN O O
a NN O O
turkish NN O O
family NN O O
with NN O O
the NN O O
diagnosis NN O O
of NN O O
Li-Fraumeni NN B-SpecificDisease B-MSH:D016864
syndrome NN I-SpecificDisease I-MSH:D016864
, NN O O
we NN O O
analyzed NN O O
the NN O O
mutation NN O O
pattern NN O O
of NN O O
tp NN O O
53, NN O O
p NN O O
57 NN O O
kip NN O O
2, NN O O
p NN O O
15 NN O O
ink NN O O
4 NN O O
b, NN O O
and NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a NN O O
in NN O O
the NN O O
peripheral NN O O
blood, NN O O
and NN O O
loss NN O O
of NN O O
heterozygosity NN O O
. NN O O

homo/hemizygous NN O O
deletion) NN O O
pattern NN O O
of NN O O
tp NN O O
53 NN O O
and NN O O
p NN O O
15 NN O O
ink NN O O
4 NN O O
b/p NN O O
16 NN O O
ink NN O O
4 NN O O
a NN O O
in NN O O
two NN O O
tumor NN B-Modifier B-MSH:D009369
tissues. NN O O
the NN O O
propositus NN O O
had NN O O
a NN O O
seminoma NN B-SpecificDisease B-MSH:D018239
, NN O O
his NN O O
daughter NN O O
a NN O O
medulloblastoma NN B-SpecificDisease B-MSH:D008527
, NN O O
and NN O O
one NN O O
of NN O O
his NN O O
healthy NN O O
cousins, NN O O
a NN O O
tp NN O O
53 NN O O
codon NN O O
292 NN O O
missense NN O O
point NN O O
mutation NN O O
(aaa-- NN O O
> NN O O
ata; NN O O
lys-- NN O O
> NN O O
ile) NN O O
in NN O O
the NN O O
peripheral NN O O
blood NN O O
cells. NN O O
tumor NN O O
tissue NN O O
obtained NN O O
from NN O O
the NN O O
propositus NN O O
with NN O O
the NN O O
seminoma NN B-SpecificDisease B-MSH:D018239
revealed NN O O
loss NN O O
of NN O O
heterozygosity NN O O
in NN O O
the NN O O
tp NN O O
53 NN O O
gene. NN O O
in NN O O
the NN O O
analyses NN O O
of NN O O
tumor NN B-Modifier B-MSH:D009369
tissues NN O O
from NN O O
the NN O O
propositus NN O O
and NN O O
his NN O O
daughter, NN O O
a NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a NN O O
codon NN O O
94 NN O O
missense NN O O
point NN O O
mutation NN O O
(gcg-- NN O O
> NN O O
gag; NN O O
ala-- NN O O
> NN O O
glu) NN O O
was NN O O
observed NN O O
with NN O O
the NN O O
hereditary NN O O
tp NN O O
53 NN O O
mutation. NN O O
p NN O O
16 NN O O
ink NN O O
. NN O O

a NN O O
codon NN O O
94 NN O O
mutation NN O O
observed NN O O
in NN O O
our NN O O
family NN O O
is NN O O
a NN O O
novel NN O O
mutation NN O O
in NN O O
Li-Fraumeni NN B-SpecificDisease B-MSH:D016864
syndrome NN I-SpecificDisease I-MSH:D016864
. NN O O
no NN O O
other NN O O
gene NN O O
alteration NN O O
in NN O O
tp NN O O
53, NN O O
p NN O O
57 NN O O
kip NN O O
2, NN O O
p NN O O
15 NN O O
ink NN O O
4 NN O O
b, NN O O
and NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a NN O O
was NN O O
observed. NN O O
existence NN O O
of NN O O
the NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a NN O O
mutation NN O O
and NN O O
the NN O O
hereditary NN O O
tp NN O O
53 NN O O
mutation NN O O
with NN O O
or NN O O
without NN O O
loss NN O O
of NN O O
heterozygosity NN O O
in NN O O
the NN O O
tp NN O O
53 NN O O
gene NN O O
( NN O O
seminoma NN B-SpecificDisease B-MSH:D018239
/ NN O O
medulloblastoma NN B-SpecificDisease B-MSH:D008527
) NN O O
may NN O O
be NN O O
evidence NN O O
for NN O O
a NN O O
common NN O O
mechanism NN O O
involved NN O O
in NN O O
tumorogenesis NN B-DiseaseClass B-MSH:D002471
. NN O O
the NN O O
gene NN O O
alterations NN O O
in NN O O
tp NN O O
53 NN O O
and NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a NN O O
genes NN O O
may NN O O
be NN O O
used NN O O
as NN O O
tumor NN B-Modifier B-MSH:D009369
markers NN O O
in NN O O
our NN O O
family. NN O O
. NN O O

an NN O O
amino-acid NN O O
substitution NN O O
involved NN O O
in NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
is NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
dna NN O O
haplotype NN O O
2 NN O O
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
human NN I-DiseaseClass I-MSH:D030342
genetic NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah, NN O O
phenylalanine NN O O
4-monooxygenase, NN O O
ec NN O O
1. NN O O
14. NN O O
16. NN O O
1). NN O O
PKU NN B-SpecificDisease B-MSH:D010661
is NN O O
a NN O O
common NN O O
inborn NN B-DiseaseClass B-MSH:D000592
error NN I-DiseaseClass I-MSH:D000592
of NN I-DiseaseClass I-MSH:D000592
amino-acid NN I-DiseaseClass I-MSH:D000592
metabolism NN I-DiseaseClass I-MSH:D000592
in NN O O
caucasian NN O O
populations NN O O
and NN O O
approximately NN O O
1 NN O O
in NN O O
50 NN O O
individuals NN O O
are NN O O
carriers NN O O
of NN O O
a NN O O
PKU NN B-Modifier B-MSH:D010661
allele. NN O O
to NN O O
define NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
PKU NN B-SpecificDisease B-MSH:D010661
, NN O O
we NN O O
characterized NN O O
twelve NN O O
restriction NN O O
fragment-length NN O O
polymorphism NN O O
(rflp) NN O O
haplotypes NN O O
of NN O O
the NN O O
pah NN O O
locus NN O O
in NN O O
the NN O O
northern NN O O
european NN O O
population NN O O
and NN O O
observed NN O O
that NN O O
90% NN O O
of NN O O
the NN O O
PKU NN B-Modifier B-MSH:D010661
alleles NN O O
in NN O O
this NN O O
population NN O O
are NN O O
confined NN O O
to NN O O
four NN O O
common NN O O
rflp NN O O
haplotypes. NN O O
we NN O O
have NN O O
recently NN O O
reported NN O O
a NN O O
splicing NN O O
mutation NN O O
in NN O O
the NN O O
pah NN O O
gene NN O O
that NN O O
is NN O O
associated NN O O
with NN O O
rflp NN O O
haplotype NN O O
3 NN O O
which NN O O
is NN O O
present NN O O
at NN O O
about NN O O
40% NN O O
of NN O O
mutan NN O O
. NN O O

alleles. NN O O
we NN O O
now NN O O
report NN O O
the NN O O
molecular NN B-DiseaseClass B-MSH:D030342
lesion NN I-DiseaseClass I-MSH:D030342
associated NN O O
with NN O O
the NN O O
rflp NN O O
haplotype NN O O
2 NN O O
mutant NN O O
allele. NN O O
this NN O O
defect NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
c-to-t NN O O
transition NN O O
in NN O O
exon NN O O
12 NN O O
resulting NN O O
in NN O O
an NN O O
amino-acid NN O O
substitution NN O O
(arg NN O O
to NN O O
trp) NN O O
at NN O O
residue NN O O
408 NN O O
of NN O O
pah. NN O O
direct NN O O
hybridization NN O O
analysis NN O O
of NN O O
the NN O O
point NN O O
mutation NN O O
using NN O O
a NN O O
specific NN O O
oligonucleotide NN O O
probe NN O O
demonstrated NN O O
that NN O O
this NN O O
mutation NN O O
is NN O O
also NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
rflp NN O O
haplotype NN O O
2 NN O O
alleles NN O O
that NN O O
make NN O O
up NN O O
about NN O O
20% NN O O
of NN O O
mutant NN O O
pah NN O O
gene NN O O
. NN O O

the NN O O
effects NN O O
of NN O O
dystrophin NN O O
gene NN O O
mutations NN O O
on NN O O
the NN O O
erg NN O O
in NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O
the NN O O
erg NN O O
in NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O

purpose. NN O O
the NN O O
authors NN O O
earlier NN O O
findings NN O O
of NN O O
a NN O O
negative NN O O
electroretinogram NN O O
(erg) NN O O
in NN O O
a NN O O
boy NN O O
with NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
led NN O O
them NN O O
to NN O O
investigate NN O O
dystrophin NN O O
gene NN O O
deletions NN O O
and NN O O
ergs NN O O
in NN O O
five NN O O
boys NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
the NN O O
authors NN O O
wanted NN O O
to NN O O
determined NN O O
whether NN O O
there NN O O
were NN O O
similar NN O O
erg NN O O
findings NN O O
in NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
DMD NN B-SpecificDisease B-MSH:D020388
, NN O O
the NN O O
mdx NN O O
mouse. NN O O
methods. NN O O
ganzfeld NN O O
ergs NN O O
were NN O O
recorded NN O O
in NN O O
five NN O O
boys NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
after NN O O
a NN O O
complete NN O O
ophthalmic NN O O
examination. NN O O
the NN O O
dystrophin NN O O
gene NN O O
was NN O O
analyzed NN O O
by NN O O
southern NN O O
blot NN O O
hybridization. NN O O
ergs NN O O
were NN O O
recorded NN O O
in NN O O
anesthetized NN O O
mdx NN O O
and NN O O
control NN O O
mice NN O O
with NN O O
a NN O O
modified NN O O
grass NN O O
photostimulator NN O O
(grass NN O O
instrument NN O O
company, NN O O
quincy, NN O O
ma). NN O O
results. NN O O
ophthalmic NN O O
examinations NN O O
in NN O O
all NN O O
five NN O O
boys NN O O
had NN O O
normal NN O O
findings, NN O O
yet NN O O
an NN O O
abnormal NN O O
negative NN O O
erg NN O O
was NN O O
recorded NN O O
for NN O O
each NN O O
subject. NN O O
the NN O O
subjects NN O O
gene NN O O
deletions NN O O
were NN O O
variabl NN O O
. NN O O

, NN O O
ranging NN O O
from NN O O
large NN O O
deletions NN O O
to NN O O
no NN O O
detectable NN O O
deletions. NN O O
the NN O O
ergs NN O O
of NN O O
the NN O O
mdx NN O O
mice NN O O
were NN O O
normal NN O O
and NN O O
did NN O O
not NN O O
differ NN O O
significantly NN O O
from NN O O
those NN O O
of NN O O
the NN O O
control NN O O
mice. NN O O
conclusions. NN O O
the NN O O
authors NN O O
believe NN O O
the NN O O
unique NN O O
erg NN O O
recorded NN O O
for NN O O
the NN O O
human NN O O
subjects NN O O
is NN O O
a NN O O
manifestation NN O O
of NN O O
DMD NN B-SpecificDisease B-MSH:D020388
associated NN O O
with NN O O
defects NN O O
at NN O O
the NN O O
dystrophin NN O O
gene NN O O
locus NN O O
and NN O O
represents NN O O
a NN O O
new NN O O
clinical NN O O
entity. NN O O
the NN O O
erg NN O O
of NN O O
the NN O O
mdx NN O O
mouse NN O O
may NN O O
be NN O O
spared NN O O
for NN O O
several NN O O
reasons, NN O O
including NN O O
milder NN O O
effects NN O O
of NN O O
the NN O O
mouse NN O O
gene NN O O
defect, NN O O
differences NN O O
in NN O O
muscle NN O O
and NN O O
retinal NN O O
gene NN O O
product, NN O O
or NN O O
species NN O O
differences NN O O
in NN O O
the NN O O
biochemical NN O O
role NN O O
of NN O O
dystrophin. NN O O
the NN O O
erg NN O O
shows NN O O
promise NN O O
of NN O O
becoming NN O O
a NN O O
noninvasive NN O O
diagnostic NN O O
tool NN O O
for NN O O
DMD NN B-SpecificDisease B-MSH:D020388
and NN O O
its NN O O
milder NN O O
allelic NN O O
forms. NN O O
. NN O O

eight NN O O
novel NN O O
inactivating NN O O
germ NN O O
line NN O O
mutations NN O O
at NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
identified NN O O
by NN O O
denaturing NN O O
gradient NN O O
gel NN O O
electrophoresis NN O O
. NN O O

familial NN O O
adenomatous NN O O
polyposis NN O O
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
) NN O O
is NN O O
a NN O O
dominantly NN O O
inherited NN O O
condition NN O O
predisposing NN O O
to NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O
the NN O O
recent NN O O
isolation NN O O
of NN O O
the NN O O
responsible NN O O
gene NN O O
( NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
or NN O O
APC NN B-SpecificDisease B-MSH:D011125
) NN O O
has NN O O
facilitated NN O O
the NN O O
search NN O O
for NN O O
germ NN O O
line NN O O
mutations NN O O
in NN O O
affected NN O O
individuals. NN O O
previous NN O O
authors NN O O
have NN O O
used NN O O
the NN O O
rnase NN O O
protection NN O O
assay NN O O
and NN O O
the NN O O
single-strand NN O O
conformation NN O O
polymorphisms NN O O
procedure NN O O
to NN O O
screen NN O O
for NN O O
mutations. NN O O
in NN O O
this NN O O
study NN O O
we NN O O
used NN O O
denaturing NN O O
gradient NN O O
gel NN O O
electrophoresis NN O O
(dgge). NN O O
dgge NN O O
analysis NN O O
of NN O O
10 NN O O
APC NN B-Modifier B-MSH:D011125
exons NN O O
(4, NN O O
5, NN O O
7, NN O O
8, NN O O
9, NN O O
10, NN O O
12, NN O O
13, NN O O
14, NN O O
and NN O O
part NN O O
of NN O O
15) NN O O
in NN O O
33 NN O O
unrelated NN O O
dutch NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
has NN O O
led NN O O
to NN O O
the NN O O
identification NN O O
of NN O O
eight NN O O
novel NN O O
germ NN O O
line NN O O
mutations NN O O
resulting NN O O
in NN O O
stop NN O O
codons NN O O
or NN O O
frameshifts. NN O O
the NN O O
results NN O O
reported NN O O
here NN O O
indicate NN O O
that NN O O
(1) NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125

adenomatous NN O O
polyposis NN O O
is NN O O
caused NN O O
by NN O O
an NN O O
extremely NN O O
heterogeneous NN O O
spectrum NN O O
of NN O O
point NN O O
mutations; NN O O
(2) NN O O
all NN O O
the NN O O
mutations NN O O
found NN O O
in NN O O
this NN O O
study NN O O
are NN O O
chain NN O O
terminating; NN O O
and NN O O
(3) NN O O
dgge NN O O
represents NN O O
a NN O O
rapid NN O O
and NN O O
sensitive NN O O
technique NN O O
for NN O O
the NN O O
detection NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
unusually NN O O
large NN O O
APC NN B-Modifier B-MSH:D011125
gene. NN O O
an NN O O
extension NN O O
of NN O O
the NN O O
dgge NN O O
analysis NN O O
to NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
in NN O O
a NN O O
sufficient NN O O
number NN O O
of NN O O
clinically NN O O
well-characterized, NN O O
unrelated NN O O
patients NN O O
will NN O O
facilitate NN O O
the NN O O
establishment NN O O
of NN O O
genotype-phenotype NN O O
correlations. NN O O
on NN O O
the NN O O
other NN O O
hand, NN O O
the NN O O
occurrence NN O O
of NN O O
an NN O O
extremely NN O O
heterogeneous NN O O
spectrum NN O O
of NN O O
mutations NN O O
spread NN O O
throughout NN O O
the NN O O
entire NN O O
length NN O O
of NN O O
the NN O O
large NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
among NN O O
the NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
indicates NN O O
that NN O O
this NN O O
approach NN O O
may NN O O
not NN O O
be NN O O
useful NN O O
as NN O O
a NN O O
rapid NN O O
presymptomatic NN O O
diagnostic NN O O
procedure NN O O
in NN O O
a NN O O
routine NN O O
laboratory. NN O O
nevertheless, NN O O
the NN O O
above NN O O
dgge NN O O
approach NN O O
has NN O O
incidentally NN O O
led NN O O
t NN O O
. NN O O

the NN O O
identification NN O O
of NN O O
a NN O O
common NN O O
polymorphism NN O O
in NN O O
exon NN O O
13. NN O O
such NN O O
intragenic NN O O
polymorphisms NN O O
offer NN O O
a NN O O
practical NN O O
approach NN O O
to NN O O
a NN O O
more NN O O
rapid NN O O
procedure NN O O
for NN O O
presymptomatic NN O O
diagnosis NN O O
of NN O O
FAP NN B-SpecificDisease B-MSH:D011125
by NN O O
linkage NN O O
analysis NN O O
in NN O O
informative NN O O
families. NN O O
. NN O O

novel NN O O
mutations NN O O
in NN O O
xlrs NN O O
1 NN O O
causing NN O O
retinoschisis NN B-SpecificDisease B-MSH:D041441
, NN O O
including NN O O
first NN O O
evidence NN O O
of NN O O
putative NN O O
leader NN O O
sequence NN O O
change NN O O
. NN O O

juvenile NN O O
retinoschisis NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
recessive NN I-DiseaseClass I-MSH:D040181
disease NN I-DiseaseClass I-MSH:D040181
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
xlrs NN O O
1 NN O O
gene. NN O O
we NN O O
screened NN O O
31 NN O O
new NN O O
unrelated NN O O
patients NN O O
and NN O O
families NN O O
for NN O O
xlrs NN O O
1 NN O O
mutations NN O O
in NN O O
addition NN O O
to NN O O
previously NN O O
reported NN O O
mutations NN O O
for NN O O
60 NN O O
of NN O O
our NN O O
families NN O O
( NN O O
Retinoschisis NN B-Modifier B-MSH:D041441
consortium, NN O O
hum NN O O
mol NN O O
genet NN O O
1998; NN O O
7 NN O O
1185-1192). NN O O
twenty-three NN O O
different NN O O
mutations NN O O
including NN O O
12 NN O O
novel NN O O
ones NN O O
were NN O O
identified NN O O
in NN O O
28 NN O O
patients. NN O O
mutations NN O O
identified NN O O
in NN O O
this NN O O
study NN O O
include NN O O
19 NN O O
missense NN O O
mutations, NN O O
two NN O O
nonsense NN O O
mutations, NN O O
one NN O O
intragenic NN O O
deletion, NN O O
four NN O O
microdeletions, NN O O
one NN O O
insertion, NN O O
and NN O O
one NN O O
intronic NN O O
sequence NN O O
substitution NN O O
that NN O O
is NN O O
likely NN O O
to NN O O
result NN O O
in NN O O
a NN O O
splice NN O O
site NN O O
defect. NN O O
two NN O O
novel NN O O
mutations, NN O O
c. NN O O
38 NN O O
t-- NN O O
> NN O O
c NN O O
(l NN O O
13 NN O O
p) NN O O
and NN O O
c. NN O O
667 NN O O
t-- NN O O
> NN O O
c NN O O
(c NN O O
22 NN O O
. NN O O

r), NN O O
respectively, NN O O
present NN O O
the NN O O
first NN O O
genetic NN O O
evidence NN O O
for NN O O
the NN O O
functional NN O O
significance NN O O
of NN O O
the NN O O
putative NN O O
leader NN O O
peptide NN O O
sequence NN O O
and NN O O
for NN O O
the NN O O
functional NN O O
significance NN O O
at NN O O
the NN O O
carboxyl NN O O
terminal NN O O
of NN O O
the NN O O
xlrs NN O O
1 NN O O
protein NN O O
beyond NN O O
the NN O O
discoidin NN O O
domain. NN O O
mutations NN O O
in NN O O
25 NN O O
of NN O O
the NN O O
families NN O O
were NN O O
localized NN O O
to NN O O
exons NN O O
4-6, NN O O
emphasizing NN O O
the NN O O
critical NN O O
functional NN O O
significance NN O O
of NN O O
the NN O O
discoidin NN O O
domain NN O O
of NN O O
the NN O O
xlrs NN O O
1 NN O O
protei NN O O
. NN O O
25 NN O O
of NN O O
the NN O O
families NN O O
were NN O O
localized NN O O
to NN O O
exons NN O O
4-6, NN O O
emphasizing NN O O
the NN O O
critical NN O O
functional NN O O
significance NN O O
of NN O O
the NN O O
discoidin NN O O
domain NN O O
of NN O O
the NN O O
xlrs NN O O
1 NN O O
protei NN O O
. NN O O

clinical NN O O
use NN O O
of NN O O
dna NN O O
markers NN O O
linked NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
. NN O O

seventy NN O O
families NN O O
with NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
known NN O O
to NN O O
the NN O O
institute NN O O
of NN O O
child NN O O
health NN O O
fall NN O O
into NN O O
three NN O O
categories NN O O
with NN O O
respect NN O O
to NN O O
potential NN O O
linkage NN O O
analysis NN O O
with NN O O
the NN O O
x NN O O
chromosome NN O O
dna NN O O
markers NN O O
rc NN O O
8 NN O O
and NN O O
l NN O O
1. NN O O
28 NN O O
that NN O O
bridge NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene. NN O O
families NN O O
in NN O O
which NN O O
there NN O O
is NN O O
at NN O O
least NN O O
one NN O O
obligatory NN O O
female NN O O
heterozygote NN O O
(n NN O O
= NN O O
13). NN O O
here NN O O
prediction NN O O
and NN O O
exclusion NN O O
of NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
transmission NN O O
may NN O O
be NN O O
possible, NN O O
the NN O O
accuracy NN O O
being NN O O
dependent NN O O
on NN O O
the NN O O
closeness NN O O
of NN O O
the NN O O
linkage NN O O
of NN O O
the NN O O
dna NN O O
marker NN O O
(s) NN O O
to NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene; NN O O
an NN O O
illustrative NN O O
case NN O O
is NN O O
reported. NN O O
families NN O O
in NN O O
which NN O O
there NN O O
is NN O O
a NN O O
single NN O O
affected NN O O
boy, NN O O
who NN O O
also NN O O
has NN O O
one NN O O
or NN O O
more NN O O
healthy NN O O
brothers NN O O
(n NN O O
= NN O O
26). NN O O
given NN O O
an NN O O
informative NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
(rflp), NN O O
the NN O O
probability NN O O
tha NN O O
. NN O O

the NN O O
boy NN O O
represents NN O O
a NN O O
new NN O O
mutation NN O O
can NN O O
be NN O O
reassessed; NN O O
it NN O O
is NN O O
also NN O O
possible NN O O
to NN O O
exclude NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
in NN O O
a NN O O
sister. NN O O
families NN O O
with NN O O
a NN O O
single NN O O
affected NN O O
boy NN O O
with NN O O
no NN O O
brother NN O O
(n NN O O
= NN O O
30). NN O O
here NN O O
exclusion NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
in NN O O
a NN O O
sister NN O O
may NN O O
be NN O O
possible. NN O O
only NN O O
in NN O O
one NN O O
family NN O O
was NN O O
there NN O O
no NN O O
possibility NN O O
of NN O O
useful NN O O
linkage NN O O
analysis. NN O O
the NN O O
linkage NN O O
analysis NN O O
required NN O O
is NN O O
described, NN O O
and NN O O
the NN O O
need NN O O
to NN O O
check NN O O
DMD NN B-Modifier B-MSH:D020388
families NN O O
for NN O O
informative NN O O
rflps NN O O
is NN O O
stressed NN O O
. NN O O

molecular NN O O
characterization NN O O
of NN O O
glucose-6-phosphate NN B-SpecificDisease B-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
patients NN O O
of NN O O
chinese NN O O
descent NN O O
and NN O O
identification NN O O
of NN O O
new NN O O
base NN O O
substitutions NN O O
in NN O O
the NN O O
human NN O O
g NN O O
6 NN O O
pd NN O O
gene NN O O
. NN O O

the NN O O
underlying NN O O
dna NN O O
changes NN O O
associated NN O O
with NN O O
glucose-6-phosphate NN B-Modifier B-MSH:D005955
dehydrogenase NN I-Modifier I-MSH:D005955
(G6PD) NN I-Modifier I-MSH:D005955
-deficient NN I-Modifier I-MSH:D005955
asians NN O O
have NN O O
not NN O O
been NN O O
extensively NN O O
investigated. NN O O
to NN O O
fill NN O O
this NN O O
gap, NN O O
we NN O O
sequenced NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
gene NN O O
of NN O O
43 NN O O
G6PD-deficient NN B-Modifier B-MSH:D005955
chinese NN O O
whose NN O O
g NN O O
6 NN O O
pd NN O O
was NN O O
well NN O O
characterized NN O O
biochemically. NN O O
dna NN O O
samples NN O O
were NN O O
obtained NN O O
from NN O O
peripheral NN O O
blood NN O O
of NN O O
these NN O O
individuals NN O O
for NN O O
sequencing NN O O
using NN O O
a NN O O
direct NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
sequencing NN O O
procedure. NN O O
from NN O O
these NN O O
43 NN O O
samples, NN O O
we NN O O
have NN O O
identified NN O O
five NN O O
different NN O O
types NN O O
of NN O O
nucleotide NN O O
substitutions NN O O
in NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
gene NN O O
at NN O O
cdna NN O O
1388 NN O O
from NN O O
g NN O O
to NN O O
a NN O O
(arg NN O O
to NN O O
his); NN O O
at NN O O
cdna NN O O
1376 NN O O
from NN O O
g NN O O
to NN O O
t NN O O
(arg NN O O
to NN O O
leu); NN O O
at NN O O
cdna NN O O
1024 NN O O
from NN O O
c NN O O
to NN O O
t NN O O
(leu NN O O
to NN O O
phe); NN O O
at NN O O
cdn NN O O
. NN O O

392 NN O O
from NN O O
g NN O O
to NN O O
t NN O O
(gly NN O O
to NN O O
val); NN O O
at NN O O
cdna NN O O
95 NN O O
from NN O O
a NN O O
to NN O O
g NN O O
(his NN O O
to NN O O
arg). NN O O
these NN O O
five NN O O
nucleotide NN O O
substitutions NN O O
account NN O O
for NN O O
over NN O O
83% NN O O
of NN O O
our NN O O
43 NN O O
G6PD-deficient NN B-Modifier B-MSH:D005955
samples NN O O
and NN O O
these NN O O
substitutions NN O O
have NN O O
not NN O O
been NN O O
reported NN O O
in NN O O
non-asians. NN O O
the NN O O
substitutions NN O O
found NN O O
at NN O O
cdna NN O O
392 NN O O
and NN O O
cdna NN O O
1024 NN O O
are NN O O
new NN O O
findings. NN O O
the NN O O
substitutions NN O O
at NN O O
cdna NN O O
1376 NN O O
and NN O O
1388 NN O O
account NN O O
for NN O O
over NN O O
50% NN O O
of NN O O
the NN O O
43 NN O O
samples NN O O
examined NN O O
indicating NN O O
a NN O O
high NN O O
prevalence NN O O
of NN O O
these NN O O
two NN O O
alleles NN O O
among NN O O
G6PD-deficient NN B-Modifier B-MSH:D005955
chinese. NN O O
our NN O O
findings NN O O
add NN O O
support NN O O
to NN O O
the NN O O
notion NN O O
that NN O O
diverse NN O O
point NN O O
mutations NN O O
may NN O O
account NN O O
largely NN O O
for NN O O
much NN O O
of NN O O
the NN O O
phenotypic NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
. NN O O
. NN O O

norrie NN O O
disease NN O O
gene: NN O O
characterization NN O O
of NN O O
deletions NN O O
and NN O O
possible NN O O
function NN O O
. NN O O

positional NN O O
cloning NN O O
experiments NN O O
have NN O O
resulted NN O O
recently NN O O
in NN O O
the NN O O
isolation NN O O
of NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
Norrie NN B-SpecificDisease B-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
( NN O O
pseudoglioma NN B-SpecificDisease B-MSH:C537849
; NN O O
NDP NN B-SpecificDisease B-MSH:C537849
), NN O O
a NN O O
severe NN O O
X-linked NN B-DiseaseClass B-MSH:D038901
neurodevelopmental NN I-DiseaseClass I-MSH:D038901
disorder NN I-DiseaseClass I-MSH:D038901
. NN O O
here NN O O
we NN O O
report NN O O
the NN O O
isolation NN O O
and NN O O
analysis NN O O
of NN O O
human NN O O
genomic NN O O
dna NN O O
clones NN O O
encompassing NN O O
the NN O O
NDP NN B-Modifier B-MSH:C537849
gene. NN O O
the NN O O
gene NN O O
spans NN O O
28 NN O O
kb NN O O
and NN O O
consists NN O O
of NN O O
3 NN O O
exons, NN O O
the NN O O
first NN O O
of NN O O
which NN O O
is NN O O
entirely NN O O
contained NN O O
within NN O O
the NN O O
5 NN O O
untranslated NN O O
region. NN O O
detailed NN O O
analysis NN O O
of NN O O
genomic NN O O
deletions NN O O
in NN O O
Norrie NN B-Modifier B-MSH:C537849
patients NN O O
shows NN O O
that NN O O
they NN O O
are NN O O
heterogeneous, NN O O
both NN O O
in NN O O
size NN O O
and NN O O
in NN O O
position. NN O O
by NN O O
pcr NN O O
analysis, NN O O
we NN O O
found NN O O
that NN O O
expression NN O O
of NN O O
the NN O O
NDP NN B-Modifier B-MSH:C537849
gene NN O O
was NN O O
not NN O O
confined NN O O
to NN O O
the NN O O
eye NN O O
or NN O O
to NN O O
the NN O O
brain. NN O O
an NN O O
extensive NN O O
dna NN O O
and NN O O
protein NN O O
sequence NN O O
comparison NN O O
between NN O O
the NN O O
human NN O O
NDP NN B-Modifier B-MSH:C537849
gene NN O O
and NN O O
related NN O O
genes NN O O
from NN O O
the NN O O
database NN O O
revealed NN O O
homology NN O O
with NN O O
cysteine-rich NN O O
protei NN O O
. NN O O

-binding NN O O
domains NN O O
of NN O O
immediate--early NN O O
genes NN O O
implicated NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
cell NN O O
proliferation. NN O O
we NN O O
propose NN O O
that NN O O
ndp NN O O
is NN O O
a NN O O
molecule NN O O
related NN O O
in NN O O
function NN O O
to NN O O
these NN O O
genes NN O O
and NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
a NN O O
pathway NN O O
that NN O O
regulates NN O O
neural NN O O
cell NN O O
differentiation NN O O
and NN O O
proliferation. NN O O
. NN O O

prenatal NN O O
diagnosis NN O O
of NN O O
Wolman NN B-SpecificDisease B-MSH:D015223
disease NN I-SpecificDisease I-MSH:D015223
. NN O O

two NN O O
pregnancies NN O O
at NN O O
risk NN O O
for NN O O
Wolman NN B-SpecificDisease B-MSH:D015223
disease NN I-SpecificDisease I-MSH:D015223
were NN O O
monitored NN O O
by NN O O
assay NN O O
and NN O O
electrophoresis NN O O
of NN O O
acid NN O O
lipase NN O O
in NN O O
cultured NN O O
amniotic-fluid NN O O
cells. NN O O
cells NN O O
from NN O O
patient NN O O
1 NN O O
had NN O O
5% NN O O
of NN O O
control NN O O
levels NN O O
of NN O O
acid NN O O
lipase, NN O O
using NN O O
14 NN O O
c-triolein NN O O
as NN O O
substrate; NN O O
however, NN O O
when NN O O
artificial NN O O
substrates NN O O
(esters NN O O
of NN O O
4-methylumbelliferone NN O O
and NN O O
p-nitrophenol) NN O O
were NN O O
used NN O O
to NN O O
measure NN O O
acid NN O O
lipase, NN O O
these NN O O
cells NN O O
had NN O O
30% NN O O
of NN O O
control NN O O
levels. NN O O
electrophoresis NN O O
of NN O O
cell NN O O
extracts NN O O
revealed NN O O
the NN O O
absence NN O O
of NN O O
the NN O O
a NN O O
form NN O O
of NN O O
acid NN O O
lipase, NN O O
consistent NN O O
with NN O O
the NN O O
diagnosis NN O O
of NN O O
Wolman NN B-SpecificDisease B-MSH:D015223
disease NN I-SpecificDisease I-MSH:D015223
. NN O O
analysis NN O O
of NN O O
fetal NN O O
tissues NN O O
following NN O O
prostaglandin NN O O
termination NN O O
of NN O O
this NN O O
pregnancy NN O O
confirmed NN O O
the NN O O
diagnosis. NN O O
assay NN O O
of NN O O
fetal-skin NN O O
fibroblasts NN O O
with NN O O
14 NN O O
c-triolein, NN O O
as NN O O
well NN O O
as NN O O
with NN O O
artificial NN O O
substrates, NN O O
showed NN O O
marked NN O O
deficiency NN O O
of NN O O
acid NN O O
lipase NN O O
activit NN O O
. NN O O

. NN O O
electrophoresis NN O O
of NN O O
fetal-tissue NN O O
extracts NN O O
also NN O O
demonstrated NN O O
the NN O O
absence NN O O
of NN O O
the NN O O
a NN O O
form NN O O
of NN O O
acid NN O O
lipase. NN O O
amniotic-fluid NN O O
cells NN O O
from NN O O
patient NN O O
2 NN O O
showed NN O O
normal NN O O
levels NN O O
of NN O O
acid NN O O
lipase NN O O
with NN O O
all NN O O
substrates NN O O
tested; NN O O
the NN O O
electrophoretic NN O O
pattern NN O O
of NN O O
acid NN O O
lipase NN O O
was NN O O
normal. NN O O
the NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
prenatal NN O O
diagnosis NN O O
of NN O O
Wolman NN B-SpecificDisease B-MSH:D015223
disease NN I-SpecificDisease I-MSH:D015223
be NN O O
made NN O O
using NN O O
the NN O O
radioassay NN O O
of NN O O
acid NN O O
lipase NN O O
and/or NN O O
electrophoresis. NN O O
. NN O O

somatic NN O O
mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
in NN O O
sporadic NN B-SpecificDisease B-MSH:D010051
ovarian NN I-SpecificDisease I-MSH:D010051
tumours NN I-SpecificDisease I-MSH:D010051
. NN O O

the NN O O
brca NN O O
1 NN O O
gene NN O O
on NN O O
chromosome NN O O
17 NN O O
q NN O O
21 NN O O
is NN O O
responsible NN O O
for NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
syndrome NN I-DiseaseClass I-MSH:D030342
of NN O O
increased NN O O
susceptibility NN O O
to NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
but NN O O
no NN O O
somatic NN O O
mutations NN O O
in NN O O
tumours NN B-DiseaseClass B-MSH:D009369
have NN O O
yet NN O O
been NN O O
described. NN O O
to NN O O
study NN O O
the NN O O
potential NN O O
role NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
sporadic NN O O
carcinogenesis, NN O O
we NN O O
analysed NN O O
the NN O O
genomic NN O O
dna NN O O
of NN O O
tumour NN B-DiseaseClass B-MSH:D009369
and NN O O
normal NN O O
fractions NN O O
of NN O O
47 NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
for NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
using NN O O
the NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
technique. NN O O
we NN O O
now NN O O
describe NN O O
somatic NN O O
mutations NN O O
in NN O O
the NN O O
dna NN O O
of NN O O
four NN O O
tumours NN B-DiseaseClass B-MSH:D009369
which NN O O
also NN O O
had NN O O
loss NN O O
of NN O O
heterozygosity NN O O
(loh) NN O O
at NN O O
a NN O O
brca NN O O
1 NN O O
intragenic NN O O
marker. NN O O
our NN O O
data NN O O
support NN O O
a NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
mechanism NN O O
for NN O O
brca NN O O
1; NN O O
somatic NN O O
mutations NN O O
and NN O O
loh NN O O
may NN O O
result NN O O
in NN O O
inactivation NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
at NN O O
least NN O O
a NN O O
small NN O O
number NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
. NN O O
. NN O O

skewed NN O O
x NN O O
inactivation NN O O
in NN O O
a NN O O
female NN O O
mz NN O O
twin NN O O
results NN O O
in NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
. NN O O

one NN O O
of NN O O
female NN O O
mz NN O O
twins NN O O
presented NN O O
with NN O O
muscular NN B-DiseaseClass B-MSH:D009136
dystrophy NN I-DiseaseClass I-MSH:D009136
. NN O O
physical NN O O
examination, NN O O
creatine NN O O
phosphokinase NN O O
levels, NN O O
and NN O O
muscle NN O O
biopsy NN O O
were NN O O
consistent NN O O
with NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
however, NN O O
because NN O O
of NN O O
her NN O O
sex NN O O
she NN O O
was NN O O
diagnosed NN O O
as NN O O
having NN O O
limb-girdle NN B-SpecificDisease B-MSH:D049288
muscular NN I-SpecificDisease I-MSH:D049288
dystrophy NN I-SpecificDisease I-MSH:D049288
. NN O O
with NN O O
cdna NN O O
probes NN O O
to NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene, NN O O
a NN O O
gene NN O O
deletion NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
twins NN O O
and NN O O
their NN O O
mother. NN O O
the NN O O
de NN O O
novo NN O O
mutation NN O O
which NN O O
arose NN O O
in NN O O
the NN O O
mother NN O O
was NN O O
shown NN O O
by NN O O
novel NN O O
junction NN O O
fragments NN O O
generated NN O O
by NN O O
hindiii, NN O O
psti, NN O O
or NN O O
taqi NN O O
when NN O O
probed NN O O
with NN O O
cdna NN O O
8. NN O O
additional NN O O
evidence NN O O
of NN O O
a NN O O
large NN O O
gene NN O O
deletion NN O O
was NN O O
given NN O O
by NN O O
novel NN O O
sfii NN O O
junction NN O O
fragments NN O O
detected NN O O
by NN O O
probes NN O O
p NN O O
20, NN O O
j-bir, NN O O
and NN O O
j-66 NN O O
on NN O O
pulsed-field NN O O
gel NN O O
electrophoresis NN O O
(pfge). NN O O
immunoblot NN O O
analysis NN O O
of NN O O
muscle NN O O
from NN O O
th NN O O
. NN O O

affected NN O O
twin NN O O
showed NN O O
dystrophin NN O O
of NN O O
normal NN O O
size NN O O
but NN O O
of NN O O
reduced NN O O
amount. NN O O
immunofluorescent NN O O
visualization NN O O
of NN O O
dystrophin NN O O
revealed NN O O
foci NN O O
of NN O O
dystrophin-positive NN O O
fibers NN O O
adjacent NN O O
to NN O O
foci NN O O
of NN O O
dystrophin-negative NN O O
fibers. NN O O
these NN O O
data NN O O
indicate NN O O
that NN O O
the NN O O
affected NN O O
twin NN O O
is NN O O
a NN O O
manifesting NN O O
carrier NN O O
of NN O O
an NN O O
abnormal NN O O
DMD NN B-Modifier B-MSH:D020388
gene, NN O O
her NN O O
myopathy NN B-DiseaseClass B-MSH:D009135
being NN O O
a NN O O
direct NN O O
result NN O O
of NN O O
underexpression NN O O
of NN O O
dystrophin. NN O O
cytogenetic NN O O
analysis NN O O
revealed NN O O
normal NN O O
karyotypes, NN O O
eliminating NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
translocation NN O O
affecting NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
function. NN O O
both NN O O
linkage NN O O
analysis NN O O
and NN O O
dna NN O O
fingerprint NN O O
analysis NN O O
revealed NN O O
that NN O O
each NN O O
twin NN O O
has NN O O
two NN O O
different NN O O
x NN O O
chromosomes, NN O O
eliminating NN O O
the NN O O
possibility NN O O
of NN O O
uniparental NN B-SpecificDisease B-MSH:D024182
disomy NN I-SpecificDisease I-MSH:D024182
as NN O O
a NN O O
mechanism NN O O
for NN O O
DMD NN B-Modifier B-MSH:D020388
expression. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
methylation NN O O
differences NN O O
of NN O O
the NN O O
paternal NN O O
and NN O O
maternal NN O O
x NN O O
chromosomes NN O O
in NN O O
these NN O O
mz NN O O
twins, NN O O
we NN O O
propose NN O O
uneven NN O O
lyonization NN O O
(x NN O O
chromosome NN O O
inactivation) NN O O
as NN O O
the NN O O
underlying NN O O
mechanism NN O O
for NN O O
diseas NN O O
. NN O O

expression NN O O
in NN O O
the NN O O
affected NN O O
female. NN O O
. NN O O

coincident NN O O
Kaposi NN B-SpecificDisease B-MSH:D012514
sarcoma NN I-SpecificDisease I-MSH:D012514
and NN O O
T-cell NN B-SpecificDisease B-MSH:D016399
lymphoma NN I-SpecificDisease I-MSH:D016399
in NN O O
a NN O O
patient NN O O
with NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
. NN O O

a NN O O
24 NN O O
year NN O O
old NN O O
male NN O O
with NN O O
a NN O O
history NN O O
of NN O O
eczema NN B-DiseaseClass B-MSH:D004485
, NN O O
recurrent NN O O
mild NN O O
infections, NN O O
and NN O O
thrombocytopenia NN B-SpecificDisease B-MSH:D013921
consistent NN O O
with NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
) NN O O
presented NN O O
with NN O O
a NN O O
mediastinal NN O O
mass, NN O O
generalized NN O O
lymphadenopathy NN B-SpecificDisease B-MSH:D008206
, NN O O
splenomegaly NN B-SpecificDisease B-MSH:D013163
, NN O O
and NN O O
severe NN O O
thrombocytopenia NN B-SpecificDisease B-MSH:D013921
. NN O O
studies NN O O
of NN O O
immune NN O O
function NN O O
including NN O O
immunoglobulin NN O O
levels NN O O
and NN O O
t-cell NN O O
subsets NN O O
were NN O O
normal. NN O O
furthermore, NN O O
his NN O O
t NN O O
lymphocytes NN O O
proliferated NN O O
normally NN O O
in NN O O
response NN O O
to NN O O
phytohemagglutinin, NN O O
concanavalin NN O O
a, NN O O
and NN O O
the NN O O
combination NN O O
of NN O O
neuraminidase/galactose NN O O
oxidase. NN O O
however, NN O O
their NN O O
proliferative NN O O
responses NN O O
to NN O O
anti-cd NN O O
43 NN O O
antibody NN O O
and NN O O
periodate NN O O
were NN O O
diminished, NN O O
consistent NN O O
with NN O O
the NN O O
clinical NN O O
diagnosis NN O O
of NN O O
WAS NN B-SpecificDisease B-MSH:D014923
. NN O O
an NN O O
initial NN O O
inguinal NN O O
lymph NN O O
node NN O O
biopsy NN O O
surprisingly NN O O
revealed NN O O
Kaposi NN B-SpecificDisease B-MSH:D012514
sarcoma NN I-SpecificDisease I-MSH:D012514
. NN O O
however, NN O O
following NN O O
splenectomy NN O O
to NN O O
increase NN O O
the NN O O
platelet NN O O
count, NN O O
biopsy NN O O
of NN O O
the NN O O
mediastinal NN O O
mass NN O O
revealed NN O O
T-cell NN B-SpecificDisease B-MSH:D016399
large NN I-SpecificDisease I-MSH:D016399
cell NN I-SpecificDisease I-MSH:D016399
lymphoma NN I-SpecificDisease I-MSH:D016399
. NN O O
studie NN O O
. NN O O

of NN O O
biopsied NN O O
tissue NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
Epstein-Barr NN B-SpecificDisease B-MSH:D020031
virus NN I-SpecificDisease I-MSH:D020031
and NN O O
cytomegalovirus NN B-SpecificDisease B-MSH:D003586
were NN O O
negative, NN O O
as NN O O
were NN O O
studies NN O O
of NN O O
blood, NN O O
including NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction, NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
human NN B-SpecificDisease B-MSH:D015658
immunodeficiency NN I-SpecificDisease I-MSH:D015658
virus NN I-SpecificDisease I-MSH:D015658
( NN O O
HIV NN B-SpecificDisease B-MSH:D015658
). NN O O
this NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
Kaposi NN B-SpecificDisease B-MSH:D012514
sarcoma NN I-SpecificDisease I-MSH:D012514
arising NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
congenital NN B-DiseaseClass B-MSH:D007153
immunodeficiency NN I-DiseaseClass I-MSH:D007153
syndrome NN I-DiseaseClass I-MSH:D007153
. NN O O
although NN O O
Kaposi NN B-SpecificDisease B-MSH:D012514
sarcoma NN I-SpecificDisease I-MSH:D012514
can NN O O
arise NN O O
in NN O O
the NN O O
face NN O O
of NN O O
the NN O O
severe NN O O
immunosuppression NN O O
that NN O O
follows NN O O
allograft NN O O
transplantation NN O O
and NN O O
in NN O O
patients NN O O
infected NN O O
with NN O O
HIV NN B-SpecificDisease B-MSH:D015658
, NN O O
we NN O O
postulate NN O O
that NN O O
longevity NN O O
in NN O O
the NN O O
face NN O O
of NN O O
mild NN O O
immunosuppression NN O O
was NN O O
the NN O O
major NN O O
factor NN O O
in NN O O
the NN O O
development NN O O
of NN O O
Kaposi NN B-SpecificDisease B-MSH:D012514
sarcoma NN I-SpecificDisease I-MSH:D012514
in NN O O
this NN O O
patient. NN O O
. NN O O

treatment NN O O
of NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
: NN O O
effects NN O O
of NN O O
chenodeoxycholic NN O O
acid, NN O O
pravastatin, NN O O
and NN O O
combined NN O O
use NN O O
. NN O O

treatments NN O O
by NN O O
oral NN O O
administration NN O O
of NN O O
chenodeoxycholic NN O O
acid NN O O
(cdca) NN O O
alone, NN O O
3-hydroxy-3-methylglutaryl NN O O
(hmg) NN O O
coa NN O O
reductase NN O O
inhibitor NN O O
(pravastatin) NN O O
alone, NN O O
and NN O O
combination NN O O
of NN O O
the NN O O
two NN O O
drugs NN O O
were NN O O
attempted NN O O
for NN O O
7 NN O O
patients NN O O
with NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
( NN O O
CTX NN B-SpecificDisease B-MSH:D019294
). NN O O
cdca NN O O
treatment NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
300 NN O O
mg/day NN O O
reduced NN O O
serum NN O O
cholestanol NN O O
(67. NN O O
3% NN O O
reduction), NN O O
lathosterol NN O O
(50. NN O O
8%), NN O O
campesterol NN O O
(61. NN O O
7%) NN O O
and NN O O
sitosterol NN O O
(12. NN O O
7%). NN O O
however, NN O O
the NN O O
sera NN O O
of NN O O
the NN O O
patients NN O O
changed NN O O
to NN O O
be NN O O
" NN O O
atherogenic NN O O
"; NN O O
total NN O O
cholesterol, NN O O
triglyceride NN O O
and NN O O
low-density NN O O
lipoprotein NN O O
(ldl) NN O O
-cholesterol NN O O
were NN O O
increased, NN O O
while NN O O
high-density NN O O
lipoprotein NN O O
(hdl) NN O O
-cholesterol NN O O
was NN O O
decreased. NN O O
contrarily, NN O O
pravastati NN O O
. NN O O

at NN O O
a NN O O
dose NN O O
of NN O O
10 NN O O
mg/day NN O O
improved NN O O
the NN O O
sera NN O O
of NN O O
the NN O O
patients NN O O
to NN O O
be NN O O
markedly NN O O
" NN O O
anti-atherogenic NN O O
", NN O O
but NN O O
the NN O O
reductions NN O O
of NN O O
cholestanol NN O O
(30. NN O O
4%), NN O O
lathosterol NN O O
(44. NN O O
0%), NN O O
campesterol NN O O
(22. NN O O
9%) NN O O
and NN O O
sitosterol NN O O
(9. NN O O
6%) NN O O
were NN O O
inadequate. NN O O
combined NN O O
treatment NN O O
with NN O O
cdca NN O O
and NN O O
pravastatin NN O O
showed NN O O
good NN O O
overlapping NN O O
of NN O O
the NN O O
effects NN O O
of NN O O
each NN O O
drug NN O O
alone. NN O O
the NN O O
sera NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
apparently NN O O
more NN O O
" NN O O
anti-atherogenic NN O O
" NN O O
than NN O O
those NN O O
after NN O O
cdca NN O O
treatment. NN O O
serum NN O O
cholestanol NN O O
concentration NN O O
was NN O O
still NN O O
2. NN O O
7 NN O O
times NN O O
higher NN O O
than NN O O
in NN O O
controls, NN O O
but NN O O
the NN O O
serum NN O O
lathosterol NN O O
level NN O O
was NN O O
within NN O O
the NN O O
normal NN O O
range, NN O O
indicating NN O O
that NN O O
the NN O O
enhancement NN O O
of NN O O
overall NN O O
cholesterol NN O O
synthesis NN O O
in NN O O
the NN O O
patients NN O O
was NN O O
sufficiently NN O O
suppressed. NN O O
plant NN O O
sterol NN O O
level NN O O
. NN O O
pravastatin NN O O
showed NN O O
good NN O O
overlapping NN O O
of NN O O
the NN O O
effects NN O O
of NN O O
each NN O O
drug NN O O
alone. NN O O
the NN O O
sera NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
apparently NN O O
more NN O O
" NN O O
anti-atherogenic NN O O
" NN O O
than NN O O
those NN O O
after NN O O
cdca NN O O
treatment. NN O O
serum NN O O
cholestanol NN O O
concentration NN O O
was NN O O
still NN O O
2. NN O O
7 NN O O
times NN O O
higher NN O O
than NN O O
in NN O O
controls, NN O O
but NN O O
the NN O O
serum NN O O
lathosterol NN O O
level NN O O
was NN O O
within NN O O
the NN O O
normal NN O O
range, NN O O
indicating NN O O
that NN O O
the NN O O
enhancement NN O O
of NN O O
overall NN O O
cholesterol NN O O
synthesis NN O O
in NN O O
the NN O O
patients NN O O
was NN O O
sufficiently NN O O
suppressed. NN O O
plant NN O O
sterol NN O O
level NN O O
. NN O O

were NN O O
also NN O O
within NN O O
the NN O O
normal NN O O
range. NN O O
the NN O O
combination NN O O
of NN O O
cdca NN O O
and NN O O
pravastatin NN O O
was NN O O
a NN O O
good NN O O
treatment NN O O
for NN O O
CTX NN B-SpecificDisease B-MSH:D019294
, NN O O
based NN O O
on NN O O
the NN O O
improvement NN O O
of NN O O
serum NN O O
lipoprotein NN O O
metabolism, NN O O
the NN O O
suppression NN O O
of NN O O
cholesterol NN O O
synthesis, NN O O
and NN O O
reductions NN O O
of NN O O
cholestanol NN O O
and NN O O
plant NN O O
sterol NN O O
levels. NN O O
in NN O O
all NN O O
of NN O O
7 NN O O
patients, NN O O
the NN O O
progression NN O O
of NN O O
disease NN O O
was NN O O
arrested, NN O O
but NN O O
dramatic NN O O
effects NN O O
on NN O O
clinical NN O O
manifestations, NN O O
xanthoma NN B-DiseaseClass B-MSH:D014973
, NN O O
and NN O O
electrophysiological NN O O
findings NN O O
could NN O O
not NN O O
be NN O O
found NN O O
after NN O O
the NN O O
treatment NN O O
of NN O O
these NN O O
drug NN O O
. NN O O

combined NN O O
genetic NN O O
deficiency NN O O
of NN O O
c NN O O
6 NN O O
and NN O O
c NN O O
7 NN O O
in NN O O
man NN O O
. NN O O

by NN O O
routine NN O O
screening NN O O
of NN O O
sera, NN O O
a NN O O
subject NN O O
was NN O O
discovered NN O O
who NN O O
showed NN O O
a NN O O
sub-total NN B-CompositeMention B-OMIM:610102
deficiency NN I-CompositeMention I-OMIM:610102
of NN I-CompositeMention I-OMIM:610102
C6 NN I-CompositeMention I-OMIM:610102
and NN I-CompositeMention I-OMIM:610102
C7 NN I-CompositeMention I-OMIM:610102
. NN O O
no NN O O
clinical NN O O
disease NN O O
was NN O O
associated NN O O
with NN O O
this NN O O
deficiency NN O O
which NN O O
was NN O O
transmitted NN O O
through NN O O
the NN O O
subjects NN O O
family NN O O
as NN O O
a NN O O
single NN O O
genetic NN O O
characteristic, NN O O
the NN O O
C6 NN B-SpecificDisease B-OMIM:612446
deficiency NN I-SpecificDisease I-OMIM:612446
being NN O O
associated NN O O
with NN O O
a NN O O
silent NN O O
allele NN O O
at NN O O
the NN O O
structural NN O O
locus. NN O O
the NN O O
propositus NN O O
was NN O O
found NN O O
to NN O O
have NN O O
low NN O O
quantities NN O O
of NN O O
an NN O O
abnormal NN O O
c NN O O
6 NN O O
which NN O O
was NN O O
both NN O O
antigenically NN O O
deficient NN O O
and NN O O
smaller NN O O
in NN O O
size NN O O
than NN O O
normal NN O O
c NN O O
6 NN O O
(110, NN O O
000 NN O O
daltons NN O O
compared NN O O
with NN O O
140, NN O O
000 NN O O
daltons) NN O O
and NN O O
small NN O O
quantities NN O O
of NN O O
apparently NN O O
normal NN O O
c NN O O
7. NN O O
it NN O O
is NN O O
concluded NN O O
that NN O O
the NN O O
most NN O O
likely NN O O
explanation NN O O
for NN O O
this NN O O
defect NN O O
is NN O O
that NN O O
the NN O O
subject NN O O
has NN O O
a NN O O
structural NN O O
mutation NN O O
in NN O O
his NN O O
c NN O O
6 NN O O
gene NN O O
which NN O O
produces NN O O
hyopsynthesis NN O O
not NN O O
only NN O O
of NN O O
c NN O O
6 NN O O
bu NN O O
. NN O O

also NN O O
of NN O O
the NN O O
closely NN O O
linked NN O O
gene NN O O
for NN O O
c NN O O
7. NN O O
these NN O O
findings NN O O
suggest NN O O
the NN O O
possibility NN O O
that NN O O
c NN O O
6 NN O O
and NN O O
c NN O O
7 NN O O
may NN O O
function NN O O
as NN O O
a NN O O
single NN O O
genetic NN O O
unit NN O O
and NN O O
that NN O O
the NN O O
primary NN O O
transcript NN O O
copied NN O O
from NN O O
the NN O O
genome NN O O
includes NN O O
information NN O O
for NN O O
both NN O O
proteins. NN O O
. NN O O

partial NN O O
deletion NN O O
8 NN O O
q NN O O
without NN O O
Langer-Giedion NN B-SpecificDisease B-MSH:D015826
syndrome NN I-SpecificDisease I-MSH:D015826
: NN O O
a NN O O
recognisable NN O O
syndrome NN O O
. NN O O

we NN O O
report NN O O
two NN O O
de NN O O
novo NN O O
cases NN O O
of NN O O
del NN O O
(8) NN O O
(pter----q NN O O
24. NN O O
1 NN O O
) NN O O
with NN O O
breakpoints NN O O
involving NN O O
the NN O O
distal NN O O
part NN O O
of NN O O
band NN O O
8 NN O O
q NN O O
24. NN O O
1 NN O O
1. NN O O
the NN O O
clinical NN O O
features NN O O
were NN O O
similar NN O O
and NN O O
there NN O O
were NN O O
no NN O O
obvious NN O O
stigmata NN O O
of NN O O
Langer-Giedion NN B-SpecificDisease B-MSH:D015826
syndrome NN I-SpecificDisease I-MSH:D015826
( NN O O
LGS NN B-SpecificDisease B-MSH:D015826
). NN O O
there NN O O
are NN O O
three NN O O
other NN O O
cases NN O O
reported NN O O
with NN O O
a NN O O
deletion NN O O
of NN O O
chromosome NN O O
8 NN O O
at NN O O
approximately NN O O
the NN O O
same NN O O
breakpoint, NN O O
one NN O O
without NN O O
LGS NN B-SpecificDisease B-MSH:D015826
and NN O O
some NN O O
similarities NN O O
to NN O O
our NN O O
cases, NN O O
the NN O O
other NN O O
two NN O O
with NN O O
LGS NN B-SpecificDisease B-MSH:D015826
. NN O O
our NN O O
findings NN O O
would NN O O
support NN O O
the NN O O
observation NN O O
that NN O O
the NN O O
critical NN O O
segment NN O O
for NN O O
the NN O O
assignment NN O O
of NN O O
LGS NN B-SpecificDisease B-MSH:D015826
is NN O O
proximal NN O O
to NN O O
or NN O O
involves NN O O
the NN O O
proximal NN O O
part NN O O
of NN O O
8 NN O O
q NN O O
24. NN O O
1, NN O O
but NN O O
a NN O O
review NN O O
of NN O O
published NN O O
reports NN O O
suggests NN O O
that NN O O
the NN O O
aetiology NN O O
of NN O O
LGS NN B-SpecificDisease B-MSH:D015826
may NN O O
be NN O O
a NN O O
more NN O O
complex NN O O
issu NN O O
. NN O O

iron-dependent NN O O
self-assembly NN O O
of NN O O
recombinant NN O O
yeast NN O O
frataxin: NN O O
implications NN O O
for NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
. NN O O

frataxin NN O O
deficiency NN O O
is NN O O
the NN O O
primary NN O O
cause NN O O
of NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
( NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
), NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
cardiodegenerative NN I-DiseaseClass I-MSH:D030342
and NN I-DiseaseClass I-MSH:D030342
neurodegenerative NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
. NN O O
frataxin NN O O
is NN O O
a NN O O
nuclear-encoded NN O O
mitochondrial NN O O
protein NN O O
that NN O O
is NN O O
widely NN O O
conserved NN O O
among NN O O
eukaryotes. NN O O
genetic NN O O
inactivation NN O O
of NN O O
the NN O O
yeast NN O O
frataxin NN O O
homologue NN O O
(yfh NN O O
1 NN O O
p) NN O O
results NN O O
in NN O O
mitochondrial NN B-SpecificDisease B-MSH:D028361
iron NN I-SpecificDisease I-MSH:D028361
accumulation NN I-SpecificDisease I-MSH:D028361
and NN O O
hypersensitivity NN B-SpecificDisease B-MSH:D004194
to NN I-SpecificDisease I-MSH:D004194
oxidative NN I-SpecificDisease I-MSH:D004194
stress NN I-SpecificDisease I-MSH:D004194
. NN O O
increased NN O O
iron NN O O
deposition NN O O
and NN O O
evidence NN O O
of NN O O
oxidative NN O O
damage NN O O
have NN O O
also NN O O
been NN O O
observed NN O O
in NN O O
cardiac NN O O
tissue NN O O
and NN O O
cultured NN O O
fibroblasts NN O O
from NN O O
patients NN O O
with NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
. NN O O
these NN O O
findings NN O O
indicate NN O O
that NN O O
frataxin NN O O
is NN O O
essential NN O O
for NN O O
mitochondrial NN O O
iron NN O O
homeostasis NN O O
and NN O O
protection NN O O
from NN O O
iron-induced NN O O
formation NN O O
of NN O O
free NN O O
radicals. NN O O
the NN O O
functional NN O O
mechanism NN O O
of NN O O
frataxin, NN O O
however, NN O O
is NN O O
still NN O O
unknown. NN O O
we NN O O
have NN O O
expressed NN O O
the NN O O
mature NN O O
form NN O O
of NN O O
yfh NN O O
1 NN O O
p NN O O
(myfh NN O O
1 NN O O
p) NN O O
in NN O O
escherichia NN O O
coli NN O O
and NN O O
have NN O O
analyzed NN O O
its NN O O
function NN O O
i NN O O
. NN O O

vitro. NN O O
isolated NN O O
myfh NN O O
1 NN O O
p NN O O
is NN O O
a NN O O
soluble NN O O
monomer NN O O
(13, NN O O
783 NN O O
da) NN O O
that NN O O
contains NN O O
no NN O O
iron NN O O
and NN O O
shows NN O O
no NN O O
significant NN O O
tendency NN O O
to NN O O
self-associate. NN O O
aerobic NN O O
addition NN O O
of NN O O
ferrous NN O O
iron NN O O
to NN O O
myfh NN O O
1 NN O O
p NN O O
results NN O O
in NN O O
assembly NN O O
of NN O O
regular NN O O
spherical NN O O
multimers NN O O
with NN O O
a NN O O
molecular NN O O
mass NN O O
of NN O O
approximately NN O O
1. NN O O
1 NN O O
mda NN O O
(megadaltons) NN O O
and NN O O
a NN O O
diameter NN O O
of NN O O
13 NN O O
+/-2 NN O O
nm. NN O O
each NN O O
multimer NN O O
consists NN O O
of NN O O
approximately NN O O
60 NN O O
subunits NN O O
and NN O O
can NN O O
sequester NN O O
> NN O O
3, NN O O
000 NN O O
atoms NN O O
of NN O O
iron. NN O O
titration NN O O
of NN O O
myfh NN O O
1 NN O O
p NN O O
with NN O O
increasing NN O O
iron NN O O
concentrations NN O O
supports NN O O
a NN O O
stepwise NN O O
mechanism NN O O
of NN O O
multimer NN O O
assembly. NN O O
sequential NN O O
addition NN O O
of NN O O
an NN O O
iron NN O O
chelator NN O O
and NN O O
a NN O O
reducing NN O O
agent NN O O
results NN O O
in NN O O
quantitative NN O O
iron NN O O
release NN O O
with NN O O
concomitant NN O O
disassembly NN O O
of NN O O
the NN O O
multimer, NN O O
indicating NN O O
that NN O O
myfh NN O O
1 NN O O
p NN O O
sequesters NN O O
iron NN O O
in NN O O
an NN O O
available NN O O
form. NN O O
i NN O O
. NN O O
l NN O O
addition NN O O
of NN O O
an NN O O
iron NN O O
chelator NN O O
and NN O O
a NN O O
reducing NN O O
agent NN O O
results NN O O
in NN O O
quantitative NN O O
iron NN O O
release NN O O
with NN O O
concomitant NN O O
disassembly NN O O
of NN O O
the NN O O
multimer, NN O O
indicating NN O O
that NN O O
myfh NN O O
1 NN O O
p NN O O
sequesters NN O O
iron NN O O
in NN O O
an NN O O
available NN O O
form. NN O O
i NN O O
. NN O O

yeast NN O O
mitochondria, NN O O
native NN O O
myfh NN O O
1 NN O O
p NN O O
exists NN O O
as NN O O
monomer NN O O
and NN O O
a NN O O
higher-order NN O O
species NN O O
with NN O O
a NN O O
molecular NN O O
weight NN O O
> NN O O
600, NN O O
000. NN O O
after NN O O
addition NN O O
of NN O O
(55) NN O O
fe NN O O
to NN O O
the NN O O
medium, NN O O
immunoprecipitates NN O O
of NN O O
this NN O O
species NN O O
contain NN O O
> NN O O
16 NN O O
atoms NN O O
of NN O O
(55) NN O O
fe NN O O
per NN O O
molecule NN O O
of NN O O
myfh NN O O
1 NN O O
p. NN O O
we NN O O
propose NN O O
that NN O O
iron-dependent NN O O
self-assembly NN O O
of NN O O
recombinant NN O O
myfh NN O O
1 NN O O
p NN O O
reflects NN O O
a NN O O
physiological NN O O
role NN O O
for NN O O
frataxin NN O O
in NN O O
mitochondrial NN O O
iron NN O O
sequestration NN O O
and NN O O
bioavailability. NN O O
. NN O O

human NN O O
mutations NN O O
in NN O O
glucose NN O O
6-phosphate NN O O
dehydrogenase NN O O
reflect NN O O
evolutionary NN O O
history NN O O
. NN O O

glucose NN O O
6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
is NN O O
a NN O O
cytosolic NN O O
enzyme NN O O
encoded NN O O
by NN O O
a NN O O
housekeeping NN O O
x-linked NN O O
gene NN O O
whose NN O O
main NN O O
function NN O O
is NN O O
to NN O O
produce NN O O
nadph, NN O O
a NN O O
key NN O O
electron NN O O
donor NN O O
in NN O O
the NN O O
defense NN O O
against NN O O
oxidizing NN O O
agents NN O O
and NN O O
in NN O O
reductive NN O O
biosynthetic NN O O
reactions. NN O O
inherited NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
is NN O O
associated NN O O
with NN O O
either NN O O
episodic NN B-SpecificDisease B-MSH:D000743
hemolytic NN I-SpecificDisease I-MSH:D000743
anemia NN I-SpecificDisease I-MSH:D000743
(triggered NN O O
by NN O O
fava NN O O
beans NN O O
or NN O O
other NN O O
agents) NN O O
or NN O O
life-long NN B-SpecificDisease B-MSH:D000745
hemolytic NN I-SpecificDisease I-MSH:D000745
anemia NN I-SpecificDisease I-MSH:D000745
. NN O O
we NN O O
show NN O O
here NN O O
that NN O O
an NN O O
evolutionary NN O O
analysis NN O O
is NN O O
a NN O O
key NN O O
to NN O O
understanding NN O O
the NN O O
biology NN O O
of NN O O
a NN O O
housekeeping NN O O
gene. NN O O
from NN O O
the NN O O
alignment NN O O
of NN O O
the NN O O
amino NN O O
acid NN O O
(aa) NN O O
sequence NN O O
of NN O O
52 NN O O
glucose NN O O
6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
species NN O O
from NN O O
42 NN O O
different NN O O
organisms, NN O O
we NN O O
found NN O O
a NN O O
striking NN O O
correlation NN O O
between NN O O
the NN O O
aa NN O O
replacements NN O O
that NN O O
cause NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
humans NN O O
an NN O O
. NN O O

the NN O O
sequence NN O O
conservation NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
two-thirds NN O O
of NN O O
such NN O O
replacements NN O O
are NN O O
in NN O O
highly NN O O
and NN O O
moderately NN O O
conserved NN O O
(50-99%) NN O O
aa; NN O O
relatively NN O O
few NN O O
are NN O O
in NN O O
fully NN O O
conserved NN O O
aa NN O O
(where NN O O
they NN O O
might NN O O
be NN O O
lethal) NN O O
or NN O O
in NN O O
poorly NN O O
conserved NN O O
aa, NN O O
where NN O O
presumably NN O O
they NN O O
simply NN O O
would NN O O
not NN O O
cause NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
. NN O O
this NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
notion NN O O
that NN O O
all NN O O
human NN O O
mutants NN O O
have NN O O
residual NN O O
enzyme NN O O
activity NN O O
and NN O O
that NN O O
null NN O O
mutations NN O O
are NN O O
lethal NN O O
at NN O O
some NN O O
stage NN O O
of NN O O
development. NN O O
comparing NN O O
the NN O O
distribution NN O O
of NN O O
mutations NN O O
in NN O O
a NN O O
human NN O O
housekeeping NN O O
gene NN O O
with NN O O
evolutionary NN O O
conservation NN O O
is NN O O
a NN O O
useful NN O O
tool NN O O
for NN O O
pinpointing NN O O
amino NN O O
acid NN O O
residues NN O O
important NN O O
for NN O O
the NN O O
stability NN O O
or NN O O
the NN O O
function NN O O
of NN O O
the NN O O
corresponding NN O O
protein. NN O O
in NN O O
view NN O O
of NN O O
the NN O O
current NN O O
explosive NN O O
increase NN O O
in NN O O
full NN O O
genome NN O O
sequencing NN O O
projects, NN O O
this NN O O
tool NN O O
will NN O O
become NN O O
rapidly NN O O
available NN O O
for NN O O
numerou NN O O
. NN O O

other NN O O
genes. NN O O
. NN O O

regionally NN O O
clustered NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
severe NN O O
phenotype NN O O
and NN O O
occur NN O O
at NN O O
a NN O O
high NN O O
frequency NN O O
in NN O O
new NN O O
mutation NN O O
cases NN O O
of NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
. NN O O

germline NN O O
mutation NN O O
in NN O O
apc NN O O
at NN O O
5 NN O O
q NN O O
21-22 NN O O
results NN O O
in NN O O
the NN O O
dominantly NN O O
inherited NN O O
syndrome NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
( NN O O
APC NN B-SpecificDisease B-MSH:D011125
). NN O O
somatic NN O O
mutation NN O O
in NN O O
this NN O O
gene NN O O
is NN O O
an NN O O
early NN O O
event NN O O
in NN O O
colorectal NN O O
tumourigenesis. NN O O
both NN O O
types NN O O
of NN O O
mutation NN O O
are NN O O
concentrated NN O O
in NN O O
the NN O O
5 NN O O
half NN O O
of NN O O
exon NN O O
15. NN O O
we NN O O
have NN O O
used NN O O
single NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
(sscp) NN O O
and NN O O
heteroduplex NN O O
analysis NN O O
to NN O O
screen NN O O
for NN O O
variants NN O O
in NN O O
this NN O O
region NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
a NN O O
total NN O O
of NN O O
45 NN O O
affected NN O O
but NN O O
unrelated NN O O
individuals. NN O O
eighteen NN O O
patients NN O O
had NN O O
no NN O O
family NN O O
history NN O O
of NN O O
the NN O O
disease; NN O O
of NN O O
these NN O O
11 NN O O
were NN O O
classified NN O O
as NN O O
having NN O O
a NN O O
severe NN O O
phenotype, NN O O
based NN O O
on NN O O
an NN O O
early NN O O
age NN O O
at NN O O
presentation NN O O
or NN O O
cancer NN B-Modifier B-MSH:D009369
development. NN O O
this NN O O
compared NN O O
with NN O O
6 NN O O
of NN O O
27 NN O O
familial NN O O
cases. NN O O
a NN O O
5 NN O O
bp NN O O
deletion NN O O
at NN O O
codon NN O O
1309 NN O O
reported NN O O
to NN O O
occur NN O O
in NN O O
10-15% NN O O
o NN O O
. NN O O

unselected NN O O
APC NN B-Modifier B-MSH:D011125
patients NN O O
worldwide, NN O O
was NN O O
found NN O O
in NN O O
5 NN O O
of NN O O
the NN O O
18 NN O O
new NN O O
mutation NN O O
cases NN O O
and NN O O
4 NN O O
of NN O O
the NN O O
27 NN O O
familial NN O O
cases NN O O
all NN O O
nine NN O O
were NN O O
classed NN O O
as NN O O
severe. NN O O
a NN O O
further NN O O
3 NN O O
new NN O O
mutations NN O O
and NN O O
1 NN O O
familial NN O O
mutation NN O O
were NN O O
located NN O O
downstream NN O O
from NN O O
codon NN O O
1309, NN O O
these NN O O
individuals NN O O
similarly NN O O
being NN O O
classed NN O O
as NN O O
phenotypically NN O O
severe. NN O O
in NN O O
contrast NN O O
all NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
detected NN O O
in NN O O
affected NN O O
individuals NN O O
with NN O O
an NN O O
average NN O O
phenotype NN O O
were NN O O
located NN O O
prior NN O O
to NN O O
codon NN O O
1309. NN O O
the NN O O
frequent NN O O
association NN O O
of NN O O
a NN O O
severe NN O O
phenotype NN O O
with NN O O
fresh NN O O
mutation NN O O
may NN O O
explain NN O O
the NN O O
apparent NN O O
conflict NN O O
of NN O O
a NN O O
high NN O O
mutation NN O O
rate NN O O
(20-30%) NN O O
in NN O O
a NN O O
condition, NN O O
which NN O O
on NN O O
average, NN O O
is NN O O
lethal NN O O
at NN O O
a NN O O
post-reproductive NN O O
age. NN O O
. NN O O

analysis NN O O
of NN O O
alkaptonuria NN B-Modifier B-MSH:D000474
( NN O O
AKU NN B-Modifier B-MSH:D000474
) NN O O
mutations NN O O
and NN O O
polymorphisms NN O O
reveals NN O O
that NN O O
the NN O O
ccc NN O O
sequence NN O O
motif NN O O
is NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
in NN O O
the NN O O
homogentisate NN O O
1,2 NN O O
dioxygenase NN O O
gene NN O O
(hgo) NN O O
. NN O O

we NN O O
recently NN O O
showed NN O O
that NN O O
alkaptonuria NN B-SpecificDisease B-MSH:D000474
( NN O O
AKU NN B-SpecificDisease B-MSH:D000474
) NN O O
is NN O O
caused NN O O
by NN O O
loss-of-function NN O O
mutations NN O O
in NN O O
the NN O O
homogentisate NN O O
1, NN O O
2 NN O O
dioxygenase NN O O
gene NN O O
(hgo). NN O O
herein NN O O
we NN O O
describe NN O O
haplotype NN O O
and NN O O
mutational NN O O
analyses NN O O
of NN O O
hgo NN O O
in NN O O
seven NN O O
new NN O O
AKU NN B-Modifier B-MSH:D000474
pedigrees. NN O O
these NN O O
analyses NN O O
identified NN O O
two NN O O
novel NN O O
single-nucleotide NN O O
polymorphisms NN O O
(inv NN O O
4 NN O O
+ NN O O
31 NN O O
a-- NN O O
> NN O O
g NN O O
and NN O O
inv NN O O
11 NN O O
+ NN O O
18 NN O O
a-- NN O O
> NN O O
g) NN O O
and NN O O
six NN O O
novel NN O O
AKU NN B-Modifier B-MSH:D000474
mutations NN O O
(inv NN O O
1-1 NN O O
g-- NN O O
> NN O O
a, NN O O
w NN O O
60 NN O O
g, NN O O
y NN O O
62 NN O O
c, NN O O
a NN O O
122 NN O O
d, NN O O
p NN O O
230 NN O O
t, NN O O
and NN O O
d NN O O
291 NN O O
e), NN O O
which NN O O
further NN O O
illustrates NN O O
the NN O O
remarkable NN O O
allelic NN O O
heterogeneity NN O O
found NN O O
in NN O O
AKU NN B-SpecificDisease B-MSH:D000474
. NN O O
reexamination NN O O
of NN O O
all NN O O
29 NN O O
mutations NN O O
and NN O O
polymorphisms NN O O
thus NN O O
far NN O O
described NN O O
in NN O O
hgo NN O O
shows NN O O
that NN O O
these NN O O
nucleotide NN O O
change NN O O
. NN O O

are NN O O
not NN O O
randomly NN O O
distributed; NN O O
the NN O O
ccc NN O O
sequence NN O O
motif NN O O
and NN O O
its NN O O
inverted NN O O
complement, NN O O
ggg, NN O O
are NN O O
preferentially NN O O
mutated. NN O O
these NN O O
analyses NN O O
also NN O O
demonstrated NN O O
that NN O O
the NN O O
nucleotide NN O O
substitutions NN O O
in NN O O
hgo NN O O
do NN O O
not NN O O
involve NN O O
cpg NN O O
dinucleotides, NN O O
which NN O O
illustrates NN O O
important NN O O
differences NN O O
between NN O O
hgo NN O O
and NN O O
other NN O O
genes NN O O
for NN O O
the NN O O
occurrence NN O O
of NN O O
mutation NN O O
at NN O O
specific NN O O
short-sequence NN O O
motifs. NN O O
because NN O O
the NN O O
ccc NN O O
sequence NN O O
motifs NN O O
comprise NN O O
a NN O O
significant NN O O
proportion NN O O
(34. NN O O
5%) NN O O
of NN O O
all NN O O
mutated NN O O
bases NN O O
that NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
hgo, NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
ccc NN O O
triplet NN O O
is NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
in NN O O
hgo NN O O
. NN O O
he NN O O
ccc NN O O
triplet NN O O
is NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
in NN O O
hgo NN O O
. NN O O

further NN O O
evidence NN O O
for NN O O
heterogeneity NN O O
of NN O O
glucose-6-phosphate NN B-SpecificDisease B-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
papua NN O O
new NN O O
guinea NN O O
. NN O O

four NN O O
new NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
have NN O O
been NN O O
characterized NN O O
in NN O O
individuals NN O O
from NN O O
papua NN O O
new NN O O
guinea. NN O O
this NN O O
study NN O O
demonstrates NN O O
that NN O O
the NN O O
previously NN O O
reported NN O O
markham NN O O
variant NN O O
and NN O O
the NN O O
newly NN O O
characterized NN O O
salata NN O O
variant NN O O
may NN O O
be NN O O
widely NN O O
distributed NN O O
in NN O O
papua NN O O
new NN O O
guinea. NN O O
th NN O O
data NN O O
presented NN O O
here NN O O
together NN O O
with NN O O
those NN O O
of NN O O
previously NN O O
published NN O O
studies NN O O
demonstrate NN O O
a NN O O
degree NN O O
of NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
that NN O O
is NN O O
much NN O O
higher NN O O
than NN O O
that NN O O
in NN O O
other NN O O
regions NN O O
of NN O O
the NN O O
world NN O O
where NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
is NN O O
common. NN O O
. NN O O

overgrowth NN O O
of NN O O
oral NN O O
mucosa NN O O
and NN O O
facial NN O O
skin, NN O O
a NN O O
novel NN O O
feature NN O O
of NN O O
aspartylglucosaminuria NN B-SpecificDisease B-MSH:D054880
. NN O O

aspartylglucosaminuria NN O O
( NN O O
AGU NN B-SpecificDisease B-MSH:D054880
) NN O O
is NN O O
a NN O O
lysosomal NN B-DiseaseClass B-MSH:D016464
storage NN I-DiseaseClass I-MSH:D016464
disorder NN I-DiseaseClass I-MSH:D016464
caused NN O O
by NN O O
deficiency NN B-SpecificDisease B-MSH:D054880
of NN I-SpecificDisease I-MSH:D054880
aspartylglucosaminidase NN I-SpecificDisease I-MSH:D054880
(aga). NN O O
the NN O O
main NN O O
symptom NN O O
is NN O O
progressive NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
. NN O O
a NN O O
spectrum NN O O
of NN O O
different NN O O
mutations NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
this NN O O
disease, NN O O
one NN O O
missense NN O O
mutation NN O O
(cys NN O O
163 NN O O
ser) NN O O
being NN O O
responsible NN O O
for NN O O
the NN O O
majority NN O O
of NN O O
finnish NN O O
cases. NN O O
we NN O O
were NN O O
able NN O O
to NN O O
examine NN O O
66 NN O O
finnish NN O O
AGU NN B-Modifier B-MSH:D054880
patients NN O O
for NN O O
changes NN O O
in NN O O
the NN O O
oral NN O O
mucosa NN O O
and NN O O
44 NN O O
of NN O O
these NN O O
for NN O O
changes NN O O
in NN O O
facial NN O O
skin. NN O O
biopsy NN O O
specimens NN O O
of NN O O
16 NN O O
oral NN O O
lesions, NN O O
12 NN O O
of NN O O
them NN O O
associated NN O O
with NN O O
the NN O O
teeth, NN O O
plus NN O O
two NN O O
facial NN B-DiseaseClass B-MSH:D013568
lesions NN I-DiseaseClass I-MSH:D013568
were NN O O
studied NN O O
histologically. NN O O
immunohistochemical NN O O
staining NN O O
for NN O O
aga NN O O
was NN O O
performed NN O O
on NN O O
15 NN O O
oral NN O O
specimens. NN O O
skin NN O O
was NN O O
seborrhoeic NN O O
in NN O O
adolescent NN O O
and NN O O
adult NN O O
patients, NN O O
with NN O O
erythema NN B-SpecificDisease B-MSH:D017445
of NN I-SpecificDisease I-MSH:D017445
the NN I-SpecificDisease I-MSH:D017445
facial NN I-SpecificDisease I-MSH:D017445
skin NN I-SpecificDisease I-MSH:D017445
already NN O O
common NN O O
in NN O O
childhood. NN O O
of NN O O
44 NN O O
patients, NN O O
nine NN O O
. NN O O

20%) NN O O
had NN O O
facial NN B-SpecificDisease B-MSH:D018322
angiofibromas NN I-SpecificDisease I-MSH:D018322
, NN O O
tumours NN B-DiseaseClass B-MSH:D009369
primarily NN O O
occurring NN O O
in NN O O
association NN O O
with NN O O
tuberous NN B-SpecificDisease B-MSH:D014402
sclerosis NN I-SpecificDisease I-MSH:D014402
. NN O O
Oedemic NN B-SpecificDisease B-MSH:D007967
buccal NN I-SpecificDisease I-MSH:D007967
mucosa NN I-SpecificDisease I-MSH:D007967
( NN O O
leucoedema NN B-SpecificDisease B-MSH:D007967
) NN O O
and NN O O
gingival NN B-SpecificDisease B-MSH:D019214
overgrowths NN I-SpecificDisease I-MSH:D019214
were NN O O
more NN O O
frequent NN O O
in NN O O
AGU NN B-Modifier B-MSH:D054880
patients NN O O
than NN O O
in NN O O
controls NN O O
(p NN O O
< NN O O
0. NN O O
001). NN O O
of NN O O
16 NN O O
oral NN B-SpecificDisease B-MSH:D009059
mucosal NN I-SpecificDisease I-MSH:D009059
lesions NN I-SpecificDisease I-MSH:D009059
studied NN O O
histologically, NN O O
15 NN O O
represented NN O O
fibroepithelial NN B-CompositeMention B-MSH:D017573
or NN I-CompositeMention I-MSH:D017573
epithelial NN I-CompositeMention I-MSH:D017573
hyperplasias NN I-CompositeMention I-MSH:D017573
and NN O O
were NN O O
reactive NN O O
in NN O O
nature. NN O O
cytoplasmic NN O O
vacuolisation NN O O
was NN O O
evident NN O O
in NN O O
four. NN O O
immunohistochemically, NN O O
expression NN O O
of NN O O
aga NN O O
in NN O O
AGU NN B-Modifier B-MSH:D054880
patients NN O O
mucosal NN B-SpecificDisease B-MSH:D009059
lesions NN I-SpecificDisease I-MSH:D009059
did NN O O
not NN O O
differ NN O O
from NN O O
that NN O O
seen NN O O
in NN O O
corresponding NN O O
lesions NN O O
of NN O O
normal NN O O
subjects. NN O O
thus, NN O O
the NN O O
high NN O O
frequency NN O O
of NN O O
mucosal NN B-SpecificDisease B-MSH:D009059
overgrowth NN I-SpecificDisease I-MSH:D009059
in NN O O
AGU NN B-Modifier B-MSH:D054880
patients NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
directly NN O O
associated NN O O
with NN O O
lysosomal NN O O
storage NN O O
or NN O O
with NN O O
alterations NN O O
in NN O O
the NN O O
level NN O O
of NN O O
aga NN O O
expression NN O O
. NN O O

molecular NN O O
characterization NN O O
of NN O O
galactosemia NN B-Modifier B-MSH:D005693
(type NN O O
1) NN O O
mutations NN O O
in NN O O
japanese NN O O
. NN O O

we NN O O
characterized NN O O
two NN O O
novel NN O O
mutations NN O O
of NN O O
the NN O O
galactose-1-phosphate NN O O
uridyltransferase NN O O
(galt) NN O O
gene NN O O
in NN O O
two NN O O
japanese NN O O
patients NN O O
with NN O O
GALT NN B-SpecificDisease B-MSH:D005693
deficiency NN I-SpecificDisease I-MSH:D005693
and NN O O
identified NN O O
n NN O O
314 NN O O
d NN O O
and NN O O
r NN O O
333 NN O O
w NN O O
mutations, NN O O
previously NN O O
found NN O O
in NN O O
caucasians. NN O O
one NN O O
novel NN O O
missense NN O O
mutation NN O O
was NN O O
an NN O O
g-to-a NN O O
transition NN O O
in NN O O
exon NN O O
8, NN O O
resulting NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
arginine NN O O
by NN O O
histidine NN O O
at NN O O
the NN O O
codon NN O O
231 NN O O
(r NN O O
231 NN O O
h). NN O O
galt NN O O
activity NN O O
of NN O O
the NN O O
r NN O O
231 NN O O
h NN O O
mutant NN O O
construct NN O O
was NN O O
reduced NN O O
to NN O O
15% NN O O
of NN O O
normal NN O O
controls NN O O
in NN O O
a NN O O
cos NN O O
cell NN O O
expression NN O O
system. NN O O
the NN O O
other NN O O
was NN O O
a NN O O
splicing NN O O
mutation, NN O O
an NN O O
a-to-g NN O O
transition NN O O
at NN O O
the NN O O
38 NN O O
th NN O O
nucleotide NN O O
in NN O O
exon NN O O
3 NN O O
(318 NN O O
a-- NN O O
> NN O O
g), NN O O
resulting NN O O
in NN O O
a NN O O
38-bp NN O O
deletion NN O O
in NN O O
the NN O O
galt NN O O
cdn NN O O
. NN O O

by NN O O
activating NN O O
a NN O O
cryptic NN O O
splice NN O O
acceptor NN O O
site. NN O O
in NN O O
seven NN O O
japanese NN O O
families NN O O
(14 NN O O
alleles NN O O
for NN O O
classic NN O O
form NN O O
and NN O O
one NN O O
allele NN O O
for NN O O
duarte NN O O
variant) NN O O
with NN O O
GALT NN B-SpecificDisease B-MSH:D005693
deficiency NN I-SpecificDisease I-MSH:D005693
, NN O O
the NN O O
r NN O O
231 NN O O
h NN O O
and NN O O
318 NN O O
a-- NN O O
> NN O O
g NN O O
mutations NN O O
were NN O O
found NN O O
only NN O O
on NN O O
both NN O O
alleles NN O O
of NN O O
the NN O O
proband. NN O O
the NN O O
n NN O O
314 NN O O
d NN O O
and NN O O
r NN O O
333 NN O O
w NN O O
mutations NN O O
were NN O O
found NN O O
on NN O O
one NN O O
allele NN O O
each. NN O O
the NN O O
q NN O O
188 NN O O
r NN O O
was NN O O
prevalent NN O O
in NN O O
the NN O O
united NN O O
states NN O O
but NN O O
not NN O O
in NN O O
japanese NN O O
patients. NN O O
the NN O O
n NN O O
314 NN O O
d NN O O
mutation NN O O
was NN O O
associated NN O O
with NN O O
the NN O O
duarte NN O O
variant NN O O
in NN O O
japanese NN O O
persons, NN O O
as NN O O
well NN O O
as NN O O
in NN O O
the NN O O
united NN O O
states. NN O O
we NN O O
speculate NN O O
that NN O O
classic NN B-Modifier B-MSH:D005693
galactosemia NN I-Modifier I-MSH:D005693
mutations NN O O
appear NN O O
to NN O O
differ NN O O
between NN O O
japanese NN O O
and NN O O
caucasian NN O O
patients. NN O O
our NN O O
limited NN O O
data NN O O
set NN O O
on NN O O
galactosemia NN B-Modifier B-MSH:D005693
mutations NN O O
in NN O O
japanese NN O O
suggests NN O O
that NN O O
the NN O O
n NN O O
314 NN O O
d NN O O
galt NN O O
mutation NN O O
encoding NN O O
th NN O O
. NN O O

duarte NN O O
variant NN O O
arose NN O O
before NN O O
asian NN O O
and NN O O
caucasian NN O O
people NN O O
diverged NN O O
and NN O O
that NN O O
classic NN B-Modifier B-MSH:D005693
galactosemia NN I-Modifier I-MSH:D005693
mutations NN O O
arose NN O O
and/or NN O O
accumulated NN O O
after NN O O
the NN O O
divergence NN O O
of NN O O
asian NN O O
and NN O O
caucasian NN O O
populations. NN O O
. NN O O

linkage NN O O
disequilibrium NN O O
mapping NN O O
in NN O O
isolated NN O O
founder NN O O
populations: NN O O
diastrophic NN B-SpecificDisease B-MSH:C536170
dysplasia NN I-SpecificDisease I-MSH:C536170
in NN O O
finland NN O O
. NN O O

linkage NN O O
disequilibrium NN O O
mapping NN O O
in NN O O
isolated NN O O
populations NN O O
provides NN O O
a NN O O
powerful NN O O
tool NN O O
for NN O O
fine NN O O
structure NN O O
localization NN O O
of NN O O
disease NN O O
genes. NN O O
here, NN O O
luria NN O O
and NN O O
delbrucks NN O O
classical NN O O
methods NN O O
for NN O O
analysing NN O O
bacterial NN O O
cultures NN O O
are NN O O
adapted NN O O
to NN O O
the NN O O
study NN O O
of NN O O
human NN O O
isolated NN O O
founder NN O O
populations NN O O
in NN O O
order NN O O
to NN O O
estimate NN O O
(i) NN O O
the NN O O
recombination NN O O
fraction NN O O
between NN O O
a NN O O
disease NN O O
locus NN O O
and NN O O
a NN O O
marker; NN O O
(ii) NN O O
the NN O O
expected NN O O
degree NN O O
of NN O O
allelic NN O O
homogeneity NN O O
in NN O O
a NN O O
population; NN O O
and NN O O
(iii) NN O O
the NN O O
mutation NN O O
rate NN O O
of NN O O
marker NN O O
loci. NN O O
using NN O O
these NN O O
methods, NN O O
we NN O O
report NN O O
striking NN O O
linkage NN O O
disequilibrium NN O O
for NN O O
diastrophic NN B-SpecificDisease B-MSH:C536170
dysplasia NN I-SpecificDisease I-MSH:C536170
( NN O O
DTD NN B-SpecificDisease B-MSH:C536170
) NN O O
in NN O O
finland NN O O
indicating NN O O
that NN O O
the NN O O
DTD NN B-Modifier B-MSH:C536170
gene NN O O
should NN O O
lie NN O O
within NN O O
0. NN O O
06 NN O O
centimorgans NN O O
(or NN O O
about NN O O
60 NN O O
kilobases) NN O O
of NN O O
the NN O O
csf NN O O
1 NN O O
r NN O O
gene. NN O O
predictions NN O O
about NN O O
allelic NN O O
homogeneity NN O O
in NN O O
finland NN O O
and NN O O
mutation NN O O
rates NN O O
in NN O O
simple NN O O
sequence NN O O
repeats NN O O
are NN O O
confirmed NN O O
by NN O O
independen NN O O
. NN O O

observations NN O O
. NN O O

mutations NN O O
in NN O O
tnfrsf NN O O
11 NN O O
a, NN O O
affecting NN O O
the NN O O
signal NN O O
peptide NN O O
of NN O O
rank, NN O O
cause NN O O
familial NN B-SpecificDisease B-OMIM:174810
expansile NN I-SpecificDisease I-OMIM:174810
osteolysis NN I-SpecificDisease I-OMIM:174810
. NN O O

familial NN O O
expansile NN O O
osteolysis NN O O
( NN O O
FEO NN B-SpecificDisease B-OMIM:174810
, NN O O
mim NN O O
174810) NN O O
is NN O O
a NN O O
rare, NN O O
autosomal NN B-DiseaseClass B-MSH:D001847
dominant NN I-DiseaseClass I-MSH:D001847
bone NN I-DiseaseClass I-MSH:D001847
disorder NN I-DiseaseClass I-MSH:D001847
characterized NN O O
by NN O O
focal NN O O
areas NN O O
of NN O O
increased NN B-SpecificDisease B-MSH:D001847
bone NN I-SpecificDisease I-MSH:D001847
remodelling NN I-SpecificDisease I-MSH:D001847
. NN O O
the NN O O
osteolytic NN B-SpecificDisease B-MSH:D030981
lesions NN I-SpecificDisease I-MSH:D030981
, NN O O
which NN O O
develop NN O O
usually NN O O
in NN O O
the NN O O
long NN O O
bones NN O O
during NN O O
early NN O O
adulthood, NN O O
show NN O O
increased NN O O
osteoblast NN O O
and NN O O
osteoclast NN O O
activity. NN O O
our NN O O
previous NN O O
linkage NN O O
studies NN O O
mapped NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
FEO NN B-SpecificDisease B-OMIM:174810
to NN O O
an NN O O
interval NN O O
of NN O O
less NN O O
than NN O O
5 NN O O
cm NN O O
between NN O O
d NN O O
18 NN O O
s NN O O
64 NN O O
and NN O O
d NN O O
18 NN O O
s NN O O
51 NN O O
on NN O O
chromosome NN O O
18 NN O O
q NN O O
21. NN O O
2-21 NN O O
2-21. NN O O
3 NN O O
in NN O O
a NN O O
large NN O O
northern NN O O
irish NN O O
family. NN O O
the NN O O
gene NN O O
encoding NN O O
receptor NN O O
activator NN O O
of NN O O
nuclear NN O O
factor-kappa NN O O
b NN O O
(rank; NN O O
ref. NN O O
5), NN O O
tnfrsf NN O O
11 NN O O
a, NN O O
maps NN O O
to NN O O
this NN O O
region. NN O O
rank NN O O
is NN O O
essential NN O O
in NN O O
osteoclast NN O O
formation. NN O O
we NN O O
identified NN O O
two NN O O
heterozygous NN O O
insertion NN O O
mutations NN O O
in NN O O
exo NN O O
. NN O O

1 NN O O
of NN O O
tnfrsf NN O O
11 NN O O
a NN O O
in NN O O
affected NN O O
members NN O O
of NN O O
four NN O O
families NN O O
with NN O O
FEO NN B-SpecificDisease B-OMIM:174810
or NN O O
familial NN B-SpecificDisease B-MSH:C538098
Paget NN I-SpecificDisease I-MSH:C538098
disease NN I-SpecificDisease I-MSH:C538098
of NN I-SpecificDisease I-MSH:C538098
bone NN I-SpecificDisease I-MSH:C538098
( NN O O
PDB NN B-SpecificDisease B-MSH:C538098
). NN O O
one NN O O
was NN O O
a NN O O
duplication NN O O
of NN O O
18 NN O O
bases NN O O
and NN O O
the NN O O
other NN O O
a NN O O
duplication NN O O
of NN O O
27 NN O O
bases, NN O O
both NN O O
of NN O O
which NN O O
affected NN O O
the NN O O
signal NN O O
peptide NN O O
region NN O O
of NN O O
the NN O O
rank NN O O
molecule. NN O O
expression NN O O
of NN O O
recombinant NN O O
forms NN O O
of NN O O
the NN O O
mutant NN O O
rank NN O O
proteins NN O O
revealed NN O O
perturbations NN O O
in NN O O
expression NN O O
levels NN O O
and NN O O
lack NN O O
of NN O O
normal NN O O
cleavage NN O O
of NN O O
the NN O O
signal NN O O
peptide. NN O O
both NN O O
mutations NN O O
caused NN O O
an NN O O
increase NN O O
in NN O O
rank-mediated NN O O
nuclear NN O O
factor-kappab NN O O
(nf-kappab) NN O O
signalling NN O O
in NN O O
vitro, NN O O
consistent NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
an NN O O
activating NN O O
mutation NN O O
. NN O O

adrenoleukodystrophy-related NN O O
protein NN O O
can NN O O
compensate NN O O
functionally NN O O
for NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
protein NN I-SpecificDisease I-MSH:D000326
deficiency NN I-SpecificDisease I-MSH:D000326
( NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
): NN O O
implications NN O O
for NN O O
therapy NN O O
. NN O O

inherited NN O O
defects NN O O
in NN O O
the NN O O
peroxisomal NN O O
atp-binding NN O O
cassette NN O O
(abc) NN O O
transporter NN O O
adrenoleukodystrophy NN B-Modifier B-MSH:D000326
protein NN O O
(aldp) NN O O
lead NN O O
to NN O O
the NN O O
lethal NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
disorder NN I-DiseaseClass I-MSH:D018901
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
( NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
), NN O O
for NN O O
which NN O O
no NN O O
efficient NN O O
treatment NN O O
has NN O O
been NN O O
established NN O O
so NN O O
far. NN O O
three NN O O
other NN O O
peroxisomal NN O O
abc NN O O
transporters NN O O
currently NN O O
are NN O O
known NN O O
adrenoleukodystrophy-related NN O O
protein NN O O
(aldrp), NN O O
70 NN O O
kda NN O O
peroxisomal NN O O
membrane NN O O
protein NN O O
(pmp NN O O
70) NN O O
and NN O O
pmp NN O O
70- NN O O
related NN O O
protein. NN O O
by NN O O
using NN O O
transient NN O O
and NN O O
stable NN O O
overexpression NN O O
of NN O O
human NN O O
cdnas NN O O
encoding NN O O
aldp NN O O
and NN O O
its NN O O
closest NN O O
relative NN O O
aldrp, NN O O
we NN O O
could NN O O
restore NN O O
the NN O O
impaired NN O O
peroxisomal NN O O
beta-oxidation NN O O
in NN O O
fibroblasts NN O O
of NN O O
X-ALD NN B-Modifier B-MSH:D000326
patients. NN O O
the NN O O
pathognomonic NN O O
accumulation NN O O
of NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
could NN O O
also NN O O
be NN O O
prevented NN O O
by NN O O
overexpression NN O O
of NN O O
aldrp NN O O
in NN O O
immortalized NN O O
x-ald NN O O
cells. NN O O
immunofluorescence NN O O
analysis NN O O
demonstrated NN O O
that NN O O
th NN O O
. NN O O

functional NN O O
replacement NN O O
of NN O O
aldp NN O O
by NN O O
aldrp NN O O
was NN O O
not NN O O
due NN O O
to NN O O
stabilization NN O O
of NN O O
the NN O O
mutated NN O O
aldp NN O O
itself. NN O O
moreover, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
restore NN O O
the NN O O
peroxisomal NN O O
beta-oxidation NN O O
defect NN O O
in NN O O
the NN O O
liver NN O O
of NN O O
aldp-deficient NN O O
mice NN O O
by NN O O
stimulation NN O O
of NN O O
aldrp NN O O
and NN O O
pmp NN O O
70 NN O O
gene NN O O
expression NN O O
through NN O O
a NN O O
dietary NN O O
treatment NN O O
with NN O O
the NN O O
peroxisome NN O O
proliferator NN O O
fenofibrate. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
a NN O O
correction NN O O
of NN O O
the NN O O
biochemical NN O O
defect NN O O
in NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
could NN O O
be NN O O
possible NN O O
by NN O O
drug-induced NN O O
overexpression NN O O
or NN O O
ectopic NN O O
expression NN O O
of NN O O
aldrp. NN O O
. NN O O

the NN O O
normal NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
( NN O O
HD NN B-Modifier B-MSH:D006816
) NN O O
allele, NN O O
or NN O O
a NN O O
closely NN O O
linked NN O O
gene, NN O O
influences NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O

we NN O O
evaluated NN O O
the NN O O
hypothesis NN O O
that NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
is NN O O
influenced NN O O
by NN O O
the NN O O
normal NN O O
HD NN B-Modifier B-MSH:D006816
allele NN O O
by NN O O
comparing NN O O
transmission NN O O
patterns NN O O
of NN O O
genetically NN O O
linked NN O O
markers NN O O
at NN O O
the NN O O
d NN O O
4 NN O O
s NN O O
10 NN O O
locus NN O O
in NN O O
the NN O O
normal NN O O
parent NN O O
against NN O O
age NN O O
at NN O O
onset NN O O
in NN O O
the NN O O
affected NN O O
offspring. NN O O
analysis NN O O
of NN O O
information NN O O
from NN O O
21 NN O O
sibships NN O O
in NN O O
14 NN O O
kindreds NN O O
showed NN O O
a NN O O
significant NN O O
tendency NN O O
for NN O O
sibs NN O O
who NN O O
have NN O O
similar NN O O
onset NN O O
ages NN O O
to NN O O
share NN O O
the NN O O
same NN O O
d NN O O
4 NN O O
s NN O O
10 NN O O
allele NN O O
from NN O O
the NN O O
normal NN O O
parent. NN O O
affected NN O O
sibs NN O O
who NN O O
inherited NN O O
different NN O O
d NN O O
4 NN O O
s NN O O
10 NN O O
alleles NN O O
from NN O O
the NN O O
normal NN O O
parent NN O O
tended NN O O
to NN O O
have NN O O
more NN O O
variable NN O O
ages NN O O
at NN O O
onset. NN O O
these NN O O
findings NN O O
suggest NN O O
that NN O O
the NN O O
expression NN O O
of NN O O
HD NN B-SpecificDisease B-MSH:D006816
is NN O O
modulated NN O O
by NN O O
the NN O O
normal NN O O
HD NN B-Modifier B-MSH:D006816
allele NN O O
or NN O O
by NN O O
a NN O O
closely NN O O
linked NN O O
locus. NN O O
. NN O O

synergistic NN O O
effect NN O O
of NN O O
histone NN O O
hyperacetylation NN O O
and NN O O
dna NN O O
demethylation NN O O
in NN O O
the NN O O
reactivation NN O O
of NN O O
the NN O O
fmr NN O O
1 NN O O
gene NN O O
. NN O O

most NN O O
fragile NN B-Modifier B-MSH:D005600
X NN I-Modifier I-MSH:D005600
syndrome NN I-Modifier I-MSH:D005600
patients NN O O
have NN O O
expansion NN O O
of NN O O
a NN O O
(cgg) NN O O
(n) NN O O
sequence NN O O
with NN O O
> NN O O
200 NN O O
repeats NN O O
(full NN O O
mutation) NN O O
in NN O O
the NN O O
fmr NN O O
1 NN O O
gene NN O O
responsible NN O O
for NN O O
this NN O O
condition. NN O O
hypermethylation NN O O
of NN O O
the NN O O
expanded NN O O
repeat NN O O
and NN O O
of NN O O
the NN O O
fmr NN O O
1 NN O O
promoter NN O O
is NN O O
almost NN O O
always NN O O
present NN O O
and NN O O
apparently NN O O
suppresses NN O O
transcription, NN O O
resulting NN O O
in NN O O
absence NN O O
of NN O O
the NN O O
fmr NN O O
1 NN O O
protein. NN O O
we NN O O
recently NN O O
showed NN O O
that NN O O
transcriptional NN O O
reactivation NN O O
of NN O O
fmr NN O O
1 NN O O
full NN O O
mutations NN O O
can NN O O
be NN O O
achieved NN O O
by NN O O
inducing NN O O
dna NN O O
demethylation NN O O
with NN O O
5-azadeoxycytidine NN O O
(5-azadc). NN O O
the NN O O
level NN O O
of NN O O
histone NN O O
acetylation NN O O
is NN O O
another NN O O
important NN O O
factor NN O O
in NN O O
regulating NN O O
gene NN O O
expression; NN O O
therefore, NN O O
we NN O O
treated NN O O
lymphoblastoid NN O O
cell NN O O
lines NN O O
of NN O O
non-mosaic NN O O
full NN O O
mutation NN O O
patients NN O O
with NN O O
three NN O O
drugs NN O O
capable NN O O
of NN O O
inducing NN O O
histone NN O O
hyperacetylation. NN O O
we NN O O
observed NN O O
a NN O O
consistent, NN O O
although NN O O
modest, NN O O
reactivation NN O O
of NN O O
the NN O O
fm NN O O
. NN O O

1 NN O O
gene NN O O
with NN O O
4-phenylbutyrate, NN O O
sodium NN O O
butyrate NN O O
and NN O O
trichostatin NN O O
a, NN O O
as NN O O
shown NN O O
by NN O O
rt-pcr. NN O O
however, NN O O
we NN O O
report NN O O
that NN O O
combining NN O O
these NN O O
drugs NN O O
with NN O O
5-azadc NN O O
results NN O O
in NN O O
a NN O O
2- NN O O
to NN O O
5-fold NN O O
increase NN O O
in NN O O
fmr NN O O
1 NN O O
mrna NN O O
levels NN O O
obtained NN O O
with NN O O
5-azadc NN O O
alone, NN O O
thus NN O O
showing NN O O
a NN O O
marked NN O O
synergistic NN O O
effect NN O O
of NN O O
histone NN O O
hyperacetylation NN O O
and NN O O
dna NN O O
demethylation NN O O
in NN O O
the NN O O
reactivation NN O O
of NN O O
fmr NN O O
1 NN O O
full NN O O
mutations. NN O O
. NN O O
yrate, NN O O
sodium NN O O
butyrate NN O O
and NN O O
trichostatin NN O O
a, NN O O
as NN O O
shown NN O O
by NN O O
rt-pcr. NN O O
however, NN O O
we NN O O
report NN O O
that NN O O
combining NN O O
these NN O O
drugs NN O O
with NN O O
5-azadc NN O O
results NN O O
in NN O O
a NN O O
2- NN O O
to NN O O
5-fold NN O O
increase NN O O
in NN O O
fmr NN O O
1 NN O O
mrna NN O O
levels NN O O
obtained NN O O
with NN O O
5-azadc NN O O
alone, NN O O
thus NN O O
showing NN O O
a NN O O
marked NN O O
synergistic NN O O
effect NN O O
of NN O O
histone NN O O
hyperacetylation NN O O
and NN O O
dna NN O O
demethylation NN O O
in NN O O
the NN O O
reactivation NN O O
of NN O O
fmr NN O O
1 NN O O
full NN O O
mutations. NN O O
. NN O O

genetic NN O O
heterogeneity NN O O
in NN O O
X-linked NN B-SpecificDisease B-MSH:C538243
amelogenesis NN I-SpecificDisease I-MSH:C538243
imperfecta NN I-SpecificDisease I-MSH:C538243
. NN O O

the NN O O
amelx NN O O
gene NN O O
located NN O O
at NN O O
xp NN O O
22. NN O O
1-p NN O O
22. NN O O
3 NN O O
encodes NN O O
for NN O O
the NN O O
enamel NN O O
protein NN O O
amelogenin NN O O
and NN O O
has NN O O
been NN O O
implicated NN O O
as NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
the NN O O
inherited NN B-DiseaseClass B-MSH:D014071
dental NN I-DiseaseClass I-MSH:D014071
abnormality NN I-DiseaseClass I-MSH:D014071
X-linked NN B-SpecificDisease B-MSH:C538243
amelogenesis NN I-SpecificDisease I-MSH:C538243
imperfecta NN I-SpecificDisease I-MSH:C538243
( NN O O
XAI NN B-SpecificDisease B-MSH:C538243
). NN O O
three NN O O
families NN O O
with NN O O
XAI NN B-SpecificDisease B-MSH:C538243
have NN O O
been NN O O
investigated NN O O
using NN O O
polymorphic NN O O
dna NN O O
markers NN O O
flanking NN O O
the NN O O
position NN O O
of NN O O
amelx. NN O O
using NN O O
two-point NN O O
linkage NN O O
analysis, NN O O
linkage NN O O
was NN O O
established NN O O
between NN O O
XAI NN B-SpecificDisease B-MSH:C538243
and NN O O
several NN O O
of NN O O
these NN O O
markers NN O O
in NN O O
two NN O O
families, NN O O
with NN O O
a NN O O
combined NN O O
lod NN O O
score NN O O
of NN O O
6. NN O O
05 NN O O
for NN O O
dxs NN O O
16 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
04 NN O O
04. NN O O
this NN O O
supports NN O O
the NN O O
involvement NN O O
of NN O O
amelx, NN O O
located NN O O
close NN O O
to NN O O
dxs NN O O
16, NN O O
in NN O O
the NN O O
XAI NN B-SpecificDisease B-MSH:C538243
disease NN I-SpecificDisease I-MSH:C538243
process NN O O
(aih NN O O
1) NN O O
in NN O O
those NN O O
families. NN O O
using NN O O
multipoint NN O O
linkage NN O O
analysis, NN O O
the NN O O
combined NN O O
maximum NN O O
lod NN O O
score NN O O
for NN O O
these NN O O
two NN O O
familie NN O O
. NN O O

was NN O O
7. NN O O
30 NN O O
for NN O O
a NN O O
location NN O O
of NN O O
aih NN O O
1 NN O O
at NN O O
2 NN O O
cm NN O O
distal NN O O
to NN O O
dxs NN O O
16. NN O O
the NN O O
support NN O O
interval NN O O
around NN O O
this NN O O
location NN O O
extended NN O O
about NN O O
8 NN O O
cm NN O O
proximal NN O O
to NN O O
dxs NN O O
92, NN O O
and NN O O
the NN O O
aih NN O O
1 NN O O
location NN O O
could NN O O
not NN O O
be NN O O
precisely NN O O
defined NN O O
by NN O O
multipoint NN O O
mapping. NN O O
study NN O O
of NN O O
recombination NN O O
events NN O O
indicated NN O O
that NN O O
aih NN O O
1 NN O O
lies NN O O
in NN O O
the NN O O
interval NN O O
between NN O O
dxs NN O O
143 NN O O
and NN O O
dxs NN O O
85. NN O O
there NN O O
was NN O O
significant NN O O
evidence NN O O
against NN O O
linkage NN O O
to NN O O
this NN O O
region NN O O
in NN O O
the NN O O
third NN O O
family, NN O O
indicating NN O O
locus NN O O
heterogeneity NN O O
in NN O O
XAI NN B-SpecificDisease B-MSH:C538243
. NN O O
further NN O O
analysis NN O O
with NN O O
markers NN O O
on NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome NN O O
showed NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
dxs NN O O
144 NN O O
e NN O O
and NN O O
f NN O O
9 NN O O
with NN O O
no NN O O
recombination NN O O
with NN O O
either NN O O
of NN O O
these NN O O
markers. NN O O
two-point NN O O
analysis NN O O
gave NN O O
a NN O O
peak NN O O
lod NN O O
score NN O O
at NN O O
dxs NN O O
144 NN O O
e NN O O
with NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
2. NN O O
8 NN O O
. NN O O

at NN O O
theta NN O O
= NN O O
0, NN O O
with NN O O
a NN O O
peak NN O O
lod NN O O
score NN O O
in NN O O
multipoint NN O O
linkage NN O O
analysis NN O O
of NN O O
2. NN O O
84 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
the NN O O
support NN O O
interval NN O O
extended NN O O
9 NN O O
cm NN O O
proximal NN O O
to NN O O
dxs NN O O
144 NN O O
e NN O O
and NN O O
14 NN O O
cm NN O O
distal NN O O
to NN O O
f NN O O
9. NN O O
(abstract NN O O
truncated NN O O
at NN O O
250 NN O O
words) NN O O
. NN O O

anonymous NN O O
marker NN O O
loci NN O O
within NN O O
400 NN O O
kb NN O O
of NN O O
hla-a NN O O
generate NN O O
haplotypes NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
the NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
gene NN O O
(hfe) NN O O
the NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
gene NN O O
(hfe) NN O O
maps NN O O
to NN O O
6 NN O O
p NN O O
21. NN O O
3 NN O O
and NN O O
is NN O O
less NN O O
than NN O O
1 NN O O
cm NN O O
from NN O O
the NN O O
hla NN O O
class NN O O
i NN O O
genes; NN O O
however, NN O O
the NN O O
precise NN O O
physical NN O O
location NN O O
of NN O O
the NN O O
gene NN O O
has NN O O
remained NN O O
elusive NN O O
and NN O O
controversial. NN O O
the NN O O
unambiguous NN O O
identification NN O O
of NN O O
a NN O O
crossover NN O O
event NN O O
within NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
families NN O O
is NN O O
very NN O O
difficult; NN O O
it NN O O
is NN O O
particularly NN O O
hampered NN O O
by NN O O
the NN O O
variability NN O O
of NN O O
the NN O O
phenotypic NN O O
expression NN O O
as NN O O
well NN O O
as NN O O
by NN O O
the NN O O
sex- NN O O
and NN O O
age-related NN O O
penetrance NN O O
of NN O O
the NN O O
disease. NN O O
for NN O O
these NN O O
practical NN O O
considerations, NN O O
traditional NN O O
linkage NN O O
analysis NN O O
could NN O O
prove NN O O
of NN O O
limited NN O O
value NN O O
in NN O O
further NN O O
refining NN O O
the NN O O
extrapolated NN O O
physical NN O O
position NN O O
of NN O O
hfe. NN O O
we NN O O
therefore NN O O
embarked NN O O
upon NN O O
a NN O O
linkage-disequilibrium NN O O
analysis NN O O
of NN O O
hfe NN O O
and NN O O
norma NN O O
. NN O O

chromosomes NN O O
from NN O O
the NN O O
brittany NN O O
population. NN O O
in NN O O
the NN O O
present NN O O
report, NN O O
66 NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
families NN O O
yielding NN O O
151 NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
chromosomes NN O O
and NN O O
182 NN O O
normal NN O O
chromosomes NN O O
were NN O O
rflp-typed NN O O
with NN O O
a NN O O
battery NN O O
of NN O O
probes, NN O O
including NN O O
two NN O O
newly NN O O
derived NN O O
polymorphic NN O O
markers NN O O
from NN O O
the NN O O
6. NN O O
7 NN O O
and NN O O
hla-f NN O O
loci NN O O
located NN O O
150 NN O O
and NN O O
250 NN O O
kb NN O O
telomeric NN O O
to NN O O
hla-a, NN O O
respectively. NN O O
the NN O O
results NN O O
suggest NN O O
a NN O O
strong NN O O
peak NN O O
of NN O O
existing NN O O
linkage NN O O
disequilibrium NN O O
focused NN O O
within NN O O
the NN O O
i NN O O
82-to-6. NN O O
7 NN O O
interval NN O O
(approximately NN O O
250 NN O O
kb). NN O O
the NN O O
zone NN O O
of NN O O
linkage NN O O
disequilibrium NN O O
is NN O O
flanked NN O O
by NN O O
the NN O O
i NN O O
97 NN O O
locus, NN O O
positioned NN O O
30 NN O O
kb NN O O
proximal NN O O
to NN O O
i NN O O
82, NN O O
and NN O O
the NN O O
hla-f NN O O
gene, NN O O
found NN O O
250 NN O O
kb NN O O
distal NN O O
to NN O O
hla-a, NN O O
markers NN O O
of NN O O
which NN O O
display NN O O
no NN O O
significant NN O O
association NN O O
with NN O O
hfe. NN O O
these NN O O
data NN O O
support NN O O
th NN O O
. NN O O

possibility NN O O
that NN O O
hfe NN O O
resides NN O O
within NN O O
the NN O O
400-kb NN O O
expanse NN O O
of NN O O
dna NN O O
between NN O O
i NN O O
97 NN O O
and NN O O
hla-f. NN O O
alternatively, NN O O
the NN O O
very NN O O
tight NN O O
association NN O O
of NN O O
hla-a NN O O
3 NN O O
and NN O O
allele NN O O
1 NN O O
of NN O O
the NN O O
6. NN O O
7 NN O O
locus, NN O O
both NN O O
of NN O O
which NN O O
are NN O O
comprised NN O O
by NN O O
the NN O O
major NN O O
ancestral NN O O
or NN O O
founder NN O O
hfe NN O O
haplotype NN O O
in NN O O
brittany, NN O O
supports NN O O
the NN O O
possibility NN O O
that NN O O
the NN O O
disease NN O O
gene NN O O
may NN O O
reside NN O O
immediately NN O O
telomeric NN O O
to NN O O
the NN O O
6. NN O O
7 NN O O
locus NN O O
within NN O O
the NN O O
linkage-disequilibrium NN O O
zone. NN O O
additionally, NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
haplotypes NN O O
possessing NN O O
hla-a NN O O
11 NN O O
and NN O O
the NN O O
low-frequency NN O O
hla-f NN O O
polymorphism NN O O
(allele NN O O
2) NN O O
are NN O O
supportive NN O O
of NN O O
a NN O O
separate NN O O
founder NN O O
chromosome NN O O
containing NN O O
a NN O O
second, NN O O
independently NN O O
arising NN O O
mutant NN O O
allele. NN O O
overall, NN O O
the NN O O
establishment NN O O
of NN O O
a NN O O
likely NN O O
" NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
critical NN O O
region NN O O
" NN O O
centromeric NN O O
boundary NN O O
and NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
linkage NN O O
. NN O O

disequilibrium NN O O
zone NN O O
both NN O O
significantly NN O O
contribute NN O O
to NN O O
a NN O O
reduction NN O O
in NN O O
the NN O O
amount NN O O
of NN O O
dna NN O O
required NN O O
to NN O O
be NN O O
searched NN O O
for NN O O
novel NN O O
coding NN O O
sequences NN O O
constituting NN O O
the NN O O
HFE NN B-SpecificDisease B-MSH:D006432
defect NN I-SpecificDisease I-MSH:D006432
. NN O O

natural NN O O
selection NN O O
of NN O O
hemi- NN O O
and NN O O
heterozygotes NN O O
for NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
africa NN O O
by NN O O
resistance NN O O
to NN O O
severe NN O O
malaria NN B-SpecificDisease B-MSH:D008288
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
deficiency, NN O O
the NN O O
most NN O O
common NN O O
enzymopathy NN B-DiseaseClass B-MSH:D008661
of NN O O
humans, NN O O
affects NN O O
over NN O O
400 NN O O
million NN O O
people. NN O O
the NN O O
geographical NN O O
correlation NN O O
of NN O O
its NN O O
distribution NN O O
with NN O O
the NN O O
historical NN O O
endemicity NN O O
of NN O O
malaria NN B-SpecificDisease B-MSH:D008288
suggests NN O O
that NN O O
this NN O O
disorder NN O O
has NN O O
risen NN O O
in NN O O
frequency NN O O
through NN O O
natural NN O O
selection NN O O
by NN O O
malaria NN B-SpecificDisease B-MSH:D008288
. NN O O
however, NN O O
attempts NN O O
to NN O O
confirm NN O O
that NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
is NN O O
protective NN O O
in NN O O
case-control NN O O
studies NN O O
of NN O O
malaria NN B-SpecificDisease B-MSH:D008288
have NN O O
yielded NN O O
conflicting NN O O
results. NN O O
hence, NN O O
for NN O O
this NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
, NN O O
it NN O O
is NN O O
unclear NN O O
whether NN O O
both NN O O
male NN O O
hemizygotes NN O O
and NN O O
female NN O O
heterozygotes NN O O
are NN O O
protected NN O O
or, NN O O
as NN O O
frequently NN O O
suggested, NN O O
only NN O O
females. NN O O
furthermore, NN O O
how NN O O
much NN O O
protection NN O O
may NN O O
be NN O O
afforded NN O O
is NN O O
unknown. NN O O
here NN O O
we NN O O
report NN O O
that, NN O O
in NN O O
two NN O O
large NN O O
case-control NN O O
studies NN O O
of NN O O
over NN O O
2, NN O O
000 NN O O
african NN O O
children, NN O O
the NN O O
common NN O O
africa NN O O
. NN O O

form NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
( NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
A- NN I-SpecificDisease I-MSH:D005955
) NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
46-58% NN O O
reduction NN O O
in NN O O
risk NN O O
of NN O O
severe NN O O
malaria NN B-SpecificDisease B-MSH:D008288
for NN O O
both NN O O
female NN O O
heterozygotes NN O O
and NN O O
male NN O O
hemizygotes. NN O O
a NN O O
mathematical NN O O
model NN O O
incorporating NN O O
the NN O O
measured NN O O
selective NN O O
advantage NN O O
against NN O O
malaria NN B-SpecificDisease B-MSH:D008288
suggests NN O O
that NN O O
a NN O O
counterbalancing NN O O
selective NN O O
disadvantage, NN O O
associated NN O O
with NN O O
this NN O O
enzyme NN B-DiseaseClass B-MSH:D008661
deficiency NN I-DiseaseClass I-MSH:D008661
, NN O O
has NN O O
retarded NN O O
its NN O O
rise NN O O
in NN O O
frequency NN O O
in NN O O
malaria NN B-Modifier B-MSH:D008288
-endemic NN O O
regions. NN O O
although NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
is NN O O
now NN O O
regarded NN O O
as NN O O
a NN O O
generally NN O O
benign NN O O
disorder, NN O O
in NN O O
earlier NN O O
environmental NN O O
conditions NN O O
it NN O O
could NN O O
have NN O O
been NN O O
significantly NN O O
disadvantageous. NN O O
. NN O O

prader-willi NN O O
syndrome NN O O
and NN O O
chromosome NN O O
15. NN O O
a NN O O
clinical NN O O
discussion NN O O
of NN O O
20 NN O O
cases NN O O
. NN O O

a NN O O
chromosome NN B-SpecificDisease B-MSH:D002869
15 NN I-SpecificDisease I-MSH:D002869
anomaly NN I-SpecificDisease I-MSH:D002869
was NN O O
observed NN O O
in NN O O
12 NN O O
of NN O O
20 NN O O
patients, NN O O
17 NN O O
of NN O O
whom NN O O
were NN O O
clinically NN O O
suspected NN O O
of NN O O
having NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
the NN O O
clinical NN O O
features NN O O
of NN O O
eight NN O O
cases NN O O
with NN O O
15 NN O O
q NN O O
11-12 NN O O
deletion NN O O
were NN O O
very NN O O
similar NN O O
to NN O O
those NN O O
originally NN O O
described NN O O
in NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
on NN O O
the NN O O
other NN O O
hand, NN O O
the NN O O
group NN O O
of NN O O
normal NN O O
karyotype NN O O
patients NN O O
is NN O O
heterogeneous, NN O O
and NN O O
their NN O O
features NN O O
do NN O O
not NN O O
strictly NN O O
correspond NN O O
to NN O O
the NN O O
clinical NN O O
definition NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
however, NN O O
the NN O O
hypothesis NN O O
that NN O O
PWS NN B-SpecificDisease B-MSH:D011218
is NN O O
associated NN O O
with NN O O
deletion NN O O
of NN O O
15 NN O O
q NN O O
11-12 NN O O
can NN O O
neither NN O O
explain NN O O
the NN O O
apparently NN O O
balanced NN O O
translocations NN O O
of NN O O
chromosome NN O O
15 NN O O
nor NN O O
account NN O O
for NN O O
the NN O O
small NN O O
supernumerary NN O O
metacentric NN O O
chromosomes NN O O
corresponding NN O O
to NN O O
an NN O O
isochromosome NN O O
15 NN O O
for NN O O
band NN O O
15 NN O O
q NN O O
11 NN O O
observed NN O O
in NN O O
some NN O O
cases. NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
and NN O O
related NN O O
hyperphenylalaninemias NN B-DiseaseClass B-MSH:D010661
: NN O O
mutations NN O O
and NN O O
polymorphisms NN O O
in NN O O
the NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
producing NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
or NN O O
hyperphenylalaninemia NN B-DiseaseClass B-MSH:D010661
have NN O O
now NN O O
been NN O O
identified NN O O
in NN O O
many NN O O
patients NN O O
from NN O O
various NN O O
ethnic NN O O
groups. NN O O
these NN O O
mutations NN O O
all NN O O
exhibit NN O O
a NN O O
high NN O O
degree NN O O
of NN O O
association NN O O
with NN O O
specific NN O O
restriction NN O O
fragment-length NN O O
polymorphism NN O O
haplotypes NN O O
at NN O O
the NN O O
pah NN O O
locus. NN O O
about NN O O
50 NN O O
of NN O O
these NN O O
mutations NN O O
are NN O O
single-base NN O O
substitutions, NN O O
including NN O O
six NN O O
nonsense NN O O
mutations NN O O
and NN O O
eight NN O O
splicing NN O O
mutations, NN O O
with NN O O
the NN O O
remainder NN O O
being NN O O
missense NN O O
mutations. NN O O
one NN O O
splicing NN O O
mutation NN O O
results NN O O
in NN O O
a NN O O
3 NN O O
amino NN O O
acid NN O O
in-frame NN O O
insertion. NN O O
two NN O O
or NN O O
3 NN O O
large NN O O
deletions, NN O O
2 NN O O
single NN O O
codon NN O O
deletions, NN O O
and NN O O
2 NN O O
single NN O O
base NN O O
deletions NN O O
have NN O O
been NN O O
found. NN O O
twelve NN O O
of NN O O
the NN O O
missense NN O O
mutations NN O O
apparently NN O O
result NN O O
from NN O O
the NN O O
methylation NN O O
and NN O O
subsequent NN O O
deamination NN O O
of NN O O
highly NN O O
mutagenic NN O O
cpg NN O O
dinucleotides. NN O O
recurrent NN O O
mutation NN O O
has NN O O
been NN O O
observed NN O O
at NN O O
several NN O O
of NN O O
these NN O O
sites, NN O O
producing NN O O
associations NN O O
with NN O O
differen NN O O
. NN O O

haplotypes NN O O
in NN O O
different NN O O
populations. NN O O
about NN O O
half NN O O
of NN O O
all NN O O
missense NN O O
mutations NN O O
have NN O O
been NN O O
examined NN O O
by NN O O
in NN O O
vitro NN O O
expression NN O O
analysis, NN O O
and NN O O
a NN O O
significant NN O O
correlation NN O O
has NN O O
been NN O O
observed NN O O
between NN O O
residual NN O O
pah NN O O
activity NN O O
and NN O O
disease NN O O
phenotype. NN O O
since NN O O
continuing NN O O
advances NN O O
in NN O O
molecular NN O O
methodologies NN O O
have NN O O
dramatically NN O O
accelerated NN O O
the NN O O
rate NN O O
in NN O O
which NN O O
new NN O O
mutations NN O O
are NN O O
being NN O O
identified NN O O
and NN O O
characterized, NN O O
this NN O O
register NN O O
of NN O O
mutations NN O O
will NN O O
be NN O O
updated NN O O
periodically. NN O O
. NN O O
expression NN O O
analysis, NN O O
and NN O O
a NN O O
significant NN O O
correlation NN O O
has NN O O
been NN O O
observed NN O O
between NN O O
residual NN O O
pah NN O O
activity NN O O
and NN O O
disease NN O O
phenotype. NN O O
since NN O O
continuing NN O O
advances NN O O
in NN O O
molecular NN O O
methodologies NN O O
have NN O O
dramatically NN O O
accelerated NN O O
the NN O O
rate NN O O
in NN O O
which NN O O
new NN O O
mutations NN O O
are NN O O
being NN O O
identified NN O O
and NN O O
characterized, NN O O
this NN O O
register NN O O
of NN O O
mutations NN O O
will NN O O
be NN O O
updated NN O O
periodically. NN O O
. NN O O

the NN O O
intron NN O O
7 NN O O
donor NN O O
splice NN O O
site NN O O
transition: NN O O
a NN O O
second NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
mutation NN O O
in NN O O
french NN O O
canada NN O O
. NN O O

mutations NN O O
at NN O O
the NN O O
hexosaminidase NN O O
a NN O O
(hexa) NN O O
gene NN O O
which NN O O
cause NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
) NN O O
have NN O O
elevated NN O O
frequency NN O O
in NN O O
the NN O O
ashkenazi NN O O
jewish NN O O
and NN O O
french-canadian NN O O
populations. NN O O
we NN O O
report NN O O
a NN O O
novel NN O O
TSD NN B-Modifier B-MSH:D013661
allele NN O O
in NN O O
the NN O O
french-canadian NN O O
population NN O O
associated NN O O
with NN O O
the NN O O
infantile NN O O
form NN O O
of NN O O
the NN O O
disease. NN O O
the NN O O
mutation, NN O O
a NN O O
g-- NN O O
> NN O O
a NN O O
transition NN O O
at NN O O
the NN O O
+ NN O O
1 NN O O
position NN O O
of NN O O
intron NN O O
7, NN O O
abolishes NN O O
the NN O O
donor NN O O
splice NN O O
site. NN O O
cultured NN O O
human NN O O
fibroblasts NN O O
from NN O O
a NN O O
compound NN O O
heterozygote NN O O
for NN O O
this NN O O
transition NN O O
(and NN O O
for NN O O
a NN O O
deletion NN O O
mutation) NN O O
produce NN O O
no NN O O
detectable NN O O
hexa NN O O
mrna. NN O O
the NN O O
intron NN O O
7 NN O O
+ NN O O
1 NN O O
mutation NN O O
occurs NN O O
in NN O O
the NN O O
base NN O O
adjacent NN O O
to NN O O
the NN O O
site NN O O
of NN O O
the NN O O
adult-onset NN O O
TSD NN B-Modifier B-MSH:D013661
mutation NN O O
(g NN O O
805 NN O O
a). NN O O
in NN O O
both NN O O
mutations NN O O
a NN O O
restriction NN O O
site NN O O
for NN O O
the NN O O
endonuclease NN O O
ecorii NN O O
is NN O O
abolished NN O O
. NN O O

unambiguous NN O O
diagnosis, NN O O
therefore, NN O O
requires NN O O
allele-specific NN O O
oligonucleotide NN O O
hybridization NN O O
to NN O O
distinguish NN O O
between NN O O
these NN O O
two NN O O
mutant NN O O
alleles. NN O O
the NN O O
intron NN O O
7 NN O O
+ NN O O
1 NN O O
mutation NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
three NN O O
unrelated NN O O
families. NN O O
obligate NN O O
heterozygotes NN O O
for NN O O
the NN O O
intron NN O O
7 NN O O
+ NN O O
1 NN O O
mutation NN O O
were NN O O
born NN O O
in NN O O
the NN O O
saguenay-lac-st-jean NN O O
region NN O O
of NN O O
quebec. NN O O
the NN O O
most NN O O
recent NN O O
ancestors NN O O
common NN O O
to NN O O
obligate NN O O
carriers NN O O
of NN O O
this NN O O
mutation NN O O
were NN O O
from NN O O
the NN O O
charlevoix NN O O
region NN O O
of NN O O
the NN O O
province NN O O
of NN O O
quebec. NN O O
this NN O O
mutation NN O O
thus NN O O
has NN O O
a NN O O
different NN O O
geographic NN O O
centre NN O O
of NN O O
diffusion NN O O
and NN O O
is NN O O
probably NN O O
less NN O O
common NN O O
than NN O O
the NN O O
exon NN O O
1 NN O O
deletion NN O O
TSD NN B-Modifier B-MSH:D013661
mutation NN O O
in NN O O
french NN O O
canadians. NN O O
neither NN O O
mutation NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
france, NN O O
the NN O O
ancestral NN O O
homeland NN O O
of NN O O
french NN O O
canada. NN O O
. NN O O

recessively NN O O
inherited NN O O
multiple NN B-SpecificDisease B-MSH:D010009
epiphyseal NN I-SpecificDisease I-MSH:D010009
dysplasia NN I-SpecificDisease I-MSH:D010009
with NN O O
normal NN O O
stature, NN O O
club NN B-SpecificDisease B-MSH:D003025
foot NN I-SpecificDisease I-MSH:D003025
, NN O O
and NN O O
double NN B-DiseaseClass B-MSH:C535504
layered NN I-DiseaseClass I-MSH:C535504
patella NN I-DiseaseClass I-MSH:C535504
caused NN O O
by NN O O
a NN O O
dtdst NN O O
mutation NN O O
. NN O O

we NN O O
have NN O O
observed NN O O
over NN O O
25 NN O O
different NN O O
mutations NN O O
in NN O O
the NN O O
diastrophic NN B-Modifier B-MSH:C536170
dysplasia NN I-Modifier I-MSH:C536170
sulphate NN O O
transporter NN O O
gene NN O O
(dtdst) NN O O
in NN O O
association NN O O
with NN O O
the NN O O
recessive NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
achondrogenesis NN B-SpecificDisease B-MSH:C536016
1B NN I-SpecificDisease I-MSH:C536016
, NN O O
atelosteogenesis NN B-SpecificDisease B-MSH:C535395
2 NN I-SpecificDisease I-MSH:C535395
, NN O O
and NN O O
diastrophic NN B-SpecificDisease B-MSH:C536170
dysplasia NN I-SpecificDisease I-MSH:C536170
. NN O O
the NN O O
c NN O O
862 NN O O
t NN O O
(r NN O O
279 NN O O
w) NN O O
transition NN O O
is NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
non-finnish NN O O
patients, NN O O
but NN O O
in NN O O
these NN O O
disorders NN O O
it NN O O
is NN O O
usually NN O O
combined NN O O
with NN O O
other NN O O
dtdst NN O O
mutations. NN O O
we NN O O
had NN O O
not NN O O
seen NN O O
a NN O O
case NN O O
of NN O O
homozygosity NN O O
for NN O O
c NN O O
862 NN O O
t NN O O
(r NN O O
279 NN O O
w) NN O O
until NN O O
we NN O O
analysed NN O O
dna NN O O
from NN O O
a NN O O
36 NN O O
year NN O O
old NN O O
male NN O O
with NN O O
tall-normal NN O O
stature NN O O
(180 NN O O
cm) NN O O
who NN O O
asked NN O O
for NN O O
genetic NN O O
counselling NN O O
for NN O O
suspected NN O O
multiple NN B-SpecificDisease B-MSH:D010009
epiphyseal NN I-SpecificDisease I-MSH:D010009
dysplasia NN I-SpecificDisease I-MSH:D010009
. NN O O
he NN O O
was NN O O
treated NN O O
for NN O O
club NN B-SpecificDisease B-MSH:D003025
foot NN I-SpecificDisease I-MSH:D003025
and NN O O
hip NN B-SpecificDisease B-MSH:D006618
dysplasia NN I-SpecificDisease I-MSH:D006618
at NN O O
birth. NN O O
skeletal NN O O
changes NN O O
consistent NN O O
with NN O O
multiple NN B-SpecificDisease B-MSH:D010009
epiphyseal NN I-SpecificDisease I-MSH:D010009
dysplasia NN I-SpecificDisease I-MSH:D010009
, NN O O
with NN O O
the NN O O
peculiar NN O O
finding NN O O
o NN O O
. NN O O

a NN O O
double NN B-DiseaseClass B-MSH:C535504
layered NN I-DiseaseClass I-MSH:C535504
patella NN I-DiseaseClass I-MSH:C535504
, NN O O
were NN O O
recognised NN O O
during NN O O
childhood. NN O O
Cleft NN B-SpecificDisease B-MSH:D002972
palate NN I-SpecificDisease I-MSH:D002972
, NN O O
swelling NN B-DiseaseClass B-MSH:D004427
of NN I-DiseaseClass I-MSH:D004427
the NN I-DiseaseClass I-MSH:D004427
ear NN I-DiseaseClass I-MSH:D004427
pinna NN I-DiseaseClass I-MSH:D004427
, NN O O
and NN O O
hitch NN B-DiseaseClass B-MSH:C536903
hiker NN I-DiseaseClass I-MSH:C536903
thumb NN I-DiseaseClass I-MSH:C536903
were NN O O
absent. NN O O
he NN O O
was NN O O
found NN O O
to NN O O
be NN O O
homozygous, NN O O
and NN O O
both NN O O
healthy NN O O
parents NN O O
heterozygous, NN O O
for NN O O
the NN O O
r NN O O
279 NN O O
w NN O O
mutation NN O O
in NN O O
dtdst, NN O O
and NN O O
his NN O O
fibroblasts NN O O
showed NN O O
a NN O O
sulphate NN O O
incorporation NN O O
defect NN O O
typical NN O O
of NN O O
DTDST NN B-SpecificDisease B-MSH:D030342
disorders NN I-SpecificDisease I-MSH:D030342
. NN O O
counselling NN O O
was NN O O
given NN O O
for NN O O
a NN O O
recessive NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
, NN O O
thereby NN O O
considerably NN O O
reducing NN O O
the NN O O
probability NN O O
of NN O O
affected NN O O
offspring. NN O O
Multiple NN B-SpecificDisease B-MSH:D010009
epiphyseal NN I-SpecificDisease I-MSH:D010009
dysplasia NN I-SpecificDisease I-MSH:D010009
is NN O O
more NN O O
frequently NN O O
caused NN O O
by NN O O
dominant NN O O
mutations NN O O
in NN O O
the NN O O
comp NN O O
( NN O O
EDM1 NN B-SpecificDisease B-OMIM:132400
, NN O O
mckusick NN O O
132400) NN O O
and NN O O
col NN O O
9 NN O O
a NN O O
2 NN O O
genes NN O O
( NN O O
EDM2 NN B-SpecificDisease B-OMIM:600204
, NN O O
mckusick NN O O
600204). NN O O
a NN O O
few NN O O
other NN O O
patients NN O O
and NN O O
families NN O O
with NN O O
features NN O O
similar NN O O
to NN O O
our NN O O
proband NN O O
have NN O O
been NN O O
described NN O O
previously NN O O
and NN O O
considered NN O O
to NN O O
have NN O O
autosomal NN O O
recessive NN O O
MED NN B-SpecificDisease B-MSH:D010009
( NN O O
EDM4 NN B-SpecificDisease B-OMIM:226900
, NN O O
mckusic NN O O
. NN O O

226900). NN O O
this NN O O
observation NN O O
confirms NN O O
the NN O O
existence NN O O
of NN O O
this NN O O
entity NN O O
and NN O O
assigns NN O O
it NN O O
to NN O O
the NN O O
phenotypic NN O O
spectrum NN O O
associated NN O O
with NN O O
mutations NN O O
at NN O O
the NN O O
dtdst NN O O
locus. NN O O
. NN O O

myotonic NN O O
dystrophy: NN O O
size- NN O O
and NN O O
sex-dependent NN O O
dynamics NN O O
of NN O O
ctg NN O O
meiotic NN O O
instability, NN O O
and NN O O
somatic NN O O
mosaicism NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
a NN O O
progressive NN O O
neuromuscular NN B-DiseaseClass B-MSH:D009468
disorder NN I-DiseaseClass I-MSH:D009468
which NN O O
results NN O O
from NN O O
elongations NN O O
of NN O O
an NN O O
unstable NN O O
(ctg) NN O O
n NN O O
repeat, NN O O
located NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
gene. NN O O
a NN O O
correlation NN O O
has NN O O
been NN O O
demonstrated NN O O
between NN O O
the NN O O
increase NN O O
in NN O O
the NN O O
repeat NN O O
number NN O O
of NN O O
this NN O O
sequence NN O O
and NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
disease. NN O O
however, NN O O
the NN O O
clinical NN O O
status NN O O
of NN O O
patients NN O O
cannot NN O O
be NN O O
unambiguously NN O O
ascertained NN O O
solely NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
number NN O O
of NN O O
ctg NN O O
repeats. NN O O
moreover, NN O O
the NN O O
exclusive NN O O
maternal NN O O
inheritance NN O O
of NN O O
the NN O O
congenital NN O O
form NN O O
remains NN O O
unexplained. NN O O
our NN O O
observation NN O O
of NN O O
differently NN O O
sized NN O O
repeats NN O O
in NN O O
various NN O O
DM NN B-Modifier B-MSH:D009223
tissues NN O O
from NN O O
the NN O O
same NN O O
individual NN O O
may NN O O
explain NN O O
why NN O O
the NN O O
size NN O O
of NN O O
the NN O O
mutation NN O O
observed NN O O
in NN O O
lymphocytes NN O O
does NN O O
not NN O O
necessarily NN O O
correlate NN O O
with NN O O
the NN O O
severity NN O O
and NN O O
nature NN O O
of NN O O
symptoms. NN O O
through NN O O
a NN O O
molecular NN O O
and NN O O
genetic NN O O
study NN O O
of NN O O
142 NN O O
families NN O O
including NN O O
418 NN O O
DM NN B-Modifier B-MSH:D009223
. NN O O

patients, NN O O
we NN O O
have NN O O
investigated NN O O
the NN O O
dynamics NN O O
of NN O O
the NN O O
ctg NN O O
repeat NN O O
meiotic NN O O
instability. NN O O
a NN O O
positive NN O O
correlation NN O O
between NN O O
the NN O O
size NN O O
of NN O O
the NN O O
repeat NN O O
and NN O O
the NN O O
intergenerational NN O O
enlargement NN O O
was NN O O
observed NN O O
similarly NN O O
through NN O O
male NN O O
and NN O O
female NN O O
meioses NN O O
for NN O O
< NN O O
or NN O O
= NN O O
0. NN O O
5-kb NN O O
ctg NN O O
sequences. NN O O
beyond NN O O
0. NN O O
5 NN O O
kb, NN O O
the NN O O
intergenerational NN O O
variation NN O O
was NN O O
more NN O O
important NN O O
through NN O O
female NN O O
meioses, NN O O
whereas NN O O
a NN O O
tendency NN O O
to NN O O
compression NN O O
was NN O O
observed NN O O
almost NN O O
exclusively NN O O
in NN O O
male NN O O
meioses, NN O O
for NN O O
> NN O O
or NN O O
= NN O O
1. NN O O
5-kb NN O O
fragments. NN O O
this NN O O
implies NN O O
a NN O O
size- NN O O
and NN O O
sex-dependent NN O O
meiotic NN O O
instability. NN O O
moreover, NN O O
segregation NN O O
analysis NN O O
supports NN O O
the NN O O
hypothesis NN O O
of NN O O
a NN O O
maternal NN O O
as NN O O
well NN O O
as NN O O
a NN O O
familial NN O O
predisposition NN O O
for NN O O
the NN O O
occurrence NN O O
of NN O O
the NN O O
congenital NN O O
form. NN O O
finally, NN O O
this NN O O
analysis NN O O
reveals NN O O
a NN O O
significant NN O O
excess NN O O
of NN O O
transmitting NN O O
grandfathers NN O O
partially NN O O
accounted NN O O
for NN O O
by NN O O
increased NN O O
fertilit NN O O
. NN O O

in NN O O
affected NN O O
male NN O O
. NN O O

fatal NN O O
pyoderma NN B-SpecificDisease B-MSH:D017511
gangrenosum NN I-SpecificDisease I-MSH:D017511
in NN O O
association NN O O
with NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficiency NN I-SpecificDisease I-OMIM:610102
. NN O O

although NN O O
pyoderma NN B-SpecificDisease B-MSH:D017511
gangrenosum NN I-SpecificDisease I-MSH:D017511
( NN O O
PG NN B-SpecificDisease B-MSH:D017511
) NN O O
is NN O O
often NN O O
associated NN O O
with NN O O
systemic NN B-DiseaseClass B-MSH:D034721
diseases NN I-DiseaseClass I-MSH:D034721
, NN O O
it NN O O
has NN O O
not NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
congenital NN B-DiseaseClass B-MSH:D007153
complement NN I-DiseaseClass I-MSH:D007153
deficiencies NN I-DiseaseClass I-MSH:D007153
. NN O O
we NN O O
describe NN O O
an NN O O
aggressive NN O O
and NN O O
ultimately NN O O
fatal NN O O
case NN O O
of NN O O
PG NN B-SpecificDisease B-MSH:D017511
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
congenital NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficiency NN I-SpecificDisease I-OMIM:610102
. NN O O
Deficiencies NN B-SpecificDisease B-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
C7 NN I-SpecificDisease I-OMIM:610102
can NN O O
be NN O O
associated NN O O
with NN O O
decreased NN O O
neutrophil NN O O
chemotaxis, NN O O
phagocytosis, NN O O
and NN O O
opsonization, NN O O
similar NN O O
to NN O O
the NN O O
immunologic NN B-DiseaseClass B-MSH:D007153
abnormalities NN I-DiseaseClass I-MSH:D007153
described NN O O
in NN O O
patients NN O O
with NN O O
PG NN B-SpecificDisease B-MSH:D017511
. NN O O
our NN O O
patients NN O O
decreased NN O O
complement NN O O
level, NN O O
if NN O O
not NN O O
directly NN O O
related NN O O
to NN O O
the NN O O
development NN O O
of NN O O
PG NN B-SpecificDisease B-MSH:D017511
, NN O O
may NN O O
have NN O O
contributed NN O O
to NN O O
the NN O O
aggressive NN O O
nature NN O O
of NN O O
her NN O O
disease. NN O O
. NN O O

emerin NN O O
deficiency NN O O
at NN O O
the NN O O
nuclear NN O O
membrane NN O O
in NN O O
patients NN O O
with NN O O
Emery-Dreifuss NN B-SpecificDisease B-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
. NN O O

mutations NN O O
in NN O O
the NN O O
sta NN O O
gene NN O O
at NN O O
the NN O O
xq NN O O
28 NN O O
locus NN O O
have NN O O
been NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
X-linked NN B-SpecificDisease B-MSH:D020389
Emery-Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
( NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
). NN O O
this NN O O
gene NN O O
encodes NN O O
a NN O O
hitherto NN O O
unknown NN O O
protein NN O O
named NN O O
emerin. NN O O
to NN O O
elucidate NN O O
the NN O O
subcellular NN O O
localization NN O O
of NN O O
emerin, NN O O
we NN O O
raised NN O O
two NN O O
antisera NN O O
against NN O O
synthetic NN O O
peptide NN O O
fragments NN O O
predicted NN O O
from NN O O
emerin NN O O
cdna. NN O O
using NN O O
both NN O O
antisera, NN O O
we NN O O
found NN O O
positive NN O O
nuclear NN O O
membrane NN O O
staining NN O O
in NN O O
skeletal, NN O O
cardiac NN O O
and NN O O
smooth NN O O
muscles NN O O
in NN O O
the NN O O
normal NN O O
controls NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
neuromuscular NN B-DiseaseClass B-MSH:D009468
diseases NN I-DiseaseClass I-MSH:D009468
other NN O O
than NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
. NN O O
in NN O O
contrast, NN O O
a NN O O
deficiency NN O O
in NN O O
immunofluorescent NN O O
staining NN O O
of NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle NN O O
from NN O O
EDMD NN B-Modifier B-MSH:D020389
patients NN O O
was NN O O
observed. NN O O
a NN O O
34 NN O O
kd NN O O
protein NN O O
is NN O O
immunoreactive NN O O
with NN O O
the NN O O
antisera--the NN O O
protein NN O O
is NN O O
equivalent NN O O
to NN O O
that NN O O
predicted NN O O
for NN O O
emerin. NN O O
together, NN O O
our NN O O
findings NN O O
suggest NN O O
the NN O O
specific NN O O
deficiency NN B-SpecificDisease B-MSH:D020389
of NN I-SpecificDisease I-MSH:D020389
emerin NN I-SpecificDisease I-MSH:D020389
. NN O O

in NN O O
the NN O O
nuclear NN O O
membrane NN O O
of NN O O
muscle NN O O
cells NN O O
in NN O O
patients NN O O
with NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
. NN O O
. NN O O

a NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a-insensitive NN O O
cdk NN O O
4 NN O O
mutant NN O O
targeted NN O O
by NN O O
cytolytic NN O O
t NN O O
lymphocytes NN O O
in NN O O
a NN O O
human NN O O
melanoma NN B-SpecificDisease B-MSH:D008545
. NN O O

a NN O O
mutated NN O O
cyclin-dependent NN O O
kinase NN O O
4 NN O O
(cdk NN O O
4) NN O O
was NN O O
identified NN O O
as NN O O
a NN O O
tumor NN B-Modifier B-MSH:D009369
-specific NN O O
antigen NN O O
recognized NN O O
by NN O O
hla-a NN O O
2. NN O O
1-restricted NN O O
autologous NN O O
cytolytic NN O O
t NN O O
lymphocytes NN O O
(ctls) NN O O
in NN O O
a NN O O
human NN O O
melanoma NN B-SpecificDisease B-MSH:D008545
. NN O O
the NN O O
mutated NN O O
cdk NN O O
4 NN O O
allele NN O O
was NN O O
present NN O O
in NN O O
autologous NN O O
cultured NN O O
melanoma NN B-Modifier B-MSH:D008545
cells NN O O
and NN O O
metastasis NN O O
tissue, NN O O
but NN O O
not NN O O
in NN O O
the NN O O
patients NN O O
lymphocytes. NN O O
the NN O O
mutation, NN O O
an NN O O
arginine-to-cysteine NN O O
exchange NN O O
at NN O O
residue NN O O
24, NN O O
was NN O O
part NN O O
of NN O O
the NN O O
cdk NN O O
4 NN O O
peptide NN O O
recognized NN O O
by NN O O
ctls NN O O
and NN O O
prevented NN O O
binding NN O O
of NN O O
the NN O O
cdk NN O O
4 NN O O
inhibitor NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a, NN O O
but NN O O
not NN O O
of NN O O
p NN O O
21 NN O O
or NN O O
of NN O O
p NN O O
27 NN O O
kip NN O O
1. NN O O
the NN O O
same NN O O
mutation NN O O
was NN O O
found NN O O
in NN O O
one NN O O
additional NN O O
melanoma NN B-SpecificDisease B-MSH:D008545
among NN O O
28 NN O O
melanomas NN B-SpecificDisease B-MSH:D008545
analyzed. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
mutation NN O O
of NN O O
cdk NN O O
4 NN O O
can NN O O
create NN O O
a NN O O
tumor NN B-Modifier B-MSH:D009369
. NN O O

-specific NN O O
antigen NN O O
and NN O O
can NN O O
disrupt NN O O
the NN O O
cell-cycle NN O O
regulation NN O O
exerted NN O O
by NN O O
the NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
p NN O O
16 NN O O
ink NN O O
4 NN O O
a. NN O O
. NN O O

molecular NN O O
analysis NN O O
in NN O O
familial NN B-SpecificDisease B-OMIM:125700
neurohypophyseal NN I-SpecificDisease I-OMIM:125700
diabetes NN I-SpecificDisease I-OMIM:125700
insipidus NN I-SpecificDisease I-OMIM:125700
: NN O O
early NN O O
diagnosis NN O O
of NN O O
an NN O O
asymptomatic NN O O
carrier NN O O
. NN O O

familial NN O O
neurohypophyseal NN O O
diabetes NN O O
insipidus NN O O
( NN O O
FNDI NN B-SpecificDisease B-OMIM:125700
) NN O O
is NN O O
an NN O O
inherited NN O O
deficiency NN B-DiseaseClass B-OMIM:125700
of NN I-DiseaseClass I-OMIM:125700
the NN I-DiseaseClass I-OMIM:125700
hormone NN I-DiseaseClass I-OMIM:125700
arginine NN I-DiseaseClass I-OMIM:125700
vasopressin NN I-DiseaseClass I-OMIM:125700
(avp) NN O O
and NN O O
is NN O O
transmitted NN O O
as NN O O
an NN O O
autosomal NN O O
dominant NN O O
trait. NN O O
in NN O O
the NN O O
present NN O O
study NN O O
we NN O O
have NN O O
analyzed NN O O
the NN O O
avp-neurophysin NN O O
ii NN O O
(avp-npii) NN O O
gene NN O O
in NN O O
a NN O O
spanish NN O O
kindred. NN O O
studies NN O O
were NN O O
performed NN O O
on NN O O
seven NN O O
members NN O O
(four NN O O
clinically NN O O
affected) NN O O
of NN O O
the NN O O
family. NN O O
patients NN O O
were NN O O
diagnosed NN O O
at NN O O
the NN O O
hospital NN O O
universitario NN O O
gregorio NN O O
maranon NN O O
(madrid, NN O O
spain). NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
avp-npii NN O O
gene NN O O
of NN O O
all NN O O
family NN O O
members NN O O
was NN O O
amplified NN O O
by NN O O
pcr NN O O
and NN O O
sequenced. NN O O
all NN O O
affected NN O O
individuals NN O O
presented NN O O
a NN O O
missense NN O O
mutation NN O O
(g NN O O
1757-- NN O O
> NN O O
a) NN O O
that NN O O
replaces NN O O
glycine NN O O
at NN O O
position NN O O
23 NN O O
with NN O O
arginine NN O O
within NN O O
the NN O O
npii NN O O
domain. NN O O
the NN O O
substitution NN O O
was NN O O
confirmed NN O O
by NN O O
restriction NN O O
endonuclease NN O O
analysis NN O O
and NN O O
wa NN O O
. NN O O

present NN O O
in NN O O
heterozygosis. NN O O
additionally, NN O O
one NN O O
of NN O O
the NN O O
asymptomatic NN O O
relatives NN O O
(a NN O O
girl NN O O
8 NN O O
months NN O O
old NN O O
at NN O O
the NN O O
time NN O O
of NN O O
study) NN O O
was NN O O
identified NN O O
as NN O O
carrier NN O O
of NN O O
the NN O O
same NN O O
mutation NN O O
and NN O O
developed NN O O
the NN O O
disease NN O O
3 NN O O
months NN O O
later. NN O O
the NN O O
alteration NN O O
found NN O O
in NN O O
the NN O O
second NN O O
exon NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
this NN O O
family NN O O
seems NN O O
to NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
disease, NN O O
as NN O O
all NN O O
individuals NN O O
harboring NN O O
the NN O O
mutation NN O O
had NN O O
been NN O O
previously NN O O
diagnosed NN O O
or NN O O
have NN O O
eventually NN O O
developed NN O O
FNDI NN B-SpecificDisease B-OMIM:125700
. NN O O
identification NN O O
of NN O O
the NN O O
molecular NN O O
defect NN O O
underlying NN O O
FNDI NN B-SpecificDisease B-OMIM:125700
in NN O O
affected NN O O
families NN O O
is NN O O
a NN O O
powerful NN O O
tool NN O O
for NN O O
early NN O O
asymptomatic NN O O
diagnosis NN O O
in NN O O
infants. NN O O
. NN O O

sialophorin, NN O O
a NN O O
surface NN O O
sialoglycoprotein NN O O
defective NN O O
in NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
, NN O O
is NN O O
involved NN O O
in NN O O
human NN O O
t NN O O
lymphocyte NN O O
proliferation NN O O
. NN O O

the NN O O
mab NN O O
l NN O O
10 NN O O
was NN O O
used NN O O
to NN O O
determine NN O O
the NN O O
distribution NN O O
and NN O O
the NN O O
function NN O O
of NN O O
sialophorin, NN O O
the NN O O
heavily NN O O
glycosylated NN O O
surface NN O O
molecule NN O O
that NN O O
is NN O O
deficient/defective NN O O
in NN O O
lymphocytes NN O O
of NN O O
patients NN O O
with NN O O
the NN O O
X-linked NN B-SpecificDisease B-MSH:D014923
immunodeficiency NN I-SpecificDisease I-MSH:D014923
Wiskott-Aldrich NN I-SpecificDisease I-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
. NN O O
dual-parameter NN O O
facs NN O O
analysis NN O O
indicated NN O O
that NN O O
sialophorin NN O O
is NN O O
expressed NN O O
on NN O O
cd NN O O
4 NN O O
+ NN O O
and NN O O
cd NN O O
8 NN O O
+ NN O O
lymphocytes, NN O O
on NN O O
a NN O O
subpopulation NN O O
of NN O O
peripheral NN O O
blood NN O O
b NN O O
lymphocytes, NN O O
on NN O O
all NN O O
thymocytes, NN O O
and NN O O
on NN O O
a NN O O
subpopulation NN O O
of NN O O
bone NN O O
marrow NN O O
cells. NN O O
functional NN O O
studies NN O O
demonstrated NN O O
that NN O O
l NN O O
10 NN O O
mab NN O O
stimulates NN O O
the NN O O
proliferation NN O O
of NN O O
peripheral NN O O
blood NN O O
t NN O O
lymphocytes NN O O
as NN O O
measured NN O O
by NN O O
stimulation NN O O
of NN O O
[3 NN O O
h] NN O O
thymidine NN O O
incorporation. NN O O
the NN O O
time NN O O
course NN O O
and NN O O
magnitude NN O O
of NN O O
increased NN O O
[3 NN O O
h] NN O O
thymidine NN O O
incorporation NN O O
by NN O O
t NN O O
lymphocytes NN O O
in NN O O
response NN O O
to NN O O
l NN O O
10 NN O O
mab NN O O
paralleled NN O O
that NN O O
induced NN O O
by NN O O
anti-cd NN O O
. NN O O

mab. NN O O
effective NN O O
stimulation NN O O
was NN O O
dependent NN O O
on NN O O
the NN O O
presence NN O O
of NN O O
monocytes NN O O
and NN O O
the NN O O
fc NN O O
portion NN O O
of NN O O
l NN O O
10 NN O O
mab. NN O O
stimulation NN O O
of NN O O
lymphocytes NN O O
by NN O O
l NN O O
10, NN O O
like NN O O
stimulation NN O O
by NN O O
anti-cd NN O O
3 NN O O
mab, NN O O
involves NN O O
increased NN O O
expression NN O O
of NN O O
4 NN O O
f NN O O
2, NN O O
hla-dr, NN O O
and NN O O
il-2-r. NN O O
these NN O O
observations NN O O
suggest NN O O
that NN O O
sialophorin NN O O
functions NN O O
in NN O O
t NN O O
cell NN O O
activation. NN O O
. NN O O
servations NN O O
suggest NN O O
that NN O O
sialophorin NN O O
functions NN O O
in NN O O
t NN O O
cell NN O O
activation. NN O O
. NN O O

characterization NN O O
of NN O O
the NN O O
rat NN O O
spinocerebellar NN O O
ataxia NN O O
type NN O O
3 NN O O
gene NN O O
. NN O O

machado-joseph NN O O
disease NN O O
( NN O O
MJD NN B-SpecificDisease B-MSH:D017827
) NN O O
belongs NN O O
to NN O O
a NN O O
group NN O O
of NN O O
clinically NN O O
and NN O O
genetically NN O O
heterogeneous NN O O
neurodegenerative NN B-DiseaseClass B-MSH:D019636
disorders NN I-DiseaseClass I-MSH:D019636
characterized NN O O
by NN O O
progressive NN B-SpecificDisease B-MSH:D002524
cerebellar NN I-SpecificDisease I-MSH:D002524
ataxia NN I-SpecificDisease I-MSH:D002524
. NN O O
the NN O O
disease-causing NN O O
mutation NN O O
has NN O O
recently NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
unstable NN O O
and NN O O
expanded NN O O
(cag) NN O O
n NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
a NN O O
novel NN O O
gene NN O O
of NN O O
unknown NN O O
function. NN O O
in NN O O
caucasians, NN O O
repeat NN O O
expansions NN O O
in NN O O
the NN O O
mjd NN O O
1 NN O O
gene NN O O
have NN O O
also NN O O
been NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
clinically NN O O
distinct NN O O
autosomal NN O O
dominant NN O O
spinocerebellar NN B-SpecificDisease B-MSH:D017827
ataxia NN I-SpecificDisease I-MSH:D017827
type NN I-SpecificDisease I-MSH:D017827
3 NN I-SpecificDisease I-MSH:D017827
( NN O O
SCA3 NN B-SpecificDisease B-MSH:D017827
). NN O O
in NN O O
order NN O O
to NN O O
gain NN O O
insight NN O O
into NN O O
the NN O O
biology NN O O
of NN O O
the NN O O
mjd NN O O
1/sca NN O O
3 NN O O
gene NN O O
we NN O O
cloned NN O O
the NN O O
rat NN O O
homologue NN O O
and NN O O
studied NN O O
its NN O O
expression. NN O O
the NN O O
rat NN O O
and NN O O
human NN O O
ataxin-3 NN O O
genes NN O O
are NN O O
highly NN O O
homologous NN O O
with NN O O
an NN O O
overall NN O O
sequence NN O O
identity NN O O
of NN O O
approximately NN O O
88%. NN O O
however, NN O O
the NN O O
c-terminal NN O O
end NN O O
of NN O O
the NN O O
putativ NN O O
. NN O O

protein NN O O
differs NN O O
strongly NN O O
from NN O O
the NN O O
published NN O O
human NN O O
sequence. NN O O
the NN O O
(cag) NN O O
n NN O O
block NN O O
in NN O O
the NN O O
rat NN O O
cdna NN O O
consists NN O O
of NN O O
just NN O O
three NN O O
interrupted NN O O
units NN O O
suggesting NN O O
that NN O O
a NN O O
long NN O O
polyglutamine NN O O
stretch NN O O
is NN O O
not NN O O
essential NN O O
for NN O O
the NN O O
normal NN O O
function NN O O
of NN O O
the NN O O
ataxin-3 NN O O
protein NN O O
in NN O O
rodents. NN O O
the NN O O
expression NN O O
pattern NN O O
of NN O O
the NN O O
sca NN O O
3 NN O O
gene NN O O
in NN O O
various NN O O
rat NN O O
and NN O O
human NN O O
tissues NN O O
was NN O O
investigated NN O O
by NN O O
northern NN O O
blot NN O O
analyses. NN O O
the NN O O
mature NN O O
transcript NN O O
is NN O O
approximately NN O O
6 NN O O
kb NN O O
in NN O O
length. NN O O
in NN O O
rat NN O O
testis, NN O O
a NN O O
smaller NN O O
transcript NN O O
of NN O O
1. NN O O
3 NN O O
kb NN O O
was NN O O
identified. NN O O
transcription NN O O
of NN O O
rsca NN O O
3 NN O O
was NN O O
detected NN O O
in NN O O
most NN O O
rat NN O O
tissues NN O O
including NN O O
brain. NN O O
analyzing NN O O
the NN O O
expression NN O O
level NN O O
of NN O O
the NN O O
sca NN O O
3 NN O O
gene NN O O
in NN O O
several NN O O
human NN O O
brain NN O O
sections NN O O
revealed NN O O
no NN O O
significant NN O O
higher NN O O
mrna NN O O
level NN O O
in NN O O
regions NN O O
predominantly NN O O
affected NN O O
in NN O O
MJD NN B-SpecificDisease B-MSH:D017827
. NN O O
thus NN O O
additional NN O O
molecules NN O O
and/or NN O O
regulator NN O O
. NN O O

events NN O O
are NN O O
necessary NN O O
to NN O O
explain NN O O
the NN O O
exclusive NN O O
degeneration NN B-DiseaseClass B-MSH:D001927
of NN I-DiseaseClass I-MSH:D001927
certain NN I-DiseaseClass I-MSH:D001927
brain NN I-DiseaseClass I-MSH:D001927
areas NN I-DiseaseClass I-MSH:D001927
. NN O O

the NN O O
alveolar NN B-Modifier B-MSH:D018232
rhabdomyosarcoma NN I-Modifier I-MSH:D018232
pax NN O O
3/fkhr NN O O
fusion NN O O
protein NN O O
is NN O O
a NN O O
transcriptional NN O O
activator NN O O
. NN O O

chimeric NN O O
transcription NN O O
factors, NN O O
created NN O O
by NN O O
gene NN O O
fusions NN O O
as NN O O
the NN O O
result NN O O
of NN O O
chromosomal NN O O
translocations, NN O O
have NN O O
been NN O O
implicated NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
several NN O O
pathologically NN O O
disparate NN O O
solid NN B-DiseaseClass B-MSH:D009369
tumors NN I-DiseaseClass I-MSH:D009369
. NN O O
the NN O O
pax NN O O
3/fkhr NN O O
fusion NN O O
gene, NN O O
formed NN O O
by NN O O
a NN O O
t NN O O
(2; NN O O
13) NN O O
(q NN O O
35; NN O O
q NN O O
14) NN O O
in NN O O
alveolar NN B-SpecificDisease B-MSH:D018232
rhabdomyosarcoma NN I-SpecificDisease I-MSH:D018232
, NN O O
encodes NN O O
a NN O O
hybrid NN O O
protein NN O O
that NN O O
contains NN O O
both NN O O
pax NN O O
3 NN O O
dna NN O O
binding NN O O
domains, NN O O
the NN O O
paired NN O O
box NN O O
and NN O O
homeodomain, NN O O
linked NN O O
to NN O O
the NN O O
bisected NN O O
dna NN O O
binding NN O O
domain NN O O
of NN O O
fkhr, NN O O
a NN O O
member NN O O
of NN O O
the NN O O
forkhead NN O O
family NN O O
of NN O O
transcription NN O O
factors. NN O O
here NN O O
we NN O O
report NN O O
that NN O O
pax NN O O
3 NN O O
and NN O O
pax NN O O
3/fkhr NN O O
display NN O O
similar, NN O O
but NN O O
not NN O O
identical NN O O
transactivation NN O O
activities NN O O
when NN O O
tested NN O O
with NN O O
model NN O O
pax NN O O
recognition NN O O
sequences. NN O O
no NN O O
functional NN O O
role NN O O
could NN O O
be NN O O
ascribed NN O O
solely NN O O
to NN O O
the NN O O
residual NN O O
fkhr NN O O
binding NN O O
domain NN O O
present NN O O
in NN O O
the NN O O
fusion NN O O
protei NN O O
. NN O O

, NN O O
but NN O O
fkhr NN O O
was NN O O
found NN O O
to NN O O
contribute NN O O
a NN O O
strong NN O O
carboxyl NN O O
terminal NN O O
activation NN O O
domain NN O O
replacing NN O O
the NN O O
one NN O O
located NN O O
in NN O O
the NN O O
unrearranged NN O O
pax NN O O
3 NN O O
gene. NN O O
we NN O O
show NN O O
that NN O O
the NN O O
native NN O O
pax NN O O
3/fkhr NN O O
protein NN O O
present NN O O
in NN O O
tumor NN B-Modifier B-MSH:D009369
cells NN O O
with NN O O
this NN O O
translocation NN O O
has NN O O
transcriptional NN O O
characteristics NN O O
similar NN O O
to NN O O
the NN O O
in NN O O
vitro NN O O
expressed NN O O
protein. NN O O
the NN O O
ability NN O O
of NN O O
the NN O O
pax NN O O
3/fkhr NN O O
hybrid NN O O
protein NN O O
to NN O O
bind NN O O
dna NN O O
in NN O O
a NN O O
sequence NN O O
specific NN O O
manner NN O O
and NN O O
to NN O O
transactivate NN O O
the NN O O
expression NN O O
of NN O O
artificial NN O O
reporter NN O O
genes NN O O
suggests NN O O
that NN O O
its NN O O
aberrant NN O O
expression NN O O
could NN O O
subvert NN O O
the NN O O
transcriptional NN O O
programs NN O O
that NN O O
normally NN O O
control NN O O
the NN O O
growth, NN O O
differentiation, NN O O
and NN O O
survival NN O O
of NN O O
primitive NN O O
myogenic NN O O
precursors NN O O
in NN O O
vivo. NN O O
. NN O O

myotonia NN O O
levior NN O O
is NN O O
a NN O O
chloride NN B-DiseaseClass B-OMIM:160800
channel NN I-DiseaseClass I-OMIM:160800
disorder NN I-DiseaseClass I-OMIM:160800
. NN O O

the NN O O
group NN O O
of NN O O
dominant NN B-DiseaseClass B-MSH:C536245
non-dystrophic NN I-DiseaseClass I-MSH:C536245
myotonias NN I-DiseaseClass I-MSH:C536245
, NN O O
comprising NN O O
disorders NN O O
characterized NN O O
by NN O O
clinically NN O O
similar NN O O
forms NN O O
of NN O O
myogenic NN O O
muscle NN O O
stiffness, NN O O
is NN O O
genetically NN O O
inhomogeneous. NN O O
Dominant NN B-SpecificDisease B-MSH:D009224
myotonia NN I-SpecificDisease I-MSH:D009224
congenita NN I-SpecificDisease I-MSH:D009224
( NN O O
Thomsens NN B-SpecificDisease B-MSH:D009224
disease NN I-SpecificDisease I-MSH:D009224
) NN O O
is NN O O
linked NN O O
to NN O O
clcn NN O O
1, NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
major NN O O
muscle NN O O
chloride NN O O
channel, NN O O
localized NN O O
on NN O O
chromosome NN O O
7 NN O O
q NN O O
35. NN O O
in NN O O
contrast, NN O O
dominant NN B-DiseaseClass B-MSH:D009224
myotonias NN I-DiseaseClass I-MSH:D009224
sensitive NN O O
to NN O O
potassium NN O O
are NN O O
caused NN O O
by NN O O
point NN O O
mutations NN O O
in NN O O
scn NN O O
4 NN O O
a NN O O
on NN O O
chromosome NN O O
17 NN O O
q, NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
alpha NN O O
subunit NN O O
of NN O O
the NN O O
adult NN O O
skeletal NN O O
muscle NN O O
sodium NN O O
channel. NN O O
no NN O O
linkage NN O O
or NN O O
molecular NN O O
genetic NN O O
data NN O O
are NN O O
as NN O O
yet NN O O
available NN O O
on NN O O
myotonia NN B-SpecificDisease B-MSH:D009224
levior NN I-SpecificDisease I-MSH:D009224
characterized NN O O
by NN O O
milder NN O O
symptoms NN O O
and NN O O
later NN O O
onset NN O O
of NN O O
myotonia NN B-DiseaseClass B-MSH:D009222
than NN O O
in NN O O
Thomsens NN B-SpecificDisease B-MSH:D009224
disease NN I-SpecificDisease I-MSH:D009224
, NN O O
and NN O O
absence NN O O
of NN O O
muscle NN B-SpecificDisease B-MSH:C536106
hypertrophy NN I-SpecificDisease I-MSH:C536106
. NN O O
we NN O O
report NN O O
a NN O O
clcn NN O O
1 NN O O
gln-552-arg NN O O
substitution NN O O
for NN O O
a NN O O
family NN O O
with NN O O
dominant NN O O
inheritanc NN O O
. NN O O

previously NN O O
diagnosed NN O O
to NN O O
have NN O O
myotonia NN B-SpecificDisease B-MSH:D009224
levior NN I-SpecificDisease I-MSH:D009224
. NN O O
thus, NN O O
this NN O O
disorder NN O O
appears NN O O
as NN O O
a NN O O
variant NN O O
of NN O O
Thomsens NN B-SpecificDisease B-MSH:D009224
disease NN I-SpecificDisease I-MSH:D009224
due NN O O
to NN O O
mutations NN O O
leading NN O O
to NN O O
low NN O O
clinical NN O O
expressivity. NN O O
in NN O O
addition, NN O O
we NN O O
report NN O O
a NN O O
novel NN O O
ile-290-met NN O O
clcn NN O O
1 NN O O
mutation NN O O
for NN O O
a NN O O
typical NN O O
thomsen NN O O
pedigree. NN O O
in NN O O
another NN O O
family NN O O
previously NN O O
diagnosed NN O O
as NN O O
having NN O O
Thomsens NN B-SpecificDisease B-MSH:D009224
disease NN I-SpecificDisease I-MSH:D009224
, NN O O
we NN O O
unexpectedly NN O O
found NN O O
a NN O O
clcn NN O O
1 NN O O
14 NN O O
bp NN O O
deletion NN O O
known NN O O
to NN O O
cause NN O O
recessive NN B-DiseaseClass B-MSH:D009224
myotonia NN I-DiseaseClass I-MSH:D009224
, NN O O
and NN O O
a NN O O
rare NN O O
trp-118-gly NN O O
polymorphism. NN O O
. NN O O

markedly NN O O
accelerated NN O O
catabolism NN O O
of NN O O
apolipoprotein NN O O
a-ii NN O O
(apoa-ii) NN O O
and NN O O
high NN O O
density NN O O
lipoproteins NN O O
containing NN O O
apoa-ii NN O O
in NN O O
classic NN O O
lecithin: NN O O
cholesterol NN B-SpecificDisease B-MSH:D007863
acyltransferase NN I-SpecificDisease I-MSH:D007863
deficiency NN I-SpecificDisease I-MSH:D007863
and NN O O
fish-eye NN B-SpecificDisease B-MSH:D007863
disease NN I-SpecificDisease I-MSH:D007863
. NN O O

classic NN O O
(complete) NN O O
lecithin NN O O
cholesterol NN O O
acyltransferase NN O O
(lcat) NN O O
deficiency NN O O
and NN O O
Fish-eye NN B-SpecificDisease B-MSH:D007863
disease NN I-SpecificDisease I-MSH:D007863
( NN O O
partial NN B-SpecificDisease B-MSH:D007863
LCAT NN I-SpecificDisease I-MSH:D007863
deficiency NN I-SpecificDisease I-MSH:D007863
) NN O O
are NN O O
genetic NN O O
syndromes NN O O
associated NN O O
with NN O O
markedly NN O O
decreased NN O O
plasma NN O O
levels NN O O
of NN O O
high NN O O
density NN O O
lipoprotein NN O O
(hdl) NN O O
cholesterol NN O O
but NN O O
not NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
atherosclerotic NN B-SpecificDisease B-MSH:D050197
cardiovascular NN I-SpecificDisease I-MSH:D050197
disease NN I-SpecificDisease I-MSH:D050197
. NN O O
we NN O O
investigated NN O O
the NN O O
metabolism NN O O
of NN O O
the NN O O
hdl NN O O
apolipoproteins NN O O
(apo) NN O O
apoa-i NN O O
and NN O O
apoa-ii NN O O
in NN O O
a NN O O
total NN O O
of NN O O
five NN O O
patients NN O O
with NN O O
LCAT NN B-SpecificDisease B-MSH:D007863
deficiency NN I-SpecificDisease I-MSH:D007863
, NN O O
one NN O O
with NN O O
classic NN B-SpecificDisease B-MSH:D007863
LCAT NN I-SpecificDisease I-MSH:D007863
deficiency NN I-SpecificDisease I-MSH:D007863
and NN O O
four NN O O
with NN O O
Fish-eye NN B-SpecificDisease B-MSH:D007863
disease NN I-SpecificDisease I-MSH:D007863
. NN O O
plasma NN O O
levels NN O O
of NN O O
apoa-ii NN O O
were NN O O
decreased NN O O
to NN O O
a NN O O
proportionately NN O O
greater NN O O
extent NN O O
(23% NN O O
of NN O O
normal) NN O O
than NN O O
apoa-i NN O O
(30% NN O O
of NN O O
normal). NN O O
in NN O O
addition, NN O O
plasma NN O O
concentrations NN O O
of NN O O
hdl NN O O
particles NN O O
containing NN O O
both NN O O
apoa-i NN O O
and NN O O
apoa-ii NN O O
(lpa NN O O
. NN O O

i NN O O
a-ii) NN O O
were NN O O
much NN O O
lower NN O O
(18% NN O O
of NN O O
normal) NN O O
than NN O O
those NN O O
of NN O O
particles NN O O
containing NN O O
only NN O O
apoa-i NN O O
(lpa-i) NN O O
(51% NN O O
of NN O O
normal). NN O O
the NN O O
metabolic NN O O
basis NN O O
for NN O O
the NN O O
low NN O O
levels NN O O
of NN O O
apoa-ii NN O O
and NN O O
lpa-i NN O O
a-ii NN O O
was NN O O
investigated NN O O
in NN O O
all NN O O
five NN O O
patients NN O O
using NN O O
both NN O O
exogenous NN O O
radiotracer NN O O
and NN O O
endogenous NN O O
stable NN O O
isotope NN O O
labeling NN O O
techniques. NN O O
the NN O O
mean NN O O
plasma NN O O
residence NN O O
time NN O O
of NN O O
apoa-i NN O O
was NN O O
decreased NN O O
at NN O O
2. NN O O
08 NN O O
+/- NN O O
0. NN O O
27 NN O O
d NN O O
(controls NN O O
4. NN O O
74 NN O O
+/- NN O O
0. NN O O
65 NN O O
days); NN O O
however, NN O O
the NN O O
residence NN O O
time NN O O
of NN O O
apoa-ii NN O O
was NN O O
even NN O O
shorter NN O O
at NN O O
1. NN O O
66 NN O O
+/- NN O O
0. NN O O
24 NN O O
d NN O O
(controls NN O O
5. NN O O
25 NN O O
+/- NN O O
0. NN O O
6 NN O O
. NN O O
6 NN O O
. NN O O

d). NN O O
in NN O O
addition, NN O O
the NN O O
catabolism NN O O
of NN O O
apoa-i NN O O
in NN O O
lpa-i NN O O
a-ii NN O O
was NN O O
substantially NN O O
faster NN O O
than NN O O
that NN O O
of NN O O
apoa-i NN O O
in NN O O
lpa-i. NN O O
in NN O O
summary, NN O O
genetic NN O O
syndromes NN O O
of NN O O
either NN O O
complete NN B-CompositeMention B-MSH:D007863
or NN I-CompositeMention I-MSH:D007863
partial NN I-CompositeMention I-MSH:D007863
LCAT NN I-CompositeMention I-MSH:D007863
deficiency NN I-CompositeMention I-MSH:D007863
result NN O O
in NN O O
low NN O O
levels NN O O
of NN O O
hdl NN O O
through NN O O
preferential NN O O
hypercatabolism NN O O
of NN O O
apoa-ii NN O O
and NN O O
hdl NN O O
particles NN O O
containing NN O O
apoa-ii. NN O O
because NN O O
lpa-i NN O O
has NN O O
been NN O O
proposed NN O O
to NN O O
be NN O O
more NN O O
protective NN O O
than NN O O
lpa-i NN O O
a-ii NN O O
against NN O O
atherosclerosis NN B-SpecificDisease B-MSH:D050197
, NN O O
this NN O O
selective NN O O
effect NN O O
on NN O O
the NN O O
metabolism NN O O
of NN O O
lpa-i NN O O
a-ii NN O O
may NN O O
provide NN O O
a NN O O
potential NN O O
explanation NN O O
why NN O O
patients NN O O
with NN O O
classic NN B-SpecificDisease B-MSH:D007863
LCAT NN I-SpecificDisease I-MSH:D007863
deficiency NN I-SpecificDisease I-MSH:D007863
and NN O O
Fish-eye NN B-SpecificDisease B-MSH:D007863
disease NN I-SpecificDisease I-MSH:D007863
are NN O O
not NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
premature NN O O
atherosclerosis NN B-SpecificDisease B-MSH:D050197
despite NN O O
markedly NN O O
decreased NN O O
levels NN O O
of NN O O
hdl NN O O
cholesterol NN O O
and NN O O
apoa- NN O O
. NN O O

the NN O O
identical NN O O
5' NN O O
splice-site NN O O
acceptor NN O O
mutation NN O O
in NN O O
five NN O O
attenuated NN B-Modifier B-MSH:C538265
APC NN I-Modifier I-MSH:C538265
families NN O O
from NN O O
newfoundland NN O O
demonstrates NN O O
a NN O O
founder NN O O
effect NN O O
. NN O O

inherited NN O O
mutations NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
predispose NN O O
carriers NN O O
to NN O O
multiple NN O O
adenomatous NN B-CompositeMention B-MSH:D011125
polyps NN I-CompositeMention I-MSH:D011125
of NN I-CompositeMention I-MSH:D011125
the NN I-CompositeMention I-MSH:D011125
colon NN I-CompositeMention I-MSH:D011125
and NN I-CompositeMention I-MSH:D011125
rectum NN I-CompositeMention I-MSH:D011125
and NN O O
to NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O
mutations NN O O
located NN O O
at NN O O
the NN O O
extreme NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene, NN O O
however, NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
less NN O O
severe NN O O
disease NN O O
known NN O O
as NN O O
attenuated NN B-SpecificDisease B-MSH:C538265
adenomatous NN I-SpecificDisease I-MSH:C538265
polyposis NN I-SpecificDisease I-MSH:C538265
coli NN I-SpecificDisease I-MSH:C538265
( NN O O
AAPC NN B-SpecificDisease B-MSH:C538265
). NN O O
many NN O O
individuals NN O O
with NN O O
AAPC NN B-SpecificDisease B-MSH:C538265
develop NN O O
relatively NN O O
few NN O O
colorectal NN B-SpecificDisease B-MSH:D003111
polyps NN I-SpecificDisease I-MSH:D003111
but NN O O
are NN O O
still NN O O
at NN O O
high NN O O
risk NN O O
for NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O
we NN O O
report NN O O
here NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
5 NN O O
APC NN B-Modifier B-MSH:D011125
germline NN O O
mutation NN O O
in NN O O
five NN O O
separately NN O O
ascertained NN O O
AAPC NN B-Modifier B-MSH:C538265
families NN O O
from NN O O
newfoundland, NN O O
canada. NN O O
this NN O O
disease-causing NN O O
mutation NN O O
is NN O O
a NN O O
single NN O O
basepair NN O O
change NN O O
(g NN O O
to NN O O
a) NN O O
in NN O O
the NN O O
splice-acceptor NN O O
region NN O O
of NN O O
APC NN B-Modifier B-MSH:D011125
intron NN O O
3 NN O O
that NN O O
creates NN O O
a NN O O
mutant NN O O
rna NN O O
without NN O O
exon NN O O
4 NN O O
of NN O O
apc. NN O O
the NN O O
observation NN O O
of NN O O
the NN O O
same NN O O
APC NN B-Modifier B-MSH:D011125
mutation NN O O
in NN O O
five NN O O
familie NN O O
. NN O O

from NN O O
the NN O O
same NN O O
geographic NN O O
area NN O O
demonstrates NN O O
a NN O O
founder NN O O
effect. NN O O
furthermore, NN O O
the NN O O
identification NN O O
of NN O O
this NN O O
germline NN O O
mutation NN O O
strengthens NN O O
the NN O O
correlation NN O O
between NN O O
the NN O O
5 NN O O
location NN O O
of NN O O
an NN O O
APC NN B-Modifier B-MSH:D011125
disease-causing NN O O
mutation NN O O
and NN O O
the NN O O
attenuated NN B-Modifier B-MSH:C538265
polyposis NN I-Modifier I-MSH:C538265
phenotype. NN O O
. NN O O

linkage NN O O
of NN O O
aspartylglucosaminuria NN B-SpecificDisease B-MSH:D054880
( NN O O
AGU NN B-SpecificDisease B-MSH:D054880
) NN O O
to NN O O
marker NN O O
loci NN O O
on NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
4 NN O O
. NN O O

aspartylglucosaminuria NN O O
( NN O O
AGU NN B-SpecificDisease B-MSH:D054880
) NN O O
is NN O O
caused NN O O
by NN O O
deficient NN O O
activity NN O O
of NN O O
the NN O O
enzyme NN O O
aspartylglucosaminidase NN O O
(aga). NN O O
the NN O O
structural NN O O
gene NN O O
for NN O O
aga NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
the NN O O
region NN O O
4 NN O O
q NN O O
21-qter NN O O
of NN O O
chromosome NN O O
4. NN O O
we NN O O
have NN O O
studied NN O O
the NN O O
map NN O O
position NN O O
of NN O O
the NN O O
agu NN O O
locus NN O O
in NN O O
relation NN O O
to NN O O
other NN O O
marker NN O O
loci NN O O
on NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
4 NN O O
using NN O O
linkage NN O O
analyses. NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
alleles NN O O
for NN O O
the NN O O
adh NN O O
2, NN O O
adh NN O O
3, NN O O
egf, NN O O
fg NN O O
alpha NN O O
and NN O O
fg NN O O
beta NN O O
loci NN O O
and NN O O
blood NN O O
group NN O O
antigens NN O O
for NN O O
the NN O O
mns NN O O
locus NN O O
were NN O O
determined NN O O
in NN O O
a NN O O
panel NN O O
of NN O O
12 NN O O
finnish NN O O
AGU NN B-Modifier B-MSH:D054880
families. NN O O
the NN O O
heterozygous NN O O
family NN O O
members NN O O
were NN O O
identified NN O O
by NN O O
reduced NN O O
activity NN O O
of NN O O
aga NN O O
in NN O O
lymphocytes. NN O O
linkage NN O O
studies NN O O
were NN O O
performed NN O O
using NN O O
both NN O O
pairwise NN O O
and NN O O
multipoint NN O O
analyses. NN O O
loose NN O O
linkage NN O O
of NN O O
the NN O O
AGU NN B-Modifier B-MSH:D054880
locus NN O O
to NN O O
the NN O O
fg NN O O
and NN O O
mn NN O O
. NN O O

loci NN O O
was NN O O
observed NN O O
(z NN O O
= NN O O
1. NN O O
16, NN O O
z NN O O
= NN O O
1. NN O O
39, NN O O
respectively). NN O O
multipoint NN O O
analysis NN O O
to NN O O
the NN O O
fixed NN O O
map NN O O
[adh- NN O O
(0. NN O O
03) NN O O
-egf- NN O O
(0. NN O O
35) NN O O
-fg- NN O O
(0. NN O O
11) NN O O
-mns] NN O O
suggests NN O O
that NN O O
the NN O O
location NN O O
of NN O O
the NN O O
agu NN O O
locus NN O O
is NN O O
0. NN O O
05-0. NN O O
30 NN O O
recombination NN O O
units NN O O
distal NN O O
to NN O O
mns NN O O
(z NN O O
= NN O O
3. NN O O
03). NN O O
the NN O O
order NN O O
cen-adh-egf-fg-mns-agu NN O O
is NN O O
35 NN O O
times NN O O
more NN O O
likely NN O O
than NN O O
the NN O O
next NN O O
best NN O O
order NN O O
cen-adh-egf-agu-fg-mns NN O O
. NN O O

linkage NN O O
analysis NN O O
in NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
and NN O O
application NN O O
in NN O O
post- NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
. NN O O

we NN O O
have NN O O
performed NN O O
linkage NN O O
analysis NN O O
with NN O O
the NN O O
dna NN O O
markers NN O O
dxs NN O O
52 NN O O
and NN O O
the NN O O
clotting NN O O
factor NN O O
viii NN O O
gene NN O O
(f NN O O
8 NN O O
c), NN O O
in NN O O
several NN O O
large NN O O
families NN O O
with NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
). NN O O
the NN O O
tight NN O O
linkage NN O O
to NN O O
dxs NN O O
52 NN O O
could NN O O
be NN O O
extended NN O O
giving NN O O
a NN O O
maximal NN O O
lod NN O O
score NN O O
of NN O O
22. NN O O
5 NN O O
at NN O O
1 NN O O
cm. NN O O
f NN O O
8 NN O O
c NN O O
was NN O O
also NN O O
tightly NN O O
linked NN O O
to NN O O
ALD NN B-SpecificDisease B-MSH:D000326
with NN O O
a NN O O
maximal NN O O
lod NN O O
score NN O O
of NN O O
7. NN O O
8 NN O O
without NN O O
recombination. NN O O
multipoint NN O O
linkage NN O O
analysis NN O O
with NN O O
the NN O O
markers NN O O
dxs NN O O
304, NN O O
dxs NN O O
52, NN O O
and NN O O
f NN O O
8 NN O O
c NN O O
indicated NN O O
that NN O O
both NN O O
the NN O O
gene NN O O
for NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
for NN O O
f NN O O
8 NN O O
c NN O O
are NN O O
distal NN O O
to NN O O
dxs NN O O
52. NN O O
in NN O O
four NN O O
patients NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
, NN O O
no NN O O
major NN O O
structural NN O O
rearrangement NN O O
in NN O O
the NN O O
xqter NN O O
region NN O O
was NN O O
observed; NN O O
in NN O O
particular, NN O O
there NN O O
were NN O O
no NN O O
abnormalities NN B-DiseaseClass B-MSH:D003117
in NN I-DiseaseClass I-MSH:D003117
the NN I-DiseaseClass I-MSH:D003117
vision NN I-DiseaseClass I-MSH:D003117
blindness NN I-DiseaseClass I-MSH:D003117
genes NN I-DiseaseClass I-MSH:D003117

blindness NN O O
genes. NN O O
dna NN O O
analysis NN O O
appeared NN O O
to NN O O
be NN O O
of NN O O
use NN O O
in NN O O
determination NN O O
of NN O O
the NN O O
carrier NN O O
status NN O O
of NN O O
females NN O O
at NN O O
risk, NN O O
for NN O O
the NN O O
determination NN O O
of NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
a NN O O
particular NN O O
family, NN O O
and NN O O
for NN O O
prenatal NN O O
diagnosis NN O O
. NN O O

multicentric NN O O
origin NN O O
of NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
gene NN O O
(hfe) NN O O
mutations NN O O
. NN O O

genetic NN O O
hemochromatosis NN O O
( NN O O
GH NN B-SpecificDisease B-MSH:D006432
) NN O O
is NN O O
believed NN O O
to NN O O
be NN O O
a NN O O
disease NN O O
restricted NN O O
to NN O O
those NN O O
of NN O O
european NN O O
ancestry. NN O O
in NN O O
northwestern NN O O
europe, NN O O
> NN O O
80% NN O O
of NN O O
GH NN B-Modifier B-MSH:D006432
patients NN O O
are NN O O
homozygous NN O O
for NN O O
one NN O O
mutation, NN O O
the NN O O
substitution NN O O
of NN O O
tyrosine NN O O
for NN O O
cysteine NN O O
at NN O O
position NN O O
282 NN O O
(c NN O O
282 NN O O
y) NN O O
in NN O O
the NN O O
unprocessed NN O O
protein. NN O O
in NN O O
a NN O O
proportion NN O O
of NN O O
GH NN B-Modifier B-MSH:D006432
patients, NN O O
two NN O O
mutations NN O O
are NN O O
present, NN O O
c NN O O
282 NN O O
y NN O O
and NN O O
h NN O O
63 NN O O
d. NN O O
the NN O O
clinical NN O O
significance NN O O
of NN O O
this NN O O
second NN O O
mutation NN O O
is NN O O
such NN O O
that NN O O
it NN O O
appears NN O O
to NN O O
predispose NN O O
1% NN O O
-2% NN O O
of NN O O
compound NN O O
heterozygotes NN O O
to NN O O
expression NN O O
of NN O O
the NN O O
disease. NN O O
the NN O O
distribution NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
differ, NN O O
c NN O O
282 NN O O
y NN O O
being NN O O
limited NN O O
to NN O O
those NN O O
of NN O O
northwestern NN O O
european NN O O
ancestry NN O O
and NN O O
h NN O O
63 NN O O
d NN O O
being NN O O
found NN O O
at NN O O
allele NN O O
frequencies NN O O
> NN O O
5%, NN O O
in NN O O
europe, NN O O
in NN O O
countries NN O O
bordering NN O O
th NN O O
. NN O O

mediterranean, NN O O
in NN O O
the NN O O
middle NN O O
east, NN O O
and NN O O
in NN O O
the NN O O
indian NN O O
subcontinent. NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
occurs NN O O
on NN O O
a NN O O
haplotype NN O O
that NN O O
extends NN O O
</= NN O O
6 NN O O
mb, NN O O
suggesting NN O O
that NN O O
this NN O O
mutation NN O O
has NN O O
arisen NN O O
during NN O O
the NN O O
past NN O O
2, NN O O
000 NN O O
years. NN O O
the NN O O
h NN O O
63 NN O O
d NN O O
mutation NN O O
is NN O O
older NN O O
and NN O O
does NN O O
not NN O O
occur NN O O
on NN O O
such NN O O
a NN O O
large NN O O
extended NN O O
haplotype, NN O O
the NN O O
haplotype NN O O
in NN O O
this NN O O
case NN O O
extending NN O O
</= NN O O
700 NN O O
kb. NN O O
here NN O O
we NN O O
report NN O O
the NN O O
finding NN O O
of NN O O
the NN O O
h NN O O
63 NN O O
d NN O O
and NN O O
c NN O O
282 NN O O
y NN O O
mutations NN O O
on NN O O
new NN O O
haplotypes. NN O O
in NN O O
sri NN O O
lanka NN O O
we NN O O
have NN O O
found NN O O
h NN O O
63 NN O O
d NN O O
on NN O O
three NN O O
new NN O O
haplotypes NN O O
and NN O O
have NN O O
found NN O O
c NN O O
282 NN O O
y NN O O
on NN O O
one NN O O
new NN O O
haplotype, NN O O
demonstrating NN O O
that NN O O
these NN O O
mutations NN O O
have NN O O
arisen NN O O
independently NN O O
on NN O O
this NN O O
island. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
hfe NN O O
gene NN O O
has NN O O
been NN O O
the NN O O
subject NN O O
o NN O O
. NN O O
plotype NN O O
in NN O O
this NN O O
case NN O O
extending NN O O
</= NN O O
700 NN O O
kb. NN O O
here NN O O
we NN O O
report NN O O
the NN O O
finding NN O O
of NN O O
the NN O O
h NN O O
63 NN O O
d NN O O
and NN O O
c NN O O
282 NN O O
y NN O O
mutations NN O O
on NN O O
new NN O O
haplotypes. NN O O
in NN O O
sri NN O O
lanka NN O O
we NN O O
have NN O O
found NN O O
h NN O O
63 NN O O
d NN O O
on NN O O
three NN O O
new NN O O
haplotypes NN O O
and NN O O
have NN O O
found NN O O
c NN O O
282 NN O O
y NN O O
on NN O O
one NN O O
new NN O O
haplotype, NN O O
demonstrating NN O O
that NN O O
these NN O O
mutations NN O O
have NN O O
arisen NN O O
independently NN O O
on NN O O
this NN O O
island. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
hfe NN O O
gene NN O O
has NN O O
been NN O O
the NN O O
subject NN O O
o NN O O
. NN O O

selection NN O O
pressure. NN O O
these NN O O
selection NN O O
pressures NN O O
could NN O O
be NN O O
due NN O O
to NN O O
infectious NN B-DiseaseClass B-MSH:D003141
diseases NN I-DiseaseClass I-MSH:D003141
, NN O O
environmental NN O O
conditions, NN O O
or NN O O
other NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
such NN O O
as NN O O
anemia NN B-DiseaseClass B-MSH:D000740
. NN O O

identification NN O O
and NN O O
localization NN O O
of NN O O
mutations NN O O
at NN O O
the NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
locus NN O O
by NN O O
ribonuclease NN O O
a NN O O
cleavage NN O O
. NN O O

many NN O O
mutations NN O O
leading NN O O
to NN O O
human NN O O
disease NN O O
are NN O O
the NN O O
result NN O O
of NN O O
single NN O O
dna NN O O
base NN O O
pair NN O O
changes NN O O
that NN O O
cannot NN O O
be NN O O
identified NN O O
by NN O O
southern NN O O
analysis. NN O O
this NN O O
has NN O O
prompted NN O O
the NN O O
development NN O O
of NN O O
alternative NN O O
assays NN O O
for NN O O
point NN O O
mutation NN O O
detection. NN O O
the NN O O
recently NN O O
described NN O O
ribonuclease NN O O
a NN O O
cleavage NN O O
procedure, NN O O
with NN O O
a NN O O
polyuridylic NN O O
acid-paper NN O O
affinity NN O O
chromatography NN O O
step, NN O O
has NN O O
been NN O O
used NN O O
to NN O O
identify NN O O
the NN O O
mutational NN O O
lesions NN O O
in NN O O
the NN O O
hypoxanthine NN O O
phosphoribosyltransferase NN O O
(hprt) NN O O
messenger NN O O
rnas NN O O
of NN O O
patients NN O O
with NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O
distinctive NN O O
ribonuclease NN O O
a NN O O
cleavage NN O O
patterns NN O O
were NN O O
identified NN O O
in NN O O
messenger NN O O
rna NN O O
from NN O O
5 NN O O
of NN O O
14 NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
patients NN O O
who NN O O
were NN O O
chosen NN O O
because NN O O
no NN O O
hprt NN O O
southern NN O O
or NN O O
northern NN O O
blotting NN O O
pattern NN O O
changes NN O O
had NN O O
been NN O O
found. NN O O
this NN O O
approach NN O O
now NN O O
allows NN O O
hprt NN O O
mutation NN O O
detection NN O O
in NN O O
50 NN O O
percent NN O O
of NN O O
the NN O O
cases NN O O
of NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O
the NN O O
polyuridylic NN O O
acid-paper NN O O
affinity NN O O
procedure NN O O
provide NN O O
. NN O O

a NN O O
general NN O O
method NN O O
for NN O O
analysis NN O O
of NN O O
low NN O O
abundance NN O O
messenger NN O O
rnas. NN O O
. NN O O

mefv-gene NN O O
analysis NN O O
in NN O O
armenian NN O O
patients NN O O
with NN O O
Familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
: NN O O
diagnostic NN O O
value NN O O
and NN O O
unfavorable NN O O
renal NN O O
prognosis NN O O
of NN O O
the NN O O
m NN O O
694 NN O O
v NN O O
homozygous NN O O
genotype-genetic NN O O
and NN O O
therapeutic NN O O
implications NN O O
. NN O O

familial NN O O
mediterranean NN O O
fever NN O O
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
) NN O O
is NN O O
a NN O O
recessively NN B-DiseaseClass B-MSH:D030342
inherited NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
that NN O O
is NN O O
common NN O O
in NN O O
patients NN O O
of NN O O
armenian NN O O
ancestry. NN O O
to NN O O
date, NN O O
its NN O O
diagnosis, NN O O
which NN O O
can NN O O
be NN O O
made NN O O
only NN O O
retrospectively, NN O O
is NN O O
one NN O O
of NN O O
exclusion, NN O O
based NN O O
entirely NN O O
on NN O O
nonspecific NN O O
clinical NN O O
signs NN O O
that NN O O
result NN O O
from NN O O
serosal NN B-SpecificDisease B-MSH:D007249
inflammation NN I-SpecificDisease I-MSH:D007249
and NN O O
that NN O O
may NN O O
lead NN O O
to NN O O
unnecessary NN O O
surgery. NN O O
Renal NN B-SpecificDisease B-MSH:C538249
amyloidosis NN I-SpecificDisease I-MSH:C538249
, NN O O
prevented NN O O
by NN O O
colchicine, NN O O
is NN O O
the NN O O
most NN O O
severe NN O O
complication NN O O
of NN O O
FMF NN B-SpecificDisease B-MSH:D010505
, NN O O
a NN O O
disorder NN O O
associated NN O O
with NN O O
mutations NN O O
in NN O O
the NN O O
mefv NN O O
gene. NN O O
to NN O O
evaluate NN O O
the NN O O
diagnostic NN O O
and NN O O
prognostic NN O O
value NN O O
of NN O O
mefv-gene NN O O
analysis, NN O O
we NN O O
investigated NN O O
90 NN O O
armenian NN O O
FMF NN B-Modifier B-MSH:D010505
patients NN O O
from NN O O
77 NN O O
unrelated NN O O
families NN O O
that NN O O
were NN O O
not NN O O
selected NN O O
through NN O O
genetic-linkage NN O O
analysis. NN O O
eight NN O O
mutations, NN O O
one NN O O
of NN O O
which NN O O
(r NN O O
408 NN O O
q) NN O O
is NN O O
new, NN O O
were NN O O
found NN O O
to NN O O
account NN O O
for NN O O
93% NN O O
of NN O O
the NN O O
163 NN O O
independen NN O O
. NN O O

fmf NN O O
alleles, NN O O
with NN O O
both NN O O
FMF NN B-Modifier B-MSH:D010505
alleles NN O O
identified NN O O
in NN O O
89% NN O O
of NN O O
the NN O O
patients. NN O O
in NN O O
several NN O O
instances, NN O O
family NN O O
studies NN O O
provided NN O O
molecular NN O O
evidence NN O O
for NN O O
pseudodominant NN O O
transmission NN O O
and NN O O
incomplete NN O O
penetrance NN O O
of NN O O
the NN O O
disease NN O O
phenotype. NN O O
the NN O O
m NN O O
694 NN O O
v NN O O
homozygous NN O O
genotype NN O O
was NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
higher NN O O
prevalence NN O O
of NN O O
renal NN B-SpecificDisease B-MSH:C538249
amyloidosis NN I-SpecificDisease I-MSH:C538249
and NN O O
arthritis NN B-SpecificDisease B-MSH:D001168
, NN O O
compared NN O O
with NN O O
other NN O O
genotypes NN O O
(p NN O O
=. NN O O
0002 NN O O
and NN O O
p NN O O
=. NN O O
006, NN O O
respectively). NN O O
the NN O O
demonstration NN O O
of NN O O
both NN O O
the NN O O
diagnostic NN O O
and NN O O
prognostic NN O O
value NN O O
of NN O O
mefv NN O O
analysis NN O O
and NN O O
particular NN O O
modes NN O O
of NN O O
inheritance NN O O
should NN O O
lead NN O O
to NN O O
new NN O O
ways NN O O
for NN O O
management NN O O
of NN O O
fmf-including NN O O
genetic NN O O
counseling NN O O
and NN O O
therapeutic NN O O
decisions NN O O
in NN O O
affected NN O O
families NN O O
. NN O O

identification NN O O
and NN O O
localization NN O O
of NN O O
huntingtin NN O O
in NN O O
brain NN O O
and NN O O
human NN O O
lymphoblastoid NN O O
cell NN O O
lines NN O O
with NN O O
anti-fusion NN O O
protein NN O O
antibodies NN O O
. NN O O

the NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
( NN O O
HD NN B-Modifier B-MSH:D006816
) NN O O
phenotype NN O O
is NN O O
associated NN O O
with NN O O
expansion NN O O
of NN O O
a NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
it NN O O
15 NN O O
gene, NN O O
which NN O O
is NN O O
predicted NN O O
to NN O O
encode NN O O
a NN O O
348-kda NN O O
protein NN O O
named NN O O
huntington. NN O O
we NN O O
used NN O O
polyclonal NN O O
and NN O O
monoclonal NN O O
anti-fusion NN O O
protein NN O O
antibodies NN O O
to NN O O
identify NN O O
native NN O O
huntingtin NN O O
in NN O O
rat, NN O O
monkey, NN O O
and NN O O
human. NN O O
western NN O O
blots NN O O
revealed NN O O
a NN O O
protein NN O O
with NN O O
the NN O O
expected NN O O
molecular NN O O
weight NN O O
which NN O O
is NN O O
present NN O O
in NN O O
the NN O O
soluble NN O O
fraction NN O O
of NN O O
rat NN O O
and NN O O
monkey NN O O
brain NN O O
tissues NN O O
and NN O O
lymphoblastoid NN O O
cells NN O O
from NN O O
control NN O O
cases. NN O O
in NN O O
lymphoblastoid NN O O
cell NN O O
lines NN O O
from NN O O
juvenile-onset NN O O
heterozygote NN O O
HD NN B-Modifier B-MSH:D006816
cases, NN O O
both NN O O
normal NN O O
and NN O O
mutant NN O O
huntingtin NN O O
are NN O O
expressed, NN O O
and NN O O
increasing NN O O
repeat NN O O
expansion NN O O
leads NN O O
to NN O O
lower NN O O
levels NN O O
of NN O O
the NN O O
mutant NN O O
protein. NN O O
immunocytochemistry NN O O
indicates NN O O
that NN O O
huntingtin NN O O
is NN O O
located NN O O
in NN O O
neurons NN O O
throughout NN O O
the NN O O
brain, NN O O
with NN O O
the NN O O
highest NN O O
levels NN O O
evident NN O O
in NN O O
larger NN O O
neurons NN O O
. NN O O

in NN O O
the NN O O
human NN O O
striatum, NN O O
huntingtin NN O O
is NN O O
enriched NN O O
in NN O O
a NN O O
patch-like NN O O
distribution, NN O O
potentially NN O O
corresponding NN O O
to NN O O
the NN O O
first NN O O
areas NN O O
affected NN O O
in NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
subcellular NN O O
localization NN O O
of NN O O
huntingtin NN O O
is NN O O
consistent NN O O
with NN O O
a NN O O
cytosolic NN O O
protein NN O O
primarily NN O O
found NN O O
in NN O O
somatodendritic NN O O
regions. NN O O
huntingtin NN O O
appears NN O O
to NN O O
particularly NN O O
associate NN O O
with NN O O
microtubules, NN O O
although NN O O
some NN O O
is NN O O
also NN O O
associated NN O O
with NN O O
synaptic NN O O
vesicles. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
localization NN O O
of NN O O
huntingtin NN O O
in NN O O
association NN O O
with NN O O
microtubules, NN O O
we NN O O
speculate NN O O
that NN O O
the NN O O
mutation NN O O
impairs NN O O
the NN O O
cytoskeletal NN O O
anchoring NN O O
or NN O O
transport NN O O
of NN O O
mitochondria, NN O O
vesicles, NN O O
or NN O O
other NN O O
organelles NN O O
or NN O O
molecules. NN O O
. NN O O

correlation NN O O
between NN O O
the NN O O
location NN O O
of NN O O
germ-line NN O O
mutations NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
and NN O O
the NN O O
number NN O O
of NN O O
colorectal NN B-SpecificDisease B-MSH:D003111
polyps NN I-SpecificDisease I-MSH:D003111
in NN O O
familial NN B-Modifier B-MSH:D011125
adenomatous NN I-Modifier I-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
patients NN O O
. NN O O

recently NN O O
we NN O O
have NN O O
isolated NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
( NN O O
APC NN B-Modifier B-MSH:D011125
) NN O O
gene NN O O
which NN O O
causes NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
), NN O O
and NN O O
its NN O O
germ-line NN O O
mutations NN O O
in NN O O
a NN O O
substantial NN O O
number NN O O
of NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
have NN O O
been NN O O
identified. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
this NN O O
information, NN O O
we NN O O
compared NN O O
the NN O O
location NN O O
of NN O O
germ-line NN O O
mutations NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
in NN O O
22 NN O O
unrelated NN O O
patients NN O O
(12 NN O O
of NN O O
whom NN O O
have NN O O
been NN O O
reported NN O O
previously) NN O O
with NN O O
the NN O O
number NN O O
of NN O O
colorectal NN B-SpecificDisease B-MSH:D003111
polyps NN I-SpecificDisease I-MSH:D003111
developed NN O O
in NN O O
FAP NN B-Modifier B-MSH:D011125
patients; NN O O
17 NN O O
were NN O O
sparse NN O O
types NN O O
and NN O O
five NN O O
were NN O O
profuse NN O O
types. NN O O
all NN O O
but NN O O
one NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
considered NN O O
to NN O O
cause NN O O
truncation NN O O
of NN O O
the NN O O
gene NN O O
product NN O O
by NN O O
frame-shift NN O O
due NN O O
to NN O O
deletion NN O O
(14 NN O O
cases) NN O O
or NN O O
nonsense NN O O
mutation NN O O
(seven NN O O
cases). NN O O
the NN O O
location NN O O
of NN O O
the NN O O
germ-line NN O O
mutations NN O O
seems NN O O
to NN O O
correlate NN O O
with NN O O
the NN O O
tw NN O O
. NN O O

clinical NN O O
types; NN O O
germ-line NN O O
mutations NN O O
in NN O O
five NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
with NN O O
profuse NN O O
polyps NN B-DiseaseClass B-MSH:D011127
were NN O O
observed NN O O
between NN O O
codon NN O O
1250 NN O O
and NN O O
codon NN O O
1464, NN O O
whereas NN O O
mutations NN O O
in NN O O
17 NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
with NN O O
fewer NN O O
polyps NN B-DiseaseClass B-MSH:D011127
were NN O O
observed NN O O
in NN O O
the NN O O
other NN O O
regions NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene. NN O O
the NN O O
result NN O O
suggests NN O O
that NN O O
the NN O O
number NN O O
of NN O O
colorectal NN B-SpecificDisease B-MSH:D003111
polyps NN I-SpecificDisease I-MSH:D003111
in NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
difference NN O O
in NN O O
the NN O O
stability NN O O
or NN O O
biological NN O O
function NN O O
of NN O O
the NN O O
truncated NN O O
APC NN B-Modifier B-MSH:D011125
protein. NN O O
. NN O O

duchenne/becker NN O O
muscular NN O O
dystrophy: NN O O
correlation NN O O
of NN O O
phenotype NN O O
by NN O O
electroretinography NN O O
with NN O O
sites NN O O
of NN O O
dystrophin NN O O
mutations NN O O
. NN O O

the NN O O
dark-adapted NN O O
electroretinogram NN O O
(erg) NN O O
of NN O O
patients NN O O
with NN O O
Duchenne NN B-CompositeMention B-MSH:D020388
and NN I-CompositeMention I-MSH:D020388
Becker NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
/ NN O O
BMD NN B-SpecificDisease B-MSH:C537666
) NN O O
shows NN O O
a NN O O
marked NN O O
reduction NN O O
in NN O O
b-wave NN O O
amplitude. NN O O
genotype-phenotype NN O O
studies NN O O
of NN O O
mouse NN O O
models NN O O
for NN O O
DMD NN B-SpecificDisease B-MSH:D020388
show NN O O
position-specific NN O O
effects NN O O
of NN O O
the NN O O
mutations NN O O
upon NN O O
the NN O O
phenotype NN O O
mice NN O O
with NN O O
5 NN O O
defects NN O O
of NN O O
dystrophin NN O O
have NN O O
normal NN O O
ergs, NN O O
those NN O O
with NN O O
defects NN O O
in NN O O
the NN O O
central NN O O
region NN O O
have NN O O
a NN O O
normal NN O O
b-wave NN O O
amplitude NN O O
associated NN O O
with NN O O
prolonged NN O O
implicit NN O O
times NN O O
for NN O O
both NN O O
the NN O O
b-wave NN O O
and NN O O
oscillatory NN O O
potentials, NN O O
and NN O O
mice NN O O
with NN O O
3 NN O O
defects NN O O
have NN O O
a NN O O
phenotype NN O O
similar NN O O
to NN O O
that NN O O
seen NN O O
in NN O O
DMD NN B-Modifier B-MSH:D020388
/ NN O O
BMD NN B-Modifier B-MSH:C537666
patients. NN O O
the NN O O
mouse NN O O
studies NN O O
suggest NN O O
a NN O O
key NN O O
role NN O O
for NN O O
the NN O O
carboxyl NN O O
terminal NN O O
dystrophin NN O O
isoform, NN O O
dp NN O O
260, NN O O
in NN O O
retinal NN O O
electrophysiology. NN O O
we NN O O
have NN O O
undertaken NN O O
a NN O O
systematic NN O O
evaluation NN O O
of NN O O
DMD NN B-Modifier B-MSH:D020388
/ NN O O
BMD NN B-Modifier B-MSH:C537666
patient NN O O
. NN O O

through NN O O
clinical NN O O
examination NN O O
and NN O O
review NN O O
of NN O O
the NN O O
literature NN O O
in NN O O
order NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
position-specific NN O O
effects NN O O
of NN O O
mutations NN O O
noted NN O O
in NN O O
the NN O O
mouse NN O O
are NN O O
present NN O O
in NN O O
man. NN O O
we NN O O
have NN O O
found NN O O
that, NN O O
in NN O O
man, NN O O
a NN O O
wider NN O O
variation NN O O
of NN O O
DMD NN B-DiseaseClass B-MSH:D020388
defects NN I-DiseaseClass I-MSH:D020388
correlate NN O O
with NN O O
reductions NN O O
in NN O O
the NN O O
b-wave NN O O
amplitude. NN O O
individuals NN O O
with NN O O
normal NN O O
ergs NN O O
have NN O O
mutations NN O O
predominantly NN O O
located NN O O
5 NN O O
of NN O O
the NN O O
transcript NN O O
initiation NN O O
site NN O O
of NN O O
dp NN O O
260. NN O O
our NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
most NN O O
important NN O O
determinant NN O O
in NN O O
the NN O O
erg NN O O
b-wave NN O O
phenotype NN O O
is NN O O
the NN O O
mutation NN O O
position, NN O O
rather NN O O
than NN O O
muscle NN B-Modifier B-MSH:D009135
disease NN I-Modifier I-MSH:D009135
severity. NN O O
forty-six NN O O
per NN O O
cent NN O O
of NN O O
patients NN O O
with NN O O
mutations NN O O
5 NN O O
of NN O O
the NN O O
dp NN O O
260 NN O O
transcript NN O O
start NN O O
site NN O O
have NN O O
abnormal NN O O
ergs, NN O O
as NN O O
opposed NN O O
to NN O O
94% NN O O
with NN O O
more NN O O
distal NN O O
mutations. NN O O
the NN O O
human NN O O
genotype-phenotype NN O O
correlations NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
role NN O O
fo NN O O
. NN O O

dp NN O O
260 NN O O
in NN O O
normal NN O O
retinal NN O O
electrophysiology NN O O
and NN O O
may NN O O
also NN O O
reflect NN O O
the NN O O
expression NN O O
of NN O O
other NN O O
c-terminal NN O O
dystrophin NN O O
isoforms NN O O
and NN O O
their NN O O
contributions NN O O
to NN O O
retinal NN O O
signal NN O O
transmission. NN O O
. NN O O

molecular NN O O
characterization NN O O
of NN O O
two NN O O
galactosemia NN B-Modifier B-MSH:D005693
mutations NN O O
and NN O O
one NN O O
polymorphism: NN O O
implications NN O O
for NN O O
structure-function NN O O
analysis NN O O
of NN O O
human NN O O
galactose-1-phosphate NN O O
uridyltransferase NN O O
. NN O O

we NN O O
report NN O O
here NN O O
the NN O O
molecular NN O O
characterization NN O O
of NN O O
two NN O O
galactosemia NN B-Modifier B-MSH:D005693
mutations, NN O O
l NN O O
74 NN O O
p NN O O
and NN O O
f NN O O
171 NN O O
s, NN O O
and NN O O
one NN O O
polymorphism, NN O O
s NN O O
135 NN O O
l, NN O O
in NN O O
human NN O O
galactose-1-phosphate NN O O
uridyltransferase NN O O
(galt). NN O O
both NN O O
galactosemia NN B-Modifier B-MSH:D005693
mutations NN O O
result NN O O
in NN O O
reduced NN O O
enzymatic NN O O
activity NN O O
when NN O O
reconstructed NN O O
in NN O O
the NN O O
cdna NN O O
and NN O O
overexpressed. NN O O
the NN O O
polymorphism, NN O O
in NN O O
contrast, NN O O
has NN O O
near NN O O
normal NN O O
activity. NN O O
both NN O O
mutations NN O O
affect NN O O
evolutionarily NN O O
conserved NN O O
residues, NN O O
suggesting NN O O
that NN O O
they NN O O
are NN O O
functionally NN O O
important, NN O O
while NN O O
the NN O O
polymorphism NN O O
occurs NN O O
in NN O O
a NN O O
nonconserved NN O O
domain NN O O
which NN O O
is NN O O
presumably NN O O
not NN O O
critical NN O O
for NN O O
enzymatic NN O O
function. NN O O
the NN O O
f NN O O
171 NN O O
s NN O O
mutation NN O O
is NN O O
close NN O O
to NN O O
the NN O O
putative NN O O
active-site NN O O
nucleophile. NN O O
our NN O O
data NN O O
further NN O O
support NN O O
the NN O O
notion NN O O
of NN O O
molecular NN O O
heterogeneity NN O O
of NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
and NN O O
suggest NN O O
that NN O O
galactosemia NN B-Modifier B-MSH:D005693
mutations NN O O
and NN O O
galt NN O O
polymorphisms NN O O
may NN O O
be NN O O
useful NN O O
tools NN O O
in NN O O
highlighting NN O O
different NN O O
functional NN O O
domain NN O O
. NN O O

in NN O O
human NN O O
galt. NN O O
. NN O O

gaucher NN O O
disease: NN O O
the NN O O
origins NN O O
of NN O O
the NN O O
ashkenazi NN O O
jewish NN O O
n NN O O
370 NN O O
s NN O O
and NN O O
84 NN O O
gg NN O O
acid NN O O
beta-glucosidase NN O O
mutations NN O O
. NN O O

type NN O O
1 NN O O
Gaucher NN B-SpecificDisease B-MSH:D005776
disease NN I-SpecificDisease I-MSH:D005776
( NN O O
GD NN B-SpecificDisease B-MSH:D005776
), NN O O
a NN O O
non-neuronopathic NN O O
lysosomal NN B-DiseaseClass B-MSH:D016464
storage NN I-DiseaseClass I-MSH:D016464
disorder NN I-DiseaseClass I-MSH:D016464
, NN O O
results NN O O
from NN O O
the NN O O
deficient NN O O
activity NN O O
of NN O O
acid NN O O
beta-glucosidase NN O O
(gba). NN O O
type NN O O
1 NN O O
disease NN O O
is NN O O
panethnic NN O O
but NN O O
is NN O O
more NN O O
prevalent NN O O
in NN O O
individuals NN O O
of NN O O
ashkenazi NN O O
jewish NN O O
(aj) NN O O
descent. NN O O
of NN O O
the NN O O
causative NN O O
gba NN O O
mutations, NN O O
n NN O O
370 NN O O
s NN O O
is NN O O
particularly NN O O
frequent NN O O
in NN O O
the NN O O
aj NN O O
population, NN O O
(q NN O O
approximately. NN O O
03), NN O O
whereas NN O O
the NN O O
84 NN O O
gg NN O O
insertion NN O O
(q NN O O
approximately. NN O O
003) NN O O
occurs NN O O
exclusively NN O O
in NN O O
the NN O O
ashkenazim. NN O O
to NN O O
investigate NN O O
the NN O O
genetic NN O O
history NN O O
of NN O O
these NN O O
mutations NN O O
in NN O O
the NN O O
aj NN O O
population, NN O O
short NN O O
tandem NN O O
repeat NN O O
(str) NN O O
markers NN O O
were NN O O
used NN O O
to NN O O
map NN O O
a NN O O
9. NN O O
3-cm NN O O
region NN O O
containing NN O O
the NN O O
gba NN O O
locus NN O O
and NN O O
to NN O O
genotype NN O O
261 NN O O
aj NN O O
n NN O O
370 NN O O
s NN O O
chromosomes, NN O O
60 NN O O
european NN O O
non-jewis NN O O
. NN O O

n NN O O
370 NN O O
s NN O O
chromosomes, NN O O
and NN O O
62 NN O O
aj NN O O
84 NN O O
gg NN O O
chromosomes. NN O O
a NN O O
highly NN O O
conserved NN O O
haplotype NN O O
at NN O O
four NN O O
markers NN O O
flanking NN O O
gba NN O O
(pklr, NN O O
d NN O O
1 NN O O
s NN O O
1595, NN O O
d NN O O
1 NN O O
s NN O O
2721, NN O O
and NN O O
d NN O O
1 NN O O
s NN O O
2777) NN O O
was NN O O
observed NN O O
on NN O O
both NN O O
the NN O O
aj NN O O
chromosomes NN O O
and NN O O
the NN O O
non-jewish NN O O
n NN O O
370 NN O O
s NN O O
chromosomes, NN O O
suggesting NN O O
the NN O O
occurrence NN O O
of NN O O
a NN O O
founder NN O O
common NN O O
to NN O O
both NN O O
populations. NN O O
of NN O O
note, NN O O
the NN O O
presence NN O O
of NN O O
different NN O O
divergent NN O O
haplotypes NN O O
suggested NN O O
the NN O O
occurrence NN O O
of NN O O
de NN O O
novo, NN O O
recurrent NN O O
n NN O O
370 NN O O
s NN O O
mutations. NN O O
in NN O O
contrast, NN O O
a NN O O
different NN O O
conserved NN O O
haplotype NN O O
at NN O O
these NN O O
markers NN O O
was NN O O
identified NN O O
on NN O O
the NN O O
84 NN O O
gg NN O O
chromosomes, NN O O
which NN O O
was NN O O
unique NN O O
to NN O O
the NN O O
aj NN O O
population. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
linkage NN O O
disequilibrium NN O O
(ld) NN O O
delta NN O O
values, NN O O
the NN O O
non-jewish NN O O
european NN O O
n NN O O
370 NN O O
s NN O O
chromosomes NN O O
had NN O O
greate NN O O
. NN O O
ype NN O O
at NN O O
four NN O O
markers NN O O
flanking NN O O
gba NN O O
(pklr, NN O O
d NN O O
1 NN O O
s NN O O
1595, NN O O
d NN O O
1 NN O O
s NN O O
2721, NN O O
and NN O O
d NN O O
1 NN O O
s NN O O
2777) NN O O
was NN O O
observed NN O O
on NN O O
both NN O O
the NN O O
aj NN O O
chromosomes NN O O
and NN O O
the NN O O
non-jewish NN O O
n NN O O
370 NN O O
s NN O O
chromosomes, NN O O
suggesting NN O O
the NN O O
occurrence NN O O
of NN O O
a NN O O
founder NN O O
common NN O O
to NN O O
both NN O O
populations. NN O O
of NN O O
note, NN O O
the NN O O
presence NN O O
of NN O O
different NN O O
divergent NN O O
haplotypes NN O O
suggested NN O O
the NN O O
occurrence NN O O
of NN O O
de NN O O
novo, NN O O
recurrent NN O O
n NN O O
370 NN O O
s NN O O
mutations. NN O O
in NN O O
contrast, NN O O
a NN O O
different NN O O
conserved NN O O
haplotype NN O O
at NN O O
these NN O O
markers NN O O
was NN O O
identified NN O O
on NN O O
the NN O O
84 NN O O
gg NN O O
chromosomes, NN O O
which NN O O
was NN O O
unique NN O O
to NN O O
the NN O O
aj NN O O
population. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
linkage NN O O
disequilibrium NN O O
(ld) NN O O
delta NN O O
values, NN O O
the NN O O
non-jewish NN O O
european NN O O
n NN O O
370 NN O O
s NN O O
chromosomes NN O O
had NN O O
greate NN O O
. NN O O

haplotype NN O O
diversity NN O O
and NN O O
less NN O O
ld NN O O
at NN O O
the NN O O
markers NN O O
flanking NN O O
the NN O O
conserved NN O O
haplotype NN O O
than NN O O
did NN O O
the NN O O
aj NN O O
n NN O O
370 NN O O
s NN O O
chromosomes. NN O O
this NN O O
finding NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
n NN O O
370 NN O O
s NN O O
mutation NN O O
in NN O O
the NN O O
non-jewish NN O O
european NN O O
population NN O O
prior NN O O
to NN O O
the NN O O
founding NN O O
of NN O O
the NN O O
aj NN O O
population. NN O O
coalescence NN O O
analyses NN O O
for NN O O
the NN O O
n NN O O
370 NN O O
s NN O O
and NN O O
84 NN O O
gg NN O O
mutations NN O O
estimated NN O O
similar NN O O
coalescence NN O O
times, NN O O
of NN O O
48 NN O O
and NN O O
55.5 NN O O
generations NN O O
ago, NN O O
respectively. NN O O
the NN O O
results NN O O
of NN O O
these NN O O
studies NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
significant NN O O
bottleneck NN O O
occurring NN O O
in NN O O
the NN O O
aj NN O O
population NN O O
during NN O O
the NN O O
first NN O O
millennium, NN O O
when NN O O
the NN O O
population NN O O
became NN O O
established NN O O
in NN O O
europe NN O O
. NN O O
type NN O O
than NN O O
did NN O O
the NN O O
aj NN O O
n NN O O
370 NN O O
s NN O O
chromosomes. NN O O
this NN O O
finding NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
n NN O O
370 NN O O
s NN O O
mutation NN O O
in NN O O
the NN O O
non-jewish NN O O
european NN O O
population NN O O
prior NN O O
to NN O O
the NN O O
founding NN O O
of NN O O
the NN O O
aj NN O O
population. NN O O
coalescence NN O O
analyses NN O O
for NN O O
the NN O O
n NN O O
370 NN O O
s NN O O
and NN O O
84 NN O O
gg NN O O
mutations NN O O
estimated NN O O
similar NN O O
coalescence NN O O
times, NN O O
of NN O O
48 NN O O
and NN O O
55.5 NN O O
generations NN O O
ago, NN O O
respectively. NN O O
the NN O O
results NN O O
of NN O O
these NN O O
studies NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
significant NN O O
bottleneck NN O O
occurring NN O O
in NN O O
the NN O O
aj NN O O
population NN O O
during NN O O
the NN O O
first NN O O
millennium, NN O O
when NN O O
the NN O O
population NN O O
became NN O O
established NN O O
in NN O O
europe NN O O
. NN O O

investigation NN O O
of NN O O
thermoregulatory NN O O
characteristics NN O O
in NN O O
patients NN O O
with NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
. NN O O

a NN O O
survey NN O O
instrument NN O O
is NN O O
used NN O O
to NN O O
assess NN O O
temperature NN O O
regulation NN O O
characteristics NN O O
in NN O O
children NN O O
with NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
compared NN O O
to NN O O
3 NN O O
control NN O O
groups NN O O
sibs NN O O
of NN O O
PWS NN B-Modifier B-MSH:D011218
patients NN O O
(sib), NN O O
neurodevelopmentally NN B-Modifier B-MSH:D009422
handicapped NN I-Modifier I-MSH:D009422
children NN O O
(nd), NN O O
and NN O O
age NN O O
and NN O O
gender NN O O
matched NN O O
well NN O O
children NN O O
(wc). NN O O
significant NN O O
differences NN O O
were NN O O
found NN O O
between NN O O
PWS NN B-Modifier B-MSH:D011218
patients, NN O O
sib NN O O
controls, NN O O
and NN O O
wc NN O O
controls NN O O
in NN O O
the NN O O
prevalence NN O O
of NN O O
febrile NN O O
convulsions, NN O O
fever-associated NN O O
symptoms, NN O O
and NN O O
temperature NN O O
less NN O O
than NN O O
94 NN O O
degrees NN O O
f. NN O O
no NN O O
differences NN O O
were NN O O
noted NN O O
in NN O O
any NN O O
variable NN O O
between NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
patients NN O O
and NN O O
the NN O O
nd NN O O
controls, NN O O
suggesting NN O O
that NN O O
these NN O O
abnormalities NN O O
are NN O O
not NN O O
unique NN O O
to NN O O
PWS NN B-SpecificDisease B-MSH:D011218
, NN O O
but NN O O
can NN O O
occur NN O O
in NN O O
any NN O O
neurodevelopmentally NN B-Modifier B-MSH:D009422
handicapped NN I-Modifier I-MSH:D009422
individual, NN O O
further NN O O
suggesting NN O O
these NN O O
do NN O O
not NN O O
necessarily NN O O
reflect NN O O
syndrome-specific NN O O
hypothalamic NN B-DiseaseClass B-MSH:D007027
abnormalities NN I-DiseaseClass I-MSH:D007027
. NN O O
. NN O O

abnormal NN O O
high NN O O
density NN O O
lipoproteins NN O O
in NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
. NN O O

the NN O O
plasma NN O O
lipoprotein NN O O
profiles NN O O
and NN O O
high NN O O
density NN O O
lipoproteins NN O O
(hdl) NN O O
were NN O O
characterized NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
( NN O O
CTX NN B-SpecificDisease B-MSH:D019294
). NN O O
Abnormalities NN B-DiseaseClass B-MSH:D052456
in NN I-DiseaseClass I-MSH:D052456
the NN I-DiseaseClass I-MSH:D052456
HDL NN I-DiseaseClass I-MSH:D052456
may NN O O
contribute NN O O
to NN O O
their NN O O
increased NN O O
atherogenesis NN O O
and NN O O
excessive NN O O
deposits NN O O
of NN O O
tissue NN O O
sterols NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
low NN O O
or NN O O
low-normal NN O O
concentrations NN O O
of NN O O
plasma NN O O
cholesterol NN O O
(165 NN O O
+/- NN O O
25 NN O O
mg/dl) NN O O
and NN O O
low NN O O
density NN O O
lipoproteins NN O O
(ldl). NN O O
the NN O O
mean NN O O
hdl-cholesterol NN O O
concentration NN O O
in NN O O
the NN O O
CTX NN B-Modifier B-MSH:D019294
plasmas NN O O
was NN O O
14. NN O O
5 NN O O
+/- NN O O
3. NN O O
2 NN O O
mg/dl, NN O O
about NN O O
one-third NN O O
the NN O O
normal NN O O
value. NN O O
the NN O O
low NN O O
hdl-cholesterol NN O O
reflects NN O O
a NN O O
low NN O O
concentration NN O O
and NN O O
an NN O O
abnormal NN O O
lipid NN O O
composition NN O O
of NN O O
the NN O O
plasma NN O O
hdl. NN O O
relative NN O O
to NN O O
normal NN O O
hdl, NN O O
the NN O O
cholesteryl NN O O
esters NN O O
are NN O O
low, NN O O
free NN O O
cholesterol NN O O
and NN O O
phospholipids NN O O
essentially NN O O
norma NN O O
. NN O O

, NN O O
and NN O O
triglycerides NN O O
increased. NN O O
the NN O O
ratio NN O O
of NN O O
apoprotein NN O O
(apo) NN O O
to NN O O
total NN O O
cholesterol NN O O
in NN O O
the NN O O
hdl NN O O
of NN O O
CTX NN B-SpecificDisease B-MSH:D019294
was NN O O
two NN O O
to NN O O
three NN O O
times NN O O
greater NN O O
than NN O O
normal. NN O O
in NN O O
the NN O O
CTX NN B-Modifier B-MSH:D019294
hdl, NN O O
the NN O O
ratio NN O O
of NN O O
apoai NN O O
to NN O O
apoaii NN O O
was NN O O
high, NN O O
the NN O O
proportion NN O O
of NN O O
apoc NN O O
low, NN O O
and NN O O
a NN O O
normally NN O O
minor NN O O
form NN O O
of NN O O
apoai NN O O
increased NN O O
relative NN O O
to NN O O
other NN O O
forms. NN O O
the NN O O
hdl NN O O
in NN O O
electron NN O O
micrographs NN O O
appeared NN O O
normal NN O O
morphologically NN O O
and NN O O
in NN O O
particle NN O O
size. NN O O
the NN O O
abnormalities NN O O
in NN O O
lipoprotein NN O O
distribution NN O O
profile NN O O
and NN O O
composition NN O O
of NN O O
the NN O O
plasma NN O O
hdl NN O O
result NN O O
from NN O O
metabolic NN O O
defects NN O O
that NN O O
are NN O O
not NN O O
understood NN O O
but NN O O
may NN O O
be NN O O
linked NN O O
to NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
in NN O O
bile NN O O
acid NN O O
synthesis NN O O
in NN O O
CTX NN B-SpecificDisease B-MSH:D019294
. NN O O
as NN O O
a NN O O
consequence, NN O O
it NN O O
is NN O O
probable NN O O
that NN O O
the NN O O
normal NN O O
functions NN O O
of NN O O
the NN O O
hdl, NN O O
possibly NN O O
including NN O O
modulation NN O O
of NN O O
ldl-cholesterol NN O O
uptake NN O O
and NN O O
the NN O O
removal NN O O
of NN O O
excess NN O O
cholesterol NN O O
fro NN O O
. NN O O

peripheral NN O O
tissues, NN O O
are NN O O
perturbed NN O O
significantly NN O O
in NN O O
this NN O O
disease NN O O
. NN O O

splicing NN O O
defects NN O O
in NN O O
the NN O O
ataxia-telangiectasia NN B-Modifier B-MSH:D001260
gene, NN O O
atm: NN O O
underlying NN O O
mutations NN O O
and NN O O
consequences NN O O
. NN O O

mutations NN O O
resulting NN O O
in NN O O
defective NN O O
splicing NN O O
constitute NN O O
a NN O O
significant NN O O
proportion NN O O
(30/62 NN O O
[48%]) NN O O
of NN O O
a NN O O
new NN O O
series NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
atm NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
( NN O O
AT NN B-SpecificDisease B-MSH:D001260
) NN O O
that NN O O
were NN O O
detected NN O O
by NN O O
the NN O O
protein-truncation NN O O
assay NN O O
followed NN O O
by NN O O
sequence NN O O
analysis NN O O
of NN O O
genomic NN O O
dna. NN O O
fewer NN O O
than NN O O
half NN O O
of NN O O
the NN O O
splicing NN O O
mutations NN O O
involved NN O O
the NN O O
canonical NN O O
ag NN O O
splice-acceptor NN O O
site NN O O
or NN O O
gt NN O O
splice-donor NN O O
site. NN O O
a NN O O
higher NN O O
percentage NN O O
of NN O O
mutations NN O O
occurred NN O O
at NN O O
less NN O O
stringently NN O O
conserved NN O O
sites, NN O O
including NN O O
silent NN O O
mutations NN O O
of NN O O
the NN O O
last NN O O
nucleotide NN O O
of NN O O
exons, NN O O
mutations NN O O
in NN O O
nucleotides NN O O
other NN O O
than NN O O
the NN O O
conserved NN O O
ag NN O O
and NN O O
gt NN O O
in NN O O
the NN O O
consensus NN O O
splice NN O O
sites, NN O O
and NN O O
creation NN O O
of NN O O
splice-acceptor NN O O
or NN O O
splice-donor NN O O
sites NN O O
in NN O O
either NN O O
introns NN O O
or NN O O
exons. NN O O
these NN O O
splicing NN O O
mutations NN O O
led NN O O
to NN O O
a NN O O
variety NN O O
of NN O O
consequence NN O O
. NN O O

, NN O O
including NN O O
exon NN O O
skipping NN O O
and, NN O O
to NN O O
a NN O O
lesser NN O O
degree, NN O O
intron NN O O
retention, NN O O
activation NN O O
of NN O O
cryptic NN O O
splice NN O O
sites, NN O O
or NN O O
creation NN O O
of NN O O
new NN O O
splice NN O O
sites. NN O O
in NN O O
addition, NN O O
5 NN O O
of NN O O
12 NN O O
nonsense NN O O
mutations NN O O
and NN O O
1 NN O O
missense NN O O
mutation NN O O
were NN O O
associated NN O O
with NN O O
deletion NN O O
in NN O O
the NN O O
cdna NN O O
of NN O O
the NN O O
exons NN O O
in NN O O
which NN O O
the NN O O
mutations NN O O
occurred. NN O O
no NN O O
atm NN O O
protein NN O O
was NN O O
detected NN O O
by NN O O
western NN O O
blotting NN O O
in NN O O
any NN O O
AT NN B-Modifier B-MSH:D001260
cell NN O O
line NN O O
in NN O O
which NN O O
splicing NN O O
mutations NN O O
were NN O O
identified. NN O O
several NN O O
cases NN O O
of NN O O
exon NN O O
skipping NN O O
in NN O O
both NN O O
normal NN O O
controls NN O O
and NN O O
patients NN O O
for NN O O
whom NN O O
no NN O O
underlying NN O O
defect NN O O
could NN O O
be NN O O
found NN O O
in NN O O
genomic NN O O
dna NN O O
were NN O O
also NN O O
observed, NN O O
suggesting NN O O
caution NN O O
in NN O O
the NN O O
interpretation NN O O
of NN O O
exon NN O O
deletions NN O O
observed NN O O
in NN O O
atm NN O O
cdna NN O O
when NN O O
there NN O O
is NN O O
no NN O O
accompanying NN O O
identification NN O O
of NN O O
genomic NN O O
mutations. NN O O
. NN O O

mutations NN O O
of NN O O
the NN O O
cathepsin NN O O
c NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
Papillon-Lefevre NN B-SpecificDisease B-MSH:D010214
syndrome NN I-SpecificDisease I-MSH:D010214
. NN O O

papillon-lefevre NN O O
syndrome NN O O
( NN O O
PLS NN B-SpecificDisease B-MSH:D010214
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterised NN O O
by NN O O
palmoplantar NN B-SpecificDisease B-MSH:D007645
hyperkeratosis NN I-SpecificDisease I-MSH:D007645
and NN O O
severe NN O O
early NN O O
onset NN O O
periodontitis NN B-SpecificDisease B-MSH:D010518
that NN O O
results NN O O
in NN O O
the NN O O
premature NN O O
loss NN O O
of NN O O
the NN O O
primary NN O O
and NN O O
secondary NN O O
dentitions. NN O O
a NN O O
major NN O O
gene NN O O
locus NN O O
for NN O O
PLS NN B-SpecificDisease B-MSH:D010214
has NN O O
been NN O O
mapped NN O O
to NN O O
a NN O O
2. NN O O
8 NN O O
cm NN O O
interval NN O O
on NN O O
chromosome NN O O
11 NN O O
q NN O O
14. NN O O
correlation NN O O
of NN O O
physical NN O O
and NN O O
genetic NN O O
maps NN O O
of NN O O
this NN O O
interval NN O O
indicate NN O O
it NN O O
includes NN O O
at NN O O
least NN O O
40 NN O O
ests NN O O
and NN O O
six NN O O
known NN O O
genes NN O O
including NN O O
the NN O O
lysosomal NN O O
protease NN O O
cathepsin NN O O
c NN O O
gene NN O O
(ctsc). NN O O
the NN O O
ctsc NN O O
message NN O O
is NN O O
expressed NN O O
at NN O O
high NN O O
levels NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
immune NN O O
cells NN O O
including NN O O
polymorphonuclear NN O O
leucocytes, NN O O
macrophages, NN O O
and NN O O
their NN O O
precursors. NN O O
by NN O O
rt-pcr, NN O O
we NN O O
found NN O O
ctsc NN O O
is NN O O
also NN O O
expressed NN O O
in NN O O
epithelial NN O O
regions NN O O
commonly NN O O
affected NN O O
by NN O O
PLS NN B-SpecificDisease B-MSH:D010214
, NN O O
including NN O O
the NN O O
palms, NN O O
soles, NN O O
knees, NN O O
and NN O O
ora NN O O
. NN O O

keratinised NN O O
gingiva. NN O O
the NN O O
4. NN O O
7 NN O O
kb NN O O
ctsc NN O O
gene NN O O
consists NN O O
of NN O O
two NN O O
exons. NN O O
sequence NN O O
analysis NN O O
of NN O O
ctsc NN O O
from NN O O
subjects NN O O
affected NN O O
with NN O O
PLS NN B-SpecificDisease B-MSH:D010214
from NN O O
five NN O O
consanguineous NN O O
turkish NN O O
families NN O O
identified NN O O
four NN O O
different NN O O
mutations. NN O O
an NN O O
exon NN O O
1 NN O O
nonsense NN O O
mutation NN O O
(856 NN O O
c-- NN O O
> NN O O
t) NN O O
introduces NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
at NN O O
amino NN O O
acid NN O O
286. NN O O
three NN O O
exon NN O O
2 NN O O
mutations NN O O
were NN O O
identified, NN O O
including NN O O
a NN O O
single NN O O
nucleotide NN O O
deletion NN O O
(2692 NN O O
dela) NN O O
of NN O O
codon NN O O
349 NN O O
introducing NN O O
a NN O O
frameshift NN O O
and NN O O
premature NN O O
termination NN O O
codon, NN O O
a NN O O
2 NN O O
bp NN O O
deletion NN O O
(2673-2674 NN O O
delct) NN O O
that NN O O
results NN O O
in NN O O
introduction NN O O
of NN O O
a NN O O
stop NN O O
codon NN O O
at NN O O
amino NN O O
acid NN O O
343, NN O O
and NN O O
a NN O O
g-- NN O O
> NN O O
a NN O O
substitution NN O O
in NN O O
codon NN O O
429 NN O O
(2931 NN O O
g-- NN O O
> NN O O
a) NN O O
introducing NN O O
a NN O O
premature NN O O
termination NN O O
codon. NN O O
all NN O O
PLS NN B-Modifier B-MSH:D010214
patients NN O O
were NN O O
homozygous NN O O
for NN O O
cathepsin NN O O
. NN O O

mutations NN O O
inherited NN O O
from NN O O
a NN O O
common NN O O
ancestor. NN O O
parents NN O O
and NN O O
sibs NN O O
heterozygous NN O O
for NN O O
cathepsin NN O O
c NN O O
mutations NN O O
do NN O O
not NN O O
show NN O O
either NN O O
the NN O O
palmoplantar NN B-SpecificDisease B-MSH:D007645
hyperkeratosis NN I-SpecificDisease I-MSH:D007645
or NN O O
severe NN O O
early NN O O
onset NN O O
periodontitis NN B-SpecificDisease B-MSH:D010518
characteristic NN O O
of NN O O
PLS NN B-SpecificDisease B-MSH:D010214
. NN O O
a NN O O
more NN O O
complete NN O O
understanding NN O O
of NN O O
the NN O O
functional NN O O
physiology NN O O
of NN O O
cathepsin NN O O
c NN O O
carries NN O O
significant NN O O
implications NN O O
for NN O O
understanding NN O O
normal NN O O
and NN O O
abnormal NN O O
skin NN O O
development NN O O
and NN O O
periodontal NN B-Modifier B-MSH:D010510
disease NN I-Modifier I-MSH:D010510
susceptibilit NN O O
. NN O O

identification NN O O
of NN O O
a NN O O
single NN O O
nucleotide NN O O
change NN O O
in NN O O
the NN O O
hypoxanthine-guanine NN O O
phosphoribosyltransferase NN O O
gene NN O O
(hprtyale) NN O O
responsible NN O O
for NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O

complete NN O O
deficiency NN B-SpecificDisease B-MSH:D007926
of NN I-SpecificDisease I-MSH:D007926
hypoxanthine-guanine NN I-SpecificDisease I-MSH:D007926
phosphoribosyltransferase NN I-SpecificDisease I-MSH:D007926
(hprt) NN O O
causes NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O
previous NN O O
characterization NN O O
of NN O O
a NN O O
mutant NN O O
form NN O O
of NN O O
hprt, NN O O
hprtyale, NN O O
from NN O O
a NN O O
subject NN O O
with NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
revealed NN O O
normal NN O O
mrna NN O O
and NN O O
protein NN O O
concentrations, NN O O
no NN O O
residual NN O O
catalytic NN O O
activity, NN O O
and NN O O
cathodal NN O O
migration NN O O
upon NN O O
page. NN O O
we NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
hprtyale NN O O
cdna. NN O O
the NN O O
nucleotide NN O O
sequence NN O O
of NN O O
full-length NN O O
hprtyale NN O O
cdna NN O O
revealed NN O O
a NN O O
single NN O O
nucleotide NN O O
substitution NN O O
compared NN O O
with NN O O
normal NN O O
hprt NN O O
cdna NN O O
g----c NN O O
at NN O O
nucleotide NN O O
position NN O O
211. NN O O
this NN O O
transversion NN O O
predicts NN O O
substitution NN O O
of NN O O
arginine NN O O
for NN O O
glycine NN O O
at NN O O
amino NN O O
acid NN O O
position NN O O
71, NN O O
explaining NN O O
the NN O O
cathodal NN O O
migration NN O O
of NN O O
hprtyale. NN O O
chou-fasman NN O O
secondary NN O O
structure NN O O
analysis NN O O
predicts NN O O
a NN O O
change NN O O
in NN O O
the NN O O
probability NN O O
of NN O O
beta-turn NN O O
formation NN O O
in NN O O
the NN O O
region NN O O
containing NN O O
the NN O O
mutation. NN O O
inclusion NN O O
o NN O O
. NN O O

the NN O O
bulky NN O O
arginine NN O O
side NN O O
chain NN O O
in NN O O
place NN O O
of NN O O
glycine NN O O
probably NN O O
disrupts NN O O
protein NN O O
folding NN O O
as NN O O
well. NN O O
cloning NN O O
mutant NN O O
forms NN O O
of NN O O
cdna NN O O
allows NN O O
identification NN O O
of NN O O
specific NN O O
mutations, NN O O
provides NN O O
insight NN O O
into NN O O
mutational NN O O
mechanisms, NN O O
and NN O O
facilitates NN O O
structure-function NN O O
analysis NN O O
of NN O O
mutant NN O O
proteins. NN O O
. NN O O
facilitates NN O O
structure-function NN O O
analysis NN O O
of NN O O
mutant NN O O
proteins. NN O O
. NN O O

molecular NN O O
detection NN O O
of NN O O
chromosomal NN O O
translocations NN O O
that NN O O
disrupt NN O O
the NN O O
putative NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
susceptibility NN O O
locus NN O O
. NN O O

a NN O O
candidate NN O O
dna NN O O
sequence NN O O
with NN O O
many NN O O
of NN O O
the NN O O
properties NN O O
predicted NN O O
for NN O O
the NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
susceptibility NN O O
(rb NN O O
1) NN O O
locus NN O O
has NN O O
been NN O O
cloned NN O O
(s. NN O O
h. NN O O
friend, NN O O
r. NN O O
bernards, NN O O
s. NN O O
rogelj, NN O O
r. NN O O
a. NN O O
weinberg, NN O O
j. NN O O
m. NN O O
rapaport, NN O O
d. NN O O
m. NN O O
albert, NN O O
and NN O O
t. NN O O
p. NN O O
dryja, NN O O
nature NN O O
[london] NN O O
323 NN O O
643-645, NN O O
1986). NN O O
the NN O O
large NN O O
size NN O O
of NN O O
this NN O O
gene NN O O
(ca. NN O O
200 NN O O
kilobases NN O O
[kb]) NN O O
and NN O O
its NN O O
multiple NN O O
dispersed NN O O
exons NN O O
(wiggs NN O O
et NN O O
al., NN O O
n. NN O O
engl. NN O O
j. NN O O
med. NN O O
318 NN O O
151-157, NN O O
1988) NN O O
complicate NN O O
molecular NN O O
screening NN O O
strategies NN O O
important NN O O
in NN O O
prenatal NN O O
and NN O O
presymptomatic NN O O
diagnosis NN O O
and NN O O
in NN O O
carrier NN O O
detection. NN O O
here NN O O
we NN O O
used NN O O
field NN O O
inversion NN O O
gel NN O O
electrophoresis NN O O
(fige NN O O
. NN O O

to NN O O
construct NN O O
a NN O O
restriction NN O O
map NN O O
of NN O O
approximately NN O O
1, NN O O
000 NN O O
kb NN O O
of NN O O
dna NN O O
surrounding NN O O
the NN O O
rb NN O O
1 NN O O
locus NN O O
and NN O O
to NN O O
detect NN O O
the NN O O
translocation NN O O
breakpoints NN O O
in NN O O
three NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
patients. NN O O
dna NN O O
probes NN O O
from NN O O
either NN O O
the NN O O
5 NN O O
or NN O O
3 NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
were NN O O
used NN O O
to NN O O
detect NN O O
a NN O O
250-kb NN O O
eagi NN O O
restriction NN O O
fragment NN O O
in NN O O
dna NN O O
from NN O O
unaffected NN O O
individuals. NN O O
both NN O O
probes NN O O
identified NN O O
an NN O O
additional NN O O
hybridizing NN O O
fragment NN O O
in NN O O
the NN O O
dna NN O O
from NN O O
each NN O O
patient, NN O O
permitting NN O O
the NN O O
breakpoints NN O O
in NN O O
all NN O O
three NN O O
to NN O O
be NN O O
mapped NN O O
within NN O O
the NN O O
cloned NN O O
rb NN O O
1 NN O O
gene. NN O O
analysis NN O O
of NN O O
the NN O O
breakpoint NN O O
in NN O O
one NN O O
translocation NN O O
cell NN O O
line NN O O
allowed NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
to NN O O
be NN O O
oriented NN O O
with NN O O
its NN O O
5 NN O O
end NN O O
toward NN O O
the NN O O
centromere. NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
also NN O O
appeared NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
clustering NN O O
of NN O O
sites NN O O
for NN O O
several NN O O
infrequently NN O O
cleaving NN O O
restriction NN O O
enzymes, NN O O
indicating NN O O
the NN O O
presence NN O O
o NN O O
. NN O O

an NN O O
hpaii NN O O
tiny NN O O
fragment NN O O
island. NN O O
the NN O O
detection NN O O
and NN O O
mapping NN O O
of NN O O
the NN O O
translocation NN O O
breakpoints NN O O
of NN O O
all NN O O
three NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
patients NN O O
to NN O O
within NN O O
the NN O O
putative NN O O
rb NN O O
1 NN O O
gene NN O O
substantiated NN O O
the NN O O
authenticity NN O O
of NN O O
this NN O O
candidate NN O O
sequence NN O O
and NN O O
demonstrated NN O O
the NN O O
utility NN O O
of NN O O
fige NN O O
in NN O O
detecting NN O O
chromosomal NN O O
rearrangements NN O O
affecting NN O O
this NN O O
locus NN O O
. NN O O

constitutional NN O O
mutations NN O O
in NN O O
the NN O O
wt NN O O
1 NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
. NN O O

the NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
is NN O O
characterised NN O O
by NN O O
a NN O O
typical NN O O
nephropathy NN B-DiseaseClass B-MSH:D007674
, NN O O
genital NN B-DiseaseClass B-MSH:D014564
abnormalities NN I-DiseaseClass I-MSH:D014564
and NN O O
also NN O O
predisposes NN O O
to NN O O
the NN O O
development NN O O
of NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
. NN O O
these NN O O
patients NN O O
eventually NN O O
go NN O O
into NN O O
end NN O O
stage NN O O
renal NN B-SpecificDisease B-MSH:D051437
failure NN I-SpecificDisease I-MSH:D051437
. NN O O
a NN O O
candidate NN O O
Wilms NN B-Modifier B-MSH:D009396
tumor NN I-Modifier I-MSH:D009396
gene, NN O O
wt NN O O
1, NN O O
from NN O O
the NN O O
11 NN O O
p NN O O
13 NN O O
chromosome NN O O
region NN O O
has NN O O
recently NN O O
been NN O O
cloned. NN O O
we NN O O
have NN O O
analysed NN O O
the NN O O
dna NN O O
sequence NN O O
in NN O O
constitutional NN O O
cells NN O O
from NN O O
eight NN O O
patients NN O O
and NN O O
have NN O O
shown NN O O
heterozygous NN O O
mutations NN O O
in NN O O
six NN O O
of NN O O
them. NN O O
four NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
in NN O O
exon NN O O
9, NN O O
all NN O O
resulting NN O O
in NN O O
missense NN O O
mutations. NN O O
three NN O O
were NN O O
at NN O O
nucleotide NN O O
position NN O O
1180 NN O O
resulting NN O O
in NN O O
an NN O O
arg NN O O
> NN O O
trp NN O O
amino NN O O
acid NN O O
change. NN O O
the NN O O
other NN O O
was NN O O
at NN O O
position NN O O
1186 NN O O
converting NN O O
an NN O O
asp NN O O
> NN O O
asn NN O O
in NN O O
the NN O O
predicted NN O O
resultant NN O O
protein. NN O O
one NN O O
patient NN O O
had NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
8, NN O O
converting NN O O
an NN O O
arg NN O O
> NN O O
hi NN O O
. NN O O

. NN O O
a NN O O
single NN O O
base NN O O
pair NN O O
insertion NN O O
at NN O O
nucleotide NN O O
position NN O O
821 NN O O
in NN O O
exon NN O O
6 NN O O
resulted NN O O
in NN O O
the NN O O
generation NN O O
of NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
in NN O O
the NN O O
last NN O O
patient. NN O O
we NN O O
were NN O O
unable NN O O
to NN O O
find NN O O
a NN O O
mutation NN O O
in NN O O
one NN O O
patient NN O O
despite NN O O
complete NN O O
sequencing NN O O
of NN O O
the NN O O
genomic NN O O
sequence NN O O
of NN O O
the NN O O
gene. NN O O
the NN O O
last NN O O
patient NN O O
carried NN O O
a NN O O
constitutional NN O O
deletion NN O O
of NN O O
the NN O O
11 NN O O
p NN O O
13 NN O O
region NN O O
and NN O O
no NN O O
additional NN O O
mutation NN O O
was NN O O
found. NN O O
there NN O O
was NN O O
no NN O O
obvious NN O O
correlation NN O O
between NN O O
the NN O O
type NN O O
of NN O O
mutation NN O O
and NN O O
phenotypic NN O O
expression. NN O O
these NN O O
results NN O O
further NN O O
demonstrate NN O O
that NN O O
the NN O O
wt NN O O
1 NN O O
gene NN O O
is NN O O
important NN O O
in NN O O
both NN O O
the NN O O
development NN O O
of NN O O
the NN O O
kidney NN O O
and NN O O
the NN O O
genito-urinary NN O O
system. NN O O
. NN O O
nomic NN O O
sequence NN O O
of NN O O
the NN O O
gene. NN O O
the NN O O
last NN O O
patient NN O O
carried NN O O
a NN O O
constitutional NN O O
deletion NN O O
of NN O O
the NN O O
11 NN O O
p NN O O
13 NN O O
region NN O O
and NN O O
no NN O O
additional NN O O
mutation NN O O
was NN O O
found. NN O O
there NN O O
was NN O O
no NN O O
obvious NN O O
correlation NN O O
between NN O O
the NN O O
type NN O O
of NN O O
mutation NN O O
and NN O O
phenotypic NN O O
expression. NN O O
these NN O O
results NN O O
further NN O O
demonstrate NN O O
that NN O O
the NN O O
wt NN O O
1 NN O O
gene NN O O
is NN O O
important NN O O
in NN O O
both NN O O
the NN O O
development NN O O
of NN O O
the NN O O
kidney NN O O
and NN O O
the NN O O
genito-urinary NN O O
system. NN O O
. NN O O

four NN O O
novel NN O O
pepd NN O O
alleles NN O O
causing NN O O
prolidase NN B-SpecificDisease B-MSH:D056732
deficiency NN I-SpecificDisease I-MSH:D056732
. NN O O

mutations NN O O
at NN O O
the NN O O
pepd NN O O
locus NN O O
cause NN O O
prolidase NN B-SpecificDisease B-MSH:D056732
deficiency NN I-SpecificDisease I-MSH:D056732
(mckusick NN O O
170100), NN O O
a NN O O
rare NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
iminodipeptiduria NN B-SpecificDisease B-MSH:D000592
, NN O O
skin NN B-SpecificDisease B-MSH:D012883
ulcers NN I-SpecificDisease I-MSH:D012883
, NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
and NN O O
recurrent NN O O
infections. NN O O
four NN O O
pepd NN O O
mutations NN O O
from NN O O
five NN O O
severely NN O O
affected NN O O
individuals NN O O
were NN O O
characterized NN O O
by NN O O
analysis NN O O
of NN O O
reverse-transcribed, NN O O
pcr-amplified NN O O
(rt-pcr) NN O O
cdna. NN O O
we NN O O
used NN O O
sscp NN O O
analysis NN O O
on NN O O
four NN O O
overlapping NN O O
cdna NN O O
fragments NN O O
covering NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
pepd NN O O
gene NN O O
and NN O O
detected NN O O
abnormal NN O O
sscp NN O O
bands NN O O
for NN O O
the NN O O
fragment NN O O
spanning NN O O
all NN O O
or NN O O
part NN O O
of NN O O
exons NN O O
13-15 NN O O
in NN O O
three NN O O
of NN O O
the NN O O
probands. NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
mutant NN O O
cdnas NN O O
showed NN O O
a NN O O
g-- NN O O
> NN O O
a, NN O O
1342 NN O O
substitution NN O O
(g NN O O
448 NN O O
r) NN O O
in NN O O
two NN O O
patients NN O O
and NN O O
a NN O O
3-bp NN O O
deletion NN O O
(delta NN O O
e NN O O
452 NN O O
or NN O O
delta NN O O
e NN O O
453) NN O O
i NN O O
. NN O O

another. NN O O
in NN O O
the NN O O
other NN O O
two NN O O
probands NN O O
the NN O O
amplified NN O O
products NN O O
were NN O O
of NN O O
reduced NN O O
size. NN O O
direct NN O O
sequencing NN O O
of NN O O
these NN O O
mutant NN O O
cdnas NN O O
revealed NN O O
a NN O O
deletion NN O O
of NN O O
exon NN O O
5 NN O O
in NN O O
one NN O O
patient NN O O
and NN O O
of NN O O
exon NN O O
7 NN O O
in NN O O
the NN O O
other. NN O O
intronic NN O O
sequences NN O O
flanking NN O O
exons NN O O
5 NN O O
and NN O O
7 NN O O
were NN O O
identified NN O O
using NN O O
inverse NN O O
pcr NN O O
followed NN O O
by NN O O
direct NN O O
sequencing. NN O O
conventional NN O O
pcr NN O O
and NN O O
direct NN O O
sequencing NN O O
then NN O O
established NN O O
the NN O O
intron-exon NN O O
borders NN O O
of NN O O
the NN O O
mutant NN O O
genomic NN O O
dna NN O O
revealing NN O O
two NN O O
splice NN O O
acceptor NN O O
mutations NN O O
a NN O O
g-- NN O O
> NN O O
c NN O O
substitution NN O O
at NN O O
position NN O O
-1 NN O O
of NN O O
intron NN O O
4 NN O O
and NN O O
an NN O O
a-- NN O O
> NN O O
g NN O O
substitution NN O O
at NN O O
position NN O O
-2 NN O O
of NN O O
intron NN O O
6. NN O O
our NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
severe NN O O
form NN O O
of NN O O
prolidase NN B-SpecificDisease B-MSH:D056732
deficiency NN I-SpecificDisease I-MSH:D056732
is NN O O
caused NN O O
by NN O O
multiple NN O O
pepd NN O O
alleles. NN O O
in NN O O
this NN O O
report NN O O
we NN O O
attempt NN O O
to NN O O
begin NN O O
the NN O O
process NN O O
of NN O O
describing NN O O
these NN O O
alleles NN O O
and NN O O
cataloging NN O O
thei NN O O
. NN O O

phenotypic NN O O
expression. NN O O
. NN O O

translocation NN O O
t(5;11)(q NN O O
13.1;p NN O O
13) NN O O
associated NN O O
with NN O O
familial NN O O
isolated NN B-SpecificDisease B-MSH:D015783
aniridia NN I-SpecificDisease I-MSH:D015783
. NN O O

a NN O O
father NN O O
and NN O O
daughter NN O O
with NN O O
isolated NN B-SpecificDisease B-MSH:D015783
aniridia NN I-SpecificDisease I-MSH:D015783
were NN O O
observed NN O O
to NN O O
have NN O O
an NN O O
apparently NN O O
balanced, NN O O
reciprocal NN O O
translocation NN O O
involving NN O O
chromosomes NN O O
5 NN O O
and NN O O
11 NN O O
[t NN O O
(5; NN O O
11) NN O O
(q NN O O
13. NN O O
1; NN O O
p NN O O
13)]. NN O O
no NN O O
other NN O O
clinical NN O O
characteristics NN O O
often NN O O
associated NN O O
with NN O O
the NN O O
deletion NN O O
of NN O O
11 NN O O
p NN O O
13 NN O O
were NN O O
observed NN O O
in NN O O
this NN O O
family. NN O O
this NN O O
finding, NN O O
in NN O O
association NN O O
with NN O O
3 NN O O
other NN O O
instances NN O O
of NN O O
single NN O O
breaks NN O O
at NN O O
11 NN O O
p NN O O
13 NN O O
and NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
supports NN O O
the NN O O
assignment NN O O
of NN O O
an NN O O
2 NN O O
to NN O O
11 NN O O
p NN O O
13 NN O O
. NN O O

genotype-phenotype NN O O
analysis NN O O
in NN O O
X-linked NN B-SpecificDisease B-MSH:D020389
Emery-Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
and NN O O
identification NN O O
of NN O O
a NN O O
missense NN O O
mutation NN O O
associated NN O O
with NN O O
a NN O O
milder NN O O
phenotype NN O O
. NN O O

direct NN O O
sequencing NN O O
of NN O O
the NN O O
emerin NN O O
gene NN O O
in NN O O
22 NN O O
families NN O O
with NN O O
Emery-Dreifuss NN B-SpecificDisease B-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
( NN O O
EMD NN B-SpecificDisease B-MSH:D020389
) NN O O
revealed NN O O
mutations NN O O
in NN O O
21 NN O O
(95%), NN O O
confirming NN O O
that NN O O
emerin NN O O
mutations NN O O
can NN O O
be NN O O
identified NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
families NN O O
with NN O O
X-linked NN B-SpecificDisease B-MSH:D020389
EMD NN I-SpecificDisease I-MSH:D020389
. NN O O
most NN O O
emerin NN O O
mutations NN O O
result NN O O
in NN O O
absence NN O O
of NN O O
the NN O O
protein. NN O O
in NN O O
this NN O O
study NN O O
three NN O O
mutations NN O O
(a NN O O
missense NN O O
mutation NN O O
pro NN O O
183 NN O O
thr NN O O
and NN O O
two NN O O
in-frame NN O O
deletions NN O O
removing NN O O
residues NN O O
95-99 NN O O
and NN O O
236-241, NN O O
respectively) NN O O
were NN O O
unusual NN O O
in NN O O
being NN O O
associated NN O O
with NN O O
expression NN O O
of NN O O
mutant NN O O
protein. NN O O
the NN O O
phenotype NN O O
in NN O O
these NN O O
families NN O O
was NN O O
compared NN O O
in NN O O
detail NN O O
with NN O O
the NN O O
clinical NN O O
features NN O O
in NN O O
cases NN O O
with NN O O
typical NN O O
null NN O O
mutations. NN O O
for NN O O
the NN O O
in-frame NN O O
deletions NN O O
there NN O O
were NN O O
no NN O O
significant NN O O
differences. NN O O
in NN O O
the NN O O
family NN O O
with NN O O
the NN O O
missense NN O O
mutation NN O O
the NN O O
phenotype NN O O
was NN O O
milder NN O O
. NN O O

age NN O O
at NN O O
onset NN O O
was NN O O
later NN O O
for NN O O
first NN O O
symptoms NN O O
and NN O O
for NN O O
development NN O O
of NN O O
ankle NN B-DiseaseClass B-MSH:D003286
contractures NN I-DiseaseClass I-MSH:D003286
and NN O O
muscle NN B-DiseaseClass B-MSH:D018908
weakness NN I-DiseaseClass I-MSH:D018908
. NN O O
these NN O O
findings NN O O
have NN O O
diagnostic NN O O
implications NN O O
as NN O O
well NN O O
as NN O O
pointing NN O O
to NN O O
functionally NN O O
important NN O O
regions NN O O
of NN O O
the NN O O
emerin NN O O
protein. NN O O
. NN O O

asef, NN O O
a NN O O
link NN O O
between NN O O
the NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
apc NN O O
and NN O O
g-protein NN O O
signaling NN O O
. NN O O

the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
gene NN O O
(apc) NN O O
is NN O O
mutated NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
and NN O O
in NN O O
sporadic NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
tumors NN I-SpecificDisease I-MSH:D015179
. NN O O
here NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
product NN O O
is NN O O
shown NN O O
to NN O O
bind NN O O
through NN O O
its NN O O
armadillo NN O O
repeat NN O O
domain NN O O
to NN O O
a NN O O
rac-specific NN O O
guanine NN O O
nucleotide NN O O
exchange NN O O
factor NN O O
(gef), NN O O
termed NN O O
asef. NN O O
endogenous NN O O
apc NN O O
colocalized NN O O
with NN O O
asef NN O O
in NN O O
mouse NN O O
colon NN O O
epithelial NN O O
cells NN O O
and NN O O
neuronal NN O O
cells. NN O O
furthermore, NN O O
apc NN O O
enhanced NN O O
the NN O O
gef NN O O
activity NN O O
of NN O O
asef NN O O
and NN O O
stimulated NN O O
asef-mediated NN O O
cell NN O O
flattening, NN O O
membrane NN O O
ruffling, NN O O
and NN O O
lamellipodia NN O O
formation NN O O
in NN O O
mdck NN O O
cells. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
apc-asef NN O O
complex NN O O
may NN O O
regulate NN O O
the NN O O
actin NN O O
cytoskeletal NN O O
network, NN O O
cell NN O O
morphology NN O O
and NN O O
migration, NN O O
and NN O O
neuronal NN O O
function. NN O O
. NN O O

localization NN O O
of NN O O
the NN O O
region NN O O
homologous NN O O
to NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
locus NN O O
on NN O O
the NN O O
mouse NN O O
x NN O O
chromosome NN O O
. NN O O

recent NN O O
progress NN O O
has NN O O
resulted NN O O
in NN O O
part NN O O
of NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
Duchenne NN B-CompositeMention B-MSH:D020388
and NN I-CompositeMention I-MSH:D020388
the NN I-CompositeMention I-MSH:D020388
milder NN I-CompositeMention I-MSH:D020388
Becker NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophies NN I-CompositeMention I-MSH:D020388
being NN O O
cloned NN O O
and NN O O
has NN O O
suggested NN O O
that NN O O
the NN O O
gene NN O O
itself NN O O
extends NN O O
over NN O O
1, NN O O
000 NN O O
to NN O O
2, NN O O
000 NN O O
kilobases NN O O
(kb). NN O O
to NN O O
study NN O O
how NN O O
mutations NN O O
in NN O O
this NN O O
gene NN O O
affect NN O O
muscle NN O O
development NN O O
and NN O O
integrity, NN O O
it NN O O
would NN O O
be NN O O
of NN O O
interest NN O O
to NN O O
have NN O O
available NN O O
a NN O O
mouse NN O O
model NN O O
of NN O O
the NN O O
human NN O O
disease. NN O O
the NN O O
mouse NN O O
mdx NN O O
mutation NN O O
affects NN O O
muscle NN O O
and NN O O
confers NN O O
a NN O O
mild NN O O
dystrophic NN B-SpecificDisease B-MSH:D009136
syndrome NN I-SpecificDisease I-MSH:D009136
, NN O O
but NN O O
it NN O O
is NN O O
not NN O O
clear NN O O
whether NN O O
this NN O O
mutation NN O O
is NN O O
equivalent NN O O
to NN O O
Duchenne/Becker NN B-CompositeMention B-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
in NN O O
man. NN O O
here NN O O
we NN O O
describe NN O O
the NN O O
use NN O O
of NN O O
two NN O O
sequences NN O O
from NN O O
the NN O O
human NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
gene NN O O
that NN O O
cross-hybridize NN O O
to NN O O
mouse NN O O
x-linked NN O O
sequences NN O O
to NN O O
localize NN O O
the NN O O
gene NN O O
homologous NN O O
to NN O O
DMD NN B-SpecificDisease B-MSH:D020388
in NN O O
the NN O O
mous NN O O
. NN O O

. NN O O
both NN O O
sequences NN O O
map NN O O
to NN O O
the NN O O
region NN O O
of NN O O
10 NN O O
centimorgan NN O O
lying NN O O
between NN O O
the NN O O
tabby NN O O
(ta) NN O O
and NN O O
st NN O O
14-1 NN O O
(dxpas NN O O
8) NN O O
loci, NN O O
close NN O O
to NN O O
the NN O O
phosphorylase NN O O
b NN O O
kinase NN O O
locus NN O O
(phk). NN O O
by NN O O
analogy NN O O
with NN O O
the NN O O
human NN O O
x-chromosome, NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
region NN O O
in NN O O
the NN O O
mouse NN O O
around NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
and NN O O
st NN O O
14-1 NN O O
loci NN O O
may NN O O
contain NN O O
two NN O O
genes NN O O
corresponding NN O O
to NN O O
distinct NN O O
human NN O O
myopathies NN B-DiseaseClass B-MSH:D009135
Emery NN B-SpecificDisease B-MSH:D020389
Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
which NN O O
is NN O O
known NN O O
to NN O O
be NN O O
closely NN O O
linked NN O O
to NN O O
st NN O O
14-1 NN O O
in NN O O
man NN O O
and NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
homologue NN O O
described NN O O
here. NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
hexosaminidase NN B-SpecificDisease B-MSH:D013661
A NN I-SpecificDisease I-MSH:D013661
deficiency NN I-SpecificDisease I-MSH:D013661
and NN O O
pseudodeficiency NN O O
in NN O O
the NN O O
berks NN O O
county NN O O
pennsylvania NN O O
dutch NN O O
. NN O O

following NN O O
the NN O O
birth NN O O
of NN O O
two NN O O
infants NN O O
with NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
), NN O O
a NN O O
non-jewish, NN O O
pennsylvania NN O O
dutch NN O O
kindred NN O O
was NN O O
screened NN O O
for NN O O
TSD NN B-Modifier B-MSH:D013661
carriers NN O O
using NN O O
the NN O O
biochemical NN O O
assay. NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
individuals NN O O
who NN O O
appeared NN O O
to NN O O
be NN O O
TSD NN B-Modifier B-MSH:D013661
heterozygotes NN O O
was NN O O
detected NN O O
(kelly NN O O
et NN O O
al., NN O O
1975). NN O O
clinical NN O O
and NN O O
biochemical NN O O
evidence NN O O
suggested NN O O
that NN O O
the NN O O
increased NN O O
carrier NN O O
frequency NN O O
was NN O O
due NN O O
to NN O O
at NN O O
least NN O O
two NN O O
altered NN O O
alleles NN O O
for NN O O
the NN O O
hexosaminidase NN O O
a NN O O
alpha-subunit. NN O O
we NN O O
now NN O O
report NN O O
two NN O O
mutant NN O O
alleles NN O O
in NN O O
this NN O O
pennsylvania NN O O
dutch NN O O
kindred, NN O O
and NN O O
one NN O O
polymorphism. NN O O
one NN O O
allele, NN O O
reported NN O O
originally NN O O
in NN O O
a NN O O
french NN O O
TSD NN B-Modifier B-MSH:D013661
patient NN O O
(akli NN O O
et NN O O
al., NN O O
1991), NN O O
is NN O O
a NN O O
gt-- NN O O
> NN O O
at NN O O
transition NN O O
at NN O O
the NN O O
donor NN O O
splice-site NN O O
of NN O O
intron NN O O
9. NN O O
the NN O O
second, NN O O
a NN O O
c NN O O
. NN O O

- NN O O
> NN O O
t NN O O
transition NN O O
at NN O O
nucleotide NN O O
739 NN O O
(arg NN O O
247 NN O O
trp), NN O O
has NN O O
been NN O O
shown NN O O
by NN O O
triggs-raine NN O O
et NN O O
al. NN O O
(1992) NN O O
to NN O O
be NN O O
a NN O O
clinically NN O O
benign NN O O
" NN O O
pseudodeficient NN O O
" NN O O
allele NN O O
associated NN O O
with NN O O
reduced NN O O
enzyme NN O O
activity NN O O
against NN O O
artificial NN O O
substrate. NN O O
finally, NN O O
a NN O O
polymorphism NN O O
[g-- NN O O
> NN O O
a NN O O
(759)], NN O O
which NN O O
leaves NN O O
valine NN O O
at NN O O
codon NN O O
253 NN O O
unchanged, NN O O
is NN O O
described NN O O
. NN O O

gene NN O O
transfer NN O O
and NN O O
expression NN O O
of NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
genetic NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
the NN I-SpecificDisease I-OMIM:261600
enzyme NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah). NN O O
a NN O O
full-length NN O O
complementary NN O O
dna NN O O
clone NN O O
of NN O O
human NN O O
pah NN O O
was NN O O
inserted NN O O
into NN O O
a NN O O
eukaryotic NN O O
expression NN O O
vector NN O O
and NN O O
transferred NN O O
into NN O O
mouse NN O O
nih NN O O
3 NN O O
t NN O O
3 NN O O
cells NN O O
which NN O O
do NN O O
not NN O O
normally NN O O
express NN O O
pah. NN O O
the NN O O
transformed NN O O
mouse NN O O
cells NN O O
expressed NN O O
pah NN O O
messenger NN O O
rna, NN O O
immunoreactive NN O O
protein, NN O O
and NN O O
enzymatic NN O O
activity NN O O
that NN O O
are NN O O
characteristic NN O O
of NN O O
the NN O O
normal NN O O
human NN O O
liver NN O O
products, NN O O
demonstrating NN O O
that NN O O
a NN O O
single NN O O
gene NN O O
contains NN O O
all NN O O
of NN O O
the NN O O
necessary NN O O
genetic NN O O
information NN O O
to NN O O
code NN O O
for NN O O
functional NN O O
pah. NN O O
these NN O O
results NN O O
support NN O O
the NN O O
use NN O O
of NN O O
the NN O O
human NN O O
pah NN O O
probe NN O O
in NN O O
prenatal NN O O
diagnosis NN O O
and NN O O
detection NN O O
of NN O O
carriers, NN O O
to NN O O
provide NN O O
new NN O O
opportunities NN O O
for NN O O
the NN O O
biochemical NN O O
characterization NN O O
of NN O O
normal NN O O
and NN O O
mutant NN O O
enzymes, NN O O
and NN O O
in NN O O
the NN O O
investigation NN O O
of NN O O
alternative NN O O
genetic NN O O
therapies NN O O
for NN O O
PKU NN B-SpecificDisease B-MSH:D010661
. NN O O
. NN O O

macular NN O O
dystrophy NN O O
associated NN O O
with NN O O
mutations NN O O
at NN O O
codon NN O O
172 NN O O
in NN O O
the NN O O
human NN O O
retinal NN B-Modifier B-MSH:D012162
degeneration NN I-Modifier I-MSH:D012162
slow NN O O
gene NN O O
. NN O O

background NN O O
recently, NN O O
mutations NN O O
in NN O O
the NN O O
retinal NN B-Modifier B-MSH:D012162
degeneration NN I-Modifier I-MSH:D012162
slow NN O O
(rds) NN O O
gene NN O O
which NN O O
codes NN O O
for NN O O
peripherin-rds NN O O
have NN O O
been NN O O
implicated NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
autosomal NN B-SpecificDisease B-MSH:D012174
dominant NN I-SpecificDisease I-MSH:D012174
retinitis NN I-SpecificDisease I-MSH:D012174
pigmentosa NN I-SpecificDisease I-MSH:D012174
. NN O O
because NN O O
this NN O O
gene NN O O
is NN O O
expressed NN O O
in NN O O
both NN O O
rods NN O O
and NN O O
cones, NN O O
mutations NN O O
in NN O O
the NN O O
rds NN O O
gene NN O O
might NN O O
be NN O O
expected NN O O
to NN O O
cause NN O O
degeneration NN O O
affecting NN O O
either NN O O
the NN O O
scotopic NN O O
or NN O O
photopic NN O O
systems. NN O O
mutations NN O O
at NN O O
codon NN O O
172 NN O O
of NN O O
the NN O O
rds NN O O
gene NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
three NN O O
families NN O O
with NN O O
autosomal NN O O
dominantly NN O O
inherited, NN O O
progressive NN O O
macular NN B-SpecificDisease B-MSH:D008268
dystrophy NN I-SpecificDisease I-MSH:D008268
. NN O O
methods NN O O
affected NN O O
individuals NN O O
underwent NN O O
ophthalmic NN O O
examination, NN O O
scotopic NN O O
perimetry, NN O O
dark NN O O
adaptometry, NN O O
measurement NN O O
of NN O O
color-contrast NN O O
sensitivity, NN O O
and NN O O
electroretinography NN O O
to NN O O
characterize NN O O
the NN O O
photoreceptor NN O O
dysfunction. NN O O
results NN O O
in NN O O
all NN O O
but NN O O
one NN O O
affected NN O O
member, NN O O
symptoms NN O O
of NN O O
progressive NN O O
central NN O O
visual NN B-SpecificDisease B-MSH:C531604
loss NN I-SpecificDisease I-MSH:C531604
developed NN O O
in NN O O
the NN O O
third NN O O
or NN O O
fourth NN O O
decade NN O O
of NN O O
life NN O O
accompanied NN O O
by NN O O
central NN B-SpecificDisease B-MSH:D012607
scotoma NN I-SpecificDisease I-MSH:D012607
an NN O O
. NN O O

well-demarcated NN O O
atrophy NN B-SpecificDisease B-MSH:C536309
of NN I-SpecificDisease I-MSH:C536309
the NN I-SpecificDisease I-MSH:C536309
retinal NN I-SpecificDisease I-MSH:C536309
pigment NN I-SpecificDisease I-MSH:C536309
epithelium NN I-SpecificDisease I-MSH:C536309
and NN O O
choriocapillaris NN B-SpecificDisease B-MSH:D008268
of NN I-SpecificDisease I-MSH:D008268
the NN I-SpecificDisease I-MSH:D008268
macula NN I-SpecificDisease I-MSH:D008268
. NN O O
in NN O O
general, NN O O
cone NN O O
and NN O O
rod NN O O
thresholds NN O O
were NN O O
elevated, NN O O
and NN O O
color-contrast NN O O
sensitivity NN O O
was NN O O
absent NN O O
in NN O O
the NN O O
central NN O O
visual NN O O
field. NN O O
peripherally, NN O O
the NN O O
scotopic NN O O
sensitivities NN O O
were NN O O
normal, NN O O
as NN O O
was NN O O
the NN O O
recovery NN O O
from NN O O
bleach. NN O O
cone NN O O
electroretinograms NN O O
were NN O O
diminished NN O O
in NN O O
amplitude, NN O O
and NN O O
delayed NN O O
in NN O O
all NN O O
affected NN O O
adults NN O O
except NN O O
one. NN O O
rod NN O O
electroretinograms NN O O
were NN O O
normal NN O O
or NN O O
near NN O O
normal NN O O
in NN O O
amplitude, NN O O
and NN O O
had NN O O
normal NN O O
implicit NN O O
times. NN O O
affected NN O O
asymptomatic NN O O
children NN O O
had NN O O
macular NN O O
changes, NN O O
abnormal NN O O
color-contrast NN O O
sensitivity, NN O O
and NN O O
reduced NN O O
pattern NN O O
and NN O O
cone NN O O
electroretinograms. NN O O
conclusion NN O O
these NN O O
results NN O O
indicate NN O O
that NN O O
mutations NN O O
in NN O O
the NN O O
rds NN O O
gene NN O O
can NN O O
be NN O O
expressed NN O O
as NN O O
a NN O O
macular NN B-SpecificDisease B-MSH:D008268
dystrophy NN I-SpecificDisease I-MSH:D008268
, NN O O
with NN O O
evidence NN O O
of NN O O
primary NN O O
cone NN B-DiseaseClass B-OMIM:180020
dysfunction NN I-DiseaseClass I-OMIM:180020
and NN O O
preservation NN O O
of NN O O
peripheral NN O O
rod NN O O
function. NN O O
. NN O O

glucose NN O O
6-phosphate NN O O
dehydrogenase NN O O
variants: NN O O
gd NN O O
(+) NN O O
alexandra NN O O
associated NN O O
with NN O O
neonatal NN B-SpecificDisease B-MSH:D007567
jaundice NN I-SpecificDisease I-MSH:D007567
and NN O O
gd NN O O
(-) NN O O
camperdown NN O O
in NN O O
a NN O O
young NN O O
man NN O O
with NN O O
lamellar NN B-SpecificDisease B-MSH:C535342
cataracts NN I-SpecificDisease I-MSH:C535342
. NN O O

two NN O O
male NN O O
subjects NN O O
are NN O O
described, NN O O
with NN O O
unusual NN O O
clinical NN O O
presentations NN O O
and NN O O
with NN O O
hitherto NN O O
undescribed NN O O
g NN O O
6 NN O O
pd NN O O
variants. NN O O
the NN O O
first, NN O O
of NN O O
italian NN O O
extraction, NN O O
suffered NN O O
from NN O O
severe NN O O
neonatal NN B-SpecificDisease B-MSH:D007567
jaundice NN I-SpecificDisease I-MSH:D007567
following NN O O
maternal NN O O
ingestion NN O O
of NN O O
fresh NN O O
broad NN O O
beans NN O O
(vicia NN O O
fava) NN O O
both NN O O
prenatally NN O O
and NN O O
postnatally NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
enzymatic NN O O
defect NN O O
was NN O O
much NN O O
more NN O O
severe NN O O
in NN O O
the NN O O
neonatal NN O O
period NN O O
than NN O O
on NN O O
retesting NN O O
in NN O O
adolescence, NN O O
when NN O O
biochemical NN O O
characterization NN O O
showed NN O O
unique NN O O
features NN O O
which NN O O
justify NN O O
designation NN O O
as NN O O
a NN O O
new NN O O
variant NN O O
gd NN O O
(+) NN O O
alexandra. NN O O
the NN O O
second NN O O
patient, NN O O
a NN O O
boy NN O O
of NN O O
maltese NN O O
extraction NN O O
who NN O O
was NN O O
found NN O O
to NN O O
have NN O O
bilateral NN B-SpecificDisease B-MSH:C535342
lamellar NN I-SpecificDisease I-MSH:C535342
cataracts NN I-SpecificDisease I-MSH:C535342
at NN O O
the NN O O
age NN O O
of NN O O
4 NN O O
years, NN O O
was NN O O
identified NN O O
as NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficient NN I-SpecificDisease I-MSH:D005955
only NN O O
as NN O O
a NN O O
result NN O O
of NN O O
a NN O O
survey NN O O
of NN O O
children NN O O
of NN O O
mediterranean NN O O
origin NN O O
with NN O O
unexplained NN O O
cataract NN B-Modifier B-MSH:D002386
formation; NN O O
he NN O O
has NN O O
approximately NN O O
15% NN O O
of NN O O
norma NN O O
. NN O O

enzyme NN O O
activity, NN O O
with NN O O
another NN O O
unique NN O O
combination NN O O
of NN O O
biochemical NN O O
characteristics NN O O
which NN O O
has NN O O
led NN O O
to NN O O
its NN O O
designation NN O O
as NN O O
gd NN O O
(-) NN O O
camperdown. NN O O
although NN O O
this NN O O
association NN O O
may NN O O
be NN O O
coincidental, NN O O
it NN O O
prompts NN O O
further NN O O
attention NN O O
to NN O O
the NN O O
possibility NN O O
that NN O O
under NN O O
certain NN O O
circumstances NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
may NN O O
favor NN O O
cataract NN B-Modifier B-MSH:D002386
formation. NN O O
the NN O O
two NN O O
cases NN O O
illustrate NN O O
the NN O O
value NN O O
of NN O O
characterization NN O O
of NN O O
the NN O O
mutant NN O O
enzyme NN O O
whenever NN O O
unexpected NN O O
clinical NN O O
or NN O O
laboratory NN O O
results NN O O
are NN O O
obtained. NN O O
. NN O O

dna NN O O
restriction NN O O
fragments NN O O
associated NN O O
with NN O O
alpha NN O O
1-antitrypsin NN O O
indicate NN O O
a NN O O
single NN O O
origin NN O O
for NN O O
deficiency NN O O
allele NN O O
pi NN O O
z NN O O
. NN O O

the NN O O
alpha NN O O
1-protease NN O O
inhibitor, NN O O
or NN O O
alpha-antitrypsin NN O O
(aat), NN O O
a NN O O
major NN O O
plasma NN O O
inhibitor NN O O
of NN O O
leukocyte NN O O
elastase NN O O
and NN O O
bacterial NN O O
proteases, NN O O
is NN O O
encoded NN O O
at NN O O
the NN O O
pi NN O O
locus NN O O
on NN O O
chromosome NN O O
14 NN O O
(14 NN O O
q NN O O
24. NN O O
3-q NN O O
32. NN O O
1). NN O O
a NN O O
deficiency NN B-SpecificDisease B-MSH:C531610
of NN I-SpecificDisease I-MSH:C531610
AAT NN I-SpecificDisease I-MSH:C531610
in NN O O
individuals NN O O
homozygous NN O O
for NN O O
the NN O O
pi NN O O
z NN O O
allele NN O O
occurs NN O O
in NN O O
about NN O O
1 NN O O
in NN O O
2, NN O O
000-8, NN O O
000 NN O O
caucasians NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
early NN O O
adult NN O O
onset NN O O
emphysema NN B-DiseaseClass B-MSH:D004646
and NN O O
liver NN B-DiseaseClass B-MSH:D008107
disease NN I-DiseaseClass I-MSH:D008107
in NN O O
childhood. NN O O
we NN O O
have NN O O
now NN O O
used NN O O
dna NN O O
polymorphisms NN O O
associated NN O O
with NN O O
the NN O O
aat NN O O
gene NN O O
to NN O O
investigate NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
pi NN O O
z NN O O
allele. NN O O
using NN O O
two NN O O
genomic NN O O
probes NN O O
extending NN O O
into NN O O
the NN O O
5 NN O O
and NN O O
3 NN O O
flanking NN O O
regions, NN O O
respectively, NN O O
we NN O O
have NN O O
identified NN O O
eight NN O O
polymorphic NN O O
restriction NN O O
sites. NN O O
extensive NN O O
linkage NN O O
disequilibrium NN O O
occurs NN O O
throughou NN O O
. NN O O

the NN O O
probed NN O O
region NN O O
with NN O O
the NN O O
pi NN O O
z NN O O
allele, NN O O
but NN O O
not NN O O
with NN O O
normal NN O O
pi NN O O
m NN O O
alleles. NN O O
the NN O O
z NN O O
allele NN O O
occurs NN O O
mainly NN O O
with NN O O
one NN O O
haplotype, NN O O
indicating NN O O
a NN O O
single, NN O O
relatively NN O O
recent, NN O O
origin NN O O
in NN O O
caucasian NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
in NN O O
transgenic NN O O
mice NN O O
expressing NN O O
an NN O O
expanded NN O O
cug NN O O
repeat NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
), NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
muscular NN B-SpecificDisease B-MSH:D009136
dystrophy NN I-SpecificDisease I-MSH:D009136
in NN O O
adult NN O O
humans, NN O O
results NN O O
from NN O O
expansion NN O O
of NN O O
a NN O O
ctg NN O O
repeat NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
dmpk NN O O
gene. NN O O
the NN O O
mutant NN O O
dmpk NN O O
messenger NN O O
rna NN O O
(mrna) NN O O
contains NN O O
an NN O O
expanded NN O O
cug NN O O
repeat NN O O
and NN O O
is NN O O
retained NN O O
in NN O O
the NN O O
nucleus. NN O O
we NN O O
have NN O O
expressed NN O O
an NN O O
untranslated NN O O
cug NN O O
repeat NN O O
in NN O O
an NN O O
unrelated NN O O
mrna NN O O
in NN O O
transgenic NN O O
mice. NN O O
mice NN O O
that NN O O
expressed NN O O
expanded NN O O
cug NN O O
repeats NN O O
developed NN O O
myotonia NN B-DiseaseClass B-MSH:D009222
and NN O O
myopathy NN B-DiseaseClass B-MSH:D009135
, NN O O
whereas NN O O
mice NN O O
expressing NN O O
a NN O O
nonexpanded NN O O
repeat NN O O
did NN O O
not. NN O O
thus, NN O O
transcripts NN O O
with NN O O
expanded NN O O
cug NN O O
repeats NN O O
are NN O O
sufficient NN O O
to NN O O
generate NN O O
a NN O O
DM NN B-Modifier B-MSH:D009223
phenotype. NN O O
this NN O O
result NN O O
supports NN O O
a NN O O
role NN O O
for NN O O
rna NN O O
gain NN O O
of NN O O
function NN O O
in NN O O
disease NN O O
pathogenesis. NN O O
. NN O O

submicroscopic NN O O
deletion NN O O
in NN O O
cousins NN O O
with NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
causes NN O O
a NN O O
grandmatrilineal NN O O
inheritance NN O O
pattern: NN O O
effects NN O O
of NN O O
imprinting NN O O
. NN O O

the NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
critical NN O O
region NN O O
on NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
is NN O O
subject NN O O
to NN O O
imprinting. NN O O
PWS NN B-SpecificDisease B-MSH:D011218
becomes NN O O
apparent NN O O
when NN O O
genes NN O O
on NN O O
the NN O O
paternally NN O O
inherited NN O O
chromosome NN O O
are NN O O
not NN O O
expressed. NN O O
Familial NN B-SpecificDisease B-MSH:D011218
PWS NN I-SpecificDisease I-MSH:D011218
is NN O O
rare. NN O O
we NN O O
report NN O O
on NN O O
a NN O O
family NN O O
in NN O O
which NN O O
a NN O O
male NN O O
and NN O O
a NN O O
female NN O O
paternal NN O O
first NN O O
cousin NN O O
both NN O O
have NN O O
PWS NN B-SpecificDisease B-MSH:D011218
with NN O O
cytogenetically NN O O
normal NN O O
karyotypes. NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
(fish) NN O O
analysis NN O O
shows NN O O
a NN O O
submicroscopic NN O O
deletion NN O O
of NN O O
snrpn, NN O O
but NN O O
not NN O O
the NN O O
closely NN O O
associated NN O O
loci NN O O
d NN O O
15 NN O O
s NN O O
10, NN O O
d NN O O
15 NN O O
s NN O O
11, NN O O
d NN O O
15 NN O O
s NN O O
63, NN O O
and NN O O
gabrb NN O O
3. NN O O
the NN O O
cousins NN O O
fathers NN O O
and NN O O
two NN O O
paternal NN O O
aunts NN O O
have NN O O
the NN O O
same NN O O
deletion NN O O
and NN O O
are NN O O
clinically NN O O
normal. NN O O
the NN O O
grandmother NN O O
of NN O O
the NN O O
cousins NN O O
is NN O O
deceased NN O O
and NN O O
not NN O O
available NN O O
for NN O O
study, NN O O
and NN O O
their NN O O
grandfather NN O O
is NN O O
not NN O O
deleted NN O O
fo NN O O
. NN O O

snrpn. NN O O
dna NN O O
methylation NN O O
analysis NN O O
of NN O O
d NN O O
15 NN O O
s NN O O
63 NN O O
is NN O O
consistent NN O O
with NN O O
an NN O O
abnormality NN O O
of NN O O
the NN O O
imprinting NN O O
center NN O O
associated NN O O
with NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
" NN O O
grandmatrilineal NN O O
" NN O O
inheritance NN O O
occurs NN O O
when NN O O
a NN O O
woman NN O O
with NN O O
deletion NN O O
of NN O O
an NN O O
imprinted, NN O O
paternally NN O O
expressed NN O O
gene NN O O
is NN O O
at NN O O
risk NN O O
of NN O O
having NN O O
affected NN O O
grandchildren NN O O
through NN O O
her NN O O
sons. NN O O
in NN O O
this NN O O
case, NN O O
PWS NN B-SpecificDisease B-MSH:D011218
does NN O O
not NN O O
become NN O O
evident NN O O
as NN O O
long NN O O
as NN O O
the NN O O
deletion NN O O
is NN O O
passed NN O O
through NN O O
the NN O O
matrilineal NN O O
line. NN O O
this NN O O
represents NN O O
a NN O O
unique NN O O
inheritance NN O O
pattern NN O O
due NN O O
to NN O O
imprinting. NN O O
. NN O O

expression NN O O
and NN O O
imprinting NN O O
of NN O O
magel NN O O
2 NN O O
suggest NN O O
a NN O O
role NN O O
in NN O O
Prader-willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
and NN O O
the NN O O
homologous NN O O
murine NN O O
imprinting NN O O
phenotype NN O O
. NN O O

prader-willi NN O O
syndrome NN O O
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
is NN O O
caused NN O O
by NN O O
the NN O O
loss NN O O
of NN O O
expression NN O O
of NN O O
imprinted NN O O
genes NN O O
in NN O O
chromosome NN O O
15 NN O O
q NN O O
11-q NN O O
13. NN O O
affected NN O O
individuals NN O O
exhibit NN O O
neonatal NN B-SpecificDisease B-MSH:D009123
hypotonia NN I-SpecificDisease I-MSH:D009123
, NN O O
developmental NN B-DiseaseClass B-MSH:D002658
delay NN I-DiseaseClass I-MSH:D002658
and NN O O
childhood-onset NN B-DiseaseClass B-MSH:D009765
obesity NN I-DiseaseClass I-MSH:D009765
. NN O O
necdin, NN O O
a NN O O
protein NN O O
implicated NN O O
in NN O O
the NN O O
terminal NN O O
differentiation NN O O
of NN O O
neurons, NN O O
is NN O O
the NN O O
only NN O O
PWS NN B-Modifier B-MSH:D011218
candidate NN O O
gene NN O O
to NN O O
reduce NN O O
viability NN O O
when NN O O
disrupted NN O O
in NN O O
a NN O O
mouse NN O O
model. NN O O
in NN O O
this NN O O
study, NN O O
we NN O O
have NN O O
characterized NN O O
magel NN O O
2 NN O O
(also NN O O
known NN O O
as NN O O
ndnl NN O O
1), NN O O
a NN O O
gene NN O O
with NN O O
51% NN O O
amino NN O O
acid NN O O
sequence NN O O
similarity NN O O
to NN O O
necdin NN O O
and NN O O
located NN O O
41 NN O O
kb NN O O
distal NN O O
to NN O O
ndn NN O O
in NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
deletion NN O O
region. NN O O
magel NN O O
2 NN O O
is NN O O
expressed NN O O
predominantly NN O O
in NN O O
brain, NN O O
the NN O O
primary NN O O
tissue NN O O
affected NN O O
in NN O O
PWS NN B-SpecificDisease B-MSH:D011218
and NN O O
in NN O O
several NN O O
fetal NN O O
tissues NN O O
as NN O O
shown NN O O
by NN O O
northern NN O O
blot NN O O
analysis. NN O O
magel NN O O
2 NN O O
is NN O O
imprinted NN O O
wit NN O O
. NN O O

monoallelic NN O O
expression NN O O
in NN O O
control NN O O
brain, NN O O
and NN O O
paternal-only NN O O
expression NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
as NN O O
demonstrated NN O O
by NN O O
its NN O O
lack NN O O
of NN O O
expression NN O O
in NN O O
brain NN O O
from NN O O
a NN O O
PWS NN B-Modifier B-MSH:D011218
-affected NN O O
individual. NN O O
the NN O O
orthologous NN O O
mouse NN O O
gene NN O O
(magel NN O O
2) NN O O
is NN O O
located NN O O
within NN O O
150 NN O O
kb NN O O
of NN O O
ndn NN O O
, NN O O
is NN O O
imprinted NN O O
with NN O O
paternal-only NN O O
expression NN O O
and NN O O
is NN O O
expressed NN O O
predominantly NN O O
in NN O O
late NN O O
developmental NN O O
stages NN O O
and NN O O
adult NN O O
brain NN O O
as NN O O
shown NN O O
by NN O O
northern NN O O
blotting, NN O O
rt-pcr NN O O
and NN O O
whole-mount NN O O
rna NN O O
in NN O O
situ NN O O
hybridization. NN O O
magel NN O O
2 NN O O
distribution NN O O
partially NN O O
overlaps NN O O
that NN O O
of NN O O
ndn NN O O
, NN O O
with NN O O
strong NN O O
expression NN O O
being NN O O
detected NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
in NN O O
mid-gestation NN O O
mouse NN O O
embryos NN O O
by NN O O
in NN O O
situ NN O O
hybridization. NN O O
we NN O O
hypothesize NN O O
that, NN O O
although NN O O
loss NN O O
of NN O O
necdin NN O O
expression NN O O
may NN O O
be NN O O
important NN O O
in NN O O
the NN O O
neonatal NN O O
presentation NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
, NN O O
loss NN O O
of NN O O
magel NN O O
2 NN O O
may NN O O
be NN O O
critica NN O O
. NN O O

to NN O O
abnormalities NN B-DiseaseClass B-MSH:D002658
in NN I-DiseaseClass I-MSH:D002658
brain NN I-DiseaseClass I-MSH:D002658
development NN I-DiseaseClass I-MSH:D002658
and NN O O
dysmorphic NN B-DiseaseClass B-MSH:D057215
features NN I-DiseaseClass I-MSH:D057215
in NN O O
individuals NN O O
with NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
. NN O O

a NN O O
single NN O O
origin NN O O
of NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
in NN O O
yemenite NN O O
jews NN O O
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
a NN O O
metabolic NN B-DiseaseClass B-MSH:D008659
disease NN I-DiseaseClass I-MSH:D008659
caused NN O O
by NN O O
recessive NN O O
mutations NN O O
of NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
hepatic NN O O
enzyme NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah). NN O O
the NN O O
incidence NN O O
of NN O O
PKU NN B-SpecificDisease B-MSH:D010661
varies NN O O
widely NN O O
across NN O O
different NN O O
geographic NN O O
areas, NN O O
and NN O O
is NN O O
highest NN O O
(about NN O O
1 NN O O
in NN O O
5, NN O O
000 NN O O
live NN O O
births) NN O O
in NN O O
ireland NN O O
and NN O O
western NN O O
scotland, NN O O
and NN O O
among NN O O
yemenite NN O O
jews. NN O O
a NN O O
limited NN O O
number NN O O
of NN O O
point NN O O
mutations NN O O
account NN O O
for NN O O
most NN O O
of NN O O
the NN O O
PKU NN B-Modifier B-MSH:D010661
cases NN O O
in NN O O
the NN O O
european NN O O
population. NN O O
here NN O O
we NN O O
report NN O O
that NN O O
a NN O O
single NN O O
molecular NN O O
defect--a NN O O
deletion NN O O
spanning NN O O
the NN O O
third NN O O
exon NN O O
of NN O O
the NN O O
pah NN O O
gene--is NN O O
responsible NN O O
for NN O O
all NN O O
the NN O O
PKU NN B-Modifier B-MSH:D010661
cases NN O O
among NN O O
the NN O O
yemenite NN O O
jews. NN O O
examination NN O O
of NN O O
a NN O O
random NN O O
sample NN O O
of NN O O
yemenite NN O O
jews NN O O
using NN O O
a NN O O
molecular NN O O
probe NN O O
that NN O O
detects NN O O
the NN O O
carriers NN O O
of NN O O
this NN O O
deletion NN O O
indicated NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
the NN O O
defective NN O O
gene NN O O
i NN O O
. NN O O

this NN O O
community. NN O O
although NN O O
the NN O O
deleted NN O O
pah NN O O
gene NN O O
was NN O O
traced NN O O
to NN O O
25 NN O O
different NN O O
locations NN O O
throughout NN O O
yemen, NN O O
family NN O O
histories NN O O
and NN O O
official NN O O
documents NN O O
of NN O O
the NN O O
yemenite NN O O
jewish NN O O
community NN O O
showed NN O O
that NN O O
the NN O O
common NN O O
ancestor NN O O
of NN O O
all NN O O
the NN O O
carriers NN O O
of NN O O
this NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
lived NN O O
in NN O O
sana, NN O O
the NN O O
capital NN O O
of NN O O
yemen, NN O O
before NN O O
the NN O O
eighteenth NN O O
century. NN O O
. NN O O

high NN O O
resolution NN O O
genetic NN O O
analysis NN O O
suggests NN O O
one NN O O
ancestral NN O O
predisposing NN O O
haplotype NN O O
for NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
mutation NN O O
. NN O O

the NN O O
mutation NN O O
causing NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
has NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
amplification NN O O
of NN O O
an NN O O
unstable NN O O
trinucleotide NN O O
(ctg) NN O O
n NN O O
repeat NN O O
in NN O O
over NN O O
99% NN O O
of NN O O
the NN O O
global NN O O
DM NN B-Modifier B-MSH:D009223
population. NN O O
it NN O O
is NN O O
in NN O O
complete NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
an NN O O
alu NN O O
element NN O O
polymorphism NN O O
within NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
gene, NN O O
suggesting NN O O
that NN O O
DM NN B-SpecificDisease B-MSH:D009223
is NN O O
a NN O O
consequence NN O O
of NN O O
one NN O O
or NN O O
few NN O O
ancestral NN O O
mutations. NN O O
a NN O O
recent NN O O
analysis NN O O
utilizing NN O O
this NN O O
polymorphism NN O O
as NN O O
well NN O O
as NN O O
a NN O O
flanking NN O O
dinucleotide NN O O
marker, NN O O
suggested NN O O
that NN O O
similar NN O O
to NN O O
Fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
, NN O O
DM NN B-SpecificDisease B-MSH:D009223
exhibited NN O O
a NN O O
founder NN O O
effect NN O O
(imbert NN O O
et NN O O
al., NN O O
1993 NN O O
nature NN O O
genet. NN O O
4, NN O O
72-76). NN O O
in NN O O
contrast, NN O O
the NN O O
low NN O O
reproductive NN O O
fitness NN O O
of NN O O
individuals NN O O
with NN O O
congenital NN O O
DM NN B-SpecificDisease B-MSH:D009223
(the NN O O
endpoint NN O O
of NN O O
genetic NN O O
anticipation NN O O
in NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
) NN O O
suggests NN O O
a NN O O
higher NN O O
rate NN O O
of NN O O
new NN O O
mutations. NN O O
we NN O O
present NN O O
. NN O O

high NN O O
resolution NN O O
genetic NN O O
analysis NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
locus NN O O
using NN O O
pcr NN O O
based NN O O
assays NN O O
of NN O O
nine NN O O
polymorphisms, NN O O
spanning NN O O
a NN O O
physical NN O O
distance NN O O
of NN O O
30 NN O O
kb, NN O O
within NN O O
and NN O O
immediately NN O O
flanking NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
gene. NN O O
the NN O O
persistent NN O O
complete NN O O
allelic NN O O
association NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
mutation NN O O
with NN O O
all NN O O
these NN O O
polymorphisms NN O O
provides NN O O
further NN O O
support NN O O
to NN O O
previous NN O O
observations NN O O
and NN O O
suggests NN O O
more NN O O
strongly NN O O
that NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
mutation NN O O
occurred NN O O
on NN O O
the NN O O
background NN O O
of NN O O
a NN O O
particular NN O O
haplotype NN O O
in NN O O
which NN O O
the NN O O
(ctg) NN O O
n NN O O
repeat NN O O
became NN O O
inherently NN O O
unstable NN O O
and NN O O
therefore NN O O
predisposed NN O O
to NN O O
amplification NN O O
. NN O O

identification NN O O
and NN O O
rapid NN O O
detection NN O O
of NN O O
three NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
mutations NN O O
in NN O O
the NN O O
moroccan NN O O
jewish NN O O
population NN O O
. NN O O

infantile NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
) NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
hexa NN O O
gene NN O O
that NN O O
result NN O O
in NN O O
the NN O O
complete NN O O
absence NN O O
of NN O O
beta-hexosaminidase NN O O
a NN O O
activity. NN O O
it NN O O
is NN O O
well NN O O
known NN O O
that NN O O
an NN O O
elevated NN O O
frequency NN O O
of NN O O
TSD NN B-Modifier B-MSH:D013661
mutations NN O O
exists NN O O
among NN O O
ashkenazi NN O O
jews. NN O O
more NN O O
recently NN O O
it NN O O
has NN O O
become NN O O
apparent NN O O
that NN O O
elevated NN O O
carrier NN O O
frequencies NN O O
for NN O O
TSD NN B-SpecificDisease B-MSH:D013661
also NN O O
occur NN O O
in NN O O
several NN O O
other NN O O
ethnic NN O O
groups, NN O O
including NN O O
moroccan NN O O
jews, NN O O
a NN O O
subgroup NN O O
of NN O O
sephardic NN O O
jews. NN O O
elsewhere NN O O
we NN O O
reported NN O O
an NN O O
in-frame NN O O
deletion NN O O
of NN O O
one NN O O
of NN O O
the NN O O
two NN O O
adjacent NN O O
phenylalanine NN O O
codons NN O O
at NN O O
position NN O O
304 NN O O
or NN O O
305 NN O O
(delta NN O O
f NN O O
304/305) NN O O
in NN O O
one NN O O
hexa NN O O
allele NN O O
of NN O O
a NN O O
moroccan NN O O
jewish NN O O
TSD NN B-Modifier B-MSH:D013661
patient NN O O
and NN O O
in NN O O
three NN O O
obligate NN O O
carriers NN O O
from NN O O
six NN O O
unrelated NN O O
moroccan NN O O
jewish NN O O
families. NN O O
we NN O O
have NN O O
now NN O O
identified NN O O
two NN O O
additional NN O O
mutations NN O O
within NN O O
exon NN O O
5 NN O O
of NN O O
the NN O O
hexa NN O O
gene NN O O
tha NN O O
. NN O O

account NN O O
for NN O O
the NN O O
remaining NN O O
TSD NN B-Modifier B-MSH:D013661
alleles NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
carriers. NN O O
one NN O O
of NN O O
the NN O O
mutations NN O O
is NN O O
a NN O O
novel NN O O
c-to-g NN O O
transversion, NN O O
resulting NN O O
in NN O O
a NN O O
replacement NN O O
of NN O O
tyr NN O O
180 NN O O
by NN O O
a NN O O
stop NN O O
codon. NN O O
the NN O O
other NN O O
mutation NN O O
is NN O O
a NN O O
g-to-a NN O O
transition NN O O
resulting NN O O
in NN O O
an NN O O
arg NN O O
170-to-gln NN O O
substitution. NN O O
this NN O O
mutation NN O O
is NN O O
at NN O O
a NN O O
cpg NN O O
site NN O O
in NN O O
a NN O O
japanese NN O O
infant NN O O
with NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
and NN O O
was NN O O
described NN O O
elsewhere. NN O O
analysis NN O O
of NN O O
nine NN O O
obligate NN O O
carriers NN O O
from NN O O
seven NN O O
unrelated NN O O
families NN O O
showed NN O O
that NN O O
four NN O O
harbor NN O O
the NN O O
delta NN O O
f NN O O
304/305 NN O O
mutation, NN O O
two NN O O
the NN O O
arg NN O O
170----gln NN O O
mutation, NN O O
and NN O O
one NN O O
the NN O O
tyr NN O O
180----stop NN O O
mutation. NN O O
we NN O O
also NN O O
have NN O O
developed NN O O
rapid, NN O O
nonradioactive NN O O
assays NN O O
for NN O O
the NN O O
detection NN O O
of NN O O
each NN O O
mutation NN O O
. NN O O

which NN O O
should NN O O
be NN O O
helpful NN O O
for NN O O
carrier NN O O
screening. NN O O
. NN O O

mapping NN O O
of NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
the NN O O
Wilson NN B-Modifier B-MSH:D006527
disease NN I-Modifier I-MSH:D006527
gene NN O O
to NN O O
mouse NN O O
chromosome NN O O
8 NN O O
. NN O O

atp NN O O
7 NN O O
b, NN O O
the NN O O
gene NN O O
altered NN O O
in NN O O
Wilson NN B-Modifier B-MSH:D006527
disease NN I-Modifier I-MSH:D006527
( NN O O
WD NN B-Modifier B-MSH:D006527
) NN O O
patients, NN O O
lies NN O O
in NN O O
a NN O O
block NN O O
of NN O O
homology NN O O
shared NN O O
between NN O O
human NN O O
chromosome NN O O
13 NN O O
q NN O O
14 NN O O
and NN O O
the NN O O
central NN O O
region NN O O
of NN O O
mouse NN O O
chromosome NN O O
14. NN O O
however, NN O O
we NN O O
have NN O O
mapped NN O O
the NN O O
murine NN O O
homologue NN O O
of NN O O
atp NN O O
7 NN O O
b NN O O
(atp NN O O
7 NN O O
b) NN O O
to NN O O
mouse NN O O
chromosome NN O O
8 NN O O
by NN O O
somatic NN O O
cell NN O O
hybrid NN O O
analysis. NN O O
analysis NN O O
of NN O O
80 NN O O
interspecific NN O O
backcross NN O O
offspring NN O O
was NN O O
used NN O O
to NN O O
position NN O O
atp NN O O
7 NN O O
b NN O O
close NN O O
to NN O O
d NN O O
8 NN O O
mit NN O O
3 NN O O
and NN O O
another NN O O
atpase NN O O
locus, NN O O
atp NN O O
4 NN O O
b, NN O O
on NN O O
mouse NN O O
chromosome NN O O
8. NN O O
atp NN O O
4 NN O O
b NN O O
lies NN O O
in NN O O
13 NN O O
q NN O O
34 NN O O
and NN O O
is NN O O
separated NN O O
from NN O O
atp NN O O
7 NN O O
b NN O O
by NN O O
several NN O O
loci NN O O
whose NN O O
mouse NN O O
homologues NN O O
map NN O O
to NN O O
mouse NN O O
chromosome NN O O
14. NN O O
the NN O O
assignment NN O O
of NN O O
atp NN O O
7 NN O O
b NN O O
to NN O O
mouse NN O O
chromosome NN O O
8 NN O O
identifies NN O O
a NN O O
previously NN O O
unrecognized NN O O
region NN O O
o NN O O
. NN O O

homology NN O O
between NN O O
this NN O O
chromosome NN O O
and NN O O
human NN O O
chromosome NN O O
13. NN O O
this NN O O
assignment NN O O
suggests NN O O
a NN O O
possible NN O O
location NN O O
for NN O O
the NN O O
toxic NN O O
milk NN O O
mutation NN O O
in NN O O
the NN O O
mouse, NN O O
which NN O O
has NN O O
been NN O O
proposed NN O O
as NN O O
a NN O O
homologue NN O O
of NN O O
WD NN B-SpecificDisease B-MSH:D006527
. NN O O
. NN O O

characteristics NN O O
of NN O O
intergenerational NN O O
contractions NN O O
of NN O O
the NN O O
ctg NN O O
repeat NN O O
in NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
. NN O O

in NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
), NN O O
the NN O O
size NN O O
of NN O O
a NN O O
ctg NN O O
repeat NN O O
in NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
gene NN O O
generally NN O O
increases NN O O
in NN O O
successive NN O O
generations NN O O
with NN O O
clinical NN O O
evidence NN O O
of NN O O
anticipation. NN O O
however, NN O O
there NN O O
have NN O O
also NN O O
been NN O O
cases NN O O
with NN O O
an NN O O
intergenerational NN O O
contraction NN O O
of NN O O
the NN O O
repeat. NN O O
we NN O O
examined NN O O
1, NN O O
489 NN O O
DM NN B-Modifier B-MSH:D009223
parent-offspring NN O O
pairs, NN O O
of NN O O
which NN O O
95 NN O O
(6. NN O O
4%) NN O O
showed NN O O
such NN O O
contractions NN O O
in NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
(pbl). NN O O
in NN O O
56 NN O O
of NN O O
the NN O O
95 NN O O
pairs, NN O O
clinical NN O O
data NN O O
allowed NN O O
an NN O O
analysis NN O O
of NN O O
their NN O O
anticipation NN O O
status. NN O O
it NN O O
is NN O O
surprising NN O O
that NN O O
anticipation NN O O
occurred NN O O
in NN O O
27 NN O O
(48%) NN O O
of NN O O
these NN O O
56 NN O O
pairs, NN O O
while NN O O
none NN O O
clearly NN O O
showed NN O O
a NN O O
later NN O O
onset NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
in NN O O
the NN O O
symptomatic NN O O
offspring. NN O O
the NN O O
contraction NN O O
occurred NN O O
in NN O O
76 NN O O
(10%) NN O O
of NN O O
753 NN O O
paternal NN O O
transmissions NN O O
and NN O O
in NN O O
19 NN O O
. NN O O

3%) NN O O
of NN O O
736 NN O O
maternal NN O O
transmissions. NN O O
anticipation NN O O
was NN O O
observed NN O O
more NN O O
frequently NN O O
in NN O O
maternal NN O O
(85%) NN O O
than NN O O
in NN O O
paternal NN O O
(37%) NN O O
transmissions NN O O
(p NN O O
<. NN O O
001). NN O O
the NN O O
parental NN O O
repeat NN O O
size NN O O
correlated NN O O
with NN O O
the NN O O
size NN O O
of NN O O
intergenerational NN O O
contraction NN O O
(r NN O O
2 NN O O
=. NN O O
50, NN O O
p NN O O
< NN O O
<. NN O O
001), NN O O
and NN O O
the NN O O
slope NN O O
of NN O O
linear NN O O
regression NN O O
was NN O O
steeper NN O O
in NN O O
paternal NN O O
(-. NN O O
62) NN O O
than NN O O
in NN O O
maternal NN O O
(-. NN O O
30) NN O O
transmissions NN O O
(p NN O O
< NN O O
<. NN O O
001). NN O O
sixteen NN O O
DM NN B-Modifier B-MSH:D009223
parents NN O O
had NN O O
multiple NN O O
DM NN B-Modifier B-MSH:D009223
offspring NN O O
with NN O O
the NN O O
ctg NN O O
repeat NN O O
contractions. NN O O
this NN O O
frequency NN O O
was NN O O
higher NN O O
than NN O O
the NN O O
frequency NN O O
expected NN O O
from NN O O
the NN O O
probability NN O O
of NN O O
the NN O O
repeat NN O O
contractions NN O O
(6. NN O O
4%) NN O O
and NN O O
the NN O O
size NN O O
of NN O O
DM NN B-Modifier B-MSH:D009223
sib NN O O
population NN O O
(1. NN O O
54 NN O O
DM NN B-Modifier B-MSH:D009223
offspring NN O O
per NN O O
DM NN B-Modifier B-MSH:D009223
. NN O O

parent, NN O O
in NN O O
968 NN O O
DM NN B-Modifier B-MSH:D009223
parents). NN O O
we NN O O
conclude NN O O
that NN O O
(1) NN O O
intergenerational NN O O
contractions NN O O
of NN O O
the NN O O
ctg NN O O
repeat NN O O
in NN O O
leukocyte NN O O
dna NN O O
frequently NN O O
accompanies NN O O
apparent NN O O
anticipation, NN O O
especially NN O O
when NN O O
DM NN B-SpecificDisease B-MSH:D009223
is NN O O
maternally NN O O
transmitted, NN O O
and NN O O
(2) NN O O
the NN O O
paternal NN O O
origin NN O O
of NN O O
the NN O O
repeat NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
repeat NN O O
contraction NN O O
in NN O O
a NN O O
sibling NN O O
increase NN O O
the NN O O
probability NN O O
of NN O O
the NN O O
ctg NN O O
repeat NN O O
contractio NN O O
. NN O O

splice-site NN O O
mutation NN O O
in NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
may NN O O
result NN O O
in NN O O
intrafamilial NN O O
variability NN O O
for NN O O
deafness NN B-SpecificDisease B-MSH:D003638
in NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
. NN O O

pendred NN O O
syndrome NN O O
is NN O O
a NN O O
recessive NN B-DiseaseClass B-MSH:D030342
inherited NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
that NN O O
consists NN O O
of NN O O
developmental NN B-DiseaseClass B-MSH:D015834
abnormalities NN I-DiseaseClass I-MSH:D015834
of NN I-DiseaseClass I-MSH:D015834
the NN I-DiseaseClass I-MSH:D015834
cochlea NN I-DiseaseClass I-MSH:D015834
, NN O O
sensorineural NN B-SpecificDisease B-MSH:D006319
hearing NN I-SpecificDisease I-MSH:D006319
loss NN I-SpecificDisease I-MSH:D006319
, NN O O
and NN O O
diffuse NN B-SpecificDisease B-MSH:D013959
thyroid NN I-SpecificDisease I-MSH:D013959
enlargement NN I-SpecificDisease I-MSH:D013959
( NN O O
goiter NN B-SpecificDisease B-MSH:D006042
). NN O O
this NN O O
disorder NN O O
may NN O O
account NN O O
for NN O O
up NN O O
to NN O O
10% NN O O
of NN O O
cases NN O O
of NN O O
hereditary NN B-SpecificDisease B-MSH:D030342
deafness NN I-SpecificDisease I-MSH:D030342
. NN O O
the NN O O
disease NN O O
gene NN O O
( NN O O
PDS NN B-SpecificDisease B-MSH:C536648
) NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
7 NN O O
q NN O O
22-q NN O O
31, NN O O
and NN O O
encodes NN O O
a NN O O
chloride-iodide NN O O
transport NN O O
protein. NN O O
we NN O O
performed NN O O
mutation NN O O
analysis NN O O
of NN O O
individual NN O O
exons NN O O
of NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
in NN O O
one NN O O
spanish NN O O
family NN O O
that NN O O
shows NN O O
intrafamilial NN O O
variability NN O O
of NN O O
the NN O O
deafness NN B-Modifier B-MSH:D003638
phenotype NN O O
(two NN O O
patients NN O O
with NN O O
profound NN O O
and NN O O
one NN O O
with NN O O
moderate-severe NN O O
deafness NN B-SpecificDisease B-MSH:D003638
). NN O O
we NN O O
identified NN O O
a NN O O
new NN O O
splice-site NN O O
mutation NN O O
affecting NN O O
intron NN O O
4 NN O O
of NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene, NN O O
at NN O O
nucleotide NN O O
position NN O O
639 NN O O
+ NN O O
7. NN O O
rna NN O O
analysis NN O O
from NN O O
lymphocytes NN O O
of NN O O
the NN O O
affected NN O O
patients NN O O
showed NN O O
tha NN O O
. NN O O

mutation NN O O
639 NN O O
+ NN O O
7 NN O O
a-- NN O O
> NN O O
g NN O O
generates NN O O
a NN O O
new NN O O
donor NN O O
splice NN O O
site, NN O O
leading NN O O
to NN O O
an NN O O
mrna NN O O
with NN O O
an NN O O
insertion NN O O
of NN O O
six NN O O
nucleotides NN O O
from NN O O
intron NN O O
4 NN O O
of NN O O
pds. NN O O
since NN O O
the NN O O
newly NN O O
created NN O O
donor NN O O
splice NN O O
site NN O O
is NN O O
likely NN O O
to NN O O
compete NN O O
with NN O O
the NN O O
normal NN O O
one, NN O O
variations NN O O
of NN O O
the NN O O
levels NN O O
of NN O O
normal NN O O
and NN O O
aberrant NN O O
transcripts NN O O
of NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
in NN O O
the NN O O
cochlea NN O O
may NN O O
explain NN O O
the NN O O
variability NN O O
in NN O O
the NN O O
deafness NN B-Modifier B-MSH:D003638
presentation. NN O O
. NN O O

heterozygous NN O O
loss NN O O
of NN O O
six NN O O
5 NN O O
in NN O O
mice NN O O
is NN O O
sufficient NN O O
to NN O O
cause NN O O
ocular NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
. NN O O

myotonic NN O O
dystrophy NN O O
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
disorde NN I-DiseaseClass I-MSH:D030342
r NN O O
characterized NN O O
by NN O O
skeletal NN O O
muscle NN B-SpecificDisease B-MSH:D009133
wasting NN I-SpecificDisease I-MSH:D009133
, NN O O
myotonia NN B-DiseaseClass B-MSH:D009222
, NN O O
cardiac NN B-DiseaseClass B-MSH:D001145
arrhythmia NN I-DiseaseClass I-MSH:D001145
, NN O O
hyperinsulinaemia NN B-SpecificDisease B-MSH:D006946
, NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
and NN O O
ocular NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
. NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
in NN O O
DM NN B-SpecificDisease B-MSH:D009223
is NN O O
a NN O O
ctg NN O O
repeat NN O O
expansion NN O O
located NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
dmpk NN O O
and NN O O
5 NN O O
of NN O O
a NN O O
homeodomain-encoding NN O O
gene, NN O O
six NN O O
5 NN O O
(formerly NN O O
dmahp; NN O O
refs NN O O
2-5). NN O O
there NN O O
are NN O O
three NN O O
mechanisms NN O O
by NN O O
which NN O O
ctg NN O O
expansion NN O O
can NN O O
result NN O O
in NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O
first, NN O O
repeat NN O O
expansion NN O O
may NN O O
alter NN O O
the NN O O
processing NN O O
or NN O O
transport NN O O
of NN O O
the NN O O
mutant NN O O
dmpk NN O O
mrna NN O O
and NN O O
consequently NN O O
reduce NN O O
dmpk NN O O
levels. NN O O
second, NN O O
ctg NN O O
expansion NN O O
may NN O O
establish NN O O
a NN O O
region NN O O
of NN O O
heterochromatin NN O O
3 NN O O
of NN O O
the NN O O
repeat NN O O
sequence NN O O
and NN O O
decrease NN O O
six NN O O
5 NN O O
transcription. NN O O
third, NN O O
toxic NN O O
effects NN O O
of NN O O
the NN O O
repeat NN O O
expansion NN O O
may NN O O
be NN O O
intrinsic NN O O
to NN O O
the NN O O
repeated NN O O
elements NN O O
at NN O O
th NN O O
. NN O O

level NN O O
of NN O O
dna NN O O
or NN O O
rna NN O O
(refs NN O O
10, NN O O
11). NN O O
previous NN O O
studies NN O O
have NN O O
demonstrated NN O O
that NN O O
a NN O O
dose-dependent NN O O
loss NN O O
of NN O O
dm NN O O
15 NN O O
(the NN O O
mouse NN O O
dmpk NN O O
homologue) NN O O
in NN O O
mice NN O O
produces NN O O
a NN O O
partial NN O O
DM NN B-Modifier B-MSH:D009223
phenotype NN O O
characterized NN O O
by NN O O
decreased NN O O
development NN O O
of NN O O
skeletal NN O O
muscle NN O O
force NN O O
and NN O O
cardiac NN B-DiseaseClass B-MSH:D001145
conduction NN I-DiseaseClass I-MSH:D001145
disorders NN I-DiseaseClass I-MSH:D001145
. NN O O
to NN O O
test NN O O
the NN O O
role NN O O
of NN O O
six NN O O
5 NN O O
loss NN O O
in NN O O
DM NN B-SpecificDisease B-MSH:D009223
, NN O O
we NN O O
have NN O O
analysed NN O O
a NN O O
strain NN O O
of NN O O
mice NN O O
in NN O O
which NN O O
six NN O O
5 NN O O
was NN O O
deleted. NN O O
our NN O O
results NN O O
demonstrate NN O O
that NN O O
the NN O O
rate NN O O
and NN O O
severity NN O O
of NN O O
cataract NN B-Modifier B-MSH:D002386
formation NN O O
is NN O O
inversely NN O O
related NN O O
to NN O O
six NN O O
5 NN O O
dosage NN O O
and NN O O
is NN O O
temporally NN O O
progressive. NN O O
six NN O O
5 NN O O
+/- NN O O
and NN O O
six NN O O
5-/- NN O O
mice NN O O
show NN O O
increased NN O O
steady-state NN O O
levels NN O O
of NN O O
the NN O O
na NN O O
+/k NN O O
+ NN O O
-atpase NN O O
alpha-1 NN O O
subunit NN O O
and NN O O
decreased NN O O
dm NN O O
15 NN O O
mrna NN O O
levels. NN O O
thus, NN O O
altere NN O O
. NN O O

ion NN O O
homeostasis NN O O
within NN O O
the NN O O
lens NN O O
may NN O O
contribute NN O O
to NN O O
cataract NN B-Modifier B-MSH:D002386
formation. NN O O
as NN O O
ocular NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
are NN O O
a NN O O
characteristic NN O O
feature NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
, NN O O
these NN O O
results NN O O
demonstrate NN O O
that NN O O
decreased NN O O
six NN O O
5 NN O O
transcription NN O O
is NN O O
important NN O O
in NN O O
the NN O O
aetiology NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O
our NN O O
data NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
DM NN B-SpecificDisease B-MSH:D009223
is NN O O
a NN O O
contiguous NN O O
gene NN O O
syndrome NN O O
associated NN O O
with NN O O
the NN O O
partial NN O O
loss NN O O
of NN O O
both NN O O
dmpk NN O O
and NN O O
six NN O O
5. NN O O
. NN O O

cis NN O O
and NN O O
trans NN O O
effects NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
( NN O O
DM NN B-Modifier B-MSH:D009223
) NN O O
mutation NN O O
in NN O O
a NN O O
cell NN O O
culture NN O O
model NN O O
. NN O O

the NN O O
mutation NN O O
causing NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
has NN O O
been NN O O
identified NN O O
as NN O O
a NN O O
ctg NN O O
expansion NN O O
in NN O O
the NN O O
3-untranslated NN O O
region NN O O
(3-utr) NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
protein NN O O
kinase NN O O
gene NN O O
(dmpk), NN O O
but NN O O
the NN O O
mechanism NN O O
(s) NN O O
of NN O O
pathogenesis NN O O
remain NN O O
unknown. NN O O
studies NN O O
using NN O O
DM NN B-Modifier B-MSH:D009223
patient NN O O
materials NN O O
have NN O O
often NN O O
produced NN O O
confusing NN O O
results. NN O O
therefore, NN O O
to NN O O
study NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
mutation NN O O
in NN O O
a NN O O
controlled NN O O
environment, NN O O
we NN O O
have NN O O
established NN O O
a NN O O
cell NN O O
culture NN O O
model NN O O
system NN O O
using NN O O
c NN O O
2 NN O O
c NN O O
12 NN O O
mouse NN O O
myoblasts. NN O O
by NN O O
expressing NN O O
chimeric NN O O
reporter NN O O
constructs NN O O
containing NN O O
a NN O O
reporter NN O O
gene NN O O
fused NN O O
to NN O O
a NN O O
human NN O O
dmpk NN O O
3-utr, NN O O
we NN O O
identified NN O O
both NN O O
cis NN O O
and NN O O
trans NN O O
effects NN O O
that NN O O
are NN O O
mediated NN O O
by NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
mutation. NN O O
our NN O O
data NN O O
show NN O O
that NN O O
a NN O O
mutant NN O O
dmpk NN O O
3-utr, NN O O
with NN O O
as NN O O
few NN O O
as NN O O
57 NN O O
ctgs NN O O
. NN O O

had NN O O
a NN O O
negative NN O O
cis NN O O
effect NN O O
on NN O O
protein NN O O
expression NN O O
and NN O O
resulted NN O O
in NN O O
the NN O O
aggregation NN O O
of NN O O
reporter NN O O
transcripts NN O O
into NN O O
discrete NN O O
nuclear NN O O
foci. NN O O
we NN O O
determined NN O O
by NN O O
deletion NN O O
analysis NN O O
that NN O O
an NN O O
expanded NN O O
(ctg) NN O O
(n) NN O O
tract NN O O
alone NN O O
was NN O O
sufficient NN O O
to NN O O
mediate NN O O
these NN O O
cis NN O O
effects. NN O O
furthermore, NN O O
in NN O O
contrast NN O O
to NN O O
the NN O O
normal NN O O
dmpk NN O O
3-utr NN O O
mrna, NN O O
a NN O O
mutant NN O O
dmpk NN O O
3-utr NN O O
mrna NN O O
with NN O O
(cug) NN O O
(200) NN O O
selectively NN O O
inhibited NN O O
myogenic NN O O
differentiation NN O O
of NN O O
c NN O O
2 NN O O
c NN O O
12 NN O O
myoblasts. NN O O
genetic NN O O
analysis NN O O
and NN O O
the NN O O
cre- NN O O
loxp NN O O
system NN O O
were NN O O
used NN O O
to NN O O
clearly NN O O
demonstrate NN O O
that NN O O
the NN O O
myoblast NN O O
fusion NN O O
defect NN O O
could NN O O
be NN O O
rescued NN O O
by NN O O
eliminating NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
dmpk NN O O
3-utr NN O O
transcript. NN O O
characterization NN O O
of NN O O
spontaneous NN O O
deletion NN O O
events NN O O
mapped NN O O
the NN O O
inhibitory NN O O
effect NN O O
to NN O O
the NN O O
(ctg) NN O O
(n) NN O O
expansion NN O O
and/or NN O O
the NN O O
. NN O O
acterization NN O O
of NN O O
spontaneous NN O O
deletion NN O O
events NN O O
mapped NN O O
the NN O O
inhibitory NN O O
effect NN O O
to NN O O
the NN O O
(ctg) NN O O
(n) NN O O
expansion NN O O
and/or NN O O
the NN O O
. NN O O

end NN O O
of NN O O
the NN O O
dmpk NN O O
3-utr. NN O O
these NN O O
results NN O O
provide NN O O
evidence NN O O
that NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
mutation NN O O
acts NN O O
in NN O O
cis NN O O
to NN O O
reduce NN O O
protein NN O O
production NN O O
(consistent NN O O
with NN O O
DMPK NN B-SpecificDisease B-MSH:D058495
haploinsufficiency NN I-SpecificDisease I-MSH:D058495
) NN O O
and NN O O
in NN O O
trans NN O O
as NN O O
a NN O O
riboregulator NN O O
to NN O O
inhibit NN O O
myogenesis. NN O O
. NN O O

intelligence NN O O
quotient NN O O
profile NN O O
in NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
, NN O O
intergenerational NN O O
deficit, NN O O
and NN O O
correlation NN O O
with NN O O
ctg NN O O
amplification NN O O
. NN O O

an NN O O
abbreviated NN O O
wechsler NN O O
adult NN O O
intelligence NN O O
scale NN O O
revised NN O O
(wais-r) NN O O
was NN O O
used NN O O
to NN O O
assess NN O O
verbal NN O O
and NN O O
arithmetical NN O O
cognitive NN O O
performance NN O O
in NN O O
55 NN O O
subjects NN O O
with NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
), NN O O
covering NN O O
all NN O O
grades NN O O
of NN O O
disease NN O O
severity, NN O O
and NN O O
31 NN O O
controls NN O O
at NN O O
50% NN O O
risk NN O O
of NN O O
inheriting NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O
scaled NN O O
scores NN O O
from NN O O
the NN O O
assessment NN O O
were NN O O
converted NN O O
into NN O O
an NN O O
intelligence NN O O
quotient NN O O
(iq) NN O O
estimation NN O O
on NN O O
each NN O O
person. NN O O
significant NN O O
iq NN O O
differences NN O O
were NN O O
found NN O O
between NN O O
(1) NN O O
all NN O O
55 NN O O
DM NN B-Modifier B-MSH:D009223
subjects NN O O
(mean NN O O
90. NN O O
2, NN O O
sd NN O O
16. NN O O
1) NN O O
and NN O O
31 NN O O
controls NN O O
(102. NN O O
6, NN O O
sd NN O O
9. NN O O
4), NN O O
with NN O O
no NN O O
sex NN O O
differences NN O O
in NN O O
either NN O O
group; NN O O
(2) NN O O
15 NN O O
affected NN O O
parents NN O O
(99. NN O O
3, NN O O
sd NN O O
12. NN O O
2) NN O O
and NN O O
their NN O O
affected NN O O
children NN O O
(88. NN O O
1, NN O O
s NN O O
. NN O O

17. NN O O
2), NN O O
where NN O O
significance NN O O
was NN O O
dependent NN O O
on NN O O
parental NN O O
sex NN O O
being NN O O
female; NN O O
and NN O O
(3) NN O O
15 NN O O
pairs NN O O
of NN O O
affected NN O O
sibs NN O O
(89. NN O O
6, NN O O
sd NN O O
13. NN O O
2) NN O O
and NN O O
their NN O O
normal NN O O
sibs NN O O
(100. NN O O
2, NN O O
sd NN O O
7. NN O O
6). NN O O
iq NN O O
steadily NN O O
declined NN O O
as NN O O
(1) NN O O
the NN O O
age NN O O
of NN O O
onset NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
decreased, NN O O
and NN O O
(2) NN O O
the NN O O
ctg NN O O
expansion NN O O
size NN O O
increased. NN O O
the NN O O
correlation NN O O
appeared NN O O
to NN O O
be NN O O
more NN O O
linear NN O O
with NN O O
age NN O O
of NN O O
onset. NN O O
the NN O O
correlation NN O O
of NN O O
iq NN O O
difference NN O O
and NN O O
ctg NN O O
expansion NN O O
difference NN O O
in NN O O
both NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
parent-child NN O O
pairs NN O O
and NN O O
normal NN O O
sib-affected NN O O
sib NN O O
pairs NN O O
was NN O O
poor, NN O O
indicating NN O O
that NN O O
ctg NN O O
expansion NN O O
is NN O O
not NN O O
a NN O O
reliable NN O O
predictor NN O O
of NN O O
iq NN O O
either NN O O
in NN O O
individual NN O O
persons NN O O
or NN O O
families. NN O O
further NN O O
analysis NN O O
of NN O O
cognitive NN O O
function NN O O
in NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O

is NN O O
required NN O O
to NN O O
clarify NN O O
specific NN O O
deficits NN O O
characteristic NN O O
of NN O O
this NN O O
patient NN O O
grou NN O O
. NN O O

complement NN O O
factor NN O O
2 NN O O
deficiency: NN O O
a NN O O
clinical NN O O
and NN O O
serological NN O O
family NN O O
study NN O O
. NN O O

inherited NN O O
complement NN O O
deficiencies NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
variety NN O O
of NN O O
connective NN O O
tissue NN O O
diseases. NN O O
a NN O O
family NN O O
with NN O O
inherited NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
of NN I-SpecificDisease I-OMIM:217000
complement NN I-SpecificDisease I-OMIM:217000
factor NN I-SpecificDisease I-OMIM:217000
2 NN I-SpecificDisease I-OMIM:217000
(c NN O O
2) NN O O
is NN O O
described NN O O
in NN O O
which NN O O
two NN O O
family NN O O
members NN O O
with NN O O
homozygous NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
developed NN O O
cutaneous NN B-SpecificDisease B-MSH:D018366
vasculitis NN I-SpecificDisease I-MSH:D018366
and NN O O
sicca NN B-SpecificDisease B-MSH:D012859
syndrome NN I-SpecificDisease I-MSH:D012859
. NN O O
the NN O O
other NN O O
family NN O O
members NN O O
had NN O O
heterozygous NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
and NN O O
each NN O O
member NN O O
had NN O O
the NN O O
hla-a NN O O
25, NN O O
b NN O O
18, NN O O
dr NN O O
2 NN O O
(w NN O O
15) NN O O
haplotype. NN O O
the NN O O
mother NN O O
had NN O O
seropositive NN B-SpecificDisease B-MSH:D001172
rheumatoid NN I-SpecificDisease I-MSH:D001172
arthritis NN I-SpecificDisease I-MSH:D001172
. NN O O
further NN O O
studies NN O O
showed NN O O
the NN O O
presence NN O O
of NN O O
cryoglobulins, NN O O
antibodies NN O O
against NN O O
endothelial NN O O
cells, NN O O
and NN O O
anticardiolipin NN O O
antibodies. NN O O
. NN O O

oncogenic NN O O
point NN O O
mutations NN O O
in NN O O
exon NN O O
20 NN O O
of NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
in NN O O
families NN O O
showing NN O O
incomplete NN O O
penetrance NN O O
and NN O O
mild NN O O
expression NN O O
of NN O O
the NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
phenotype NN O O
. NN O O

the NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
-predisposition NN O O
gene, NN O O
rb NN O O
1, NN O O
segregates NN O O
as NN O O
an NN O O
autosomal NN O O
dominant NN O O
trait NN O O
with NN O O
high NN O O
(90%) NN O O
penetrance. NN O O
certain NN O O
families, NN O O
however, NN O O
show NN O O
an NN O O
unusual NN O O
low-penetrance NN O O
phenotype NN O O
with NN O O
many NN O O
individuals NN O O
being NN O O
unaffected, NN O O
unilaterally NN O O
affected, NN O O
or NN O O
with NN O O
evidence NN O O
of NN O O
spontaneously NN O O
regressed NN O O
tumors NN B-DiseaseClass B-MSH:D009369
. NN O O
we NN O O
have NN O O
used NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
and NN O O
pcr NN O O
sequencing NN O O
to NN O O
study NN O O
two NN O O
such NN O O
families. NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
exon NN O O
20 NN O O
of NN O O
rb NN O O
1 NN O O
in NN O O
both NN O O
cases. NN O O
in NN O O
one NN O O
family NN O O
a NN O O
c----t NN O O
transition NN O O
in NN O O
codon NN O O
661 NN O O
converts NN O O
an NN O O
arginine NN O O
(cgg) NN O O
to NN O O
a NN O O
tryptophan NN O O
(tgg) NN O O
codon. NN O O
in NN O O
this NN O O
family, NN O O
incomplete NN O O
penetrance NN O O
and NN O O
mild NN O O
phenotypic NN O O
expression NN O O
were NN O O
observed NN O O
in NN O O
virtually NN O O
all NN O O
patients, NN O O
possibly NN O O
indicating NN O O
that NN O O
single NN O O
amino NN O O
acid NN O O
changes NN O O
may NN O O
modify NN O O
protein NN O O
structure NN O O
. NN O O

function NN O O
such NN O O
that NN O O
tumorigenesis NN O O
is NN O O
not NN O O
inevitable. NN O O
in NN O O
the NN O O
second NN O O
family NN O O
the NN O O
mutation NN O O
in NN O O
codon NN O O
675 NN O O
is NN O O
a NN O O
g----t NN O O
transversion NN O O
that NN O O
converts NN O O
a NN O O
glutamine NN O O
(gaa) NN O O
to NN O O
a NN O O
stop NN O O
(taa) NN O O
codon. NN O O
however, NN O O
this NN O O
mutation NN O O
also NN O O
occurs NN O O
near NN O O
a NN O O
potential NN O O
cryptic NN O O
splice NN O O
acceptor NN O O
site, NN O O
raising NN O O
the NN O O
possibility NN O O
of NN O O
alternative NN O O
splicing NN O O
resulting NN O O
in NN O O
a NN O O
less NN O O
severely NN O O
disrupted NN O O
protein. NN O O
. NN O O
ve NN O O
splicing NN O O
resulting NN O O
in NN O O
a NN O O
less NN O O
severely NN O O
disrupted NN O O
protein. NN O O
. NN O O

identification NN O O
of NN O O
a NN O O
novel NN O O
r NN O O
21 NN O O
x NN O O
mutation NN O O
in NN O O
the NN O O
liver-type NN O O
arginase NN O O
gene NN O O
(arg NN O O
1) NN O O
in NN O O
four NN O O
portuguese NN O O
patients NN O O
with NN O O
argininemia NN B-SpecificDisease B-MSH:D020162
. NN O O

argininemia NN O O
is NN O O
a NN O O
rare NN O O
autossomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
deficiency NN B-DiseaseClass B-MSH:D020162
in NN I-DiseaseClass I-MSH:D020162
the NN I-DiseaseClass I-MSH:D020162
cytosolic NN I-DiseaseClass I-MSH:D020162
liver-type NN I-DiseaseClass I-MSH:D020162
arginase NN I-DiseaseClass I-MSH:D020162
enzyme NN I-DiseaseClass I-MSH:D020162
(l-arginine NN O O
urea-hydrolase; NN O O
e. NN O O
c. NN O O
3. NN O O
5. NN O O
3. NN O O
1). NN O O
in NN O O
order NN O O
to NN O O
investigate NN O O
the NN O O
molecular NN O O
basis NN O O
for NN O O
argininemia NN B-SpecificDisease B-MSH:D020162
in NN O O
four NN O O
unrelated NN O O
portuguese NN O O
patients NN O O
(two NN O O
from NN O O
northern NN O O
portugal NN O O
and NN O O
two NN O O
from NN O O
madeira NN O O
island) NN O O
we NN O O
performed NN O O
a NN O O
dna NN O O
sequence NN O O
analysis NN O O
of NN O O
all NN O O
the NN O O
exons NN O O
and NN O O
exon/intron NN O O
boundaries NN O O
of NN O O
the NN O O
liver-type NN O O
arginase NN O O
gene NN O O
(arg NN O O
1). NN O O
all NN O O
patients NN O O
were NN O O
found NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
newly NN O O
identified NN O O
c NN O O
- NN O O
> NN O O
t NN O O
transition NN O O
in NN O O
codon NN O O
21 NN O O
(exon NN O O
2) NN O O
substituting NN O O
arginine NN O O
for NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
(r NN O O
21 NN O O
x NN O O
cga NN O O
to NN O O
tga) NN O O
and NN O O
generating NN O O
a NN O O
nlaiii NN O O
restriction NN O O
site. NN O O
restriction NN O O
digestion NN O O
following NN O O
pc NN O O
. NN O O

amplification NN O O
of NN O O
arg NN O O
1 NN O O
exon NN O O
2 NN O O
confirmed NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
mutation NN O O
. NN O O

a NN O O
mutation NN O O
in NN O O
the NN O O
pleckstrin NN O O
homology NN O O
(ph) NN O O
domain NN O O
of NN O O
the NN O O
fgd NN O O
1 NN O O
gene NN O O
in NN O O
an NN O O
italian NN O O
family NN O O
with NN O O
faciogenital NN B-SpecificDisease B-MSH:C535331
dysplasia NN I-SpecificDisease I-MSH:C535331
( NN O O
Aarskog-Scott NN B-SpecificDisease B-MSH:C535331
syndrome NN I-SpecificDisease I-MSH:C535331
) NN O O
. NN O O

aarskog-scott NN O O
syndrome NN O O
( NN O O
AAS NN B-SpecificDisease B-MSH:C535331
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
characterised NN O O
by NN O O
short NN B-DiseaseClass B-MSH:D006130
stature NN I-DiseaseClass I-MSH:D006130
and NN O O
multiple NN O O
facial, NN B-CompositeMention B-MSH:D019465
limb NN I-CompositeMention I-MSH:D019465
and NN I-CompositeMention I-MSH:D019465
genital NN I-CompositeMention I-MSH:D019465
abnormalities NN I-CompositeMention I-MSH:D019465
. NN O O
a NN O O
gene, NN O O
fgd NN O O
1, NN O O
altered NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
AAS NN B-Modifier B-MSH:C535331
phenotype, NN O O
has NN O O
been NN O O
identified NN O O
and NN O O
found NN O O
to NN O O
encode NN O O
a NN O O
protein NN O O
with NN O O
homology NN O O
to NN O O
rho/rac NN O O
guanine NN O O
nucleotide NN O O
exchange NN O O
factors NN O O
(rho/rac NN O O
gef). NN O O
however, NN O O
since NN O O
this NN O O
original NN O O
report NN O O
on NN O O
identification NN O O
of NN O O
a NN O O
mutated NN O O
fgd NN O O
1 NN O O
gene NN O O
in NN O O
an NN O O
AAS NN B-Modifier B-MSH:C535331
patient, NN O O
no NN O O
additional NN O O
mutations NN O O
in NN O O
the NN O O
fgd NN O O
1 NN O O
gene NN O O
have NN O O
been NN O O
described. NN O O
we NN O O
analysed NN O O
13 NN O O
independent NN O O
patients NN O O
with NN O O
clinical NN O O
diagnosis NN O O
of NN O O
AAS NN B-SpecificDisease B-MSH:C535331
. NN O O
one NN O O
patient NN O O
presented NN O O
a NN O O
mutation NN O O
that NN O O
results NN O O
in NN O O
a NN O O
nucleotide NN O O
change NN O O
in NN O O
exon NN O O
10 NN O O
of NN O O
the NN O O
fgd NN O O
1 NN O O
gene NN O O
(g NN O O
2559 NN O O
> NN O O
a) NN O O
substituting NN O O
a NN O O
gln NN O O
for NN O O
arg NN O O
in NN O O
positio NN O O
. NN O O

610. NN O O
the NN O O
mutation NN O O
was NN O O
found NN O O
to NN O O
segregate NN O O
with NN O O
the NN O O
AAS NN B-Modifier B-MSH:C535331
phenotype NN O O
in NN O O
affected NN O O
males NN O O
and NN O O
carrier NN O O
females NN O O
in NN O O
the NN O O
family NN O O
of NN O O
this NN O O
patient. NN O O
interestingly, NN O O
arg-610 NN O O
is NN O O
located NN O O
within NN O O
one NN O O
of NN O O
the NN O O
two NN O O
pleckstrin NN O O
homology NN O O
(ph) NN O O
domains NN O O
of NN O O
the NN O O
fgd NN O O
1 NN O O
gene NN O O
and NN O O
it NN O O
corresponds NN O O
to NN O O
a NN O O
highly NN O O
conserved NN O O
residue NN O O
which NN O O
has NN O O
been NN O O
involved NN O O
in NN O O
insp NN O O
binding NN O O
in NN O O
ph NN O O
domains NN O O
of NN O O
other NN O O
proteins. NN O O
the NN O O
same NN O O
residue NN O O
is NN O O
often NN O O
mutated NN O O
in NN O O
the NN O O
brutons NN O O
tyrosine NN O O
kinase NN O O
(btk) NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
an NN O O
X-linked NN B-SpecificDisease B-OMIM:300755
agammaglobulinemia NN I-SpecificDisease I-OMIM:300755
. NN O O
the NN O O
arg NN O O
610 NN O O
gln NN O O
mutation NN O O
represents NN O O
the NN O O
first NN O O
case NN O O
of NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
ph NN O O
domain NN O O
of NN O O
the NN O O
fgd NN O O
1 NN O O
gene NN O O
and NN O O
additional NN O O
evidence NN O O
that NN O O
mutations NN O O
in NN O O
ph NN O O
domains NN O O
can NN O O
be NN O O
associated NN O O
to NN O O
human NN O O
diseases. NN O O
. NN O O

localization NN O O
of NN O O
histidase NN O O
to NN O O
human NN O O
chromosome NN O O
region NN O O
12 NN O O
q NN O O
22----q NN O O
24.1 NN O O
and NN O O
mouse NN O O
chromosome NN O O
region NN O O
10 NN O O
c NN O O
2----d NN O O
1 NN O O
. NN O O

the NN O O
human NN O O
gene NN O O
for NN O O
histidase NN O O
(histidine NN O O
ammonia-lyase; NN O O
hal), NN O O
the NN O O
enzyme NN O O
deficient NN O O
in NN O O
histidinemia NN B-SpecificDisease B-MSH:C538320
, NN O O
was NN O O
assigned NN O O
to NN O O
human NN O O
chromosome NN O O
12 NN O O
by NN O O
southern NN O O
blot NN O O
analysis NN O O
of NN O O
human NN O O
x NN O O
mouse NN O O
somatic NN O O
cell NN O O
hybrid NN O O
dna. NN O O
the NN O O
gene NN O O
was NN O O
sublocalized NN O O
to NN O O
region NN O O
12 NN O O
q NN O O
22----q NN O O
24. NN O O
1 NN O O
by NN O O
in NN O O
situ NN O O
hybridization, NN O O
using NN O O
a NN O O
human NN O O
histidase NN O O
cdna. NN O O
the NN O O
homologous NN O O
locus NN O O
in NN O O
the NN O O
mouse NN O O
(hal) NN O O
was NN O O
mapped NN O O
to NN O O
region NN O O
10 NN O O
c NN O O
2----d NN O O
1 NN O O
by NN O O
in NN O O
situ NN O O
hybridization, NN O O
using NN O O
a NN O O
cell NN O O
line NN O O
from NN O O
a NN O O
mouse NN O O
homozygous NN O O
for NN O O
a NN O O
1. NN O O
10 NN O O
robertsonian NN O O
translocation. NN O O
these NN O O
assignments NN O O
extend NN O O
the NN O O
conserved NN O O
syntenic NN O O
region NN O O
between NN O O
human NN O O
chromosome NN O O
12 NN O O
and NN O O
mouse NN O O
chromosome NN O O
10 NN O O
that NN O O
includes NN O O
the NN O O
genes NN O O
for NN O O
phenylalanine NN O O
hydroxylase, NN O O
gamma NN O O
interferon, NN O O
peptidase, NN O O
and NN O O
citrat NN O O
. NN O O

synthase. NN O O
the NN O O
localization NN O O
of NN O O
histidase NN O O
to NN O O
mouse NN O O
chromosome NN O O
10 NN O O
suggests NN O O
that NN O O
the NN O O
histidase NN O O
regulatory NN O O
locus NN O O
(hsd) NN O O
and NN O O
the NN O O
histidinemia NN O O
mutation NN O O
(his), NN O O
which NN O O
are NN O O
both NN O O
known NN O O
to NN O O
be NN O O
on NN O O
chromosome NN O O
10, NN O O
may NN O O
be NN O O
alleles NN O O
of NN O O
the NN O O
histidase NN O O
structural NN O O
gene NN O O
locus NN O O
. NN O O
tory NN O O
locus NN O O
(hsd) NN O O
and NN O O
the NN O O
histidinemia NN O O
mutation NN O O
(his), NN O O
which NN O O
are NN O O
both NN O O
known NN O O
to NN O O
be NN O O
on NN O O
chromosome NN O O
10, NN O O
may NN O O
be NN O O
alleles NN O O
of NN O O
the NN O O
histidase NN O O
structural NN O O
gene NN O O
locus NN O O
. NN O O

noninvasive NN O O
test NN O O
for NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
, NN O O
using NN O O
hair NN O O
root NN O O
analysis NN O O
. NN O O

identification NN O O
of NN O O
the NN O O
fmr NN O O
1 NN O O
gene NN O O
and NN O O
the NN O O
repeat-amplification NN O O
mechanism NN O O
causing NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
led NN O O
to NN O O
development NN O O
of NN O O
reliable NN O O
dna-based NN O O
diagnostic NN O O
methods, NN O O
including NN O O
southern NN O O
blot NN O O
hybridization NN O O
and NN O O
pcr. NN O O
both NN O O
methods NN O O
are NN O O
performed NN O O
on NN O O
dna NN O O
isolated NN O O
from NN O O
peripheral NN O O
blood NN O O
cells NN O O
and NN O O
measure NN O O
the NN O O
repeat NN O O
size NN O O
in NN O O
fmr NN O O
1. NN O O
using NN O O
an NN O O
immunocytochemical NN O O
technique NN O O
on NN O O
blood NN O O
smears, NN O O
we NN O O
recently NN O O
developed NN O O
a NN O O
novel NN O O
test NN O O
for NN O O
identification NN O O
of NN O O
patients NN O O
with NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
. NN O O
this NN O O
method, NN O O
also NN O O
called NN O O
" NN O O
antibody NN O O
test, NN O O
" NN O O
uses NN O O
monoclonal NN O O
antibodies NN O O
against NN O O
the NN O O
fmr NN O O
1 NN O O
gene NN O O
product NN O O
(fmrp) NN O O
and NN O O
is NN O O
based NN O O
on NN O O
absence NN O O
of NN O O
fmrp NN O O
in NN O O
patients NN O O
cells. NN O O
here NN O O
we NN O O
describe NN O O
a NN O O
new NN O O
diagnostic NN O O
test NN O O
to NN O O
identify NN O O
male NN O O
patients NN O O
with NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
, NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
lack NN O O
of NN O O
fmrp NN O O
in NN O O
their NN O O
hair NN O O
roots. NN O O
expression NN O O
o NN O O
. NN O O

fmrp NN O O
in NN O O
hair NN O O
roots NN O O
was NN O O
studied NN O O
by NN O O
use NN O O
of NN O O
an NN O O
fmrp-specific NN O O
antibody NN O O
test, NN O O
and NN O O
the NN O O
percentage NN O O
of NN O O
fmrp-expressing NN O O
hair NN O O
roots NN O O
in NN O O
controls NN O O
and NN O O
in NN O O
male NN O O
fragile NN B-Modifier B-MSH:D005600
X NN I-Modifier I-MSH:D005600
patients NN O O
was NN O O
determined. NN O O
control NN O O
individuals NN O O
showed NN O O
clear NN O O
expression NN O O
of NN O O
fmrp NN O O
in NN O O
nearly NN O O
every NN O O
hair NN O O
root, NN O O
whereas NN O O
male NN O O
fragile NN B-Modifier B-MSH:D005600
X NN I-Modifier I-MSH:D005600
patients NN O O
lacked NN O O
expression NN O O
of NN O O
fmrp NN O O
in NN O O
almost NN O O
all NN O O
their NN O O
hair NN O O
roots. NN O O
Mentally NN B-Modifier B-MSH:D008607
retarded NN I-Modifier I-MSH:D008607
female NN O O
patients NN O O
with NN O O
a NN O O
full NN O O
mutation NN O O
showed NN O O
fmrp NN O O
expression NN O O
in NN O O
only NN O O
some NN O O
of NN O O
their NN O O
hair NN O O
roots NN O O
(< NN O O
55%), NN O O
and NN O O
no NN O O
overlap NN O O
with NN O O
normal NN O O
female NN O O
controls NN O O
was NN O O
observed. NN O O
the NN O O
advantages NN O O
of NN O O
this NN O O
test NN O O
are NN O O
(1) NN O O
plucking NN O O
of NN O O
hair NN O O
follicles NN O O
does NN O O
no NN O O
appreciable NN O O
harm NN O O
to NN O O
the NN O O
mentally NN B-Modifier B-MSH:D008607
retarded NN I-Modifier I-MSH:D008607
patient, NN O O
(2) NN O O
hairs NN O O
can NN O O
be NN O O
sent NN O O
in NN O O
a NN O O
simple NN O O
envelope NN O O
to NN O O
a NN O O
diagnostic NN O O
center, NN O O
and NN O O
. NN O O

3) NN O O
the NN O O
result NN O O
of NN O O
the NN O O
test NN O O
is NN O O
available NN O O
within NN O O
5 NN O O
h NN O O
of NN O O
plucking. NN O O
in NN O O
addition, NN O O
this NN O O
test NN O O
enabled NN O O
us NN O O
to NN O O
identify NN O O
two NN O O
fragile NN B-Modifier B-MSH:D005600
X NN I-Modifier I-MSH:D005600
patients NN O O
who NN O O
did NN O O
not NN O O
show NN O O
the NN O O
full NN O O
mutation NN O O
by NN O O
analysis NN O O
of NN O O
dna NN O O
isolated NN O O
from NN O O
blood NN O O
cells. NN O O
. NN O O

pelizaeus-merzbacher NN O O
disease: NN O O
detection NN O O
of NN O O
mutations NN O O
thr NN O O
181----pro NN O O
and NN O O
leu NN O O
223----pro NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene, NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
. NN O O
d NN O O
prenatal NN O O
diagnosis NN O O
. NN O O

a NN O O
family NN O O
with NN O O
an NN O O
apparent NN O O
history NN O O
of NN O O
x-linked NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
presented NN O O
for NN O O
genetic NN O O
counseling, NN O O
requesting NN O O
carrier NN O O
detection NN O O
and NN O O
prenatal NN O O
diagnosis. NN O O
rflp NN O O
analysis NN O O
using NN O O
the NN O O
proteolipid NN O O
protein NN O O
(plp) NN O O
gene NN O O
probe NN O O
was NN O O
uninformative NN O O
in NN O O
this NN O O
family. NN O O
a NN O O
prenatal NN O O
diagnosis NN O O
on NN O O
a NN O O
chorionic NN O O
villus NN O O
sample NN O O
(cvs) NN O O
was NN O O
carried NN O O
out NN O O
using NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
analysis NN O O
of NN O O
a NN O O
variant NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
the NN O O
plp NN O O
gene. NN O O
the NN O O
fetus NN O O
was NN O O
predicted NN O O
to NN O O
be NN O O
unaffected. NN O O
sequencing NN O O
of NN O O
the NN O O
exon NN O O
from NN O O
the NN O O
cvs, NN O O
the NN O O
predicted-carrier NN O O
mother, NN O O
and NN O O
the NN O O
obligate-carrier NN O O
grandmother NN O O
revealed NN O O
an NN O O
a-to-c NN O O
change NN O O
at NN O O
nucleotide NN O O
541 NN O O
in NN O O
the NN O O
two NN O O
women NN O O
but NN O O
not NN O O
in NN O O
the NN O O
fetus. NN O O
as NN O O
this NN O O
change NN O O
results NN O O
in NN O O
a NN O O
thr-to-pro NN O O
change NN O O
a NN O O
. NN O O

amino NN O O
acid NN O O
181 NN O O
in NN O O
a NN O O
region NN O O
of NN O O
the NN O O
gene NN O O
predicted NN O O
to NN O O
be NN O O
part NN O O
of NN O O
a NN O O
transmembrane NN O O
segment, NN O O
it NN O O
was NN O O
concluded NN O O
that NN O O
this NN O O
was NN O O
the NN O O
mutation NN O O
causing NN O O
the NN O O
disease NN O O
in NN O O
this NN O O
family. NN O O
in NN O O
addition, NN O O
in NN O O
a NN O O
second NN O O
family, NN O O
an NN O O
exon NN O O
5 NN O O
variant NN O O
band NN O O
pattern NN O O
on NN O O
sscp NN O O
analysis NN O O
was NN O O
shown NN O O
by NN O O
sequencing NN O O
to NN O O
be NN O O
due NN O O
to NN O O
a NN O O
t-to-c NN O O
change NN O O
at NN O O
nucleotide NN O O
668. NN O O
this NN O O
results NN O O
in NN O O
a NN O O
leu-to-pro NN O O
change NN O O
in NN O O
a NN O O
carrier NN O O
mother NN O O
and NN O O
in NN O O
her NN O O
two NN O O
affected NN O O
sons. NN O O
these NN O O
results NN O O
provide NN O O
further NN O O
examples NN O O
of NN O O
mutations NN O O
in NN O O
plp NN O O
that NN O O
cause NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
and NN O O
illustrate NN O O
the NN O O
value NN O O
of NN O O
sscp NN O O
in NN O O
genetic NN O O
analysis. NN O O
. NN O O

a NN O O
normal NN O O
male NN O O
with NN O O
an NN O O
inherited NN O O
deletion NN O O
of NN O O
one NN O O
exon NN O O
within NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
. NN O O

we NN O O
describe NN O O
two NN O O
brothers NN O O
with NN O O
identical NN O O
inherited NN O O
deletions NN O O
of NN O O
one NN O O
single NN O O
exon NN O O
within NN O O
the NN O O
middle NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene; NN O O
one NN O O
brother NN O O
has NN O O
Becker NN B-SpecificDisease B-MSH:C537666
muscular NN I-SpecificDisease I-MSH:C537666
dystrophy NN I-SpecificDisease I-MSH:C537666
diagnosed NN O O
at NN O O
11 NN O O
years NN O O
of NN O O
age, NN O O
whereas NN O O
the NN O O
older NN O O
brother NN O O
is NN O O
normal NN O O
at NN O O
18. NN O O
these NN O O
results NN O O
have NN O O
implications NN O O
for NN O O
genetic NN O O
counselling NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
in NN O O
families NN O O
with NN O O
Becker NN B-SpecificDisease B-MSH:C537666
muscular NN I-SpecificDisease I-MSH:C537666
dystrophy NN I-SpecificDisease I-MSH:C537666
. NN O O
. NN O O

small NN O O
deletions NN O O
in NN O O
the NN O O
type NN O O
ii NN O O
collagen NN O O
triple NN O O
helix NN O O
produce NN O O
kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
. NN O O

kniest NN O O
dysplasia NN O O
is NN O O
a NN O O
moderately NN O O
severe NN O O
type NN B-DiseaseClass B-MSH:C535964
II NN I-DiseaseClass I-MSH:C535964
collagenopathy NN I-DiseaseClass I-MSH:C535964
, NN O O
characterized NN O O
by NN O O
short NN O O
trunk NN O O
and NN O O
limbs, NN O O
kyphoscoliosis NN B-DiseaseClass B-OMIM:610170
, NN O O
midface NN B-SpecificDisease B-OMIM:300194
hypoplasia NN I-SpecificDisease I-OMIM:300194
, NN O O
severe NN O O
myopia NN B-DiseaseClass B-MSH:D009216
, NN O O
and NN O O
hearing NN B-DiseaseClass B-MSH:D034381
loss NN I-DiseaseClass I-MSH:D034381
. NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
that NN O O
encodes NN O O
type NN O O
ii NN O O
collagen NN O O
(col NN O O
2 NN O O
a NN O O
1), NN O O
the NN O O
predominant NN O O
protein NN O O
of NN O O
cartilage, NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
a NN O O
number NN O O
of NN O O
individuals NN O O
with NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
. NN O O
all NN O O
but NN O O
two NN O O
of NN O O
these NN O O
previously NN O O
described NN O O
mutations NN O O
cause NN O O
in-frame NN O O
deletions NN O O
in NN O O
type NN O O
ii NN O O
collagen, NN O O
either NN O O
by NN O O
small NN O O
deletions NN O O
in NN O O
the NN O O
gene NN O O
or NN O O
splice NN O O
site NN O O
alterations. NN O O
furthermore, NN O O
all NN O O
but NN O O
one NN O O
of NN O O
these NN O O
mutations NN O O
is NN O O
located NN O O
between NN O O
exons NN O O
12 NN O O
and NN O O
24 NN O O
in NN O O
the NN O O
col NN O O
2 NN O O
a NN O O
1 NN O O
gene. NN O O
we NN O O
used NN O O
heteroduplex NN O O
analysis NN O O
to NN O O
identify NN O O
sequence NN O O
anomalies NN O O
in NN O O
five NN O O
individuals NN O O
with NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
. NN O O
sequencing NN O O
of NN O O
the NN O O
index NN O O
patients NN O O
genomic NN O O
dna NN O O
identified NN O O
fou NN O O
. NN O O

new NN O O
dominant NN O O
mutations NN O O
in NN O O
col NN O O
2 NN O O
a NN O O
1 NN O O
that NN O O
result NN O O
in NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
a NN O O
21-bp NN O O
deletion NN O O
in NN O O
exon NN O O
16, NN O O
an NN O O
18-bp NN O O
deletion NN O O
in NN O O
exon NN O O
19, NN O O
and NN O O
4-bp NN O O
deletions NN O O
in NN O O
the NN O O
splice NN O O
donor NN O O
sites NN O O
of NN O O
introns NN O O
14 NN O O
and NN O O
20. NN O O
a NN O O
previously NN O O
described NN O O
28-bp NN O O
deletion NN O O
at NN O O
the NN O O
col NN O O
2 NN O O
a NN O O
1 NN O O
exon NN O O
12-intron NN O O
12 NN O O
junction, NN O O
deleting NN O O
the NN O O
splice NN O O
donor NN O O
site, NN O O
was NN O O
identified NN O O
in NN O O
the NN O O
fifth NN O O
case. NN O O
the NN O O
latter NN O O
three NN O O
mutations NN O O
are NN O O
predicted NN O O
to NN O O
result NN O O
in NN O O
exon NN O O
skipping NN O O
in NN O O
the NN O O
mrna NN O O
encoded NN O O
from NN O O
the NN O O
mutant NN O O
allele. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
results NN O O
from NN O O
shorter NN O O
type NN O O
ii NN O O
collagen NN O O
monomers, NN O O
and NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
alteration NN O O
of NN O O
a NN O O
specific NN O O
col NN O O
2 NN O O
a NN O O
1 NN O O
domain, NN O O
which NN O O
may NN O O
span NN O O
from NN O O
exons NN O O
12 NN O O
to NN O O
24, NN O O
leads NN O O
t NN O O
. NN O O

the NN O O
Kniest NN B-Modifier B-MSH:C537207
dysplasia NN I-Modifier I-MSH:C537207
phenotype. NN O O
. NN O O

adenomatous NN O O
polyposis NN O O
coli NN O O
and NN O O
a NN O O
cytogenetic NN O O
deletion NN O O
of NN O O
chromosome NN O O
5 NN O O
resulting NN O O
from NN O O
a NN O O
maternal NN O O
intrachromosomal NN O O
insertion NN O O
. NN O O
s NN O O
coli NN O O
and NN O O
a NN O O
cytogenetic NN O O
deletion NN O O
of NN O O
chromosome NN O O
5 NN O O
resulting NN O O
from NN O O
a NN O O
maternal NN O O
intrachromosomal NN O O
insertion NN O O
. NN O O

we NN O O
present NN O O
the NN O O
clinical NN O O
and NN O O
laboratory NN O O
findings NN O O
in NN O O
an NN O O
institutionalised NN O O
adult NN O O
patient NN O O
originally NN O O
referred NN O O
for NN O O
autism NN B-SpecificDisease B-MSH:D001321
. NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
was NN O O
predicted NN O O
when NN O O
an NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5, NN O O
del NN O O
(5) NN O O
(q NN O O
15 NN O O
q NN O O
22. NN O O
3), NN O O
was NN O O
detected NN O O
in NN O O
her NN O O
lymphocytes NN O O
and NN O O
deletion NN O O
of NN O O
the NN O O
mcc NN O O
and NN O O
APC NN B-Modifier B-MSH:D011125
genes NN O O
confirmed NN O O
by NN O O
molecular NN O O
analysis. NN O O
Adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
and NN O O
carcinoma NN B-SpecificDisease B-MSH:D012004
of NN I-SpecificDisease I-MSH:D012004
the NN I-SpecificDisease I-MSH:D012004
rectum NN I-SpecificDisease I-MSH:D012004
were NN O O
subsequently NN O O
diagnosed NN O O
in NN O O
the NN O O
patient. NN O O
she NN O O
was NN O O
profoundly NN O O
mentally NN B-Modifier B-MSH:D008607
retarded NN I-Modifier I-MSH:D008607
, NN O O
autistic NN B-Modifier B-MSH:D001321
, NN O O
and NN O O
had NN O O
minor NN O O
dysmorphic NN B-SpecificDisease B-MSH:D000013
features NN I-SpecificDisease I-MSH:D000013
consistent NN O O
with NN O O
those NN O O
of NN O O
previous NN O O
patients NN O O
with NN O O
similar NN O O
deletions. NN O O
the NN O O
deletion NN O O
arose NN O O
as NN O O
a NN O O
result NN O O
of NN O O
recombination NN O O
within NN O O
the NN O O
small NN O O
insertion NN O O
loop NN O O
formed NN O O
at NN O O
meiosis NN O O
by NN O O
the NN O O
direct NN O O
insertion NN O O
(dir NN O O
ins NN O O
(5) NN O O
(q NN O O
22. NN O O
3 NN O O
q NN O O
14 NN O O
. NN O O

2 NN O O
q NN O O
15)) NN O O
found NN O O
in NN O O
the NN O O
patients NN O O
mother. NN O O
this NN O O
family NN O O
further NN O O
confirms NN O O
the NN O O
cytogenetic NN O O
mapping NN O O
of NN O O
both NN O O
mcc NN O O
and NN O O
APC NN B-Modifier B-MSH:D011125
genes NN O O
to NN O O
5 NN O O
q NN O O
22 NN O O
and NN O O
comparison NN O O
with NN O O
other NN O O
recent NN O O
cases NN O O
suggests NN O O
that NN O O
both NN O O
genes NN O O
and NN O O
their NN O O
closely NN O O
linked NN O O
markers NN O O
lie NN O O
within NN O O
the NN O O
5 NN O O
q NN O O
22. NN O O
1 NN O O
subban NN O O
. NN O O

somatic NN O O
mutations NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
in NN O O
colorectal NN B-DiseaseClass B-MSH:D015179
tumors NN I-DiseaseClass I-MSH:D015179
: NN O O
mutation NN O O
cluster NN O O
region NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
. NN O O

we NN O O
examined NN O O
somatic NN O O
mutations NN O O
of NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
( NN O O
APC NN B-Modifier B-MSH:D011125
) NN O O
gene NN O O
in NN O O
63 NN O O
colorectal NN B-DiseaseClass B-MSH:D015179
tumors NN I-DiseaseClass I-MSH:D015179
(16 NN O O
adenomas NN B-DiseaseClass B-MSH:D000236
and NN O O
47 NN O O
carcinomas NN B-DiseaseClass B-MSH:D009369
) NN O O
developed NN O O
in NN O O
familial NN B-Modifier B-MSH:D011125
adenomatous NN I-Modifier I-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
( NN O O
FAP NN B-Modifier B-MSH:D011125
) NN O O
and NN O O
non-fap NN O O
patients. NN O O
in NN O O
addition NN O O
to NN O O
loss NN O O
of NN O O
heterozygosity NN O O
(loh) NN O O
at NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
locus NN O O
in NN O O
30 NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
43 NN O O
other NN O O
somatic NN O O
mutations NN O O
were NN O O
detected. NN O O
twenty-one NN O O
of NN O O
them NN O O
were NN O O
point NN O O
mutations; NN O O
16 NN O O
nonsense NN O O
and NN O O
two NN O O
missense NN O O
mutations, NN O O
and NN O O
three NN O O
occurred NN O O
in NN O O
introns NN O O
at NN O O
the NN O O
splicing NN O O
site. NN O O
twenty-two NN O O
tumors NN B-DiseaseClass B-MSH:D009369
had NN O O
frameshift NN O O
mutations NN O O
due NN O O
to NN O O
deletion NN O O
or NN O O
insertion; NN O O
nineteen NN O O
of NN O O
them NN O O
were NN O O
deletions NN O O
of NN O O
one NN O O
to NN O O
31 NN O O
bp NN O O
and NN O O
three NN O O
were NN O O
a NN O O
1-bp NN O O
insertion. NN O O
one NN O O
tumor NN B-DiseaseClass B-MSH:D009369
had NN O O
a NN O O
1-bp NN O O
deletion NN O O
in NN O O
an NN O O
intron NN O O
near NN O O
the NN O O
splicing NN O O
site. NN O O
hence, NN O O
41 NN O O
. NN O O

95%) NN O O
of NN O O
43 NN O O
mutations NN O O
resulted NN O O
in NN O O
truncation NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
protein. NN O O
over NN O O
60% NN O O
of NN O O
the NN O O
somatic NN O O
mutations NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
were NN O O
clustered NN O O
within NN O O
a NN O O
small NN O O
region NN O O
of NN O O
exon NN O O
15, NN O O
designated NN O O
as NN O O
mcr NN O O
(mutation NN O O
cluster NN O O
region), NN O O
which NN O O
accounted NN O O
for NN O O
less NN O O
than NN O O
10% NN O O
of NN O O
the NN O O
coding NN O O
region. NN O O
combining NN O O
these NN O O
data NN O O
and NN O O
the NN O O
results NN O O
of NN O O
loh, NN O O
more NN O O
than NN O O
80% NN O O
of NN O O
tumors NN B-DiseaseClass B-MSH:D009369
(14 NN O O
adenomas NN B-DiseaseClass B-MSH:D000236
and NN O O
39 NN O O
carcinomas NN B-DiseaseClass B-MSH:D009369
) NN O O
had NN O O
at NN O O
least NN O O
one NN O O
mutation NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene, NN O O
of NN O O
which NN O O
more NN O O
than NN O O
60% NN O O
(9 NN O O
adenomas NN B-DiseaseClass B-MSH:D000236
and NN O O
23 NN O O
carcinomas NN B-DiseaseClass B-MSH:D009369
) NN O O
had NN O O
two NN O O
mutations. NN O O
these NN O O
results NN O O
strongly NN O O
suggest NN O O
that NN O O
somatic NN O O
mutations NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
are NN O O
associated NN O O
with NN O O
development NN O O
of NN O O
a NN O O
great NN O O
majority NN O O
of NN O O
colorectal NN B-DiseaseClass B-MSH:D015179
tumors NN I-DiseaseClass I-MSH:D015179
. NN O O
. NN O O

identification NN O O
of NN O O
an NN O O
altered NN O O
splice NN O O
site NN O O
in NN O O
ashkenazi NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
. NN O O

tay-sachs NN O O
disease NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
genetic NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
resulting NN O O
from NN O O
mutation NN O O
of NN O O
the NN O O
hexa NN O O
gene NN O O
encoding NN O O
the NN O O
alpha-subunit NN O O
of NN O O
the NN O O
lysosomal NN O O
enzyme, NN O O
beta-n-acetylhexosaminidase NN O O
a NN O O
(ref. NN O O
1). NN O O
a NN O O
relatively NN O O
high NN O O
frequency NN O O
of NN O O
carriers NN O O
(1/27) NN O O
of NN O O
a NN O O
lethal, NN O O
infantile NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
is NN O O
found NN O O
in NN O O
the NN O O
ashkenazi NN O O
jewish NN O O
population, NN O O
but NN O O
it NN O O
is NN O O
not NN O O
yet NN O O
evident NN O O
whether NN O O
this NN O O
has NN O O
resulted NN O O
from NN O O
a NN O O
founder NN O O
effect NN O O
and NN O O
random NN O O
genetic NN O O
drift NN O O
or NN O O
from NN O O
a NN O O
selective NN O O
advantage NN O O
of NN O O
heterozygotes. NN O O
we NN O O
have NN O O
identified NN O O
a NN O O
single-base NN O O
mutation NN O O
in NN O O
a NN O O
cloned NN O O
fragment NN O O
of NN O O
the NN O O
hexa NN O O
gene NN O O
from NN O O
an NN O O
ashkenazi NN O O
jewish NN O O
patient. NN O O
this NN O O
change, NN O O
the NN O O
substitution NN O O
of NN O O
a NN O O
c NN O O
for NN O O
g NN O O
in NN O O
the NN O O
first NN O O
nucleotide NN O O
of NN O O
intron NN O O
12 NN O O
is NN O O
expected NN O O
to NN O O
result NN O O
in NN O O
defective NN O O
splicing NN O O
o NN O O
. NN O O

the NN O O
messenger NN O O
rna. NN O O
a NN O O
test NN O O
for NN O O
the NN O O
mutant NN O O
allele NN O O
based NN O O
on NN O O
amplification NN O O
of NN O O
dna NN O O
by NN O O
the NN O O
polymerase NN O O
chain NN O O
rection NN O O
and NN O O
cleavage NN O O
of NN O O
a NN O O
ddei NN O O
restriction NN O O
site NN O O
generated NN O O
by NN O O
the NN O O
mutation NN O O
revealed NN O O
that NN O O
this NN O O
case NN O O
and NN O O
two NN O O
other NN O O
cases NN O O
of NN O O
the NN O O
ashkenazi, NN O O
infantile NN O O
form NN O O
of NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
are NN O O
heterozygous NN O O
for NN O O
two NN O O
different NN O O
mutations. NN O O
the NN O O
occurrence NN O O
of NN O O
multiple NN O O
mutant NN O O
alleles NN O O
warrants NN O O
further NN O O
examination NN O O
of NN O O
the NN O O
selective NN O O
advantage NN O O
hypothesis. NN O O
. NN O O

coats' NN O O
disease NN O O
of NN O O
the NN O O
retina NN O O
( NN O O
unilateral NN B-SpecificDisease B-MSH:D058456
retinal NN I-SpecificDisease I-MSH:D058456
telangiectasis NN I-SpecificDisease I-MSH:D058456
) NN O O
caused NN O O
by NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
ndp NN O O
gene: NN O O
a NN O O
role NN O O
for NN O O
norrin NN O O
in NN O O
retinal NN O O
angiogenesis NN O O
. NN O O

coats NN O O
disease NN O O
is NN O O
characterized NN O O
by NN O O
abnormal NN B-DiseaseClass B-MSH:D058456
retinal NN I-DiseaseClass I-MSH:D058456
vascular NN I-DiseaseClass I-MSH:D058456
development NN I-DiseaseClass I-MSH:D058456
(so-called NN O O
retinal NN B-SpecificDisease B-MSH:D058456
telangiectasis NN I-SpecificDisease I-MSH:D058456
) NN O O
which NN O O
results NN O O
in NN O O
massive NN O O
intraretinal NN B-CompositeMention B-MSH:D006949
and NN I-CompositeMention I-MSH:D006949
subretinal NN I-CompositeMention I-MSH:D006949
lipid NN I-CompositeMention I-MSH:D006949
accumulation NN I-CompositeMention I-MSH:D006949
( NN O O
exudative NN B-DiseaseClass B-MSH:D012163
retinal NN I-DiseaseClass I-MSH:D012163
detachment NN I-DiseaseClass I-MSH:D012163
). NN O O
the NN O O
classical NN O O
form NN O O
of NN O O
Coats NN B-SpecificDisease B-MSH:D058456
disease NN I-SpecificDisease I-MSH:D058456
is NN O O
almost NN O O
invariably NN O O
isolated, NN O O
unilateral NN O O
and NN O O
seen NN O O
in NN O O
males. NN O O
a NN O O
female NN O O
with NN O O
a NN O O
unilateral NN O O
variant NN O O
of NN O O
Coats NN B-SpecificDisease B-MSH:D058456
disease NN I-SpecificDisease I-MSH:D058456
gave NN O O
birth NN O O
to NN O O
a NN O O
son NN O O
affected NN O O
by NN O O
Norrie NN B-SpecificDisease B-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
. NN O O
both NN O O
carried NN O O
a NN O O
missense NN O O
mutation NN O O
within NN O O
the NN O O
ndp NN O O
gene NN O O
on NN O O
chromosome NN O O
xp NN O O
11. NN O O
2 NN O O
2. NN O O
subsequently NN O O
analysis NN O O
of NN O O
the NN O O
retinas NN O O
of NN O O
nine NN O O
enucleated NN O O
eyes NN O O
from NN O O
males NN O O
with NN O O
Coats NN B-SpecificDisease B-MSH:D058456
disease NN I-SpecificDisease I-MSH:D058456
demonstrated NN O O
in NN O O
one NN O O
a NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
ndp NN O O
gene NN O O
which NN O O
was NN O O
not NN O O
present NN O O
within NN O O
non-retinal NN O O
tissue. NN O O
we NN O O
suggest NN O O
that NN O O
Coats NN B-SpecificDisease B-MSH:D058456
telangiectasis NN I-SpecificDisease I-MSH:D058456
is NN O O
secondary NN O O
to NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
ndp NN O O
gene NN O O
which NN O O
results NN O O
in NN O O
a NN O O
deficiency NN B-DiseaseClass B-MSH:C537849
of NN I-DiseaseClass I-MSH:C537849
norrin NN I-DiseaseClass I-MSH:C537849
. NN O O

the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
ndp NN O O
gene) NN O O
within NN O O
the NN O O
developing NN O O
retina. NN O O
this NN O O
supports NN O O
recent NN O O
observations NN O O
that NN O O
the NN O O
protein NN O O
is NN O O
critical NN O O
for NN O O
normal NN O O
retinal NN O O
vasculogenesis NN O O
. NN O O

trisomy NN O O
15 NN O O
with NN O O
loss NN O O
of NN O O
the NN O O
paternal NN O O
15 NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
due NN O O
to NN O O
maternal NN B-SpecificDisease B-MSH:D024182
disomy NN I-SpecificDisease I-MSH:D024182
. NN O O

uniparental NN O O
disomy NN O O
has NN O O
recently NN O O
been NN O O
recognized NN O O
to NN O O
cause NN O O
human NN O O
disorders, NN O O
including NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
we NN O O
describe NN O O
a NN O O
particularly NN O O
instructive NN O O
case NN O O
which NN O O
raises NN O O
important NN O O
issues NN O O
concerning NN O O
the NN O O
mechanisms NN O O
producing NN O O
uniparental NN B-SpecificDisease B-MSH:D024182
disomy NN I-SpecificDisease I-MSH:D024182
and NN O O
whose NN O O
evaluation NN O O
provides NN O O
evidence NN O O
that NN O O
trisomy NN O O
may NN O O
precede NN O O
uniparental NN B-SpecificDisease B-MSH:D024182
disomy NN I-SpecificDisease I-MSH:D024182
in NN O O
a NN O O
fetus. NN O O
chorionic NN O O
villus NN O O
sampling NN O O
performed NN O O
for NN O O
advanced NN O O
maternal NN O O
age NN O O
revealed NN O O
trisomy NN B-SpecificDisease B-MSH:C538037
15 NN I-SpecificDisease I-MSH:C538037
in NN O O
all NN O O
direct NN O O
and NN O O
cultured NN O O
cells, NN O O
though NN O O
the NN O O
fetus NN O O
appeared NN O O
normal. NN O O
chromosome NN O O
analysis NN O O
of NN O O
amniocytes NN O O
obtained NN O O
at NN O O
15 NN O O
wk NN O O
was NN O O
normal NN O O
in NN O O
over NN O O
100 NN O O
cells NN O O
studied. NN O O
the NN O O
child NN O O
was NN O O
hypotonic NN B-SpecificDisease B-MSH:D009123
at NN O O
birth, NN O O
and NN O O
high-resolution NN O O
banding NN O O
failed NN O O
to NN O O
reveal NN O O
the NN O O
deletion NN O O
of NN O O
15 NN O O
q NN O O
11-13, NN O O
a NN O O
deletion NN O O
which NN O O
is NN O O
found NN O O
in NN O O
50% NN O O
-70% NN O O
of NN O O
patients NN O O
with NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
over NN O O
time, NN O O
typical NN O O
features NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
developed NN O O
. NN O O

molecular NN O O
genetic NN O O
analysis NN O O
using NN O O
probes NN O O
for NN O O
chromosome NN O O
15 NN O O
revealed NN O O
maternal NN O O
disomy. NN O O
maternal NN O O
nondisjunction NN O O
with NN O O
fertilization NN O O
of NN O O
a NN O O
disomic NN O O
egg NN O O
by NN O O
a NN O O
normal NN O O
sperm, NN O O
followed NN O O
by NN O O
loss NN O O
of NN O O
the NN O O
paternal NN O O
15, NN O O
is NN O O
a NN O O
likely NN O O
cause NN O O
of NN O O
confined NN O O
placental NN O O
mosaicism NN O O
and NN O O
uniparental NN B-SpecificDisease B-MSH:D024182
disomy NN I-SpecificDisease I-MSH:D024182
in NN O O
this NN O O
case NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
, NN O O
and NN O O
advanced NN O O
maternal NN O O
age NN O O
may NN O O
be NN O O
a NN O O
predisposing NN O O
factor. NN O O
. NN O O

genetic NN O O
defect NN B-SpecificDisease B-OMIM:609536
in NN I-SpecificDisease I-OMIM:609536
secretion NN I-SpecificDisease I-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
complement NN I-SpecificDisease I-OMIM:609536
C5 NN I-SpecificDisease I-OMIM:609536
in NN O O
mice NN O O
. NN O O

a NN O O
genetic NN O O
deficiency NN B-SpecificDisease B-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
the NN I-SpecificDisease I-OMIM:609536
fifth NN I-SpecificDisease I-OMIM:609536
(C5) NN I-SpecificDisease I-OMIM:609536
component NN I-SpecificDisease I-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
complement1-3 NN I-SpecificDisease I-OMIM:609536
, NN O O
a NN O O
serum NN O O
glycoprotein NN O O
of NN O O
molecular NN O O
weight NN O O
(mw) NN O O
220, NN O O
000 NN O O
(ref. NN O O
4), NN O O
has NN O O
been NN O O
found NN O O
in NN O O
39% NN O O
of NN O O
inbred NN O O
strains NN O O
of NN O O
mice NN O O
3. NN O O
sera NN O O
of NN O O
deficient NN O O
mice NN O O
lack NN O O
detectable NN O O
c NN O O
5 NN O O
activity NN O O
and NN O O
protein NN O O
2, NN O O
3. NN O O
in NN O O
addition NN O O
deficient NN O O
mice NN O O
produce NN O O
antibody NN O O
to NN O O
mouse NN O O
c NN O O
5 NN O O
when NN O O
injected NN O O
with NN O O
sera NN O O
from NN O O
c NN O O
5 NN O O
sufficient NN O O
(normal) NN O O
strains. NN O O
levy NN O O
et NN O O
al. NN O O
5 NN O O
showed NN O O
that NN O O
somatic NN O O
cell NN O O
hybrids NN O O
between NN O O
c NN O O
5 NN O O
deficient NN O O
(b NN O O
10. NN O O
d NN O O
2/old NN O O
line) NN O O
macrophages NN O O
and NN O O
either NN O O
c NN O O
5 NN O O
sufficient NN O O
(b NN O O
10. NN O O
d NN O O
2/new NN O O
line) NN O O
mouse NN O O
kidney NN O O
or NN O O
chicken NN O O
erythroblasts NN O O
secreted NN O O
haemolytically NN O O
active NN O O
mouse NN O O
c NN O O
5 NN O O
in NN O O
vitro NN O O
. NN O O

several NN O O
possible NN O O
molecular NN O O
mechanisms NN O O
to NN O O
account NN O O
for NN O O
the NN O O
findings NN O O
were NN O O
considered, NN O O
but NN O O
insufficient NN O O
direct NN O O
data NN O O
were NN O O
available NN O O
to NN O O
choose NN O O
among NN O O
them. NN O O
we NN O O
recently NN O O
reported NN O O
that NN O O
mouse NN O O
(cd. NN O O
1 NN O O
strain) NN O O
peritoneal NN O O
cells NN O O
in NN O O
culture NN O O
synthesise NN O O
and NN O O
secrete NN O O
a NN O O
single NN O O
chain NN O O
precursor, NN O O
pro-c NN O O
5 NN O O
(mw NN O O
approximately NN O O
210, NN O O
000), NN O O
of NN O O
the NN O O
two-chain NN O O
(alpha NN O O
chain, NN O O
125, NN O O
000 NN O O
and NN O O
beta NN O O
chain NN O O
83, NN O O
000 NN O O
mw) NN O O
c NN O O
5 NN O O
protein NN O O
6. NN O O
radiolabelled NN O O
precursor NN O O
c NN O O
5 NN O O
was NN O O
contained NN O O
within NN O O
the NN O O
cells NN O O
and NN O O
was NN O O
secreted NN O O
into NN O O
the NN O O
tissue NN O O
culture NN O O
media. NN O O
using NN O O
similar NN O O
methods, NN O O
we NN O O
now NN O O
find NN O O
that NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
in NN O O
each NN O O
of NN O O
five NN O O
different NN O O
mouse NN O O
strains NN O O
(akr, NN O O
swr, NN O O
dba/2 NN O O
j NN O O
8 NN O O
a/hej NN O O
and NN O O
b NN O O
10. NN O O
d NN O O
2/ol NN O O
. NN O O

line) NN O O
is NN O O
due NN O O
to NN O O
a NN O O
failure NN O O
in NN O O
secretion NN O O
of NN O O
c NN O O
5 NN O O
protein NN O O
and NN O O
not NN O O
to NN O O
a NN O O
failure NN O O
in NN O O
biosynthesis NN O O
of NN O O
pro-c NN O O
. NN O O

wasp NN O O
gene NN O O
mutations NN O O
in NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
and NN O O
X-linked NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
. NN O O

the NN O O
wasp NN O O
gene NN O O
has NN O O
been NN O O
recently NN O O
cloned NN O O
from NN O O
xp NN O O
11. NN O O
23 NN O O
and NN O O
shown NN O O
to NN O O
be NN O O
mutated NN O O
in NN O O
three NN O O
patients NN O O
with NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
). NN O O
we NN O O
have NN O O
developed NN O O
a NN O O
screening NN O O
protocol NN O O
for NN O O
identifying NN O O
wasp NN O O
gene NN O O
alterations NN O O
in NN O O
genomic NN O O
dna NN O O
and NN O O
have NN O O
identified NN O O
a NN O O
spectrum NN O O
of NN O O
novel NN O O
mutations NN O O
in NN O O
12 NN O O
additional NN O O
unrelated NN O O
families. NN O O
these NN O O
missense, NN O O
nonsense NN O O
and NN O O
frameshift NN O O
mutations NN O O
involve NN O O
eight NN O O
of NN O O
the NN O O
12 NN O O
exons NN O O
of NN O O
the NN O O
gene. NN O O
two NN O O
mutations NN O O
creating NN O O
premature NN O O
termination NN O O
codons NN O O
were NN O O
associated NN O O
with NN O O
lack NN O O
of NN O O
detectable NN O O
mrna NN O O
on NN O O
northern NN O O
blots. NN O O
four NN O O
amino NN O O
acid NN O O
substitutions, NN O O
leu NN O O
27 NN O O
phe, NN O O
thr NN O O
48 NN O O
ile, NN O O
val NN O O
75 NN O O
met NN O O
and NN O O
arg NN O O
477 NN O O
lys, NN O O
were NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
congenital NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
and NN O O
no NN O O
clinically NN O O
evident NN O O
immune NN O O
defect NN O O
indicating NN O O
that NN O O
the NN O O
wasp NN O O
gene NN O O
is NN O O
the NN O O
site NN O O
for NN O O
mutations NN O O
in NN O O
X-linked NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900

thrombocytopenia NN O O
as NN O O
well NN O O
as NN O O
in NN O O
WAS NN B-SpecificDisease B-MSH:D014923
. NN O O
a NN O O
t-cell NN O O
line NN O O
from NN O O
a NN O O
WAS NN B-Modifier B-MSH:D014923
patient NN O O
contained NN O O
two NN O O
independent NN O O
dna NN O O
alterations, NN O O
a NN O O
constitutional NN O O
frameshift NN O O
mutation, NN O O
also NN O O
present NN O O
in NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
from NN O O
the NN O O
patient, NN O O
and NN O O
compensatory NN O O
splice NN O O
site NN O O
mutation NN O O
unique NN O O
to NN O O
the NN O O
cell NN O O
line. NN O O
the NN O O
distribution NN O O
of NN O O
eight NN O O
missense NN O O
mutations NN O O
provides NN O O
valuable NN O O
information NN O O
on NN O O
amino NN O O
acids NN O O
which NN O O
are NN O O
essential NN O O
for NN O O
normal NN O O
protein NN O O
function, NN O O
and NN O O
suggests NN O O
that NN O O
sites NN O O
in NN O O
the NN O O
first NN O O
two NN O O
exons NN O O
are NN O O
hot-spots NN O O
for NN O O
mutation NN O O
. NN O O

detection NN O O
of NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
the NN O O
dystrophin NN O O
gene NN O O
by NN O O
multiple NN O O
sscp NN O O
. NN O O
ultiple NN O O
sscp NN O O
. NN O O

a NN O O
combination NN O O
of NN O O
multiplex NN O O
pcr NN O O
with NN O O
the NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
technique NN O O
was NN O O
employed NN O O
to NN O O
screen NN O O
for NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
dystrophin NN O O
gene. NN O O
co-amplification NN O O
of NN O O
11 NN O O
exons NN O O
from NN O O
genomic NN O O
dna NN O O
of NN O O
Duchenne NN B-Modifier B-MSH:D020388
and NN I-Modifier I-MSH:D020388
Becker NN I-Modifier I-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
/ NN O O
BMD NN B-Modifier B-MSH:C537666
) NN O O
patients NN O O
with NN O O
no NN O O
deletion NN O O
or NN O O
duplication NN O O
was NN O O
performed NN O O
and NN O O
the NN O O
samples NN O O
subjected NN O O
to NN O O
multiple NN O O
sscp NN O O
analysis. NN O O
we NN O O
report NN O O
the NN O O
case NN O O
of NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
a NN O O
Duchenne NN B-Modifier B-MSH:D020388
patient NN O O
identified NN O O
by NN O O
this NN O O
approach. NN O O
the NN O O
mutation NN O O
introduces NN O O
a NN O O
termination NN O O
codon NN O O
within NN O O
exon NN O O
8 NN O O
of NN O O
the NN O O
dystrophin NN O O
gene. NN O O
it NN O O
is NN O O
predicted NN O O
to NN O O
cause NN O O
a NN O O
very NN O O
premature NN O O
translational NN O O
termination NN O O
accounting NN O O
for NN O O
the NN O O
severe NN O O
phenotype NN O O
observed. NN O O
the NN O O
patient NN O O
inherited NN O O
this NN O O
mutation NN O O
from NN O O
his NN O O
mother. NN O O
in NN O O
addition NN O O
the NN O O
analysis NN O O
revealed NN O O
5 NN O O
polymorphisms NN O O
useful NN O O
for NN O O
internal NN O O
control. NN O O
. NN O O

molecular NN O O
mechanisms NN O O
of NN O O
oncogenic NN O O
mutations NN O O
in NN O O
tumors NN B-DiseaseClass B-MSH:D009369
from NN O O
patients NN O O
with NN O O
bilateral NN B-CompositeMention B-MSH:D012175
and NN I-CompositeMention I-MSH:D012175
unilateral NN I-CompositeMention I-MSH:D012175
retinoblastoma NN I-CompositeMention I-MSH:D012175
. NN O O

the NN O O
rb NN O O
1 NN O O
gene NN O O
from NN O O
12 NN O O
human NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
tumors NN I-SpecificDisease I-MSH:D012175
has NN O O
been NN O O
analyzed NN O O
exon-by-exon NN O O
with NN O O
the NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
technique. NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
all NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
and NN O O
one-third NN O O
of NN O O
the NN O O
tumors NN B-DiseaseClass B-MSH:D009369
had NN O O
independent NN O O
mutations NN O O
in NN O O
both NN O O
alleles NN O O
neither NN O O
of NN O O
which NN O O
were NN O O
found NN O O
in NN O O
the NN O O
germ NN O O
line, NN O O
confirming NN O O
their NN O O
true NN O O
sporadic NN O O
nature. NN O O
in NN O O
the NN O O
remaining NN O O
two-thirds NN O O
of NN O O
the NN O O
tumors NN B-DiseaseClass B-MSH:D009369
only NN O O
one NN O O
mutation NN O O
was NN O O
found, NN O O
consistent NN O O
with NN O O
the NN O O
loss-of-heterozygosity NN O O
theory NN O O
of NN O O
tumorigenesis. NN O O
point NN O O
mutations, NN O O
the NN O O
majority NN O O
of NN O O
which NN O O
were NN O O
c-- NN O O
> NN O O
t NN O O
transitions, NN O O
were NN O O
the NN O O
most NN O O
common NN O O
abnormality NN O O
and NN O O
usually NN O O
resulted NN O O
in NN O O
the NN O O
conversion NN O O
of NN O O
an NN O O
arginine NN O O
codon NN O O
to NN O O
a NN O O
stop NN O O
codon. NN O O
small NN O O
deletions NN O O
were NN O O
the NN O O
second NN O O
most NN O O
common NN O O
abnormality NN O O
and NN O O
most NN O O
often NN O O
created NN O O
a NN O O
downstream NN O O
stop NN O O
codo NN O O
. NN O O

as NN O O
the NN O O
result NN O O
of NN O O
a NN O O
reading NN O O
frameshift. NN O O
deletions NN O O
and NN O O
point NN O O
mutations NN O O
also NN O O
affected NN O O
splice NN O O
junctions. NN O O
direct NN O O
repeats NN O O
were NN O O
present NN O O
at NN O O
the NN O O
breakpoint NN O O
junctions NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
deletions, NN O O
supporting NN O O
a NN O O
slipped-mispairing NN O O
mechanism. NN O O
point NN O O
mutations NN O O
generally NN O O
produced NN O O
dna NN O O
sequences NN O O
which NN O O
resulted NN O O
in NN O O
perfect NN O O
homology NN O O
with NN O O
endogenous NN O O
sequences NN O O
which NN O O
lay NN O O
within NN O O
14 NN O O
bp. NN O O
. NN O O

pax NN O O
6 NN O O
gene NN O O
dosage NN O O
effect NN O O
in NN O O
a NN O O
family NN O O
with NN O O
congenital NN B-SpecificDisease B-MSH:D002386
cataracts NN I-SpecificDisease I-MSH:D002386
, NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
anophthalmia NN B-SpecificDisease B-MSH:D000853
and NN O O
central NN B-DiseaseClass B-MSH:D009421
nervous NN I-DiseaseClass I-MSH:D009421
system NN I-DiseaseClass I-MSH:D009421
defects NN I-DiseaseClass I-MSH:D009421
. NN O O

the NN O O
human NN O O
eye NN O O
malformation NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
results NN O O
from NN O O
haploinsufficiency NN B-SpecificDisease B-OMIM:106210
of NN I-SpecificDisease I-OMIM:106210
PAX6 NN I-SpecificDisease I-OMIM:106210
, NN O O
a NN O O
paired NN O O
box NN O O
dna-binding NN O O
protein. NN O O
to NN O O
study NN O O
this NN O O
dosage NN O O
effect, NN O O
we NN O O
characterized NN O O
two NN O O
pax NN O O
6 NN O O
mutations NN O O
in NN O O
a NN O O
family NN O O
segregating NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
and NN O O
a NN O O
milder NN O O
syndrome NN O O
consisting NN O O
of NN O O
congenital NN B-SpecificDisease B-MSH:D002386
cataracts NN I-SpecificDisease I-MSH:D002386
and NN O O
late NN O O
onset NN O O
corneal NN B-SpecificDisease B-MSH:D003317
dystrophy NN I-SpecificDisease I-MSH:D003317
. NN O O
the NN O O
nonsense NN O O
mutations, NN O O
at NN O O
codons NN O O
103 NN O O
and NN O O
353, NN O O
truncate NN O O
pax NN O O
6 NN O O
within NN O O
the NN O O
n-terminal NN O O
paired NN O O
and NN O O
c-terminal NN O O
pst NN O O
domains, NN O O
respectively. NN O O
the NN O O
wild-type NN O O
pst NN O O
domain NN O O
activates NN O O
transcription NN O O
autonomously NN O O
and NN O O
the NN O O
mutant NN O O
form NN O O
has NN O O
partial NN O O
activity. NN O O
a NN O O
compound NN O O
heterozygote NN O O
had NN O O
severe NN O O
craniofacial NN B-CompositeMention B-MSH:D019465
and NN I-CompositeMention I-MSH:D019465
central NN I-CompositeMention I-MSH:D019465
nervous NN I-CompositeMention I-MSH:D019465
system NN I-CompositeMention I-MSH:D019465
defects NN I-CompositeMention I-MSH:D019465
and NN O O
no NN B-DiseaseClass B-MSH:D000853
eyes NN I-DiseaseClass I-MSH:D000853
. NN O O
the NN O O
pattern NN O O
of NN O O
malformations NN O O
is NN O O
similar NN O O
to NN O O
that NN O O
in NN O O
homozygous NN O O
sey NN O O
mice NN O O
and NN O O
suggests NN O O
a NN O O
critical NN O O
role NN O O
for NN O O
pax NN O O
6 NN O O
in NN O O
controlling NN O O
the NN O O
migration NN O O
and NN O O
differentiation NN O O
of NN O O
specific NN O O
neurona NN O O
. NN O O

progenitor NN O O
cells NN O O
in NN O O
the NN O O
brain. NN O O
. NN O O

hereditary NN O O
c NN O O
7 NN O O
deficiency. NN O O
diagnosis NN O O
and NN O O
hla NN O O
studies NN O O
in NN O O
a NN O O
french-canadian NN O O
family NN O O
. NN O O

the NN O O
serum NN O O
of NN O O
a NN O O
44-yr-old NN O O
woman NN O O
of NN O O
french-canadian NN O O
descent NN O O
having NN O O
a NN O O
b-27 NN O O
positive NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
was NN O O
deficient NN B-SpecificDisease B-OMIM:610102
in NN I-SpecificDisease I-OMIM:610102
the NN I-SpecificDisease I-OMIM:610102
seventh NN I-SpecificDisease I-OMIM:610102
component NN I-SpecificDisease I-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
complement NN I-SpecificDisease I-OMIM:610102
(c NN O O
7) NN O O
as NN O O
determined NN O O
by NN O O
hemolytic NN O O
and NN O O
immunochemical NN O O
methods. NN O O
no NN O O
inhibitor NN O O
against NN O O
c NN O O
7 NN O O
was NN O O
detected, NN O O
and NN O O
the NN O O
levels NN O O
of NN O O
all NN O O
other NN O O
complement NN O O
components NN O O
were NN O O
normal. NN O O
no NN O O
deficiency NN O O
in NN O O
the NN O O
opsonic NN O O
activity NN O O
of NN O O
the NN O O
serum NN O O
was NN O O
found, NN O O
and NN O O
the NN O O
results NN O O
of NN O O
basic NN O O
coagulation NN O O
studies NN O O
of NN O O
the NN O O
plasma NN O O
were NN O O
normal. NN O O
on NN O O
investigation NN O O
of NN O O
the NN O O
patients NN O O
family, NN O O
two NN O O
sisters NN O O
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
same NN O O
deficiency NN O O
but NN O O
were NN O O
otherwise NN O O
in NN O O
good NN O O
health. NN O O
the NN O O
seven NN O O
other NN O O
siblings NN O O
were NN O O
heterozygous NN O O
for NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficiency NN I-SpecificDisease I-OMIM:610102
, NN O O
while NN O O
the NN O O
paternal NN O O
aunt NN O O
had NN O O
a NN O O
normal NN O O
c NN O O
7 NN O O
level. NN O O
in NN O O
the NN O O
third NN O O
generation, NN O O
six NN O O
children NN O O
o NN O O
. NN O O

the NN O O
three NN O O
homozygous NN O O
sisters NN O O
and NN O O
five NN O O
children NN O O
of NN O O
heterozygotes NN O O
were NN O O
available NN O O
for NN O O
testing. NN O O
studies NN O O
of NN O O
the NN O O
hla NN O O
antigens NN O O
in NN O O
all NN O O
the NN O O
22 NN O O
subjects NN O O
and NN O O
in NN O O
three NN O O
spouses NN O O
indicated NN O O
no NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
CM NN B-SpecificDisease B-OMIM:610102
deficienty NN I-SpecificDisease I-OMIM:610102
and NN O O
the NN O O
hla NN O O
system. NN O O
in NN O O
addition, NN O O
the NN O O
simultaneous NN O O
occurrence NN O O
of NN O O
two NN O O
hereditary NN O O
complement NN B-CompositeMention B-OMIM:610102
deficiencies NN I-CompositeMention I-OMIM:610102
(C2 NN I-CompositeMention I-OMIM:610102
and NN I-CompositeMention I-OMIM:610102
C7) NN I-CompositeMention I-OMIM:610102
was NN O O
discovered NN O O
in NN O O
one NN O O
family NN O O
of NN O O
this NN O O
remarkable NN O O
kindred. NN O O
. NN O O

alstrom NN O O
syndrome: NN O O
further NN O O
evidence NN O O
for NN O O
linkage NN O O
to NN O O
human NN O O
chromosome NN O O
2 NN O O
p NN O O
13 NN O O
. NN O O

alstrom NN O O
syndrome NN O O
is NN O O
a NN O O
rare NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
retinal NN B-SpecificDisease B-MSH:D012162
degeneration NN I-SpecificDisease I-MSH:D012162
, NN O O
sensorineural NN B-SpecificDisease B-MSH:D006319
hearing NN I-SpecificDisease I-MSH:D006319
loss NN I-SpecificDisease I-MSH:D006319
, NN O O
early-onset NN O O
obesity NN B-SpecificDisease B-MSH:D009765
, NN O O
and NN O O
non-insulin-dependent NN B-SpecificDisease B-MSH:D003924
diabetes NN I-SpecificDisease I-MSH:D003924
mellitus NN I-SpecificDisease I-MSH:D003924
. NN O O
the NN O O
gene NN O O
for NN O O
Alstrom NN B-SpecificDisease B-MSH:D056769
syndrome NN I-SpecificDisease I-MSH:D056769
(alms NN O O
1) NN O O
has NN O O
been NN O O
previously NN O O
localized NN O O
to NN O O
human NN O O
chromosome NN O O
2 NN O O
p NN O O
13 NN O O
by NN O O
homozygosity NN O O
mapping NN O O
in NN O O
two NN O O
distinct NN O O
isolated NN O O
populations NN O O
- NN O O
french NN O O
acadian NN O O
and NN O O
north NN O O
african. NN O O
pair-wise NN O O
analyses NN O O
resulted NN O O
in NN O O
maximum NN O O
lod NN O O
(logarithm NN O O
of NN O O
the NN O O
odds NN O O
ratio) NN O O
scores NN O O
of NN O O
3. NN O O
84 NN O O
and NN O O
2. NN O O
9, NN O O
respectively. NN O O
to NN O O
confirm NN O O
these NN O O
findings, NN O O
a NN O O
large NN O O
linkage NN O O
study NN O O
was NN O O
performed NN O O
in NN O O
twelve NN O O
additional NN O O
families NN O O
segregating NN O O
for NN O O
Alstrom NN B-SpecificDisease B-MSH:D056769
syndrome NN I-SpecificDisease I-MSH:D056769
. NN O O
a NN O O
maximum NN O O
two-point NN O O
lod NN O O
score NN O O
of NN O O
7. NN O O
13 NN O O
(theta NN O O
= NN O O
0. NN O O
00) NN O O
for NN O O
marker NN O O
d NN O O
2 NN O O
s NN O O
2110 NN O O
and NN O O
a NN O O
maximum NN O O
cumulativ NN O O
. NN O O

multipoint NN O O
lod NN O O
score NN O O
of NN O O
9. NN O O
16 NN O O
for NN O O
marker NN O O
d NN O O
2 NN O O
s NN O O
2110 NN O O
were NN O O
observed, NN O O
further NN O O
supporting NN O O
linkage NN O O
to NN O O
chromosome NN O O
2 NN O O
p NN O O
13. NN O O
no NN O O
evidence NN O O
of NN O O
genetic NN O O
heterogeneity NN O O
was NN O O
observed NN O O
in NN O O
these NN O O
families. NN O O
meiotic NN O O
recombination NN O O
events NN O O
have NN O O
localized NN O O
the NN O O
critical NN O O
region NN O O
containing NN O O
alms NN O O
1 NN O O
to NN O O
a NN O O
6. NN O O
1-cm NN O O
interval NN O O
flanked NN O O
by NN O O
markers NN O O
d NN O O
2 NN O O
s NN O O
327 NN O O
and NN O O
d NN O O
2 NN O O
s NN O O
286. NN O O
a NN O O
fine NN O O
resolution NN O O
radiation NN O O
hybrid NN O O
map NN O O
of NN O O
31 NN O O
genes NN O O
and NN O O
markers NN O O
has NN O O
been NN O O
constructed NN O O
. NN O O

haplotype NN O O
and NN O O
multipoint NN O O
linkage NN O O
analysis NN O O
in NN O O
finnish NN O O
choroideremia NN B-Modifier B-MSH:D015794
families NN O O
. NN O O

multipoint NN O O
linkage NN O O
analysis NN O O
of NN O O
choroideremia NN B-SpecificDisease B-MSH:D015794
( NN O O
TCD NN B-SpecificDisease B-MSH:D015794
) NN O O
and NN O O
seven NN O O
x NN O O
chromosomal NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
(rflps) NN O O
was NN O O
carried NN O O
out NN O O
in NN O O
18 NN O O
finnish NN O O
TCD NN B-Modifier B-MSH:D015794
families. NN O O
the NN O O
data NN O O
place NN O O
TCD NN B-SpecificDisease B-MSH:D015794
distal NN O O
to NN O O
pgk NN O O
and NN O O
dxs NN O O
72, NN O O
very NN O O
close NN O O
to NN O O
dxys NN O O
1 NN O O
and NN O O
dxys NN O O
5 NN O O
(zmax NN O O
= NN O O
24 NN O O
at NN O O
theta NN O O
= NN O O
0) NN O O
and NN O O
proximal NN O O
to NN O O
dxys NN O O
4 NN O O
and NN O O
dxys NN O O
12. NN O O
this NN O O
agrees NN O O
with NN O O
the NN O O
data NN O O
obtained NN O O
from NN O O
other NN O O
linkage NN O O
studies NN O O
and NN O O
from NN O O
physical NN O O
mapping. NN O O
all NN O O
the NN O O
TCD NN B-Modifier B-MSH:D015794
males NN O O
and NN O O
carrier NN O O
females NN O O
studied NN O O
have NN O O
the NN O O
same NN O O
dxys NN O O
1 NN O O
allele NN O O
in NN O O
coupling NN O O
with NN O O
TCD NN B-SpecificDisease B-MSH:D015794
. NN O O
in NN O O
northeastern NN O O
finland, NN O O
66/69 NN O O
chromosomes NN O O
carrying NN O O
TCD NN B-SpecificDisease B-MSH:D015794
had NN O O
the NN O O
same NN O O
haplotype NN O O
at NN O O
loci NN O O
dxs NN O O
72, NN O O
dxys NN O O
1, NN O O
dxys NN O O
4, NN O O
and NN O O
dxys NN O O
12. NN O O
the NN O O
same NN O O
haplotype NN O O
is NN O O
seen NN O O
in NN O O
only NN O O
15/99 NN O O
chromosomes NN O O
no NN O O
. NN O O

carrying NN O O
TCD NN B-SpecificDisease B-MSH:D015794
. NN O O
moreover, NN O O
in NN O O
71/104 NN O O
non-tcd NN O O
chromosomes, NN O O
the NN O O
haplotype NN O O
at NN O O
six NN O O
marker NN O O
loci NN O O
is NN O O
different NN O O
from NN O O
those NN O O
seen NN O O
in NN O O
any NN O O
of NN O O
the NN O O
76 NN O O
TCD NN B-Modifier B-MSH:D015794
chromosomes. NN O O
this NN O O
supports NN O O
the NN O O
previously NN O O
described NN O O
hypothesis NN O O
that NN O O
the NN O O
large NN O O
northern NN O O
finnish NN O O
choroideremia NN B-Modifier B-MSH:D015794
pedigrees, NN O O
comprising NN O O
a NN O O
total NN O O
of NN O O
over NN O O
80 NN O O
living NN O O
patients NN O O
representing NN O O
more NN O O
than NN O O
a NN O O
fifth NN O O
of NN O O
all NN O O
TCD NN B-Modifier B-MSH:D015794
patients NN O O
described NN O O
worldwide, NN O O
carry NN O O
the NN O O
same NN O O
mutation. NN O O
these NN O O
linkage NN O O
and NN O O
haplotype NN O O
data NN O O
provide NN O O
improved NN O O
opportunities NN O O
for NN O O
prenatal NN O O
diagnosis NN O O
based NN O O
on NN O O
rflp NN O O
studies. NN O O
. NN O O

genetic NN O O
heterogeneity NN O O
at NN O O
the NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
locus NN O O
in NN O O
southern NN O O
italy: NN O O
a NN O O
study NN O O
on NN O O
a NN O O
population NN O O
from NN O O
the NN O O
matera NN O O
district NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
has NN O O
been NN O O
analyzed NN O O
by NN O O
gel NN O O
electrophoresis NN O O
and NN O O
by NN O O
quantitative NN O O
assay NN O O
in NN O O
an NN O O
unselected NN O O
sample NN O O
of NN O O
1524 NN O O
schoolboys NN O O
from NN O O
the NN O O
province NN O O
of NN O O
matera NN O O
(lucania) NN O O
in NN O O
southern NN O O
italy. NN O O
we NN O O
have NN O O
identified NN O O
43 NN O O
subjects NN O O
with NN O O
a NN O O
g NN O O
6 NN O O
pd NN O O
variant. NN O O
of NN O O
these, NN O O
31 NN O O
had NN O O
severe NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
, NN O O
nine NN O O
had NN O O
mild NN O O
to NN O O
moderate NN O O
deficiency, NN O O
and NN O O
three NN O O
had NN O O
a NN O O
non-deficient NN O O
electrophoretic NN O O
variant. NN O O
the NN O O
overall NN O O
rate NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
was NN O O
2. NN O O
6%. NN O O
the NN O O
frequency NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
, NN O O
ranging NN O O
from NN O O
7. NN O O
2% NN O O
on NN O O
the NN O O
ionian NN O O
coast NN O O
to NN O O
zero NN O O
on NN O O
the NN O O
eastern NN O O
side NN O O
of NN O O
the NN O O
lucanian NN O O
apennines, NN O O
appears NN O O
to NN O O
be NN O O
inversely NN O O
related NN O O
to NN O O
the NN O O
distance NN O O
of NN O O
each NN O O
town NN O O
examined NN O O
from NN O O
the NN O O
ionian NN O O
coast NN O O
. NN O O

suggesting NN O O
that NN O O
this NN O O
geographic NN O O
distribution NN O O
may NN O O
reflect, NN O O
at NN O O
least NN O O
in NN O O
part, NN O O
gene NN O O
flow NN O O
from NN O O
greek NN O O
settlers. NN O O
biochemical NN O O
characterization NN O O
has NN O O
shown NN O O
that NN O O
most NN O O
of NN O O
the NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
this NN O O
population NN O O
is NN O O
accounted NN O O
for NN O O
by NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean. NN O O
in NN O O
addition, NN O O
we NN O O
have NN O O
found NN O O
several NN O O
examples NN O O
of NN O O
two NN O O
other NN O O
known NN O O
polymorphic NN O O
variants NN O O
(g NN O O
6 NN O O
pd NN O O
cagliari NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
a-); NN O O
three NN O O
new NN O O
polymorphic NN O O
variants, NN O O
g NN O O
6 NN O O
pd NN O O
metaponto NN O O
(class NN O O
iii), NN O O
g NN O O
6 NN O O
pd NN O O
montalbano NN O O
(class NN O O
iii), NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
pisticci NN O O
(class NN O O
iv); NN O O
and NN O O
two NN O O
sporadic NN O O
variants, NN O O
g NN O O
6 NN O O
pd NN O O
tursi NN O O
(class NN O O
iii) NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
ferrandina NN O O
(class NN O O
ii). NN O O
these NN O O
data NN O O
provide NN O O
further NN O O
evidence NN O O
for NN O O
the NN O O
marked NN O O
genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955

deficiency NN O O
within NN O O
a NN O O
relatively NN O O
narrow NN O O
geographic NN O O
area NN O O
and NN O O
they NN O O
prove NN O O
the NN O O
presence NN O O
in NN O O
the NN O O
italian NN O O
peninsula NN O O
of NN O O
a NN O O
gene NN O O
(gda-) NN O O
regarded NN O O
as NN O O
characteristically NN O O
african NN O O
. NN O O

defective NN O O
ctla-4 NN O O
cycling NN O O
pathway NN O O
in NN O O
Chediak-Higashi NN B-SpecificDisease B-MSH:D002609
syndrome NN I-SpecificDisease I-MSH:D002609
: NN O O
a NN O O
possible NN O O
mechanism NN O O
for NN O O
deregulation NN O O
of NN O O
t NN O O
lymphocyte NN O O
activation NN O O
. NN O O

cytotoxic NN O O
t NN O O
lymphocyte-associated NN O O
antigen NN O O
4 NN O O
(ctla-4, NN O O
also NN O O
known NN O O
as NN O O
cd NN O O
152) NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
play NN O O
a NN O O
major NN O O
role NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
t NN O O
cell NN O O
activation. NN O O
its NN O O
membrane NN O O
expression NN O O
is NN O O
highly NN O O
regulated NN O O
by NN O O
endocytosis NN O O
and NN O O
trafficking NN O O
through NN O O
the NN O O
secretory NN O O
lysosome NN O O
pathway. NN O O
Chediak-Higashi NN B-SpecificDisease B-MSH:D002609
syndrome NN I-SpecificDisease I-MSH:D002609
( NN O O
CHS NN B-SpecificDisease B-MSH:D002609
) NN O O
is NN O O
an NN O O
inherited NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
lysosomal NN O O
trafficking NN O O
regulator NN O O
gene, NN O O
lyst. NN O O
it NN O O
results NN O O
in NN O O
defective NN O O
membrane NN O O
targeting NN O O
of NN O O
the NN O O
proteins NN O O
present NN O O
in NN O O
secretory NN O O
lysosomes, NN O O
and NN O O
it NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
variety NN O O
of NN O O
features, NN O O
including NN O O
a NN O O
lymphoproliferative NN B-SpecificDisease B-MSH:D008232
syndrome NN I-SpecificDisease I-MSH:D008232
with NN O O
hemophagocytosis NN B-DiseaseClass B-MSH:D051359
. NN O O
the NN O O
murine NN O O
equivalent NN O O
of NN O O
CHS NN B-SpecificDisease B-MSH:D002609
, NN O O
beige NN O O
mice, NN O O
present NN O O
similar NN O O
characteristics NN O O
but NN O O
do NN O O
not NN O O
develop NN O O
the NN O O
lymphoproliferative NN B-SpecificDisease B-MSH:D008232
syndrome NN I-SpecificDisease I-MSH:D008232
. NN O O
we NN O O
show NN O O
herein NN O O
that NN O O
ctla-4 NN O O
is NN O O
present NN O O
in NN O O
enlarged, NN O O
abnormal NN O O
vesicles NN O O
in NN O O
CHS NN B-Modifier B-MSH:D002609
. NN O O

t NN O O
cells NN O O
and NN O O
is NN O O
not NN O O
properly NN O O
expressed NN O O
at NN O O
the NN O O
cell NN O O
surface NN O O
after NN O O
t NN O O
cell NN O O
activation, NN O O
whereas NN O O
its NN O O
surface NN O O
expression NN O O
is NN O O
not NN O O
impaired. NN O O
it NN O O
is NN O O
therefore NN O O
proposed NN O O
that NN O O
the NN O O
defective NN O O
surface NN O O
expression NN O O
of NN O O
ctla-4 NN O O
by NN O O
CHS NN B-Modifier B-MSH:D002609
t NN O O
cells NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
generation NN O O
of NN O O
lymphoproliferative NN B-SpecificDisease B-MSH:D008232
disease NN I-SpecificDisease I-MSH:D008232
. NN O O
this NN O O
observation NN O O
may NN O O
provide NN O O
insight NN O O
into NN O O
the NN O O
role NN O O
of NN O O
ctla-4 NN O O
in NN O O
humans. NN O O
. NN O O

beta-catenin NN O O
accumulation NN O O
and NN O O
mutation NN O O
of NN O O
the NN O O
ctnnb NN O O
1 NN O O
gene NN O O
in NN O O
hepatoblastoma NN B-SpecificDisease B-MSH:D018197
. NN O O

hepatoblastoma NN O O
is NN O O
a NN O O
rare NN O O
malignant NN B-DiseaseClass B-MSH:D008113
tumor NN I-DiseaseClass I-MSH:D008113
of NN I-DiseaseClass I-MSH:D008113
the NN I-DiseaseClass I-MSH:D008113
liver NN I-DiseaseClass I-MSH:D008113
that NN O O
occurs NN O O
in NN O O
children NN O O
at NN O O
an NN O O
average NN O O
age NN O O
of NN O O
2 NN O O
to NN O O
3 NN O O
years. NN O O
epidemiologic NN O O
studies NN O O
have NN O O
shown NN O O
an NN O O
increased NN O O
frequency NN O O
of NN O O
this NN O O
tumor NN B-Modifier B-MSH:D009369
type NN O O
in NN O O
families NN O O
affected NN O O
by NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
. NN O O
in NN O O
addition NN O O
to NN O O
the NN O O
epidemiologic NN O O
data, NN O O
molecular NN O O
genetic NN O O
studies NN O O
suggest NN O O
that NN O O
inactivation NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
tumor NN I-Modifier I-MSH:D011125
suppressor NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
hepatoblastoma NN B-Modifier B-MSH:D018197
tumorigenesis. NN O O
a NN O O
major NN O O
function NN O O
of NN O O
apc NN O O
is NN O O
the NN O O
downregulation NN O O
of NN O O
beta-catenin, NN O O
a NN O O
transcription-activating NN O O
protein NN O O
with NN O O
oncogenic NN O O
potential. NN O O
in NN O O
an NN O O
ongoing NN O O
immunohistochemical NN O O
study NN O O
of NN O O
beta-catenin NN O O
expression NN O O
in NN O O
sporadic NN O O
cases NN O O
of NN O O
tumor NN B-Modifier B-MSH:D009369
types NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
, NN O O
we NN O O
observed NN O O
increased NN O O
beta-catenin NN O O
levels NN O O
in NN O O
the NN O O
cytoplasm NN O O
and NN O O
in NN O O
the NN O O
nuclei NN O O
of NN O O
three NN O O
investigated NN O O
hepatoblastomas NN B-SpecificDisease B-MSH:D018197
. NN O O
sequencing NN O O
of NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
beta NN O O
. NN O O

catenin NN O O
gene NN O O
(ctnnb NN O O
1) NN O O
revealed NN O O
an NN O O
activating NN O O
mutation NN O O
in NN O O
one NN O O
of NN O O
the NN O O
tumor NN B-Modifier B-MSH:D009369
samples. NN O O
our NN O O
data NN O O
indicate NN O O
for NN O O
the NN O O
first NN O O
time NN O O
that NN O O
beta-catenin NN O O
accumulation NN O O
may NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
development NN O O
of NN O O
hepatoblastoma NN B-SpecificDisease B-MSH:D018197
and NN O O
that NN O O
activating NN O O
mutations NN O O
of NN O O
the NN O O
beta-catenin NN O O
gene NN O O
may NN O O
substitute NN O O
biallelic NN O O
apc NN O O
inactivation NN O O
in NN O O
this NN O O
tumor NN B-Modifier B-MSH:D009369
type. NN O O
genes NN O O
chromosomes NN O O
cancer NN O O
25 NN O O
399-402, NN O O
1999. NN O O
. NN O O

sequence NN O O
of NN O O
dna NN O O
flanking NN O O
the NN O O
exons NN O O
of NN O O
the NN O O
hexa NN O O
gene, NN O O
and NN O O
identification NN O O
of NN O O
mutations NN O O
in NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
. NN O O

the NN O O
rapid NN O O
identification NN O O
of NN O O
mutations NN O O
causing NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
requires NN O O
the NN O O
capacity NN O O
to NN O O
readily NN O O
screen NN O O
the NN O O
regions NN O O
of NN O O
the NN O O
hexa NN O O
gene NN O O
most NN O O
likely NN O O
to NN O O
be NN O O
affected NN O O
by NN O O
mutation. NN O O
we NN O O
have NN O O
sequenced NN O O
the NN O O
portions NN O O
of NN O O
the NN O O
introns NN O O
flanking NN O O
each NN O O
of NN O O
the NN O O
14 NN O O
hexa NN O O
exons NN O O
in NN O O
order NN O O
to NN O O
specify NN O O
oligonucleotide NN O O
primers NN O O
for NN O O
the NN O O
pcr-dependent NN O O
amplification NN O O
of NN O O
each NN O O
exon NN O O
and NN O O
splice-junction NN O O
sequence. NN O O
the NN O O
amplified NN O O
products NN O O
were NN O O
analyzed, NN O O
by NN O O
electrophoresis NN O O
in NN O O
nondenaturing NN O O
polyacrylamide NN O O
gels, NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
either NN O O
heteroduplexes, NN O O
derived NN O O
from NN O O
the NN O O
annealing NN O O
of NN O O
normal NN O O
and NN O O
mutant NN O O
dna NN O O
strands, NN O O
or NN O O
single-strand NN O O
conformational NN O O
polymorphisms NN O O
(sscp), NN O O
derived NN O O
from NN O O
the NN O O
renaturation NN O O
of NN O O
single-stranded NN O O
dna. NN O O
five NN O O
novel NN O O
mutations NN O O
from NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
patients NN O O
were NN O O
detected NN O O
a NN O O
5-bp NN O O
deletion NN O O
of NN O O
tctcc NN O O
in NN O O
ivs-9 NN O O
. NN O O

a NN O O
2-bp NN O O
deletion NN O O
of NN O O
tg NN O O
in NN O O
exon NN O O
5; NN O O
g NN O O
78 NN O O
to NN O O
a, NN O O
giving NN O O
a NN O O
stop NN O O
codon NN O O
in NN O O
exon NN O O
1; NN O O
g NN O O
533 NN O O
to NN O O
t NN O O
in NN O O
exon NN O O
5, NN O O
producing NN O O
the NN O O
third NN O O
amino NN O O
acid NN O O
substitution NN O O
detected NN O O
at NN O O
this NN O O
site; NN O O
and NN O O
g NN O O
to NN O O
c NN O O
at NN O O
position NN O O
1 NN O O
of NN O O
ivs-2, NN O O
expected NN O O
to NN O O
produce NN O O
abnormal NN O O
splicing. NN O O
in NN O O
addition, NN O O
two NN O O
mutations, NN O O
(g NN O O
1496 NN O O
to NN O O
a NN O O
in NN O O
exon NN O O
13 NN O O
and NN O O
a NN O O
4-bp NN O O
insertion NN O O
in NN O O
exon NN O O
11) NN O O
that NN O O
have NN O O
previously NN O O
been NN O O
reported NN O O
were NN O O
identified. NN O O
. NN O O

in NN O O
vivo NN O O
modulation NN O O
of NN O O
hmgic NN O O
reduces NN O O
obesity NN B-SpecificDisease B-MSH:D009765
. NN O O

the NN O O
hmgi NN O O
family NN O O
of NN O O
proteins NN O O
consists NN O O
of NN O O
three NN O O
members, NN O O
hmgic, NN O O
hmgi NN O O
and NN O O
hmgi NN O O
(y), NN O O
that NN O O
function NN O O
as NN O O
architectural NN O O
factors NN O O
and NN O O
are NN O O
essential NN O O
components NN O O
of NN O O
the NN O O
enhancesome. NN O O
hmgic NN O O
is NN O O
predominantly NN O O
expressed NN O O
in NN O O
proliferating, NN O O
undifferentiated NN O O
mesenchymal NN O O
cells NN O O
and NN O O
is NN O O
not NN O O
detected NN O O
in NN O O
adult NN O O
tissues. NN O O
it NN O O
is NN O O
disrupted NN O O
and NN O O
misexpressed NN O O
in NN O O
a NN O O
number NN O O
of NN O O
mesenchymal NN B-Modifier B-MSH:D008637
tumour NN I-Modifier I-MSH:D008637
cell NN O O
types, NN O O
including NN O O
fat-cell NN B-DiseaseClass B-MSH:D018205
tumours NN I-DiseaseClass I-MSH:D018205
( NN O O
lipomas NN B-DiseaseClass B-MSH:D008067
). NN O O
in NN O O
addition NN O O
hmgic-/- NN O O
mice NN O O
have NN O O
a NN O O
deficiency NN O O
in NN O O
fat NN O O
tissue. NN O O
to NN O O
study NN O O
its NN O O
role NN O O
in NN O O
adipogenesis NN O O
and NN O O
obesity NN B-SpecificDisease B-MSH:D009765
, NN O O
we NN O O
examined NN O O
hmgic NN O O
expression NN O O
in NN O O
the NN O O
adipose NN O O
tissue NN O O
of NN O O
adult, NN O O
obese NN B-Modifier B-MSH:D009765
mice. NN O O
mice NN O O
with NN O O
a NN O O
partial NN B-CompositeMention B-OMIM:600698
or NN I-CompositeMention I-OMIM:600698
complete NN I-CompositeMention I-OMIM:600698
deficiency NN I-CompositeMention I-OMIM:600698
of NN I-CompositeMention I-OMIM:600698
Hmgic NN I-CompositeMention I-OMIM:600698
resisted NN O O
diet-induced NN O O
obesity NN B-SpecificDisease B-MSH:D009765
. NN O O
disruption NN O O
of NN O O
hmgic NN O O
caused NN O O
a NN O O
reduction NN O O
in NN O O
the NN O O
obesity NN B-SpecificDisease B-MSH:D009765
induced NN O O
by NN O O
leptin NN B-SpecificDisease B-OMIM:164160
deficiency NN I-SpecificDisease I-OMIM:164160
(lepo NN O O
. NN O O

/lepob) NN O O
in NN O O
a NN O O
gene-dose-dependent NN O O
manner. NN O O
our NN O O
studies NN O O
implicate NN O O
a NN O O
role NN O O
for NN O O
hmgic NN O O
in NN O O
fat-cell NN O O
proliferation, NN O O
indicating NN O O
that NN O O
it NN O O
may NN O O
be NN O O
an NN O O
adipose-specific NN O O
target NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
obesity NN B-SpecificDisease B-MSH:D009765
. NN O O
. NN O O

prenatal NN O O
diagnosis NN O O
by NN O O
fish NN O O
in NN O O
a NN O O
family NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
caused NN O O
by NN O O
duplication NN O O
of NN O O
plp NN O O
gene NN O O
. NN O O

a NN O O
diagnosis NN O O
of NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
(mim NN O O
312080) NN O O
was NN O O
made NN O O
in NN O O
a NN O O
young NN O O
boy. NN O O
no NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
(plp) NN O O
gene NN O O
had NN O O
been NN O O
found. NN O O
the NN O O
boys NN O O
maternal NN O O
aunt NN O O
came NN O O
for NN O O
prenatal NN O O
diagnosis NN O O
when NN O O
16 NN O O
+ NN O O
weeks NN O O
pregnant NN O O
and NN O O
carrying NN O O
a NN O O
male NN O O
fetus. NN O O
samples NN O O
were NN O O
tested NN O O
for NN O O
duplication NN O O
of NN O O
the NN O O
plp NN O O
gene, NN O O
by NN O O
interphase NN O O
fish, NN O O
in NN O O
lymphocyte NN O O
preparations NN O O
from NN O O
the NN O O
proband, NN O O
his NN O O
aunt NN O O
and NN O O
an NN O O
amniotic NN O O
fluid NN O O
cell NN O O
preparation NN O O
from NN O O
the NN O O
fetus. NN O O
the NN O O
proband NN O O
was NN O O
found NN O O
to NN O O
carry NN O O
the NN O O
duplication, NN O O
thus NN O O
confirming NN O O
the NN O O
diagnosis NN O O
of NN O O
Pelizaeus NN B-SpecificDisease B-OMIM:312080
Merzbacher NN I-SpecificDisease I-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
, NN O O
but NN O O
neither NN O O
the NN O O
aunt NN O O
nor NN O O
the NN O O
fetus NN O O
carried NN O O
a NN O O
duplication. NN O O
. NN O O

somatic NN O O
rearrangement NN O O
of NN O O
chromosome NN O O
14 NN O O
in NN O O
human NN O O
lymphocytes NN O O
. NN O O

ataxia-telangiectasia NN O O
is NN O O
a NN O O
rare NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
associated NN O O
with NN O O
immune NN B-DiseaseClass B-MSH:D007153
deficiency NN I-DiseaseClass I-MSH:D007153
, NN O O
chromosome NN B-DiseaseClass B-MSH:D043171
instability NN I-DiseaseClass I-MSH:D043171
, NN O O
and NN O O
a NN O O
predisposition NN O O
to NN O O
lymphoid NN B-SpecificDisease B-MSH:D008223
malignancy NN I-SpecificDisease I-MSH:D008223
. NN O O
we NN O O
have NN O O
detected NN O O
chromosomally NN O O
anomalous NN O O
clones NN O O
of NN O O
lymphocytes NN O O
in NN O O
eight NN O O
patients NN O O
with NN O O
this NN O O
disorder. NN O O
chromosome NN O O
banding NN O O
disclosed NN O O
that NN O O
the NN O O
clones NN O O
are NN O O
consistently NN O O
marked NN O O
by NN O O
structural NN O O
rearrangement NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
(q) NN O O
of NN O O
chromosome NN O O
14. NN O O
a NN O O
translocation NN O O
involving NN O O
14 NN O O
q NN O O
was NN O O
found NN O O
in NN O O
clones NN O O
obtained NN O O
from NN O O
seven NN O O
of NN O O
the NN O O
eight NN O O
patients NN O O
whereas NN O O
a NN O O
ring NN O O
14 NN O O
chromosome NN O O
was NN O O
found NN O O
in NN O O
a NN O O
clone NN O O
obtained NN O O
from NN O O
the NN O O
other. NN O O
these NN O O
findings NN O O
as NN O O
well NN O O
as NN O O
data NN O O
obtained NN O O
by NN O O
others NN O O
for NN O O
patients NN O O
with NN O O
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
suggest NN O O
that NN O O
structural NN O O
rearrangement NN O O
of NN O O
14 NN O O
q NN O O
is NN O O
the NN O O
initial NN O O
chromosomal NN O O
change NN O O
in NN O O
lymphocyte NN O O
clones NN O O
of NN O O
patients NN O O
with NN O O
this NN O O
disorder. NN O O
chromosomes NN O O
of NN O O
lymphocytes NN O O
from NN O O
one NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
studied NN O O
before NN O O
an NN O O
. NN O O

after NN O O
the NN O O
onset NN O O
of NN O O
chronic NN B-SpecificDisease B-MSH:D015451
lymphocytic NN I-SpecificDisease I-MSH:D015451
leukemia NN I-SpecificDisease I-MSH:D015451
. NN O O
before NN O O
leukemia NN B-DiseaseClass B-MSH:D007938
was NN O O
diagnosed, NN O O
the NN O O
patient NN O O
had NN O O
a NN O O
lymphocyte NN O O
clone NN O O
with NN O O
a NN O O
14 NN O O
q NN O O
translocation. NN O O
this NN O O
clone NN O O
appears NN O O
to NN O O
have NN O O
given NN O O
rise NN O O
to NN O O
the NN O O
leukemic NN B-Modifier B-MSH:D007938
cells. NN O O
we NN O O
hypothesize NN O O
that NN O O
structural NN O O
rearrangement NN O O
of NN O O
14 NN O O
q NN O O
is NN O O
directly NN O O
related NN O O
to NN O O
abnormal NN O O
growth NN O O
of NN O O
lymphocytes NN O O
and NN O O
that NN O O
it NN O O
may NN O O
be NN O O
a NN O O
step NN O O
toward NN O O
the NN O O
development NN O O
of NN O O
lymphoid NN B-SpecificDisease B-MSH:D008223
malignancies NN I-SpecificDisease I-MSH:D008223
. NN O O
increasing NN O O
evidence, NN O O
provided NN O O
by NN O O
others, NN O O
for NN O O
the NN O O
nonrandom NN O O
involvement NN O O
of NN O O
14 NN O O
q NN O O
in NN O O
african-type NN O O
Burkitts NN B-SpecificDisease B-MSH:D002051
lymphoma NN I-SpecificDisease I-MSH:D002051
and NN O O
other NN O O
lymphoid NN B-DiseaseClass B-MSH:D008223
neoplasms NN I-DiseaseClass I-MSH:D008223
further NN O O
strengthens NN O O
this NN O O
hypothesis. NN O O
. NN O O

two NN O O
missense NN O O
mutations NN O O
causing NN O O
mild NN O O
hyperphenylalaninemia NN B-DiseaseClass B-MSH:D010661
associated NN O O
with NN O O
dna NN O O
haplotype NN O O
12 NN O O
. NN O O

the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defects NN I-DiseaseClass I-MSH:D030342
responsible NN O O
for NN O O
most NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
and NN O O
hyperphenylalaninemia NN B-DiseaseClass B-MSH:D010661
( NN O O
HPA NN B-DiseaseClass B-MSH:D010661
) NN O O
cases NN O O
are NN O O
located NN O O
in NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
gene. NN O O
approximately NN O O
50-60 NN O O
mutations NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
caucasians NN O O
and NN O O
are NN O O
reflected NN O O
in NN O O
a NN O O
wide NN O O
range NN O O
of NN O O
clinical NN O O
severities. NN O O
most NN O O
mutations NN O O
are NN O O
linked NN O O
to NN O O
specific NN O O
haplotypes, NN O O
as NN O O
defined NN O O
by NN O O
eight NN O O
polymorphic NN O O
restriction NN O O
sites NN O O
in NN O O
the NN O O
pah NN O O
gene. NN O O
we NN O O
hypothesized NN O O
that NN O O
there NN O O
is NN O O
at NN O O
least NN O O
one NN O O
mild NN O O
mutation NN O O
linked NN O O
to NN O O
haplotype NN O O
12 NN O O
in NN O O
the NN O O
swedish NN O O
PKU NN B-Modifier B-MSH:D010661
/ NN O O
HPA NN B-Modifier B-MSH:D010661
population, NN O O
since NN O O
7 NN O O
of NN O O
8 NN O O
patients NN O O
carrying NN O O
haplotype NN O O
12 NN O O
had NN O O
mild NN O O
HPA NN B-DiseaseClass B-MSH:D010661
. NN O O
sequence NN O O
analysis NN O O
revealed NN O O
a NN O O
c-to-g NN O O
transversion NN O O
at NN O O
the NN O O
second NN O O
base NN O O
of NN O O
codon NN O O
322, NN O O
resulting NN O O
in NN O O
a NN O O
substitution NN O O
of NN O O
glycine NN O O
for NN O O
alanine, NN O O
in NN O O
four NN O O
mutant NN O O
haplotype NN O O
12 NN O O
genes, NN O O
and NN O O
a NN O O
g NN O O
. NN O O

to-a NN O O
transition NN O O
at NN O O
the NN O O
second NN O O
base NN O O
of NN O O
codon NN O O
408, NN O O
resulting NN O O
in NN O O
a NN O O
substitution NN O O
of NN O O
glutamine NN O O
for NN O O
arginine, NN O O
in NN O O
another NN O O
three NN O O
mutant NN O O
haplotype NN O O
12 NN O O
genes. NN O O
these NN O O
mutations NN O O
segregated NN O O
with NN O O
mutant NN O O
haplotype NN O O
12 NN O O
alleles NN O O
in NN O O
nuclear NN O O
families NN O O
but NN O O
were NN O O
not NN O O
present NN O O
on NN O O
normal NN O O
or NN O O
other NN O O
mutant NN O O
alleles. NN O O
both NN O O
mutations NN O O
were NN O O
tested NN O O
in NN O O
a NN O O
eukaryotic NN O O
expression NN O O
system NN O O
in NN O O
which NN O O
enzyme NN O O
activities NN O O
of NN O O
different NN O O
mutant NN O O
pah NN O O
enzymes NN O O
reflect NN O O
the NN O O
relative NN O O
severities NN O O
of NN O O
the NN O O
mutations, NN O O
although NN O O
these NN O O
in NN O O
vitro NN O O
activities NN O O
cannot NN O O
be NN O O
translated NN O O
directly NN O O
into NN O O
in NN O O
vivo NN O O
hepatic NN O O
activities. NN O O
the NN O O
a NN O O
322 NN O O
g NN O O
mutant NN O O
pah NN O O
had NN O O
about NN O O
75% NN O O
and NN O O
the NN O O
r NN O O
408 NN O O
q NN O O
mutant NN O O
pah NN O O
about NN O O
55% NN O O
of NN O O
the NN O O
wild-type NN O O
pah NN O O
enzyme NN O O
activity. NN O O
these NN O O
in NN O O
vitro NN O O
activities NN O O
are NN O O
the NN O O
highest NN O O
reported NN O O
for NN O O
mutant NN O O
pah NN O O
enzymes NN O O
produced NN O O
in NN O O
the NN O O
same NN O O
expression NN O O
system NN O O
. NN O O
ant NN O O
pah NN O O
had NN O O
about NN O O
75% NN O O
and NN O O
the NN O O
r NN O O
408 NN O O
q NN O O
mutant NN O O
pah NN O O
about NN O O
55% NN O O
of NN O O
the NN O O
wild-type NN O O
pah NN O O
enzyme NN O O
activity. NN O O
these NN O O
in NN O O
vitro NN O O
activities NN O O
are NN O O
the NN O O
highest NN O O
reported NN O O
for NN O O
mutant NN O O
pah NN O O
enzymes NN O O
produced NN O O
in NN O O
the NN O O
same NN O O
expression NN O O
system NN O O
. NN O O

(abstract NN O O
truncated NN O O
at NN O O
250 NN O O
words) NN O O
. NN O O

genomic NN O O
organization NN O O
of NN O O
the NN O O
adrenoleukodystrophy NN B-Modifier B-MSH:D000326
gene NN O O
. NN O O

adrenoleukodystrophy NN O O
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
), NN O O
the NN O O
most NN O O
frequent NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
disorder NN I-DiseaseClass I-MSH:D018901
, NN O O
is NN O O
a NN O O
severe NN O O
neurodegenerative NN B-DiseaseClass B-MSH:D019636
disease NN I-DiseaseClass I-MSH:D019636
associated NN O O
with NN O O
an NN O O
impairment NN B-DiseaseClass B-OMIM:300100
of NN I-DiseaseClass I-OMIM:300100
very NN I-DiseaseClass I-OMIM:300100
long NN I-DiseaseClass I-OMIM:300100
chain NN I-DiseaseClass I-OMIM:300100
fatty NN I-DiseaseClass I-OMIM:300100
acids NN I-DiseaseClass I-OMIM:300100
beta-oxidation NN I-DiseaseClass I-OMIM:300100
. NN O O
we NN O O
have NN O O
recently NN O O
identified NN O O
by NN O O
positional NN O O
cloning NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
ALD NN B-SpecificDisease B-MSH:D000326
, NN O O
located NN O O
in NN O O
xq NN O O
28. NN O O
it NN O O
encodes NN O O
a NN O O
new NN O O
member NN O O
of NN O O
the NN O O
" NN O O
abc NN O O
" NN O O
superfamily NN O O
of NN O O
membrane-associated NN O O
transporters NN O O
that NN O O
shows, NN O O
in NN O O
particular, NN O O
significant NN O O
homology NN O O
to NN O O
the NN O O
70-kda NN O O
peroxisomal NN O O
membrane NN O O
protein NN O O
(pmp NN O O
70). NN O O
we NN O O
report NN O O
here NN O O
a NN O O
detailed NN O O
characterization NN O O
of NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
structure. NN O O
it NN O O
extends NN O O
over NN O O
21 NN O O
kb NN O O
and NN O O
consists NN O O
of NN O O
10 NN O O
exons. NN O O
to NN O O
facilitate NN O O
the NN O O
detection NN O O
of NN O O
mutations NN O O
in NN O O
ALD NN B-Modifier B-MSH:D000326
patients, NN O O
we NN O O
have NN O O
determined NN O O
the NN O O
intronic NN O O
sequences NN O O
flanking NN O O
the NN O O
exons NN O O
as NN O O
well NN O O
as NN O O
the NN O O
sequence NN O O
of NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
and NN O O
of NN O O
th NN O O
. NN O O

immediate NN O O
5 NN O O
promoter NN O O
region. NN O O
sequences NN O O
present NN O O
in NN O O
distal NN O O
exons NN O O
cross-hybridize NN O O
strongly NN O O
to NN O O
additional NN O O
sequences NN O O
in NN O O
the NN O O
human NN O O
genome. NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
has NN O O
been NN O O
positioned NN O O
on NN O O
a NN O O
pulsed-field NN O O
map NN O O
between NN O O
dxs NN O O
15 NN O O
and NN O O
the NN O O
l NN O O
1 NN O O
cam NN O O
gene, NN O O
about NN O O
650 NN O O
kb NN O O
upstream NN O O
from NN O O
the NN O O
color NN O O
pigment NN O O
genes. NN O O
the NN O O
frequent NN O O
occurrence NN O O
of NN O O
color NN O O
vision NN O O
anomalies NN O O
observed NN O O
in NN O O
patients NN O O
with NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
(the NN O O
adult NN O O
onset NN O O
form NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
thus NN O O
does NN O O
not NN O O
represent NN O O
a NN O O
contiguous NN B-DiseaseClass B-MSH:D025063
gene NN I-DiseaseClass I-MSH:D025063
syndrome NN I-DiseaseClass I-MSH:D025063
but NN O O
a NN O O
secondary NN O O
manifestation NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
. NN O O

brca NN O O
1 NN O O
interacts NN O O
with NN O O
components NN O O
of NN O O
the NN O O
histone NN O O
deacetylase NN O O
complex NN O O
. NN O O

germ-line NN O O
mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
tumor-suppressor NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
susceptibility NN O O
to NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
. NN O O
brca NN O O
1 NN O O
contains NN O O
a NN O O
carboxyl-terminal NN O O
domain NN O O
(brct) NN O O
that NN O O
is NN O O
shared NN O O
with NN O O
several NN O O
other NN O O
proteins NN O O
involved NN O O
in NN O O
maintaining NN O O
genome NN O O
integrity. NN O O
in NN O O
an NN O O
effort NN O O
to NN O O
understand NN O O
the NN O O
function NN O O
of NN O O
brca NN O O
1, NN O O
we NN O O
sought NN O O
to NN O O
isolate NN O O
proteins NN O O
that NN O O
interact NN O O
with NN O O
the NN O O
brct NN O O
domain. NN O O
purified NN O O
brct NN O O
polypeptide NN O O
was NN O O
used NN O O
as NN O O
a NN O O
probe NN O O
to NN O O
screen NN O O
a NN O O
human NN O O
placenta NN O O
cdna NN O O
expression NN O O
library NN O O
by NN O O
far NN O O
western NN O O
analysis. NN O O
here NN O O
we NN O O
report NN O O
that NN O O
brca NN O O
1 NN O O
interacts NN O O
in NN O O
vivo NN O O
and NN O O
in NN O O
vitro NN O O
with NN O O
the NN O O
rb-binding NN O O
proteins, NN O O
rbap NN O O
46 NN O O
and NN O O
rbap NN O O
48, NN O O
as NN O O
well NN O O
as NN O O
with NN O O
rb. NN O O
moreover, NN O O
the NN O O
brct NN O O
domain NN O O
associates NN O O
with NN O O
the NN O O
histone NN O O
deacetylases NN O O
hdac NN O O
1 NN O O
and NN O O
hdac NN O O
2. NN O O
thes NN O O
. NN O O

results NN O O
demonstrate NN O O
that NN O O
brca NN O O
1 NN O O
interacts NN O O
with NN O O
components NN O O
of NN O O
the NN O O
histone NN O O
deacetylase NN O O
complex, NN O O
and NN O O
therefore NN O O
may NN O O
explain NN O O
the NN O O
involvement NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
multiple NN O O
processes NN O O
such NN O O
as NN O O
transcription, NN O O
dna NN O O
repair, NN O O
and NN O O
recombination. NN O O
. NN O O
ent NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
multiple NN O O
processes NN O O
such NN O O
as NN O O
transcription, NN O O
dna NN O O
repair, NN O O
and NN O O
recombination. NN O O
. NN O O

deletion NN O O
of NN O O
the NN O O
kit NN O O
and NN O O
pdgfra NN O O
genes NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
piebaldism NN B-SpecificDisease B-MSH:D016116
. NN O O

we NN O O
have NN O O
previously NN O O
shown NN O O
that NN O O
human NN O O
piebaldism NN B-SpecificDisease B-MSH:D016116
results NN O O
from NN O O
mutations NN O O
of NN O O
the NN O O
kit NN O O
gene, NN O O
which NN O O
encodes NN O O
the NN O O
receptor NN O O
for NN O O
the NN O O
mast/stem NN O O
cell NN O O
growth NN O O
factor NN O O
and NN O O
is NN O O
located NN O O
in NN O O
chromosome NN O O
segment NN O O
4 NN O O
q NN O O
12. NN O O
using NN O O
dna NN O O
of NN O O
a NN O O
patient NN O O
with NN O O
piebaldism NN B-SpecificDisease B-MSH:D016116
, NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
and NN O O
multiple NN B-DiseaseClass B-MSH:D000013
congenital NN I-DiseaseClass I-MSH:D000013
anomalies NN I-DiseaseClass I-MSH:D000013
associated NN O O
with NN O O
a NN O O
46, NN O O
xy, NN O O
del NN O O
(4) NN O O
(q NN O O
12 NN O O
q NN O O
21. NN O O
1) NN O O
karyotype, NN O O
we NN O O
carried NN O O
out NN O O
quantitative NN O O
southern NN O O
blot NN O O
hybridization NN O O
analyses NN O O
of NN O O
the NN O O
kit NN O O
gene NN O O
and NN O O
the NN O O
adjacent NN O O
pdgfra NN O O
(platelet-derived NN O O
growth NN O O
factor NN O O
receptor NN O O
alpha NN O O
subunit) NN O O
genes. NN O O
the NN O O
patient NN O O
was NN O O
hemizygous NN O O
for NN O O
both NN O O
the NN O O
kit NN O O
and NN O O
pdgfra NN O O
genes, NN O O
indicating NN O O
that NN O O
both NN O O
of NN O O
these NN O O
genes NN O O
are NN O O
included NN O O
within NN O O
the NN O O
deleted NN O O
region. NN O O
therefore, NN O O
deletion NN O O
of NN O O
the NN O O
kit NN O O
and NN O O
pdgfra NN O O
genes NN O O
may NN O O
account NN O O
for NN O O
the NN O O
piebald NN B-Modifier B-MSH:D016116
. NN O O

phenotype NN O O
in NN O O
this NN O O
patient NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
variants NN O O
and NN O O
their NN O O
frequency NN O O
in NN O O
guangdong, NN O O
china NN O O
. NN O O

erythrocyte NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
was NN O O
characterized NN O O
in NN O O
blood NN O O
samples NN O O
obtained NN O O
from NN O O
97 NN O O
randomly NN O O
selected NN O O
males NN O O
with NN O O
enzyme NN B-DiseaseClass B-MSH:D008661
deficiency NN I-DiseaseClass I-MSH:D008661
from NN O O
various NN O O
regions NN O O
of NN O O
guangdong NN O O
province, NN O O
china. NN O O
nine NN O O
new NN O O
variants NN O O
(gd NN O O
kaiping, NN O O
gd NN O O
boluo, NN O O
gd NN O O
huiyang, NN O O
gd NN O O
gaomin, NN O O
gd NN O O
qing-baijiang, NN O O
gd NN O O
gaozhou, NN O O
gd NN O O
huazhou, NN O O
gd NN O O
nanhai, NN O O
and NN O O
gd NN O O
guangzhou) NN O O
were NN O O
identified. NN O O
of NN O O
the NN O O
31 NN O O
variants NN O O
found NN O O
in NN O O
this NN O O
province, NN O O
gd NN O O
kaiping, NN O O
gd NN O O
taiwan-hakka, NN O O
gd NN O O
haad NN O O
yai, NN O O
gd NN O O
haad NN O O
yai-like NN O O
and NN O O
gd NN O O
huiyang NN O O
occurred NN O O
most NN O O
frequently. NN O O
the NN O O
frequency NN O O
of NN O O
each NN O O
variant NN O O
was NN O O
calculated. NN O O
the NN O O
results NN O O
demonstrated NN O O
that NN O O
the NN O O
genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
was NN O O
high NN O O
in NN O O
this NN O O
area. NN O O
. NN O O

a NN O O
common NN O O
molecular NN O O
basis NN O O
for NN O O
rearrangement NN B-DiseaseClass B-MSH:D002869
disorders NN I-DiseaseClass I-MSH:D002869
on NN O O
chromosome NN O O
22 NN O O
q NN O O
11 NN O O
. NN O O

the NN O O
chromosome NN O O
22 NN O O
q NN O O
11 NN O O
region NN O O
is NN O O
susceptible NN O O
to NN O O
rearrangements NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
congenital NN B-DiseaseClass B-MSH:D000013
anomaly NN I-DiseaseClass I-MSH:D000013
disorders NN I-DiseaseClass I-MSH:D000013
and NN O O
malignant NN B-DiseaseClass B-MSH:D018198
tumors NN I-DiseaseClass I-MSH:D018198
. NN O O
three NN O O
congenital NN B-DiseaseClass B-MSH:D000013
anomaly NN I-DiseaseClass I-MSH:D000013
disorders NN I-DiseaseClass I-MSH:D000013
, NN O O
cat-eye NN B-SpecificDisease B-MSH:C535918
syndrome NN I-SpecificDisease I-MSH:C535918
, NN O O
der NN B-SpecificDisease B-MSH:C535733
() NN I-SpecificDisease I-MSH:C535733
syndrome NN I-SpecificDisease I-MSH:C535733
and NN O O
velo-cardio-facial NN B-SpecificDisease B-MSH:D004062
syndrome NN I-SpecificDisease I-MSH:D004062
/ NN O O
DiGeorge NN B-SpecificDisease B-MSH:D004062
syndrome NN I-SpecificDisease I-MSH:D004062
( NN O O
VCFS NN B-SpecificDisease B-MSH:D004062
/ NN O O
DGS NN B-SpecificDisease B-MSH:D004062
) NN O O
are NN O O
associated NN O O
with NN O O
tetrasomy, NN O O
trisomy NN O O
or NN O O
monosomy, NN O O
respectively, NN O O
for NN O O
part NN O O
of NN O O
chromosome NN O O
22 NN O O
q NN O O
11. NN O O
VCFS NN B-SpecificDisease B-MSH:D004062
/ NN O O
DGS NN B-SpecificDisease B-MSH:D004062
is NN O O
the NN O O
most NN O O
common NN O O
syndrome NN O O
associated NN O O
with NN O O
22 NN O O
q NN O O
11 NN O O
rearrangements. NN O O
in NN O O
order NN O O
to NN O O
determine NN O O
whether NN O O
there NN O O
are NN O O
particular NN O O
regions NN O O
on NN O O
22 NN O O
q NN O O
11 NN O O
that NN O O
are NN O O
prone NN O O
to NN O O
rearrangements, NN O O
the NN O O
deletion NN O O
end-points NN O O
in NN O O
a NN O O
large NN O O
number NN O O
of NN O O
VCFS NN B-Modifier B-MSH:D004062
/ NN O O
DGS NN B-Modifier B-MSH:D004062
patients NN O O
were NN O O
defined NN O O
by NN O O
haplotype NN O O
analysis. NN O O
most NN O O
VCFS NN B-Modifier B-MSH:D004062
/ NN O O
DGS NN B-Modifier B-MSH:D004062
patients NN O O
have NN O O
a NN O O
similar NN O O
3 NN O O
mb NN O O
deletion, NN O O
some NN O O
have NN O O
a NN O O
nested NN O O
dista NN O O
. NN O O

deletion NN O O
breakpoint NN O O
resulting NN O O
in NN O O
a NN O O
1. NN O O
5 NN O O
mb NN O O
deletion NN O O
and NN O O
a NN O O
few NN O O
rare NN O O
patients NN O O
have NN O O
unique NN O O
deletions NN O O
or NN O O
translocations. NN O O
the NN O O
high NN O O
prevalence NN O O
of NN O O
the NN O O
disorder NN O O
in NN O O
the NN O O
population NN O O
and NN O O
the NN O O
fact NN O O
that NN O O
most NN O O
cases NN O O
occur NN O O
sporadically NN O O
suggest NN O O
that NN O O
sequences NN O O
at NN O O
or NN O O
near NN O O
the NN O O
breakpoints NN O O
confer NN O O
susceptibility NN O O
to NN O O
chromosome NN O O
rearrangements. NN O O
to NN O O
investigate NN O O
this NN O O
hypothesis, NN O O
we NN O O
developed NN O O
hamster-human NN O O
somatic NN O O
hybrid NN O O
cell NN O O
lines NN O O
from NN O O
VCFS NN B-Modifier B-MSH:D004062
/ NN O O
DGS NN B-Modifier B-MSH:D004062
patients NN O O
with NN O O
all NN O O
three NN O O
classes NN O O
of NN O O
deletions NN O O
and NN O O
we NN O O
now NN O O
show NN O O
that NN O O
the NN O O
breakpoints NN O O
occur NN O O
within NN O O
similar NN O O
low NN O O
copy NN O O
repeats, NN O O
termed NN O O
lcr NN O O
22 NN O O
s. NN O O
to NN O O
support NN O O
this NN O O
idea NN O O
further, NN O O
we NN O O
identified NN O O
a NN O O
family NN O O
that NN O O
carries NN O O
an NN O O
interstitial NN O O
duplication NN O O
of NN O O
the NN O O
same NN O O
3 NN O O
mb NN O O
region NN O O
that NN O O
is NN O O
deleted NN O O
in NN O O
VCFS NN B-Modifier B-MSH:D004062
/ NN O O
DGS NN B-Modifier B-MSH:D004062
patients. NN O O
we NN O O
present NN O O
models NN O O
to NN O O
explain NN O O
how NN O O
the NN O O
lcr NN O O
22 NN O O
s NN O O
can NN O O
mediate NN O O
different NN O O
homologou NN O O
. NN O O

recombination NN O O
events, NN O O
thereby NN O O
generating NN O O
a NN O O
number NN O O
of NN O O
rearrangements NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
congenital NN B-DiseaseClass B-MSH:D000013
anomaly NN I-DiseaseClass I-MSH:D000013
disorders NN I-DiseaseClass I-MSH:D000013
. NN O O
we NN O O
identified NN O O
five NN O O
additional NN O O
copies NN O O
of NN O O
the NN O O
lcr NN O O
22 NN O O
on NN O O
22 NN O O
q NN O O
11 NN O O
that NN O O
may NN O O
mediate NN O O
other NN O O
rearrangements NN O O
leading NN O O
to NN O O
disease NN O O
. NN O O

typical NN O O
and NN O O
partial NN O O
cat NN B-SpecificDisease B-MSH:C535918
eye NN I-SpecificDisease I-MSH:C535918
syndrome NN I-SpecificDisease I-MSH:C535918
: NN O O
identification NN O O
of NN O O
the NN O O
marker NN O O
chromosome NN O O
by NN O O
fish NN O O
. NN O O

three NN O O
children NN O O
are NN O O
reported NN O O
with NN O O
typical NN O O
cat NN B-SpecificDisease B-MSH:C535918
eye NN I-SpecificDisease I-MSH:C535918
syndrome NN I-SpecificDisease I-MSH:C535918
( NN O O
CES NN B-SpecificDisease B-MSH:C535918
) NN O O
and NN O O
three NN O O
more NN O O
children NN O O
with NN O O
partial NN O O
CES NN B-SpecificDisease B-MSH:C535918
because NN O O
of NN O O
absence NN O O
of NN O O
coloboma, NN O O
in NN O O
which NN O O
the NN O O
supernumerary NN O O
marker NN O O
chromosome NN O O
was NN O O
studied NN O O
by NN O O
fish. NN O O
using NN O O
a NN O O
genomic NN O O
library, NN O O
and NN O O
also NN O O
a NN O O
centromeric NN O O
and NN O O
particularly NN O O
a NN O O
cosmid NN O O
probe NN O O
of NN O O
22 NN O O
q NN O O
11, NN O O
partial NN O O
tetrasomy NN B-DiseaseClass B-MSH:D058670
was NN O O
shown NN O O
in NN O O
all NN O O
cases. NN O O
. NN O O

an NN O O
intrachromosomal NN O O
insertion NN O O
causing NN O O
5 NN O O
q NN O O
22 NN O O
deletion NN O O
and NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
in NN O O
two NN O O
generations NN O O
. NN O O

we NN O O
report NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
( NN O O
FAPC NN B-SpecificDisease B-MSH:D011125
) NN O O
with NN O O
epidermoid NN B-SpecificDisease B-MSH:D004814
cysts NN I-SpecificDisease I-MSH:D004814
, NN O O
osteomata NN B-SpecificDisease B-MSH:D010016
, NN O O
and NN O O
areas NN O O
of NN O O
congenital NN B-SpecificDisease B-MSH:D012164
hypertrophy NN I-SpecificDisease I-MSH:D012164
of NN I-SpecificDisease I-MSH:D012164
the NN I-SpecificDisease I-MSH:D012164
retinal NN I-SpecificDisease I-MSH:D012164
pigment NN I-SpecificDisease I-MSH:D012164
epithelium NN I-SpecificDisease I-MSH:D012164
( NN O O
CHRPEs NN B-SpecificDisease B-MSH:D012164
) NN O O
in NN O O
a NN O O
male NN O O
patient NN O O
and NN O O
his NN O O
maternal NN O O
aunt, NN O O
both NN O O
of NN O O
whom NN O O
suffered NN O O
a NN O O
mild NN O O
to NN O O
moderate NN O O
degree NN O O
of NN O O
mental NN B-DiseaseClass B-MSH:D008607
handicap NN I-DiseaseClass I-MSH:D008607
. NN O O
both NN O O
had NN O O
an NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5 NN O O
(del NN O O
(5) NN O O
(q NN O O
22 NN O O
q NN O O
23. NN O O
2)). NN O O
two NN O O
other NN O O
normal NN O O
family NN O O
members NN O O
had NN O O
the NN O O
underlying NN O O
direct NN O O
insertion NN O O
of NN O O
chromosome NN O O
5 NN O O
(dir NN O O
ins NN O O
(5) NN O O
(q NN O O
31. NN O O
3 NN O O
q NN O O
22 NN O O
q NN O O
23 NN O O
3 NN O O
q NN O O
22 NN O O
q NN O O
23. NN O O
2)). NN O O
molecular NN O O
genetic NN O O
and NN O O
fluorescent NN O O
hybridisation NN O O
studies NN O O
have NN O O
shown NN O O
that NN O O
loci NN O O
d NN O O
5 NN O O
s NN O O
37 NN O O
and NN O O
d NN O O
5 NN O O
s NN O O
98 NN O O
are NN O O
outside NN O O
the NN O O
deletion NN O O
whereas NN O O
loc NN O O
. NN O O

detected NN O O
by NN O O
probes NN O O
ef NN O O
5. NN O O
44 NN O O
and NN O O
yn NN O O
5. NN O O
48 NN O O
are NN O O
lost. NN O O
as NN O O
expected, NN O O
the NN O O
molecular NN O O
analyses NN O O
indicate NN O O
loss NN O O
of NN O O
one NN O O
allele NN O O
at NN O O
the NN O O
mcc NN O O
and NN O O
APC NN B-Modifier B-MSH:D011125
loci. NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
is NN O O
located NN O O
within NN O O
band NN O O
5 NN O O
q NN O O
22. NN O O
familial NN O O
direct NN O O
insertions NN O O
should NN O O
be NN O O
considered NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
recurrent NN O O
microdeletion NN O O
syndromes NN O O
. NN O O

cloning NN O O
of NN O O
the NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
region NN O O
in NN O O
yeast NN O O
artificial NN O O
chromosomes NN O O
. NN O O

the NN O O
gene NN O O
responsible NN O O
for NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
has NN O O
been NN O O
localized NN O O
to NN O O
a NN O O
2. NN O O
5 NN O O
million NN O O
base NN O O
pair NN O O
(mb) NN O O
region NN O O
between NN O O
the NN O O
loci NN O O
d NN O O
4 NN O O
s NN O O
10 NN O O
and NN O O
d NN O O
4 NN O O
s NN O O
168 NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
chromosome NN O O
4. NN O O
as NN O O
part NN O O
of NN O O
a NN O O
strategy NN O O
to NN O O
clone NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
its NN O O
chromosomal NN O O
location, NN O O
we NN O O
isolated NN O O
genomic NN O O
dna NN O O
from NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
region NN O O
as NN O O
a NN O O
set NN O O
of NN O O
overlapping NN O O
yeast NN O O
artificial NN O O
chromosome NN O O
(yac) NN O O
clones. NN O O
twenty-eight NN O O
yac NN O O
clones NN O O
were NN O O
identified NN O O
by NN O O
screening NN O O
human NN O O
yac NN O O
libraries NN O O
with NN O O
twelve NN O O
pcr-based NN O O
sequence-tagged NN O O
sites NN O O
(stss) NN O O
from NN O O
the NN O O
region. NN O O
we NN O O
assembled NN O O
the NN O O
yac NN O O
clones NN O O
into NN O O
overlapping NN O O
sets NN O O
by NN O O
hybridizing NN O O
them NN O O
to NN O O
a NN O O
large NN O O
number NN O O
of NN O O
dna NN O O
probes NN O O
from NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
region, NN O O
including NN O O
the NN O O
stss. NN O O
in NN O O
addition, NN O O
we NN O O
isolate NN O O
. NN O O

the NN O O
ends NN O O
of NN O O
the NN O O
human NN O O
dna NN O O
inserts NN O O
of NN O O
most NN O O
of NN O O
the NN O O
yac NN O O
clones NN O O
to NN O O
assist NN O O
in NN O O
the NN O O
construction NN O O
of NN O O
the NN O O
contig. NN O O
although NN O O
almost NN O O
half NN O O
of NN O O
the NN O O
yacs NN O O
appear NN O O
to NN O O
contain NN O O
chimeric NN O O
inserts NN O O
and NN O O
several NN O O
contain NN O O
internal NN O O
deletions NN O O
or NN O O
other NN O O
rearrangements, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
obtain NN O O
over NN O O
2. NN O O
2 NN O O
mb NN O O
of NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
region NN O O
in NN O O
yacs, NN O O
including NN O O
one NN O O
continuous NN O O
segment NN O O
of NN O O
2. NN O O
0 NN O O
mb NN O O
covering NN O O
the NN O O
region NN O O
that NN O O
most NN O O
likely NN O O
contains NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene. NN O O
ten NN O O
of NN O O
the NN O O
twenty NN O O
eight NN O O
yac NN O O
clones NN O O
comprise NN O O
a NN O O
minimal NN O O
set NN O O
spanning NN O O
the NN O O
2. NN O O
2 NN O O
mb. NN O O
these NN O O
clones NN O O
provide NN O O
reagents NN O O
for NN O O
the NN O O
complete NN O O
characterization NN O O
of NN O O
this NN O O
region NN O O
of NN O O
the NN O O
genome NN O O
and NN O O
for NN O O
the NN O O
eventual NN O O
isolation NN O O
of NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
. NN O O

three NN O O
novel NN O O
mutations NN O O
in NN O O
five NN O O
unrelated NN O O
subjects NN O O
with NN O O
hereditary NN O O
protein NN B-SpecificDisease B-MSH:D018455
S NN I-SpecificDisease I-MSH:D018455
deficiency NN I-SpecificDisease I-MSH:D018455
type NN I-SpecificDisease I-MSH:D018455
I NN I-SpecificDisease I-MSH:D018455
. NN O O

a NN O O
panel NN O O
of NN O O
eight NN O O
unrelated NN O O
subjects NN O O
with NN O O
inherited NN O O
type NN B-SpecificDisease B-MSH:D018455
I NN I-SpecificDisease I-MSH:D018455
protein NN I-SpecificDisease I-MSH:D018455
S NN I-SpecificDisease I-MSH:D018455
deficiency NN I-SpecificDisease I-MSH:D018455
was NN O O
screened NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
pros NN O O
1 NN O O
gene. NN O O
in NN O O
five NN O O
subjects NN O O
an NN O O
abnormality NN O O
was NN O O
found NN O O
but NN O O
mutations NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
remaining NN O O
three NN O O
subjects. NN O O
two NN O O
subjects NN O O
shared NN O O
a NN O O
g-- NN O O
> NN O O
a NN O O
transition NN O O
at NN O O
position NN O O
+ NN O O
5 NN O O
of NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
consensus NN O O
sequence NN O O
of NN O O
intron NN O O
10. NN O O
also NN O O
in NN O O
two NN O O
subjects NN O O
an NN O O
a-- NN O O
> NN O O
t NN O O
transversion NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
stopcodon NN O O
of NN O O
the NN O O
pros NN O O
1 NN O O
gene; NN O O
this NN O O
transversion NN O O
predicts NN O O
a NN O O
protein NN O O
s NN O O
molecule NN O O
that NN O O
is NN O O
extended NN O O
by NN O O
14 NN O O
amino NN O O
acids. NN O O
the NN O O
fifth NN O O
subject NN O O
was NN O O
found NN O O
to NN O O
possess NN O O
two NN O O
sequence NN O O
abnormalities. NN O O
one NN O O
allele NN O O
carried NN O O
a NN O O
g-- NN O O
> NN O O
a NN O O
transition NN O O
near NN O O
the NN O O
donor NN O O
splice NN O O
junction NN O O
of NN O O
intron NN O O
2, NN O O
but NN O O
this NN O O
abnormality NN O O
is NN O O
probably NN O O
neutral NN O O
. NN O O

since NN O O
it NN O O
was NN O O
inherited NN O O
from NN O O
the NN O O
parent NN O O
with NN O O
normal NN O O
protein NN O O
s NN O O
antigen NN O O
levels. NN O O
in NN O O
the NN O O
other NN O O
allele NN O O
a NN O O
single NN O O
t NN O O
insertion NN O O
in NN O O
codon NN O O
-25 NN O O
was NN O O
found. NN O O
analysis NN O O
of NN O O
platelet NN O O
rna NN O O
showed NN O O
that NN O O
only NN O O
the NN O O
mrna NN O O
with NN O O
the NN O O
a-- NN O O
> NN O O
t NN O O
mutation NN O O
in NN O O
the NN O O
stopcodon NN O O
is NN O O
present NN O O
in NN O O
amounts NN O O
comparable NN O O
to NN O O
wildtype NN O O
rna. NN O O
mrna NN O O
from NN O O
the NN O O
alleles NN O O
with NN O O
the NN O O
other NN O O
two NN O O
mutations NN O O
was NN O O
either NN O O
undetectable NN O O
or NN O O
present NN O O
in NN O O
greatly NN O O
reduced NN O O
amounts. NN O O
the NN O O
latter NN O O
indicates NN O O
that NN O O
a NN O O
mrna NN O O
based NN O O
approach NN O O
is NN O O
not NN O O
feasible NN O O
for NN O O
the NN O O
genetic NN O O
analysis NN O O
of NN O O
protein NN B-SpecificDisease B-MSH:D018455
S NN I-SpecificDisease I-MSH:D018455
deficiency NN I-SpecificDisease I-MSH:D018455
type NN I-SpecificDisease I-MSH:D018455
I NN I-SpecificDisease I-MSH:D018455
. NN O O
. NN O O

a NN O O
potential NN O O
animal NN O O
model NN O O
for NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
through NN O O
introduction NN O O
of NN O O
hprt NN O O
mutations NN O O
into NN O O
mice NN O O
. NN O O

the NN O O
human NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
is NN O O
a NN O O
rare NN O O
neurological NN B-DiseaseClass B-MSH:D009422
and NN I-DiseaseClass I-MSH:D009422
behavioural NN I-DiseaseClass I-MSH:D009422
disorder NN I-DiseaseClass I-MSH:D009422
, NN O O
affecting NN O O
only NN O O
males, NN O O
which NN O O
is NN O O
caused NN O O
by NN O O
an NN O O
inherited NN B-DiseaseClass B-MSH:D030342
deficiency NN I-DiseaseClass I-MSH:D030342
in NN O O
the NN O O
level NN O O
of NN O O
activity NN O O
of NN O O
the NN O O
purine NN O O
salvage NN O O
enzyme NN O O
hypoxanthine-guanosine NN O O
phosphoribosyl NN O O
transferase NN O O
(hprt). NN O O
how NN O O
the NN O O
resulting NN O O
alterations NN O O
in NN O O
purine NN O O
metabolism NN O O
lead NN O O
to NN O O
the NN O O
severe NN O O
symptoms NN O O
characteristic NN O O
of NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
patients NN O O
is NN O O
still NN O O
not NN O O
understood. NN O O
no NN O O
mutations NN O O
at NN O O
the NN O O
hprt NN O O
locus NN O O
leading NN O O
to NN O O
loss NN O O
of NN O O
activity NN O O
have NN O O
been NN O O
described NN O O
in NN O O
laboratory NN O O
animals. NN O O
to NN O O
derive NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
, NN O O
we NN O O
have NN O O
used NN O O
cultured NN O O
mouse NN O O
embryonic NN O O
stem NN O O
cells, NN O O
mutagenized NN O O
by NN O O
retroviral NN O O
insertion NN O O
and NN O O
selected NN O O
for NN O O
loss NN O O
of NN O O
hprt NN O O
activity, NN O O
to NN O O
construct NN O O
chimaeric NN O O
mice. NN O O
two NN O O
clonal NN O O
lines NN O O
carrying NN O O
different NN O O
mutant NN O O
hprt NN O O
alleles NN O O
have NN O O
given NN O O
rise NN O O
to NN O O
germ NN O O
cells NN O O
in NN O O
chimaeras NN O O
. NN O O

allowing NN O O
the NN O O
derivation NN O O
of NN O O
strains NN O O
of NN O O
mutant NN O O
mice NN O O
having NN O O
the NN O O
same NN O O
biochemical NN O O
defect NN O O
as NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
patients. NN O O
male NN O O
mice NN O O
carrying NN O O
the NN O O
mutant NN O O
alleles NN O O
are NN O O
viable NN O O
and NN O O
analysis NN O O
of NN O O
their NN O O
cells NN O O
shows NN O O
a NN O O
total NN O O
lack NN O O
of NN O O
hprt NN O O
activity. NN O O
. NN O O

duplicational NN O O
mutation NN O O
at NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
locus: NN O O
its NN O O
frequency, NN O O
distribution, NN O O
origin, NN O O
and NN O O
phenotypegenotype NN O O
correlation NN O O
. NN O O

partial NN O O
gene NN O O
deletion NN O O
is NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
mutation NN O O
leading NN O O
to NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
and NN O O
Becker NN B-SpecificDisease B-MSH:C537666
muscular NN I-SpecificDisease I-MSH:C537666
dystrophy NN I-SpecificDisease I-MSH:C537666
( NN O O
BMD NN B-SpecificDisease B-MSH:C537666
). NN O O
partial NN O O
gene NN O O
duplication NN O O
has NN O O
also NN O O
been NN O O
recognized NN O O
in NN O O
a NN O O
few NN O O
cases. NN O O
we NN O O
have NN O O
conducted NN O O
a NN O O
survey NN O O
for NN O O
duplication NN O O
in NN O O
72 NN O O
unrelated NN O O
nondeletion NN O O
patients, NN O O
analyzed NN O O
by NN O O
southern NN O O
blot NN O O
hybridization NN O O
with NN O O
clones NN O O
representing NN O O
the NN O O
entire NN O O
DMD NN B-Modifier B-MSH:D020388
cdna. NN O O
with NN O O
careful NN O O
quantitative NN O O
analysis NN O O
of NN O O
hybridization NN O O
band NN O O
intensity, NN O O
10 NN O O
cases NN O O
were NN O O
found NN O O
to NN O O
carry NN O O
a NN O O
duplication NN O O
of NN O O
part NN O O
of NN O O
the NN O O
gene, NN O O
a NN O O
frequency NN O O
of NN O O
14% NN O O
for NN O O
nondeletion NN O O
cases NN O O
(10/72), NN O O
or NN O O
6% NN O O
for NN O O
all NN O O
cases NN O O
(10/181). NN O O
the NN O O
extent NN O O
of NN O O
these NN O O
duplications NN O O
has NN O O
been NN O O
characterized NN O O
according NN O O
to NN O O
the NN O O
published NN O O
exon-containing NN O O
hindiii NN O O
fragment NN O O
map, NN O O
and NN O O
in NN O O
six NN O O
of NN O O
the NN O O
10 NN O O
duplications NN O O
a NN O O
nove NN O O
. NN O O

restriction NN O O
fragment NN O O
that NN O O
spanned NN O O
the NN O O
duplication NN O O
junction NN O O
was NN O O
detected. NN O O
the NN O O
resulting NN O O
translational NN O O
reading NN O O
frame NN O O
of NN O O
mrna NN O O
has NN O O
been NN O O
predicted NN O O
for NN O O
nine NN O O
duplications. NN O O
a NN O O
shift NN O O
of NN O O
the NN O O
reading NN O O
frame NN O O
was NN O O
predicted NN O O
in NN O O
four NN O O
of NN O O
the NN O O
six NN O O
DMD NN B-Modifier B-MSH:D020388
cases NN O O
and NN O O
in NN O O
one NN O O
of NN O O
the NN O O
two NN O O
intermediate NN O O
cases, NN O O
while NN O O
the NN O O
reading NN O O
frame NN O O
remained NN O O
uninterrupted NN O O
in NN O O
both NN O O
BMD NN B-Modifier B-MSH:C537666
cases. NN O O
rflp NN O O
and NN O O
quantitative NN O O
southern NN O O
blot NN O O
analyses NN O O
revealed NN O O
a NN O O
grandpaternal NN O O
origin NN O O
of NN O O
duplication NN O O
in NN O O
four NN O O
families NN O O
and NN O O
grandmaternal NN O O
origin NN O O
in NN O O
one NN O O
family. NN O O
in NN O O
all NN O O
five NN O O
families, NN O O
the NN O O
duplication NN O O
was NN O O
found NN O O
to NN O O
originate NN O O
from NN O O
a NN O O
single NN O O
x NN O O
chromosome. NN O O
unequal NN O O
sister-chromatid NN O O
exchange NN O O
is NN O O
proposed NN O O
to NN O O
be NN O O
the NN O O
mechanism NN O O
for NN O O
the NN O O
formation NN O O
of NN O O
these NN O O
duplications. NN O O
. NN O O

molecular NN O O
evidence NN O O
for NN O O
new NN O O
mutation NN O O
at NN O O
the NN O O
hprt NN O O
locus NN O O
in NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
patients NN O O
. NN O O

hypoxanthine-guanine NN O O
phosphoribosyltransferase NN O O
(hprt; NN O O
ec NN O O
2. NN O O
4. NN O O
2. NN O O
8), NN O O
which NN O O
functions NN O O
in NN O O
the NN O O
metabolic NN O O
salvage NN O O
of NN O O
purines, NN O O
is NN O O
encoded NN O O
by NN O O
an NN O O
x-linked NN O O
gene NN O O
in NN O O
man. NN O O
partial NN O O
HPRT NN B-DiseaseClass B-OMIM:300323
deficiencies NN I-DiseaseClass I-OMIM:300323
are NN O O
associated NN O O
with NN O O
gouty NN B-SpecificDisease B-MSH:D015210
arthritis NN I-SpecificDisease I-MSH:D015210
, NN O O
while NN O O
absence NN O O
of NN O O
activity NN O O
results NN O O
in NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
( NN O O
L-N NN B-SpecificDisease B-MSH:D007926
). NN O O
L-N NN B-Modifier B-MSH:D007926
patients NN O O
fail NN O O
to NN O O
reproduce NN O O
and NN O O
the NN O O
heterozygous NN O O
state NN O O
appears NN O O
to NN O O
confer NN O O
no NN O O
selective NN O O
advantage. NN O O
thus, NN O O
haldanes NN O O
principle NN O O
predicts NN O O
that NN O O
new NN O O
mutations NN O O
at NN O O
the NN O O
hprt NN O O
locus NN O O
must NN O O
occur NN O O
frequently NN O O
in NN O O
order NN O O
for NN O O
L-N NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
to NN O O
be NN O O
maintained NN O O
in NN O O
the NN O O
population. NN O O
this NN O O
constant NN O O
introduction NN O O
of NN O O
new NN O O
mutations NN O O
would NN O O
be NN O O
expected NN O O
to NN O O
result NN O O
in NN O O
a NN O O
heterogeneous NN O O
collection NN O O
of NN O O
genetic NN B-DiseaseClass B-MSH:D020022
lesions NN I-DiseaseClass I-MSH:D020022
, NN O O
some NN O O
of NN O O
which NN O O
may NN O O
be NN O O
novel. NN O O
as NN O O
we NN O O
report NN O O
here NN O O
. NN O O

the NN O O
mutations NN O O
in NN O O
the NN O O
hprt NN O O
gene NN O O
of NN O O
seven NN O O
L-N NN B-Modifier B-MSH:D007926
patients, NN O O
selected NN O O
from NN O O
an NN O O
initial NN O O
survey NN O O
of NN O O
28 NN O O
patients, NN O O
have NN O O
been NN O O
characterized NN O O
and NN O O
all NN O O
were NN O O
found NN O O
to NN O O
be NN O O
distinctly NN O O
different, NN O O
as NN O O
predicted. NN O O
the NN O O
origin NN O O
of NN O O
one NN O O
unusual NN O O
mutation NN O O
has NN O O
been NN O O
identified NN O O
by NN O O
analysis NN O O
of NN O O
dna NN O O
from NN O O
four NN O O
generations NN O O
of NN O O
family NN O O
members. NN O O
further NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
origin NN O O
of NN O O
new NN O O
mutations NN O O
at NN O O
the NN O O
hprt NN O O
locus NN O O
should NN O O
aid NN O O
in NN O O
resolving NN O O
the NN O O
issue NN O O
of NN O O
an NN O O
apparent NN O O
difference NN O O
in NN O O
the NN O O
frequency NN O O
of NN O O
hprt NN O O
mutations NN O O
in NN O O
males NN O O
and NN O O
female NN O O
. NN O O

the NN O O
mapping NN O O
of NN O O
a NN O O
cdna NN O O
from NN O O
the NN O O
human NN O O
X-linked NN B-Modifier B-MSH:D020388
Duchenne NN I-Modifier I-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
gene NN O O
to NN O O
the NN O O
mouse NN O O
x NN O O
chromosome NN O O
. NN O O

the NN O O
recent NN O O
discovery NN O O
of NN O O
sequences NN O O
at NN O O
the NN O O
site NN O O
of NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
gene NN O O
in NN O O
humans NN O O
has NN O O
opened NN O O
up NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
detailed NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
genes NN O O
in NN O O
humans NN O O
and NN O O
in NN O O
related NN O O
mammalian NN O O
species. NN O O
until NN O O
relatively NN O O
recently, NN O O
there NN O O
was NN O O
no NN O O
obvious NN O O
mouse NN O O
model NN O O
of NN O O
this NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
for NN O O
the NN O O
development NN O O
of NN O O
therapeutic NN O O
strategies. NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
mouse NN O O
x-linked NN O O
mutant NN O O
showing NN O O
muscular NN B-SpecificDisease B-MSH:D009136
dystrophy NN I-SpecificDisease I-MSH:D009136
, NN O O
mdx, NN O O
has NN O O
provided NN O O
a NN O O
candidate NN O O
mouse NN O O
genetic NN O O
homologue NN O O
to NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
locus; NN O O
the NN O O
relatively NN O O
mild NN O O
pathological NN O O
features NN O O
of NN O O
mdx NN O O
suggest NN O O
it NN O O
may NN O O
have NN O O
more NN O O
in NN O O
common NN O O
with NN O O
mutations NN O O
of NN O O
the NN O O
Becker NN B-Modifier B-MSH:C537666
muscular NN I-Modifier I-MSH:C537666
dystrophy NN I-Modifier I-MSH:C537666
type NN O O
at NN O O
the NN O O
same NN O O
human NN O O
locus, NN O O
however. NN O O
but NN O O
the NN O O
close NN O O
genetic NN O O
linkage NN O O
of NN O O
mdx NN O O
to NN O O
g NN O O
6 NN O O
pd NN O O
and NN O O
hprt NN O O
on NN O O
the NN O O
mouse NN O O
x NN O O
chromosome, NN O O
coupled NN O O
with NN O O
it NN O O
. NN O O

comparatively NN O O
mild NN O O
pathology, NN O O
have NN O O
suggested NN O O
that NN O O
the NN O O
mdx NN O O
mutation NN O O
may NN O O
instead NN O O
correspond NN O O
to NN O O
Emery NN B-SpecificDisease B-MSH:D020389
Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
which NN O O
itself NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
dna NN O O
markers NN O O
at NN O O
xq NN O O
28-qter NN O O
in NN O O
the NN O O
region NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
on NN O O
the NN O O
human NN O O
x NN O O
chromosome. NN O O
using NN O O
an NN O O
interspecific NN O O
mouse NN O O
domesticus/spretus NN O O
cross, NN O O
segregating NN O O
for NN O O
a NN O O
variety NN O O
of NN O O
markers NN O O
on NN O O
the NN O O
mouse NN O O
x NN O O
chromosome, NN O O
we NN O O
have NN O O
positioned NN O O
on NN O O
the NN O O
mouse NN O O
x NN O O
chromosome NN O O
sequences NN O O
homologous NN O O
to NN O O
a NN O O
DMD NN B-Modifier B-MSH:D020388
cdna NN O O
clone. NN O O
these NN O O
sequences NN O O
map NN O O
provocatively NN O O
close NN O O
to NN O O
the NN O O
mdx NN O O
mutation NN O O
and NN O O
unexpectedly NN O O
distant NN O O
from NN O O
sparse NN O O
fur, NN O O
spf, NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
otc NN O O
(ornithine NN O O
transcarbamylase) NN O O
which NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
DMD NN B-SpecificDisease B-MSH:D020388
on NN O O
the NN O O
human NN O O
x NN O O
chromosome. NN O O
. NN O O

identification NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
the NN O O
alkaptonuria NN B-Modifier B-MSH:D000474
mouse NN O O
model NN O O
. NN O O

alkaptonuria NN O O
( NN O O
aku NN B-SpecificDisease B-MSH:D000474
), NN O O
an NN O O
inborn NN B-DiseaseClass B-MSH:D008661
error NN I-DiseaseClass I-MSH:D008661
of NN I-DiseaseClass I-MSH:D008661
metabolism NN I-DiseaseClass I-MSH:D008661
caused NN O O
by NN O O
the NN O O
loss NN O O
of NN O O
homogentisate NN O O
1, NN O O
2-dioxygenase NN O O
(hgd), NN O O
has NN O O
been NN O O
described NN O O
in NN O O
a NN O O
mouse NN O O
model NN O O
created NN O O
by NN O O
ethylnitrosourea NN O O
mutagenesis NN O O
but NN O O
the NN O O
mutation NN O O
in NN O O
these NN O O
mice NN O O
has NN O O
not NN O O
previously NN O O
been NN O O
identified. NN O O
we NN O O
used NN O O
rt-pcr NN O O
to NN O O
amplify NN O O
the NN O O
hgd NN O O
cdna NN O O
from NN O O
hgd NN O O
(aku)/hgd NN O O
(aku) NN O O
mice. NN O O
two NN O O
products NN O O
shorter NN O O
than NN O O
the NN O O
wild-type NN O O
product NN O O
were NN O O
amplified. NN O O
restriction NN O O
mapping NN O O
and NN O O
dna NN O O
sequencing NN O O
were NN O O
then NN O O
used NN O O
to NN O O
identify NN O O
the NN O O
hgd NN O O
(aku) NN O O
mouse NN O O
mutation, NN O O
found NN O O
to NN O O
be NN O O
a NN O O
single NN O O
base NN O O
change NN O O
in NN O O
a NN O O
splice NN O O
donor NN O O
consensus NN O O
sequence, NN O O
causing NN O O
exon NN O O
skipping NN O O
and NN O O
frame-shifted NN O O
products. NN O O
this NN O O
base NN O O
change NN O O
allowed NN O O
us NN O O
to NN O O
create NN O O
a NN O O
non-radioactive NN O O
genotyping NN O O
assay NN O O
for NN O O
this NN O O
allele NN O O
. NN O O

common NN O O
sequence NN O O
motifs NN O O
at NN O O
the NN O O
rearrangement NN O O
sites NN O O
of NN O O
a NN O O
constitutional NN O O
x/autosome NN O O
translocation NN O O
and NN O O
associated NN O O
deletion NN O O
. NN O O
of NN O O
a NN O O
constitutional NN O O
x/autosome NN O O
translocation NN O O
and NN O O
associated NN O O
deletion NN O O
. NN O O

reciprocal NN O O
chromosome NN O O
translocations NN O O
are NN O O
common NN O O
de NN O O
novo NN O O
rearrangements NN O O
that NN O O
occur NN O O
randomly NN O O
throughout NN O O
the NN O O
human NN O O
genome. NN O O
to NN O O
learn NN O O
about NN O O
causative NN O O
mechanisms, NN O O
we NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
the NN O O
breakpoints NN O O
of NN O O
a NN O O
cytologically NN O O
balanced NN O O
constitutional NN O O
reciprocal NN O O
translocation, NN O O
t NN O O
(x; NN O O
4) NN O O
(p NN O O
21. NN O O
2; NN O O
q NN O O
31. NN O O
22), NN O O
present NN O O
in NN O O
a NN O O
girl NN O O
with NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
physical NN O O
mapping NN O O
of NN O O
the NN O O
derivative NN O O
chromosomes, NN O O
after NN O O
their NN O O
separation NN O O
in NN O O
somatic NN O O
cell NN O O
hybrids, NN O O
reveals NN O O
that NN O O
the NN O O
translocation NN O O
disrupts NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
in NN O O
xp NN O O
21 NN O O
within NN O O
the NN O O
18-kb NN O O
intron NN O O
16. NN O O
restriction NN O O
mapping NN O O
and NN O O
sequencing NN O O
of NN O O
clones NN O O
that NN O O
span NN O O
both NN O O
translocation NN O O
breakpoints NN O O
as NN O O
well NN O O
as NN O O
the NN O O
corresponding NN O O
normal NN O O
regions NN O O
indicate NN O O
the NN O O
loss NN O O
of NN O O
approximately NN O O
5 NN O O
kb NN O O
in NN O O
the NN O O
formation NN O O
of NN O O
the NN O O
derivative NN O O
x NN O O
chromosome, NN O O
with NN O O
4-6 NN O O
b NN O O
. NN O O

deleted NN O O
from NN O O
chromosome NN O O
4. NN O O
rflp NN O O
and NN O O
southern NN O O
analyses NN O O
indicate NN O O
that NN O O
the NN O O
de NN O O
novo NN O O
translocation NN O O
is NN O O
a NN O O
paternal NN O O
origin NN O O
and NN O O
that NN O O
the NN O O
fathers NN O O
x NN O O
chromosome NN O O
contains NN O O
the NN O O
dna NN O O
that NN O O
is NN O O
deleted NN O O
in NN O O
the NN O O
derivative NN O O
x. NN O O
most NN O O
likely, NN O O
deletion NN O O
and NN O O
translation NN O O
arose NN O O
simultaneously NN O O
from NN O O
a NN O O
complex NN O O
rearrangement NN O O
event NN O O
that NN O O
involves NN O O
three NN O O
chromosomal NN O O
breakpoints. NN O O
short NN O O
regions NN O O
of NN O O
sequence NN O O
homology NN O O
were NN O O
present NN O O
at NN O O
the NN O O
three NN O O
sites. NN O O
a NN O O
5-bp NN O O
sequence, NN O O
ggaat, NN O O
found NN O O
exactly NN O O
at NN O O
the NN O O
translocation NN O O
breakpoints NN O O
on NN O O
both NN O O
normal NN O O
chromosomes NN O O
x NN O O
and NN O O
4, NN O O
has NN O O
been NN O O
preserved NN O O
only NN O O
on NN O O
the NN O O
der NN O O
(4) NN O O
chromosome. NN O O
it NN O O
is NN O O
likely NN O O
that NN O O
the NN O O
x-derived NN O O
sequence NN O O
ggaatca NN O O
has NN O O
been NN O O
lost NN O O
in NN O O
the NN O O
formation NN O O
of NN O O
the NN O O
der NN O O
(x) NN O O
chromosome, NN O O
as NN O O
it NN O O
matches NN O O
an NN O O
inverted NN O O
gaatca NN O O
sequence NN O O
present NN O O
on NN O O
the NN O O
opposite NN O O
strand NN O O
exactly NN O O
at NN O O
th NN O O
. NN O O
somes NN O O
x NN O O
and NN O O
4, NN O O
has NN O O
been NN O O
preserved NN O O
only NN O O
on NN O O
the NN O O
der NN O O
(4) NN O O
chromosome. NN O O
it NN O O
is NN O O
likely NN O O
that NN O O
the NN O O
x-derived NN O O
sequence NN O O
ggaatca NN O O
has NN O O
been NN O O
lost NN O O
in NN O O
the NN O O
formation NN O O
of NN O O
the NN O O
der NN O O
(x) NN O O
chromosome, NN O O
as NN O O
it NN O O
matches NN O O
an NN O O
inverted NN O O
gaatca NN O O
sequence NN O O
present NN O O
on NN O O
the NN O O
opposite NN O O
strand NN O O
exactly NN O O
at NN O O
th NN O O
. NN O O

other NN O O
end NN O O
of NN O O
the NN O O
deleted NN O O
5-kb NN O O
fragment NN O O
. NN O O

the NN O O
human NN O O
factor NN O O
ix NN O O
gene NN O O
as NN O O
germline NN O O
mutagen NN O O
test: NN O O
samples NN O O
from NN O O
mainland NN O O
china NN O O
have NN O O
the NN O O
putatively NN O O
endogenous NN O O
pattern NN O O
of NN O O
mutation NN O O
. NN O O

germline NN O O
mutations NN O O
are NN O O
the NN O O
major NN O O
source NN O O
of NN O O
genetic NN O O
variation NN O O
that NN O O
allows NN O O
a NN O O
species NN O O
to NN O O
evolve NN O O
over NN O O
time NN O O
but NN O O
at NN O O
the NN O O
cost NN O O
of NN O O
Mendelian NN B-DiseaseClass B-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
and NN O O
genetic NN O O
predisposition NN O O
to NN O O
multifactorial NN B-DiseaseClass B-MSH:D004194
diseases NN I-DiseaseClass I-MSH:D004194
. NN O O
previous NN O O
analyses NN O O
have NN O O
revealed NN O O
that NN O O
the NN O O
pattern NN O O
of NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
factor NN O O
ix NN O O
gene NN O O
(f NN O O
9) NN O O
is NN O O
similar NN O O
among NN O O
a NN O O
variety NN O O
of NN O O
ethnically NN O O
and NN O O
geographically NN O O
diverse NN O O
populations NN O O
and NN O O
compatible NN O O
with NN O O
the NN O O
ancient NN O O
pattern NN O O
that NN O O
has NN O O
shaped NN O O
the NN O O
mammalian NN O O
genome. NN O O
here, NN O O
we NN O O
compare NN O O
the NN O O
pattern NN O O
of NN O O
germline NN O O
mutation NN O O
in NN O O
a NN O O
population NN O O
of NN O O
hemophilia NN B-Modifier B-MSH:D002836
B NN I-Modifier I-MSH:D002836
patients NN O O
from NN O O
mainland NN O O
china NN O O
(n NN O O
= NN O O
66) NN O O
to NN O O
that NN O O
in NN O O
u. NN O O
s. NN O O
caucasians, NN O O
blacks, NN O O
and NN O O
mexican NN O O
hispanics NN O O
and NN O O
stratify NN O O
by NN O O
disease NN O O
severity NN O O
and NN O O
ethnicity. NN O O
the NN O O
similar NN O O
pattern NN O O
of NN O O
germline NN O O
mutation NN O O
in NN O O
all NN O O
ethnic NN O O
groups NN O O
studied NN O O
to NN O O
date NN O O
provides NN O O
additional NN O O
data NN O O
compatible NN O O
with NN O O
the NN O O
inferenc NN O O
. NN O O

that NN O O
endogenous NN O O
processes NN O O
predominate NN O O
in NN O O
germline NN O O
mutations NN O O
. NN O O

phenotype NN O O
heterogeneity NN O O
among NN O O
hemizygotes NN O O
in NN O O
a NN O O
family NN O O
biochemically NN O O
screened NN O O
for NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
. NN O O

we NN O O
report NN O O
on NN O O
two NN O O
clinically, NN O O
neurologically NN O O
normal NN O O
relatives NN O O
of NN O O
a NN O O
boy NN O O
affected NN O O
by NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
); NN O O
they NN O O
were NN O O
found NN O O
repeatedly NN O O
to NN O O
have NN O O
the NN O O
biochemical NN O O
defect NN O O
of NN O O
an NN O O
ALD NN B-Modifier B-MSH:D000326
hemizygote. NN O O
the NN O O
assay NN O O
consisted NN O O
in NN O O
the NN O O
determination NN O O
of NN O O
very-long-chain NN O O
fatty NN O O
acids NN O O
in NN O O
lyophilized NN O O
and NN O O
reconstituted NN O O
plasma. NN O O
while NN O O
no NN O O
evidence NN O O
of NN O O
neurologic NN B-DiseaseClass B-MSH:D009422
disease NN I-DiseaseClass I-MSH:D009422
( NN O O
leukodystrophy NN B-SpecificDisease B-MSH:D007966
or NN O O
myeloneuropathy NN B-SpecificDisease B-MSH:D009422
) NN O O
was NN O O
present NN O O
in NN O O
these NN O O
hemizygotes, NN O O
adrenocortical NN B-DiseaseClass B-MSH:D000224
insufficiency NN I-DiseaseClass I-MSH:D000224
provoking NN O O
compensatory NN O O
high NN O O
acth NN O O
release NN O O
was NN O O
found NN O O
in NN O O
both. NN O O
these NN O O
findings NN O O
should NN O O
be NN O O
taken NN O O
into NN O O
consideration NN O O
when NN O O
counseling NN O O
families NN O O
in NN O O
which NN O O
cases NN O O
with NN O O
clinically NN O O
expressed NN O O
ALD NN B-SpecificDisease B-MSH:D000326
are NN O O
represented NN O O
in NN O O
several NN O O
generations. NN O O
. NN O O

novel NN O O
mutations NN O O
of NN O O
the NN O O
atp NN O O
7 NN O O
b NN O O
gene NN O O
in NN O O
japanese NN O O
patients NN O O
with NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
. NN O O

wilson NN O O
disease NN O O
( NN O O
WD NN B-SpecificDisease B-MSH:D006527
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
copper NN O O
accumulation NN O O
in NN O O
the NN O O
liver, NN O O
brain, NN O O
kidneys, NN O O
and NN O O
corneas, NN O O
and NN O O
culminating NN O O
in NN O O
copper NN O O
toxication NN O O
in NN O O
these NN O O
organs. NN O O
in NN O O
this NN O O
study, NN O O
we NN O O
analyzed NN O O
mutations NN O O
of NN O O
the NN O O
responsible NN O O
gene, NN O O
atp NN O O
7 NN O O
b, NN O O
in NN O O
four NN O O
japanese NN O O
patients NN O O
with NN O O
WD NN B-SpecificDisease B-MSH:D006527
. NN O O
by NN O O
direct NN O O
sequencing, NN O O
we NN O O
identified NN O O
five NN O O
mutations, NN O O
of NN O O
which NN O O
two NN O O
were NN O O
novel, NN O O
and NN O O
16 NN O O
polymorphisms, NN O O
of NN O O
which NN O O
6 NN O O
were NN O O
novel. NN O O
the NN O O
mutations NN O O
2871 NN O O
delc NN O O
and NN O O
2513 NN O O
dela NN O O
shift NN O O
the NN O O
reading NN O O
frame NN O O
so NN O O
that NN O O
truncated NN O O
abnormal NN O O
protein NN O O
is NN O O
expected. NN O O
in NN O O
contrast NN O O
to NN O O
these NN O O
mutations NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
hepatic-type NN O O
of NN O O
early NN O O
onset, NN O O
the NN O O
mutations NN O O
a NN O O
874 NN O O
v, NN O O
r NN O O
778 NN O O
l, NN O O
and NN O O
3892 NN O O
delgtc NN O O
were NN O O
either NN O O
missense NN O O
mutations NN O O
or NN O O
in NN O O
frame NN O O
1-amin NN O O
. NN O O

acid NN O O
deletion, NN O O
and NN O O
occurred NN O O
in NN O O
the NN O O
patients NN O O
with NN O O
hepato-neurologic NN O O
type NN O O
of NN O O
late NN O O
onset. NN O O
the NN O O
mutations NN O O
2871 NN O O
delc NN O O
and NN O O
r NN O O
778 NN O O
l NN O O
have NN O O
been NN O O
previously NN O O
reported NN O O
in NN O O
a NN O O
relatively NN O O
large NN O O
number NN O O
of NN O O
japanese NN O O
patients. NN O O
in NN O O
particular, NN O O
r NN O O
778 NN O O
l NN O O
is NN O O
known NN O O
to NN O O
be NN O O
more NN O O
prevalent NN O O
in NN O O
asian NN O O
countries NN O O
than NN O O
in NN O O
other NN O O
countries NN O O
of NN O O
the NN O O
world. NN O O
our NN O O
data NN O O
are NN O O
compatible NN O O
with NN O O
the NN O O
hypothesis NN O O
that NN O O
the NN O O
mutations NN O O
tend NN O O
to NN O O
occur NN O O
in NN O O
a NN O O
population-specific NN O O
manner. NN O O
therefore, NN O O
the NN O O
accumulation NN O O
of NN O O
the NN O O
types NN O O
of NN O O
mutations NN O O
in NN O O
japanese NN O O
patients NN O O
with NN O O
WD NN B-SpecificDisease B-MSH:D006527
will NN O O
facilitate NN O O
the NN O O
fast NN O O
and NN O O
effective NN O O
genetic NN O O
diagnosis NN O O
of NN O O
WD NN B-SpecificDisease B-MSH:D006527
in NN O O
japanese NN O O
patients. NN O O
. NN O O

structural NN O O
analysis NN O O
of NN O O
the NN O O
5' NN O O
region NN O O
of NN O O
mouse NN O O
and NN O O
human NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
genes NN O O
reveals NN O O
conservation NN O O
of NN O O
putative NN O O
promoter NN O O
region NN O O
and NN O O
di- NN O O
and NN O O
trinucleotide NN O O
polymorphisms NN O O
. NN O O

we NN O O
have NN O O
previously NN O O
cloned NN O O
and NN O O
characterized NN O O
the NN O O
murine NN O O
homologue NN O O
of NN O O
the NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
( NN O O
HD NN B-Modifier B-MSH:D006816
) NN O O
gene NN O O
and NN O O
shown NN O O
that NN O O
it NN O O
maps NN O O
to NN O O
mouse NN O O
chromosome NN O O
5 NN O O
within NN O O
a NN O O
region NN O O
of NN O O
conserved NN O O
synteny NN O O
with NN O O
human NN O O
chromosome NN O O
4 NN O O
p NN O O
16. NN O O
3 NN O O
3. NN O O
here NN O O
we NN O O
present NN O O
a NN O O
detailed NN O O
comparison NN O O
of NN O O
the NN O O
sequence NN O O
of NN O O
the NN O O
putative NN O O
promoter NN O O
and NN O O
the NN O O
organization NN O O
of NN O O
the NN O O
5 NN O O
genomic NN O O
region NN O O
of NN O O
the NN O O
murine NN O O
(hdh) NN O O
and NN O O
human NN O O
HD NN B-Modifier B-MSH:D006816
genes NN O O
encompassing NN O O
the NN O O
first NN O O
five NN O O
exons. NN O O
we NN O O
show NN O O
that NN O O
in NN O O
this NN O O
region NN O O
these NN O O
two NN O O
genes NN O O
share NN O O
identical NN O O
exon NN O O
boundaries, NN O O
but NN O O
have NN O O
different-size NN O O
introns. NN O O
two NN O O
dinucleotide NN O O
(ct) NN O O
and NN O O
one NN O O
trinucleotide NN O O
intronic NN O O
polymorphism NN O O
in NN O O
hdh NN O O
and NN O O
an NN O O
intronic NN O O
ca NN O O
polymorphism NN O O
in NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
were NN O O
identified. NN O O
comparison NN O O
of NN O O
940-bp NN O O
sequence NN O O
5 NN O O
to NN O O
the NN O O
putative NN O O
translation NN O O
start NN O O
site NN O O
reveals NN O O
a NN O O
highl NN O O
. NN O O

conserved NN O O
region NN O O
(78. NN O O
8% NN O O
nucleotide NN O O
identity) NN O O
between NN O O
hdh NN O O
and NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
from NN O O
nucleotide NN O O
-56 NN O O
to NN O O
-206 NN O O
(of NN O O
hdh). NN O O
neither NN O O
hdh NN O O
nor NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
have NN O O
typical NN O O
tata NN O O
or NN O O
ccaat NN O O
elements, NN O O
but NN O O
both NN O O
show NN O O
one NN O O
putative NN O O
ap NN O O
2 NN O O
binding NN O O
site NN O O
and NN O O
numerous NN O O
potential NN O O
sp NN O O
1 NN O O
binding NN O O
sites. NN O O
the NN O O
high NN O O
sequence NN O O
identity NN O O
between NN O O
hdh NN O O
and NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
for NN O O
approximately NN O O
200 NN O O
bp NN O O
5 NN O O
to NN O O
the NN O O
putative NN O O
translation NN O O
start NN O O
site NN O O
indicates NN O O
that NN O O
these NN O O
sequences NN O O
may NN O O
play NN O O
a NN O O
role NN O O
in NN O O
regulating NN O O
expression NN O O
of NN O O
the NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
gen NN O O
. NN O O

complement NN O O
deficiency NN O O
and NN O O
nephritis NN B-SpecificDisease B-MSH:D009393
. NN O O
a NN O O
report NN O O
of NN O O
a NN O O
family NN O O
. NN O O

a NN O O
family NN O O
is NN O O
described NN O O
in NN O O
which NN O O
three NN O O
children NN O O
had NN O O
homozygous NN O O
deficiency NN B-SpecificDisease B-OMIM:613779
of NN I-SpecificDisease I-OMIM:613779
C3 NN I-SpecificDisease I-OMIM:613779
and NN O O
in NN O O
which NN O O
both NN O O
parents NN O O
and NN O O
two NN O O
other NN O O
children NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
c NN O O
3 NN O O
null NN O O
gene. NN O O
one NN O O
child NN O O
with NN O O
heterozygous NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
was NN O O
found NN O O
to NN O O
have NN O O
membranoproliferative NN O O
glomerulonephritis NN B-SpecificDisease B-MSH:D005921
; NN O O
proteinuria NN B-SpecificDisease B-MSH:D011507
and/or NN O O
microscopical NN O O
haematuria NN B-SpecificDisease B-MSH:D006417
was NN O O
present NN O O
in NN O O
all NN O O
three NN O O
homozygous NN O O
C3-deficient NN B-Modifier B-OMIM:613779
children. NN O O
all NN O O
children NN O O
with NN O O
homozygous NN O O
or NN O O
heterozygous NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
were, NN O O
to NN O O
a NN O O
varying NN O O
degree, NN O O
susceptible NN O O
to NN O O
infection. NN O O
the NN O O
only NN O O
child NN O O
of NN O O
the NN O O
family NN O O
with NN O O
normal NN O O
complement NN O O
had NN O O
no NN O O
increased NN O O
risk NN O O
of NN O O
infection NN O O
and NN O O
no NN O O
renal NN B-DiseaseClass B-MSH:D007674
disease NN I-DiseaseClass I-MSH:D007674
. NN O O
this NN O O
family NN O O
study NN O O
provides NN O O
further NN O O
support NN O O
for NN O O
the NN O O
proposal NN O O
that NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
predisposes NN O O
to NN O O
nephritis NN B-SpecificDisease B-MSH:D009393
. NN O O
. NN O O

cytogenetic NN O O
investigations NN O O
in NN O O
families NN O O
with NN O O
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
. NN O O

chromosomal NN O O
studies NN O O
were NN O O
performed NN O O
on NN O O
peripheral NN O O
blood NN O O
lymphocytes NN O O
and NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
five NN O O
israeli-moroccan NN O O
families NN O O
with NN O O
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
. NN O O
a NN O O
total NN O O
of NN O O
24 NN O O
individuals, NN O O
including NN O O
seven NN O O
propositi, NN O O
was NN O O
investigated. NN O O
among NN O O
the NN O O
probands, NN O O
significantly NN O O
elevated NN O O
rates NN O O
of NN O O
chromosome NN O O
damage NN O O
were NN O O
observed NN O O
in NN O O
both NN O O
blood NN O O
and NN O O
skin. NN O O
skin NN O O
fibroblasts NN O O
of NN O O
affected NN O O
individuals NN O O
showed NN O O
several NN O O
orders NN O O
of NN O O
magnitude NN O O
more NN O O
chromosome NN O O
breakage NN O O
than NN O O
lymphocytes. NN O O
increased NN O O
rates NN O O
of NN O O
chromosome NN O O
damage NN O O
were NN O O
also NN O O
observed NN O O
in NN O O
the NN O O
fibroblasts NN O O
of NN O O
some NN O O
phenotypically NN O O
normal NN O O
family NN O O
members NN O O
(obligate NN O O
heterozygotes NN O O
and NN O O
sibs) NN O O
when NN O O
compared NN O O
to NN O O
normal NN O O
controls. NN O O
an NN O O
apparent NN O O
abnormal NN O O
clone NN O O
of NN O O
cells, NN O O
possessing NN O O
a NN O O
large NN O O
acrocentric NN O O
marker NN O O
chromosome NN O O
(14 NN O O
q NN O O
+), NN O O
was NN O O
observed NN O O
in NN O O
varying NN O O
proportions NN O O
among NN O O
cells NN O O
of NN O O
all NN O O
the NN O O
propositi NN O O
(2-5% NN O O
of NN O O
lymphocytes; NN O O
1- NN O O
. NN O O

% NN O O
of NN O O
fibroblasts). NN O O
. NN O O

predominance NN O O
of NN O O
the NN O O
adrenomyeloneuropathy NN B-Modifier B-MSH:D000326
phenotype NN O O
of NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
in NN O O
the NN O O
netherlands: NN O O
a NN O O
survey NN O O
of NN O O
30 NN O O
kindreds NN O O
. NN O O

x-linked NN O O
adrenoleukodystrophy NN O O
( NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
is NN O O
an NN O O
inherited NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
of NN O O
peroxisomal NN O O
beta-oxidation NN O O
associated NN O O
with NN O O
accumulation NN O O
of NN O O
saturated NN O O
very NN O O
long-chain NN O O
fatty NN O O
acids, NN O O
which NN O O
results NN O O
in NN O O
central NN O O
and NN O O
peripheral NN O O
demyelination NN B-DiseaseClass B-MSH:D003711
and NN O O
in NN O O
impaired NN B-CompositeMention B-MSH:D000303
function NN I-CompositeMention I-MSH:D000303
of NN I-CompositeMention I-MSH:D000303
adrenal NN I-CompositeMention I-MSH:D000303
cortex NN I-CompositeMention I-MSH:D000303
and NN I-CompositeMention I-MSH:D000303
testes NN I-CompositeMention I-MSH:D000303
. NN O O
the NN O O
phenotypic NN O O
expression NN O O
is NN O O
highly NN O O
variable, NN O O
childhood NN B-SpecificDisease B-MSH:D000326
cerebral NN I-SpecificDisease I-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
( NN O O
CCALD NN B-SpecificDisease B-MSH:D000326
) NN O O
and NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
AMN NN B-SpecificDisease B-MSH:D000326
) NN O O
being NN O O
the NN O O
main NN O O
variants. NN O O
we NN O O
explored NN O O
the NN O O
30 NN O O
dutch NN O O
kindreds NN O O
well NN O O
known NN O O
to NN O O
the NN O O
dutch NN O O
X-ALD NN B-Modifier B-MSH:D000326
/ NN O O
AMN NN B-Modifier B-MSH:D000326
study NN O O
group NN O O
and NN O O
phenotyped NN O O
77 NN O O
male NN O O
patients NN O O
35 NN O O
(46%) NN O O
had NN O O
AMN NN B-SpecificDisease B-MSH:D000326
and NN O O
24 NN O O
(31%) NN O O
CCALD NN B-SpecificDisease B-MSH:D000326
or NN O O
adolescent NN B-SpecificDisease B-MSH:D000326
cerebral NN I-SpecificDisease I-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
( NN O O
AdolCALD NN B-SpecificDisease B-MSH:D000326
). NN O O
these NN O O
percentages NN O O
differ NN O O
significantly NN O O
from NN O O
previous NN O O
reports, NN O O
in NN O O
which NN O O
25 NN O O
to NN O O
28% NN O O
of NN O O
the NN O O
patients NN O O
developed NN O O
AMN NN B-SpecificDisease B-MSH:D000326
and NN O O
53 NN O O
to NN O O
57% NN O O
CCALD NN B-SpecificDisease B-MSH:D000326
. NN O O

or NN O O
AdolCALD NN B-SpecificDisease B-MSH:D000326
. NN O O
our NN O O
findings NN O O
indicate NN O O
that--at NN O O
least NN O O
in NN O O
the NN O O
netherlands-- NN O O
AMN NN B-SpecificDisease B-MSH:D000326
may NN O O
be NN O O
the NN O O
most NN O O
frequent NN O O
phenotype NN O O
of NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
. NN O O

three NN O O
novel NN O O
aniridia NN B-Modifier B-MSH:D015783
mutations NN O O
in NN O O
the NN O O
human NN O O
pax NN O O
6 NN O O
gene NN O O
. NN O O

aniridia NN O O
( NN O O
iris NN B-SpecificDisease B-MSH:D007499
hypoplasia NN I-SpecificDisease I-MSH:D007499
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D005124
dominant NN I-DiseaseClass I-MSH:D005124
congenital NN I-DiseaseClass I-MSH:D005124
disorder NN I-DiseaseClass I-MSH:D005124
of NN I-DiseaseClass I-MSH:D005124
the NN I-DiseaseClass I-MSH:D005124
eye NN I-DiseaseClass I-MSH:D005124
. NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
aniridia NN B-Modifier B-MSH:D015783
(pax NN O O
6) NN O O
gene NN O O
have NN O O
now NN O O
been NN O O
identified NN O O
in NN O O
many NN O O
patients NN O O
from NN O O
various NN O O
ethnic NN O O
groups. NN O O
in NN O O
the NN O O
study NN O O
reported NN O O
here NN O O
we NN O O
describe NN O O
pax NN O O
6 NN O O
mutations NN O O
in NN O O
one NN O O
sporadic NN O O
and NN O O
five NN O O
familial NN O O
cases NN O O
with NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O O
of NN O O
the NN O O
four NN O O
different NN O O
mutations NN O O
identified, NN O O
one NN O O
was NN O O
identical NN O O
to NN O O
a NN O O
previously NN O O
reported NN O O
mutation NN O O
(c-- NN O O
> NN O O
t NN O O
transition NN O O
at NN O O
codon NN O O
240), NN O O
and NN O O
three NN O O
were NN O O
novel NN O O
two NN O O
in NN O O
the NN O O
glycine-rich NN O O
region NN O O
and NN O O
one NN O O
in NN O O
the NN O O
proline/serine/threonine-rich NN O O
(pst) NN O O
region. NN O O
one NN O O
pax NN O O
6 NN O O
mutation NN O O
found NN O O
in NN O O
the NN O O
pst NN O O
region NN O O
was NN O O
associated NN O O
with NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
in NN O O
an NN O O
aniridia NN B-Modifier B-MSH:D015783
family. NN O O
another NN O O
splice NN O O
mutation NN O O
in NN O O
the NN O O
pst NN O O
domain NN O O
occurred NN O O
in NN O O
an NN O O
aniridia NN B-Modifier B-MSH:D015783
. NN O O

patient NN O O
with NN O O
anosmia NN B-SpecificDisease B-MSH:D000857
(inability NN O O
to NN O O
smell). NN O O
the NN O O
six NN O O
new NN O O
aniridia NN B-Modifier B-MSH:D015783
cases NN O O
reported NN O O
here NN O O
have NN O O
mutations NN O O
predicted NN O O
to NN O O
generate NN O O
incomplete NN O O
pax NN O O
6 NN O O
proteins. NN O O
these NN O O
results NN O O
support NN O O
the NN O O
theory NN O O
that NN O O
human NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
is NN O O
caused NN O O
by NN O O
haploinsufficiency NN B-SpecificDisease B-OMIM:106210
of NN I-SpecificDisease I-OMIM:106210
PAX6 NN I-SpecificDisease I-OMIM:106210
. NN O O
. NN O O

hepatoblastoma, NN O O
pigmented NN B-DiseaseClass B-MSH:D015821
ocular NN I-DiseaseClass I-MSH:D015821
fundus NN I-DiseaseClass I-MSH:D015821
lesions NN I-DiseaseClass I-MSH:D015821
and NN O O
jaw NN B-DiseaseClass B-MSH:D007571
lesions NN I-DiseaseClass I-MSH:D007571
in NN O O
Gardner NN B-SpecificDisease B-MSH:D005736
syndrome NN I-SpecificDisease I-MSH:D005736
. NN O O

hepatoblastoma NN O O
is NN O O
a NN O O
rare NN O O
neoplasm NN B-DiseaseClass B-MSH:D009369
of NN O O
infants NN O O
and NN O O
children NN O O
only NN O O
recently NN O O
documented NN O O
in NN O O
association NN O O
with NN O O
hereditary NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
of NN I-SpecificDisease I-MSH:D011125
the NN I-SpecificDisease I-MSH:D011125
colon NN I-SpecificDisease I-MSH:D011125
[kingston NN O O
et NN O O
al., NN O O
1983]. NN O O
we NN O O
report NN O O
four NN O O
children NN O O
with NN O O
hepatoblastoma NN B-SpecificDisease B-MSH:D018197
from NN O O
four NN O O
unrelated NN O O
families NN O O
with NN O O
Gardner NN B-SpecificDisease B-MSH:D005736
syndrome NN I-SpecificDisease I-MSH:D005736
( NN O O
GS NN B-SpecificDisease B-MSH:D005736
). NN O O
one NN O O
child, NN O O
now NN O O
19 NN O O
years NN O O
old, NN O O
survived NN O O
after NN O O
a NN O O
resection NN O O
of NN O O
a NN O O
hepatoblastoma NN B-SpecificDisease B-MSH:D018197
in NN O O
infancy NN O O
and NN O O
recently NN O O
was NN O O
found NN O O
to NN O O
have NN O O
GS NN B-SpecificDisease B-MSH:D005736
. NN O O
he NN O O
has NN O O
an NN O O
associated NN O O
odontoma NN B-SpecificDisease B-MSH:D009810
and NN O O
pigmented NN B-DiseaseClass B-MSH:D015821
ocular NN I-DiseaseClass I-MSH:D015821
fundus NN I-DiseaseClass I-MSH:D015821
lesions NN I-DiseaseClass I-MSH:D015821
, NN O O
both NN O O
of NN O O
which NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
clinical NN O O
markers NN O O
of NN O O
GS NN B-SpecificDisease B-MSH:D005736
. NN O O
many NN O O
individuals NN O O
in NN O O
these NN O O
four NN O O
GS NN B-Modifier B-MSH:D005736
families, NN O O
both NN O O
affected NN O O
and NN O O
at NN O O
risk, NN O O
have NN O O
osteomatous NN B-DiseaseClass B-MSH:D007571
jaw NN I-DiseaseClass I-MSH:D007571
lesions NN I-DiseaseClass I-MSH:D007571
and NN O O
pigmented NN B-DiseaseClass B-MSH:D015821
ocular NN I-DiseaseClass I-MSH:D015821
fundus NN I-DiseaseClass I-MSH:D015821
lesions NN I-DiseaseClass I-MSH:D015821
. NN O O
a NN O O
search NN O O
for NN O O
colonic NN B-DiseaseClass B-MSH:D003111
polyps NN I-DiseaseClass I-MSH:D003111
should NN O O
be NN O O
made NN O O
in NN O O
families NN O O
of NN O O
infants NN O O
and NN O O
children NN O O
with NN O O
hepatoblastoma NN B-SpecificDisease B-MSH:D018197
. NN O O
if NN O O
the NN O O
chil NN O O
. NN O O

survives, NN O O
he NN O O
or NN O O
she NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
later NN O O
appearance NN O O
of NN O O
colonic NN B-DiseaseClass B-MSH:D003111
polyps NN I-DiseaseClass I-MSH:D003111
. NN O O
the NN O O
finding NN O O
of NN O O
jaw NN B-DiseaseClass B-MSH:D007571
lesions NN I-DiseaseClass I-MSH:D007571
and/or NN O O
pigmented NN B-DiseaseClass B-MSH:D015821
ocular NN I-DiseaseClass I-MSH:D015821
fundus NN I-DiseaseClass I-MSH:D015821
lesions NN I-DiseaseClass I-MSH:D015821
in NN O O
relatives NN O O
at NN O O
risk NN O O
are NN O O
indications NN O O
of NN O O
the NN O O
possible NN O O
presence NN O O
of NN O O
the NN O O
GS NN B-Modifier B-MSH:D005736
gene NN O O
. NN O O

mutation NN O O
spectrum NN O O
in NN O O
the NN O O
CHM NN B-Modifier B-MSH:D015794
gene NN O O
of NN O O
danish NN O O
and NN O O
swedish NN O O
choroideremia NN B-Modifier B-MSH:D015794
patients NN O O
. NN O O

the NN O O
recent NN O O
isolation NN O O
of NN O O
the NN O O
complete NN O O
open NN O O
reading NN O O
frame NN O O
of NN O O
the NN O O
choroideremia NN B-Modifier B-MSH:D015794
( NN O O
CHM NN B-Modifier B-MSH:D015794
) NN O O
gene NN O O
and NN O O
the NN O O
characterization NN O O
of NN O O
the NN O O
exon-intron NN O O
boundaries NN O O
has NN O O
paved NN O O
the NN O O
way NN O O
to NN O O
mutation NN O O
detection NN O O
in NN O O
patients NN O O
with NN O O
classical NN O O
choroideremia NN B-SpecificDisease B-MSH:D015794
. NN O O
we NN O O
have NN O O
performed NN O O
mutation NN O O
screening NN O O
in NN O O
patients NN O O
from NN O O
15 NN O O
danish NN O O
and NN O O
swedish NN O O
families NN O O
by NN O O
using NN O O
southern NN O O
blot NN O O
hybridization NN O O
and NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
(pcr-sscp) NN O O
technique. NN O O
causative NN O O
mutations NN O O
in NN O O
the NN O O
CHM NN B-Modifier B-MSH:D015794
gene NN O O
were NN O O
detected NN O O
in NN O O
at NN O O
least NN O O
12 NN O O
families, NN O O
indicating NN O O
that NN O O
a NN O O
substantial NN O O
part NN O O
of NN O O
the NN O O
mutations NN O O
can NN O O
be NN O O
identified NN O O
by NN O O
this NN O O
approach. NN O O
in NN O O
four NN O O
of NN O O
these NN O O
families NN O O
deletions NN O O
of NN O O
different NN O O
sizes NN O O
were NN O O
found. NN O O
thus, NN O O
in NN O O
one NN O O
patient, NN O O
the NN O O
deletion NN O O
resulted NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
only NN O O
one NN O O
exon, NN O O
while NN O O
in NN O O
another NN O O
the NN O O
deletion NN O O
comprised NN O O
the NN O O
entire NN O O
CHM NN B-Modifier B-MSH:D015794
. NN O O

gene. NN O O
mapping NN O O
of NN O O
the NN O O
deletion NN O O
endpoints NN O O
in NN O O
these NN O O
four NN O O
patients NN O O
and NN O O
in NN O O
another NN O O
11 NN O O
male NN O O
patients NN O O
with NN O O
sizeable NN O O
deletions NN O O
enabled NN O O
us NN O O
to NN O O
construct NN O O
a NN O O
very NN O O
detailed NN O O
map NN O O
of NN O O
intervals NN O O
2 NN O O
and NN O O
3 NN O O
of NN O O
xq NN O O
21. NN O O
in NN O O
the NN O O
remaining NN O O
11 NN O O
danish NN O O
and NN O O
swedish NN O O
families NN O O
at NN O O
least NN O O
8 NN O O
causative NN O O
mutations NN O O
were NN O O
found NN O O
by NN O O
pcr-sscp NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing. NN O O
interestingly, NN O O
all NN O O
CHM NN B-Modifier B-MSH:D015794
gene NN O O
mutations NN O O
detected NN O O
thus NN O O
far NN O O
in NN O O
choroideremia NN B-Modifier B-MSH:D015794
patients NN O O
give NN O O
rise NN O O
to NN O O
the NN O O
introduction NN O O
of NN O O
a NN O O
premature NN O O
stop NN O O
codon. NN O O
. NN O O

diverse NN O O
point NN O O
mutations NN O O
result NN O O
in NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
polymorphism NN O O
in NN O O
taiwan NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd; NN O O
ec NN O O
1.1. NN O O
1. NN O O
49) NN O O
deficiency NN O O
is NN O O
the NN O O
most NN O O
common NN O O
human NN O O
enzymopathy NN B-DiseaseClass B-MSH:D008661
, NN O O
affecting NN O O
more NN O O
than NN O O
200 NN O O
million NN O O
people NN O O
worldwide. NN O O
although NN O O
greater NN O O
than NN O O
400 NN O O
variants NN O O
have NN O O
been NN O O
described NN O O
based NN O O
on NN O O
clinical NN O O
and NN O O
biochemical NN O O
criteria, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
these NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiencies NN I-SpecificDisease I-MSH:D005955
. NN O O
recently, NN O O
the NN O O
gene NN O O
that NN O O
encodes NN O O
human NN O O
g NN O O
6 NN O O
pd NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
sequenced, NN O O
which NN O O
enables NN O O
us NN O O
to NN O O
examine NN O O
directly NN O O
the NN O O
heterogeneity NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
at NN O O
the NN O O
dna NN O O
level. NN O O
during NN O O
the NN O O
past NN O O
10 NN O O
years, NN O O
we NN O O
examined NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
activity NN O O
in NN O O
21, NN O O
271 NN O O
newborn NN O O
chinese NN O O
infants NN O O
(11, NN O O
400 NN O O
males NN O O
and NN O O
9, NN O O
871 NN O O
females) NN O O
and NN O O
identified NN O O
314 NN O O
(2. NN O O
8%) NN O O
males NN O O
an NN O O
. NN O O

246 NN O O
(2. NN O O
5%) NN O O
females NN O O
having NN O O
low NN O O
g NN O O
6 NN O O
pd NN O O
activity. NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
gene NN O O
from NN O O
10 NN O O
randomly NN O O
selected NN O O
affected NN O O
individuals NN O O
and NN O O
their NN O O
relatives NN O O
was NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
amplified, NN O O
subcloned, NN O O
and NN O O
sequenced. NN O O
our NN O O
results NN O O
indicate NN O O
that NN O O
at NN O O
least NN O O
four NN O O
types NN O O
of NN O O
mutation NN O O
are NN O O
responsible NN O O
for NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
polymorphism NN O O
in NN O O
taiwan. NN O O
the NN O O
first NN O O
type NN O O
of NN O O
mutation NN O O
(487 NN O O
g----a) NN O O
was NN O O
found NN O O
in NN O O
an NN O O
affected NN O O
chinese NN O O
with NN O O
a NN O O
g NN O O
to NN O O
a NN O O
change NN O O
at NN O O
nucleotide NN O O
487, NN O O
which NN O O
results NN O O
in NN O O
a NN O O
(163) NN O O
gly NN O O
to NN O O
ser NN O O
substitution. NN O O
the NN O O
second NN O O
type NN O O
of NN O O
mutation NN O O
(493 NN O O
a----g) NN O O
is NN O O
a NN O O
novel NN O O
mutation NN O O
that NN O O
has NN O O
not NN O O
been NN O O
reported NN O O
in NN O O
any NN O O
other NN O O
ethnic NN O O
group NN O O
and NN O O
was NN O O
identified NN O O
in NN O O
two NN O O
affecte NN O O
. NN O O
type NN O O
of NN O O
mutation NN O O
(487 NN O O
g----a) NN O O
was NN O O
found NN O O
in NN O O
an NN O O
affected NN O O
chinese NN O O
with NN O O
a NN O O
g NN O O
to NN O O
a NN O O
change NN O O
at NN O O
nucleotide NN O O
487, NN O O
which NN O O
results NN O O
in NN O O
a NN O O
(163) NN O O
gly NN O O
to NN O O
ser NN O O
substitution. NN O O
the NN O O
second NN O O
type NN O O
of NN O O
mutation NN O O
(493 NN O O
a----g) NN O O
is NN O O
a NN O O
novel NN O O
mutation NN O O
that NN O O
has NN O O
not NN O O
been NN O O
reported NN O O
in NN O O
any NN O O
other NN O O
ethnic NN O O
group NN O O
and NN O O
was NN O O
identified NN O O
in NN O O
two NN O O
affecte NN O O
. NN O O

chinese. NN O O
this NN O O
mutation NN O O
causes NN O O
an NN O O
a NN O O
to NN O O
g NN O O
change NN O O
at NN O O
nucleotide NN O O
position NN O O
493, NN O O
producing NN O O
an NN O O
(165) NN O O
asn NN O O
to NN O O
asp NN O O
substitution. NN O O
interestingly, NN O O
the NN O O
487 NN O O
g----a NN O O
and NN O O
493 NN O O
a----g NN O O
mutations NN O O
create NN O O
alu NN O O
i NN O O
and NN O O
ava NN O O
ii NN O O
recognition NN O O
sites, NN O O
respectively, NN O O
which NN O O
enabled NN O O
us NN O O
to NN O O
rapidly NN O O
detect NN O O
these NN O O
two NN O O
mutations NN O O
by NN O O
pcr/restriction NN O O
enzyme NN O O
(re) NN O O
digestion NN O O
method. NN O O
the NN O O
third NN O O
mutation NN O O
(1376 NN O O
g----t) NN O O
was NN O O
found NN O O
in NN O O
four NN O O
affected NN O O
chinese. NN O O
this NN O O
mutation NN O O
causes NN O O
a NN O O
g NN O O
to NN O O
t NN O O
change NN O O
at NN O O
nucleotide NN O O
position NN O O
1376 NN O O
that NN O O
results NN O O
in NN O O
an NN O O
(459) NN O O
arg NN O O
to NN O O
leu NN O O
substitution. NN O O
the NN O O
1376 NN O O
g----t NN O O
mutation NN O O
seems NN O O
to NN O O
be NN O O
the NN O O
dominant NN O O
allele NN O O
that NN O O
causes NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
i NN O O
. NN O O

taiwan. NN O O
finally, NN O O
two NN O O
affected NN O O
chinese NN O O
were NN O O
identified NN O O
as NN O O
having NN O O
the NN O O
fourth NN O O
mutation NN O O
(1388 NN O O
g----a). NN O O
this NN O O
mutation NN O O
causes NN O O
a NN O O
g NN O O
to NN O O
a NN O O
change NN O O
at NN O O
nucleotide NN O O
1388 NN O O
that NN O O
produces NN O O
an NN O O
(463) NN O O
arg NN O O
to NN O O
his NN O O
substitution. NN O O
our NN O O
studies NN O O
provide NN O O
the NN O O
direct NN O O
proof NN O O
of NN O O
the NN O O
genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
the NN O O
chinese NN O O
populations NN O O
of NN O O
taiwan NN O O
and NN O O
the NN O O
pcr/re NN O O
digestion NN O O
method NN O O
is NN O O
suitable NN O O
for NN O O
simultaneous NN O O
detection NN O O
of NN O O
the NN O O
487 NN O O
g----a NN O O
and NN O O
493 NN O O
a----g NN O O
mutations NN O O
. NN O O

fas NN O O
preassociation NN O O
required NN O O
for NN O O
apoptosis NN O O
signaling NN O O
and NN O O
dominant NN O O
inhibition NN O O
by NN O O
pathogenic NN O O
mutations NN O O
. NN O O

heterozygous NN O O
mutations NN O O
encoding NN O O
abnormal NN O O
forms NN O O
of NN O O
the NN O O
death NN O O
receptor NN O O
fas NN O O
dominantly NN O O
interfere NN O O
with NN O O
fas-induced NN O O
lymphocyte NN O O
apoptosis NN O O
in NN O O
human NN O O
autoimmune NN B-SpecificDisease B-MSH:D056735
lymphoproliferative NN I-SpecificDisease I-MSH:D056735
syndrome NN I-SpecificDisease I-MSH:D056735
. NN O O
this NN O O
effect, NN O O
rather NN O O
than NN O O
depending NN O O
on NN O O
ligand-induced NN O O
receptor NN O O
oligomerization, NN O O
was NN O O
found NN O O
to NN O O
stem NN O O
from NN O O
ligand- NN O O
independent NN O O
interaction NN O O
of NN O O
wild-type NN O O
and NN O O
mutant NN O O
fas NN O O
receptors NN O O
through NN O O
a NN O O
specific NN O O
region NN O O
in NN O O
the NN O O
extracellular NN O O
domain. NN O O
preassociated NN O O
fas NN O O
complexes NN O O
were NN O O
found NN O O
in NN O O
living NN O O
cells NN O O
by NN O O
means NN O O
of NN O O
fluorescence NN O O
resonance NN O O
energy NN O O
transfer NN O O
between NN O O
variants NN O O
of NN O O
green NN O O
fluorescent NN O O
protein. NN O O
these NN O O
results NN O O
show NN O O
that NN O O
formation NN O O
of NN O O
preassociated NN O O
receptor NN O O
complexes NN O O
is NN O O
necessary NN O O
for NN O O
fas NN O O
signaling NN O O
and NN O O
dominant NN O O
interference NN O O
in NN O O
human NN O O
disease. NN O O
. NN O O

familial NN O O
mediterranean NN O O
fever NN O O
in NN O O
the NN O O
colchicine NN O O
era: NN O O
the NN O O
fate NN O O
of NN O O
one NN O O
family NN O O
. NN O O

in NN O O
order NN O O
to NN O O
demonstrate NN O O
the NN O O
effect NN O O
of NN O O
prophylactic NN O O
colchicine NN O O
treatment NN O O
on NN O O
the NN O O
natural NN O O
history NN O O
of NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
), NN O O
a NN O O
family NN O O
is NN O O
presented NN O O
with NN O O
6 NN O O
out NN O O
of NN O O
9 NN O O
siblings NN O O
affected NN O O
by NN O O
FMF NN B-SpecificDisease B-MSH:D010505
. NN O O
each NN O O
patient NN O O
represents NN O O
a NN O O
different NN O O
stage NN O O
of NN O O
the NN O O
amyloidotic NN B-SpecificDisease B-MSH:D007674
kidney NN I-SpecificDisease I-MSH:D007674
disease NN I-SpecificDisease I-MSH:D007674
of NN O O
FMF NN B-SpecificDisease B-MSH:D010505
and NN O O
the NN O O
effect NN O O
of NN O O
continuous NN O O
colchicine NN O O
treatment NN O O
on NN O O
its NN O O
course. NN O O
considered NN O O
together, NN O O
the NN O O
members NN O O
of NN O O
this NN O O
family NN O O
present NN O O
an NN O O
almost NN O O
complete NN O O
clinical, NN O O
genetic, NN O O
and NN O O
behavioral NN O O
picture NN O O
of NN O O
the NN O O
disease. NN O O
. NN O O

two NN O O
new NN O O
arylsulfatase NN O O
a NN O O
(arsa) NN O O
mutations NN O O
in NN O O
a NN O O
juvenile NN O O
metachromatic NN B-Modifier B-MSH:D007966
leukodystrophy NN I-Modifier I-MSH:D007966
( NN O O
MLD NN B-Modifier B-MSH:D007966
) NN O O
patient NN O O
. NN O O

fragments NN O O
of NN O O
the NN O O
arylsulfatase NN O O
a NN O O
(arsa) NN O O
gene NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
juvenile-onset NN O O
metachromatic NN B-SpecificDisease B-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
( NN O O
MLD NN B-SpecificDisease B-MSH:D007966
) NN O O
were NN O O
amplified NN O O
by NN O O
pcr NN O O
and NN O O
ligated NN O O
into NN O O
mp NN O O
13 NN O O
cloning NN O O
vectors. NN O O
clones NN O O
hybridizing NN O O
with NN O O
cdna NN O O
for NN O O
human NN O O
arsa NN O O
were NN O O
selected, NN O O
examined NN O O
for NN O O
appropriate NN O O
size NN O O
inserts, NN O O
and NN O O
used NN O O
to NN O O
prepare NN O O
single-stranded NN O O
phage NN O O
dna. NN O O
examination NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
and NN O O
most NN O O
of NN O O
the NN O O
intronic NN O O
sequence NN O O
revealed NN O O
two NN O O
putative NN O O
disease-related NN O O
mutations. NN O O
one, NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
exon NN O O
3, NN O O
resulted NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
isoleucine NN O O
by NN O O
serine. NN O O
introduction NN O O
of NN O O
this NN O O
alteration NN O O
into NN O O
the NN O O
normal NN O O
arsa NN O O
cdna NN O O
sequence NN O O
resulted NN O O
in NN O O
a NN O O
substantial NN O O
decrease NN O O
in NN O O
arsa NN O O
activity NN O O
on NN O O
transient NN O O
expression NN O O
in NN O O
cultured NN O O
baby NN O O
hamster NN O O
kidney NN O O
cells. NN O O
about NN O O
5% NN O O
of NN O O
the NN O O
control NN O O
expression NN O O
was NN O O
observed, NN O O
suggesting NN O O
a NN O O
small NN O O
residual NN O O
activity NN O O
i NN O O
. NN O O

the NN O O
mutated NN O O
arsa. NN O O
the NN O O
second NN O O
mutation, NN O O
a NN O O
g-to-a NN O O
transition, NN O O
occurred NN O O
in NN O O
the NN O O
other NN O O
allele NN O O
and NN O O
resulted NN O O
in NN O O
an NN O O
altered NN O O
splice-recognition NN O O
sequence NN O O
between NN O O
exon NN O O
7 NN O O
and NN O O
the NN O O
following NN O O
intron. NN O O
the NN O O
mutation NN O O
also NN O O
resulted NN O O
in NN O O
the NN O O
loss NN O O
of NN O O
a NN O O
restriction NN O O
site. NN O O
apparently NN O O
normal NN O O
levels NN O O
of NN O O
mrna NN O O
were NN O O
generated NN O O
from NN O O
this NN O O
allele, NN O O
but NN O O
no NN O O
arsa NN O O
activity NN O O
or NN O O
immuno-cross-reactive NN O O
material NN O O
could NN O O
be NN O O
detected. NN O O
a NN O O
collection NN O O
of NN O O
dna NN O O
samples NN O O
from NN O O
known NN O O
or NN O O
suspected NN O O
MLD NN B-Modifier B-MSH:D007966
patients, NN O O
members NN O O
of NN O O
their NN O O
families, NN O O
and NN O O
normal NN O O
controls NN O O
was NN O O
screened NN O O
for NN O O
these NN O O
mutations. NN O O
four NN O O
additional NN O O
individuals NN O O
carrying NN O O
each NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
found NN O O
among NN O O
the NN O O
nearly NN O O
100 NN O O
MLD NN B-Modifier B-MSH:D007966
patients NN O O
in NN O O
the NN O O
sample. NN O O
gene NN O O
segregation NN O O
in NN O O
the NN O O
original NN O O
patients NN O O
family NN O O
was NN O O
consistent NN O O
with NN O O
available NN O O
clinical NN O O
and NN O O
biochemical NN O O
data. NN O O
no NN O O
individual NN O O
. NN O O

homozygous NN O O
for NN O O
either NN O O
of NN O O
these NN O O
two NN O O
mutations NN O O
were NN O O
identified. NN O O
however, NN O O
combinations NN O O
with NN O O
other NN O O
MLD NN B-Modifier B-MSH:D007966
mutations NN O O
suggest NN O O
that NN O O
the NN O O
point NN O O
mutation NN O O
in NN O O
exon NN O O
3 NN O O
does NN O O
result NN O O
in NN O O
some NN O O
residual NN O O
enzyme NN O O
activity NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
late-onset NN O O
forms NN O O
of NN O O
the NN O O
disease. NN O O
the NN O O
splice-site NN O O
mutation NN O O
following NN O O
exon NN O O
7 NN O O
produces NN O O
late-infantile NN O O
MLD NN B-SpecificDisease B-MSH:D007966
when NN O O
combined NN O O
with NN O O
other NN O O
enzyme-null NN O O
mutations, NN O O
implying NN O O
that NN O O
it NN O O
is NN O O
completely NN O O
silent NN O O
enzymatically. NN O O
. NN O O

null NN O O
mutation NN O O
of NN O O
the NN O O
murine NN O O
atp NN O O
7 NN O O
b NN O O
( NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
) NN O O
gene NN O O
results NN O O
in NN O O
intracellular NN B-DiseaseClass B-MSH:C535468
copper NN I-DiseaseClass I-MSH:C535468
accumulation NN I-DiseaseClass I-MSH:C535468
and NN O O
late-onset NN B-DiseaseClass B-MSH:D020518
hepatic NN I-DiseaseClass I-MSH:D020518
nodular NN I-DiseaseClass I-MSH:D020518
transformation NN I-DiseaseClass I-MSH:D020518
. NN O O

the NN O O
atp NN O O
7 NN O O
b NN O O
protein NN O O
is NN O O
a NN O O
copper-transporting NN O O
atpase NN O O
expressed NN O O
predominantly NN O O
in NN O O
the NN O O
liver NN O O
and NN O O
to NN O O
a NN O O
lesser NN O O
extent NN O O
in NN O O
most NN O O
other NN O O
tissues. NN O O
mutations NN O O
in NN O O
the NN O O
atp NN O O
7 NN O O
b NN O O
gene NN O O
lead NN O O
to NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
, NN O O
a NN O O
copper NN B-DiseaseClass B-MSH:C535468
toxicity NN I-DiseaseClass I-MSH:C535468
disorder NN I-DiseaseClass I-MSH:C535468
characterized NN O O
by NN O O
dramatic NN O O
build-up NN O O
of NN O O
intracellular NN O O
hepatic NN O O
copper NN O O
with NN O O
subsequent NN O O
hepatic NN B-CompositeMention B-MSH:D008107
and NN I-CompositeMention I-MSH:D008107
neuro-logical NN I-CompositeMention I-MSH:D008107
abnormalities NN I-CompositeMention I-MSH:D008107
. NN O O
using NN O O
homologous NN O O
recombination NN O O
to NN O O
disrupt NN O O
the NN O O
normal NN O O
translation NN O O
of NN O O
atp NN O O
7 NN O O
b, NN O O
we NN O O
have NN O O
generated NN O O
a NN O O
strain NN O O
of NN O O
mice NN O O
that NN O O
are NN O O
homozygous NN O O
mutants NN O O
(null) NN O O
for NN O O
the NN O O
Wilson NN B-Modifier B-MSH:D006527
disease NN I-Modifier I-MSH:D006527
gene. NN O O
the NN O O
atp NN O O
7 NN O O
b NN O O
null NN O O
mice NN O O
display NN O O
a NN O O
gradual NN O O
accumulation NN O O
of NN O O
hepatic NN O O
copper NN O O
that NN O O
increases NN O O
to NN O O
a NN O O
level NN O O
60-fold NN O O
greater NN O O
than NN O O
normal NN O O
by NN O O
5 NN O O
months NN O O
of NN O O
age. NN O O
an NN O O
increase NN O O
in NN O O
copper NN O O
concentration NN O O
was NN O O
also NN O O
observed NN O O
in NN O O
the NN O O
kidney, NN O O
brain, NN O O
placenta NN O O
an NN O O
. NN O O

lactating NN O O
mammary NN O O
glands NN O O
of NN O O
homo-zygous NN O O
mutants, NN O O
although NN O O
milk NN O O
from NN O O
the NN O O
mutant NN O O
glands NN O O
was NN O O
copper NN B-DiseaseClass B-MSH:C535468
deficient NN I-DiseaseClass I-MSH:C535468
. NN O O
Morphological NN B-DiseaseClass B-MSH:D000013
abnormalities NN I-DiseaseClass I-MSH:D000013
resembling NN O O
cirrhosis NN B-SpecificDisease B-MSH:D008103
developed NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
the NN O O
livers NN O O
from NN O O
homozygous NN O O
mutants NN O O
older NN O O
than NN O O
7 NN O O
months NN O O
of NN O O
age. NN O O
progeny NN O O
of NN O O
the NN O O
homozygous NN O O
mutant NN O O
females NN O O
demonstrated NN O O
neurological NN B-DiseaseClass B-MSH:D009461
abnormalities NN I-DiseaseClass I-MSH:D009461
and NN O O
growth NN B-DiseaseClass B-MSH:D006130
retardation NN I-DiseaseClass I-MSH:D006130
characteristic NN O O
of NN O O
copper NN B-SpecificDisease B-MSH:C535468
deficiency NN I-SpecificDisease I-MSH:C535468
. NN O O
copper NN O O
concentration NN O O
in NN O O
the NN O O
livers NN O O
of NN O O
the NN O O
newborn NN O O
homozygous NN O O
null NN O O
mutants NN O O
was NN O O
decreased NN O O
dramatically. NN O O
in NN O O
summary, NN O O
inactivation NN O O
of NN O O
the NN O O
murine NN O O
atp NN O O
7 NN O O
b NN O O
gene NN O O
produces NN O O
a NN O O
form NN O O
of NN O O
cirrhotic NN B-DiseaseClass B-MSH:D008103
liver NN I-DiseaseClass I-MSH:D008103
disease NN I-DiseaseClass I-MSH:D008103
that NN O O
resembles NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
in NN O O
humans NN O O
and NN O O
the NN O O
toxic NN O O
milk NN O O
phenotype NN O O
in NN O O
the NN O O
mouse. NN O O
. NN O O

adrenoleukodystrophy NN O O
and NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
associated NN O O
with NN O O
partial NN O O
adrenal NN B-DiseaseClass B-MSH:D000309
insufficiency NN I-DiseaseClass I-MSH:D000309
in NN O O
three NN O O
generations NN O O
of NN O O
a NN O O
kindred NN O O
. NN O O

four NN O O
cases NN O O
of NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
and NN O O
one NN O O
case NN O O
of NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
AMN NN B-SpecificDisease B-MSH:D000326
) NN O O
have NN O O
developed NN O O
in NN O O
a NN O O
kindred NN O O
over NN O O
three NN O O
generations NN O O
demonstrating NN O O
that NN O O
AMN NN B-SpecificDisease B-MSH:D000326
is NN O O
a NN O O
clinical NN O O
variant NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
pituitary-adrenal NN O O
function NN O O
studies NN O O
were NN O O
performed NN O O
in NN O O
10 NN O O
family NN O O
members, NN O O
including NN O O
two NN O O
affected NN O O
males NN O O
and NN O O
four NN O O
females NN O O
identified NN O O
as NN O O
carriers NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
/ NN O O
AMN NN B-SpecificDisease B-MSH:D000326
. NN O O
no NN O O
pituitary-adrenal NN B-DiseaseClass B-MSH:D010900
abnormality NN I-DiseaseClass I-MSH:D010900
was NN O O
found NN O O
in NN O O
the NN O O
carriers. NN O O
however, NN O O
basal NN O O
morning NN O O
plasma NN O O
adrenocorticotropic NN O O
hormone NN O O
(acth) NN O O
levels NN O O
were NN O O
markedly NN O O
elevated NN O O
in NN O O
the NN O O
two NN O O
males NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
AMN NN B-SpecificDisease B-MSH:D000326
, NN O O
despite NN O O
the NN O O
fact NN O O
that NN O O
they NN O O
had NN O O
no NN O O
clinical NN O O
signs NN O O
of NN O O
adrenal NN B-DiseaseClass B-MSH:D000309
insufficiency NN I-DiseaseClass I-MSH:D000309
and NN O O
that NN O O
morning NN O O
plasma NN O O
cortisol NN O O
levels NN O O
and NN O O
their NN O O
response NN O O
to NN O O
maximal NN O O
exogenous NN O O
acth NN O O
stimulation NN O O
appeared NN O O
to NN O O
be NN O O
normal. NN O O
in NN O O
addition, NN O O
the NN O O
integrated NN O O
24-hour NN O O
response NN O O
to NN O O
the NN O O
administration NN O O
were NN O O
also NN O O
subnorma NN O O
. NN O O

in NN O O
these NN O O
two NN O O
cases. NN O O
thus, NN O O
people NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
AMN NN B-SpecificDisease B-MSH:D000326
may NN O O
have NN O O
subclinical NN O O
partial NN O O
adrenocrotical NN B-DiseaseClass B-MSH:D000224
insufficiency NN I-DiseaseClass I-MSH:D000224
. NN O O
no NN O O
other NN O O
endocrinologic NN B-DiseaseClass B-MSH:D004700
dysfunction NN I-DiseaseClass I-MSH:D004700
was NN O O
identified. NN O O
. NN O O

identification NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
ald-gene NN O O
of NN O O
20 NN O O
families NN O O
with NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
/ NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
. NN O O

adrenoleukodystrophy NN O O
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
), NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D008661
inherited NN I-DiseaseClass I-MSH:D008661
metabolic NN I-DiseaseClass I-MSH:D008661
disorder NN I-DiseaseClass I-MSH:D008661
, NN O O
is NN O O
the NN O O
most NN O O
frequent NN O O
inborn NN B-DiseaseClass B-MSH:D018901
peroxisomal NN I-DiseaseClass I-MSH:D018901
disease NN I-DiseaseClass I-MSH:D018901
. NN O O
it NN O O
leads NN O O
to NN O O
demyelination NN B-DiseaseClass B-MSH:D003711
in NN I-DiseaseClass I-MSH:D003711
the NN I-DiseaseClass I-MSH:D003711
central NN I-DiseaseClass I-MSH:D003711
and NN I-DiseaseClass I-MSH:D003711
peripheral NN I-DiseaseClass I-MSH:D003711
nervous NN I-DiseaseClass I-MSH:D003711
system NN I-DiseaseClass I-MSH:D003711
. NN O O
defective NN O O
beta-oxidation NN O O
of NN O O
saturated NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
(vlcfas; NN O O
c NN O O
22 NN O O
0-c NN O O
26 NN O O
0) NN O O
in NN O O
peroxisomes NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
lead NN O O
to NN O O
an NN O O
accumulation NN O O
of NN O O
vlcfas NN O O
in NN O O
leukoid NN O O
areas NN O O
of NN O O
the NN O O
central NN O O
nervous NN O O
system, NN O O
peripheral NN O O
nerves, NN O O
adrenal NN O O
gland, NN O O
and NN O O
blood. NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
has NN O O
been NN O O
recently NN O O
identified NN O O
and NN O O
encodes NN O O
a NN O O
745-amino-acid NN O O
protein. NN O O
we NN O O
screened NN O O
patients NN O O
with NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
/ NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
/ NN O O
AMN NN B-SpecificDisease B-MSH:D000326
) NN O O
from NN O O
20 NN O O
kindreds NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene. NN O O
eleven NN O O
missense NN O O
and NN O O
two NN O O
nonsense NN O O
mutations, NN O O
five NN O O
deletions, NN O O
and NN O O
one NN O O
insertion NN O O
were NN O O
detected NN O O
b NN O O
. NN O O

direct NN O O
sequencing NN O O
of NN O O
eight NN O O
reverse NN O O
transcribed NN O O
fragments NN O O
of NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
-gene NN O O
mrna. NN O O
four NN O O
mutations NN O O
could NN O O
be NN O O
shown NN O O
to NN O O
be NN O O
de NN O O
novo. NN O O
all NN O O
mutations NN O O
could NN O O
be NN O O
confirmed NN O O
in NN O O
carriers NN O O
by NN O O
sequencing NN O O
genomic NN O O
dna. NN O O
no NN O O
correlation NN O O
between NN O O
the NN O O
type NN O O
of NN O O
mutation NN O O
and NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
phenotype NN O O
could NN O O
be NN O O
observed. NN O O
the NN O O
mutations NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
of NN O O
30 NN O O
healthy NN O O
persons. NN O O
. NN O O

gonosomal NN O O
mosaicism NN O O
in NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
patients: NN O O
involvement NN O O
of NN O O
mitotic NN O O
events NN O O
in NN O O
(ctg)n NN O O
repeat NN O O
variation NN O O
and NN O O
selection NN O O
against NN O O
extreme NN O O
expansion NN O O
in NN O O
sperm NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
caused NN O O
by NN O O
abnormal NN O O
expansion NN O O
of NN O O
a NN O O
polymorphic NN O O
(ctg) NN O O
n NN O O
repeat, NN O O
located NN O O
in NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
protein NN O O
kinase NN O O
gene. NN O O
we NN O O
determined NN O O
the NN O O
(ctg) NN O O
n NN O O
repeat NN O O
lengths NN O O
in NN O O
a NN O O
broad NN O O
range NN O O
of NN O O
tissue NN O O
dnas NN O O
from NN O O
patients NN O O
with NN O O
mild, NN O O
classical, NN O O
or NN O O
congenital NN O O
manifestation NN O O
of NN O O
DM NN B-Modifier B-MSH:D009223
. NN O O
differences NN O O
in NN O O
the NN O O
repeat NN O O
length NN O O
were NN O O
seen NN O O
in NN O O
somatic NN O O
tissues NN O O
from NN O O
single NN O O
DM NN B-Modifier B-MSH:D009223
individuals NN O O
and NN O O
twins. NN O O
repeats NN O O
appeared NN O O
to NN O O
expand NN O O
to NN O O
a NN O O
similar NN O O
extent NN O O
in NN O O
tissues NN O O
originating NN O O
from NN O O
the NN O O
same NN O O
embryonal NN O O
origin. NN O O
in NN O O
most NN O O
male NN O O
patients NN O O
carrying NN O O
intermediate- NN O O
or NN O O
small-sized NN O O
expansions NN O O
in NN O O
blood, NN O O
the NN O O
repeat NN O O
lengths NN O O
covered NN O O
a NN O O
markedly NN O O
wider NN O O
range NN O O
in NN O O
sperm. NN O O
in NN O O
contrast, NN O O
male NN O O
patients NN O O
with NN O O
large NN O O
allele NN O O
expansions NN O O
in NN O O
blood NN O O
(> NN O O
700 NN O O
ctgs) NN O O
had NN O O
similar NN O O
or NN O O
smaller NN O O
repeats NN O O
in NN O O
sperm NN O O
. NN O O

when NN O O
detectable. NN O O
sperm NN O O
alleles NN O O
with NN O O
> NN O O
1, NN O O
000 NN O O
ctgs NN O O
were NN O O
not NN O O
seen. NN O O
we NN O O
conclude NN O O
that NN O O
DM NN B-Modifier B-MSH:D009223
patients NN O O
can NN O O
be NN O O
considered NN O O
gonosomal NN O O
mosaics, NN O O
i. NN O O
e NN O O
e., NN O O
combined NN O O
somatic NN O O
and NN O O
germ-line NN O O
tissue NN O O
mosaics. NN O O
most NN O O
remarkably, NN O O
we NN O O
observed NN O O
multiple NN O O
cases NN O O
where NN O O
the NN O O
length NN O O
distributions NN O O
of NN O O
intermediate- NN O O
or NN O O
small-sized NN O O
alleles NN O O
in NN O O
fathers NN O O
sperm NN O O
were NN O O
significantly NN O O
different NN O O
from NN O O
that NN O O
in NN O O
their NN O O
offsprings NN O O
blood. NN O O
our NN O O
combined NN O O
findings NN O O
indicate NN O O
that NN O O
intergenerational NN O O
length NN O O
changes NN O O
in NN O O
the NN O O
unstable NN O O
ctg NN O O
repeat NN O O
are NN O O
most NN O O
likely NN O O
to NN O O
occur NN O O
during NN O O
early NN O O
embryonic NN O O
mitotic NN O O
divisions NN O O
in NN O O
both NN O O
somatic NN O O
and NN O O
germ-line NN O O
tissue NN O O
formation. NN O O
both NN O O
the NN O O
initial NN O O
ctg NN O O
length, NN O O
the NN O O
overall NN O O
number NN O O
of NN O O
cell NN O O
divisions NN O O
involved NN O O
in NN O O
tissue NN O O
formation, NN O O
and NN O O
perhaps NN O O
a NN O O
specific NN O O
selection NN O O
process NN O O
in NN O O
spermatogenesis NN O O
may NN O O
influence NN O O
the NN O O
dynamics NN O O
of NN O O
this NN O O
process. NN O O
. NN O O

model NN O O
explaining NN O O
mitotic NN O O
instability NN O O
and NN O O
sex-dependent NN O O
segregation NN O O
phenomena NN O O
in NN O O
DM NN B-Modifier B-MSH:D009223
manifestation NN O O
is NN O O
discusse NN O O
. NN O O

combined NN O O
analysis NN O O
of NN O O
hereditary NN B-Modifier B-MSH:C537243
prostate NN I-Modifier I-MSH:C537243
cancer NN I-Modifier I-MSH:C537243
linkage NN O O
to NN O O
1 NN O O
q NN O O
24-25: NN O O
results NN O O
from NN O O
772 NN O O
hereditary NN B-Modifier B-MSH:C537243
prostate NN I-Modifier I-MSH:C537243
cancer NN I-Modifier I-MSH:C537243
families NN O O
from NN O O
the NN O O
international NN O O
consortium NN O O
for NN O O
Prostate NN B-Modifier B-MSH:D011471
Cancer NN I-Modifier I-MSH:D011471
genetics NN O O
. NN O O

a NN O O
previous NN O O
linkage NN O O
study NN O O
provided NN O O
evidence NN O O
for NN O O
a NN O O
prostate NN B-Modifier B-MSH:D011471
cancer NN I-Modifier I-MSH:D011471
-susceptibility NN O O
locus NN O O
at NN O O
1 NN O O
q NN O O
24-25. NN O O
subsequent NN O O
reports NN O O
in NN O O
additional NN O O
collections NN O O
of NN O O
families NN O O
have NN O O
yielded NN O O
conflicting NN O O
results. NN O O
in NN O O
addition, NN O O
evidence NN O O
for NN O O
locus NN O O
heterogeneity NN O O
has NN O O
been NN O O
provided NN O O
by NN O O
the NN O O
identification NN O O
of NN O O
other NN O O
putative NN O O
hereditary NN B-Modifier B-MSH:C537243
prostate NN I-Modifier I-MSH:C537243
cancer NN I-Modifier I-MSH:C537243
loci NN O O
on NN O O
xq NN O O
27-28, NN O O
1 NN O O
q NN O O
42-43, NN O O
and NN O O
1 NN O O
p NN O O
36. NN O O
the NN O O
present NN O O
study NN O O
describes NN O O
a NN O O
combined NN O O
analysis NN O O
for NN O O
six NN O O
markers NN O O
in NN O O
the NN O O
1 NN O O
q NN O O
24-25 NN O O
region NN O O
in NN O O
772 NN O O
families NN O O
affected NN O O
by NN O O
hereditary NN B-SpecificDisease B-MSH:C537243
prostate NN I-SpecificDisease I-MSH:C537243
cancer NN I-SpecificDisease I-MSH:C537243
and NN O O
ascertained NN O O
by NN O O
the NN O O
members NN O O
of NN O O
the NN O O
international NN O O
consortium NN O O
for NN O O
Prostate NN B-Modifier B-MSH:D011471
Cancer NN I-Modifier I-MSH:D011471
genetics NN O O
(icpcg) NN O O
from NN O O
north NN O O
america, NN O O
australia, NN O O
finland, NN O O
norway, NN O O
sweden, NN O O
and NN O O
the NN O O
united NN O O
kingdom. NN O O
overall, NN O O
there NN O O
was NN O O
some NN O O
evidence NN O O
for NN O O
linkage, NN O O
with NN O O
a NN O O
pea NN O O
. NN O O

parametric NN O O
multipoint NN O O
lod NN O O
score NN O O
assuming NN O O
heterogeneity NN O O
(hlod) NN O O
of NN O O
1. NN O O
40 NN O O
(p NN O O
=. NN O O
01) NN O O
at NN O O
d NN O O
1 NN O O
s NN O O
212. NN O O
the NN O O
estimated NN O O
proportion NN O O
of NN O O
families NN O O
(alpha) NN O O
linked NN O O
to NN O O
the NN O O
locus NN O O
was. NN O O
06 NN O O
(1-lod NN O O
support NN O O
interval. NN O O
01-. NN O O
12). NN O O
this NN O O
evidence NN O O
was NN O O
not NN O O
observed NN O O
by NN O O
a NN O O
nonparametric NN O O
approach, NN O O
presumably NN O O
because NN O O
of NN O O
the NN O O
extensive NN O O
heterogeneity. NN O O
further NN O O
parametric NN O O
analysis NN O O
revealed NN O O
a NN O O
significant NN O O
effect NN O O
of NN O O
the NN O O
presence NN O O
of NN O O
male-to-male NN O O
disease NN O O
transmission NN O O
within NN O O
the NN O O
families. NN O O
in NN O O
the NN O O
subset NN O O
of NN O O
491 NN O O
such NN O O
families, NN O O
the NN O O
peak NN O O
hlod NN O O
was NN O O
2. NN O O
in NN O O
the NN O O
subset NN O O
of NN O O
491 NN O O
such NN O O
families, NN O O
the NN O O
peak NN O O
hlod NN O O
was NN O O
2. NN O O
56 NN O O
(p NN O O
=. NN O O
0006) NN O O
and NN O O
alpha NN O O
=. NN O O
11 NN O O
(1-lod NN O O
support NN O O
interval. NN O O
0 NN O O
. NN O O
11 NN O O
(1-lod NN O O
support NN O O
interval. NN O O
0 NN O O
. NN O O

-. NN O O
19), NN O O
compared NN O O
with NN O O
hlods NN O O
of NN O O
0 NN O O
in NN O O
the NN O O
remaining NN O O
281 NN O O
families. NN O O
within NN O O
the NN O O
families NN O O
with NN O O
male-to-male NN O O
disease NN O O
transmission, NN O O
alpha NN O O
increased NN O O
with NN O O
the NN O O
early NN O O
mean NN O O
age NN O O
at NN O O
diagnosis NN O O
(< NN O O
65 NN O O
years, NN O O
alpha NN O O
=. NN O O
19, NN O O
with NN O O
1-lod NN O O
support NN O O
interval. NN O O
06-. NN O O
34) NN O O
and NN O O
the NN O O
number NN O O
of NN O O
affected NN O O
family NN O O
members NN O O
(five NN O O
or NN O O
more NN O O
family NN O O
members, NN O O
alpha NN O O
=. NN O O
15, NN O O
with NN O O
1-lod NN O O
support NN O O
interval. NN O O
04-. NN O O
28). NN O O
the NN O O
highest NN O O
value NN O O
of NN O O
alpha NN O O
was NN O O
observed NN O O
for NN O O
the NN O O
48 NN O O
families NN O O
that NN O O
met NN O O
all NN O O
three NN O O
criteria NN O O
(peak NN O O
hlod NN O O
= NN O O
2. NN O O
25, NN O O
p NN O O
=. NN O O
001, NN O O
alpha NN O O
=. NN O O
29, NN O O
with NN O O
1-lod NN O O
support NN O O
interval. NN O O
08-. NN O O
53). NN O O
these NN O O
result NN O O
. NN O O

support NN O O
the NN O O
finding NN O O
of NN O O
a NN O O
prostate NN B-Modifier B-MSH:D011471
cancer NN I-Modifier I-MSH:D011471
-susceptibility NN O O
gene NN O O
linked NN O O
to NN O O
1 NN O O
q NN O O
24-25, NN O O
albeit NN O O
in NN O O
a NN O O
defined NN O O
subset NN O O
of NN O O
prostate NN B-Modifier B-MSH:D011471
cancer NN I-Modifier I-MSH:D011471
families. NN O O
although NN O O
hpc NN O O
1 NN O O
accounts NN O O
for NN O O
only NN O O
a NN O O
small NN O O
proportion NN O O
of NN O O
all NN O O
families NN O O
affected NN O O
by NN O O
hereditary NN B-SpecificDisease B-MSH:C537243
prostate NN I-SpecificDisease I-MSH:C537243
cancer NN I-SpecificDisease I-MSH:C537243
, NN O O
it NN O O
appears NN O O
to NN O O
play NN O O
a NN O O
more NN O O
prominent NN O O
role NN O O
in NN O O
the NN O O
subset NN O O
of NN O O
families NN O O
with NN O O
several NN O O
members NN O O
affected NN O O
at NN O O
an NN O O
early NN O O
age NN O O
and NN O O
with NN O O
male-to-male NN O O
disease NN O O
transmission NN O O
. NN O O

a NN O O
novel NN O O
disease NN O O
with NN O O
deficiency NN B-SpecificDisease B-MSH:C536353
of NN I-SpecificDisease I-MSH:C536353
mitochondrial NN I-SpecificDisease I-MSH:C536353
very-long-chain NN I-SpecificDisease I-MSH:C536353
acyl-CoA NN I-SpecificDisease I-MSH:C536353
dehydrogenase NN I-SpecificDisease I-MSH:C536353
. NN O O

palmitoyl-coa NN O O
dehydrogenase NN O O
activity NN O O
in NN O O
skin NN O O
fibroblasts NN O O
from NN O O
seven NN O O
patients NN O O
with NN O O
unidentified NN O O
defects NN O O
of NN O O
fatty NN O O
acid NN O O
oxidation NN O O
was NN O O
measured NN O O
in NN O O
the NN O O
presence NN O O
and NN O O
absence NN O O
of NN O O
antibodies NN O O
against NN O O
medium-chain, NN O O
long-chain, NN O O
and NN O O
very-long-chain NN O O
acyl-coa NN O O
dehydrogenases NN O O
(vlcad). NN O O
two NN O O
of NN O O
the NN O O
patients, NN O O
4-5 NN O O
month NN O O
old NN O O
boys, NN O O
were NN O O
found NN O O
to NN O O
have NN O O
a NN O O
novel NN O O
disease, NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
, NN O O
as NN O O
judged NN O O
from NN O O
the NN O O
results NN O O
of NN O O
very NN O O
low NN O O
palmitoyl-coa NN O O
dehydrogenase NN O O
activity NN O O
and NN O O
the NN O O
lack NN O O
of NN O O
immunoreactivity NN O O
toward NN O O
antibody NN O O
raised NN O O
to NN O O
purified NN O O
vlcad. NN O O
. NN O O

inherited NN O O
wt NN O O
1 NN O O
mutation NN O O
in NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
. NN O O

patients NN O O
with NN O O
the NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
( NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
, NN O O
genital NN B-DiseaseClass B-MSH:D014564
anomalies NN I-DiseaseClass I-MSH:D014564
, NN O O
and NN O O
nephropathy NN B-SpecificDisease B-MSH:D007674
) NN O O
have NN O O
been NN O O
demonstrated NN O O
to NN O O
carry NN O O
de NN O O
novo NN O O
constitutional NN O O
mutations NN O O
in NN O O
wt NN O O
1, NN O O
the NN O O
Wilms NN B-Modifier B-MSH:D009396
tumor NN I-Modifier I-MSH:D009396
gene NN O O
at NN O O
chromosome NN O O
11 NN O O
p NN O O
13. NN O O
we NN O O
report NN O O
three NN O O
new NN O O
cases, NN O O
two NN O O
carrying NN O O
a NN O O
previously NN O O
described NN O O
wt NN O O
1 NN O O
exon NN O O
9 NN O O
mutation NN O O
and NN O O
one NN O O
with NN O O
a NN O O
novel NN O O
wt NN O O
1 NN O O
exon NN O O
8 NN O O
mutation. NN O O
however, NN O O
unlike NN O O
patients NN O O
in NN O O
previous NN O O
reports, NN O O
one NN O O
of NN O O
our NN O O
three NN O O
patients NN O O
inherited NN O O
the NN O O
affected NN O O
allele NN O O
from NN O O
his NN O O
phenotypically NN O O
unaffected NN O O
father. NN O O
this NN O O
observation NN O O
indicates NN O O
that NN O O
the NN O O
wt NN O O
1 NN O O
exon NN O O
9 NN O O
mutation NN O O
affecting NN O O
394 NN O O
arg NN O O
demonstrated NN O O
in NN O O
over NN O O
one-half NN O O
of NN O O
the NN O O
patients NN O O
with NN O O
the NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
may NN O O
exhibit NN O O
incomplete NN O O
penetrance. NN O O
consequently, NN O O
familial NN O O
studies NN O O
in NN O O
patients NN O O
affected NN O O
by NN O O
this NN O O
syndrome NN O O
are NN O O
recommended. NN O O
. NN O O

glucose/galactose NN O O
malabsorption NN O O
caused NN O O
by NN O O
a NN O O
defect NN O O
in NN O O
the NN O O
na+/glucose NN O O
cotransporter NN O O
. NN O O

glucose/galactose NN O O
malabsorption NN O O
( NN O O
GGM NN B-SpecificDisease B-OMIM:606824
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
manifesting NN O O
within NN O O
the NN O O
first NN O O
weeks NN O O
of NN O O
life NN O O
and NN O O
characterized NN O O
by NN O O
a NN O O
selective NN O O
failure NN O O
to NN O O
absorb NN O O
dietary NN O O
glucose NN O O
and NN O O
galactose NN O O
from NN O O
the NN O O
intestine. NN O O
the NN O O
consequent NN O O
severe NN O O
diarrhoea NN B-SpecificDisease B-MSH:D003967
and NN O O
dehydration NN B-SpecificDisease B-MSH:D003681
are NN O O
usually NN O O
fatal NN O O
unless NN O O
these NN O O
sugars NN O O
are NN O O
eliminated NN O O
from NN O O
the NN O O
diet. NN O O
intestinal NN O O
biopsies NN O O
of NN O O
GGM NN B-Modifier B-OMIM:606824
patients NN O O
have NN O O
revealed NN O O
a NN O O
specific NN O O
defect NN O O
in NN O O
na NN O O
(+) NN O O
-dependent NN O O
absorption NN O O
of NN O O
glucose NN O O
in NN O O
the NN O O
brush NN O O
border. NN O O
normal NN O O
glucose NN O O
absorption NN O O
is NN O O
mediated NN O O
by NN O O
the NN O O
na NN O O
+/glucose NN O O
cotransporter NN O O
in NN O O
the NN O O
brush NN O O
border NN O O
membrane NN O O
of NN O O
the NN O O
intestinal NN O O
epithelium. NN O O
cellular NN O O
influx NN O O
is NN O O
driven NN O O
by NN O O
the NN O O
transmembrane NN O O
na NN O O
+ NN O O
electrochemical NN O O
potential NN O O
gradient; NN O O
thereafter NN O O
the NN O O
sugar NN O O
moves NN O O
to NN O O
the NN O O
blood NN O O
across NN O O
the NN O O
basolateral NN O O
membrane NN O O
via NN O O
the NN O O
facilitated NN O O
glucose NN O O
carrier. NN O O
we NN O O
have NN O O
previously NN O O
cloned NN O O
and NN O O
sequenced NN O O
a NN O O
na NN O O
+ NN O O
. NN O O

glucose NN O O
cotransporter NN O O
from NN O O
normal NN O O
human NN O O
ileum NN O O
and NN O O
shown NN O O
that NN O O
this NN O O
gene, NN O O
sglt NN O O
1, NN O O
resides NN O O
on NN O O
the NN O O
distal NN O O
q NN O O
arm NN O O
of NN O O
chromosome NN O O
22. NN O O
we NN O O
have NN O O
now NN O O
amplified NN O O
sglt NN O O
1 NN O O
complementary NN O O
dna NN O O
and NN O O
genomic NN O O
dna NN O O
from NN O O
members NN O O
of NN O O
a NN O O
family NN O O
affected NN O O
with NN O O
GGM NN B-SpecificDisease B-OMIM:606824
by NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction. NN O O
sequence NN O O
analysis NN O O
of NN O O
the NN O O
amplified NN O O
products NN O O
has NN O O
revealed NN O O
a NN O O
single NN O O
missense NN O O
mutation NN O O
in NN O O
sglt NN O O
1 NN O O
which NN O O
cosegregates NN O O
with NN O O
the NN O O
GGM NN B-Modifier B-OMIM:606824
phenotype NN O O
and NN O O
results NN O O
in NN O O
a NN O O
complete NN O O
loss NN O O
of NN O O
na NN O O
(+) NN O O
-dependent NN O O
glucose NN O O
transport NN O O
in NN O O
xenopus NN O O
oocytes NN O O
injected NN O O
with NN O O
this NN O O
complementary NN O O
rna. NN O O
. NN O O

atm NN O O
and NN O O
bax NN O O
cooperate NN O O
in NN O O
ionizing NN O O
radiation-induced NN O O
apoptosis NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
. NN O O

ataxia-telangiectasia NN O O
is NN O O
a NN O O
hereditary NN B-DiseaseClass B-MSH:D030342
multisystemic NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
resulting NN O O
from NN O O
mutations NN O O
of NN O O
ataxia NN B-SpecificDisease B-MSH:D001260
telangiectasia NN I-SpecificDisease I-MSH:D001260
, NN O O
mutated NN O O
(atm) NN O O
and NN O O
is NN O O
characterized NN O O
by NN O O
neurodegeneration NN B-DiseaseClass B-MSH:D019636
, NN O O
cancer NN B-DiseaseClass B-MSH:D009369
, NN O O
immune NN B-DiseaseClass B-MSH:D007154
defects NN I-DiseaseClass I-MSH:D007154
, NN O O
and NN O O
hypersensitivity NN B-DiseaseClass B-MSH:D004194
to NN I-DiseaseClass I-MSH:D004194
ionizing NN I-DiseaseClass I-MSH:D004194
radiation NN I-DiseaseClass I-MSH:D004194
. NN O O
the NN O O
molecular NN O O
details NN O O
of NN O O
atm NN O O
function NN O O
in NN O O
the NN O O
nervous NN O O
system NN O O
are NN O O
unclear, NN O O
although NN O O
the NN O O
neurological NN B-DiseaseClass B-MSH:D019636
lesion NN I-DiseaseClass I-MSH:D019636
in NN O O
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
becomes NN O O
apparent NN O O
early NN O O
in NN O O
life, NN O O
suggesting NN O O
a NN O O
developmental NN O O
origin. NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
(cns) NN O O
of NN O O
atm-null NN O O
mice NN O O
shows NN O O
a NN O O
pronounced NN O O
defect NN O O
in NN O O
apoptosis NN O O
induced NN O O
by NN O O
genotoxic NN O O
stress, NN O O
suggesting NN O O
atm NN O O
functions NN O O
to NN O O
eliminate NN O O
neurons NN O O
with NN O O
excessive NN O O
genomic NN O O
damage. NN O O
here, NN O O
we NN O O
report NN O O
that NN O O
the NN O O
death NN O O
effector NN O O
bax NN O O
is NN O O
required NN O O
for NN O O
a NN O O
large NN O O
proportion NN O O
of NN O O
atm-dependent NN O O
apoptosis NN O O
in NN O O
the NN O O
developing NN O O
cns NN O O
after NN O O
ionizing NN O O
radiation NN O O
(ir). NN O O
although NN O O
many NN O O
of NN O O
the NN O O
same NN O O
regions NN O O
o NN O O
. NN O O

the NN O O
cns NN O O
in NN O O
both NN O O
bax-/- NN O O
and NN O O
atm-/- NN O O
mice NN O O
were NN O O
radioresistant, NN O O
mice NN O O
nullizygous NN O O
for NN O O
both NN O O
bax NN O O
and NN O O
atm NN O O
showed NN O O
additional NN O O
reduction NN O O
in NN O O
ir-induced NN O O
apoptosis NN O O
in NN O O
the NN O O
cns. NN O O
therefore, NN O O
although NN O O
the NN O O
major NN O O
ir-induced NN O O
apoptotic NN O O
pathway NN O O
in NN O O
the NN O O
cns NN O O
requires NN O O
atm NN O O
and NN O O
bax, NN O O
a NN O O
p NN O O
53-dependent NN O O
collateral NN O O
pathway NN O O
exists NN O O
that NN O O
has NN O O
both NN O O
atm- NN O O
and NN O O
bax-independent NN O O
branches. NN O O
further, NN O O
atm- NN O O
and NN O O
bax-dependent NN O O
apoptosis NN O O
in NN O O
the NN O O
cns NN O O
also NN O O
required NN O O
caspase-3 NN O O
activation. NN O O
these NN O O
data NN O O
implicate NN O O
bax NN O O
and NN O O
caspase-3 NN O O
as NN O O
death NN O O
effectors NN O O
in NN O O
neurodegenerative NN O O
pathways. NN O O
. NN O O
x-dependent NN O O
apoptosis NN O O
in NN O O
the NN O O
cns NN O O
also NN O O
required NN O O
caspase-3 NN O O
activation. NN O O
these NN O O
data NN O O
implicate NN O O
bax NN O O
and NN O O
caspase-3 NN O O
as NN O O
death NN O O
effectors NN O O
in NN O O
neurodegenerative NN O O
pathways. NN O O
. NN O O

novel NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
mutations NN O O
from NN O O
china NN O O
. NN O O

we NN O O
describe NN O O
three NN O O
hexa NN O O
mutations NN O O
associated NN O O
with NN O O
infantile NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
) NN O O
in NN O O
three NN O O
unrelated NN O O
nonconsanguineous NN O O
chinese NN O O
families. NN O O
novel NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
two NN O O
of NN O O
these NN O O
families. NN O O
the NN O O
third NN O O
is NN O O
a NN O O
previously NN O O
reported NN O O
mutation NN O O
(g-- NN O O
> NN O O
a NN O O
transition NN O O
at NN O O
nt NN O O
1444) NN O O
(nakano NN O O
et NN O O
al., NN O O
1988). NN O O
direct NN O O
sequencing NN O O
of NN O O
pcr NN O O
products NN O O
identified NN O O
a NN O O
novel NN O O
insertion NN O O
of NN O O
an NN O O
a NN O O
after NN O O
nt NN O O
547 NN O O
in NN O O
family NN O O
1. NN O O
this NN O O
change NN O O
generates NN O O
an NN O O
early NN O O
termination NN O O
codon NN O O
6 NN O O
bp NN O O
downstream NN O O
from NN O O
the NN O O
insertion NN O O
site. NN O O
allele-specific NN O O
oligonucleotide NN O O
hybridization NN O O
confirmed NN O O
homozygosity NN O O
in NN O O
the NN O O
proband. NN O O
single NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing NN O O
of NN O O
amplified NN O O
exon NN O O
13 NN O O
revealed NN O O
a NN O O
t-- NN O O
> NN O O
c NN O O
transition NN O O
at NN O O
nt NN O O
1453 NN O O
with NN O O
the NN O O
corresponding NN O O
amino NN O O
acid NN O O
substitution NN O O
w NN O O
485 NN O O
r NN O O
in NN O O
the NN O O
second NN O O
famil NN O O
. NN O O

. NN O O
this NN O O
mutation NN O O
creates NN O O
an NN O O
fnu NN O O
4 NN O O
hi NN O O
restriction NN O O
site. NN O O
the NN O O
proband NN O O
is NN O O
homozygous NN O O
for NN O O
this NN O O
allele. NN O O
when NN O O
the NN O O
site-specific NN O O
mutagenized NN O O
alpha NN O O
cdna NN O O
carrying NN O O
the NN O O
t-- NN O O
> NN O O
c NN O O
transition NN O O
at NN O O
nt NN O O
1453 NN O O
was NN O O
expressed NN O O
in NN O O
cos NN O O
1 NN O O
cells NN O O
hexosaminidase NN O O
s NN O O
activity NN O O
was NN O O
not NN O O
detectable NN O O
above NN O O
background. NN O O
a NN O O
g-- NN O O
> NN O O
a NN O O
transition NN O O
at NN O O
nt NN O O
1444 NN O O
(exon NN O O
13) NN O O
corresponding NN O O
to NN O O
the NN O O
e NN O O
482 NN O O
k NN O O
substitution NN O O
was NN O O
found NN O O
in NN O O
the NN O O
third NN O O
family. NN O O
this NN O O
mutation NN O O
occurs NN O O
at NN O O
a NN O O
cpg NN O O
dinucleotide. NN O O
it NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
an NN O O
italian NN O O
TSD NN B-Modifier B-MSH:D013661
proband NN O O
and NN O O
causes NN O O
defective NN O O
intracellular NN O O
transport NN O O
of NN O O
the NN O O
alpha-subunit NN O O
from NN O O
the NN O O
rough NN O O
endoplasmic NN O O
reticulum NN O O
to NN O O
the NN O O
golgi NN O O
apparatus NN O O
. NN O O

glucose NN O O
6-phosphate NN O O
dehydrogenase NN O O
deficiency NN O O
and NN O O
incidence NN O O
of NN O O
hematologic NN B-DiseaseClass B-MSH:D019337
malignancy NN I-DiseaseClass I-MSH:D019337
. NN O O

we NN O O
have NN O O
evaluated NN O O
the NN O O
hypothesis NN O O
of NN O O
a NN O O
negative NN O O
association NN O O
between NN O O
glucose NN B-SpecificDisease B-MSH:D005955
6-phosphate NN I-SpecificDisease I-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
and NN O O
cancer NN B-DiseaseClass B-MSH:D009369
in NN O O
a NN O O
cohort NN O O
of NN O O
481 NN O O
sardinian NN O O
males NN O O
with NN O O
hematological NN B-DiseaseClass B-MSH:D019337
malignancies NN I-DiseaseClass I-MSH:D019337
. NN O O
the NN O O
frequency NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
the NN O O
patients NN O O
was NN O O
not NN O O
different NN O O
from NN O O
the NN O O
incidence NN O O
in NN O O
a NN O O
group NN O O
of NN O O
16, NN O O
219 NN O O
controls. NN O O
the NN O O
same NN O O
conclusion NN O O
resulted NN O O
from NN O O
the NN O O
comparison NN O O
of NN O O
the NN O O
frequency NN O O
of NN O O
expression NN O O
of NN O O
the NN O O
gdb NN O O
gene NN O O
in NN O O
23 NN O O
heterozygous NN O O
women NN O O
having NN O O
a NN O O
clonal NN O O
hematologic NN B-DiseaseClass B-MSH:D006402
disease NN I-DiseaseClass I-MSH:D006402
and NN O O
a NN O O
control NN O O
group NN O O
of NN O O
37 NN O O
healthy NN O O
heterozygotes. NN O O
therefore NN O O
at NN O O
present NN O O
there NN O O
is NN O O
no NN O O
evidence NN O O
that NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
has NN O O
a NN O O
protective NN O O
effect NN O O
against NN O O
development NN O O
of NN O O
hematologic NN B-DiseaseClass B-MSH:D019337
neoplasms NN I-DiseaseClass I-MSH:D019337
. NN O O
. NN O O

a NN O O
physical NN O O
map NN O O
and NN O O
candidate NN O O
genes NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
region NN O O
on NN O O
chromosome NN O O
17 NN O O
q NN O O
12-21 NN O O
. NN O O

we NN O O
have NN O O
constructed NN O O
a NN O O
physical NN O O
map NN O O
of NN O O
a NN O O
4 NN O O
cm NN O O
region NN O O
on NN O O
chromosome NN O O
17 NN O O
q NN O O
12-21 NN O O
that NN O O
contains NN O O
the NN O O
hereditary NN B-Modifier B-MSH:D061325
breast NN I-Modifier I-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
gene NN O O
brca NN O O
1. NN O O
the NN O O
map NN O O
comprises NN O O
a NN O O
contig NN O O
of NN O O
137 NN O O
overlapping NN O O
yeast NN O O
artificial NN O O
chromosomes NN O O
and NN O O
p NN O O
1 NN O O
clones, NN O O
onto NN O O
which NN O O
we NN O O
have NN O O
placed NN O O
112 NN O O
pcr NN O O
markers. NN O O
we NN O O
have NN O O
localized NN O O
more NN O O
than NN O O
20 NN O O
genes NN O O
on NN O O
this NN O O
map, NN O O
ten NN O O
of NN O O
which NN O O
had NN O O
not NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
region NN O O
previously, NN O O
and NN O O
have NN O O
isolated NN O O
30 NN O O
cdna NN O O
clones NN O O
representing NN O O
partial NN O O
sequences NN O O
of NN O O
as NN O O
yet NN O O
unidentified NN O O
genes. NN O O
two NN O O
genes NN O O
that NN O O
lie NN O O
within NN O O
a NN O O
narrow NN O O
region NN O O
defined NN O O
by NN O O
meiotic NN O O
breakpoints NN O O
in NN O O
brca NN O O
1 NN O O
patients NN O O
have NN O O
been NN O O
sequenced NN O O
in NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
patients NN O O
without NN O O
revealing NN O O
any NN O O
deleterious NN O O
mutations. NN O O
these NN O O
new NN O O
reagents NN O O
should NN O O
facilitate NN O O
the NN O O
identification NN O O
of NN O O
brca NN O O
1. NN O O
. NN O O

sulfate NN O O
transport NN O O
is NN O O
not NN O O
impaired NN O O
in NN O O
pendred NN B-Modifier B-MSH:C536648
syndrome NN I-Modifier I-MSH:C536648
thyrocytes NN O O
. NN O O

pendred NN O O
syndrome NN O O
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
syndromic NN B-DiseaseClass B-MSH:D003638
deafness NN I-DiseaseClass I-MSH:D003638
, NN O O
characterized NN O O
by NN O O
dyshormonogenic NN B-SpecificDisease B-MSH:D006042
goiter NN I-SpecificDisease I-MSH:D006042
associated NN O O
with NN O O
sensory-neural NN B-DiseaseClass B-MSH:D006319
deafness NN I-DiseaseClass I-MSH:D006319
. NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
the NN O O
disease NN O O
( NN O O
PDS NN B-SpecificDisease B-MSH:C536648
) NN O O
has NN O O
been NN O O
cloned, NN O O
but NN O O
its NN O O
function NN O O
is NN O O
as NN O O
yet NN O O
unknown NN O O
and NN O O
the NN O O
connection NN O O
between NN O O
thyroid NN B-DiseaseClass B-MSH:D006042
goiter NN I-DiseaseClass I-MSH:D006042
and NN O O
sensory-neural NN B-DiseaseClass B-MSH:D006319
deafness NN I-DiseaseClass I-MSH:D006319
remains NN O O
an NN O O
enigma. NN O O
pds NN O O
codes NN O O
for NN O O
a NN O O
novel NN O O
protein, NN O O
pendrin, NN O O
which NN O O
is NN O O
closely NN O O
related NN O O
to NN O O
a NN O O
number NN O O
of NN O O
sufate NN O O
transporters. NN O O
mechanisms NN O O
by NN O O
which NN O O
abnormal NN O O
sulfate NN O O
transport NN O O
could NN O O
deleteriously NN O O
affect NN O O
iodide NN O O
organification NN O O
have NN O O
been NN O O
proposed. NN O O
we NN O O
tested NN O O
sulfate NN O O
transport NN O O
in NN O O
thyrocytes NN O O
obtained NN O O
from NN O O
Pendred NN B-Modifier B-MSH:C536648
syndrome NN I-Modifier I-MSH:C536648
patients NN O O
and NN O O
found NN O O
that NN O O
it NN O O
was NN O O
not NN O O
defective. NN O O
this NN O O
suggests NN O O
that NN O O
pendrin NN O O
in NN O O
fact NN O O
may NN O O
not NN O O
be NN O O
a NN O O
sulfate NN O O
transporter, NN O O
and NN O O
emphasizes NN O O
the NN O O
importance NN O O
of NN O O
functional NN O O
studies NN O O
on NN O O
this NN O O
novel NN O O
protein. NN O O
. NN O O

spinal NN O O
xanthomatosis: NN O O
a NN O O
variant NN O O
of NN O O
cerebrotendinous NN B-DiseaseClass B-MSH:D019294
xanthomatosis NN I-DiseaseClass I-MSH:D019294
. NN O O

we NN O O
describe NN O O
seven NN O O
dutch NN O O
patients NN O O
from NN O O
six NN O O
families NN O O
with NN O O
a NN O O
slowly NN O O
progressive, NN O O
mainly NN O O
spinal NN B-SpecificDisease B-MSH:D013118
cord NN I-SpecificDisease I-MSH:D013118
syndrome NN I-SpecificDisease I-MSH:D013118
that NN O O
remained NN O O
for NN O O
many NN O O
years NN O O
the NN O O
sole NN O O
expression NN O O
of NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
( NN O O
CTX NN B-SpecificDisease B-MSH:D019294
). NN O O
mri NN O O
demonstrated NN O O
white NN B-DiseaseClass B-MSH:D002493
matter NN I-DiseaseClass I-MSH:D002493
abnormalities NN I-DiseaseClass I-MSH:D002493
in NN O O
the NN O O
lateral NN O O
and NN O O
dorsal NN O O
columns NN O O
of NN O O
the NN O O
spinal NN O O
cord. NN O O
post-mortem NN O O
examination NN O O
of NN O O
one NN O O
of NN O O
the NN O O
patients NN O O
showed NN O O
extensive NN O O
myelin NN O O
loss NN O O
in NN O O
these NN O O
columns. NN O O
an NN O O
array NN O O
of NN O O
genotypes NN O O
was NN O O
found NN O O
in NN O O
these NN O O
patients. NN O O
we NN O O
conclude NN O O
that NN O O
spinal NN B-SpecificDisease B-MSH:D014973
xanthomatosis NN I-SpecificDisease I-MSH:D014973
is NN O O
a NN O O
clinical NN O O
and NN O O
radiological NN O O
separate NN O O
entity NN O O
of NN O O
CTX NN B-SpecificDisease B-MSH:D019294
that NN O O
should NN O O
be NN O O
included NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
of NN O O
chronic NN B-DiseaseClass B-MSH:D002908
myelopathy NN I-DiseaseClass I-MSH:D002908
. NN O O
. NN O O

the NN O O
exon NN O O
13 NN O O
duplication NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
is NN O O
a NN O O
founder NN O O
mutation NN O O
present NN O O
in NN O O
geographically NN O O
diverse NN O O
populations. NN O O
the NN O O
brca NN O O
1 NN O O
exon NN O O
13 NN O O
duplication NN O O
screening NN O O
group NN O O
. NN O O

recently, NN O O
a NN O O
6-kb NN O O
duplication NN O O
of NN O O
exon NN O O
13, NN O O
which NN O O
creates NN O O
a NN O O
frameshift NN O O
in NN O O
the NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
gene, NN O O
has NN O O
been NN O O
described NN O O
in NN O O
three NN O O
unrelated NN O O
u. NN O O
s NN O O
s. NN O O
families NN O O
of NN O O
european NN O O
ancestry NN O O
and NN O O
in NN O O
one NN O O
portuguese NN O O
family. NN O O
here, NN O O
our NN O O
goal NN O O
was NN O O
to NN O O
estimate NN O O
the NN O O
frequency NN O O
and NN O O
geographic NN O O
diversity NN O O
of NN O O
carriers NN O O
of NN O O
this NN O O
duplication. NN O O
to NN O O
do NN O O
this, NN O O
a NN O O
collaborative NN O O
screening NN O O
study NN O O
was NN O O
set NN O O
up NN O O
that NN O O
involved NN O O
39 NN O O
institutions NN O O
from NN O O
19 NN O O
countries NN O O
and NN O O
included NN O O
3, NN O O
580 NN O O
unrelated NN O O
individuals NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
the NN O O
disease NN O O
and NN O O
934 NN O O
early-onset NN O O
breast NN B-Modifier B-MSH:D061325
and/or NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
cases. NN O O
a NN O O
total NN O O
of NN O O
11 NN O O
additional NN O O
families NN O O
carrying NN O O
this NN O O
mutation NN O O
were NN O O
identified NN O O
in NN O O
australia NN O O
(1), NN O O
belgium NN O O
(1), NN O O
canada NN O O
(1), NN O O
great NN O O
britain NN O O
( NN O O
. NN O O

), NN O O
and NN O O
the NN O O
united NN O O
states NN O O
(2). NN O O
haplotyping NN O O
showed NN O O
that NN O O
they NN O O
are NN O O
likely NN O O
to NN O O
derive NN O O
from NN O O
a NN O O
common NN O O
ancestor, NN O O
possibly NN O O
of NN O O
northern NN O O
british NN O O
origin. NN O O
our NN O O
results NN O O
demonstrate NN O O
that NN O O
it NN O O
is NN O O
strongly NN O O
advisable, NN O O
for NN O O
laboratories NN O O
carrying NN O O
out NN O O
screening NN O O
either NN O O
in NN O O
english-speaking NN O O
countries NN O O
or NN O O
in NN O O
countries NN O O
with NN O O
historical NN O O
links NN O O
with NN O O
britain, NN O O
to NN O O
include NN O O
within NN O O
their NN O O
brca NN O O
1 NN O O
screening NN O O
protocols NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction-based NN O O
assay NN O O
described NN O O
in NN O O
this NN O O
report NN O O
. NN O O

germline NN O O
mutations NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
in NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families NN O O
provide NN O O
evidence NN O O
for NN O O
a NN O O
genotype-phenotype NN O O
correlation NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene, NN O O
discovered NN O O
in NN O O
1994, NN O O
are NN O O
associated NN O O
with NN O O
an NN O O
80-90% NN O O
lifetime NN O O
risk NN O O
of NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O
we NN O O
have NN O O
analysed NN O O
60 NN O O
families NN O O
with NN O O
a NN O O
history NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D061325
and/or NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
for NN O O
germline NN O O
mutations NN O O
in NN O O
brca NN O O
1. NN O O
twenty-two NN O O
different NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
32 NN O O
families NN O O
(53%), NN O O
of NN O O
which NN O O
14 NN O O
are NN O O
previously NN O O
unreported. NN O O
we NN O O
observed NN O O
a NN O O
significant NN O O
correlation NN O O
between NN O O
the NN O O
location NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
the NN O O
gene NN O O
and NN O O
the NN O O
ratio NN O O
of NN O O
breast NN B-Modifier B-MSH:D001943
to NN I-Modifier I-MSH:D001943
ovarian NN I-Modifier I-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
incidence NN O O
within NN O O
each NN O O
family. NN O O
our NN O O
data NN O O
suggest NN O O
a NN O O
transition NN O O
in NN O O
risk NN O O
such NN O O
that NN O O
mutations NN O O
in NN O O
the NN O O
3 NN O O
third NN O O
of NN O O
the NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
lower NN O O
proportion NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
haplotype NN O O
analysis NN O O
supports NN O O
previous NN O O
data NN O O
which NN O O
suggest NN O O
some NN O O
brca NN O O
1 NN O O
mutation NN O O
carriers NN O O
have NN O O
common NN O O
ancestors; NN O O
howeve NN O O
. NN O O

, NN O O
we NN O O
have NN O O
found NN O O
at NN O O
least NN O O
two NN O O
examples NN O O
where NN O O
recurrent NN O O
mutations NN O O
appear NN O O
to NN O O
have NN O O
arisen NN O O
independently. NN O O
. NN O O

inactivation NN O O
of NN O O
the NN O O
Friedreich NN B-Modifier B-MSH:D005621
ataxia NN I-Modifier I-MSH:D005621
mouse NN O O
gene NN O O
leads NN O O
to NN O O
early NN O O
embryonic NN B-SpecificDisease B-MSH:D020964
lethality NN I-SpecificDisease I-MSH:D020964
without NN O O
iron NN O O
accumulation NN O O
. NN O O

friedreich NN O O
ataxia NN O O
( NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
), NN O O
the NN O O
most NN O O
common NN O O
autosomal NN B-DiseaseClass B-MSH:D013132
recessive NN I-DiseaseClass I-MSH:D013132
ataxia NN I-DiseaseClass I-MSH:D013132
, NN O O
is NN O O
caused NN O O
in NN O O
almost NN O O
all NN O O
cases NN O O
by NN O O
homozygous NN O O
intronic NN O O
expansions NN O O
resulting NN O O
in NN O O
the NN O O
loss NN O O
of NN O O
frataxin, NN O O
a NN O O
mitochondrial NN O O
protein NN O O
conserved NN O O
through NN O O
evolution, NN O O
and NN O O
involved NN O O
in NN O O
mitochondrial NN O O
iron NN O O
homeostasis. NN O O
yeast NN O O
knockout NN O O
models, NN O O
and NN O O
histological NN O O
and NN O O
biochemical NN O O
data NN O O
from NN O O
patient NN O O
heart NN O O
biopsies NN O O
or NN O O
autopsies NN O O
indicate NN O O
that NN O O
the NN O O
frataxin NN O O
defect NN O O
causes NN O O
a NN O O
specific NN O O
iron-sulfur NN B-SpecificDisease B-OMIM:255125
protein NN I-SpecificDisease I-OMIM:255125
deficiency NN I-SpecificDisease I-OMIM:255125
and NN O O
mitochondrial NN O O
iron NN O O
accumulation NN O O
leading NN O O
to NN O O
the NN O O
pathological NN O O
changes. NN O O
affected NN O O
human NN O O
tissues NN O O
are NN O O
rarely NN O O
available NN O O
to NN O O
further NN O O
examine NN O O
this NN O O
hypothesis. NN O O
to NN O O
study NN O O
the NN O O
mechanism NN O O
of NN O O
the NN O O
disease, NN O O
we NN O O
generated NN O O
a NN O O
mouse NN O O
model NN O O
by NN O O
deletion NN O O
of NN O O
exon NN O O
4 NN O O
leading NN O O
to NN O O
inactivation NN O O
of NN O O
the NN O O
Frda NN B-Modifier B-MSH:D005621
gene NN O O
product. NN O O
we NN O O
show NN O O
that NN O O
homozygous NN O O
deletions NN O O
cause NN O O
embryonic NN B-SpecificDisease B-MSH:D020964
lethality NN I-SpecificDisease I-MSH:D020964
a NN O O
few NN O O
days NN O O
after NN O O
implantation, NN O O
demonstrating NN O O
an NN O O
important NN O O
role NN O O
fo NN O O
. NN O O

frataxin NN O O
during NN O O
early NN O O
development. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
milder NN O O
phenotype NN O O
in NN O O
humans NN O O
is NN O O
due NN O O
to NN O O
residual NN O O
frataxin NN O O
expression NN O O
associated NN O O
with NN O O
the NN O O
expansion NN O O
mutations. NN O O
surprisingly, NN O O
in NN O O
the NN O O
frataxin NN O O
knockout NN O O
mouse, NN O O
no NN O O
iron NN O O
accumulation NN O O
was NN O O
observed NN O O
during NN O O
embryonic NN O O
resorption, NN O O
suggesting NN O O
that NN O O
cell NN O O
death NN O O
could NN O O
be NN O O
due NN O O
to NN O O
a NN O O
mechanism NN O O
independent NN O O
of NN O O
iron NN O O
accumulation. NN O O
. NN O O

a NN O O
glycine NN O O
250--> NN O O
aspartate NN O O
substitution NN O O
in NN O O
the NN O O
alpha-subunit NN O O
of NN O O
hexosaminidase NN O O
a NN O O
causes NN O O
juvenile-onset NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
in NN O O
a NN O O
lebanese-canadian NN O O
family NN O O
. NN O O

the NN O O
mutation NN O O
causing NN O O
juvenile NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
) NN O O
in NN O O
two NN O O
sibs NN O O
of NN O O
lebanese-maronite NN O O
origin NN O O
is NN O O
described. NN O O
an NN O O
mrna-containing NN O O
extract NN O O
of NN O O
cultured NN O O
fibroblasts NN O O
obtained NN O O
from NN O O
one NN O O
of NN O O
the NN O O
probands NN O O
was NN O O
used NN O O
as NN O O
a NN O O
template NN O O
to NN O O
amplify NN O O
the NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
hexosaminidase NN O O
a NN O O
(hex NN O O
a) NN O O
alpha-subunit. NN O O
sequencing NN O O
of NN O O
amplified NN O O
cdna NN O O
fragments NN O O
revealed NN O O
a NN O O
single NN O O
alteration, NN O O
guanine NN O O
to NN O O
adenine NN O O
at NN O O
nt NN O O
749 NN O O
creating NN O O
a NN O O
g NN O O
250 NN O O
d NN O O
mutation. NN O O
the NN O O
mutation NN O O
introduces NN O O
a NN O O
new NN O O
recognition NN O O
site NN O O
for NN O O
the NN O O
restriction NN O O
enzyme NN O O
eco NN O O
rv, NN O O
permitting NN O O
identification NN O O
of NN O O
heterozygotes NN O O
for NN O O
this NN O O
allele NN O O
following NN O O
pcr NN O O
amplification NN O O
and NN O O
eco NN O O
rv NN O O
digestion NN O O
of NN O O
exon NN O O
7 NN O O
sequences NN O O
from NN O O
genomic NN O O
dna NN O O
templates. NN O O
in NN O O
order NN O O
to NN O O
test NN O O
the NN O O
effect NN O O
of NN O O
this NN O O
substitution, NN O O
an NN O O
in NN O O
vitro NN O O
mutagenized NN O O
cdna NN O O
construct NN O O
was NN O O
introduced NN O O
into NN O O
a NN O O
mammalian NN O O
expressio NN O O
. NN O O

vector NN O O
and NN O O
transfected NN O O
into NN O O
monkey NN O O
cos-1 NN O O
cells NN O O
separately NN O O
or NN O O
along NN O O
with NN O O
a NN O O
beta-cdna NN O O
expression NN O O
vector. NN O O
when NN O O
the NN O O
mutant NN O O
alpha-cdna NN O O
was NN O O
the NN O O
only NN O O
gene NN O O
introduced NN O O
into NN O O
cos NN O O
cells NN O O
no NN O O
enzymatic NN O O
activity NN O O
above NN O O
endogenous NN O O
cos NN O O
cell NN O O
activity NN O O
was NN O O
detected. NN O O
cotransfection NN O O
of NN O O
normal NN O O
alpha-cdna NN O O
and NN O O
beta-cdna NN O O
followed NN O O
by NN O O
immunoprecipitation NN O O
of NN O O
human NN O O
hex NN O O
a NN O O
resulted NN O O
in NN O O
20-fold NN O O
increase NN O O
in NN O O
the NN O O
ratio NN O O
between NN O O
positive NN O O
and NN O O
negative NN O O
(mock NN O O
transfection) NN O O
control NN O O
values. NN O O
this NN O O
allowed NN O O
the NN O O
detection NN O O
of NN O O
some NN O O
residual NN O O
activity NN O O
(12% NN O O
of NN O O
the NN O O
positive NN O O
control) NN O O
when NN O O
the NN O O
mutant NN O O
alpha-cdna NN O O
replaced NN O O
its NN O O
wild-type NN O O
counterpart. NN O O
the NN O O
predicted NN O O
protein NN O O
environment NN O O
in NN O O
which NN O O
the NN O O
mutation NN O O
occurs NN O O
is NN O O
compared NN O O
to NN O O
that NN O O
of NN O O
the NN O O
adult-onset NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
mutation NN O O
caused NN O O
by NN O O
a NN O O
gly NN O O
269 NN O O
. NN O O

- NN O O
> NN O O
ser NN O O
substitution NN O O
in NN O O
exon NN O O
7. NN O O
(abstract NN O O
truncated NN O O
at NN O O
250 NN O O
words) NN O O
. NN O O

restriction NN O O
of NN O O
ocular NN O O
fundus NN O O
lesions NN O O
to NN O O
a NN O O
specific NN O O
subgroup NN O O
of NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
in NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
patients NN O O
. NN O O

in NN O O
humans, NN O O
alteration NN O O
of NN O O
the NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
gene, NN O O
APC NN B-Modifier B-MSH:D011125
, NN O O
causes NN O O
adenomatous NN B-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
, NN O O
a NN O O
condition NN O O
causing NN O O
predisposition NN O O
to NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O
the NN O O
syndrome NN O O
inconsistently NN O O
associates NN O O
characteristic NN O O
patches NN O O
of NN O O
congenital NN B-SpecificDisease B-MSH:D012164
hypertrophy NN I-SpecificDisease I-MSH:D012164
of NN I-SpecificDisease I-MSH:D012164
the NN I-SpecificDisease I-MSH:D012164
retinal NN I-SpecificDisease I-MSH:D012164
pigment NN I-SpecificDisease I-MSH:D012164
epithelium NN I-SpecificDisease I-MSH:D012164
( NN O O
CHRPE NN B-SpecificDisease B-MSH:D012164
). NN O O
ocular NN O O
examination NN O O
revealed NN O O
that NN O O
patients NN O O
expressing NN O O
CHRPE NN B-SpecificDisease B-MSH:D012164
tend NN O O
to NN O O
cluster NN O O
within NN O O
specific NN O O
families. NN O O
the NN O O
exact NN O O
APC NN B-Modifier B-MSH:D011125
mutation NN O O
was NN O O
identified NN O O
in NN O O
42 NN O O
unrelated NN O O
patients. NN O O
in NN O O
all NN O O
cases NN O O
these NN O O
mutations NN O O
were NN O O
predicted NN O O
to NN O O
lead NN O O
to NN O O
the NN O O
synthesis NN O O
of NN O O
a NN O O
truncated NN O O
protein. NN O O
the NN O O
extent NN O O
of NN O O
CHRPE NN B-SpecificDisease B-MSH:D012164
was NN O O
found NN O O
to NN O O
be NN O O
dependent NN O O
on NN O O
the NN O O
position NN O O
of NN O O
the NN O O
mutation NN O O
along NN O O
the NN O O
coding NN O O
sequence. NN O O
CHRPE NN B-Modifier B-MSH:D012164
lesions NN O O
are NN O O
almost NN O O
always NN O O
absent NN O O
if NN O O
the NN O O
mutation NN O O
occurs NN O O
before NN O O
exon NN O O
9, NN O O
but NN O O
are NN O O
systematically NN O O
present NN O O
if NN O O
it NN O O
occurs NN O O
after NN O O
this NN O O
exon. NN O O
thus, NN O O
the NN O O
range NN O O
of NN O O
phenotypic NN O O
expression NN O O
observed NN O O
among NN O O
affecte NN O O
. NN O O

patients NN O O
may NN O O
result NN O O
in NN O O
part NN O O
from NN O O
different NN O O
allelic NN O O
manifestations NN O O
of NN O O
APC NN B-Modifier B-MSH:D011125
mutations. NN O O
. NN O O

linkage NN O O
analysis NN O O
of NN O O
26 NN O O
canadian NN O O
breast NN B-Modifier B-MSH:D001943
and NN I-Modifier I-MSH:D001943
breast-ovarian NN I-Modifier I-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
families NN O O
. NN O O

we NN O O
have NN O O
examined NN O O
26 NN O O
canadian NN O O
families NN O O
with NN O O
hereditary NN B-CompositeMention B-MSH:D061325
breast NN I-CompositeMention I-MSH:D061325
or NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
for NN O O
linkage NN O O
to NN O O
markers NN O O
flanking NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
on NN O O
chromosome NN O O
17 NN O O
q NN O O
12-q NN O O
21. NN O O
of NN O O
the NN O O
15 NN O O
families NN O O
that NN O O
contain NN O O
cases NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
, NN O O
94% NN O O
were NN O O
estimated NN O O
to NN O O
be NN O O
linked NN O O
to NN O O
brca NN O O
1. NN O O
in NN O O
contrast, NN O O
there NN O O
was NN O O
no NN O O
overall NN O O
evidence NN O O
of NN O O
linkage NN O O
in NN O O
the NN O O
group NN O O
of NN O O
10 NN O O
families NN O O
with NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
without NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
a NN O O
genetic NN O O
recombinant NN O O
in NN O O
a NN O O
breast-ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
family NN O O
indicates NN O O
a NN O O
placement NN O O
of NN O O
brca NN O O
1 NN O O
telomeric NN O O
to NN O O
d NN O O
17 NN O O
s NN O O
776, NN O O
and NN O O
helps NN O O
to NN O O
define NN O O
the NN O O
region NN O O
of NN O O
assignment NN O O
of NN O O
the NN O O
cancer NN B-Modifier B-MSH:D009369
susceptibility NN O O
gene. NN O O
other NN O O
cancers NN B-DiseaseClass B-MSH:D009369
of NN O O
interest NN O O
that NN O O
appeared NN O O
in NN O O
the NN O O
brca NN O O
1-linked NN O O
families NN O O
included NN O O
primary NN B-SpecificDisease B-MSH:D010534
peritoneal NN I-SpecificDisease I-MSH:D010534
cancer NN I-SpecificDisease I-MSH:D010534
, NN O O
cancer NN B-SpecificDisease B-MSH:D005185
of NN I-SpecificDisease I-MSH:D005185
the NN I-SpecificDisease I-MSH:D005185
fallopian NN I-SpecificDisease I-MSH:D005185
tube NN I-SpecificDisease I-MSH:D005185
, NN O O
and NN O O
malignant NN B-SpecificDisease B-MSH:D008545
melanoma NN I-SpecificDisease I-MSH:D008545
. NN O O

. NN O O

malignant NN O O
neoplasms NN O O
in NN O O
the NN O O
families NN O O
of NN O O
patients NN O O
with NN O O
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
. NN O O

ataxia-telangiectasia NN O O
( NN O O
A-T NN B-SpecificDisease B-MSH:D001260
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
syndrome NN I-DiseaseClass I-MSH:D030342
associated NN O O
with NN O O
a NN O O
greatly NN O O
increased NN O O
incidence NN O O
of NN O O
malignant NN B-DiseaseClass B-MSH:D009369
neoplasms NN I-DiseaseClass I-MSH:D009369
in NN O O
homozygous NN O O
affected NN O O
individuals. NN O O
heterozygotes NN O O
for NN O O
the NN O O
gene NN O O
for NN O O
A-T NN B-SpecificDisease B-MSH:D001260
are NN O O
thought NN O O
to NN O O
comprise NN O O
about NN O O
1% NN O O
of NN O O
the NN O O
general NN O O
population NN O O
and, NN O O
therefore, NN O O
it NN O O
is NN O O
important NN O O
to NN O O
know NN O O
whether NN O O
this NN O O
gene NN O O
also NN O O
predisposes NN O O
the NN O O
heterozygous NN O O
carrier NN O O
to NN O O
cancers NN B-DiseaseClass B-MSH:D009369
. NN O O
heterozygous NN O O
carriers NN O O
of NN O O
this NN O O
gene NN O O
are NN O O
common NN O O
among NN O O
the NN O O
close NN O O
relatives NN O O
of NN O O
patients NN O O
with NN O O
A-T NN B-SpecificDisease B-MSH:D001260
, NN O O
although NN O O
individual NN O O
carriers NN O O
cannot NN O O
be NN O O
identified NN O O
by NN O O
any NN O O
clinical NN O O
criterion NN O O
or NN O O
laboratory NN O O
test. NN O O
for NN O O
this NN O O
reason, NN O O
we NN O O
compared NN O O
the NN O O
incidence NN O O
of NN O O
death NN O O
from NN O O
malignant NN B-DiseaseClass B-MSH:D009369
neoplasms NN I-DiseaseClass I-MSH:D009369
in NN O O
2 NN O O
families NN O O
of NN O O
patients NN O O
with NN O O
A-T NN B-SpecificDisease B-MSH:D001260
to NN O O
that NN O O
expected NN O O
in NN O O
a NN O O
random NN O O
sample NN O O
of NN O O
the NN O O
general NN O O
population. NN O O
there NN O O
were NN O O
59 NN O O
deaths NN O O
from NN O O
malignant NN B-DiseaseClass B-MSH:D009369
neoplasms NN I-DiseaseClass I-MSH:D009369
i NN O O
. NN O O

relatives NN O O
dying NN O O
before NN O O
age NN O O
75, NN O O
compared NN O O
to NN O O
42. NN O O
6 NN O O
expected NN O O
(p NN O O
less NN O O
than NN O O
0. NN O O
02). NN O O
for NN O O
A-T NN B-Modifier B-MSH:D001260
heterozygotes NN O O
younger NN O O
than NN O O
age NN O O
45, NN O O
the NN O O
risk NN O O
of NN O O
dying NN O O
from NN O O
a NN O O
malignant NN B-DiseaseClass B-MSH:D009369
neoplasm NN I-DiseaseClass I-MSH:D009369
was NN O O
estimated NN O O
to NN O O
be NN O O
greater NN O O
than NN O O
5 NN O O
times NN O O
the NN O O
risk NN O O
for NN O O
the NN O O
general NN O O
population. NN O O
A-T NN B-Modifier B-MSH:D001260
heterozygotes NN O O
may NN O O
comprise NN O O
more NN O O
than NN O O
5% NN O O
of NN O O
all NN O O
persons NN O O
dying NN O O
from NN O O
a NN O O
cancer NN B-DiseaseClass B-MSH:D009369
before NN O O
age NN O O
45. NN O O
the NN O O
incidence NN O O
of NN O O
ovarian, NN B-CompositeMention B-MSH:D010051
gastric, NN I-CompositeMention I-MSH:D010051
and NN I-CompositeMention I-MSH:D010051
biliary NN I-CompositeMention I-MSH:D010051
system NN I-CompositeMention I-MSH:D010051
carcinomas NN I-CompositeMention I-MSH:D010051
and NN O O
of NN O O
leukemia NN B-DiseaseClass B-MSH:D007938
and NN O O
lymphoma NN B-DiseaseClass B-MSH:D008223
was NN O O
increased NN O O
in NN O O
these NN O O
A-T NN B-Modifier B-MSH:D001260
families. NN O O
other NN O O
neoplasms NN B-DiseaseClass B-MSH:D009369
that NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
this NN O O
gene NN O O
in NN O O
heterozygotes NN O O
include NN O O
pancreatic, NN B-CompositeMention B-MSH:D010190
basal NN I-CompositeMention I-MSH:D010190
cell, NN I-CompositeMention I-MSH:D010190
colonic, NN I-CompositeMention I-MSH:D010190
breast, NN I-CompositeMention I-MSH:D010190
and NN I-CompositeMention I-MSH:D010190
cervical NN I-CompositeMention I-MSH:D010190
carcinomas NN I-CompositeMention I-MSH:D010190
. NN O O

molecular NN O O
genetics NN O O
of NN O O
PKU NN B-SpecificDisease B-MSH:D010661
in NN O O
eastern NN O O
europe: NN O O
a NN O O
nonsense NN O O
mutation NN O O
associated NN O O
with NN O O
haplotype NN O O
4 NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
a NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
secondary NN O O
to NN O O
a NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah). NN O O
several NN O O
mutations NN O O
in NN O O
the NN O O
pah NN O O
gene NN O O
have NN O O
recently NN O O
been NN O O
reported, NN O O
and NN O O
linkage NN O O
disequilibrium NN O O
was NN O O
observed NN O O
between NN O O
rflp NN O O
haplotypes NN O O
and NN O O
specific NN O O
mutations. NN O O
a NN O O
new NN O O
molecular NN B-DiseaseClass B-MSH:D030342
lesion NN I-DiseaseClass I-MSH:D030342
has NN O O
been NN O O
identified NN O O
in NN O O
exon NN O O
7 NN O O
of NN O O
the NN O O
pah NN O O
gene NN O O
in NN O O
a NN O O
hungarian NN O O
PKU NN B-Modifier B-MSH:D010661
patient NN O O
by NN O O
direct NN O O
sequencing NN O O
of NN O O
pcr-amplified NN O O
dna. NN O O
the NN O O
c-to-t NN O O
transition NN O O
causes NN O O
the NN O O
substitution NN O O
of NN O O
arg NN O O
243 NN O O
to NN O O
a NN O O
termination NN O O
codon, NN O O
and NN O O
the NN O O
mutant NN O O
allele NN O O
is NN O O
associated NN O O
with NN O O
haplotype NN O O
4 NN O O
of NN O O
the NN O O
pah NN O O
gene. NN O O
the NN O O
mutation NN O O
is NN O O
present NN O O
in NN O O
two NN O O
of NN O O
nine NN O O
mutant NN O O
haplotype NN O O
4 NN O O
alleles NN O O
among NN O O
eastern NN O O
europeans NN O O
and NN O O
is NN O O
not NN O O
present NN O O
among NN O O
western NN O O
europeans NN O O
and NN O O
asians. NN O O
the NN O O
rarity NN O O
of NN O O
this NN O O
mutant NN O O
allele NN O O
and NN O O
its NN O O
restricted NN O O
geographic NN O O
distribution NN O O
sugges NN O O
. NN O O

that NN O O
the NN O O
mutational NN O O
event NN O O
occurred NN O O
recently NN O O
on NN O O
a NN O O
normal NN O O
haplotype NN O O
4 NN O O
background NN O O
in NN O O
eastern NN O O
europe. NN O O
. NN O O

isolation NN O O
of NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
brca NN O O
1 NN O O
and NN O O
genetic NN O O
mapping NN O O
to NN O O
mouse NN O O
chromosome NN O O
11 NN O O
. NN O O

the NN O O
brca NN O O
1 NN O O
gene NN O O
is NN O O
in NN O O
large NN O O
part NN O O
responsible NN O O
for NN O O
hereditary NN B-CompositeMention B-MSH:D061325
human NN I-CompositeMention I-MSH:D061325
breast NN I-CompositeMention I-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
. NN O O
here NN O O
we NN O O
report NN O O
the NN O O
isolation NN O O
of NN O O
the NN O O
murine NN O O
brca NN O O
1 NN O O
homologue NN O O
cdna NN O O
clones. NN O O
in NN O O
addition, NN O O
we NN O O
identified NN O O
genomic NN O O
p NN O O
1 NN O O
clones NN O O
that NN O O
contain NN O O
most, NN O O
if NN O O
not NN O O
all, NN O O
of NN O O
the NN O O
mouse NN O O
brca NN O O
1 NN O O
locus. NN O O
dna NN O O
sequence NN O O
analysis NN O O
revealed NN O O
that NN O O
the NN O O
mouse NN O O
and NN O O
human NN O O
coding NN O O
regions NN O O
are NN O O
75% NN O O
identical NN O O
at NN O O
the NN O O
nucleotide NN O O
level NN O O
while NN O O
the NN O O
predicted NN O O
amino NN O O
acid NN O O
identity NN O O
is NN O O
only NN O O
58%. NN O O
a NN O O
dna NN O O
sequence NN O O
variant NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
locus NN O O
was NN O O
identified NN O O
and NN O O
used NN O O
to NN O O
map NN O O
this NN O O
gene NN O O
on NN O O
a NN O O
(mus NN O O
m. NN O O
musculus NN O O
czech NN O O
ii NN O O
x NN O O
c NN O O
57 NN O O
bl/ksj) NN O O
f NN O O
1 NN O O
x NN O O
c NN O O
57 NN O O
bl/ksj NN O O
intersubspecific NN O O
backcross NN O O
to NN O O
distal NN O O
mouse NN O O
chromosome NN O O
11. NN O O
the NN O O
mapping NN O O
of NN O O
this NN O O
gene NN O O
t NN O O
. NN O O

a NN O O
region NN O O
highly NN O O
syntenic NN O O
with NN O O
human NN O O
chromosome NN O O
17, NN O O
coupled NN O O
with NN O O
southern NN O O
and NN O O
northern NN O O
analyses, NN O O
confirms NN O O
that NN O O
we NN O O
isolated NN O O
the NN O O
murine NN O O
brca NN O O
1 NN O O
homologue NN O O
rather NN O O
than NN O O
a NN O O
related NN O O
ring NN O O
finger NN O O
gene. NN O O
the NN O O
isolation NN O O
of NN O O
the NN O O
mouse NN O O
brca NN O O
1 NN O O
homologue NN O O
will NN O O
facilitate NN O O
the NN O O
creation NN O O
of NN O O
mouse NN O O
models NN O O
for NN O O
germline NN O O
BRCA1 NN B-SpecificDisease B-OMIM:604370
defects NN I-SpecificDisease I-OMIM:604370
. NN O O
. NN O O

human NN O O
deficiency NN B-SpecificDisease B-OMIM:612446
of NN I-SpecificDisease I-OMIM:612446
the NN I-SpecificDisease I-OMIM:612446
sixth NN I-SpecificDisease I-OMIM:612446
component NN I-SpecificDisease I-OMIM:612446
of NN I-SpecificDisease I-OMIM:612446
complement NN I-SpecificDisease I-OMIM:612446
in NN O O
a NN O O
patient NN O O
with NN O O
meningococcal NN B-SpecificDisease B-MSH:D008585
meningitis NN I-SpecificDisease I-MSH:D008585
and NN O O
no NN O O
haemostasis NN B-DiseaseClass B-MSH:D020141
abnormality NN I-DiseaseClass I-MSH:D020141
. NN O O

a NN O O
case NN O O
of NN O O
human NN O O
complete NN O O
C6 NN B-SpecificDisease B-OMIM:612446
deficiency NN I-SpecificDisease I-OMIM:612446
is NN O O
reported. NN O O
the NN O O
patient, NN O O
a NN O O
31 NN O O
year NN O O
old NN O O
white NN O O
male, NN O O
was NN O O
seen NN O O
on NN O O
the NN O O
occasion NN O O
of NN O O
an NN O O
isolated NN O O
episode NN O O
of NN O O
meningococcal NN B-SpecificDisease B-MSH:D008585
meningitis NN I-SpecificDisease I-MSH:D008585
. NN O O
serum NN O O
complement NN O O
hemolytic NN O O
and NN O O
bactericidal NN O O
activities NN O O
were NN O O
lacking NN O O
and NN O O
could NN O O
be NN O O
restored NN O O
to NN O O
normal NN O O
by NN O O
addition NN O O
of NN O O
appropriate NN O O
amounts NN O O
of NN O O
purified NN O O
c NN O O
6. NN O O
no NN O O
hemostatic NN B-DiseaseClass B-MSH:D020141
abnormalities NN I-DiseaseClass I-MSH:D020141
were NN O O
observed. NN O O
. NN O O

the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
: NN O O
refinement NN O O
of NN O O
the NN O O
localization NN O O
on NN O O
xp NN O O
and NN O O
identification NN O O
of NN O O
another NN O O
closely NN O O
linked NN O O
marker NN O O
locus, NN O O
oatl NN O O
1 NN O O
. NN O O

the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
) NN O O
has NN O O
previously NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
proximal NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome NN O O
between NN O O
the NN O O
dxs NN O O
14 NN O O
and NN O O
dxs NN O O
7 NN O O
loci. NN O O
in NN O O
this NN O O
study, NN O O
further NN O O
segregation NN O O
analysis NN O O
has NN O O
been NN O O
performed NN O O
using NN O O
a NN O O
newly NN O O
identified NN O O
WAS NN B-Modifier B-MSH:D014923
family NN O O
as NN O O
well NN O O
as NN O O
an NN O O
additional NN O O
marker NN O O
probe, NN O O
hoatl NN O O
1. NN O O
the NN O O
results NN O O
indicate NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
WAS NN B-SpecificDisease B-MSH:D014923
and NN O O
oatl NN O O
1 NN O O
loci NN O O
(z NN O O
= NN O O
6. NN O O
08 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
00) NN O O
and NN O O
localize NN O O
the NN O O
timp, NN O O
oatl NN O O
1, NN O O
dxs NN O O
255, NN O O
and NN O O
WAS NN B-Modifier B-MSH:D014923
loci NN O O
distal NN O O
to NN O O
dxs NN O O
146 NN O O
and NN O O
the NN O O
oatl NN O O
1 NN O O
and NN O O
WAS NN B-Modifier B-MSH:D014923
loci NN O O
proximal NN O O
to NN O O
timp. NN O O
these NN O O
linkage NN O O
data NN O O
narrow NN O O
the NN O O
boundaries NN O O
within NN O O
which NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
locus NN O O
maps NN O O
to NN O O
the NN O O
chromosomal NN O O
region NN O O
bracketed NN O O
by NN O O
timp NN O O
and NN O O
dxs NN O O
146 NN O O
and NN O O
support NN O O
the NN O O
loci NN O O
order NN O O
xpter NN O O
. NN O O

dxs NN O O
7-timp- NN O O
(oatl NN O O
1, NN O O
was, NN O O
dxs NN O O
255) NN O O
-dxs NN O O
146 NN O O
. NN O O

hereditary NN O O
deficiency NN O O
of NN O O
the NN O O
third NN O O
component NN O O
of NN O O
complement NN O O
in NN O O
a NN O O
child NN O O
with NN O O
fever NN B-DiseaseClass B-MSH:D005334
, NN O O
skin NN B-DiseaseClass B-MSH:D005076
rash NN I-DiseaseClass I-MSH:D005076
, NN O O
and NN O O
arthralgias NN B-DiseaseClass B-MSH:D018771
: NN O O
response NN O O
to NN O O
transfusion NN O O
of NN O O
whole NN O O
blood NN O O
. NN O O

a NN O O
previously NN O O
well NN O O
34-month-old NN O O
male NN O O
presenting NN O O
with NN O O
fever NN B-DiseaseClass B-MSH:D005334
, NN O O
skin NN B-DiseaseClass B-MSH:D005076
rash NN I-DiseaseClass I-MSH:D005076
, NN O O
and NN O O
arthralgias NN B-DiseaseClass B-MSH:D018771
was NN O O
found NN O O
to NN O O
lack NN O O
c NN O O
3 NN O O
by NN O O
immunochemical NN O O
(undetectable) NN O O
and NN O O
hemolytic NN O O
(1% NN O O
normal) NN O O
assays. NN O O
no NN O O
infectious NN O O
agent NN O O
could NN O O
be NN O O
demonstrated. NN O O
protein NN O O
levels NN O O
of NN O O
clq. NN O O
c NN O O
4, NN O O
c NN O O
5, NN O O
properdin, NN O O
and NN O O
c NN O O
3 NN O O
b-ina NN O O
and NN O O
hemolytic NN O O
activities NN O O
of NN O O
complement NN O O
components NN O O
c NN O O
1 NN O O
to NN O O
c NN O O
9 NN O O
except NN O O
c NN O O
3 NN O O
were NN O O
normal NN O O
or NN O O
elevated; NN O O
total NN O O
hemolytic NN O O
complement NN O O
activity NN O O
was NN O O
13% NN O O
of NN O O
normal NN O O
and NN O O
was NN O O
reconstituted NN O O
by NN O O
purified NN O O
c NN O O
3. NN O O
properdin NN O O
factor NN O O
b NN O O
was NN O O
702 NN O O
(normal NN O O
175 NN O O
to NN O O
275) NN O O
mug/ml, NN O O
and NN O O
was NN O O
not NN O O
cleaver NN O O
upon NN O O
addition NN O O
of NN O O
zymosan NN O O
or NN O O
cobra NN O O
venom NN O O
factor. NN O O
the NN O O
serum NN O O
had NN O O
normal NN O O
immune NN O O
adherence NN O O
activity, NN O O
but NN O O
was NN O O
deficient NN O O
i NN O O
. NN O O

ability NN O O
to NN O O
opsonize NN O O
candida NN O O
albicans NN O O
for NN O O
uptake NN O O
and NN O O
escherichia NN O O
coli NN O O
for NN O O
killing NN O O
by NN O O
neurophils, NN O O
generate NN O O
neutrophil NN O O
chemotactic NN O O
factors NN O O
and NN O O
inhibit NN O O
the NN O O
growth NN O O
of NN O O
e. NN O O
coli; NN O O
these NN O O
activities NN O O
were NN O O
restored NN O O
by NN O O
purified NN O O
c NN O O
3. NN O O
a NN O O
transfusion NN O O
of NN O O
320 NN O O
ml NN O O
1-hour-old NN O O
normal NN O O
whole NN O O
blood NN O O
on NN O O
the NN O O
fifty-second NN O O
day NN O O
resulted NN O O
in NN O O
transitory NN O O
elevation NN O O
of NN O O
the NN O O
c NN O O
3 NN O O
level NN O O
to NN O O
25 NN O O
mg/dl NN O O
with NN O O
a NN O O
fall-off NN O O
(approximately NN O O
2 NN O O
1/2% NN O O
per NN O O
hour) NN O O
to NN O O
undetectable NN O O
levels NN O O
by NN O O
69 NN O O
hours; NN O O
it NN O O
was NN O O
followed NN O O
by NN O O
disappearance NN O O
of NN O O
the NN O O
skin NN B-DiseaseClass B-MSH:D005076
rash NN I-DiseaseClass I-MSH:D005076
and NN O O
arthralgias NN B-DiseaseClass B-MSH:D018771
and NN O O
return NN O O
to NN O O
normal NN O O
of NN O O
the NN O O
previously NN O O
elevated NN O O
temperature NN O O
and NN O O
crp NN O O
levels. NN O O
c NN O O
3 NN O O
levels NN O O
in NN O O
family NN O O
members NN O O
(seven NN O O
of NN O O
24 NN O O
half-normal), NN O O
lack NN O O
of NN O O
anti-c NN O O
3 NN O O
activity, NN O O
norma NN O O
. NN O O

c NN O O
3 NN O O
b-ina NN O O
levels NN O O
and NN O O
a NN O O
normal NN O O
rate NN O O
of NN O O
catabolism NN O O
of NN O O
transfused NN O O
c NN O O
3 NN O O
indicated NN O O
that NN O O
the NN O O
deficiency NN O O
was NN O O
inherited NN O O
with NN O O
autosomal NN O O
codominance NN O O
and NN O O
involved NN O O
decreased NN B-DiseaseClass B-OMIM:613779
synthesis NN I-DiseaseClass I-OMIM:613779
of NN I-DiseaseClass I-OMIM:613779
C3 NN I-DiseaseClass I-OMIM:613779
. NN O O
thus, NN O O
this NN O O
child NN O O
is NN O O
a NN O O
unique NN O O
individual NN O O
with NN O O
inherited NN B-SpecificDisease B-OMIM:613779
C3 NN I-SpecificDisease I-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
presenting NN O O
with NN O O
absence NN O O
of NN O O
repeated NN O O
infections, NN O O
whose NN O O
symptoms NN O O
of NN O O
fever NN B-DiseaseClass B-MSH:D005334
, NN O O
skin NN B-DiseaseClass B-MSH:D005076
rash NN I-DiseaseClass I-MSH:D005076
, NN O O
and NN O O
arthralgia NN B-DiseaseClass B-MSH:D018771
were NN O O
abated NN O O
by NN O O
whole NN O O
blood NN O O
transfusion. NN O O
. NN O O

cloning NN O O
of NN O O
breakpoints NN O O
of NN O O
a NN O O
chromosome NN O O
translocation NN O O
identifies NN O O
the NN O O
an NN O O
2 NN O O
locus NN O O
. NN O O

chromosome NN O O
translocations NN O O
involving NN O O
11 NN O O
p NN O O
13 NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D015783
aniridia NN I-SpecificDisease I-MSH:D015783
in NN O O
two NN O O
kindreds NN O O
highlighting NN O O
the NN O O
chromosomal NN O O
localization NN O O
of NN O O
the NN O O
an NN O O
2 NN O O
locus. NN O O
this NN O O
locus NN O O
is NN O O
also NN O O
part NN O O
of NN O O
the NN O O
WAGR NN B-Modifier B-MSH:D017624
complex NN O O
( NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
, NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
genitourinary NN B-DiseaseClass B-MSH:D014564
abnormalities NN I-DiseaseClass I-MSH:D014564
, NN O O
and NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
). NN O O
in NN O O
one NN O O
kindred, NN O O
the NN O O
translocation NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
deletion, NN O O
and NN O O
probes NN O O
for NN O O
this NN O O
region NN O O
were NN O O
used NN O O
to NN O O
identify NN O O
and NN O O
clone NN O O
the NN O O
breakpoints NN O O
of NN O O
the NN O O
translocation NN O O
in NN O O
the NN O O
second NN O O
kindred. NN O O
comparison NN O O
of NN O O
phage NN O O
restriction NN O O
maps NN O O
exclude NN O O
the NN O O
presence NN O O
of NN O O
any NN O O
sizable NN O O
deletion NN O O
in NN O O
this NN O O
case. NN O O
sequences NN O O
at NN O O
the NN O O
chromosome NN O O
11 NN O O
breakpoint NN O O
are NN O O
conserved NN O O
in NN O O
multiple NN O O
species, NN O O
suggesting NN O O
that NN O O
the NN O O
translocation NN O O
falls NN O O
within NN O O
the NN O O
an NN O O
2 NN O O
gene. NN O O
. NN O O

study NN O O
of NN O O
the NN O O
voltage-gated NN O O
sodium NN O O
channel NN O O
beta NN O O
1 NN O O
subunit NN O O
gene NN O O
(scn NN O O
1 NN O O
b) NN O O
in NN O O
the NN O O
benign NN B-SpecificDisease B-MSH:D020936
familial NN I-SpecificDisease I-MSH:D020936
infantile NN I-SpecificDisease I-MSH:D020936
convulsions NN I-SpecificDisease I-MSH:D020936
syndrome NN I-SpecificDisease I-MSH:D020936
( NN O O
BFIC NN B-SpecificDisease B-MSH:D020936
) NN O O
. NN O O

benign NN O O
familial NN O O
infantile NN O O
convulsions NN O O
( NN O O
BFIC NN B-SpecificDisease B-MSH:D020936
) NN O O
is NN O O
a NN O O
rare NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
epilepsy NN I-DiseaseClass I-MSH:D030342
syndrome NN I-DiseaseClass I-MSH:D030342
. NN O O
this NN O O
syndrome NN O O
has NN O O
been NN O O
recently NN O O
described NN O O
in NN O O
italian NN O O
and NN O O
french NN O O
pedigrees. NN O O
patients NN O O
present NN O O
with NN O O
partial, NN O O
then NN O O
generalized NN O O
seizures, NN O O
with NN O O
onset NN O O
at NN O O
age NN O O
three NN O O
months. NN O O
the NN O O
seizures NN O O
usually NN O O
spontaneously NN O O
cease NN O O
after NN O O
one NN O O
year NN O O
without NN O O
treatment, NN O O
leaving NN O O
no NN O O
neurological NN B-DiseaseClass B-MSH:D009461
abnormalities NN I-DiseaseClass I-MSH:D009461
. NN O O
we NN O O
have NN O O
mapped NN O O
BFIC NN B-SpecificDisease B-MSH:D020936
to NN O O
chromosome NN O O
19 NN O O
q NN O O
in NN O O
five NN O O
italian NN O O
pedigrees. NN O O
the NN O O
sodium NN O O
channel NN O O
beta NN O O
1 NN O O
subunit NN O O
gene NN O O
(scn NN O O
1 NN O O
b) NN O O
maps NN O O
to NN O O
this NN O O
candidate NN O O
region NN O O
and NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
involved NN O O
in NN O O
one NN O O
australian NN O O
pedigree NN O O
with NN O O
generalized NN B-SpecificDisease B-MSH:D004829
epilepsy NN I-SpecificDisease I-MSH:D004829
and NN I-SpecificDisease I-MSH:D004829
febrile NN I-SpecificDisease I-MSH:D004829
seizures NN I-SpecificDisease I-MSH:D004829
" NN I-SpecificDisease I-MSH:D004829
plus NN I-SpecificDisease I-MSH:D004829
" NN I-SpecificDisease I-MSH:D004829
(gefs NN O O
+). NN O O
in NN O O
this NN O O
family, NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
scn NN O O
1 NN O O
b NN O O
cosegregates NN O O
with NN O O
the NN O O
gefs NN O O
+ NN O O
phenotype. NN O O
BFIC NN B-SpecificDisease B-MSH:D020936
and NN O O
gefs NN O O
+ NN O O
have NN O O
clinical NN O O
features NN O O
i NN O O
. NN O O

common, NN O O
therefore NN O O
scn NN O O
1 NN O O
b NN O O
is NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
BFIC NN B-SpecificDisease B-MSH:D020936
. NN O O
we NN O O
studied NN O O
scn NN O O
1 NN O O
b NN O O
exons NN O O
1, NN O O
2, NN O O
3, NN O O
4, NN O O
and NN O O
5, NN O O
using NN O O
four NN O O
sscp NN O O
methods NN O O
in NN O O
10 NN O O
caucasian NN O O
BFIC NN B-Modifier B-MSH:D020936
probands NN O O
of NN O O
western NN O O
europe. NN O O
we NN O O
found NN O O
no NN O O
exon NN O O
variants. NN O O
one NN O O
variant NN O O
was NN O O
identified NN O O
in NN O O
intron NN O O
5 NN O O
(ivs NN O O
5-10 NN O O
c NN O O
> NN O O
g), NN O O
which NN O O
did NN O O
not NN O O
segregate NN O O
with NN O O
BFIC NN B-SpecificDisease B-MSH:D020936
and NN O O
was NN O O
observed NN O O
in NN O O
9. NN O O
2% NN O O
controls. NN O O
a NN O O
second NN O O
variant NN O O
in NN O O
intron NN O O
5 NN O O
was NN O O
identified NN O O
(ivs NN O O
5 NN O O
+ NN O O
30 NN O O
g NN O O
> NN O O
a). NN O O
it NN O O
was NN O O
rare, NN O O
as NN O O
not NN O O
observed NN O O
in NN O O
controls, NN O O
but NN O O
not NN O O
segregating NN O O
with NN O O
the NN O O
BFIC NN B-Modifier B-MSH:D020936
phenotype NN O O
. NN O O

brain NN O O
disease NN O O
and NN O O
molecular NN O O
analysis NN O O
in NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
. NN O O

abnormal NN O O
amplification NN O O
of NN O O
a NN O O
ctg NN O O
repeat NN O O
on NN O O
chromosome NN O O
19 NN O O
is NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
). NN O O
expansion NN O O
of NN O O
the NN O O
repeat NN O O
has NN O O
been NN O O
correlated NN O O
with NN O O
severity NN O O
of NN O O
several NN O O
clinical NN O O
features NN O O
of NN O O
the NN O O
disease. NN O O
we NN O O
performed NN O O
extensive NN O O
cognitive NN O O
testing, NN O O
cerebral NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
(mri) NN O O
and NN O O
a NN O O
molecular NN O O
analysis NN O O
in NN O O
28 NN O O
cases NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
to NN O O
determine NN O O
the NN O O
relationship NN O O
between NN O O
the NN O O
molecular NN O O
defect NN O O
and NN O O
brain NN B-DiseaseClass B-MSH:D001927
disease NN I-DiseaseClass I-MSH:D001927
. NN O O
performance NN O O
in NN O O
two NN O O
or NN O O
more NN O O
cognitive NN O O
tests NN O O
was NN O O
pathological NN O O
in NN O O
10 NN O O
cases. NN O O
fourteen NN O O
patients NN O O
had NN O O
subcortical NN O O
white NN B-DiseaseClass B-MSH:D056784
matter NN I-DiseaseClass I-MSH:D056784
lesions NN I-DiseaseClass I-MSH:D056784
on NN O O
mri, NN O O
14 NN O O
had NN O O
cerebral NN B-SpecificDisease B-MSH:D001284
atrophy NN I-SpecificDisease I-MSH:D001284
. NN O O
amplification NN O O
of NN O O
the NN O O
ctg NN O O
repeat NN O O
showed NN O O
a NN O O
strong NN O O
correlation NN O O
with NN O O
cognitive NN O O
test NN O O
deficits NN O O
when NN O O
exceeding NN O O
a NN O O
length NN O O
of NN O O
over NN O O
1000 NN O O
trinucleotides. NN O O
mri NN O O
lesions NN O O
were NN O O
associated NN O O
with NN O O
impaired NN O O
psychometric NN O O
performance, NN O O
but NN O O
mri NN O O
and NN O O
molecular NN O O
findings NN O O
were NN O O
only NN O O
weakly NN O O
related NN O O
. NN O O

disease NN O O
duration NN O O
influenced NN O O
the NN O O
appearance NN O O
and NN O O
amount NN O O
of NN O O
white NN B-DiseaseClass B-MSH:D056784
matter NN I-DiseaseClass I-MSH:D056784
lesions NN I-DiseaseClass I-MSH:D056784
on NN O O
mri. NN O O
quantification NN O O
of NN O O
ctg NN O O
repeat NN O O
size NN O O
may NN O O
allow NN O O
an NN O O
early NN O O
estimate NN O O
on NN O O
the NN O O
probability NN O O
of NN O O
brain NN O O
involvement NN O O
in NN O O
DM NN B-SpecificDisease B-MSH:D009223
; NN O O
cognitive NN B-DiseaseClass B-MSH:D003072
dysfunction NN I-DiseaseClass I-MSH:D003072
is NN O O
associated NN O O
with NN O O
white NN B-DiseaseClass B-MSH:D056784
matter NN I-DiseaseClass I-MSH:D056784
lesions NN I-DiseaseClass I-MSH:D056784
and NN O O
cerebral NN B-SpecificDisease B-MSH:D001284
atrophy NN I-SpecificDisease I-MSH:D001284
later NN O O
on NN O O
in NN O O
the NN O O
course. NN O O
. NN O O

a NN O O
highly NN O O
accurate, NN O O
low NN O O
cost NN O O
test NN O O
for NN O O
brca NN O O
1 NN O O
mutations NN O O
. NN O O

the NN O O
hereditary NN B-CompositeMention B-MSH:D061325
breast NN I-CompositeMention I-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
syndrome NN I-CompositeMention I-MSH:D061325
is NN O O
associated NN O O
with NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
brca NN O O
1 NN O O
mutations. NN O O
however, NN O O
the NN O O
widespread NN O O
use NN O O
of NN O O
brca NN O O
1 NN O O
testing NN O O
has NN O O
been NN O O
limited NN O O
to NN O O
date NN O O
by NN O O
three NN O O
principal NN O O
concerns NN O O
the NN O O
fear NN O O
of NN O O
loss NN O O
of NN O O
health NN O O
and NN O O
life NN O O
insurance, NN O O
the NN O O
uncertain NN O O
clinical NN O O
value NN O O
of NN O O
a NN O O
positive NN O O
test NN O O
result, NN O O
and NN O O
the NN O O
current NN O O
lack NN O O
of NN O O
an NN O O
inexpensive NN O O
and NN O O
sensitive NN O O
screening NN O O
test NN O O
for NN O O
brca NN O O
1 NN O O
mutations. NN O O
we NN O O
have NN O O
developed NN O O
an NN O O
inexpensive NN O O
system NN O O
for NN O O
gene NN O O
mutational NN O O
scanning, NN O O
based NN O O
on NN O O
a NN O O
combination NN O O
of NN O O
extensive NN O O
multiplex NN O O
pcr NN O O
amplification NN O O
and NN O O
two NN O O
dimensional NN O O
electrophoresis. NN O O
the NN O O
efficiency NN O O
of NN O O
this NN O O
system, NN O O
as NN O O
a NN O O
screening NN O O
test NN O O
for NN O O
brca NN O O
1 NN O O
mutations, NN O O
was NN O O
evaluated NN O O
in NN O O
a NN O O
panel NN O O
of NN O O
60 NN O O
samples NN O O
from NN O O
high NN O O
risk NN O O
women, NN O O
14 NN O O
of NN O O
which NN O O
contained NN O O
a NN O O
previously NN O O
identified NN O O
mutation NN O O
in NN O O
brca NN O O
1. NN O O
all NN O O
14 NN O O
mutation NN O O
. NN O O

were NN O O
identified, NN O O
as NN O O
well NN O O
as NN O O
an NN O O
additional NN O O
five NN O O
that NN O O
had NN O O
previously NN O O
escaped NN O O
detection. NN O O
in NN O O
addition NN O O
to NN O O
the NN O O
19 NN O O
mutations, NN O O
a NN O O
total NN O O
of NN O O
15 NN O O
different NN O O
polymorphic NN O O
variants NN O O
were NN O O
scored, NN O O
most NN O O
of NN O O
which NN O O
were NN O O
recurring. NN O O
all NN O O
were NN O O
confirmed NN O O
by NN O O
nucleotide NN O O
sequencing. NN O O
the NN O O
cost NN O O
of NN O O
screening NN O O
per NN O O
sample NN O O
was NN O O
calculated NN O O
to NN O O
be NN O O
approximately NN O O
us NN O O
$ NN O O
70 NN O O
for NN O O
the NN O O
manual NN O O
technique NN O O
used NN O O
in NN O O
this NN O O
study, NN O O
and NN O O
may NN O O
be NN O O
reduced NN O O
to NN O O
approximately NN O O
us NN O O
$ NN O O
10 NN O O
with NN O O
the NN O O
introduction NN O O
of NN O O
commercially NN O O
available NN O O
pcr NN O O
robotics NN O O
and NN O O
fluorescent NN O O
imaging. NN O O
implementation NN O O
of NN O O
this NN O O
method NN O O
of NN O O
mutation NN O O
screening NN O O
in NN O O
the NN O O
research NN O O
and NN O O
clinical NN O O
setting NN O O
should NN O O
permit NN O O
rapid NN O O
accrual NN O O
of NN O O
quantitative NN O O
data NN O O
on NN O O
genotype-phenotype NN O O
associations NN O O
for NN O O
the NN O O
evaluation NN O O
of NN O O
diagnostic NN O O
testing. NN O O
. NN O O
at NN O O
had NN O O
previously NN O O
escaped NN O O
detection. NN O O
in NN O O
addition NN O O
to NN O O
the NN O O
19 NN O O
mutations, NN O O
a NN O O
total NN O O
of NN O O
15 NN O O
different NN O O
polymorphic NN O O
variants NN O O
were NN O O
scored, NN O O
most NN O O
of NN O O
which NN O O
were NN O O
recurring. NN O O
all NN O O
were NN O O
confirmed NN O O
by NN O O
nucleotide NN O O
sequencing. NN O O
the NN O O
cost NN O O
of NN O O
screening NN O O
per NN O O
sample NN O O
was NN O O
calculated NN O O
to NN O O
be NN O O
approximately NN O O
us NN O O
$ NN O O
70 NN O O
for NN O O
the NN O O
manual NN O O
technique NN O O
used NN O O
in NN O O
this NN O O
study, NN O O
and NN O O
may NN O O
be NN O O
reduced NN O O
to NN O O
approximately NN O O
us NN O O
$ NN O O
10 NN O O
with NN O O
the NN O O
introduction NN O O
of NN O O
commercially NN O O
available NN O O
pcr NN O O
robotics NN O O
and NN O O
fluorescent NN O O
imaging. NN O O
implementation NN O O
of NN O O
this NN O O
method NN O O
of NN O O
mutation NN O O
screening NN O O
in NN O O
the NN O O
research NN O O
and NN O O
clinical NN O O
setting NN O O
should NN O O
permit NN O O
rapid NN O O
accrual NN O O
of NN O O
quantitative NN O O
data NN O O
on NN O O
genotype-phenotype NN O O
associations NN O O
for NN O O
the NN O O
evaluation NN O O
of NN O O
diagnostic NN O O
testing. NN O O
. NN O O

germline NN O O
mutations NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
in NN O O
korean NN O O
familial NN B-Modifier B-MSH:D011125
adenomatous NN I-Modifier I-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
patients NN O O
. NN O O

we NN O O
extensively NN O O
analyzed NN O O
genomic NN O O
dna NN O O
and NN O O
messenger NN O O
rna NN O O
(mrna) NN O O
from NN O O
62 NN O O
unrelated NN O O
korean NN O O
patients NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
) NN O O
for NN O O
identification NN O O
of NN O O
germline NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
( NN O O
APC NN B-Modifier B-MSH:D011125
) NN O O
gene NN O O
mutations. NN O O
we NN O O
adopted NN O O
both NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
analysis NN O O
and NN O O
a NN O O
method NN O O
of NN O O
analysis NN O O
involving NN O O
the NN O O
reverse NN O O
transcription-polymerase NN O O
chain NN O O
reaction NN O O
(rt-pcr) NN O O
followed NN O O
by NN O O
a NN O O
protein NN O O
truncation NN O O
test NN O O
(ptt). NN O O
dna NN O O
sequencing NN O O
confirmed NN O O
all NN O O
alterations NN O O
represented NN O O
by NN O O
aberrant NN O O
bands. NN O O
germline NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
38 NN O O
patients NN O O
(61%). NN O O
nineteen NN O O
of NN O O
the NN O O
detected NN O O
mutations NN O O
were NN O O
presumed NN O O
to NN O O
be NN O O
novel, NN O O
thus NN O O
emphasizing NN O O
the NN O O
heterogeneity NN O O
of NN O O
the NN O O
mutational NN O O
spectrum NN O O
in NN O O
korean NN O O
FAP NN B-Modifier B-MSH:D011125
patients. NN O O
in NN O O
the NN O O
initial NN O O
48 NN O O
patients, NN O O
sscp NN O O
analysis NN O O
was NN O O
followed NN O O
by NN O O
ptt NN O O
for NN O O
those NN O O
patients NN O O
for NN O O
whom NN O O
n NN O O
. NN O O

detectable NN O O
mutations NN O O
were NN O O
found NN O O
by NN O O
sscp. NN O O
using NN O O
this NN O O
combined NN O O
approach, NN O O
we NN O O
identified NN O O
germline NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
mutations NN O O
in NN O O
29 NN O O
of NN O O
the NN O O
48 NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
(60%), NN O O
including NN O O
6 NN O O
patients NN O O
in NN O O
whom NN O O
sscp NN O O
analysis NN O O
failed NN O O
to NN O O
distinguish NN O O
the NN O O
mutant NN O O
allele. NN O O
in NN O O
the NN O O
14 NN O O
later NN O O
patients, NN O O
we NN O O
identified NN O O
truncating NN O O
mutations NN O O
in NN O O
9 NN O O
patients NN O O
(64%) NN O O
using NN O O
ptt NN O O
only. NN O O
our NN O O
results NN O O
confirm NN O O
that NN O O
the NN O O
mutation NN O O
detection NN O O
rate NN O O
with NN O O
ptt NN O O
was NN O O
superior NN O O
to NN O O
that NN O O
with NN O O
sscp, NN O O
and NN O O
suggest NN O O
that NN O O
ptt NN O O
would NN O O
be NN O O
a NN O O
more NN O O
practical NN O O
screening NN O O
method NN O O
to NN O O
detect NN O O
germline NN O O
mutations NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
in NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
. NN O O

homozygosity NN O O
mapping NN O O
in NN O O
a NN O O
family NN O O
with NN O O
microcephaly NN B-DiseaseClass B-MSH:D008831
, NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
and NN O O
short NN B-DiseaseClass B-MSH:D006130
stature NN I-DiseaseClass I-MSH:D006130
to NN O O
a NN O O
Cohen NN B-Modifier B-MSH:C536438
syndrome NN I-Modifier I-MSH:C536438
region NN O O
on NN O O
8 NN O O
q NN O O
21.3-8 NN O O
q NN O O
22.1: NN O O
redefining NN O O
a NN O O
clinical NN O O
entity NN O O
. NN O O

a NN O O
syndrome NN O O
of NN O O
microcephaly NN B-DiseaseClass B-MSH:D008831
, NN O O
progressive NN O O
postnatal NN B-DiseaseClass B-MSH:D006130
growth NN I-DiseaseClass I-MSH:D006130
deficiency NN I-DiseaseClass I-MSH:D006130
, NN O O
and NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
was NN O O
observed NN O O
in NN O O
two NN O O
brothers NN O O
and NN O O
their NN O O
cousin NN O O
from NN O O
a NN O O
multiply NN O O
consanguineous NN O O
kindred NN O O
of NN O O
lebanese NN O O
descent. NN O O
Hypotonia NN B-DiseaseClass B-MSH:D009123
, NN O O
chorioretinal NN B-DiseaseClass B-MSH:D015862
dystrophy NN I-DiseaseClass I-MSH:D015862
, NN O O
and NN O O
myopia NN B-DiseaseClass B-MSH:D009216
were NN O O
also NN O O
identified. NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
condition NN O O
varied NN O O
among NN O O
the NN O O
closely NN O O
related NN O O
patients. NN O O
because NN O O
of NN O O
absence NN O O
of NN O O
a NN O O
distinctive NN O O
facial NN O O
appearance, NN O O
the NN O O
degree NN O O
of NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
and NN O O
short NN B-DiseaseClass B-MSH:D006130
stature NN I-DiseaseClass I-MSH:D006130
, NN O O
the NN O O
initially NN O O
considered NN O O
clinical NN O O
diagnosis NN O O
of NN O O
Cohen NN B-SpecificDisease B-MSH:C536438
syndrome NN I-SpecificDisease I-MSH:C536438
was NN O O
withdrawn NN O O
and NN O O
a NN O O
novel NN O O
genetic NN O O
entity NN O O
was NN O O
assumed. NN O O
homozygosity NN O O
mapping NN O O
in NN O O
this NN O O
family NN O O
assigned NN O O
the NN O O
gene NN O O
to NN O O
a NN O O
26. NN O O
8-cm NN O O
region NN O O
on NN O O
the NN O O
chromosome NN O O
band NN O O
8 NN O O
q NN O O
21. NN O O
3 NN O O
-22. NN O O
1, NN O O
between NN O O
the NN O O
microsatellites NN O O
at NN O O
d NN O O
8 NN O O
s NN O O
270 NN O O
and NN O O
d NN O O
8 NN O O
s NN O O
514. NN O O
the NN O O
maximum NN O O
two-point NN O O
lo NN O O
. NN O O

score NN O O
was NN O O
found NN O O
for NN O O
marker NN O O
at NN O O
d NN O O
8 NN O O
s NN O O
267 NN O O
(zmax NN O O
= NN O O
3.. NN O O
237 NN O O
at NN O O
omax NN O O
= NN O O
0. NN O O
00). NN O O
intriguingly NN O O
enough, NN O O
the NN O O
identified NN O O
gene NN O O
region NN O O
overlaps NN O O
the NN O O
refined NN O O
gene NN O O
region NN O O
for NN O O
Cohen NN B-SpecificDisease B-MSH:C536438
syndrome NN I-SpecificDisease I-MSH:C536438
(coh NN O O
1) NN O O
[kolehmainen NN O O
et NN O O
al., NN O O
1997 NN O O
euro NN O O
j NN O O
hum NN O O
genet NN O O
5 NN O O
206-213]. NN O O
this NN O O
fact NN O O
encourages NN O O
the NN O O
hypothesis NN O O
that NN O O
the NN O O
described NN O O
kindred NN O O
segregates NN O O
for NN O O
a NN O O
variant NN O O
of NN O O
Cohen NN B-SpecificDisease B-MSH:C536438
syndrome NN I-SpecificDisease I-MSH:C536438
and NN O O
suggests NN O O
a NN O O
redefinition NN O O
of NN O O
its NN O O
phenotyp NN O O
. NN O O

spontaneous NN O O
reversion NN O O
of NN O O
novel NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
mutation NN O O
by NN O O
hprt NN O O
gene NN O O
rearrangement NN O O
. NN O O

molecular NN O O
analysis NN O O
of NN O O
an NN O O
unusual NN O O
patient NN O O
with NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
has NN O O
suggested NN O O
that NN O O
the NN O O
mutation NN O O
is NN O O
due NN O O
to NN O O
a NN O O
partial NN O O
hprt NN O O
gene NN O O
duplication. NN O O
we NN O O
now NN O O
report NN O O
the NN O O
cloning NN O O
and NN O O
sequencing NN O O
of NN O O
the NN O O
mutant NN O O
hprt NN O O
cdna NN O O
which NN O O
shows NN O O
the NN O O
precise NN O O
duplication NN O O
of NN O O
exons NN O O
2 NN O O
and NN O O
3. NN O O
this NN O O
mutation NN O O
is NN O O
the NN O O
result NN O O
of NN O O
an NN O O
internal NN O O
duplication NN O O
of NN O O
16-20 NN O O
kilobases NN O O
of NN O O
the NN O O
gene. NN O O
the NN O O
structure NN O O
of NN O O
the NN O O
mutant NN O O
gene NN O O
suggests NN O O
that NN O O
the NN O O
duplication NN O O
was NN O O
not NN O O
generated NN O O
by NN O O
a NN O O
single NN O O
unequal NN O O
crossing-over NN O O
event NN O O
between NN O O
two NN O O
normal NN O O
hprt NN O O
alleles. NN O O
growth NN O O
of NN O O
Epstein-Barr NN B-Modifier B-MSH:D020031
virus-transformed NN O O
lymphoblasts NN O O
from NN O O
this NN O O
patient NN O O
in NN O O
selective NN O O
medium NN O O
has NN O O
permitted NN O O
isolation NN O O
of NN O O
spontaneous NN O O
hprt NN O O
+ NN O O
revertants NN O O
of NN O O
this NN O O
mutation. NN O O
the NN O O
reversion NN O O
event NN O O
involves NN O O
a NN O O
second NN O O
major NN O O
hprt NN O O
gene NN O O
rearrangement NN O O
where NN O O
most NN O O
or NN O O
all NN O O
of NN O O
the NN O O
duplicated NN O O
portion NN O O
o NN O O
. NN O O

the NN O O
mutant NN O O
gene NN O O
is NN O O
deleted. NN O O
the NN O O
original NN O O
mutation NN O O
therefore NN O O
has NN O O
the NN O O
potential NN O O
for NN O O
spontaneous NN O O
somatic NN O O
reversion. NN O O
this NN O O
may NN O O
explain NN O O
the NN O O
relatively NN O O
mild NN O O
symptoms NN O O
of NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
exhibited NN O O
by NN O O
this NN O O
patient. NN O O
. NN O O

nephropathy NN O O
in NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
. NN O O

nephropathy NN O O
was NN O O
detected NN O O
in NN O O
five NN O O
of NN O O
32 NN O O
patients NN O O
with NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
who NN O O
were NN O O
participating NN O O
in NN O O
a NN O O
study NN O O
of NN O O
transfer NN O O
factor NN O O
(tf) NN O O
therapy. NN O O
in NN O O
two NN O O
patients, NN O O
nephropathy NN B-SpecificDisease B-MSH:D007674
was NN O O
present NN O O
before NN O O
tf NN O O
and NN O O
did NN O O
not NN O O
appear NN O O
changed NN O O
by NN O O
tf NN O O
therapy. NN O O
one NN O O
of NN O O
these NN O O
patients NN O O
subsequently NN O O
developed NN O O
progressive NN O O
renal NN B-SpecificDisease B-MSH:D051437
failure NN I-SpecificDisease I-MSH:D051437
requiring NN O O
dialysis NN O O
beginning NN O O
5 NN O O
1/2 NN O O
years NN O O
after NN O O
tf NN O O
therapy. NN O O
in NN O O
two NN O O
patients, NN O O
decreased NN O O
renal NN O O
function NN O O
appeared NN O O
very NN O O
soon NN O O
after NN O O
the NN O O
administration NN O O
of NN O O
tf. NN O O
one NN O O
patient NN O O
showed NN O O
gradually NN O O
decreasing NN O O
renal NN O O
function NN O O
beginning NN O O
after NN O O
two NN O O
years NN O O
of NN O O
tf NN O O
therapy. NN O O
an NN O O
additional NN O O
patient NN O O
was NN O O
identified NN O O
who NN O O
died NN O O
with NN O O
renal NN B-SpecificDisease B-MSH:D051437
failure NN I-SpecificDisease I-MSH:D051437
without NN O O
having NN O O
received NN O O
tf. NN O O
the NN O O
results NN O O
suggest NN O O
that NN O O
renal NN B-SpecificDisease B-MSH:D051437
failure NN I-SpecificDisease I-MSH:D051437
occurs NN O O
in NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
more NN O O
frequently NN O O
than NN O O
generally NN O O
recognized NN O O
and NN O O
that NN O O
administration NN O O
of NN O O
tf NN O O
may NN O O
precipitate NN O O
or NN O O
accelerat NN O O
. NN O O

the NN O O
renal NN B-SpecificDisease B-MSH:D007674
disease NN I-SpecificDisease I-MSH:D007674
in NN O O
patients NN O O
with NN O O
this NN O O
syndrome. NN O O
. NN O O

aniridia-associated NN O O
cytogenetic NN O O
rearrangements NN O O
suggest NN O O
that NN O O
a NN O O
position NN O O
effect NN O O
may NN O O
cause NN O O
the NN O O
mutant NN O O
phenotype NN O O
. NN O O
ed NN O O
cytogenetic NN O O
rearrangements NN O O
suggest NN O O
that NN O O
a NN O O
position NN O O
effect NN O O
may NN O O
cause NN O O
the NN O O
mutant NN O O
phenotype NN O O
. NN O O

current NN O O
evidence NN O O
suggests NN O O
that NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
( NN O O
absence NN B-SpecificDisease B-MSH:D015783
of NN I-SpecificDisease I-MSH:D015783
iris NN I-SpecificDisease I-MSH:D015783
) NN O O
is NN O O
caused NN O O
by NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
one NN O O
copy NN O O
of NN O O
the NN O O
pax NN O O
6 NN O O
gene, NN O O
which NN O O
maps NN O O
to NN O O
11 NN O O
p NN O O
13. NN O O
we NN O O
present NN O O
the NN O O
further NN O O
characterisation NN O O
of NN O O
two NN O O
aniridia NN B-Modifier B-MSH:D015783
pedigrees NN O O
in NN O O
which NN O O
the NN O O
disease NN O O
segregates NN O O
with NN O O
chromosomal NN O O
rearrangements NN O O
which NN O O
involve NN O O
11 NN O O
p NN O O
13 NN O O
but NN O O
do NN O O
not NN O O
disrupt NN O O
the NN O O
pax NN O O
6 NN O O
gene. NN O O
we NN O O
have NN O O
isolated NN O O
three NN O O
human NN O O
yac NN O O
clones NN O O
which NN O O
encompass NN O O
the NN O O
pax NN O O
6 NN O O
locus NN O O
and NN O O
we NN O O
have NN O O
used NN O O
these NN O O
to NN O O
show NN O O
that NN O O
in NN O O
both NN O O
cases NN O O
the NN O O
chromosomal NN O O
breakpoint NN O O
is NN O O
at NN O O
least NN O O
85 NN O O
kb NN O O
distal NN O O
of NN O O
the NN O O
3 NN O O
end NN O O
of NN O O
pax NN O O
6. NN O O
in NN O O
addition, NN O O
the NN O O
open NN O O
reading NN O O
frame NN O O
of NN O O
pax NN O O
6 NN O O
is NN O O
apparently NN O O
free NN O O
of NN O O
mutations. NN O O
we NN O O
propose NN O O
that NN O O
the NN O O
pax NN O O
6 NN O O
gene NN O O
on NN O O
the NN O O
rearranged NN O O
chromosome NN O O
11 NN O O
is NN O O
in NN O O
an NN O O
inappropriate NN O O
chromatin NN O O
environment NN O O
for NN O O
norma NN O O
. NN O O

expression NN O O
and NN O O
therefore NN O O
that NN O O
a NN O O
position NN O O
effect NN O O
is NN O O
the NN O O
underlying NN O O
mechanism NN O O
of NN O O
disease NN O O
in NN O O
these NN O O
families. NN O O
. NN O O

genetic NN O O
cholesteryl NN B-SpecificDisease B-OMIM:143470
ester NN I-SpecificDisease I-OMIM:143470
transfer NN I-SpecificDisease I-OMIM:143470
protein NN I-SpecificDisease I-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
caused NN O O
by NN O O
two NN O O
prevalent NN O O
mutations NN O O
as NN O O
a NN O O
major NN O O
determinant NN O O
of NN O O
increased NN O O
levels NN O O
of NN O O
high NN O O
density NN O O
lipoprotein NN O O
cholesterol NN O O
. NN O O

genetic NN O O
determinants NN O O
of NN O O
hdl NN O O
cholesterol NN O O
(hdl-c) NN O O
levels NN O O
in NN O O
the NN O O
general NN O O
population NN O O
are NN O O
poorly NN O O
understood. NN O O
we NN O O
previously NN O O
described NN O O
plasma NN O O
cholesteryl NN B-SpecificDisease B-OMIM:143470
ester NN I-SpecificDisease I-OMIM:143470
transfer NN I-SpecificDisease I-OMIM:143470
protein NN I-SpecificDisease I-OMIM:143470
(CETP) NN I-SpecificDisease I-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
due NN O O
to NN O O
an NN O O
intron NN O O
14 NN O O
g NN O O
(+ NN O O
1) NN O O
-to-a NN O O
mutation NN O O
(int NN O O
14 NN O O
a) NN O O
in NN O O
several NN O O
families NN O O
with NN O O
very NN O O
high NN O O
hdl-c NN O O
levels NN O O
in NN O O
japan. NN O O
subjects NN O O
with NN O O
hdl-c NN O O
> NN O O
or NN O O
= NN O O
100 NN O O
mg/dl NN O O
(n NN O O
= NN O O
130) NN O O
were NN O O
screened NN O O
by NN O O
pcr NN O O
single NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
of NN O O
the NN O O
cetp NN O O
gene. NN O O
two NN O O
other NN O O
mutations NN O O
were NN O O
identified NN O O
by NN O O
dna NN O O
sequencing NN O O
or NN O O
primer-mediated NN O O
restriction NN O O
map NN O O
modification NN O O
of NN O O
pcr NN O O
products NN O O
a NN O O
novel NN O O
intron NN O O
14 NN O O
splice NN O O
donor NN O O
site NN O O
mutation NN O O
caused NN O O
by NN O O
a NN O O
t NN O O
insertion NN O O
at NN O O
position NN O O
+ NN O O
3 NN O O
from NN O O
the NN O O
exon NN O O
14/intron NN O O
14 NN O O
boundary NN O O
(in NN O O
. NN O O

14 NN O O
t) NN O O
and NN O O
a NN O O
missense NN O O
mutation NN O O
(asp NN O O
442 NN O O
to NN O O
gly) NN O O
within NN O O
exon NN O O
15 NN O O
(d NN O O
442 NN O O
g). NN O O
the NN O O
int NN O O
14 NN O O
t NN O O
mutation NN O O
was NN O O
only NN O O
found NN O O
in NN O O
one NN O O
family. NN O O
however, NN O O
the NN O O
d NN O O
442 NN O O
g NN O O
and NN O O
int NN O O
14 NN O O
a NN O O
mutations NN O O
were NN O O
highly NN O O
prevalent NN O O
in NN O O
subjects NN O O
with NN O O
hdl-c NN O O
> NN O O
or NN O O
= NN O O
60 NN O O
mg/dl, NN O O
with NN O O
combined NN O O
allele NN O O
frequencies NN O O
of NN O O
9%, NN O O
12%, NN O O
21% NN O O
and NN O O
43% NN O O
for NN O O
hdl-c NN O O
60-79, NN O O
80-99, NN O O
100-119, NN O O
and NN O O
> NN O O
or NN O O
= NN O O
120 NN O O
mg/dl, NN O O
respectively. NN O O
furthermore, NN O O
prevalences NN O O
of NN O O
the NN O O
d NN O O
442 NN O O
g NN O O
and NN O O
int NN O O
14 NN O O
a NN O O
mutations NN O O
were NN O O
extremely NN O O
high NN O O
in NN O O
a NN O O
general NN O O
sample NN O O
of NN O O
japanese NN O O
men NN O O
(n NN O O
= NN O O
236), NN O O
with NN O O
heterozygote NN O O
frequencies NN O O
of NN O O
7 NN O O
. NN O O
ent NN O O
in NN O O
subjects NN O O
with NN O O
hdl-c NN O O
> NN O O
or NN O O
= NN O O
60 NN O O
mg/dl, NN O O
with NN O O
combined NN O O
allele NN O O
frequencies NN O O
of NN O O
9%, NN O O
12%, NN O O
21% NN O O
and NN O O
43% NN O O
for NN O O
hdl-c NN O O
60-79, NN O O
80-99, NN O O
100-119, NN O O
and NN O O
> NN O O
or NN O O
= NN O O
120 NN O O
mg/dl, NN O O
respectively. NN O O
furthermore, NN O O
prevalences NN O O
of NN O O
the NN O O
d NN O O
442 NN O O
g NN O O
and NN O O
int NN O O
14 NN O O
a NN O O
mutations NN O O
were NN O O
extremely NN O O
high NN O O
in NN O O
a NN O O
general NN O O
sample NN O O
of NN O O
japanese NN O O
men NN O O
(n NN O O
= NN O O
236), NN O O
with NN O O
heterozygote NN O O
frequencies NN O O
of NN O O
7 NN O O
. NN O O

and NN O O
2%, NN O O
respectively. NN O O
these NN O O
two NN O O
mutations NN O O
accounted NN O O
for NN O O
about NN O O
10% NN O O
of NN O O
the NN O O
total NN O O
variance NN O O
of NN O O
hdl-c NN O O
in NN O O
this NN O O
population. NN O O
the NN O O
phenotype NN O O
in NN O O
a NN O O
genetic NN O O
compound NN O O
heterozygote NN O O
(int NN O O
14 NN O O
t NN O O
and NN O O
int NN O O
14 NN O O
a) NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
of NN O O
int NN O O
14 NN O O
a NN O O
homozygotes NN O O
(no NN O O
detectable NN O O
cetp NN O O
and NN O O
markedly NN O O
increased NN O O
hdl-c), NN O O
indicating NN O O
that NN O O
the NN O O
int NN O O
14 NN O O
t NN O O
produces NN O O
a NN O O
null NN O O
allele. NN O O
in NN O O
four NN O O
d NN O O
442 NN O O
g NN O O
homozygotes, NN O O
mean NN O O
hdl-c NN O O
levels NN O O
(86 NN O O
+/- NN O O
26 NN O O
mg/dl) NN O O
were NN O O
lower NN O O
than NN O O
in NN O O
int NN O O
14 NN O O
a NN O O
homozygotes NN O O
(158 NN O O
+/- NN O O
35 NN O O
mg/dl), NN O O
reflecting NN O O
residual NN O O
cetp NN O O
activity NN O O
in NN O O
plasma. NN O O
in NN O O
47 NN O O
d NN O O
442 NN O O
g NN O O
heterozygotes, NN O O
mean NN O O
hdl-c NN O O
levels NN O O
were NN O O
91 NN O O
+/- NN O O
2 NN O O
. NN O O
a) NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
of NN O O
int NN O O
14 NN O O
a NN O O
homozygotes NN O O
(no NN O O
detectable NN O O
cetp NN O O
and NN O O
markedly NN O O
increased NN O O
hdl-c), NN O O
indicating NN O O
that NN O O
the NN O O
int NN O O
14 NN O O
t NN O O
produces NN O O
a NN O O
null NN O O
allele. NN O O
in NN O O
four NN O O
d NN O O
442 NN O O
g NN O O
homozygotes, NN O O
mean NN O O
hdl-c NN O O
levels NN O O
(86 NN O O
+/- NN O O
26 NN O O
mg/dl) NN O O
were NN O O
lower NN O O
than NN O O
in NN O O
int NN O O
14 NN O O
a NN O O
homozygotes NN O O
(158 NN O O
+/- NN O O
35 NN O O
mg/dl), NN O O
reflecting NN O O
residual NN O O
cetp NN O O
activity NN O O
in NN O O
plasma. NN O O
in NN O O
47 NN O O
d NN O O
442 NN O O
g NN O O
heterozygotes, NN O O
mean NN O O
hdl-c NN O O
levels NN O O
were NN O O
91 NN O O
+/- NN O O
2 NN O O
. NN O O

mg/dl, NN O O
similar NN O O
to NN O O
the NN O O
level NN O O
in NN O O
d NN O O
442 NN O O
g NN O O
homozygotes, NN O O
and NN O O
significantly NN O O
greater NN O O
than NN O O
mean NN O O
hdl-c NN O O
levels NN O O
in NN O O
int NN O O
14 NN O O
a NN O O
heterozygotes NN O O
(69 NN O O
+/- NN O O
15 NN O O
mg/dl). NN O O
thus, NN O O
the NN O O
d NN O O
442 NN O O
g NN O O
mutation NN O O
acts NN O O
differently NN O O
to NN O O
the NN O O
null NN O O
mutations NN O O
with NN O O
weaker NN O O
effects NN O O
on NN O O
hdl NN O O
in NN O O
the NN O O
homozygous NN O O
state NN O O
and NN O O
stronger NN O O
effects NN O O
in NN O O
the NN O O
heterozygotes, NN O O
suggesting NN O O
dominant NN O O
expression NN O O
of NN O O
a NN O O
partially NN O O
defective NN O O
allele. NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
, NN O O
reflecting NN O O
two NN O O
prevalent NN O O
mutations NN O O
(d NN O O
442 NN O O
g NN O O
and NN O O
int NN O O
14 NN O O
a), NN O O
is NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
genetic NN B-Modifier B-MSH:D030342
deficiency NN I-Modifier I-MSH:D030342
state NN O O
which NN O O
is NN O O
sufficiently NN O O
common NN O O
to NN O O
explain NN O O
a NN O O
significant NN O O
fraction NN O O
of NN O O
the NN O O
variation NN O O
in NN O O
hdl-c NN O O
in NN O O
the NN O O
general NN O O
population. NN O O
. NN O O

x-linked NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
deficiency NN O O
in NN O O
mus NN O O
musculus NN O O
. NN O O

a NN O O
mouse NN O O
with NN O O
X-linked NN B-SpecificDisease B-MSH:D005955
glucose-6-phosphate NN I-SpecificDisease I-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
has NN O O
been NN O O
recovered NN O O
in NN O O
offspring NN O O
of NN O O
1-ethyl-1-nitrosourea-treated NN O O
male NN O O
mice. NN O O
the NN O O
activity NN O O
alteration NN O O
was NN O O
detected NN O O
in NN O O
blood NN O O
but NN O O
can NN O O
also NN O O
be NN O O
observed NN O O
in NN O O
other NN O O
tissue NN O O
extracts. NN O O
hemizygous, NN O O
heterozygous, NN O O
and NN O O
homozygous NN O O
mutants NN O O
have, NN O O
respectively, NN O O
about NN O O
15, NN O O
60, NN O O
and NN O O
15% NN O O
g NN O O
6 NN O O
pd NN O O
remaining NN O O
activity NN O O
in NN O O
the NN O O
blood NN O O
as NN O O
compared NN O O
to NN O O
the NN O O
wild NN O O
type. NN O O
erythrocyte NN O O
indices NN O O
did NN O O
not NN O O
show NN O O
differences NN O O
between NN O O
mutants NN O O
and NN O O
wild NN O O
types. NN O O
the NN O O
mutation NN O O
does NN O O
not NN O O
affect NN O O
the NN O O
electrophoretic NN O O
migration, NN O O
the NN O O
isoelectric NN O O
point, NN O O
or NN O O
the NN O O
thermal NN O O
stability. NN O O
kinetic NN O O
properties, NN O O
such NN O O
as NN O O
the NN O O
km NN O O
for NN O O
glucose-6-phosphate NN O O
or NN O O
for NN O O
nadp NN O O
and NN O O
the NN O O
relative NN O O
utilization NN O O
of NN O O
substrate NN O O
analogue NN O O
. NN O O

, NN O O
showed NN O O
no NN O O
differences NN O O
between NN O O
wild NN O O
types NN O O
and NN O O
mutants NN O O
with NN O O
the NN O O
exception NN O O
of NN O O
the NN O O
relative NN O O
utilization NN O O
of NN O O
deamino-nadp NN O O
which NN O O
was NN O O
significantly NN O O
lower NN O O
in NN O O
mutants. NN O O
this NN O O
is NN O O
presently NN O O
the NN O O
only NN O O
animal NN O O
model NN O O
for NN O O
X-linked NN B-SpecificDisease B-MSH:D005955
G6PD NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
humans. NN O O
. NN O O

human NN O O
glycine NN O O
decarboxylase NN O O
gene NN O O
(gldc) NN O O
and NN O O
its NN O O
highly NN O O
conserved NN O O
processed NN O O
pseudogene NN O O
(psigldc): NN O O
their NN O O
structure NN O O
and NN O O
expression, NN O O
and NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
large NN O O
deletion NN O O
in NN O O
a NN O O
family NN O O
with NN O O
nonketotic NN B-SpecificDisease B-MSH:D020158
hyperglycinemia NN I-SpecificDisease I-MSH:D020158
. NN O O

mutations NN O O
in NN O O
the NN O O
glycine NN O O
decarboxylase NN O O
gene NN O O
(gldc) NN O O
cause NN O O
nonketotic NN B-SpecificDisease B-MSH:D020158
hyperglycinemia NN I-SpecificDisease I-MSH:D020158
( NN O O
NKH NN B-SpecificDisease B-MSH:D020158
), NN O O
an NN O O
in-born NN B-DiseaseClass B-MSH:D008661
error NN I-DiseaseClass I-MSH:D008661
of NN I-DiseaseClass I-MSH:D008661
metabolism NN I-DiseaseClass I-MSH:D008661
characterized NN O O
by NN O O
severe NN O O
neurological NN B-DiseaseClass B-MSH:D009461
disturbance NN I-DiseaseClass I-MSH:D009461
. NN O O
we NN O O
have NN O O
determined NN O O
the NN O O
structure NN O O
of NN O O
gldc NN O O
and NN O O
of NN O O
its NN O O
pseudogene NN O O
(psigldc) NN O O
and NN O O
studied NN O O
their NN O O
expression NN O O
for NN O O
a NN O O
molecular NN O O
analysis NN O O
of NN O O
NKH NN B-SpecificDisease B-MSH:D020158
. NN O O
the NN O O
gldc NN O O
gene NN O O
spans NN O O
at NN O O
least NN O O
135 NN O O
kb NN O O
and NN O O
consists NN O O
of NN O O
25 NN O O
exons. NN O O
all NN O O
donor NN O O
and NN O O
acceptor NN O O
sites NN O O
adhere NN O O
to NN O O
the NN O O
canonical NN O O
gt-ag NN O O
rule, NN O O
except NN O O
for NN O O
the NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
21, NN O O
where NN O O
a NN O O
variant NN O O
form NN O O
gc NN O O
is NN O O
used NN O O
instead NN O O
of NN O O
gt. NN O O
the NN O O
transcription NN O O
initiation NN O O
site NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
a NN O O
residue NN O O
163 NN O O
bp NN O O
upstream NN O O
from NN O O
the NN O O
translation NN O O
initiation NN O O
triplet NN O O
by NN O O
primer NN O O
extension NN O O
analysis. NN O O
the NN O O
psigldc NN O O
gene NN O O
has NN O O
no NN O O
intron NN O O
and NN O O
shares NN O O
97. NN O O
5% NN O O
homology NN O O
with NN O O
th NN O O
. NN O O

coding NN O O
region NN O O
of NN O O
functional NN O O
gldc, NN O O
suggesting NN O O
that NN O O
psigldc NN O O
is NN O O
a NN O O
processed NN O O
pseudogene NN O O
that NN O O
arose NN O O
from NN O O
the NN O O
gldc NN O O
transcript NN O O
about NN O O
4-8 NN O O
million NN O O
years NN O O
ago. NN O O
rna NN O O
blotting NN O O
analysis NN O O
has NN O O
revealed NN O O
that NN O O
gldc NN O O
is NN O O
expressed NN O O
in NN O O
human NN O O
liver, NN O O
kidney, NN O O
brain, NN O O
and NN O O
placenta. NN O O
we NN O O
have NN O O
also NN O O
examined NN O O
a NN O O
patient NN O O
with NN O O
NKH NN B-SpecificDisease B-MSH:D020158
with NN O O
no NN O O
detectable NN O O
gldc NN O O
mrna NN O O
in NN O O
his NN O O
lymphoblasts. NN O O
exons NN O O
1-3 NN O O
of NN O O
the NN O O
functional NN O O
gldc NN O O
gene NN O O
from NN O O
this NN O O
patient NN O O
are NN O O
not NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr), NN O O
whereas NN O O
those NN O O
from NN O O
control NN O O
subjects NN O O
are. NN O O
these NN O O
results NN O O
suggest NN O O
a NN O O
large NN O O
homozygous NN O O
deletion NN O O
(at NN O O
least NN O O
30 NN O O
kb) NN O O
in NN O O
the NN O O
patient. NN O O
furthermore, NN O O
we NN O O
have NN O O
devised NN O O
a NN O O
semi-quantitative NN O O
pcr NN O O
to NN O O
estimate NN O O
the NN O O
number NN O O
of NN O O
gldc NN O O
alleles NN O O
by NN O O
using NN O O
psigldc NN O O
as NN O O
an NN O O
internal NN O O
control NN O O
and NN O O
have NN O O
confirmed NN O O
the NN O O
homozygosit NN O O
. NN O O

and NN O O
heterozygosity NN O O
of NN O O
the NN O O
deletion NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
his NN O O
parents, NN O O
respectively. NN O O
structural NN O O
information NN O O
of NN O O
gldc NN O O
and NN O O
psigldc NN O O
should NN O O
facilitate NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
NKH NN B-SpecificDisease B-MSH:D020158
. NN O O

growth NN O O
retardation NN O O
and NN O O
tumour NN B-Modifier B-MSH:D009369
inhibition NN O O
by NN O O
brca NN O O
1 NN O O
. NN O O

inherited NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
predispose NN O O
to NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
, NN O O
but NN O O
the NN O O
role NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
sporadic NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
has NN O O
previously NN O O
been NN O O
elusive. NN O O
here, NN O O
we NN O O
show NN O O
that NN O O
retroviral NN O O
transfer NN O O
of NN O O
the NN O O
wild-type NN O O
brca NN O O
1 NN O O
gene NN O O
inhibits NN O O
growth NN O O
in NN O O
vitro NN O O
of NN O O
all NN O O
breast NN B-Modifier B-MSH:D001943
and NN I-Modifier I-MSH:D001943
ovarian NN I-Modifier I-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
cell NN O O
lines NN O O
tested, NN O O
but NN O O
not NN O O
colon NN B-Modifier B-MSH:D003110
or NN I-Modifier I-MSH:D003110
lung NN I-Modifier I-MSH:D003110
cancer NN I-Modifier I-MSH:D003110
cells NN O O
or NN O O
fibroblasts. NN O O
mutant NN O O
brca NN O O
1 NN O O
has NN O O
no NN O O
effect NN O O
on NN O O
growth NN O O
of NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
cells; NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
cell NN O O
growth NN O O
is NN O O
not NN O O
affected NN O O
by NN O O
brca NN O O
1 NN O O
mutations NN O O
in NN O O
the NN O O
5 NN O O
portion NN O O
of NN O O
the NN O O
gene, NN O O
but NN O O
is NN O O
inhibited NN O O
by NN O O
3 NN O O
brca NN O O
1 NN O O
mutations. NN O O
development NN O O
of NN O O
MCF-7 NN B-DiseaseClass B-MSH:D009369
tumours NN I-DiseaseClass I-MSH:D009369
in NN O O
nude NN O O
mice NN O O
is NN O O
inhibited NN O O
when NN O O
mcf-7 NN O O
cells NN O O
are NN O O
transfected NN O O
with NN O O
wild-type, NN O O
but NN O O
not NN O O
mutant, NN O O
brca NN O O
1. NN O O
mos NN O O
. NN O O

importantly, NN O O
among NN O O
mice NN O O
with NN O O
established NN O O
MCF-7 NN B-DiseaseClass B-MSH:D009369
tumours NN I-DiseaseClass I-MSH:D009369
, NN O O
peritoneal NN O O
treatment NN O O
with NN O O
a NN O O
retroviral NN O O
vector NN O O
expressing NN O O
wild-type NN O O
brca NN O O
1 NN O O
significantly NN O O
inhibits NN O O
tumour NN B-Modifier B-MSH:D009369
growth NN O O
and NN O O
increased NN O O
survival. NN O O
. NN O O

striking NN O O
prevalence NN O O
of NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
in NN O O
"healthy" NN O O
w NN O O
27 NN O O
positive NN O O
males NN O O
and NN O O
females NN O O
. NN O O

ankylosing NN O O
spondylitis NN O O
is NN O O
diagnosed NN O O
once NN O O
or NN O O
twice NN O O
in NN O O
each NN O O
1000 NN O O
males NN O O
and NN O O
one NN O O
tenth NN O O
as NN O O
frequently NN O O
in NN O O
females, NN O O
but NN O O
the NN O O
true NN O O
prevalence NN O O
is NN O O
unknown. NN O O
indentification NN O O
of NN O O
genetic NN O O
marker, NN O O
hl-a NN O O
w NN O O
27, NN O O
for NN O O
susceptible NN O O
persons NN O O
has NN O O
provided NN O O
a NN O O
tool NN O O
facilitating NN O O
epidemiologic NN O O
studies NN O O
and NN O O
allowing NN O O
identification NN O O
of NN O O
" NN O O
control NN O O
" NN O O
populations NN O O
without NN O O
the NN O O
marker. NN O O
evaluation NN O O
by NN O O
postal NN O O
questionnaires, NN O O
and NN O O
pelvic NN O O
radiography NN O O
of NN O O
78 NN O O
hl-a NN O O
27 NN O O
w-positive NN O O
blood NN O O
donors NN O O
selected NN O O
from NN O O
a NN O O
group NN O O
of NN O O
apparently NN O O
healthy NN O O
subjects NN O O
revealed NN O O
14 NN O O
who NN O O
satisfied NN O O
the NN O O
criteria NN O O
for NN O O
definite NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
. NN O O
the NN O O
prevalence NN O O
was NN O O
similar NN O O
in NN O O
both NN O O
sexes. NN O O
one NN O O
hundred NN O O
and NN O O
twenty-six NN O O
w NN O O
27-negative NN O O
controls NN O O
matched NN O O
for NN O O
race, NN O O
sex, NN O O
and NN O O
age NN O O
failed NN O O
to NN O O
yield NN O O
a NN O O
single NN O O
case. NN O O
for NN O O
a NN O O
person NN O O
of NN O O
either NN O O
sex NN O O
with NN O O
hl NN O O
. NN O O

a NN O O
w NN O O
27, NN O O
there NN O O
appears NN O O
to NN O O
be NN O O
about NN O O
a NN O O
20 NN O O
per NN O O
cent NN O O
chance NN O O
that NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
will NN O O
develop, NN O O
suggesting NN O O
a NN O O
prevalence NN O O
of NN O O
10 NN O O
to NN O O
15 NN O O
per NN O O
thousand. NN O O
hitherto NN O O
accepted NN O O
figures NN O O
may NN O O
underestimate NN O O
the NN O O
frequency NN O O
by NN O O
a NN O O
factor NN O O
of NN O O
10 NN O O
to NN O O
20. NN O O
. NN O O

rapid NN O O
detection NN O O
of NN O O
brca NN O O
1 NN O O
mutations NN O O
by NN O O
the NN O O
protein NN O O
truncation NN O O
test NN O O
. NN O O

more NN O O
than NN O O
75% NN O O
of NN O O
the NN O O
reported NN O O
mutations NN O O
in NN O O
the NN O O
hereditary NN B-Modifier B-MSH:D061325
breast NN I-Modifier I-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
gene, NN O O
brca NN O O
1, NN O O
result NN O O
in NN O O
truncated NN O O
proteins. NN O O
we NN O O
have NN O O
used NN O O
the NN O O
protein NN O O
truncation NN O O
test NN O O
(ptt) NN O O
to NN O O
screen NN O O
for NN O O
mutations NN O O
in NN O O
exon NN O O
11, NN O O
which NN O O
encodes NN O O
61% NN O O
of NN O O
brca NN O O
1. NN O O
in NN O O
45 NN O O
patients NN O O
from NN O O
breast NN B-Modifier B-MSH:D001943
and/or NN I-Modifier I-MSH:D001943
ovarian NN I-Modifier I-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
families NN O O
we NN O O
found NN O O
six NN O O
novel NN O O
mutations NN O O
two NN O O
single NN O O
nucleotide NN O O
insertions, NN O O
three NN O O
small NN O O
deletions NN O O
(1-5 NN O O
bp) NN O O
and NN O O
a NN O O
nonsense NN O O
mutation NN O O
identified NN O O
two NN O O
unrelated NN O O
families. NN O O
furthermore, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
amplify NN O O
the NN O O
remaining NN O O
coding NN O O
region NN O O
by NN O O
rt-pcr NN O O
using NN O O
lymphocyte NN O O
rna. NN O O
combined NN O O
with NN O O
ptt, NN O O
we NN O O
detected NN O O
aberrantly NN O O
spliced NN O O
products NN O O
affecting NN O O
exons NN O O
5 NN O O
and NN O O
6 NN O O
in NN O O
one NN O O
of NN O O
two NN O O
brca NN O O
1-linked NN O O
families NN O O
examined. NN O O
the NN O O
protein NN O O
truncation NN O O
test NN O O
promises NN O O
t NN O O
. NN O O

become NN O O
a NN O O
valuable NN O O
technique NN O O
in NN O O
detecting NN O O
brca NN O O
1 NN O O
mutations. NN O O
. NN O O

new NN O O
variant NN O O
in NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
(plp) NN O O
gene NN O O
in NN O O
a NN O O
family NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
. NN O O

a NN O O
c--greater NN O O
than NN O O
g NN O O
transversion NN O O
has NN O O
been NN O O
found NN O O
in NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
plp NN O O
gene NN O O
of NN O O
affected NN O O
males NN O O
and NN O O
their NN O O
mother NN O O
in NN O O
a NN O O
single NN O O
sibship NN O O
with NN O O
Pelizaeus-merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
( NN O O
PMD NN B-SpecificDisease B-OMIM:312080
). NN O O
the NN O O
transversion NN O O
should NN O O
not NN O O
result NN O O
in NN O O
an NN O O
amino NN O O
acid NN O O
change NN O O
in NN O O
the NN O O
protein NN O O
but NN O O
it NN O O
does NN O O
result NN O O
in NN O O
the NN O O
loss NN O O
of NN O O
a NN O O
haeiii NN O O
restriction NN O O
endonuclease NN O O
cleavage NN O O
site. NN O O
it NN O O
is NN O O
concordant NN O O
with NN O O
the NN O O
disease NN O O
in NN O O
this NN O O
family. NN O O
one-hundred-ten NN O O
unrelated NN O O
x NN O O
chromosomes NN O O
are NN O O
negative NN O O
for NN O O
this NN O O
mutation. NN O O
no NN O O
other NN O O
sequence NN O O
defect NN O O
was NN O O
found NN O O
in NN O O
the NN O O
plp NN O O
exons NN O O
of NN O O
the NN O O
affected NN O O
males. NN O O
the NN O O
cause NN O O
of NN O O
disease NN O O
in NN O O
this NN O O
family NN O O
remains NN O O
unknown, NN O O
but NN O O
the NN O O
association NN O O
between NN O O
this NN O O
rare NN O O
mutation NN O O
and NN O O
PMD NN B-SpecificDisease B-OMIM:312080
is NN O O
intriguing. NN O O
the NN O O
mutation NN O O
can NN O O
serve NN O O
as NN O O
a NN O O
marker NN O O
for NN O O
following NN O O
segregation NN O O
of NN O O
the NN O O
plp NN O O
gen NN O O
. NN O O

. NN O O
. NN O O

variants NN O O
of NN O O
erythrocyte NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
in NN O O
bulgarian NN O O
populations NN O O
. NN O O

ten NN O O
variants NN O O
of NN O O
erythrocyte NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
were NN O O
identified NN O O
in NN O O
22 NN O O
patients NN O O
with NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
from NN O O
three NN O O
districts NN O O
of NN O O
bulgaria. NN O O
corinth-like NN O O
and NN O O
fayoum-like NN O O
variants NN O O
were NN O O
the NN O O
most NN O O
frequent; NN O O
mediterranean, NN O O
ohut NN O O
ii, NN O O
kilgore, NN O O
boston, NN O O
poznan, NN O O
and NN O O
panay NN O O
variants NN O O
and NN O O
two NN O O
new NN O O
variants, NN O O
petrich NN O O
and NN O O
gotze NN O O
delchev, NN O O
were NN O O
each NN O O
found NN O O
in NN O O
one NN O O
or NN O O
two NN O O
carriers. NN O O
no NN O O
correlation NN O O
was NN O O
revealed NN O O
between NN O O
clinical NN O O
and NN O O
biochemical NN O O
polymorphism. NN O O
. NN O O

the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
causing NN O O
hereditary NN B-SpecificDisease B-MSH:D006432
hemochromatosis NN I-SpecificDisease I-MSH:D006432
does NN O O
not NN O O
produce NN O O
a NN O O
null NN O O
allele NN O O
. NN O O

targeted NN O O
mutagenesis NN O O
was NN O O
used NN O O
to NN O O
produce NN O O
two NN O O
mutations NN O O
in NN O O
the NN O O
murine NN O O
hemochromatosis NN B-Modifier B-MSH:D006432
gene NN O O
(hfe) NN O O
locus. NN O O
the NN O O
first NN O O
mutation NN O O
deletes NN O O
a NN O O
large NN O O
portion NN O O
of NN O O
the NN O O
coding NN O O
sequence, NN O O
generating NN O O
a NN O O
null NN O O
allele. NN O O
the NN O O
second NN O O
mutation NN O O
introduces NN O O
a NN O O
missense NN O O
mutation NN O O
(c NN O O
282 NN O O
y) NN O O
into NN O O
the NN O O
hfe NN O O
locus, NN O O
but NN O O
otherwise NN O O
leaves NN O O
the NN O O
gene NN O O
intact. NN O O
this NN O O
mutation NN O O
is NN O O
identical NN O O
to NN O O
the NN O O
disease-causing NN O O
mutation NN O O
in NN O O
patients NN O O
with NN O O
hereditary NN B-SpecificDisease B-MSH:D006432
hemochromatosis NN I-SpecificDisease I-MSH:D006432
. NN O O
mice NN O O
carrying NN O O
each NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
were NN O O
bred NN O O
and NN O O
analyzed. NN O O
homozygosity NN O O
for NN O O
either NN O O
mutation NN O O
results NN O O
in NN O O
postnatal NN O O
iron NN O O
loading. NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
null NN O O
mutation NN O O
are NN O O
more NN O O
severe NN O O
than NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation. NN O O
mice NN O O
heterozygous NN O O
for NN O O
either NN O O
mutation NN O O
accumulate NN O O
more NN O O
iron NN O O
than NN O O
normal NN O O
controls. NN O O
interestingly, NN O O
although NN O O
liver NN O O
iron NN O O
stores NN O O
are NN O O
greatly NN O O
increased, NN O O
splenic NN O O
iro NN O O
. NN O O

is NN O O
decreased. NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
does NN O O
not NN O O
result NN O O
in NN O O
a NN O O
null NN O O
allele. NN O O
. NN O O

regional NN O O
localisation NN O O
of NN O O
the NN O O
Friedreich NN B-Modifier B-MSH:D005621
ataxia NN I-Modifier I-MSH:D005621
locus NN O O
to NN O O
human NN O O
chromosome NN O O
9 NN O O
q NN O O
13----q NN O O
21.1 NN O O
. NN O O

we NN O O
have NN O O
previously NN O O
assigned NN O O
the NN O O
Friedreich NN B-Modifier B-MSH:D005621
ataxia NN I-Modifier I-MSH:D005621
locus NN O O
(frda) NN O O
to NN O O
chromosome NN O O
9; NN O O
the NN O O
current NN O O
maximal NN O O
lod NN O O
score NN O O
between NN O O
frda NN O O
and NN O O
mct NN O O
112 NN O O
(d NN O O
9 NN O O
s NN O O
15) NN O O
is NN O O
greater NN O O
than NN O O
50 NN O O
at NN O O
a NN O O
recombination NN O O
fraction NN O O
of NN O O
theta NN O O
= NN O O
0. NN O O
the NN O O
physical NN O O
assignment NN O O
of NN O O
the NN O O
locus NN O O
defined NN O O
by NN O O
mct NN O O
112, NN O O
and NN O O
hence NN O O
frda, NN O O
has NN O O
not NN O O
been NN O O
determined, NN O O
although NN O O
linkage NN O O
analysis NN O O
of NN O O
mct NN O O
112 NN O O
with NN O O
other NN O O
chromosome NN O O
9 NN O O
markers NN O O
inferred NN O O
a NN O O
location NN O O
close NN O O
to NN O O
the NN O O
centromere. NN O O
we NN O O
have NN O O
used NN O O
in NN O O
situ NN O O
hybridisation NN O O
with NN O O
mct NN O O
112, NN O O
a NN O O
corresponding NN O O
cosmid NN O O
mj NN O O
1, NN O O
and NN O O
dr NN O O
47 NN O O
(d NN O O
9 NN O O
s NN O O
5), NN O O
coupled NN O O
with NN O O
mapping NN O O
studies NN O O
on NN O O
hybrid NN O O
cell NN O O
panels, NN O O
to NN O O
define NN O O
more NN O O
precisely NN O O
the NN O O
location NN O O
of NN O O
the NN O O
disease NN O O
locus. NN O O
the NN O O
in NN O O
situ NN O O
location NN O O
of NN O O
all NN O O
three NN O O
probes NN O O
is NN O O
9 NN O O
. NN O O

13----q NN O O
21. NN O O
1, NN O O
distal NN O O
to NN O O
the NN O O
variable NN O O
heterochromatin NN O O
region. NN O O
physical NN O O
assignment NN O O
of NN O O
frda NN O O
will NN O O
allow NN O O
us NN O O
to NN O O
identify NN O O
hybrid NN O O
cell NN O O
lines NN O O
containing NN O O
the NN O O
mutated NN O O
gene NN O O
. NN O O
atin NN O O
region. NN O O
physical NN O O
assignment NN O O
of NN O O
frda NN O O
will NN O O
allow NN O O
us NN O O
to NN O O
identify NN O O
hybrid NN O O
cell NN O O
lines NN O O
containing NN O O
the NN O O
mutated NN O O
gene NN O O
. NN O O

mxi NN O O
1 NN O O
mutations NN O O
in NN O O
human NN O O
neurofibrosarcomas NN B-SpecificDisease B-MSH:D018319
. NN O O

mxi NN O O
1 NN O O
is NN O O
thought NN O O
to NN O O
negatively NN O O
regulate NN O O
myc NN O O
function NN O O
and NN O O
may NN O O
therefore NN O O
be NN O O
a NN O O
potential NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
gene. NN O O
little NN O O
effort NN O O
has NN O O
yet NN O O
been NN O O
made NN O O
to NN O O
find NN O O
alterations NN O O
involving NN O O
this NN O O
gene NN O O
in NN O O
human NN O O
solid NN B-DiseaseClass B-MSH:D009369
tumors NN I-DiseaseClass I-MSH:D009369
. NN O O
we NN O O
screened NN O O
31 NN O O
human NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancers NN I-SpecificDisease I-MSH:D013274
, NN O O
7 NN O O
esophageal NN B-SpecificDisease B-MSH:D004938
cancers NN I-SpecificDisease I-MSH:D004938
, NN O O
85 NN O O
bone NN B-CompositeMention B-MSH:D001859
and NN I-CompositeMention I-MSH:D001859
soft NN I-CompositeMention I-MSH:D001859
tissue NN I-CompositeMention I-MSH:D001859
tumors NN I-CompositeMention I-MSH:D001859
of NN O O
various NN O O
types, NN O O
including NN O O
4 NN O O
neurofibrosarcomas NN B-SpecificDisease B-MSH:D018319
. NN O O
we NN O O
also NN O O
examined NN O O
29 NN O O
human NN O O
tumor NN B-Modifier B-MSH:D009369
cell NN O O
lines NN O O
consisting NN O O
of NN O O
12 NN O O
esophageal NN B-SpecificDisease B-MSH:D004938
cancers NN I-SpecificDisease I-MSH:D004938
, NN O O
7 NN O O
glioma NN B-SpecificDisease B-MSH:D005910
/ NN O O
glioblastomas NN B-SpecificDisease B-MSH:D005909
and NN O O
10 NN O O
others NN O O
for NN O O
mxi NN O O
1 NN O O
mutations NN O O
in NN O O
exons NN O O
1, NN O O
2, NN O O
4 NN O O
(hlh NN O O
domain), NN O O
5 NN O O
and NN O O
6. NN O O
polymerase NN O O
chain NN O O
reaction-single-strand NN O O
conformation NN O O
polymorphism NN O O
(pcr-sscp) NN O O
and NN O O
subsequent NN O O
sequencing NN O O
revealed NN O O
three NN O O
distinct NN O O
polymorphisms NN O O
in NN O O
the NN O O
intron-exon NN O O
boundary NN O O
upstream NN O O
from NN O O
exon NN O O
6. NN O O
we NN O O
discovered NN O O
a NN O O
missense NN O O
mutation NN O O
. NN O O

gca NN O O
to NN O O
gta NN O O
(ala NN O O
54 NN O O
val), NN O O
in NN O O
exon NN O O
2 NN O O
in NN O O
a NN O O
neurofibrosarcoma NN B-Modifier B-MSH:D018319
patient NN O O
(case NN O O
1), NN O O
two NN O O
missense NN O O
mutations, NN O O
aaa NN O O
to NN O O
caa NN O O
(lys NN O O
118 NN O O
gln) NN O O
and NN O O
gaa NN O O
to NN O O
gga NN O O
(glu NN O O
154 NN O O
gly) NN O O
in NN O O
exon NN O O
5 NN O O
of NN O O
another NN O O
neurofibrosarcoma NN B-Modifier B-MSH:D018319
patient NN O O
(case NN O O
2), NN O O
and NN O O
3 NN O O
amino NN O O
acid NN O O
substitutions, NN O O
gtg NN O O
to NN O O
gcg NN O O
(val NN O O
179 NN O O
ala), NN O O
gtt NN O O
to NN O O
gct NN O O
(val NN O O
181 NN O O
ala) NN O O
and NN O O
ttc NN O O
to NN O O
ctc NN O O
(phe NN O O
186 NN O O
leu), NN O O
in NN O O
a NN O O
third NN O O
neurofibrosarcoma NN B-Modifier B-MSH:D018319
patient NN O O
(case NN O O
3). NN O O
in NN O O
case NN O O
3, NN O O
loss NN O O
of NN O O
heterozygosity NN O O
was NN O O
also NN O O
demonstrated NN O O
by NN O O
informative NN O O
(ttc) NN O O
3/(ttc) NN O O
2 NN O O
polymorphism. NN O O
our NN O O
data NN O O
demonstrate NN O O
that NN O O
mutations NN O O
occur NN O O
in NN O O
the NN O O
mxi NN O O
1 NN O O
gene NN O O
in NN O O
neurofibrosarcoma NN B-SpecificDisease B-MSH:D018319
. NN O O
missense NN O O
mutations NN O O
in NN O O
the NN O O
functional NN O O
domai NN O O
. NN O O

of NN O O
mxi NN O O
1 NN O O
in NN O O
these NN O O
cases NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
neurofibrosarcoma NN B-SpecificDisease B-MSH:D018319
. NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
essential NN B-SpecificDisease B-MSH:C538068
fructosuria NN I-SpecificDisease I-MSH:C538068
: NN O O
molecular NN O O
cloning NN O O
and NN O O
mutational NN O O
analysis NN O O
of NN O O
human NN O O
ketohexokinase NN O O
(fructokinase) NN O O
. NN O O

essential NN O O
fructosuria NN O O
is NN O O
one NN O O
of NN O O
the NN O O
oldest NN O O
known NN O O
inborn NN B-DiseaseClass B-MSH:D008661
errors NN I-DiseaseClass I-MSH:D008661
of NN I-DiseaseClass I-MSH:D008661
metabolism NN I-DiseaseClass I-MSH:D008661
. NN O O
it NN O O
is NN O O
a NN O O
benign NN O O
condition NN O O
which NN O O
is NN O O
believed NN O O
to NN O O
result NN O O
from NN O O
deficiency NN B-SpecificDisease B-MSH:C538068
of NN I-SpecificDisease I-MSH:C538068
hepatic NN I-SpecificDisease I-MSH:C538068
fructokinase NN I-SpecificDisease I-MSH:C538068
(ketohexokinase, NN O O
khk, NN O O
e. NN O O
c. NN O O
2. NN O O
7. NN O O
1. NN O O
3). NN O O
this NN O O
enzyme NN O O
catalyses NN O O
the NN O O
first NN O O
step NN O O
of NN O O
metabolism NN O O
of NN O O
dietary NN O O
fructose, NN O O
conversion NN O O
of NN O O
fructose NN O O
to NN O O
fructose-1-phosphate. NN O O
despite NN O O
the NN O O
early NN O O
recognition NN O O
of NN O O
this NN O O
disorder, NN O O
the NN O O
primary NN O O
structure NN O O
of NN O O
human NN O O
khk NN O O
and NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
essential NN B-SpecificDisease B-MSH:C538068
fructosuria NN I-SpecificDisease I-MSH:C538068
have NN O O
not NN O O
been NN O O
previously NN O O
defined. NN O O
in NN O O
this NN O O
report, NN O O
the NN O O
isolation NN O O
and NN O O
sequencing NN O O
of NN O O
full-length NN O O
cdna NN O O
clones NN O O
encoding NN O O
human NN O O
ketohexokinase NN O O
are NN O O
described. NN O O
alternative NN O O
mrna NN O O
species NN O O
and NN O O
alternative NN O O
khk NN O O
isozymes NN O O
are NN O O
produced NN O O
by NN O O
alternative NN O O
polyadenylation NN O O
and NN O O
splicing NN O O
of NN O O
the NN O O
khk NN O O
gene. NN O O
the NN O O
khk NN O O
proteins NN O O
show NN O O
a NN O O
hig NN O O
. NN O O

level NN O O
of NN O O
sequence NN O O
conservation NN O O
relative NN O O
to NN O O
rat NN O O
khk. NN O O
direct NN O O
evidence NN O O
that NN O O
mutation NN O O
of NN O O
the NN O O
khk NN O O
structural NN O O
gene NN O O
is NN O O
the NN O O
cause NN O O
of NN O O
essential NN B-SpecificDisease B-MSH:C538068
fructosuria NN I-SpecificDisease I-MSH:C538068
was NN O O
also NN O O
obtained. NN O O
in NN O O
a NN O O
well-characterized NN O O
family, NN O O
in NN O O
which NN O O
three NN O O
of NN O O
eight NN O O
siblings NN O O
have NN O O
fructosuria NN B-DiseaseClass B-MSH:C538068
, NN O O
all NN O O
affected NN O O
individuals NN O O
are NN O O
compound NN O O
heterozygotes NN O O
for NN O O
two NN O O
mutations NN O O
gly NN O O
40 NN O O
arg NN O O
and NN O O
ala NN O O
43 NN O O
thr. NN O O
both NN O O
mutations NN O O
result NN O O
from NN O O
g-- NN O O
> NN O O
a NN O O
transitions, NN O O
and NN O O
each NN O O
alters NN O O
the NN O O
same NN O O
conserved NN O O
region NN O O
of NN O O
the NN O O
khk NN O O
protein. NN O O
neither NN O O
mutation NN O O
was NN O O
seen NN O O
in NN O O
a NN O O
sample NN O O
of NN O O
52 NN O O
unrelated NN O O
control NN O O
individuals. NN O O
an NN O O
additional NN O O
conservative NN O O
amino NN O O
acid NN O O
change NN O O
(val NN O O
49 NN O O
iie) NN O O
was NN O O
present NN O O
on NN O O
the NN O O
khk NN O O
allele NN O O
bearing NN O O
ala NN O O
43 NN O O
th NN O O
. NN O O

loss NN O O
of NN O O
the NN O O
ataxia-telangiectasia NN B-Modifier B-MSH:D001260
gene NN O O
product NN O O
causes NN O O
oxidative NN O O
damage NN O O
in NN O O
target NN O O
organs NN O O
. NN O O

ataxia-telangiectasia NN O O
( NN O O
A-T NN B-SpecificDisease B-MSH:D001260
) NN O O
is NN O O
characterized NN O O
by NN O O
a NN O O
markedly NN O O
increased NN O O
sensitivity NN O O
to NN O O
ionizing NN O O
radiation, NN O O
increased NN O O
incidence NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
, NN O O
and NN O O
neurodegeneration NN B-DiseaseClass B-MSH:D019636
, NN O O
especially NN O O
of NN O O
the NN O O
cerebellar NN O O
purkinje NN O O
cells. NN O O
ionizing NN O O
radiation NN O O
oxidizes NN O O
macromolecules NN O O
and NN O O
causes NN O O
tissue NN O O
damage NN O O
through NN O O
the NN O O
generation NN O O
of NN O O
reactive NN O O
oxygen NN O O
species NN O O
(ros). NN O O
we NN O O
therefore NN O O
hypothesized NN O O
that NN O O
A-T NN B-SpecificDisease B-MSH:D001260
is NN O O
due NN O O
to NN O O
oxidative NN O O
damage NN O O
resulting NN O O
from NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260
gene NN O O
product. NN O O
to NN O O
assess NN O O
this NN O O
hypothesis, NN O O
we NN O O
employed NN O O
an NN O O
animal NN O O
model NN O O
of NN O O
A-T NN B-SpecificDisease B-MSH:D001260
, NN O O
the NN O O
mouse NN O O
with NN O O
a NN O O
disrupted NN O O
atm NN O O
gene. NN O O
we NN O O
show NN O O
that NN O O
organs NN O O
which NN O O
develop NN O O
pathologic NN O O
changes NN O O
in NN O O
the NN O O
atm-deficient NN O O
mice NN O O
are NN O O
targets NN O O
of NN O O
oxidative NN O O
damage, NN O O
and NN O O
that NN O O
cerebellar NN O O
purkinje NN O O
cells NN O O
are NN O O
particularly NN O O
affected. NN O O
these NN O O
observations NN O O
provide NN O O
a NN O O
mechanistic NN O O
basis NN O O
for NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260

t NN O O
phenotype NN O O
and NN O O
lay NN O O
a NN O O
rational NN O O
foundation NN O O
for NN O O
therapeutic NN O O
intervention. NN O O
. NN O O

family NN O O
studies NN O O
in NN O O
Bechterew's NN B-SpecificDisease B-MSH:D013167
syndrome NN I-SpecificDisease I-MSH:D013167
( NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
) NN O O
iii. NN O O
genetics NN O O
. NN O O

the NN O O
results NN O O
of NN O O
segregation NN O O
analyses NN O O
in NN O O
75 NN O O
families NN O O
where NN O O
the NN O O
proband NN O O
had NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
, NN O O
are NN O O
presented. NN O O
of NN O O
the NN O O
278 NN O O
adult, NN O O
living NN O O
first NN O O
degree NN O O
relatives, NN O O
approximately NN O O
85% NN O O
cooperated NN O O
in NN O O
the NN O O
study. NN O O
clinical NN O O
and NN O O
radiographical NN O O
examinations NN O O
were NN O O
performed NN O O
and NN O O
hla NN O O
typing NN O O
was NN O O
conducted. NN O O
the NN O O
results NN O O
were NN O O
in NN O O
agreement NN O O
with NN O O
our NN O O
hypothesis NN O O
that NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
is NN O O
part NN O O
of NN O O
a NN O O
syndrome NN O O
where NN O O
different NN O O
genetic NN O O
factors NN O O
interact. NN O O
such NN O O
known NN O O
factors NN O O
are NN O O
hla NN O O
b NN O O
27 NN O O
associated NN O O
disease NN O O
susceptibility, NN O O
susceptibility NN O O
to NN O O
psoriatic NN B-SpecificDisease B-MSH:D015535
arthropathy NN I-SpecificDisease I-MSH:D015535
and NN O O
susceptibility NN O O
to NN O O
entero-arthropathy NN B-SpecificDisease B-MSH:C538273
. NN O O
radiographical NN O O
sacro-iliitis NN B-SpecificDisease B-MSH:D058566
was NN O O
restricted NN O O
to NN O O
hla NN O O
b NN O O
27 NN O O
positive NN O O
relatives, NN O O
and NN O O
was NN O O
more NN O O
frequently NN O O
found NN O O
in NN O O
relatives NN O O
to NN O O
probands NN O O
with NN O O
psoriasis NN B-SpecificDisease B-MSH:D011565
than NN O O
in NN O O
relatives NN O O
to NN O O
probands NN O O
without NN O O
psoriasis NN B-SpecificDisease B-MSH:D011565
. NN O O
environmental NN O O
factors NN O O
(intestinal NN O O
bacteria) NN O O
are NN O O
known NN O O
to NN O O
trigger NN O O
the NN O O
disease NN O O
at NN O O
least NN O O
in NN O O
som NN O O
. NN O O

persons, NN O O
and NN O O
we NN O O
have NN O O
postulated NN O O
that NN O O
all NN O O
or NN O O
most NN O O
of NN O O
them NN O O
have NN O O
the NN O O
predisposition NN O O
to NN O O
develop NN O O
disease. NN O O
thus, NN O O
the NN O O
syndrome NN O O
has NN O O
a NN O O
multifactorial NN O O
etiology. NN O O
the NN O O
phenotypic NN O O
expressions NN O O
of NN O O
the NN O O
different NN O O
genetic NN O O
predispositions NN O O
involved, NN O O
include NN O O
sacro-iliitis NN B-SpecificDisease B-MSH:D058566
, NN O O
psoriasis NN B-SpecificDisease B-MSH:D011565
, NN O O
acute NN B-SpecificDisease B-MSH:D014606
anterior NN I-SpecificDisease I-MSH:D014606
uveitis NN I-SpecificDisease I-MSH:D014606
, NN O O
peripheral NN O O
arthropathy NN B-SpecificDisease B-MSH:D007592
and NN O O
inflammatory NN B-SpecificDisease B-MSH:D015212
bowel NN I-SpecificDisease I-MSH:D015212
disease NN I-SpecificDisease I-MSH:D015212
. NN O O
we NN O O
suggest NN O O
the NN O O
descriptive NN O O
name NN O O
HEREDITARY NN B-SpecificDisease B-MSH:D007249
MULTIFOCAL NN I-SpecificDisease I-MSH:D007249
RELAPSING NN I-SpecificDisease I-MSH:D007249
INFLAMMATION NN I-SpecificDisease I-MSH:D007249
( NN O O
HEMRI NN B-SpecificDisease B-MSH:D007249
) NN O O
for NN O O
this NN O O
syndrome. NN O O
Ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
, NN O O
psoriatic NN B-SpecificDisease B-MSH:D015535
arthropathy NN I-SpecificDisease I-MSH:D015535
and NN O O
entero-arthropathy NN B-SpecificDisease B-MSH:C538273
may NN O O
be NN O O
regarded NN O O
as NN O O
clinical NN O O
sub-types NN O O
of NN O O
the NN O O
syndrome. NN O O
. NN O O

chromosome NN O O
mapping NN O O
of NN O O
the NN O O
rod NN O O
photoreceptor NN O O
cgmp NN O O
phosphodiesterase NN O O
beta-subunit NN O O
gene NN O O
in NN O O
mouse NN O O
and NN O O
human: NN O O
tight NN O O
linkage NN O O
to NN O O
the NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
region NN O O
(4 NN O O
p NN O O
16.3) NN O O
. NN O O

the NN O O
retinal NN B-Modifier B-MSH:D012162
degeneration NN I-Modifier I-MSH:D012162
mouse NN O O
(gene NN O O
symbol, NN O O
rd) NN O O
is NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
certain NN O O
forms NN O O
of NN O O
human NN O O
hereditary NN B-DiseaseClass B-MSH:D015785
retinopathies NN I-DiseaseClass I-MSH:D015785
. NN O O
recent NN O O
findings NN O O
of NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
the NN O O
rd NN O O
mouse NN O O
pde NN O O
beta-subunit NN O O
gene NN O O
(pdeb) NN O O
prompted NN O O
us NN O O
to NN O O
investigate NN O O
the NN O O
chromosome NN O O
locations NN O O
of NN O O
the NN O O
mouse NN O O
and NN O O
human NN O O
genes. NN O O
we NN O O
have NN O O
utilized NN O O
backcross NN O O
analysis NN O O
in NN O O
mice NN O O
to NN O O
verify NN O O
and NN O O
define NN O O
more NN O O
precisely NN O O
the NN O O
location NN O O
of NN O O
the NN O O
pdeb NN O O
locus NN O O
6. NN O O
1 NN O O
+/- NN O O
2. NN O O
3 NN O O
cm NN O O
distal NN O O
of NN O O
mgsa NN O O
on NN O O
mouse NN O O
chromosome NN O O
5. NN O O
we NN O O
have NN O O
determined NN O O
that NN O O
the NN O O
human NN O O
gene NN O O
(pdeb) NN O O
maps NN O O
to NN O O
4 NN O O
p NN O O
16. NN O O
3, NN O O
very NN O O
close NN O O
to NN O O
the NN O O
Huntington NN B-Modifier B-MSH:D006816
disease NN I-Modifier I-MSH:D006816
( NN O O
HD NN B-Modifier B-MSH:D006816
) NN O O
region. NN O O
analysis NN O O
of NN O O
the NN O O
comparative NN O O
map NN O O
for NN O O
mice NN O O
and NN O O
humans NN O O
shows NN O O
that NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
will NN O O
resid NN O O
. NN O O

on NN O O
chromosome NN O O
5. NN O O
linkage NN O O
of NN O O
the NN O O
mouse NN O O
pdeb NN O O
locus NN O O
with NN O O
other NN O O
homologues NN O O
in NN O O
the NN O O
human NN O O
4 NN O O
p NN O O
16. NN O O
3 NN O O
region NN O O
is NN O O
maintained NN O O
but NN O O
gene NN O O
order NN O O
is NN O O
not, NN O O
suggesting NN O O
at NN O O
least NN O O
three NN O O
possible NN O O
sites NN O O
for NN O O
the NN O O
corresponding NN O O
mouse NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
. NN O O

hereditary NN O O
deficiency NN O O
of NN O O
the NN O O
fifth NN O O
component NN O O
of NN O O
complement NN O O
in NN O O
man. NN O O
ii. NN O O
biological NN O O
properties NN O O
of NN O O
C5-deficient NN B-Modifier B-OMIM:609536
human NN O O
serum NN O O
. NN O O

the NN O O
first NN O O
known NN O O
human NN O O
kindred NN O O
with NN O O
hereditary NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
the NN I-SpecificDisease I-OMIM:609536
fifth NN I-SpecificDisease I-OMIM:609536
component NN I-SpecificDisease I-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
complement NN I-SpecificDisease I-OMIM:609536
(c NN O O
5) NN O O
was NN O O
documented NN O O
in NN O O
the NN O O
accompanying NN O O
report. NN O O
this NN O O
study NN O O
examines NN O O
several NN O O
biological NN O O
properties NN O O
of NN O O
C5-deficient NN B-Modifier B-OMIM:609536
( NN O O
C5D NN B-Modifier B-OMIM:609536
) NN O O
human NN O O
serum, NN O O
particularly NN O O
sera NN O O
obtained NN O O
from NN O O
two NN O O
C5D NN B-Modifier B-OMIM:609536
homozygotes. NN O O
the NN O O
proband, NN O O
who NN O O
has NN O O
inactive NN O O
systemic NN B-SpecificDisease B-MSH:D008180
lupus NN I-SpecificDisease I-MSH:D008180
erythematosus NN I-SpecificDisease I-MSH:D008180
is NN O O
completely NN O O
lacking NN O O
c NN O O
5, NN O O
while NN O O
her NN O O
healthy NN O O
half-sister NN O O
has NN O O
1-2% NN O O
of NN O O
normal NN O O
levels. NN O O
both NN O O
sera NN O O
were NN O O
severely NN O O
impaired NN O O
in NN O O
their NN O O
ability NN O O
to NN O O
generate NN O O
chemotactic NN O O
activity NN O O
for NN O O
normal NN O O
human NN O O
neutrophils NN O O
upon NN O O
incubation NN O O
with NN O O
aggregated NN O O
human NN O O
gamma-globulin NN O O
or NN O O
escherichia NN O O
coli NN O O
endotoxin. NN O O
this NN O O
function NN O O
was NN O O
fully NN O O
restored NN O O
in NN O O
the NN O O
siblings NN O O
serum, NN O O
and NN O O
substantially NN O O
improved NN O O
in NN O O
the NN O O
probands NN O O
serum, NN O O
by NN O O
addition NN O O
of NN O O
highly NN O O
purified NN O O
human NN O O
c NN O O
5 NN O O
t NN O O
. NN O O

normal NN O O
serum NN O O
concentrations. NN O O
sera NN O O
from NN O O
eight NN O O
family NN O O
members NN O O
who NN O O
were NN O O
apparently NN O O
heterozygous NN O O
for NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
gave NN O O
normal NN O O
chemotactic NN O O
scores. NN O O
the NN O O
ability NN O O
of NN O O
C5D NN B-Modifier B-OMIM:609536
serum NN O O
to NN O O
opsonize NN O O
saccharomyces NN O O
cerevisiae NN O O
(bakers NN O O
yeast) NN O O
or NN O O
candida NN O O
albicans NN O O
for NN O O
ingestion NN O O
by NN O O
normal NN O O
neutrophils NN O O
was NN O O
completely NN O O
normal. NN O O
in NN O O
addition, NN O O
C5D NN B-Modifier B-OMIM:609536
serum NN O O
was NN O O
capable NN O O
of NN O O
promoting NN O O
normal NN O O
phagocytosis NN O O
and NN O O
intracellular NN O O
killing NN O O
of NN O O
staphylococcus NN O O
aureus. NN O O
the NN O O
probands NN O O
serum NN O O
was NN O O
incapable NN O O
of NN O O
mediating NN O O
lysis NN O O
of NN O O
erythrocytes NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
paroxysmal NN B-SpecificDisease B-MSH:D006457
nocturnal NN I-SpecificDisease I-MSH:D006457
hemoglobinuria NN I-SpecificDisease I-MSH:D006457
in NN O O
both NN O O
the NN O O
sucrose NN O O
hemolysia NN O O
and NN O O
acid NN O O
hemolysis NN O O
tests, NN O O
and NN O O
also NN O O
lacked NN O O
bactericidal NN O O
activity NN O O
against NN O O
sensitized NN O O
or NN O O
unsensitized NN O O
salmonella NN O O
typhi. NN O O
the NN O O
siblings NN O O
serum, NN O O
containing NN O O
only NN O O
1-2% NN O O
of NN O O
normal NN O O
c NN O O
5, NN O O
effectively NN O O
lysed NN O O
s. NN O O
typhi, NN O O
but NN O O
only NN O O
at NN O O
eightfold NN O O
lower NN O O
serum NN O O
dilutions NN O O
as NN O O
compared NN O O
to NN O O
normal NN O O
. NN O O

. NN O O
these NN O O
findings NN O O
underscore NN O O
the NN O O
critical NN O O
role NN O O
of NN O O
c NN O O
5 NN O O
in NN O O
the NN O O
generation NN O O
of NN O O
chemotactic NN O O
activity NN O O
and NN O O
in NN O O
cytolytic NN O O
reactions, NN O O
as NN O O
opposed NN O O
to NN O O
a NN O O
nonobligatory NN O O
or NN O O
minimal NN O O
role NN O O
in NN O O
opsonization, NN O O
at NN O O
least NN O O
for NN O O
the NN O O
organisms NN O O
under NN O O
study. NN O O
. NN O O

the NN O O
gene NN O O
for NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
, NN O O
mefv, NN O O
is NN O O
expressed NN O O
in NN O O
early NN O O
leukocyte NN O O
development NN O O
and NN O O
is NN O O
regulated NN O O
in NN O O
response NN O O
to NN O O
inflammatory NN O O
mediators NN O O
. NN O O

familial NN O O
mediterranean NN O O
fever NN O O
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
) NN O O
is NN O O
a NN O O
recessive NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
episodes NN O O
of NN O O
fever NN B-DiseaseClass B-MSH:D005334
and NN O O
neutrophil-mediated NN B-SpecificDisease B-MSH:D007249
serosal NN I-SpecificDisease I-MSH:D007249
inflammation NN I-SpecificDisease I-MSH:D007249
. NN O O
we NN O O
recently NN O O
identified NN O O
the NN O O
gene NN O O
causing NN O O
FMF NN B-SpecificDisease B-MSH:D010505
, NN O O
designated NN O O
mefv, NN O O
and NN O O
found NN O O
it NN O O
to NN O O
be NN O O
expressed NN O O
in NN O O
mature NN O O
neutrophils, NN O O
suggesting NN O O
that NN O O
it NN O O
functions NN O O
as NN O O
an NN O O
inflammatory NN O O
regulator. NN O O
to NN O O
facilitate NN O O
our NN O O
understanding NN O O
of NN O O
the NN O O
normal NN O O
function NN O O
of NN O O
mefv, NN O O
we NN O O
extended NN O O
our NN O O
previous NN O O
studies. NN O O
mefv NN O O
messenger NN O O
rna NN O O
was NN O O
detected NN O O
by NN O O
reverse NN O O
transcriptase-polymerase NN O O
chain NN O O
reaction NN O O
in NN O O
bone NN O O
marrow NN O O
leukocytes, NN O O
with NN O O
differential NN O O
expression NN O O
observed NN O O
among NN O O
cells NN O O
by NN O O
in NN O O
situ NN O O
hybridization. NN O O
cd NN O O
34 NN O O
hematopoietic NN O O
stem-cell NN O O
cultures NN O O
induced NN O O
toward NN O O
the NN O O
granulocytic NN O O
lineage NN O O
expressed NN O O
mefv NN O O
at NN O O
the NN O O
myelocyte NN O O
stage, NN O O
concurrently NN O O
with NN O O
lineage NN O O
commitment. NN O O
the NN O O
prepromyelocytic NN O O
cell NN O O
line NN O O
hl NN O O
60 NN O O
expressed NN O O
mefv NN O O
only NN O O
at NN O O
granulocytic NN O O
and NN O O
monocytic NN O O
differentiation. NN O O
mefv NN O O
was NN O O
also NN O O
expresse NN O O
. NN O O

in NN O O
the NN O O
monocytic NN O O
cell NN O O
lines NN O O
u NN O O
937 NN O O
and NN O O
thp-1. NN O O
among NN O O
peripheral NN O O
blood NN O O
leukocytes, NN O O
mefv NN O O
expression NN O O
was NN O O
detected NN O O
in NN O O
neutrophils, NN O O
eosinophils, NN O O
and NN O O
to NN O O
varying NN O O
degrees, NN O O
monocytes. NN O O
consistent NN O O
with NN O O
the NN O O
tissue NN O O
specificity NN O O
of NN O O
expression, NN O O
complete NN O O
sequencing NN O O
and NN O O
analysis NN O O
of NN O O
upstream NN O O
regulatory NN O O
regions NN O O
of NN O O
mefv NN O O
revealed NN O O
homology NN O O
to NN O O
myeloid-specific NN O O
promoters NN O O
and NN O O
to NN O O
more NN O O
broadly NN O O
expressed NN O O
inflammatory NN O O
promoter NN O O
elements. NN O O
in NN O O
vitro NN O O
stimulation NN O O
of NN O O
monocytes NN O O
with NN O O
the NN O O
proinflammatory NN O O
agents NN O O
interferon NN O O
(ifn) NN O O
gamma, NN O O
tumor NN B-Modifier B-MSH:D009369
necrosis NN O O
factor, NN O O
and NN O O
lipopolysaccharide NN O O
induced NN O O
mefv NN O O
expression, NN O O
whereas NN O O
the NN O O
antiinflammatory NN O O
cytokines NN O O
interleukin NN O O
(il) NN O O
4, NN O O
il-10, NN O O
and NN O O
transforming NN O O
growth NN O O
factor NN O O
beta NN O O
inhibited NN O O
such NN O O
expression. NN O O
induction NN O O
by NN O O
ifn-gamma NN O O
occurred NN O O
rapidly NN O O
and NN O O
was NN O O
resistant NN O O
to NN O O
cycloheximide. NN O O
ifn-alpha NN O O
also NN O O
induced NN O O
mefv NN O O
expression. NN O O
in NN O O
granulocytes, NN O O
mef NN O O
. NN O O

was NN O O
up-regulated NN O O
by NN O O
ifn-gamma NN O O
and NN O O
the NN O O
combination NN O O
of NN O O
ifn-alpha NN O O
and NN O O
colchicine. NN O O
these NN O O
results NN O O
refine NN O O
understanding NN O O
of NN O O
mefv NN O O
by NN O O
placing NN O O
the NN O O
gene NN O O
in NN O O
the NN O O
myelomonocytic-specific NN O O
proinflammatory NN O O
pathway NN O O
and NN O O
identifying NN O O
it NN O O
as NN O O
an NN O O
ifn-gamma NN O O
immediate NN O O
early NN O O
gene. NN O O
. NN O O

spectrum NN O O
of NN O O
hsnf NN O O
5/ini NN O O
1 NN O O
somatic NN O O
mutations NN O O
in NN O O
human NN O O
cancer NN B-DiseaseClass B-MSH:D009369
and NN O O
genotype-phenotype NN O O
correlations NN O O
. NN O O

the NN O O
hsnf NN O O
5/ini NN O O
1 NN O O
gene NN O O
which NN O O
encodes NN O O
a NN O O
member NN O O
of NN O O
the NN O O
swi/snf NN O O
chromatin NN O O
atp-dependent NN O O
remodeling NN O O
complex, NN O O
is NN O O
a NN O O
new NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
gene NN O O
localized NN O O
on NN O O
chromosome NN O O
22 NN O O
q NN O O
11. NN O O
2 NN O O
and NN O O
recently NN O O
shown NN O O
to NN O O
be NN O O
mutated NN O O
in NN O O
malignant NN B-DiseaseClass B-MSH:D018335
rhabdoid NN I-DiseaseClass I-MSH:D018335
tumors NN I-DiseaseClass I-MSH:D018335
. NN O O
we NN O O
have NN O O
searched NN O O
for NN O O
hsnf NN O O
5/ini NN O O
1 NN O O
mutations NN O O
in NN O O
229 NN O O
tumors NN B-DiseaseClass B-MSH:D009369
of NN O O
various NN O O
origins NN O O
using NN O O
a NN O O
screening NN O O
method NN O O
based NN O O
on NN O O
denaturing NN O O
high-performance NN O O
liquid NN O O
chromatography. NN O O
a NN O O
total NN O O
of NN O O
31 NN O O
homozygous NN O O
deletions NN O O
and NN O O
36 NN O O
point NN O O
alterations NN O O
were NN O O
identified. NN O O
point NN O O
mutations NN O O
were NN O O
scattered NN O O
along NN O O
the NN O O
coding NN O O
sequence NN O O
and NN O O
included NN O O
15 NN O O
nonsense, NN O O
15 NN O O
frameshift, NN O O
three NN O O
splice NN O O
site, NN O O
two NN O O
missense NN O O
and NN O O
one NN O O
editing NN O O
mutations. NN O O
mutations NN O O
were NN O O
retrieved NN O O
in NN O O
most NN O O
rhabdoid NN B-DiseaseClass B-MSH:D018335
tumors NN I-DiseaseClass I-MSH:D018335
, NN O O
whatever NN O O
their NN O O
sites NN O O
of NN O O
occurrence, NN O O
indicating NN O O
the NN O O
common NN O O
pathogenetic NN O O
origin NN O O
of NN O O
these NN O O
tumors NN B-DiseaseClass B-MSH:D009369
. NN O O

recurrent NN O O
hsnf NN O O
5/ini NN O O
1 NN O O
alterations NN O O
were NN O O
also NN O O
observed NN O O
in NN O O
choroid NN B-SpecificDisease B-MSH:D020288
plexus NN I-SpecificDisease I-MSH:D020288
carcinomas NN I-SpecificDisease I-MSH:D020288
and NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
central NN O O
primitive NN O O
neuroectodermal NN B-DiseaseClass B-MSH:D017599
tumors NN I-DiseaseClass I-MSH:D017599
(cpnets) NN O O
and NN O O
medulloblastomas NN B-SpecificDisease B-MSH:D008527
. NN O O
in NN O O
contrast, NN O O
hsnf NN O O
5/ini NN O O
1 NN O O
point NN O O
mutations NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancers NN I-SpecificDisease I-MSH:D001943
, NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumors NN I-SpecificDisease I-MSH:D009396
, NN O O
gliomas NN B-SpecificDisease B-MSH:D005910
, NN O O
ependymomas NN B-SpecificDisease B-MSH:D004806
, NN O O
sarcomas NN B-DiseaseClass B-MSH:D012509
and NN O O
other NN O O
tumor NN B-Modifier B-MSH:D009369
types, NN O O
even NN O O
though NN O O
most NN O O
analyzed NN O O
cases NN O O
harbored NN O O
loss NN O O
of NN O O
heterozygosity NN O O
at NN O O
22 NN O O
q NN O O
11. NN O O
2 NN O O
loci. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
rhabdoid NN B-DiseaseClass B-MSH:D018335
tumors NN I-DiseaseClass I-MSH:D018335
, NN O O
choroid NN B-SpecificDisease B-MSH:D020288
plexus NN I-SpecificDisease I-MSH:D020288
carcinomas NN I-SpecificDisease I-MSH:D020288
and NN O O
a NN O O
subset NN O O
of NN O O
medulloblastomas NN B-SpecificDisease B-MSH:D008527
and NN O O
cpnets NN O O
share NN O O
common NN O O
pathways NN O O
of NN O O
oncogenesis NN O O
related NN O O
to NN O O
hsnf NN O O
5/ini NN O O
1 NN O O
alteration NN O O
and NN O O
that NN O O
hsnf NN O O
5/ini NN O O
1 NN O O
mutations NN O O
define NN O O
a NN O O
genetically NN O O
homogeneous NN O O
family NN O O
of NN O O
highly NN O O
aggressive NN O O
cancers NN B-DiseaseClass B-MSH:D009369
mainly NN O O
occurring NN O O
in NN O O
young NN O O
children NN O O
and NN O O
frequently, NN O O
but NN O O
not NN O O
always, NN O O
exhibiting NN O O
a NN O O
rhabdoid NN B-Modifier B-MSH:D018335
phenotyp NN O O
. NN O O

heterogeneity NN O O
of NN O O
glucose-6-phosphate NN B-SpecificDisease B-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
algeria. NN O O
study NN O O
in NN O O
northern NN O O
algeria NN O O
with NN O O
description NN O O
of NN O O
five NN O O
new NN O O
variants NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
deficiency NN O O
was NN O O
found NN O O
in NN O O
3. NN O O
2% NN O O
of NN O O
the NN O O
male NN O O
population NN O O
living NN O O
in NN O O
the NN O O
urban NN O O
area NN O O
of NN O O
algiers. NN O O
the NN O O
deficient NN O O
subjects NN O O
originated NN O O
from NN O O
multiple NN O O
geographic NN O O
regions NN O O
of NN O O
northern NN O O
algeria, NN O O
with NN O O
prevalence NN O O
of NN O O
individuals NN O O
of NN O O
berber-kabyle NN O O
origin. NN O O
red NN O O
blood NN O O
cell NN O O
g NN O O
6 NN O O
pd NN O O
was NN O O
partially NN O O
purified NN O O
and NN O O
characterized NN O O
in NN O O
deficient NN O O
males NN O O
from NN O O
17 NN O O
families, NN O O
and NN O O
six NN O O
different NN O O
variants NN O O
were NN O O
found. NN O O
among NN O O
them, NN O O
only NN O O
one, NN O O
the NN O O
gd NN O O
(-) NN O O
kabyle NN O O
variant, NN O O
had NN O O
been NN O O
previously NN O O
described. NN O O
it NN O O
was NN O O
detected NN O O
in NN O O
nine NN O O
families. NN O O
the NN O O
other NN O O
five NN O O
variants NN O O
were NN O O
new NN O O
gd NN O O
(-) NN O O
laghouat NN O O
(four NN O O
cases), NN O O
gd NN O O
(-) NN O O
blida NN O O
(one NN O O
case), NN O O
gd NN O O
(-) NN O O
thenia NN O O
(one NN O O
case) NN O O
. NN O O
nd NN O O
in NN O O
3. NN O O
2% NN O O
of NN O O
the NN O O
male NN O O
population NN O O
living NN O O
in NN O O
the NN O O
urban NN O O
area NN O O
of NN O O
algiers. NN O O
the NN O O
deficient NN O O
subjects NN O O
originated NN O O
from NN O O
multiple NN O O
geographic NN O O
regions NN O O
of NN O O
northern NN O O
algeria, NN O O
with NN O O
prevalence NN O O
of NN O O
individuals NN O O
of NN O O
berber-kabyle NN O O
origin. NN O O
red NN O O
blood NN O O
cell NN O O
g NN O O
6 NN O O
pd NN O O
was NN O O
partially NN O O
purified NN O O
and NN O O
characterized NN O O
in NN O O
deficient NN O O
males NN O O
from NN O O
17 NN O O
families, NN O O
and NN O O
six NN O O
different NN O O
variants NN O O
were NN O O
found. NN O O
among NN O O
them, NN O O
only NN O O
one, NN O O
the NN O O
gd NN O O
(-) NN O O
kabyle NN O O
variant, NN O O
had NN O O
been NN O O
previously NN O O
described. NN O O
it NN O O
was NN O O
detected NN O O
in NN O O
nine NN O O
families. NN O O
the NN O O
other NN O O
five NN O O
variants NN O O
were NN O O
new NN O O
gd NN O O
(-) NN O O
laghouat NN O O
(four NN O O
cases), NN O O
gd NN O O
(-) NN O O
blida NN O O
(one NN O O
case), NN O O
gd NN O O
(-) NN O O
thenia NN O O
(one NN O O
case) NN O O
. NN O O

gd NN O O
(-) NN O O
titteri NN O O
(one NN O O
case), NN O O
and NN O O
gd NN O O
(-) NN O O
alger NN O O
(two NN O O
brothers). NN O O
strikingly, NN O O
the NN O O
common NN O O
mediterranean NN O O
variant NN O O
was NN O O
not NN O O
found. NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
is NN O O
heterogeneous NN O O
in NN O O
northern NN O O
algeria NN O O
where NN O O
autochtonous NN O O
variants NN O O
seem NN O O
to NN O O
prevail. NN O O
the NN O O
kabyle NN O O
variant NN O O
may NN O O
be NN O O
common NN O O
in NN O O
this NN O O
country NN O O
. NN O O

fragile NN O O
x NN O O
syndrome NN O O
without NN O O
ccg NN O O
amplification NN O O
has NN O O
an NN O O
fmr NN O O
1 NN O O
deletion NN O O
. NN O O

we NN O O
describe NN O O
a NN O O
patient NN O O
with NN O O
typical NN O O
clinical NN O O
features NN O O
of NN O O
the NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
, NN O O
but NN O O
without NN O O
cytogenetic NN O O
expression NN O O
of NN O O
the NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
or NN O O
an NN O O
amplified NN O O
ccg NN O O
trinucleotide NN O O
repeat NN O O
fragment. NN O O
the NN O O
patient NN O O
has NN O O
a NN O O
previously NN O O
uncharacterized NN O O
submicroscopic NN O O
deletion NN O O
encompassing NN O O
the NN O O
ccg NN O O
repeat, NN O O
the NN O O
entire NN O O
fmr NN O O
1 NN O O
gene NN O O
and NN O O
about NN O O
2. NN O O
5 NN O O
megabases NN O O
of NN O O
flanking NN O O
sequences. NN O O
this NN O O
finding NN O O
confirms NN O O
that NN O O
the NN O O
fragile NN B-Modifier B-MSH:D005600
X NN I-Modifier I-MSH:D005600
phenotype NN O O
can NN O O
exist, NN O O
without NN O O
amplification NN O O
of NN O O
the NN O O
ccg NN O O
repeat NN O O
or NN O O
cytogenetic NN O O
expression NN O O
of NN O O
the NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
, NN O O
and NN O O
that NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
is NN O O
a NN O O
genetically NN O O
homogeneous NN O O
disorder NN O O
involving NN O O
fmr NN O O
1. NN O O
we NN O O
also NN O O
found NN O O
random NN O O
x-inactivation NN O O
in NN O O
the NN O O
mother NN O O
of NN O O
the NN O O
patient NN O O
who NN O O
was NN O O
shown NN O O
to NN O O
be NN O O
a NN O O
carrier NN O O
of NN O O
this NN O O
deletion NN O O
. NN O O

confirmation NN O O
of NN O O
linkage NN O O
of NN O O
Van NN B-SpecificDisease B-MSH:C536528
der NN I-SpecificDisease I-MSH:C536528
Woude NN I-SpecificDisease I-MSH:C536528
syndrome NN I-SpecificDisease I-MSH:C536528
to NN O O
chromosome NN O O
1 NN O O
q NN O O
32: NN O O
evidence NN O O
of NN O O
association NN O O
with NN O O
str NN O O
alleles NN O O
suggests NN O O
possible NN O O
unique NN O O
origin NN O O
of NN O O
the NN O O
disease NN O O
mutation NN O O
. NN O O

van NN O O
der NN O O
woude NN O O
syndrome NN O O
( NN O O
VWS NN B-SpecificDisease B-MSH:C536528
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D019465
dominant NN I-DiseaseClass I-MSH:D019465
craniofacial NN I-DiseaseClass I-MSH:D019465
disorder NN I-DiseaseClass I-MSH:D019465
with NN O O
high NN O O
penetrance NN O O
and NN O O
variable NN O O
expression. NN O O
its NN O O
clinical NN O O
features NN O O
are NN O O
variably NN O O
expressed, NN O O
but NN O O
include NN O O
cleft NN B-SpecificDisease B-MSH:D002971
lip NN I-SpecificDisease I-MSH:D002971
and/or NN O O
cleft NN B-SpecificDisease B-MSH:D002972
palate NN I-SpecificDisease I-MSH:D002972
, NN O O
lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
and NN O O
hypodontia NN B-SpecificDisease B-MSH:D000848
. NN O O
all NN O O
VWS NN B-Modifier B-MSH:C536528
families NN O O
studied NN O O
to NN O O
date NN O O
map NN O O
the NN O O
disease NN O O
gene NN O O
to NN O O
a NN O O
< NN O O
2 NN O O
cm NN O O
region NN O O
of NN O O
chromosome NN O O
1 NN O O
q NN O O
32, NN O O
with NN O O
no NN O O
evidence NN O O
of NN O O
locus NN O O
heterogeneity. NN O O
the NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
refine NN O O
the NN O O
localization NN O O
of NN O O
the NN O O
VWS NN B-Modifier B-MSH:C536528
gene NN O O
and NN O O
to NN O O
further NN O O
assess NN O O
possible NN O O
heterogeneity. NN O O
we NN O O
analyzed NN O O
four NN O O
multiplex NN O O
VWS NN B-Modifier B-MSH:C536528
families. NN O O
all NN O O
available NN O O
members NN O O
were NN O O
clinically NN O O
assessed NN O O
and NN O O
genotyped NN O O
for NN O O
19 NN O O
short NN O O
tandem NN O O
repeat NN O O
markers NN O O
on NN O O
chromosome NN O O
1 NN O O
in NN O O
the NN O O
VWS NN B-Modifier B-MSH:C536528
candidate NN O O
gene NN O O
region. NN O O
we NN O O
performed NN O O
two-point NN O O
and NN O O
multipoint NN O O
limit NN O O
of NN O O
detection NN O O
(lod) NN O O
score NN O O
analyses NN O O
using NN O O
. NN O O

high NN O O
penetrance NN O O
autosomal NN O O
dominant NN O O
model. NN O O
all NN O O
families NN O O
showed NN O O
positive NN O O
lod NN O O
scores NN O O
without NN O O
any NN O O
recombination NN O O
in NN O O
the NN O O
candidate NN O O
region. NN O O
the NN O O
largest NN O O
two-point NN O O
lod NN O O
score NN O O
was NN O O
5. NN O O
87 NN O O
87. NN O O
our NN O O
assay NN O O
method NN O O
for NN O O
short NN O O
tandem NN O O
repeat NN O O
(str) NN O O
markers NN O O
provided NN O O
highly NN O O
accurate NN O O
size NN O O
estimation NN O O
of NN O O
marker NN O O
allele NN O O
fragment NN O O
sizes, NN O O
and NN O O
therefore NN O O
enabled NN O O
us NN O O
to NN O O
determine NN O O
the NN O O
specific NN O O
alleles NN O O
segregating NN O O
with NN O O
the NN O O
VWS NN B-Modifier B-MSH:C536528
gene NN O O
in NN O O
each NN O O
of NN O O
our NN O O
four NN O O
families. NN O O
we NN O O
observed NN O O
a NN O O
striking NN O O
pattern NN O O
of NN O O
str NN O O
allele NN O O
sharing NN O O
at NN O O
several NN O O
closely NN O O
linked NN O O
loci NN O O
among NN O O
our NN O O
four NN O O
caucasian NN O O
VWS NN B-Modifier B-MSH:C536528
families NN O O
recruited NN O O
at NN O O
three NN O O
different NN O O
locations NN O O
in NN O O
the NN O O
us. NN O O
these NN O O
results NN O O
suggest NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
unique NN O O
origin NN O O
for NN O O
a NN O O
mutation NN O O
responsible NN O O
for NN O O
many NN O O
or NN O O
most NN O O
cases NN O O
of NN O O
VWS NN B-SpecificDisease B-MSH:C536528
. NN O O

the NN O O
carrier NN O O
frequency NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
185 NN O O
delag NN O O
mutation NN O O
is NN O O
approximately NN O O
1 NN O O
percent NN O O
in NN O O
ashkenazi NN O O
jewish NN O O
individuals NN O O
. NN O O

since NN O O
brca NN O O
1, NN O O
the NN O O
first NN O O
major NN O O
gene NN O O
responsible NN O O
for NN O O
inherited NN B-SpecificDisease B-MSH:D061325
breast NN I-SpecificDisease I-MSH:D061325
cancer NN I-SpecificDisease I-MSH:D061325
, NN O O
was NN O O
cloned, NN O O
more NN O O
than NN O O
50 NN O O
unique NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
the NN O O
germline NN O O
of NN O O
individuals NN O O
with NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
. NN O O
in NN O O
high-risk NN O O
pedigrees, NN O O
female NN O O
carriers NN O O
of NN O O
brca NN O O
1 NN O O
mutations NN O O
have NN O O
an NN O O
80-90% NN O O
lifetime NN O O
risk NN O O
of NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
, NN O O
and NN O O
a NN O O
40-50% NN O O
risk NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
however, NN O O
the NN O O
mutation NN O O
stats NN O O
of NN O O
individuals NN O O
unselected NN O O
for NN O O
breast NN B-CompositeMention B-MSH:D010051
or NN I-CompositeMention I-MSH:D010051
ovarian NN I-CompositeMention I-MSH:D010051
cancer NN I-CompositeMention I-MSH:D010051
has NN O O
not NN O O
been NN O O
determined, NN O O
and NN O O
it NN O O
is NN O O
not NN O O
known NN O O
whether NN O O
mutations NN O O
in NN O O
such NN O O
individuals NN O O
confer NN O O
the NN O O
same NN O O
risk NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
as NN O O
in NN O O
individuals NN O O
from NN O O
the NN O O
high-risk NN O O
families NN O O
studied NN O O
so NN O O
far. NN O O
following NN O O
the NN O O
finding NN O O
of NN O O
a NN O O
185 NN O O
delag NN O O
frameshift NN O O
mutation NN O O
in NN O O
several NN O O
ashkenazi NN O O
jewish NN O O
breast/ovarian NN O O
families, NN O O
we NN O O
have NN O O
determined NN O O
th NN O O
. NN O O

frequency NN O O
of NN O O
this NN O O
mutation NN O O
in NN O O
858 NN O O
ashkenazim NN O O
seeking NN O O
genetic NN O O
testing NN O O
for NN O O
conditions NN O O
unrelated NN O O
to NN O O
cancer NN B-DiseaseClass B-MSH:D009369
, NN O O
and NN O O
in NN O O
815 NN O O
reference NN O O
individuals NN O O
not NN O O
selected NN O O
for NN O O
ethnic NN O O
origin. NN O O
we NN O O
observed NN O O
the NN O O
185 NN O O
delag NN O O
mutation NN O O
in NN O O
0. NN O O
9% NN O O
of NN O O
ashkenazim NN O O
(95% NN O O
confidence NN O O
limit, NN O O
0. NN O O
4-1. NN O O
8%) NN O O
and NN O O
in NN O O
none NN O O
of NN O O
the NN O O
reference NN O O
samples. NN O O
our NN O O
results NN O O
suggest NN O O
that NN O O
one NN O O
in NN O O
a NN O O
hundred NN O O
women NN O O
of NN O O
ashkenazi NN O O
descent NN O O
may NN O O
be NN O O
at NN O O
especially NN O O
high NN O O
risk NN O O
of NN O O
developing NN O O
breast NN B-CompositeMention B-MSH:D010051
and/or NN I-CompositeMention I-MSH:D010051
ovarian NN I-CompositeMention I-MSH:D010051
cancer NN I-CompositeMention I-MSH:D010051
. NN O O

targeted NN O O
modification NN O O
of NN O O
the NN O O
apolipoprotein NN O O
b NN O O
gene NN O O
results NN O O
in NN O O
hypobetalipoproteinemia NN B-SpecificDisease B-MSH:D006995
and NN O O
developmental NN B-DiseaseClass B-MSH:D006130
abnormalities NN I-DiseaseClass I-MSH:D006130
in NN O O
mice NN O O
. NN O O

familial NN O O
hypobetalipoproteinemia NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
codominant NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
resulting NN O O
in NN O O
a NN O O
dramatic NN O O
reduction NN O O
in NN O O
plasma NN O O
concentrations NN O O
of NN O O
apolipoprotein NN O O
(apo) NN O O
b, NN O O
cholesterol, NN O O
and NN O O
beta-migrating NN O O
lipoproteins. NN O O
a NN O O
benefit NN O O
of NN O O
hypobetalipoproteinemia NN B-SpecificDisease B-MSH:D006995
is NN O O
that NN O O
mildly NN O O
affected NN O O
individuals NN O O
may NN O O
be NN O O
protected NN O O
from NN O O
coronary NN B-DiseaseClass B-MSH:D003323
vascular NN I-DiseaseClass I-MSH:D003323
disease NN I-DiseaseClass I-MSH:D003323
. NN O O
we NN O O
have NN O O
used NN O O
gene NN O O
targeting NN O O
to NN O O
generate NN O O
mice NN O O
with NN O O
a NN O O
modified NN O O
apob NN O O
allele. NN O O
mice NN O O
containing NN O O
this NN O O
allele NN O O
display NN O O
all NN O O
of NN O O
the NN O O
hallmarks NN O O
of NN O O
human NN O O
hypobetalipoproteinemia NN B-SpecificDisease B-MSH:D006995
they NN O O
produce NN O O
a NN O O
truncated NN O O
apob NN O O
protein, NN O O
apob NN O O
70, NN O O
and NN O O
have NN O O
markedly NN O O
decreased NN O O
plasma NN O O
concentrations NN O O
of NN O O
apob, NN O O
beta-lipoproteins, NN O O
and NN O O
total NN O O
cholesterol. NN O O
in NN O O
addition, NN O O
the NN O O
mice NN O O
manifest NN O O
several NN O O
characteristics NN O O
that NN O O
are NN O O
occasionally NN O O
observed NN O O
in NN O O
human NN O O
hypobetalipoproteinemia NN B-SpecificDisease B-MSH:D006995
, NN O O
including NN O O
reduced NN O O
plasma NN O O
triglyceride NN O O
concentrations, NN O O
fasting NN O O
chylomicronemia NN B-SpecificDisease B-OMIM:238600
, NN O O
and NN O O
reduced NN O O
high NN O O
density NN O O
lipoprotein NN O O
cholesterol. NN O O
an NN O O
unexpected NN O O
finding NN O O
is NN O O
that NN O O
the NN O O
modified NN O O
apo NN O O
. NN O O

allele NN O O
is NN O O
strongly NN O O
associated NN O O
with NN O O
exencephalus NN B-SpecificDisease B-MSH:D009436
and NN O O
hydrocephalus NN B-SpecificDisease B-MSH:D006849
. NN O O
these NN O O
mice NN O O
should NN O O
help NN O O
increase NN O O
our NN O O
understanding NN O O
of NN O O
hypobetalipoproteinemia NN B-SpecificDisease B-MSH:D006995
, NN O O
atherogenesis NN B-DiseaseClass B-MSH:D050197
, NN O O
and NN O O
the NN O O
etiology NN O O
of NN O O
exencephalus NN B-SpecificDisease B-MSH:D009436
and NN O O
hydrocephalus NN B-SpecificDisease B-MSH:D006849
. NN O O
. NN O O

common NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
and NN O O
brca NN O O
2 NN O O
do NN O O
not NN O O
contribute NN O O
to NN O O
early NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
in NN O O
jewish NN O O
men NN O O
. NN O O

background NN O O
families NN O O
with NN O O
a NN O O
high NN O O
incidence NN O O
of NN O O
hereditary NN B-SpecificDisease B-MSH:D001943
breast NN I-SpecificDisease I-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
, NN O O
and NN O O
subsequently NN O O
shown NN O O
to NN O O
have NN O O
terminating NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
or NN O O
brca NN O O
2, NN O O
appear NN O O
to NN O O
have NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
among NN O O
male NN O O
relatives. NN O O
we NN O O
aimed NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
common NN O O
germline NN O O
mutations NN O O
of NN O O
brca NN O O
1 NN O O
or NN O O
brca NN O O
2 NN O O
in NN O O
ashkenazi NN O O
jewish NN O O
men NN O O
predisposed NN O O
them NN O O
to NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
. NN O O
methods NN O O
we NN O O
examined NN O O
genomic NN O O
dna NN O O
from NN O O
83 NN O O
(for NN O O
brca NN O O
1 NN O O
185 NN O O
delag) NN O O
or NN O O
82 NN O O
(for NN O O
brca NN O O
2 NN O O
6174 NN O O
delt) NN O O
ashkenazi NN O O
jewish NN O O
prostate NN B-Modifier B-MSH:D011471
cancer NN I-Modifier I-MSH:D011471
patients, NN O O
most NN O O
of NN O O
whom NN O O
were NN O O
treated NN O O
at NN O O
a NN O O
relatively NN O O
young NN O O
age, NN O O
for NN O O
the NN O O
most NN O O
common NN O O
germline NN O O
mutation NN O O
in NN O O
each NN O O
gene NN O O
seen NN O O
in NN O O
the NN O O
ashkenazi NN O O
population. NN O O
results NN O O
our NN O O
study NN O O
should NN O O
have NN O O
been NN O O
able NN O O
to NN O O
detect NN O O
a NN O O
4-5-fold NN O O
increase NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
. NN O O

due NN O O
to NN O O
mutation NN O O
of NN O O
brca NN O O
1 NN O O
or NN O O
brca NN O O
2. NN O O
however, NN O O
only NN O O
one NN O O
(1. NN O O
15%; NN O O
95% NN O O
confidence NN O O
interval, NN O O
0-3. NN O O
6%) NN O O
of NN O O
the NN O O
patients NN O O
was NN O O
heterozygous NN O O
for NN O O
the NN O O
brca NN O O
1 NN O O
mutant NN O O
allele, NN O O
and NN O O
only NN O O
two NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
brca NN O O
2 NN O O
mutation NN O O
(2. NN O O
4%; NN O O
95% NN O O
confidence NN O O
interval, NN O O
0-6. NN O O
2%). NN O O
conclusions NN O O
the NN O O
incidence NN O O
of NN O O
each NN O O
of NN O O
the NN O O
germline NN O O
mutations NN O O
in NN O O
these NN O O
prostate NN B-Modifier B-MSH:D011471
cancer NN I-Modifier I-MSH:D011471
patients NN O O
closely NN O O
matched NN O O
their NN O O
incidence NN O O
(about NN O O
1%) NN O O
in NN O O
the NN O O
general NN O O
ashkenazi NN O O
jewish NN O O
population. NN O O
this NN O O
suggests NN O O
that NN O O
unlike NN O O
cases NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancers NN I-CompositeMention I-MSH:D001943
, NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
or NN O O
brca NN O O
2 NN O O
do NN O O
not NN O O
significantly NN O O
predispose NN O O
men NN O O
to NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
. NN O O

two NN O O
new NN O O
variants NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
associated NN O O
with NN O O
hereditary NN B-SpecificDisease B-MSH:D000746
non-spherocytic NN I-SpecificDisease I-MSH:D000746
hemolytic NN I-SpecificDisease I-MSH:D000746
anemia NN I-SpecificDisease I-MSH:D000746
: NN O O
g NN O O
6 NN O O
pd NN O O
wayne NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
huron NN O O
. NN O O

two NN O O
new NN O O
deficient NN O O
variants NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
causing NN O O
hereditary NN B-SpecificDisease B-MSH:D000746
nonspherocytic NN I-SpecificDisease I-MSH:D000746
hemolytic NN I-SpecificDisease I-MSH:D000746
anemia NN I-SpecificDisease I-MSH:D000746
( NN O O
HNSHA NN B-SpecificDisease B-MSH:D000746
) NN O O
are NN O O
described. NN O O
both NN O O
of NN O O
these NN O O
are NN O O
unique NN O O
and NN O O
they NN O O
have NN O O
been NN O O
named NN O O
g NN O O
6 NN O O
pd NN O O
wayne NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
huron. NN O O
patients NN O O
with NN O O
g NN O O
6 NN O O
pd NN O O
wayne NN O O
underwent NN O O
splenectomy NN O O
and NN O O
no NN O O
objective NN O O
improvement NN O O
was NN O O
noted. NN O O
the NN O O
patients NN O O
with NN O O
g NN O O
6 NN O O
pd NN O O
huron NN O O
were NN O O
under NN O O
medical NN O O
observation NN O O
for NN O O
a NN O O
considerable NN O O
period NN O O
of NN O O
time NN O O
without NN O O
the NN O O
diagnosis NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
being NN O O
entertained NN O O
because NN O O
the NN O O
family NN O O
was NN O O
of NN O O
northern NN O O
european NN O O
origin. NN O O
since NN O O
sporadic NN O O
variants NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
causing NN O O
HNSHA NN B-SpecificDisease B-MSH:D000746
show NN O O
no NN O O
special NN O O
racial NN O O
predilection, NN O O
the NN O O
diagnosis NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
should NN O O
always NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
with NN O O
this NN O O
syndrome. NN O O
. NN O O

the NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
gene NN O O
in NN O O
north NN O O
american NN O O
jewish NN O O
populations: NN O O
geographic NN O O
variations NN O O
and NN O O
origin NN O O
. NN O O

from NN O O
data NN O O
collected NN O O
in NN O O
a NN O O
north NN O O
american NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
disease NN I-Modifier I-MSH:D013661
( NN O O
TSD NN B-Modifier B-MSH:D013661
) NN O O
heterozygote NN O O
screening NN O O
program, NN O O
the NN O O
TSD NN B-Modifier B-MSH:D013661
carrier NN O O
frequency NN O O
among NN O O
46, NN O O
304 NN O O
jewish NN O O
individuals NN O O
was NN O O
found NN O O
to NN O O
be. NN O O
0324 NN O O
(1 NN O O
in NN O O
31 NN O O
individuals). NN O O
this NN O O
frequency NN O O
is NN O O
consistent NN O O
with NN O O
earlier NN O O
estimates NN O O
based NN O O
on NN O O
TSD NN B-Modifier B-MSH:D013661
incidence NN O O
data. NN O O
TSD NN B-Modifier B-MSH:D013661
carrier NN O O
frequencies NN O O
were NN O O
then NN O O
examined NN O O
by NN O O
single NN O O
country NN O O
and NN O O
single NN O O
region NN O O
of NN O O
origin NN O O
in NN O O
28, NN O O
029 NN O O
jews NN O O
within NN O O
this NN O O
sample NN O O
for NN O O
whom NN O O
such NN O O
data NN O O
were NN O O
available NN O O
for NN O O
analysis. NN O O
jews NN O O
with NN O O
polish NN O O
and/or NN O O
russian NN O O
ancestry NN O O
constituted NN O O
88% NN O O
of NN O O
this NN O O
sample NN O O
and NN O O
had NN O O
a NN O O
TSD NN B-Modifier B-MSH:D013661
carrier NN O O
frequency NN O O
of. NN O O
0327. NN O O
no NN O O
TSD NN B-Modifier B-MSH:D013661
carriers NN O O
were NN O O
observed NN O O
among NN O O
the NN O O
166 NN O O
jews NN O O
of NN O O
near NN O O
eastern NN O O
origins. NN O O
relative NN O O
to NN O O
jews NN O O
of NN O O
polish NN O O
and NN O O
russian NN O O
origins, NN O O
there NN O O
was NN O O
at NN O O
least NN O O
a NN O O
twofold NN O O
increase NN O O
i NN O O
. NN O O

the NN O O
TSD NN B-Modifier B-MSH:D013661
carrier NN O O
frequency NN O O
in NN O O
jews NN O O
of NN O O
austrian, NN O O
hungarian, NN O O
and NN O O
czechoslovakian NN O O
origins NN O O
(p NN O O
less NN O O
than. NN O O
005). NN O O
these NN O O
findings NN O O
suggest NN O O
that NN O O
the NN O O
TSD NN B-Modifier B-MSH:D013661
gene NN O O
proliferated NN O O
among NN O O
the NN O O
antecedents NN O O
of NN O O
modern NN O O
ashkenazi NN O O
jewry NN O O
after NN O O
the NN O O
second NN O O
diaspora NN O O
(70 NN O O
a. NN O O
d.) NN O O
and NN O O
before NN O O
their NN O O
major NN O O
migrations NN O O
to NN O O
regions NN O O
of NN O O
poland NN O O
and NN O O
russia NN O O
(before NN O O
1100 NN O O
a. NN O O
d.) NN O O
. NN O O

novel NN O O
inherited NN O O
mutations NN O O
and NN O O
variable NN O O
expressivity NN O O
of NN O O
brca NN O O
1 NN O O
alleles, NN O O
including NN O O
the NN O O
founder NN O O
mutation NN O O
185 NN O O
delag NN O O
in NN O O
ashkenazi NN O O
jewish NN O O
families NN O O
. NN O O
. NN O O

thirty-seven NN O O
families NN O O
with NN O O
four NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
or NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
were NN O O
analyzed NN O O
for NN O O
mutations NN O O
in NN O O
brca NN O O
1. NN O O
twelve NN O O
different NN O O
germ-line NN O O
mutations, NN O O
four NN O O
novel NN O O
and NN O O
eight NN O O
previously NN O O
observed, NN O O
were NN O O
detected NN O O
in NN O O
16 NN O O
families. NN O O
five NN O O
families NN O O
of NN O O
ashkenazi NN O O
jewish NN O O
descent NN O O
carried NN O O
the NN O O
185 NN O O
delag NN O O
mutation NN O O
and NN O O
shared NN O O
the NN O O
same NN O O
haplotype NN O O
at NN O O
eight NN O O
polymorphic NN O O
markers NN O O
spanning NN O O
approximately NN O O
850 NN O O
kb NN O O
at NN O O
brca NN O O
1. NN O O
expressivity NN O O
of NN O O
185 NN O O
delag NN O O
in NN O O
these NN O O
families NN O O
varied, NN O O
from NN O O
early-onset NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
without NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
mutation NN O O
4184 NN O O
deltcaa NN O O
occurred NN O O
independently NN O O
in NN O O
two NN O O
families. NN O O
in NN O O
one NN O O
family, NN O O
penetrance NN O O
was NN O O
complete, NN O O
with NN O O
females NN O O
developing NN O O
early-onset NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
or NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
and NN O O
the NN O O
male NN O O
carrier NN O O
developing NN O O
prostatic NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
, NN O O
whereas, NN O O
in NN O O
the NN O O
other NN O O
family, NN O O
penetrance NN O O
was NN O O
incomplete NN O O
and NN O O
onl NN O O
. NN O O

breast NN O O
cancer NN O O
occurred, NN O O
diagnosed NN O O
at NN O O
ages NN O O
38-81 NN O O
years. NN O O
two NN O O
novel NN O O
nonsense NN O O
mutations NN O O
led NN O O
to NN O O
the NN O O
loss NN O O
of NN O O
mutant NN O O
brca NN O O
1 NN O O
transcript NN O O
in NN O O
families NN O O
with NN O O
10 NN O O
and NN O O
6 NN O O
cases NN O O
of NN O O
early-onset NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
and NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
a NN O O
665-nt NN O O
segment NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
3-utr NN O O
and NN O O
1. NN O O
3 NN O O
kb NN O O
of NN O O
genomic NN O O
sequence NN O O
including NN O O
the NN O O
putative NN O O
promoter NN O O
region NN O O
were NN O O
invariant NN O O
by NN O O
single-strand NN O O
conformation NN O O
analysis NN O O
in NN O O
13 NN O O
families NN O O
without NN O O
coding-sequence NN O O
mutations. NN O O
overall NN O O
in NN O O
our NN O O
series, NN O O
brca NN O O
1 NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
26 NN O O
families NN O O
16 NN O O
with NN O O
positive NN O O
brca NN O O
1 NN O O
lod NN O O
scores, NN O O
7 NN O O
with NN O O
negative NN O O
lod NN O O
scores NN O O
(reflecting NN O O
multiple NN O O
sporadic NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancers NN I-SpecificDisease I-MSH:D001943
), NN O O
and NN O O
3 NN O O
not NN O O
tested NN O O
for NN O O
linkage. NN O O
three NN O O
other NN O O
families NN O O
have NN O O
positive NN O O
lod NN O O
scores NN O O
for NN O O
linkage NN O O
to NN O O
brca NN O O
2, NN O O
bu NN O O
. NN O O

13 NN O O
families NN O O
without NN O O
detected NN O O
brca NN O O
1 NN O O
mutations NN O O
have NN O O
negative NN O O
lod NN O O
scores NN O O
for NN O O
both NN O O
brca NN O O
1 NN O O
and NN O O
brca NN O O
2 NN O O
. NN O O

transgenic NN O O
mice NN O O
carrying NN O O
large NN O O
human NN O O
genomic NN O O
sequences NN O O
with NN O O
expanded NN O O
ctg NN O O
repeat NN O O
mimic NN O O
closely NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
ctg NN O O
repeat NN O O
intergenerational NN O O
and NN O O
somatic NN O O
instability NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
ctg NN O O
repeat NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
utr NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
protein NN O O
kinase NN O O
(dmpk) NN O O
gene. NN O O
a NN O O
very NN O O
high NN O O
level NN O O
of NN O O
instability NN O O
is NN O O
observed NN O O
through NN O O
successive NN O O
generations NN O O
and NN O O
the NN O O
size NN O O
of NN O O
the NN O O
repeat NN O O
is NN O O
generally NN O O
correlated NN O O
with NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
and NN O O
with NN O O
age NN O O
at NN O O
onset. NN O O
furthermore, NN O O
tissues NN O O
from NN O O
DM NN B-Modifier B-MSH:D009223
patients NN O O
exhibit NN O O
somatic NN O O
mosaicism NN O O
that NN O O
increases NN O O
with NN O O
age. NN O O
we NN O O
generated NN O O
transgenic NN O O
mice NN O O
carrying NN O O
large NN O O
human NN O O
genomic NN O O
sequences NN O O
with NN O O
20, NN O O
55 NN O O
or NN O O
> NN O O
300 NN O O
ctg, NN O O
cloned NN O O
from NN O O
patients NN O O
from NN O O
the NN O O
same NN O O
affected NN O O
DM NN B-Modifier B-MSH:D009223
family. NN O O
using NN O O
large NN O O
human NN O O
flanking NN O O
sequences NN O O
and NN O O
a NN O O
large NN O O
amplification, NN O O
we NN O O
demonstrate NN O O
that NN O O
the NN O O
intergenerational NN O O
ctg NN O O
repeat NN O O
instability NN O O
is NN O O
reproduced NN O O
in NN O O
mice, NN O O
with NN O O
a NN O O
strong NN O O
bias NN O O
towards NN O O
expansions NN O O
and NN O O
with NN O O
the NN O O
same NN O O
sex- NN O O
and NN O O
size-dependent NN O O
characteristic NN O O
. NN O O

as NN O O
in NN O O
humans. NN O O
moreover, NN O O
a NN O O
high NN O O
level NN O O
of NN O O
instability, NN O O
increasing NN O O
with NN O O
age, NN O O
can NN O O
be NN O O
observed NN O O
in NN O O
tissues NN O O
and NN O O
in NN O O
sperm. NN O O
although NN O O
we NN O O
did NN O O
not NN O O
observe NN O O
dramatic NN O O
expansions NN O O
(or NN O O
big NN O O
jumps NN O O
over NN O O
several NN O O
hundred NN O O
ctg NN O O
repeats) NN O O
as NN O O
in NN O O
congenital NN O O
forms NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
, NN O O
our NN O O
model NN O O
carrying NN O O
> NN O O
300 NN O O
ctg NN O O
is NN O O
the NN O O
first NN O O
to NN O O
show NN O O
instability NN O O
so NN O O
close NN O O
to NN O O
the NN O O
human NN O O
DM NN B-Modifier B-MSH:D009223
situation. NN O O
our NN O O
three NN O O
models NN O O
carrying NN O O
different NN O O
sizes NN O O
of NN O O
ctg NN O O
repeat NN O O
provide NN O O
insight NN O O
on NN O O
the NN O O
different NN O O
factors NN O O
modulating NN O O
the NN O O
ctg NN O O
repeat NN O O
instability. NN O O
. NN O O

linkage NN O O
of NN O O
gene NN O O
for NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
and NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
mhc NN O O
in NN O O
man. NN O O
family NN O O
study NN O O
of NN O O
a NN O O
further NN O O
case NN O O
. NN O O

close NN O O
linkage NN O O
between NN O O
hl-a NN O O
and NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
was NN O O
first NN O O
reported NN O O
by NN O O
fu NN O O
and NN O O
co-workers NN O O
in NN O O
1974. NN O O
we NN O O
present NN O O
here NN O O
a NN O O
pedigree NN O O
of NN O O
a NN O O
31-year-old NN O O
C2-deficient NN B-Modifier B-OMIM:217000
individual NN O O
with NN O O
clinical NN O O
manifestations NN O O
of NN O O
Hodgkins NN B-SpecificDisease B-MSH:D006689
disease NN I-SpecificDisease I-MSH:D006689
. NN O O
the NN O O
following NN O O
markers NN O O
were NN O O
tested NN O O
c NN O O
2 NN O O
levels, NN O O
factor NN O O
b NN O O
polymorphism, NN O O
blood NN O O
groups, NN O O
and NN O O
enzyme NN O O
typing. NN O O
in NN O O
addition NN O O
to NN O O
close NN O O
linkage NN O O
between NN O O
hl-a NN O O
and NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
, NN O O
both NN O O
parents NN O O
were NN O O
heterozygous NN O O
for NN O O
bf NN O O
(hl-a NN O O
linked, NN O O
electrophoretic NN O O
variation NN O O
of NN O O
b). NN O O
the NN O O
two NN O O
hl-a NN O O
haplotypes NN O O
closely NN O O
linked NN O O
to NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
are NN O O
different NN O O
2, NN O O
w NN O O
18 NN O O
and NN O O
w NN O O
24, NN O O
w NN O O
18. NN O O
they NN O O
share, NN O O
however, NN O O
the NN O O
sd NN O O
2 NN O O
antigen NN O O
w NN O O
18 NN O O
and NN O O
the NN O O
ld NN O O
type NN O O
7 NN O O
. NN O O

. NN O O
. NN O O

age NN O O
of NN O O
onset NN O O
in NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
: NN O O
sex NN O O
specific NN O O
influence NN O O
of NN O O
apolipoprotein NN O O
e NN O O
genotype NN O O
and NN O O
normal NN O O
cag NN O O
repeat NN O O
length NN O O
. NN O O

age NN O O
of NN O O
onset NN O O
(ao) NN O O
of NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
is NN O O
known NN O O
to NN O O
be NN O O
correlated NN O O
with NN O O
the NN O O
length NN O O
of NN O O
an NN O O
expanded NN O O
cag NN O O
repeat NN O O
in NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene. NN O O
apolipoprotein NN O O
e NN O O
(apoe) NN O O
genotype, NN O O
in NN O O
turn, NN O O
is NN O O
known NN O O
to NN O O
influence NN O O
ao NN O O
in NN O O
Alzheimer NN B-SpecificDisease B-MSH:D000544
disease NN I-SpecificDisease I-MSH:D000544
, NN O O
rendering NN O O
the NN O O
apoe NN O O
gene NN O O
a NN O O
likely NN O O
candidate NN O O
to NN O O
affect NN O O
ao NN O O
in NN O O
other NN O O
neurological NN B-DiseaseClass B-MSH:D020271
diseases NN I-DiseaseClass I-MSH:D020271
too. NN O O
we NN O O
therefore NN O O
determined NN O O
apoe NN O O
genotype NN O O
and NN O O
normal NN O O
cag NN O O
repeat NN O O
length NN O O
in NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
for NN O O
138 NN O O
HD NN B-Modifier B-MSH:D006816
patients NN O O
who NN O O
were NN O O
previously NN O O
analysed NN O O
with NN O O
respect NN O O
to NN O O
cag NN O O
repeat NN O O
length. NN O O
genotyping NN O O
for NN O O
apoe NN O O
was NN O O
performed NN O O
blind NN O O
to NN O O
clinical NN O O
information. NN O O
in NN O O
addition NN O O
to NN O O
highlighting NN O O
the NN O O
effect NN O O
of NN O O
the NN O O
normal NN O O
repeat NN O O
length NN O O
upon NN O O
ao NN O O
in NN O O
maternally NN O O
inherited NN O O
HD NN B-SpecificDisease B-MSH:D006816
and NN O O
in NN O O
male NN O O
patients, NN O O
we NN O O
show NN O O
that NN O O
the NN O O
apoe NN O O
epsilon NN O O
2 NN O O
epsilon NN O O
3 NN O O
genotype NN O O
is NN O O
associated NN O O
with NN O O
significantl NN O O
. NN O O

earlier NN O O
ao NN O O
in NN O O
males NN O O
than NN O O
in NN O O
females. NN O O
such NN O O
a NN O O
sex NN O O
difference NN O O
in NN O O
ao NN O O
was NN O O
not NN O O
apparent NN O O
for NN O O
any NN O O
of NN O O
the NN O O
other NN O O
apoe NN O O
genotypes. NN O O
our NN O O
findings NN O O
suggest NN O O
that NN O O
subtle NN O O
differences NN O O
in NN O O
the NN O O
course NN O O
of NN O O
the NN O O
neurodegeneration NN B-DiseaseClass B-MSH:D019636
in NN O O
HD NN B-SpecificDisease B-MSH:D006816
may NN O O
allow NN O O
interacting NN O O
genes NN O O
to NN O O
exert NN O O
gender NN O O
specific NN O O
effects NN O O
upon NN O O
ao NN O O
. NN O O

genetic NN O O
linkage NN O O
map NN O O
of NN O O
six NN O O
polymorphic NN O O
dna NN O O
markers NN O O
around NN O O
the NN O O
gene NN O O
for NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
on NN O O
chromosome NN O O
5 NN O O
. NN O O

a NN O O
genetic NN O O
linkage NN O O
map NN O O
of NN O O
six NN O O
polymorphic NN O O
dna NN O O
markers NN O O
close NN O O
to NN O O
the NN O O
gene NN O O
(apc) NN O O
for NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
) NN O O
on NN O O
chromosome NN O O
5 NN O O
q NN O O
is NN O O
reported. NN O O
one NN O O
hundred NN O O
fifty-five NN O O
typed NN O O
members NN O O
of NN O O
nine NN O O
FAP NN B-Modifier B-MSH:D011125
kindred NN O O
provided NN O O
more NN O O
than NN O O
90 NN O O
meioses NN O O
for NN O O
linkage NN O O
analysis. NN O O
a NN O O
number NN O O
of NN O O
crucial NN O O
recombination NN O O
events NN O O
have NN O O
been NN O O
identified NN O O
which NN O O
are NN O O
informative NN O O
at NN O O
three NN O O
or NN O O
more NN O O
loci, NN O O
allowing NN O O
confident NN O O
ordering NN O O
of NN O O
parts NN O O
of NN O O
the NN O O
map. NN O O
there NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
genetic NN O O
heterogeneity, NN O O
with NN O O
all NN O O
families NN O O
showing NN O O
linkage NN O O
of NN O O
at NN O O
least NN O O
one NN O O
chromosome NN O O
5 NN O O
marker NN O O
to NN O O
the NN O O
gene. NN O O
recombination NN O O
data NN O O
and NN O O
two-point NN O O
linkage NN O O
analysis NN O O
support NN O O
a NN O O
locus NN O O
order NN O O
of NN O O
centromere-pi NN O O
227-c NN O O
11 NN O O
p NN O O
11-ecb NN O O
27-l NN O O
5. NN O O
62-apc-ef NN O O
5 NN O O
62-apc NN O O
. NN O O

ef NN O O
5. NN O O
44-yn NN O O
5 NN O O
44-yn NN O O
5. NN O O
48-telomer NN O O
e, NN O O
although NN O O
ef NN O O
5. NN O O
44 NN O O
could NN O O
lie NN O O
in NN O O
the NN O O
interval NN O O
l NN O O
5. NN O O
62-apc NN O O
or NN O O
ecb NN O O
27-l NN O O
5. NN O O
62. NN O O
no NN O O
recombinants NN O O
were NN O O
identified NN O O
between NN O O
apc NN O O
and NN O O
either NN O O
ef NN O O
5. NN O O
44 NN O O
or NN O O
yn NN O O
5. NN O O
48, NN O O
but NN O O
published NN O O
deletion NN O O
mapping NN O O
in NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
carcinomas NN I-SpecificDisease I-MSH:D015179
and NN O O
linkage NN O O
analysis NN O O
in NN O O
FAP NN B-SpecificDisease B-MSH:D011125
suggest NN O O
that NN O O
yn NN O O
5. NN O O
48 NN O O
is NN O O
1-3 NN O O
cm NN O O
from NN O O
apc. NN O O
the NN O O
present NN O O
study NN O O
suggests NN O O
that NN O O
yn NN O O
5. NN O O
48 NN O O
and NN O O
l NN O O
5. NN O O
62 NN O O
delineate NN O O
a NN O O
small NN O O
region NN O O
of NN O O
chromosome NN O O
5 NN O O
within NN O O
which NN O O
the NN O O
ef NN O O
5. NN O O
44 NN O O
locus NN O O
lies NN O O
very NN O O
close NN O O
to NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene. NN O O
these NN O O
data NN O O
not NN O O
only NN O O
allow NN O O
use NN O O
of NN O O
flanking NN O O
markers NN O O
for NN O O
presymptomatic NN O O
diagnosis NN O O
of NN O O
FAP NN B-SpecificDisease B-MSH:D011125
but NN O O
also NN O O
provid NN O O
. NN O O

a NN O O
high-density NN O O
map NN O O
of NN O O
the NN O O
region NN O O
for NN O O
isolation NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
itself NN O O
and NN O O
for NN O O
further NN O O
assessment NN O O
of NN O O
the NN O O
role NN O O
of NN O O
chromosome NN O O
5 NN O O
deletions NN O O
in NN O O
the NN O O
biology NN O O
of NN O O
sporadic NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O

detection NN O O
of NN O O
a NN O O
novel NN O O
arginine NN O O
vasopressin NN O O
defect NN O O
by NN O O
dideoxy NN O O
fingerprinting NN O O
. NN O O

autosomal NN O O
dominant NN O O
neurohypophyseal NN O O
diabetes NN O O
insipidus NN O O
is NN O O
a NN O O
familial NN O O
form NN O O
of NN O O
diabetes NN B-DiseaseClass B-MSH:D003919
insipidus NN I-DiseaseClass I-MSH:D003919
. NN O O
this NN O O
disorder NN O O
is NN O O
associated NN O O
with NN O O
variable NN O O
levels NN O O
of NN O O
arginine NN O O
vasopressin NN O O
(avp) NN O O
and NN O O
diabetes NN B-DiseaseClass B-MSH:D003919
insipidus NN I-DiseaseClass I-MSH:D003919
of NN O O
varying NN O O
severity, NN O O
which NN O O
responds NN O O
to NN O O
exogenous NN O O
avp. NN O O
to NN O O
determine NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
autosomal NN B-SpecificDisease B-OMIM:125700
dominant NN I-SpecificDisease I-OMIM:125700
neurohypophyseal NN I-SpecificDisease I-OMIM:125700
diabetes NN I-SpecificDisease I-OMIM:125700
insipidus NN I-SpecificDisease I-OMIM:125700
, NN O O
the NN O O
avp NN O O
genes NN O O
of NN O O
members NN O O
of NN O O
a NN O O
large NN O O
kindred NN O O
were NN O O
analyzed. NN O O
a NN O O
new NN O O
method, NN O O
called NN O O
dideoxy NN O O
fingerprinting, NN O O
was NN O O
used NN O O
to NN O O
detect NN O O
an NN O O
avp NN O O
mutation NN O O
that NN O O
was NN O O
characterized NN O O
by NN O O
dna NN O O
sequencing. NN O O
the NN O O
novel NN O O
defect NN O O
found NN O O
changes NN O O
the NN O O
last NN O O
codon NN O O
of NN O O
the NN O O
avp NN O O
signal NN O O
peptide NN O O
from NN O O
alanine NN O O
to NN O O
threonine, NN O O
which NN O O
should NN O O
perturb NN O O
cleavage NN O O
of NN O O
mature NN O O
avp NN O O
from NN O O
its NN O O
precursor NN O O
protein NN O O
and NN O O
inhibit NN O O
its NN O O
secretion NN O O
or NN O O
action. NN O O
. NN O O

association NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
tumor NN I-Modifier I-MSH:D011125
suppressor NN O O
protein NN O O
with NN O O
catenins NN O O
. NN O O

mutations NN O O
of NN O O
apc NN O O
appear NN O O
to NN O O
initiate NN O O
sporadic NN O O
and NN O O
inherited NN O O
forms NN O O
of NN O O
human NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O
although NN O O
these NN O O
mutations NN O O
have NN O O
been NN O O
well NN O O
characterized, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
function NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
product. NN O O
two NN O O
cellular NN O O
proteins NN O O
that NN O O
associate NN O O
with NN O O
APC NN B-SpecificDisease B-MSH:D011125
were NN O O
identified NN O O
by NN O O
nucleotide NN O O
sequence NN O O
analysis NN O O
and NN O O
peptide NN O O
mapping NN O O
as NN O O
the NN O O
e-cadherin-associated NN O O
proteins NN O O
alpha- NN O O
and NN O O
beta-catenin. NN O O
a NN O O
27-residue NN O O
fragment NN O O
of NN O O
apc NN O O
containing NN O O
a NN O O
15-amino NN O O
acid NN O O
repeat NN O O
was NN O O
sufficient NN O O
for NN O O
the NN O O
interaction NN O O
with NN O O
the NN O O
catenins. NN O O
these NN O O
results NN O O
suggest NN O O
an NN O O
important NN O O
link NN O O
between NN O O
tumor NN B-Modifier B-MSH:D009369
initiation NN O O
and NN O O
cell NN O O
adhesion. NN O O
. NN O O

myotonic NN O O
dystrophy NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
muscle-type NN O O
creatine NN O O
kinase NN O O
(ckmm) NN O O
. NN O O

we NN O O
have NN O O
studied NN O O
genetic NN O O
linkage NN O O
between NN O O
the NN O O
gene NN O O
for NN O O
creatine NN O O
kinase NN O O
muscle NN O O
type NN O O
(ckmm) NN O O
and NN O O
the NN O O
gene NN O O
for NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
). NN O O
in NN O O
a NN O O
panel NN O O
of NN O O
65 NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
families NN O O
from NN O O
canada NN O O
and NN O O
the NN O O
netherlands, NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
(zmax) NN O O
of NN O O
22. NN O O
8 NN O O
at NN O O
a NN O O
recombination NN O O
frequency NN O O
(theta) NN O O
of NN O O
0. NN O O
03 NN O O
was NN O O
obtained. NN O O
tight NN O O
linkage NN O O
was NN O O
also NN O O
demonstrated NN O O
for NN O O
ckmm NN O O
and NN O O
the NN O O
gene NN O O
for NN O O
apolipoprotein NN O O
c NN O O
2 NN O O
(apoc NN O O
2). NN O O
this NN O O
establishes NN O O
ckmm NN O O
as NN O O
a NN O O
useful NN O O
marker NN O O
for NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
. NN O O

discordant NN O O
clinical NN O O
outcome NN O O
in NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
relatives NN O O
showing NN O O
(ctg)n NN O O
> NN O O
700 NN O O
repeats NN O O
. NN O O

a NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
( NN O O
DM NN B-Modifier B-MSH:D009223
) NN O O
family NN O O
is NN O O
described NN O O
in NN O O
which NN O O
discordant NN O O
DM NN B-Modifier B-MSH:D009223
phenotypes NN O O
were NN O O
found NN O O
in NN O O
the NN O O
children NN O O
of NN O O
two NN O O
affected NN O O
sisters NN O O
with NN O O
similar NN O O
ctg NN O O
expansion NN O O
and NN O O
clinical NN O O
manifestations. NN O O
in NN O O
this NN O O
family, NN O O
congenital NN O O
as NN O O
well NN O O
as NN O O
early NN O O
severe NN O O
childhood NN O O
and NN O O
later NN O O
childhood NN O O
onset NN O O
DM NN B-SpecificDisease B-MSH:D009223
coexist. NN O O
this NN O O
observation NN O O
strengthens NN O O
the NN O O
limited NN O O
ability NN O O
of NN O O
lymphocytes NN O O
ctg NN O O
repeat NN O O
number NN O O
analysis NN O O
in NN O O
predicting NN O O
genotype-phenotype NN O O
correlations NN O O
in NN O O
DM NN B-Modifier B-MSH:D009223
patients. NN O O
. NN O O

constitutional NN O O
von NN B-Modifier B-MSH:D006623
Hippel-Lindau NN I-Modifier I-MSH:D006623
( NN O O
VHL NN B-Modifier B-MSH:D006623
) NN O O
gene NN O O
deletions NN O O
detected NN O O
in NN O O
VHL NN B-Modifier B-MSH:D006623
families NN O O
by NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

von NN O O
hippel-lindau NN O O
(vhl) NN O O
disease NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D009386
dominantly NN I-DiseaseClass I-MSH:D009386
inherited NN I-DiseaseClass I-MSH:D009386
cancer NN I-DiseaseClass I-MSH:D009386
syndrome NN I-DiseaseClass I-MSH:D009386
predisposing NN O O
to NN O O
a NN O O
variety NN O O
of NN O O
tumor NN B-Modifier B-MSH:D009369
types NN O O
that NN O O
include NN O O
retinal NN O O
hemangioblastomas NN B-DiseaseClass B-MSH:D018325
, NN O O
hemangioblastomas NN B-DiseaseClass B-MSH:D018325
of NN O O
the NN O O
central NN O O
nervous NN O O
system, NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinomas NN I-SpecificDisease I-MSH:D002292
, NN O O
pancreatic NN B-CompositeMention B-MSH:D010181
cysts NN I-CompositeMention I-MSH:D010181
and NN I-CompositeMention I-MSH:D010181
tumors NN I-CompositeMention I-MSH:D010181
, NN O O
pheochromocytomas NN B-DiseaseClass B-MSH:D010673
, NN O O
endolymphatic NN B-DiseaseClass B-MSH:D036821
sac NN I-DiseaseClass I-MSH:D036821
tumors NN I-DiseaseClass I-MSH:D036821
, NN O O
and NN O O
epididymal NN B-DiseaseClass B-MSH:D003537
cystadenomas NN I-DiseaseClass I-MSH:D003537
[w. NN O O
m. NN O O
linehan NN O O
et NN O O
al., NN O O
j. NN O O
am. NN O O
med. NN O O
assoc., NN O O
273 NN O O
564-570, NN O O
1995; NN O O
e. NN O O
a. NN O O
maher NN O O
and NN O O
w. NN O O
g. NN O O
kaelin, NN O O
jr., NN O O
medicine NN O O
(baltimore), NN O O
76 NN O O
381-391, NN O O
1997; NN O O
w. NN O O
m. NN O O
linehan NN O O
and NN O O
r. NN O O
d. NN O O
klausner, NN O O
in NN O O
b. NN O O
vogelstein NN O O
and NN O O
k. NN O O
kinzler NN O O
(eds.), NN O O
the NN O O
genetic NN O O
basis NN O O
of NN O O
human NN O O
cancer, NN O O
pp. NN O O
45 NN O O
. NN O O

-473, NN O O
mcgraw-hill, NN O O
1998]. NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
was NN O O
localized NN O O
to NN O O
chromosome NN O O
3 NN O O
p NN O O
25-26 NN O O
and NN O O
cloned NN O O
[f. NN O O
latif NN O O
et NN O O
al., NN O O
science NN O O
(washington NN O O
dc), NN O O
260 NN O O
1317-1320, NN O O
1993]. NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
VHL NN B-Modifier B-MSH:D006623
kindreds. NN O O
the NN O O
reported NN O O
frequency NN O O
of NN O O
detection NN O O
of NN O O
VHL NN B-Modifier B-MSH:D006623
germline NN O O
mutations NN O O
has NN O O
varied NN O O
from NN O O
39 NN O O
to NN O O
80% NN O O
(j. NN O O
m. NN O O
whaley NN O O
et NN O O
al., NN O O
am. NN O O
j. NN O O
hum. NN O O
genet., NN O O
55 NN O O
1092-1102, NN O O
1994; NN O O
clinical NN O O
research NN O O
group NN O O
for NN O O
japan, NN O O
hum. NN O O
mol. NN O O
genet., NN O O
4 NN O O
2233-2237, NN O O
1995; NN O O
f. NN O O
chen NN O O
et NN O O
al., NN O O
hum. NN O O
mutat., NN O O
5 NN O O
66-7 NN O O
. NN O O

, NN O O
1995; NN O O
e. NN O O
r. NN O O
maher NN O O
et NN O O
al., NN O O
j. NN O O
med. NN O O
genet., NN O O
33 NN O O
328-332, NN O O
1996; NN O O
b. NN O O
zbar, NN O O
cancer NN O O
surv., NN O O
25 NN O O
219-232, NN O O
1995). NN O O
recently NN O O
a NN O O
quantitative NN O O
southern NN O O
blotting NN O O
procedure NN O O
was NN O O
found NN O O
to NN O O
improve NN O O
this NN O O
frequency NN O O
(c. NN O O
stolle NN O O
et NN O O
al., NN O O
hum. NN O O
mutat., NN O O
12 NN O O
417-423, NN O O
1998). NN O O
in NN O O
the NN O O
present NN O O
study, NN O O
we NN O O
report NN O O
the NN O O
use NN O O
of NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
(fish) NN O O
as NN O O
a NN O O
method NN O O
to NN O O
detect NN O O
and NN O O
characterize NN O O
VHL NN B-Modifier B-MSH:D006623
germline NN O O
deletions. NN O O
we NN O O
reexamined NN O O
a NN O O
group NN O O
of NN O O
VHL NN B-Modifier B-MSH:D006623
patients NN O O
shown NN O O
previously NN O O
by NN O O
single-strand NN O O
conformation NN O O
and NN O O
sequencing NN O O
analysis NN O O
not NN O O
to NN O O
harbor NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
locus. NN O O
we NN O O
found NN O O
constitutional NN O O
deletions NN O O
in NN O O
29 NN O O
of NN O O
30 NN O O
VHL NN B-Modifier B-MSH:D006623
patient NN O O
. NN O O

in NN O O
this NN O O
group NN O O
using NN O O
cosmid NN O O
and NN O O
p NN O O
1 NN O O
probes NN O O
that NN O O
cover NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
locus. NN O O
we NN O O
then NN O O
tested NN O O
six NN O O
phenotypically NN O O
normal NN O O
offspring NN O O
from NN O O
four NN O O
of NN O O
these NN O O
VHL NN B-Modifier B-MSH:D006623
families NN O O
two NN O O
were NN O O
found NN O O
to NN O O
carry NN O O
the NN O O
deletion NN O O
and NN O O
the NN O O
other NN O O
four NN O O
were NN O O
deletion-free. NN O O
in NN O O
addition, NN O O
germline NN O O
mosaicism NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
was NN O O
identified NN O O
in NN O O
one NN O O
family. NN O O
in NN O O
sum, NN O O
fish NN O O
was NN O O
found NN O O
to NN O O
be NN O O
a NN O O
simple NN O O
and NN O O
reliable NN O O
method NN O O
to NN O O
detect NN O O
VHL NN B-Modifier B-MSH:D006623
germline NN O O
deletions NN O O
and NN O O
practically NN O O
useful NN O O
in NN O O
cases NN O O
where NN O O
other NN O O
methods NN O O
of NN O O
screening NN O O
have NN O O
failed NN O O
to NN O O
detect NN O O
a NN O O
VHL NN B-SpecificDisease B-MSH:D006623
gene NN I-SpecificDisease I-MSH:D006623
abnormality NN I-SpecificDisease I-MSH:D006623
. NN O O

aberrant NN O O
subcellular NN O O
localization NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O

the NN O O
brca NN O O
1 NN O O
gene NN O O
product NN O O
was NN O O
identified NN O O
as NN O O
a NN O O
220-kilodalton NN O O
nuclear NN O O
phosphoprotein NN O O
in NN O O
normal NN O O
cells, NN O O
including NN O O
breast NN O O
ductal NN O O
epithelial NN O O
cells, NN O O
and NN O O
in NN O O
18 NN O O
of NN O O
20 NN O O
tumor NN B-Modifier B-MSH:D009369
cell NN O O
lines NN O O
derived NN O O
from NN O O
tissues NN O O
other NN O O
than NN O O
breast NN O O
and NN O O
ovary. NN O O
in NN O O
16 NN O O
of NN O O
17 NN O O
breast NN B-Modifier B-MSH:D001943
and NN I-Modifier I-MSH:D001943
ovarian NN I-Modifier I-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
lines NN O O
and NN O O
17 NN O O
of NN O O
17 NN O O
samples NN O O
of NN O O
cells NN O O
obtained NN O O
from NN O O
malignant NN O O
effusions, NN O O
however, NN O O
brca NN O O
1 NN O O
localized NN O O
mainly NN O O
in NN O O
cytoplasm. NN O O
absence NN O O
of NN O O
brca NN O O
1 NN O O
or NN O O
aberrant NN O O
subcellular NN O O
location NN O O
was NN O O
also NN O O
observed NN O O
to NN O O
a NN O O
variable NN O O
extent NN O O
in NN O O
histological NN O O
sections NN O O
of NN O O
many NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
biopsies. NN O O
these NN O O
findings NN O O
suggest NN O O
that NN O O
BRCA1 NN B-DiseaseClass B-OMIM:604370
abnormalities NN I-DiseaseClass I-OMIM:604370
may NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
many NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancers NN I-SpecificDisease I-MSH:D001943
, NN O O
sporadic NN O O
as NN O O
well NN O O
as NN O O
familial. NN O O
. NN O O

hla NN O O
b NN O O
27 NN O O
and NN O O
the NN O O
genetics NN O O
of NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
. NN O O

one NN O O
hundred NN O O
and NN O O
twenty-eight NN O O
of NN O O
145 NN O O
patients NN O O
with NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
( NN O O
AS NN B-SpecificDisease B-MSH:D013167
) NN O O
were NN O O
found NN O O
to NN O O
be NN O O
hla NN O O
b NN O O
27 NN O O
positive. NN O O
five NN O O
patients NN O O
had NN O O
evidence NN O O
of NN O O
a NN O O
sero-negative NN O O
peripheral NN B-SpecificDisease B-MSH:D001168
arthritis NN I-SpecificDisease I-MSH:D001168
resembling NN O O
peripheral NN B-SpecificDisease B-MSH:D015535
psoriatic NN I-SpecificDisease I-MSH:D015535
arthritis NN I-SpecificDisease I-MSH:D015535
and NN O O
3 NN O O
of NN O O
these NN O O
were NN O O
b NN O O
27 NN O O
negative. NN O O
one NN O O
further NN O O
b NN O O
27 NN O O
negative NN O O
patients NN O O
had NN O O
a NN O O
sister NN O O
with NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
and NN O O
ulcerative NN B-SpecificDisease B-MSH:D003093
colitis NN I-SpecificDisease I-MSH:D003093
and NN O O
a NN O O
mother NN O O
with NN O O
ulcerative NN B-SpecificDisease B-MSH:D003093
colitis NN I-SpecificDisease I-MSH:D003093
. NN O O
there NN O O
was NN O O
evidence NN O O
of NN O O
a NN O O
somewhat NN O O
later NN O O
age NN O O
of NN O O
onset NN O O
of NN O O
symptoms NN O O
in NN O O
b NN O O
27 NN O O
negative NN O O
patients. NN O O
these NN O O
findings NN O O
are NN O O
interpreted NN O O
as NN O O
suggesting NN O O
some NN O O
degree NN O O
of NN O O
clinical NN O O
and NN O O
genetic NN O O
heterogeneity NN O O
in NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
with NN O O
genes NN O O
for NN O O
psoriasis NN B-SpecificDisease B-MSH:D011565
and NN O O
inflammatory NN B-SpecificDisease B-MSH:D015212
bowel NN I-SpecificDisease I-MSH:D015212
disease NN I-SpecificDisease I-MSH:D015212
being NN O O
important NN O O
in NN O O
some NN O O
individuals, NN O O
particularly NN O O
those NN O O
who NN O O
are NN O O
b NN O O
27 NN O O
negative. NN O O
twenty-five NN O O
first-degree NN O O
relatives NN O O
with NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
were NN O O
all NN O O
b NN O O
2 NN O O
. NN O O

positive. NN O O
the NN O O
only NN O O
instance NN O O
of NN O O
disassociation NN O O
of NN O O
b NN O O
27 NN O O
and NN O O
spondylitis NN B-SpecificDisease B-MSH:D013166
in NN O O
a NN O O
family NN O O
was NN O O
where NN O O
the NN O O
proband NN O O
had NN O O
ulcerative NN B-SpecificDisease B-MSH:D003093
colitis NN I-SpecificDisease I-MSH:D003093
as NN O O
well NN O O
as NN O O
spondylitis NN B-SpecificDisease B-MSH:D013166
. NN O O
of NN O O
13 NN O O
b NN O O
27 NN O O
positive NN O O
fathers NN O O
3 NN O O
could NN O O
be NN O O
diagnosed NN O O
as NN O O
having NN O O
definite NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
(23%). NN O O
these NN O O
findings NN O O
are NN O O
thought NN O O
to NN O O
provide NN O O
evidence NN O O
against NN O O
the NN O O
concept NN O O
that NN O O
the NN O O
gene NN O O
for NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
is NN O O
not NN O O
b NN O O
27 NN O O
but NN O O
a NN O O
closely NN O O
linked NN O O
gene NN O O
and NN O O
favour NN O O
the NN O O
occurrence NN O O
of NN O O
an NN O O
environmental NN O O
event NN O O
affecting NN O O
approximately NN O O
one-fifth NN O O
of NN O O
b NN O O
27 NN O O
positive NN O O
males NN O O
to NN O O
result NN O O
in NN O O
disease. NN O O
. NN O O

late NN O O
infantile NN O O
metachromatic NN B-SpecificDisease B-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
in NN O O
israel NN O O
. NN O O

metachromatic NN O O
leukodystrophy NN O O
( NN O O
MLD NN B-SpecificDisease B-MSH:D007966
) NN O O
is NN O O
a NN O O
neurodegenerative NN B-DiseaseClass B-MSH:D019636
disease NN I-DiseaseClass I-MSH:D019636
in NN O O
which NN O O
the NN O O
lysosomal NN O O
enzyme, NN O O
aryl NN O O
sulfatase NN O O
a NN O O
(arsa) NN O O
is NN O O
deficient. NN O O
the NN O O
disease NN O O
is NN O O
inherited NN O O
as NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
and NN O O
its NN O O
frequency NN O O
is NN O O
estimated NN O O
to NN O O
be NN O O
1/40, NN O O
000 NN O O
live NN O O
births. NN O O
the NN O O
gene NN O O
of NN O O
arsa NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
up NN O O
to NN O O
now NN O O
eight NN O O
mutations NN O O
causing NN O O
MLD NN B-SpecificDisease B-MSH:D007966
have NN O O
been NN O O
reported. NN O O
another NN O O
mutation, NN O O
pd, NN O O
leads NN O O
to NN O O
the NN O O
deficiency NN O O
of NN O O
the NN O O
enzyme NN O O
in NN O O
vitro NN O O
(pseudodeficiency) NN O O
without NN O O
any NN O O
known NN O O
clinical NN O O
effect. NN O O
the NN O O
pd NN O O
mutation NN O O
is NN O O
frequent NN O O
in NN O O
all NN O O
populations. NN O O
in NN O O
israel, NN O O
late NN O O
infantile NN O O
MLD NN B-SpecificDisease B-MSH:D007966
was NN O O
found NN O O
to NN O O
be NN O O
very NN O O
frequent NN O O
in NN O O
a NN O O
small NN O O
jewish NN O O
isolate, NN O O
the NN O O
habbanite NN O O
jews NN O O
(1/75 NN O O
live NN O O
births). NN O O
the NN O O
molecular NN O O
analysis NN O O
demonstrated NN O O
that NN O O
in NN O O
the NN O O
habbanite NN O O
population, NN O O
the NN O O
mutatio NN O O
. NN O O

occurred NN O O
on NN O O
an NN O O
allele NN O O
with NN O O
the NN O O
pd NN O O
mutation. NN O O
the NN O O
loss NN O O
of NN O O
arsa NN O O
activity NN O O
is NN O O
due NN O O
to NN O O
a NN O O
point NN O O
mutation NN O O
c NN O O
> NN O O
t NN O O
leading NN O O
to NN O O
a NN O O
change NN O O
of NN O O
proline NN O O
to NN O O
leucine. NN O O
MLD NN B-SpecificDisease B-MSH:D007966
is NN O O
also NN O O
frequent NN O O
among NN O O
moslem NN O O
arabs NN O O
in NN O O
jerusalem. NN O O
the NN O O
mutation NN O O
is NN O O
a NN O O
transition NN O O
g NN O O
> NN O O
a NN O O
destroying NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
exon NN O O
2. NN O O
this NN O O
mutation NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
late NN O O
infantile NN O O
MLD NN B-SpecificDisease B-MSH:D007966
from NN O O
different NN O O
ethnic NN O O
groups. NN O O
the NN O O
christian NN O O
arabs NN O O
in NN O O
israel NN O O
also NN O O
have NN O O
a NN O O
high NN O O
incidence NN O O
of NN O O
the NN O O
disease NN O O
(1/10, NN O O
000 NN O O
live NN O O
births); NN O O
the NN O O
mutation NN O O
in NN O O
this NN O O
population NN O O
is NN O O
still NN O O
unknown. NN O O
knowledge NN O O
of NN O O
the NN O O
different NN O O
mutations NN O O
causing NN O O
MLD NN B-SpecificDisease B-MSH:D007966
in NN O O
these NN O O
defined NN O O
populations NN O O
will NN O O
allow NN O O
a NN O O
carrier NN O O
screening NN O O
program NN O O
to NN O O
be NN O O
carried NN O O
out NN O O
and NN O O
prevent NN O O
the NN O O
birth NN O O
of NN O O
additional NN O O
affected NN O O
children. NN O O
. NN O O

genomic NN O O
rearrangements NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
tumor NN I-Modifier I-MSH:D011125
-suppressor NN O O
gene NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
. NN O O

germline NN O O
mutations NN O O
of NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
(APC) NN I-Modifier I-MSH:D011125
tumor NN I-Modifier I-MSH:D011125
-suppressor NN O O
gene NN O O
result NN O O
in NN O O
the NN O O
hereditary NN B-SpecificDisease B-MSH:D015179
colorectal NN I-SpecificDisease I-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
syndrome NN I-SpecificDisease I-MSH:D015179
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
). NN O O
almost NN O O
all NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
that NN O O
have NN O O
been NN O O
identified NN O O
are NN O O
single-nucleotide NN O O
alterations, NN O O
small NN O O
insertions, NN O O
or NN O O
small NN O O
deletions NN O O
that NN O O
would NN O O
truncate NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene. NN O O
no NN O O
well-characterized NN O O
intragenic NN O O
rearrangement NN O O
of NN O O
apc NN O O
has NN O O
been NN O O
described, NN O O
and NN O O
the NN O O
prevalence NN O O
of NN O O
this NN O O
type NN O O
of NN O O
mutation NN O O
in NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
is NN O O
not NN O O
clear. NN O O
we NN O O
screened NN O O
49 NN O O
potential NN O O
FAP NN B-Modifier B-MSH:D011125
families NN O O
and NN O O
identified NN O O
26 NN O O
different NN O O
germline NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
in NN O O
30 NN O O
families. NN O O
four NN O O
of NN O O
these NN O O
mutations NN O O
were NN O O
genomic NN O O
rearrangements NN O O
resulting NN O O
from NN O O
homologous NN O O
and NN O O
nonhomologous NN O O
recombinations NN O O
mediated NN O O
by NN O O
alu NN O O
elements. NN O O
two NN O O
of NN O O
these NN O O
four NN O O
rearrangements NN O O
were NN O O
complex, NN O O
involving NN O O
deletion NN O O
and NN O O
insertion NN O O
of NN O O
nucleotides. NN O O
of NN O O
these NN O O
four NN O O
rearrangements NN O O
. NN O O

one NN O O
resulted NN O O
in NN O O
the NN O O
deletion NN O O
of NN O O
exons NN O O
11 NN O O
and NN O O
12 NN O O
and NN O O
two NN O O
others NN O O
resulted NN O O
in NN O O
either NN O O
complete NN O O
or NN O O
partial NN O O
deletion NN O O
of NN O O
exon NN O O
14. NN O O
the NN O O
fourth NN O O
rearrangement NN O O
grossly NN O O
altered NN O O
the NN O O
sequence NN O O
within NN O O
intron NN O O
14. NN O O
although NN O O
this NN O O
rearrangement NN O O
did NN O O
not NN O O
affect NN O O
any NN O O
coding NN O O
sequence NN O O
of NN O O
apc NN O O
at NN O O
the NN O O
genomic NN O O
dna NN O O
level, NN O O
it NN O O
caused NN O O
inappropriate NN O O
splicing NN O O
of NN O O
exon NN O O
14. NN O O
these NN O O
rearrangements NN O O
were NN O O
initially NN O O
revealed NN O O
by NN O O
analyzing NN O O
cdnas NN O O
and NN O O
could NN O O
not NN O O
have NN O O
been NN O O
identified NN O O
by NN O O
using NN O O
mutation NN O O
detection NN O O
methods NN O O
that NN O O
screened NN O O
each NN O O
exon NN O O
individually. NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
rearrangement NN O O
that NN O O
did NN O O
not NN O O
alter NN O O
any NN O O
coding NN O O
exons NN O O
yet NN O O
affected NN O O
the NN O O
splicing NN O O
further NN O O
underscores NN O O
the NN O O
importance NN O O
of NN O O
using NN O O
cdna NN O O
for NN O O
mutation NN O O
analysis. NN O O
the NN O O
identification NN O O
of NN O O
four NN O O
genomic NN O O
rearrangements NN O O
among NN O O
30 NN O O
mutations NN O O
suggests NN O O
that NN O O
genomic NN O O
rearrangements NN O O
are NN O O
frequent NN O O
germline NN O O
APC NN B-Modifier B-MSH:D011125
mutations. NN O O
. NN O O

familial NN O O
male NN O O
breast NN O O
cancer NN O O
is NN O O
not NN O O
linked NN O O
to NN O O
the NN O O
brca NN O O
1 NN O O
locus NN O O
on NN O O
chromosome NN O O
17 NN O O
q NN O O
. NN O O

breast NN O O
cancer NN O O
in NN O O
men NN O O
is NN O O
about NN O O
a NN O O
hundredfold NN O O
less NN O O
common NN O O
than NN O O
in NN O O
women NN O O
and NN O O
this NN O O
has NN O O
hindered NN O O
research NN O O
into NN O O
its NN O O
genetic NN O O
basis. NN O O
we NN O O
have NN O O
examined NN O O
22 NN O O
families NN O O
with NN O O
at NN O O
least NN O O
one NN O O
case NN O O
of NN O O
male NN B-SpecificDisease B-MSH:D018567
breast NN I-SpecificDisease I-MSH:D018567
cancer NN I-SpecificDisease I-MSH:D018567
for NN O O
linkage NN O O
to NN O O
the NN O O
hereditary NN B-Modifier B-MSH:D061325
breast NN I-Modifier I-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
locus, NN O O
brca NN O O
1, NN O O
on NN O O
chromosome NN O O
17 NN O O
q. NN O O
we NN O O
found NN O O
strong NN O O
evidence NN O O
against NN O O
linkage NN O O
to NN O O
brca NN O O
1 NN O O
(lod NN O O
score-16. NN O O
63) NN O O
and NN O O
the NN O O
best NN O O
estimate NN O O
of NN O O
the NN O O
proportion NN O O
of NN O O
linked NN O O
families NN O O
was NN O O
0% NN O O
(95% NN O O
ci NN O O
0-18%). NN O O
our NN O O
results NN O O
indicate NN O O
that NN O O
there NN O O
is NN O O
a NN O O
gene NN O O
(s) NN O O
other NN O O
than NN O O
brca NN O O
1 NN O O
which NN O O
predisposes NN O O
to NN O O
early-onset NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
in NN O O
women NN O O
and NN O O
which NN O O
confers NN O O
a NN O O
higher NN O O
risk NN O O
of NN O O
male NN B-SpecificDisease B-MSH:D018567
breast NN I-SpecificDisease I-MSH:D018567
cancer NN I-SpecificDisease I-MSH:D018567
. NN O O
identification NN O O
of NN O O
additional NN O O
pedigrees NN O O
that NN O O
include NN O O
cases NN O O
o NN O O
. NN O O

male NN O O
breast NN O O
cancer NN O O
may NN O O
therefore NN O O
facilitate NN O O
the NN O O
mapping NN O O
and NN O O
isolation NN O O
of NN O O
this NN O O
gene NN O O
. NN O O

evidence NN O O
for NN O O
inter-generational NN O O
instability NN O O
in NN O O
the NN O O
cag NN O O
repeat NN O O
in NN O O
the NN O O
mjd NN O O
1 NN O O
gene NN O O
and NN O O
for NN O O
conserved NN O O
haplotypes NN O O
at NN O O
flanking NN O O
markers NN O O
amongst NN O O
japanese NN O O
and NN O O
caucasian NN O O
subjects NN O O
with NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
. NN O O

the NN O O
size NN O O
of NN O O
the NN O O
(cag)n NN O O
repeat NN O O
array NN O O
in NN O O
the NN O O
3' NN O O
end NN O O
of NN O O
the NN O O
mjd NN O O
1 NN O O
gene NN O O
and NN O O
the NN O O
haplotype NN O O
at NN O O
a NN O O
series NN O O
of NN O O
microsatellite NN O O
markers NN O O
surrounding NN O O
the NN O O
mjd NN O O
1 NN O O
gene NN O O
were NN O O
examined NN O O
in NN O O
a NN O O
large NN O O
cohort NN O O
of NN O O
japanese NN O O
and NN O O
caucasian NN O O
subjects NN O O
affected NN O O
with NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
( NN O O
MJD NN B-SpecificDisease B-MSH:D017827
). NN O O
our NN O O
data NN O O
provide NN O O
five NN O O
novel NN O O
observations. NN O O
first, NN O O
MJD NN B-SpecificDisease B-MSH:D017827
is NN O O
associated NN O O
with NN O O
expansion NN O O
fo NN O O
the NN O O
array NN O O
from NN O O
the NN O O
normal NN O O
range NN O O
of NN O O
14-37 NN O O
repeats NN O O
to NN O O
68-84 NN O O
repeats NN O O
in NN O O
most NN O O
japanese NN O O
and NN O O
caucasian NN O O
subjects, NN O O
but NN O O
no NN O O
subjects NN O O
were NN O O
observed NN O O
with NN O O
expansions NN O O
intermediate NN O O
in NN O O
size NN O O
between NN O O
those NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
MJD NN B-Modifier B-MSH:D017827
affected NN O O
groups. NN O O
second, NN O O
the NN O O
expanded NN O O
allele NN O O
associated NN O O
with NN O O
MJD NN B-SpecificDisease B-MSH:D017827
displays NN O O
inter-generational NN O O
instability, NN O O
particularly NN O O
in NN O O
male NN O O
meioses, NN O O
and NN O O
this NN O O
instability NN O O
was NN O O
associated NN O O
with NN O O
the NN O O
clinica NN O O
. NN O O

phenomenon NN O O
of NN O O
anticipation. NN O O
third, NN O O
the NN O O
size NN O O
of NN O O
the NN O O
expanded NN O O
allele NN O O
is NN O O
not NN O O
only NN O O
inversely NN O O
correlated NN O O
with NN O O
the NN O O
age-of-onset NN O O
of NN O O
MJD NN B-SpecificDisease B-MSH:D017827
(r NN O O
= NN O O
-0.738, NN O O
p NN O O
< NN O O
0.001), NN O O
but NN O O
is NN O O
also NN O O
correlated NN O O
with NN O O
the NN O O
frequency NN O O
of NN O O
other NN O O
clinical NN O O
features NN O O
[e.g. NN O O
pseudoexophthalmos NN O O
and NN O O
pyramidal NN O O
signs NN O O
were NN O O
more NN O O
frequent NN O O
in NN O O
subjects NN O O
with NN O O
large NN O O
repeats NN O O
(p NN O O
< NN O O
0.001 NN O O
and NN O O
p NN O O
< NN O O
0.05 NN O O
respectively)]. NN O O
fourth, NN O O
the NN O O
disease NN O O
phenotype NN O O
is NN O O
significantly NN O O
more NN O O
severe NN O O
and NN O O
had NN O O
an NN O O
early NN O O
age NN O O
of NN O O
onset NN O O
(16 NN O O
years) NN O O
in NN O O
a NN O O
subject NN O O
homozygous NN O O
for NN O O
the NN O O
expanded NN O O
allele, NN O O
which NN O O
contrasts NN O O
with NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
and NN O O
suggests NN O O
that NN O O
the NN O O
expanded NN O O
allele NN O O
in NN O O
the NN O O
mjd NN O O
1 NN O O
gene NN O O
could NN O O
exert NN O O
its NN O O
effect NN O O
either NN O O
by NN O O
a NN O O
dominant NN O O
negative NN O O
effec NN O O
. NN O O

(putatively NN O O
excluded NN O O
in NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
or NN O O
by NN O O
a NN O O
gain NN O O
of NN O O
function NN O O
effect NN O O
as NN O O
proposed NN O O
for NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
finally, NN O O
japanese NN O O
and NN O O
caucasian NN O O
subjects NN O O
affected NN O O
with NN O O
MJD NN B-SpecificDisease B-MSH:D017827
share NN O O
haplotypes NN O O
at NN O O
several NN O O
markers NN O O
surrounding NN O O
the NN O O
mjd NN O O
1 NN O O
gene, NN O O
which NN O O
are NN O O
uncommon NN O O
in NN O O
the NN O O
normal NN O O
japanese NN O O
and NN O O
caucasian NN O O
population, NN O O
and NN O O
which NN O O
suggests NN O O
the NN O O
existence NN O O
either NN O O
of NN O O
common NN O O
founders NN O O
in NN O O
these NN O O
populations NN O O
or NN O O
of NN O O
chromosomes NN O O
susceptible NN O O
to NN O O
pathologic NN O O
expansion NN O O
of NN O O
the NN O O
cag NN O O
repeat NN O O
in NN O O
the NN O O
mjd NN O O
1 NN O O
gene NN O O
. NN O O

familial NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
with NN O O
apparently NN O O
normal NN O O
chromosomes NN O O
. NN O O

we NN O O
report NN O O
on NN O O
4 NN O O
sibs NN O O
(2 NN O O
f, NN O O
2 NN O O
m) NN O O
with NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
diagnosis NN O O
was NN O O
made NN O O
clinically NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
history, NN O O
behavior, NN O O
and NN O O
physical NN O O
findings NN O O
in NN O O
3 NN O O
of NN O O
the NN O O
sibs. NN O O
the NN O O
other NN O O
child NN O O
had NN O O
died NN O O
at NN O O
age NN O O
10 NN O O
months NN O O
with NN O O
a NN O O
history NN O O
and NN O O
clinical NN O O
findings NN O O
typical NN O O
of NN O O
first NN O O
phase NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
results NN O O
of NN O O
chromosome NN O O
studies NN O O
on NN O O
the NN O O
parents NN O O
and NN O O
surviving NN O O
sibs NN O O
were NN O O
normal. NN O O
the NN O O
implications NN O O
of NN O O
this NN O O
unusual NN O O
familial NN O O
occurrence NN O O
for NN O O
our NN O O
understanding NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
are NN O O
discussed. NN O O
. NN O O

age NN O O
at NN O O
diagnosis NN O O
as NN O O
an NN O O
indicator NN O O
of NN O O
eligibility NN O O
for NN O O
brca NN O O
1 NN O O
dna NN O O
testing NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D001943
breast NN I-SpecificDisease I-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O

we NN O O
searched NN O O
for NN O O
criteria NN O O
that NN O O
could NN O O
indicate NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
families NN O O
with NN O O
a NN O O
high NN O O
prior NN O O
probability NN O O
of NN O O
being NN O O
caused NN O O
by NN O O
the NN O O
breast/ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
susceptibility NN O O
locus NN O O
brca NN O O
1 NN O O
on NN O O
chromosome NN O O
17. NN O O
to NN O O
this NN O O
end, NN O O
we NN O O
performed NN O O
a NN O O
linkage NN O O
study NN O O
with NN O O
59 NN O O
consecutively NN O O
collected NN O O
dutch NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
families, NN O O
including NN O O
16 NN O O
with NN O O
at NN O O
least NN O O
one NN O O
case NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
we NN O O
used NN O O
an NN O O
intake NN O O
cut-off NN O O
of NN O O
at NN O O
least NN O O
three NN O O
first-degree NN O O
relatives NN O O
with NN O O
breast NN B-CompositeMention B-MSH:D001943
and/or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
at NN O O
any NN O O
age. NN O O
significant NN O O
evidence NN O O
for NN O O
linkage NN O O
was NN O O
found NN O O
only NN O O
among NN O O
the NN O O
13 NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
families NN O O
with NN O O
a NN O O
mean NN O O
age NN O O
at NN O O
diagnosis NN O O
of NN O O
less NN O O
than NN O O
45 NN O O
years. NN O O
an NN O O
unexpectedly NN O O
low NN O O
proportion NN O O
of NN O O
the NN O O
breast-ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families NN O O
were NN O O
estimated NN O O
to NN O O
be NN O O
linked NN O O
to NN O O
brca NN O O
1, NN O O
which NN O O
could NN O O
be NN O O
due NN O O
to NN O O
a NN O O
founder NN O O
effec NN O O
. NN O O

in NN O O
the NN O O
dutch NN O O
population. NN O O
given NN O O
the NN O O
expected NN O O
logistical NN O O
problems NN O O
in NN O O
clinical NN O O
management NN O O
now NN O O
that NN O O
brca NN O O
1 NN O O
has NN O O
been NN O O
identified, NN O O
we NN O O
propose NN O O
an NN O O
interim NN O O
period NN O O
in NN O O
which NN O O
only NN O O
families NN O O
with NN O O
a NN O O
strong NN O O
positive NN O O
family NN O O
history NN O O
for NN O O
early NN O O
onset NN O O
breast NN B-CompositeMention B-MSH:D001943
and/or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
will NN O O
be NN O O
offered NN O O
brca NN O O
1 NN O O
mutation NN O O
testing. NN O O
. NN O O

some NN O O
mexican NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
variants NN O O
revisited NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
deficiency NN O O
appears NN O O
to NN O O
be NN O O
fairly NN O O
common NN O O
in NN O O
mexico. NN O O
we NN O O
have NN O O
now NN O O
examined NN O O
the NN O O
dna NN O O
of NN O O
three NN O O
previously NN O O
reported NN O O
electrophoretically NN O O
fast NN O O
mexican NN O O
g NN O O
6 NN O O
pd NN O O
variants, NN O O
-g NN O O
6 NN O O
pd NN O O
distrito NN O O
federal, NN O O
g NN O O
6 NN O O
pd NN O O
tepic, NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
castilla. NN O O
all NN O O
three NN O O
of NN O O
these NN O O
variants, NN O O
believed NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
biochemical NN O O
characterization NN O O
and NN O O
population NN O O
origin NN O O
to NN O O
be NN O O
unique, NN O O
have NN O O
the NN O O
g----a NN O O
transition NN O O
at NN O O
nucleotide NN O O
202 NN O O
and NN O O
the NN O O
a----g NN O O
transition NN O O
at NN O O
nucleotide NN O O
376, NN O O
mutations NN O O
that NN O O
we NN O O
now NN O O
recognize NN O O
to NN O O
be NN O O
characteristic NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
a-. NN O O
two NN O O
other NN O O
mexican NN O O
males NN O O
with NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
same NN O O
mutation. NN O O
all NN O O
five NN O O
have NN O O
the NN O O
(nlaiii NN O O
. NN O O

foki/pvuii/psti) NN O O
haplotype NN O O
characteristic NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
a NN O O
-in NN O O
africa. NN O O
since NN O O
the NN O O
pvuii NN O O
+ NN O O
genotype NN O O
seems NN O O
to NN O O
be NN O O
rare NN O O
in NN O O
europe, NN O O
we NN O O
conclude NN O O
that NN O O
all NN O O
of NN O O
these NN O O
g NN O O
6 NN O O
pd NN O O
a NN O O
- NN O O
genes NN O O
had NN O O
their NN O O
ancient NN O O
origin NN O O
in NN O O
africa, NN O O
although NN O O
in NN O O
many NN O O
of NN O O
the NN O O
mexican NN O O
patients NN O O
with NN O O
g NN O O
6 NN O O
pd NN O O
a NN O O
-202 NN O O
a/376 NN O O
g NN O O
the NN O O
gene NN O O
may NN O O
have NN O O
been NN O O
imported NN O O
more NN O O
recently NN O O
from NN O O
spain, NN O O
where NN O O
this NN O O
variant, NN O O
formerly NN O O
known NN O O
as NN O O
g NN O O
6 NN O O
pd NN O O
betica, NN O O
is NN O O
also NN O O
prevalent. NN O O
. NN O O

inactivation NN O O
of NN O O
germline NN O O
mutant NN O O
APC NN B-Modifier B-MSH:D011125
alleles NN O O
by NN O O
attenuated NN O O
somatic NN O O
mutations: NN O O
a NN O O
molecular NN O O
genetic NN O O
mechanism NN O O
for NN O O
attenuated NN B-SpecificDisease B-MSH:C538265
familial NN I-SpecificDisease I-MSH:C538265
adenomatous NN I-SpecificDisease I-MSH:C538265
polyposis NN I-SpecificDisease I-MSH:C538265
. NN O O

germline NN O O
mutations NN O O
of NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
(APC) NN I-Modifier I-MSH:D011125
tumor NN I-Modifier I-MSH:D011125
-suppressor NN O O
gene NN O O
result NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
). NN O O
patients NN O O
with NN O O
FAP NN B-SpecificDisease B-MSH:D011125
typically NN O O
develop NN O O
hundreds NN O O
to NN O O
thousands NN O O
of NN O O
benign NN B-SpecificDisease B-MSH:D015179
colorectal NN I-SpecificDisease I-MSH:D015179
tumors NN I-SpecificDisease I-MSH:D015179
and NN O O
early-onset NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O
a NN O O
subset NN O O
of NN O O
germline NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
results NN O O
in NN O O
an NN O O
attenuated NN B-Modifier B-MSH:C538265
FAP NN I-Modifier I-MSH:C538265
( NN O O
AFAP NN B-Modifier B-MSH:C538265
) NN O O
phenotype, NN O O
in NN O O
which NN O O
patients NN O O
develop NN O O
fewer NN O O
tumors NN B-DiseaseClass B-MSH:D009369
and NN O O
develop NN O O
them NN O O
at NN O O
an NN O O
older NN O O
age. NN O O
although NN O O
a NN O O
genotype-phenotype NN O O
correlation NN O O
between NN O O
the NN O O
locations NN O O
of NN O O
APC NN B-Modifier B-MSH:D011125
germline NN O O
mutations NN O O
and NN O O
the NN O O
development NN O O
of NN O O
AFAP NN B-SpecificDisease B-MSH:C538265
has NN O O
been NN O O
well NN O O
documented, NN O O
the NN O O
mechanism NN O O
for NN O O
AFAP NN B-SpecificDisease B-MSH:C538265
has NN O O
not NN O O
been NN O O
well NN O O
defined. NN O O
we NN O O
investigated NN O O
the NN O O
mechanism NN O O
for NN O O
AFAP NN B-SpecificDisease B-MSH:C538265
in NN O O
patients NN O O
carrying NN O O
a NN O O
mutant NN O O
APC NN B-Modifier B-MSH:D011125
allele NN O O
(apc NN O O
(as NN O O
9)) NN O O
that NN O O
has NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
alternatively NN O O
spliced NN O O
region NN O O
of NN O O
exon NN O O
9. NN O O
apc NN O O
. NN O O

as NN O O
9) NN O O
was NN O O
found NN O O
to NN O O
down-regulate NN O O
beta-catenin-regulated NN O O
transcription, NN O O
the NN O O
major NN O O
tumor NN B-Modifier B-MSH:D009369
-suppressor NN O O
function NN O O
of NN O O
apc, NN O O
as NN O O
did NN O O
the NN O O
wild-type NN O O
apc. NN O O
mutation NN O O
analysis NN O O
showed NN O O
that NN O O
both NN O O
apc NN O O
(as NN O O
9) NN O O
and NN O O
the NN O O
wild-type NN O O
APC NN B-Modifier B-MSH:D011125
alleles NN O O
were NN O O
somatically NN O O
mutated NN O O
in NN O O
most NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
tumors NN I-SpecificDisease I-MSH:D015179
from NN O O
these NN O O
patients. NN O O
functional NN O O
analysis NN O O
showed NN O O
that NN O O
4666 NN O O
insa, NN O O
a NN O O
common NN O O
somatic NN O O
mutation NN O O
in NN O O
apc NN O O
(as NN O O
9) NN O O
in NN O O
these NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
did NN O O
not NN O O
inactivate NN O O
the NN O O
wild-type NN O O
apc. NN O O
our NN O O
results NN O O
indicate NN O O
that NN O O
carriers NN O O
of NN O O
apc NN O O
(as NN O O
9) NN O O
develop NN O O
fewer NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
tumors NN I-SpecificDisease I-MSH:D015179
than NN O O
do NN O O
typical NN O O
patients NN O O
with NN O O
FAP NN B-SpecificDisease B-MSH:D011125
because NN O O
somatic NN O O
inactivation NN O O
of NN O O
both NN O O
APC NN B-Modifier B-MSH:D011125
alleles NN O O
is NN O O
necessary NN O O
for NN O O
colorectal NN O O
tumorigenesis. NN O O
however, NN O O
these NN O O
patients NN O O
develop NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
tumors NN I-SpecificDisease I-MSH:D015179
more NN O O
frequently NN O O
than NN O O
does NN O O
the NN O O
general NN O O
population NN O O
becaus NN O O
. NN O O

apc NN O O
(as NN O O
9) NN O O
is NN O O
inactivated NN O O
by NN O O
mutations NN O O
that NN O O
do NN O O
not NN O O
inactivate NN O O
the NN O O
wild-type NN O O
apc. NN O O
. NN O O

submicroscopic NN O O
deletions NN O O
at NN O O
the NN O O
WAGR NN B-Modifier B-MSH:D017624
locus, NN O O
revealed NN O O
by NN O O
nonradioactive NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
(fish) NN O O
with NN O O
biotin-labeled NN O O
probes NN O O
mapping NN O O
to NN O O
11 NN O O
p NN O O
13 NN O O
has NN O O
been NN O O
used NN O O
for NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
deletions NN O O
of NN O O
the NN O O
WAGR NN B-Modifier B-MSH:D017624
( NN O O
Wilms NN B-Modifier B-MSH:D009396
tumor NN I-Modifier I-MSH:D009396
, NN O O
aniridia NN B-Modifier B-MSH:D015783
, NN O O
genitourinary NN B-Modifier B-MSH:D014564
abnormalities NN I-Modifier I-MSH:D014564
, NN O O
and NN O O
mental NN B-Modifier B-MSH:D008607
retardation NN I-Modifier I-MSH:D008607
) NN O O
locus. NN O O
we NN O O
have NN O O
detected NN O O
a NN O O
submicroscopic NN O O
11 NN O O
p NN O O
13 NN O O
deletion NN O O
in NN O O
a NN O O
child NN O O
with NN O O
inherited NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
who NN O O
subsequently NN O O
presented NN O O
with NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
in NN O O
a NN O O
horseshoe NN O O
kidney, NN O O
only NN O O
revealed NN O O
at NN O O
surgery. NN O O
the NN O O
mother, NN O O
who NN O O
has NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
was NN O O
also NN O O
found NN O O
to NN O O
carry NN O O
a NN O O
deletion NN O O
including NN O O
both NN O O
the NN O O
aniridia NN B-Modifier B-MSH:D015783
candidate NN O O
gene NN O O
(an NN O O
2) NN O O
and NN O O
the NN O O
Wilms NN B-Modifier B-MSH:D009396
tumor NN I-Modifier I-MSH:D009396
predisposition NN O O
gene NN O O
(wt NN O O
1). NN O O
this NN O O
is NN O O
therefore NN O O
a NN O O
rare NN O O
case NN O O
of NN O O
an NN O O
inherited NN O O
WAGR NN B-Modifier B-MSH:D017624
deletion. NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
has NN O O
so NN O O
far NN O O
only NN O O
been NN O O
associated NN O O
with NN O O
sporadic NN O O
de NN O O
novo NN O O
aniridia NN B-Modifier B-MSH:D015783
cases. NN O O
we NN O O
have NN O O
show NN O O
. NN O O

that NN O O
a NN O O
cosmid NN O O
probe NN O O
for NN O O
a NN O O
candidate NN O O
aniridia NN B-Modifier B-MSH:D015783
gene, NN O O
homologous NN O O
to NN O O
the NN O O
mouse NN O O
pax-6 NN O O
gene, NN O O
is NN O O
deleted NN O O
in NN O O
cell NN O O
lines NN O O
from NN O O
aniridia NN B-Modifier B-MSH:D015783
patients NN O O
with NN O O
previously NN O O
characterized NN O O
deletions NN O O
at NN O O
11 NN O O
p NN O O
13, NN O O
while NN O O
another NN O O
cosmid NN O O
marker NN O O
mapping NN O O
between NN O O
two NN O O
aniridia NN B-Modifier B-MSH:D015783
-associated NN O O
translocation NN O O
breakpoints NN O O
(and NN O O
hence NN O O
a NN O O
second NN O O
candidate NN O O
marker) NN O O
is NN O O
present NN O O
on NN O O
both NN O O
chromosomes. NN O O
these NN O O
results NN O O
support NN O O
the NN O O
pax-6 NN O O
homologue NN O O
as NN O O
a NN O O
strong NN O O
candidate NN O O
for NN O O
the NN O O
an NN O O
2 NN O O
gene. NN O O
fish NN O O
with NN O O
cosmid NN O O
probes NN O O
has NN O O
proved NN O O
to NN O O
be NN O O
a NN O O
fast NN O O
and NN O O
reliable NN O O
technique NN O O
for NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
deletions. NN O O
it NN O O
can NN O O
be NN O O
used NN O O
with NN O O
limited NN O O
amounts NN O O
of NN O O
material NN O O
and NN O O
has NN O O
strong NN O O
potential NN O O
for NN O O
clinical NN O O
applications. NN O O
. NN O O

haplotype NN O O
studies NN O O
in NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
. NN O O

in NN O O
51 NN O O
families NN O O
with NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
, NN O O
we NN O O
have NN O O
studied NN O O
dna NN O O
haplotypes NN O O
of NN O O
dinucleotide NN O O
repeat NN O O
polymorphisms NN O O
(ca NN O O
repeats) NN O O
in NN O O
the NN O O
13 NN O O
q NN O O
14. NN O O
3 NN O O
region, NN O O
to NN O O
examine NN O O
these NN O O
markers NN O O
for NN O O
association NN O O
with NN O O
the NN O O
Wilson NN B-Modifier B-MSH:D006527
disease NN I-Modifier I-MSH:D006527
gene NN O O
( NN O O
WND NN B-SpecificDisease B-MSH:D006527
). NN O O
in NN O O
addition NN O O
to NN O O
a NN O O
marker NN O O
(d NN O O
13 NN O O
s NN O O
133) NN O O
described NN O O
elsewhere, NN O O
we NN O O
have NN O O
developed NN O O
three NN O O
new NN O O
highly NN O O
polymorphic NN O O
markers NN O O
(d NN O O
13 NN O O
s NN O O
314, NN O O
d NN O O
13 NN O O
s NN O O
315, NN O O
and NN O O
d NN O O
13 NN O O
s NN O O
316) NN O O
close NN O O
to NN O O
the NN O O
WND NN B-SpecificDisease B-MSH:D006527
locus. NN O O
we NN O O
have NN O O
examined NN O O
the NN O O
distribution NN O O
of NN O O
marker NN O O
alleles NN O O
at NN O O
the NN O O
loci NN O O
studied NN O O
and NN O O
have NN O O
found NN O O
that NN O O
d NN O O
13 NN O O
s NN O O
314, NN O O
d NN O O
13 NN O O
s NN O O
133, NN O O
and NN O O
d NN O O
13 NN O O
s NN O O
316 NN O O
each NN O O
show NN O O
nonrandom NN O O
distribution NN O O
on NN O O
chromosomes NN O O
carrying NN O O
the NN O O
WND NN B-SpecificDisease B-MSH:D006527
mutation. NN O O
we NN O O
have NN O O
studied NN O O
haplotypes NN O O
of NN O O
these NN O O
three NN O O
markers NN O O
an NN O O
. NN O O

have NN O O
found NN O O
that NN O O
there NN O O
are NN O O
highly NN O O
significant NN O O
differences NN O O
between NN O O
WND NN B-SpecificDisease B-MSH:D006527
and NN O O
normal NN O O
haplotypes NN O O
in NN O O
northern NN O O
european NN O O
families. NN O O
these NN O O
findings NN O O
have NN O O
important NN O O
implications NN O O
for NN O O
mutation NN O O
detection NN O O
and NN O O
molecular NN O O
diagnosis NN O O
in NN O O
families NN O O
with NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
. NN O O

growth NN O O
hormone NN O O
treatment NN O O
increases NN O O
co(2) NN O O
response, NN O O
ventilation NN O O
and NN O O
central NN O O
inspiratory NN O O
drive NN O O
in NN O O
children NN O O
with NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
. NN O O

we NN O O
studied NN O O
whether NN O O
the NN O O
beneficial NN O O
effects NN O O
of NN O O
growth NN O O
hormone NN O O
(gh) NN O O
treatment NN O O
on NN O O
growth NN O O
and NN O O
body NN O O
composition NN O O
in NN O O
PWS NN B-SpecificDisease B-MSH:D011218
are NN O O
accompanied NN O O
by NN O O
an NN O O
improvement NN O O
in NN O O
respiratory NN O O
function. NN O O
we NN O O
measured NN O O
resting NN O O
ventilation, NN O O
airway NN O O
occlusion NN O O
pressure NN O O
(p NN O O
(0. NN O O
1)) NN O O
and NN O O
ventilatory NN O O
response NN O O
to NN O O
co NN O O
(2) NN O O
in NN O O
nine NN O O
children, NN O O
aged NN O O
7-14 NN O O
years, NN O O
before NN O O
and NN O O
6-9 NN O O
months NN O O
after NN O O
the NN O O
start NN O O
of NN O O
gh NN O O
treatment. NN O O
during NN O O
gh NN O O
treatment, NN O O
resting NN O O
ventilation NN O O
increased NN O O
by NN O O
26%, NN O O
p NN O O
(0. NN O O
1) NN O O
by NN O O
72% NN O O
and NN O O
the NN O O
response NN O O
to NN O O
co NN O O
(2) NN O O
by NN O O
65% NN O O
(p NN O O
< NN O O
0. NN O O
002, NN O O
< NN O O
0. NN O O
04 NN O O
and NN O O
< NN O O
0. NN O O
02, NN O O
respectively). NN O O
this NN O O
observed NN O O
increase NN O O
in NN O O
ventilatory NN O O
output NN O O
was NN O O
not NN O O
correlated NN O O
to NN O O
changes NN O O
in NN O O
bod NN O O
. NN O O

mass NN O O
index. NN O O
conclusion NN O O
treatment NN O O
of NN O O
children NN O O
with NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
seems NN O O
to NN O O
have NN O O
a NN O O
stimulatory NN O O
effect NN O O
on NN O O
central NN O O
respiratory NN O O
structures. NN O O
the NN O O
observed NN O O
increase NN O O
in NN O O
ventilation NN O O
and NN O O
inspiratory NN O O
drive NN O O
may NN O O
contribute NN O O
to NN O O
the NN O O
improved NN O O
activity NN O O
level NN O O
reported NN O O
by NN O O
parents NN O O
of NN O O
PWS NN B-Modifier B-MSH:D011218
children NN O O
during NN O O
growth NN O O
hormone NN O O
therap NN O O
. NN O O

somatic NN O O
von NN B-Modifier B-MSH:D006623
Hippel-Lindau NN I-Modifier I-MSH:D006623
mutation NN O O
in NN O O
clear NN O O
cell NN O O
papillary NN B-SpecificDisease B-MSH:D018292
cystadenoma NN I-SpecificDisease I-MSH:D018292
of NN I-SpecificDisease I-MSH:D018292
the NN I-SpecificDisease I-MSH:D018292
epididymis NN I-SpecificDisease I-MSH:D018292
. NN O O

papillary NN O O
cystadenoma NN O O
of NN O O
the NN O O
epididymis NN O O
is NN O O
an NN O O
uncommon NN O O
benign NN O O
lesion NN O O
that NN O O
may NN O O
occur NN O O
sporadically NN O O
or NN O O
as NN O O
a NN O O
manifestation NN O O
of NN O O
von NN B-SpecificDisease B-MSH:D006623
Hippel-Lindau NN I-SpecificDisease I-MSH:D006623
(VHL) NN I-SpecificDisease I-MSH:D006623
disease NN I-SpecificDisease I-MSH:D006623
. NN O O
neither NN O O
immunohistochemical NN O O
studies NN O O
nor NN O O
molecular NN O O
genetic NN O O
analyses NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
have NN O O
been NN O O
reported NN O O
previously NN O O
for NN O O
this NN O O
lesion. NN O O
the NN O O
authors NN O O
describe NN O O
two NN O O
cases NN O O
of NN O O
clear NN O O
cell NN O O
papillary NN B-SpecificDisease B-MSH:D018292
cystadenoma NN I-SpecificDisease I-MSH:D018292
of NN I-SpecificDisease I-MSH:D018292
the NN I-SpecificDisease I-MSH:D018292
epididymis NN I-SpecificDisease I-MSH:D018292
, NN O O
both NN O O
of NN O O
which NN O O
were NN O O
initially NN O O
confused NN O O
with NN O O
metastatic NN B-SpecificDisease B-MSH:C538445
renal NN I-SpecificDisease I-MSH:C538445
cell NN I-SpecificDisease I-MSH:C538445
carcinoma NN I-SpecificDisease I-MSH:C538445
. NN O O
both NN O O
lesions NN O O
showed NN O O
positive NN O O
immunohistochemical NN O O
staining NN O O
for NN O O
low NN O O
and NN O O
intermediate NN O O
molecular NN O O
weight NN O O
keratins NN O O
(cam NN O O
5. NN O O
2 NN O O
and NN O O
ae NN O O
1/ae NN O O
3), NN O O
ema, NN O O
vimentin, NN O O
alpha NN O O
1-antitrypsin, NN O O
and NN O O
alpha NN O O
1-antichymotrypsin. NN O O
each NN O O
was NN O O
negative NN O O
for NN O O
cea. NN O O
because NN O O
clear NN O O
cell NN O O
papillary NN B-SpecificDisease B-MSH:D018292
cystadenoma NN I-SpecificDisease I-MSH:D018292
is NN O O
similar NN O O
to NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
histologically, NN O O
and NN O O
because NN O O
both NN O O
occur NN O O
as NN O O
components NN O O
o NN O O
. NN O O

the NN O O
von NN B-Modifier B-MSH:D006623
Hippel-Lindau NN I-Modifier I-MSH:D006623
disease NN I-Modifier I-MSH:D006623
complex, NN O O
the NN O O
authors NN O O
analyzed NN O O
both NN O O
cases NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene. NN O O
a NN O O
somatic NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
mutation NN O O
was NN O O
detected NN O O
in NN O O
one NN O O
of NN O O
the NN O O
two NN O O
tumors NN B-DiseaseClass B-MSH:D009369
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
followed NN O O
by NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
analysis. NN O O
direct NN O O
sequencing NN O O
revealed NN O O
a NN O O
cytosine NN O O
to NN O O
thymine NN O O
transition NN O O
at NN O O
nucleotide NN O O
694, NN O O
resulting NN O O
in NN O O
the NN O O
replacement NN O O
of NN O O
an NN O O
arginine NN O O
with NN O O
a NN O O
stop NN O O
codon NN O O
after NN O O
the NN O O
sixth NN O O
amino NN O O
acid NN O O
of NN O O
exon NN O O
3. NN O O
as NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
is NN O O
believed NN O O
to NN O O
function NN O O
as NN O O
a NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
gene, NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
mutations NN O O
may NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
initiation NN O O
of NN O O
tumorigenesis NN O O
in NN O O
sporadic NN O O
cystadenomas NN B-SpecificDisease B-MSH:D003537
of NN I-SpecificDisease I-MSH:D003537
the NN I-SpecificDisease I-MSH:D003537
epididymis NN I-SpecificDisease I-MSH:D003537
. NN O O

an NN O O
evaluation NN O O
of NN O O
genetic NN O O
heterogeneity NN O O
in NN O O
145 NN O O
breast-ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families. NN O O
Breast NN B-Modifier B-MSH:D001943
Cancer NN I-Modifier I-MSH:D001943
linkage NN O O
consortium NN O O
. NN O O

the NN O O
breast-ovary NN B-SpecificDisease B-MSH:D061325
cancer-family NN I-SpecificDisease I-MSH:D061325
syndrome NN I-SpecificDisease I-MSH:D061325
is NN O O
a NN O O
dominant NN O O
predisposition NN O O
to NN O O
cancer NN B-CompositeMention B-MSH:D001943
of NN I-CompositeMention I-MSH:D001943
the NN I-CompositeMention I-MSH:D001943
breast NN I-CompositeMention I-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovaries NN I-CompositeMention I-MSH:D001943
which NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
region NN O O
17 NN O O
q NN O O
12-q NN O O
21. NN O O
the NN O O
majority, NN O O
but NN O O
not NN O O
all, NN O O
of NN O O
breast-ovary NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families NN O O
show NN O O
linkage NN O O
to NN O O
this NN O O
susceptibility NN O O
locus, NN O O
designated NN O O
brca NN O O
1. NN O O
we NN O O
report NN O O
here NN O O
the NN O O
results NN O O
of NN O O
a NN O O
linkage NN O O
analysis NN O O
of NN O O
145 NN O O
families NN O O
with NN O O
both NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
. NN O O
these NN O O
families NN O O
contain NN O O
either NN O O
a NN O O
total NN O O
of NN O O
three NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
early-onset NN O O
(before NN O O
age NN O O
60 NN O O
years) NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
or NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
all NN O O
families NN O O
contained NN O O
at NN O O
least NN O O
one NN O O
case NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O
overall, NN O O
an NN O O
estimated NN O O
76% NN O O
of NN O O
the NN O O
145 NN O O
families NN O O
are NN O O
linked NN O O
to NN O O
the NN O O
brca NN O O
1 NN O O
locus. NN O O
none NN O O
of NN O O
the NN O O
13 NN O O
families NN O O
with NN O O
cases NN O O
o NN O O
. NN O O

male NN O O
breast NN O O
cancer NN O O
appear NN O O
to NN O O
be NN O O
linked, NN O O
but NN O O
it NN O O
is NN O O
estimated NN O O
that NN O O
92% NN O O
(95% NN O O
confidence NN O O
interval NN O O
76% NN O O
-100%) NN O O
of NN O O
families NN O O
with NN O O
no NN O O
male NN B-SpecificDisease B-MSH:D018567
breast NN I-SpecificDisease I-MSH:D018567
cancer NN I-SpecificDisease I-MSH:D018567
and NN O O
with NN O O
two NN O O
or NN O O
more NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
are NN O O
linked NN O O
to NN O O
brca NN O O
1. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
the NN O O
breast-ovarian NN B-SpecificDisease B-MSH:D061325
cancer-family NN I-SpecificDisease I-MSH:D061325
syndrome NN I-SpecificDisease I-MSH:D061325
is NN O O
genetically NN O O
heterogeneous. NN O O
however, NN O O
the NN O O
large NN O O
majority NN O O
of NN O O
families NN O O
with NN O O
early-onset NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
and NN O O
with NN O O
two NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
are NN O O
likely NN O O
to NN O O
be NN O O
due NN O O
to NN O O
brca NN O O
1 NN O O
mutations. NN O O
. NN O O

genetic NN O O
analysis NN O O
in NN O O
families NN O O
with NN O O
van NN B-SpecificDisease B-MSH:C536528
der NN I-SpecificDisease I-MSH:C536528
Woude NN I-SpecificDisease I-MSH:C536528
syndrome NN I-SpecificDisease I-MSH:C536528
. NN O O

we NN O O
have NN O O
brought NN O O
together NN O O
information NN O O
on NN O O
864 NN O O
affected NN O O
individuals NN O O
in NN O O
164 NN O O
families NN O O
(including NN O O
three NN O O
new NN O O
pedigrees) NN O O
reported NN O O
in NN O O
the NN O O
137 NN O O
year NN O O
period NN O O
since NN O O
1845 NN O O
when NN O O
demarquay NN O O
first NN O O
described NN O O
a NN O O
family NN O O
with NN O O
what NN O O
was NN O O
later NN O O
called NN O O
van NN B-SpecificDisease B-MSH:C536528
der NN I-SpecificDisease I-MSH:C536528
Woude NN I-SpecificDisease I-MSH:C536528
syndrome NN I-SpecificDisease I-MSH:C536528
( NN O O
VWS NN B-SpecificDisease B-MSH:C536528
). NN O O
both NN O O
types NN O O
of NN O O
oral NN B-SpecificDisease B-MSH:D002971
cleft NN I-SpecificDisease I-MSH:D002971
, NN O O
cleft NN B-SpecificDisease B-MSH:D002972
palate NN I-SpecificDisease I-MSH:D002972
( NN O O
CP NN B-SpecificDisease B-MSH:D002972
) NN O O
and NN O O
cleft NN B-SpecificDisease B-MSH:D002971
lip NN I-SpecificDisease I-MSH:D002971
with NN O O
or NN O O
without NN O O
CP NN B-SpecificDisease B-MSH:D002972
( NN O O
CLP NN B-SpecificDisease B-MSH:D002971
), NN O O
segregate NN O O
in NN O O
these NN O O
families NN O O
together NN O O
with NN O O
lower NN O O
lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
or NN O O
fistulae NN B-SpecificDisease B-MSH:D005402
in NN O O
an NN O O
autosomal NN O O
dominant NN O O
mode NN O O
with NN O O
high NN O O
penetrance NN O O
estimated NN O O
to NN O O
be NN O O
k NN O O
=. NN O O
89 NN O O
and. NN O O
99 NN O O
by NN O O
different NN O O
methods. NN O O
cleft NN O O
types NN O O
( NN O O
CLP NN B-SpecificDisease B-MSH:D002971
and NN O O
CP NN B-SpecificDisease B-MSH:D002972
) NN O O
occur NN O O
in NN O O
VWS NN B-SpecificDisease B-MSH:C536528
in NN O O
the NN O O
same NN O O
proportions NN O O
as NN O O
in NN O O
the NN O O
general NN O O
non-vws NN O O
population, NN O O
ie, NN O O
about NN O O
twice NN O O
as NN O O
many NN O O
cleft-bearing NN O O
individuals NN O O
have NN O O
CLP NN B-SpecificDisease B-MSH:D002971
as NN O O
have NN O O
CP NN B-SpecificDisease B-MSH:D002972
. NN O O
o NN O O
. NN O O

the NN O O
other NN O O
hand, NN O O
we NN O O
do NN O O
not NN O O
find NN O O
the NN O O
usually NN O O
observed NN O O
excess NN O O
of NN O O
females NN O O
with NN O O
CP NN B-SpecificDisease B-MSH:D002972
and NN O O
excess NN O O
of NN O O
males NN O O
with NN O O
CLP NN B-SpecificDisease B-MSH:D002971
; NN O O
in NN O O
VWS NN B-SpecificDisease B-MSH:C536528
the NN O O
sex NN O O
ratios NN O O
are NN O O
more NN O O
nearly NN O O
equal. NN O O
Lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
also NN O O
are NN O O
equally NN O O
distributed NN O O
between NN O O
the NN O O
sexes. NN O O
affected NN O O
males NN O O
and NN O O
females NN O O
are NN O O
equally NN O O
likely NN O O
to NN O O
transmit NN O O
VWS NN B-SpecificDisease B-MSH:C536528
. NN O O
however, NN O O
there NN O O
is NN O O
an NN O O
excess NN O O
of NN O O
less NN O O
severely NN O O
affected NN O O
individuals NN O O
among NN O O
transmitters NN O O
and NN O O
a NN O O
deficiency NN O O
of NN O O
more NN O O
severely NN O O
affected, NN O O
brought NN O O
about NN O O
by NN O O
a NN O O
proband NN O O
bias NN O O
and NN O O
differential NN O O
fecundity. NN O O
the NN O O
expression NN O O
of NN O O
VWS NN B-SpecificDisease B-MSH:C536528
is NN O O
significantly NN O O
modified NN O O
by NN O O
the NN O O
genetic NN O O
background NN O O
more NN O O
extreme NN O O
phenotypes NN O O
in NN O O
parents NN O O
tend NN O O
to NN O O
produce NN O O
more NN O O
extreme NN O O
expression NN O O
in NN O O
their NN O O
children. NN O O
for NN O O
a NN O O
VWS NN B-Modifier B-MSH:C536528
gene NN O O
carrier NN O O
the NN O O
relative NN O O
risk NN O O
of NN O O
transmitting NN O O
a NN O O
cleft NN O O
is NN O O
26. NN O O
45%; NN O O
that NN O O
of NN O O
transmitting NN O O
lower NN O O
lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
is NN O O
23. NN O O
55 NN O O
. NN O O

. NN O O
three NN O O
pedigrees NN O O
of NN O O
lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
in NN O O
the NN O O
literature NN O O
show NN O O
no NN O O
clefts NN O O
among NN O O
a NN O O
significant NN O O
number NN O O
of NN O O
affected NN O O
individuals. NN O O
control NN O O
of NN O O
gene NN O O
expression NN O O
in NN O O
VWS NN B-SpecificDisease B-MSH:C536528
in NN O O
the NN O O
three NN O O
target NN O O
tissues NN O O
appears NN O O
to NN O O
be NN O O
independent NN O O
and NN O O
separately NN O O
designated. NN O O
mutation NN O O
rate NN O O
of NN O O
the NN O O
VWS NN B-Modifier B-MSH:C536528
gene NN O O
is NN O O
calculated NN O O
to NN O O
be NN O O
1. NN O O
8 NN O O
x NN O O
10 NN O O
(-5 NN O O
. NN O O

molecular NN O O
and NN O O
phenotypic NN O O
analysis NN O O
of NN O O
patients NN O O
with NN O O
deletions NN O O
within NN O O
the NN O O
deletion-rich NN O O
region NN O O
of NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
gene NN O O
. NN O O

eighty NN O O
unrelated NN O O
individuals NN O O
with NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
)or NN O O
Becker NN B-SpecificDisease B-MSH:C537666
muscular NN I-SpecificDisease I-MSH:C537666
dystrophy NN I-SpecificDisease I-MSH:C537666
( NN O O
BMD NN B-SpecificDisease B-MSH:C537666
) NN O O
were NN O O
found NN O O
to NN O O
have NN O O
deletions NN O O
in NN O O
the NN O O
major NN O O
deletion-rich NN O O
region NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
locus. NN O O
this NN O O
region NN O O
includes NN O O
the NN O O
last NN O O
five NN O O
exons NN O O
detected NN O O
by NN O O
cdna NN O O
5 NN O O
b-7, NN O O
all NN O O
exons NN O O
detected NN O O
by NN O O
cdna NN O O
8, NN O O
and NN O O
the NN O O
first NN O O
two NN O O
exons NN O O
detected NN O O
by NN O O
cdna NN O O
9. NN O O
these NN O O
80 NN O O
individuals NN O O
account NN O O
for NN O O
approximately NN O O
75% NN O O
of NN O O
109 NN O O
deletions NN O O
of NN O O
the NN O O
gene, NN O O
detected NN O O
among NN O O
181 NN O O
patients NN O O
analyzed NN O O
with NN O O
the NN O O
entire NN O O
dystrophin NN O O
cdna. NN O O
endpoints NN O O
for NN O O
many NN O O
of NN O O
these NN O O
deletions NN O O
were NN O O
further NN O O
characterized NN O O
using NN O O
two NN O O
genomic NN O O
probes, NN O O
p NN O O
20 NN O O
(dxs NN O O
269; NN O O
wapenaar NN O O
et NN O O
al.) NN O O
and NN O O
gmgx NN O O
11 NN O O
(dxs NN O O
239; NN O O
present NN O O
paper). NN O O
clinical NN O O
findings NN O O
are NN O O
presented NN O O
for NN O O
all NN O O
80 NN O O
patients NN O O
allowing NN O O
a NN O O
correlation NN O O
o NN O O
. NN O O

phenotypic NN O O
severity NN O O
with NN O O
the NN O O
genotype. NN O O
thirty-eight NN O O
independent NN O O
patients NN O O
were NN O O
old NN O O
enough NN O O
to NN O O
be NN O O
classified NN O O
as NN O O
DMD NN B-SpecificDisease B-MSH:D020388
, NN O O
BMD NN B-SpecificDisease B-MSH:C537666
, NN O O
or NN O O
intermediate NN O O
phenotype NN O O
and NN O O
had NN O O
deletions NN O O
of NN O O
exons NN O O
with NN O O
sequenced NN O O
intron/exon NN O O
boundaries. NN O O
of NN O O
these, NN O O
eight NN O O
BMD NN B-Modifier B-MSH:C537666
patients NN O O
and NN O O
one NN O O
intermediate NN O O
patient NN O O
had NN O O
gene NN O O
deletions NN O O
predicted NN O O
to NN O O
leave NN O O
the NN O O
reading NN O O
frame NN O O
intact, NN O O
while NN O O
21 NN O O
DMD NN B-Modifier B-MSH:D020388
patients, NN O O
7 NN O O
intermediate NN O O
patients, NN O O
and NN O O
1 NN O O
BMD NN B-Modifier B-MSH:C537666
patient NN O O
had NN O O
gene NN O O
deletions NN O O
predicted NN O O
to NN O O
disrupt NN O O
the NN O O
reading NN O O
frame. NN O O
thus, NN O O
with NN O O
two NN O O
exceptions, NN O O
frameshift NN O O
deletions NN O O
of NN O O
the NN O O
gene NN O O
resulted NN O O
in NN O O
more NN O O
severe NN O O
phenotype NN O O
than NN O O
did NN O O
in-frame NN O O
deletions. NN O O
this NN O O
is NN O O
in NN O O
agreement NN O O
with NN O O
recent NN O O
findings NN O O
by NN O O
baumbach NN O O
et NN O O
al. NN O O
and NN O O
koenig NN O O
et NN O O
al. NN O O
but NN O O
is NN O O
in NN O O
contrast NN O O
to NN O O
findings, NN O O
by NN O O
malhotra NN O O
et NN O O
al. NN O O
at NN O O
the NN O O
5 NN O O
' NN O O
end NN O O
of NN O O
th NN O O
. NN O O

gene NN O O
. NN O O

proteolipoprotein NN O O
gene NN O O
analysis NN O O
in NN O O
82 NN O O
patients NN O O
with NN O O
sporadic NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
Disease NN I-SpecificDisease I-OMIM:312080
: NN O O
duplications, NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
the NN O O
disease, NN O O
originate NN O O
more NN O O
frequently NN O O
in NN O O
male NN O O
germ NN O O
cells, NN O O
but NN O O
point NN O O
mutations NN O O
do NN O O
not. NN O O
the NN O O
clinical NN O O
european NN O O
network NN O O
on NN O O
Brain NN B-DiseaseClass B-MSH:D020279
Dysmyelinating NN I-DiseaseClass I-MSH:D020279
Disease NN I-DiseaseClass I-MSH:D020279
. NN O O

pelizaeus-merzbacher NN O O
disease NN O O
( NN O O
PMD NN B-SpecificDisease B-MSH:D020371
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D020279
developmental NN I-DiseaseClass I-MSH:D020279
defect NN I-DiseaseClass I-MSH:D020279
of NN I-DiseaseClass I-MSH:D020279
myelination NN I-DiseaseClass I-MSH:D020279
affecting NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
and NN O O
segregating NN O O
with NN O O
the NN O O
proteolipoprotein NN O O
(plp) NN O O
locus. NN O O
investigating NN O O
82 NN O O
strictly NN O O
selected NN O O
sporadic NN O O
cases NN O O
of NN O O
PMD NN B-SpecificDisease B-MSH:D020371
, NN O O
we NN O O
found NN O O
plp NN O O
mutations NN O O
in NN O O
77%; NN O O
complete NN O O
plp-gene NN O O
duplications NN O O
were NN O O
the NN O O
most NN O O
frequent NN O O
abnormality NN O O
(62%), NN O O
whereas NN O O
point NN O O
mutations NN O O
in NN O O
coding NN O O
or NN O O
splice-site NN O O
regions NN O O
of NN O O
the NN O O
gene NN O O
were NN O O
involved NN O O
less NN O O
frequently NN O O
(38%). NN O O
we NN O O
analyzed NN O O
the NN O O
maternal NN O O
status NN O O
of NN O O
56 NN O O
cases NN O O
to NN O O
determine NN O O
the NN O O
origin NN O O
of NN O O
both NN O O
types NN O O
of NN O O
plp NN O O
mutation, NN O O
since NN O O
this NN O O
is NN O O
relevant NN O O
to NN O O
genetic NN O O
counseling. NN O O
in NN O O
the NN O O
22 NN O O
point NN O O
mutations, NN O O
68% NN O O
of NN O O
mothers NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
mutation, NN O O
a NN O O
value NN O O
identical NN O O
to NN O O
the NN O O
two-thirds NN O O
of NN O O
carrier NN O O
mothers NN O O
tha NN O O
. NN O O

would NN O O
be NN O O
expected NN O O
if NN O O
there NN O O
were NN O O
an NN O O
equal NN O O
mutation NN O O
rate NN O O
in NN O O
male NN O O
and NN O O
female NN O O
germ NN O O
cells. NN O O
in NN O O
sharp NN O O
contrast, NN O O
among NN O O
the NN O O
34 NN O O
duplicated NN O O
cases, NN O O
91% NN O O
of NN O O
mothers NN O O
were NN O O
carriers, NN O O
a NN O O
value NN O O
significantly NN O O
(chi NN O O
2 NN O O
= NN O O
9. NN O O
20, NN O O
p NN O O
<. NN O O
01) NN O O
in NN O O
favor NN O O
of NN O O
a NN O O
male NN O O
bias, NN O O
with NN O O
an NN O O
estimation NN O O
of NN O O
the NN O O
male/female NN O O
mutation NN O O
frequency NN O O
(k) NN O O
of NN O O
9. NN O O
3 NN O O
3. NN O O
moreover, NN O O
we NN O O
observed NN O O
the NN O O
occurrence NN O O
of NN O O
de NN O O
novo NN O O
mutations NN O O
between NN O O
parental NN O O
and NN O O
grandparental NN O O
generations NN O O
in NN O O
17 NN O O
three-generation NN O O
families, NN O O
which NN O O
allowed NN O O
a NN O O
direct NN O O
estimation NN O O
of NN O O
the NN O O
k NN O O
value NN O O
(k NN O O
= NN O O
11). NN O O
again, NN O O
a NN O O
significant NN O O
male NN O O
mutation NN O O
imbalance NN O O
was NN O O
observed NN O O
only NN O O
for NN O O
the NN O O
duplications NN O O
. NN O O
s, NN O O
with NN O O
an NN O O
estimation NN O O
of NN O O
the NN O O
male/female NN O O
mutation NN O O
frequency NN O O
(k) NN O O
of NN O O
9. NN O O
3 NN O O
3. NN O O
moreover, NN O O
we NN O O
observed NN O O
the NN O O
occurrence NN O O
of NN O O
de NN O O
novo NN O O
mutations NN O O
between NN O O
parental NN O O
and NN O O
grandparental NN O O
generations NN O O
in NN O O
17 NN O O
three-generation NN O O
families, NN O O
which NN O O
allowed NN O O
a NN O O
direct NN O O
estimation NN O O
of NN O O
the NN O O
k NN O O
value NN O O
(k NN O O
= NN O O
11). NN O O
again, NN O O
a NN O O
significant NN O O
male NN O O
mutation NN O O
imbalance NN O O
was NN O O
observed NN O O
only NN O O
for NN O O
the NN O O
duplications NN O O
. NN O O

haplotype NN O O
analysis NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
in NN O O
turkish NN O O
phenylketonuria NN B-Modifier B-MSH:D010661
families NN O O
. NN O O

we NN O O
have NN O O
estimated NN O O
the NN O O
haplotype NN O O
distribution NN O O
of NN O O
mutant NN O O
and NN O O
normal NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
alleles NN O O
for NN O O
17 NN O O
turkish NN O O
phenylketonuria NN B-Modifier B-MSH:D010661
( NN O O
PKU NN B-Modifier B-MSH:D010661
) NN O O
families NN O O
20 NN O O
normal NN O O
and NN O O
27 NN O O
mutated NN O O
pah NN O O
alleles NN O O
could NN O O
be NN O O
identified. NN O O
of NN O O
the NN O O
latter, NN O O
the NN O O
most NN O O
prevalent NN O O
were NN O O
associated NN O O
with NN O O
haplotype NN O O
6 NN O O
(29. NN O O
6%), NN O O
1 NN O O
(18. NN O O
5%) NN O O
and NN O O
36 NN O O
(11. NN O O
1%), NN O O
while NN O O
the NN O O
normal NN O O
alleles NN O O
were NN O O
preferentially NN O O
associated NN O O
with NN O O
haplotype NN O O
1 NN O O
(20%). NN O O
of NN O O
the NN O O
19 NN O O
different NN O O
haplotypes NN O O
observed, NN O O
5 NN O O
have NN O O
not NN O O
been NN O O
described NN O O
previously. NN O O
the NN O O
haplotype NN O O
distribution NN O O
differed NN O O
significantly NN O O
from NN O O
that NN O O
of NN O O
the NN O O
northern NN O O
european NN O O
population. NN O O
two NN O O
of NN O O
the NN O O
eight NN O O
polymorphic NN O O
sites NN O O
were NN O O
in NN O O
association NN O O
with NN O O
PKU NN B-SpecificDisease B-MSH:D010661
. NN O O
no NN O O
deletions NN O O
of NN O O
exon NN O O
sequences NN O O
were NN O O
found NN O O
in NN O O
the NN O O
families NN O O
analysed NN O O
. NN O O

cloning NN O O
of NN O O
human NN O O
very-long-chain NN O O
acyl-coenzyme NN O O
a NN O O
dehydrogenase NN O O
and NN O O
molecular NN O O
characterization NN O O
of NN O O
its NN O O
deficiency NN O O
in NN O O
two NN O O
patients NN O O
. NN O O

two NN O O
overlapping NN O O
cdna NN O O
clones NN O O
(1, NN O O
991 NN O O
bp NN O O
and NN O O
736 NN O O
bp, NN O O
respectively) NN O O
encoding NN O O
the NN O O
precursor NN O O
of NN O O
human NN O O
mitochondrial NN O O
very-long-chain NN O O
acyl-coenzyme NN O O
a NN O O
dehydrogenase NN O O
(vlcad) NN O O
were NN O O
cloned NN O O
and NN O O
sequenced. NN O O
the NN O O
cdna NN O O
inserts NN O O
of NN O O
these NN O O
clones NN O O
together NN O O
encompass NN O O
a NN O O
region NN O O
of NN O O
2, NN O O
177 NN O O
bases, NN O O
encoding NN O O
the NN O O
entire NN O O
protein NN O O
of NN O O
655 NN O O
amino NN O O
acids, NN O O
including NN O O
a NN O O
40-amino NN O O
acid NN O O
leader NN O O
peptide NN O O
and NN O O
a NN O O
615-amino NN O O
acid NN O O
mature NN O O
polypeptide. NN O O
pcr-amplified NN O O
vlcad NN O O
cdnas NN O O
were NN O O
sequenced NN O O
in NN O O
cultured NN O O
fibroblasts NN O O
from NN O O
two NN O O
VLCAD-deficient NN B-Modifier B-MSH:C536353
patients. NN O O
in NN O O
both NN O O
patients, NN O O
a NN O O
105-bp NN O O
deletion NN O O
encompassing NN O O
bases NN O O
1078-1182 NN O O
in NN O O
vlcad NN O O
cdna NN O O
was NN O O
identified. NN O O
the NN O O
deletion NN O O
seems NN O O
to NN O O
occur NN O O
due NN O O
to NN O O
exon NN O O
skipping NN O O
during NN O O
processing NN O O
of NN O O
vlcad NN O O
pre-mrna. NN O O
this NN O O
is NN O O
the NN O O
first NN O O
demonstratio NN O O
. NN O O

of NN O O
a NN O O
mutation NN O O
causing NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
. NN O O
quantitative NN O O
cdna NN O O
expression NN O O
of NN O O
normal NN O O
human NN O O
vlcad NN O O
was NN O O
performed NN O O
in NN O O
the NN O O
patients NN O O
fibroblasts, NN O O
using NN O O
vaccinia NN O O
viral NN O O
system, NN O O
which NN O O
demonstrated NN O O
that NN O O
the NN O O
deficiency NN B-SpecificDisease B-MSH:C536353
of NN I-SpecificDisease I-MSH:C536353
the NN I-SpecificDisease I-MSH:C536353
normal NN I-SpecificDisease I-MSH:C536353
VLCAD NN I-SpecificDisease I-MSH:C536353
protein NN I-SpecificDisease I-MSH:C536353
causes NN O O
impaired NN O O
long-chain NN O O
fatty NN O O
acid NN O O
beta-oxidation NN O O
activity NN O O
in NN O O
the NN O O
patients NN O O
fibroblasts. NN O O
in NN O O
patient NN O O
fibroblasts, NN O O
raising NN O O
vlcad NN O O
activity NN O O
to NN O O
approximately NN O O
20% NN O O
of NN O O
normal NN O O
control NN O O
fibroblast NN O O
activity NN O O
raised NN O O
palmitic NN O O
acid NN O O
beta-oxidation NN O O
flux NN O O
to NN O O
the NN O O
level NN O O
found NN O O
in NN O O
control NN O O
fibroblasts, NN O O
which NN O O
may NN O O
offer NN O O
important NN O O
information NN O O
for NN O O
the NN O O
rational NN O O
design NN O O
of NN O O
future NN O O
somatic NN O O
gene NN O O
therapy NN O O
for NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
. NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
and NN O O
their NN O O
effects NN O O
on NN O O
transcription NN O O
. NN O O

inactivation NN O O
of NN O O
both NN O O
alleles NN O O
of NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
during NN O O
normal NN O O
retinal NN O O
development NN O O
initiates NN O O
the NN O O
formation NN O O
of NN O O
a NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
(RB) NN I-SpecificDisease I-MSH:D012175
tumor NN I-SpecificDisease I-MSH:D012175
. NN O O
to NN O O
identify NN O O
the NN O O
mutations NN O O
which NN O O
inactivate NN O O
rb NN O O
1, NN O O
21 NN O O
RB NN B-SpecificDisease B-MSH:D012175
tumors NN I-SpecificDisease I-MSH:D012175
isolated NN O O
from NN O O
19 NN O O
patients NN O O
were NN O O
analyzed NN O O
with NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
or NN O O
an NN O O
rnase NN O O
protection NN O O
assay NN O O
or NN O O
both. NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
13 NN O O
of NN O O
21 NN O O
RB NN B-SpecificDisease B-MSH:D012175
tumors NN I-SpecificDisease I-MSH:D012175
; NN O O
in NN O O
8 NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
the NN O O
precise NN O O
errors NN O O
in NN O O
nucleotide NN O O
sequence NN O O
were NN O O
characterized. NN O O
each NN O O
of NN O O
four NN O O
germ NN O O
line NN O O
mutations NN O O
involved NN O O
a NN O O
small NN O O
deletion NN O O
or NN O O
duplication, NN O O
while NN O O
three NN O O
somatic NN O O
mutations NN O O
were NN O O
point NN O O
mutations NN O O
leading NN O O
to NN O O
splice NN O O
alterations NN O O
and NN O O
loss NN O O
of NN O O
an NN O O
exon NN O O
from NN O O
the NN O O
mature NN O O
rb NN O O
1 NN O O
mrna. NN O O
we NN O O
were NN O O
unable NN O O
to NN O O
detect NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
allele NN O O
in NN O O
lymphoblasts NN O O
of NN O O
three NN O O
bilaterally NN O O
affected NN O O
patients, NN O O
although NN O O
the NN O O
mutation NN O O
was NN O O
present NN O O
in NN O O
the NN O O
genomi NN O O
. NN O O

dna NN O O
and NN O O
transcripts NN O O
containing NN O O
the NN O O
mutations NN O O
were NN O O
obvious NN O O
in NN O O
the NN O O
RB NN B-SpecificDisease B-MSH:D012175
tumors NN I-SpecificDisease I-MSH:D012175
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
normal NN O O
rb NN O O
1 NN O O
allele. NN O O
the NN O O
variations NN O O
in NN O O
the NN O O
level NN O O
of NN O O
expression NN O O
of NN O O
mutant NN O O
transcripts NN O O
suggest NN O O
deregulation NN O O
of NN O O
rb NN O O
1 NN O O
transcription NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
functional NN O O
rb NN O O
1 NN O O
gene NN O O
product. NN O O
. NN O O

resolution NN O O
of NN O O
the NN O O
two NN O O
loci NN O O
for NN O O
autosomal NN O O
dominant NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
an NN O O
1 NN O O
and NN O O
an NN O O
2, NN O O
to NN O O
a NN O O
single NN O O
locus NN O O
on NN O O
chromosome NN O O
11 NN O O
p NN O O
13 NN O O
. NN O O

two NN O O
distinct NN O O
loci NN O O
have NN O O
been NN O O
proposed NN O O
for NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
; NN O O
an NN O O
1 NN O O
for NN O O
autosomal NN O O
dominant NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
on NN O O
chromosome NN O O
2 NN O O
p NN O O
and NN O O
an NN O O
2 NN O O
for NN O O
the NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
in NN O O
the NN O O
WAGR NN B-SpecificDisease B-MSH:D017624
contiguous NN I-SpecificDisease I-MSH:D017624
gene NN I-SpecificDisease I-MSH:D017624
syndrome NN I-SpecificDisease I-MSH:D017624
on NN O O
chromosome NN O O
11 NN O O
p NN O O
13. NN O O
in NN O O
this NN O O
report, NN O O
the NN O O
kindred NN O O
segregating NN O O
for NN O O
autosomal NN O O
dominant NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
which NN O O
suggested NN O O
linkage NN O O
to NN O O
acid NN O O
phosphatase-1 NN O O
(acp NN O O
1) NN O O
and NN O O
led NN O O
to NN O O
the NN O O
assignment NN O O
of NN O O
the NN O O
an NN O O
1 NN O O
locus NN O O
on NN O O
chromosome NN O O
2 NN O O
p, NN O O
has NN O O
been NN O O
updated NN O O
and NN O O
expanded. NN O O
linkage NN O O
analysis NN O O
between NN O O
the NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
phenotype NN O O
and NN O O
acp NN O O
1 NN O O
does NN O O
not NN O O
support NN O O
the NN O O
original NN O O
linkage NN O O
results, NN O O
excluding NN O O
linkage NN O O
up NN O O
to NN O O
theta NN O O
= NN O O
0. NN O O
17 NN O O
with NN O O
z NN O O
= NN O O
-2. NN O O
tests NN O O
for NN O O
linkage NN O O
to NN O O
other NN O O
chromosome NN O O
2 NN O O
p NN O O
markers. NN O O
apob, NN O O
d NN O O
2 NN O O
s NN O O
71, NN O O
d NN O O
2 NN O O
s NN O O
5, NN O O
and NN O O
d NN O O
2 NN O O
. NN O O

1, NN O O
also NN O O
excluded NN O O
linkage NN O O
to NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O O
markers NN O O
that NN O O
have NN O O
been NN O O
isolated NN O O
from NN O O
the NN O O
chromosome NN O O
11 NN O O
p NN O O
13 NN O O
region NN O O
were NN O O
then NN O O
analyzed NN O O
in NN O O
this NN O O
aniridia NN B-Modifier B-MSH:D015783
family. NN O O
two NN O O
rflps NN O O
at NN O O
the NN O O
d NN O O
11 NN O O
s NN O O
323 NN O O
locus NN O O
give NN O O
significant NN O O
evidence NN O O
for NN O O
linkage. NN O O
the NN O O
pvuii NN O O
polymorphism NN O O
detected NN O O
by NN O O
probe NN O O
p NN O O
5 NN O O
s NN O O
1. NN O O
6 NN O O
detects NN O O
no NN O O
recombinants, NN O O
with NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
z NN O O
= NN O O
6. NN O O
97 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
00 NN O O
00. NN O O
the NN O O
haeiii NN O O
polymorphism NN O O
detected NN O O
by NN O O
the NN O O
probe NN O O
p NN O O
5 NN O O
be NN O O
1. NN O O
2 NN O O
gives NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
z NN O O
= NN O O
2. NN O O
57 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
00 NN O O
00. NN O O
locus NN O O
d NN O O
11 NN O O
s NN O O
325 NN O O
gives NN O O
a NN O O
lod NN O O
score NN O O
of NN O O
z NN O O
= NN O O
1. NN O O
53 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
00 NN O O
00. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
a NN O O
locus NN O O
fo NN O O
. NN O O

aniridia NN O O
(an NN O O
1) NN O O
on NN O O
chromosome NN O O
2 NN O O
p NN O O
has NN O O
been NN O O
misassigned NN O O
and NN O O
that NN O O
this NN O O
autosomal NN O O
dominant NN O O
aniridia NN B-Modifier B-MSH:D015783
family NN O O
is NN O O
segregating NN O O
for NN O O
an NN O O
aniridia NN B-Modifier B-MSH:D015783
mutation NN O O
linked NN O O
to NN O O
markers NN O O
in NN O O
the NN O O
11 NN O O
p NN O O
13 NN O O
region NN O O
. NN O O

gt NN O O
to NN O O
at NN O O
transition NN O O
at NN O O
a NN O O
splice NN O O
donor NN O O
site NN O O
causes NN O O
skipping NN O O
of NN O O
the NN O O
preceding NN O O
exon NN O O
in NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
. NN O O

classical NN O O
phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
human NN I-DiseaseClass I-MSH:D030342
genetic NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah). NN O O
we NN O O
isolated NN O O
several NN O O
mutant NN O O
pah NN O O
cdna NN O O
clones NN O O
from NN O O
a NN O O
PKU NN B-Modifier B-MSH:D010661
carrier NN O O
individual NN O O
and NN O O
showed NN O O
that NN O O
they NN O O
contained NN O O
an NN O O
internal NN O O
116 NN O O
base NN O O
pair NN O O
deletion, NN O O
corresponding NN O O
precisely NN O O
to NN O O
exon NN O O
12 NN O O
of NN O O
the NN O O
human NN O O
chromosomal NN O O
pah NN O O
gene. NN O O
the NN O O
deletion NN O O
causes NN O O
the NN O O
synthesis NN O O
of NN O O
a NN O O
truncated NN O O
protein NN O O
lacking NN O O
the NN O O
c-terminal NN O O
52 NN O O
amino NN O O
acids. NN O O
gene NN O O
transfer NN O O
and NN O O
expression NN O O
studies NN O O
using NN O O
the NN O O
mutant NN O O
pah NN O O
cdna NN O O
indicated NN O O
that NN O O
the NN O O
deletion NN O O
abolishes NN O O
pah NN O O
activity NN O O
in NN O O
the NN O O
cell NN O O
as NN O O
a NN O O
result NN O O
of NN O O
protein NN O O
instability. NN O O
to NN O O
determine NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
the NN O O
deletion, NN O O
the NN O O
mutant NN O O
chromosomal NN O O
pah NN O O
gene NN O O
was NN O O
isolated NN O O
from NN O O
this NN O O
individual NN O O
and NN O O
shown NN O O
to NN O O
contain NN O O
a NN O O
gt-- NN O O
greater NN O O
than NN O O
at NN O O
substitution NN O O
at NN O O
the NN O O
5 NN O O
splic NN O O
. NN O O

donor NN O O
site NN O O
of NN O O
intron NN O O
12. NN O O
thus, NN O O
the NN O O
consequence NN O O
of NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
mutation NN O O
in NN O O
the NN O O
human NN O O
liver NN O O
is NN O O
the NN O O
skipping NN O O
of NN O O
the NN O O
preceding NN O O
exon NN O O
during NN O O
rna NN O O
splicing. NN O O
. NN O O

clinical NN O O
and NN O O
molecular NN O O
genetic NN O O
analysis NN O O
of NN O O
19 NN O O
Wolfram NN B-Modifier B-OMIM:222300
syndrome NN I-Modifier I-OMIM:222300
kindreds NN O O
demonstrating NN O O
a NN O O
wide NN O O
spectrum NN O O
of NN O O
mutations NN O O
in NN O O
wfs NN O O
1 NN O O
. NN O O

wolfram NN O O
syndrome NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D020271
recessive NN I-DiseaseClass I-MSH:D020271
neurodegenerative NN I-DiseaseClass I-MSH:D020271
disorder NN I-DiseaseClass I-MSH:D020271
characterized NN O O
by NN O O
juvenile-onset NN B-SpecificDisease B-MSH:D003922
diabetes NN I-SpecificDisease I-MSH:D003922
mellitus NN I-SpecificDisease I-MSH:D003922
and NN O O
progressive NN O O
optic NN B-SpecificDisease B-MSH:D009896
atrophy NN I-SpecificDisease I-MSH:D009896
. NN O O
mtdna NN O O
deletions NN O O
have NN O O
been NN O O
described, NN O O
and NN O O
a NN O O
gene NN O O
(wfs NN O O
1) NN O O
recently NN O O
has NN O O
been NN O O
identified, NN O O
on NN O O
chromosome NN O O
4 NN O O
p NN O O
16, NN O O
encoding NN O O
a NN O O
predicted NN O O
890 NN O O
amino NN O O
acid NN O O
transmembrane NN O O
protein. NN O O
direct NN O O
dna NN O O
sequencing NN O O
was NN O O
done NN O O
to NN O O
screen NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
wfs NN O O
1 NN O O
gene NN O O
in NN O O
30 NN O O
patients NN O O
from NN O O
19 NN O O
british NN O O
kindreds NN O O
with NN O O
Wolfram NN B-SpecificDisease B-OMIM:222300
syndrome NN I-SpecificDisease I-OMIM:222300
. NN O O
dna NN O O
was NN O O
also NN O O
screened NN O O
for NN O O
structural NN O O
rearrangements NN O O
(deletions NN O O
and NN O O
duplications) NN O O
and NN O O
point NN O O
mutations NN O O
in NN O O
mtdna. NN O O
no NN O O
pathogenic NN O O
mtdna NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
our NN O O
cohort. NN O O
we NN O O
identified NN O O
24 NN O O
mutations NN O O
in NN O O
the NN O O
wfs NN O O
1 NN O O
gene NN O O
8 NN O O
nonsense NN O O
mutations, NN O O
8 NN O O
missense NN O O
mutations, NN O O
3 NN O O
in-frame NN O O
deletions, NN O O
1 NN O O
in-frame NN O O
insertion, NN O O
and NN O O
4 NN O O
frameshif NN O O
. NN O O

mutations. NN O O
of NN O O
these, NN O O
23 NN O O
were NN O O
novel NN O O
mutations, NN O O
and NN O O
most NN O O
occurred NN O O
in NN O O
exon NN O O
8. NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
were NN O O
compound NN O O
heterozygotes NN O O
for NN O O
two NN O O
mutations, NN O O
and NN O O
there NN O O
was NN O O
no NN O O
common NN O O
founder NN O O
mutation. NN O O
the NN O O
data NN O O
were NN O O
also NN O O
analyzed NN O O
for NN O O
genotype-phenotype NN O O
relationships. NN O O
although NN O O
some NN O O
interesting NN O O
cases NN O O
were NN O O
noted, NN O O
consideration NN O O
of NN O O
the NN O O
small NN O O
sample NN O O
size NN O O
and NN O O
frequency NN O O
of NN O O
each NN O O
mutation NN O O
indicated NN O O
no NN O O
clear-cut NN O O
correlations NN O O
between NN O O
any NN O O
of NN O O
the NN O O
observed NN O O
mutations NN O O
and NN O O
disease NN O O
severity. NN O O
there NN O O
were NN O O
no NN O O
obvious NN O O
mutation NN O O
hot NN O O
spots NN O O
or NN O O
clusters. NN O O
hence, NN O O
molecular NN O O
screening NN O O
for NN O O
Wolfram NN B-SpecificDisease B-OMIM:222300
syndrome NN I-SpecificDisease I-OMIM:222300
in NN O O
affected NN O O
families NN O O
and NN O O
for NN O O
Wolfram NN B-Modifier B-OMIM:222300
syndrome NN I-Modifier I-OMIM:222300
-carrier NN O O
status NN O O
in NN O O
subjects NN O O
with NN O O
psychiatric NN B-DiseaseClass B-MSH:D001523
disorders NN I-DiseaseClass I-MSH:D001523
or NN O O
diabetes NN B-SpecificDisease B-MSH:D003920
mellitus NN I-SpecificDisease I-MSH:D003920
will NN O O
require NN O O
complete NN O O
analysis NN O O
of NN O O
exon NN O O
8 NN O O
and NN O O
upstream NN O O
exons. NN O O
. NN O O

maternal NN O O
uniparental NN O O
disomy NN O O
for NN O O
chromosome NN O O
14 NN O O
in NN O O
a NN O O
boy NN O O
with NN O O
a NN O O
normal NN O O
karyotype NN O O
. NN O O

we NN O O
report NN O O
on NN O O
a NN O O
boy NN O O
with NN O O
a NN O O
maternal NN B-SpecificDisease B-MSH:D024182
uniparental NN I-SpecificDisease I-MSH:D024182
disomy NN I-SpecificDisease I-MSH:D024182
for NN I-SpecificDisease I-MSH:D024182
chromosome NN I-SpecificDisease I-MSH:D024182
14 NN I-SpecificDisease I-MSH:D024182
( NN O O
UPD NN B-SpecificDisease B-MSH:D024182
(14)). NN O O
at NN O O
7 NN O O
years NN O O
of NN O O
age NN O O
he NN O O
was NN O O
referred NN O O
to NN O O
us NN O O
by NN O O
the NN O O
paediatrician NN O O
because NN O O
of NN O O
symptoms NN O O
of NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
he NN O O
showed NN O O
short NN B-DiseaseClass B-MSH:D006130
stature NN I-DiseaseClass I-MSH:D006130
, NN O O
obesity NN B-SpecificDisease B-MSH:D009765
, NN O O
mild NN O O
developmental NN B-DiseaseClass B-MSH:D002658
delay NN I-DiseaseClass I-MSH:D002658
, NN O O
cryptorchidism NN B-SpecificDisease B-MSH:D003456
, NN O O
and NN O O
some NN O O
mild NN O O
dysmorphic NN B-DiseaseClass B-MSH:D000013
features NN I-DiseaseClass I-MSH:D000013
. NN O O
the NN O O
history NN O O
further NN O O
indicated NN O O
intrauterine NN B-DiseaseClass B-MSH:D005317
growth NN I-DiseaseClass I-MSH:D005317
retardation NN I-DiseaseClass I-MSH:D005317
at NN O O
the NN O O
end NN O O
of NN O O
the NN O O
pregnancy. NN O O
his NN O O
mother NN O O
was NN O O
44 NN O O
years NN O O
of NN O O
age NN O O
at NN O O
the NN O O
time NN O O
of NN O O
his NN O O
birth. NN O O
after NN O O
birth NN O O
he NN O O
showed NN O O
hypotonia NN B-DiseaseClass B-MSH:D009123
with NN O O
poor NN O O
sucking, NN O O
for NN O O
which NN O O
gavage NN O O
feeding NN O O
was NN O O
needed. NN O O
motor NN O O
development NN O O
was NN O O
delayed. NN O O
after NN O O
1 NN O O
year NN O O
he NN O O
became NN O O
obese NN B-Modifier B-MSH:D009765
despite NN O O
a NN O O
normal NN O O
appetite. NN O O
recurrent NN O O
middle NN B-SpecificDisease B-MSH:D010033
ear NN I-SpecificDisease I-MSH:D010033
infections NN I-SpecificDisease I-MSH:D010033
, NN O O
a NN O O
high NN O O
pain NN O O
threshold, NN O O
and NN O O
a NN O O
great NN O O
skill NN O O
with NN O O
jigsa NN O O
. NN O O

puzzles NN O O
were NN O O
reported. NN O O
there NN O O
were NN O O
no NN O O
behavioural NN O O
problems NN O O
or NN O O
sleep NN O O
disturbance. NN O O
chromosomal NN O O
analysis NN O O
was NN O O
normal NN O O
(46, NN O O
xy). NN O O
dna NN O O
analysis NN O O
for NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
showed NN O O
no NN O O
abnormalities. NN O O
two NN O O
years NN O O
later NN O O
he NN O O
was NN O O
re-examined NN O O
because NN O O
we NN O O
thought NN O O
his NN O O
features NN O O
fitted NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
-like NN O O
phenotype NN O O
associated NN O O
with NN O O
maternal NN O O
UPD NN B-SpecificDisease B-MSH:D024182
(14). NN O O
at NN O O
that NN O O
time NN O O
precocious NN O O
puberty NN O O
was NN O O
evident. NN O O
dna NN O O
analysis NN O O
showed NN O O
maternal NN B-DiseaseClass B-MSH:D024182
heterodisomy NN I-DiseaseClass I-MSH:D024182
for NN O O
chromosome NN O O
14. NN O O
in NN O O
all NN O O
the NN O O
previously NN O O
described NN O O
11 NN O O
cases NN O O
with NN O O
maternal NN O O
UPD NN B-SpecificDisease B-MSH:D024182
(14), NN O O
a NN O O
robertsonian NN O O
translocation NN O O
involving NN O O
chromosome NN O O
14 NN O O
was NN O O
detected NN O O
cytogenetically NN O O
before NN O O
dna NN O O
analysis. NN O O
this NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
diagnosis NN O O
of NN O O
maternal NN O O
UPD NN B-SpecificDisease B-MSH:D024182
(14) NN O O
based NN O O
on NN O O
clinical NN O O
features. NN O O
this NN O O
finding NN O O
underlines NN O O
the NN O O
importance NN O O
of NN O O
dna NN O O
analysis NN O O
for NN O O
maternal NN O O
upd NN O O
(14) NN O O
in NN O O
patients NN O O
wit NN O O
. NN O O

a NN O O
similar NN O O
PWS NN B-Modifier B-MSH:D011218
-like NN O O
phenotype NN O O
even NN O O
without NN O O
previous NN O O
identification NN O O
of NN O O
a NN O O
robertsonian NN O O
translocation NN O O
involving NN O O
chromosome NN O O
14. NN O O
. NN O O

detection NN O O
of NN O O
eight NN O O
brca NN O O
1 NN O O
mutations NN O O
in NN O O
10 NN O O
breast/ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families, NN O O
including NN O O
1 NN O O
family NN O O
with NN O O
male NN B-SpecificDisease B-MSH:D018567
breast NN I-SpecificDisease I-MSH:D018567
cancer NN I-SpecificDisease I-MSH:D018567
. NN O O

genetic NN O O
epidemiological NN O O
evidence NN O O
suggests NN O O
that NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
may NN O O
be NN O O
responsible NN O O
for NN O O
approximately NN O O
one NN O O
half NN O O
of NN O O
early NN O O
onset NN O O
familial NN B-SpecificDisease B-MSH:D001943
breast NN I-SpecificDisease I-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
and NN O O
the NN O O
majority NN O O
of NN O O
familial NN B-CompositeMention B-MSH:D061325
breast/ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
. NN O O
the NN O O
recent NN O O
cloning NN O O
of NN O O
brca NN O O
1 NN O O
allows NN O O
for NN O O
the NN O O
direct NN O O
detection NN O O
of NN O O
mutations, NN O O
but NN O O
the NN O O
feasibility NN O O
of NN O O
presymptomatic NN O O
screening NN O O
for NN O O
cancer NN B-Modifier B-MSH:D009369
susceptibility NN O O
is NN O O
unknown. NN O O
we NN O O
analyzed NN O O
genomic NN O O
dna NN O O
from NN O O
one NN O O
affected NN O O
individual NN O O
from NN O O
each NN O O
of NN O O
24 NN O O
families NN O O
with NN O O
at NN O O
least NN O O
three NN O O
cases NN O O
of NN O O
ovarian NN B-CompositeMention B-MSH:D010051
or NN I-CompositeMention I-MSH:D010051
breast NN I-CompositeMention I-MSH:D010051
cancer NN I-CompositeMention I-MSH:D010051
, NN O O
using NN O O
sscp NN O O
assays. NN O O
variant NN O O
sscp NN O O
bands NN O O
were NN O O
subcloned NN O O
and NN O O
sequenced. NN O O
allele-specific NN O O
oligonucleotide NN O O
hybridization NN O O
was NN O O
used NN O O
to NN O O
verify NN O O
sequence NN O O
changes NN O O
and NN O O
to NN O O
screen NN O O
dna NN O O
from NN O O
control NN O O
individuals. NN O O
six NN O O
frameshift NN O O
and NN O O
two NN O O
missense NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
10 NN O O
different NN O O
families. NN O O
a NN O O
frameshift NN O O
mutation NN O O
was NN O O
detected NN O O
in NN O O
a NN O O
male NN O O
proband NN O O
affected NN O O
with NN O O
both NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
prostate NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943

prostate NN O O
cancer. NN O O
a NN O O
40-bp NN O O
deletion NN O O
was NN O O
detected NN O O
in NN O O
a NN O O
patient NN O O
who NN O O
developed NN O O
intra-abdominal NN B-DiseaseClass B-MSH:D000008
carcinomatosis NN I-DiseaseClass I-MSH:D000008
1 NN O O
year NN O O
after NN O O
prophylactic NN O O
oophorectomy. NN O O
mutations NN O O
were NN O O
detected NN O O
throughout NN O O
the NN O O
gene, NN O O
and NN O O
only NN O O
one NN O O
was NN O O
detected NN O O
in NN O O
more NN O O
than NN O O
a NN O O
single NN O O
family. NN O O
these NN O O
results NN O O
provide NN O O
further NN O O
evidence NN O O
that NN O O
inherited NN B-CompositeMention B-MSH:D061325
breast NN I-CompositeMention I-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
can NN O O
occur NN O O
as NN O O
a NN O O
consequence NN O O
of NN O O
a NN O O
wide NN O O
array NN O O
of NN O O
brca NN O O
1 NN O O
mutations. NN O O
these NN O O
results NN O O
suggests NN O O
that NN O O
development NN O O
of NN O O
a NN O O
screening NN O O
test NN O O
for NN O O
brca NN O O
1 NN O O
mutations NN O O
will NN O O
be NN O O
technically NN O O
challenging. NN O O
the NN O O
finding NN O O
of NN O O
a NN O O
mutation NN O O
in NN O O
a NN O O
family NN O O
with NN O O
male NN B-SpecificDisease B-MSH:D018567
breast NN I-SpecificDisease I-MSH:D018567
cancer NN I-SpecificDisease I-MSH:D018567
, NN O O
not NN O O
previously NN O O
thought NN O O
to NN O O
be NN O O
related NN O O
to NN O O
brca NN O O
1, NN O O
also NN O O
illustrates NN O O
the NN O O
potential NN O O
difficulties NN O O
of NN O O
genetic NN O O
counseling NN O O
for NN O O
individuals NN O O
known NN O O
to NN O O
carry NN O O
mutations. NN O O
. NN O O

color NN O O
vision NN O O
defects NN O O
in NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
. NN O O

the NN O O
relationship NN O O
between NN O O
abnormal NN B-DiseaseClass B-MSH:D003117
color NN I-DiseaseClass I-MSH:D003117
vision NN I-DiseaseClass I-MSH:D003117
and NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
AMN NN B-SpecificDisease B-MSH:D000326
) NN O O
was NN O O
investigated NN O O
in NN O O
27 NN O O
AMN NN B-Modifier B-MSH:D000326
patients NN O O
and NN O O
31 NN O O
age-matched NN O O
controls NN O O
by NN O O
using NN O O
the NN O O
farnsworth-munsell NN O O
100 NN O O
hue NN O O
test. NN O O
twelve NN O O
(44%) NN O O
of NN O O
27 NN O O
patients NN O O
showed NN O O
test NN O O
scores NN O O
significantly NN O O
above NN O O
normal. NN O O
the NN O O
axes NN O O
of NN O O
bipolarity NN O O
determined NN O O
by NN O O
the NN O O
testing NN O O
differed NN O O
widely NN O O
between NN O O
the NN O O
patients NN O O
with NN O O
abnormal NN O O
scores, NN O O
compatible NN O O
with NN O O
the NN O O
notion NN O O
that NN O O
different NN O O
alterations NN O O
in NN O O
visual NN O O
pigment NN O O
genes NN O O
occur NN O O
in NN O O
different NN O O
AMN NN B-Modifier B-MSH:D000326
kindreds. NN O O
these NN O O
observations NN O O
confirm NN O O
our NN O O
earlier NN O O
impression NN O O
that NN O O
the NN O O
frequency NN O O
of NN O O
abnormal NN B-DiseaseClass B-MSH:D003117
color NN I-DiseaseClass I-MSH:D003117
vision NN I-DiseaseClass I-MSH:D003117
is NN O O
increased NN O O
in NN O O
these NN O O
kindreds, NN O O
and NN O O
it NN O O
supports NN O O
our NN O O
contentions NN O O
that NN O O
(1) NN O O
AMN NN B-SpecificDisease B-MSH:D000326
(and NN O O
its NN O O
companion, NN O O
adrenoleukodystrophy NN B-DiseaseClass B-MSH:D000326
) NN O O
are NN O O
very NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
visual NN O O
pigment NN O O
loci NN O O
at NN O O
xq NN O O
28 NN O O
and NN O O
(2) NN O O
this NN O O
proximity NN O O
might NN O O
provide NN O O
the NN O O
opportunit NN O O
. NN O O

to NN O O
observe NN O O
contiguous NN B-DiseaseClass B-MSH:D025063
gene NN I-DiseaseClass I-MSH:D025063
defects NN I-DiseaseClass I-MSH:D025063
. NN O O
. NN O O

patterns NN O O
of NN O O
exon NN O O
deletions NN O O
in NN O O
Duchenne NN B-CompositeMention B-MSH:D020388
and NN I-CompositeMention I-MSH:D020388
Becker NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
. NN O O

a NN O O
panel NN O O
of NN O O
patients NN O O
with NN O O
Duchenne NN B-CompositeMention B-MSH:D020388
and NN I-CompositeMention I-MSH:D020388
Becker NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
and NN O O
BMD NN B-SpecificDisease B-MSH:C537666
) NN O O
has NN O O
been NN O O
screened NN O O
with NN O O
the NN O O
cdna NN O O
probes NN O O
cf NN O O
56 NN O O
a NN O O
and NN O O
cf NN O O
23 NN O O
a, NN O O
which NN O O
detect NN O O
exons NN O O
in NN O O
the NN O O
central NN O O
part NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene. NN O O
one NN O O
or NN O O
more NN O O
exons NN O O
were NN O O
deleted NN O O
in NN O O
60% NN O O
of NN O O
patients. NN O O
the NN O O
deletions NN O O
were NN O O
mapped NN O O
and NN O O
prove NN O O
to NN O O
be NN O O
heterogeneous NN O O
in NN O O
size NN O O
and NN O O
extent, NN O O
particularly NN O O
in NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
deletions NN O O
specific NN O O
to NN O O
DMD NN B-SpecificDisease B-MSH:D020388
and NN O O
to NN O O
BMD NN B-SpecificDisease B-MSH:C537666
are NN O O
described. NN O O
half NN O O
of NN O O
all NN O O
BMD NN B-Modifier B-MSH:C537666
patients NN O O
have NN O O
a NN O O
deletion NN O O
of NN O O
one NN O O
particular NN O O
small NN O O
group NN O O
of NN O O
exons; NN O O
smaller NN O O
deletions NN O O
within NN O O
this NN O O
same NN O O
group NN O O
produce NN O O
the NN O O
more NN O O
severe NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
. NN O O

the NN O O
lec NN O O
rat NN O O
has NN O O
a NN O O
deletion NN O O
in NN O O
the NN O O
copper NN O O
transporting NN O O
atpase NN O O
gene NN O O
homologous NN O O
to NN O O
the NN O O
Wilson NN B-Modifier B-MSH:D006527
disease NN I-Modifier I-MSH:D006527
gene NN O O
. NN O O

the NN O O
long-evans NN O O
cinnamon NN O O
(lec) NN O O
rat NN O O
shows NN O O
similarity NN O O
to NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
in NN O O
many NN O O
clinical NN O O
and NN O O
biochemical NN O O
features. NN O O
we NN O O
have NN O O
cloned NN O O
cdnas NN O O
for NN O O
the NN O O
rat NN O O
gene NN O O
(atp NN O O
7 NN O O
b) NN O O
homologous NN O O
to NN O O
the NN O O
human NN O O
Wilson NN B-Modifier B-MSH:D006527
disease NN I-Modifier I-MSH:D006527
gene NN O O
(atp NN O O
7 NN O O
b) NN O O
and NN O O
have NN O O
used NN O O
them NN O O
to NN O O
identify NN O O
a NN O O
partial NN O O
deletion NN O O
in NN O O
the NN O O
atp NN O O
7 NN O O
b NN O O
gene NN O O
in NN O O
the NN O O
lec NN O O
rat. NN O O
the NN O O
deletion NN O O
removes NN O O
at NN O O
least NN O O
900 NN O O
bp NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
at NN O O
the NN O O
3 NN O O
end, NN O O
includes NN O O
the NN O O
crucial NN O O
atp NN O O
binding NN O O
domain NN O O
and NN O O
extends NN O O
downstream NN O O
of NN O O
the NN O O
gene. NN O O
our NN O O
results NN O O
provide NN O O
convincing NN O O
evidence NN O O
for NN O O
defining NN O O
the NN O O
lec NN O O
rat NN O O
as NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
. NN O O
this NN O O
model NN O O
will NN O O
be NN O O
important NN O O
for NN O O
studying NN O O
liver NN O O
pathophysiology, NN O O
for NN O O
developing NN O O
therapy NN O O
for NN O O
Wilson NN B-SpecificDisease B-MSH:D006527
disease NN I-SpecificDisease I-MSH:D006527
and NN O O
for NN O O
studying NN O O
the NN O O
pathway NN O O
of NN O O
copper NN O O
transport NN O O
and NN O O
its NN O O
possibl NN O O
. NN O O

interaction NN O O
with NN O O
other NN O O
heavy NN O O
metals. NN O O
. NN O O

detection NN O O
of NN O O
a NN O O
new NN O O
submicroscopic NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
deletion NN O O
interval NN O O
with NN O O
a NN O O
novel NN O O
dna NN O O
probe NN O O
isolated NN O O
by NN O O
differential NN O O
alu NN O O
pcr NN O O
fingerprint NN O O
cloning NN O O
. NN O O

differential NN O O
alu NN O O
pcr NN O O
fingerprint NN O O
cloning NN O O
was NN O O
used NN O O
to NN O O
isolate NN O O
a NN O O
dna NN O O
probe NN O O
from NN O O
the NN O O
xp NN O O
11. NN O O
4-- NN O O
> NN O O
p NN O O
11. NN O O
21 NN O O
region NN O O
of NN O O
the NN O O
human NN O O
x NN O O
chromosome. NN O O
this NN O O
novel NN O O
sequence, NN O O
cpxr NN O O
318 NN O O
(dxs NN O O
742), NN O O
detects NN O O
a NN O O
new NN O O
submicroscopic NN O O
deletion NN O O
interval NN O O
at NN O O
the NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
locus NN O O
(ndp). NN O O
combining NN O O
our NN O O
data NN O O
with NN O O
the NN O O
consensus NN O O
genetic NN O O
map NN O O
of NN O O
the NN O O
proximal NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome, NN O O
we NN O O
propose NN O O
the NN O O
physical NN O O
order NN O O
xcen-dxs NN O O
14-dxs NN O O
255- NN O O
(dxs NN O O
426, NN O O
timp) NN O O
- NN O O
(dxs NN O O
742- NN O O
([maob-maoa-dxs NN O O
7], NN O O
ndp) NN O O
-dxs NN O O
77-dxs NN O O
228) NN O O
-dxs NN O O
209-dxs NN O O
148-dxs NN O O
196- NN O O
+ NN O O
+ NN O O
+ NN O O
xpter. NN O O
the NN O O
cpxr NN O O
318 NN O O
probe NN O O
and NN O O
. NN O O

subclone NN O O
from NN O O
a NN O O
cosmid NN O O
corresponding NN O O
to NN O O
the NN O O
dxs NN O O
7 NN O O
locus NN O O
were NN O O
converted NN O O
into NN O O
sequence-tagged NN O O
sites. NN O O
finally, NN O O
dxs NN O O
742, NN O O
dsx NN O O
7, NN O O
dxs NN O O
77, NN O O
and NN O O
maoa NN O O
were NN O O
integrated NN O O
into NN O O
a NN O O
physical NN O O
map NN O O
spanning NN O O
the NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
locu NN O O
. NN O O

genetic NN O O
analysis NN O O
of NN O O
a NN O O
japanese NN O O
family NN O O
with NN O O
normotriglyceridemic NN B-SpecificDisease B-MSH:D000012
abetalipoproteinemia NN I-SpecificDisease I-MSH:D000012
indicates NN O O
a NN O O
lack NN O O
of NN O O
linkage NN O O
to NN O O
the NN O O
apolipoprotein NN O O
b NN O O
gene NN O O
. NN O O

normotriglyceridemic NN O O
abetalipoproteinemia NN O O
is NN O O
a NN O O
rare NN O O
familial NN B-DiseaseClass B-MSH:D009358
disorder NN I-DiseaseClass I-MSH:D009358
characterized NN O O
by NN O O
an NN O O
isolated NN O O
deficiency NN B-SpecificDisease B-OMIM:200100
of NN I-SpecificDisease I-OMIM:200100
apoB-100 NN I-SpecificDisease I-OMIM:200100
. NN O O
we NN O O
have NN O O
previously NN O O
reported NN O O
a NN O O
patient NN O O
with NN O O
this NN O O
disease, NN O O
who NN O O
had NN O O
normal NN O O
apob-48 NN O O
but NN O O
no NN O O
apob-100. NN O O
to NN O O
elucidate NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
abnormalities NN I-DiseaseClass I-MSH:D030342
in NN O O
this NN O O
family, NN O O
we NN O O
studied NN O O
the NN O O
linkage NN O O
of NN O O
apob NN O O
gene NN O O
using NN O O
three NN O O
genetic NN O O
markers. NN O O
the NN O O
proband NN O O
and NN O O
her NN O O
affected NN O O
brother NN O O
showed NN O O
completely NN O O
different NN O O
apob NN O O
gene NN O O
alleles, NN O O
suggesting NN O O
that NN O O
the NN O O
apob NN O O
gene NN O O
itself NN O O
is NN O O
not NN O O
related NN O O
to NN O O
this NN O O
disorder NN O O
in NN O O
this NN O O
family. NN O O
by NN O O
contrast, NN O O
an NN O O
american NN O O
case NN O O
had NN O O
a NN O O
point NN O O
substitution NN O O
in NN O O
the NN O O
apob NN O O
gene NN O O
generating NN O O
an NN O O
in-frame NN O O
stop NN O O
codon. NN O O
these NN O O
results NN O O
indicate NN O O
that NN O O
this NN O O
disorder NN O O
can NN O O
be NN O O
caused NN O O
by NN O O
defect NN O O
(s) NN O O
of NN O O
either NN O O
an NN O O
apob NN O O
gene NN O O
or NN O O
other NN O O
genes. NN O O
. NN O O

founder NN O O
mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
in NN O O
polish NN O O
families NN O O
with NN O O
breast-ovarian NN B-CompositeMention B-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
. NN O O

we NN O O
have NN O O
undertaken NN O O
a NN O O
hospital-based NN O O
study, NN O O
to NN O O
identify NN O O
possible NN O O
brca NN O O
1 NN O O
and NN O O
brca NN O O
2 NN O O
founder NN O O
mutations NN O O
in NN O O
the NN O O
polish NN O O
population. NN O O
the NN O O
study NN O O
group NN O O
consisted NN O O
of NN O O
66 NN O O
polish NN O O
families NN O O
with NN O O
cancer NN B-DiseaseClass B-MSH:D009369
who NN O O
have NN O O
at NN O O
least NN O O
three NN O O
related NN O O
females NN O O
affected NN O O
with NN O O
breast NN B-CompositeMention B-MSH:D001943
or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
and NN O O
who NN O O
had NN O O
cancer NN B-DiseaseClass B-MSH:D009369
diagnosed, NN O O
in NN O O
at NN O O
least NN O O
one NN O O
of NN O O
the NN O O
three NN O O
affected NN O O
females, NN O O
at NN O O
age NN O O
< NN O O
50 NN O O
years. NN O O
a NN O O
total NN O O
of NN O O
26 NN O O
families NN O O
had NN O O
both NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancers NN I-CompositeMention I-MSH:D001943
, NN O O
4 NN O O
families NN O O
had NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
only, NN O O
and NN O O
36 NN O O
families NN O O
had NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancers NN I-SpecificDisease I-MSH:D001943
only. NN O O
genomic NN O O
dna NN O O
was NN O O
prepared NN O O
from NN O O
the NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
of NN O O
at NN O O
least NN O O
one NN O O
affected NN O O
woman NN O O
from NN O O
each NN O O
family. NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
brca NN O O
1 NN O O
and NN O O
brca NN O O
2 NN O O
was NN O O
screened NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
germline NN O O
mutations, NN O O
by NN O O
use NN O O
of NN O O
sscp NN O O
followed NN O O
b NN O O
. NN O O

direct NN O O
sequencing NN O O
of NN O O
observed NN O O
variants. NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
35 NN O O
(53%) NN O O
of NN O O
the NN O O
66 NN O O
families NN O O
studied. NN O O
all NN O O
but NN O O
one NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
detected NN O O
within NN O O
the NN O O
brca NN O O
1 NN O O
gene. NN O O
BRCA1 NN B-DiseaseClass B-OMIM:604370
abnormalities NN I-DiseaseClass I-OMIM:604370
were NN O O
identified NN O O
in NN O O
all NN O O
four NN O O
families NN O O
with NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
only, NN O O
in NN O O
67% NN O O
of NN O O
27 NN O O
families NN O O
with NN O O
both NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
, NN O O
and NN O O
in NN O O
34% NN O O
of NN O O
35 NN O O
families NN O O
with NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
only. NN O O
the NN O O
single NN O O
family NN O O
with NN O O
a NN O O
brca NN O O
2 NN O O
mutation NN O O
had NN O O
the NN O O
breast-ovarian NN B-SpecificDisease B-MSH:D061325
cancer NN I-SpecificDisease I-MSH:D061325
syndrome NN I-SpecificDisease I-MSH:D061325
. NN O O
seven NN O O
distinct NN O O
mutations NN O O
were NN O O
identified; NN O O
five NN O O
of NN O O
these NN O O
occurred NN O O
in NN O O
two NN O O
or NN O O
more NN O O
families. NN O O
in NN O O
total, NN O O
recurrent NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
33 NN O O
(94%) NN O O
of NN O O
the NN O O
35 NN O O
families NN O O
with NN O O
detected NN O O
mutations. NN O O
three NN O O
BRCA1 NN B-DiseaseClass B-OMIM:604370
abnormalities NN I-DiseaseClass I-OMIM:604370
- NN O O
5382 NN O O
insc, NN O O
c NN O O
61 NN O O
g, NN O O
an NN O O
. NN O O

4153 NN O O
dela NN O O
- NN O O
accounted NN O O
for NN O O
51%, NN O O
20%, NN O O
and NN O O
11% NN O O
of NN O O
the NN O O
identified NN O O
mutations, NN O O
respectively. NN O O
. NN O O

new NN O O
founder NN O O
haplotypes NN O O
at NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
locus NN O O
in NN O O
southern NN O O
africa NN O O
. NN O O

the NN O O
association NN O O
between NN O O
normal NN O O
alleles NN O O
at NN O O
the NN O O
ctg NN O O
repeat NN O O
and NN O O
two NN O O
nearby NN O O
polymorphisms NN O O
in NN O O
the NN O O
myotonin NN O O
protein NN O O
kinase NN O O
gene, NN O O
the NN O O
alu NN O O
insertion/deletion NN O O
polymorphism NN O O
and NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
kinase NN O O
(dmk) NN O O
(g/t) NN O O
intron NN O O
9/hinfi NN O O
polymorphism, NN O O
has NN O O
been NN O O
analyzed NN O O
in NN O O
south NN O O
african NN O O
negroids, NN O O
a NN O O
population NN O O
in NN O O
which NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
has NN O O
not NN O O
been NN O O
described. NN O O
south NN O O
african NN O O
negroids NN O O
have NN O O
a NN O O
ctg NN O O
allelic NN O O
distribution NN O O
that NN O O
is NN O O
significantly NN O O
different NN O O
from NN O O
that NN O O
in NN O O
caucasoids NN O O
and NN O O
japanese NN O O
the NN O O
ctg NN O O
repeat NN O O
lengths NN O O
of NN O O
> NN O O
or NN O O
= NN O O
19 NN O O
are NN O O
very NN O O
rare. NN O O
the NN O O
striking NN O O
linkage NN O O
disequilibrium NN O O
between NN O O
specific NN O O
alleles NN O O
at NN O O
the NN O O
alu NN O O
polymorphism NN O O
(alu NN O O
(ins) NN O O
and NN O O
alu NN O O
(del)), NN O O
the NN O O
hinfi NN O O
polymorphism NN O O
(hinfi-1 NN O O
and NN O O
hinfi-2), NN O O
and NN O O
the NN O O
ctg NN O O
repeat NN O O
polymorphism NN O O
see NN O O
. NN O O

in NN O O
caucasoid NN O O
(europeans NN O O
and NN O O
canadians) NN O O
populations NN O O
was NN O O
also NN O O
found NN O O
in NN O O
the NN O O
south NN O O
african NN O O
negroid NN O O
population. NN O O
numerous NN O O
haplotypes, NN O O
not NN O O
previously NN O O
described NN O O
in NN O O
europeans, NN O O
were, NN O O
however, NN O O
found. NN O O
it NN O O
thus NN O O
seems NN O O
likely NN O O
that NN O O
only NN O O
a NN O O
small NN O O
number NN O O
of NN O O
these NN O O
" NN O O
african NN O O
" NN O O
chromosomes NN O O
were NN O O
present NN O O
in NN O O
the NN O O
progenitors NN O O
of NN O O
all NN O O
non-african NN O O
peoples. NN O O
these NN O O
data NN O O
provide NN O O
support NN O O
for NN O O
the NN O O
" NN O O
out NN O O
of NN O O
africa NN O O
" NN O O
model NN O O
for NN O O
the NN O O
origin NN O O
of NN O O
modern NN O O
humans NN O O
and NN O O
suggest NN O O
that NN O O
the NN O O
rare NN O O
ancestral NN O O
DM NN B-Modifier B-MSH:D009223
mutation NN O O
event NN O O
may NN O O
have NN O O
occurred NN O O
after NN O O
the NN O O
migration NN O O
from NN O O
africa, NN O O
hence NN O O
the NN O O
absence NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
in NN O O
sub-saharan NN O O
negroid NN O O
peoples. NN O O
. NN O O

marked NN O O
phenotypic NN O O
heterogeneity NN O O
associated NN O O
with NN O O
expansion NN O O
of NN O O
a NN O O
cag NN O O
repeat NN O O
sequence NN O O
at NN O O
the NN O O
spinocerebellar NN B-Modifier B-MSH:D017827
ataxia NN I-Modifier I-MSH:D017827
3/Machado-Joseph NN I-Modifier I-MSH:D017827
disease NN I-Modifier I-MSH:D017827
locus NN O O
. NN O O

the NN O O
spinocerebellar NN B-Modifier B-MSH:D017827
ataxia NN I-Modifier I-MSH:D017827
3 NN I-Modifier I-MSH:D017827
locus NN O O
( NN O O
SCA3 NN B-SpecificDisease B-MSH:D017827
) NN O O
for NN O O
type NN B-SpecificDisease B-OMIM:109150
I NN I-SpecificDisease I-OMIM:109150
autosomal NN I-SpecificDisease I-OMIM:109150
dominant NN I-SpecificDisease I-OMIM:109150
cerebellar NN I-SpecificDisease I-OMIM:109150
ataxia NN I-SpecificDisease I-OMIM:109150
( NN O O
ADCA NN B-SpecificDisease B-OMIM:109150
type NN I-SpecificDisease I-OMIM:109150
I NN I-SpecificDisease I-OMIM:109150
), NN O O
a NN O O
clinically NN O O
and NN O O
genetically NN O O
heterogeneous NN O O
group NN O O
of NN O O
neurodegenerative NN B-DiseaseClass B-MSH:D019636
disorders NN I-DiseaseClass I-MSH:D019636
, NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
14 NN O O
q NN O O
32. NN O O
1 NN O O
1. NN O O
ADCA NN B-Modifier B-OMIM:109150
type NN I-Modifier I-OMIM:109150
I NN I-Modifier I-OMIM:109150
patients NN O O
from NN O O
families NN O O
segregating NN O O
SCA3 NN B-SpecificDisease B-MSH:D017827
share NN O O
clinical NN O O
features NN O O
in NN O O
common NN O O
with NN O O
those NN O O
with NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
( NN O O
MJD NN B-SpecificDisease B-MSH:D017827
), NN O O
the NN O O
gene NN O O
of NN O O
which NN O O
maps NN O O
to NN O O
the NN O O
same NN O O
region. NN O O
we NN O O
show NN O O
here NN O O
that NN O O
the NN O O
disease NN O O
gene NN O O
segregating NN O O
in NN O O
each NN O O
of NN O O
three NN O O
french NN O O
ADCA NN B-Modifier B-OMIM:109150
type NN I-Modifier I-OMIM:109150
I NN I-Modifier I-OMIM:109150
kindreds NN O O
and NN O O
in NN O O
a NN O O
french NN O O
family NN O O
with NN O O
neuropathological NN O O
findings NN O O
suggesting NN O O
the NN O O
ataxochoreic NN O O
form NN O O
of NN O O
dentatorubropallidoluysian NN B-SpecificDisease B-OMIM:125370
atrophy NN I-SpecificDisease I-OMIM:125370
carries NN O O
an NN O O
expanded NN O O
cag NN O O
repeat NN O O
sequence NN O O
located NN O O
at NN O O
the NN O O
same NN O O
locus NN O O
as NN O O
that NN O O
for NN O O
MJD NN B-SpecificDisease B-MSH:D017827
. NN O O
analysis NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
these NN O O
families NN O O
shows NN O O
a NN O O
strong NN O O
negative NN O O
correlation NN O O
betwee NN O O
. NN O O

size NN O O
of NN O O
the NN O O
expanded NN O O
cag NN O O
repeat NN O O
and NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
clinical NN O O
disease. NN O O
instability NN O O
of NN O O
the NN O O
expanded NN O O
triplet NN O O
repeat NN O O
was NN O O
not NN O O
found NN O O
to NN O O
be NN O O
affected NN O O
by NN O O
sex NN O O
of NN O O
the NN O O
parent NN O O
transmitting NN O O
the NN O O
mutation. NN O O
evidence NN O O
was NN O O
found NN O O
for NN O O
somatic NN O O
and NN O O
gonadal NN O O
mosaicism NN O O
for NN O O
alleles NN O O
carrying NN O O
expanded NN O O
trinucleotide NN O O
repeats NN O O
. NN O O

the NN O O
red-green NN O O
visual NN O O
pigment NN O O
gene NN O O
region NN O O
in NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
. NN O O

although NN O O
recent NN O O
data NN O O
established NN O O
that NN O O
a NN O O
specific NN O O
very-long-chain NN O O
fatty NN O O
acyl-coa NN O O
synthetase NN O O
is NN O O
defective NN O O
in NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
), NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
is NN O O
still NN O O
unidentified. NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
locus NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
xq NN O O
28, NN O O
like NN O O
the NN O O
red NN O O
and NN O O
green NN O O
color NN O O
pigment NN O O
genes. NN O O
Abnormal NN B-DiseaseClass B-MSH:D003117
color NN I-DiseaseClass I-MSH:D003117
vision NN I-DiseaseClass I-MSH:D003117
has NN O O
been NN O O
observed NN O O
in NN O O
12 NN O O
of NN O O
27 NN O O
patients NN O O
with NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
AMN NN B-SpecificDisease B-MSH:D000326
), NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
furthermore, NN O O
rearrangements NN O O
of NN O O
the NN O O
color NN O O
vision NN O O
gene NN O O
cluster NN O O
were NN O O
found NN O O
in NN O O
four NN O O
of NN O O
eight NN O O
ALD NN B-Modifier B-MSH:D000326
kindreds. NN O O
this NN O O
led NN O O
us NN O O
to NN O O
propose NN O O
that NN O O
a NN O O
single NN O O
dna NN O O
rearrangement NN O O
could NN O O
underlie NN O O
both NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
abnormal NN B-SpecificDisease B-MSH:D003117
color NN I-SpecificDisease I-MSH:D003117
vision NN I-SpecificDisease I-MSH:D003117
in NN O O
these NN O O
patients. NN O O
study NN O O
of NN O O
34 NN O O
french NN O O
ALD NN B-Modifier B-MSH:D000326
patients NN O O
failed NN O O
to NN O O
reveal NN O O
a NN O O
higher NN O O
than NN O O
expected NN O O
frequency NN O O
of NN O O
green/red NN O O
visual NN O O
pigment NN O O
rearrangements NN O O
3 NN O O
t NN O O
. NN O O

the NN O O
red/green NN O O
color NN O O
vision NN O O
gene NN O O
complex. NN O O
the NN O O
previous NN O O
report NN O O
of NN O O
such NN O O
rearrangements NN O O
was NN O O
based NN O O
on NN O O
small NN O O
numbers NN O O
and NN O O
lack NN O O
of NN O O
knowledge NN O O
that NN O O
the NN O O
frequency NN O O
of NN O O
" NN O O
abnormal NN O O
" NN O O
color NN O O
vision NN O O
arrays NN O O
on NN O O
molecular NN O O
analysis NN O O
was NN O O
twice NN O O
as NN O O
high NN O O
as NN O O
expected NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
frequency NN O O
of NN O O
phenotypic NN B-SpecificDisease B-MSH:D003117
color NN I-SpecificDisease I-MSH:D003117
vision NN I-SpecificDisease I-MSH:D003117
defects NN I-SpecificDisease I-MSH:D003117
. NN O O
the NN O O
red/green NN O O
color NN O O
pigment NN O O
(r/gcp) NN O O
region NN O O
was NN O O
studied NN O O
by NN O O
pulsed-field NN O O
gel NN O O
electrophoresis NN O O
in NN O O
14 NN O O
of NN O O
these NN O O
patients, NN O O
and NN O O
we NN O O
did NN O O
not NN O O
find NN O O
any NN O O
fragment NN O O
size NN O O
difference NN O O
between NN O O
the NN O O
patients NN O O
and NN O O
normal NN O O
individuals NN O O
who NN O O
have NN O O
the NN O O
same NN O O
number NN O O
of NN O O
pigment NN O O
genes. NN O O
the NN O O
r/gcp NN O O
region NN O O
was NN O O
also NN O O
analyzed NN O O
in NN O O
29 NN O O
french NN O O
and NN O O
seven NN O O
north NN O O
american NN O O
ALD NN B-Modifier B-MSH:D000326
patients NN O O
by NN O O
using NN O O
six NN O O
genomic NN O O
dna NN O O
probes, NN O O
isolated NN O O
from NN O O
a NN O O
cosmid NN O O
walk, NN O O
that NN O O
flank NN O O
the NN O O
color NN O O
visio NN O O
. NN O O

genes. NN O O
no NN O O
deletions NN O O
were NN O O
found NN O O
with NN O O
probes NN O O
that NN O O
lie NN O O
3 NN O O
of NN O O
the NN O O
green NN O O
pigment NN O O
genes. NN O O
one NN O O
of NN O O
the NN O O
eight NN O O
previously NN O O
reported NN O O
ALD NN B-Modifier B-MSH:D000326
individuals NN O O
has NN O O
a NN O O
long NN O O
deletion NN O O
5 NN O O
of NN O O
the NN O O
red NN O O
pigment NN O O
gene, NN O O
a NN O O
deletion NN O O
causing NN O O
blue NN O O
cone NN O O
monochromacy. NN O O
this NN O O
finding NN O O
and NN O O
the NN O O
previous NN O O
findings NN O O
of NN O O
a NN O O
45% NN O O
frequency NN O O
of NN O O
phenotypic NN O O
color NN O O
vision NN O O
defects NN O O
in NN O O
patients NN O O
with NN O O
AMN NN B-SpecificDisease B-MSH:D000326
may NN O O
suggest NN O O
that NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
/ NN O O
AMN NN B-Modifier B-MSH:D000326
gene NN O O
lies NN O O
5 NN O O
to NN O O
the NN O O
red NN O O
pigment NN O O
gene NN O O
and NN O O
that NN O O
the NN O O
frequent NN O O
phenotypic NN O O
color NN B-DiseaseClass B-MSH:D003117
vision NN I-DiseaseClass I-MSH:D003117
anomalies NN I-DiseaseClass I-MSH:D003117
owe NN O O
their NN O O
origin NN O O
to NN O O
deleted NN O O
dna NN O O
that NN O O
includes NN O O
regulatory NN O O
genes NN O O
for NN O O
color NN O O
vision. NN O O
it NN O O
is NN O O
possible, NN O O
however, NN O O
that NN O O
phenotypic NN O O
color NN B-DiseaseClass B-MSH:D003117
vision NN I-DiseaseClass I-MSH:D003117
anomalies NN I-DiseaseClass I-MSH:D003117
in NN O O
AMN NN B-SpecificDisease B-MSH:D000326
may NN O O
be NN O O
phenocopies NN O O
secondary NN O O
to NN O O
retinal NN O O
or NN O O
neural NN O O
involvement NN O O
by NN O O
the NN O O
disease. NN O O
the NN O O
single NN O O
case NN O O
of NN O O
blue NN O O
cone NN O O
monochromacy NN O O
may NN O O
therefore NN O O
be NN O O
a NN O O
fortuitous NN O O
coincidence NN O O
o NN O O
. NN O O

two NN O O
diseases. NN O O
. NN O O

haim-munk NN O O
syndrome NN O O
and NN O O
Papillon-Lefevre NN B-SpecificDisease B-MSH:D010214
syndrome NN I-SpecificDisease I-MSH:D010214
are NN O O
allelic NN O O
mutations NN O O
in NN O O
cathepsin NN O O
c NN O O
. NN O O

of NN O O
the NN O O
many NN O O
palmoplantar NN B-DiseaseClass B-MSH:D007645
keratoderma NN I-DiseaseClass I-MSH:D007645
(PPK) NN I-DiseaseClass I-MSH:D007645
conditions NN I-DiseaseClass I-MSH:D007645
, NN O O
only NN O O
Papillon-Lefevre NN B-SpecificDisease B-MSH:D010214
syndrome NN I-SpecificDisease I-MSH:D010214
( NN O O
PLS NN B-SpecificDisease B-MSH:D010214
) NN O O
and NN O O
Haim-Munk NN B-SpecificDisease B-MSH:C537627
syndrome NN I-SpecificDisease I-MSH:C537627
( NN O O
HMS NN B-SpecificDisease B-MSH:C537627
) NN O O
are NN O O
associated NN O O
with NN O O
premature NN O O
periodontal NN O O
destruction. NN O O
although NN O O
both NN O O
PLS NN B-SpecificDisease B-MSH:D010214
and NN O O
HMS NN B-SpecificDisease B-MSH:C537627
share NN O O
the NN O O
cardinal NN O O
features NN O O
of NN O O
PPK NN B-DiseaseClass B-MSH:D007645
and NN O O
severe NN O O
periodontitis NN B-SpecificDisease B-MSH:D010518
, NN O O
a NN O O
number NN O O
of NN O O
additional NN O O
findings NN O O
are NN O O
reported NN O O
in NN O O
HMS NN B-SpecificDisease B-MSH:C537627
including NN O O
arachnodactyly NN B-SpecificDisease B-MSH:D054119
, NN O O
acro-osteolysis NN B-SpecificDisease B-MSH:D030981
, NN O O
atrophic NN B-SpecificDisease B-MSH:D009260
changes NN I-SpecificDisease I-MSH:D009260
of NN I-SpecificDisease I-MSH:D009260
the NN I-SpecificDisease I-MSH:D009260
nails NN I-SpecificDisease I-MSH:D009260
, NN O O
and NN O O
a NN O O
radiographic NN B-SpecificDisease B-MSH:D006226
deformity NN I-SpecificDisease I-MSH:D006226
of NN I-SpecificDisease I-MSH:D006226
the NN I-SpecificDisease I-MSH:D006226
fingers NN I-SpecificDisease I-MSH:D006226
. NN O O
while NN O O
PLS NN B-Modifier B-MSH:D010214
cases NN O O
have NN O O
been NN O O
identified NN O O
throughout NN O O
the NN O O
world, NN O O
HMS NN B-SpecificDisease B-MSH:C537627
has NN O O
only NN O O
been NN O O
described NN O O
among NN O O
descendants NN O O
of NN O O
a NN O O
religious NN O O
isolate NN O O
originally NN O O
from NN O O
cochin, NN O O
india. NN O O
parental NN O O
consanguinity NN O O
is NN O O
a NN O O
characteristic NN O O
of NN O O
many NN O O
cases NN O O
of NN O O
both NN O O
conditions. NN O O
although NN O O
autosomal NN O O
recessive NN O O
transmission NN O O
of NN O O
PLS NN B-SpecificDisease B-MSH:D010214
is NN O O
evident, NN O O
a NN O O
more NN O O
" NN O O
complex NN O O
" NN O O
autosomal NN O O
recessive NN O O
pattern NN O O
of NN O O
inheritance NN O O
with NN O O
phenotypic NN O O
influences NN O O
fro NN O O
. NN O O

a NN O O
closely NN O O
linked NN O O
modifying NN O O
locus NN O O
has NN O O
been NN O O
hypothesised NN O O
for NN O O
HMS NN B-SpecificDisease B-MSH:C537627
. NN O O
recently, NN O O
mutations NN O O
of NN O O
the NN O O
cathepsin NN O O
c NN O O
gene NN O O
have NN O O
been NN O O
identified NN O O
as NN O O
the NN O O
underlying NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
in NN O O
PLS NN B-SpecificDisease B-MSH:D010214
. NN O O
to NN O O
determine NN O O
if NN O O
a NN O O
cathepsin NN O O
c NN O O
mutation NN O O
is NN O O
also NN O O
responsible NN O O
for NN O O
HMS NN B-SpecificDisease B-MSH:C537627
, NN O O
we NN O O
sequenced NN O O
the NN O O
gene NN O O
in NN O O
affected NN O O
and NN O O
unaffected NN O O
subjects NN O O
from NN O O
the NN O O
cochin NN O O
isolate NN O O
in NN O O
which NN O O
both NN O O
the NN O O
PLS NN B-Modifier B-MSH:D010214
and NN O O
HMS NN B-Modifier B-MSH:C537627
phenotypes NN O O
appear. NN O O
here NN O O
we NN O O
report NN O O
identification NN O O
of NN O O
a NN O O
mutation NN O O
of NN O O
cathepsin NN O O
c NN O O
(exon NN O O
6, NN O O
2127 NN O O
a-- NN O O
> NN O O
g) NN O O
that NN O O
changes NN O O
a NN O O
highly NN O O
conserved NN O O
amino NN O O
acid NN O O
in NN O O
the NN O O
cathepsin NN O O
c NN O O
peptide. NN O O
this NN O O
mutation NN O O
segregates NN O O
with NN O O
HMS NN B-SpecificDisease B-MSH:C537627
in NN O O
four NN O O
nuclear NN O O
families. NN O O
additionally, NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
shared NN O O
common NN O O
haplotype NN O O
for NN O O
genetic NN O O
loci NN O O
flanking NN O O
the NN O O
cathepsin NN O O
c NN O O
gene NN O O
suggests NN O O
that NN O O
affected NN O O
subjects NN O O
descended NN O O
from NN O O
the NN O O
cochin NN O O
isolate NN O O
are NN O O
homozygous NN O O
for NN O O
. NN O O

mutation NN O O
inherited NN O O
" NN O O
identical NN O O
by NN O O
descent NN O O
" NN O O
from NN O O
a NN O O
common NN O O
ancestor. NN O O
this NN O O
finding NN O O
supports NN O O
simple NN O O
autosomal NN O O
recessive NN O O
inheritance NN O O
for NN O O
HMS NN B-SpecificDisease B-MSH:C537627
in NN O O
these NN O O
families. NN O O
we NN O O
also NN O O
report NN O O
a NN O O
mutation NN O O
of NN O O
the NN O O
same NN O O
exon NN O O
6 NN O O
ctsc NN O O
codon NN O O
(2126 NN O O
c-- NN O O
> NN O O
t) NN O O
in NN O O
a NN O O
turkish NN O O
family NN O O
with NN O O
classical NN O O
PLS NN B-SpecificDisease B-MSH:D010214
. NN O O
these NN O O
findings NN O O
provide NN O O
evidence NN O O
that NN O O
PLS NN B-SpecificDisease B-MSH:D010214
and NN O O
HMS NN B-SpecificDisease B-MSH:C537627
are NN O O
allelic NN O O
variants NN O O
of NN O O
cathepsin NN O O
c NN O O
gene NN O O
mutations. NN O O
. NN O O

x NN O O
inactivation NN O O
and NN O O
somatic NN O O
cell NN O O
selection NN O O
rescue NN O O
female NN O O
mice NN O O
carrying NN O O
a NN O O
piga-null NN O O
mutation NN O O
. NN O O

a NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
x NN O O
linked NN O O
piga NN O O
gene NN O O
is NN O O
responsible NN O O
for NN O O
the NN O O
deficiency NN B-DiseaseClass B-MSH:C537277
of NN I-DiseaseClass I-MSH:C537277
glycosyl NN I-DiseaseClass I-MSH:C537277
phosphatidylinositol NN I-DiseaseClass I-MSH:C537277
(GPI) NN I-DiseaseClass I-MSH:C537277
-anchored NN I-DiseaseClass I-MSH:C537277
proteins NN I-DiseaseClass I-MSH:C537277
on NN O O
blood NN O O
cells NN O O
from NN O O
patients NN O O
with NN O O
paroxysmal NN B-SpecificDisease B-MSH:D006457
nocturnal NN I-SpecificDisease I-MSH:D006457
hemoglobinuria NN I-SpecificDisease I-MSH:D006457
. NN O O
no NN O O
inherited NN O O
form NN O O
of NN O O
GPI-anchor NN B-SpecificDisease B-MSH:C537277
deficiency NN I-SpecificDisease I-MSH:C537277
has NN O O
been NN O O
described. NN O O
because NN O O
conventional NN O O
piga NN O O
gene NN O O
knockout NN O O
is NN O O
associated NN O O
with NN O O
high NN O O
embryonic NN B-SpecificDisease B-MSH:D020964
lethality NN I-SpecificDisease I-MSH:D020964
in NN O O
chimeric NN O O
mice, NN O O
we NN O O
used NN O O
the NN O O
cre/loxp NN O O
system. NN O O
we NN O O
generated NN O O
mice NN O O
in NN O O
which NN O O
two NN O O
loxp NN O O
sites NN O O
flank NN O O
part NN O O
of NN O O
piga NN O O
exon NN O O
2. NN O O
after NN O O
crossbreeding NN O O
with NN O O
female NN O O
mice NN O O
of NN O O
the NN O O
eiia-cre NN O O
strain, NN O O
the NN O O
floxed NN O O
allele NN O O
undergoes NN O O
cre-mediated NN O O
recombination NN O O
with NN O O
high NN O O
efficiency NN O O
during NN O O
early NN O O
embryonic NN O O
development. NN O O
because NN O O
of NN O O
x NN O O
chromosome NN O O
inactivation, NN O O
female NN O O
offspring NN O O
are NN O O
mosaic NN O O
for NN O O
cells NN O O
that NN O O
express NN O O
or NN O O
lack NN O O
gpi-linked NN O O
proteins. NN O O
analysis NN O O
of NN O O
mosaic NN O O
mice NN O O
showed NN O O
that NN O O
in NN O O
hear NN O O
. NN O O

, NN O O
lung, NN O O
kidney, NN O O
brain, NN O O
and NN O O
liver, NN O O
mainly NN O O
wild-type NN O O
piga NN O O
is NN O O
active, NN O O
suggesting NN O O
that NN O O
these NN O O
tissues NN O O
require NN O O
gpi-linked NN O O
proteins. NN O O
the NN O O
salient NN O O
exceptions NN O O
were NN O O
spleen, NN O O
thymus, NN O O
and NN O O
red NN O O
blood NN O O
cells, NN O O
which NN O O
had NN O O
almost NN O O
equal NN O O
numbers NN O O
of NN O O
cells NN O O
expressing NN O O
the NN O O
wild-type NN O O
or NN O O
the NN O O
recombined NN O O
allele, NN O O
implying NN O O
that NN O O
gpi-linked NN O O
proteins NN O O
are NN O O
not NN O O
essential NN O O
for NN O O
the NN O O
derivation NN O O
of NN O O
these NN O O
tissues. NN O O
piga NN O O
(-) NN O O
cells NN O O
had NN O O
no NN O O
growth NN O O
advantage, NN O O
suggesting NN O O
that NN O O
other NN O O
factors NN O O
are NN O O
needed NN O O
for NN O O
their NN O O
clonal NN O O
dominance NN O O
in NN O O
patients NN O O
with NN O O
paroxysmal NN B-SpecificDisease B-MSH:D006457
nocturnal NN I-SpecificDisease I-MSH:D006457
hemoglobinuria NN I-SpecificDisease I-MSH:D006457
. NN O O
. NN O O

the NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
gene NN O O
maps NN O O
to NN O O
a NN O O
150 NN O O
kb NN O O
region NN O O
on NN O O
chromosome NN O O
xp NN O O
11.3 NN O O
. NN O O

norrie NN O O
disease NN O O
is NN O O
a NN O O
human NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
recessive NN I-DiseaseClass I-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
of NN O O
unknown NN O O
etiology NN O O
characterized NN O O
by NN O O
congenital NN B-SpecificDisease B-MSH:D057130
blindness NN I-SpecificDisease I-MSH:D057130
, NN O O
sensory NN B-SpecificDisease B-MSH:D006319
neural NN I-SpecificDisease I-MSH:D006319
deafness NN I-SpecificDisease I-MSH:D006319
and NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
. NN O O
this NN O O
disease NN O O
gene NN O O
was NN O O
previously NN O O
linked NN O O
to NN O O
the NN O O
dxs NN O O
7 NN O O
(l NN O O
1. NN O O
28) NN O O
locus NN O O
and NN O O
the NN O O
mao NN O O
genes NN O O
in NN O O
band NN O O
xp NN O O
11. NN O O
3 NN O O
3. NN O O
we NN O O
report NN O O
here NN O O
fine NN O O
physical NN O O
mapping NN O O
of NN O O
the NN O O
obligate NN O O
region NN O O
containing NN O O
the NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
gene NN O O
(ndp) NN O O
defined NN O O
by NN O O
a NN O O
recombination NN O O
and NN O O
by NN O O
the NN O O
smallest NN O O
submicroscopic NN O O
chromosomal NN O O
deletion NN O O
associated NN O O
with NN O O
Norrie NN B-SpecificDisease B-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
identified NN O O
to NN O O
date. NN O O
analysis, NN O O
using NN O O
in NN O O
addition NN O O
two NN O O
overlapping NN O O
yac NN O O
clones NN O O
from NN O O
this NN O O
region, NN O O
allowed NN O O
orientation NN O O
of NN O O
the NN O O
maoa NN O O
and NN O O
maob NN O O
genes NN O O
in NN O O
a NN O O
5-3-3-5 NN O O
configuration. NN O O
a NN O O
recombination NN O O
event NN O O
between NN O O
a NN O O
(gt) NN O O
n NN O O
polymorphism NN O O
in NN O O
intron NN O O
2 NN O O
of NN O O
the NN O O
maob NN O O
gen NN O O
. NN O O

and NN O O
the NN O O
ndp NN O O
locus, NN O O
in NN O O
a NN O O
family NN O O
previously NN O O
reported NN O O
to NN O O
have NN O O
a NN O O
recombination NN O O
between NN O O
dxs NN O O
7 NN O O
and NN O O
ndp, NN O O
delineates NN O O
a NN O O
flanking NN O O
marker NN O O
telomeric NN O O
to NN O O
this NN O O
disease NN O O
gene. NN O O
an NN O O
anonymous NN O O
dna NN O O
probe, NN O O
dc NN O O
12, NN O O
present NN O O
in NN O O
one NN O O
of NN O O
the NN O O
yacs NN O O
and NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
submicroscopic NN O O
deletion NN O O
which NN O O
includes NN O O
maoa NN O O
and NN O O
maob NN O O
but NN O O
not NN O O
l NN O O
1. NN O O
28, NN O O
serves NN O O
as NN O O
a NN O O
flanking NN O O
marker NN O O
centromeric NN O O
to NN O O
the NN O O
disease NN O O
gene. NN O O
an NN O O
alu-pcr NN O O
fragment NN O O
from NN O O
the NN O O
right NN O O
arm NN O O
of NN O O
the NN O O
mao NN O O
yac NN O O
(ymao. NN O O
alur) NN O O
is NN O O
not NN O O
deleted NN O O
in NN O O
this NN O O
patient NN O O
and NN O O
also NN O O
delineates NN O O
the NN O O
centromeric NN O O
extent NN O O
of NN O O
the NN O O
obligate NN O O
disease NN O O
region. NN O O
the NN O O
apparent NN O O
order NN O O
of NN O O
these NN O O
loci NN O O
is NN O O
telomere. NN O O
dxs NN O O
7-maoa-maob-ndp-dc NN O O
12-ymao NN O O
dxs NN O O
7-maoa-maob NN O O
. NN O O
ineates NN O O
the NN O O
centromeric NN O O
extent NN O O
of NN O O
the NN O O
obligate NN O O
disease NN O O
region. NN O O
the NN O O
apparent NN O O
order NN O O
of NN O O
these NN O O
loci NN O O
is NN O O
telomere. NN O O
dxs NN O O
7-maoa-maob-ndp-dc NN O O
12-ymao NN O O
dxs NN O O
7-maoa-maob NN O O
. NN O O

ndp-dc NN O O
12-ymao. NN O O
alur. NN O O
centromere. NN O O
together NN O O
these NN O O
data NN O O
define NN O O
the NN O O
obligate NN O O
region NN O O
containing NN O O
the NN O O
ndp NN O O
gene NN O O
to NN O O
a NN O O
chromosomal NN O O
segment NN O O
less NN O O
than NN O O
150 NN O O
kb NN O O
. NN O O

molecular NN O O
genetics NN O O
of NN O O
the NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
mediterranean NN O O
variant NN O O
and NN O O
description NN O O
of NN O O
a NN O O
new NN O O
g NN O O
6 NN O O
pd NN O O
mutant, NN O O
g NN O O
6 NN O O
pd NN O O
andalus NN O O
1361 NN O O
a NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd; NN O O
e. NN O O
c. NN O O
1. NN O O
1. NN O O
1. NN O O
49) NN O O
deficiency NN O O
is NN O O
the NN O O
most NN O O
common NN O O
human NN O O
enzymopathy NN B-DiseaseClass B-MSH:D008661
; NN O O
more NN O O
than NN O O
300 NN O O
different NN O O
biochemical NN O O
variants NN O O
of NN O O
the NN O O
enzyme NN O O
have NN O O
been NN O O
described. NN O O
in NN O O
many NN O O
parts NN O O
of NN O O
the NN O O
world NN O O
the NN O O
mediterranean NN O O
type NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
is NN O O
prevalent. NN O O
however, NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
has NN O O
come NN O O
to NN O O
be NN O O
regarded NN O O
as NN O O
a NN O O
generic NN O O
term NN O O
applied NN O O
to NN O O
similar NN O O
g NN O O
6 NN O O
pd NN O O
mutations NN O O
thought, NN O O
however, NN O O
to NN O O
represent NN O O
a NN O O
somewhat NN O O
heterogeneous NN O O
group. NN O O
a NN O O
c----t NN O O
mutation NN O O
at NN O O
nucleotide NN O O
563 NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
has NN O O
been NN O O
identified NN O O
by NN O O
vulliamy NN O O
et NN O O
al., NN O O
and NN O O
the NN O O
same NN O O
mutation NN O O
has NN O O
been NN O O
found NN O O
by NN O O
de NN O O
vita NN O O
et NN O O
al. NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean, NN O O
g NN O O
. NN O O

pd NN O O
sassari, NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
cagliari. NN O O
the NN O O
latter NN O O
subjects NN O O
had NN O O
an NN O O
additional NN O O
mutation, NN O O
at NN O O
nucleotide NN O O
1311, NN O O
that NN O O
did NN O O
not NN O O
produce NN O O
a NN O O
coding NN O O
change. NN O O
we NN O O
have NN O O
examined NN O O
genomic NN O O
dna NN O O
of NN O O
five NN O O
patients--four NN O O
of NN O O
spanish NN O O
origin NN O O
and NN O O
one NN O O
of NN O O
jewish NN O O
origin--having NN O O
enzymatically NN O O
documented NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean. NN O O
all NN O O
had NN O O
both NN O O
the NN O O
mutation NN O O
at NN O O
nucleotide NN O O
563 NN O O
and NN O O
that NN O O
at NN O O
nucleotide NN O O
1311. NN O O
a NN O O
sixth NN O O
sample, NN O O
resembling NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
kinetically NN O O
but NN O O
with NN O O
a NN O O
slightly NN O O
rapid NN O O
electrophoretic NN O O
mobility, NN O O
was NN O O
designated NN O O
g NN O O
6 NN O O
pd NN O O
andalus NN O O
and NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
different NN O O
mutation, NN O O
a NN O O
g----a NN O O
transition NN O O
at NN O O
nucleotide NN O O
1361, NN O O
producing NN O O
an NN O O
arginine-to-histidine NN O O
substitution. NN O O
these NN O O
studies NN O O
suggest NN O O
that NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
is, NN O O
after NN O O
all, NN O O
relativel NN O O
. NN O O
ented NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean. NN O O
all NN O O
had NN O O
both NN O O
the NN O O
mutation NN O O
at NN O O
nucleotide NN O O
563 NN O O
and NN O O
that NN O O
at NN O O
nucleotide NN O O
1311. NN O O
a NN O O
sixth NN O O
sample, NN O O
resembling NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
kinetically NN O O
but NN O O
with NN O O
a NN O O
slightly NN O O
rapid NN O O
electrophoretic NN O O
mobility, NN O O
was NN O O
designated NN O O
g NN O O
6 NN O O
pd NN O O
andalus NN O O
and NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
different NN O O
mutation, NN O O
a NN O O
g----a NN O O
transition NN O O
at NN O O
nucleotide NN O O
1361, NN O O
producing NN O O
an NN O O
arginine-to-histidine NN O O
substitution. NN O O
these NN O O
studies NN O O
suggest NN O O
that NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
is, NN O O
after NN O O
all, NN O O
relativel NN O O
. NN O O

homogeneous NN O O
. NN O O

small NN O O
nuclear NN O O
ribonucleoprotein NN O O
polypeptide NN O O
n NN O O
(snrpn), NN O O
an NN O O
expressed NN O O
gene NN O O
in NN O O
the NN O O
Prader-Willi NN B-Modifier B-MSH:D011218
syndrome NN I-Modifier I-MSH:D011218
critical NN O O
region NN O O
. NN O O

prader-willi NN O O
syndrome NN O O
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
is NN O O
associated NN O O
with NN O O
paternally NN O O
derived NN O O
chromosomal NN O O
deletions NN O O
in NN O O
region NN O O
15 NN O O
q NN O O
11-13 NN O O
or NN O O
with NN O O
maternal NN B-SpecificDisease B-MSH:C538037
disomy NN I-SpecificDisease I-MSH:C538037
for NN I-SpecificDisease I-MSH:C538037
chromosome NN I-SpecificDisease I-MSH:C538037
15 NN I-SpecificDisease I-MSH:C538037
. NN O O
therefore, NN O O
loss NN O O
of NN O O
the NN O O
expressed NN O O
paternal NN O O
alleles NN O O
of NN O O
maternally NN O O
imprinted NN O O
genes NN O O
must NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
phenotype. NN O O
we NN O O
have NN O O
mapped NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
small NN O O
nuclear NN O O
rna NN O O
associated NN O O
polypeptide NN O O
smn NN O O
(snrpn) NN O O
to NN O O
human NN O O
chromosome NN O O
15 NN O O
q NN O O
12 NN O O
and NN O O
a NN O O
processed NN O O
pseudogene NN O O
snrpnp NN O O
1 NN O O
to NN O O
chromosome NN O O
region NN O O
6 NN O O
pter-p NN O O
21. NN O O
furthermore, NN O O
snrpn NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
minimal NN O O
deletion NN O O
interval NN O O
that NN O O
is NN O O
critical NN O O
for NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
the NN O O
fact NN O O
that NN O O
the NN O O
mouse NN O O
snrpn NN O O
gene NN O O
is NN O O
maternally NN O O
imprinted NN O O
in NN O O
brain NN O O
suggests NN O O
that NN O O
loss NN O O
of NN O O
the NN O O
paternally NN O O
derived NN O O
snrpn NN O O
allele NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
phenotype. NN O O
. NN O O

increased NN O O
incidence NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
in NN O O
patients NN O O
with NN O O
cartilage-hair NN B-SpecificDisease B-MSH:C535916
hypoplasia NN I-SpecificDisease I-MSH:C535916
. NN O O

objective NN O O
previous NN O O
reports NN O O
have NN O O
suggested NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
among NN O O
patients NN O O
with NN O O
cartilage-hair NN B-SpecificDisease B-MSH:C535916
hypoplasia NN I-SpecificDisease I-MSH:C535916
( NN O O
CHH NN B-SpecificDisease B-MSH:C535916
). NN O O
this NN O O
study NN O O
was NN O O
carried NN O O
out NN O O
to NN O O
further NN O O
evaluate NN O O
this NN O O
risk NN O O
among NN O O
patients NN O O
with NN O O
CHH NN B-SpecificDisease B-MSH:C535916
and NN O O
their NN O O
first-degree NN O O
relatives. NN O O
study NN O O
design NN O O
one NN O O
hundred NN O O
twenty-two NN O O
patients NN O O
with NN O O
CHH NN B-SpecificDisease B-MSH:C535916
were NN O O
identified NN O O
through NN O O
2 NN O O
countrywide NN O O
epidemiologic NN O O
surveys NN O O
in NN O O
1974 NN O O
and NN O O
in NN O O
1986. NN O O
their NN O O
parents NN O O
and NN O O
nonaffected NN O O
siblings NN O O
were NN O O
identified NN O O
through NN O O
the NN O O
population NN O O
register NN O O
center. NN O O
this NN O O
cohort NN O O
underwent NN O O
follow-up NN O O
for NN O O
cancer NN B-Modifier B-MSH:D009369
incidence NN O O
through NN O O
the NN O O
finnish NN O O
cancer NN O O
registry NN O O
to NN O O
the NN O O
end NN O O
of NN O O
1995. NN O O
results NN O O
a NN O O
statistically NN O O
significant NN O O
excess NN O O
risk NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
was NN O O
seen NN O O
among NN O O
the NN O O
patients NN O O
with NN O O
CHH NN B-SpecificDisease B-MSH:C535916
(standardized NN O O
incidence NN O O
ratio NN O O
6. NN O O
9, NN O O
95% NN O O
confidence NN O O
interval NN O O
2. NN O O
3 NN O O
to NN O O
16), NN O O
which NN O O
was NN O O
mainly NN O O
attributable NN O O
to NN O O
non-Hodgkins NN B-SpecificDisease B-MSH:D008228
lymphoma NN I-SpecificDisease I-MSH:D008228

lymphoma NN O O
(standardized NN O O
incidence NN O O
ratio NN O O
90, NN O O
95% NN O O
confidence NN O O
interval NN O O
18 NN O O
to NN O O
264). NN O O
in NN O O
addition, NN O O
a NN O O
significant NN O O
excess NN O O
risk NN O O
of NN O O
basal NN B-SpecificDisease B-MSH:D002280
cell NN I-SpecificDisease I-MSH:D002280
carcinoma NN I-SpecificDisease I-MSH:D002280
was NN O O
seen NN O O
(standardized NN O O
incidence NN O O
ratio NN O O
35, NN O O
95% NN O O
confidence NN O O
interval NN O O
7. NN O O
2 NN O O
to NN O O
102). NN O O
the NN O O
cancer NN B-Modifier B-MSH:D009369
incidence NN O O
among NN O O
the NN O O
siblings NN O O
or NN O O
the NN O O
parents NN O O
did NN O O
not NN O O
differ NN O O
from NN O O
the NN O O
average NN O O
cancer NN B-Modifier B-MSH:D009369
incidence NN O O
in NN O O
the NN O O
finnish NN O O
population. NN O O
conclusions NN O O
this NN O O
study NN O O
confirms NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
, NN O O
especially NN O O
non-Hodgkins NN B-SpecificDisease B-MSH:D008228
lymphoma NN I-SpecificDisease I-MSH:D008228
, NN O O
probably NN O O
attributable NN O O
to NN O O
defective NN O O
immunity, NN O O
among NN O O
patients NN O O
with NN O O
CHH NN B-SpecificDisease B-MSH:C535916
. NN O O

genetic NN O O
polymorphism NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
in NN O O
a NN O O
bulgarian NN O O
population NN O O
. NN O O

considerable NN O O
genetic NN O O
heterogeneity NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
was NN O O
found NN O O
in NN O O
the NN O O
bulgarian NN O O
population-14 NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
isolated NN O O
from NN O O
117 NN O O
hemizygous NN O O
carriers NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
. NN O O
of NN O O
these, NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
type NN O O
was NN O O
a NN O O
polymorphic NN O O
variant NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
corinth NN O O
occurred NN O O
with NN O O
high NN O O
frequency. NN O O
two NN O O
new NN O O
variants NN O O
were NN O O
identified-g NN O O
6 NN O O
pd NN O O
rudosem NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
nedelino. NN O O
in NN O O
a NN O O
selected NN O O
group NN O O
of NN O O
78 NN O O
subjects NN O O
with NN O O
clinical NN O O
manifestations, NN O O
four NN O O
variants NN O O
were NN O O
established NN O O
g NN O O
6 NN O O
pd NN O O
mediterranian, NN O O
g NN O O
6 NN O O
pd NN O O
corinth, NN O O
g NN O O
6 NN O O
pd NN O O
seattle NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
ohut NN O O
ii. NN O O
. NN O O

a NN O O
genetic NN O O
etiology NN O O
for NN O O
DiGeorge NN B-SpecificDisease B-MSH:D004062
syndrome NN I-SpecificDisease I-MSH:D004062
: NN O O
consistent NN O O
deletions NN O O
and NN O O
microdeletions NN O O
of NN O O
22 NN O O
q NN O O
11 NN O O
. NN O O

digeorge NN O O
syndrome NN O O
( NN O O
DGS NN B-SpecificDisease B-MSH:D004062
), NN O O
a NN O O
developmental NN O O
field NN O O
defect NN O O
of NN O O
the NN O O
third NN O O
and NN O O
fourth NN O O
pharyngeal NN O O
pouches, NN O O
is NN O O
characterized NN O O
by NN O O
aplasia NN B-CompositeMention B-MSH:C536288
or NN I-CompositeMention I-MSH:C536288
hypoplasia NN I-CompositeMention I-MSH:C536288
of NN I-CompositeMention I-MSH:C536288
the NN I-CompositeMention I-MSH:C536288
thymus NN I-CompositeMention I-MSH:C536288
and NN I-CompositeMention I-MSH:C536288
parathyroid NN I-CompositeMention I-MSH:C536288
glands NN I-CompositeMention I-MSH:C536288
and NN O O
by NN O O
conotruncal NN B-SpecificDisease B-MSH:C535464
cardiac NN I-SpecificDisease I-MSH:C535464
malformations NN I-SpecificDisease I-MSH:C535464
. NN O O
cytogenetic NN O O
studies NN O O
support NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
DGS NN B-Modifier B-MSH:D004062
critical NN O O
region NN O O
in NN O O
band NN O O
22 NN O O
q NN O O
11. NN O O
in NN O O
the NN O O
present NN O O
study, NN O O
we NN O O
report NN O O
the NN O O
results NN O O
of NN O O
clinical, NN O O
cytogenetic, NN O O
and NN O O
molecular NN O O
studies NN O O
of NN O O
14 NN O O
patients NN O O
with NN O O
DGS NN B-SpecificDisease B-MSH:D004062
. NN O O
chromosome NN O O
analysis, NN O O
utilizing NN O O
high-resolution NN O O
banding NN O O
techniques, NN O O
detected NN O O
interstitial NN O O
deletions NN O O
in NN O O
five NN O O
probands NN O O
and NN O O
was NN O O
inconclusive NN O O
for NN O O
a NN O O
deletion NN O O
in NN O O
three NN O O
probands. NN O O
the NN O O
remaining NN O O
six NN O O
patients NN O O
had NN O O
normal NN O O
karyotypes. NN O O
in NN O O
contrast, NN O O
molecular NN O O
analysis NN O O
detected NN O O
dna NN O O
deletions NN O O
in NN O O
all NN O O
14 NN O O
probands. NN O O
two NN O O
of NN O O
10 NN O O
loci NN O O
tested, NN O O
d NN O O
22 NN O O
s NN O O
75 NN O O
and NN O O
d NN O O
22 NN O O
s NN O O
259, NN O O
are NN O O
delete NN O O
. NN O O

in NN O O
all NN O O
14 NN O O
patients. NN O O
a NN O O
third NN O O
locus, NN O O
d NN O O
22 NN O O
s NN O O
66, NN O O
is NN O O
deleted NN O O
in NN O O
the NN O O
eight NN O O
DGS NN B-Modifier B-MSH:D004062
probands NN O O
tested. NN O O
physical NN O O
mapping NN O O
using NN O O
somatic NN O O
cell NN O O
hybrids NN O O
places NN O O
d NN O O
22 NN O O
s NN O O
66 NN O O
between NN O O
d NN O O
22 NN O O
s NN O O
75 NN O O
and NN O O
d NN O O
22 NN O O
s NN O O
259, NN O O
suggesting NN O O
that NN O O
it NN O O
should NN O O
be NN O O
deleted NN O O
in NN O O
the NN O O
remaining NN O O
six NN O O
cases. NN O O
parent-of-origin NN O O
studies NN O O
were NN O O
performed NN O O
in NN O O
five NN O O
families. NN O O
four NN O O
probands NN O O
failed NN O O
to NN O O
inherit NN O O
a NN O O
maternal NN O O
allele, NN O O
and NN O O
one NN O O
failed NN O O
to NN O O
inherit NN O O
a NN O O
paternal NN O O
allele. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
these NN O O
families, NN O O
and NN O O
of NN O O
six NN O O
maternally NN O O
and NN O O
five NN O O
paternally NN O O
derived NN O O
unbalanced-translocation NN O O
DGS NN B-Modifier B-MSH:D004062
probands NN O O
in NN O O
the NN O O
literature, NN O O
parent NN O O
of NN O O
origin NN O O
or NN O O
imprinting NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
play NN O O
an NN O O
important NN O O
role NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
DGS NN B-SpecificDisease B-MSH:D004062
. NN O O
deletion NN O O
of NN O O
the NN O O
same NN O O
three NN O O
loci NN O O
in NN O O
all NN O O
14 NN O O
DGS NN B-Modifier B-MSH:D004062
. NN O O

probands NN O O
begins NN O O
to NN O O
delineate NN O O
the NN O O
region NN O O
of NN O O
chromosome NN O O
22 NN O O
critical NN O O
for NN O O
DGS NN B-SpecificDisease B-MSH:D004062
and NN O O
confirms NN O O
the NN O O
hypothesis NN O O
that NN O O
submicroscopic NN O O
deletions NN O O
of NN O O
22 NN O O
q NN O O
11 NN O O
are NN O O
etiologic NN O O
in NN O O
the NN O O
vast NN O O
majority NN O O
of NN O O
cases. NN O O
. NN O O

characterisation NN O O
of NN O O
a NN O O
new NN O O
rare NN O O
fragile NN O O
site NN O O
easily NN O O
confused NN O O
with NN O O
the NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
. NN O O

a NN O O
new NN O O
fragile NN O O
site NN O O
(fraxe) NN O O
in NN O O
xq NN O O
28 NN O O
is NN O O
described. NN O O
it NN O O
appears NN O O
to NN O O
be NN O O
a NN O O
typical NN O O
folate NN O O
sensitive NN O O
fragile NN O O
site. NN O O
the NN O O
fragile NN O O
site NN O O
is NN O O
not NN O O
associated NN O O
with NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
it NN O O
does NN O O
not NN O O
give NN O O
abnormal NN O O
results NN O O
when NN O O
subjected NN O O
to NN O O
southern NN O O
analysis NN O O
with NN O O
probe NN O O
pfxa NN O O
3 NN O O
which NN O O
detects NN O O
the NN O O
unstable NN O O
dna NN O O
sequence NN O O
characteristic NN O O
of NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
. NN O O
in NN O O
situ NN O O
hybridization NN O O
mapping NN O O
locates NN O O
the NN O O
fragile NN O O
site NN O O
between NN O O
150 NN O O
kb NN O O
and NN O O
600 NN O O
kb NN O O
distal NN O O
to NN O O
fraxa. NN O O
the NN O O
distinction NN O O
between NN O O
the NN O O
two NN O O
fragile NN O O
sites NN O O
is NN O O
important NN O O
clinically NN O O
since NN O O
cytogenetic NN O O
detection NN O O
of NN O O
fraxe, NN O O
without NN O O
molecular NN O O
analysis, NN O O
could NN O O
result NN O O
in NN O O
misdiagnosis NN O O
of NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
. NN O O
. NN O O

brca NN O O
1 NN O O
mutations NN O O
in NN O O
primary NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
carcinomas NN I-CompositeMention I-MSH:D001943
. NN O O

loss NN O O
of NN O O
heterozygosity NN O O
data NN O O
from NN O O
familial NN B-DiseaseClass B-MSH:D009386
tumors NN I-DiseaseClass I-MSH:D009386
suggest NN O O
that NN O O
brca NN O O
1, NN O O
a NN O O
gene NN O O
that NN O O
confers NN O O
susceptibility NN O O
to NN O O
ovarian NN B-CompositeMention B-MSH:D010051
and NN I-CompositeMention I-MSH:D010051
early-onset NN I-CompositeMention I-MSH:D010051
breast NN B-CompositeMention B-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
, NN O O
encodes NN O O
a NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor. NN O O
the NN O O
brca NN O O
1 NN O O
region NN O O
is NN O O
also NN O O
subject NN O O
to NN O O
allelic NN O O
loss NN O O
in NN O O
sporadic NN B-SpecificDisease B-MSH:D001943
breast NN I-SpecificDisease I-MSH:D001943
and NN I-SpecificDisease I-MSH:D001943
ovarian NN I-SpecificDisease I-MSH:D001943
cancers NN I-SpecificDisease I-MSH:D001943
, NN O O
an NN O O
indication NN O O
that NN O O
brca NN O O
1 NN O O
mutations NN O O
may NN O O
occur NN O O
somatically NN O O
in NN O O
these NN O O
tumors NN B-DiseaseClass B-MSH:D009369
. NN O O
the NN O O
brca NN O O
1 NN O O
coding NN O O
region NN O O
was NN O O
examined NN O O
for NN O O
mutations NN O O
in NN O O
primary NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
tumors NN I-CompositeMention I-MSH:D001943
that NN O O
show NN O O
allele NN O O
loss NN O O
at NN O O
the NN O O
brca NN O O
1 NN O O
locus. NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
3 NN O O
of NN O O
32 NN O O
breast NN O O
and NN O O
1 NN O O
of NN O O
12 NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
carcinomas NN I-SpecificDisease I-MSH:D010051
; NN O O
all NN O O
four NN O O
mutations NN O O
were NN O O
germline NN O O
alterations NN O O
and NN O O
occurred NN O O
in NN O O
early-onset NN O O
cancers NN B-DiseaseClass B-MSH:D009369
. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
mutation NN O O
of NN O O
brca NN O O
1 NN O O
may NN O O
not NN O O
be NN O O
critical NN O O
in NN O O
the NN O O
development NN O O
of NN O O
the NN O O
majority NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
and NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancers NN I-CompositeMention I-MSH:D001943
that NN O O
aris NN O O
. NN O O

in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
mutant NN O O
germline NN O O
allele. NN O O
. NN O O

genomic NN O O
structure NN O O
of NN O O
the NN O O
ews NN O O
gene NN O O
and NN O O
its NN O O
relationship NN O O
to NN O O
ewsr NN O O
1, NN O O
a NN O O
site NN O O
of NN O O
tumor NN B-Modifier B-MSH:D009369
-associated NN O O
chromosome NN O O
translocation NN O O
. NN O O

the NN O O
ews NN O O
gene NN O O
has NN O O
been NN O O
identified NN O O
based NN O O
on NN O O
its NN O O
location NN O O
at NN O O
the NN O O
chromosome NN O O
22 NN O O
breakpoint NN O O
of NN O O
the NN O O
t NN O O
(11; NN O O
22) NN O O
(q NN O O
24; NN O O
q NN O O
12) NN O O
translocation NN O O
that NN O O
characterizes NN O O
Ewing NN B-SpecificDisease B-MSH:D012512
sarcoma NN I-SpecificDisease I-MSH:D012512
and NN O O
related NN O O
neuroectodermal NN B-SpecificDisease B-MSH:D017599
tumors NN I-SpecificDisease I-MSH:D017599
. NN O O
the NN O O
ews NN O O
gene NN O O
spans NN O O
about NN O O
40 NN O O
kb NN O O
of NN O O
dna NN O O
and NN O O
is NN O O
encoded NN O O
by NN O O
17 NN O O
exons. NN O O
the NN O O
nucleotide NN O O
sequence NN O O
of NN O O
the NN O O
exons NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
of NN O O
the NN O O
previously NN O O
described NN O O
cdna. NN O O
the NN O O
first NN O O
7 NN O O
exons NN O O
encode NN O O
the NN O O
n-terminal NN O O
domain NN O O
of NN O O
ews, NN O O
which NN O O
consists NN O O
of NN O O
a NN O O
repeated NN O O
degenerated NN O O
polypeptide NN O O
of NN O O
7 NN O O
to NN O O
12 NN O O
residues NN O O
rich NN O O
in NN O O
tyrosine, NN O O
serine, NN O O
threonine, NN O O
glycine, NN O O
and NN O O
glutamine. NN O O
exons NN O O
11, NN O O
12, NN O O
and NN O O
13 NN O O
encode NN O O
the NN O O
putative NN O O
rna NN O O
binding NN O O
domain. NN O O
the NN O O
three NN O O
glycine- NN O O
and NN O O
arginine-rich NN O O
motifs NN O O
of NN O O
the NN O O
gene NN O O
are NN O O
mainly NN O O
encoded NN O O
b NN O O
. NN O O

exons NN O O
8-9, NN O O
14, NN O O
and NN O O
16. NN O O
the NN O O
dna NN O O
sequence NN O O
in NN O O
the NN O O
5 NN O O
region NN O O
of NN O O
the NN O O
gene NN O O
has NN O O
features NN O O
of NN O O
a NN O O
cpg-rich NN O O
island NN O O
and NN O O
lacks NN O O
canonical NN O O
promoter NN O O
elements, NN O O
such NN O O
as NN O O
tata NN O O
and NN O O
ccaat NN O O
consensus NN O O
sequences. NN O O
positions NN O O
of NN O O
the NN O O
chromosome NN O O
22 NN O O
breakpoints NN O O
were NN O O
determined NN O O
for NN O O
19 NN O O
Ewing NN B-DiseaseClass B-MSH:D012512
tumors NN I-DiseaseClass I-MSH:D012512
. NN O O
they NN O O
were NN O O
localized NN O O
in NN O O
introns NN O O
7 NN O O
or NN O O
8 NN O O
in NN O O
18 NN O O
cases NN O O
and NN O O
in NN O O
intron NN O O
10 NN O O
in NN O O
1 NN O O
case. NN O O
. NN O O

pax NN O O
6 NN O O
mutations NN O O
in NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O O

aniridia NN O O
is NN O O
a NN O O
congenital NN B-DiseaseClass B-MSH:D005124
malformation NN I-DiseaseClass I-MSH:D005124
of NN I-DiseaseClass I-MSH:D005124
the NN I-DiseaseClass I-MSH:D005124
eye NN I-DiseaseClass I-MSH:D005124
, NN O O
chiefly NN O O
characterised NN O O
by NN O O
iris NN B-SpecificDisease B-MSH:D007499
hypoplasia NN I-SpecificDisease I-MSH:D007499
, NN O O
which NN O O
can NN O O
cause NN O O
blindness NN B-SpecificDisease B-MSH:D001766
. NN O O
the NN O O
pax NN O O
6 NN O O
gene NN O O
was NN O O
isolated NN O O
as NN O O
a NN O O
candidate NN O O
aniridia NN B-Modifier B-MSH:D015783
gene NN O O
by NN O O
positional NN O O
cloning NN O O
from NN O O
the NN O O
smallest NN O O
region NN O O
of NN O O
overlap NN O O
of NN O O
aniridia NN B-Modifier B-MSH:D015783
-associated NN O O
deletions. NN O O
subsequently NN O O
pax NN O O
6 NN O O
intragenic NN O O
mutations NN O O
were NN O O
demonstrated NN O O
in NN O O
smalleye, NN O O
a NN O O
mouse NN O O
mutant NN O O
which NN O O
is NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
and NN O O
six NN O O
human NN O O
aniridia NN B-Modifier B-MSH:D015783
patients. NN O O
in NN O O
this NN O O
paper NN O O
we NN O O
describe NN O O
four NN O O
additional NN O O
pax NN O O
6 NN O O
point NN O O
mutations NN O O
in NN O O
aniridia NN B-Modifier B-MSH:D015783
patients, NN O O
both NN O O
sporadic NN O O
and NN O O
familial. NN O O
these NN O O
mutations NN O O
highlight NN O O
regions NN O O
of NN O O
the NN O O
gene NN O O
which NN O O
are NN O O
essential NN O O
for NN O O
normal NN O O
pax NN O O
6 NN O O
function. NN O O
in NN O O
addition, NN O O
the NN O O
frequency NN O O
at NN O O
which NN O O
we NN O O
have NN O O
found NN O O
pax NN O O
6 NN O O
mutations NN O O
suggests NN O O
that NN O O
lesions NN O O
in NN O O
pax NN O O
6 NN O O
will NN O O
account NN O O
for NN O O
most NN O O
cases NN O O
of NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
pax NN O O
6 NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
hereditary NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O O

the NN O O
14 NN O O
exons NN O O
of NN O O
the NN O O
pax NN O O
6 NN O O
gene NN O O
have NN O O
been NN O O
analysed NN O O
exon-by-exon NN O O
using NN O O
sscp NN O O
in NN O O
6 NN O O
aniridia NN B-Modifier B-MSH:D015783
families. NN O O
in NN O O
each NN O O
family NN O O
band NN O O
shifts NN O O
were NN O O
observed NN O O
on NN O O
the NN O O
sscp NN O O
gels NN O O
for NN O O
only NN O O
one NN O O
exon NN O O
and NN O O
direct NN O O
pcr-sequencing NN O O
revealed NN O O
mutations NN O O
in NN O O
each NN O O
case. NN O O
two NN O O
mutations NN O O
involved NN O O
c-- NN O O
> NN O O
t NN O O
transitions NN O O
in NN O O
cgaarg NN O O
codons NN O O
in NN O O
exons NN O O
9 NN O O
and NN O O
11. NN O O
another NN O O
c-- NN O O
> NN O O
t NN O O
transition NN O O
converted NN O O
a NN O O
cag-glutamine NN O O
to NN O O
a NN O O
tag-stop NN O O
in NN O O
exon NN O O
7. NN O O
small NN O O
insertions NN O O
created NN O O
frameshifts NN O O
which NN O O
produced NN O O
downstream NN O O
stop NN O O
codons NN O O
in NN O O
another NN O O
two NN O O
patients NN O O
and NN O O
an NN O O
a-- NN O O
> NN O O
t NN O O
mutation NN O O
disrupted NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
exon NN O O
5 NN O O
in NN O O
the NN O O
remaining NN O O
family. NN O O
thus, NN O O
complete NN O O
inactivation NN O O
of NN O O
the NN O O
pax NN O O
6 NN O O
gene NN O O
is NN O O
predicted NN O O
in NN O O
all NN O O
cases. NN O O
analysis NN O O
of NN O O
othe NN O O
. NN O O

affected NN O O
members NN O O
of NN O O
the NN O O
families NN O O
showed NN O O
that, NN O O
in NN O O
each NN O O
case, NN O O
all NN O O
affected NN O O
individuals NN O O
carried NN O O
the NN O O
same NN O O
family-specific NN O O
mutation. NN O O
one NN O O
polymorphism NN O O
was NN O O
found NN O O
in NN O O
exon NN O O
7. NN O O
this NN O O
data NN O O
strongly NN O O
supports NN O O
the NN O O
candidature NN O O
of NN O O
pax NN O O
6 NN O O
as NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
hereditary NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O O
. NN O O

locus NN O O
heterogeneity NN O O
in NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
. NN O O

friedreich NN O O
ataxia NN O O
( NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
autosomal NN B-DiseaseClass B-OMIM:610743
recessive NN I-DiseaseClass I-OMIM:610743
ataxia NN I-DiseaseClass I-OMIM:610743
. NN O O
the NN O O
disease NN O O
locus NN O O
was NN O O
assigned NN O O
to NN O O
chromosome NN O O
9 NN O O
and NN O O
the NN O O
disease NN O O
gene, NN O O
stm NN O O
7/x NN O O
25, NN O O
has NN O O
been NN O O
isolated. NN O O
to NN O O
date NN O O
most NN O O
data NN O O
suggest NN O O
locus NN O O
homogeneity NN O O
in NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
. NN O O
we NN O O
now NN O O
provide NN O O
strong NN O O
evidence NN O O
of NN O O
a NN O O
second NN O O
FRDA NN B-Modifier B-MSH:D005621
locus. NN O O
studying NN O O
two NN O O
siblings NN O O
with NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
from NN O O
two NN O O
families NN O O
we NN O O
did NN O O
not NN O O
detect NN O O
a NN O O
mutation NN O O
in NN O O
stm NN O O
7/x NN O O
25. NN O O
haplotype NN O O
analysis NN O O
of NN O O
the NN O O
stm NN O O
7/x NN O O
25 NN O O
region NN O O
of NN O O
chromosome NN O O
9 NN O O
demonstrated NN O O
that NN O O
the NN O O
relevant NN O O
portion NN O O
of NN O O
chromosome NN O O
9 NN O O
differs NN O O
in NN O O
the NN O O
patients. NN O O
although NN O O
the NN O O
patients NN O O
studied NN O O
had NN O O
typical NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
, NN O O
one NN O O
sibpair NN O O
had NN O O
the NN O O
uncommon NN O O
symptom NN O O
of NN O O
retained NN O O
tendon NN O O
reflexes. NN O O
in NN O O
order NN O O
to NN O O
investigate NN O O
whether NN O O
retained NN O O
tendon NN O O
reflexes NN O O
are NN O O
characteristic NN O O
of NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
caused NN O O
by NN O O
th NN O O
. NN O O

second NN O O
locus, NN O O
frda NN O O
2, NN O O
we NN O O
studied NN O O
an NN O O
unrelated NN O O
FRDA NN B-Modifier B-MSH:D005621
patient NN O O
with NN O O
retained NN O O
tendon NN O O
reflexes. NN O O
the NN O O
observation NN O O
of NN O O
typical NN O O
mutations NN O O
in NN O O
stm NN O O
7/x NN O O
25 NN O O
(gaa NN O O
expansions) NN O O
in NN O O
this NN O O
patient NN O O
demonstrates NN O O
that NN O O
the NN O O
two NN O O
genetically NN O O
different NN O O
forms NN O O
of NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
cannot NN O O
be NN O O
distinguished NN O O
clinically. NN O O
. NN O O

haploinsufficiency NN O O
of NN O O
the NN O O
transcription NN O O
factors NN O O
foxc NN O O
1 NN O O
and NN O O
foxc NN O O
2 NN O O
results NN O O
in NN O O
aberrant NN O O
ocular NN O O
development NN O O
. NN O O

anterior NN O O
segment NN O O
developmental NN O O
disorders, NN O O
including NN O O
Axenfeld-Rieger NN B-SpecificDisease B-MSH:C535679
anomaly NN I-SpecificDisease I-MSH:C535679
( NN O O
ARA NN B-SpecificDisease B-MSH:C535679
), NN O O
variably NN O O
associate NN O O
with NN O O
harmfully NN O O
elevated NN O O
intraocular NN O O
pressure NN O O
(iop), NN O O
which NN O O
causes NN O O
glaucoma NN B-SpecificDisease B-MSH:D005901
. NN O O
clinically NN O O
observed NN O O
dysgenesis NN O O
does NN O O
not NN O O
correlate NN O O
with NN O O
iop, NN O O
however, NN O O
and NN O O
the NN O O
etiology NN O O
of NN O O
glaucoma NN B-Modifier B-MSH:D005901
development NN O O
is NN O O
not NN O O
understood. NN O O
the NN O O
forkhead NN O O
transcription NN O O
factor NN O O
genes NN O O
foxc NN O O
1 NN O O
(formerly NN O O
mf NN O O
1) NN O O
and NN O O
foxc NN O O
2 NN O O
(formerly NN O O
mfh NN O O
1) NN O O
are NN O O
expressed NN O O
in NN O O
the NN O O
mesenchyme NN O O
from NN O O
which NN O O
the NN O O
ocular NN O O
drainage NN O O
structures NN O O
derive. NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
homolog NN O O
of NN O O
foxc NN O O
1, NN O O
fkhl NN O O
7, NN O O
cause NN O O
dominant NN O O
anterior NN B-DiseaseClass B-MSH:C537775
segment NN I-DiseaseClass I-MSH:C537775
defects NN I-DiseaseClass I-MSH:C537775
and NN O O
glaucoma NN B-SpecificDisease B-MSH:D005901
in NN O O
various NN O O
families. NN O O
we NN O O
show NN O O
that NN O O
foxc NN O O
1 NN O O
(+/-) NN O O
mice NN O O
have NN O O
anterior NN B-DiseaseClass B-MSH:C537775
segment NN I-DiseaseClass I-MSH:C537775
abnormalities NN I-DiseaseClass I-MSH:C537775
similar NN O O
to NN O O
those NN O O
reported NN O O
in NN O O
human NN O O
patients. NN O O
these NN O O
abnormalities NN O O
include NN O O
small NN O O
or NN O O
absent NN O O
schlemms NN O O
canal, NN O O
aberrantly NN O O
develope NN O O
. NN O O

trabecular NN O O
meshwork, NN O O
iris NN B-SpecificDisease B-MSH:D007499
hypoplasia NN I-SpecificDisease I-MSH:D007499
, NN O O
severely NN O O
eccentric NN O O
pupils NN O O
and NN O O
displaced NN O O
schwalbes NN O O
line. NN O O
the NN O O
penetrance NN O O
of NN O O
clinically NN O O
obvious NN O O
abnormalities NN O O
varies NN O O
with NN O O
genetic NN O O
background. NN O O
in NN O O
some NN O O
affected NN O O
eyes, NN O O
collagen NN O O
bundles NN O O
were NN O O
half NN O O
normal NN O O
diameter, NN O O
or NN O O
collagen NN O O
and NN O O
elastic NN O O
tissue NN O O
were NN O O
very NN O O
sparse. NN O O
thus, NN O O
abnormalities NN O O
in NN O O
extracellular NN O O
matrix NN O O
synthesis NN O O
or NN O O
organization NN O O
may NN O O
contribute NN O O
to NN O O
development NN O O
of NN O O
the NN O O
ocular NN O O
phenotypes. NN O O
despite NN O O
the NN O O
abnormalities NN O O
in NN O O
ocular NN O O
drainage NN O O
structures NN O O
in NN O O
foxc NN O O
1 NN O O
(+/-) NN O O
mice, NN O O
iop NN O O
was NN O O
normal NN O O
in NN O O
almost NN O O
all NN O O
mice NN O O
analyzed, NN O O
on NN O O
all NN O O
genetic NN O O
backgrounds NN O O
and NN O O
at NN O O
all NN O O
ages. NN O O
similar NN O O
abnormalities NN O O
were NN O O
found NN O O
in NN O O
foxc NN O O
2 NN O O
(+/-) NN O O
mice, NN O O
but NN O O
no NN O O
disease-associated NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
the NN O O
human NN O O
homolog NN O O
fkhl NN O O
14 NN O O
in NN O O
32 NN O O
ARA NN B-Modifier B-MSH:C535679
patients. NN O O
foxc NN O O
1 NN O O
(+/-) NN O O
an NN O O
. NN O O

foxc NN O O
2 NN O O
(+/-) NN O O
mice NN O O
are NN O O
useful NN O O
models NN O O
for NN O O
studying NN O O
anterior NN O O
segment NN O O
development NN O O
and NN O O
its NN O O
anomalies, NN O O
and NN O O
may NN O O
allow NN O O
identification NN O O
of NN O O
genes NN O O
that NN O O
interact NN O O
with NN O O
foxc NN O O
1 NN O O
and NN O O
foxc NN O O
2 NN O O
(or NN O O
fkhl NN O O
7 NN O O
and NN O O
fkhl NN O O
14) NN O O
to NN O O
produce NN O O
a NN O O
phenotype NN O O
with NN O O
elevated NN O O
iop NN O O
and NN O O
glaucoma NN B-SpecificDisease B-MSH:D005901
. NN O O
. NN O O

the NN O O
dermatofibrosarcoma NN B-Modifier B-MSH:C538219
protuberans NN I-Modifier I-MSH:C538219
-associated NN O O
collagen NN O O
type NN O O
ialpha NN O O
1/platelet-derived NN O O
growth NN O O
factor NN O O
(pdgf) NN O O
b-chain NN O O
fusion NN O O
gene NN O O
generates NN O O
a NN O O
transforming NN O O
protein NN O O
that NN O O
is NN O O
processed NN O O
to NN O O
functional NN O O
pdgf-bb NN O O
. NN O O

dermatofibrosarcoma NN O O
protuberans NN O O
( NN O O
DFSP NN B-SpecificDisease B-MSH:C538219
) NN O O
displays NN O O
chromosomal NN O O
rearrangements NN O O
involving NN O O
chromosome NN O O
17 NN O O
and NN O O
22, NN O O
which NN O O
fuse NN O O
the NN O O
collagen NN O O
type NN O O
ialpha NN O O
1 NN O O
(colia NN O O
1) NN O O
gene NN O O
to NN O O
the NN O O
platelet-derived NN O O
growth NN O O
factor NN O O
(pdgf) NN O O
b-chain NN O O
(pdgfb) NN O O
gene. NN O O
to NN O O
characterize NN O O
the NN O O
functional NN O O
and NN O O
structural NN O O
properties NN O O
of NN O O
the NN O O
colia NN O O
1/pdgfb NN O O
fusion NN O O
protein, NN O O
we NN O O
generated NN O O
a NN O O
stable NN O O
nih NN O O
3 NN O O
t NN O O
3 NN O O
cell NN O O
line NN O O
that NN O O
contained NN O O
a NN O O
tumor-derived NN O O
chimeric NN O O
gene NN O O
resulting NN O O
from NN O O
a NN O O
coia NN O O
1 NN O O
intron NN O O
7-pdgfb NN O O
intron NN O O
1 NN O O
fusion. NN O O
expression NN O O
of NN O O
the NN O O
fusion NN O O
protein NN O O
led NN O O
to NN O O
morphological NN O O
transformation NN O O
and NN O O
increased NN O O
growth NN O O
rate NN O O
of NN O O
these NN O O
cells. NN O O
the NN O O
pdgf NN O O
receptor NN O O
kinase NN O O
inhibitor NN O O
cgp NN O O
57148 NN O O
b NN O O
reversed NN O O
the NN O O
transformed NN O O
phenotype NN O O
and NN O O
reduced NN O O
the NN O O
growth NN O O
rate NN O O
of NN O O
colia NN O O
1/pdgfb-expressing NN O O
cells NN O O
but NN O O
had NN O O
no NN O O
effects NN O O
on NN O O
control NN O O
cell NN O O
. NN O O

. NN O O
the NN O O
presence NN O O
of NN O O
dimeric NN O O
colia NN O O
1/pdgfb NN O O
precursors NN O O
was NN O O
demonstrated NN O O
through NN O O
pdgfb NN O O
immunoprecipitations NN O O
of NN O O
metabolically NN O O
labeled NN O O
cells NN O O
and NN O O
also NN O O
by NN O O
pdgfb NN O O
immunoprecipitations NN O O
followed NN O O
by NN O O
immunoblotting NN O O
with NN O O
colia NN O O
1 NN O O
antibodies. NN O O
pulse-chase NN O O
studies NN O O
demonstrated NN O O
that NN O O
the NN O O
colia NN O O
1/pdgfb NN O O
precursor NN O O
was NN O O
processed NN O O
to NN O O
an NN O O
end NN O O
product NN O O
that NN O O
was NN O O
indistinguishable NN O O
from NN O O
wild-type NN O O
pdgf-bb. NN O O
finally, NN O O
colia NN O O
1/pdgfb-expressing NN O O
cells NN O O
generated NN O O
tumors NN B-DiseaseClass B-MSH:D009369
after NN O O
s. NN O O
c NN O O
c. NN O O
injection NN O O
into NN O O
nude NN O O
mice, NN O O
and NN O O
tumor NN B-Modifier B-MSH:D009369
growth NN O O
was NN O O
reduced NN O O
by NN O O
treatment NN O O
with NN O O
cgp NN O O
57148 NN O O
b. NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
colia NN O O
1/pdgfb NN O O
fusion NN O O
associated NN O O
with NN O O
DFSP NN B-SpecificDisease B-MSH:C538219
contributes NN O O
to NN O O
tumor NN B-Modifier B-MSH:D009369
development NN O O
through NN O O
ectopic NN O O
production NN O O
of NN O O
pdgf-bb NN O O
and NN O O
the NN O O
formation NN O O
of NN O O
an NN O O
autocrine NN O O
loop. NN O O
our NN O O
findings, NN O O
thus, NN O O
suggest NN O O
that NN O O
pdgf NN O O
receptors NN O O
could NN O O
be NN O O
a NN O O
target NN O O
fo NN O O
. NN O O

pharmacological NN O O
treatment NN O O
of NN O O
DFSP NN B-SpecificDisease B-MSH:C538219
and NN O O
giant NN B-SpecificDisease B-MSH:C538219
cell NN I-SpecificDisease I-MSH:C538219
fibroblastoma NN I-SpecificDisease I-MSH:C538219
, NN O O
e. NN O O
g., NN O O
through NN O O
the NN O O
use NN O O
of NN O O
pdgf NN O O
receptor NN O O
kinase NN O O
inhibitors NN O O
such NN O O
as NN O O
cgp NN O O
57148 NN O O
b NN O O
. NN O O

founder NN O O
effect NN O O
of NN O O
a NN O O
prevalent NN O O
phenylketonuria NN B-Modifier B-MSH:D010661
mutation NN O O
in NN O O
the NN O O
oriental NN O O
population NN O O
. NN O O

a NN O O
missense NN O O
mutation NN O O
has NN O O
been NN O O
identified NN O O
in NN O O
the NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
[pah; NN O O
phenylalanine NN O O
4-monooxygenase; NN O O
l-phenylalanine, NN O O
tetrahydrobiopterin NN O O
oxygen NN O O
oxidoreductase NN O O
(4-hydroxylating), NN O O
ec NN O O
1. NN O O
14. NN O O
16. NN O O
1] NN O O
gene NN O O
in NN O O
a NN O O
chinese NN O O
patient NN O O
with NN O O
classic NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
). NN O O
a NN O O
g-to-c NN O O
transition NN O O
at NN O O
the NN O O
second NN O O
base NN O O
of NN O O
codon NN O O
413 NN O O
in NN O O
exon NN O O
12 NN O O
of NN O O
the NN O O
gene NN O O
results NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
pro NN O O
413 NN O O
for NN O O
arg NN O O
413 NN O O
in NN O O
the NN O O
mutant NN O O
protein. NN O O
this NN O O
mutation NN O O
(r NN O O
413 NN O O
p) NN O O
results NN O O
in NN O O
negligible NN O O
enzymatic NN O O
activity NN O O
when NN O O
expressed NN O O
in NN O O
heterologous NN O O
mammalian NN O O
cells NN O O
and NN O O
is NN O O
compatible NN O O
with NN O O
a NN O O
classic NN O O
PKU NN B-Modifier B-MSH:D010661
phenotype NN O O
in NN O O
the NN O O
patient. NN O O
population NN O O
genetic NN O O
studies NN O O
reveal NN O O
that NN O O
this NN O O
mutation NN O O
is NN O O
tightly NN O O
linked NN O O
to NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
haplotype NN O O
4, NN O O
which NN O O
is NN O O
the NN O O
predominan NN O O
. NN O O

haplotype NN O O
of NN O O
the NN O O
pah NN O O
locus NN O O
in NN O O
the NN O O
oriental NN O O
population. NN O O
it NN O O
accounts NN O O
for NN O O
13. NN O O
8% NN O O
of NN O O
northern NN O O
chinese NN O O
and NN O O
27% NN O O
of NN O O
japanese NN O O
PKU NN B-Modifier B-MSH:D010661
alleles, NN O O
but NN O O
it NN O O
is NN O O
rare NN O O
in NN O O
southern NN O O
chinese NN O O
(2. NN O O
2%) NN O O
and NN O O
is NN O O
absent NN O O
in NN O O
the NN O O
caucasian NN O O
population. NN O O
the NN O O
data NN O O
demonstrate NN O O
unambiguously NN O O
that NN O O
the NN O O
mutation NN O O
occurred NN O O
after NN O O
racial NN O O
divergence NN O O
of NN O O
orientals NN O O
and NN O O
caucasians NN O O
and NN O O
suggest NN O O
that NN O O
the NN O O
allele NN O O
has NN O O
spread NN O O
throughout NN O O
the NN O O
orient NN O O
by NN O O
a NN O O
founder NN O O
effect. NN O O
previous NN O O
protein NN O O
polymorphism NN O O
studies NN O O
in NN O O
eastern NN O O
asia NN O O
have NN O O
led NN O O
to NN O O
the NN O O
hypothesis NN O O
that NN O O
" NN O O
northern NN O O
mongoloids NN O O
" NN O O
represented NN O O
a NN O O
founding NN O O
population NN O O
in NN O O
asia. NN O O
our NN O O
results NN O O
are NN O O
compatible NN O O
with NN O O
this NN O O
hypothesis NN O O
in NN O O
that NN O O
the NN O O
PKU NN B-Modifier B-MSH:D010661
mutation NN O O
might NN O O
have NN O O
occurred NN O O
in NN O O
northern NN O O
mongoloids NN O O
and NN O O
subsequently NN O O
spread NN O O
to NN O O
the NN O O
chinese NN O O
and NN O O
japanese NN O O
populations NN O O
. NN O O

late-onset NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
): NN O O
a NN O O
subset NN O O
with NN O O
distinct NN O O
clinical, NN O O
demographic, NN O O
and NN O O
molecular NN O O
genetic NN O O
characteristics NN O O
. NN O O

to NN O O
determine NN O O
the NN O O
prevalence NN O O
and NN O O
characterize NN O O
demographic, NN O O
clinical, NN O O
and NN O O
genetic NN O O
features NN O O
of NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
( NN O O
FMF NN B-SpecificDisease B-MSH:D010505
) NN O O
of NN O O
late NN O O
onset, NN O O
all NN O O
patients NN O O
experiencing NN O O
their NN O O
first NN O O
FMF NN B-Modifier B-MSH:D010505
attack NN O O
at NN O O
age NN O O
40 NN O O
years NN O O
or NN O O
more NN O O
were NN O O
identified NN O O
using NN O O
the NN O O
computerized NN O O
registry NN O O
of NN O O
our NN O O
FMF NN B-Modifier B-MSH:D010505
clinic, NN O O
and NN O O
then NN O O
thoroughly NN O O
interviewed NN O O
and NN O O
examined. NN O O
the NN O O
control NN O O
group NN O O
consisted NN O O
of NN O O
40 NN O O
consecutive NN O O
FMF NN B-Modifier B-MSH:D010505
patients, NN O O
who NN O O
arrived NN O O
at NN O O
the NN O O
FMF NN B-Modifier B-MSH:D010505
clinic NN O O
for NN O O
their NN O O
regular NN O O
follow-up NN O O
visit NN O O
and NN O O
were NN O O
40 NN O O
years NN O O
of NN O O
age NN O O
or NN O O
older NN O O
at NN O O
the NN O O
time NN O O
of NN O O
the NN O O
examination. NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
in NN O O
patients NN O O
and NN O O
controls NN O O
was NN O O
determined NN O O
using NN O O
a NN O O
modified NN O O
score, NN O O
developed NN O O
previously. NN O O
mutational NN O O
analysis NN O O
in NN O O
the NN O O
FMF NN B-Modifier B-MSH:D010505
gene NN O O
was NN O O
performed NN O O
using NN O O
a NN O O
commercial NN O O
kit. NN O O
only NN O O
20 NN O O
of NN O O
4000 NN O O
(0. NN O O
5%) NN O O
patients NN O O
had NN O O
late-onse NN O O
. NN O O

fmf. NN O O
these NN O O
patients NN O O
were NN O O
mostly NN O O
men, NN O O
of NN O O
non-north NN O O
african NN O O
origin, NN O O
p NN O O
< NN O O
0. NN O O
05 NN O O
compared NN O O
to NN O O
controls. NN O O
all NN O O
had NN O O
abdominal NN O O
attacks NN O O
and NN O O
in NN O O
most NN O O
these NN O O
were NN O O
the NN O O
only NN O O
manifestation NN O O
of NN O O
their NN O O
disease, NN O O
p NN O O
< NN O O
0. NN O O
001 NN O O
001. NN O O
none NN O O
had NN O O
chronic NN O O
or NN O O
prolonged NN O O
manifestations NN O O
of NN O O
FMF NN B-SpecificDisease B-MSH:D010505
, NN O O
for NN O O
example, NN O O
amyloidosis NN B-SpecificDisease B-MSH:D000686
, NN O O
chronic NN B-SpecificDisease B-MSH:D001168
arthritis NN I-SpecificDisease I-MSH:D001168
, NN O O
or NN O O
protracted NN O O
myalgia NN B-SpecificDisease B-MSH:D059352
, NN O O
p NN O O
< NN O O
0. NN O O
001. NN O O
the NN O O
response NN O O
to NN O O
treatment NN O O
was NN O O
good NN O O
despite NN O O
using NN O O
low NN O O
colchicine NN O O
dose, NN O O
p NN O O
< NN O O
0. NN O O
05. NN O O
the NN O O
overall NN O O
severity NN O O
score NN O O
indicated NN O O
a NN O O
mild NN O O
disease, NN O O
p NN O O
< NN O O
0. NN O O
001. NN O O
mutational NN O O
analysis NN O O
revealed NN O O
absence NN O O
of NN O O
m NN O O
694 NN O O
v NN O O
homozygosity, NN O O
p NN O O
< NN O O
0. NN O O
01, NN O O
compared NN O O
to NN O O
our NN O O
regular NN O O
FMF NN B-Modifier B-MSH:D010505
population. NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
onset NN O O
of NN O O
FMF NN B-SpecificDisease B-MSH:D010505
in NN O O
a NN O O
lat NN O O
. NN O O

age NN O O
defines NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
disease NN O O
with NN O O
typical NN O O
clinical, NN O O
demographic, NN O O
and NN O O
molecular NN O O
genetic NN O O
characteristic NN O O
. NN O O

structure NN O O
of NN O O
the NN O O
human NN O O
na+/glucose NN O O
cotransporter NN O O
gene NN O O
sglt NN O O
1 NN O O
. NN O O

intestinal NN O O
uptake NN O O
of NN O O
dietary NN O O
glucose NN O O
and NN O O
galactose NN O O
is NN O O
mediated NN O O
by NN O O
the NN O O
sglt NN O O
1 NN O O
na NN O O
+/glucose NN O O
cotransporter NN O O
of NN O O
the NN O O
brush NN O O
border. NN O O
an NN O O
sglt NN O O
1 NN O O
missense NN O O
mutation NN O O
underlies NN O O
hereditary NN B-SpecificDisease B-OMIM:606824
glucose/galactose NN I-SpecificDisease I-OMIM:606824
malabsorption NN I-SpecificDisease I-OMIM:606824
, NN O O
characterized NN O O
by NN O O
potentially NN O O
fatal NN O O
diarrhea NN B-SpecificDisease B-MSH:D003967
; NN O O
conversely, NN O O
oral NN O O
rehydration NN O O
therapy NN O O
exploits NN O O
normal NN O O
transport NN O O
to NN O O
alleviate NN O O
life-threatening NN O O
diarrhea NN B-SpecificDisease B-MSH:D003967
of NN O O
infectious NN O O
origin. NN O O
we NN O O
have NN O O
mapped NN O O
the NN O O
entire NN O O
human NN O O
sglt NN O O
1 NN O O
na NN O O
+/glucose NN O O
cotransporter NN O O
gene NN O O
from NN O O
cosmid NN O O
and NN O O
lambda NN O O
phage NN O O
clones NN O O
representing NN O O
a NN O O
genomic NN O O
region NN O O
of NN O O
112 NN O O
kilobases. NN O O
transcription NN O O
initiation NN O O
occurred NN O O
from NN O O
a NN O O
site NN O O
27 NN O O
base NN O O
pairs NN O O
3 NN O O
of NN O O
a NN O O
tataa NN O O
sequence. NN O O
all NN O O
exon-flanking NN O O
regions NN O O
were NN O O
sequenced, NN O O
and NN O O
the NN O O
entire NN O O
112-kilobase NN O O
region NN O O
mapped NN O O
with NN O O
four NN O O
restriction NN O O
enzymes. NN O O
sglt NN O O
1 NN O O
is NN O O
comprised NN O O
of NN O O
15 NN O O
exons NN O O
(spanning NN O O
72 NN O O
kilobases); NN O O
a NN O O
possible NN O O
evolutionary NN O O
origi NN O O
. NN O O

from NN O O
a NN O O
six-membrane-span NN O O
ancestral NN O O
precursor NN O O
via NN O O
a NN O O
gene NN O O
duplication NN O O
event NN O O
is NN O O
suggested NN O O
from NN O O
comparison NN O O
of NN O O
exons NN O O
against NN O O
protein NN O O
secondary NN O O
structure NN O O
and NN O O
from NN O O
sequence NN O O
considerations. NN O O
a NN O O
new NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
1 NN O O
causing NN O O
glucose/galactose NN B-SpecificDisease B-OMIM:606824
malabsorption NN I-SpecificDisease I-OMIM:606824
is NN O O
also NN O O
described. NN O O
this NN O O
is NN O O
the NN O O
first NN O O
na NN O O
(+) NN O O
-dependent NN O O
cotransporter NN O O
gene NN O O
structure NN O O
reported. NN O O
these NN O O
data NN O O
facilitate NN O O
the NN O O
search NN O O
for NN O O
new NN O O
glucose/galactose NN B-Modifier B-OMIM:606824
malabsorption NN I-Modifier I-OMIM:606824
-related NN O O
mutations NN O O
in NN O O
this NN O O
important NN O O
gene NN O O
and NN O O
provide NN O O
a NN O O
basis NN O O
for NN O O
future NN O O
evolutionary NN O O
comparisons NN O O
with NN O O
other NN O O
na NN O O
(+) NN O O
-dependent NN O O
cotransporters. NN O O
. NN O O

atm NN O O
phosphorylates NN O O
p NN O O
95/nbs NN O O
1 NN O O
in NN O O
an NN O O
s-phase NN O O
checkpoint NN O O
pathway NN O O
. NN O O

the NN O O
rare NN B-DiseaseClass B-MSH:D035583
diseases NN I-DiseaseClass I-MSH:D035583
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
( NN O O
AT NN B-SpecificDisease B-MSH:D001260
), NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
atm NN O O
gene, NN O O
and NN O O
Nijmegen NN B-SpecificDisease B-MSH:D049932
breakage NN I-SpecificDisease I-MSH:D049932
syndrome NN I-SpecificDisease I-MSH:D049932
( NN O O
NBS NN B-SpecificDisease B-MSH:D049932
), NN O O
with NN O O
mutations NN O O
in NN O O
the NN O O
p NN O O
95/nbs NN O O
1 NN O O
gene, NN O O
share NN O O
a NN O O
variety NN O O
of NN O O
phenotypic NN B-DiseaseClass B-MSH:D004194
abnormalities NN I-DiseaseClass I-MSH:D004194
such NN O O
as NN O O
chromosomal NN B-DiseaseClass B-MSH:D043171
instability NN I-DiseaseClass I-MSH:D043171
, NN O O
radiation NN O O
sensitivity NN O O
and NN O O
defects NN O O
in NN O O
cell-cycle NN O O
checkpoints NN O O
in NN O O
response NN O O
to NN O O
ionizing NN O O
radiation. NN O O
the NN O O
atm NN O O
gene NN O O
encodes NN O O
a NN O O
protein NN O O
kinase NN O O
that NN O O
is NN O O
activated NN O O
by NN O O
ionizing NN O O
radiation NN O O
or NN O O
radiomimetic NN O O
drugs, NN O O
whereas NN O O
p NN O O
95/nbs NN O O
1 NN O O
is NN O O
part NN O O
of NN O O
a NN O O
protein NN O O
complex NN O O
that NN O O
is NN O O
involved NN O O
in NN O O
responses NN O O
to NN O O
dna NN O O
double-strand NN O O
breaks. NN O O
here, NN O O
because NN O O
of NN O O
the NN O O
similarities NN O O
between NN O O
AT NN B-SpecificDisease B-MSH:D001260
and NN O O
NBS NN B-SpecificDisease B-MSH:D049932
, NN O O
we NN O O
evaluated NN O O
the NN O O
functional NN O O
interactions NN O O
between NN O O
atm NN O O
and NN O O
p NN O O
95/nbs NN O O
1. NN O O
activation NN O O
of NN O O
the NN O O
atm NN O O
kinase NN O O
by NN O O
ionizing NN O O
radiation NN O O
and NN O O
induction NN O O
o NN O O
. NN O O

atm-dependent NN O O
responses NN O O
in NN O O
NBS NN B-Modifier B-MSH:D049932
cells NN O O
indicated NN O O
that NN O O
p NN O O
95/nbs NN O O
1 NN O O
may NN O O
not NN O O
be NN O O
required NN O O
for NN O O
signalling NN O O
to NN O O
atm NN O O
after NN O O
ionizing NN O O
radiation. NN O O
however, NN O O
p NN O O
95/nbs NN O O
1 NN O O
was NN O O
phosphorylated NN O O
on NN O O
serine NN O O
343 NN O O
in NN O O
an NN O O
atm-dependent NN O O
manner NN O O
in NN O O
vitro NN O O
and NN O O
in NN O O
vivo NN O O
after NN O O
ionizing NN O O
radiation. NN O O
a NN O O
p NN O O
95/nbs NN O O
1 NN O O
construct NN O O
mutated NN O O
at NN O O
the NN O O
atm NN O O
phosphorylation NN O O
site NN O O
abrogated NN O O
an NN O O
s-phase NN O O
checkpoint NN O O
induced NN O O
by NN O O
ionizing NN O O
radiation NN O O
in NN O O
normal NN O O
cells NN O O
and NN O O
failed NN O O
to NN O O
compensate NN O O
for NN O O
this NN O O
functional NN O O
deficiency NN O O
in NN O O
NBS NN B-Modifier B-MSH:D049932
cells. NN O O
these NN O O
observations NN O O
link NN O O
atm NN O O
and NN O O
p NN O O
95/nbs NN O O
1 NN O O
in NN O O
a NN O O
common NN O O
signalling NN O O
pathway NN O O
and NN O O
provide NN O O
an NN O O
explanation NN O O
for NN O O
phenotypic NN O O
similarities NN O O
in NN O O
these NN O O
two NN O O
diseases. NN O O
. NN O O

two NN O O
distinct NN O O
mutations NN O O
at NN O O
a NN O O
single NN O O
bamhi NN O O
site NN O O
in NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
. NN O O

classical NN O O
phenylketonuria NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah). NN O O
the NN O O
abolition NN O O
of NN O O
an NN O O
invariant NN O O
bamhi NN O O
site NN O O
located NN O O
in NN O O
the NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
pah NN O O
gene NN O O
(exon NN O O
7) NN O O
led NN O O
to NN O O
the NN O O
recognition NN O O
of NN O O
two NN O O
new NN O O
point NN O O
mutations NN O O
at NN O O
codon NN O O
272 NN O O
and NN O O
273 NN O O
(272 NN O O
gly----stop NN O O
and NN O O
273 NN O O
ser----phe, NN O O
respectively). NN O O
both NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
north NN O O
eastern NN O O
france NN O O
or NN O O
belgium NN O O
and NN O O
occurred NN O O
on NN O O
the NN O O
background NN O O
of NN O O
rflp NN O O
haplotype NN O O
7 NN O O
alleles. NN O O
the NN O O
present NN O O
study NN O O
supports NN O O
the NN O O
view NN O O
that NN O O
the NN O O
clinical NN O O
heterogeneity NN O O
in NN O O
PKU NN B-SpecificDisease B-MSH:D010661
is NN O O
accounted NN O O
for NN O O
by NN O O
the NN O O
large NN O O
variety NN O O
of NN O O
mutant NN O O
genotypes NN O O
associated NN O O
with NN O O
PAH NN B-SpecificDisease B-OMIM:261600
deficiencies NN I-SpecificDisease I-OMIM:261600
. NN O O
. NN O O

functional NN O O
link NN O O
between NN O O
ataxia-telangiectasia NN B-Modifier B-MSH:D001260
and NN O O
Nijmegen NN B-Modifier B-MSH:D049932
breakage NN I-Modifier I-MSH:D049932
syndrome NN I-Modifier I-MSH:D049932
gene NN O O
products NN O O
. NN O O

ataxia-telangiectasia NN O O
( NN O O
A-T NN B-SpecificDisease B-MSH:D001260
) NN O O
and NN O O
Nijmegen NN B-SpecificDisease B-MSH:D049932
breakage NN I-SpecificDisease I-MSH:D049932
syndrome NN I-SpecificDisease I-MSH:D049932
( NN O O
NBS NN B-SpecificDisease B-MSH:D049932
) NN O O
are NN O O
recessive NN B-DiseaseClass B-MSH:D030342
genetic NN I-DiseaseClass I-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
with NN O O
susceptibility NN O O
to NN O O
cancer NN B-DiseaseClass B-MSH:D009369
and NN O O
similar NN O O
cellular NN O O
phenotypes. NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
A-T NN B-SpecificDisease B-MSH:D001260
, NN O O
designated NN O O
atm, NN O O
is NN O O
a NN O O
member NN O O
of NN O O
a NN O O
family NN O O
of NN O O
kinases NN O O
characterized NN O O
by NN O O
a NN O O
carboxy-terminal NN O O
phosphatidylinositol NN O O
3-kinase-like NN O O
domain. NN O O
the NN O O
nbs NN O O
1 NN O O
protein NN O O
is NN O O
specifically NN O O
mutated NN O O
in NN O O
patients NN O O
with NN O O
Nijmegen NN B-SpecificDisease B-MSH:D049932
breakage NN I-SpecificDisease I-MSH:D049932
syndrome NN I-SpecificDisease I-MSH:D049932
and NN O O
forms NN O O
a NN O O
complex NN O O
with NN O O
the NN O O
dna NN O O
repair NN O O
proteins NN O O
rad NN O O
50 NN O O
and NN O O
mrel NN O O
1. NN O O
here NN O O
we NN O O
show NN O O
that NN O O
phosphorylation NN O O
of NN O O
nbs NN O O
1, NN O O
induced NN O O
by NN O O
ionizing NN O O
radiation, NN O O
requires NN O O
catalytically NN O O
active NN O O
atm. NN O O
complexes NN O O
containing NN O O
atm NN O O
and NN O O
nbs NN O O
1 NN O O
exist NN O O
in NN O O
vivo NN O O
in NN O O
both NN O O
untreated NN O O
cells NN O O
and NN O O
cells NN O O
treated NN O O
with NN O O
ionizing NN O O
radiation. NN O O
we NN O O
have NN O O
identified NN O O
two NN O O
residues NN O O
of NN O O
nbs NN O O
. NN O O

, NN O O
ser NN O O
278 NN O O
and NN O O
ser NN O O
343 NN O O
that NN O O
are NN O O
phosphorylated NN O O
in NN O O
vitro NN O O
by NN O O
atm NN O O
and NN O O
whose NN O O
modification NN O O
in NN O O
vivo NN O O
is NN O O
essential NN O O
for NN O O
the NN O O
cellular NN O O
response NN O O
to NN O O
dna NN O O
damage. NN O O
this NN O O
response NN O O
includes NN O O
s-phase NN O O
checkpoint NN O O
activation, NN O O
formation NN O O
of NN O O
the NN O O
nbs NN O O
1/mrel NN O O
1/rad NN O O
50 NN O O
nuclear NN O O
foci NN O O
and NN O O
rescue NN O O
of NN O O
hypersensitivity NN B-DiseaseClass B-MSH:D004194
to NN I-DiseaseClass I-MSH:D004194
ionizing NN I-DiseaseClass I-MSH:D004194
radiation NN I-DiseaseClass I-MSH:D004194
. NN O O
together, NN O O
these NN O O
results NN O O
demonstrate NN O O
a NN O O
biochemical NN O O
link NN O O
between NN O O
cell-cycle NN O O
checkpoints NN O O
activated NN O O
by NN O O
dna NN O O
damage NN O O
and NN O O
dna NN O O
repair NN O O
in NN O O
two NN O O
genetic NN B-DiseaseClass B-MSH:D030342
diseases NN I-DiseaseClass I-MSH:D030342
with NN O O
overlapping NN O O
phenotypes. NN O O
. NN O O

structure NN O O
and NN O O
genomic NN O O
sequence NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
( NN O O
DM NN B-Modifier B-MSH:D009223
kinase) NN O O
gene NN O O
. NN O O

the NN O O
mutation NN O O
causing NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
has NN O O
recently NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
unstable NN O O
ctg NN O O
trinucleotide NN O O
repeat NN O O
located NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
a NN O O
gene NN O O
encoding NN O O
for NN O O
a NN O O
protein NN O O
with NN O O
putative NN O O
serine-threonine NN O O
protein NN O O
kinase NN O O
activity. NN O O
in NN O O
this NN O O
report NN O O
we NN O O
present NN O O
the NN O O
genomic NN O O
sequences NN O O
of NN O O
the NN O O
human NN O O
and NN O O
murine NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
gene. NN O O
a NN O O
comparison NN O O
of NN O O
these NN O O
sequences NN O O
with NN O O
each NN O O
other NN O O
and NN O O
with NN O O
known NN O O
cdna NN O O
sequences NN O O
from NN O O
both NN O O
species, NN O O
led NN O O
us NN O O
to NN O O
predict NN O O
a NN O O
translation NN O O
initiation NN O O
codon, NN O O
as NN O O
well NN O O
as NN O O
determine NN O O
the NN O O
organization NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
gene. NN O O
several NN O O
polymorphisms NN O O
within NN O O
the NN O O
human NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
gene NN O O
have NN O O
been NN O O
identified, NN O O
and NN O O
pcr NN O O
assays NN O O
to NN O O
detect NN O O
two NN O O
of NN O O
these NN O O
are NN O O
described. NN O O
the NN O O
complete NN O O
sequence NN O O
and NN O O
characterization NN O O
of NN O O
the NN O O
structure NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
gene, NN O O
as NN O O
well NN O O
as NN O O
the NN O O
identification NN O O
of NN O O
novel NN O O
polymorphism NN O O
. NN O O

within NN O O
the NN O O
gene, NN O O
represent NN O O
an NN O O
important NN O O
step NN O O
in NN O O
a NN O O
further NN O O
understanding NN O O
of NN O O
the NN O O
genetics NN O O
of NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
and NN O O
the NN O O
molecular NN O O
biology NN O O
of NN O O
the NN O O
gene. NN O O
. NN O O

identification NN O O
of NN O O
novel NN O O
imprinted NN O O
transcripts NN O O
in NN O O
the NN O O
Prader-Willi NN B-Modifier B-MSH:D011218
syndrome NN I-Modifier I-MSH:D011218
and NN O O
Angelman NN B-Modifier B-MSH:D017204
syndrome NN I-Modifier I-MSH:D017204
deletion NN O O
region: NN O O
further NN O O
evidence NN O O
for NN O O
regional NN O O
imprinting NN O O
control NN O O
. NN O O

deletions NN O O
and NN O O
other NN O O
abnormalities NN O O
of NN O O
human NN O O
chromosome NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
are NN O O
associated NN O O
with NN O O
two NN O O
developmental NN O O
disorders, NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
and NN O O
Angelman NN B-SpecificDisease B-MSH:D017204
syndrome NN I-SpecificDisease I-MSH:D017204
( NN O O
AS NN B-SpecificDisease B-MSH:D017204
). NN O O
loss NN O O
of NN O O
expression NN O O
of NN O O
imprinted, NN O O
paternally NN O O
expressed NN O O
genes NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
however, NN O O
the NN O O
number NN O O
of NN O O
imprinted NN O O
genes NN O O
that NN O O
contribute NN O O
to NN O O
PWS NN B-SpecificDisease B-MSH:D011218
, NN O O
and NN O O
the NN O O
range NN O O
over NN O O
which NN O O
the NN O O
imprinting NN O O
signal NN O O
acts NN O O
to NN O O
silence NN O O
one NN O O
copy NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
a NN O O
parent-of-origin-specific NN O O
manner, NN O O
are NN O O
unknown. NN O O
to NN O O
identify NN O O
additional NN O O
imprinted NN O O
genes NN O O
that NN O O
could NN O O
contribute NN O O
to NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
phenotype NN O O
and NN O O
to NN O O
understand NN O O
the NN O O
regional NN O O
control NN O O
of NN O O
imprinting NN O O
in NN O O
15 NN O O
q NN O O
11-q NN O O
13, NN O O
we NN O O
have NN O O
constructed NN O O
an NN O O
imprinted NN O O
transcript NN O O
map NN O O
of NN O O
the NN O O
pws-as NN O O
deletion NN O O
interval. NN O O
the NN O O
imprinting NN O O
status NN O O
of NN O O
22 NN O O
expresse NN O O
. NN O O

sequence NN O O
tags NN O O
derived NN O O
from NN O O
the NN O O
radiation-hybrid NN O O
human NN O O
transcript NN O O
maps NN O O
or NN O O
physical NN O O
maps NN O O
was NN O O
determined NN O O
in NN O O
a NN O O
reverse NN O O
transcriptase-pcr NN O O
assay NN O O
and NN O O
correlated NN O O
with NN O O
the NN O O
position NN O O
of NN O O
the NN O O
transcripts NN O O
on NN O O
the NN O O
physical NN O O
map. NN O O
seven NN O O
new NN O O
paternally NN O O
expressed NN O O
transcripts NN O O
localize NN O O
to NN O O
an NN O O
approximately NN O O
1. NN O O
5-mb NN O O
domain NN O O
surrounding NN O O
the NN O O
snrpn-associated NN O O
imprinting NN O O
center, NN O O
which NN O O
already NN O O
includes NN O O
four NN O O
imprinted, NN O O
paternally NN O O
expressed NN O O
genes. NN O O
all NN O O
other NN O O
tested NN O O
new NN O O
transcripts NN O O
in NN O O
the NN O O
deletion NN O O
region NN O O
were NN O O
expressed NN O O
from NN O O
both NN O O
alleles. NN O O
a NN O O
domain NN O O
of NN O O
exclusive NN O O
paternal NN O O
expression NN O O
surrounding NN O O
the NN O O
imprinting NN O O
center NN O O
suggests NN O O
strong NN O O
regional NN O O
control NN O O
of NN O O
the NN O O
imprinting NN O O
process. NN O O
this NN O O
study NN O O
provides NN O O
the NN O O
means NN O O
for NN O O
further NN O O
investigation NN O O
of NN O O
additional NN O O
genes NN O O
that NN O O
cause NN O O
or NN O O
modify NN O O
the NN O O
phenotypes NN O O
associated NN O O
with NN O O
rearrangements NN O O
of NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
. NN O O
paternal NN O O
expression NN O O
surrounding NN O O
the NN O O
imprinting NN O O
center NN O O
suggests NN O O
strong NN O O
regional NN O O
control NN O O
of NN O O
the NN O O
imprinting NN O O
process. NN O O
this NN O O
study NN O O
provides NN O O
the NN O O
means NN O O
for NN O O
further NN O O
investigation NN O O
of NN O O
additional NN O O
genes NN O O
that NN O O
cause NN O O
or NN O O
modify NN O O
the NN O O
phenotypes NN O O
associated NN O O
with NN O O
rearrangements NN O O
of NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
. NN O O

penetrances NN O O
of NN O O
brca NN O O
1 NN O O
1675 NN O O
dela NN O O
and NN O O
1135 NN O O
insa NN O O
with NN O O
respect NN O O
to NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
and NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
. NN O O

for NN O O
genetic NN O O
counseling NN O O
and NN O O
predictive NN O O
testing NN O O
in NN O O
families NN O O
with NN O O
inherited NN B-CompositeMention B-MSH:D061325
breast-ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
, NN O O
penetrances NN O O
and NN O O
expressions NN O O
of NN O O
the NN O O
underlying NN O O
mutations NN O O
should NN O O
be NN O O
known. NN O O
we NN O O
have NN O O
previously NN O O
reported NN O O
two NN O O
brca NN O O
1 NN O O
founder NN O O
mutations NN O O
in NN O O
the NN O O
norwegian NN O O
population. NN O O
index NN O O
cases NN O O
for NN O O
the NN O O
present NN O O
study NN O O
were NN O O
found NN O O
two NN O O
different NN O O
ways NN O O
through NN O O
a NN O O
series NN O O
of NN O O
consecutive NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
(n NN O O
= NN O O
16) NN O O
and NN O O
through NN O O
our NN O O
family NN O O
cancer NN B-Modifier B-MSH:D009369
clinic NN O O
(n NN O O
= NN O O
14). NN O O
altogether, NN O O
20 NN O O
of NN O O
the NN O O
patients NN O O
had NN O O
brca NN O O
1 NN O O
1675 NN O O
dela, NN O O
and NN O O
10 NN O O
had NN O O
1135 NN O O
insa. NN O O
their NN O O
relatives NN O O
were NN O O
described NN O O
with NN O O
respect NN O O
to NN O O
absence/presence NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D001943
and/or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
. NN O O
of NN O O
133 NN O O
living NN O O
female NN O O
relatives, NN O O
83 NN O O
(62%) NN O O
were NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
mutation. NN O O
no NN O O
difference, NN O O
in NN O O
penetrance NN O O
and NN O O
expression, NN O O
betwee NN O O
. NN O O

the NN O O
two NN O O
mutations NN O O
were NN O O
found, NN O O
whereas NN O O
differences NN O O
according NN O O
to NN O O
method NN O O
of NN O O
ascertainment NN O O
were NN O O
seen. NN O O
the NN O O
overall NN O O
findings NN O O
were NN O O
that NN O O
disease NN O O
started NN O O
to NN O O
occur NN O O
at NN O O
age NN O O
30 NN O O
years NN O O
and NN O O
that NN O O
by NN O O
age NN O O
50 NN O O
years NN O O
48% NN O O
of NN O O
the NN O O
mutation-carrying NN O O
women NN O O
had NN O O
experienced NN O O
breast NN B-CompositeMention B-MSH:D001943
and/or NN I-CompositeMention I-MSH:D001943
ovarian NN I-CompositeMention I-MSH:D001943
cancer NN I-CompositeMention I-MSH:D001943
. NN O O
more NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
than NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancers NN I-SpecificDisease I-MSH:D001943
were NN O O
recorded. NN O O
both NN O O
penetrance NN O O
and NN O O
expression NN O O
( NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
vs. NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
) NN O O
were NN O O
different NN O O
from NN O O
those NN O O
in NN O O
reports NN O O
of NN O O
the NN O O
ashkenazi NN O O
founder NN O O
mutations. NN O O
whether NN O O
the NN O O
reported NN O O
differences NN O O
reflect NN O O
true NN O O
differences NN O O
and/or NN O O
methodological NN O O
problems NN O O
is NN O O
discussed. NN O O
an NN O O
observed NN O O
excess NN O O
of NN O O
mutation NN O O
carriers NN O O
could NN O O
not NN O O
be NN O O
accounted NN O O
for NN O O
by NN O O
methodological NN O O
problems; NN O O
possible NN O O
explanations NN O O
were NN O O
a NN O O
" NN O O
true NN O O
" NN O O
low NN O O
penetrance NN O O
or NN O O
preferential NN O O
segregation. NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
subtotal NN B-SpecificDisease B-OMIM:612446
complement NN I-SpecificDisease I-OMIM:612446
C6 NN I-SpecificDisease I-OMIM:612446
deficiency NN I-SpecificDisease I-OMIM:612446
. NN O O
a NN O O
carboxy-terminally NN O O
truncated NN O O
but NN O O
functionally NN O O
active NN O O
c NN O O
6 NN O O
. NN O O

individuals NN O O
with NN O O
subtotal NN B-SpecificDisease B-OMIM:612446
complement NN I-SpecificDisease I-OMIM:612446
C6 NN I-SpecificDisease I-OMIM:612446
deficiency NN I-SpecificDisease I-OMIM:612446
possess NN O O
a NN O O
c NN O O
6 NN O O
molecule NN O O
that NN O O
is NN O O
14% NN O O
shorter NN O O
than NN O O
normal NN O O
c NN O O
6 NN O O
and NN O O
present NN O O
in NN O O
low NN O O
but NN O O
detectable NN O O
concentrations NN O O
(1-2% NN O O
of NN O O
the NN O O
normal NN O O
mean). NN O O
we NN O O
now NN O O
show NN O O
that NN O O
this NN O O
dysmorphic NN O O
c NN O O
6 NN O O
is NN O O
bactericidally NN O O
active NN O O
and NN O O
lacks NN O O
an NN O O
epitope NN O O
that NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
most NN O O
carboxy-terminal NN O O
part NN O O
of NN O O
c NN O O
6 NN O O
using NN O O
c NN O O
6 NN O O
cdna NN O O
fragments NN O O
expressed NN O O
as NN O O
fusion NN O O
proteins NN O O
in NN O O
the NN O O
puex NN O O
expression NN O O
system. NN O O
we NN O O
thus NN O O
predicted NN O O
that NN O O
the NN O O
abnormal NN O O
c NN O O
6 NN O O
molecule NN O O
might NN O O
be NN O O
carboxy-terminally NN O O
truncated NN O O
and NN O O
sought NN O O
a NN O O
mutation NN O O
in NN O O
an NN O O
area NN O O
approximately NN O O
14% NN O O
from NN O O
the NN O O
carboxy-terminal NN O O
end NN O O
of NN O O
the NN O O
coding NN O O
sequence. NN O O
by NN O O
sequencing NN O O
pcr-amplified NN O O
products NN O O
from NN O O
this NN O O
region, NN O O
we NN O O
found, NN O O
in NN O O
three NN O O
individuals NN O O
from NN O O
two NN O O
families, NN O O
a NN O O
mutatio NN O O
. NN O O

that NN O O
might NN O O
plausibly NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
defect. NN O O
all NN O O
three NN O O
have NN O O
an NN O O
abnormal NN O O
5 NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
15, NN O O
which NN O O
would NN O O
probably NN O O
prevent NN O O
splicing. NN O O
an NN O O
in-frame NN O O
stop NN O O
codon NN O O
is NN O O
found NN O O
17 NN O O
codons NN O O
downstream NN O O
from NN O O
the NN O O
intron NN O O
boundary, NN O O
which NN O O
would NN O O
lead NN O O
to NN O O
a NN O O
truncated NN O O
polypeptide NN O O
13. NN O O
5% NN O O
smaller NN O O
than NN O O
normal NN O O
c NN O O
6. NN O O
this NN O O
result NN O O
was NN O O
unexpected, NN O O
as NN O O
earlier NN O O
studies NN O O
mapped NN O O
the NN O O
c NN O O
5 NN O O
b NN O O
binding NN O O
site, NN O O
or NN O O
a NN O O
putative NN O O
enzymatic NN O O
region, NN O O
to NN O O
this NN O O
part NN O O
of NN O O
c NN O O
6. NN O O
interestingly, NN O O
all NN O O
three NN O O
subjects NN O O
were NN O O
probably NN O O
heterozygous NN O O
for NN O O
both NN O O
subtotal NN B-CompositeMention B-OMIM:612446
C6 NN I-CompositeMention I-OMIM:612446
and NN I-CompositeMention I-OMIM:612446
complete NN I-CompositeMention I-OMIM:612446
C6 NN I-CompositeMention I-OMIM:612446
deficiency NN I-CompositeMention I-OMIM:612446
. NN O O

mutations NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
in NN O O
sporadic NN B-SpecificDisease B-MSH:D002292
renal NN I-SpecificDisease I-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
: NN O O
definition NN O O
of NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
VHL NN B-Modifier B-MSH:D006623
patients NN O O
to NN O O
develop NN O O
an NN O O
RCC NN B-SpecificDisease B-MSH:D002292
. NN O O

to NN O O
investigate NN O O
the NN O O
nature NN O O
of NN O O
somatic NN O O
von NN B-Modifier B-MSH:D006623
Hippel-Lindau NN I-Modifier I-MSH:D006623
( NN O O
VHL NN B-Modifier B-MSH:D006623
) NN O O
mutations, NN O O
we NN O O
analyzed NN O O
173 NN O O
primary NN O O
sporadic NN O O
human NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinomas NN I-SpecificDisease I-MSH:D002292
for NN O O
mutations NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
tumor NN I-Modifier I-MSH:D006623
suppressor NN O O
gene, NN O O
using NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
and NN O O
single-strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
(sscp) NN O O
of NN O O
dna. NN O O
we NN O O
detected NN O O
abnormal NN O O
sscp NN O O
pattern NN O O
in NN O O
73 NN O O
samples. NN O O
after NN O O
sequencing, NN O O
we NN O O
identified NN O O
microdeletions NN O O
in NN O O
58% NN O O
of NN O O
cases, NN O O
microinsertions NN O O
in NN O O
17%, NN O O
nonsense NN O O
mutations NN O O
in NN O O
8%, NN O O
and NN O O
missense NN O O
mutations NN O O
in NN O O
17%. NN O O
among NN O O
these NN O O
mutations, NN O O
50% NN O O
correspond NN O O
to NN O O
new NN O O
mutations. NN O O
VHL NN B-Modifier B-MSH:D006623
mutations NN O O
were NN O O
found NN O O
only NN O O
in NN O O
the NN O O
nonpapillary NN B-Modifier B-MSH:D002292
renal NN I-Modifier I-MSH:D002292
cell NN I-Modifier I-MSH:D002292
carcinoma NN I-Modifier I-MSH:D002292
( NN O O
RCC NN B-Modifier B-MSH:D002292
) NN O O
subtype, NN O O
as NN O O
previously NN O O
reported. NN O O
to NN O O
compare NN O O
somatic NN O O
and NN O O
germline NN O O
mutations, NN O O
we NN O O
used NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
database, NN O O
which NN O O
includes NN O O
507 NN O O
mutation NN O O
. NN O O

. NN O O
the NN O O
study NN O O
of NN O O
mutational NN O O
events NN O O
revealed NN O O
a NN O O
significant NN O O
difference NN O O
between NN O O
somatic NN O O
and NN O O
germline NN O O
mutations NN O O
with NN O O
mutations NN O O
leading NN O O
to NN O O
truncated NN O O
proteins NN O O
observed NN O O
in NN O O
78% NN O O
of NN O O
somatic NN O O
mutations NN O O
vs NN O O
only NN O O
37% NN O O
in NN O O
germline NN O O
mutations NN O O
(p NN O O
< NN O O
0. NN O O
001). NN O O
we NN O O
postulated NN O O
that NN O O
a NN O O
specific NN O O
pattern NN O O
of NN O O
VHL NN B-Modifier B-MSH:D006623
mutations NN O O
is NN O O
associated NN O O
with NN O O
sporadic NN B-SpecificDisease B-MSH:D002292
RCC NN I-SpecificDisease I-MSH:D002292
. NN O O
this NN O O
pattern NN O O
corresponds NN O O
to NN O O
mutations NN O O
leading NN O O
mainly NN O O
to NN O O
truncated NN O O
proteins NN O O
with NN O O
few NN O O
specific NN O O
missense NN O O
mutations. NN O O
we NN O O
then NN O O
analyzed NN O O
the NN O O
occurrence NN O O
of NN O O
RCC NN B-SpecificDisease B-MSH:D002292
in NN O O
VHL NN B-Modifier B-MSH:D006623
families, NN O O
based NN O O
on NN O O
the NN O O
nature NN O O
of NN O O
mutations. NN O O
we NN O O
observed NN O O
RCC NN B-SpecificDisease B-MSH:D002292
in NN O O
at NN O O
least NN O O
one NN O O
member NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
families NN O O
in NN O O
77% NN O O
of NN O O
cases NN O O
with NN O O
mutations NN O O
leading NN O O
to NN O O
truncated NN O O
proteins NN O O
versus NN O O
55% NN O O
in NN O O
cases NN O O
with NN O O
missense NN O O
mutations NN O O
(p NN O O
< NN O O
0. NN O O
05). NN O O
thus, NN O O
mutations NN O O
resulting NN O O
in NN O O
truncated NN O O
proteins NN O O
may NN O O
lea NN O O
. NN O O

to NN O O
a NN O O
higher NN O O
risk NN O O
of NN O O
RCC NN B-SpecificDisease B-MSH:D002292
in NN O O
VHL NN B-Modifier B-MSH:D006623
patient NN O O
. NN O O

myotonic NN O O
dystrophy: NN O O
the NN O O
role NN O O
of NN O O
the NN O O
cug NN O O
triplet NN O O
repeats NN O O
in NN O O
splicing NN O O
of NN O O
a NN O O
novel NN O O
dmpk NN O O
exon NN O O
and NN O O
altered NN O O
cytoplasmic NN O O
dmpk NN O O
mrna NN O O
isoform NN O O
ratios NN O O
. NN O O
f NN O O
the NN O O
cug NN O O
triplet NN O O
repeats NN O O
in NN O O
splicing NN O O
of NN O O
a NN O O
novel NN O O
dmpk NN O O
exon NN O O
and NN O O
altered NN O O
cytoplasmic NN O O
dmpk NN O O
mrna NN O O
isoform NN O O
ratios NN O O
. NN O O

the NN O O
mechanism NN O O
by NN O O
which NN O O
(ctg) NN O O
n NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
utr NN O O
of NN O O
the NN O O
dmpk NN O O
gene NN O O
causes NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
unknown. NN O O
we NN O O
identified NN O O
four NN O O
rna NN O O
splicing NN O O
factors--hnrnp NN O O
c, NN O O
u NN O O
2 NN O O
af NN O O
(u NN O O
2 NN O O
auxiliary NN O O
factor), NN O O
ptb NN O O
(polypyrimidine NN O O
tract NN O O
binding NN O O
protein), NN O O
and NN O O
psf NN O O
(ptb NN O O
associated NN O O
splicing NN O O
factor) NN O O
--that NN O O
bind NN O O
to NN O O
two NN O O
short NN O O
regions NN O O
3 NN O O
of NN O O
the NN O O
(cug) NN O O
n, NN O O
and NN O O
found NN O O
a NN O O
novel NN O O
3 NN O O
dmpk NN O O
exon NN O O
resulting NN O O
in NN O O
an NN O O
mrna NN O O
lacking NN O O
the NN O O
repeats. NN O O
we NN O O
propose NN O O
that NN O O
the NN O O
(cug) NN O O
n NN O O
is NN O O
an NN O O
essential NN O O
cis NN O O
acting NN O O
element NN O O
for NN O O
this NN O O
splicing NN O O
event. NN O O
in NN O O
contrast NN O O
to NN O O
(cug) NN O O
n NN O O
containing NN O O
mrnas, NN O O
the NN O O
novel NN O O
isoform NN O O
is NN O O
not NN O O
retained NN O O
in NN O O
the NN O O
nucleus NN O O
in NN O O
DM NN B-Modifier B-MSH:D009223
cells, NN O O
resulting NN O O
in NN O O
imbalances NN O O
i NN O O
. NN O O

relative NN O O
levels NN O O
of NN O O
cytoplasmic NN O O
dmpk NN O O
mrna NN O O
isoforms NN O O
and NN O O
a NN O O
new NN O O
dominant NN O O
effect NN O O
of NN O O
the NN O O
mutation NN O O
on NN O O
dmpk. NN O O
. NN O O

mechanism NN O O
of NN O O
increased NN O O
iron NN O O
absorption NN O O
in NN O O
murine NN O O
model NN O O
of NN O O
hereditary NN B-SpecificDisease B-MSH:D006432
hemochromatosis NN I-SpecificDisease I-MSH:D006432
: NN O O
increased NN O O
duodenal NN O O
expression NN O O
of NN O O
the NN O O
iron NN O O
transporter NN O O
dmt NN O O
1 NN O O
. NN O O

hereditary NN O O
hemochromatosis NN O O
( NN O O
HH NN B-SpecificDisease B-MSH:D006432
) NN O O
is NN O O
a NN O O
common NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
tissue NN O O
iron NN O O
deposition NN O O
secondary NN O O
to NN O O
excessive NN O O
dietary NN O O
iron NN O O
absorption. NN O O
we NN O O
recently NN O O
reported NN O O
that NN O O
hfe, NN O O
the NN O O
protein NN O O
defective NN O O
in NN O O
HH NN B-SpecificDisease B-MSH:D006432
, NN O O
was NN O O
physically NN O O
associated NN O O
with NN O O
the NN O O
transferrin NN O O
receptor NN O O
(tfr) NN O O
in NN O O
duodenal NN O O
crypt NN O O
cells NN O O
and NN O O
proposed NN O O
that NN O O
mutations NN O O
in NN O O
hfe NN O O
attenuate NN O O
the NN O O
uptake NN O O
of NN O O
transferrin-bound NN O O
iron NN O O
from NN O O
plasma NN O O
by NN O O
duodenal NN O O
crypt NN O O
cells, NN O O
leading NN O O
to NN O O
up-regulation NN O O
of NN O O
transporters NN O O
for NN O O
dietary NN O O
iron. NN O O
here, NN O O
we NN O O
tested NN O O
the NN O O
hypothesis NN O O
that NN O O
hfe-/- NN O O
mice NN O O
have NN O O
increased NN O O
duodenal NN O O
expression NN O O
of NN O O
the NN O O
divalent NN O O
metal NN O O
transporter NN O O
(dmt NN O O
1). NN O O
by NN O O
4 NN O O
weeks NN O O
of NN O O
age, NN O O
the NN O O
hfe-/- NN O O
mice NN O O
demonstrated NN O O
iron NN O O
loading NN O O
when NN O O
compared NN O O
with NN O O
hfe NN O O
+/+ NN O O
littermates, NN O O
with NN O O
elevated NN O O
transferrin NN O O
saturations NN O O
(68. NN O O
4 NN O O
. NN O O

vs. NN O O
49. NN O O
8%) NN O O
and NN O O
elevated NN O O
liver NN O O
iron NN O O
concentrations NN O O
(985 NN O O
micrograms NN O O
vs. NN O O
381 NN O O
micrograms). NN O O
by NN O O
using NN O O
northern NN O O
blot NN O O
analyses, NN O O
we NN O O
quantitated NN O O
duodenal NN O O
expression NN O O
of NN O O
both NN O O
classes NN O O
of NN O O
dmt NN O O
1 NN O O
transcripts NN O O
one NN O O
containing NN O O
an NN O O
iron NN O O
responsive NN O O
element NN O O
(ire), NN O O
called NN O O
dmt NN O O
1 NN O O
(ire), NN O O
and NN O O
one NN O O
containing NN O O
no NN O O
ire, NN O O
called NN O O
dmt NN O O
1 NN O O
(non-ire). NN O O
the NN O O
positive NN O O
control NN O O
for NN O O
dmt NN O O
1 NN O O
up-regulation NN O O
was NN O O
a NN O O
murine NN O O
model NN O O
of NN O O
dietary NN B-SpecificDisease B-MSH:D018798
iron NN I-SpecificDisease I-MSH:D018798
deficiency NN I-SpecificDisease I-MSH:D018798
that NN O O
demonstrated NN O O
greatly NN O O
increased NN O O
levels NN O O
of NN O O
duodenal NN O O
dmt NN O O
1 NN O O
(ire) NN O O
mrna. NN O O
hfe-/- NN O O
mice NN O O
also NN O O
demonstrated NN O O
an NN O O
increase NN O O
in NN O O
duodenal NN O O
dmt NN O O
1 NN O O
(ire) NN O O
mrna NN O O
(average NN O O
7. NN O O
7-fold), NN O O
despite NN O O
their NN O O
elevated NN O O
transferrin NN O O
saturation NN O O
and NN O O
hepatic NN O O
iron NN O O
content. NN O O
duodenal NN O O
expression NN O O
o NN O O
. NN O O

dmt NN O O
1 NN O O
(non-ire) NN O O
was NN O O
not NN O O
increased, NN O O
nor NN O O
was NN O O
hepatic NN O O
expression NN O O
of NN O O
dmt NN O O
1 NN O O
increased. NN O O
these NN O O
data NN O O
support NN O O
the NN O O
model NN O O
for NN O O
hh NN O O
in NN O O
which NN O O
hfe NN O O
mutations NN O O
lead NN O O
to NN O O
inappropriately NN O O
low NN O O
crypt NN O O
cell NN O O
iron, NN O O
with NN O O
resultant NN O O
stabilization NN O O
of NN O O
dmt NN O O
1 NN O O
(ire) NN O O
mrna, NN O O
up-regulation NN O O
of NN O O
dmt NN O O
1, NN O O
and NN O O
increased NN O O
absorption NN O O
of NN O O
dietary NN O O
iron NN O O
. NN O O

yeast NN O O
artificial NN O O
chromosomes NN O O
for NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
familial NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
APC NN I-Modifier I-MSH:D011125
gene NN O O
region NN O O
. NN O O

two NN O O
yeast NN O O
artificial NN O O
chromosomes NN O O
(yacs) NN O O
spanning NN O O
a NN O O
total NN O O
distance NN O O
of NN O O
1. NN O O
1 NN O O
megabase NN O O
pairs NN O O
of NN O O
dna NN O O
around NN O O
the NN O O
mcc NN O O
(for NN O O
mutated NN O O
in NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
carcinoma NN I-SpecificDisease I-MSH:D015179
) NN O O
and NN O O
APC NN B-Modifier B-MSH:D011125
(for NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
) NN O O
genes NN O O
at NN O O
5 NN O O
q NN O O
21 NN O O
have NN O O
been NN O O
isolated NN O O
and NN O O
characterized. NN O O
starting NN O O
from NN O O
the NN O O
mcc NN O O
gene, NN O O
a NN O O
strategy NN O O
was NN O O
undertaken NN O O
to NN O O
identify NN O O
constitutional NN O O
submicroscopic NN O O
deletions NN O O
in NN O O
familial NN B-Modifier B-MSH:D011125
adenomatous NN I-Modifier I-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
patients NN O O
that NN O O
might NN O O
considerably NN O O
narrow NN O O
down NN O O
the NN O O
position NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene. NN O O
to NN O O
this NN O O
end, NN O O
yacs NN O O
identified NN O O
by NN O O
the NN O O
mcc NN O O
gene NN O O
were NN O O
screened NN O O
across NN O O
a NN O O
chromosome NN O O
5-specific NN O O
cosmid NN O O
library NN O O
to NN O O
provide NN O O
a NN O O
source NN O O
of NN O O
dna NN O O
probes NN O O
for NN O O
genomic NN O O
scanning. NN O O
the NN O O
cosmids NN O O
isolated NN O O
from NN O O
these NN O O
experiments NN O O
were NN O O
used NN O O
to NN O O
screen NN O O
a NN O O
panel NN O O
of NN O O
somatic NN O O
cell NN O O
hybrids NN O O
containing NN O O
chromosome NN O O
5 NN O O
segregated NN O O
from NN O O
patients NN O O
suspected NN O O
to NN O O
carry NN O O
putative NN O O
interstitial NN O O
deletions NN O O
. NN O O

this NN O O
screening NN O O
approach NN O O
led NN O O
to NN O O
the NN O O
confirmation NN O O
of NN O O
a NN O O
small NN O O
heterozygous NN O O
deletion NN O O
in NN O O
a NN O O
polyposis NN B-Modifier B-MSH:D011125
patient NN O O
that NN O O
overlaps NN O O
one NN O O
of NN O O
the NN O O
two NN O O
isolated NN O O
yacs. NN O O
this NN O O
yac NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
contain NN O O
the NN O O
entire NN O O
APC NN B-Modifier B-MSH:D011125
gene, NN O O
in NN O O
addition NN O O
to NN O O
a NN O O
significant NN O O
portion NN O O
of NN O O
dna NN O O
flanking NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
gene, NN O O
and NN O O
should NN O O
therefore NN O O
prove NN O O
a NN O O
valuable NN O O
resource NN O O
for NN O O
functional NN O O
studies NN O O
by NN O O
transfer NN O O
to NN O O
colorectal NN B-Modifier B-MSH:D015179
tumor NN I-Modifier I-MSH:D015179
-derived NN O O
cell NN O O
lines NN O O
. NN O O

analbuminemia NN O O
in NN O O
an NN O O
american NN O O
indian NN O O
girl NN O O
. NN O O

analbuminemia NN O O
was NN O O
fortuitously NN O O
detected NN O O
in NN O O
a NN O O
nonedematous NN O O
12-year-old NN O O
american NN O O
indian NN O O
girl NN O O
with NN O O
atopic NN B-SpecificDisease B-MSH:D003876
dermatitis NN I-SpecificDisease I-MSH:D003876
, NN O O
mild NN O O
bronchial NN B-SpecificDisease B-MSH:D001249
asthma NN I-SpecificDisease I-MSH:D001249
, NN O O
a NN O O
mild NN O O
seizure NN B-SpecificDisease B-MSH:D004827
disorder NN I-SpecificDisease I-MSH:D004827
, NN O O
and NN O O
hyperlipoproteinemia NN B-SpecificDisease B-MSH:D006951
with NN O O
a NN O O
corneal NN B-SpecificDisease B-MSH:D001112
arcus NN I-SpecificDisease I-MSH:D001112
. NN O O
immunologic NN O O
methods NN O O
revealed NN O O
trace NN O O
amounts NN O O
(17 NN O O
mg/100 NN O O
ml) NN O O
of NN O O
apparently NN O O
normal NN O O
serum NN O O
albumin. NN O O
the NN O O
patients NN O O
parents NN O O
were NN O O
remotely NN O O
related. NN O O
the NN O O
pedigree NN O O
and NN O O
clinical NN O O
findings NN O O
were NN O O
compatible NN O O
with NN O O
autosomal NN O O
recessive NN O O
transmission NN O O
of NN O O
analbuminemia NN B-SpecificDisease B-OMIM:103600
. NN O O
heterozygotes NN O O
had NN O O
subnormal NN O O
levels NN O O
of NN O O
serum NN O O
albumin. NN O O
the NN O O
gc-locus NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
structural NN O O
albumin NN O O
locus. NN O O
gc-protein NN O O
levels NN O O
were NN O O
normal NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
together NN O O
with NN O O
normal NN O O
chromosomal NN O O
banding NN O O
studies NN O O
make NN O O
it NN O O
unlikely NN O O
that NN O O
a NN O O
chromosomal NN O O
deletion NN O O
caused NN O O
analbuminemia NN B-SpecificDisease B-OMIM:103600
. NN O O
gc-types NN O O
in NN O O
the NN O O
family NN O O
were NN O O
compatible NN O O
with, NN O O
but NN O O
did NN O O
not NN O O
prove, NN O O
linkage NN O O
of NN O O
analbuminemia NN B-SpecificDisease B-OMIM:103600
t NN O O
. NN O O

the NN O O
gc-locus. NN O O
these NN O O
findings NN O O
suggest NN O O
a NN O O
" NN O O
thalassemia NN B-Modifier B-MSH:D013789
" NN O O
-like NN O O
mutation NN O O
for NN O O
this NN O O
disorder. NN O O
. NN O O

treatment NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
with NN O O
growth NN O O
hormone NN O O
inhibitors NN O O
. NN O O

a NN O O
controlled, NN O O
double-blind NN O O
therapeutic NN O O
trial NN O O
with NN O O
the NN O O
drug NN O O
mazindol, NN O O
a NN O O
growth NN O O
hormone NN O O
inhibitor, NN O O
was NN O O
performed NN O O
in NN O O
a NN O O
pair NN O O
of NN O O
7 NN O O
1/2 NN O O
year-old NN O O
monozygotic NN O O
twins, NN O O
with NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
the NN O O
rationale NN O O
for NN O O
this NN O O
trial NN O O
was NN O O
based NN O O
on NN O O
a NN O O
patient NN O O
(reported NN O O
previously) NN O O
affected NN O O
simultaneously NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
and NN O O
growth NN B-SpecificDisease B-OMIM:262400
hormone NN I-SpecificDisease I-OMIM:262400
(GH) NN I-SpecificDisease I-OMIM:262400
deficiency NN I-SpecificDisease I-OMIM:262400
, NN O O
who NN O O
is NN O O
showing NN O O
a NN O O
benign NN O O
course NN O O
of NN O O
the NN O O
dystrophic NN B-DiseaseClass B-MSH:D009136
process NN I-DiseaseClass I-MSH:D009136
and NN O O
is NN O O
still NN O O
walking NN O O
at NN O O
18 NN O O
years. NN O O
one NN O O
of NN O O
the NN O O
twins NN O O
received NN O O
2 NN O O
mg NN O O
of NN O O
mazindol NN O O
daily, NN O O
while NN O O
the NN O O
other NN O O
received NN O O
a NN O O
placebo. NN O O
the NN O O
assessment, NN O O
repeated NN O O
every NN O O
2 NN O O
months, NN O O
included NN O O
weight NN O O
and NN O O
height NN O O
measurements, NN O O
functional NN O O
and NN O O
motor NN O O
ability NN O O
tests, NN O O
ergometry NN O O
and NN O O
determinations NN O O
of NN O O
serum NN O O
enzymes NN O O
and NN O O
gh NN O O
levels. NN O O
after NN O O
one NN O O
year NN O O
of NN O O
trial NN O O
th NN O O
. NN O O

code NN O O
was NN O O
broken NN O O
and NN O O
it NN O O
was NN O O
seen NN O O
that NN O O
the NN O O
twin NN O O
under NN O O
placebo NN O O
treatment NN O O
was NN O O
strikingly NN O O
worse NN O O
than NN O O
his NN O O
brother, NN O O
the NN O O
progression NN O O
of NN O O
whose NN O O
condition NN O O
was NN O O
practically NN O O
arrested. NN O O
these NN O O
results NN O O
strongly NN O O
suggest NN O O
that NN O O
treatment NN O O
with NN O O
a NN O O
gh NN O O
inhibitor NN O O
is NN O O
beneficial NN O O
for NN O O
DMD NN B-Modifier B-MSH:D020388
patients. NN O O
. NN O O

identification NN O O
of NN O O
wasp NN O O
mutations NN O O
in NN O O
patients NN O O
with NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
and NN O O
isolated NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
reveals NN O O
allelic NN O O
heterogeneity NN O O
at NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
locus NN O O
. NN O O

mutation NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
recently NN O O
isolated NN O O
wasp NN O O
protein NN O O
has NN O O
now NN O O
been NN O O
identified NN O O
as NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
responsible NN O O
for NN O O
the NN O O
X-linked NN B-SpecificDisease B-MSH:D014923
Wiskott-Aldrich NN I-SpecificDisease I-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
), NN O O
a NN O O
primary NN O O
immunodeficiency NN B-DiseaseClass B-MSH:D007153
disease NN I-DiseaseClass I-MSH:D007153
associated NN O O
with NN O O
extensive NN O O
phenotypic NN O O
variability. NN O O
to NN O O
elucidate NN O O
the NN O O
range NN O O
of NN O O
wasp NN O O
mutations NN O O
responsible NN O O
for NN O O
WAS NN B-SpecificDisease B-MSH:D014923
, NN O O
we NN O O
used NN O O
pcr-sscp NN O O
analysis NN O O
to NN O O
screen NN O O
for NN O O
wasp NN O O
gene NN O O
mutation NN O O
in NN O O
19 NN O O
unrelated NN O O
boys NN O O
with NN O O
the NN O O
diagnosis NN O O
of NN O O
classical NN O O
or NN O O
attenuated NN O O
WAS NN B-SpecificDisease B-MSH:D014923
or NN O O
isolated NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
. NN O O
all NN O O
19 NN O O
patients NN O O
had NN O O
wasp NN O O
mutations, NN O O
each NN O O
of NN O O
which NN O O
localized NN O O
to NN O O
the NN O O
initial NN O O
three NN O O
or NN O O
terminal NN O O
three NN O O
exons NN O O
of NN O O
the NN O O
gene, NN O O
and NN O O
the NN O O
majority NN O O
of NN O O
which NN O O
were NN O O
unique NN O O
in NN O O
each NN O O
case. NN O O
however, NN O O
a NN O O
missense NN O O
mutation NN O O
which NN O O
results NN O O
in NN O O
substitution NN O O
of NN O O
the NN O O
arginine NN O O
at NN O O
WAS NN B-Modifier B-MSH:D014923
codon NN O O
86 NN O O
was NN O O
identified NN O O
in NN O O
three NN O O
boys NN O O
with NN O O
severe NN O O
WAS NN B-SpecificDisease B-MSH:D014923
a NN O O
. NN O O

well NN O O
as NN O O
in NN O O
one NN O O
boy NN O O
presenting NN O O
with NN O O
thrombocytopenia NN B-SpecificDisease B-MSH:D013921
alone. NN O O
while NN O O
the NN O O
three NN O O
mutations NN O O
found NN O O
in NN O O
the NN O O
isolated NN B-Modifier B-OMIM:313900
thrombocytopenia NN I-Modifier I-OMIM:313900
patients NN O O
leave NN O O
the NN O O
reading NN O O
frame NN O O
intact, NN O O
about NN O O
one-half NN O O
of NN O O
the NN O O
gene NN O O
alterations NN O O
detected NN O O
in NN O O
both NN O O
severe NN O O
and NN O O
attenuated NN O O
WAS NN B-SpecificDisease B-MSH:D014923
patients NN O O
result NN O O
in NN O O
frameshifted NN O O
transcript NN O O
and NN O O
premature NN O O
translation NN O O
termination. NN O O
these NN O O
findings NN O O
therefore NN O O
confirm NN O O
the NN O O
association NN O O
of NN O O
WAS NN B-SpecificDisease B-MSH:D014923
with NN O O
wasp NN O O
mutation NN O O
and NN O O
identify NN O O
wasp NN O O
mutation NN O O
as NN O O
a NN O O
cause NN O O
for NN O O
isolated NN O O
congenital NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
in NN O O
males. NN O O
while NN O O
the NN O O
wasp NN O O
gene NN O O
defects NN O O
responsible NN O O
for NN O O
isolated NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
and NN O O
other NN O O
mild NN O O
presentations NN O O
of NN O O
WAS NN B-SpecificDisease B-MSH:D014923
do NN O O
not NN O O
appear NN O O
distinct NN O O
from NN O O
those NN O O
resulting NN O O
in NN O O
severe NN O O
WAS NN B-SpecificDisease B-MSH:D014923
, NN O O
these NN O O
data NN O O
indicate NN O O
that NN O O
analysis NN O O
of NN O O
wasp NN O O
gene NN O O
mutation NN O O
provides NN O O
a NN O O
valuable NN O O
tool NN O O
for NN O O
distinguishing NN O O
the NN O O
spectrum NN O O
of NN O O
WAS NN B-Modifier B-MSH:D014923
patients NN O O
and NN O O
the NN O O
subset NN O O
of NN O O
males NN O O
with NN O O
isolated NN B-SpecificDisease B-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
who NN O O
represent NN O O
mild NN O O
cases NN O O
of NN O O
WAS NN B-SpecificDisease B-MSH:D014923
. NN O O
. NN O O

huntington NN O O
disease NN O O
without NN O O
cag NN O O
expansion: NN O O
phenocopies NN O O
or NN O O
errors NN O O
in NN O O
assignment? NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
an NN O O
expanded NN O O
cag NN O O
repeat NN O O
within NN O O
a NN O O
novel NN O O
gene NN O O
on NN O O
4 NN O O
p NN O O
16. NN O O
3 NN O O
(it NN O O
15). NN O O
a NN O O
total NN O O
of NN O O
30 NN O O
of NN O O
1, NN O O
022 NN O O
affected NN O O
persons NN O O
(2. NN O O
9% NN O O
of NN O O
our NN O O
cohort) NN O O
did NN O O
not NN O O
have NN O O
an NN O O
expanded NN O O
cag NN O O
in NN O O
the NN O O
disease NN O O
range. NN O O
the NN O O
reasons NN O O
for NN O O
not NN O O
observing NN O O
expansion NN O O
in NN O O
affected NN O O
individuals NN O O
are NN O O
important NN O O
for NN O O
determining NN O O
the NN O O
sensitivity NN O O
of NN O O
using NN O O
repeat NN O O
length NN O O
both NN O O
for NN O O
diagnosis NN O O
of NN O O
affected NN O O
patients NN O O
and NN O O
for NN O O
predictive NN O O
testing NN O O
programs NN O O
and NN O O
may NN O O
have NN O O
biological NN O O
relevance NN O O
for NN O O
the NN O O
understanding NN O O
of NN O O
the NN O O
molecular NN O O
mechanism NN O O
underlying NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
here NN O O
we NN O O
show NN O O
that NN O O
the NN O O
majority NN O O
(18) NN O O
of NN O O
the NN O O
individuals NN O O
with NN O O
normal NN O O
sized NN O O
alleles NN O O
represent NN O O
misdiagnosis, NN O O
sample NN O O
mix NN O O
. NN O O

up, NN O O
or NN O O
clerical NN O O
error. NN O O
the NN O O
remaining NN O O
12 NN O O
patients NN O O
represent NN O O
possible NN O O
phenocopies NN O O
for NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
in NN O O
at NN O O
least NN O O
four NN O O
cases, NN O O
family NN O O
studies NN O O
of NN O O
these NN O O
phenocopies NN O O
excluded NN O O
4 NN O O
p NN O O
16. NN O O
3 NN O O
as NN O O
the NN O O
region NN O O
responsible NN O O
for NN O O
the NN O O
phenotype. NN O O
mutations NN O O
in NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
that NN O O
are NN O O
other NN O O
than NN O O
cag NN O O
expansion NN O O
have NN O O
not NN O O
been NN O O
excluded NN O O
for NN O O
the NN O O
remaining NN O O
eight NN O O
cases; NN O O
however, NN O O
in NN O O
as NN O O
many NN O O
as NN O O
seven NN O O
of NN O O
these NN O O
persons, NN O O
retrospective NN O O
review NN O O
of NN O O
these NN O O
patients NN O O
clinical NN O O
features NN O O
identified NN O O
characteristics NN O O
not NN O O
typical NN O O
for NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
this NN O O
study NN O O
shows NN O O
that NN O O
on NN O O
rare NN O O
occasions NN O O
mutations NN O O
in NN O O
other, NN O O
as-yet-undefined NN O O
genes NN O O
can NN O O
present NN O O
with NN O O
a NN O O
clinical NN O O
phenotype NN O O
very NN O O
similar NN O O
to NN O O
that NN O O
of NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O

allelic NN O O
exclusion NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
in NN O O
platelets NN O O
and NN O O
t NN O O
lymphocytes NN O O
from NN O O
a NN O O
Wiskott-Aldrich NN B-Modifier B-MSH:D014923
syndrome NN I-Modifier I-MSH:D014923
carrier NN O O
. NN O O

an NN O O
obligate NN O O
carrier NN O O
of NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
) NN O O
who NN O O
was NN O O
also NN O O
heterozygous NN O O
for NN O O
the NN O O
a NN O O
and NN O O
b NN O O
types NN O O
of NN O O
x-linked NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
was NN O O
found. NN O O
with NN O O
her NN O O
it NN O O
became NN O O
possible NN O O
to NN O O
determine NN O O
whether NN O O
allelic NN O O
exclusion NN O O
occurs NN O O
in NN O O
particular NN O O
cell-types NN O O
of NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
carrier. NN O O
if NN O O
so, NN O O
the NN O O
remaining NN O O
cells NN O O
of NN O O
a NN O O
particular NN O O
cell-type NN O O
would NN O O
express NN O O
only NN O O
the NN O O
normal NN O O
x NN O O
chromosome NN O O
and NN O O
only NN O O
one NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
isoenzyme NN O O
would NN O O
be NN O O
demonstrable. NN O O
this NN O O
carrier NN O O
had NN O O
only NN O O
the NN O O
b NN O O
isoenzyme NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
in NN O O
platelets NN O O
and NN O O
thymus-derived NN O O
t NN O O
lymphocytes, NN O O
although NN O O
both NN O O
isoenzymes NN O O
a NN O O
and NN O O
b NN O O
were NN O O
present NN O O
in NN O O
erythrocytes NN O O
and NN O O
neutrophils. NN O O
these NN O O
findings NN O O
suggest NN O O
that NN O O
selection NN O O
against NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
gene NN O O
occurs NN O O
in NN O O
platelets NN O O
and NN O O
thymus NN O O
. NN O O

derived NN O O
t NN O O
lymphocytes NN O O
and NN O O
that NN O O
the NN O O
defects NN O O
associated NN O O
with NN O O
WAS NN B-SpecificDisease B-MSH:D014923
expressed NN O O
in NN O O
these NN O O
cell-types NN O O
may NN O O
be NN O O
implicated NN O O
in NN O O
the NN O O
genesis NN O O
of NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
. NN O O
. NN O O

a NN O O
novel NN O O
mutation NN O O
in NN O O
the NN O O
sodium/iodide NN O O
symporter NN O O
gene NN O O
in NN O O
the NN O O
largest NN O O
family NN O O
with NN O O
iodide NN B-DiseaseClass B-OMIM:274400
transport NN I-DiseaseClass I-OMIM:274400
defect NN I-DiseaseClass I-OMIM:274400
. NN O O

we NN O O
previously NN O O
reported NN O O
nine NN O O
children NN O O
with NN O O
an NN O O
autosomally NN O O
recessive NN O O
form NN O O
of NN O O
congenital NN B-SpecificDisease B-MSH:D003409
hypothyroidism NN I-SpecificDisease I-MSH:D003409
due NN O O
to NN O O
an NN O O
iodide NN B-DiseaseClass B-OMIM:274400
transport NN I-DiseaseClass I-OMIM:274400
defect NN I-DiseaseClass I-OMIM:274400
in NN O O
a NN O O
large NN O O
hutterite NN O O
family NN O O
with NN O O
extensive NN O O
consanguinity NN O O
living NN O O
in NN O O
central NN O O
canada. NN O O
since NN O O
the NN O O
original NN O O
report, NN O O
we NN O O
have NN O O
diagnosed NN O O
congenital NN B-SpecificDisease B-MSH:D003409
hypothyroidism NN I-SpecificDisease I-MSH:D003409
by NN O O
newborn NN O O
tsh NN O O
screening NN O O
in NN O O
9 NN O O
additional NN O O
children NN O O
from NN O O
the NN O O
family. NN O O
we NN O O
performed NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
pcr NN O O
products NN O O
of NN O O
each NN O O
nis NN O O
(sodium/iodide NN O O
symporter) NN O O
gene NN O O
exon NN O O
with NN O O
flanking NN O O
introns NN O O
amplified NN O O
from NN O O
genomic NN O O
dna NN O O
extracted NN O O
from NN O O
peripheral NN O O
blood NN O O
cells NN O O
of NN O O
the NN O O
patients. NN O O
we NN O O
identified NN O O
a NN O O
novel NN O O
nis NN O O
gene NN O O
mutation, NN O O
g NN O O
395 NN O O
r NN O O
(gly NN O O
395-- NN O O
> NN O O
arg; NN O O
gga-- NN O O
> NN O O
aga), NN O O
in NN O O
10 NN O O
patients NN O O
examined NN O O
in NN O O
the NN O O
present NN O O
study. NN O O
all NN O O
of NN O O
the NN O O
parents NN O O
tested NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
mutation, NN O O
suggesting NN O O
that NN O O
the NN O O
patients NN O O
wer NN O O
. NN O O

homozygous. NN O O
the NN O O
mutation NN O O
was NN O O
located NN O O
in NN O O
the NN O O
10 NN O O
th NN O O
transmembrane NN O O
helix. NN O O
expression NN O O
experiments NN O O
by NN O O
transfection NN O O
of NN O O
the NN O O
mutant NN O O
nis NN O O
complimentary NN O O
dna NN O O
into NN O O
cos-7 NN O O
cells NN O O
showed NN O O
no NN O O
perchlorate-sensitive NN O O
iodide NN O O
uptake, NN O O
confirming NN O O
that NN O O
the NN O O
mutation NN O O
is NN O O
the NN O O
direct NN O O
cause NN O O
of NN O O
the NN O O
iodide NN B-DiseaseClass B-OMIM:274400
transport NN I-DiseaseClass I-OMIM:274400
defect NN I-DiseaseClass I-OMIM:274400
in NN O O
these NN O O
patients. NN O O
a NN O O
patient NN O O
who NN O O
showed NN O O
an NN O O
intermediate NN O O
saliva/serum NN O O
technetium NN O O
ratio NN O O
(14. NN O O
0; NN O O
normal, NN O O
> NN O O
or NN O O
= NN O O
20) NN O O
and NN O O
was NN O O
considered NN O O
to NN O O
have NN O O
a NN O O
partial NN O O
or NN O O
less NN O O
severe NN O O
defect NN O O
in NN O O
the NN O O
previous NN O O
report NN O O
(ix-24) NN O O
did NN O O
not NN O O
have NN O O
a NN O O
nis NN O O
gene NN O O
mutation. NN O O
it NN O O
is NN O O
now NN O O
possible NN O O
to NN O O
use NN O O
gene NN O O
diagnostics NN O O
of NN O O
this NN O O
unique NN O O
nis NN O O
mutation NN O O
to NN O O
identify NN O O
patients NN O O
with NN O O
congenital NN B-SpecificDisease B-MSH:D003409
hypothyroidism NN I-SpecificDisease I-MSH:D003409
due NN O O
to NN O O
an NN O O
iodide NN B-DiseaseClass B-OMIM:274400
transport NN I-DiseaseClass I-OMIM:274400
defect NN I-DiseaseClass I-OMIM:274400
in NN O O
this NN O O
family NN O O
and NN O O
to NN O O
determine NN O O
the NN O O
carrier NN O O
state NN O O
of NN O O
potentia NN O O
. NN O O

parents NN O O
for NN O O
genetic NN O O
counseling NN O O
and NN O O
arranging NN O O
rapid NN O O
and NN O O
early NN O O
diagnosis NN O O
of NN O O
their NN O O
infants NN O O
. NN O O

determination NN O O
of NN O O
the NN O O
mutations NN O O
responsible NN O O
for NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
in NN O O
17 NN O O
subjects NN O O
. NN O O

hypoxanthine--guanine NN O O
phosphoribosyltransferase NN O O
(hprt) NN O O
is NN O O
a NN O O
purine NN O O
salvage NN O O
enzyme NN O O
that NN O O
catalyzes NN O O
the NN O O
conversion NN O O
of NN O O
hypoxanthine NN O O
to NN O O
inosine NN O O
monophosphate NN O O
and NN O O
guanine NN O O
to NN O O
guanosine NN O O
monophosphate. NN O O
previous NN O O
studies NN O O
of NN O O
mutant NN O O
hprt NN O O
proteins NN O O
analyzed NN O O
at NN O O
the NN O O
molecular NN O O
level NN O O
have NN O O
shown NN O O
a NN O O
significant NN O O
heterogeneity. NN O O
this NN O O
investigation NN O O
further NN O O
verifies NN O O
this NN O O
heterogeneity NN O O
and NN O O
identifies NN O O
insertions, NN O O
deletions, NN O O
and NN O O
point NN O O
mutations. NN O O
the NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction-amplified NN O O
product NN O O
of NN O O
reverse-transcribed NN O O
hprt NN O O
mrna NN O O
enabled NN O O
the NN O O
rapid NN O O
identification NN O O
of NN O O
the NN O O
mutations NN O O
found NN O O
in NN O O
17 NN O O
previously NN O O
uncharacterized NN O O
cell NN O O
lines NN O O
derived NN O O
from NN O O
patients NN O O
with NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O
. NN O O

a NN O O
new NN O O
ct NN O O
pattern NN O O
in NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
. NN O O

a NN O O
new NN O O
ct NN O O
pattern NN O O
was NN O O
observed NN O O
in NN O O
2 NN O O
patients NN O O
with NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
). NN O O
this NN O O
pattern, NN O O
which NN O O
the NN O O
authors NN O O
call NN O O
type NN O O
ii, NN O O
is NN O O
characterized NN O O
by NN O O
the NN O O
absence NN O O
of NN O O
posterior NN O O
periventricular NN O O
areas NN O O
of NN O O
decreased NN O O
attenuation NN O O
around NN O O
the NN O O
trigone NN O O
on NN O O
non-contrast NN O O
scans NN O O
after NN O O
contrast NN O O
infusion, NN O O
however, NN O O
there NN O O
is NN O O
striking NN O O
enhancement NN O O
of NN O O
various NN O O
white-matter NN O O
structures NN O O
(tracts NN O O
or NN O O
fiber NN O O
systems) NN O O
such NN O O
as NN O O
the NN O O
internal NN O O
capsules, NN O O
corpus NN O O
callosum, NN O O
corona NN O O
radiata, NN O O
forceps NN O O
major, NN O O
and NN O O
cerebral NN O O
peduncles. NN O O
this NN O O
is NN O O
different NN O O
from NN O O
numerous NN O O
previous NN O O
descriptions NN O O
of NN O O
the NN O O
ct NN O O
pattern NN O O
in NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
Type NN B-SpecificDisease B-MSH:D000326
II NN I-SpecificDisease I-MSH:D000326
ALD NN I-SpecificDisease I-MSH:D000326
does NN O O
not NN O O
appear NN O O
to NN O O
have NN O O
been NN O O
seen NN O O
in NN O O
any NN O O
other NN O O
leukoencephalopathy NN B-DiseaseClass B-MSH:D056784
and NN O O
is NN O O
probably NN O O
specific NN O O
for NN O O
a NN O O
phenotypic NN O O
variant NN O O
or NN O O
an NN O O
evolving NN O O
stage NN O O
of NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
. NN O O

genetic NN O O
analysis, NN O O
phenotypic NN O O
diagnosis, NN O O
and NN O O
risk NN O O
of NN O O
venous NN B-SpecificDisease B-MSH:D020246
thrombosis NN I-SpecificDisease I-MSH:D020246
in NN O O
families NN O O
with NN O O
inherited NN O O
deficiencies NN B-SpecificDisease B-MSH:D018455
of NN I-SpecificDisease I-MSH:D018455
protein NN I-SpecificDisease I-MSH:D018455
S NN I-SpecificDisease I-MSH:D018455
. NN O O

protein NN O O
s NN O O
deficiency NN O O
is NN O O
a NN O O
recognized NN O O
risk NN O O
factor NN O O
for NN O O
venous NN B-SpecificDisease B-MSH:D020246
thrombosis NN I-SpecificDisease I-MSH:D020246
. NN O O
of NN O O
all NN O O
the NN O O
inherited NN O O
thrombophilic NN B-DiseaseClass B-MSH:D019851
conditions NN I-DiseaseClass I-MSH:D019851
, NN O O
it NN O O
remains NN O O
the NN O O
most NN O O
difficult NN O O
to NN O O
diagnose NN O O
because NN O O
of NN O O
phenotypic NN O O
variability, NN O O
which NN O O
can NN O O
lead NN O O
to NN O O
inconclusive NN O O
results. NN O O
we NN O O
have NN O O
overcome NN O O
this NN O O
problem NN O O
by NN O O
studying NN O O
a NN O O
cohort NN O O
of NN O O
patients NN O O
from NN O O
a NN O O
single NN O O
center NN O O
where NN O O
the NN O O
diagnosis NN O O
was NN O O
confirmed NN O O
at NN O O
the NN O O
genetic NN O O
level. NN O O
twenty-eight NN O O
index NN O O
patients NN O O
with NN O O
protein NN B-SpecificDisease B-MSH:D018455
S NN I-SpecificDisease I-MSH:D018455
deficiency NN I-SpecificDisease I-MSH:D018455
and NN O O
a NN O O
PROS1 NN B-SpecificDisease B-OMIM:612336
gene NN I-SpecificDisease I-OMIM:612336
defect NN I-SpecificDisease I-OMIM:612336
were NN O O
studied, NN O O
together NN O O
with NN O O
109 NN O O
first-degree NN O O
relatives. NN O O
to NN O O
avoid NN O O
selection NN O O
bias, NN O O
we NN O O
confined NN O O
analysis NN O O
of NN O O
total NN O O
and NN O O
free NN O O
protein NN O O
s NN O O
levels NN O O
and NN O O
thrombotic NN O O
risk NN O O
to NN O O
the NN O O
patients NN O O
relatives. NN O O
in NN O O
this NN O O
group NN O O
of NN O O
relatives, NN O O
a NN O O
low NN O O
free NN O O
protein NN O O
s NN O O
level NN O O
was NN O O
the NN O O
most NN O O
reliable NN O O
predictor NN O O
of NN O O
a NN O O
PROS1 NN B-SpecificDisease B-OMIM:612336
gene NN I-SpecificDisease I-OMIM:612336
defect NN I-SpecificDisease I-OMIM:612336
(sensitivity NN O O
97. NN O O
. NN O O

%, NN O O
specificity NN O O
100%). NN O O
first-degree NN O O
relatives NN O O
with NN O O
a NN O O
PROS1 NN B-SpecificDisease B-OMIM:612336
gene NN I-SpecificDisease I-OMIM:612336
defect NN I-SpecificDisease I-OMIM:612336
had NN O O
a NN O O
5. NN O O
0-fold NN O O
higher NN O O
risk NN O O
of NN O O
thrombosis NN B-SpecificDisease B-MSH:D013927
(95% NN O O
confidence NN O O
interval, NN O O
1. NN O O
5-16. NN O O
8) NN O O
than NN O O
those NN O O
with NN O O
a NN O O
normal NN O O
pros NN O O
1 NN O O
gene NN O O
and NN O O
no NN O O
other NN O O
recognized NN O O
thrombophilic NN B-SpecificDisease B-MSH:D019851
defect NN I-SpecificDisease I-MSH:D019851
. NN O O
although NN O O
pregnancy/puerperium NN O O
and NN O O
immobility/ NN O O
trauma NN B-SpecificDisease B-MSH:D014947
were NN O O
important NN O O
precipitating NN O O
factors NN O O
for NN O O
thrombosis NN B-SpecificDisease B-MSH:D013927
, NN O O
almost NN O O
half NN O O
of NN O O
the NN O O
events NN O O
were NN O O
spontaneous. NN O O
relatives NN O O
with NN O O
splice-site NN O O
or NN O O
major NN O O
structural NN O O
defects NN B-SpecificDisease B-OMIM:612336
in NN I-SpecificDisease I-OMIM:612336
the NN I-SpecificDisease I-OMIM:612336
PROS1 NN I-SpecificDisease I-OMIM:612336
gene NN I-SpecificDisease I-OMIM:612336
were NN O O
more NN O O
likely NN O O
to NN O O
have NN O O
had NN O O
a NN O O
thrombotic NN O O
event NN O O
and NN O O
had NN O O
significantly NN O O
lower NN O O
total NN O O
and NN O O
free NN O O
protein NN O O
s NN O O
levels NN O O
than NN O O
those NN O O
relatives NN O O
having NN O O
missense NN O O
mutations. NN O O
we NN O O
conclude NN O O
that NN O O
persons NN O O
with NN O O
PROS1 NN B-SpecificDisease B-OMIM:612336
gene NN I-SpecificDisease I-OMIM:612336
defects NN I-SpecificDisease I-OMIM:612336
and NN O O
protein NN B-SpecificDisease B-MSH:D018455
S NN I-SpecificDisease I-MSH:D018455
deficiency NN I-SpecificDisease I-MSH:D018455
are NN O O
at NN O O
increased NN O O
risk NN O O
of NN O O
thrombosis NN B-SpecificDisease B-MSH:D013927
an NN O O
. NN O O

that NN O O
free NN O O
protein NN O O
s NN O O
estimation NN O O
offers NN O O
the NN O O
most NN O O
reliable NN O O
way NN O O
of NN O O
diagnosing NN O O
the NN O O
deficiency. NN O O
(blood. NN O O
2000; NN O O
95 NN O O
1935-1941) NN O O
. NN O O

severe NN O O
clinical NN O O
expression NN O O
in NN O O
X-linked NN B-SpecificDisease B-MSH:D020389
Emery-Dreifuss NN I-SpecificDisease I-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
. NN O O

x-linked NN O O
emery-dreifuss NN O O
muscular NN O O
dystrophy NN O O
( NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
) NN O O
is NN O O
a NN O O
relatively NN O O
rare NN O O
benign NN B-DiseaseClass B-MSH:D009468
neuromuscular NN I-DiseaseClass I-MSH:D009468
disorder NN I-DiseaseClass I-MSH:D009468
which NN O O
can NN O O
vary NN O O
remarkably NN O O
in NN O O
onset, NN O O
course NN O O
and NN O O
severity. NN O O
in NN O O
the NN O O
present NN O O
study, NN O O
a NN O O
tctac NN O O
deletion NN O O
spanning NN O O
the NN O O
nucleotides NN O O
631-635 NN O O
of NN O O
the NN O O
emerin NN O O
gene NN O O
caused NN O O
an NN O O
unusually NN O O
severe NN O O
disease NN O O
phenotype NN O O
including NN O O
loss NN B-DiseaseClass B-MSH:D051346
of NN I-DiseaseClass I-MSH:D051346
ambulation NN I-DiseaseClass I-MSH:D051346
and NN O O
severe NN O O
muscle NN B-DiseaseClass B-MSH:D009133
wasting NN I-DiseaseClass I-MSH:D009133
in NN O O
two NN O O
affected NN O O
brothers. NN O O
the NN O O
same NN O O
mutation NN O O
has NN O O
been NN O O
reported NN O O
previously NN O O
in NN O O
an NN O O
unrelated NN O O
family NN O O
showing NN O O
a NN O O
significantly NN O O
milder NN O O
phenotype. NN O O
the NN O O
interfamilial NN O O
heterogeneity NN O O
in NN O O
distribution NN O O
and NN O O
in NN O O
severity NN O O
of NN O O
the NN O O
features NN O O
in NN O O
the NN O O
two NN O O
families NN O O
point NN O O
to NN O O
environmental NN O O
or NN O O
genetic NN O O
modification NN O O
as NN O O
the NN O O
cause NN O O
of NN O O
clinical NN O O
variability NN O O
in NN O O
Emery-Dreifuss NN B-SpecificDisease B-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
. NN O O
. NN O O

the NN O O
gene NN O O
for NN O O
spinal NN B-Modifier B-MSH:D013132
cerebellar NN I-Modifier I-MSH:D013132
ataxia NN I-Modifier I-MSH:D013132
3 NN O O
(sca NN O O
3) NN O O
is NN O O
located NN O O
in NN O O
a NN O O
region NN O O
of NN O O
approximately NN O O
3 NN O O
cm NN O O
on NN O O
chromosome NN O O
14 NN O O
q NN O O
24.3-q NN O O
32.2 NN O O
. NN O O

sca NN O O
3, NN O O
the NN O O
gene NN O O
for NN O O
spinal NN B-Modifier B-MSH:D013132
cerebellar NN I-Modifier I-MSH:D013132
ataxia NN I-Modifier I-MSH:D013132
3, NN O O
was NN O O
recently NN O O
mapped NN O O
to NN O O
a NN O O
15-cm NN O O
interval NN O O
between NN O O
d NN O O
14 NN O O
s NN O O
67 NN O O
and NN O O
d NN O O
14 NN O O
s NN O O
81 NN O O
on NN O O
chromosome NN O O
14 NN O O
q, NN O O
by NN O O
linkage NN O O
analysis NN O O
in NN O O
two NN O O
families NN O O
of NN O O
french NN O O
ancestry. NN O O
the NN O O
sca NN O O
3 NN O O
candidate NN O O
region NN O O
has NN O O
now NN O O
been NN O O
refined NN O O
by NN O O
linkage NN O O
analysis NN O O
with NN O O
four NN O O
new NN O O
microsatellite NN O O
markers NN O O
(d NN O O
14 NN O O
s NN O O
256, NN O O
d NN O O
14 NN O O
s NN O O
291, NN O O
d NN O O
14 NN O O
s NN O O
280, NN O O
and NN O O
afm NN O O
343 NN O O
vf NN O O
1) NN O O
in NN O O
the NN O O
same NN O O
two NN O O
families, NN O O
in NN O O
which NN O O
19 NN O O
additional NN O O
individuals NN O O
were NN O O
genotyped, NN O O
and NN O O
in NN O O
a NN O O
third NN O O
french NN O O
family. NN O O
combined NN O O
two-point NN O O
linkage NN O O
analyses NN O O
show NN O O
that NN O O
the NN O O
new NN O O
markers, NN O O
d NN O O
14 NN O O
s NN O O
280 NN O O
and NN O O
afm NN O O
343 NN O O
vf NN O O
1, NN O O
are NN O O
tightly NN O O
linked NN O O
to NN O O
the NN O O
sca NN O O
3 NN O O
locus, NN O O
with NN O O
maximal NN O O
lod NN O O
score NN O O
. NN O O

, NN O O
at NN O O
recombination NN O O
fraction, NN O O
(theta) NN O O
=. NN O O
00, NN O O
of NN O O
7. NN O O
05 NN O O
and NN O O
13. NN O O
70, NN O O
respectively. NN O O
combined NN O O
multipoint NN O O
and NN O O
recombinant NN O O
haplotype NN O O
analyses NN O O
localize NN O O
the NN O O
sca NN O O
3 NN O O
locus NN O O
to NN O O
a NN O O
3-cm NN O O
interval NN O O
flanked NN O O
by NN O O
d NN O O
14 NN O O
s NN O O
291 NN O O
and NN O O
d NN O O
14 NN O O
s NN O O
81. NN O O
the NN O O
same NN O O
allele NN O O
for NN O O
d NN O O
14 NN O O
s NN O O
280 NN O O
segregates NN O O
with NN O O
the NN O O
disease NN O O
locus NN O O
in NN O O
the NN O O
three NN O O
kindreds. NN O O
this NN O O
allele NN O O
is NN O O
frequent NN O O
in NN O O
the NN O O
french NN O O
population, NN O O
however, NN O O
and NN O O
linkage NN O O
disequilibrium NN O O
is NN O O
not NN O O
clearly NN O O
established. NN O O
the NN O O
sca NN O O
3 NN O O
locus NN O O
remains NN O O
within NN O O
the NN O O
29-cm NN O O
region NN O O
on NN O O
14 NN O O
q NN O O
24. NN O O
3-q NN O O
32. NN O O
2 NN O O
containing NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
, NN O O
which NN O O
is NN O O
clinically NN O O
related NN O O
to NN O O
the NN O O
phenotype NN O O
determined NN O O
by NN O O
sca NN O O
3, NN O O
but NN O O
it NN O O
cannot NN O O
yet NN O O
be NN O O
concluded NN O O
tha NN O O
. NN O O

both NN O O
diseases NN O O
result NN O O
from NN O O
alterations NN O O
of NN O O
the NN O O
same NN O O
gen NN O O
. NN O O

huntington NN O O
disease NN O O
and NN O O
childhood-onset NN O O
Tourette NN B-SpecificDisease B-MSH:D005879
syndrome NN I-SpecificDisease I-MSH:D005879
. NN O O

a NN O O
40-year-old NN O O
man NN O O
with NN O O
childhood-onset NN O O
Tourette NN B-SpecificDisease B-MSH:D005879
syndrome NN I-SpecificDisease I-MSH:D005879
( NN O O
TS NN B-SpecificDisease B-MSH:D005879
) NN O O
developed NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
). NN O O
we NN O O
believe NN O O
this NN O O
to NN O O
be NN O O
the NN O O
first NN O O
reported NN O O
case NN O O
of NN O O
childhood-onset NN O O
TS NN B-SpecificDisease B-MSH:D005879
with NN O O
adult NN O O
onset NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
discovery NN O O
of NN O O
other NN O O
cases NN O O
with NN O O
both NN O O
disorders NN O O
may NN O O
provide NN O O
clues NN O O
to NN O O
the NN O O
pathophysiology NN O O
of NN O O
both NN O O
conditions. NN O O
. NN O O

the NN O O
protein NN O O
deficient NN O O
in NN O O
Lowe NN B-SpecificDisease B-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
is NN O O
a NN O O
phosphatidylinositol-4,5-bisphosphate NN O O
5-phosphatase NN O O
. NN O O

lowe NN O O
syndrome, NN O O
also NN O O
known NN O O
as NN O O
oculocerebrorenal NN B-SpecificDisease B-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
, NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
x NN O O
chromosome-encoded NN O O
ocrl NN O O
gene. NN O O
the NN O O
ocrl NN O O
protein NN O O
is NN O O
51% NN O O
identical NN O O
to NN O O
inositol NN O O
polyphosphate NN O O
5-phosphatase NN O O
ii NN O O
(5-phosphatase NN O O
ii) NN O O
from NN O O
human NN O O
platelets NN O O
over NN O O
a NN O O
span NN O O
of NN O O
744 NN O O
aa, NN O O
suggesting NN O O
that NN O O
ocrl NN O O
may NN O O
be NN O O
a NN O O
similar NN O O
enzyme. NN O O
we NN O O
engineered NN O O
a NN O O
construct NN O O
of NN O O
the NN O O
ocrl NN O O
cdna NN O O
that NN O O
encodes NN O O
amino NN O O
acids NN O O
homologous NN O O
to NN O O
the NN O O
platelet NN O O
5-phosphatase NN O O
for NN O O
expression NN O O
in NN O O
baculovirus-infected NN O O
sf NN O O
9 NN O O
insect NN O O
cells. NN O O
this NN O O
cdna NN O O
encodes NN O O
aa NN O O
264-968 NN O O
of NN O O
the NN O O
ocrl NN O O
protein. NN O O
the NN O O
recombinant NN O O
protein NN O O
was NN O O
found NN O O
to NN O O
catalyze NN O O
the NN O O
reactions NN O O
also NN O O
carried NN O O
out NN O O
by NN O O
platelet NN O O
5-phosphatase NN O O
ii. NN O O
thus NN O O
ocrl NN O O
converts NN O O
inositol NN O O
1, NN O O
4, NN O O
5-trisphosphate NN O O
to NN O O
inositol NN O O
1, NN O O
4-bisphosphat NN O O
. NN O O

, NN O O
and NN O O
it NN O O
converts NN O O
inositol NN O O
1, NN O O
3, NN O O
4, NN O O
5-tetrakisphosphate NN O O
to NN O O
inositol NN O O
1, NN O O
3, NN O O
4-trisphosphate. NN O O
most NN O O
important, NN O O
the NN O O
enzyme NN O O
converts NN O O
phosphatidylinositol NN O O
4, NN O O
5-bisphosphate NN O O
to NN O O
phosphatidylinositol NN O O
4-phosphate. NN O O
the NN O O
relative NN O O
ability NN O O
of NN O O
ocrl NN O O
to NN O O
catalyze NN O O
the NN O O
three NN O O
reactions NN O O
is NN O O
different NN O O
from NN O O
that NN O O
of NN O O
5-phosphatase NN O O
ii NN O O
and NN O O
from NN O O
that NN O O
of NN O O
another NN O O
5-phosphatase NN O O
isoenzyme NN O O
from NN O O
platelets, NN O O
5-phosphatase NN O O
i. NN O O
the NN O O
recombinant NN O O
ocrl NN O O
protein NN O O
hydrolyzes NN O O
the NN O O
phospholipid NN O O
substrate NN O O
10- NN O O
to NN O O
30-fold NN O O
better NN O O
than NN O O
5-phosphatase NN O O
ii, NN O O
and NN O O
5-phosphatase NN O O
i NN O O
does NN O O
not NN O O
cleave NN O O
the NN O O
lipid NN O O
at NN O O
all. NN O O
we NN O O
also NN O O
show NN O O
that NN O O
ocrl NN O O
functions NN O O
as NN O O
a NN O O
phosphatidylinositol NN O O
4, NN O O
5-bisphosphate NN O O
5-phosphatase NN O O
in NN O O
ocrl-expressing NN O O
sf NN O O
9 NN O O
cells. NN O O
these NN O O
results NN O O
sugges NN O O
. NN O O
to NN O O
inositol NN O O
1, NN O O
3, NN O O
4-trisphosphate. NN O O
most NN O O
important, NN O O
the NN O O
enzyme NN O O
converts NN O O
phosphatidylinositol NN O O
4, NN O O
5-bisphosphate NN O O
to NN O O
phosphatidylinositol NN O O
4-phosphate. NN O O
the NN O O
relative NN O O
ability NN O O
of NN O O
ocrl NN O O
to NN O O
catalyze NN O O
the NN O O
three NN O O
reactions NN O O
is NN O O
different NN O O
from NN O O
that NN O O
of NN O O
5-phosphatase NN O O
ii NN O O
and NN O O
from NN O O
that NN O O
of NN O O
another NN O O
5-phosphatase NN O O
isoenzyme NN O O
from NN O O
platelets, NN O O
5-phosphatase NN O O
i. NN O O
the NN O O
recombinant NN O O
ocrl NN O O
protein NN O O
hydrolyzes NN O O
the NN O O
phospholipid NN O O
substrate NN O O
10- NN O O
to NN O O
30-fold NN O O
better NN O O
than NN O O
5-phosphatase NN O O
ii, NN O O
and NN O O
5-phosphatase NN O O
i NN O O
does NN O O
not NN O O
cleave NN O O
the NN O O
lipid NN O O
at NN O O
all. NN O O
we NN O O
also NN O O
show NN O O
that NN O O
ocrl NN O O
functions NN O O
as NN O O
a NN O O
phosphatidylinositol NN O O
4, NN O O
5-bisphosphate NN O O
5-phosphatase NN O O
in NN O O
ocrl-expressing NN O O
sf NN O O
9 NN O O
cells. NN O O
these NN O O
results NN O O
sugges NN O O
. NN O O

that NN O O
ocrl NN O O
is NN O O
mainly NN O O
a NN O O
lipid NN O O
phosphatase NN O O
that NN O O
may NN O O
control NN O O
cellular NN O O
levels NN O O
of NN O O
a NN O O
critical NN O O
metabolite, NN O O
phosphatidylinositol NN O O
4, NN O O
5-bisphosphate. NN O O
deficiency NN O O
of NN O O
this NN O O
enzyme NN O O
apparently NN O O
causes NN O O
the NN O O
protean NN O O
manifestations NN O O
of NN O O
Lowe NN B-SpecificDisease B-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
. NN O O
. NN O O

microdeletions NN O O
at NN O O
chromosome NN O O
bands NN O O
1 NN O O
q NN O O
32-q NN O O
41 NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
Van NN B-SpecificDisease B-MSH:C536528
der NN I-SpecificDisease I-MSH:C536528
Woude NN I-SpecificDisease I-MSH:C536528
syndrome NN I-SpecificDisease I-MSH:C536528
. NN O O

van NN O O
der NN O O
woude NN O O
syndrome NN O O
( NN O O
VWS NN B-SpecificDisease B-MSH:C536528
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
comprising NN O O
cleft NN B-SpecificDisease B-MSH:D002971
lip NN I-SpecificDisease I-MSH:D002971
and/or NN O O
cleft NN B-SpecificDisease B-MSH:D002972
palate NN I-SpecificDisease I-MSH:D002972
and NN O O
lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
. NN O O
we NN O O
reported NN O O
previously NN O O
a NN O O
family NN O O
whose NN O O
underlying NN O O
mutation NN O O
is NN O O
a NN O O
500-800 NN O O
kb NN O O
deletion NN O O
localized NN O O
to NN O O
chromosome NN O O
bands NN O O
1 NN O O
q NN O O
32-q NN O O
41 NN O O
[sander NN O O
et NN O O
al., NN O O
1994 NN O O
hum NN O O
mol NN O O
genet NN O O
3 NN O O
576-578]. NN O O
along NN O O
with NN O O
cleft NN B-CompositeMention B-MSH:D002971
lip/palate NN I-CompositeMention I-MSH:D002971
and NN O O
lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
, NN O O
affected NN O O
relatives NN O O
exhibit NN O O
developmental NN B-DiseaseClass B-MSH:D006130
delays NN I-DiseaseClass I-MSH:D006130
, NN O O
suggesting NN O O
that NN O O
the NN O O
function NN O O
of NN O O
a NN O O
gene NN O O
nearby NN O O
may NN O O
also NN O O
be NN O O
disrupted. NN O O
to NN O O
further NN O O
localize NN O O
the NN O O
VWS NN B-Modifier B-MSH:C536528
gene NN O O
we NN O O
searched NN O O
for NN O O
other NN O O
deletions NN O O
that NN O O
cause NN O O
VWS NN B-SpecificDisease B-MSH:C536528
. NN O O
an NN O O
allele NN O O
loss NN O O
assay NN O O
was NN O O
performed NN O O
using NN O O
a NN O O
novel NN O O
highly NN O O
polymorphic NN O O
marker, NN O O
d NN O O
1 NN O O
s NN O O
3753. NN O O
from NN O O
a NN O O
panel NN O O
of NN O O
37 NN O O
unrelated NN O O
individuals, NN O O
we NN O O
detected NN O O
an NN O O
allele NN O O
los NN O O
. NN O O

in NN O O
one NN O O
family, NN O O
indicating NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
deletion. NN O O
in NN O O
this NN O O
family, NN O O
the NN O O
phenotype NN O O
in NN O O
three NN O O
generations NN O O
of NN O O
affected NN O O
individuals NN O O
was NN O O
confined NN O O
to NN O O
the NN O O
cardinal NN O O
signs NN O O
of NN O O
VWS NN B-SpecificDisease B-MSH:C536528
. NN O O
surprisingly, NN O O
mapping NN O O
of NN O O
the NN O O
new NN O O
deletion NN O O
showed NN O O
that NN O O
it NN O O
extended NN O O
0. NN O O
2-1 NN O O
mb NN O O
beyond NN O O
the NN O O
proximal NN O O
breakpoint NN O O
for NN O O
the NN O O
deletion NN O O
described NN O O
previously. NN O O
no NN O O
deletions NN O O
were NN O O
detected NN O O
in NN O O
seven NN O O
cases NN O O
of NN O O
popliteal NN B-SpecificDisease B-OMIM:119500
pterygia NN I-SpecificDisease I-OMIM:119500
syndrome NN I-SpecificDisease I-OMIM:119500
, NN O O
76 NN O O
cases NN O O
of NN O O
mixed NN O O
syndromic NN B-CompositeMention B-MSH:D002971
forms NN I-CompositeMention I-MSH:D002971
of NN I-CompositeMention I-MSH:D002971
cleft NN I-CompositeMention I-MSH:D002971
lip NN I-CompositeMention I-MSH:D002971
and NN I-CompositeMention I-MSH:D002971
palate NN I-CompositeMention I-MSH:D002971
, NN O O
and NN O O
178 NN O O
cases NN O O
of NN O O
nonsyndromic NN B-CompositeMention B-OMIM:119530
cleft NN I-CompositeMention I-OMIM:119530
lip NN I-CompositeMention I-OMIM:119530
and NN I-CompositeMention I-OMIM:119530
palate NN I-CompositeMention I-OMIM:119530
. NN O O

mucopolysaccharidosis NN O O
type NN O O
iva: NN O O
common NN O O
double NN O O
deletion NN O O
in NN O O
the NN O O
n-acetylgalactosamine-6-sulfatase NN O O
gene NN O O
(galns) NN O O
. NN O O

mucopolysaccharidosis NN O O
iva NN O O
( NN O O
MPS NN B-SpecificDisease B-OMIM:253000
IVA NN I-SpecificDisease I-OMIM:253000
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-MSH:D009085
in NN I-SpecificDisease I-MSH:D009085
N-acetylgalactosamine-6-sulfatase NN I-SpecificDisease I-MSH:D009085
(galns). NN O O
we NN O O
found NN O O
two NN O O
separate NN O O
deletions NN O O
of NN O O
nearly NN O O
8. NN O O
0 NN O O
and NN O O
6. NN O O
0 NN O O
kb NN O O
in NN O O
the NN O O
galns NN O O
gene, NN O O
including NN O O
some NN O O
exons. NN O O
there NN O O
are NN O O
alu NN O O
repetitive NN O O
elements NN O O
near NN O O
the NN O O
breakpoints NN O O
of NN O O
the NN O O
8. NN O O
0-kb NN O O
deletion, NN O O
and NN O O
this NN O O
deletion NN O O
resulted NN O O
from NN O O
an NN O O
alu-alu NN O O
recombination. NN O O
the NN O O
other NN O O
6. NN O O
0-kb NN O O
deletion NN O O
involved NN O O
illegitimate NN O O
recombinational NN O O
events NN O O
between NN O O
incomplete NN O O
short NN O O
direct NN O O
repeats NN O O
of NN O O
8 NN O O
bp NN O O
at NN O O
deletion NN O O
breakpoints. NN O O
the NN O O
same NN O O
rearrangement NN O O
has NN O O
been NN O O
observed NN O O
in NN O O
a NN O O
heteroallelic NN O O
state NN O O
in NN O O
four NN O O
unrelated NN O O
patients. NN O O
this NN O O
is NN O O
the NN O O
first NN O O
documentation NN O O
of NN O O
a NN O O
common NN O O
double NN O O
deletion NN O O
a NN O O
gene NN O O
that NN O O
is NN O O
not NN O O
a NN O O
member NN O O
of NN O O
a NN O O
gene NN O O
cluster NN O O
. NN O O

segregation NN O O
analysis NN O O
of NN O O
a NN O O
marker NN O O
localised NN O O
xp NN O O
21.2-xp NN O O
21.3 NN O O
in NN O O
Duchenne NN B-CompositeMention B-MSH:D020388
and NN I-CompositeMention I-MSH:D020388
Becker NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
families NN O O
. NN O O

a NN O O
dna NN O O
marker NN O O
c NN O O
7, NN O O
localised NN O O
xp NN O O
21. NN O O
1-xp NN O O
21. NN O O
3, NN O O
has NN O O
been NN O O
studied NN O O
in NN O O
kindreds NN O O
segregating NN O O
for NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
and NN O O
Becker NN B-SpecificDisease B-MSH:C537666
muscular NN I-SpecificDisease I-MSH:C537666
dystrophy NN I-SpecificDisease I-MSH:C537666
( NN O O
BMD NN B-SpecificDisease B-MSH:C537666
). NN O O
in NN O O
DMD NN B-Modifier B-MSH:D020388
families NN O O
four NN O O
crossovers NN O O
were NN O O
observed NN O O
in NN O O
38 NN O O
informative NN O O
meioses NN O O
between NN O O
c NN O O
7 NN O O
and NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
locus NN O O
(theta NN O O
= NN O O
0. NN O O
12, NN O O
z NN O O
max NN O O
= NN O O
+ NN O O
2. NN O O
72). NN O O
in NN O O
BMD NN B-Modifier B-MSH:C537666
families NN O O
no NN O O
recombinants NN O O
were NN O O
observed NN O O
in NN O O
the NN O O
16 NN O O
informative NN O O
meioses NN O O
studied. NN O O
these NN O O
data NN O O
are NN O O
consistent NN O O
with NN O O
the NN O O
localisation NN O O
of NN O O
the NN O O
mutations NN O O
in NN O O
these NN O O
disorders NN O O
being NN O O
in NN O O
the NN O O
same NN O O
region NN O O
of NN O O
xp NN O O
21. NN O O
studies NN O O
in NN O O
families NN O O
also NN O O
segregating NN O O
for NN O O
the NN O O
dna NN O O
marker NN O O
754 NN O O
support NN O O
the NN O O
previously NN O O
reported NN O O
physical NN O O
order NN O O
of NN O O
these NN O O
loci NN O O
as NN O O
x NN O O
centromere-754-dmd-bmd-c NN O O
7 NN O O
. NN O O

x NN O O
telomere. NN O O
a NN O O
recombination NN O O
fraction NN O O
of NN O O
0. NN O O
11 NN O O
(z NN O O
max NN O O
= NN O O
+ NN O O
5. NN O O
58) NN O O
was NN O O
found NN O O
between NN O O
dmd-754 NN O O
by NN O O
combining NN O O
our NN O O
previously NN O O
published NN O O
data NN O O
with NN O O
the NN O O
data NN O O
presented NN O O
here. NN O O
c NN O O
7 NN O O
and NN O O
754 NN O O
thus NN O O
provide NN O O
good NN O O
bridging NN O O
markers NN O O
for NN O O
the NN O O
diagnosis NN O O
of NN O O
DMD NN B-SpecificDisease B-MSH:D020388
and NN O O
BMD NN B-SpecificDisease B-MSH:C537666
. NN O O

genetic NN O O
analysis NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
region NN O O
in NN O O
a NN O O
large NN O O
breast/ovarian NN O O
family: NN O O
refinement NN O O
of NN O O
the NN O O
minimal NN O O
region NN O O
containing NN O O
brca NN O O
1 NN O O
. NN O O

we NN O O
have NN O O
analyzed NN O O
a NN O O
single NN O O
multi-affected NN O O
breast/ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
pedigree NN O O
(bov NN O O
3) NN O O
and NN O O
have NN O O
shown NN O O
consistent NN O O
inheritance NN O O
of NN O O
markers NN O O
on NN O O
chromosome NN O O
17 NN O O
q NN O O
with NN O O
the NN O O
disease NN O O
confirming NN O O
that NN O O
this NN O O
family NN O O
is NN O O
due NN O O
to NN O O
the NN O O
brca NN O O
1 NN O O
gene. NN O O
analysis NN O O
of NN O O
17 NN O O
q NN O O
haplotypes NN O O
shows NN O O
a NN O O
recombination NN O O
event NN O O
in NN O O
a NN O O
bilateral NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
case NN O O
which NN O O
suggests NN O O
that NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
lies NN O O
distal NN O O
to NN O O
d NN O O
17 NN O O
s NN O O
857; NN O O
d NN O O
17 NN O O
s NN O O
857 NN O O
is NN O O
thus NN O O
the NN O O
new NN O O
proximal NN O O
boundary NN O O
for NN O O
the NN O O
region NN O O
containing NN O O
brca NN O O
1. NN O O
combining NN O O
this NN O O
information NN O O
with NN O O
previously NN O O
published NN O O
mapping NN O O
information NN O O
suggests NN O O
that NN O O
brca NN O O
1 NN O O
is NN O O
contained NN O O
in NN O O
a NN O O
region NN O O
estimated NN O O
at NN O O
1-1. NN O O
5 NN O O
mb NN O O
in NN O O
length. NN O O
all NN O O
seven NN O O
breast NN B-Modifier B-MSH:D001943
tumour NN I-Modifier I-MSH:D001943
/blood NN O O
pairs NN O O
examined NN O O
from NN O O
this NN O O
family NN O O
show NN O O
loss NN O O
of NN O O
heterozygosity NN O O
in NN O O
the NN O O
tumours NN B-DiseaseClass B-MSH:D009369
. NN O O
the NN O O
allel NN O O
retaine NN O O
. NN O O

in NN O O
each NN O O
tumour NN B-DiseaseClass B-MSH:D009369
was NN O O
from NN O O
the NN O O
disease-bearing NN O O
chromosome NN O O
implicating NN O O
brca NN O O
1 NN O O
as NN O O
a NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
gene. NN O O
we NN O O
have NN O O
sequenced NN O O
the NN O O
17 NN O O
beta-oestradiol NN O O
dehydrogenase NN O O
genes NN O O
(edh NN O O
17 NN O O
b NN O O
1 NN O O
and NN O O
edh NN O O
17 NN O O
b NN O O
2) NN O O
which NN O O
have NN O O
been NN O O
suggested NN O O
as NN O O
candidate NN O O
genes NN O O
for NN O O
brca NN O O
1 NN O O
in NN O O
four NN O O
members NN O O
of NN O O
this NN O O
family. NN O O
no NN O O
germline NN O O
mutations NN O O
were NN O O
detected NN O O
. NN O O

a NN O O
point NN O O
mutation NN O O
thr(799)met NN O O
on NN O O
the NN O O
alpha(2) NN O O
integrin NN O O
leads NN O O
to NN O O
the NN O O
formation NN O O
of NN O O
new NN O O
human NN O O
platelet NN O O
alloantigen NN O O
sit(a) NN O O
and NN O O
affects NN O O
collagen-induced NN O O
aggregation NN O O
. NN O O
uman NN O O
platelet NN O O
alloantigen NN O O
sit(a) NN O O
and NN O O
affects NN O O
collagen-induced NN O O
aggregation NN O O
. NN O O

a NN O O
new NN O O
platelet-specific NN O O
alloantigen, NN O O
termed NN O O
sit NN O O
(a), NN O O
was NN O O
identified NN O O
in NN O O
a NN O O
severe NN O O
case NN O O
of NN O O
neonatal NN B-SpecificDisease B-MSH:D054098
alloimmune NN I-SpecificDisease I-MSH:D054098
thrombocytopenia NN I-SpecificDisease I-MSH:D054098
. NN O O
the NN O O
sit NN O O
(a) NN O O
alloantigen NN O O
is NN O O
of NN O O
low NN O O
frequency NN O O
(1/400) NN O O
in NN O O
the NN O O
german NN O O
population. NN O O
immunochemical NN O O
studies NN O O
demonstrated NN O O
that NN O O
the NN O O
sit NN O O
(a) NN O O
epitopes NN O O
reside NN O O
on NN O O
platelet NN O O
glycoprotein NN O O
(gp) NN O O
ia. NN O O
nucleotide NN O O
sequence NN O O
analysis NN O O
of NN O O
gpia NN O O
cdna NN O O
derived NN O O
from NN O O
sit NN O O
(a) NN O O
-positive NN O O
platelets NN O O
showed NN O O
c NN O O
(2531) NN O O
-- NN O O
> NN O O
t NN O O
(2531) NN O O
point NN O O
mutation, NN O O
resulting NN O O
in NN O O
thr NN O O
(799) NN O O
met NN O O
dimorphism. NN O O
analysis NN O O
of NN O O
genomic NN O O
dna NN O O
from NN O O
22 NN O O
sit NN O O
(a) NN O O
-negative NN O O
normal NN O O
individuals NN O O
showed NN O O
that NN O O
the NN O O
thr NN O O
(799) NN O O
is NN O O
encoded NN O O
by NN O O
acg NN O O
(2532) NN O O
(90. NN O O
9%) NN O O
or NN O O
aca NN O O
(253 NN O O
. NN O O

) NN O O
(9. NN O O
1%). NN O O
to NN O O
establish NN O O
a NN O O
dna NN O O
typing NN O O
technique, NN O O
we NN O O
elucidated NN O O
the NN O O
organization NN O O
of NN O O
the NN O O
gpia NN O O
gene NN O O
adjacent NN O O
to NN O O
the NN O O
polymorphic NN O O
bases. NN O O
the NN O O
introns NN O O
(421 NN O O
bp NN O O
and NN O O
1. NN O O
2 NN O O
kb) NN O O
encompass NN O O
a NN O O
142-bp NN O O
exon NN O O
with NN O O
the NN O O
2 NN O O
polymorphic NN O O
bases NN O O
2531 NN O O
and NN O O
2532. NN O O
polymerase NN O O
chain NN O O
reaction-restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
analysis NN O O
on NN O O
dna NN O O
derived NN O O
from NN O O
100 NN O O
donors NN O O
using NN O O
the NN O O
restriction NN O O
enzyme NN O O
mae NN O O
iii NN O O
showed NN O O
that NN O O
the NN O O
met NN O O
(799) NN O O
form NN O O
of NN O O
gpia NN O O
is NN O O
restricted NN O O
to NN O O
sit NN O O
(a) NN O O
(+) NN O O
phenotype. NN O O
analysis NN O O
of NN O O
stable NN O O
chinese NN O O
hamster NN O O
ovary NN O O
transfectants NN O O
expressing NN O O
allele-specific NN O O
recombinant NN O O
forms NN O O
of NN O O
gpia NN O O
showed NN O O
that NN O O
anti-sit NN O O
(a) NN O O
exclusively NN O O
reacted NN O O
with NN O O
the NN O O
glu NN O O
(505) NN O O
met NN O O
(799), NN O O
but NN O O
not NN O O
with NN O O
the NN O O
glu NN O O
. NN O O
bases. NN O O
the NN O O
introns NN O O
(421 NN O O
bp NN O O
and NN O O
1. NN O O
2 NN O O
kb) NN O O
encompass NN O O
a NN O O
142-bp NN O O
exon NN O O
with NN O O
the NN O O
2 NN O O
polymorphic NN O O
bases NN O O
2531 NN O O
and NN O O
2532. NN O O
polymerase NN O O
chain NN O O
reaction-restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
analysis NN O O
on NN O O
dna NN O O
derived NN O O
from NN O O
100 NN O O
donors NN O O
using NN O O
the NN O O
restriction NN O O
enzyme NN O O
mae NN O O
iii NN O O
showed NN O O
that NN O O
the NN O O
met NN O O
(799) NN O O
form NN O O
of NN O O
gpia NN O O
is NN O O
restricted NN O O
to NN O O
sit NN O O
(a) NN O O
(+) NN O O
phenotype. NN O O
analysis NN O O
of NN O O
stable NN O O
chinese NN O O
hamster NN O O
ovary NN O O
transfectants NN O O
expressing NN O O
allele-specific NN O O
recombinant NN O O
forms NN O O
of NN O O
gpia NN O O
showed NN O O
that NN O O
anti-sit NN O O
(a) NN O O
exclusively NN O O
reacted NN O O
with NN O O
the NN O O
glu NN O O
(505) NN O O
met NN O O
(799), NN O O
but NN O O
not NN O O
with NN O O
the NN O O
glu NN O O
. NN O O

505) NN O O
thr NN O O
(799) NN O O
and NN O O
the NN O O
lys NN O O
(505) NN O O
thr NN O O
(799) NN O O
isoforms. NN O O
in NN O O
contrast, NN O O
anti-br NN O O
(a) NN O O
(hpa-5 NN O O
b) NN O O
only NN O O
recognized NN O O
the NN O O
lys NN O O
(505) NN O O
thr NN O O
(799) NN O O
form, NN O O
whereas NN O O
anti-br NN O O
(b) NN O O
(hpa-5 NN O O
a) NN O O
reacted NN O O
with NN O O
both NN O O
glu NN O O
(505) NN O O
thr NN O O
(799) NN O O
and NN O O
glu NN O O
(505) NN O O
met NN O O
(799) NN O O
isoforms. NN O O
these NN O O
results NN O O
demonstrated NN O O
that NN O O
the NN O O
met NN O O
(799) NN O O
is NN O O
responsible NN O O
for NN O O
formation NN O O
of NN O O
the NN O O
sit NN O O
(a) NN O O
alloantigenic NN O O
determinants, NN O O
whereas NN O O
amino NN O O
acid NN O O
505 NN O O
(lys NN O O
or NN O O
glu) NN O O
specifically NN O O
controls NN O O
the NN O O
expression NN O O
of NN O O
br NN O O
(a) NN O O
and NN O O
br NN O O
(b) NN O O
epitopes, NN O O
respectively. NN O O
platelet NN O O
aggregation NN O O
responses NN O O
of NN O O
sit NN O O
(a) NN O O
( NN O O
. NN O O
99) NN O O
form, NN O O
whereas NN O O
anti-br NN O O
(b) NN O O
(hpa-5 NN O O
a) NN O O
reacted NN O O
with NN O O
both NN O O
glu NN O O
(505) NN O O
thr NN O O
(799) NN O O
and NN O O
glu NN O O
(505) NN O O
met NN O O
(799) NN O O
isoforms. NN O O
these NN O O
results NN O O
demonstrated NN O O
that NN O O
the NN O O
met NN O O
(799) NN O O
is NN O O
responsible NN O O
for NN O O
formation NN O O
of NN O O
the NN O O
sit NN O O
(a) NN O O
alloantigenic NN O O
determinants, NN O O
whereas NN O O
amino NN O O
acid NN O O
505 NN O O
(lys NN O O
or NN O O
glu) NN O O
specifically NN O O
controls NN O O
the NN O O
expression NN O O
of NN O O
br NN O O
(a) NN O O
and NN O O
br NN O O
(b) NN O O
epitopes, NN O O
respectively. NN O O
platelet NN O O
aggregation NN O O
responses NN O O
of NN O O
sit NN O O
(a) NN O O
( NN O O
. NN O O

) NN O O
individuals NN O O
were NN O O
diminished NN O O
in NN O O
response NN O O
to NN O O
collagen, NN O O
indicating NN O O
that NN O O
the NN O O
thr NN O O
(799) NN O O
met NN O O
mutation NN O O
affects NN O O
the NN O O
function NN O O
of NN O O
the NN O O
gpia/iia NN O O
comple NN O O
. NN O O
e NN O O
gpia/iia NN O O
comple NN O O
. NN O O

estimation NN O O
of NN O O
the NN O O
male NN O O
to NN O O
female NN O O
ratio NN O O
of NN O O
mutation NN O O
rates NN O O
from NN O O
the NN O O
segregation NN O O
of NN O O
x-chromosomal NN O O
dna NN O O
haplotypes NN O O
in NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
families NN O O
. NN O O

a NN O O
novel NN O O
procedure NN O O
is NN O O
presented NN O O
to NN O O
estimate NN O O
the NN O O
ratio NN O O
of NN O O
male NN O O
to NN O O
female NN O O
mutation NN O O
rates NN O O
for NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
x-specific NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
are NN O O
used NN O O
to NN O O
establish NN O O
dna NN O O
haplotypes NN O O
in NN O O
three-generation NN O O
DMD NN B-Modifier B-MSH:D020388
families. NN O O
from NN O O
the NN O O
proportion NN O O
of NN O O
DMD NN B-Modifier B-MSH:D020388
patients NN O O
who NN O O
have NN O O
inherited NN O O
their NN O O
maternal NN O O
grandfathers NN O O
x NN O O
chromosome, NN O O
the NN O O
ratio NN O O
of NN O O
mutation NN O O
rates NN O O
can NN O O
be NN O O
calculated. NN O O
in NN O O
contrast NN O O
to NN O O
classical NN O O
methods, NN O O
the NN O O
proposed NN O O
procedure NN O O
is NN O O
not NN O O
restricted NN O O
to NN O O
sporadic NN O O
or NN O O
familiar NN O O
cases NN O O
nor NN O O
is NN O O
any NN O O
information NN O O
on NN O O
the NN O O
carrier NN O O
status NN O O
of NN O O
female NN O O
relatives NN O O
required. NN O O
. NN O O

genetic NN O O
analysis NN O O
of NN O O
an NN O O
inherited NN O O
deficiency NN B-SpecificDisease B-OMIM:613779
of NN I-SpecificDisease I-OMIM:613779
the NN I-SpecificDisease I-OMIM:613779
third NN I-SpecificDisease I-OMIM:613779
component NN I-SpecificDisease I-OMIM:613779
of NN I-SpecificDisease I-OMIM:613779
complement NN I-SpecificDisease I-OMIM:613779
in NN O O
brittany NN O O
spaniel NN O O
dogs NN O O
. NN O O

genetically NN O O
determined NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
in NN O O
brittany NN O O
spaniel NN O O
dogs NN O O
shares NN O O
a NN O O
number NN O O
of NN O O
biochemical NN O O
and NN O O
clinical NN O O
characteristics NN O O
with NN O O
the NN O O
human NN O O
disorder. NN O O
in NN O O
humans, NN O O
the NN O O
gene NN O O
for NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
is NN O O
a NN O O
null NN O O
gene NN O O
that NN O O
is NN O O
allelic NN O O
to NN O O
the NN O O
structural NN O O
gene NN O O
for NN O O
c NN O O
3 NN O O
and NN O O
is NN O O
not NN O O
linked NN O O
to NN O O
the NN O O
major NN O O
histocompatibility NN O O
locus. NN O O
the NN O O
current NN O O
study NN O O
used NN O O
allotype NN O O
analysis NN O O
of NN O O
canine NN O O
c NN O O
3 NN O O
in NN O O
order NN O O
to NN O O
demonstrate NN O O
that NN O O
the NN O O
gene NN O O
for NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
in NN O O
these NN O O
dogs NN O O
is NN O O
also NN O O
a NN O O
null NN O O
gene NN O O
allelic NN O O
to NN O O
the NN O O
structural NN O O
gene NN O O
for NN O O
c NN O O
3. NN O O
in NN O O
addition, NN O O
preliminary NN O O
pedigree NN O O
analysis NN O O
suggests NN O O
that NN O O
the NN O O
gene NN O O
for NN O O
canine NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
is NN O O
apparently NN O O
not NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
of NN O O
the NN O O
dog. NN O O
thus, NN O O
it NN O O
appears NN O O
that NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
in NN O O
brittany NN O O
spaniel NN O O
dogs NN O O
not NN O O
only NN O O
shares NN O O
biochemical NN O O
and NN O O
clinica NN O O
. NN O O

features NN O O
with NN O O
C3 NN B-SpecificDisease B-OMIM:613779
deficiency NN I-SpecificDisease I-OMIM:613779
in NN O O
humans, NN O O
but NN O O
also NN O O
shares NN O O
some NN O O
genetic NN O O
characteristics NN O O
with NN O O
the NN O O
human NN O O
disorder. NN O O
. NN O O

a NN O O
novel NN O O
frameshift NN O O
mutation NN O O
in NN O O
the NN O O
McLeod NN B-Modifier B-OMIM:300842
syndrome NN I-Modifier I-OMIM:300842
gene NN O O
in NN O O
a NN O O
japanese NN O O
family NN O O
. NN O O

we NN O O
report NN O O
a NN O O
novel NN O O
mutation NN O O
in NN O O
the NN O O
xk NN O O
gene NN O O
(xk) NN O O
in NN O O
a NN O O
japanese NN O O
patient NN O O
with NN O O
McLeod NN B-SpecificDisease B-OMIM:300842
syndrome NN I-SpecificDisease I-OMIM:300842
. NN O O
a NN O O
50-year-old NN O O
man NN O O
showed NN O O
progressive NN O O
muscular NN B-DiseaseClass B-MSH:D009133
atrophy NN I-DiseaseClass I-MSH:D009133
, NN O O
choreic NN B-DiseaseClass B-MSH:D002819
movement NN I-DiseaseClass I-MSH:D002819
, NN O O
elevated NN O O
level NN O O
of NN O O
serum NN O O
creatinine NN O O
kinase, NN O O
and NN O O
acanthocytosis NN B-SpecificDisease B-MSH:D000012
. NN O O
the NN O O
expression NN O O
level NN O O
of NN O O
all NN O O
the NN O O
kell NN O O
antigens NN O O
in NN O O
erythrocyte NN O O
was NN O O
decreased NN O O
and NN O O
molecular NN O O
analysis NN O O
revealed NN O O
a NN O O
single-base NN O O
(t) NN O O
deletion NN O O
at NN O O
the NN O O
nucleotide NN O O
position NN O O
1095 NN O O
in NN O O
xk. NN O O
this NN O O
deletion NN O O
caused NN O O
a NN O O
frameshift NN O O
in NN O O
translation, NN O O
leading NN O O
to NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
at NN O O
the NN O O
amino NN O O
acid NN O O
position NN O O
408. NN O O
we NN O O
conclude NN O O
this NN O O
single-base NN O O
deletion NN O O
causes NN O O
defective NN O O
kx NN O O
protein, NN O O
which NN O O
is NN O O
responsible NN O O
for NN O O
the NN O O
McLeod NN B-Modifier B-OMIM:300842
phenotype NN O O
in NN O O
this NN O O
patient. NN O O
. NN O O

alpha-cardiac NN O O
actin NN O O
is NN O O
a NN O O
novel NN O O
disease NN O O
gene NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D024741
hypertrophic NN I-SpecificDisease I-MSH:D024741
cardiomyopathy NN I-SpecificDisease I-MSH:D024741
. NN O O

we NN O O
identified NN O O
the NN O O
alpha-cardiac NN O O
actin NN O O
gene NN O O
(actc) NN O O
as NN O O
a NN O O
novel NN O O
disease NN O O
gene NN O O
in NN O O
a NN O O
pedigree NN O O
suffering NN O O
from NN O O
familial NN B-SpecificDisease B-MSH:D024741
hypertrophic NN I-SpecificDisease I-MSH:D024741
cardiomyopathy NN I-SpecificDisease I-MSH:D024741
( NN O O
FHC NN B-SpecificDisease B-MSH:D024741
). NN O O
linkage NN O O
analyses NN O O
excluded NN O O
all NN O O
the NN O O
previously NN O O
reported NN O O
FHC NN B-Modifier B-MSH:D024741
loci NN O O
as NN O O
possible NN O O
disease NN O O
loci NN O O
in NN O O
the NN O O
family NN O O
studied, NN O O
with NN O O
lod NN O O
scores NN O O
varying NN O O
between NN O O
-2. NN O O
5 NN O O
and NN O O
-6. NN O O
0 NN O O
0. NN O O
further NN O O
linkage NN O O
analyses NN O O
of NN O O
plausible NN O O
candidate NN O O
genes NN O O
highly NN O O
expressed NN O O
in NN O O
the NN O O
adult NN O O
human NN O O
heart NN O O
identified NN O O
actc NN O O
as NN O O
the NN O O
most NN O O
likely NN O O
disease NN O O
gene, NN O O
showing NN O O
a NN O O
maximal NN O O
lod NN O O
score NN O O
of NN O O
3. NN O O
6 NN O O
6. NN O O
mutation NN O O
analysis NN O O
of NN O O
actc NN O O
revealed NN O O
an NN O O
ala NN O O
295 NN O O
ser NN O O
mutation NN O O
in NN O O
exon NN O O
5 NN O O
close NN O O
to NN O O
2 NN O O
missense NN O O
mutations NN O O
recently NN O O
described NN O O
to NN O O
cause NN O O
the NN O O
inherited NN O O
form NN O O
of NN O O
idiopathic NN B-SpecificDisease B-MSH:C536277
dilated NN I-SpecificDisease I-MSH:C536277
cardiomyopathy NN I-SpecificDisease I-MSH:C536277
( NN O O
IDC NN B-SpecificDisease B-MSH:C536277
) NN O O
. NN O O

the NN O O
ews NN O O
gene, NN O O
involved NN O O
in NN O O
Ewing NN B-DiseaseClass B-MSH:D012512
family NN I-DiseaseClass I-MSH:D012512
of NN I-DiseaseClass I-MSH:D012512
tumors NN I-DiseaseClass I-MSH:D012512
, NN O O
malignant NN B-DiseaseClass B-MSH:D008545
melanoma NN I-DiseaseClass I-MSH:D008545
of NN I-DiseaseClass I-MSH:D008545
soft NN I-DiseaseClass I-MSH:D008545
parts NN I-DiseaseClass I-MSH:D008545
and NN O O
desmoplastic NN B-SpecificDisease B-MSH:D058405
small NN I-SpecificDisease I-MSH:D058405
round NN I-SpecificDisease I-MSH:D058405
cell NN I-SpecificDisease I-MSH:D058405
tumors NN I-SpecificDisease I-MSH:D058405
, NN O O
codes NN O O
for NN O O
an NN O O
rna NN O O
binding NN O O
protein NN O O
with NN O O
novel NN O O
regulatory NN O O
domains NN O O
. NN O O

the NN O O
ews NN O O
gene, NN O O
which NN O O
maps NN O O
to NN O O
band NN O O
q NN O O
12 NN O O
of NN O O
human NN O O
chromosome NN O O
22, NN O O
is NN O O
involved NN O O
in NN O O
a NN O O
wide NN O O
variety NN O O
of NN O O
human NN O O
solid NN B-DiseaseClass B-MSH:D009369
tumors NN I-DiseaseClass I-MSH:D009369
including NN O O
Ewing NN B-SpecificDisease B-MSH:D012512
sarcoma NN I-SpecificDisease I-MSH:D012512
, NN O O
related NN O O
primitive NN O O
neuroectodermal NN B-DiseaseClass B-MSH:D017599
tumors NN I-DiseaseClass I-MSH:D017599
, NN O O
malignant NN B-DiseaseClass B-MSH:D008545
melanoma NN I-DiseaseClass I-MSH:D008545
of NN I-DiseaseClass I-MSH:D008545
soft NN I-DiseaseClass I-MSH:D008545
parts NN I-DiseaseClass I-MSH:D008545
and NN O O
desmoplastic NN B-DiseaseClass B-MSH:D058405
small NN I-DiseaseClass I-MSH:D058405
round NN I-DiseaseClass I-MSH:D058405
cell NN I-DiseaseClass I-MSH:D058405
tumors NN I-DiseaseClass I-MSH:D058405
. NN O O
in NN O O
these NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
the NN O O
ews NN O O
is NN O O
fused NN O O
to NN O O
genes NN O O
encoding NN O O
transcriptional NN O O
activators/repressors, NN O O
like NN O O
fli-1 NN O O
or NN O O
erg NN O O
or NN O O
atf NN O O
1 NN O O
or NN O O
wt NN O O
1. NN O O
to NN O O
better NN O O
understand NN O O
the NN O O
function NN O O
of NN O O
the NN O O
ews NN O O
protein, NN O O
we NN O O
cloned NN O O
the NN O O
ews NN O O
cdna. NN O O
sequence NN O O
analysis NN O O
of NN O O
this NN O O
cdna NN O O
revealed NN O O
differential NN O O
splicing NN O O
involving NN O O
two NN O O
exons NN O O
encoding NN O O
72 NN O O
amino NN O O
acids. NN O O
both NN O O
alternatively NN O O
spliced NN O O
transcripts, NN O O
ews NN O O
and NN O O
ews-b, NN O O
are NN O O
expressed NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
cells. NN O O
because NN O O
ews NN O O
proteins NN O O
contain NN O O
putative NN O O
conserved NN O O
rna NN O O
binding NN O O
motifs, NN O O
we NN O O
studied NN O O
the NN O O
rn NN O O
. NN O O

binding NN O O
properties NN O O
of NN O O
the NN O O
ews NN O O
protein. NN O O
the NN O O
ews-b NN O O
protein NN O O
binds NN O O
to NN O O
rna NN O O
in NN O O
vitro NN O O
and, NN O O
specifically, NN O O
to NN O O
poly NN O O
g NN O O
and NN O O
poly NN O O
u. NN O O
the NN O O
rna NN O O
binding NN O O
activity NN O O
was NN O O
localized NN O O
to NN O O
the NN O O
carboxy NN O O
terminal NN O O
86 NN O O
amino NN O O
acids, NN O O
which NN O O
constitute NN O O
rgg NN O O
box. NN O O
thus NN O O
the NN O O
amino NN O O
terminal NN O O
domain NN O O
of NN O O
ews NN O O
(ntd-ews), NN O O
which NN O O
is NN O O
involved NN O O
in NN O O
chromosome NN O O
translocation NN O O
may NN O O
regulate NN O O
the NN O O
specificity NN O O
of NN O O
rna NN O O
binding NN O O
activity NN O O
of NN O O
ews. NN O O
an NN O O
ews-erg NN O O
chimeric NN O O
protein, NN O O
which NN O O
is NN O O
found NN O O
in NN O O
Ewings NN B-Modifier B-MSH:D012512
sarcoma NN I-Modifier I-MSH:D012512
cells, NN O O
functions NN O O
as NN O O
a NN O O
transcriptional NN O O
activator. NN O O
mutational NN O O
analysis NN O O
of NN O O
ews-erg NN O O
chimeric NN O O
protein NN O O
revealed NN O O
that NN O O
ntd-ews NN O O
functions NN O O
as NN O O
a NN O O
regulatory NN O O
domain NN O O
for NN O O
the NN O O
transcriptional NN O O
activation NN O O
properties NN O O
of NN O O
ews-erg NN O O
chimeric NN O O
protein. NN O O
. NN O O

a NN O O
mutation NN O O
common NN O O
in NN O O
non-jewish NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
: NN O O
frequency NN O O
and NN O O
rna NN O O
studies NN O O
. NN O O

tay-sachs NN O O
disease NN O O
( NN O O
TSD NN B-SpecificDisease B-MSH:D013661
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
genetic NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
resulting NN O O
from NN O O
mutation NN O O
of NN O O
the NN O O
hexa NN O O
gene NN O O
encoding NN O O
the NN O O
alpha-subunit NN O O
of NN O O
the NN O O
lysosomal NN O O
enzyme, NN O O
beta-n-acetylhexosaminidase NN O O
a NN O O
(hex NN O O
a). NN O O
we NN O O
have NN O O
discovered NN O O
that NN O O
a NN O O
Tay-Sachs NN B-Modifier B-MSH:D013661
mutation, NN O O
ivs-9 NN O O
+ NN O O
1 NN O O
g-- NN O O
> NN O O
a, NN O O
first NN O O
detected NN O O
by NN O O
akli NN O O
et NN O O
al. NN O O
(genomics NN O O
11 NN O O
124-134, NN O O
1991), NN O O
is NN O O
a NN O O
common NN O O
disease NN O O
allele NN O O
in NN O O
non-jewish NN O O
caucasians NN O O
(10/58 NN O O
alleles NN O O
examined). NN O O
a NN O O
pcr-based NN O O
diagnostic NN O O
test, NN O O
which NN O O
detects NN O O
an NN O O
nlaiii NN O O
site NN O O
generated NN O O
by NN O O
the NN O O
mutation, NN O O
revealed NN O O
a NN O O
frequency NN O O
among NN O O
enzyme-defined NN O O
carriers NN O O
of NN O O
9/64 NN O O
(14%). NN O O
most NN O O
of NN O O
those NN O O
carrying NN O O
the NN O O
allele NN O O
trace NN O O
their NN O O
origin NN O O
. NN O O

to NN O O
the NN O O
united NN O O
kingdom, NN O O
ireland, NN O O
or NN O O
western NN O O
europe. NN O O
it NN O O
was NN O O
not NN O O
identified NN O O
among NN O O
12 NN O O
black NN O O
american NN O O
TSD NN B-Modifier B-MSH:D013661
alleles NN O O
or NN O O
in NN O O
any NN O O
of NN O O
18 NN O O
ashkenazi NN O O
jewish, NN O O
enzyme-defined NN O O
carriers NN O O
who NN O O
did NN O O
not NN O O
carry NN O O
any NN O O
of NN O O
the NN O O
mutations NN O O
common NN O O
to NN O O
this NN O O
population. NN O O
no NN O O
normally NN O O
spliced NN O O
rna NN O O
was NN O O
detected NN O O
in NN O O
pcr NN O O
products NN O O
generated NN O O
from NN O O
reverse NN O O
transcription NN O O
of NN O O
rna NN O O
carrying NN O O
the NN O O
ivs-9 NN O O
mutation. NN O O
instead, NN O O
the NN O O
low NN O O
levels NN O O
of NN O O
mrna NN O O
from NN O O
this NN O O
allele NN O O
were NN O O
comprised NN O O
of NN O O
aberrant NN O O
species NN O O
resulting NN O O
from NN O O
the NN O O
use NN O O
of NN O O
either NN O O
of NN O O
two NN O O
cryptic NN O O
donor NN O O
sites, NN O O
one NN O O
truncating NN O O
exon NN O O
9 NN O O
and NN O O
the NN O O
other NN O O
within NN O O
ivs-9, NN O O
spliced NN O O
to NN O O
exon NN O O
10. NN O O
numerous NN O O
additional NN O O
splice NN O O
products NN O O
were NN O O
detected, NN O O
most NN O O
involving NN O O
skipping NN O O
of NN O O
one NN O O
or NN O O
more NN O O
surrounding NN O O
exons. NN O O
together NN O O
with NN O O
a NN O O
recently NN O O
identified NN O O
allele NN O O
responsible NN O O
for NN O O
hex NN O O
a NN O O
pseudodeficienc NN O O
. NN O O

(triggs-raine NN O O
et NN O O
al. NN O O
am NN O O
j NN O O
hum NN O O
genet, NN O O
1992), NN O O
these NN O O
two NN O O
alleles NN O O
accounted NN O O
for NN O O
almost NN O O
50% NN O O
(29/64) NN O O
of NN O O
TSD NN B-Modifier B-MSH:D013661
or NN O O
carrier NN O O
alleles NN O O
ascertained NN O O
by NN O O
enzyme NN O O
screening NN O O
tests NN O O
in NN O O
non-jewish NN O O
caucasians. NN O O
. NN O O

characterization NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
region NN O O
predicts NN O O
multiple NN O O
protein NN O O
isoform-encoding NN O O
mrnas NN O O
. NN O O

the NN O O
mutation NN O O
underlying NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
has NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
polymorphic NN O O
ctg-repeat NN O O
in NN O O
a NN O O
gene NN O O
encoding NN O O
protein NN O O
kinase NN O O
activity. NN O O
brain NN O O
and NN O O
heart NN O O
transcripts NN O O
of NN O O
the NN O O
dm-kinase NN O O
(dmr-b NN O O
15) NN O O
gene NN O O
are NN O O
subject NN O O
to NN O O
alternative NN O O
rna NN O O
splicing NN O O
in NN O O
both NN O O
human NN O O
and NN O O
mouse. NN O O
the NN O O
unstable NN O O
[ctg] NN O O
5-30 NN O O
motif NN O O
is NN O O
found NN O O
uniquely NN O O
in NN O O
humans, NN O O
although NN O O
the NN O O
flanking NN O O
nucleotides NN O O
are NN O O
also NN O O
present NN O O
in NN O O
mouse. NN O O
characterization NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
region NN O O
of NN O O
both NN O O
species NN O O
reveals NN O O
another NN O O
active NN O O
gene NN O O
(dmr-n NN O O
9) NN O O
in NN O O
close NN O O
proximity NN O O
to NN O O
the NN O O
kinase NN O O
gene. NN O O
dmr-n NN O O
9 NN O O
transcripts, NN O O
mainly NN O O
expressed NN O O
in NN O O
brain NN O O
and NN O O
testis, NN O O
possess NN O O
a NN O O
single, NN O O
large NN O O
open NN O O
reading NN O O
frame, NN O O
but NN O O
the NN O O
function NN O O
of NN O O
its NN O O
protein NN O O
product NN O O
is NN O O
unknown. NN O O
clinica NN O O
. NN O O

manifestation NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
may NN O O
be NN O O
caused NN O O
by NN O O
the NN O O
expanded NN O O
ctg-repeat NN O O
compromising NN O O
the NN O O
(alternative) NN O O
expression NN O O
of NN O O
dm-kinase NN O O
or NN O O
dmr-n NN O O
9 NN O O
proteins. NN O O
. NN O O

paroxysmal NN O O
nocturnal NN O O
haemoglobinuria NN O O
with NN O O
coexisting NN O O
deficiency NN B-SpecificDisease B-OMIM:613825
of NN I-SpecificDisease I-OMIM:613825
the NN I-SpecificDisease I-OMIM:613825
ninth NN I-SpecificDisease I-OMIM:613825
component NN I-SpecificDisease I-OMIM:613825
of NN I-SpecificDisease I-OMIM:613825
complement NN I-SpecificDisease I-OMIM:613825
: NN O O
lack NN O O
of NN O O
massive NN O O
haemolytic NN B-SpecificDisease B-MSH:D006461
attack NN I-SpecificDisease I-MSH:D006461
. NN O O

a NN O O
47-year-old NN O O
woman NN O O
with NN O O
paroxysmal NN B-SpecificDisease B-MSH:D006457
nocturnal NN I-SpecificDisease I-MSH:D006457
haemoglobinuria NN I-SpecificDisease I-MSH:D006457
( NN O O
PNH NN B-SpecificDisease B-MSH:D006457
) NN O O
was NN O O
found NN O O
to NN O O
have NN O O
an NN O O
inherited NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
in NN I-SpecificDisease I-OMIM:613825
the NN I-SpecificDisease I-OMIM:613825
ninth NN I-SpecificDisease I-OMIM:613825
complement NN I-SpecificDisease I-OMIM:613825
component NN I-SpecificDisease I-OMIM:613825
(c NN O O
9). NN O O
in NN O O
complement-sensitivity NN O O
lysis NN O O
tests, NN O O
80% NN O O
of NN O O
her NN O O
erythrocytes NN O O
were NN O O
markedly NN O O
complement-sensitive NN O O
(pnh-iii). NN O O
laser NN O O
cytofluorimetry NN O O
with NN O O
a NN O O
monoclonal NN O O
antibody NN O O
against NN O O
decay-accelerating NN O O
factor NN O O
(daf) NN O O
revealed NN O O
that NN O O
95% NN O O
of NN O O
her NN O O
erythrocytes NN O O
were NN O O
daf-negative. NN O O
surprisingly, NN O O
she NN O O
has NN O O
suffered NN O O
only NN O O
mild NN O O
haemolysis NN B-SpecificDisease B-MSH:D006461
and NN O O
has NN O O
never NN O O
experienced NN O O
massive NN O O
spontaneous NN O O
haemolysis NN B-SpecificDisease B-MSH:D006461
. NN O O
gross NN O O
haemoglobinuria NN B-SpecificDisease B-MSH:D006456
and NN O O
jaundice NN B-SpecificDisease B-MSH:D007565
occurred NN O O
only NN O O
after NN O O
receiving NN O O
postoperative NN O O
transfusion NN O O
of NN O O
whole NN O O
blood. NN O O
in NN O O
her NN O O
serum, NN O O
c NN O O
9 NN O O
was NN O O
not NN O O
detectable NN O O
either NN O O
by NN O O
immunological NN O O
or NN O O
by NN O O
functional NN O O
assays. NN O O
both NN O O
the NN O O
ham NN O O
test NN O O
and NN O O
the NN O O
sugar NN O O
water NN O O
test NN O O
using NN O O
normal NN O O
human NN O O
seru NN O O
. NN O O

or NN O O
plasma NN O O
yielded NN O O
marked NN O O
haemolysis NN O O
of NN O O
the NN O O
patients NN O O
erythrocytes. NN O O
when NN O O
the NN O O
patients NN O O
serum NN O O
or NN O O
plasma NN O O
was NN O O
used, NN O O
only NN O O
a NN O O
trace NN O O
of NN O O
lysis NN O O
was NN O O
detected. NN O O
addition NN O O
of NN O O
purified NN O O
human NN O O
c NN O O
9 NN O O
to NN O O
her NN O O
plasma NN O O
fully NN O O
restored NN O O
haemolysis. NN O O
these NN O O
observations NN O O
indicated NN O O
that NN O O
c NN O O
9 NN O O
may NN O O
play NN O O
a NN O O
critical NN O O
role NN O O
in NN O O
haemolytic NN B-DiseaseClass B-MSH:D006461
attacks NN I-DiseaseClass I-MSH:D006461
in NN O O
patients NN O O
with NN O O
PNH NN B-SpecificDisease B-MSH:D006457
and NN O O
that NN O O
characteristic NN O O
haemolysis NN B-SpecificDisease B-MSH:D006461
in NN O O
PNH NN B-SpecificDisease B-MSH:D006457
may NN O O
be NN O O
tempered NN O O
by NN O O
coexisting NN O O
C9 NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
. NN O O
. NN O O

brca NN O O
1 NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
human NN O O
swi/snf-related NN O O
complex: NN O O
linking NN O O
chromatin NN O O
remodeling NN O O
to NN O O
breast NN B-SpecificDisease B-MSH:D001943
cancer NN I-SpecificDisease I-MSH:D001943
. NN O O

germline NN O O
mutations NN O O
in NN O O
the NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
gene, NN O O
brca NN O O
1, NN O O
predispose NN O O
individuals NN O O
to NN O O
breast NN B-CompositeMention B-MSH:D010051
and NN I-CompositeMention I-MSH:D010051
ovarian NN I-CompositeMention I-MSH:D010051
cancers NN I-CompositeMention I-MSH:D010051
. NN O O
using NN O O
a NN O O
combination NN O O
of NN O O
affinity- NN O O
and NN O O
conventional NN O O
chromatographic NN O O
techniques, NN O O
we NN O O
have NN O O
isolated NN O O
a NN O O
predominant NN O O
form NN O O
of NN O O
a NN O O
multiprotein NN O O
brca NN O O
1-containing NN O O
complex NN O O
from NN O O
human NN O O
cells NN O O
displaying NN O O
chromatin-remodeling NN O O
activity. NN O O
mass NN O O
spectrometric NN O O
sequencing NN O O
of NN O O
components NN O O
of NN O O
this NN O O
complex NN O O
indicated NN O O
that NN O O
brca NN O O
1 NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
swi/snf-related NN O O
complex. NN O O
we NN O O
show NN O O
that NN O O
brca NN O O
1 NN O O
can NN O O
directly NN O O
interact NN O O
with NN O O
the NN O O
brg NN O O
1 NN O O
subunit NN O O
of NN O O
the NN O O
swi/snf NN O O
complex. NN O O
moreover, NN O O
p NN O O
53-mediated NN O O
stimulation NN O O
of NN O O
transcription NN O O
by NN O O
brca NN O O
1 NN O O
was NN O O
completely NN O O
abrogated NN O O
by NN O O
either NN O O
a NN O O
dominant-negative NN O O
mutant NN O O
of NN O O
brg NN O O
1 NN O O
or NN O O
the NN O O
cancer NN B-DiseaseClass B-MSH:D009369
-causing NN O O
deletion NN O O
in NN O O
exon NN O O
11 NN O O
of NN O O
brca NN O O
1. NN O O
these NN O O
findings NN O O
reveal NN O O
a NN O O
direct NN O O
functio NN O O
. NN O O

for NN O O
brca NN O O
1 NN O O
in NN O O
transcriptional NN O O
control NN O O
through NN O O
modulation NN O O
of NN O O
chromatin NN O O
structure. NN O O
. NN O O

germinal NN O O
mosaicism NN O O
in NN O O
a NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
family: NN O O
implications NN O O
for NN O O
genetic NN O O
counselling NN O O
. NN O O

in NN O O
this NN O O
study NN O O
we NN O O
describe NN O O
a NN O O
three-generation NN O O
family NN O O
in NN O O
which NN O O
two NN O O
siblings NN O O
were NN O O
affected NN O O
by NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
immunohistochemical NN O O
analysis NN O O
of NN O O
muscle NN O O
dystrophin NN O O
and NN O O
haplotype NN O O
analysis NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
locus NN O O
revealed NN O O
that NN O O
the NN O O
x NN O O
chromosome NN O O
carrying NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
was NN O O
transmitted NN O O
from NN O O
the NN O O
healthy NN O O
maternal NN O O
grandfather NN O O
to NN O O
his NN O O
three NN O O
daughters, NN O O
including NN O O
the NN O O
probands NN O O
mother. NN O O
these NN O O
findings NN O O
indicate NN O O
that NN O O
the NN O O
grandfather NN O O
was NN O O
a NN O O
germinal NN O O
mosaic NN O O
for NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene. NN O O
the NN O O
definition NN O O
of NN O O
the NN O O
carrier NN O O
status NN O O
in NN O O
two NN O O
possible NN O O
carriers NN O O
led NN O O
us NN O O
to NN O O
give NN O O
accurate NN O O
genetic NN O O
counselling NN O O
and NN O O
to NN O O
prevent NN O O
the NN O O
birth NN O O
of NN O O
an NN O O
affected NN O O
boy. NN O O
the NN O O
results NN O O
of NN O O
this NN O O
study NN O O
demonstrate NN O O
the NN O O
usefulness NN O O
of NN O O
haplotype NN O O
analysis NN O O
and NN O O
immunohistochemical NN O O
muscle NN O O
dystrophin NN O O
studies NN O O
to NN O O
detect NN O O
hidden NN O O
germinal NN O O
mosaicism NN O O
and NN O O
to NN O O
improve NN O O
genetic NN O O
counselling. NN O O
. NN O O

centrosome NN O O
amplification NN O O
and NN O O
a NN O O
defective NN O O
g NN O O
2-m NN O O
cell NN O O
cycle NN O O
checkpoint NN O O
induce NN O O
genetic NN O O
instability NN O O
in NN O O
brca NN O O
1 NN O O
exon NN O O
11 NN O O
isoform-deficient NN O O
cells NN O O
. NN O O

germline NN O O
mutations NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
tumor NN B-Modifier B-MSH:D009369
suppressor NN O O
gene NN O O
predispose NN O O
women NN O O
to NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancers NN I-CompositeMention I-MSH:D061325
. NN O O
to NN O O
study NN O O
mechanisms NN O O
underlying NN O O
brca NN O O
1-related NN O O
tumorigenesis, NN O O
we NN O O
derived NN O O
mouse NN O O
embryonic NN O O
fibroblast NN O O
cells NN O O
carrying NN O O
a NN O O
targeted NN O O
deletion NN O O
of NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
gene. NN O O
we NN O O
show NN O O
that NN O O
the NN O O
mutant NN O O
cells NN O O
maintain NN O O
an NN O O
intact NN O O
g NN O O
1-s NN O O
cell NN O O
cycle NN O O
checkpoint NN O O
and NN O O
proliferate NN O O
poorly. NN O O
however, NN O O
a NN O O
defective NN O O
g NN O O
2-m NN O O
checkpoint NN O O
in NN O O
these NN O O
cells NN O O
is NN O O
accompanied NN O O
by NN O O
extensive NN O O
chromosomal NN B-DiseaseClass B-MSH:D002869
abnormalities NN I-DiseaseClass I-MSH:D002869
. NN O O
mutant NN O O
fibroblasts NN O O
contain NN O O
multiple, NN O O
functional NN O O
centrosomes, NN O O
which NN O O
lead NN O O
to NN O O
unequal NN O O
chromosome NN O O
segregation, NN O O
abnormal NN O O
nuclear NN O O
division, NN O O
and NN O O
aneuploidy NN B-SpecificDisease B-MSH:D000782
. NN O O
these NN O O
data NN O O
uncover NN O O
an NN O O
essential NN O O
role NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
maintaining NN O O
genetic NN O O
stability NN O O
through NN O O
the NN O O
regulation NN O O
of NN O O
centrosome NN O O
duplication NN O O
and NN O O
the NN O O
g NN O O
2-m NN O O
checkpoint NN O O
and NN O O
provide NN O O
a NN O O
molecular NN O O
basis NN O O
for NN O O
th NN O O
. NN O O

role NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
tumorigenesis. NN O O
. NN O O

aberrant NN O O
splicing NN O O
of NN O O
phenylalanine NN O O
hydroxylase NN O O
mrna: NN O O
the NN O O
major NN O O
cause NN O O
for NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
in NN O O
parts NN O O
of NN O O
southern NN O O
europe NN O O
. NN O O

we NN O O
report NN O O
a NN O O
mutation NN O O
within NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
gene NN O O
that NN O O
causes NN O O
aberrant NN O O
splicing NN O O
of NN O O
the NN O O
mrna NN O O
and NN O O
that NN O O
is NN O O
in NN O O
tight NN O O
association NN O O
with NN O O
chromosomal NN O O
haplotypes NN O O
6, NN O O
10, NN O O
and NN O O
36. NN O O
because NN O O
of NN O O
the NN O O
high NN O O
frequency NN O O
of NN O O
these NN O O
particular NN O O
haplotypes NN O O
in NN O O
bulgaria, NN O O
italy, NN O O
and NN O O
turkey, NN O O
it NN O O
appears NN O O
to NN O O
be NN O O
one NN O O
of NN O O
the NN O O
more NN O O
frequent NN O O
defects NN O O
in NN O O
the NN O O
pah NN O O
gene NN O O
causing NN O O
classical NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
in NN O O
this NN O O
part NN O O
of NN O O
europe. NN O O
the NN O O
mutation NN O O
is NN O O
a NN O O
g NN O O
to NN O O
a NN O O
transition NN O O
at NN O O
position NN O O
546 NN O O
in NN O O
intron NN O O
10 NN O O
of NN O O
the NN O O
pah NN O O
gene, NN O O
11 NN O O
bp NN O O
upstream NN O O
from NN O O
the NN O O
intron NN O O
10/exon NN O O
11 NN O O
boundary. NN O O
it NN O O
activates NN O O
a NN O O
cryptic NN O O
splice NN O O
site NN O O
and NN O O
results NN O O
in NN O O
an NN O O
in-frame NN O O
insertion NN O O
of NN O O
9 NN O O
nucleotides NN O O
between NN O O
exon NN O O
10 NN O O
and NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
processed NN O O
mrna. NN O O
normal NN O O
amounts NN O O
of NN O O
liver NN O O
pah NN O O
protei NN O O
. NN O O

are NN O O
present NN O O
in NN O O
homozygous NN O O
patients, NN O O
but NN O O
no NN O O
catalytic NN O O
activity NN O O
can NN O O
be NN O O
detected. NN O O
this NN O O
loss NN O O
of NN O O
enzyme NN O O
activity NN O O
is NN O O
probably NN O O
caused NN O O
by NN O O
conformational NN O O
changes NN O O
resulting NN O O
from NN O O
the NN O O
insertion NN O O
of NN O O
three NN O O
additional NN O O
amino NN O O
acids NN O O
(gly-leu-gln) NN O O
between NN O O
the NN O O
normal NN O O
sequences NN O O
encoded NN O O
by NN O O
exon NN O O
10 NN O O
and NN O O
exon NN O O
11. NN O O
. NN O O

biochemical NN O O
and NN O O
structural NN O O
analysis NN O O
of NN O O
missense NN O O
mutations NN O O
in NN O O
n-acetylgalactosamine-6-sulfate NN O O
sulfatase NN O O
causing NN O O
mucopolysaccharidosis NN B-Modifier B-OMIM:253000
IVA NN I-Modifier I-OMIM:253000
phenotypes NN O O
. NN O O

mucopolysaccharidosis NN O O
iva NN O O
( NN O O
MPS NN B-SpecificDisease B-OMIM:253000
IVA NN I-SpecificDisease I-OMIM:253000
; NN O O
omim NN O O
# NN O O
253000), NN O O
a NN O O
lysosomal NN B-DiseaseClass B-MSH:D016464
storage NN I-DiseaseClass I-MSH:D016464
disorder NN I-DiseaseClass I-MSH:D016464
caused NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-OMIM:253000
of NN I-SpecificDisease I-OMIM:253000
N NN I-SpecificDisease I-OMIM:253000
-acetylgalactosamine-6-sulfate NN I-SpecificDisease I-OMIM:253000
sulfatase NN I-SpecificDisease I-OMIM:253000
(galns), NN O O
has NN O O
variable NN O O
clinical NN O O
phenotypes. NN O O
to NN O O
date NN O O
we NN O O
have NN O O
identified NN O O
65 NN O O
missense NN O O
mutations NN O O
in NN O O
the NN O O
galns NN O O
gene NN O O
from NN O O
MPS NN B-Modifier B-OMIM:253000
IVA NN I-Modifier I-OMIM:253000
patients, NN O O
but NN O O
the NN O O
correlation NN O O
between NN O O
genotype NN O O
and NN O O
phenotype NN O O
has NN O O
remained NN O O
unclear. NN O O
we NN O O
studied NN O O
17 NN O O
missense NN O O
mutations NN O O
using NN O O
biochemical NN O O
approaches NN O O
and NN O O
32 NN O O
missense NN O O
mutations, NN O O
using NN O O
structural NN O O
analyses. NN O O
fifteen NN O O
missense NN O O
mutations NN O O
and NN O O
two NN O O
newly NN O O
engineered NN O O
active NN O O
site NN O O
mutations NN O O
(c NN O O
79 NN O O
s, NN O O
c NN O O
79 NN O O
t) NN O O
were NN O O
characterized NN O O
by NN O O
transient NN O O
expression NN O O
analysis. NN O O
mutant NN O O
proteins, NN O O
except NN O O
for NN O O
c NN O O
79 NN O O
s NN O O
and NN O O
c NN O O
79 NN O O
t, NN O O
were NN O O
destabilized NN O O
and NN O O
detected NN O O
as NN O O
insoluble NN O O
precursor NN O O
forms NN O O
while NN O O
the NN O O
c NN O O
79 NN O O
s NN O O
and NN O O
c NN O O
79 NN O O
t NN O O
mutants NN O O
wer NN O O
. NN O O

of NN O O
a NN O O
soluble NN O O
mature NN O O
size. NN O O
mutants NN O O
found NN O O
in NN O O
the NN O O
severe NN O O
phenotype NN O O
had NN O O
no NN O O
activity. NN O O
mutants NN O O
found NN O O
in NN O O
the NN O O
mild NN O O
phenotype NN O O
had NN O O
a NN O O
considerable NN O O
residual NN O O
activity NN O O
(1. NN O O
3-13. NN O O
3% NN O O
of NN O O
wild-type NN O O
galns NN O O
activity). NN O O
sulfatases, NN O O
including NN O O
galns, NN O O
are NN O O
members NN O O
of NN O O
a NN O O
highly NN O O
conserved NN O O
gene NN O O
family NN O O
sharing NN O O
an NN O O
extensive NN O O
sequence NN O O
homology. NN O O
thus, NN O O
a NN O O
tertiary NN O O
structural NN O O
model NN O O
of NN O O
human NN O O
galns NN O O
was NN O O
constructed NN O O
from NN O O
the NN O O
x-ray NN O O
crystal NN O O
structure NN O O
of NN O O
n NN O O
-acetylgalacto-samine-4-sulfatase NN O O
and NN O O
arylsulfatase NN O O
a, NN O O
using NN O O
homology NN O O
modeling, NN O O
and NN O O
32 NN O O
missense NN O O
mutations NN O O
were NN O O
investigated. NN O O
consequently, NN O O
we NN O O
propose NN O O
that NN O O
there NN O O
are NN O O
at NN O O
least NN O O
three NN O O
different NN O O
reasons NN O O
for NN O O
the NN O O
severe NN O O
phenotype NN O O
(i) NN O O
destruction NN O O
of NN O O
the NN O O
hydrophobic NN O O
core NN O O
or NN O O
modification NN O O
of NN O O
the NN O O
packing; NN O O
(ii) NN O O
remova NN O O
. NN O O
sharing NN O O
an NN O O
extensive NN O O
sequence NN O O
homology. NN O O
thus, NN O O
a NN O O
tertiary NN O O
structural NN O O
model NN O O
of NN O O
human NN O O
galns NN O O
was NN O O
constructed NN O O
from NN O O
the NN O O
x-ray NN O O
crystal NN O O
structure NN O O
of NN O O
n NN O O
-acetylgalacto-samine-4-sulfatase NN O O
and NN O O
arylsulfatase NN O O
a, NN O O
using NN O O
homology NN O O
modeling, NN O O
and NN O O
32 NN O O
missense NN O O
mutations NN O O
were NN O O
investigated. NN O O
consequently, NN O O
we NN O O
propose NN O O
that NN O O
there NN O O
are NN O O
at NN O O
least NN O O
three NN O O
different NN O O
reasons NN O O
for NN O O
the NN O O
severe NN O O
phenotype NN O O
(i) NN O O
destruction NN O O
of NN O O
the NN O O
hydrophobic NN O O
core NN O O
or NN O O
modification NN O O
of NN O O
the NN O O
packing; NN O O
(ii) NN O O
remova NN O O
. NN O O

of NN O O
a NN O O
salt NN O O
bridge NN O O
to NN O O
destabilize NN O O
the NN O O
entire NN O O
conformation; NN O O
(iii) NN O O
modification NN O O
of NN O O
the NN O O
active NN O O
site. NN O O
in NN O O
contrast, NN O O
mild NN O O
mutations NN O O
were NN O O
mostly NN O O
located NN O O
on NN O O
the NN O O
surface NN O O
of NN O O
the NN O O
galns NN O O
protein. NN O O
these NN O O
studies NN O O
shed NN O O
further NN O O
light NN O O
on NN O O
the NN O O
genotype-phenotype NN O O
correlation NN O O
of NN O O
MPS NN B-SpecificDisease B-OMIM:253000
IVA NN I-SpecificDisease I-OMIM:253000
and NN O O
structure-function NN O O
relationship NN O O
in NN O O
the NN O O
sulfatase NN O O
family NN O O
. NN O O

wiskott-aldrich NN O O
syndrome: NN O O
cellular NN O O
impairments NN O O
and NN O O
their NN O O
implication NN O O
for NN O O
carrier NN O O
detection NN O O
. NN O O

a NN O O
family NN O O
in NN O O
which NN O O
two NN O O
male NN O O
siblings NN O O
were NN O O
affected NN O O
with NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
) NN O O
was NN O O
studied NN O O
using NN O O
g-6-pd NN O O
isoenzymes NN O O
as NN O O
an NN O O
x-linked NN O O
marker NN O O
in NN O O
order NN O O
to NN O O
investigate NN O O
the NN O O
nature NN O O
of NN O O
cellular NN O O
abnormalities. NN O O
isolated NN O O
peripheral NN O O
blood NN O O
cell NN O O
types NN O O
from NN O O
the NN O O
doubly NN O O
heterozygous NN O O
mother NN O O
of NN O O
the NN O O
affected NN O O
males NN O O
seemingly NN O O
failed NN O O
to NN O O
express NN O O
the NN O O
g-6-pd NN O O
allele NN O O
in NN O O
cis NN O O
position NN O O
with NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
allele NN O O
while NN O O
her NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
expressed NN O O
both NN O O
g-6-pd NN O O
alleles. NN O O
additionally, NN O O
a NN O O
histogram NN O O
analysis NN O O
of NN O O
platelet NN O O
size NN O O
revealed NN O O
a NN O O
single NN O O
population NN O O
of NN O O
abnormally NN O O
small NN O O
platelets NN O O
in NN O O
the NN O O
affected NN O O
propositus, NN O O
whereas NN O O
the NN O O
heterozygous NN O O
mother NN O O
had NN O O
no NN O O
appreciable NN O O
small NN O O
platelet NN O O
subpopulation. NN O O
in NN O O
vitro NN O O
culture NN O O
of NN O O
hemopoietic NN O O
progenitor NN O O
cells NN O O
of NN O O
the NN O O
heterozygous NN O O
mother NN O O
showed NN O O
that NN O O
the NN O O
majority NN O O
of NN O O
progenitor NN O O
cells NN O O
did NN O O
no NN O O
. NN O O

express NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
allele. NN O O
however, NN O O
a NN O O
small NN O O
number NN O O
of NN O O
cells NN O O
expressing NN O O
the NN O O
g-6-pd NN O O
type NN O O
linked NN O O
with NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
allele NN O O
were NN O O
detected. NN O O
the NN O O
proportion NN O O
of NN O O
the NN O O
latter NN O O
progenitors NN O O
was NN O O
significantly NN O O
higher NN O O
among NN O O
more NN O O
primitive NN O O
progenitors NN O O
(those NN O O
giving NN O O
rise NN O O
to NN O O
later NN O O
appearing NN O O
colonies). NN O O
this NN O O
observation NN O O
suggests NN O O
that NN O O
selection NN O O
against NN O O
cells NN O O
expressing NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
defect NN I-SpecificDisease I-MSH:D014923
takes NN O O
place NN O O
in NN O O
the NN O O
hemopoietic NN O O
system NN O O
of NN O O
the NN O O
heterozygous NN O O
female NN O O
and NN O O
offers NN O O
a NN O O
possible NN O O
means NN O O
of NN O O
carrier NN O O
detection NN O O
in NN O O
some NN O O
women. NN O O
linkage NN O O
studies NN O O
in NN O O
this NN O O
family NN O O
revealed NN O O
one NN O O
example NN O O
of NN O O
probable NN O O
recombination NN O O
between NN O O
the NN O O
loci NN O O
for NN O O
WAS NN B-SpecificDisease B-MSH:D014923
and NN O O
g-6-pd NN O O
among NN O O
three NN O O
informative NN O O
subjects, NN O O
suggesting NN O O
that NN O O
these NN O O
two NN O O
loci NN O O
may NN O O
not NN O O
be NN O O
closely NN O O
linked NN O O
on NN O O
the NN O O
x-chromosome. NN O O
. NN O O

familial NN O O
deficiency NN O O
of NN O O
the NN O O
seventh NN O O
component NN O O
of NN O O
complement NN O O
associated NN O O
with NN O O
recurrent NN O O
meningococcal NN B-SpecificDisease B-MSH:D008589
infections NN I-SpecificDisease I-MSH:D008589
. NN O O

we NN O O
describe NN O O
an NN O O
11-year-old NN O O
girl NN O O
suffering NN O O
from NN O O
recurrent NN B-SpecificDisease B-MSH:D008581
meningitis NN I-SpecificDisease I-MSH:D008581
with NN O O
a NN O O
complete NN O O
absence NN B-SpecificDisease B-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
the NN I-SpecificDisease I-OMIM:610102
seventh NN I-SpecificDisease I-OMIM:610102
component NN I-SpecificDisease I-OMIM:610102
of NN I-SpecificDisease I-OMIM:610102
complemen NN I-SpecificDisease I-OMIM:610102
t NN O O
(c NN O O
7). NN O O
diagnosis NN O O
was NN O O
established NN O O
by NN O O
haemolytic NN O O
titration NN O O
and NN O O
western NN O O
blotting. NN O O
the NN O O
patients NN O O
serum NN O O
lacked NN O O
the NN O O
85 NN O O
kda NN O O
c NN O O
7 NN O O
chain. NN O O
haemolytic NN O O
activity NN O O
of NN O O
serum NN O O
was NN O O
reconstituted NN O O
with NN O O
either NN O O
pooled NN O O
normal NN O O
human NN O O
serum NN O O
or NN O O
with NN O O
purified NN O O
c NN O O
7. NN O O
the NN O O
relatives NN O O
(parents NN O O
and NN O O
one NN O O
sister) NN O O
had NN O O
half-normal NN O O
levels NN O O
of NN O O
both NN O O
immunochemically NN O O
and NN O O
functionally NN O O
determined NN O O
c NN O O
7, NN O O
indicating NN O O
a NN O O
heterozygous NN O O
state NN O O
for NN O O
C7 NN B-SpecificDisease B-OMIM:610102
deficiency NN I-SpecificDisease I-OMIM:610102
. NN O O
. NN O O

non-syndromic NN O O
hearing NN O O
loss NN O O
associated NN O O
with NN O O
enlarged NN B-SpecificDisease B-OMIM:600791
vestibular NN I-SpecificDisease I-OMIM:600791
aqueduct NN I-SpecificDisease I-OMIM:600791
is NN O O
caused NN O O
by NN O O
PDS NN B-Modifier B-MSH:C536648
mutations NN O O
. NN O O

enlarged NN O O
vestibular NN O O
aqueduct NN O O
( NN O O
EVA NN B-SpecificDisease B-OMIM:600791
), NN O O
known NN O O
as NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
inner NN B-DiseaseClass B-MSH:D007759
ear NN I-DiseaseClass I-MSH:D007759
abnormality NN I-DiseaseClass I-MSH:D007759
, NN O O
has NN O O
recently NN O O
been NN O O
of NN O O
particular NN O O
genetic NN O O
interest NN O O
because NN O O
this NN O O
anomaly NN O O
is NN O O
inherited NN O O
in NN O O
a NN O O
recessive NN O O
manner. NN O O
the NN O O
locus NN O O
for NN O O
non-syndromic NN B-SpecificDisease B-MSH:C537845
sensorineural NN I-SpecificDisease I-MSH:C537845
hearing NN I-SpecificDisease I-MSH:C537845
loss NN I-SpecificDisease I-MSH:C537845
with NN O O
EVA NN B-SpecificDisease B-OMIM:600791
has NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
same NN O O
chromosomal NN O O
region, NN O O
7 NN O O
q NN O O
31, NN O O
as NN O O
the NN O O
Pendred NN B-Modifier B-MSH:C536648
syndrome NN I-Modifier I-MSH:C536648
locus. NN O O
in NN O O
the NN O O
present NN O O
study, NN O O
seven NN O O
mutations NN O O
in NN O O
the NN O O
PDS NN B-Modifier B-MSH:C536648
gene NN O O
(pds), NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
, NN O O
have NN O O
been NN O O
found NN O O
in NN O O
families NN O O
of NN O O
non-syndromic NN B-SpecificDisease B-MSH:C537845
sensorineural NN I-SpecificDisease I-MSH:C537845
hearing NN I-SpecificDisease I-MSH:C537845
loss NN I-SpecificDisease I-MSH:C537845
with NN O O
EVA NN B-SpecificDisease B-OMIM:600791
. NN O O
one NN O O
family NN O O
is NN O O
homozygous, NN O O
three NN O O
families NN O O
are NN O O
compound NN O O
heterozygotes, NN O O
and NN O O
two NN O O
families NN O O
are NN O O
heterozygous NN O O
but NN O O
with NN O O
no NN O O
other NN O O
mutation NN O O
detected. NN O O
the NN O O
present NN O O
results NN O O
provide NN O O
evidence NN O O
that NN O O
mutations NN O O
in NN O O
pds NN O O
cause NN O O
both NN O O
syndromic NN B-CompositeMention B-MSH:D034381
and NN I-CompositeMention I-MSH:D034381
non-syndromic NN I-CompositeMention I-MSH:D034381
hearing NN I-CompositeMention I-MSH:D034381
loss NN I-CompositeMention I-MSH:D034381

syndromic NN O O
hearing NN O O
loss. NN O O
. NN O O

deletions NN O O
of NN O O
a NN O O
dna NN O O
sequence NN O O
in NN O O
retinoblastomas NN B-SpecificDisease B-MSH:D012175
and NN O O
mesenchymal NN B-DiseaseClass B-MSH:C535700
tumors NN I-DiseaseClass I-MSH:C535700
: NN O O
organization NN O O
of NN O O
the NN O O
sequence NN O O
and NN O O
its NN O O
encoded NN O O
protein NN O O
. NN O O

retinoblastoma NN O O
is NN O O
a NN O O
childhood NN B-DiseaseClass B-MSH:D009369
tumor NN I-DiseaseClass I-MSH:D009369
that NN O O
can NN O O
arise NN O O
because NN O O
of NN O O
mutant NN O O
alleles NN O O
acquired NN O O
as NN O O
somatic NN O O
or NN O O
germinal NN O O
mutations. NN O O
the NN O O
mutant NN O O
allele NN O O
can NN O O
be NN O O
carried NN O O
in NN O O
the NN O O
germ NN O O
line. NN O O
the NN O O
mutations NN O O
creating NN O O
these NN O O
alleles NN O O
act NN O O
by NN O O
inactivating NN O O
copies NN O O
of NN O O
a NN O O
recessive NN O O
oncogene NN O O
located NN O O
within NN O O
band NN O O
q NN O O
14 NN O O
of NN O O
chromosome NN O O
13 NN O O
and NN O O
termed NN O O
the NN O O
rb NN O O
1 NN O O
locus. NN O O
we NN O O
have NN O O
reported NN O O
isolation NN O O
of NN O O
a NN O O
cdna NN O O
fragment NN O O
that NN O O
recognizes NN O O
chromosomal NN O O
sequences NN O O
possessing NN O O
many NN O O
of NN O O
the NN O O
attributes NN O O
of NN O O
the NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
gene NN O O
associated NN O O
with NN O O
the NN O O
rb NN O O
1 NN O O
locus. NN O O
we NN O O
now NN O O
report NN O O
that NN O O
this NN O O
segment NN O O
is NN O O
additionally NN O O
the NN O O
target NN O O
of NN O O
somatic NN O O
mutations NN O O
in NN O O
mesenchymal NN B-DiseaseClass B-MSH:C535700
tumors NN I-DiseaseClass I-MSH:C535700
among NN O O
patients NN O O
having NN O O
no NN O O
apparent NN O O
predisposition NN O O
to NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
and NN O O
no NN O O
previous NN O O
evidence NN O O
of NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
. NN O O
these NN O O
tumors NN B-DiseaseClass B-MSH:D009369
provide NN O O
additional NN O O
evidence NN O O
that NN O O
the NN O O
cloned NN O O
sequences NN O O
are NN O O
representative NN O O
of NN O O
a NN O O
gene NN O O
that NN O O
is NN O O
a NN O O
frequent NN O O
target NN O O
of NN O O
inactivation NN O O
during NN O O
tumorigenesi NN O O
. NN O O

. NN O O
sequence NN O O
analysis NN O O
of NN O O
this NN O O
cdna NN O O
provides NN O O
little NN O O
insight NN O O
into NN O O
its NN O O
normal NN O O
functional NN O O
role. NN O O
. NN O O

genetically NN O O
determined NN O O
low NN O O
c NN O O
4: NN O O
a NN O O
predisposing NN O O
factor NN O O
to NN O O
autoimmune NN B-SpecificDisease B-MSH:D006521
chronic NN I-SpecificDisease I-MSH:D006521
active NN I-SpecificDisease I-MSH:D006521
hepatitis NN I-SpecificDisease I-MSH:D006521
. NN O O

of NN O O
26 NN O O
patients NN O O
with NN O O
autoimmune NN B-SpecificDisease B-MSH:D006521
chronic NN I-SpecificDisease I-MSH:D006521
active NN I-SpecificDisease I-MSH:D006521
hepatitis NN I-SpecificDisease I-MSH:D006521
( NN O O
CAH NN B-SpecificDisease B-MSH:D006521
) NN O O
starting NN O O
in NN O O
childhood NN O O
18 NN O O
(69%) NN O O
had NN O O
low NN O O
c NN O O
4 NN O O
and NN O O
5 NN O O
(19%) NN O O
had NN O O
low NN O O
c NN O O
3 NN O O
serum NN O O
levels. NN O O
impaired NN O O
hepatic NN O O
synthesis NN O O
and NN O O
immune-consumption NN O O
were NN O O
unlikely NN O O
since NN O O
transferrin NN O O
levels NN O O
were NN O O
normal NN O O
in NN O O
all NN O O
patients, NN O O
albumin NN O O
levels NN O O
were NN O O
persistently NN O O
low NN O O
in NN O O
only NN O O
3, NN O O
and NN O O
only NN O O
3 NN O O
had NN O O
raised NN O O
levels NN O O
of NN O O
activation NN O O
fragment NN O O
c NN O O
3 NN O O
d. NN O O
c NN O O
4 NN O O
d NN O O
was NN O O
normal NN O O
in NN O O
all NN O O
patients NN O O
studied. NN O O
in NN O O
the NN O O
families NN O O
of NN O O
12 NN O O
probands NN O O
with NN O O
low NN O O
c NN O O
4, NN O O
7 NN O O
parents NN O O
had NN O O
low NN O O
c NN O O
4 NN O O
and NN O O
2 NN O O
had NN O O
levels NN O O
which NN O O
were NN O O
at NN O O
the NN O O
lower NN O O
limit NN O O
of NN O O
normal. NN O O
5 NN O O
of NN O O
10 NN O O
siblings NN O O
from NN O O
5 NN O O
families NN O O
had NN O O
low NN O O
c NN O O
4. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
low NN O O
c NN O O
4 NN O O
levels NN O O
in NN O O
CAH NN B-SpecificDisease B-MSH:D006521
are NN O O
geneticall NN O O
. NN O O

determined. NN O O
c NN O O
4 NN O O
phenotyping NN O O
in NN O O
20 NN O O
patients NN O O
and NN O O
in NN O O
26 NN O O
parents NN O O
showed NN O O
that NN O O
90% NN O O
and NN O O
81%, NN O O
respectively, NN O O
had NN O O
null NN O O
allotypes NN O O
at NN O O
either NN O O
the NN O O
c NN O O
4 NN O O
a NN O O
or NN O O
c NN O O
4 NN O O
b NN O O
locus NN O O
compared NN O O
with NN O O
59% NN O O
in NN O O
controls, NN O O
indicating NN O O
that NN O O
defective NN O O
expression NN O O
of NN O O
structural NN O O
genes NN O O
may NN O O
contribute NN O O
to NN O O
the NN O O
observed NN O O
C4 NN B-SpecificDisease B-OMIM:614380
deficiency NN I-SpecificDisease I-OMIM:614380
. NN O O
. NN O O

tight NN O O
linkage NN O O
between NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
and NN O O
apolipoprotein NN O O
e NN O O
genes NN O O
revealed NN O O
with NN O O
allele-specific NN O O
oligonucleotides NN O O
. NN O O

in NN O O
16 NN O O
families NN O O
with NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
a NN O O
novel NN O O
approach NN O O
based NN O O
on NN O O
use NN O O
of NN O O
allele-specific NN O O
oligonucleotides NN O O
has NN O O
been NN O O
employed NN O O
to NN O O
study NN O O
the NN O O
linkage NN O O
relationship NN O O
between NN O O
the NN O O
apolipoprotein NN O O
e NN O O
(apoe) NN O O
gene NN O O
and NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O
synthetic NN O O
oligonucleotides, NN O O
designed NN O O
to NN O O
discriminate NN O O
between NN O O
apoe NN O O
alleles NN O O
epsilon NN O O
3 NN O O
and NN O O
epsilon NN O O
4, NN O O
enabled NN O O
us NN O O
to NN O O
distinguish NN O O
heterozygous NN O O
carriers NN O O
in NN O O
a NN O O
hybridization NN O O
assay. NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
families, NN O O
the NN O O
relevant NN O O
segment NN O O
of NN O O
the NN O O
apoe NN O O
gene NN O O
was NN O O
enzymatically NN O O
amplified NN O O
to NN O O
increase NN O O
the NN O O
sensitivity NN O O
of NN O O
the NN O O
method. NN O O
for NN O O
dm NN O O
and NN O O
apoe, NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
(zmax NN O O
of NN O O
7. NN O O
47 NN O O
was NN O O
obtained NN O O
at NN O O
a NN O O
recombination NN O O
frequency NN O O
(theta) NN O O
of NN O O
0. NN O O
047 NN O O
(male NN O O
theta NN O O
= NN O O
female NN O O
theta). NN O O
no NN O O
recombination NN O O
(maximum NN O O
lod NN O O
score NN O O
of NN O O
5. NN O O
61 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

0) NN O O
was NN O O
found NN O O
between NN O O
apoe NN O O
and NN O O
the NN O O
apolipoprotein NN O O
cii NN O O
(apoc NN O O
2) NN O O
gene. NN O O
these NN O O
results NN O O
suggest NN O O
that, NN O O
in NN O O
addition NN O O
to NN O O
apoc NN O O
2, NN O O
apoe NN O O
is NN O O
a NN O O
useful NN O O
marker NN O O
for NN O O
presymptomatic NN O O
DM NN B-Modifier B-MSH:D009223
diagnosis NN O O
. NN O O

confirmation NN O O
of NN O O
brca NN O O
1 NN O O
by NN O O
analysis NN O O
of NN O O
germline NN O O
mutations NN O O
linked NN O O
to NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
in NN O O
ten NN O O
families NN O O
. NN O O

we NN O O
provide NN O O
genetic NN O O
evidence NN O O
supporting NN O O
the NN O O
identity NN O O
of NN O O
the NN O O
candidate NN O O
gene NN O O
for NN O O
brca NN O O
1 NN O O
through NN O O
the NN O O
characterization NN O O
of NN O O
germline NN O O
mutations NN O O
in NN O O
63 NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
patients NN O O
and NN O O
10 NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
patients NN O O
in NN O O
ten NN O O
families NN O O
with NN O O
cancer NN B-DiseaseClass B-MSH:D009369
linked NN O O
to NN O O
chromosome NN O O
17 NN O O
q NN O O
21. NN O O
nine NN O O
different NN O O
mutations NN O O
were NN O O
detected NN O O
by NN O O
screening NN O O
brca NN O O
1 NN O O
dna NN O O
and NN O O
rna NN O O
by NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing. NN O O
seven NN O O
mutations NN O O
lead NN O O
to NN O O
protein NN O O
truncations NN O O
at NN O O
sites NN O O
throughout NN O O
the NN O O
gene. NN O O
one NN O O
missense NN O O
mutation NN O O
(which NN O O
occurred NN O O
independently NN O O
in NN O O
two NN O O
families) NN O O
leads NN O O
to NN O O
loss NN O O
of NN O O
a NN O O
cysteine NN O O
in NN O O
the NN O O
zinc NN O O
binding NN O O
domain. NN O O
an NN O O
intronic NN O O
single NN O O
basepair NN O O
substitution NN O O
destroys NN O O
an NN O O
acceptor NN O O
site NN O O
and NN O O
activates NN O O
a NN O O
cryptic NN O O
splice NN O O
site, NN O O
leading NN O O
to NN O O
a NN O O
59 NN O O
basepair NN O O
insertion NN O O
and NN O O
chain NN O O
termination. NN O O
the NN O O
four NN O O
families NN O O
with NN O O
both NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
had NN O O
chain NN O O
termination NN O O
mutations NN O O
i NN O O
. NN O O

the NN O O
n-terminal NN O O
half NN O O
of NN O O
the NN O O
protein. NN O O
. NN O O

genetic NN O O
instability NN O O
in NN O O
human NN O O
ovarian NN B-Modifier B-MSH:D010051
cancer NN I-Modifier I-MSH:D010051
cell NN O O
lines NN O O
. NN O O

we NN O O
have NN O O
analyzed NN O O
the NN O O
stability NN O O
of NN O O
microsatellites NN O O
in NN O O
cell NN O O
lines NN O O
derived NN O O
from NN O O
human NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
and NN O O
found NN O O
that NN O O
5 NN O O
out NN O O
of NN O O
10 NN O O
of NN O O
the NN O O
ovarian NN B-Modifier B-MSH:D010051
tumor NN I-Modifier I-MSH:D010051
cell NN O O
lines NN O O
are NN O O
genetically NN O O
unstable NN O O
at NN O O
the NN O O
majority NN O O
of NN O O
the NN O O
loci NN O O
analyzed. NN O O
in NN O O
clones NN O O
and NN O O
subclones NN O O
derived NN O O
serially NN O O
from NN O O
one NN O O
of NN O O
these NN O O
cell NN O O
lines NN O O
(2774; NN O O
serous NN B-SpecificDisease B-MSH:D018284
cystadenocarcinoma NN I-SpecificDisease I-MSH:D018284
), NN O O
a NN O O
very NN O O
high NN O O
proportion NN O O
of NN O O
microsatellites NN O O
distributed NN O O
in NN O O
many NN O O
different NN O O
regions NN O O
of NN O O
the NN O O
genome NN O O
change NN O O
their NN O O
size NN O O
in NN O O
a NN O O
mercurial NN O O
fashion. NN O O
we NN O O
conclude NN O O
that NN O O
genomic NN O O
instability NN O O
in NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
tumors NN I-SpecificDisease I-MSH:D010051
is NN O O
a NN O O
dynamic NN O O
and NN O O
ongoing NN O O
process NN O O
whose NN O O
high NN O O
frequency NN O O
may NN O O
have NN O O
been NN O O
previously NN O O
underestimated NN O O
by NN O O
pcr-based NN O O
allelotyping NN O O
of NN O O
bulk NN O O
tumor NN B-Modifier B-MSH:D009369
tissue. NN O O
we NN O O
have NN O O
identified NN O O
the NN O O
source NN O O
of NN O O
the NN O O
genetic NN O O
instability NN O O
in NN O O
one NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
tumor NN I-SpecificDisease I-MSH:D010051
as NN O O
a NN O O
point NN O O
mutation NN O O
(r NN O O
524 NN O O
p) NN O O
in NN O O
the NN O O
human NN O O
mismatch-repai NN O O
. NN O O

gene NN O O
msh NN O O
2 NN O O
(salmonella NN O O
muts NN O O
homologue), NN O O
which NN O O
has NN O O
recently NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
involved NN O O
in NN O O
hereditary NN B-SpecificDisease B-MSH:D003123
nonpolyposis NN I-SpecificDisease I-MSH:D003123
colorectal NN I-SpecificDisease I-MSH:D003123
cancer NN I-SpecificDisease I-MSH:D003123
. NN O O
patient NN O O
2774 NN O O
was NN O O
a NN O O
38-year-old NN O O
heterozygote, NN O O
and NN O O
her NN O O
normal NN O O
tissue NN O O
carried NN O O
both NN O O
mutant NN O O
and NN O O
wild-type NN O O
alleles NN O O
of NN O O
the NN O O
human NN O O
msh NN O O
2 NN O O
gene. NN O O
however NN O O
the NN O O
wild-type NN O O
allele NN O O
was NN O O
lost NN O O
at NN O O
some NN O O
point NN O O
early NN O O
during NN O O
tumorigenesis NN O O
so NN O O
that NN O O
dna NN O O
isolated NN O O
either NN O O
from NN O O
the NN O O
patients NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
tumor NN I-SpecificDisease I-MSH:D010051
or NN O O
from NN O O
the NN O O
2774 NN O O
cell NN O O
line NN O O
carries NN O O
only NN O O
the NN O O
mutant NN O O
allele NN O O
of NN O O
the NN O O
human NN O O
msh NN O O
2 NN O O
gene. NN O O
the NN O O
genetic NN O O
instability NN O O
observed NN O O
in NN O O
the NN O O
tumor NN B-DiseaseClass B-MSH:D009369
and NN O O
cell NN O O
line NN O O
dna, NN O O
together NN O O
with NN O O
the NN O O
germ-line NN O O
mutation NN O O
in NN O O
a NN O O
mismatch-repair NN O O
gene, NN O O
suggest NN O O
that NN O O
the NN O O
msh NN O O
2 NN O O
gene NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
onset NN O O
and/or NN O O
progression NN O O
in NN O O
a NN O O
subset NN O O
o NN O O
. NN O O

ovarian NN O O
cancer. NN O O
. NN O O

retroviral-mediated NN O O
gene NN O O
transfer NN O O
of NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
into NN O O
nih NN O O
3 NN O O
t NN O O
3 NN O O
and NN O O
hepatoma NN B-Modifier B-MSH:D006528
cells NN O O
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
caused NN O O
by NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
the NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
enzyme NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah). NN O O
a NN O O
full-length NN O O
human NN O O
pah NN O O
cdna NN O O
sequence NN O O
has NN O O
been NN O O
inserted NN O O
into NN O O
pzip-neosv NN O O
(x), NN O O
which NN O O
is NN O O
a NN O O
retroviral NN O O
vector NN O O
containing NN O O
the NN O O
bacterial NN O O
neo NN O O
gene. NN O O
the NN O O
recombinant NN O O
has NN O O
been NN O O
transfected NN O O
into NN O O
psi NN O O
2 NN O O
cells, NN O O
which NN O O
provide NN O O
synthesis NN O O
of NN O O
the NN O O
retroviral NN O O
capsid. NN O O
recombinant NN O O
virus NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
culture NN O O
medium NN O O
of NN O O
the NN O O
transfected NN O O
psi NN O O
2 NN O O
cells, NN O O
which NN O O
is NN O O
capable NN O O
of NN O O
transmitting NN O O
the NN O O
human NN O O
pah NN O O
gene NN O O
into NN O O
mouse NN O O
nih NN O O
3 NN O O
t NN O O
3 NN O O
cells NN O O
by NN O O
infection NN O O
leading NN O O
to NN O O
stable NN O O
incorporation NN O O
of NN O O
the NN O O
recombinant NN O O
provirus. NN O O
infected NN O O
cells NN O O
express NN O O
pah NN O O
mrna, NN O O
immunoreactive NN O O
pah NN O O
protein, NN O O
and NN O O
exhibit NN O O
pterin-dependent NN O O
phenylalanine NN O O
hydroxylase NN O O
activity. NN O O
the NN O O
recombinant NN O O
virus NN O O
is NN O O
also NN O O
capable NN O O
of NN O O
infecting NN O O
a NN O O
mouse NN O O
hepatoma NN B-Modifier B-MSH:D006528
cell NN O O
lin NN O O
. NN O O

that NN O O
does NN O O
not NN O O
normally NN O O
synthesize NN O O
pah. NN O O
pah NN O O
activity NN O O
is NN O O
present NN O O
in NN O O
the NN O O
cellular NN O O
extracts NN O O
and NN O O
the NN O O
entire NN O O
hydroxylation NN O O
system NN O O
is NN O O
reconstituted NN O O
in NN O O
the NN O O
hepatoma NN B-Modifier B-MSH:D006528
cells NN O O
infected NN O O
with NN O O
the NN O O
recombinant NN O O
viruses. NN O O
thus, NN O O
recombinant NN O O
viruses NN O O
containing NN O O
human NN O O
pah NN O O
cdna NN O O
provide NN O O
a NN O O
means NN O O
for NN O O
introducing NN O O
functional NN O O
pah NN O O
into NN O O
mammalian NN O O
cells NN O O
of NN O O
hepatic NN O O
origin NN O O
and NN O O
can NN O O
potentially NN O O
be NN O O
introduced NN O O
into NN O O
whole NN O O
animals NN O O
as NN O O
a NN O O
model NN O O
for NN O O
somatic NN O O
gene NN O O
therapy NN O O
for NN O O
PKU NN B-SpecificDisease B-MSH:D010661
. NN O O
. NN O O

characterisation NN O O
of NN O O
molecular NN O O
defects NN O O
in NN O O
X-linked NN B-SpecificDisease B-MSH:C538243
amelogenesis NN I-SpecificDisease I-MSH:C538243
imperfecta NN I-SpecificDisease I-MSH:C538243
(aih NN O O
1) NN O O
. NN O O

amelogenins NN O O
are NN O O
an NN O O
heterogenous NN O O
family NN O O
of NN O O
proteins NN O O
produced NN O O
by NN O O
ameloblasts NN O O
of NN O O
the NN O O
enamel NN O O
organ NN O O
during NN O O
tooth NN O O
development. NN O O
disturbances NN O O
of NN O O
enamel NN O O
formation NN O O
occur NN O O
in NN O O
amelogenesis NN B-DiseaseClass B-MSH:D000567
imperfecta NN I-DiseaseClass I-MSH:D000567
, NN O O
a NN O O
clinically NN O O
heterogenous NN O O
group NN O O
of NN O O
inherited NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
characterised NN O O
by NN O O
defective NN O O
enamel NN O O
biomineralisation. NN O O
an NN O O
amelogenin NN O O
gene, NN O O
amgx, NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
short NN O O
of NN O O
the NN O O
x NN O O
chromosome NN O O
(xp NN O O
22. NN O O
1-p NN O O
22. NN O O
3) NN O O
and NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
the NN O O
molecular NN O O
pathology NN O O
of NN O O
X-linked NN B-SpecificDisease B-MSH:C538243
amelogenesis NN I-SpecificDisease I-MSH:C538243
imperfecta NN I-SpecificDisease I-MSH:C538243
( NN O O
AIH1 NN B-SpecificDisease B-MSH:C538243
). NN O O
we NN O O
have NN O O
identified NN O O
three NN O O
families NN O O
exhibiting NN O O
AIH1 NN B-SpecificDisease B-MSH:C538243
and NN O O
screened NN O O
the NN O O
amgx NN O O
gene NN O O
for NN O O
mutations NN O O
using NN O O
single-strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
and NN O O
dna NN O O
sequencing. NN O O
three NN O O
novel NN O O
mutations NN O O
were NN O O
identified NN O O
a NN O O
c-t NN O O
substitution NN O O
in NN O O
exon NN O O
5, NN O O
and NN O O
a NN O O
g-t NN O O
substitution NN O O
and NN O O
single NN O O
cytosine NN O O
deletion NN O O
in NN O O
exon NN O O
6 NN O O
. NN O O

confirming NN O O
the NN O O
existence NN O O
of NN O O
extensive NN O O
allelic NN O O
heterogeneity NN O O
in NN O O
this NN O O
condition. NN O O
the NN O O
identification NN O O
of NN O O
family-specific NN O O
mutations NN O O
will NN O O
enable NN O O
early NN O O
identification NN O O
of NN O O
affected NN O O
individuals NN O O
and NN O O
correlation NN O O
of NN O O
clinical NN O O
phenotype NN O O
with NN O O
genotype NN O O
will NN O O
facilitate NN O O
an NN O O
objective NN O O
system NN O O
of NN O O
disease NN O O
classification NN O O
. NN O O

the NN O O
Pendred NN B-Modifier B-MSH:C536648
syndrome NN I-Modifier I-MSH:C536648
gene NN O O
encodes NN O O
a NN O O
chloride-iodide NN O O
transport NN O O
protein NN O O
. NN O O

pendred NN O O
syndrome NN O O
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
syndromic NN B-DiseaseClass B-MSH:D003638
deafness NN I-DiseaseClass I-MSH:D003638
and NN O O
characterized NN O O
by NN O O
congenital NN O O
sensorineural NN B-SpecificDisease B-MSH:D006319
hearing NN I-SpecificDisease I-MSH:D006319
loss NN I-SpecificDisease I-MSH:D006319
and NN O O
goitre NN B-SpecificDisease B-MSH:D006042
. NN O O
this NN O O
disorder NN O O
was NN O O
mapped NN O O
to NN O O
chromosome NN O O
7 NN O O
and NN O O
the NN O O
gene NN O O
causing NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
( NN O O
PDS NN B-SpecificDisease B-MSH:C536648
) NN O O
was NN O O
subsequently NN O O
identified NN O O
by NN O O
positional NN O O
cloning. NN O O
pds NN O O
encodes NN O O
a NN O O
putative NN O O
transmembrane NN O O
protein NN O O
designated NN O O
pendrin. NN O O
pendrin NN O O
is NN O O
closely NN O O
related NN O O
to NN O O
a NN O O
family NN O O
of NN O O
sulfate NN O O
transport NN O O
proteins NN O O
that NN O O
includes NN O O
the NN O O
rat NN O O
sulfate-anion NN O O
transporter NN O O
(encoded NN O O
by NN O O
sat-1; NN O O
29% NN O O
amino NN O O
acid NN O O
sequence NN O O
identity), NN O O
the NN O O
human NN O O
diastrophic NN B-Modifier B-MSH:C536170
dysplasia NN I-Modifier I-MSH:C536170
sulfate NN O O
transporter NN O O
(encoded NN O O
by NN O O
dtd; NN O O
32%) NN O O
and NN O O
the NN O O
human NN O O
sulfate NN O O
transporter NN O O
downregulated NN O O
in NN O O
adenoma NN B-DiseaseClass B-MSH:D000236
(encoded NN O O
by NN O O
dra; NN O O
45%). NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
this NN O O
homology NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
slightly NN O O
modified NN O O
sulfate-transporter NN O O
signature NN O O
sequence NN O O
comprising NN O O
its NN O O
putative NN O O
second NN O O
transmembran NN O O
. NN O O

domain, NN O O
pendrin NN O O
has NN O O
been NN O O
proposed NN O O
to NN O O
function NN O O
as NN O O
a NN O O
sulfate NN O O
transporter. NN O O
we NN O O
were NN O O
unable NN O O
to NN O O
detect NN O O
evidence NN O O
of NN O O
sulfate NN O O
transport NN O O
following NN O O
the NN O O
expression NN O O
of NN O O
pendrin NN O O
in NN O O
xenopus NN O O
laevis NN O O
oocytes NN O O
by NN O O
microinjection NN O O
of NN O O
pds NN O O
crna NN O O
or NN O O
in NN O O
sf NN O O
9 NN O O
cells NN O O
following NN O O
infection NN O O
with NN O O
pds-recombinant NN O O
baculovirus. NN O O
the NN O O
rates NN O O
of NN O O
transport NN O O
for NN O O
iodide NN O O
and NN O O
chloride NN O O
were NN O O
significantly NN O O
increased NN O O
following NN O O
the NN O O
expression NN O O
of NN O O
pendrin NN O O
in NN O O
both NN O O
cell NN O O
systems. NN O O
our NN O O
results NN O O
demonstrate NN O O
that NN O O
pendrin NN O O
functions NN O O
as NN O O
a NN O O
transporter NN O O
of NN O O
chloride NN O O
and NN O O
iodide, NN O O
but NN O O
not NN O O
sulfate, NN O O
and NN O O
may NN O O
provide NN O O
insight NN O O
into NN O O
thyroid NN O O
physiology NN O O
and NN O O
the NN O O
pathophysiology NN O O
of NN O O
Pendred NN B-SpecificDisease B-MSH:C536648
syndrome NN I-SpecificDisease I-MSH:C536648
. NN O O
. NN O O

linkage NN O O
relationship NN O O
of NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
, NN O O
hla NN O O
and NN O O
glyoxalase NN O O
i NN O O
loci NN O O
. NN O O

immunogenetic NN O O
analysis NN O O
of NN O O
a NN O O
homozygous NN O O
C2-deficient NN B-Modifier B-OMIM:217000
individual NN O O
and NN O O
family NN O O
members NN O O
demonstrated NN O O
linkage NN O O
of NN O O
hla-a NN O O
25, NN O O
b NN O O
18 NN O O
and NN O O
c NN O O
2 NN O O
o. NN O O
hla-d NN O O
typing NN O O
showed NN O O
that NN O O
5 NN O O
members NN O O
typed NN O O
with NN O O
homozygous NN O O
dw NN O O
2 NN O O
typing NN O O
cells NN O O
from NN O O
an NN O O
individual NN O O
with NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
but NN O O
not NN O O
with NN O O
dw NN O O
2 NN O O
typing NN O O
cells NN O O
from NN O O
2 NN O O
individuals NN O O
with NN O O
normal NN O O
c NN O O
2. NN O O
the NN O O
homozygous NN O O
C2-deficient NN B-Modifier B-OMIM:217000
propositus NN O O
and NN O O
brother NN O O
were NN O O
hla-a NN O O
and NN O O
b NN O O
homozygous NN O O
but NN O O
heterozygous NN O O
at NN O O
the NN O O
hla-d NN O O
and NN O O
glyoxalase NN O O
i NN O O
loci. NN O O
therefore, NN O O
in NN O O
this NN O O
family, NN O O
the NN O O
c NN O O
2 NN O O
o NN O O
gene NN O O
is NN O O
linked NN O O
with NN O O
two NN O O
distinct NN O O
haplotypes NN O O
hla-a NN O O
25, NN O O
b NN O O
18, NN O O
dw NN O O
2, NN O O
glo NN O O
1 NN O O
and NN O O
hla-a NN O O
25, NN O O
b NN O O
18, NN O O
d NN O O
unknown, NN O O
gl NN O O
02. NN O O
these NN O O
result NN O O
. NN O O

could NN O O
be NN O O
explained NN O O
by NN O O
an NN O O
ancestral NN O O
recombinant NN O O
event, NN O O
which NN O O
occurred NN O O
between NN O O
the NN O O
c NN O O
2 NN O O
o NN O O
locus NN O O
and NN O O
hla-d NN O O
locus NN O O
in NN O O
which NN O O
c NN O O
2 NN O O
o NN O O
segregated NN O O
with NN O O
hla-b. NN O O
this NN O O
would NN O O
suggest NN O O
that NN O O
the NN O O
locus NN O O
for NN O O
the NN O O
c NN O O
2 NN O O
o NN O O
gene NN O O
maps NN O O
between NN O O
hla-b NN O O
and NN O O
hla-d NN O O
on NN O O
the NN O O
sixth NN O O
chromosome. NN O O
. NN O O

a NN O O
71-kilodalton NN O O
protein NN O O
is NN O O
a NN O O
major NN O O
product NN O O
of NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
gene NN O O
in NN O O
brain NN O O
and NN O O
other NN O O
nonmuscle NN O O
tissues NN O O
. NN O O

the NN O O
known NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
gene NN O O
products, NN O O
the NN O O
muscle- NN O O
and NN O O
brain-type NN O O
dystrophin NN O O
isoforms, NN O O
are NN O O
427-kda NN O O
proteins NN O O
translated NN O O
from NN O O
14-kilobase NN O O
(kb) NN O O
mrnas. NN O O
recently NN O O
we NN O O
described NN O O
a NN O O
6. NN O O
5-kb NN O O
mrna NN O O
that NN O O
also NN O O
is NN O O
transcribed NN O O
from NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene. NN O O
cloning NN O O
and NN O O
in NN O O
vitro NN O O
transcription NN O O
and NN O O
translation NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
show NN O O
that NN O O
the NN O O
6. NN O O
5-kb NN O O
mrna NN O O
encodes NN O O
a NN O O
70. NN O O
8-kda NN O O
protein NN O O
that NN O O
is NN O O
a NN O O
major NN O O
product NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene. NN O O
it NN O O
contains NN O O
the NN O O
c-terminal NN O O
and NN O O
the NN O O
cysteine-rich NN O O
domains NN O O
of NN O O
dystrophin, NN O O
seven NN O O
additional NN O O
amino NN O O
acids NN O O
at NN O O
the NN O O
n NN O O
terminus, NN O O
and NN O O
some NN O O
modifications NN O O
formed NN O O
by NN O O
alternative NN O O
splicing NN O O
in NN O O
the NN O O
c-terminal NN O O
domain. NN O O
it NN O O
lacks NN O O
the NN O O
entire NN O O
large NN O O
domain NN O O
of NN O O
spectri NN O O
. NN O O

-like NN O O
repeats NN O O
and NN O O
the NN O O
actin-binding NN O O
n-terminal NN O O
domain NN O O
of NN O O
dystrophin. NN O O
this NN O O
protein NN O O
is NN O O
the NN O O
major NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
product NN O O
in NN O O
brain NN O O
and NN O O
other NN O O
nonmuscle NN O O
tissues NN O O
but NN O O
is NN O O
undetectable NN O O
in NN O O
skeletal NN O O
muscle NN O O
extracts NN O O
. NN O O

histidinemia. NN O O
classical NN O O
and NN O O
atypical NN O O
form NN O O
in NN O O
siblings NN O O
. NN O O

two NN O O
brothers, NN O O
6 NN O O
and NN O O
13 NN O O
years NN O O
old, NN O O
had NN O O
histidinemia NN B-SpecificDisease B-MSH:C538320
. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
clinical NN O O
and NN O O
biochemical NN O O
observations, NN O O
the NN O O
younger NN O O
boy NN O O
was NN O O
considered NN O O
to NN O O
have NN O O
a NN O O
classical NN O O
type NN O O
of NN O O
the NN O O
disease, NN O O
while NN O O
the NN O O
older NN O O
boy NN O O
had NN O O
an NN O O
atypical NN O O
form NN O O
characterized NN O O
by NN O O
partial NN O O
impairment NN O O
of NN O O
the NN O O
skin NN O O
histidase NN O O
activity NN O O
and NN O O
a NN O O
moderately NN O O
prolonged NN O O
half-life NN O O
of NN O O
blood NN O O
histidine. NN O O
the NN O O
mother NN O O
is NN O O
a NN O O
heterozygous NN O O
carrier, NN O O
while NN O O
the NN O O
father NN O O
and NN O O
sister NN O O
seem NN O O
to NN O O
be NN O O
normal. NN O O
. NN O O

hypoxanthine-guanine NN O O
phosphoribosyltransferase NN O O
deficiency: NN O O
analysis NN O O
of NN O O
hprt NN O O
mutations NN O O
by NN O O
direct NN O O
sequencing NN O O
and NN O O
allele-specific NN O O
amplification NN O O
. NN O O
iciency: NN O O
analysis NN O O
of NN O O
hprt NN O O
mutations NN O O
by NN O O
direct NN O O
sequencing NN O O
and NN O O
allele-specific NN O O
amplification NN O O
. NN O O

the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
is NN O O
a NN O O
severe NN O O
X NN B-DiseaseClass B-MSH:D040181
chromosome-linked NN I-DiseaseClass I-MSH:D040181
human NN I-DiseaseClass I-MSH:D040181
disease NN I-DiseaseClass I-MSH:D040181
caused NN O O
by NN O O
a NN O O
virtual NN O O
absence NN B-SpecificDisease B-MSH:D007926
of NN I-SpecificDisease I-MSH:D007926
hypoxanthine-guanine NN I-SpecificDisease I-MSH:D007926
phosphoribosyltransferase NN I-SpecificDisease I-MSH:D007926
(HPRT) NN I-SpecificDisease I-MSH:D007926
activity NN I-SpecificDisease I-MSH:D007926
. NN O O
a NN O O
partial NN O O
deficiency NN O O
in NN O O
the NN O O
activity NN O O
of NN O O
this NN O O
enzyme NN O O
can NN O O
result NN O O
in NN O O
gouty NN B-SpecificDisease B-MSH:D015210
arthritis NN I-SpecificDisease I-MSH:D015210
. NN O O
to NN O O
determine NN O O
the NN O O
genetic NN O O
basis NN O O
for NN O O
reduction NN O O
or NN O O
loss NN O O
of NN O O
enzyme NN O O
activity, NN O O
we NN O O
have NN O O
amplified NN O O
and NN O O
sequenced NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
hprt NN O O
cdna NN O O
from NN O O
four NN O O
patients NN O O
one NN O O
with NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
(hprtperth) NN O O
and NN O O
three NN O O
with NN O O
partial NN B-DiseaseClass B-OMIM:300323
deficiencies NN I-DiseaseClass I-OMIM:300323
of NN I-DiseaseClass I-OMIM:300323
HPRT NN I-DiseaseClass I-OMIM:300323
activity NN I-DiseaseClass I-OMIM:300323
, NN O O
which NN O O
have NN O O
been NN O O
designated NN O O
hprturangan, NN O O
hprtswan NN O O
and NN O O
hprttoowong. NN O O
in NN O O
all NN O O
four NN O O
patients, NN O O
the NN O O
only NN O O
mutation NN O O
identified NN O O
was NN O O
a NN O O
single NN O O
base NN O O
substitution NN O O
in NN O O
exons NN O O
2 NN O O
or NN O O
3 NN O O
of NN O O
the NN O O
coding NN O O
region, NN O O
which NN O O
in NN O O
each NN O O
case NN O O
predicts NN O O
a NN O O
single NN O O
amino NN O O
acid NN O O
substitution NN O O
in NN O O
the NN O O
translated NN O O
protein. NN O O
each NN O O
bas NN O O
. NN O O

change NN O O
was NN O O
confirmed NN O O
by NN O O
allele-specific NN O O
amplification NN O O
of NN O O
the NN O O
patients NN O O
genomic NN O O
dna. NN O O
it NN O O
is NN O O
interesting NN O O
to NN O O
note NN O O
that NN O O
the NN O O
mutation NN O O
found NN O O
for NN O O
hprtperth NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
reported NN O O
for NN O O
hprtflint. NN O O
it NN O O
appears NN O O
that NN O O
the NN O O
two NN O O
mutations NN O O
are NN O O
de NN O O
novo NN O O
events. NN O O
. NN O O

sjogren-larsson NN O O
syndrome. NN O O
impaired NN O O
fatty NN O O
alcohol NN O O
oxidation NN O O
in NN O O
cultured NN O O
fibroblasts NN O O
due NN O O
to NN O O
deficient NN O O
fatty NN O O
alcohol:nicotinamide NN O O
adenine NN O O
dinucleotide NN O O
oxidoreductase NN O O
activity NN O O
. NN O O

lipid NN O O
metabolism NN O O
was NN O O
studied NN O O
in NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
patients NN O O
with NN O O
the NN O O
inherited NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
, NN O O
Sjogren-Larsson NN B-SpecificDisease B-MSH:D016111
syndrome NN I-SpecificDisease I-MSH:D016111
( NN O O
SLS NN B-SpecificDisease B-MSH:D016111
). NN O O
intact NN O O
SLS NN B-Modifier B-MSH:D016111
fibroblasts NN O O
incubated NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
[1-14 NN O O
c] NN O O
palmitate NN O O
accumulated NN O O
more NN O O
radioactive NN O O
hexadecanol NN O O
than NN O O
did NN O O
normal NN O O
cells, NN O O
whereas NN O O
incorporation NN O O
of NN O O
radioactivity NN O O
into NN O O
other NN O O
cellular NN O O
lipids NN O O
was NN O O
unaltered. NN O O
the NN O O
hexadecanol NN O O
content NN O O
of NN O O
SLS NN B-Modifier B-MSH:D016111
fibroblasts NN O O
was NN O O
abnormally NN O O
elevated. NN O O
hexadecanol NN O O
accumulation NN O O
was NN O O
not NN O O
due NN O O
to NN O O
increased NN O O
fatty NN O O
alcohol NN O O
synthesis NN O O
nor NN O O
its NN O O
deficient NN O O
utilization NN O O
for NN O O
glycerol NN O O
ether NN O O
synthesis. NN O O
the NN O O
half-life NN O O
of NN O O
intracellular NN O O
hexadecanol NN O O
loaded NN O O
into NN O O
SLS NN B-Modifier B-MSH:D016111
fibroblasts NN O O
was NN O O
increased NN O O
(70 NN O O
min) NN O O
compared NN O O
with NN O O
normal NN O O
(15 NN O O
min), NN O O
and NN O O
intact NN O O
SLS NN B-Modifier B-MSH:D016111
fibroblasts NN O O
showed NN O O
impaired NN O O
oxidation NN O O
of NN O O
[14 NN O O
c] NN O O
-hexadecanol NN O O
to NN O O
fatty NN O O
acid. NN O O
fatty NN O O
alcohol NN O O
nad NN O O
+ NN O O
oxidoreductase, NN O O
the NN O O
enzyme NN O O
catalyzing NN O O
thi NN O O
. NN O O

reaction, NN O O
was NN O O
deficient NN O O
in NN O O
SLS NN B-Modifier B-MSH:D016111
fibroblasts. NN O O
mean NN O O
total NN O O
activity NN O O
in NN O O
SLS NN B-Modifier B-MSH:D016111
fibroblasts NN O O
(n NN O O
= NN O O
5) NN O O
was NN O O
13% NN O O
of NN O O
that NN O O
in NN O O
normal NN O O
fibroblasts, NN O O
and NN O O
palmitoyl NN O O
coa-inhibitable NN O O
activity NN O O
was NN O O
1% NN O O
of NN O O
normal. NN O O
fibroblasts NN O O
from NN O O
two NN O O
obligate NN O O
SLS NN B-Modifier B-MSH:D016111
heterozygotes NN O O
had NN O O
enzyme NN O O
activities NN O O
intermediate NN O O
between NN O O
that NN O O
in NN O O
normal NN O O
fibroblasts NN O O
and NN O O
individuals NN O O
with NN O O
SLS NN B-SpecificDisease B-MSH:D016111
. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
primary NN O O
defect NN O O
in NN O O
SLS NN B-SpecificDisease B-MSH:D016111
is NN O O
deficiency NN B-SpecificDisease B-MSH:D016111
of NN I-SpecificDisease I-MSH:D016111
fatty NN I-SpecificDisease I-MSH:D016111
alcohol NN I-SpecificDisease I-MSH:D016111
NAD NN I-SpecificDisease I-MSH:D016111
+ NN I-SpecificDisease I-MSH:D016111
oxidoreductase NN I-SpecificDisease I-MSH:D016111
. NN O O
SLS NN B-SpecificDisease B-MSH:D016111
represents NN O O
the NN O O
first NN O O
inherited NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
in NN O O
man NN O O
associated NN O O
with NN O O
an NN O O
isolated NN O O
abnormality NN B-DiseaseClass B-MSH:D005235
in NN I-DiseaseClass I-MSH:D005235
fatty NN I-DiseaseClass I-MSH:D005235
alcohol NN I-DiseaseClass I-MSH:D005235
metabolism NN I-DiseaseClass I-MSH:D005235
. NN O O
. NN O O

glycerol NN O O
as NN O O
a NN O O
correlate NN O O
of NN O O
impaired NN B-SpecificDisease B-MSH:D018149
glucose NN I-SpecificDisease I-MSH:D018149
tolerance NN I-SpecificDisease I-MSH:D018149
: NN O O
dissection NN O O
of NN O O
a NN O O
complex NN O O
system NN O O
by NN O O
use NN O O
of NN O O
a NN O O
simple NN O O
genetic NN O O
trait NN O O
. NN O O

glycerol NN O O
kinase NN O O
(gk) NN O O
represents NN O O
the NN O O
primary NN O O
entry NN O O
of NN O O
glycerol NN O O
into NN O O
glucose NN O O
and NN O O
triglyceride NN O O
metabolism. NN O O
Impaired NN B-SpecificDisease B-MSH:D018149
glucose NN I-SpecificDisease I-MSH:D018149
tolerance NN I-SpecificDisease I-MSH:D018149
( NN O O
IGT NN B-SpecificDisease B-MSH:D018149
) NN O O
and NN O O
hypertriglyceridemia NN B-SpecificDisease B-MSH:D015228
are NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
diabetes NN B-SpecificDisease B-MSH:D003920
mellitus NN I-SpecificDisease I-MSH:D003920
and NN O O
cardiovascular NN B-SpecificDisease B-MSH:D002318
disease NN I-SpecificDisease I-MSH:D002318
. NN O O
the NN O O
relationship NN O O
between NN O O
glycerol NN O O
and NN O O
the NN O O
risk NN O O
of NN O O
IGT NN B-SpecificDisease B-MSH:D018149
, NN O O
however, NN O O
is NN O O
poorly NN O O
understood. NN O O
we NN O O
therefore NN O O
undertook NN O O
the NN O O
study NN O O
of NN O O
fasting NN O O
plasma NN O O
glycerol NN O O
levels NN O O
in NN O O
a NN O O
cohort NN O O
of NN O O
1, NN O O
056 NN O O
unrelated NN O O
men NN O O
and NN O O
women NN O O
of NN O O
french-canadian NN O O
descent. NN O O
family NN O O
screening NN O O
in NN O O
the NN O O
initial NN O O
cohort NN O O
identified NN O O
18 NN O O
men NN O O
from NN O O
five NN O O
families NN O O
with NN O O
severe NN O O
hyperglycerolemia NN B-SpecificDisease B-MSH:C538138
(values NN O O
above NN O O
2. NN O O
0 NN O O
mmol/liter) NN O O
and NN O O
demonstrated NN O O
an NN O O
x-linked NN O O
pattern NN O O
of NN O O
inheritance. NN O O
linkage NN O O
analysis NN O O
of NN O O
the NN O O
data NN O O
from NN O O
12 NN O O
microsatellite NN O O
markers NN O O
surrounding NN O O
the NN O O
xp NN O O
21. NN O O
3 NN O O
gk NN O O
gene NN O O
resulted NN O O
in NN O O
a NN O O
peak NN O O
lod NN O O
score NN O O
o NN O O
. NN O O

3. NN O O
46, NN O O
centered NN O O
around NN O O
marker NN O O
dxs NN O O
8039. NN O O
in NN O O
addition, NN O O
since NN O O
all NN O O
of NN O O
the NN O O
families NN O O
originated NN O O
in NN O O
a NN O O
population NN O O
with NN O O
a NN O O
proven NN O O
founder NN O O
effect-the NN O O
saguenay NN O O
lac-st. NN O O
-jean NN O O
region NN O O
of NN O O
quebec-a NN O O
common NN O O
disease NN O O
haplotype NN O O
was NN O O
sought. NN O O
indeed, NN O O
a NN O O
six-marker NN O O
haplotype NN O O
extending NN O O
over NN O O
a NN O O
region NN O O
of NN O O
5. NN O O
5 NN O O
cm NN O O
was NN O O
observed NN O O
in NN O O
all NN O O
families. NN O O
resequencing NN O O
of NN O O
the NN O O
gk NN O O
gene NN O O
in NN O O
family NN O O
members NN O O
led NN O O
to NN O O
the NN O O
discovery NN O O
of NN O O
a NN O O
n NN O O
288 NN O O
d NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
10, NN O O
which NN O O
resulted NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
a NN O O
highly NN O O
conserved NN O O
asparagine NN O O
residue NN O O
by NN O O
a NN O O
negatively NN O O
charged NN O O
aspartic NN O O
acid NN O O
. NN O O

assignment NN O O
of NN O O
the NN O O
aspartylglucosaminidase NN O O
gene NN O O
(aga) NN O O
to NN O O
4 NN O O
q NN O O
33----q NN O O
35 NN O O
based NN O O
on NN O O
decreased NN O O
activity NN O O
in NN O O
a NN O O
girl NN O O
with NN O O
a NN O O
46,xx,del(4)(q NN O O
33) NN O O
karyotype NN O O
. NN O O

aspartylglucosaminuria NN O O
( NN O O
AGU NN B-SpecificDisease B-MSH:D054880
) NN O O
is NN O O
a NN O O
recessive NN O O
autosomally NN O O
inherited NN O O
lysosomal NN B-DiseaseClass B-MSH:D016464
storage NN I-DiseaseClass I-MSH:D016464
disorder NN I-DiseaseClass I-MSH:D016464
due NN O O
to NN O O
deficiency NN B-SpecificDisease B-MSH:D054880
of NN I-SpecificDisease I-MSH:D054880
the NN I-SpecificDisease I-MSH:D054880
enzyme NN I-SpecificDisease I-MSH:D054880
aspartylglucosaminidase NN I-SpecificDisease I-MSH:D054880
(aga). NN O O
the NN O O
structural NN O O
gene NN O O
for NN O O
this NN O O
human NN O O
enzyme NN O O
(aga) NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
the NN O O
region NN O O
4 NN O O
q NN O O
21----qter. NN O O
we NN O O
determined NN O O
the NN O O
aga NN O O
activity NN O O
in NN O O
cultured NN O O
fibroblasts NN O O
of NN O O
a NN O O
girl NN O O
with NN O O
a NN O O
46, NN O O
xx, NN O O
del NN O O
(4) NN O O
(q NN O O
33) NN O O
karyotype. NN O O
the NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
girl NN O O
is NN O O
a NN O O
hemizygote NN O O
for NN O O
aga, NN O O
permitting NN O O
the NN O O
assignment NN O O
of NN O O
human NN O O
aga NN O O
to NN O O
the NN O O
region NN O O
4 NN O O
q NN O O
33----qter. NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
fibrinogen NN O O
aalpha NN O O
gene NN O O
account NN O O
for NN O O
the NN O O
majority NN O O
of NN O O
cases NN O O
of NN O O
congenital NN B-SpecificDisease B-MSH:C531603
afibrinogenemia NN I-SpecificDisease I-MSH:C531603
. NN O O

congenital NN O O
afibrinogenemia NN O O
is NN O O
a NN O O
rare, NN O O
autosomal, NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
the NN O O
complete NN O O
absence NN O O
of NN O O
detectable NN O O
fibrinogen. NN O O
we NN O O
previously NN O O
identified NN O O
the NN O O
first NN O O
causative NN O O
mutations NN O O
in NN O O
a NN O O
nonconsanguineous NN O O
swiss NN O O
family; NN O O
the NN O O
4 NN O O
affected NN O O
persons NN O O
have NN O O
homozygous NN O O
deletions NN O O
of NN O O
approximately NN O O
11 NN O O
kb NN O O
of NN O O
the NN O O
fibrinogen NN O O
alpha NN O O
(fga) NN O O
gene. NN O O
haplotype NN O O
data NN O O
implied NN O O
that NN O O
these NN O O
deletions NN O O
occurred NN O O
on NN O O
distinct NN O O
ancestral NN O O
chromosomes, NN O O
suggesting NN O O
that NN O O
this NN O O
region NN O O
may NN O O
be NN O O
susceptible NN O O
to NN O O
deletion NN O O
by NN O O
a NN O O
common NN O O
mechanism. NN O O
we NN O O
subsequently NN O O
showed NN O O
that NN O O
all NN O O
the NN O O
deletions NN O O
were NN O O
identical NN O O
to NN O O
the NN O O
base NN O O
pair NN O O
and NN O O
probably NN O O
resulted NN O O
from NN O O
a NN O O
nonhomologous NN O O
recombination NN O O
mediated NN O O
by NN O O
7-bp NN O O
direct NN O O
repeats. NN O O
in NN O O
this NN O O
study, NN O O
we NN O O
have NN O O
collected NN O O
data NN O O
on NN O O
13 NN O O
additional NN O O
unrelated NN O O
patients NN O O
to NN O O
identify NN O O
the NN O O
causative NN O O
mutations NN O O
and NN O O
to NN O O
determine NN O O
the NN O O
prevalence NN O O
of NN O O
the NN O O
11-kb NN O O
deletion. NN O O
a NN O O
common NN O O
recurrent NN O O
mutatio NN O O
. NN O O

, NN O O
at NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
fga NN O O
intron NN O O
4 NN O O
(ivs NN O O
4 NN O O
+ NN O O
1 NN O O
g NN O O
> NN O O
t), NN O O
accounted NN O O
for NN O O
14 NN O O
of NN O O
the NN O O
26 NN O O
(54%) NN O O
alleles. NN O O
one NN O O
patient NN O O
was NN O O
heterozygous NN O O
for NN O O
the NN O O
previously NN O O
identified NN O O
deletion. NN O O
three NN O O
more NN O O
frameshift NN O O
mutations, NN O O
2 NN O O
nonsense NN O O
mutations, NN O O
and NN O O
a NN O O
second NN O O
splice NN O O
site NN O O
mutation NN O O
were NN O O
also NN O O
identified. NN O O
consequently, NN O O
86% NN O O
of NN O O
afibrinogenemia NN B-Modifier B-MSH:D000347
alleles NN O O
analyzed NN O O
to NN O O
date NN O O
have NN O O
truncating NN O O
mutations NN O O
of NN O O
fga, NN O O
though NN O O
mutations NN O O
in NN O O
all NN O O
3 NN O O
fibrinogen NN O O
genes, NN O O
fgg, NN O O
fga, NN O O
and NN O O
fgb, NN O O
might NN O O
be NN O O
predicted NN O O
to NN O O
cause NN O O
congenital NN B-SpecificDisease B-MSH:C531603
afibrinogenemia NN I-SpecificDisease I-MSH:C531603
. NN O O
. NN O O

utilization NN O O
of NN O O
purines NN O O
by NN O O
an NN O O
hprt NN O O
variant NN O O
in NN O O
an NN O O
intelligent, NN O O
nonmutilative NN O O
patient NN O O
with NN O O
features NN O O
of NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O

the NN O O
patient, NN O O
h. NN O O
chr. NN O O
b., NN O O
was NN O O
among NN O O
the NN O O
first NN O O
reported NN O O
with NN O O
hyperuricemia NN B-SpecificDisease B-MSH:D033461
and NN O O
central NN B-DiseaseClass B-MSH:D002493
nervous NN I-DiseaseClass I-MSH:D002493
system NN I-DiseaseClass I-MSH:D002493
symptoms NN I-DiseaseClass I-MSH:D002493
. NN O O
he NN O O
has NN O O
been NN O O
found NN O O
to NN O O
have NN O O
a NN O O
variant NN O O
of NN O O
hypoxanthine NN O O
guanine NN O O
phosphoribosyl NN O O
transferase NN O O
(hprt; NN O O
e. NN O O
c. NN O O
2. NN O O
4. NN O O
2. NN O O
8) NN O O
distinct NN O O
from NN O O
the NN O O
enzyme NN O O
present NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O
the NN O O
patient NN O O
had NN O O
chroeoathetosis NN B-SpecificDisease B-MSH:C537181
, NN O O
spasticity NN B-SpecificDisease B-MSH:D009128
, NN O O
dysarthric NN B-SpecificDisease B-MSH:D004401
speech NN I-SpecificDisease I-MSH:D004401
, NN O O
and NN O O
hyperuricemia NN B-SpecificDisease B-MSH:D033461
. NN O O
however, NN O O
his NN O O
intelligence NN O O
was NN O O
normal NN O O
and NN O O
he NN O O
had NN O O
no NN O O
evidence NN O O
of NN O O
self-mutilation. NN O O
there NN O O
was NN O O
no NN O O
activity NN O O
of NN O O
hprt NN O O
in NN O O
the NN O O
lysates NN O O
of NN O O
erythrocytes NN O O
and NN O O
cultured NN O O
fibroblasts NN O O
when NN O O
analyzed NN O O
in NN O O
the NN O O
usual NN O O
manner. NN O O
using NN O O
a NN O O
newly NN O O
developed NN O O
method NN O O
for NN O O
the NN O O
study NN O O
of NN O O
purine NN O O
metabolism NN O O
in NN O O
intact NN O O
cultured NN O O
cells, NN O O
this NN O O
patient NN O O
was NN O O
found NN O O
to NN O O
metabolize NN O O
some NN O O
9 NN O O
. NN O O

of NN O O
8-14 NN O O
c-hypoxanthine, NN O O
and NN O O
90% NN O O
of NN O O
the NN O O
isotope NN O O
utilized NN O O
was NN O O
converted NN O O
to NN O O
adenine NN O O
and NN O O
guanine NN O O
nucleotides. NN O O
in NN O O
contrast, NN O O
cells NN O O
from NN O O
patients NN O O
with NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
were NN O O
virtually NN O O
completely NN O O
unable NN O O
to NN O O
convert NN O O
hypoxanthine NN O O
to NN O O
nucleotides. NN O O
the NN O O
patients NN O O
fibroblasts NN O O
were NN O O
even NN O O
more NN O O
efficient NN O O
in NN O O
the NN O O
metabolism NN O O
of NN O O
8-14 NN O O
c-guanine, NN O O
which NN O O
was NN O O
utilized NN O O
to NN O O
the NN O O
extent NN O O
of NN O O
27%, NN O O
over NN O O
80% NN O O
of NN O O
which NN O O
was NN O O
converted NN O O
to NN O O
guanine NN O O
and NN O O
adenine NN O O
nucleotides. NN O O
the NN O O
growth NN O O
of NN O O
the NN O O
cultured NN O O
fibroblasts NN O O
of NN O O
this NN O O
patient NN O O
was NN O O
intermediate NN O O
in NN O O
media NN O O
containing NN O O
hypoxanthine NN O O
aminopterin NN O O
thymidine NN O O
(hat), NN O O
whereas NN O O
the NN O O
growth NN O O
of NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
cells NN O O
was NN O O
inhibited NN O O
and NN O O
normal NN O O
cells NN O O
grew NN O O
normally. NN O O
similarly NN O O
in NN O O
8-azaguanine, NN O O
6-thioguanine, NN O O
and NN O O
8-azahypoxanthine, NN O O
the NN O O
growt NN O O
. NN O O

of NN O O
the NN O O
patients NN O O
cells NN O O
was NN O O
intermediate NN O O
between NN O O
normal NN O O
and NN O O
Lesch-Nyhan NN B-Modifier B-MSH:D007926
cells. NN O O
these NN O O
observations NN O O
provide NN O O
further NN O O
evidence NN O O
for NN O O
genetic NN O O
heterogeneity NN O O
among NN O O
patients NN O O
with NN O O
disorders NN O O
in NN O O
purine NN O O
metabolism NN O O
involving NN O O
the NN O O
hprt NN O O
gene. NN O O
they NN O O
document NN O O
that NN O O
this NN O O
famous NN O O
patient NN O O
did NN O O
not NN O O
have NN O O
the NN O O
Lesch-Nyhan NN B-SpecificDisease B-MSH:D007926
syndrome NN I-SpecificDisease I-MSH:D007926
. NN O O

canavan NN O O
disease: NN O O
mutations NN O O
among NN O O
jewish NN O O
and NN O O
non-jewish NN O O
patients NN O O
. NN O O

canavan NN O O
disease NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D007966
recessive NN I-DiseaseClass I-MSH:D007966
leukodystrophy NN I-DiseaseClass I-MSH:D007966
caused NN O O
by NN O O
the NN O O
deficiency NN B-SpecificDisease B-MSH:D017825
of NN I-SpecificDisease I-MSH:D017825
aspartoacylase NN I-SpecificDisease I-MSH:D017825
(aspa). NN O O
sixty-four NN O O
probands NN O O
were NN O O
analyzed NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
aspa NN O O
gene. NN O O
three NN O O
point NN O O
mutations--693 NN O O
c-- NN O O
> NN O O
a, NN O O
854 NN O O
a-- NN O O
> NN O O
c, NN O O
and NN O O
914 NN O O
c-- NN O O
> NN O O
a--were NN O O
identified NN O O
in NN O O
the NN O O
coding NN O O
sequence. NN O O
the NN O O
693 NN O O
c-- NN O O
> NN O O
a NN O O
and NN O O
914 NN O O
c-- NN O O
> NN O O
a NN O O
base NN O O
changes, NN O O
resulting NN O O
in NN O O
nonsense NN O O
tyr NN O O
231-- NN O O
> NN O O
ter NN O O
and NN O O
missense NN O O
ala NN O O
305-- NN O O
> NN O O
glu NN O O
mutations, NN O O
respectively, NN O O
lead NN O O
to NN O O
complete NN O O
loss NN O O
of NN O O
aspa NN O O
activity NN O O
in NN O O
in NN O O
vitro NN O O
expression NN O O
studies. NN O O
the NN O O
854 NN O O
a-- NN O O
> NN O O
c NN O O
transversion NN O O
converted NN O O
glu NN O O
to NN O O
ala NN O O
in NN O O
codon NN O O
285. NN O O
the NN O O
glu NN O O
285-- NN O O
> NN O O
ala NN O O
mutan NN O O
. NN O O

aspa NN O O
has NN O O
2. NN O O
5% NN O O
of NN O O
the NN O O
activity NN O O
expressed NN O O
by NN O O
the NN O O
wild-type NN O O
enzyme. NN O O
a NN O O
fourth NN O O
mutation, NN O O
433 NN O O
--2 NN O O
(a-- NN O O
> NN O O
g) NN O O
transition, NN O O
was NN O O
identified NN O O
at NN O O
the NN O O
splice-acceptor NN O O
site NN O O
in NN O O
intron NN O O
2. NN O O
the NN O O
splice-site NN O O
mutation NN O O
would NN O O
lead NN O O
to NN O O
skipping NN O O
of NN O O
exon NN O O
3, NN O O
accompanied NN O O
by NN O O
a NN O O
frameshift, NN O O
and NN O O
thus NN O O
would NN O O
produce NN O O
aberrant NN O O
aspa. NN O O
of NN O O
the NN O O
128 NN O O
unrelated NN O O
Canavan NN B-Modifier B-MSH:D017825
chromosomes NN O O
analyzed, NN O O
88 NN O O
were NN O O
from NN O O
probands NN O O
of NN O O
ashkenazi NN O O
jewish NN O O
descent. NN O O
the NN O O
glu NN O O
285-- NN O O
> NN O O
ala NN O O
mutation NN O O
was NN O O
predominant NN O O
(82. NN O O
9%) NN O O
in NN O O
this NN O O
population, NN O O
followed NN O O
by NN O O
the NN O O
tyr NN O O
231-- NN O O
> NN O O
ter NN O O
(14. NN O O
8%) NN O O
and NN O O
433 NN O O
--2 NN O O
(a-- NN O O
> NN O O
g) NN O O
(1. NN O O
1 NN O O
. NN O O

) NN O O
mutations. NN O O
the NN O O
three NN O O
mutations NN O O
account NN O O
for NN O O
98. NN O O
8% NN O O
of NN O O
the NN O O
Canavan NN B-Modifier B-MSH:D017825
chromosomes NN O O
of NN O O
ashkenazi NN O O
jewish NN O O
origin. NN O O
the NN O O
ala NN O O
305-- NN O O
> NN O O
glu NN O O
mutation NN O O
was NN O O
found NN O O
exclusively NN O O
in NN O O
non-jewish NN O O
probands NN O O
of NN O O
european NN O O
descent NN O O
and NN O O
constituted NN O O
60% NN O O
of NN O O
the NN O O
40 NN O O
mutant NN O O
chromosomes. NN O O
predominant NN O O
occurrence NN O O
of NN O O
certain NN O O
mutations NN O O
among NN O O
ashkenazi NN O O
jewish NN O O
and NN O O
non-jewish NN O O
patients NN O O
with NN O O
Canavan NN B-SpecificDisease B-MSH:D017825
disease NN I-SpecificDisease I-MSH:D017825
would NN O O
suggest NN O O
a NN O O
founding-father NN O O
effect NN O O
in NN O O
propagation NN O O
of NN O O
these NN O O
mutant NN O O
chromosome NN O O
. NN O O

identification NN O O
of NN O O
deletion NN O O
mutations NN O O
and NN O O
three NN O O
new NN O O
genes NN O O
at NN O O
the NN O O
familial NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
locus NN O O
. NN O O

small NN O O
(100-260 NN O O
kb), NN O O
nested NN O O
deletions NN O O
were NN O O
characterized NN O O
in NN O O
dna NN O O
from NN O O
two NN O O
unrelated NN O O
patients NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
coli NN I-SpecificDisease I-MSH:D011125
( NN O O
APC NN B-SpecificDisease B-MSH:D011125
). NN O O
three NN O O
candidate NN O O
genes NN O O
located NN O O
within NN O O
the NN O O
deleted NN O O
region NN O O
were NN O O
ascertained NN O O
and NN O O
a NN O O
previous NN O O
candidate NN O O
gene, NN O O
mcc, NN O O
was NN O O
shown NN O O
to NN O O
be NN O O
located NN O O
outside NN O O
the NN O O
deleted NN O O
region. NN O O
one NN O O
of NN O O
the NN O O
new NN O O
genes NN O O
contained NN O O
sequence NN O O
identical NN O O
to NN O O
srp NN O O
19, NN O O
the NN O O
gene NN O O
coding NN O O
for NN O O
the NN O O
19 NN O O
kd NN O O
component NN O O
of NN O O
the NN O O
ribosomal NN O O
signal NN O O
recognition NN O O
particle. NN O O
the NN O O
second, NN O O
provisionally NN O O
designated NN O O
dp NN O O
1 NN O O
(deleted NN O O
in NN O O
polyposis NN O O
1), NN O O
was NN O O
found NN O O
to NN O O
be NN O O
transcribed NN O O
in NN O O
the NN O O
same NN O O
orientation NN O O
as NN O O
mcc. NN O O
two NN O O
other NN O O
cdnas, NN O O
dp NN O O
2 NN O O
and NN O O
dp NN O O
3, NN O O
were NN O O
found NN O O
to NN O O
overlap, NN O O
forming NN O O
a NN O O
single NN O O
gene, NN O O
dp NN O O
2. NN O O
5, NN O O
that NN O O
is NN O O
transcribed NN O O
in NN O O
the NN O O
same NN O O
orientatio NN O O
. NN O O

as NN O O
srp NN O O
19 NN O O
. NN O O

genotype-phenotype NN O O
correlations NN O O
in NN O O
families NN O O
with NN O O
deletions NN O O
in NN O O
the NN O O
von NN B-Modifier B-MSH:D006623
Hippel-Lindau NN I-Modifier I-MSH:D006623
( NN O O
VHL NN B-Modifier B-MSH:D006623
) NN O O
gene NN O O
. NN O O

von NN O O
hippel-lindau NN O O
(vhl) NN O O
disease NN O O
is NN O O
a NN O O
hereditary NN B-DiseaseClass B-MSH:D009386
tumor NN I-DiseaseClass I-MSH:D009386
syndrome NN I-DiseaseClass I-MSH:D009386
characterized NN O O
by NN O O
predisposition NN O O
for NN O O
bilateral NN B-CompositeMention B-MSH:D018325
and NN I-CompositeMention I-MSH:D018325
multi-centric NN I-CompositeMention I-MSH:D018325
hemangioblastoma NN I-CompositeMention I-MSH:D018325
in NN O O
the NN O O
retina NN O O
and NN O O
central NN O O
nervous NN O O
system, NN O O
pheochromocytoma NN B-SpecificDisease B-MSH:D010673
, NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
, NN O O
and NN O O
cysts NN B-CompositeMention B-MSH:D052177
in NN I-CompositeMention I-MSH:D052177
the NN I-CompositeMention I-MSH:D052177
kidney, NN I-CompositeMention I-MSH:D052177
pancreas, NN I-CompositeMention I-MSH:D052177
and NN I-CompositeMention I-MSH:D052177
epididymis NN I-CompositeMention I-MSH:D052177
. NN O O
we NN O O
describe NN O O
five NN O O
families NN O O
for NN O O
which NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
had NN O O
failed NN O O
to NN O O
identify NN O O
the NN O O
family-specific NN O O
mutation. NN O O
further NN O O
molecular NN O O
analysis NN O O
revealed NN O O
deletions NN O O
involving NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
in NN O O
each NN O O
of NN O O
these NN O O
families. NN O O
in NN O O
four NN O O
families, NN O O
partial NN O O
deletions NN O O
of NN O O
one NN O O
or NN O O
more NN O O
exons NN O O
were NN O O
detected NN O O
by NN O O
southern NN O O
blot NN O O
analysis. NN O O
in NN O O
the NN O O
fifth NN O O
family, NN O O
fish NN O O
analysis NN O O
demonstrated NN O O
the NN O O
deletion NN O O
of NN O O
the NN O O
entire NN O O
VHL NN B-Modifier B-MSH:D006623
gene. NN O O
our NN O O
results NN O O
show NN O O
that NN O O
(quantitative) NN O O
southern NN O O
blot NN O O
analysis NN O O
is NN O O
a NN O O
sensitive NN O O
method NN O O
for NN O O
detecting NN O O
germlin NN O O
. NN O O

deletions NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
and NN O O
should NN O O
be NN O O
implemented NN O O
in NN O O
routine NN O O
dna NN O O
diagnosis NN O O
for NN O O
VHL NN B-SpecificDisease B-MSH:D006623
disease NN I-SpecificDisease I-MSH:D006623
. NN O O
our NN O O
data NN O O
support NN O O
the NN O O
previously NN O O
established NN O O
observation NN O O
that NN O O
families NN O O
with NN O O
a NN O O
germline NN O O
deletion NN O O
have NN O O
a NN O O
low NN O O
risk NN O O
for NN O O
pheochromocytoma NN B-SpecificDisease B-MSH:D010673
. NN O O
further NN O O
unraveling NN O O
of NN O O
genotype-phenotype NN O O
correlations NN O O
in NN O O
VHL NN B-SpecificDisease B-MSH:D006623
disease NN I-SpecificDisease I-MSH:D006623
has NN O O
revealed NN O O
that NN O O
families NN O O
with NN O O
a NN O O
full NN O O
or NN O O
partial NN O O
deletion NN O O
of NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
exhibit NN O O
a NN O O
phenotype NN O O
with NN O O
a NN O O
preponderance NN O O
of NN O O
central NN B-SpecificDisease B-MSH:D018325
nervous NN I-SpecificDisease I-MSH:D018325
system NN I-SpecificDisease I-MSH:D018325
hemangioblastoma NN I-SpecificDisease I-MSH:D018325
. NN O O
. NN O O

understanding NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
. NN O O

fragile NN O O
x NN O O
syndrome, NN O O
a NN O O
common NN O O
form NN O O
of NN O O
inherited NN B-DiseaseClass B-MSH:D038901
mental NN I-DiseaseClass I-MSH:D038901
retardation NN I-DiseaseClass I-MSH:D038901
, NN O O
is NN O O
mainly NN O O
caused NN O O
by NN O O
massive NN O O
expansion NN O O
of NN O O
cgg NN O O
triplet NN O O
repeats NN O O
located NN O O
in NN O O
the NN O O
5-untranslated NN O O
region NN O O
of NN O O
the NN O O
fragile NN B-Modifier B-OMIM:300624
X NN I-Modifier I-OMIM:300624
mental NN I-Modifier I-OMIM:300624
retardation NN I-Modifier I-OMIM:300624
-1 NN O O
(fmr NN O O
1) NN O O
gene. NN O O
in NN O O
patients NN O O
with NN O O
fragile NN B-SpecificDisease B-MSH:D005600
X NN I-SpecificDisease I-MSH:D005600
syndrome NN I-SpecificDisease I-MSH:D005600
, NN O O
the NN O O
expanded NN O O
cgg NN O O
triplet NN O O
repeats NN O O
are NN O O
hypermethylated NN O O
and NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
fmr NN O O
1 NN O O
gene NN O O
is NN O O
repressed, NN O O
which NN O O
leads NN O O
to NN O O
the NN O O
absence NN O O
of NN O O
fmr NN O O
1 NN O O
protein NN O O
(fmrp) NN O O
and NN O O
subsequent NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
. NN O O
fmrp NN O O
is NN O O
an NN O O
rna-binding NN O O
protein NN O O
that NN O O
shuttles NN O O
between NN O O
the NN O O
nucleus NN O O
and NN O O
cytoplasm. NN O O
this NN O O
protein NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
protein NN O O
translation NN O O
as NN O O
it NN O O
is NN O O
found NN O O
associated NN O O
with NN O O
polyribosomes NN O O
and NN O O
the NN O O
rough NN O O
endoplasmic NN O O
reticulum. NN O O
we NN O O
discuss NN O O
here NN O O
the NN O O
recent NN O O
progress NN O O
made NN O O
towards NN O O
understanding NN O O
the NN O O
molecular NN O O
mechanism NN O O
of NN O O
cgg NN O O
repeat NN O O
expansion NN O O
and NN O O
physiological NN O O
functio NN O O
. NN O O

(s) NN O O
of NN O O
fmrp. NN O O
these NN O O
studies NN O O
will NN O O
not NN O O
only NN O O
help NN O O
to NN O O
illuminate NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
the NN O O
general NN O O
class NN O O
of NN O O
human NN O O
diseases NN O O
with NN O O
trinucleotide NN O O
repeat NN O O
expansion NN O O
but NN O O
also NN O O
provide NN O O
an NN O O
avenue NN O O
to NN O O
understand NN O O
aspects NN O O
of NN O O
human NN O O
cognition NN O O
and NN O O
intelligence. NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
deficiency NN O O
in NN O O
papua NN O O
new NN O O
guinea. NN O O
the NN O O
description NN O O
of NN O O
13 NN O O
new NN O O
variants NN O O
. NN O O

a NN O O
total NN O O
of NN O O
362 NN O O
males NN O O
from NN O O
various NN O O
regions NN O O
of NN O O
papua NN O O
new NN O O
guinea NN O O
were NN O O
screened NN O O
for NN O O
red NN O O
cell NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
activity. NN O O
twenty-six NN O O
G6PD NN B-Modifier B-MSH:D005955
deficient NN I-Modifier I-MSH:D005955
individuals NN O O
were NN O O
identified. NN O O
biochemical NN O O
characterization NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
purified NN O O
from NN O O
these NN O O
subjects NN O O
has NN O O
revealed NN O O
13 NN O O
new NN O O
variants NN O O
and NN O O
several NN O O
copies NN O O
of NN O O
previously NN O O
described NN O O
forms NN O O
of NN O O
g NN O O
6 NN O O
pd. NN O O
this NN O O
study NN O O
illustrates NN O O
the NN O O
extreme NN O O
heterogeneity NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
among NN O O
the NN O O
people NN O O
of NN O O
papua NN O O
new NN O O
guinea. NN O O
. NN O O

regional NN O O
mapping NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
and NN O O
the NN O O
phenylketonuria NN B-Modifier B-MSH:D010661
locus NN O O
in NN O O
the NN O O
human NN O O
genome NN O O
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
of NN O O
amino NN O O
acid NN O O
metabolism NN O O
caused NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
the NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
enzyme NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah; NN O O
phenylalanine NN O O
4-monooxygenase, NN O O
ec NN O O
1. NN O O
14. NN O O
16. NN O O
1). NN O O
a NN O O
cdna NN O O
clone NN O O
for NN O O
human NN O O
pah NN O O
has NN O O
previously NN O O
been NN O O
used NN O O
to NN O O
assign NN O O
the NN O O
corresponding NN O O
gene NN O O
to NN O O
human NN O O
chromosome NN O O
12. NN O O
to NN O O
define NN O O
the NN O O
regional NN O O
map NN O O
position NN O O
of NN O O
the NN O O
disease NN O O
locus NN O O
and NN O O
the NN O O
pah NN O O
gene NN O O
on NN O O
human NN O O
chromosome NN O O
12, NN O O
dna NN O O
was NN O O
isolated NN O O
from NN O O
human-hamster NN O O
somatic NN O O
cell NN O O
hybrids NN O O
with NN O O
various NN O O
deletions NN O O
of NN O O
human NN O O
chromosome NN O O
12 NN O O
and NN O O
was NN O O
analyzed NN O O
by NN O O
southern NN O O
blot NN O O
analysis NN O O
using NN O O
the NN O O
human NN O O
cdna NN O O
pah NN O O
clone NN O O
as NN O O
a NN O O
hybridization NN O O
probe. NN O O
from NN O O
these NN O O
results, NN O O
together NN O O
with NN O O
detailed NN O O
biochemical NN O O
and NN O O
cytogenetic NN O O
characterization NN O O
of NN O O
the NN O O
hybrid NN O O
cells, NN O O
the NN O O
region NN O O
on NN O O
chromosome NN O O
12 NN O O
containing NN O O
the NN O O
human NN O O
pa NN O O
. NN O O

gene NN O O
has NN O O
been NN O O
defined NN O O
as NN O O
12 NN O O
q NN O O
14. NN O O
3----qter NN O O
3----qter. NN O O
the NN O O
pah NN O O
map NN O O
position NN O O
on NN O O
chromosome NN O O
12 NN O O
was NN O O
further NN O O
localized NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
of NN O O
125 NN O O
i-labeled NN O O
human NN O O
pah NN O O
cdna NN O O
to NN O O
chromosomes NN O O
prepared NN O O
from NN O O
a NN O O
human NN O O
lymphoblastoid NN O O
cell NN O O
line. NN O O
results NN O O
of NN O O
these NN O O
experiments NN O O
demonstrated NN O O
that NN O O
the NN O O
region NN O O
on NN O O
chromosome NN O O
12 NN O O
containing NN O O
the NN O O
pah NN O O
gene NN O O
and NN O O
the NN O O
PKU NN B-Modifier B-MSH:D010661
locus NN O O
in NN O O
man NN O O
is NN O O
12 NN O O
q NN O O
22----12 NN O O
q NN O O
24. NN O O
1. NN O O
these NN O O
results NN O O
not NN O O
only NN O O
provide NN O O
a NN O O
regionalized NN O O
map NN O O
position NN O O
for NN O O
a NN O O
major NN O O
human NN O O
disease NN O O
locus NN O O
but NN O O
also NN O O
can NN O O
serve NN O O
as NN O O
a NN O O
reference NN O O
point NN O O
for NN O O
linkage NN O O
analysis NN O O
with NN O O
other NN O O
dna NN O O
markers NN O O
on NN O O
human NN O O
chromosome NN O O
1 NN O O
. NN O O

total NN O O
deficiency NN O O
of NN O O
plasma NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
in NN O O
subjects NN O O
homozygous NN O O
and NN O O
heterozygous NN O O
for NN O O
the NN O O
intron NN O O
14 NN O O
splicing NN O O
defect NN O O
. NN O O

the NN O O
molecular NN O O
basis NN O O
of NN O O
cholesteryl NN B-SpecificDisease B-OMIM:143470
ester NN I-SpecificDisease I-OMIM:143470
transfer NN I-SpecificDisease I-OMIM:143470
protein NN I-SpecificDisease I-OMIM:143470
(CETP) NN I-SpecificDisease I-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
was NN O O
investigated NN O O
in NN O O
4 NN O O
unrelated NN O O
CETP-deficient NN B-Modifier B-OMIM:143470
families. NN O O
the NN O O
high NN O O
density NN O O
lipoprotein-cholesterol NN O O
levels NN O O
of NN O O
the NN O O
probands NN O O
exceeded NN O O
150 NN O O
mg/dl. NN O O
the NN O O
plasma NN O O
of NN O O
the NN O O
probands NN O O
was NN O O
totally NN O O
deficient NN O O
in NN O O
cetp NN O O
activity NN O O
and NN O O
mass. NN O O
the NN O O
genomic NN O O
dna NN O O
of NN O O
the NN O O
patients NN O O
was NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction, NN O O
using NN O O
two NN O O
oligonucleotide NN O O
primers NN O O
located NN O O
in NN O O
the NN O O
intron NN O O
12 NN O O
and NN O O
14 NN O O
of NN O O
the NN O O
cetp NN O O
gene, NN O O
and NN O O
the NN O O
amplified NN O O
products NN O O
were NN O O
directly NN O O
sequenced. NN O O
two NN O O
patients NN O O
were NN O O
homozygous NN O O
for NN O O
a NN O O
g-to-a NN O O
change NN O O
at NN O O
the NN O O
5-splice NN O O
donor NN O O
site NN O O
of NN O O
the NN O O
intron NN O O
14. NN O O
the NN O O
g-to-a NN O O
change NN O O
would NN O O
cause NN O O
impaired NN O O
splicing NN O O
of NN O O
pre-messenger NN O O
rna. NN O O
the NN O O
other NN O O
two NN O O
probands NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
mutation NN O O
. NN O O

but NN O O
totally NN O O
lacked NN O O
cetp. NN O O
their NN O O
lipoprotein NN O O
patterns NN O O
were NN O O
also NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
the NN O O
two NN O O
homozygotes. NN O O
thus, NN O O
other NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defects NN I-DiseaseClass I-MSH:D030342
or NN O O
metabolic NN O O
factors NN O O
influencing NN O O
cetp NN O O
expression NN O O
are NN O O
implicated. NN O O
the NN O O
data NN O O
suggest NN O O
that NN O O
the NN O O
g-to-a NN O O
mutation NN O O
may NN O O
be NN O O
common NN O O
in NN O O
human NN O O
plasma NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
. NN O O
furthermore, NN O O
there NN O O
could NN O O
be NN O O
compound NN O O
heterozygotes NN O O
who NN O O
totally NN O O
lack NN O O
plasma NN O O
cetp NN O O
and NN O O
have NN O O
lipoprotein NN O O
profiles NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
homozygotes. NN O O
. NN O O

heterogeneity NN O O
of NN O O
type NN B-SpecificDisease B-MSH:D056725
I NN I-SpecificDisease I-MSH:D056725
von NN I-SpecificDisease I-MSH:D056725
Willebrand NN I-SpecificDisease I-MSH:D056725
disease NN I-SpecificDisease I-MSH:D056725
: NN O O
evidence NN O O
for NN O O
a NN O O
subgroup NN O O
with NN O O
an NN O O
abnormal NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
. NN O O

type NN O O
i NN O O
von NN O O
willebrand NN O O
disease NN O O
( NN O O
vWD NN B-SpecificDisease B-MSH:D014842
) NN O O
is NN O O
characterized NN O O
by NN O O
equally NN O O
low NN O O
plasma NN O O
concentrations NN O O
of NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
antigen NN O O
(vwf NN O O
ag) NN O O
and NN O O
ristocetin NN O O
cofactor NN O O
(ricof) NN O O
and NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
all NN O O
vwf NN O O
multimers NN O O
in NN O O
sodium NN O O
dodecyl NN O O
sulfate NN O O
(sds) NN O O
-agarose NN O O
gel NN O O
electrophoresis. NN O O
for NN O O
17 NN O O
patients NN O O
(13 NN O O
kindreds) NN O O
diagnosed NN O O
with NN O O
these NN O O
criteria, NN O O
we NN O O
have NN O O
studied NN O O
the NN O O
platelet NN O O
contents NN O O
of NN O O
vwf NN O O
ag NN O O
and NN O O
ricof NN O O
and NN O O
the NN O O
changes NN O O
of NN O O
these NN O O
in NN O O
plasma NN O O
after NN O O
ddavp NN O O
infusion. NN O O
platelet NN O O
vwf NN O O
ag NN O O
and NN O O
ricof NN O O
were NN O O
normal NN O O
in NN O O
four NN O O
kindreds NN O O
(called NN O O
" NN O O
platelet NN O O
normal NN O O
" NN O O
subgroup); NN O O
following NN O O
1-deamino-8-d-arginine NN O O
vasopressin; NN O O
plasma NN O O
vwf NN O O
ag, NN O O
ricof NN O O
and NN O O
the NN O O
bleeding NN O O
time NN O O
(bt) NN O O
became NN O O
normal. NN O O
in NN O O
six NN O O
kindreds, NN O O
platelet NN O O
vwf NN O O
ag NN O O
and NN O O
ricof NN O O
wer NN O O
. NN O O

equally NN O O
low NN O O
(platelet NN O O
low); NN O O
after NN O O
ddavp, NN O O
plasma NN O O
vwf NN O O
ag NN O O
and NN O O
ricof NN O O
remained NN O O
low, NN O O
and NN O O
the NN O O
bt NN O O
was NN O O
prolonged. NN O O
in NN O O
three NN O O
additional NN O O
kindreds, NN O O
platelets NN O O
contained NN O O
normal NN O O
concentrations NN O O
of NN O O
vwf NN O O
ag, NN O O
but NN O O
ricof NN O O
was NN O O
very NN O O
low NN O O
(platelet NN O O
discordant); NN O O
even NN O O
though NN O O
a NN O O
complete NN O O
set NN O O
of NN O O
multimers NN O O
was NN O O
found NN O O
in NN O O
plasma NN O O
and NN O O
platelets, NN O O
there NN O O
was NN O O
a NN O O
relatively NN O O
small NN O O
amount NN O O
of NN O O
large NN O O
multimers. NN O O
after NN O O
ddavp, NN O O
plasma NN O O
vwf NN O O
ag NN O O
became NN O O
normal, NN O O
but NN O O
ricof NN O O
remained NN O O
low NN O O
and NN O O
the NN O O
bt NN O O
was NN O O
very NN O O
prolonged. NN O O
these NN O O
findings NN O O
demonstrated NN O O
that NN O O
there NN O O
can NN O O
be NN O O
an NN O O
abnormal NN O O
vwf NN O O
(ricof NN O O
less NN O O
than NN O O
vwf NN O O
ag) NN O O
even NN O O
in NN O O
type NN B-SpecificDisease B-MSH:D056725
I NN I-SpecificDisease I-MSH:D056725
vWD NN I-SpecificDisease I-MSH:D056725
, NN O O
coexisting NN O O
with NN O O
a NN O O
complete NN O O
set NN O O
of NN O O
vwf NN O O
multimers NN O O
(platelet NN O O
discordant); NN O O
that NN O O
the NN O O
abnormal NN O O
vwf NN O O
can NN O O
be NN O O
shown NN O O
more NN O O
clearly NN O O
in NN O O
platelets NN O O
than NN O O
i NN O O
. NN O O

plasma NN O O
or NN O O
else NN O O
in NN O O
plasma NN O O
after NN O O
ddavp NN O O
infusion; NN O O
and NN O O
that NN O O
ddavp NN O O
normalizes NN O O
the NN O O
bt NN O O
only NN O O
in NN O O
those NN O O
patients NN O O
with NN O O
normal NN O O
platelet NN O O
levels NN O O
of NN O O
both NN O O
vwf NN O O
ag NN O O
and NN O O
ricof NN O O
(platelet NN O O
normal). NN O O
. NN O O

characterization NN O O
of NN O O
a NN O O
yac NN O O
containing NN O O
part NN O O
or NN O O
all NN O O
of NN O O
the NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
locus NN O O
. NN O O

it NN O O
has NN O O
been NN O O
shown NN O O
from NN O O
pulsed-field NN O O
gel NN O O
electrophoresis NN O O
(pfge) NN O O
that NN O O
the NN O O
monoamine NN O O
oxidase NN O O
genes NN O O
a NN O O
and NN O O
b NN O O
(maoa NN O O
& NN O O
maob) NN O O
and NN O O
dxs NN O O
7 NN O O
loci NN O O
are NN O O
physically NN O O
very NN O O
close. NN O O
we NN O O
have NN O O
therefore NN O O
extended NN O O
studies NN O O
on NN O O
their NN O O
relationship NN O O
through NN O O
the NN O O
characterisation NN O O
of NN O O
a NN O O
650 NN O O
kb NN O O
yac NN O O
isolated NN O O
using NN O O
l NN O O
1. NN O O
28 NN O O
(recognising NN O O
the NN O O
dxs NN O O
7 NN O O
locus) NN O O
as NN O O
a NN O O
probe. NN O O
restriction NN O O
mapping NN O O
of NN O O
the NN O O
yac NN O O
indicates NN O O
that NN O O
it NN O O
contains NN O O
both NN O O
maoa NN O O
and NN O O
maob NN O O
genes NN O O
in NN O O
addition NN O O
to NN O O
the NN O O
dxs NN O O
7 NN O O
locus. NN O O
the NN O O
map NN O O
derived NN O O
from NN O O
the NN O O
yl NN O O
1. NN O O
28-yac NN O O
is NN O O
compatible NN O O
both NN O O
with NN O O
the NN O O
map NN O O
from NN O O
an NN O O
independently NN O O
derived NN O O
yac NN O O
carrying NN O O
maoa NN O O
and NN O O
b NN O O
genes NN O O
and NN O O
with NN O O
the NN O O
long NN O O
range NN O O
genomic NN O O
map NN O O
for NN O O
the NN O O
region. NN O O
a NN O O
series NN O O
of NN O O
subclones NN O O
prepared NN O O
from NN O O
a NN O O
phage NN O O
library NN O O
(lambda NN O O
das NN O O
. NN O O
e NN O O
monoamine NN O O
oxidase NN O O
genes NN O O
a NN O O
and NN O O
b NN O O
(maoa NN O O
& NN O O
maob) NN O O
and NN O O
dxs NN O O
7 NN O O
loci NN O O
are NN O O
physically NN O O
very NN O O
close. NN O O
we NN O O
have NN O O
therefore NN O O
extended NN O O
studies NN O O
on NN O O
their NN O O
relationship NN O O
through NN O O
the NN O O
characterisation NN O O
of NN O O
a NN O O
650 NN O O
kb NN O O
yac NN O O
isolated NN O O
using NN O O
l NN O O
1. NN O O
28 NN O O
(recognising NN O O
the NN O O
dxs NN O O
7 NN O O
locus) NN O O
as NN O O
a NN O O
probe. NN O O
restriction NN O O
mapping NN O O
of NN O O
the NN O O
yac NN O O
indicates NN O O
that NN O O
it NN O O
contains NN O O
both NN O O
maoa NN O O
and NN O O
maob NN O O
genes NN O O
in NN O O
addition NN O O
to NN O O
the NN O O
dxs NN O O
7 NN O O
locus. NN O O
the NN O O
map NN O O
derived NN O O
from NN O O
the NN O O
yl NN O O
1. NN O O
28-yac NN O O
is NN O O
compatible NN O O
both NN O O
with NN O O
the NN O O
map NN O O
from NN O O
an NN O O
independently NN O O
derived NN O O
yac NN O O
carrying NN O O
maoa NN O O
and NN O O
b NN O O
genes NN O O
and NN O O
with NN O O
the NN O O
long NN O O
range NN O O
genomic NN O O
map NN O O
for NN O O
the NN O O
region. NN O O
a NN O O
series NN O O
of NN O O
subclones NN O O
prepared NN O O
from NN O O
a NN O O
phage NN O O
library NN O O
(lambda NN O O
das NN O O
. NN O O

ii) NN O O
of NN O O
the NN O O
yac NN O O
have NN O O
been NN O O
characterised NN O O
and NN O O
have NN O O
been NN O O
employed NN O O
to NN O O
determine NN O O
the NN O O
end NN O O
point NN O O
of NN O O
the NN O O
deletion NN O O
of NN O O
a NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
( NN O O
NDP NN B-Modifier B-MSH:C537849
) NN O O
patient NN O O
who NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
lack NN O O
both NN O O
dxs NN O O
7 NN O O
and NN O O
mao NN O O
coding NN O O
sequences. NN O O
the NN O O
pattern NN O O
of NN O O
retention NN O O
of NN O O
subclones NN O O
in NN O O
the NN O O
deletion NN O O
patient NN O O
place NN O O
the NN O O
end NN O O
point NN O O
of NN O O
the NN O O
deletion NN O O
within NN O O
30-130 NN O O
kb NN O O
of NN O O
the NN O O
proximal NN O O
end NN O O
of NN O O
the NN O O
yac. NN O O
by NN O O
combining NN O O
the NN O O
data NN O O
with NN O O
established NN O O
recombination NN O O
analysis, NN O O
we NN O O
provide NN O O
evidence NN O O
that NN O O
all NN O O
or NN O O
part NN O O
of NN O O
the NN O O
ndp NN O O
lies NN O O
in NN O O
the NN O O
interval NN O O
of NN O O
approximately NN O O
250 NN O O
kb NN O O
within NN O O
the NN O O
yac NN O O
. NN O O

identification NN O O
of NN O O
mutations NN O O
in NN O O
danish NN O O
choroideremia NN B-Modifier B-MSH:D015794
families NN O O
. NN O O

we NN O O
have NN O O
searched NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
choroideremia NN B-Modifier B-MSH:D015794
gene NN O O
( NN O O
CHM NN B-Modifier B-MSH:D015794
) NN O O
in NN O O
patients NN O O
from NN O O
12 NN O O
danish NN O O
families NN O O
in NN O O
which NN O O
CHM NN B-SpecificDisease B-MSH:D015794
is NN O O
segregating. NN O O
employing NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr), NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
analysis, NN O O
and NN O O
direct NN O O
dna NN O O
sequencing, NN O O
different NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
6 NN O O
patients. NN O O
all NN O O
the NN O O
mutations NN O O
will NN O O
interfere NN O O
with NN O O
the NN O O
correct NN O O
translation NN O O
of NN O O
the NN O O
mrna NN O O
predicting NN O O
a NN O O
truncated NN O O
protein NN O O
or NN O O
no NN O O
gene NN O O
product NN O O
at NN O O
all. NN O O
. NN O O

g NN O O
130 NN O O
v, NN O O
a NN O O
common NN O O
FRDA NN B-Modifier B-MSH:D005621
point NN O O
mutation, NN O O
appears NN O O
to NN O O
have NN O O
arisen NN O O
from NN O O
a NN O O
common NN O O
founder NN O O
. NN O O

friedreich NN O O
ataxia NN O O
( NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
inherited NN B-DiseaseClass B-MSH:D013132
ataxia NN I-DiseaseClass I-MSH:D013132
. NN O O
about NN O O
98% NN O O
of NN O O
mutant NN O O
alleles NN O O
have NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
gaa NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
affected NN O O
gene, NN O O
frda. NN O O
the NN O O
other NN O O
2% NN O O
are NN O O
point NN O O
mutations. NN O O
of NN O O
the NN O O
17 NN O O
point NN O O
mutations NN O O
so NN O O
far NN O O
described, NN O O
three NN O O
appear NN O O
to NN O O
be NN O O
more NN O O
common. NN O O
one NN O O
of NN O O
these NN O O
is NN O O
the NN O O
g NN O O
130 NN O O
v NN O O
mutation NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
frda. NN O O
g NN O O
130 NN O O
v, NN O O
when NN O O
present NN O O
with NN O O
an NN O O
expanded NN O O
gaa NN O O
repeat NN O O
on NN O O
the NN O O
other NN O O
allele, NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
atypical NN O O
FRDA NN B-Modifier B-MSH:D005621
phenotype. NN O O
haplotype NN O O
analysis NN O O
was NN O O
undertaken NN O O
on NN O O
the NN O O
four NN O O
families NN O O
who NN O O
have NN O O
been NN O O
described NN O O
with NN O O
this NN O O
mutation. NN O O
the NN O O
results NN O O
suggest NN O O
a NN O O
common NN O O
founder NN O O
for NN O O
this NN O O
mutation. NN O O
although NN O O
marked NN O O
differences NN O O
in NN O O
extragenic NN O O
marker NN O O
haplotypes NN O O
were NN O O
seen NN O O
in NN O O
one NN O O
family, NN O O
similar NN O O
intrageni NN O O
. NN O O

haplotyping NN O O
suggests NN O O
the NN O O
same NN O O
mutation NN O O
founder NN O O
for NN O O
this NN O O
family NN O O
with NN O O
the NN O O
differences NN O O
explicable NN O O
by NN O O
two NN O O
recombination NN O O
events. NN O O
. NN O O

frequency NN O O
of NN O O
exon NN O O
15 NN O O
missense NN O O
mutation NN O O
(442 NN O O
d:g) NN O O
in NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
gene NN O O
in NN O O
hyperalphalipoproteinemic NN B-Modifier B-OMIM:143470
japanese NN O O
subjects NN O O
. NN O O

cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
(cetp) NN O O
transfers NN O O
cholesteryl NN O O
ester NN O O
from NN O O
high NN O O
density NN O O
lipoprotein NN O O
(hdl) NN O O
to NN O O
apo NN O O
b-containing NN O O
lipoproteins. NN O O
the NN O O
hyperalphalipoproteinemia NN B-SpecificDisease B-OMIM:143470
caused NN O O
by NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
is NN O O
fairly NN O O
common NN O O
in NN O O
japan NN O O
and NN O O
one NN O O
of NN O O
the NN O O
most NN O O
common NN O O
mutations NN O O
in NN O O
the NN O O
cetp NN O O
gene NN O O
is NN O O
the NN O O
splicing NN O O
defect NN O O
of NN O O
the NN O O
intron NN O O
14, NN O O
the NN O O
allelic NN O O
frequency NN O O
of NN O O
which NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
0. NN O O
0049 NN O O
in NN O O
the NN O O
japanese NN O O
general NN O O
population. NN O O
recently, NN O O
we NN O O
have NN O O
reported NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
15 NN O O
of NN O O
the NN O O
cetp NN O O
gene NN O O
(442 NN O O
d NN O O
g), NN O O
showing NN O O
a NN O O
dominant NN O O
effect NN O O
on NN O O
the NN O O
cetp NN O O
activity NN O O
and NN O O
hdl-cholesterol NN O O
level. NN O O
in NN O O
the NN O O
current NN O O
study, NN O O
we NN O O
determined NN O O
the NN O O
frequency NN O O
of NN O O
this NN O O
new NN O O
mutation NN O O
in NN O O
japanese NN O O
hyperalphalipoproteinemic NN B-Modifier B-OMIM:143470
(hdl-cholesterol NN O O
> NN O O
or NN O O
= NN O O
100 NN O O
mg/dl) NN O O
subjects. NN O O
. NN O O

rapid NN O O
and NN O O
easy NN O O
screening NN O O
method NN O O
for NN O O
this NN O O
new NN O O
mutation NN O O
was NN O O
developed NN O O
using NN O O
a NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
-mediated NN O O
site-directed NN O O
mutagenesis. NN O O
among NN O O
117 NN O O
japanese NN O O
hyperalphalipoproteinemic NN B-Modifier B-OMIM:143470
subjects NN O O
(hdl-cholesterol; NN O O
116. NN O O
7 NN O O
+/- NN O O
16. NN O O
5 NN O O
mg/dl, NN O O
mean NN O O
+/- NN O O
s. NN O O
d.) NN O O
without NN O O
the NN O O
intron NN O O
14 NN O O
splice NN O O
defect, NN O O
three NN O O
homozygotes NN O O
(2. NN O O
5%) NN O O
and NN O O
34 NN O O
heterozygotes NN O O
(29. NN O O
1%) NN O O
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
442 NN O O
d NN O O
g NN O O
mutation. NN O O
the NN O O
relative NN O O
allelic NN O O
frequency NN O O
of NN O O
this NN O O
mutation NN O O
was NN O O
calculated NN O O
to NN O O
be NN O O
0. NN O O
17. NN O O
one NN O O
of NN O O
the NN O O
homozygotes NN O O
for NN O O
the NN O O
442 NN O O
d NN O O
g NN O O
mutation NN O O
was NN O O
the NN O O
patient NN O O
previously NN O O
described NN O O
by NN O O
us NN O O
as NN O O
having NN O O
hyperalphalipoproteinemia NN B-SpecificDisease B-OMIM:143470
with NN O O
corneal NN B-SpecificDisease B-MSH:D003318
opacity NN I-SpecificDisease I-MSH:D003318
and NN O O
coronary NN B-SpecificDisease B-MSH:D003327
heart NN I-SpecificDisease I-MSH:D003327
disease NN I-SpecificDisease I-MSH:D003327
. NN O O
this NN O O
was NN O O
the NN O O
first NN O O
reporte NN O O
. NN O O

subject NN O O
homozygous NN O O
for NN O O
the NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
who NN O O
also NN O O
demonstrated NN O O
atherosclerotic NN B-DiseaseClass B-MSH:D050197
symptoms NN I-DiseaseClass I-MSH:D050197
. NN O O
in NN O O
homozygous NN O O
subjects, NN O O
cetp NN O O
activity NN O O
ranged NN O O
from NN O O
37% NN O O
to NN O O
62% NN O O
of NN O O
the NN O O
normal NN O O
value, NN O O
which NN O O
was NN O O
consistent NN O O
with NN O O
the NN O O
results NN O O
obtained NN O O
from NN O O
the NN O O
transient NN O O
expression NN O O
experiment NN O O
previously NN O O
reported; NN O O
however, NN O O
the NN O O
specific NN O O
activity NN O O
of NN O O
cetp NN O O
was NN O O
not NN O O
as NN O O
low NN O O
as NN O O
expected. NN O O
(abstract NN O O
truncated NN O O
at NN O O
250 NN O O
words NN O O
. NN O O

fibroblast NN O O
growth NN O O
factor NN O O
homologous NN O O
factor NN O O
2 NN O O
(fhf NN O O
2): NN O O
gene NN O O
structure, NN O O
expression NN O O
and NN O O
mapping NN O O
to NN O O
the NN O O
Borjeson-Forssman-Lehmann NN B-Modifier B-MSH:C536575
syndrome NN I-Modifier I-MSH:C536575
region NN O O
in NN O O
xq NN O O
26 NN O O
delineated NN O O
by NN O O
a NN O O
duplication NN O O
breakpoint NN O O
in NN O O
a NN O O
BFLS NN B-Modifier B-MSH:C536575
-like NN O O
patient NN O O
. NN O O

borjeson-forssman-lehmann NN O O
syndrome NN O O
( NN O O
BFLS NN B-SpecificDisease B-MSH:C536575
) NN O O
is NN O O
a NN O O
syndromal NN O O
X-linked NN B-DiseaseClass B-MSH:D038901
mental NN I-DiseaseClass I-MSH:D038901
retardation NN I-DiseaseClass I-MSH:D038901
, NN O O
which NN O O
maps NN O O
by NN O O
linkage NN O O
to NN O O
the NN O O
q NN O O
26 NN O O
region NN O O
of NN O O
the NN O O
human NN O O
x NN O O
chromosome. NN O O
we NN O O
have NN O O
identified NN O O
a NN O O
male NN O O
patient NN O O
with NN O O
BFLS NN B-Modifier B-MSH:C536575
-like NN O O
features NN O O
and NN O O
a NN O O
duplication, NN O O
46, NN O O
y, NN O O
dup NN O O
(x) NN O O
(q NN O O
26 NN O O
q NN O O
28), NN O O
inherited NN O O
from NN O O
his NN O O
phenotypically NN O O
normal NN O O
mother. NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridisation NN O O
using NN O O
yeast NN O O
artificial NN O O
chromosome NN O O
clones NN O O
from NN O O
xq NN O O
26 NN O O
localised NN O O
the NN O O
duplication NN O O
breakpoint NN O O
to NN O O
an NN O O
approximately NN O O
400-kb NN O O
interval NN O O
in NN O O
the NN O O
xq NN O O
26. NN O O
3 NN O O
region NN O O
between NN O O
dxs NN O O
155 NN O O
and NN O O
dxs NN O O
294/dxs NN O O
730. NN O O
database NN O O
searches NN O O
and NN O O
analysis NN O O
of NN O O
available NN O O
genomic NN O O
dna NN O O
sequence NN O O
from NN O O
the NN O O
region NN O O
revealed NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
fibroblast NN O O
growth NN O O
factor NN O O
homologous NN O O
factor NN O O
gene, NN O O
fhf NN O O
2, NN O O
within NN O O
the NN O O
duplicatio NN O O
. NN O O

breakpoint NN O O
interval. NN O O
the NN O O
gene NN O O
structure NN O O
of NN O O
fhf NN O O
2 NN O O
was NN O O
determined NN O O
and NN O O
two NN O O
new NN O O
exons NN O O
were NN O O
identified, NN O O
including NN O O
a NN O O
new NN O O
5 NN O O
end NN O O
exon, NN O O
1 NN O O
b. NN O O
fhf NN O O
2 NN O O
is NN O O
a NN O O
large NN O O
gene NN O O
extending NN O O
over NN O O
approximately NN O O
200 NN O O
kb NN O O
in NN O O
xq NN O O
26. NN O O
3 NN O O
and NN O O
is NN O O
composed NN O O
of NN O O
at NN O O
least NN O O
seven NN O O
exons. NN O O
it NN O O
shows NN O O
tissue-specific NN O O
alternative NN O O
splicing NN O O
and NN O O
alternative NN O O
transcription NN O O
starts. NN O O
northern NN O O
blot NN O O
hybridisation NN O O
showed NN O O
highest NN O O
expression NN O O
in NN O O
brain NN O O
and NN O O
skeletal NN O O
muscle. NN O O
the NN O O
fhf NN O O
2 NN O O
gene NN O O
localisation NN O O
and NN O O
tissue-specific NN O O
expression NN O O
pattern NN O O
suggest NN O O
it NN O O
to NN O O
be NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
familial NN O O
cases NN O O
of NN O O
the NN O O
BFLS NN B-SpecificDisease B-MSH:C536575
syndrome NN I-SpecificDisease I-MSH:C536575
and NN O O
other NN O O
syndromal NN O O
and NN O O
non-specific NN O O
forms NN O O
of NN O O
X-linked NN B-DiseaseClass B-MSH:D038901
mental NN I-DiseaseClass I-MSH:D038901
retardation NN I-DiseaseClass I-MSH:D038901
mapping NN O O
to NN O O
the NN O O
region NN O O
. NN O O

illegitimate NN O O
transcription NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
in NN O O
lymphocytes NN O O
for NN O O
identification NN O O
of NN O O
mutations NN O O
in NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
. NN O O

taking NN O O
advantage NN O O
of NN O O
the NN O O
illegitimate NN O O
transcription NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
gene, NN O O
we NN O O
have NN O O
been NN O O
able NN O O
to NN O O
analyse NN O O
the NN O O
pah NN O O
cdna NN O O
sequence NN O O
of NN O O
hyperphenylalaninemic NN B-Modifier B-MSH:D010661
children NN O O
in NN O O
circulating NN O O
lymphocytes. NN O O
using NN O O
this NN O O
approach, NN O O
we NN O O
have NN O O
also NN O O
identified NN O O
3 NN O O
novel NN O O
mutations NN O O
in NN O O
cdna NN O O
from NN O O
liver NN O O
and NN O O
lymphocytes NN O O
of NN O O
two NN O O
patients. NN O O
one NN O O
mutation, NN O O
detected NN O O
by NN O O
the NN O O
abnormal NN O O
pattern NN O O
of NN O O
migration NN O O
of NN O O
an NN O O
amplified NN O O
fragment, NN O O
is NN O O
a NN O O
c NN O O
to NN O O
t NN O O
transition NN O O
in NN O O
the NN O O
splice NN O O
acceptor NN O O
site NN O O
of NN O O
intron NN O O
10, NN O O
which NN O O
resulted NN O O
in NN O O
the NN O O
skipping NN O O
of NN O O
exon NN O O
11 NN O O
with NN O O
the NN O O
premature NN O O
termination NN O O
of NN O O
rna NN O O
translation NN O O
downstream NN O O
from NN O O
exon NN O O
12 NN O O
(-3 NN O O
ivs NN O O
10). NN O O
the NN O O
other NN O O
two NN O O
mutations NN O O
are NN O O
missense NN O O
mutations NN O O
in NN O O
exons NN O O
10 NN O O
and NN O O
11 NN O O
(respectively, NN O O
l NN O O
333 NN O O
f NN O O
and NN O O
e NN O O
390 NN O O
g). NN O O
the NN O O
present NN O O
study NN O O
supports NN O O
the NN O O
view NN O O
tha NN O O
. NN O O

circulating NN O O
lymphocytes NN O O
give NN O O
easy NN O O
access NN O O
to NN O O
pah NN O O
gene NN O O
transcripts NN O O
whose NN O O
nucleotide NN O O
sequence NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
reported NN O O
in NN O O
liver NN O O
and NN O O
therefore NN O O
represent NN O O
a NN O O
useful NN O O
tool NN O O
for NN O O
molecular NN O O
genetic NN O O
studies NN O O
in NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
. NN O O
. NN O O

function NN O O
of NN O O
an NN O O
axonal NN O O
chemoattractant NN O O
modulated NN O O
by NN O O
metalloprotease NN O O
activity NN O O
. NN O O

the NN O O
axonal NN O O
chemoattractant NN O O
netrin-1 NN O O
guides NN O O
spinal NN O O
commissural NN O O
axons NN O O
by NN O O
activating NN O O
its NN O O
receptor NN O O
dcc NN O O
(deleted NN O O
in NN O O
Colorectal NN B-SpecificDisease B-MSH:D015179
Cancer NN I-SpecificDisease I-MSH:D015179
). NN O O
we NN O O
have NN O O
found NN O O
that NN O O
chemical NN O O
inhibitors NN O O
of NN O O
metalloproteases NN O O
potentiate NN O O
netrin-mediated NN O O
axon NN O O
outgrowth NN O O
in NN O O
vitro. NN O O
we NN O O
have NN O O
also NN O O
found NN O O
that NN O O
dcc NN O O
is NN O O
a NN O O
substrate NN O O
for NN O O
metalloprotease-dependent NN O O
ectodomain NN O O
shedding, NN O O
and NN O O
that NN O O
the NN O O
inhibitors NN O O
block NN O O
proteolytic NN O O
processing NN O O
of NN O O
dcc NN O O
and NN O O
cause NN O O
an NN O O
increase NN O O
in NN O O
dcc NN O O
protein NN O O
levels NN O O
on NN O O
axons NN O O
within NN O O
spinal NN O O
cord NN O O
explants. NN O O
thus, NN O O
potentiation NN O O
of NN O O
netrin NN O O
activity NN O O
by NN O O
inhibitors NN O O
may NN O O
result NN O O
from NN O O
stabilization NN O O
of NN O O
dcc NN O O
on NN O O
the NN O O
axons, NN O O
and NN O O
proteolytic NN O O
activity NN O O
may NN O O
regulate NN O O
axon NN O O
migration NN O O
by NN O O
controlling NN O O
the NN O O
number NN O O
of NN O O
functional NN O O
extracellular NN O O
axon NN O O
guidance NN O O
receptors. NN O O
. NN O O

choroideremia: NN O O
close NN O O
linkage NN O O
to NN O O
dxys NN O O
1 NN O O
and NN O O
dxys NN O O
12 NN O O
demonstrated NN O O
by NN O O
segregation NN O O
analysis NN O O
and NN O O
historical-genealogical NN O O
evidence NN O O
. NN O O

linkage NN O O
studies NN O O
using NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
were NN O O
conducted NN O O
in NN O O
the NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
, NN O O
choroideremia NN B-SpecificDisease B-MSH:D015794
, NN O O
designated NN O O
TCD NN B-SpecificDisease B-MSH:C531652
for NN O O
Progressive NN B-SpecificDisease B-MSH:C531652
Tapeto-Choroidal NN I-SpecificDisease I-MSH:C531652
Dystrophy NN I-SpecificDisease I-MSH:C531652
. NN O O
previously NN O O
demonstrated NN O O
close NN O O
linkage NN O O
with NN O O
locus NN O O
dxys NN O O
1 NN O O
was NN O O
confirmed NN O O
(lod NN O O
11. NN O O
44 NN O O
at NN O O
0 NN O O
recombination NN O O
distance). NN O O
in NN O O
addition, NN O O
locus NN O O
dxys NN O O
12 NN O O
was NN O O
found NN O O
to NN O O
be NN O O
closely NN O O
linked NN O O
with NN O O
TCD NN B-SpecificDisease B-MSH:C531652
(lod NN O O
3. NN O O
31 NN O O
at NN O O
0 NN O O
recombination NN O O
distance). NN O O
the NN O O
disease NN O O
mainly NN O O
occurs NN O O
in NN O O
three NN O O
large NN O O
kindreds NN O O
in NN O O
remote NN O O
northern NN O O
finland. NN O O
while NN O O
formal NN O O
genealogical NN O O
proof NN O O
is NN O O
lacking, NN O O
all NN O O
presently NN O O
living NN O O
(more NN O O
than NN O O
80 NN O O
affected NN O O
males NN O O
and NN O O
120 NN O O
carrier NN O O
females) NN O O
probably NN O O
originate NN O O
from NN O O
a NN O O
common NN O O
founder NN O O
couple NN O O
born NN O O
in NN O O
1644 NN O O
and NN O O
1646, NN O O
twelve NN O O
generations NN O O
ago. NN O O
all NN O O
36 NN O O
patients NN O O
and NN O O
48 NN O O
carriers NN O O
tested NN O O
from NN O O
the NN O O
three NN O O
kindreds NN O O
had NN O O
the NN O O
same NN O O
haplotype NN O O
. NN O O

tcd/dxys NN O O
1, NN O O
11 NN O O
kb/dxys NN O O
12, NN O O
1. NN O O
6 NN O O
kb). NN O O
given NN O O
that NN O O
at NN O O
least NN O O
105 NN O O
female NN O O
meioses NN O O
transmitting NN O O
TCD NN B-SpecificDisease B-MSH:C531652
have NN O O
occurred NN O O
since NN O O
1650 NN O O
in NN O O
these NN O O
kindreds, NN O O
extremely NN O O
close NN O O
linkage NN O O
between NN O O
TCD NN B-SpecificDisease B-MSH:C531652
, NN O O
dxys NN O O
1 NN O O
and NN O O
dxys NN O O
12 NN O O
is NN O O
suggested. NN O O
the NN O O
above NN O O
haplotype NN O O
is NN O O
a NN O O
very NN O O
useful NN O O
diagnostic NN O O
tool NN O O
in NN O O
these NN O O
TCD NN B-Modifier B-MSH:C531652
families. NN O O
we NN O O
suggest NN O O
that NN O O
our NN O O
historical-genealogical NN O O
approach NN O O
to NN O O
linkage NN O O
analysis NN O O
may NN O O
be NN O O
possible NN O O
elsewhere NN O O
in NN O O
similar NN O O
isolated NN O O
population NN O O
. NN O O

functional NN O O
consequences NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
early NN O O
growth NN O O
response NN O O
2 NN O O
gene NN O O
(egr NN O O
2) NN O O
correlate NN O O
with NN O O
severity NN O O
of NN O O
human NN O O
myelinopathies NN B-DiseaseClass B-MSH:D011115
. NN O O

the NN O O
early NN O O
growth NN O O
response NN O O
2 NN O O
gene NN O O
(egr NN O O
2) NN O O
is NN O O
a NN O O
cys NN O O
2 NN O O
his NN O O
2 NN O O
zinc NN O O
finger NN O O
transcription NN O O
factor NN O O
which NN O O
is NN O O
thought NN O O
to NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
peripheral NN O O
nervous NN O O
system NN O O
myelination. NN O O
this NN O O
idea NN O O
is NN O O
based NN O O
partly NN O O
on NN O O
the NN O O
phenotype NN O O
of NN O O
homozygous NN O O
krox NN O O
20 NN O O
(egr NN O O
2) NN O O
knockout NN O O
mice, NN O O
which NN O O
display NN O O
hypomyelination NN B-DiseaseClass B-MSH:D010523
of NN I-DiseaseClass I-MSH:D010523
the NN I-DiseaseClass I-MSH:D010523
PNS NN I-DiseaseClass I-MSH:D010523
and NN O O
a NN O O
block NN O O
of NN O O
schwann NN O O
cells NN O O
at NN O O
an NN O O
early NN O O
stage NN O O
of NN O O
differentiation. NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
egr NN O O
2 NN O O
gene NN O O
have NN O O
recently NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
inherited NN B-DiseaseClass B-MSH:C548028
peripheral NN I-DiseaseClass I-MSH:C548028
neuropathies NN I-DiseaseClass I-MSH:C548028
Charcot-Marie-Tooth NN B-SpecificDisease B-MSH:D002607
type NN I-SpecificDisease I-MSH:D002607
1 NN I-SpecificDisease I-MSH:D002607
, NN O O
Dejerine-Sottas NN B-SpecificDisease B-MSH:C538392
syndrome NN I-SpecificDisease I-MSH:C538392
and NN O O
congenital NN B-SpecificDisease B-OMIM:605253
hypomyelinating NN I-SpecificDisease I-OMIM:605253
neuropathy NN I-SpecificDisease I-OMIM:605253
. NN O O
three NN O O
of NN O O
the NN O O
four NN O O
egr NN O O
2 NN O O
mutations NN O O
are NN O O
dominant NN O O
and NN O O
occur NN O O
within NN O O
the NN O O
zinc NN O O
finger NN O O
dna-binding NN O O
domain. NN O O
the NN O O
fourth NN O O
mutation NN O O
is NN O O
recessive NN O O
and NN O O
affects NN O O
the NN O O
inhibitory NN O O
domain NN O O
(r NN O O
. NN O O

) NN O O
that NN O O
binds NN O O
the NN O O
nab NN O O
transcriptional NN O O
co-repressors. NN O O
a NN O O
combination NN O O
of NN O O
dna-binding NN O O
assays NN O O
and NN O O
transcriptional NN O O
analysis NN O O
was NN O O
used NN O O
to NN O O
determine NN O O
the NN O O
functional NN O O
consequences NN O O
of NN O O
these NN O O
mutations. NN O O
the NN O O
zinc NN O O
finger NN O O
mutations NN O O
affect NN O O
dna NN O O
binding NN O O
and NN O O
the NN O O
amount NN O O
of NN O O
residual NN O O
binding NN O O
directly NN O O
correlates NN O O
with NN O O
disease NN O O
severity. NN O O
the NN O O
r NN O O
1 NN O O
domain NN O O
mutation NN O O
prevents NN O O
interaction NN O O
of NN O O
egr NN O O
2 NN O O
with NN O O
the NN O O
nab NN O O
co-repressors NN O O
and NN O O
thereby NN O O
increases NN O O
transcriptional NN O O
activity. NN O O
these NN O O
data NN O O
provide NN O O
insight NN O O
into NN O O
the NN O O
possible NN O O
disease NN O O
mechanisms NN O O
underlying NN O O
egr NN O O
2 NN O O
mutations NN O O
and NN O O
the NN O O
reason NN O O
for NN O O
varying NN O O
severity NN O O
and NN O O
differences NN O O
in NN O O
inheritance NN O O
patterns. NN O O
. NN O O
s NN O O
in NN O O
inheritance NN O O
patterns. NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
human NN O O
von NN B-SpecificDisease B-MSH:D014842
Willebrand NN I-SpecificDisease I-MSH:D014842
disease NN I-SpecificDisease I-MSH:D014842
: NN O O
analysis NN O O
of NN O O
platelet NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
mrna NN O O
. NN O O

von NN O O
willebrand NN O O
disease NN O O
( NN O O
vWD NN B-SpecificDisease B-MSH:D014842
), NN O O
the NN O O
most NN O O
common NN O O
inherited NN B-DiseaseClass B-MSH:D025861
bleeding NN I-DiseaseClass I-MSH:D025861
disorder NN I-DiseaseClass I-MSH:D025861
in NN O O
humans, NN O O
can NN O O
result NN O O
from NN O O
either NN O O
a NN O O
quantitative NN O O
or NN O O
a NN O O
qualitative NN O O
defect NN O O
in NN O O
the NN O O
adhesive NN O O
glycoprotein, NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
(vwf). NN O O
molecular NN O O
studies NN O O
of NN O O
vWD NN B-SpecificDisease B-MSH:D014842
have NN O O
been NN O O
limited NN O O
by NN O O
the NN O O
large NN O O
size NN O O
of NN O O
the NN O O
vwf NN O O
gene NN O O
and NN O O
difficulty NN O O
in NN O O
obtaining NN O O
the NN O O
vwf NN O O
mrna NN O O
from NN O O
patients. NN O O
by NN O O
use NN O O
of NN O O
an NN O O
adaptation NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction, NN O O
vwf NN O O
mrna NN O O
was NN O O
amplified NN O O
and NN O O
sequenced NN O O
from NN O O
peripheral NN O O
blood NN O O
platelets. NN O O
a NN O O
silent NN O O
vwf NN O O
allele NN O O
was NN O O
identified, NN O O
resulting NN O O
from NN O O
a NN O O
cis NN O O
defect NN O O
in NN O O
vwf NN O O
mrna NN O O
transcription NN O O
or NN O O
processing. NN O O
in NN O O
two NN O O
type NN B-Modifier B-MSH:D056728
IIA NN I-Modifier I-MSH:D056728
vWD NN I-Modifier I-MSH:D056728
patients, NN O O
two NN O O
different NN O O
but NN O O
adjacent NN O O
missense NN O O
mutations NN O O
were NN O O
identified, NN O O
the NN O O
locations NN O O
of NN O O
which NN O O
may NN O O
identify NN O O
an NN O O
important NN O O
vwf NN O O
functional NN O O
domain. NN O O
expression NN O O
in NN O O
heterologous NN O O
cells NN O O
of NN O O
recombinant NN O O
vwf NN O O
containin NN O O
. NN O O

one NN O O
of NN O O
these NN O O
latter NN O O
mutations NN O O
reproduced NN O O
the NN O O
characteristic NN O O
structural NN O O
abnormality NN O O
seen NN O O
in NN O O
type NN B-Modifier B-MSH:D056728
IIA NN I-Modifier I-MSH:D056728
vWD NN I-Modifier I-MSH:D056728
plasma. NN O O
. NN O O

a NN O O
transgene NN O O
insertion NN O O
creating NN O O
a NN O O
heritable NN O O
chromosome NN O O
deletion NN O O
mouse NN O O
model NN O O
of NN O O
Prader-Willi NN B-CompositeMention B-MSH:D011218
and NN I-CompositeMention I-MSH:D011218
angelman NN I-CompositeMention I-MSH:D011218
syndromes NN I-CompositeMention I-MSH:D011218
. NN O O

prader-willi NN O O
syndrome NN O O
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
and NN O O
Angelman NN B-SpecificDisease B-MSH:D017204
syndrome NN I-SpecificDisease I-MSH:D017204
( NN O O
AS NN B-SpecificDisease B-MSH:D017204
) NN O O
result NN O O
from NN O O
the NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
imprinted NN O O
genes NN O O
in NN O O
human NN O O
chromosome NN O O
15 NN O O
q NN O O
11-q NN O O
13. NN O O
the NN O O
central NN O O
part NN O O
of NN O O
mouse NN O O
chromosome NN O O
7 NN O O
is NN O O
homologous NN O O
to NN O O
human NN O O
15 NN O O
q NN O O
11-q NN O O
13, NN O O
with NN O O
conservation NN O O
of NN O O
both NN O O
gene NN O O
order NN O O
and NN O O
imprinted NN O O
features. NN O O
we NN O O
report NN O O
here NN O O
the NN O O
characterization NN O O
of NN O O
a NN O O
transgene NN O O
insertion NN O O
(epstein-barr NN O O
virus NN O O
latent NN O O
membrane NN O O
protein NN O O
2 NN O O
a, NN O O
lmp NN O O
2 NN O O
a) NN O O
into NN O O
mouse NN O O
chromosome NN O O
7 NN O O
c, NN O O
which NN O O
has NN O O
resulted NN O O
in NN O O
mouse NN O O
models NN O O
for NN O O
PWS NN B-SpecificDisease B-MSH:D011218
and NN O O
AS NN B-SpecificDisease B-MSH:D017204
dependent NN O O
on NN O O
the NN O O
sex NN O O
of NN O O
the NN O O
transmitting NN O O
parent. NN O O
epigenotype NN O O
(allelic NN O O
expression NN O O
and NN O O
dna NN O O
methylation) NN O O
and NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
analyses NN O O
indicate NN O O
that NN O O
the NN O O
transgene-induced NN O O
mutation NN O O
has NN O O
generated NN O O
a NN O O
complete NN O O
deletion NN O O
of NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
/ NN O O
AS NN B-Modifier B-MSH:D017204
. NN O O

-homologous NN O O
region NN O O
but NN O O
has NN O O
not NN O O
deleted NN O O
flanking NN O O
loci. NN O O
because NN O O
the NN O O
intact NN O O
chromosome NN O O
7, NN O O
opposite NN O O
the NN O O
deleted NN O O
homolog, NN O O
maintains NN O O
the NN O O
correct NN O O
imprint NN O O
in NN O O
somatic NN O O
cells NN O O
of NN O O
PWS NN B-Modifier B-MSH:D011218
and NN O O
AS NN B-Modifier B-MSH:D017204
mice NN O O
and NN O O
establishes NN O O
the NN O O
correct NN O O
imprint NN O O
in NN O O
male NN O O
and NN O O
female NN O O
germ NN O O
cells NN O O
of NN O O
AS NN B-Modifier B-MSH:D017204
mice, NN O O
homologous NN O O
association NN O O
and NN O O
replication NN O O
asynchrony NN O O
are NN O O
not NN O O
part NN O O
of NN O O
the NN O O
imprinting NN O O
mechanism. NN O O
this NN O O
heritable-deletion NN O O
mouse NN O O
model NN O O
will NN O O
be NN O O
particularly NN O O
useful NN O O
for NN O O
the NN O O
identification NN O O
of NN O O
the NN O O
etiological NN O O
genes NN O O
and NN O O
mechanisms, NN O O
phenotypic NN O O
basis, NN O O
and NN O O
investigation NN O O
of NN O O
therapeutic NN O O
approaches NN O O
for NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
. NN O O

transgenic NN O O
mice NN O O
expressing NN O O
a NN O O
truncated NN O O
form NN O O
of NN O O
the NN O O
high NN O O
mobility NN O O
group NN O O
i-c NN O O
protein NN O O
develop NN O O
adiposity NN O O
and NN O O
an NN O O
abnormally NN O O
high NN O O
prevalence NN O O
of NN O O
lipomas NN B-DiseaseClass B-MSH:D008067
. NN O O

chromosomal NN O O
translocations NN O O
in NN O O
human NN O O
lipomas NN B-DiseaseClass B-MSH:D008067
frequently NN O O
create NN O O
fusion NN O O
transcripts NN O O
encoding NN O O
high NN O O
mobility NN O O
group NN O O
(hmg) NN O O
i-c NN O O
dna-binding NN O O
domains NN O O
and NN O O
c-terminal NN O O
sequences NN O O
from NN O O
different NN O O
presumed NN O O
transcription NN O O
factors, NN O O
suggesting NN O O
a NN O O
potential NN O O
role NN O O
for NN O O
hmg NN O O
i-c NN O O
in NN O O
the NN O O
development NN O O
of NN O O
lipomas NN B-DiseaseClass B-MSH:D008067
. NN O O
to NN O O
evaluate NN O O
the NN O O
role NN O O
of NN O O
the NN O O
hmg NN O O
i-c NN O O
component, NN O O
the NN O O
three NN O O
dna-binding NN O O
domains NN O O
of NN O O
hmg NN O O
i-c NN O O
have NN O O
now NN O O
been NN O O
expressed NN O O
in NN O O
transgenic NN O O
mice. NN O O
despite NN O O
the NN O O
ubiquitous NN O O
expression NN O O
of NN O O
the NN O O
truncated NN O O
hmg NN O O
i-c NN O O
protein, NN O O
the NN O O
transgenic NN O O
mice NN O O
develop NN O O
a NN O O
selective NN O O
abundance NN O O
of NN O O
fat NN O O
tissue NN O O
early NN O O
in NN O O
life, NN O O
show NN O O
marked NN O O
adipose NN B-SpecificDisease B-MSH:D007249
tissue NN I-SpecificDisease I-MSH:D007249
inflammation NN I-SpecificDisease I-MSH:D007249
, NN O O
and NN O O
have NN O O
an NN O O
abnormally NN O O
high NN O O
incidence NN O O
of NN O O
lipomas NN B-DiseaseClass B-MSH:D008067
. NN O O
these NN O O
findings NN O O
demonstrate NN O O
that NN O O
the NN O O
dna-binding NN O O
domains NN O O
of NN O O
hmg NN O O
i-c, NN O O
in NN O O
the NN O O
absenc NN O O
. NN O O

of NN O O
a NN O O
c-terminal NN O O
fusion NN O O
partner, NN O O
are NN O O
sufficient NN O O
to NN O O
perturb NN O O
adipogenesis NN O O
and NN O O
predispose NN O O
to NN O O
lipomas NN B-DiseaseClass B-MSH:D008067
. NN O O
we NN O O
provide NN O O
data NN O O
supporting NN O O
the NN O O
central NN O O
utility NN O O
of NN O O
this NN O O
animal NN O O
model NN O O
as NN O O
a NN O O
tool NN O O
to NN O O
understand NN O O
the NN O O
molecular NN O O
mechanisms NN O O
underlying NN O O
the NN O O
development NN O O
of NN O O
one NN O O
of NN O O
the NN O O
most NN O O
common NN O O
kind NN O O
of NN O O
human NN O O
benign NN B-DiseaseClass B-MSH:D009369
tumors NN I-DiseaseClass I-MSH:D009369
. NN O O
. NN O O

a NN O O
common NN O O
msh NN O O
2 NN O O
mutation NN O O
in NN O O
english NN O O
and NN O O
north NN O O
american NN O O
HNPCC NN B-Modifier B-MSH:D003123
families: NN O O
origin, NN O O
phenotypic NN O O
expression, NN O O
and NN O O
sex NN O O
specific NN O O
differences NN O O
in NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O

the NN O O
frequency, NN O O
origin, NN O O
and NN O O
phenotypic NN O O
expression NN O O
of NN O O
a NN O O
germline NN O O
msh NN O O
2 NN O O
gene NN O O
mutation NN O O
previously NN O O
identified NN O O
in NN O O
seven NN O O
kindreds NN O O
with NN O O
hereditary NN B-SpecificDisease B-MSH:D003123
non-polyposis NN I-SpecificDisease I-MSH:D003123
cancer NN I-SpecificDisease I-MSH:D003123
syndrome NN I-SpecificDisease I-MSH:D003123
( NN O O
HNPCC NN B-SpecificDisease B-MSH:D003123
) NN O O
was NN O O
investigated. NN O O
the NN O O
mutation NN O O
(a-- NN O O
> NN O O
t NN O O
at NN O O
nt NN O O
943 NN O O
+ NN O O
3) NN O O
disrupts NN O O
the NN O O
3 NN O O
splice NN O O
site NN O O
of NN O O
exon NN O O
5 NN O O
leading NN O O
to NN O O
the NN O O
deletion NN O O
of NN O O
this NN O O
exon NN O O
from NN O O
msh NN O O
2 NN O O
mrna NN O O
and NN O O
represents NN O O
the NN O O
only NN O O
frequent NN O O
msh NN O O
2 NN O O
mutation NN O O
so NN O O
far NN O O
reported. NN O O
although NN O O
this NN O O
mutation NN O O
was NN O O
initially NN O O
detected NN O O
in NN O O
four NN O O
of NN O O
33 NN O O
colorectal NN B-Modifier B-MSH:D015179
cancer NN I-Modifier I-MSH:D015179
families NN O O
analysed NN O O
from NN O O
eastern NN O O
england, NN O O
more NN O O
extensive NN O O
analysis NN O O
has NN O O
reduced NN O O
the NN O O
frequency NN O O
to NN O O
four NN O O
of NN O O
52 NN O O
(8%) NN O O
english NN O O
HNPCC NN B-Modifier B-MSH:D003123
kindreds NN O O
analysed. NN O O
in NN O O
contrast, NN O O
the NN O O
msh NN O O
2 NN O O
mutation NN O O
was NN O O
identified NN O O
in NN O O
10 NN O O
of NN O O
20 NN O O
(50%) NN O O
separately NN O O
identified NN O O
colorectal NN B-Modifier B-MSH:D015179
families NN O O
from NN O O
newfoundland NN O O
. NN O O

to NN O O
investigate NN O O
the NN O O
origin NN O O
of NN O O
this NN O O
mutation NN O O
in NN O O
colorectal NN B-Modifier B-MSH:D015179
cancer NN I-Modifier I-MSH:D015179
families NN O O
from NN O O
england NN O O
(n NN O O
= NN O O
4), NN O O
newfoundland NN O O
(n NN O O
= NN O O
10), NN O O
and NN O O
the NN O O
united NN O O
states NN O O
(n NN O O
= NN O O
3), NN O O
haplotype NN O O
analysis NN O O
using NN O O
microsatellite NN O O
markers NN O O
linked NN O O
to NN O O
msh NN O O
2 NN O O
was NN O O
performed. NN O O
within NN O O
the NN O O
english NN O O
and NN O O
us NN O O
families NN O O
there NN O O
was NN O O
little NN O O
evidence NN O O
for NN O O
a NN O O
recent NN O O
common NN O O
origin NN O O
of NN O O
the NN O O
msh NN O O
2 NN O O
splice NN O O
site NN O O
mutation NN O O
in NN O O
most NN O O
families. NN O O
in NN O O
contrast, NN O O
a NN O O
common NN O O
haplotype NN O O
was NN O O
identified NN O O
at NN O O
the NN O O
two NN O O
flanking NN O O
markers NN O O
(ca NN O O
5 NN O O
and NN O O
d NN O O
2 NN O O
s NN O O
288) NN O O
in NN O O
eight NN O O
of NN O O
the NN O O
newfoundland NN O O
families. NN O O
these NN O O
findings NN O O
suggested NN O O
a NN O O
founder NN O O
effect NN O O
within NN O O
newfoundland NN O O
similar NN O O
to NN O O
that NN O O
reported NN O O
by NN O O
others NN O O
for NN O O
two NN O O
mlh NN O O
1 NN O O
mutations NN O O
in NN O O
finnish NN O O
HNPCC NN B-Modifier B-MSH:D003123
families. NN O O
we NN O O
calculated NN O O
age NN O O
related NN O O
risks NN O O
of NN O O
all, NN O O
colorectal, NN B-CompositeMention B-MSH:D010051
endometrial, NN I-CompositeMention I-MSH:D010051
and NN I-CompositeMention I-MSH:D010051
ovarian NN I-CompositeMention I-MSH:D010051
cancers NN I-CompositeMention I-MSH:D010051

ovarian NN O O
cancers NN O O
in NN O O
nt NN O O
943 NN O O
+ NN O O
3 NN O O
a-- NN O O
> NN O O
t NN O O
msh NN O O
2 NN O O
mutation NN O O
carriers NN O O
(n NN O O
= NN O O
76) NN O O
for NN O O
all NN O O
patients NN O O
and NN O O
for NN O O
men NN O O
and NN O O
women NN O O
separately. NN O O
for NN O O
both NN O O
sexes NN O O
combined, NN O O
the NN O O
penetrances NN O O
at NN O O
age NN O O
60 NN O O
years NN O O
for NN O O
all NN O O
cancers NN B-DiseaseClass B-MSH:D009369
and NN O O
for NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
were NN O O
0. NN O O
86 NN O O
and NN O O
0. NN O O
57, NN O O
respectively. NN O O
the NN O O
risk NN O O
of NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
was NN O O
significantly NN O O
higher NN O O
(p NN O O
< NN O O
0. NN O O
01) NN O O
in NN O O
males NN O O
than NN O O
females NN O O
(0. NN O O
63 NN O O
v NN O O
0. NN O O
30 NN O O
and NN O O
0. NN O O
84 NN O O
v NN O O
0. NN O O
44 NN O O
at NN O O
ages NN O O
50 NN O O
and NN O O
60 NN O O
years, NN O O
respectively). NN O O
for NN O O
females NN O O
there NN O O
was NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
endometrial NN B-SpecificDisease B-MSH:D016889
cancer NN I-SpecificDisease I-MSH:D016889
(0. NN O O
5 NN O O
at NN O O
age NN O O
60 NN O O
years) NN O O
and NN O O
premenopausal NN B-SpecificDisease B-MSH:D010051
ovarian NN I-SpecificDisease I-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
(0. NN O O
2 NN O O
at NN O O
50 NN O O
years). NN O O
these NN O O
intersex NN O O
difference NN O O
. NN O O

in NN O O
colorectal NN B-Modifier B-MSH:D015179
cancer NN I-Modifier I-MSH:D015179
risks NN O O
have NN O O
implications NN O O
for NN O O
screening NN O O
programmes NN O O
and NN O O
for NN O O
attempts NN O O
to NN O O
identify NN O O
colorectal NN B-Modifier B-MSH:D015179
cancer NN I-Modifier I-MSH:D015179
susceptibility NN O O
modifiers NN O O
. NN O O

novel NN O O
mutation NN O O
at NN O O
the NN O O
initiation NN O O
codon NN O O
in NN O O
the NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
gene NN O O
in NN O O
two NN O O
japanese NN O O
families NN O O
. NN O O

we NN O O
have NN O O
identified NN O O
a NN O O
new NN O O
mutation NN O O
of NN O O
Norrie NN B-Modifier B-MSH:C537849
disease NN I-Modifier I-MSH:C537849
( NN O O
ND NN B-Modifier B-MSH:C537849
) NN O O
gene NN O O
in NN O O
two NN O O
japanese NN O O
males NN O O
from NN O O
unrelated NN O O
families; NN O O
they NN O O
showed NN O O
typical NN O O
ocular NN O O
features NN O O
of NN O O
ND NN B-SpecificDisease B-MSH:C537849
but NN O O
no NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
or NN O O
hearing NN B-DiseaseClass B-MSH:D034381
impairment NN I-DiseaseClass I-MSH:D034381
. NN O O
a NN O O
mutation NN O O
was NN O O
found NN O O
in NN O O
both NN O O
patients NN O O
at NN O O
the NN O O
initiation NN O O
codon NN O O
of NN O O
exon NN O O
2 NN O O
of NN O O
the NN O O
ND NN B-Modifier B-MSH:C537849
gene NN O O
(atg NN O O
to NN O O
gtg), NN O O
with NN O O
otherwise NN O O
normal NN O O
nucleotide NN O O
sequences. NN O O
their NN O O
mothers NN O O
had NN O O
the NN O O
normal NN O O
and NN O O
mutant NN O O
types NN O O
of NN O O
the NN O O
gene, NN O O
which NN O O
was NN O O
expected NN O O
for NN O O
heterozygotes NN O O
of NN O O
the NN O O
disease. NN O O
the NN O O
mutation NN O O
of NN O O
the NN O O
initiation NN O O
codon NN O O
would NN O O
cause NN O O
the NN O O
failure NN O O
of NN O O
ND NN B-Modifier B-MSH:C537849
gene NN O O
expression NN O O
or NN O O
a NN O O
defect NN O O
in NN O O
translation NN O O
thereby NN O O
truncating NN O O
the NN O O
amino NN O O
terminus NN O O
of NN O O
ND NN B-Modifier B-MSH:C537849
protein. NN O O
in NN O O
view NN O O
of NN O O
the NN O O
rarity NN O O
and NN O O
marked NN O O
heterogeneity NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
ND NN B-Modifier B-MSH:C537849
gene, NN O O
the NN O O
present NN O O
apparently NN O O
unrelated NN O O
japanese NN O O
families NN O O
who NN O O
have NN O O
lived NN O O
i NN O O
. NN O O

the NN O O
same NN O O
area NN O O
for NN O O
over NN O O
two NN O O
centuries NN O O
presumably NN O O
share NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
mutation. NN O O
. NN O O

haplotype NN O O
and NN O O
phenotype NN O O
analysis NN O O
of NN O O
six NN O O
recurrent NN O O
brca NN O O
1 NN O O
mutations NN O O
in NN O O
61 NN O O
families: NN O O
results NN O O
of NN O O
an NN O O
international NN O O
study NN O O
. NN O O

several NN O O
brca NN O O
1 NN O O
mutations NN O O
have NN O O
now NN O O
been NN O O
found NN O O
to NN O O
occur NN O O
in NN O O
geographically NN O O
diverse NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families. NN O O
to NN O O
investigate NN O O
mutation NN O O
origin NN O O
and NN O O
mutation-specific NN O O
phenotypes NN O O
due NN O O
to NN O O
brca NN O O
1, NN O O
we NN O O
constructed NN O O
a NN O O
haplotype NN O O
of NN O O
nine NN O O
polymorphic NN O O
markers NN O O
within NN O O
or NN O O
immediately NN O O
flanking NN O O
the NN O O
brca NN O O
1 NN O O
locus NN O O
in NN O O
a NN O O
set NN O O
of NN O O
61 NN O O
breast/ovarian NN B-Modifier B-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
families NN O O
selected NN O O
for NN O O
having NN O O
one NN O O
of NN O O
six NN O O
recurrent NN O O
brca NN O O
1 NN O O
mutations. NN O O
tests NN O O
of NN O O
both NN O O
mutations NN O O
and NN O O
family-specific NN O O
differences NN O O
in NN O O
age NN O O
at NN O O
diagnosis NN O O
were NN O O
not NN O O
significant. NN O O
a NN O O
comparison NN O O
of NN O O
the NN O O
six NN O O
mutations NN O O
in NN O O
the NN O O
relative NN O O
proportions NN O O
of NN O O
cases NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
was NN O O
suggestive NN O O
of NN O O
an NN O O
effect NN O O
(p NN O O
=. NN O O
069), NN O O
with NN O O
57% NN O O
of NN O O
women NN O O
presumed NN O O
affected NN O O
because NN O O
of NN O O
the NN O O
1294 NN O O
del NN O O
40 NN O O
brca NN O O
1 NN O O
mutation NN O O
having NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
, NN O O
compared NN O O
with NN O O
14 NN O O
. NN O O

of NN O O
affected NN O O
women NN O O
with NN O O
the NN O O
splice-site NN O O
mutation NN O O
in NN O O
intron NN O O
5 NN O O
of NN O O
brca NN O O
1. NN O O
for NN O O
the NN O O
brca NN O O
1 NN O O
mutations NN O O
studied NN O O
here, NN O O
the NN O O
individual NN O O
mutations NN O O
are NN O O
estimated NN O O
to NN O O
have NN O O
arisen NN O O
9-170 NN O O
generations NN O O
ago. NN O O
in NN O O
general, NN O O
a NN O O
high NN O O
degree NN O O
of NN O O
haplotype NN O O
conservation NN O O
across NN O O
the NN O O
region NN O O
was NN O O
observed, NN O O
with NN O O
haplotype NN O O
differences NN O O
most NN O O
often NN O O
due NN O O
to NN O O
mutations NN O O
in NN O O
the NN O O
short-tandem-repeat NN O O
markers, NN O O
although NN O O
some NN O O
likely NN O O
instances NN O O
of NN O O
recombination NN O O
also NN O O
were NN O O
observed. NN O O
for NN O O
several NN O O
of NN O O
the NN O O
instances, NN O O
there NN O O
was NN O O
evidence NN O O
for NN O O
multiple, NN O O
independent, NN O O
brca NN O O
1 NN O O
mutational NN O O
events NN O O
. NN O O

a NN O O
new NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
variant NN O O
(g NN O O
6 NN O O
pd NN O O
nagano) NN O O
associated NN O O
with NN O O
congenital NN B-SpecificDisease B-MSH:D000745
hemolytic NN I-SpecificDisease I-MSH:D000745
anemia NN I-SpecificDisease I-MSH:D000745
. NN O O

a NN O O
new NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
variant NN O O
associated NN O O
with NN O O
chronic NN B-SpecificDisease B-MSH:D000746
nonspherocytic NN I-SpecificDisease I-MSH:D000746
hemolytic NN I-SpecificDisease I-MSH:D000746
anemia NN I-SpecificDisease I-MSH:D000746
was NN O O
reported. NN O O
the NN O O
patient, NN O O
a NN O O
6-year-old NN O O
japanese NN O O
male, NN O O
was NN O O
noticed NN O O
to NN O O
have NN O O
hemolytic NN B-SpecificDisease B-MSH:D000743
anemia NN I-SpecificDisease I-MSH:D000743
soon NN O O
after NN O O
birth, NN O O
and NN O O
a NN O O
diagnosis NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
was NN O O
made NN O O
at NN O O
the NN O O
age NN O O
of NN O O
2. NN O O
he NN O O
had NN O O
episodes NN O O
of NN O O
hemolytic NN B-DiseaseClass B-MSH:D006461
crisis NN I-DiseaseClass I-MSH:D006461
several NN O O
times NN O O
after NN O O
upper NN B-SpecificDisease B-MSH:D012141
respiratory NN I-SpecificDisease I-MSH:D012141
infection NN I-SpecificDisease I-MSH:D012141
. NN O O
g NN O O
6 NN O O
pd NN O O
activity NN O O
of NN O O
the NN O O
patient NN O O
was NN O O
5. NN O O
5% NN O O
of NN O O
normal. NN O O
the NN O O
enzymatic NN O O
characteristics NN O O
were NN O O
examined NN O O
when NN O O
he NN O O
was NN O O
5 NN O O
years NN O O
old, NN O O
and NN O O
his NN O O
g NN O O
6 NN O O
pd NN O O
showed NN O O
faster-than-normal NN O O
electrophoretic NN O O
mobility, NN O O
low NN O O
km NN O O
g NN O O
6 NN O O
p, NN O O
high NN O O
km NN O O
nadp, NN O O
low NN O O
ki NN O O
nadph, NN O O
normal NN O O
utilization NN O O
of NN O O
substrate NN O O
analogues, NN O O
heat NN O O
instability, NN O O
and NN O O
. NN O O

normal NN O O
ph NN O O
optimum NN O O
curve. NN O O
from NN O O
these NN O O
results, NN O O
this NN O O
was NN O O
considered NN O O
to NN O O
be NN O O
a NN O O
new NN O O
variant NN O O
and NN O O
was NN O O
designated NN O O
g NN O O
6 NN O O
pd NN O O
nagano. NN O O
infection-induced NN O O
hemolysis NN B-SpecificDisease B-MSH:D006461
and NN O O
chronic NN B-SpecificDisease B-MSH:D000745
hemolytic NN I-SpecificDisease I-MSH:D000745
anemia NN I-SpecificDisease I-MSH:D000745
seem NN O O
to NN O O
be NN O O
due NN O O
to NN O O
markedly NN O O
impaired NN O O
enzyme NN O O
activity NN O O
and NN O O
thermal NN O O
instability NN O O
. NN O O

craniofrontonasal NN O O
dysplasia NN O O
. NN O O

we NN O O
report NN O O
on NN O O
nine NN O O
patients NN O O
with NN O O
craniofrontonasal NN B-SpecificDisease B-MSH:C536456
dysplasia NN I-SpecificDisease I-MSH:C536456
( NN O O
CFND NN B-SpecificDisease B-MSH:C536456
). NN O O
seven NN O O
classical NN O O
cases NN O O
had NN O O
facial NN O O
features NN O O
suggestive NN O O
of NN O O
frontonasal NN B-SpecificDisease B-MSH:C538065
dysplasia NN I-SpecificDisease I-MSH:C538065
and NN O O
coronal NN B-SpecificDisease B-MSH:C537369
craniosynostosis NN I-SpecificDisease I-MSH:C537369
. NN O O
Extracranial NN B-DiseaseClass B-MSH:D009139
abnormalities NN I-DiseaseClass I-MSH:D009139
such NN O O
as NN O O
brittle NN B-SpecificDisease B-MSH:D009260
nails NN I-SpecificDisease I-MSH:D009260
with NN I-SpecificDisease I-MSH:D009260
prominent NN I-SpecificDisease I-MSH:D009260
longitudinal NN I-SpecificDisease I-MSH:D009260
grooves NN I-SpecificDisease I-MSH:D009260
or NN O O
syndactyly NN B-CompositeMention B-MSH:D013576
of NN I-CompositeMention I-MSH:D013576
fingers NN I-CompositeMention I-MSH:D013576
and NN I-CompositeMention I-MSH:D013576
toes NN I-CompositeMention I-MSH:D013576
were NN O O
observed NN O O
in NN O O
individual NN O O
patients. NN O O
in NN O O
two NN O O
families NN O O
the NN O O
father NN O O
of NN O O
classical NN O O
cases NN O O
showed NN O O
a NN O O
milder NN O O
pattern NN O O
of NN O O
abnormalities, NN O O
consistent NN O O
with NN O O
the NN O O
diagnosis. NN O O
we NN O O
present NN O O
a NN O O
2- NN O O
to NN O O
13-year NN O O
follow-up NN O O
on NN O O
our NN O O
patients. NN O O
Hypotonia NN B-SpecificDisease B-MSH:D009123
and NN O O
laxity NN B-SpecificDisease B-MSH:C535884
of NN I-SpecificDisease I-MSH:C535884
joints NN I-SpecificDisease I-MSH:C535884
are NN O O
common NN O O
and NN O O
may NN O O
necessitate NN O O
supportive NN O O
measures. NN O O
mild NN O O
developmental NN B-DiseaseClass B-MSH:D002658
delay NN I-DiseaseClass I-MSH:D002658
was NN O O
noted NN O O
in NN O O
three NN O O
out NN O O
of NN O O
six NN O O
classical NN O O
cases NN O O
studied NN O O
in NN O O
detail. NN O O
unlike NN O O
almost NN O O
all NN O O
other NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
disorders NN I-DiseaseClass I-MSH:D040181
, NN O O
clinical NN O O
expression NN O O
in NN O O
CFND NN B-SpecificDisease B-MSH:C536456
is NN O O
generally NN O O
much NN O O
more NN O O
severe NN O O
in NN O O
females NN O O
than NN O O
in NN O O
males. NN O O
in NN O O
contrast NN O O
t NN O O
. NN O O

previous NN O O
reports NN O O
of NN O O
this NN O O
condition, NN O O
one NN O O
of NN O O
our NN O O
severely NN O O
affected NN O O
cases NN O O
is NN O O
a NN O O
male. NN O O
. NN O O

a NN O O
new NN O O
mutation NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
(plp) NN O O
gene NN O O
in NN O O
a NN O O
german NN O O
family NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
. NN O O

a NN O O
c-to-t NN O O
transition NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
the NN O O
plp NN O O
gene NN O O
was NN O O
found NN O O
in NN O O
2 NN O O
affected NN O O
males NN O O
and NN O O
two NN O O
obligate NN O O
carriers NN O O
in NN O O
a NN O O
german NN O O
family NN O O
with NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
. NN O O
the NN O O
mutation, NN O O
which NN O O
causes NN O O
loss NN O O
of NN O O
an NN O O
hphi NN O O
site NN O O
and NN O O
changes NN O O
amino NN O O
acid NN O O
155 NN O O
from NN O O
threonine NN O O
to NN O O
isoleucine, NN O O
was NN O O
absent NN O O
from NN O O
108 NN O O
normal NN O O
chromosomes. NN O O
there NN O O
are NN O O
5 NN O O
concordances NN O O
and NN O O
1 NN O O
discrepancy NN O O
between NN O O
these NN O O
results NN O O
and NN O O
those NN O O
obtained NN O O
by NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
in NN O O
this NN O O
family. NN O O
. NN O O

the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
and NN O O
X-linked NN B-SpecificDisease B-OMIM:313900
congenital NN I-SpecificDisease I-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
are NN O O
caused NN O O
by NN O O
mutations NN O O
of NN O O
the NN O O
same NN O O
gene NN O O
. NN O O

the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
recessive NN I-DiseaseClass I-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
characterized NN O O
by NN O O
thrombocytopenia NN B-SpecificDisease B-MSH:D013921
, NN O O
small NN O O
platelets, NN O O
eczema NN B-SpecificDisease B-MSH:D004485
, NN O O
recurrent NN O O
infections, NN O O
and NN O O
immunodeficiency NN B-DiseaseClass B-MSH:D007153
. NN O O
besides NN O O
the NN O O
classic NN O O
WAS NN B-Modifier B-MSH:D014923
phenotype, NN O O
there NN O O
is NN O O
a NN O O
group NN O O
of NN O O
patients NN O O
with NN O O
congenital NN B-SpecificDisease B-OMIM:313900
X-linked NN I-SpecificDisease I-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
( NN O O
XLT NN B-SpecificDisease B-OMIM:313900
) NN O O
who NN O O
have NN O O
small NN O O
platelets NN O O
but NN O O
only NN O O
transient NN O O
eczema NN B-SpecificDisease B-MSH:D004485
, NN O O
if NN O O
any, NN O O
and NN O O
minimal NN O O
immune NN B-DiseaseClass B-MSH:D007153
deficiency NN I-DiseaseClass I-MSH:D007153
. NN O O
because NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
WAS NN B-SpecificDisease B-MSH:D014923
has NN O O
been NN O O
sequenced, NN O O
it NN O O
was NN O O
possible NN O O
to NN O O
correlate NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
phenotypes NN O O
with NN O O
WAS NN B-Modifier B-MSH:D014923
gene NN O O
mutations. NN O O
using NN O O
a NN O O
fingerprinting NN O O
screening NN O O
technique, NN O O
we NN O O
determined NN O O
the NN O O
approximate NN O O
location NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
13 NN O O
unrelated NN O O
WAS NN B-Modifier B-MSH:D014923
patients NN O O
with NN O O
mild NN O O
to NN O O
severe NN O O
clinical NN O O
symptoms. NN O O
direct NN O O
sequence NN O O
analysis NN O O
of NN O O
cdna NN O O
and NN O O
genomic NN O O
dna NN O O
obtained NN O O
from NN O O
patient-derived NN O O
cell NN O O
lines NN O O
showed NN O O
12 NN O O
unique NN O O
mutations NN O O
distributed NN O O
throughout NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
. NN O O

gene, NN O O
including NN O O
insertions, NN O O
deletions, NN O O
and NN O O
point NN O O
mutations NN O O
resulting NN O O
in NN O O
amino NN O O
acid NN O O
substitutions, NN O O
termination, NN O O
exon NN O O
skipping, NN O O
or NN O O
splicing NN O O
defects. NN O O
of NN O O
4 NN O O
unrelated NN O O
patients NN O O
with NN O O
the NN O O
XLT NN B-Modifier B-OMIM:313900
phenotype, NN O O
3 NN O O
had NN O O
missense NN O O
mutations NN O O
affecting NN O O
exon NN O O
2 NN O O
and NN O O
1 NN O O
had NN O O
a NN O O
splice-site NN O O
mutation NN O O
affecting NN O O
exon NN O O
9. NN O O
patients NN O O
with NN O O
classic NN O O
WAS NN B-SpecificDisease B-MSH:D014923
had NN O O
more NN O O
complex NN O O
mutations, NN O O
resulting NN O O
in NN O O
termination NN O O
codons, NN O O
frameshift, NN O O
and NN O O
early NN O O
termination. NN O O
these NN O O
findings NN O O
provide NN O O
direct NN O O
evidence NN O O
that NN O O
XLT NN B-SpecificDisease B-OMIM:313900
and NN O O
WAS NN B-SpecificDisease B-MSH:D014923
are NN O O
caused NN O O
by NN O O
mutations NN O O
of NN O O
the NN O O
same NN O O
gene NN O O
and NN O O
suggest NN O O
that NN O O
severe NN O O
clinical NN O O
phenotypes NN O O
are NN O O
associated NN O O
with NN O O
complex NN O O
mutations. NN O O
. NN O O

a NN O O
3-base NN O O
pair NN O O
in-frame NN O O
deletion NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
results NN O O
in NN O O
a NN O O
kinetic NN O O
variant NN O O
of NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
due NN O O
to NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
a NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
enzyme, NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah). NN O O
the NN O O
absence NN O O
of NN O O
pah NN O O
activity NN O O
results NN O O
in NN O O
typical NN O O
PKU NN B-SpecificDisease B-MSH:D010661
while NN O O
persistence NN O O
of NN O O
a NN O O
residual NN O O
enzyme NN O O
activity NN O O
gives NN O O
rise NN O O
to NN O O
variant NN O O
forms NN O O
of NN O O
the NN O O
disease. NN O O
we NN O O
report NN O O
here NN O O
a NN O O
3-base NN O O
pair NN O O
in-frame NN O O
deletion NN O O
of NN O O
the NN O O
pah NN O O
gene NN O O
(delta NN O O
194) NN O O
in NN O O
a NN O O
mild NN O O
variant, NN O O
with NN O O
markedly NN O O
reduced NN O O
affinity NN O O
of NN O O
the NN O O
enzyme NN O O
for NN O O
phenylalanine NN O O
(km NN O O
= NN O O
160 NN O O
nm), NN O O
and NN O O
we NN O O
provide NN O O
functional NN O O
evidence NN O O
for NN O O
responsibility NN O O
of NN O O
the NN O O
deletion NN O O
in NN O O
the NN O O
mutant NN O O
phenotype. NN O O
since NN O O
the NN O O
deletion NN O O
was NN O O
located NN O O
in NN O O
the NN O O
third NN O O
exon NN O O
of NN O O
the NN O O
gene, NN O O
which NN O O
presents NN O O
no NN O O
homology NN O O
with NN O O
other NN O O
hydroxylases, NN O O
we NN O O
suggest NN O O
that NN O O
exon NN O O
3 NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
specificity NN O O
of NN O O
the NN O O
enzyme NN O O
for NN O O
phenylalanin NN O O
. NN O O

. NN O O
finally, NN O O
since NN O O
none NN O O
of NN O O
the NN O O
98 NN O O
PKU NN B-Modifier B-MSH:D010661
patients NN O O
tested NN O O
were NN O O
found NN O O
to NN O O
carry NN O O
this NN O O
particular NN O O
deletion, NN O O
our NN O O
study NN O O
suggests NN O O
that NN O O
this NN O O
molecular NN O O
event NN O O
probably NN O O
occurred NN O O
recently NN O O
on NN O O
the NN O O
background NN O O
of NN O O
a NN O O
haplotype NN O O
2 NN O O
gene NN O O
in NN O O
portugal. NN O O
. NN O O

friedreich NN O O
ataxia: NN O O
an NN O O
overview NN O O
. NN O O

friedreich NN O O
ataxia, NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D020271
recessive NN I-DiseaseClass I-MSH:D020271
neurodegenerative NN I-DiseaseClass I-MSH:D020271
disease NN I-DiseaseClass I-MSH:D020271
, NN O O
is NN O O
the NN O O
most NN O O
common NN O O
of NN O O
the NN O O
inherited NN B-SpecificDisease B-MSH:D013132
ataxias NN I-SpecificDisease I-MSH:D013132
. NN O O
the NN O O
recent NN O O
discovery NN O O
of NN O O
the NN O O
gene NN O O
that NN O O
is NN O O
mutated NN O O
in NN O O
this NN O O
condition, NN O O
frda, NN O O
has NN O O
led NN O O
to NN O O
rapid NN O O
advances NN O O
in NN O O
the NN O O
understanding NN O O
of NN O O
the NN O O
pathogenesis NN O O
of NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
. NN O O
about NN O O
98% NN O O
of NN O O
mutant NN O O
alleles NN O O
have NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
gaa NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
gene. NN O O
this NN O O
leads NN O O
to NN O O
reduced NN O O
levels NN O O
of NN O O
the NN O O
protein, NN O O
frataxin. NN O O
there NN O O
is NN O O
mounting NN O O
evidence NN O O
to NN O O
suggest NN O O
that NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
is NN O O
the NN O O
result NN O O
of NN O O
accumulation NN O O
of NN O O
iron NN O O
in NN O O
mitochondria NN O O
leading NN O O
to NN O O
excess NN O O
production NN O O
of NN O O
free NN O O
radicals, NN O O
which NN O O
then NN O O
results NN O O
in NN O O
cellular NN O O
damage NN O O
and NN O O
death. NN O O
currently NN O O
there NN O O
is NN O O
no NN O O
known NN O O
treatment NN O O
that NN O O
alters NN O O
the NN O O
natural NN O O
course NN O O
of NN O O
the NN O O
disease. NN O O
the NN O O
discovery NN O O
of NN O O
the NN O O
FRDA NN B-Modifier B-MSH:D005621
gene NN O O
and NN O O
its NN O O
possible NN O O
functio NN O O
. NN O O

has NN O O
raised NN O O
hope NN O O
that NN O O
rational NN O O
therapeutic NN O O
strategies NN O O
will NN O O
be NN O O
developed. NN O O
. NN O O

clinical NN O O
and NN O O
molecular NN O O
genetics NN O O
of NN O O
primary NN B-DiseaseClass B-MSH:D020821
dystonias NN I-DiseaseClass I-MSH:D020821
. NN O O

primary NN O O
dystonias NN O O
are NN O O
movement NN B-DiseaseClass B-MSH:D009069
disorders NN I-DiseaseClass I-MSH:D009069
with NN O O
dystonia NN B-DiseaseClass B-MSH:D004421
as NN O O
a NN O O
major NN O O
symptom. NN O O
they NN O O
are NN O O
frequently NN O O
inherited NN O O
as NN O O
mendelian NN O O
traits. NN O O
there NN O O
are NN O O
at NN O O
least NN O O
eight NN O O
clinically NN O O
distinct NN O O
autosomal NN O O
dominant NN O O
and NN O O
two NN O O
x-linked NN O O
recessive NN O O
forms. NN O O
in NN O O
addition, NN O O
pedigree NN O O
analyses NN O O
suggest NN O O
the NN O O
occurrence NN O O
of NN O O
an NN O O
autosomal NN O O
recessive NN O O
variant. NN O O
the NN O O
clinical NN O O
classification NN O O
is NN O O
increasingly NN O O
being NN O O
replaced NN O O
by NN O O
a NN O O
genetic NN O O
one. NN O O
to NN O O
date NN O O
gene NN O O
loci NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
at NN O O
least NN O O
six NN O O
autosomal NN O O
dominant NN O O
forms, NN O O
i. NN O O
e., NN O O
in NN O O
idiopathic NN B-SpecificDisease B-MSH:D004422
torsion NN I-SpecificDisease I-MSH:D004422
dystonia NN I-SpecificDisease I-MSH:D004422
(9 NN O O
q NN O O
34), NN O O
focal NN B-SpecificDisease B-MSH:D020821
dystonia NN I-SpecificDisease I-MSH:D020821
(18 NN O O
p), NN O O
adult-onset NN O O
idiopathic NN B-SpecificDisease B-MSH:D004422
torsion NN I-SpecificDisease I-MSH:D004422
dystonia NN I-SpecificDisease I-MSH:D004422
of NN O O
mixed NN O O
type NN O O
(8 NN O O
p NN O O
21-q NN O O
22), NN O O
dopa-responsive NN B-SpecificDisease B-MSH:C538007
dystonia NN I-SpecificDisease I-MSH:C538007
(14 NN O O
q NN O O
22. NN O O
1-q NN O O
22. NN O O
2), NN O O
and NN O O
paroxysmal NN B-SpecificDisease B-MSH:C537181
dystonic NN I-SpecificDisease I-MSH:C537181
choreoathetosis NN I-SpecificDisease I-MSH:C537181
. NN O O

2 NN O O
q NN O O
25-q NN O O
33; NN O O
1 NN O O
p NN O O
21-p NN O O
13. NN O O
3). NN O O
gene NN O O
loci NN O O
in NN O O
the NN O O
x-linked NN O O
recessive NN O O
forms NN O O
have NN O O
been NN O O
assigned NN O O
to NN O O
xq NN O O
13. NN O O
1 NN O O
in NN O O
the NN O O
X-linked NN B-SpecificDisease B-OMIM:314250
dystonia NN I-SpecificDisease I-OMIM:314250
parkinsonism NN I-SpecificDisease I-OMIM:314250
syndrome NN I-SpecificDisease I-OMIM:314250
and NN O O
to NN O O
xq NN O O
22 NN O O
in NN O O
X-linked NN B-DiseaseClass B-OMIM:304500
sensorineural NN I-DiseaseClass I-OMIM:304500
deafness NN I-DiseaseClass I-OMIM:304500
, NN O O
dystonia NN B-DiseaseClass B-MSH:D004421
, NN O O
and NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
. NN O O
the NN O O
disease NN O O
genes NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
two NN O O
autosomal NN O O
dominant NN O O
forms NN O O
and NN O O
in NN O O
one NN O O
x-linked NN O O
recessive NN O O
form. NN O O
mutations NN O O
in NN O O
a NN O O
gene NN O O
coding NN O O
for NN O O
an NN O O
atp-binding NN O O
protein NN O O
were NN O O
detected NN O O
in NN O O
idiopathic NN B-SpecificDisease B-MSH:D004422
torsion NN I-SpecificDisease I-MSH:D004422
dystonia NN I-SpecificDisease I-MSH:D004422
(dyt NN O O
1), NN O O
and NN O O
the NN O O
gtp NN O O
cyclohydrolase NN O O
1 NN O O
gene NN O O
is NN O O
mutated NN O O
in NN O O
dopa-responsive NN B-SpecificDisease B-MSH:C538007
dystonia NN I-SpecificDisease I-MSH:C538007
(dyt NN O O
5). NN O O
in NN O O
sensorineural NN B-DiseaseClass B-MSH:D006319
deafness NN I-DiseaseClass I-MSH:D006319
, NN O O
dystonia NN B-DiseaseClass B-MSH:D004421
, NN O O
and NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
the NN O O
gene NN O O
ddp NN O O
coding NN O O
for NN O O
a NN O O
polypeptid NN O O
. NN O O

of NN O O
unknown NN O O
function. NN O O
this NN O O
article NN O O
reviews NN O O
the NN O O
clinical NN O O
and NN O O
molecular NN O O
genetics NN O O
of NN O O
primary NN B-DiseaseClass B-MSH:D020821
dystonias NN I-DiseaseClass I-MSH:D020821
, NN O O
critically NN O O
discusses NN O O
present NN O O
findings, NN O O
and NN O O
proposes NN O O
referring NN O O
to NN O O
the NN O O
known NN O O
forms, NN O O
most NN O O
of NN O O
which NN O O
can NN O O
be NN O O
distinguished NN O O
by NN O O
genetic NN O O
criteria, NN O O
as NN O O
dystonias NN B-CompositeMention B-MSH:D020821
1-12 NN I-CompositeMention I-MSH:D020821
. NN O O

clinical NN O O
and NN O O
genetic NN O O
study NN O O
of NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
in NN O O
an NN O O
australian NN O O
population NN O O
. NN O O

friedreich NN O O
ataxia NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
FRDA NN B-Modifier B-MSH:D005621
gene NN O O
that NN O O
encodes NN O O
a NN O O
210-amino NN O O
acid NN O O
protein NN O O
called NN O O
frataxin. NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
gaa NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
gene NN O O
is NN O O
present NN O O
in NN O O
more NN O O
than NN O O
95% NN O O
of NN O O
mutant NN O O
alleles. NN O O
of NN O O
the NN O O
83 NN O O
people NN O O
we NN O O
studied NN O O
who NN O O
have NN O O
mutations NN O O
in NN O O
frda, NN O O
78 NN O O
are NN O O
homozygous NN O O
for NN O O
an NN O O
expanded NN O O
gaa NN O O
repeat; NN O O
the NN O O
other NN O O
five NN O O
patients NN O O
have NN O O
an NN O O
expansion NN O O
in NN O O
one NN O O
allele NN O O
and NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
the NN O O
other. NN O O
here NN O O
we NN O O
present NN O O
a NN O O
detailed NN O O
clinical NN O O
and NN O O
genetic NN O O
study NN O O
of NN O O
a NN O O
subset NN O O
of NN O O
51 NN O O
patients NN O O
homozygous NN O O
for NN O O
an NN O O
expansion NN O O
of NN O O
the NN O O
gaa NN O O
repeat. NN O O
we NN O O
found NN O O
a NN O O
correlation NN O O
between NN O O
the NN O O
size NN O O
of NN O O
the NN O O
smaller NN O O
of NN O O
the NN O O
two NN O O
expanded NN O O
alleles NN O O
and NN O O
age NN O O
at NN O O
onset, NN O O
age NN O O
into NN O O
wheelchair, NN O O
scoliosis NN B-DiseaseClass B-MSH:D012600
, NN O O
impaired NN O O
vibratio NN O O
. NN O O

sense, NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
foot NN B-DiseaseClass B-MSH:D005530
deformity NN I-DiseaseClass I-MSH:D005530
. NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
correlation NN O O
between NN O O
the NN O O
size NN O O
of NN O O
the NN O O
smaller NN O O
allele NN O O
and NN O O
cardiomyopathy NN B-SpecificDisease B-MSH:D009202
, NN O O
diabetes NN B-SpecificDisease B-MSH:D003920
mellitus NN I-SpecificDisease I-MSH:D003920
, NN O O
loss NN B-DiseaseClass B-MSH:D020886
of NN I-DiseaseClass I-MSH:D020886
proprioception NN I-DiseaseClass I-MSH:D020886
, NN O O
or NN O O
bladder NN B-DiseaseClass B-MSH:D001745
symptoms NN I-DiseaseClass I-MSH:D001745
. NN O O
the NN O O
larger NN O O
allele NN O O
size NN O O
correlated NN O O
with NN O O
bladder NN B-DiseaseClass B-MSH:D001745
symptoms NN I-DiseaseClass I-MSH:D001745
and NN O O
the NN O O
presence NN O O
of NN O O
foot NN B-DiseaseClass B-MSH:D005530
deformity NN I-DiseaseClass I-MSH:D005530
. NN O O
the NN O O
duration NN O O
of NN O O
disease NN O O
is NN O O
correlated NN O O
with NN O O
wheelchair NN O O
use NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
diabetes NN B-DiseaseClass B-MSH:D003920
, NN O O
scoliosis NN B-DiseaseClass B-MSH:D012600
, NN O O
bladder NN B-DiseaseClass B-MSH:D001745
symptoms NN I-DiseaseClass I-MSH:D001745
and NN O O
impaired NN B-DiseaseClass B-MSH:D020886
proprioception NN I-DiseaseClass I-MSH:D020886
, NN O O
and NN O O
vibration NN O O
sense NN O O
but NN O O
no NN O O
other NN O O
complications NN O O
studied. NN O O
. NN O O

recurrent NN O O
meningococcal NN B-SpecificDisease B-MSH:D008585
meningitis NN I-SpecificDisease I-MSH:D008585
with NN O O
absence NN B-SpecificDisease B-OMIM:612446
of NN I-SpecificDisease I-OMIM:612446
the NN I-SpecificDisease I-OMIM:612446
sixth NN I-SpecificDisease I-OMIM:612446
component NN I-SpecificDisease I-OMIM:612446
of NN I-SpecificDisease I-OMIM:612446
complement NN I-SpecificDisease I-OMIM:612446
: NN O O
an NN O O
evaluation NN O O
of NN O O
underlying NN O O
immunologic NN O O
mechanisms NN O O
. NN O O

a NN O O
51/2-year-old NN O O
black NN O O
girl NN O O
with NN O O
recurrent NN O O
meningococcal NN B-SpecificDisease B-MSH:D008585
meningitis NN I-SpecificDisease I-MSH:D008585
and NN O O
absence NN B-SpecificDisease B-OMIM:612446
of NN I-SpecificDisease I-OMIM:612446
the NN I-SpecificDisease I-OMIM:612446
sixth NN I-SpecificDisease I-OMIM:612446
component NN I-SpecificDisease I-OMIM:612446
of NN I-SpecificDisease I-OMIM:612446
complement NN I-SpecificDisease I-OMIM:612446
(c NN O O
6) NN O O
is NN O O
reported. NN O O
to NN O O
explore NN O O
the NN O O
pathogenesis NN O O
of NN O O
recurrent NN O O
neisserial NN B-SpecificDisease B-MSH:D016870
infections NN I-SpecificDisease I-MSH:D016870
in NN O O
C6 NN B-SpecificDisease B-OMIM:612446
deficiency NN I-SpecificDisease I-OMIM:612446
, NN O O
a NN O O
detailed NN O O
analysis NN O O
of NN O O
her NN O O
immune NN O O
competence NN O O
was NN O O
conducted. NN O O
her NN O O
serum NN O O
had NN O O
normal NN O O
chemotactic, NN O O
opsonic, NN O O
alternative NN O O
complement NN O O
pathway, NN O O
and NN O O
specific NN O O
antibody NN O O
activity, NN O O
but NN O O
lacked NN O O
complement-mediated NN O O
bacteriolytic NN O O
activity. NN O O
in NN O O
addition, NN O O
her NN O O
C6-deficient NN B-Modifier B-OMIM:612446
serum NN O O
was NN O O
indistinguishable NN O O
from NN O O
normal NN O O
serum NN O O
in NN O O
a NN O O
complement-dependent NN O O
assay NN O O
of NN O O
phagocyte NN O O
bactericidal NN O O
activity. NN O O
absent NN O O
bacteriolysis NN O O
remains NN O O
the NN O O
only NN O O
consistent NN O O
defect NN O O
associated NN O O
with NN O O
recurrent NN O O
neisserial NN B-SpecificDisease B-MSH:D016870
infections NN I-SpecificDisease I-MSH:D016870
and NN O O
absence NN O O
of NN O O
one NN O O
of NN O O
the NN O O
late-acting NN O O
complement NN O O
components. NN O O
. NN O O

mutation NN O O
of NN O O
the NN O O
sterol NN O O
27-hydroxylase NN O O
gene NN O O
(cyp NN O O
27) NN O O
results NN O O
in NN O O
truncation NN O O
of NN O O
mrna NN O O
expressed NN O O
in NN O O
leucocytes NN O O
in NN O O
a NN O O
japanese NN O O
family NN O O
with NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
. NN O O

objectives NN O O
a NN O O
japanese NN O O
family NN O O
with NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
( NN O O
CTX NN B-SpecificDisease B-MSH:D019294
) NN O O
was NN O O
investigated NN O O
for NN O O
a NN O O
sequence NN O O
alteration NN O O
in NN O O
the NN O O
sterol NN O O
27-hydroxylase NN O O
gene NN O O
(cyp NN O O
27). NN O O
the NN O O
expression NN O O
of NN O O
cyp NN O O
27 NN O O
has NN O O
been NN O O
mostly NN O O
explored NN O O
using NN O O
cultured NN O O
fibroblasts, NN O O
prompting NN O O
the NN O O
examination NN O O
of NN O O
the NN O O
transcripts NN O O
from NN O O
blood NN O O
leucocytes NN O O
as NN O O
a NN O O
simple NN O O
and NN O O
rapid NN O O
technique. NN O O
methods NN O O
an NN O O
alteration NN O O
in NN O O
cyp NN O O
27 NN O O
of NN O O
the NN O O
proband NN O O
was NN O O
searched NN O O
for NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction-single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
(pcr-sscp) NN O O
analysis NN O O
and NN O O
subsequent NN O O
sequencing. NN O O
samples NN O O
of NN O O
rna NN O O
were NN O O
subjected NN O O
to NN O O
reverse NN O O
transcription NN O O
pcr NN O O
(rt-pcr) NN O O
and NN O O
the NN O O
product NN O O
of NN O O
the NN O O
proband NN O O
was NN O O
amplified NN O O
with NN O O
nested NN O O
primers NN O O
and NN O O
sequenced. NN O O
results NN O O
a NN O O
homozygous NN O O
g NN O O
to NN O O
a NN O O
transition NN O O
at NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
intron NN O O
7 NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
patient. NN O O
in NN O O
rt-pc NN O O
. NN O O

analysis, NN O O
only NN O O
a NN O O
truncated NN O O
transcript NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
patient, NN O O
whereas NN O O
both NN O O
normal NN O O
and NN O O
truncated NN O O
transcripts NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
siblings. NN O O
the NN O O
sequencing NN O O
of NN O O
the NN O O
patients NN O O
cdna NN O O
fragment NN O O
disclosed NN O O
a NN O O
direct NN O O
conjuction NN O O
of NN O O
exon NN O O
6 NN O O
and NN O O
exon NN O O
8. NN O O
conclusion NN O O
the NN O O
mutation NN O O
at NN O O
splice NN O O
donor NN O O
site NN O O
and NN O O
the NN O O
truncation NN O O
of NN O O
mrna NN O O
were NN O O
identical NN O O
with NN O O
those NN O O
of NN O O
a NN O O
recently NN O O
reported NN O O
italian NN O O
patient, NN O O
although NN O O
different NN O O
in NN O O
symptomatology. NN O O
the NN O O
application NN O O
of NN O O
blood NN O O
leucocytes NN O O
can NN O O
be NN O O
a NN O O
simple NN O O
technique NN O O
on NN O O
analysing NN O O
a NN O O
constructive NN O O
abnormality NN B-SpecificDisease B-OMIM:213700
of NN I-SpecificDisease I-OMIM:213700
CYP27 NN I-SpecificDisease I-OMIM:213700
mrna. NN O O
. NN O O

frequent NN O O
detection NN O O
of NN O O
codon NN O O
877 NN O O
mutation NN O O
in NN O O
the NN O O
androgen NN O O
receptor NN O O
gene NN O O
in NN O O
advanced NN B-SpecificDisease B-MSH:D011471
prostate NN I-SpecificDisease I-MSH:D011471
cancers NN I-SpecificDisease I-MSH:D011471
. NN O O

prostatic NN O O
tissue NN O O
specimens NN O O
derived NN O O
from NN O O
transurethral NN O O
resections NN O O
of NN O O
patients NN O O
with NN O O
metastatic NN B-SpecificDisease B-MSH:D011471
prostate NN I-SpecificDisease I-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
were NN O O
analyzed NN O O
for NN O O
genetic NN O O
alterations NN O O
in NN O O
the NN O O
hormone-binding NN O O
domain NN O O
of NN O O
the NN O O
androgen NN O O
receptor NN O O
(ar) NN O O
gene. NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction-derived NN O O
dnas NN O O
of NN O O
6 NN O O
of NN O O
24 NN O O
specimens NN O O
revealed NN O O
a NN O O
codon NN O O
877 NN O O
mutation NN O O
(act-- NN O O
> NN O O
gct, NN O O
thr-- NN O O
> NN O O
ala) NN O O
in NN O O
the NN O O
hormone-binding NN O O
domain NN O O
of NN O O
the NN O O
ar NN O O
gene. NN O O
this NN O O
same NN O O
ar NN O O
mutation NN O O
has NN O O
been NN O O
reported NN O O
previously NN O O
in NN O O
a NN O O
metastatic NN B-Modifier B-MSH:D011471
prostate NN I-Modifier I-MSH:D011471
cancer NN I-Modifier I-MSH:D011471
cell NN O O
line, NN O O
lncap, NN O O
where NN O O
this NN O O
mutation NN O O
confers NN O O
upon NN O O
the NN O O
ar NN O O
an NN O O
altered NN O O
ligand-binding NN O O
specificity NN O O
which NN O O
is NN O O
stimulated NN O O
by NN O O
estrogens, NN O O
progestagens, NN O O
and NN O O
antiandrogens. NN O O
it NN O O
is NN O O
possible NN O O
that NN O O
analogous NN O O
to NN O O
an NN O O
activated/altered NN O O
growth NN O O
factor NN O O
receptor NN O O
oncogene, NN O O
codon NN O O
877 NN O O
mutant NN O O
ar NN O O
with NN O O
altere NN O O
. NN O O

ligand NN O O
binding NN O O
may NN O O
provide NN O O
a NN O O
selective NN O O
growth NN O O
advantage NN O O
in NN O O
the NN O O
genesis NN O O
of NN O O
a NN O O
subset NN O O
of NN O O
advanced NN B-SpecificDisease B-MSH:D011471
prostate NN I-SpecificDisease I-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
. NN O O
although NN O O
estrogens NN O O
are NN O O
used NN O O
infrequently, NN O O
antiandrogens NN O O
are NN O O
used NN O O
increasingly NN O O
in NN O O
hormonal NN O O
therapy NN O O
for NN O O
patients NN O O
with NN O O
advanced NN B-SpecificDisease B-MSH:D011471
prostate NN I-SpecificDisease I-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
. NN O O
the NN O O
stimulatory NN O O
effect NN O O
of NN O O
these NN O O
therapeutic NN O O
agents NN O O
on NN O O
the NN O O
codon NN O O
877 NN O O
mutant NN O O
ar NN O O
further NN O O
suggests NN O O
that NN O O
this NN O O
frequently NN O O
observed NN O O
ar NN O O
mutation NN O O
may NN O O
contribute NN O O
to NN O O
the NN O O
treatment NN O O
refractory NN O O
disease. NN O O
. NN O O

atm-dependent NN O O
phosphorylation NN O O
of NN O O
nibrin NN O O
in NN O O
response NN O O
to NN O O
radiation NN O O
exposure NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
gene NN O O
atm NN O O
are NN O O
responsible NN O O
for NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
( NN O O
A-T NN B-SpecificDisease B-MSH:D001260
), NN O O
which NN O O
is NN O O
characterized NN O O
by NN O O
cerebellar NN B-DiseaseClass B-MSH:D002526
dysfunction NN I-DiseaseClass I-MSH:D002526
, NN O O
radiosensitivity, NN O O
chromosomal NN O O
instability NN O O
and NN O O
cancer NN B-Modifier B-MSH:D009369
predisposition. NN O O
both NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260
phenotype NN O O
and NN O O
the NN O O
similarity NN O O
of NN O O
the NN O O
atm NN O O
protein NN O O
to NN O O
other NN O O
dna-damage NN O O
sensors NN O O
suggests NN O O
a NN O O
role NN O O
for NN O O
atm NN O O
in NN O O
biochemical NN O O
pathways NN O O
involved NN O O
in NN O O
the NN O O
recognition, NN O O
signalling NN O O
and NN O O
repair NN O O
of NN O O
dna NN O O
double-strand NN O O
breaks NN O O
(dsbs). NN O O
there NN O O
are NN O O
strong NN O O
parallels NN O O
between NN O O
the NN O O
pattern NN O O
of NN O O
radiosensitivity, NN O O
chromosomal NN O O
instability NN O O
and NN O O
cancer NN B-Modifier B-MSH:D009369
predisposition NN O O
in NN O O
A-T NN B-SpecificDisease B-MSH:D001260
patients NN O O
and NN O O
that NN O O
in NN O O
patients NN O O
with NN O O
Nijmegen NN B-SpecificDisease B-MSH:D049932
breakage NN I-SpecificDisease I-MSH:D049932
syndrome NN I-SpecificDisease I-MSH:D049932
( NN O O
NBS NN B-SpecificDisease B-MSH:D049932
). NN O O
the NN O O
protein NN O O
defective NN O O
in NN O O
NBS NN B-SpecificDisease B-MSH:D049932
, NN O O
nibrin NN O O
(encoded NN O O
by NN O O
nbs NN O O
1), NN O O
forms NN O O
a NN O O
complex NN O O
with NN O O
mre NN O O
11 NN O O
and NN O O
rad NN O O
50 NN O O
(refs NN O O
. NN O O

, NN O O
2). NN O O
this NN O O
complex NN O O
localizes NN O O
to NN O O
dsbs NN O O
within NN O O
30 NN O O
minutes NN O O
after NN O O
cellular NN O O
exposure NN O O
to NN O O
ionizing NN O O
radiation NN O O
(ir) NN O O
and NN O O
is NN O O
observed NN O O
in NN O O
brightly NN O O
staining NN O O
nuclear NN O O
foci NN O O
after NN O O
a NN O O
longer NN O O
period NN O O
of NN O O
time. NN O O
the NN O O
overlap NN O O
between NN O O
clinical NN O O
and NN O O
cellular NN O O
phenotypes NN O O
in NN O O
A-T NN B-SpecificDisease B-MSH:D001260
and NN O O
NBS NN B-SpecificDisease B-MSH:D049932
suggests NN O O
that NN O O
atm NN O O
and NN O O
nibrin NN O O
may NN O O
function NN O O
in NN O O
the NN O O
same NN O O
biochemical NN O O
pathway. NN O O
here NN O O
we NN O O
demonstrate NN O O
that NN O O
nibrin NN O O
is NN O O
phosphorylated NN O O
within NN O O
one NN O O
hour NN O O
of NN O O
treatment NN O O
of NN O O
cells NN O O
with NN O O
ir. NN O O
this NN O O
response NN O O
is NN O O
abrogated NN O O
in NN O O
A-T NN B-Modifier B-MSH:D001260
cells NN O O
that NN O O
either NN O O
do NN O O
not NN O O
express NN O O
atm NN O O
protein NN O O
or NN O O
express NN O O
near NN O O
full-length NN O O
mutant NN O O
protein. NN O O
we NN O O
also NN O O
show NN O O
that NN O O
atm NN O O
physically NN O O
interacts NN O O
with NN O O
and NN O O
phosphorylates NN O O
nibrin NN O O
on NN O O
serine NN O O
343 NN O O
both NN O O
in NN O O
vivo NN O O
and NN O O
in NN O O
vitro. NN O O
phosphorylation NN O O
of NN O O
this NN O O
site NN O O
appears NN O O
to NN O O
be NN O O
functionally NN O O
important NN O O
because NN O O
mutated NN O O
nibrin NN O O
(s NN O O
34 NN O O
. NN O O

a) NN O O
does NN O O
not NN O O
completely NN O O
complement NN O O
radiosensitivity NN O O
in NN O O
NBS NN B-Modifier B-MSH:D049932
cells. NN O O
atm NN O O
phosphorylation NN O O
of NN O O
nibrin NN O O
does NN O O
not NN O O
affect NN O O
nibrin-mre NN O O
11-rad NN O O
50 NN O O
association NN O O
as NN O O
revealed NN O O
by NN O O
radiation-induced NN O O
foci NN O O
formation. NN O O
our NN O O
data NN O O
provide NN O O
a NN O O
biochemical NN O O
explanation NN O O
for NN O O
the NN O O
similarity NN O O
in NN O O
phenotype NN O O
between NN O O
A-T NN B-SpecificDisease B-MSH:D001260
and NN O O
NBS NN B-SpecificDisease B-MSH:D049932
. NN O O
. NN O O

detection NN O O
of NN O O
an NN O O
unstable NN O O
fragment NN O O
of NN O O
dna NN O O
specific NN O O
to NN O O
individuals NN O O
with NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
. NN O O

myotonic NN O O
dystrophy NN O O
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
adult NN O O
muscular NN B-SpecificDisease B-MSH:D009136
dystrophy NN I-SpecificDisease I-MSH:D009136
, NN O O
with NN O O
a NN O O
prevalence NN O O
of NN O O
2-14 NN O O
per NN O O
100, NN O O
000 NN O O
individuals. NN O O
the NN O O
disease NN O O
is NN O O
characterized NN O O
by NN O O
progressive NN O O
muscle NN B-DiseaseClass B-MSH:D018908
weakness NN I-DiseaseClass I-MSH:D018908
and NN O O
sustained NN B-DiseaseClass B-MSH:D009120
muscle NN I-DiseaseClass I-MSH:D009120
contraction NN I-DiseaseClass I-MSH:D009120
, NN O O
often NN O O
with NN O O
a NN O O
wide NN O O
range NN O O
of NN O O
accompanying NN O O
symptoms. NN O O
the NN O O
age NN O O
at NN O O
onset NN O O
and NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
show NN O O
extreme NN O O
variation, NN O O
both NN O O
within NN O O
and NN O O
between NN O O
families. NN O O
despite NN O O
its NN O O
clinical NN O O
variability, NN O O
this NN O O
dominant NN O O
condition NN O O
segregates NN O O
as NN O O
a NN O O
single NN O O
locus NN O O
at NN O O
chromosome NN O O
19 NN O O
q NN O O
13. NN O O
3 NN O O
in NN O O
every NN O O
population NN O O
studied. NN O O
it NN O O
is NN O O
flanked NN O O
by NN O O
the NN O O
tightly NN O O
linked NN O O
genetic NN O O
markers NN O O
ercc NN O O
1 NN O O
proximally NN O O
and NN O O
d NN O O
19 NN O O
s NN O O
51 NN O O
distally; NN O O
these NN O O
define NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
critical NN O O
region. NN O O
we NN O O
report NN O O
the NN O O
isolation NN O O
of NN O O
an NN O O
expressed NN O O
sequence NN O O
from NN O O
this NN O O
region NN O O
which NN O O
detects NN O O
a NN O O
dna NN O O
fragment NN O O
that NN O O
is NN O O
larger NN O O
i NN O O
. NN O O

affected NN O O
individuals NN O O
than NN O O
in NN O O
normal NN O O
siblings NN O O
or NN O O
unaffected NN O O
controls. NN O O
the NN O O
size NN O O
of NN O O
this NN O O
fragment NN O O
varies NN O O
between NN O O
affected NN O O
siblings, NN O O
and NN O O
increases NN O O
in NN O O
size NN O O
through NN O O
generations NN O O
in NN O O
parallel NN O O
with NN O O
increasing NN O O
severity NN O O
of NN O O
the NN O O
disease. NN O O
we NN O O
postulate NN O O
that NN O O
this NN O O
unstable NN O O
dna NN O O
sequence NN O O
is NN O O
the NN O O
molecular NN O O
feature NN O O
that NN O O
underlies NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O

detection NN O O
of NN O O
a NN O O
novel NN O O
missense NN O O
mutation NN O O
and NN O O
second NN O O
recurrent NN O O
mutation NN O O
in NN O O
the NN O O
cacna NN O O
1 NN O O
a NN O O
gene NN O O
in NN O O
individuals NN O O
with NN O O
EA-2 NN B-SpecificDisease B-MSH:C535506
and NN O O
FHM NN B-SpecificDisease B-MSH:D020325
. NN O O

mutations NN O O
in NN O O
the NN O O
brain NN O O
specific NN O O
p/q NN O O
type NN O O
ca NN O O
2 NN O O
+ NN O O
channel NN O O
alpha NN O O
1 NN O O
subunit NN O O
gene, NN O O
cacna NN O O
1 NN O O
a, NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
three NN O O
clinically NN O O
distinct NN O O
disorders, NN O O
viz. NN O O
episodic NN B-SpecificDisease B-MSH:C535506
ataxia NN I-SpecificDisease I-MSH:C535506
type NN I-SpecificDisease I-MSH:C535506
2 NN I-SpecificDisease I-MSH:C535506
( NN O O
EA-2 NN B-SpecificDisease B-MSH:C535506
), NN O O
familial NN B-SpecificDisease B-MSH:D020325
hemiplegic NN I-SpecificDisease I-MSH:D020325
migraine NN I-SpecificDisease I-MSH:D020325
( NN O O
FHM NN B-SpecificDisease B-MSH:D020325
) NN O O
and NN O O
spinocerebellar NN B-SpecificDisease B-OMIM:183086
ataxia NN I-SpecificDisease I-OMIM:183086
6 NN I-SpecificDisease I-OMIM:183086
( NN O O
SCA6 NN B-SpecificDisease B-OMIM:183086
). NN O O
for NN O O
individuals NN O O
with NN O O
EA-2 NN B-SpecificDisease B-MSH:C535506
, NN O O
the NN O O
mutations NN O O
described NN O O
thus NN O O
far NN O O
are NN O O
presumed NN O O
to NN O O
result NN O O
in NN O O
a NN O O
truncated NN O O
protein NN O O
product. NN O O
several NN O O
different NN O O
missense NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O
FHM NN B-SpecificDisease B-MSH:D020325
. NN O O
at NN O O
least NN O O
two NN O O
of NN O O
these NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
on NN O O
two NN O O
different NN O O
chromosome NN O O
19 NN O O
p NN O O
13 NN O O
haplotypes NN O O
and NN O O
thus NN O O
represent NN O O
recurrent NN O O
mutations. NN O O
in NN O O
the NN O O
present NN O O
study, NN O O
we NN O O
have NN O O
screened NN O O
several NN O O
individuals NN O O
for NN O O
mutations NN O O
in NN O O
all NN O O
47 NN O O
exons NN O O
in NN O O
the NN O O
cacna NN O O
1 NN O O
a NN O O
gene NN O O
by NN O O
single NN O O
. NN O O

strand NN O O
conformation NN O O
analysis. NN O O
we NN O O
have NN O O
characterised NN O O
a NN O O
novel NN O O
missense NN O O
mutation, NN O O
g NN O O
5260 NN O O
a, NN O O
in NN O O
exon NN O O
32 NN O O
in NN O O
a NN O O
family NN O O
segregating NN O O
for NN O O
EA-2 NN B-SpecificDisease B-MSH:C535506
. NN O O
the NN O O
consequence NN O O
of NN O O
this NN O O
mutation NN O O
is NN O O
an NN O O
amino NN O O
acid NN O O
substitution NN O O
at NN O O
a NN O O
highly NN O O
conserved NN O O
position NN O O
within NN O O
the NN O O
cacna NN O O
1 NN O O
a NN O O
gene. NN O O
this NN O O
represents NN O O
the NN O O
first NN O O
point NN O O
mutation NN O O
not NN O O
resulting NN O O
in NN O O
a NN O O
proposed NN O O
truncated NN O O
protein. NN O O
furthermore, NN O O
this NN O O
mutation NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
a NN O O
family NN O O
member NN O O
with NN O O
mild NN O O
clinical NN O O
signs NN O O
including NN O O
only NN O O
migraine NN B-SpecificDisease B-MSH:D008881
. NN O O
additionally, NN O O
a NN O O
second NN O O
previously NN O O
identified NN O O
recurrent NN O O
muta NN O O
tion, NN O O
c NN O O
2272 NN O O
t, NN O O
in NN O O
exon NN O O
16 NN O O
has NN O O
been NN O O
discovered NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
FHM NN B-SpecificDisease B-MSH:D020325
. NN O O
. NN O O

dominant NN O O
negative NN O O
effect NN O O
of NN O O
the NN O O
apc NN O O
1309 NN O O
mutation: NN O O
a NN O O
possible NN O O
explanation NN O O
for NN O O
genotype-phenotype NN O O
correlations NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
. NN O O

inactivation NN O O
of NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
( NN O O
APC NN B-Modifier B-MSH:D011125
) NN O O
gene NN O O
product NN O O
initiates NN O O
colorectal NN O O
tumorigenesis. NN O O
patients NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D011125
APC NN I-SpecificDisease I-MSH:D011125
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
) NN O O
carry NN O O
germ-line NN O O
mutations NN O O
in NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
and NN O O
develop NN O O
multiple NN O O
colorectal NN B-SpecificDisease B-MSH:D003123
adenomas NN I-SpecificDisease I-MSH:D003123
and NN O O
subsequent NN O O
carcinomas NN B-DiseaseClass B-MSH:D009369
early NN O O
in NN O O
life. NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
correlates NN O O
with NN O O
the NN O O
position NN O O
of NN O O
the NN O O
inherited NN O O
APC NN B-Modifier B-MSH:D011125
mutation NN O O
(genotype-phenotype NN O O
correlation). NN O O
together NN O O
with NN O O
the NN O O
fact NN O O
that NN O O
both NN O O
germ-line NN O O
and NN O O
sporadic NN O O
APC NN B-Modifier B-MSH:D011125
mutations NN O O
cluster NN O O
in NN O O
the NN O O
central NN O O
region NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene, NN O O
this NN O O
points NN O O
to NN O O
a NN O O
dominant NN O O
negative NN O O
effect NN O O
of NN O O
certain NN O O
APC NN B-Modifier B-MSH:D011125
mutants. NN O O
loss NN O O
of NN O O
APC NN B-Modifier B-MSH:D011125
function NN O O
was NN O O
recently NN O O
shown NN O O
to NN O O
result NN O O
in NN O O
enhanced NN O O
beta-catenin-/tcf-mediated NN O O
transcription NN O O
in NN O O
colon NN O O
epithelial NN O O
cells. NN O O
here, NN O O
we NN O O
provide NN O O
experimental NN O O
evidence NN O O
for NN O O
a NN O O
dominant NN O O
negative NN O O
effect NN O O
of NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
products NN O O
associate NN O O
. NN O O

with NN O O
severe NN O O
polyposis NN B-SpecificDisease B-MSH:D044483
. NN O O
wild-type NN O O
APC NN B-Modifier B-MSH:D011125
activity NN O O
in NN O O
beta-catenin-/tcf-mediated NN O O
transcription NN O O
was NN O O
strongly NN O O
inhibited NN O O
by NN O O
a NN O O
mutant NN O O
APC NN B-Modifier B-MSH:D011125
that NN O O
is NN O O
truncated NN O O
at NN O O
codon NN O O
1309. NN O O
in NN O O
contrast, NN O O
mutant NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
products NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
attenuated NN B-SpecificDisease B-MSH:C538265
polyposis NN I-SpecificDisease I-MSH:C538265
(codon NN O O
386 NN O O
or NN O O
1465) NN O O
interfered NN O O
only NN O O
weakly NN O O
with NN O O
wild-type NN O O
APC NN B-Modifier B-MSH:D011125
activity. NN O O
these NN O O
results NN O O
suggest NN O O
a NN O O
molecular NN O O
explanation NN O O
for NN O O
the NN O O
genotype-phenotype NN O O
correlation NN O O
in NN O O
FAP NN B-Modifier B-MSH:D011125
patients NN O O
and NN O O
support NN O O
the NN O O
idea NN O O
that NN O O
colorectal NN B-Modifier B-MSH:D015179
tumor NN I-Modifier I-MSH:D015179
growth NN O O
might NN O O
be, NN O O
in NN O O
part, NN O O
driven NN O O
by NN O O
selection NN O O
for NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
mutation NN O O
cluster NN O O
region. NN O O
. NN O O

mutation NN O O
of NN O O
the NN O O
kit NN O O
(mast/stem NN O O
cell NN O O
growth NN O O
factor NN O O
receptor) NN O O
protooncogene NN O O
in NN O O
human NN O O
piebaldism NN B-SpecificDisease B-MSH:D016116
. NN O O

piebaldism NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
genetic NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
cogenital NN O O
patches NN O O
of NN O O
skin NN O O
and NN O O
hair NN O O
from NN O O
which NN O O
melanocytes NN O O
are NN O O
completely NN O O
absent. NN O O
a NN O O
similar NN O O
disorder NN O O
of NN O O
mouse, NN O O
dominant NN O O
white NN O O
spotting NN O O
(w), NN O O
results NN O O
from NN O O
mutations NN O O
of NN O O
the NN O O
c-kit NN O O
protooncogene, NN O O
which NN O O
encodes NN O O
and NN O O
receptor NN O O
for NN O O
mast/stem NN O O
cell NN O O
growth NN O O
factor. NN O O
we NN O O
identified NN O O
a NN O O
kit NN O O
gene NN O O
mutation NN O O
in NN O O
a NN O O
proband NN O O
with NN O O
classic NN O O
autosomal NN O O
dominant NN O O
piebaldism NN B-SpecificDisease B-MSH:D016116
. NN O O
this NN O O
mutation NN O O
results NN O O
in NN O O
a NN O O
gly----arg NN O O
substitution NN O O
at NN O O
codon NN O O
664, NN O O
within NN O O
the NN O O
tyrosine NN O O
kinase NN O O
domain. NN O O
this NN O O
substitution NN O O
was NN O O
not NN O O
seen NN O O
in NN O O
any NN O O
normal NN O O
individuals NN O O
and NN O O
was NN O O
completely NN O O
linked NN O O
to NN O O
the NN O O
piebald NN B-Modifier B-MSH:D016116
phenotype NN O O
in NN O O
the NN O O
probands NN O O
family. NN O O
Piebaldism NN B-SpecificDisease B-MSH:D016116
in NN O O
this NN O O
family NN O O
thus NN O O
appears NN O O
to NN O O
be NN O O
the NN O O
human NN O O
homologue NN O O
to NN O O
dominant NN O O
white NN O O
spotting NN O O
(w) NN O O
of NN O O
the NN O O
mouse. NN O O
. NN O O

an NN O O
arylsulfatase NN O O
a NN O O
(arsa) NN O O
missense NN O O
mutation NN O O
(t NN O O
274 NN O O
m) NN O O
causing NN O O
late-infantile NN B-SpecificDisease B-MSH:D007966
metachromatic NN I-SpecificDisease I-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
. NN O O

metachromatic NN O O
leukodystrophy NN O O
( NN O O
MLD NN B-SpecificDisease B-MSH:D007966
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D016464
recessive NN I-DiseaseClass I-MSH:D016464
lysosomal NN I-DiseaseClass I-MSH:D016464
storage NN I-DiseaseClass I-MSH:D016464
disorder NN I-DiseaseClass I-MSH:D016464
caused NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-MSH:D007966
of NN I-SpecificDisease I-MSH:D007966
arylsulfatase NN I-SpecificDisease I-MSH:D007966
A NN I-SpecificDisease I-MSH:D007966
(arsa; NN O O
ec NN O O
3. NN O O
1. NN O O
6. NN O O
8). NN O O
the NN O O
8 NN O O
arsa NN O O
exons NN O O
and NN O O
adjacent NN O O
intron NN O O
boundaries NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
late-infantile NN B-SpecificDisease B-MSH:D007966
metachromatic NN I-SpecificDisease I-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
were NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
amplified NN O O
in NN O O
seven NN O O
discrete NN O O
reactions. NN O O
amplified NN O O
arsa NN O O
exons NN O O
were NN O O
analysed NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
sequence NN O O
alterations NN O O
by NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
analysis, NN O O
followed NN O O
by NN O O
direct NN O O
sequencing NN O O
of NN O O
pcr NN O O
products. NN O O
the NN O O
patient NN O O
was NN O O
found NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
c-- NN O O
> NN O O
t NN O O
transition NN O O
in NN O O
exon NN O O
iv NN O O
that NN O O
results NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
a NN O O
highly NN O O
conserved NN O O
threonine NN O O
residue NN O O
at NN O O
amino NN O O
acid NN O O
274 NN O O
with NN O O
a NN O O
methionine NN O O
(t NN O O
274 NN O O
m). NN O O
analysis NN O O
of NN O O
a NN O O
further NN O O
29 NN O O
MLD NN B-Modifier B-MSH:D007966
patients NN O O
revealed NN O O
th NN O O
. NN O O

presence NN O O
of NN O O
five NN O O
additional NN O O
homozygotes NN O O
for NN O O
t NN O O
274 NN O O
m. NN O O
all NN O O
6 NN O O
t NN O O
274 NN O O
m NN O O
homozygotes NN O O
(representing NN O O
four NN O O
families) NN O O
were NN O O
of NN O O
lebanese NN O O
descent, NN O O
and NN O O
all NN O O
were NN O O
known NN O O
to NN O O
be NN O O
the NN O O
result NN O O
of NN O O
consanguineous NN O O
marriages. NN O O
the NN O O
altered NN O O
amino NN O O
acid NN O O
is NN O O
rigidly NN O O
conserved NN O O
among NN O O
10 NN O O
sulfatases NN O O
from NN O O
escherichia NN O O
coli NN O O
to NN O O
humans; NN O O
therefore, NN O O
it NN O O
is NN O O
most NN O O
likely NN O O
that NN O O
the NN O O
resultant NN O O
mutant NN O O
protein NN O O
will NN O O
have NN O O
little NN O O
or NN O O
no NN O O
enzyme NN O O
activity. NN O O
this NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
very NN O O
low NN O O
arsa NN O O
activity NN O O
measured NN O O
in NN O O
these NN O O
patients NN O O
and NN O O
their NN O O
uniformly NN O O
severe NN O O
clinical NN O O
presentatio NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
gene NN O O
for NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
in NN O O
patients NN O O
with NN O O
different NN O O
clinical NN O O
phenotypes NN O O
. NN O O

recently, NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
most NN O O
common NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
disorder NN I-DiseaseClass I-MSH:D018901
, NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
( NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
), NN O O
has NN O O
been NN O O
described NN O O
encoding NN O O
a NN O O
peroxisomal NN O O
membrane NN O O
transporter NN O O
protein. NN O O
we NN O O
analyzed NN O O
the NN O O
entire NN O O
protein-coding NN O O
sequence NN O O
of NN O O
this NN O O
gene NN O O
by NN O O
reverse-transcription NN O O
pcr, NN O O
sscp, NN O O
and NN O O
dna NN O O
sequencing NN O O
in NN O O
five NN O O
patients NN O O
with NN O O
different NN O O
clinical NN O O
expression NN O O
of NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
in NN O O
their NN O O
female NN O O
relatives; NN O O
these NN O O
clinical NN O O
expressions NN O O
were NN O O
cerebral NN O O
childhood NN O O
ALD NN B-SpecificDisease B-MSH:D000326
, NN O O
adrenomyeloneuropathy NN B-SpecificDisease B-MSH:D000326
( NN O O
AMN NN B-SpecificDisease B-MSH:D000326
), NN O O
and NN O O
" NN O O
Addison NN B-Modifier B-MSH:D000224
disease NN I-Modifier I-MSH:D000224
only NN I-Modifier I-MSH:D000224
" NN O O
( NN O O
ADO NN B-Modifier B-MSH:D000224
) NN O O
phenotype. NN O O
in NN O O
the NN O O
three NN O O
patients NN O O
exhibiting NN O O
the NN O O
classical NN O O
picture NN O O
of NN O O
severe NN O O
childhood NN O O
ALD NN B-SpecificDisease B-MSH:D000326
we NN O O
identified NN O O
in NN O O
the NN O O
5 NN O O
portion NN O O
of NN O O
the NN O O
X-ALD NN B-Modifier B-MSH:D000326
gene NN O O
a NN O O
38-bp NN O O
deletion NN O O
that NN O O
causes NN O O
a NN O O
frameshift NN O O
mutation, NN O O
a NN O O
3-bp NN O O
deletion NN O O
leading NN O O
to NN O O
a NN O O
deletion NN O O
of NN O O
a NN O O
. NN O O

amino NN O O
acid NN O O
in NN O O
the NN O O
atp-binding NN O O
domain NN O O
of NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
protein, NN O O
and NN O O
a NN O O
missense NN O O
mutation. NN O O
in NN O O
the NN O O
patient NN O O
with NN O O
the NN O O
clinical NN O O
phenotype NN O O
of NN O O
AMN NN B-SpecificDisease B-MSH:D000326
, NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
codon NN O O
212, NN O O
along NN O O
with NN O O
a NN O O
second NN O O
site NN O O
mutation NN O O
at NN O O
codon NN O O
178, NN O O
was NN O O
observed. NN O O
analysis NN O O
of NN O O
the NN O O
patient NN O O
with NN O O
the NN O O
ADO NN B-Modifier B-MSH:D000224
phenotype NN O O
revealed NN O O
a NN O O
further NN O O
missense NN O O
mutation NN O O
at NN O O
a NN O O
highly NN O O
conserved NN O O
position NN O O
in NN O O
the NN O O
aldp/pmp NN O O
70 NN O O
comparison. NN O O
the NN O O
disruptive NN O O
nature NN O O
of NN O O
two NN O O
mutations NN O O
(i. NN O O
e., NN O O
the NN O O
frameshift NN O O
and NN O O
the NN O O
nonsense NN O O
mutation) NN O O
in NN O O
patients NN O O
with NN O O
biochemically NN O O
proved NN O O
childhood NN O O
ALD NN B-SpecificDisease B-MSH:D000326
and NN O O
AMN NN B-SpecificDisease B-MSH:D000326
further NN O O
strongly NN O O
supports NN O O
the NN O O
hypothesis NN O O
that NN O O
alterations NN O O
in NN O O
this NN O O
gene NN O O
play NN O O
a NN O O
crucial NN O O
role NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
since NN O O
the NN O O
current NN O O
biochemical NN O O
techniques NN O O
for NN O O
X-ALD NN B-Modifier B-MSH:D000326
carrier NN O O
detection NN O O
in NN O O
affected NN O O
families NN O O
lack NN O O
sufficien NN O O
. NN O O

reliability, NN O O
our NN O O
procedure NN O O
described NN O O
for NN O O
systematic NN O O
mutation NN O O
scanning NN O O
is NN O O
also NN O O
capable NN O O
of NN O O
improving NN O O
genetic NN O O
counseling NN O O
and NN O O
prenatal NN O O
diagnosi NN O O
. NN O O

atelosteogenesis NN O O
type NN O O
ii NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
diastrophic NN B-Modifier B-MSH:C536170
dysplasia NN I-Modifier I-MSH:C536170
sulfate-transporter NN O O
gene NN O O
(dtdst): NN O O
evidence NN O O
for NN O O
a NN O O
phenotypic NN O O
series NN O O
involving NN O O
three NN O O
chondrodysplasias NN B-DiseaseClass B-MSH:D010009
. NN O O

atelosteogenesis NN O O
type NN O O
ii NN O O
( NN O O
AO NN B-SpecificDisease B-MSH:C535395
II NN I-SpecificDisease I-MSH:C535395
) NN O O
is NN O O
a NN O O
neonatally NN O O
lethal NN O O
chondrodysplasia NN B-DiseaseClass B-MSH:D010009
whose NN O O
clinical NN O O
and NN O O
histological NN O O
characteristics NN O O
resemble NN O O
those NN O O
of NN O O
another NN O O
chondrodysplasia NN B-DiseaseClass B-MSH:D010009
, NN O O
the NN O O
much NN O O
less NN O O
severe NN O O
diastrophic NN B-SpecificDisease B-MSH:C536170
dysplasia NN I-SpecificDisease I-MSH:C536170
( NN O O
DTD NN B-SpecificDisease B-MSH:C536170
). NN O O
the NN O O
similarity NN O O
suggests NN O O
a NN O O
shared NN O O
pathogenesis NN O O
involving NN O O
lesions NN O O
in NN O O
the NN O O
same NN O O
biochemical NN O O
pathway NN O O
and NN O O
perhaps NN O O
the NN O O
same NN O O
gene. NN O O
DTD NN B-SpecificDisease B-MSH:C536170
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
recently NN O O
identified NN O O
diastrophic NN B-Modifier B-MSH:C536170
dysplasia NN I-Modifier I-MSH:C536170
sulfate-transporter NN O O
gene NN O O
(dtdst). NN O O
here, NN O O
we NN O O
report NN O O
that NN O O
AOII NN B-Modifier B-MSH:C535395
patients NN O O
also NN O O
have NN O O
dtdst NN O O
mutations, NN O O
which NN O O
lead NN O O
to NN O O
defective NN O O
uptake NN O O
of NN O O
inorganic NN O O
sulfate NN O O
and NN O O
insufficient NN O O
sulfation NN O O
of NN O O
macromolecules NN O O
by NN O O
patient NN O O
mesenchymal NN O O
cells NN O O
in NN O O
vitro. NN O O
together NN O O
with NN O O
our NN O O
recent NN O O
observation NN O O
that NN O O
a NN O O
third NN O O
even NN O O
more NN O O
severe NN O O
chondrodysplasia NN B-DiseaseClass B-MSH:D010009
, NN O O
achondrogenesis NN O O
type NN O O
ib, NN O O
is NN O O
also NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
dtdst, NN O O
these NN O O
results NN O O
demonstrate NN O O
a NN O O
phenotypic NN O O
series NN O O
of NN O O
three NN O O
chondrodysplasias NN B-DiseaseClass B-MSH:D010009
of NN O O
increasing NN O O
severit NN O O
. NN O O

caused NN O O
by NN O O
lesions NN O O
in NN O O
a NN O O
single NN O O
sulfate-transporter NN O O
gene. NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
phenotype NN O O
appears NN O O
to NN O O
be NN O O
correlated NN O O
with NN O O
the NN O O
predicted NN O O
effect NN O O
of NN O O
the NN O O
mutations NN O O
on NN O O
the NN O O
residual NN O O
activity NN O O
of NN O O
the NN O O
dtdst NN O O
protein. NN O O
. NN O O

emerin, NN O O
deficiency NN O O
of NN O O
which NN O O
causes NN O O
Emery-Dreifuss NN B-SpecificDisease B-MSH:D020389
muscular NN I-SpecificDisease I-MSH:D020389
dystrophy NN I-SpecificDisease I-MSH:D020389
, NN O O
is NN O O
localized NN O O
at NN O O
the NN O O
inner NN O O
nuclear NN O O
membrane NN O O
. NN O O

x-linked NN O O
recessive NN O O
emery-dreifuss NN O O
muscular NN O O
dystrophy NN O O
( NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
) NN O O
is NN O O
an NN O O
inherited NN B-DiseaseClass B-MSH:D009135
muscle NN I-DiseaseClass I-MSH:D009135
disorder NN I-DiseaseClass I-MSH:D009135
characterized NN O O
by NN O O
the NN O O
clinical NN O O
triad NN O O
of NN O O
progressive NN O O
wasting NN B-SpecificDisease B-MSH:D019282
of NN I-SpecificDisease I-MSH:D019282
humero-peroneal NN I-SpecificDisease I-MSH:D019282
muscles NN I-SpecificDisease I-MSH:D019282
, NN O O
early NN O O
contractures NN B-CompositeMention B-MSH:D003286
of NN I-CompositeMention I-MSH:D003286
the NN I-CompositeMention I-MSH:D003286
elbows, NN I-CompositeMention I-MSH:D003286
Achilles NN I-CompositeMention I-MSH:D003286
tendons NN I-CompositeMention I-MSH:D003286
and NN I-CompositeMention I-MSH:D003286
postcervical NN I-CompositeMention I-MSH:D003286
muscles NN I-CompositeMention I-MSH:D003286
, NN O O
and NN O O
cardiac NN B-SpecificDisease B-MSH:D006327
conduction NN I-SpecificDisease I-MSH:D006327
block NN I-SpecificDisease I-MSH:D006327
with NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
sudden NN B-SpecificDisease B-MSH:D003645
death NN I-SpecificDisease I-MSH:D003645
. NN O O
the NN O O
gene NN O O
for NN O O
EDMD NN B-SpecificDisease B-MSH:D020389
on NN O O
xq NN O O
28 NN O O
encodes NN O O
a NN O O
novel NN O O
protein NN O O
named NN O O
emerin NN O O
that NN O O
localizes NN O O
at NN O O
the NN O O
nuclear NN O O
membrane NN O O
of NN O O
skeletal, NN O O
cardiac NN O O
and NN O O
smooth NN O O
muscles NN O O
and NN O O
some NN O O
other NN O O
non-muscle NN O O
tissues. NN O O
to NN O O
investigate NN O O
a NN O O
possible NN O O
physiological NN O O
role NN O O
for NN O O
emerin, NN O O
we NN O O
examined NN O O
the NN O O
ultrastructural NN O O
localization NN O O
of NN O O
the NN O O
protein NN O O
in NN O O
human NN O O
skeletal NN O O
muscle NN O O
and NN O O
hela NN O O
cells, NN O O
using NN O O
ultrathin NN O O
cryosections. NN O O
we NN O O
found NN O O
that NN O O
the NN O O
immune-labeled NN O O
colloidal NN O O
gold NN O O
particles NN O O
were NN O O
localized NN O O
on NN O O
the NN O O
nucleoplasmic NN O O
surface NN O O
of NN O O
the NN O O
inner NN O O
nuclear NN O O
membrane NN O O
. NN O O

but NN O O
not NN O O
on NN O O
the NN O O
nuclear NN O O
pore. NN O O
emerin NN O O
stayed NN O O
on NN O O
the NN O O
cytoplasmic NN O O
surface NN O O
of NN O O
the NN O O
nuclear NN O O
lamina, NN O O
even NN O O
after NN O O
detergent NN O O
treatment NN O O
that NN O O
solubilizes NN O O
membrane NN O O
lipids NN O O
and NN O O
washes NN O O
out NN O O
membrane NN O O
proteins. NN O O
these NN O O
results NN O O
suggest NN O O
that NN O O
emerin NN O O
anchors NN O O
at NN O O
the NN O O
inner NN O O
nuclear NN O O
membrane NN O O
through NN O O
the NN O O
hydrophobic NN O O
stretch, NN O O
and NN O O
protrudes NN O O
from NN O O
the NN O O
hydrophilic NN O O
region NN O O
to NN O O
the NN O O
nucleoplasm NN O O
where NN O O
it NN O O
interacts NN O O
with NN O O
the NN O O
nuclear NN O O
lamina. NN O O
we NN O O
speculate NN O O
that NN O O
emerin NN O O
contributes NN O O
to NN O O
maintain NN O O
the NN O O
nuclear NN O O
structure NN O O
and NN O O
stability, NN O O
as NN O O
well NN O O
as NN O O
nuclear NN O O
functions, NN O O
particularly NN O O
in NN O O
muscle NN O O
tissues NN O O
that NN O O
have NN O O
severe NN O O
stress NN O O
with NN O O
rigorous NN O O
contraction-relaxation NN O O
movements NN O O
and NN O O
calcium NN O O
flux. NN O O
. NN O O
n NN O O
to NN O O
the NN O O
nucleoplasm NN O O
where NN O O
it NN O O
interacts NN O O
with NN O O
the NN O O
nuclear NN O O
lamina. NN O O
we NN O O
speculate NN O O
that NN O O
emerin NN O O
contributes NN O O
to NN O O
maintain NN O O
the NN O O
nuclear NN O O
structure NN O O
and NN O O
stability, NN O O
as NN O O
well NN O O
as NN O O
nuclear NN O O
functions, NN O O
particularly NN O O
in NN O O
muscle NN O O
tissues NN O O
that NN O O
have NN O O
severe NN O O
stress NN O O
with NN O O
rigorous NN O O
contraction-relaxation NN O O
movements NN O O
and NN O O
calcium NN O O
flux. NN O O
. NN O O

identification NN O O
of NN O O
a NN O O
common NN O O
pex NN O O
1 NN O O
mutation NN O O
in NN O O
Zellweger NN B-SpecificDisease B-MSH:D015211
syndrome NN I-SpecificDisease I-MSH:D015211
. NN O O

the NN O O
Zellweger NN B-DiseaseClass B-MSH:D015211
spectrum NN I-DiseaseClass I-MSH:D015211
of NN I-DiseaseClass I-MSH:D015211
disease NN I-DiseaseClass I-MSH:D015211
, NN O O
encompassing NN O O
Zellweger NN B-SpecificDisease B-MSH:D015211
syndrome NN I-SpecificDisease I-MSH:D015211
and NN O O
the NN O O
progressively NN O O
milder NN O O
phenotypes NN O O
of NN O O
neonatal NN B-SpecificDisease B-OMIM:202370
adrenoleukodystrophy NN I-SpecificDisease I-OMIM:202370
and NN O O
infantile NN B-SpecificDisease B-MSH:D052919
Refsum NN I-SpecificDisease I-MSH:D052919
disease NN I-SpecificDisease I-MSH:D052919
, NN O O
is NN O O
due NN O O
to NN O O
a NN O O
failure NN O O
to NN O O
form NN O O
functional NN O O
peroxisomes. NN O O
cell NN O O
fusion NN O O
complementation NN O O
studies NN O O
demonstrated NN O O
that NN O O
these NN O O
diseases NN O O
are NN O O
genetically NN O O
heterogeneous, NN O O
with NN O O
two-thirds NN O O
of NN O O
all NN O O
patients NN O O
lying NN O O
within NN O O
a NN O O
single NN O O
complementation NN O O
group, NN O O
cg NN O O
1. NN O O
molecular NN O O
genetic NN O O
and NN O O
cell NN O O
biology NN O O
studies NN O O
have NN O O
shown NN O O
that NN O O
pex NN O O
1 NN O O
is NN O O
deficient NN O O
in NN O O
many NN O O
cg NN O O
1 NN O O
patients. NN O O
however, NN O O
previous NN O O
studies NN O O
have NN O O
focused NN O O
on NN O O
mildly NN O O
affected NN O O
patients NN O O
and NN O O
there NN O O
is NN O O
still NN O O
no NN O O
report NN O O
of NN O O
two NN O O
mutant NN O O
pex NN O O
1 NN O O
alleles NN O O
in NN O O
any NN O O
Zellweger NN B-Modifier B-MSH:D015211
syndrome NN I-Modifier I-MSH:D015211
patient. NN O O
furthermore, NN O O
mutations NN O O
in NN O O
the NN O O
pmp NN O O
70 NN O O
gene NN O O
have NN O O
also NN O O
been NN O O
identified NN O O
in NN O O
two NN O O
Zellweger NN B-Modifier B-MSH:D015211
syndrome NN I-Modifier I-MSH:D015211
patients NN O O
from NN O O
cg NN O O
1, NN O O
raising NN O O
the NN O O
possibility NN O O
that NN O O
cg NN O O
1 NN O O
patients NN O O
may NN O O
represent NN O O
a NN O O
mixtur NN O O
. NN O O

of NN O O
pex NN O O
1-deficient NN O O
and NN O O
pmp NN O O
70-deficient NN O O
individuals. NN O O
to NN O O
address NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
disease NN O O
in NN O O
Zellweger NN B-Modifier B-MSH:D015211
syndrome NN I-Modifier I-MSH:D015211
patients NN O O
from NN O O
cg NN O O
1, NN O O
we NN O O
examined NN O O
all NN O O
24 NN O O
pex NN O O
1 NN O O
exons NN O O
in NN O O
four NN O O
patients, NN O O
including NN O O
both NN O O
patients NN O O
that NN O O
have NN O O
mutations NN O O
in NN O O
pmp NN O O
70. NN O O
pex NN O O
1 NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
all NN O O
four NN O O
patients, NN O O
including NN O O
a NN O O
1-bp NN O O
insertion NN O O
(c. NN O O
2097 NN O O
inst) NN O O
in NN O O
exon NN O O
13 NN O O
that NN O O
was NN O O
present NN O O
in NN O O
three NN O O
of NN O O
the NN O O
four NN O O
patients. NN O O
subsequent NN O O
studies NN O O
demonstrated NN O O
that NN O O
this NN O O
mutation NN O O
is NN O O
present NN O O
in NN O O
one-half NN O O
of NN O O
all NN O O
cg NN O O
1 NN O O
patients NN O O
and NN O O
correlates NN O O
with NN O O
the NN O O
Zellweger NN B-Modifier B-MSH:D015211
syndrome NN I-Modifier I-MSH:D015211
phenotype. NN O O
as NN O O
this NN O O
mutation NN O O
leads NN O O
to NN O O
a NN O O
loss NN O O
of NN O O
protein NN O O
function NN O O
its NN O O
frequency NN O O
makes NN O O
it NN O O
the NN O O
most NN O O
common NN O O
cause NN O O
of NN O O
Zellweger NN B-SpecificDisease B-MSH:D015211
syndrome NN I-SpecificDisease I-MSH:D015211
, NN O O
helping NN O O
to NN O O
explain NN O O
the NN O O
high NN O O
percentage NN O O
of NN O O
patients NN O O
that NN O O
belon NN O O
. NN O O

to NN O O
cg NN O O
1 NN O O
. NN O O

polymorphisms NN O O
of NN O O
the NN O O
cyp NN O O
2 NN O O
d NN O O
6 NN O O
gene NN O O
increase NN O O
susceptibility NN O O
to NN O O
ankylosing NN B-SpecificDisease B-MSH:D013167
spondylitis NN I-SpecificDisease I-MSH:D013167
. NN O O

ankylosing NN O O
spondylitis NN O O
( NN O O
AS NN B-SpecificDisease B-MSH:D013167
) NN O O
is NN O O
a NN O O
common NN O O
and NN O O
highly NN O O
familial NN O O
rheumatic NN B-DiseaseClass B-MSH:D012216
disorder NN I-DiseaseClass I-MSH:D012216
. NN O O
the NN O O
sibling NN O O
recurrence NN O O
risk NN O O
ratio NN O O
for NN O O
the NN O O
disease NN O O
is NN O O
63 NN O O
and NN O O
heritability NN O O
assessed NN O O
in NN O O
twins NN O O
> NN O O
90%. NN O O
although NN O O
mhc NN O O
genes, NN O O
including NN O O
hla-b NN O O
27, NN O O
contribute NN O O
only NN O O
20-50% NN O O
of NN O O
the NN O O
genetic NN O O
risk NN O O
for NN O O
the NN O O
disease, NN O O
no NN O O
non-mhc NN O O
gene NN O O
has NN O O
yet NN O O
been NN O O
convincingly NN O O
demonstrated NN O O
to NN O O
influence NN O O
either NN O O
susceptibility NN O O
to NN O O
the NN O O
disease NN O O
or NN O O
its NN O O
phenotypic NN O O
expression. NN O O
previous NN O O
linkage NN O O
and NN O O
association NN O O
studies NN O O
have NN O O
suggested NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
susceptibility NN O O
gene NN O O
for NN O O
AS NN B-SpecificDisease B-MSH:D013167
close NN O O
to, NN O O
or NN O O
within, NN O O
the NN O O
cytochrome NN O O
p NN O O
450 NN O O
2 NN O O
d NN O O
6 NN O O
gene NN O O
(cyp NN O O
2 NN O O
d NN O O
6, NN O O
debrisoquine NN O O
hydroxylase) NN O O
located NN O O
at NN O O
chromosome NN O O
22 NN O O
q NN O O
13.1. NN O O
we NN O O
performed NN O O
a NN O O
linkage NN O O
study NN O O
of NN O O
chromosome NN O O
22 NN O O
in NN O O
200 NN O O
families NN O O
with NN O O
AS NN B-SpecificDisease B-MSH:D013167
affecte NN O O
. NN O O

sibling-pairs. NN O O
association NN O O
of NN O O
alleles NN O O
of NN O O
the NN O O
cyp NN O O
2 NN O O
d NN O O
6 NN O O
gene NN O O
was NN O O
examined NN O O
by NN O O
both NN O O
case-control NN O O
and NN O O
within-family NN O O
means. NN O O
for NN O O
case-control NN O O
studies, NN O O
617 NN O O
unrelated NN O O
individuals NN O O
with NN O O
AS NN B-SpecificDisease B-MSH:D013167
(361 NN O O
probands NN O O
from NN O O
sibling-pair NN O O
and NN O O
parent-case NN O O
trio NN O O
families NN O O
and NN O O
256 NN O O
unrelated NN O O
non-familial NN O O
sporadic NN O O
cases) NN O O
and NN O O
402 NN O O
healthy NN O O
ethnically NN O O
matched NN O O
controls NN O O
were NN O O
employed. NN O O
for NN O O
within-family NN O O
association NN O O
studies, NN O O
361 NN O O
families NN O O
including NN O O
161 NN O O
parent-case NN O O
trios NN O O
and NN O O
200 NN O O
affected NN O O
sibling-pair NN O O
families NN O O
were NN O O
employed. NN O O
homozygosity NN O O
for NN O O
poor NN O O
metabolizer NN O O
alleles NN O O
was NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
AS NN B-SpecificDisease B-MSH:D013167
. NN O O
heterozygosity NN O O
for NN O O
the NN O O
most NN O O
frequent NN O O
poor NN O O
metabolizer NN O O
allele NN O O
(cyp NN O O
2 NN O O
d NN O O
6*4) NN O O
was NN O O
not NN O O
associated NN O O
with NN O O
increased NN O O
susceptibility NN O O
to NN O O
AS NN B-SpecificDisease B-MSH:D013167
. NN O O
significant NN O O
within-family NN O O
association NN O O
of NN O O
cyp NN O O
2 NN O O
d NN O O
6* NN O O
. NN O O

alleles NN O O
and NN O O
AS NN B-SpecificDisease B-MSH:D013167
was NN O O
demonstrated. NN O O
weak NN O O
linkage NN O O
was NN O O
also NN O O
demonstrated NN O O
between NN O O
cyp NN O O
2 NN O O
d NN O O
6 NN O O
and NN O O
AS NN B-SpecificDisease B-MSH:D013167
. NN O O
we NN O O
postulate NN O O
that NN O O
altered NN O O
metabolism NN O O
of NN O O
a NN O O
natural NN O O
toxin NN O O
or NN O O
antigen NN O O
by NN O O
the NN O O
cyp NN O O
2 NN O O
d NN O O
6 NN O O
gene NN O O
may NN O O
increase NN O O
susceptibility NN O O
to NN O O
AS NN B-SpecificDisease B-MSH:D013167
. NN O O

molecular NN O O
analysis NN O O
of NN O O
the NN O O
genotype-phenotype NN O O
relationship NN O O
in NN O O
factor NN B-SpecificDisease B-MSH:D005171
X NN I-SpecificDisease I-MSH:D005171
deficiency NN I-SpecificDisease I-MSH:D005171
. NN O O

factor NN O O
x NN O O
deficiency NN O O
is NN O O
a NN O O
rare NN O O
haemorrhagic NN B-DiseaseClass B-MSH:D006474
condition NN I-DiseaseClass I-MSH:D006474
, NN O O
normally NN O O
inherited NN O O
as NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait, NN O O
in NN O O
which NN O O
a NN O O
variable NN O O
clinical NN O O
presentation NN O O
correlates NN O O
poorly NN O O
with NN O O
laboratory NN O O
phenotype. NN O O
the NN O O
factor NN O O
x NN O O
(f NN O O
10) NN O O
genes NN O O
of NN O O
14 NN O O
unrelated NN O O
individuals NN O O
with NN O O
factor NN B-SpecificDisease B-MSH:D005171
X NN I-SpecificDisease I-MSH:D005171
deficiency NN I-SpecificDisease I-MSH:D005171
(12 NN O O
familial NN O O
and NN O O
two NN O O
sporadic NN O O
cases) NN O O
were NN O O
sequenced NN O O
yielding NN O O
a NN O O
total NN O O
of NN O O
13 NN O O
novel NN O O
mutations. NN O O
family NN O O
studies NN O O
were NN O O
performed NN O O
in NN O O
order NN O O
to NN O O
distinguish NN O O
the NN O O
contributions NN O O
of NN O O
individual NN O O
mutant NN O O
f NN O O
10 NN O O
alleles NN O O
to NN O O
the NN O O
clinical NN O O
and NN O O
laboratory NN O O
phenotypes. NN O O
missense NN O O
mutations NN O O
were NN O O
studied NN O O
by NN O O
means NN O O
of NN O O
molecular NN O O
modelling, NN O O
whereas NN O O
single NN O O
basepair NN O O
substitutions NN O O
in NN O O
splice NN O O
sites NN O O
and NN O O
the NN O O
5 NN O O
flanking NN O O
region NN O O
were NN O O
examined NN O O
by NN O O
in NN O O
vitro NN O O
splicing NN O O
assay NN O O
and NN O O
luciferase NN O O
reporter NN O O
gene NN O O
assay NN O O
respectively. NN O O
the NN O O
deletion NN O O
allele NN O O
of NN O O
a NN O O
novel NN O O
hexanucleotide NN O O
insertion/deletion NN O O
polymorphism NN O O
in NN O O
the NN O O
f NN O O
10 NN O O
gene NN O O
promoter NN O O
regio NN O O
. NN O O

was NN O O
shown NN O O
by NN O O
reporter NN O O
gene NN O O
assay, NN O O
to NN O O
reduce NN O O
promoter NN O O
activity NN O O
by NN O O
approximately NN O O
20%. NN O O
one NN O O
family NN O O
manifesting NN O O
an NN O O
autosomal NN O O
dominant NN O O
pattern NN O O
of NN O O
inheritance NN O O
possessed NN O O
three NN O O
clinically NN O O
affected NN O O
members NN O O
who NN O O
were NN O O
heterozygous NN O O
for NN O O
a NN O O
splice-site NN O O
mutation NN O O
that NN O O
was NN O O
predicted NN O O
to NN O O
lead NN O O
to NN O O
the NN O O
production NN O O
of NN O O
a NN O O
truncated NN O O
protein NN O O
product. NN O O
a NN O O
model NN O O
which NN O O
accounts NN O O
for NN O O
the NN O O
dominant NN O O
negative NN O O
effect NN O O
of NN O O
this NN O O
lesion NN O O
is NN O O
presented. NN O O
variation NN O O
in NN O O
the NN O O
antigen NN O O
level NN O O
of NN O O
heterozygous NN O O
relatives NN O O
of NN O O
probands NN O O
was NN O O
found NN O O
to NN O O
be NN O O
significantly NN O O
higher NN O O
between NN O O
families NN O O
than NN O O
within NN O O
families, NN O O
consistent NN O O
with NN O O
the NN O O
view NN O O
that NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
f NN O O
10 NN O O
lesion NN O O
(s) NN O O
segregating NN O O
in NN O O
a NN O O
given NN O O
family NN O O
is NN O O
a NN O O
prime NN O O
determinant NN O O
of NN O O
the NN O O
laboratory NN O O
phenotype. NN O O
by NN O O
contrast, NN O O
no NN O O
such NN O O
relationship NN O O
could NN O O
be NN O O
discerned NN O O
between NN O O
laboratory NN O O
phenotype NN O O
and NN O O
polymorphism NN O O
genotype. NN O O
. NN O O
to NN O O
the NN O O
production NN O O
of NN O O
a NN O O
truncated NN O O
protein NN O O
product. NN O O
a NN O O
model NN O O
which NN O O
accounts NN O O
for NN O O
the NN O O
dominant NN O O
negative NN O O
effect NN O O
of NN O O
this NN O O
lesion NN O O
is NN O O
presented. NN O O
variation NN O O
in NN O O
the NN O O
antigen NN O O
level NN O O
of NN O O
heterozygous NN O O
relatives NN O O
of NN O O
probands NN O O
was NN O O
found NN O O
to NN O O
be NN O O
significantly NN O O
higher NN O O
between NN O O
families NN O O
than NN O O
within NN O O
families, NN O O
consistent NN O O
with NN O O
the NN O O
view NN O O
that NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
f NN O O
10 NN O O
lesion NN O O
(s) NN O O
segregating NN O O
in NN O O
a NN O O
given NN O O
family NN O O
is NN O O
a NN O O
prime NN O O
determinant NN O O
of NN O O
the NN O O
laboratory NN O O
phenotype. NN O O
by NN O O
contrast, NN O O
no NN O O
such NN O O
relationship NN O O
could NN O O
be NN O O
discerned NN O O
between NN O O
laboratory NN O O
phenotype NN O O
and NN O O
polymorphism NN O O
genotype. NN O O
. NN O O

restoration NN O O
of NN O O
photoreceptor NN O O
ultrastructure NN O O
and NN O O
function NN O O
in NN O O
retinal NN B-Modifier B-MSH:D012162
degeneration NN I-Modifier I-MSH:D012162
slow NN O O
mice NN O O
by NN O O
gene NN O O
therapy NN O O
. NN O O

the NN O O
gene NN O O
prph NN O O
2 NN O O
encodes NN O O
a NN O O
photoreceptor-specific NN O O
membrane NN O O
glycoprotein, NN O O
peripherin-2 NN O O
(also NN O O
known NN O O
as NN O O
peripherin/rds), NN O O
which NN O O
is NN O O
inserted NN O O
into NN O O
the NN O O
rims NN O O
of NN O O
photoreceptor NN O O
outer NN O O
segment NN O O
discs NN O O
in NN O O
a NN O O
complex NN O O
with NN O O
rom-1 NN O O
(ref. NN O O
2). NN O O
the NN O O
complex NN O O
is NN O O
necessary NN O O
for NN O O
the NN O O
stabilization NN O O
of NN O O
the NN O O
discs, NN O O
which NN O O
are NN O O
renewed NN O O
constantly NN O O
throughout NN O O
life, NN O O
and NN O O
which NN O O
contain NN O O
the NN O O
visual NN O O
pigments NN O O
necessary NN O O
for NN O O
photon NN O O
capture. NN O O
mutations NN O O
in NN O O
prph NN O O
2 NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
result NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
photoreceptor NN B-DiseaseClass B-MSH:D058499
dystrophies NN I-DiseaseClass I-MSH:D058499
, NN O O
including NN O O
autosomal NN B-SpecificDisease B-MSH:D012174
dominant NN I-SpecificDisease I-MSH:D012174
retinitis NN I-SpecificDisease I-MSH:D012174
pigmentosa NN I-SpecificDisease I-MSH:D012174
and NN O O
macular NN B-SpecificDisease B-MSH:D008268
dystrophy NN I-SpecificDisease I-MSH:D008268
. NN O O
a NN O O
common NN O O
feature NN O O
of NN O O
these NN O O
diseases NN O O
is NN O O
the NN O O
loss NN O O
of NN O O
photoreceptor NN O O
function, NN O O
also NN O O
seen NN O O
in NN O O
the NN O O
retinal NN B-Modifier B-MSH:D012162
degeneration NN I-Modifier I-MSH:D012162
slow NN O O
(rds NN O O
or NN O O
prph NN O O
2 NN O O
rd NN O O
2/rd NN O O
2) NN O O
mouse, NN O O
which NN O O
is NN O O
homozygous NN O O
for NN O O
. NN O O

null NN O O
mutation NN O O
in NN O O
prph NN O O
2. NN O O
it NN O O
is NN O O
characterized NN O O
by NN O O
a NN O O
complete NN O O
failure NN O O
to NN O O
develop NN O O
photoreceptor NN O O
discs NN O O
and NN O O
outer NN O O
segments, NN O O
downregulation NN O O
of NN O O
rhodopsin NN O O
and NN O O
apoptotic NN O O
loss NN O O
of NN O O
photoreceptor NN O O
cells. NN O O
the NN O O
electroretinograms NN O O
(ergs) NN O O
of NN O O
prph NN O O
2 NN O O
rd NN O O
2/rd NN O O
2 NN O O
mice NN O O
have NN O O
greatly NN O O
diminished NN O O
a-wave NN O O
and NN O O
b-wave NN O O
amplitudes, NN O O
which NN O O
decline NN O O
to NN O O
virtually NN O O
undetectable NN O O
concentrations NN O O
by NN O O
two NN O O
months. NN O O
subretinal NN O O
injection NN O O
of NN O O
recombinant NN O O
adeno-associated NN O O
virus NN O O
(aav) NN O O
encoding NN O O
a NN O O
prph NN O O
2 NN O O
transgene NN O O
results NN O O
in NN O O
stable NN O O
generation NN O O
of NN O O
outer NN O O
segment NN O O
structures NN O O
and NN O O
formation NN O O
of NN O O
new NN O O
stacks NN O O
of NN O O
discs NN O O
containing NN O O
both NN O O
perpherin-2 NN O O
and NN O O
rhodopsin, NN O O
which NN O O
in NN O O
many NN O O
cases NN O O
are NN O O
morphologically NN O O
similar NN O O
to NN O O
normal NN O O
outer NN O O
segments. NN O O
moreover, NN O O
the NN O O
re-establishment NN O O
of NN O O
the NN O O
structural NN O O
integrity NN O O
of NN O O
the NN O O
photoreceptor NN O O
layer NN O O
also NN O O
results NN O O
in NN O O
electrophysiological NN O O
correction. NN O O
these NN O O
studie NN O O
. NN O O
ts. NN O O
moreover, NN O O
the NN O O
re-establishment NN O O
of NN O O
the NN O O
structural NN O O
integrity NN O O
of NN O O
the NN O O
photoreceptor NN O O
layer NN O O
also NN O O
results NN O O
in NN O O
electrophysiological NN O O
correction. NN O O
these NN O O
studie NN O O
. NN O O

demonstrate NN O O
for NN O O
the NN O O
first NN O O
time NN O O
that NN O O
a NN O O
complex NN O O
ultrastructural NN O O
cell NN O O
defect NN O O
can NN O O
be NN O O
corrected NN O O
both NN O O
morphologically NN O O
and NN O O
functionally NN O O
by NN O O
in NN O O
vivo NN O O
gene NN O O
transfer. NN O O
. NN O O

phenylalanine NN O O
hydroxylase NN O O
gene NN O O
haplotypes NN O O
in NN O O
polynesians: NN O O
evolutionary NN O O
origins NN O O
and NN O O
absence NN O O
of NN O O
alleles NN O O
associated NN O O
with NN O O
severe NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
. NN O O

a NN O O
total NN O O
of NN O O
630 NN O O
haplotypes NN O O
for NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
gene NN O O
locus NN O O
were NN O O
established NN O O
in NN O O
five NN O O
groups NN O O
of NN O O
polynesians NN O O
comprising NN O O
samoans, NN O O
tongans, NN O O
cook NN O O
islanders, NN O O
maori, NN O O
and NN O O
niueans. NN O O
considerable NN O O
genetic NN O O
continuity NN O O
was NN O O
demonstrated NN O O
between NN O O
these NN O O
widely NN O O
dispersed NN O O
populations, NN O O
since NN O O
three NN O O
common NN O O
haplotypes NN O O
(4, NN O O
1, NN O O
and NN O O
7) NN O O
constituted NN O O
over NN O O
95% NN O O
of NN O O
alleles. NN O O
a NN O O
control NN O O
group NN O O
of NN O O
individuals NN O O
from NN O O
southeast NN O O
asia NN O O
shared NN O O
the NN O O
same NN O O
major NN O O
haplotypes, NN O O
4, NN O O
1, NN O O
and NN O O
7, NN O O
with NN O O
polynesians. NN O O
these NN O O
data NN O O
provide NN O O
further NN O O
support NN O O
for NN O O
the NN O O
theories NN O O
of NN O O
genetic NN O O
homogeneity NN O O
and NN O O
of NN O O
asian NN O O
affinities NN O O
of NN O O
the NN O O
polynesian NN O O
precursor NN O O
populations. NN O O
the NN O O
absence NN O O
of NN O O
severe NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
) NN O O
in NN O O
both NN O O
polynesians NN O O
and NN O O
southeast NN O O
asians NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
lack NN O O
of NN O O
pah NN O O
haplotypes NN O O
2 NN O O
and NN O O
3, NN O O
on NN O O
which NN O O
the NN O O
severe NN O O
PKU NN B-Modifier B-MSH:D010661
. NN O O

mutants NN O O
have NN O O
arisen NN O O
among NN O O
caucasians. NN O O
. NN O O

cdna NN O O
microarrays NN O O
detect NN O O
activation NN O O
of NN O O
a NN O O
myogenic NN O O
transcription NN O O
program NN O O
by NN O O
the NN O O
pax NN O O
3-fkhr NN O O
fusion NN O O
oncogene NN O O
. NN O O

alveolar NN O O
rhabdomyosarcoma NN O O
is NN O O
an NN O O
aggressive NN O O
pediatric NN B-SpecificDisease B-MSH:D019042
cancer NN I-SpecificDisease I-MSH:D019042
of NN I-SpecificDisease I-MSH:D019042
striated NN I-SpecificDisease I-MSH:D019042
muscle NN I-SpecificDisease I-MSH:D019042
characterized NN O O
in NN O O
60% NN O O
of NN O O
cases NN O O
by NN O O
a NN O O
t NN O O
(2; NN O O
13) NN O O
(q NN O O
35; NN O O
q NN O O
14). NN O O
this NN O O
results NN O O
in NN O O
the NN O O
fusion NN O O
of NN O O
pax NN O O
3, NN O O
a NN O O
developmental NN O O
transcription NN O O
factor NN O O
required NN O O
for NN O O
limb NN O O
myogenesis, NN O O
with NN O O
fkhr, NN O O
a NN O O
member NN O O
of NN O O
the NN O O
forkhead NN O O
family NN O O
of NN O O
transcription NN O O
factors. NN O O
the NN O O
resultant NN O O
pax NN O O
3-fkhr NN O O
gene NN O O
possesses NN O O
transforming NN O O
properties; NN O O
however, NN O O
the NN O O
effects NN O O
of NN O O
this NN O O
chimeric NN O O
oncogene NN O O
on NN O O
gene NN O O
expression NN O O
are NN O O
largely NN O O
unknown. NN O O
to NN O O
investigate NN O O
the NN O O
actions NN O O
of NN O O
these NN O O
transcription NN O O
factors, NN O O
both NN O O
pax NN O O
3 NN O O
and NN O O
pax NN O O
3-fkhr NN O O
were NN O O
introduced NN O O
into NN O O
nih NN O O
3 NN O O
t NN O O
3 NN O O
cells, NN O O
and NN O O
the NN O O
resultant NN O O
gene NN O O
expression NN O O
changes NN O O
were NN O O
analyzed NN O O
with NN O O
a NN O O
murine NN O O
cdna NN O O
microarray NN O O
containing NN O O
2, NN O O
225 NN O O
elements. NN O O
we NN O O
found NN O O
that NN O O
pax NN O O
3 NN O O
. NN O O

fkhr NN O O
but NN O O
not NN O O
pax NN O O
3 NN O O
activated NN O O
a NN O O
myogenic NN O O
transcription NN O O
program NN O O
including NN O O
the NN O O
induction NN O O
of NN O O
transcription NN O O
factors NN O O
myod, NN O O
myogenin, NN O O
six NN O O
1, NN O O
and NN O O
slug NN O O
as NN O O
well NN O O
as NN O O
a NN O O
battery NN O O
of NN O O
genes NN O O
involved NN O O
in NN O O
several NN O O
aspects NN O O
of NN O O
muscle NN O O
function. NN O O
notable NN O O
among NN O O
this NN O O
group NN O O
were NN O O
the NN O O
growth NN O O
factor NN O O
gene NN O O
igf NN O O
2 NN O O
and NN O O
its NN O O
binding NN O O
protein NN O O
igfbp NN O O
5. NN O O
relevance NN O O
of NN O O
this NN O O
model NN O O
was NN O O
suggested NN O O
by NN O O
verification NN O O
that NN O O
three NN O O
of NN O O
these NN O O
genes NN O O
(igfbp NN O O
5, NN O O
hsix NN O O
1, NN O O
and NN O O
slug) NN O O
were NN O O
also NN O O
expressed NN O O
in NN O O
alveolar NN B-Modifier B-MSH:D018232
rhabdomyosarcoma NN I-Modifier I-MSH:D018232
cell NN O O
lines. NN O O
this NN O O
study NN O O
utilizes NN O O
cdna NN O O
microarrays NN O O
to NN O O
elucidate NN O O
the NN O O
pattern NN O O
of NN O O
gene NN O O
expression NN O O
induced NN O O
by NN O O
an NN O O
oncogenic NN O O
transcription NN O O
factor NN O O
and NN O O
demonstrates NN O O
the NN O O
profound NN O O
myogenic NN O O
properties NN O O
of NN O O
pax NN O O
3-fkhr NN O O
in NN O O
nih NN O O
3 NN O O
t NN O O
3 NN O O
cells. NN O O
. NN O O

re-evaluation NN O O
of NN O O
the NN O O
sublocalization NN O O
of NN O O
esterase NN O O
d NN O O
and NN O O
its NN O O
relation NN O O
to NN O O
the NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
locus NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

in NN O O
situ NN O O
hybridization NN O O
of NN O O
a NN O O
cdna NN O O
probe NN O O
for NN O O
the NN O O
esterase NN O O
d NN O O
gene NN O O
(esd) NN O O
was NN O O
carried NN O O
out NN O O
on NN O O
human NN O O
chromosomes. NN O O
the NN O O
probe NN O O
hybridized NN O O
most NN O O
strongly NN O O
to NN O O
13 NN O O
q NN O O
14. NN O O
2 NN O O
and NN O O
13 NN O O
q NN O O
14. NN O O
3. NN O O
this NN O O
observation NN O O
raises NN O O
doubts NN O O
concerning NN O O
the NN O O
most NN O O
recently NN O O
published NN O O
assignment NN O O
of NN O O
esd NN O O
to NN O O
13 NN O O
q NN O O
14. NN O O
1. NN O O
a NN O O
deletion NN O O
in NN O O
an NN O O
individual NN O O
with NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
was NN O O
reported NN O O
to NN O O
separate NN O O
the NN O O
closely NN O O
linked NN O O
esd NN O O
and NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
(rb NN O O
1) NN O O
loci, NN O O
placing NN O O
esd NN O O
proximal NN O O
to NN O O
rb NN O O
1. NN O O
quantitative NN O O
in NN O O
situ NN O O
hybridization NN O O
studies NN O O
of NN O O
this NN O O
deletion NN O O
do NN O O
not NN O O
confirm NN O O
this NN O O
interpretation. NN O O
rather, NN O O
they NN O O
suggest NN O O
that NN O O
esd NN O O
is NN O O
missing NN O O
from NN O O
the NN O O
deleted NN O O
chromosome NN O O
13 NN O O
and NN O O
duplicated NN O O
on NN O O
the NN O O
normal NN O O
homolog. NN O O
from NN O O
these NN O O
findings, NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
deletion NN O O
in NN O O
this NN O O
individual NN O O
cannot NN O O
be NN O O
used NN O O
to NN O O
determin NN O O
. NN O O

the NN O O
orientation NN O O
nor NN O O
the NN O O
sublocalization NN O O
of NN O O
esd NN O O
and NN O O
rb NN O O
1 NN O O
within NN O O
the NN O O
13 NN O O
q NN O O
14 NN O O
region NN O O
. NN O O

the NN O O
dna NN O O
double-strand NN O O
break NN O O
repair NN O O
gene NN O O
hmre NN O O
11 NN O O
is NN O O
mutated NN O O
in NN O O
individuals NN O O
with NN O O
an NN O O
ataxia-telangiectasia-like NN B-SpecificDisease B-OMIM:604391
disorder NN I-SpecificDisease I-OMIM:604391
. NN O O

we NN O O
show NN O O
that NN O O
hypomorphic NN O O
mutations NN O O
in NN O O
hmre NN O O
11, NN O O
but NN O O
not NN O O
in NN O O
atm, NN O O
are NN O O
present NN O O
in NN O O
certain NN O O
individuals NN O O
with NN O O
an NN O O
ataxia-telangiectasia-like NN B-SpecificDisease B-OMIM:604391
disorder NN I-SpecificDisease I-OMIM:604391
( NN O O
ATLD NN B-SpecificDisease B-OMIM:604391
). NN O O
the NN O O
cellular NN O O
features NN O O
resulting NN O O
from NN O O
these NN O O
hmre NN O O
11 NN O O
mutations NN O O
are NN O O
similar NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
A-T NN B-SpecificDisease B-MSH:D001260
as NN O O
well NN O O
as NN O O
NBS NN B-SpecificDisease B-MSH:D049932
and NN O O
include NN O O
hypersensitivity NN B-SpecificDisease B-MSH:D004194
to NN I-SpecificDisease I-MSH:D004194
ionizing NN I-SpecificDisease I-MSH:D004194
radiation NN I-SpecificDisease I-MSH:D004194
, NN O O
radioresistant NN O O
dna NN O O
synthesis, NN O O
and NN O O
abrogation NN O O
of NN O O
atm-dependent NN O O
events, NN O O
such NN O O
as NN O O
the NN O O
activation NN O O
of NN O O
jun NN O O
kinase NN O O
following NN O O
exposure NN O O
to NN O O
gamma NN O O
irradiation. NN O O
although NN O O
the NN O O
mutant NN O O
hmre NN O O
11 NN O O
proteins NN O O
retain NN O O
some NN O O
ability NN O O
to NN O O
interact NN O O
with NN O O
hrad NN O O
50 NN O O
and NN O O
nbs NN O O
1, NN O O
formation NN O O
of NN O O
ionizing NN O O
radiation-induced NN O O
hmre NN O O
11 NN O O
and NN O O
nbs NN O O
1 NN O O
foci NN O O
was NN O O
absent NN O O
in NN O O
hmre NN O O
11 NN O O
mutant NN O O
cells. NN O O
these NN O O
data NN O O
demonstrate NN O O
that NN O O
atm NN O O
and NN O O
the NN O O
hmre NN O O
11/hrad NN O O
50/nbs NN O O
1 NN O O
protein NN O O
comple NN O O
. NN O O

act NN O O
in NN O O
the NN O O
same NN O O
dna NN O O
damage NN O O
response NN O O
pathway NN O O
and NN O O
link NN O O
hmre NN O O
11 NN O O
to NN O O
the NN O O
complex NN O O
pathology NN O O
of NN O O
A-T NN B-SpecificDisease B-MSH:D001260
. NN O O
. NN O O

duchenne NN O O
muscular NN O O
dystrophy NN O O
gene NN O O
expression NN O O
in NN O O
normal NN O O
and NN O O
diseased NN O O
human NN O O
muscle NN O O
. NN O O

a NN O O
probe NN O O
for NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
gene NN O O
was NN O O
used NN O O
to NN O O
study NN O O
expression NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
normal NN O O
human NN O O
muscle, NN O O
myogenic NN O O
cell NN O O
cultures, NN O O
and NN O O
muscle NN O O
from NN O O
patients NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
expression NN O O
was NN O O
found NN O O
in NN O O
rna NN O O
from NN O O
normal NN O O
fetal NN O O
muscle, NN O O
adult NN O O
cardiac NN O O
and NN O O
skeletal NN O O
muscle, NN O O
and NN O O
cultured NN O O
muscle NN O O
after NN O O
myoblast NN O O
fusion. NN O O
in NN O O
DMD NN B-Modifier B-MSH:D020388
muscle, NN O O
expression NN O O
of NN O O
this NN O O
portion NN O O
of NN O O
the NN O O
gene NN O O
was NN O O
also NN O O
revealed NN O O
by NN O O
in NN O O
situ NN O O
rna NN O O
hybridization, NN O O
particularly NN O O
in NN O O
regenerating NN O O
muscle NN O O
fibers. NN O O
. NN O O

localisation NN O O
of NN O O
the NN O O
Becker NN B-Modifier B-MSH:C537666
muscular NN I-Modifier I-MSH:C537666
dystrophy NN I-Modifier I-MSH:C537666
gene NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome NN O O
by NN O O
linkage NN O O
to NN O O
cloned NN O O
dna NN O O
sequences NN O O
. NN O O

a NN O O
linkage NN O O
study NN O O
in NN O O
30 NN O O
Becker NN B-SpecificDisease B-MSH:C537666
muscular NN I-SpecificDisease I-MSH:C537666
dystrophy NN I-SpecificDisease I-MSH:C537666
( NN O O
BMD NN B-SpecificDisease B-MSH:C537666
) NN O O
kindreds NN O O
using NN O O
three NN O O
cloned NN O O
dna NN O O
sequences NN O O
from NN O O
the NN O O
x NN O O
chromosome NN O O
which NN O O
demonstrate NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
(rflps), NN O O
suggests NN O O
that NN O O
the NN O O
BMD NN B-Modifier B-MSH:C537666
gene NN O O
is NN O O
located NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome, NN O O
in NN O O
the NN O O
p NN O O
21 NN O O
region. NN O O
the NN O O
genes NN O O
for NN O O
Becker NN B-CompositeMention B-MSH:D020388
and NN I-CompositeMention I-MSH:D020388
Duchenne NN I-CompositeMention I-MSH:D020388
dystrophies NN I-CompositeMention I-MSH:D020388
must NN O O
therefore NN O O
be NN O O
closely NN O O
linked, NN O O
if NN O O
not NN O O
allelic, NN O O
and NN O O
any NN O O
future NN O O
dna NN O O
probes NN O O
found NN O O
to NN O O
be NN O O
of NN O O
practical NN O O
use NN O O
in NN O O
one NN O O
disorder NN O O
should NN O O
be NN O O
equally NN O O
applicable NN O O
to NN O O
the NN O O
other. NN O O
the NN O O
linkage NN O O
analysis NN O O
also NN O O
provides NN O O
data NN O O
on NN O O
the NN O O
frequency NN O O
of NN O O
recombination NN O O
along NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome, NN O O
and NN O O
across NN O O
the NN O O
centromeric NN O O
region. NN O O
. NN O O

age NN O O
of NN O O
the NN O O
intronic NN O O
gaa NN O O
triplet NN O O
repeat NN O O
expansion NN O O
mutation NN O O
in NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
. NN O O

friedreich NN O O
ataxia NN O O
( NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
), NN O O
the NN O O
most NN O O
frequently NN O O
inherited NN B-DiseaseClass B-MSH:D013132
ataxia NN I-DiseaseClass I-MSH:D013132
, NN O O
is NN O O
due NN O O
in NN O O
the NN O O
vast NN O O
majority NN O O
of NN O O
cases NN O O
to NN O O
a NN O O
large NN O O
expansion NN O O
of NN O O
an NN O O
intronic NN O O
gaa NN O O
repeat. NN O O
using NN O O
linkage NN O O
disequilibrium NN O O
analysis NN O O
based NN O O
on NN O O
haplotype NN O O
data NN O O
of NN O O
seven NN O O
polymorphic NN O O
markers NN O O
close NN O O
to NN O O
the NN O O
frataxin NN O O
gene, NN O O
the NN O O
age NN O O
of NN O O
FRDA NN B-Modifier B-MSH:D005621
founding NN O O
mutational NN O O
event NN O O
(s) NN O O
is NN O O
estimated NN O O
to NN O O
be NN O O
at NN O O
least NN O O
682 NN O O
+/-203 NN O O
generations NN O O
(95% NN O O
confidence NN O O
interval NN O O
564-801 NN O O
g), NN O O
a NN O O
dating NN O O
which NN O O
is NN O O
consistent NN O O
with NN O O
little NN O O
or NN O O
no NN O O
negative NN O O
selection NN O O
and NN O O
provides NN O O
further NN O O
evidence NN O O
for NN O O
an NN O O
ancient NN O O
spread NN O O
of NN O O
a NN O O
pre-mutation NN O O
(at-risk NN O O
alleles) NN O O
in NN O O
western NN O O
europe. NN O O
. NN O O

the NN O O
human NN O O
magel NN O O
2 NN O O
gene NN O O
and NN O O
its NN O O
mouse NN O O
homologue NN O O
are NN O O
paternally NN O O
expressed NN O O
and NN O O
mapped NN O O
to NN O O
the NN O O
Prader-Willi NN B-Modifier B-MSH:D011218
region NN O O
. NN O O

prader-willi NN O O
syndrome NN O O
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
is NN O O
a NN O O
complex NN O O
neurogenetic NN B-DiseaseClass B-MSH:D020271
disorder NN I-DiseaseClass I-MSH:D020271
. NN O O
the NN O O
phenotype NN O O
is NN O O
likely NN O O
to NN O O
be NN O O
a NN O O
contiguous NN B-DiseaseClass B-MSH:D025063
gene NN I-DiseaseClass I-MSH:D025063
syndrome NN I-DiseaseClass I-MSH:D025063
involving NN O O
genes NN O O
which NN O O
are NN O O
paternally NN O O
expressed NN O O
only, NN O O
located NN O O
in NN O O
the NN O O
human NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
region. NN O O
four NN O O
mouse NN O O
models NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
have NN O O
been NN O O
reported NN O O
but NN O O
these NN O O
do NN O O
not NN O O
definitively NN O O
allow NN O O
the NN O O
delineation NN O O
of NN O O
the NN O O
critical NN O O
region NN O O
and NN O O
the NN O O
associated NN O O
genes NN O O
involved NN O O
in NN O O
the NN O O
aetiology NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
moreover, NN O O
targeted NN O O
mutagenesis NN O O
of NN O O
mouse NN O O
homologues NN O O
of NN O O
the NN O O
human NN O O
candidate NN O O
PWS NN B-Modifier B-MSH:D011218
genes NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
result NN O O
in NN O O
any NN O O
of NN O O
the NN O O
features NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
therefore, NN O O
the NN O O
isolation NN O O
of NN O O
new NN O O
genes NN O O
in NN O O
this NN O O
region NN O O
remains NN O O
crucial NN O O
for NN O O
a NN O O
better NN O O
understanding NN O O
of NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
in NN O O
this NN O O
manuscript, NN O O
we NN O O
report NN O O
the NN O O
characterization NN O O
of NN O O
magel NN O O
2 NN O O
and NN O O
its NN O O
mouse NN O O
homologue NN O O
magel NN O O
. NN O O

. NN O O
these NN O O
are NN O O
located NN O O
in NN O O
the NN O O
human NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
and NN O O
mouse NN O O
7 NN O O
c NN O O
regions, NN O O
in NN O O
close NN O O
proximity NN O O
to NN O O
ndn/ndn. NN O O
by NN O O
northern NN O O
blot NN O O
analysis NN O O
we NN O O
did NN O O
not NN O O
detect NN O O
any NN O O
expression NN O O
of NN O O
magel NN O O
2/magel NN O O
2 NN O O
but NN O O
by NN O O
rt-pcr NN O O
analysis, NN O O
specific NN O O
expression NN O O
was NN O O
detected NN O O
in NN O O
fetal NN O O
and NN O O
adult NN O O
brain NN O O
and NN O O
in NN O O
placenta. NN O O
both NN O O
genes NN O O
are NN O O
intronless NN O O
with NN O O
tandem NN O O
direct NN O O
repeat NN O O
sequences NN O O
contained NN O O
within NN O O
a NN O O
cpg NN O O
island NN O O
in NN O O
the NN O O
5-untranscribed NN O O
region. NN O O
the NN O O
transcripts NN O O
encode NN O O
putative NN O O
proteins NN O O
that NN O O
are NN O O
homologous NN O O
to NN O O
the NN O O
mage NN O O
proteins NN O O
and NN O O
ndn. NN O O
moreover, NN O O
magel NN O O
2/magel NN O O
2 NN O O
are NN O O
expressed NN O O
only NN O O
from NN O O
the NN O O
paternal NN O O
allele NN O O
in NN O O
brain, NN O O
suggesting NN O O
a NN O O
potential NN O O
role NN O O
in NN O O
the NN O O
aetiology NN O O
of NN O O
PWS NN B-SpecificDisease B-MSH:D011218
and NN O O
its NN O O
mouse NN O O
model, NN O O
respectively. NN O O
. NN O O

multiple NN O O
origins NN O O
for NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
in NN O O
europe NN O O
. NN O O

phenylketonuria NN O O
( NN O O
PKU NN B-SpecificDisease B-MSH:D010661
), NN O O
a NN O O
disorder NN B-DiseaseClass B-MSH:D000592
of NN I-DiseaseClass I-MSH:D000592
amino NN I-DiseaseClass I-MSH:D000592
acid NN I-DiseaseClass I-MSH:D000592
metabolism NN I-DiseaseClass I-MSH:D000592
prevalent NN O O
among NN O O
caucasians NN O O
and NN O O
other NN O O
ethnic NN O O
groups, NN O O
is NN O O
caused NN O O
primarily NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease B-OMIM:261600
of NN I-SpecificDisease I-OMIM:261600
the NN I-SpecificDisease I-OMIM:261600
hepatic NN I-SpecificDisease I-OMIM:261600
enzyme NN I-SpecificDisease I-OMIM:261600
phenylalanine NN I-SpecificDisease I-OMIM:261600
hydroxylase NN I-SpecificDisease I-OMIM:261600
(pah). NN O O
PKU NN B-SpecificDisease B-MSH:D010661
is NN O O
a NN O O
highly NN O O
heterogeneous NN O O
disorder, NN O O
with NN O O
more NN O O
than NN O O
60 NN O O
molecular NN O O
lesions NN O O
identified NN O O
in NN O O
the NN O O
pah NN O O
gene. NN O O
the NN O O
haplotype NN O O
associations, NN O O
relative NN O O
frequencies, NN O O
and NN O O
distributions NN O O
of NN O O
five NN O O
prevalent NN O O
pah NN O O
mutations NN O O
(r NN O O
158 NN O O
q, NN O O
r NN O O
261 NN O O
q, NN O O
ivs NN O O
10 NN O O
nt NN O O
546, NN O O
r NN O O
408 NN O O
w, NN O O
and NN O O
ivs NN O O
12 NN O O
n NN O O
1) NN O O
were NN O O
established NN O O
in NN O O
a NN O O
comprehensive NN O O
european NN O O
sample NN O O
population NN O O
and NN O O
subsequently NN O O
were NN O O
examined NN O O
to NN O O
determine NN O O
the NN O O
potential NN O O
roles NN O O
of NN O O
several NN O O
genetic NN O O
mechanisms NN O O
in NN O O
explaining NN O O
the NN O O
present NN O O
distribution NN O O
of NN O O
the NN O O
major NN O O
PKU NN B-Modifier B-MSH:D010661
alleles. NN O O
each NN O O
of NN O O
these NN O O
five NN O O
mutations NN O O
was NN O O
strongly NN O O
associated NN O O
with NN O O
only NN O O
one NN O O
of NN O O
the NN O O
more NN O O
than NN O O
7 NN O O
. NN O O

chromosomal NN O O
haplotypes NN O O
defined NN O O
by NN O O
eight NN O O
rflps NN O O
in NN O O
or NN O O
near NN O O
the NN O O
pah NN O O
gene. NN O O
these NN O O
findings NN O O
suggest NN O O
that NN O O
each NN O O
of NN O O
these NN O O
mutations NN O O
arose NN O O
through NN O O
a NN O O
single NN O O
founding NN O O
event NN O O
that NN O O
occurred NN O O
within NN O O
time NN O O
periods NN O O
ranging NN O O
from NN O O
several NN O O
hundred NN O O
to NN O O
several NN O O
thousand NN O O
years NN O O
ago. NN O O
from NN O O
the NN O O
significant NN O O
differences NN O O
observed NN O O
in NN O O
the NN O O
relative NN O O
frequencies NN O O
and NN O O
distributions NN O O
of NN O O
these NN O O
five NN O O
alleles NN O O
throughout NN O O
europe, NN O O
four NN O O
of NN O O
these NN O O
putative NN O O
founding NN O O
events NN O O
could NN O O
be NN O O
localized NN O O
to NN O O
specific NN O O
ethnic NN O O
subgroups. NN O O
together, NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
there NN O O
were NN O O
multiple, NN O O
geographically NN O O
and NN O O
ethnically NN O O
distinct NN O O
origins NN O O
for NN O O
PKU NN B-SpecificDisease B-MSH:D010661
within NN O O
the NN O O
european NN O O
population. NN O O
. NN O O

autoinhibition NN O O
and NN O O
activation NN O O
mechanisms NN O O
of NN O O
the NN O O
Wiskott-Aldrich NN B-Modifier B-MSH:D014923
syndrome NN I-Modifier I-MSH:D014923
protein NN O O
. NN O O

the NN O O
rho-family NN O O
gtpase, NN O O
cdc NN O O
42, NN O O
can NN O O
regulate NN O O
the NN O O
actin NN O O
cytoskeleton NN O O
through NN O O
activation NN O O
of NN O O
Wiskott-Aldrich NN B-Modifier B-MSH:D014923
syndrome NN I-Modifier I-MSH:D014923
protein NN O O
(wasp) NN O O
family NN O O
members. NN O O
activation NN O O
relieves NN O O
an NN O O
autoinhibitory NN O O
contact NN O O
between NN O O
the NN O O
gtpase-binding NN O O
domain NN O O
and NN O O
the NN O O
carboxy-terminal NN O O
region NN O O
of NN O O
wasp NN O O
proteins. NN O O
here NN O O
we NN O O
report NN O O
the NN O O
autoinhibited NN O O
structure NN O O
of NN O O
the NN O O
gtpase-binding NN O O
domain NN O O
of NN O O
wasp, NN O O
which NN O O
can NN O O
be NN O O
induced NN O O
by NN O O
the NN O O
c-terminal NN O O
region NN O O
or NN O O
by NN O O
organic NN O O
co-solvents. NN O O
in NN O O
the NN O O
autoinhibited NN O O
complex, NN O O
intramolecular NN O O
interactions NN O O
with NN O O
the NN O O
gtpase-binding NN O O
domain NN O O
occlude NN O O
residues NN O O
of NN O O
the NN O O
c NN O O
terminus NN O O
that NN O O
regulate NN O O
the NN O O
arp NN O O
2/3 NN O O
actin-nucleating NN O O
complex. NN O O
binding NN O O
of NN O O
cdc NN O O
42 NN O O
to NN O O
the NN O O
gtpase-binding NN O O
domain NN O O
causes NN O O
a NN O O
dramatic NN O O
conformational NN O O
change, NN O O
resulting NN O O
in NN O O
disruption NN O O
of NN O O
the NN O O
hydrophobic NN O O
core NN O O
and NN O O
release NN O O
of NN O O
the NN O O
. NN O O

terminus, NN O O
enabling NN O O
its NN O O
interaction NN O O
with NN O O
the NN O O
actin NN O O
regulatory NN O O
machinery. NN O O
these NN O O
data NN O O
show NN O O
that NN O O
intrinsically NN O O
unstructured NN O O
peptides NN O O
such NN O O
as NN O O
the NN O O
gtpase-binding NN O O
domain NN O O
of NN O O
wasp NN O O
can NN O O
be NN O O
induced NN O O
into NN O O
distinct NN O O
structural NN O O
and NN O O
functional NN O O
states NN O O
depending NN O O
on NN O O
context. NN O O
. NN O O
ctured NN O O
peptides NN O O
such NN O O
as NN O O
the NN O O
gtpase-binding NN O O
domain NN O O
of NN O O
wasp NN O O
can NN O O
be NN O O
induced NN O O
into NN O O
distinct NN O O
structural NN O O
and NN O O
functional NN O O
states NN O O
depending NN O O
on NN O O
context. NN O O
. NN O O

localisation NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
Norrie NN B-SpecificDisease B-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
to NN O O
between NN O O
dxs NN O O
7 NN O O
and NN O O
dxs NN O O
426 NN O O
on NN O O
xp NN O O
. NN O O

a NN O O
highly NN O O
informative NN O O
microsatellite NN O O
marker, NN O O
dxs NN O O
426, NN O O
which NN O O
maps NN O O
proximal NN O O
to NN O O
dxs NN O O
7 NN O O
in NN O O
the NN O O
interval NN O O
xp NN O O
11. NN O O
4-xp NN O O
11 NN O O
4-xp NN O O
11. NN O O
23, NN O O
has NN O O
been NN O O
used NN O O
to NN O O
refine NN O O
further NN O O
the NN O O
localisation NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
Norrie NN B-SpecificDisease B-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
( NN O O
NDP NN B-SpecificDisease B-MSH:C537849
). NN O O
the NN O O
results NN O O
from NN O O
a NN O O
multiply NN O O
informative NN O O
crossover NN O O
localize NN O O
the NN O O
NDP NN B-Modifier B-MSH:C537849
gene NN O O
proximal NN O O
to NN O O
dxs NN O O
7. NN O O
in NN O O
conjunction NN O O
with NN O O
information NN O O
from NN O O
2 NN O O
NDP NN B-Modifier B-MSH:C537849
patients NN O O
who NN O O
have NN O O
a NN O O
deletion NN O O
for NN O O
dxs NN O O
7 NN O O
but NN O O
not NN O O
for NN O O
dsx NN O O
426, NN O O
our NN O O
data NN O O
indicate NN O O
that NN O O
the NN O O
NDP NN B-Modifier B-MSH:C537849
gene NN O O
lies NN O O
between NN O O
dxs NN O O
7 NN O O
and NN O O
dxs NN O O
426 NN O O
on NN O O
proximal NN O O
xp NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
human NN O O
mitochondrial NN O O
very-long-chain NN B-SpecificDisease B-MSH:C536353
acyl-CoA NN I-SpecificDisease I-MSH:C536353
dehydrogenase NN I-SpecificDisease I-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
causing NN O O
cardiomyopathy NN B-SpecificDisease B-MSH:D009202
and NN O O
sudden NN B-SpecificDisease B-MSH:D003645
death NN I-SpecificDisease I-MSH:D003645
in NN O O
childhood NN O O
. NN O O

beta-oxidation NN O O
of NN O O
long-chain NN O O
fatty NN O O
acids NN O O
provides NN O O
the NN O O
major NN O O
source NN O O
of NN O O
energy NN O O
in NN O O
the NN O O
heart. NN O O
defects NN O O
in NN O O
enzymes NN O O
of NN O O
the NN O O
beta-oxidation NN O O
pathway NN O O
cause NN O O
sudden, NN B-SpecificDisease B-MSH:D003645
unexplained NN I-SpecificDisease I-MSH:D003645
death NN I-SpecificDisease I-MSH:D003645
in NN O O
childhood, NN O O
acute NN O O
hepatic NN B-SpecificDisease B-MSH:D006501
encephalopathy NN I-SpecificDisease I-MSH:D006501
or NN O O
liver NN B-SpecificDisease B-MSH:D017093
failure NN I-SpecificDisease I-MSH:D017093
, NN O O
skeletal NN B-SpecificDisease B-MSH:D009135
myopathy NN I-SpecificDisease I-MSH:D009135
, NN O O
and NN O O
cardiomyopathy NN B-SpecificDisease B-MSH:D009202
. NN O O
very-long-chain NN O O
acyl-coa NN O O
dehydrogenase NN O O
[vlcad; NN O O
very-long-chain-acyl-coa NN O O
(acceptor) NN O O
2, NN O O
3-oxidoreductase, NN O O
ec NN O O
1. NN O O
3 NN O O
3. NN O O
99 NN O O
99. NN O O
13] NN O O
catalyzes NN O O
the NN O O
first NN O O
step NN O O
in NN O O
beta-oxidation. NN O O
we NN O O
have NN O O
isolated NN O O
the NN O O
human NN O O
vlcad NN O O
cdna NN O O
and NN O O
gene NN O O
and NN O O
determined NN O O
the NN O O
complete NN O O
nucleotide NN O O
sequences. NN O O
polymerase NN O O
chain NN O O
reaction NN O O
amplification NN O O
of NN O O
vlcad NN O O
mrna NN O O
and NN O O
genomic NN O O
exons NN O O
defined NN O O
the NN O O
molecular NN O O
defects NN O O
in NN O O
two NN O O
patients NN O O
with NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
who NN O O
presented NN O O
with NN O O
unexplained NN O O
cardiac NN B-SpecificDisease B-MSH:D006323
arrest NN I-SpecificDisease I-MSH:D006323

arrest NN O O
and NN O O
cardiomyopathy NN B-SpecificDisease B-MSH:D009202
. NN O O
in NN O O
one, NN O O
a NN O O
homozygous NN O O
mutation NN O O
in NN O O
the NN O O
consensus NN O O
dinucleotide NN O O
of NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
(g NN O O
+ NN O O
1-- NN O O
> NN O O
a) NN O O
was NN O O
associated NN O O
with NN O O
universal NN O O
skipping NN O O
of NN O O
the NN O O
prior NN O O
exon NN O O
(exon NN O O
11). NN O O
the NN O O
second NN O O
patient NN O O
was NN O O
a NN O O
compound NN O O
heterozygote, NN O O
with NN O O
a NN O O
missense NN O O
mutation, NN O O
c NN O O
1837-- NN O O
> NN O O
t, NN O O
changing NN O O
the NN O O
arginine NN O O
at NN O O
residue NN O O
613 NN O O
to NN O O
tryptophan NN O O
on NN O O
one NN O O
allele NN O O
and NN O O
a NN O O
single NN O O
base NN O O
deletion NN O O
at NN O O
the NN O O
intron-exon NN O O
6 NN O O
boundary NN O O
as NN O O
the NN O O
second NN O O
mutation. NN O O
this NN O O
initial NN O O
delineation NN O O
of NN O O
human NN O O
mutations NN O O
in NN O O
vlcad NN O O
suggests NN O O
that NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
reduces NN O O
myocardial NN O O
fatty NN O O
acid NN O O
beta-oxidation NN O O
and NN O O
energy NN O O
production NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
cardiomyopathy NN B-SpecificDisease B-MSH:D009202
and NN O O
sudden NN B-SpecificDisease B-MSH:D003645
death NN I-SpecificDisease I-MSH:D003645
in NN O O
childhood NN O O
. NN O O

an NN O O
error NN O O
in NN O O
dystrophin NN O O
mrna NN O O
processing NN O O
in NN O O
golden NN B-SpecificDisease B-MSH:D009136
retriever NN I-SpecificDisease I-MSH:D009136
muscular NN I-SpecificDisease I-MSH:D009136
dystrophy NN I-SpecificDisease I-MSH:D009136
, NN O O
an NN O O
animal NN O O
homologue NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
. NN O O

golden NN O O
retriever NN O O
muscular NN O O
dystrophy NN O O
( NN O O
GRMD NN B-SpecificDisease B-MSH:D009136
) NN O O
is NN O O
a NN O O
spontaneous, NN O O
x-linked, NN O O
progressively NN O O
fatal NN O O
disease NN O O
of NN O O
dogs NN O O
and NN O O
is NN O O
also NN O O
a NN O O
homologue NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
two-thirds NN O O
of NN O O
DMD NN B-Modifier B-MSH:D020388
patients NN O O
carry NN O O
detectable NN O O
deletions NN O O
in NN O O
their NN O O
dystrophin NN O O
gene. NN O O
the NN O O
defect NN O O
underlying NN O O
the NN O O
remaining NN O O
one-third NN O O
of NN O O
DMD NN B-Modifier B-MSH:D020388
patients NN O O
is NN O O
undetermined. NN O O
analysis NN O O
of NN O O
the NN O O
canine NN O O
dystrophin NN O O
gene NN O O
in NN O O
normal NN O O
and NN O O
GRMD NN B-Modifier B-MSH:D009136
dogs NN O O
has NN O O
failed NN O O
to NN O O
demonstrate NN O O
any NN O O
detectable NN O O
loss NN O O
of NN O O
exons. NN O O
here, NN O O
we NN O O
have NN O O
demonstrated NN O O
a NN O O
rna NN O O
processing NN O O
error NN O O
in NN O O
GRMD NN B-SpecificDisease B-MSH:D009136
that NN O O
results NN O O
from NN O O
a NN O O
single NN O O
base NN O O
change NN O O
in NN O O
the NN O O
3 NN O O
consensus NN O O
splice NN O O
site NN O O
of NN O O
intron NN O O
6. NN O O
the NN O O
seventh NN O O
exon NN O O
is NN O O
then NN O O
skipped, NN O O
which NN O O
predicts NN O O
a NN O O
termination NN O O
of NN O O
the NN O O
dystrophin NN O O
reading NN O O
frame NN O O
within NN O O
its NN O O
n-terminal NN O O
domain NN O O
in NN O O
exon NN O O
8. NN O O
this NN O O
is NN O O
the NN O O
firs NN O O
. NN O O

example NN O O
of NN O O
dystrophin NN B-SpecificDisease B-OMIM:310200
deficiency NN I-SpecificDisease I-OMIM:310200
caused NN O O
by NN O O
a NN O O
splice-site NN O O
mutation. NN O O
. NN O O

serum NN O O
amyloid NN O O
a NN O O
and NN O O
p NN O O
protein NN O O
genes NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
. NN O O

two NN O O
recent NN O O
studies NN O O
have NN O O
suggested NN O O
the NN O O
involvement NN O O
of NN O O
serum NN O O
amyloid NN O O
a NN O O
(saa) NN O O
and NN O O
p NN O O
(apcs) NN O O
genes NN O O
in NN O O
familial NN B-SpecificDisease B-MSH:D010505
Mediterranean NN I-SpecificDisease I-MSH:D010505
fever NN I-SpecificDisease I-MSH:D010505
( NN O O
MEF NN B-SpecificDisease B-MSH:D010505
). NN O O
to NN O O
test NN O O
the NN O O
role NN O O
of NN O O
saa NN O O
and NN O O
apcs NN O O
in NN O O
MEF NN B-SpecificDisease B-MSH:D010505
and NN O O
MEF-amyloidosis NN B-SpecificDisease B-MSH:D000686
, NN O O
we NN O O
studied NN O O
17 NN O O
informative NN O O
families NN O O
(15 NN O O
armenians, NN O O
2 NN O O
non-ashkenazi NN O O
jews) NN O O
and NN O O
8 NN O O
MEF NN B-Modifier B-MSH:D010505
patients NN O O
with NN O O
amyloidosis NN B-DiseaseClass B-MSH:D000686
using NN O O
a NN O O
candidate NN O O
gene NN O O
approach. NN O O
no NN O O
evidence NN O O
for NN O O
any NN O O
MEF NN B-Modifier B-MSH:D010505
-associated NN O O
polymorphism NN O O
was NN O O
found NN O O
in NN O O
any NN O O
of NN O O
the NN O O
41 NN O O
armenian NN O O
and NN O O
jewish NN O O
MEF NN B-Modifier B-MSH:D010505
patients NN O O
tested. NN O O
our NN O O
family NN O O
studies NN O O
allowed NN O O
us NN O O
to NN O O
rule NN O O
out NN O O
tight NN O O
linkage NN O O
between NN O O
saa NN O O
and NN O O
MEF NN B-SpecificDisease B-MSH:D010505
(lod NN O O
score NN O O
= NN O O
-2. NN O O
16, NN O O
theta NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
0. NN O O
06). NN O O
for NN O O
apcs NN O O
we NN O O
found NN O O
that NN O O
the NN O O
allele NN O O
frequency NN O O
in NN O O
the NN O O
MEF-amyloidosis NN B-Modifier B-MSH:D000686
patient NN O O
. NN O O

was NN O O
similar NN O O
to NN O O
that NN O O
in NN O O
18 NN O O
unrelated NN O O
MEF NN B-Modifier B-MSH:D010505
patients NN O O
without NN O O
amyloidosis NN B-DiseaseClass B-MSH:D000686
and NN O O
their NN O O
33 NN O O
healthy NN O O
parents NN O O
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
variants NN O O
from NN O O
italian NN O O
subjects NN O O
associated NN O O
with NN O O
severe NN B-SpecificDisease B-MSH:D007567
neonatal NN I-SpecificDisease I-MSH:D007567
jaundice NN I-SpecificDisease I-MSH:D007567
. NN O O

screening NN O O
for NN O O
the NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
was NN O O
carried NN O O
out NN O O
at NN O O
the NN O O
maternity NN O O
division NN O O
of NN O O
the NN O O
galliera NN O O
hospital NN O O
in NN O O
genoa, NN O O
italy. NN O O
two NN O O
groups NN O O
of NN O O
subjects NN O O
with NN O O
hyperbilirubinaemia NN B-DiseaseClass B-MSH:D006932
of NN O O
non-immunological NN O O
origin NN O O
were NN O O
examined NN O O
(a) NN O O
302 NN O O
newborn NN O O
babies NN O O
of NN O O
sardinian NN O O
extraction NN O O
(on NN O O
cord NN O O
blood) NN O O
and NN O O
(b) NN O O
201 NN O O
newborn NN O O
babies NN O O
of NN O O
south NN O O
italian NN O O
ancestry NN O O
(on NN O O
peripheral NN O O
blood). NN O O
among NN O O
503 NN O O
subjects, NN O O
43 NN O O
showed NN O O
an NN O O
enzyme NN O O
deficiency; NN O O
in NN O O
39 NN O O
the NN O O
defect NN O O
was NN O O
of NN O O
the NN O O
mediterranean NN O O
type. NN O O
in NN O O
one NN O O
case, NN O O
previously NN O O
described, NN O O
the NN O O
enzyme NN O O
was NN O O
of NN O O
the NN O O
a- NN O O
type. NN O O
in NN O O
the NN O O
remaining NN O O
cases NN O O
three NN O O
different NN O O
variants NN O O
were NN O O
identified. NN O O
in NN O O
the NN O O
present NN O O
work NN O O
these NN O O
three NN O O
cases, NN O O
each NN O O
with NN O O
severe NN B-SpecificDisease B-MSH:D007567
neonatal NN I-SpecificDisease I-MSH:D007567
jaundice NN I-SpecificDisease I-MSH:D007567
, NN O O
are NN O O
reported. NN O O
their NN O O
parents NN O O
originated NN O O
from NN O O
calabria, NN O O
from NN O O
sardinia NN O O
and NN O O
fro NN O O
. NN O O

sicily. NN O O
the NN O O
abnormal NN O O
enzymes NN O O
are NN O O
respectively NN O O
designated NN O O
as NN O O
gddcbrousse-like, NN O O
gdgallura NN O O
and NN O O
gdagrigento. NN O O
. NN O O

loss NN O O
of NN O O
normal NN O O
allele NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
in NN O O
an NN O O
adrenocortical NN B-SpecificDisease B-MSH:D018268
carcinoma NN I-SpecificDisease I-MSH:D018268
from NN O O
a NN O O
patient NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
. NN O O

endocrine NN O O
neoplasms NN O O
have NN O O
been NN O O
reported NN O O
occasionally NN O O
in NN O O
patients NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease I-MSH:D011125
polyposis NN I-SpecificDisease I-MSH:D011125
( NN O O
FAP NN B-SpecificDisease B-MSH:D011125
). NN O O
an NN O O
adrenocorotical NN B-SpecificDisease B-MSH:D018268
carcinoma NN I-SpecificDisease I-MSH:D018268
was NN O O
studied NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
FAP NN B-SpecificDisease B-MSH:D011125
. NN O O
loss NN O O
of NN O O
heterozygosity NN O O
(loh) NN O O
in NN O O
the NN O O
region NN O O
close NN O O
to NN O O
the NN O O
adenomatous NN B-Modifier B-MSH:D011125
polyposis NN I-Modifier I-MSH:D011125
coli NN I-Modifier I-MSH:D011125
( NN O O
APC NN B-Modifier B-MSH:D011125
) NN O O
gene NN O O
was NN O O
detected NN O O
in NN O O
this NN O O
carcinoma NN B-DiseaseClass B-MSH:D002277
, NN O O
and NN O O
evidence NN O O
was NN O O
obtained NN O O
that NN O O
there NN O O
was NN O O
a NN O O
loss NN O O
of NN O O
the NN O O
normal NN O O
allele NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene. NN O O
this NN O O
is NN O O
the NN O O
first NN O O
demonstration NN O O
of NN O O
loh NN O O
at NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
locus NN O O
in NN O O
adrenocortical NN B-SpecificDisease B-MSH:D018268
tumors NN I-SpecificDisease I-MSH:D018268
. NN O O
the NN O O
present NN O O
results NN O O
and NN O O
our NN O O
previous NN O O
data NN O O
on NN O O
loh NN O O
in NN O O
a NN O O
recurring NN O O
desmoid NN B-SpecificDisease B-MSH:C535944
tumor NN I-SpecificDisease I-MSH:C535944
suggest NN O O
that NN O O
the NN O O
heterozygous NN O O
mutant/wild-type NN O O
condition NN O O
of NN O O
the NN O O
APC NN B-Modifier B-MSH:D011125
gene NN O O
may NN O O
give NN O O
rise NN O O
to NN O O
benign NN B-DiseaseClass B-MSH:D009369
tumors NN I-DiseaseClass I-MSH:D009369
, NN O O
and NN O O
that NN O O
functional NN O O
loss NN O O
of NN O O
this NN O O
gene NN O O
leads NN O O
to NN O O
development NN O O
of NN O O
tumors NN B-DiseaseClass B-MSH:D009369
not NN O O
only NN O O
in NN O O
th NN O O
. NN O O

colon NN O O
but NN O O
also NN O O
in NN O O
other NN O O
various NN O O
parts NN O O
of NN O O
the NN O O
body NN O O
in NN O O
FAP NN B-Modifier B-MSH:D011125
patients. NN O O
. NN O O

heterozygous NN O O
C2-deficiency NN B-SpecificDisease B-OMIM:217000
and NN O O
myasthenia NN B-SpecificDisease B-MSH:D009157
gravis NN I-SpecificDisease I-MSH:D009157
. NN O O

complement NN O O
deficiency NN O O
states NN O O
in NN O O
myasthenia NN B-SpecificDisease B-MSH:D009157
gravis NN I-SpecificDisease I-MSH:D009157
( NN O O
MG NN B-SpecificDisease B-MSH:D009157
) NN O O
have NN O O
not NN O O
been NN O O
reported NN O O
previously. NN O O
we NN O O
describe NN O O
a NN O O
19-year-old NN O O
woman NN O O
with NN O O
typical NN O O
MG NN B-SpecificDisease B-MSH:D009157
and NN O O
heterozygous NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
, NN O O
along NN O O
with NN O O
hla NN O O
typing NN O O
of NN O O
the NN O O
patient NN O O
and NN O O
her NN O O
immediate NN O O
family. NN O O
. NN O O

large NN O O
heterozygous NN O O
deletion NN O O
masquerading NN O O
as NN O O
homozygous NN O O
missense NN O O
mutation: NN O O
a NN O O
pitfall NN O O
in NN O O
diagnostic NN O O
mutation NN O O
analysis NN O O
. NN O O

the NN O O
clinical NN O O
use NN O O
of NN O O
molecular NN O O
analyses NN O O
in NN O O
recessive NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
relies NN O O
on NN O O
the NN O O
exact NN O O
characterization NN O O
of NN O O
both NN O O
mutant NN O O
alleles NN O O
in NN O O
the NN O O
affected NN O O
patient. NN O O
this NN O O
can NN O O
be NN O O
problematic NN O O
when NN O O
only NN O O
part NN O O
of NN O O
the NN O O
gene NN O O
is NN O O
examined NN O O
or NN O O
when NN O O
relevant NN O O
dna NN O O
alterations NN O O
are NN O O
not NN O O
recognized NN O O
by NN O O
standard NN O O
methods. NN O O
we NN O O
present NN O O
a NN O O
child NN O O
in NN O O
whom NN O O
phenylketonuria NN B-SpecificDisease B-MSH:D010661
was NN O O
apparently NN O O
caused NN O O
by NN O O
homozygosity NN O O
for NN O O
the NN O O
mutation NN O O
e NN O O
390 NN O O
g NN O O
in NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah) NN O O
gene. NN O O
however, NN O O
the NN O O
clinical NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
was NN O O
not NN O O
quite NN O O
as NN O O
mild NN O O
as NN O O
expected, NN O O
the NN O O
mutation NN O O
was NN O O
not NN O O
identified NN O O
in NN O O
the NN O O
father NN O O
despite NN O O
confirmed NN O O
paternity, NN O O
and NN O O
the NN O O
paternal NN O O
allele NN O O
showed NN O O
a NN O O
highly NN O O
unusual NN O O
pattern NN O O
of NN O O
polymorphic NN O O
markers NN O O
in NN O O
the NN O O
pah NN O O
gene. NN O O
presence NN O O
of NN O O
a NN O O
large NN O O
deletion NN O O
involving NN O O
exons NN O O
9, NN O O
10 NN O O
and NN O O
11 NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
wa NN O O
. NN O O

confirmed NN O O
by NN O O
long-range NN O O
pcr. NN O O
diagnostic NN O O
dna NN O O
analyses NN O O
should NN O O
include NN O O
a NN O O
comprehensive NN O O
examination NN O O
of NN O O
the NN O O
whole NN O O
relevant NN O O
gene NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
confirmation NN O O
of NN O O
carrier NN O O
status NN O O
in NN O O
both NN O O
parents. NN O O
. NN O O

two NN O O
point NN O O
mutations NN O O
are NN O O
responsible NN O O
for NN O O
g NN O O
6 NN O O
pd NN O O
polymorphism NN O O
in NN O O
sardinia NN O O
. NN O O

the NN O O
human NN O O
x-linked NN O O
gene NN O O
encoding NN O O
glucose NN O O
6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
is NN O O
highly NN O O
polymorphic; NN O O
more NN O O
than NN O O
300 NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
have NN O O
been NN O O
identified. NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
different NN O O
geographical NN O O
areas NN O O
appears NN O O
to NN O O
have NN O O
arisen NN O O
through NN O O
independent NN O O
mutational NN O O
events, NN O O
but NN O O
within NN O O
the NN O O
same NN O O
population NN O O
it NN O O
may NN O O
also NN O O
be NN O O
heterogeneous. NN O O
one NN O O
example NN O O
is NN O O
the NN O O
island NN O O
of NN O O
sardinia, NN O O
where NN O O
careful NN O O
clinical NN O O
and NN O O
biochemical NN O O
studies NN O O
have NN O O
identified NN O O
four NN O O
different NN O O
g NN O O
6 NN O O
pd NN O O
variants. NN O O
we NN O O
cloned NN O O
and NN O O
sequenced NN O O
the NN O O
four NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
from NN O O
sardinia NN O O
and NN O O
found NN O O
that NN O O
only NN O O
two NN O O
mutations NN O O
are NN O O
responsible NN O O
for NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
this NN O O
area NN O O
one NN O O
mutation NN O O
is NN O O
the NN O O
cause NN O O
of NN O O
the NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
Seattle-like NN I-SpecificDisease I-MSH:D005955
phenotype NN I-SpecificDisease I-MSH:D005955
, NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
; NN O O
the NN O O
other NN O O
mutation NN O O
is NN O O
responsibl NN O O
. NN O O

for NN O O
all NN O O
forms NN O O
of NN O O
very NN O O
severe NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
sardinia NN O O
and, NN O O
possibly, NN O O
in NN O O
the NN O O
mediterranean. NN O O
. NN O O

familial NN O O
discoid NN O O
lupus NN O O
erythematosus NN O O
associated NN O O
with NN O O
heterozygote NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
. NN O O

two NN O O
siblings NN O O
with NN O O
chronic NN B-SpecificDisease B-MSH:D008179
discoid NN I-SpecificDisease I-MSH:D008179
lupus NN I-SpecificDisease I-MSH:D008179
erythematosus NN I-SpecificDisease I-MSH:D008179
and NN O O
several NN O O
family NN O O
members NN O O
were NN O O
found NN O O
with NN O O
heterozygous NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
. NN O O
an NN O O
association NN O O
with NN O O
histocompatibility NN O O
markers NN O O
hla-b NN O O
18 NN O O
and NN O O
hla-dw NN O O
2 NN O O
was NN O O
demonstrated, NN O O
and NN O O
the NN O O
slow NN O O
allotype NN O O
of NN O O
factor NN O O
b NN O O
was NN O O
present. NN O O
linkage NN O O
studies NN O O
in NN O O
this NN O O
family NN O O
suggested NN O O
a NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
C2 NN B-Modifier B-OMIM:217000
deficiency NN I-Modifier I-OMIM:217000
gene NN O O
and NN O O
genes NN O O
coding NN O O
for NN O O
b NN O O
18, NN O O
dw NN O O
2, NN O O
and NN O O
bfs NN O O
antigens. NN O O
one NN O O
hla-acb/dbf NN O O
recombinant NN O O
was NN O O
observed NN O O
showing NN O O
closer NN O O
linkage NN O O
between NN O O
hla-d NN O O
and NN O O
bf NN O O
than NN O O
between NN O O
hla-b NN O O
and NN O O
bf. NN O O
. NN O O

a NN O O
strong NN O O
candidate NN O O
for NN O O
the NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
susceptibility NN O O
gene NN O O
brca NN O O
1 NN O O
. NN O O

a NN O O
strong NN O O
candidate NN O O
for NN O O
the NN O O
17 NN O O
q-linked NN O O
brca NN O O
1 NN O O
gene, NN O O
which NN O O
influences NN O O
susceptibility NN O O
to NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
, NN O O
has NN O O
been NN O O
identified NN O O
by NN O O
positional NN O O
cloning NN O O
methods. NN O O
probable NN O O
predisposing NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
five NN O O
of NN O O
eight NN O O
kindreds NN O O
presumed NN O O
to NN O O
segregate NN O O
brca NN O O
1 NN O O
susceptibility NN O O
alleles. NN O O
the NN O O
mutations NN O O
include NN O O
an NN O O
11-base NN O O
pair NN O O
deletion, NN O O
a NN O O
1-base NN O O
pair NN O O
insertion, NN O O
a NN O O
stop NN O O
codon, NN O O
a NN O O
missense NN O O
substitution, NN O O
and NN O O
an NN O O
inferred NN O O
regulatory NN O O
mutation. NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
is NN O O
expressed NN O O
in NN O O
numerous NN O O
tissues, NN O O
including NN O O
breast NN O O
and NN O O
ovary, NN O O
and NN O O
encodes NN O O
a NN O O
predicted NN O O
protein NN O O
of NN O O
1863 NN O O
amino NN O O
acids. NN O O
this NN O O
protein NN O O
contains NN O O
a NN O O
zinc NN O O
finger NN O O
domain NN O O
in NN O O
its NN O O
amino-terminal NN O O
region, NN O O
but NN O O
is NN O O
otherwise NN O O
unrelated NN O O
to NN O O
previously NN O O
described NN O O
proteins. NN O O
identification NN O O
of NN O O
brca NN O O
1 NN O O
should NN O O
facilitate NN O O
early NN O O
diagnosis NN O O
of NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325

cancer NN O O
susceptibility NN O O
in NN O O
some NN O O
individuals NN O O
as NN O O
well NN O O
as NN O O
a NN O O
better NN O O
understanding NN O O
of NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
biology. NN O O
. NN O O

recombinations NN O O
in NN O O
individuals NN O O
homozygous NN O O
by NN O O
descent NN O O
localize NN O O
the NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
locus NN O O
in NN O O
a NN O O
cloned NN O O
450-kb NN O O
interval NN O O
. NN O O

the NN O O
locus NN O O
for NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
( NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
), NN O O
a NN O O
severe NN O O
neurodegenerative NN B-DiseaseClass B-MSH:D019636
disease NN I-DiseaseClass I-MSH:D019636
, NN O O
is NN O O
tightly NN O O
linked NN O O
to NN O O
markers NN O O
d NN O O
9 NN O O
s NN O O
5 NN O O
and NN O O
d NN O O
9 NN O O
s NN O O
15, NN O O
and NN O O
analysis NN O O
of NN O O
rare NN O O
recombination NN O O
events NN O O
has NN O O
suggested NN O O
the NN O O
order NN O O
cen-frda-d NN O O
9 NN O O
s NN O O
5-d NN O O
9 NN O O
s NN O O
15-qter. NN O O
we NN O O
report NN O O
here NN O O
the NN O O
construction NN O O
of NN O O
a NN O O
yac NN O O
contig NN O O
extending NN O O
800 NN O O
kb NN O O
centromeric NN O O
to NN O O
d NN O O
9 NN O O
s NN O O
5 NN O O
and NN O O
the NN O O
isolation NN O O
of NN O O
five NN O O
new NN O O
microsatellite NN O O
markers NN O O
from NN O O
this NN O O
region. NN O O
in NN O O
order NN O O
to NN O O
map NN O O
these NN O O
markers NN O O
with NN O O
respect NN O O
to NN O O
the NN O O
FRDA NN B-Modifier B-MSH:D005621
locus, NN O O
all NN O O
within NN O O
a NN O O
1-cm NN O O
confidence NN O O
interval, NN O O
we NN O O
sought NN O O
to NN O O
increase NN O O
the NN O O
genetic NN O O
information NN O O
of NN O O
available NN O O
FRDA NN B-Modifier B-MSH:D005621
families NN O O
by NN O O
considering NN O O
homozygosity NN O O
by NN O O
descent NN O O
and NN O O
association NN O O
with NN O O
founder NN O O
haplotypes NN O O
in NN O O
isolated NN O O
populations. NN O O
this NN O O
approach NN O O
allowed NN O O
us NN O O
to NN O O
identify NN O O
one NN O O
phas NN O O
. NN O O

-known NN O O
recombination NN O O
and NN O O
one NN O O
probable NN O O
historic NN O O
recombination NN O O
on NN O O
haplotypes NN O O
from NN O O
reunion NN O O
island NN O O
patients, NN O O
both NN O O
of NN O O
which NN O O
place NN O O
three NN O O
of NN O O
the NN O O
five NN O O
markers NN O O
proximal NN O O
to NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
. NN O O
this NN O O
represents NN O O
the NN O O
first NN O O
identification NN O O
of NN O O
close NN O O
FRDA NN B-Modifier B-MSH:D005621
flanking NN O O
markers NN O O
on NN O O
the NN O O
centromeric NN O O
side. NN O O
the NN O O
two NN O O
other NN O O
markers NN O O
allowed NN O O
us NN O O
to NN O O
narrow NN O O
the NN O O
breakpoint NN O O
of NN O O
a NN O O
previously NN O O
identified NN O O
distal NN O O
recombination NN O O
that NN O O
is NN O O
> NN O O
180 NN O O
kb NN O O
from NN O O
d NN O O
9 NN O O
s NN O O
5 NN O O
(26 NN O O
p). NN O O
taken NN O O
together, NN O O
the NN O O
results NN O O
place NN O O
the NN O O
FRDA NN B-Modifier B-MSH:D005621
locus NN O O
in NN O O
a NN O O
450-kb NN O O
interval, NN O O
which NN O O
is NN O O
small NN O O
enough NN O O
for NN O O
direct NN O O
search NN O O
of NN O O
candidate NN O O
genes. NN O O
a NN O O
detailed NN O O
rare NN O O
cutter NN O O
restriction NN O O
map NN O O
and NN O O
a NN O O
cosmid NN O O
contig NN O O
covering NN O O
this NN O O
interval NN O O
were NN O O
constructed NN O O
and NN O O
should NN O O
facilitate NN O O
the NN O O
search NN O O
of NN O O
genes NN O O
in NN O O
this NN O O
region. NN O O
. NN O O

further NN O O
mapping NN O O
of NN O O
an NN O O
ataxia-telangiectasia NN B-Modifier B-MSH:D001260
locus NN O O
to NN O O
the NN O O
chromosome NN O O
11 NN O O
q NN O O
23 NN O O
region NN O O
. NN O O

we NN O O
recently NN O O
mapped NN O O
the NN O O
gene NN O O
for NN O O
ataxia-telangiectasia NN B-Modifier B-MSH:D001260
group NN O O
a NN O O
(ata) NN O O
to NN O O
chromosome NN O O
11 NN O O
q NN O O
22-23 NN O O
by NN O O
linkage NN O O
analysis, NN O O
using NN O O
the NN O O
genetic NN O O
markers NN O O
thy NN O O
1 NN O O
and NN O O
pynb NN O O
3. NN O O
12 NN O O
(d NN O O
11 NN O O
s NN O O
144). NN O O
the NN O O
most NN O O
likely NN O O
order NN O O
was NN O O
cent-at-s NN O O
144-thy NN O O
1. NN O O
the NN O O
present NN O O
paper NN O O
describes NN O O
further NN O O
mapping NN O O
of NN O O
the NN O O
AT NN B-Modifier B-MSH:D001260
locus NN O O
by NN O O
means NN O O
of NN O O
a NN O O
panel NN O O
of NN O O
10 NN O O
markers NN O O
that NN O O
span NN O O
approximately NN O O
60 NN O O
cm NN O O
in NN O O
the NN O O
11 NN O O
q NN O O
22-23 NN O O
region NN O O
centered NN O O
around NN O O
s NN O O
144 NN O O
and NN O O
thy NN O O
1. NN O O
location NN O O
scores NN O O
indicate NN O O
that NN O O
three NN O O
contiguous NN O O
subsegments NN O O
within NN O O
the NN O O
[s NN O O
144-thy NN O O
1] NN O O
segment, NN O O
as NN O O
well NN O O
as NN O O
three NN O O
contiguous NN O O
segments NN O O
telomeric NN O O
to NN O O
thy NN O O
1, NN O O
are NN O O
each NN O O
unlikely NN O O
to NN O O
contain NN O O
the NN O O
AT NN B-Modifier B-MSH:D001260
locus, NN O O
while NN O O
the NN O O
more NN O O
centromeric NN O O
. NN O O

stmy-s NN O O
144] NN O O
segment NN O O
is NN O O
most NN O O
likely NN O O
to NN O O
contain NN O O
the NN O O
AT NN B-Modifier B-MSH:D001260
locus. NN O O
these NN O O
data, NN O O
together NN O O
with NN O O
recent NN O O
refinements NN O O
in NN O O
the NN O O
linkage NN O O
and NN O O
physical NN O O
maps NN O O
of NN O O
11 NN O O
q NN O O
22-23, NN O O
place NN O O
the NN O O
AT NN B-Modifier B-MSH:D001260
locus NN O O
at NN O O
11 NN O O
q NN O O
23 NN O O
. NN O O

proliferation-related NN O O
expression NN O O
of NN O O
p NN O O
19/nm NN O O
23 NN O O
nucleoside NN O O
diphosphate NN O O
kinase NN O O
. NN O O

high NN O O
level NN O O
expression NN O O
of NN O O
the NN O O
nm NN O O
23-h NN O O
1 NN O O
gene, NN O O
which NN O O
encodes NN O O
for NN O O
a NN O O
nucleoside NN O O
diphosphate NN O O
kinase, NN O O
has NN O O
been NN O O
found NN O O
to NN O O
correlate NN O O
with NN O O
diminished NN O O
metastasis NN O O
in NN O O
some NN O O
tumors NN B-DiseaseClass B-MSH:D009369
but NN O O
not NN O O
in NN O O
others. NN O O
we NN O O
have NN O O
previously NN O O
identified NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
nm NN O O
23-h NN O O
1 NN O O
gene NN O O
in NN O O
two-dimensional NN O O
electrophoretic NN O O
gels NN O O
and NN O O
have NN O O
designated NN O O
it NN O O
p NN O O
19/nm NN O O
23. NN O O
in NN O O
neuroblastoma NN B-SpecificDisease B-MSH:D009447
, NN O O
higher NN O O
levels NN O O
of NN O O
p NN O O
19/nm NN O O
23, NN O O
which NN O O
are NN O O
associated NN O O
with NN O O
amplification NN O O
of NN O O
the NN O O
n-myc NN O O
oncogene, NN O O
large NN O O
tumor NN B-Modifier B-MSH:D009369
mass, NN O O
and NN O O
metastasis, NN O O
were NN O O
observed NN O O
in NN O O
advanced NN O O
stage NN O O
tumors NN B-DiseaseClass B-MSH:D009369
compared NN O O
with NN O O
limited NN O O
stage NN O O
disease. NN O O
because NN O O
of NN O O
the NN O O
variable NN O O
expression NN O O
of NN O O
nm NN O O
23-h NN O O
1 NN O O
in NN O O
different NN O O
tumors NN B-DiseaseClass B-MSH:D009369
, NN O O
we NN O O
have NN O O
investigated NN O O
the NN O O
relationship NN O O
between NN O O
amounts NN O O
of NN O O
the NN O O
protein NN O O
and NN O O
cell NN O O
proliferation. NN O O
th NN O O
. NN O O

levels NN O O
of NN O O
p NN O O
19/nm NN O O
23 NN O O
were NN O O
compared NN O O
between NN O O
resting NN O O
and NN O O
mitotically NN O O
stimulated NN O O
normal NN O O
human NN O O
pbls NN O O
and NN O O
in NN O O
leukemia NN B-Modifier B-MSH:D007938
cells. NN O O
the NN O O
amount NN O O
of NN O O
p NN O O
19/nm NN O O
23 NN O O
increased NN O O
in NN O O
normal NN O O
lymphocytes NN O O
in NN O O
response NN O O
to NN O O
mitotic NN O O
stimulation NN O O
and NN O O
paralleled NN O O
the NN O O
increase NN O O
in NN O O
dna NN O O
synthesis. NN O O
in NN O O
leukemia NN B-Modifier B-MSH:D007938
cells NN O O
obtained NN O O
from NN O O
patients NN O O
with NN O O
different NN O O
subtypes NN O O
of NN O O
acute NN B-SpecificDisease B-MSH:D007938
leukemia NN I-SpecificDisease I-MSH:D007938
, NN O O
p NN O O
19/nm NN O O
23 NN O O
levels NN O O
were NN O O
also NN O O
increased NN O O
relative NN O O
to NN O O
resting NN O O
normal NN O O
lymphocytes. NN O O
treatment NN O O
of NN O O
mitotically NN O O
stimulated NN O O
lymphocytes NN O O
with NN O O
cyclosporin, NN O O
which NN O O
inhibits NN O O
proliferation, NN O O
blocked NN O O
the NN O O
increase NN O O
in NN O O
p NN O O
19/nm NN O O
23; NN O O
treatment NN O O
of NN O O
the NN O O
leukemia NN B-Modifier B-MSH:D007938
cell NN O O
line NN O O
hl-60 NN O O
with NN O O
dimethylsulfoxide, NN O O
which NN O O
induces NN O O
terminal NN O O
differentiation, NN O O
resulted NN O O
in NN O O
diminished NN O O
levels NN O O
of NN O O
p NN O O
19/nm NN O O
23. NN O O
our NN O O
data NN O O
therefore NN O O
provide NN O O
evidence NN O O
that NN O O
nm NN O O
23-h NN O O
1 NN O O
expression NN O O
is NN O O
related NN O O
t NN O O
. NN O O

cell NN O O
proliferative NN O O
activity. NN O O
. NN O O

carrier NN O O
detection NN O O
of NN O O
pyruvate NN B-SpecificDisease B-MSH:D015324
carboxylase NN I-SpecificDisease I-MSH:D015324
deficiency NN I-SpecificDisease I-MSH:D015324
in NN O O
fibroblasts NN O O
and NN O O
lymphocytes NN O O
. NN O O

pyruvate NN O O
carboxylase NN O O
(e. NN O O
c. NN O O
6. NN O O
4. NN O O
1. NN O O
1) NN O O
activity NN O O
was NN O O
determined NN O O
in NN O O
the NN O O
circulating NN O O
peripheral NN O O
lymphocytes NN O O
and NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
the NN O O
family NN O O
of NN O O
a NN O O
patient NN O O
with NN O O
hepatic, NN O O
cerebral, NN O O
renal NN O O
cortical, NN O O
leukocyte, NN O O
and NN O O
fibroblast NN O O
pyruvate NN B-SpecificDisease B-MSH:D015324
carboxylase NN I-SpecificDisease I-MSH:D015324
deficiency NN I-SpecificDisease I-MSH:D015324
( NN O O
PC NN B-SpecificDisease B-MSH:D015324
Portland NN I-SpecificDisease I-MSH:D015324
deficiency NN I-SpecificDisease I-MSH:D015324
). NN O O
lymphocyte NN O O
activities NN O O
were NN O O
mother, NN O O
33--39%; NN O O
father, NN O O
11--29%; NN O O
brother, NN O O
82--103%; NN O O
and NN O O
sister, NN O O
38--48% NN O O
of NN O O
the NN O O
lowest NN O O
normal. NN O O
fibroblasts NN O O
from NN O O
the NN O O
patients NN O O
mother NN O O
and NN O O
father NN O O
had NN O O
42 NN O O
and NN O O
34%, NN O O
respectively, NN O O
of NN O O
the NN O O
activity NN O O
of NN O O
the NN O O
lowest NN O O
normal. NN O O
these NN O O
data NN O O
demonstrate NN O O
that NN O O
the NN O O
disease NN O O
is NN O O
inherited NN O O
in NN O O
an NN O O
autosomal NN O O
recessive NN O O
manner NN O O
and NN O O
that NN O O
lymphocytes NN O O
and NN O O
fibroblasts NN O O
can NN O O
be NN O O
used NN O O
to NN O O
detec NN O O
. NN O O

carriers. NN O O
neither NN O O
pyruvate NN O O
carboxylase NN O O
nor NN O O
mitochondrial NN O O
pepck NN O O
activity NN O O
in NN O O
lymphocytes NN O O
was NN O O
increased NN O O
by NN O O
a NN O O
21-hr NN O O
fast NN O O
. NN O O

complex NN O O
glycerol NN O O
kinase NN O O
deficiency: NN O O
molecular-genetic, NN O O
cytogenetic, NN O O
and NN O O
clinical NN O O
studies NN O O
of NN O O
five NN O O
japanese NN O O
patients NN O O
. NN O O

five NN O O
male NN O O
japanese NN O O
patients NN O O
with NN O O
complex NN B-SpecificDisease B-MSH:C538138
glycerol NN I-SpecificDisease I-MSH:C538138
kinase NN I-SpecificDisease I-MSH:C538138
deficiency NN I-SpecificDisease I-MSH:C538138
( NN O O
CGKD NN B-SpecificDisease B-MSH:C538138
) NN O O
and NN O O
their NN O O
relatives NN O O
were NN O O
studied NN O O
clinically, NN O O
cytogenetically, NN O O
and NN O O
molecular-genetically. NN O O
all NN O O
patients NN O O
had NN O O
muscular NN B-DiseaseClass B-MSH:D009136
dystrophy NN I-DiseaseClass I-MSH:D009136
or NN O O
muscle NN B-DiseaseClass B-MSH:D018908
weakness NN I-DiseaseClass I-MSH:D018908
, NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
congenital NN B-SpecificDisease B-MSH:D000312
adrenal NN I-SpecificDisease I-MSH:D000312
hypoplasia NN I-SpecificDisease I-MSH:D000312
, NN O O
and NN O O
glycerol NN B-DiseaseClass B-MSH:C538138
kinase NN I-DiseaseClass I-MSH:C538138
deficiency NN I-DiseaseClass I-MSH:C538138
. NN O O
high-resolution NN O O
gtg-banded NN O O
chromosomes NN O O
showed NN O O
a NN O O
microdeletion NN O O
in NN O O
the NN O O
xp NN O O
21 NN O O
region NN O O
in NN O O
all NN O O
four NN O O
patients NN O O
examined NN O O
and NN O O
in NN O O
all NN O O
five NN O O
mothers. NN O O
southern NN O O
hybridizations, NN O O
after NN O O
digestions NN O O
by NN O O
restriction NN O O
endonucleases, NN O O
with NN O O
various NN O O
cloned NN O O
dnas NN O O
(d NN O O
2, NN O O
99-6, NN O O
b NN O O
24, NN O O
c NN O O
7, NN O O
l NN O O
1-4, NN O O
cdmd NN O O
13-14, NN O O
j NN O O
66-hi, NN O O
p NN O O
20, NN O O
j-bir, NN O O
ert NN O O
87-30, NN O O
ert NN O O
87-15, NN O O
ert NN O O
87-8, NN O O
ert NN O O
87 NN O O
. NN O O

1, NN O O
xj-1. NN O O
1, NN O O
754, NN O O
cx NN O O
5. NN O O
7, NN O O
and NN O O
otc-1) NN O O
that NN O O
are NN O O
located NN O O
around NN O O
xp NN O O
21 NN O O
also NN O O
showed NN O O
a NN O O
deletion NN O O
in NN O O
the NN O O
genome NN O O
of NN O O
all NN O O
patients NN O O
and NN O O
mothers. NN O O
although NN O O
the NN O O
deletion NN O O
differed NN O O
in NN O O
size NN O O
among NN O O
patients, NN O O
a NN O O
segment NN O O
commonly NN O O
absent NN O O
was NN O O
located NN O O
between NN O O
the NN O O
genomic NN O O
sequences NN O O
corresponding NN O O
to NN O O
l NN O O
1-4 NN O O
and NN O O
cdmd NN O O
13-14. NN O O
this NN O O
finding NN O O
indicated NN O O
that NN O O
the NN O O
gene NN O O
coding NN O O
for NN O O
glycerol NN O O
kinase NN O O
(gk) NN O O
is NN O O
located NN O O
within NN O O
this NN O O
segment. NN O O
a NN O O
comparison NN O O
of NN O O
the NN O O
clinical NN O O
manifestations NN O O
of NN O O
the NN O O
present NN O O
five NN O O
patients NN O O
and NN O O
reported NN O O
CGKD NN B-Modifier B-MSH:C538138
or NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
patients NN O O
with NN O O
dna NN O O
deletion NN O O
suggests NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
certain NN O O
gene NN O O
responsible NN O O
for NN O O
gonadotropin NN B-SpecificDisease B-MSH:C535764
deficiency NN I-SpecificDisease I-MSH:C535764
( NN O O
GTD NN B-SpecificDisease B-MSH:C535764
). NN O O
the NN O O
result NN O O
of NN O O
the NN O O
present NN O O
study NN O O
and NN O O
results NN O O
of NN O O
previous NN O O
studie NN O O
. NN O O

suggest NN O O
that NN O O
genes NN O O
for NN O O
ornithine NN O O
transcarbamylase NN O O
(otc), NN O O
DMD NN B-SpecificDisease B-MSH:D020388
, NN O O
and NN O O
gk NN O O
and NN O O
putative NN O O
genes NN O O
responsible NN O O
for NN O O
congenital NN B-SpecificDisease B-MSH:D000312
adrenal NN I-SpecificDisease I-MSH:D000312
hypoplasia NN I-SpecificDisease I-MSH:D000312
( NN O O
AHC NN B-SpecificDisease B-MSH:D000312
) NN O O
and NN O O
GTD NN B-SpecificDisease B-MSH:C535764
are NN O O
arranged NN O O
from NN O O
telomere NN O O
to NN O O
centromere NN O O
as NN O O
pter--gtd--ahc--gk--dmd--otc--ce NN O O
. NN O O

duchenne NN O O
muscular NN O O
dystrophy NN O O
and NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
in NN O O
the NN O O
same NN O O
patient NN O O
. NN O O

we NN O O
report NN O O
on NN O O
the NN O O
first NN O O
patient NN O O
identified NN O O
with NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
and NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
). NN O O
the NN O O
family NN O O
of NN O O
the NN O O
propositus NN O O
had NN O O
a NN O O
strong NN O O
history NN O O
of NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
, NN O O
and NN O O
there NN O O
was NN O O
an NN O O
intrafamilial NN O O
pathological NN O O
expansion NN O O
of NN O O
the NN O O
responsible NN O O
ctg NN O O
repeat NN O O
between NN O O
the NN O O
mildly NN O O
affected NN O O
mother NN O O
(160 NN O O
repeats; NN O O
normal NN O O
27 NN O O
repeats) NN O O
and NN O O
her NN O O
more NN O O
severely NN O O
affected NN O O
son NN O O
(650 NN O O
repeats), NN O O
and NN O O
his NN O O
sister NN O O
(650 NN O O
repeats). NN O O
the NN O O
propositus NN O O
was NN O O
an NN O O
isolated NN O O
case NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
with NN O O
marked NN O O
dystrophin NN B-SpecificDisease B-OMIM:310200
deficiency NN I-SpecificDisease I-OMIM:310200
in NN O O
muscle NN O O
biopsy. NN O O
the NN O O
patient NN O O
was NN O O
still NN O O
ambulatory NN O O
post NN O O
age NN O O
16. NN O O
Myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
could NN O O
interfere NN O O
to NN O O
some NN O O
extent NN O O
with NN O O
the NN O O
progression NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
. NN O O
however, NN O O
other NN O O
interpretations NN O O
are NN O O
possible. NN O O
twelve NN O O
percent NN O O
of NN O O
dystrophin NN O O
revertant NN O O
fibers NN O O
as NN O O
observed NN O O
by NN O O
immunohistochemistry NN O O
could NN O O
be NN O O
sufficient NN O O
to NN O O
ameliorate NN O O
typical NN O O
DMD NN B-Modifier B-MSH:D020388
. NN O O

clinical NN O O
severity, NN O O
or NN O O
the NN O O
patient NN O O
may NN O O
present NN O O
a NN O O
somatic NN O O
mosaic. NN O O
the NN O O
pathophysiological NN O O
interactions NN O O
of NN O O
these NN O O
two NN O O
unlinked NN O O
disorders NN O O
are NN O O
discussed NN O O
at NN O O
the NN O O
clinical NN O O
and NN O O
histopathological NN O O
levels. NN O O
. NN O O

autosomal NN O O
recessive NN O O
transmission NN O O
of NN O O
hemophilia NN B-SpecificDisease B-MSH:D006467
A NN I-SpecificDisease I-MSH:D006467
due NN O O
to NN O O
a NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
mutation NN O O
. NN O O

the NN O O
differential NN O O
diagnosis NN O O
of NN O O
the NN O O
genetic NN B-DiseaseClass B-MSH:D025861
bleeding NN I-DiseaseClass I-MSH:D025861
disorders NN I-DiseaseClass I-MSH:D025861
, NN O O
hemophilia NN B-SpecificDisease B-MSH:D006467
A NN I-SpecificDisease I-MSH:D006467
and NN O O
von NN B-SpecificDisease B-MSH:D014842
Willebrand NN I-SpecificDisease I-MSH:D014842
disease NN I-SpecificDisease I-MSH:D014842
, NN O O
is NN O O
occasionally NN O O
confounded NN O O
by NN O O
the NN O O
close NN O O
molecular NN O O
relationship NN O O
of NN O O
coagulation NN O O
factor NN O O
viii NN O O
and NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
(vwf). NN O O
this NN O O
report NN O O
describes NN O O
the NN O O
autosomal NN O O
inheritance NN O O
of NN O O
a NN O O
hemophilia NN B-Modifier B-MSH:D006467
A NN I-Modifier I-MSH:D006467
phenotype NN O O
due NN O O
to NN O O
a NN O O
mutation NN O O
of NN O O
vwf NN O O
that NN O O
results NN O O
in NN O O
defective NN O O
factor NN O O
viii NN O O
binding. NN O O
the NN O O
proband NN O O
was NN O O
a NN O O
female NN O O
patient NN O O
with NN O O
low NN O O
levels NN O O
of NN O O
factor NN O O
viii NN O O
activity. NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
amplification NN O O
and NN O O
dna NN O O
sequencing NN O O
were NN O O
employed NN O O
to NN O O
examine NN O O
exons NN O O
encoding NN O O
the NN O O
putative NN O O
factor NN O O
viii NN O O
binding NN O O
domain NN O O
of NN O O
vwf. NN O O
the NN O O
patient NN O O
was NN O O
found NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
single NN O O
point NN O O
mutation NN O O
causing NN O O
a NN O O
thr-- NN O O
> NN O O
met NN O O
substitution NN O O
at NN O O
amino NN O O
acid NN O O
position NN O O
28 NN O O
in NN O O
the NN O O
mature NN O O
vwf NN O O
subunit. NN O O
the NN O O
phenotypic NN O O
expression NN O O
of NN O O
the NN O O
mutation NN O O
was NN O O
determined NN O O
t NN O O
. NN O O

be NN O O
recessive NN O O
because NN O O
heterozygous NN O O
family NN O O
members NN O O
were NN O O
clinically NN O O
unaffected. NN O O
recombinant NN O O
vwf NN O O
containing NN O O
the NN O O
observed NN O O
amino NN O O
acid NN O O
substitution NN O O
was NN O O
expressed NN O O
in NN O O
cos-1 NN O O
cells. NN O O
the NN O O
mutant NN O O
vwf NN O O
was NN O O
processed NN O O
and NN O O
secreted NN O O
normally, NN O O
and NN O O
was NN O O
functionally NN O O
equivalent NN O O
to NN O O
wild-type NN O O
vwf NN O O
in NN O O
its NN O O
ability NN O O
to NN O O
bind NN O O
to NN O O
platelets. NN O O
however, NN O O
the NN O O
mutant NN O O
failed NN O O
to NN O O
bind NN O O
factor NN O O
viii, NN O O
demonstrating NN O O
that NN O O
the NN O O
mutation NN O O
was NN O O
functionally NN O O
related NN O O
to NN O O
the NN O O
observed NN O O
hemophilia NN B-Modifier B-MSH:D006467
phenotype. NN O O
the NN O O
family NN O O
we NN O O
describe NN O O
demonstrates NN O O
the NN O O
recessive NN O O
inheritance NN O O
of NN O O
a NN O O
recently NN O O
recognized NN O O
class NN O O
of NN O O
genetic NN O O
bleeding NN O O
disorders, NN O O
we NN O O
call NN O O
" NN O O
autosomal NN O O
hemophilia NN B-SpecificDisease B-MSH:D006467
. NN O O
" NN O O
we NN O O
conclude NN O O
that NN O O
vwf NN O O
mutation NN O O
may NN O O
be NN O O
an NN O O
under NN O O
recognized NN O O
cause NN O O
of NN O O
hemophilia NN B-SpecificDisease B-MSH:D006467
, NN O O
especially NN O O
in NN O O
cases NN O O
where NN O O
the NN O O
inheritance NN O O
pattern NN O O
is NN O O
not NN O O
consistent NN O O
with NN O O
x-linked NN O O
transmission NN O O
. NN O O

determination NN O O
of NN O O
30 NN O O
X-linked NN B-Modifier B-MSH:D000326
adrenoleukodystrophy NN I-Modifier I-MSH:D000326
mutations, NN O O
including NN O O
15 NN O O
not NN O O
previously NN O O
described NN O O
. NN O O

x-linked NN O O
adrenoleukodystrophy NN O O
( NN O O
X-ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
is NN O O
the NN O O
most NN O O
frequent NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
disease NN I-DiseaseClass I-MSH:D018901
. NN O O
it NN O O
mainly NN O O
involves NN O O
the NN O O
nervous NN O O
system NN O O
white NN O O
matter, NN O O
adrenal NN O O
cortex NN O O
and NN O O
testes. NN O O
several NN O O
distinct NN O O
clinical NN O O
phenotypes NN O O
are NN O O
known. NN O O
the NN O O
principal NN O O
biochemical NN O O
abnormality NN O O
is NN O O
the NN O O
accumulation NN O O
of NN O O
saturated NN O O
very-long-chain NN O O
fatty NN O O
acids NN O O
(vlcfas NN O O
> NN O O
c NN O O
22 NN O O
0, NN O O
mainly NN O O
c NN O O
26 NN O O
0), NN O O
which NN O O
is NN O O
due NN O O
to NN O O
impaired NN O O
capacity NN O O
for NN O O
beta-oxidation NN O O
in NN O O
peroxisomes. NN O O
diagnosis NN O O
is NN O O
usually NN O O
based NN O O
on NN O O
the NN O O
vlcfa NN O O
levels NN O O
in NN O O
plasma NN O O
or NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
in NN O O
both NN O O
patients NN O O
and NN O O
carriers. NN O O
in NN O O
0. NN O O
1% NN O O
of NN O O
affected NN O O
males, NN O O
however, NN O O
the NN O O
plasma NN O O
c NN O O
26 NN O O
0 NN O O
level NN O O
is NN O O
borderline NN O O
normal, NN O O
and NN O O
15% NN O O
of NN O O
obligate NN O O
female NN O O
carriers NN O O
have NN O O
normal NN O O
results. NN O O
effective NN O O
mutation NN O O
detection NN O O
in NN O O
these NN O O
families NN O O
is NN O O
therefore NN O O
fundamenta NN O O
. NN O O

to NN O O
unambiguously NN O O
determine NN O O
the NN O O
genetic NN O O
status NN O O
of NN O O
each NN O O
individual NN O O
at NN O O
risk. NN O O
of NN O O
particular NN O O
concern NN O O
are NN O O
female NN O O
members NN O O
of NN O O
kindreds NN O O
segregating NN O O
X-ALD NN B-Modifier B-MSH:D000326
mutations, NN O O
because NN O O
normal NN O O
vlcfa NN O O
levels NN O O
do NN O O
not NN O O
guarantee NN O O
lack NN O O
of NN O O
carrier NN O O
status. NN O O
we NN O O
describe NN O O
a NN O O
fast NN O O
method NN O O
for NN O O
detection NN O O
of NN O O
X-ALD NN B-Modifier B-MSH:D000326
mutations. NN O O
the NN O O
method NN O O
is NN O O
based NN O O
on NN O O
sscp NN O O
analysis NN O O
of NN O O
nested NN O O
pcr NN O O
fragments NN O O
followed NN O O
by NN O O
sequence-determination NN O O
reactions. NN O O
using NN O O
this NN O O
methodology NN O O
we NN O O
have NN O O
found NN O O
X-ALD NN B-Modifier B-MSH:D000326
mutations NN O O
in NN O O
30 NN O O
kindreds, NN O O
including NN O O
15 NN O O
not NN O O
previously NN O O
reported NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
in NN O O
families NN O O
with NN O O
early-onset NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
. NN O O

we NN O O
analysed NN O O
50 NN O O
probands NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
breast NN B-CompositeMention B-MSH:D061325
and/or NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
for NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
candidate NN O O
gene, NN O O
using NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
analysis NN O O
on NN O O
pcr-amplified NN O O
genomic NN O O
dna. NN O O
a NN O O
total NN O O
of NN O O
eight NN O O
putative NN O O
disease-causing NN O O
alterations NN O O
were NN O O
identified NN O O
four NN O O
of NN O O
these NN O O
are NN O O
frameshifts NN O O
and NN O O
two NN O O
are NN O O
nonsense NN O O
mutations. NN O O
in NN O O
addition, NN O O
we NN O O
found NN O O
two NN O O
missense NN O O
mutations, NN O O
one NN O O
of NN O O
which NN O O
changes NN O O
the NN O O
final NN O O
cysteine NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
zinc NN O O
finger NN O O
motif NN O O
to NN O O
glycine. NN O O
these NN O O
data NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
model, NN O O
and NN O O
support NN O O
the NN O O
notion NN O O
that NN O O
this NN O O
candidate NN O O
gene NN O O
is NN O O
in NN O O
fact NN O O
brca NN O O
1. NN O O
the NN O O
heterogeneity NN O O
of NN O O
mutations, NN O O
coupled NN O O
with NN O O
the NN O O
large NN O O
size NN O O
of NN O O
the NN O O
gene, NN O O
indicates NN O O
that NN O O
clinical NN O O
application NN O O
of NN O O
brca NN O O
1 NN O O
mutatio NN O O
. NN O O

testing NN O O
will NN O O
be NN O O
technically NN O O
challenging. NN O O
. NN O O

screening NN O O
for NN O O
carriers NN O O
of NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
among NN O O
ashkenazi NN O O
jews. NN O O
a NN O O
comparison NN O O
of NN O O
dna-based NN O O
and NN O O
enzyme-based NN O O
tests NN O O
. NN O O

background NN O O
and NN O O
methods. NN O O
the NN O O
prevention NN O O
of NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
( NN O O
GM2 NN B-SpecificDisease B-MSH:D013661
gangliosidosis, NN I-SpecificDisease I-MSH:D013661
type NN I-SpecificDisease I-MSH:D013661
1 NN I-SpecificDisease I-MSH:D013661
) NN O O
depends NN O O
on NN O O
the NN O O
identification NN O O
of NN O O
carriers NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
this NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
. NN O O
we NN O O
compared NN O O
the NN O O
enzyme-based NN O O
test NN O O
widely NN O O
used NN O O
in NN O O
screening NN O O
for NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
with NN O O
a NN O O
test NN O O
based NN O O
on NN O O
analysis NN O O
of NN O O
dna. NN O O
we NN O O
developed NN O O
methods NN O O
to NN O O
detect NN O O
the NN O O
three NN O O
mutations NN O O
in NN O O
the NN O O
hexa NN O O
gene NN O O
that NN O O
occur NN O O
with NN O O
high NN O O
frequency NN O O
among NN O O
ashkenazi NN O O
jews NN O O
two NN O O
mutations NN O O
cause NN O O
infantile NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
, NN O O
and NN O O
the NN O O
third NN O O
causes NN O O
the NN O O
adult-onset NN O O
form NN O O
of NN O O
the NN O O
disease. NN O O
dna NN O O
segments NN O O
containing NN O O
these NN O O
mutation NN O O
sites NN O O
were NN O O
amplified NN O O
with NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
and NN O O
analyzed NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
mutations. NN O O
results. NN O O
among NN O O
62 NN O O
ashkenazi NN O O
obligate NN O O
carriers NN O O
of NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
, NN O O
the NN O O
three NN O O
specific NN O O
mutation NN O O
. NN O O

accounted NN O O
for NN O O
all NN O O
but NN O O
one NN O O
of NN O O
the NN O O
mutant NN O O
alleles NN O O
(98 NN O O
percent). NN O O
in NN O O
216 NN O O
ashkenazi NN O O
carriers NN O O
identified NN O O
by NN O O
the NN O O
enzyme NN O O
test, NN O O
dna NN O O
analysis NN O O
showed NN O O
that NN O O
177 NN O O
(82 NN O O
percent) NN O O
had NN O O
one NN O O
of NN O O
the NN O O
identified NN O O
mutations. NN O O
of NN O O
the NN O O
177, NN O O
79 NN O O
percent NN O O
had NN O O
the NN O O
exon NN O O
11 NN O O
insertion NN O O
mutation, NN O O
18 NN O O
percent NN O O
had NN O O
the NN O O
intron NN O O
12 NN O O
splice-junction NN O O
mutation, NN O O
and NN O O
3 NN O O
percent NN O O
had NN O O
the NN O O
less NN O O
severe NN O O
exon NN O O
7 NN O O
mutation NN O O
associated NN O O
with NN O O
adult-onset NN O O
disease. NN O O
the NN O O
results NN O O
of NN O O
the NN O O
enzyme NN O O
tests NN O O
in NN O O
the NN O O
39 NN O O
subjects NN O O
(18 NN O O
percent) NN O O
who NN O O
were NN O O
defined NN O O
as NN O O
carriers NN O O
but NN O O
in NN O O
whom NN O O
dna NN O O
analysis NN O O
did NN O O
not NN O O
identify NN O O
a NN O O
mutant NN O O
allele NN O O
were NN O O
probably NN O O
false NN O O
positive NN O O
(although NN O O
there NN O O
remains NN O O
some NN O O
possibility NN O O
of NN O O
unidentified NN O O
mutations). NN O O
in NN O O
addition, NN O O
of NN O O
152 NN O O
persons NN O O
defined NN O O
as NN O O
noncarriers NN O O
by NN O O
the NN O O
enzyme-base NN O O
. NN O O

test, NN O O
1 NN O O
was NN O O
identified NN O O
as NN O O
a NN O O
carrier NN O O
by NN O O
dna NN O O
analysis NN O O
(i. NN O O
e NN O O
e., NN O O
a NN O O
false NN O O
negative NN O O
enzyme-test NN O O
result). NN O O
conclusions. NN O O
the NN O O
increased NN O O
specificity NN O O
and NN O O
predictive NN O O
value NN O O
of NN O O
the NN O O
dna-based NN O O
test NN O O
make NN O O
it NN O O
a NN O O
useful NN O O
adjunct NN O O
to NN O O
the NN O O
diagnostic NN O O
tests NN O O
currently NN O O
used NN O O
to NN O O
screen NN O O
for NN O O
carriers NN O O
of NN O O
Tay-Sachs NN B-SpecificDisease B-MSH:D013661
disease NN I-SpecificDisease I-MSH:D013661
. NN O O

adrenoleukodystrophy NN O O
gene NN O O
encodes NN O O
an NN O O
80 NN O O
kda NN O O
membrane NN O O
protein NN O O
. NN O O

an NN O O
antibody NN O O
against NN O O
the NN O O
synthetic NN O O
c-terminal NN O O
peptides NN O O
deduced NN O O
from NN O O
the NN O O
cdna NN O O
of NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
X-linked NN B-SpecificDisease B-MSH:D000326
adrenoleukodystrophy NN I-SpecificDisease I-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
was NN O O
produced NN O O
to NN O O
characterize NN O O
the NN O O
product NN O O
of NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene. NN O O
the NN O O
antibody NN O O
reacted NN O O
with NN O O
the NN O O
80 NN O O
kda NN O O
band NN O O
protein NN O O
in NN O O
control NN O O
fibroblasts, NN O O
while NN O O
no NN O O
bands NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
fibroblasts NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
ALD NN B-SpecificDisease B-MSH:D000326
(# NN O O
163), NN O O
in NN O O
which NN O O
mrna NN O O
of NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
was NN O O
undetectable NN O O
based NN O O
on NN O O
northern NN O O
blot NN O O
analysis. NN O O
the NN O O
293 NN O O
t NN O O
cells NN O O
transfected NN O O
with NN O O
the NN O O
full-coding NN O O
cdna NN O O
inserted NN O O
in NN O O
the NN O O
expression NN O O
vector NN O O
produced NN O O
a NN O O
new NN O O
80 NN O O
kda NN O O
protein, NN O O
as NN O O
detected NN O O
by NN O O
western NN O O
blot. NN O O
in NN O O
an NN O O
immunocytological NN O O
study, NN O O
the NN O O
staining NN O O
was NN O O
in NN O O
a NN O O
punctate NN O O
pattern, NN O O
in NN O O
the NN O O
normal NN O O
fibroblasts. NN O O
however, NN O O
there NN O O
was NN O O
no NN O O
punctate NN O O
staining NN O O
in NN O O
the NN O O
# NN O O
16 NN O O
. NN O O

cells. NN O O
these NN O O
data NN O O
thus NN O O
indicate NN O O
that NN O O
the NN O O
ALD NN B-Modifier B-MSH:D000326
gene NN O O
encodes NN O O
an NN O O
80 NN O O
kda NN O O
membrane NN O O
protein. NN O O
. NN O O

preferential NN O O
germline NN O O
mutation NN O O
of NN O O
the NN O O
paternal NN O O
allele NN O O
in NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
. NN O O

the NN O O
event NN O O
triggering NN O O
malignant NN O O
proliferation NN O O
in NN O O
70% NN O O
of NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
tumours NN I-SpecificDisease I-MSH:D012175
is NN O O
loss NN O O
of NN O O
heterozygosity NN O O
for NN O O
chromosome NN O O
13 NN O O
q NN O O
14, NN O O
whereby NN O O
the NN O O
normal NN O O
retinoblastoma NN B-Modifier B-MSH:D012175
gene NN O O
(rb NN O O
1) NN O O
allele NN O O
is NN O O
lost NN O O
and NN O O
an NN O O
already NN O O
mutated NN O O
rb NN O O
1 NN O O
allele NN O O
remains NN O O
in NN O O
the NN O O
tumour NN B-DiseaseClass B-MSH:D009369
. NN O O
the NN O O
first NN O O
allele NN O O
suffers NN O O
a NN O O
mutational NN O O
event--deletion, NN O O
duplication NN O O
or NN O O
point NN O O
mutation NN O O
(manuscript NN O O
in NN O O
preparation) NN O O
--either NN O O
in NN O O
the NN O O
germ NN O O
line NN O O
(all NN O O
bilateral NN O O
patients) NN O O
or NN O O
in NN O O
a NN O O
somatic NN O O
retinal NN O O
cell NN O O
(most NN O O
unilateral NN O O
patients). NN O O
most NN O O
bilateral NN O O
patients NN O O
have NN O O
no NN O O
family NN O O
history NN O O
of NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
and NN O O
are NN O O
presumed NN O O
to NN O O
have NN O O
new NN O O
germline NN O O
mutations NN O O
which NN O O
arose NN O O
in NN O O
the NN O O
egg, NN O O
sperm NN O O
or NN O O
early NN O O
embryo. NN O O
we NN O O
have NN O O
determined NN O O
the NN O O
parental NN O O
origin NN O O
of NN O O
the NN O O
retained NN O O
allele NN O O
in NN O O
nine NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
tumours NN I-SpecificDisease I-MSH:D012175
from NN O O
eight NN O O
unrelated NN O O
non-familial NN O O
cases NN O O
by NN O O
usin NN O O
. NN O O

rb NN O O
1-linked NN O O
genetic NN O O
markers. NN O O
six NN O O
tumours NN B-DiseaseClass B-MSH:D009369
retained NN O O
the NN O O
paternal NN O O
allele NN O O
and NN O O
three NN O O
retained NN O O
the NN O O
maternal NN O O
allele. NN O O
of NN O O
the NN O O
three NN O O
unilateral NN B-DiseaseClass B-MSH:D009369
tumours NN I-DiseaseClass I-MSH:D009369
, NN O O
only NN O O
one NN O O
retained NN O O
the NN O O
paternal NN O O
rb NN O O
1 NN O O
allele. NN O O
thus, NN O O
there NN O O
is NN O O
no NN O O
evidence NN O O
that NN O O
the NN O O
paternal NN O O
rb NN O O
1 NN O O
allele NN O O
is NN O O
preferentially NN O O
retained NN O O
in NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
, NN O O
as NN O O
has NN O O
been NN O O
suggested NN O O
to NN O O
be NN O O
the NN O O
case NN O O
in NN O O
osteosarcoma NN B-SpecificDisease B-MSH:D012516
. NN O O
by NN O O
contrast, NN O O
tumours NN B-DiseaseClass B-MSH:D009369
from NN O O
four NN O O
of NN O O
the NN O O
five NN O O
bilateral NN O O
patients NN O O
retained NN O O
the NN O O
paternal NN O O
rb NN O O
1 NN O O
allele. NN O O
this NN O O
suggests NN O O
either NN O O
that NN O O
new NN O O
germline NN O O
rb NN O O
1 NN O O
mutations NN O O
arise NN O O
more NN O O
frequently NN O O
during NN O O
spermatogenesis NN O O
than NN O O
during NN O O
oogenesis, NN O O
or NN O O
that NN O O
imprinting NN O O
in NN O O
the NN O O
early NN O O
embryo NN O O
affects NN O O
chromosomal NN O O
susceptibility NN O O
to NN O O
mutation. NN O O
. NN O O

mutations NN O O
at NN O O
the NN O O
ataxia-telangiectasia NN B-Modifier B-MSH:D001260
locus NN O O
and NN O O
clinical NN O O
phenotypes NN O O
of NN O O
A-T NN B-Modifier B-MSH:D001260
patients NN O O
. NN O O

mutations NN O O
at NN O O
the NN O O
ataxia-telangiectasia NN B-Modifier B-MSH:D001260
( NN O O
A-T NN B-Modifier B-MSH:D001260
) NN O O
locus NN O O
on NN O O
chromosome NN O O
band NN O O
11 NN O O
q NN O O
22 NN O O
cause NN O O
a NN O O
distinctive NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
syndrome NN I-DiseaseClass I-MSH:D030342
in NN O O
homozygotes NN O O
and NN O O
predispose NN O O
heterozygotes NN O O
to NN O O
cancer NN B-DiseaseClass B-MSH:D009369
, NN O O
ischemic NN B-SpecificDisease B-MSH:D017202
heart NN I-SpecificDisease I-MSH:D017202
disease NN I-SpecificDisease I-MSH:D017202
, NN O O
and NN O O
early NN O O
mortality. NN O O
pcr NN O O
amplification NN O O
from NN O O
genomic NN O O
dna NN O O
and NN O O
automated NN O O
sequencing NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
(66 NN O O
exons) NN O O
and NN O O
splice NN O O
junctions NN O O
detected NN O O
77 NN O O
mutations NN O O
(85%) NN O O
in NN O O
90 NN O O
A-T NN B-Modifier B-MSH:D001260
chromosomes. NN O O
heteroduplex NN O O
analysis NN O O
detected NN O O
another NN O O
42 NN O O
mutations NN O O
at NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260
locus. NN O O
out NN O O
of NN O O
a NN O O
total NN O O
of NN O O
71 NN O O
unique NN O O
mutations, NN O O
50 NN O O
were NN O O
found NN O O
only NN O O
in NN O O
a NN O O
single NN O O
family, NN O O
and NN O O
51 NN O O
had NN O O
not NN O O
been NN O O
reported NN O O
previously. NN O O
most NN O O
(58/71, NN O O
82%) NN O O
mutations NN O O
were NN O O
frameshift NN O O
and NN O O
nonsense NN O O
mutations NN O O
that NN O O
are NN O O
predicted NN O O
to NN O O
cause NN O O
truncation NN O O
of NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260
protei NN O O
. NN O O

; NN O O
the NN O O
less NN O O
common NN O O
mutation NN O O
types NN O O
were NN O O
missense NN O O
(9/71, NN O O
13%), NN O O
splicing NN O O
(3/71, NN O O
4%) NN O O
and NN O O
one NN O O
in-frame NN O O
deletion, NN O O
2546 NN O O
3 NN O O
(1/71, NN O O
1%). NN O O
the NN O O
mean NN O O
survival NN O O
and NN O O
height NN O O
distribution NN O O
of NN O O
134 NN O O
A-T NN B-Modifier B-MSH:D001260
patients NN O O
correlated NN O O
significantly NN O O
with NN O O
the NN O O
specific NN O O
mutations NN O O
present NN O O
in NN O O
the NN O O
patients. NN O O
patients NN O O
homozygous NN O O
for NN O O
a NN O O
single NN O O
truncating NN O O
mutation, NN O O
typically NN O O
near NN O O
the NN O O
n-terminal NN O O
end NN O O
of NN O O
the NN O O
gene, NN O O
or NN O O
heterozygous NN O O
for NN O O
the NN O O
in-frame NN O O
deletion NN O O
2546 NN O O
3, NN O O
were NN O O
shorter NN O O
and NN O O
had NN O O
significantly NN O O
shorter NN O O
survival NN O O
than NN O O
those NN O O
heterozygous NN O O
for NN O O
a NN O O
splice NN O O
site NN O O
or NN O O
missense NN O O
mutation, NN O O
or NN O O
heterozygous NN O O
for NN O O
two NN O O
truncating NN O O
mutations. NN O O
alterations NN O O
of NN O O
the NN O O
length NN O O
or NN O O
amino NN O O
acid NN O O
composition NN O O
of NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260
gene NN O O
product NN O O
affect NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260

-t NN O O
clinical NN O O
phenotype NN O O
in NN O O
different NN O O
ways. NN O O
mutation NN O O
analysis NN O O
at NN O O
the NN O O
A-T NN B-Modifier B-MSH:D001260
locus NN O O
may NN O O
help NN O O
estimate NN O O
the NN O O
prognosis NN O O
of NN O O
A-T NN B-Modifier B-MSH:D001260
patients. NN O O
. NN O O

anticipation NN O O
resulting NN O O
in NN O O
elimination NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
gene: NN O O
a NN O O
follow NN O O
up NN O O
study NN O O
of NN O O
one NN O O
extended NN O O
family NN O O
. NN O O

we NN O O
have NN O O
re-examined NN O O
an NN O O
extended NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
( NN O O
DM NN B-Modifier B-MSH:D009223
) NN O O
family, NN O O
previously NN O O
described NN O O
in NN O O
1955, NN O O
in NN O O
order NN O O
to NN O O
study NN O O
the NN O O
long NN O O
term NN O O
effects NN O O
of NN O O
anticipation NN O O
in NN O O
DM NN B-SpecificDisease B-MSH:D009223
and NN O O
in NN O O
particular NN O O
the NN O O
implications NN O O
for NN O O
families NN O O
affected NN O O
by NN O O
this NN O O
disease. NN O O
this NN O O
follow NN O O
up NN O O
study NN O O
provides NN O O
data NN O O
on NN O O
35 NN O O
gene NN O O
carriers NN O O
and NN O O
46 NN O O
asymptomatic NN O O
at NN O O
risk NN O O
family NN O O
members NN O O
in NN O O
five NN O O
generations. NN O O
clinical NN O O
anticipation, NN O O
defined NN O O
as NN O O
the NN O O
cascade NN O O
of NN O O
mild, NN O O
adult, NN O O
childhood, NN O O
or NN O O
congenital NN B-DiseaseClass B-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
in NN O O
subsequent NN O O
generations, NN O O
appeared NN O O
to NN O O
be NN O O
a NN O O
relentless NN O O
process, NN O O
occurring NN O O
in NN O O
all NN O O
affected NN O O
branches NN O O
of NN O O
the NN O O
family. NN O O
the NN O O
cascade NN O O
was NN O O
found NN O O
to NN O O
proceed NN O O
asynchronously NN O O
in NN O O
the NN O O
different NN O O
branches, NN O O
mainly NN O O
because NN O O
of NN O O
an NN O O
unequal NN O O
number NN O O
of NN O O
generations NN O O
with NN O O
mild NN O O
disease. NN O O
the NN O O
transition NN O O
from NN O O
the NN O O
mild NN O O
to NN O O
the NN O O
adult NN O O
type NN O O
was NN O O
associated NN O O
with NN O O
transmission NN O O
through NN O O
. NN O O

male NN O O
parent. NN O O
stable NN O O
transmission NN O O
of NN O O
the NN O O
asymptomatic/mild NN O O
phenotype NN O O
showed NN O O
a NN O O
female NN O O
transmission NN O O
bias. NN O O
we NN O O
further NN O O
examined NN O O
the NN O O
extent NN O O
and NN O O
causes NN O O
of NN O O
gene NN O O
loss NN O O
in NN O O
this NN O O
pedigree. NN O O
gene NN O O
loss NN O O
in NN O O
the NN O O
patient NN O O
group NN O O
was NN O O
complete, NN O O
owing NN O O
to NN O O
infertility NN B-DiseaseClass B-MSH:D007246
of NN O O
the NN O O
male NN O O
patients NN O O
with NN O O
adult NN O O
onset NN O O
disease NN O O
and NN O O
the NN O O
fact NN O O
that NN O O
mentally NN B-DiseaseClass B-MSH:D008607
retarded NN I-DiseaseClass I-MSH:D008607
patients NN O O
did NN O O
not NN O O
procreate. NN O O
out NN O O
of NN O O
the NN O O
46 NN O O
at NN O O
risk NN O O
subjects NN O O
in NN O O
the NN O O
two NN O O
youngest NN O O
generations, NN O O
only NN O O
one NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
full NN O O
mutation. NN O O
this NN O O
is NN O O
the NN O O
only NN O O
subject NN O O
who NN O O
may NN O O
transmit NN O O
the NN O O
gene NN O O
to NN O O
the NN O O
sixth NN O O
generation. NN O O
no NN O O
protomutation NN O O
carriers NN O O
were NN O O
found NN O O
in NN O O
the NN O O
fourth NN O O
and NN O O
fifth NN O O
generations. NN O O
therefore NN O O
it NN O O
is NN O O
highly NN O O
probable NN O O
that NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
gene NN O O
will NN O O
be NN O O
eliminated NN O O
from NN O O
this NN O O
pedigree NN O O
within NN O O
one NN O O
generation. NN O O
the NN O O
high NN O O
population NN O O
frequency NN O O
of NN O O
DM NN B-SpecificDisease B-MSH:D009223
can NN O O
at NN O O
presen NN O O
. NN O O

not NN O O
be NN O O
explained NN O O
by NN O O
the NN O O
contribution NN O O
of NN O O
asymptomatic NN O O
cases NN O O
in NN O O
the NN O O
younger NN O O
generations NN O O
of NN O O
known NN O O
families, NN O O
but NN O O
is NN O O
probably NN O O
caused NN O O
by NN O O
the NN O O
events NN O O
in NN O O
the NN O O
ancestral NN O O
generations. NN O O
. NN O O

exon NN O O
9 NN O O
mutations NN O O
in NN O O
the NN O O
wt NN O O
1 NN O O
gene, NN O O
without NN O O
influencing NN O O
kts NN O O
splice NN O O
isoforms, NN O O
are NN O O
also NN O O
responsible NN O O
for NN O O
Frasier NN B-SpecificDisease B-MSH:D052159
syndrome NN I-SpecificDisease I-MSH:D052159
. NN O O

we NN O O
report NN O O
new NN O O
mutations NN O O
in NN O O
exon NN O O
9 NN O O
of NN O O
the NN O O
wt NN O O
1 NN O O
gene NN O O
that NN O O
did NN O O
not NN O O
alter NN O O
the NN O O
ratio NN O O
of NN O O
+/- NN O O
kts NN O O
splice NN O O
isoforms NN O O
in NN O O
two NN O O
unrelated NN O O
patients NN O O
with NN O O
Frasier NN B-SpecificDisease B-MSH:D052159
syndrome NN I-SpecificDisease I-MSH:D052159
( NN O O
FS NN B-SpecificDisease B-MSH:D052159
). NN O O
the NN O O
mutation NN O O
of NN O O
intron NN O O
9 NN O O
inducing NN O O
defective NN O O
alternative NN O O
splicing NN O O
was NN O O
reported NN O O
to NN O O
be NN O O
responsible NN O O
for NN O O
this NN O O
syndrome. NN O O
the NN O O
mutations NN O O
found NN O O
in NN O O
our NN O O
cases NN O O
occurred NN O O
in NN O O
the NN O O
same NN O O
exon NN O O
of NN O O
the NN O O
wt NN O O
1 NN O O
gene NN O O
as NN O O
detected NN O O
in NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
( NN O O
DDS NN B-SpecificDisease B-MSH:D030321
) NN O O
and NN O O
could NN O O
not NN O O
be NN O O
explained NN O O
by NN O O
the NN O O
previously NN O O
proposed NN O O
mechanism. NN O O
the NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
two NN O O
syndromes NN O O
originate NN O O
from NN O O
the NN O O
same NN O O
WT1 NN B-SpecificDisease B-MSH:D009396
gene NN I-SpecificDisease I-MSH:D009396
abnormality NN I-SpecificDisease I-MSH:D009396
. NN O O
from NN O O
a NN O O
molecular NN O O
biological NN O O
point NN O O
of NN O O
view, NN O O
we NN O O
concluded NN O O
that NN O O
the NN O O
two NN O O
diseases NN O O
were NN O O
not NN O O
separable, NN O O
and NN O O
that NN O O
FS NN B-SpecificDisease B-MSH:D052159
should NN O O
be NN O O
included NN O O
as NN O O
an NN O O
atypical NN O O
form NN O O
of NN O O
DDS NN B-SpecificDisease B-MSH:D030321
. NN O O
. NN O O

deficit NN O O
of NN O O
in NN O O
vivo NN O O
mitochondrial NN O O
atp NN O O
production NN O O
in NN O O
patients NN O O
with NN O O
Friedreich NN B-SpecificDisease B-MSH:D005621
ataxia NN I-SpecificDisease I-MSH:D005621
. NN O O

friedreich NN O O
ataxia NN O O
( NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
), NN O O
the NN O O
most NN O O
common NN O O
of NN O O
the NN O O
inherited NN B-DiseaseClass B-MSH:D013132
ataxias NN I-DiseaseClass I-MSH:D013132
, NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D019636
recessive NN I-DiseaseClass I-MSH:D019636
degenerative NN I-DiseaseClass I-MSH:D019636
disorder NN I-DiseaseClass I-MSH:D019636
, NN O O
characterized NN O O
clinically NN O O
by NN O O
onset NN O O
before NN O O
the NN O O
age NN O O
of NN O O
25 NN O O
of NN O O
progressive NN B-CompositeMention B-MSH:D020234
gait NN I-CompositeMention I-MSH:D020234
and NN I-CompositeMention I-MSH:D020234
limb NN I-CompositeMention I-MSH:D020234
ataxia NN I-CompositeMention I-MSH:D020234
, NN O O
absence NN B-DiseaseClass B-MSH:D012021
of NN I-DiseaseClass I-MSH:D012021
deep NN I-DiseaseClass I-MSH:D012021
tendon NN I-DiseaseClass I-MSH:D012021
reflexes NN I-DiseaseClass I-MSH:D012021
, NN O O
extensor NN B-DiseaseClass B-MSH:D001405
plantar NN I-DiseaseClass I-MSH:D001405
responses NN I-DiseaseClass I-MSH:D001405
, NN O O
and NN O O
loss NN B-CompositeMention B-MSH:D053421
of NN I-CompositeMention I-MSH:D053421
position NN I-CompositeMention I-MSH:D053421
and NN I-CompositeMention I-MSH:D053421
vibration NN I-CompositeMention I-MSH:D053421
sense NN I-CompositeMention I-MSH:D053421
in NN O O
the NN O O
lower NN O O
limbs. NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
is NN O O
caused NN O O
by NN O O
a NN O O
gaa NN O O
triplet NN O O
expansion NN O O
in NN O O
the NN O O
first NN O O
intron NN O O
of NN O O
the NN O O
FRDA NN B-Modifier B-MSH:D005621
gene NN O O
on NN O O
chromosome NN O O
9 NN O O
q NN O O
13 NN O O
in NN O O
97% NN O O
of NN O O
patients. NN O O
the NN O O
FRDA NN B-Modifier B-MSH:D005621
gene NN O O
encodes NN O O
a NN O O
widely NN O O
expressed NN O O
210-aa NN O O
protein, NN O O
frataxin, NN O O
which NN O O
is NN O O
located NN O O
in NN O O
mitochondria NN O O
and NN O O
is NN O O
severely NN O O
reduced NN O O
in NN O O
FRDA NN B-Modifier B-MSH:D005621
patients. NN O O
frataxin NN O O
function NN O O
is NN O O
still NN O O
unknown NN O O
but NN O O
the NN O O
knockout NN O O
of NN O O
the NN O O
yeast NN O O
frataxin NN O O
homologue NN O O
gene NN O O
(yfh NN O O
1) NN O O
showed NN O O
a NN O O
severe NN O O
defect NN O O
of NN O O
mitochondrial NN O O
respiration NN O O
and NN O O
los NN O O
. NN O O

of NN O O
mtdna NN O O
associated NN O O
with NN O O
elevated NN O O
intramitochondrial NN O O
iron. NN O O
here NN O O
we NN O O
report NN O O
in NN O O
vivo NN O O
evidence NN O O
of NN O O
impaired NN O O
mitochondrial NN O O
respiration NN O O
in NN O O
skeletal NN O O
muscle NN O O
of NN O O
FRDA NN B-Modifier B-MSH:D005621
patients. NN O O
using NN O O
phosphorus NN O O
magnetic NN O O
resonance NN O O
spectroscopy NN O O
we NN O O
demonstrated NN O O
a NN O O
maximum NN O O
rate NN O O
of NN O O
muscle NN O O
mitochondrial NN O O
atp NN O O
production NN O O
(v NN O O
(max)) NN O O
below NN O O
the NN O O
normal NN O O
range NN O O
in NN O O
all NN O O
12 NN O O
FRDA NN B-Modifier B-MSH:D005621
patients NN O O
and NN O O
a NN O O
strong NN O O
negative NN O O
correlation NN O O
between NN O O
mitochondrial NN O O
v NN O O
(max) NN O O
and NN O O
the NN O O
number NN O O
of NN O O
gaa NN O O
repeats NN O O
in NN O O
the NN O O
smaller NN O O
allele. NN O O
our NN O O
results NN O O
show NN O O
that NN O O
FRDA NN B-SpecificDisease B-MSH:D005621
is NN O O
a NN O O
nuclear-encoded NN O O
mitochondrial NN B-DiseaseClass B-MSH:D028361
disorder NN I-DiseaseClass I-MSH:D028361
affecting NN O O
oxidative NN O O
phosphorylation NN O O
and NN O O
give NN O O
a NN O O
rationale NN O O
for NN O O
treatments NN O O
aimed NN O O
to NN O O
improve NN O O
mitochondrial NN O O
function NN O O
in NN O O
this NN O O
condition. NN O O
. NN O O

chronic NN O O
nonspherocytic NN O O
hemolytic NN O O
anemia NN O O
( NN O O
CNSHA NN B-SpecificDisease B-MSH:D000746
) NN O O
and NN O O
glucose NN B-SpecificDisease B-MSH:D005955
6 NN I-SpecificDisease I-MSH:D005955
phosphate NN I-SpecificDisease I-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
a NN O O
patient NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D028227
amyloidotic NN I-SpecificDisease I-MSH:D028227
polyneuropathy NN I-SpecificDisease I-MSH:D028227
( NN O O
FAP NN B-SpecificDisease B-MSH:D028227
). NN O O
molecular NN O O
study NN O O
of NN O O
a NN O O
new NN O O
variant NN O O
(g NN O O
6 NN O O
pd NN O O
clinic) NN O O
with NN O O
markedly NN O O
acidic NN O O
ph NN O O
optimum NN O O
. NN O O

a NN O O
new NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
variant NN O O
with NN O O
severe NN O O
erythrocytic NN B-SpecificDisease B-MSH:D005955
G6PD NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
and NN O O
a NN O O
unique NN O O
ph NN O O
optimum NN O O
is NN O O
described NN O O
in NN O O
a NN O O
young NN O O
patient NN O O
with NN O O
chronic NN B-SpecificDisease B-MSH:D000746
nonspherocytic NN I-SpecificDisease I-MSH:D000746
hemolytic NN I-SpecificDisease I-MSH:D000746
anemia NN I-SpecificDisease I-MSH:D000746
( NN O O
CNSHA NN B-SpecificDisease B-MSH:D000746
) NN O O
and NN O O
familial NN B-SpecificDisease B-MSH:D028227
amyloidotic NN I-SpecificDisease I-MSH:D028227
polyneuropathy NN I-SpecificDisease I-MSH:D028227
( NN O O
FAP NN B-SpecificDisease B-MSH:D028227
). NN O O
Chronic NN B-SpecificDisease B-MSH:D006461
hemolysis NN I-SpecificDisease I-MSH:D006461
was NN O O
present NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
infections, NN O O
oxidant NN O O
drugs NN O O
or NN O O
ingestion NN O O
of NN O O
faba NN O O
beans. NN O O
residual NN O O
enzyme NN O O
activity NN O O
was NN O O
about NN O O
2. NN O O
6% NN O O
and NN O O
63% NN O O
of NN O O
normal NN O O
activity NN O O
in NN O O
erythrocytes NN O O
and NN O O
leucocytes, NN O O
respectively. NN O O
a NN O O
molecular NN O O
study NN O O
using NN O O
standard NN O O
methods NN O O
showed NN O O
g NN O O
6 NN O O
pd NN O O
in NN O O
the NN O O
patient NN O O
to NN O O
have NN O O
normal NN O O
electrophoretic NN O O
mobility NN O O
(at NN O O
ph NN O O
7. NN O O
0, NN O O
8. NN O O
0 NN O O
and NN O O
8. NN O O
8), NN O O
normal NN O O
apparent NN O O
affinity NN O O
for NN O O
substrates NN O O
(km, NN O O
g NN O O
6 NN O O
p NN O O
and NN O O
nadp) NN O O
and NN O O
a NN O O
slightly NN O O
abnorma NN O O
. NN O O

utilization NN O O
of NN O O
substrate NN O O
analogues NN O O
(decreased NN O O
deamino-nadp NN O O
and NN O O
increased NN O O
2-deoxyglucose-6-phosphate NN O O
utilization). NN O O
heat NN O O
stability NN O O
was NN O O
found NN O O
to NN O O
be NN O O
markedly NN O O
decreased NN O O
(8% NN O O
of NN O O
residual NN O O
activity NN O O
after NN O O
20 NN O O
min NN O O
of NN O O
incubation NN O O
at NN O O
46 NN O O
degrees NN O O
c) NN O O
and NN O O
a NN O O
particular NN O O
characteristic NN O O
of NN O O
this NN O O
enzyme NN O O
was NN O O
a NN O O
biphasic NN O O
ph NN O O
curve NN O O
with NN O O
a NN O O
greatly NN O O
increased NN O O
activity NN O O
at NN O O
low NN O O
ph. NN O O
although NN O O
molecular NN O O
characteristics NN O O
of NN O O
this NN O O
variant NN O O
closely NN O O
resemble NN O O
those NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
bangkok NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
duarte, NN O O
it NN O O
can NN O O
be NN O O
distinguished NN O O
from NN O O
these NN O O
and NN O O
all NN O O
other NN O O
previously NN O O
reported NN O O
variants NN O O
by NN O O
virtue NN O O
of NN O O
its NN O O
unusual NN O O
ph NN O O
curve. NN O O
therefore NN O O
the NN O O
present NN O O
variant NN O O
has NN O O
been NN O O
designated NN O O
g NN O O
6 NN O O
pd NN O O
clinic NN O O
to NN O O
distinguish NN O O
it NN O O
from NN O O
other NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
previously NN O O
describe NN O O
. NN O O
enzyme NN O O
was NN O O
a NN O O
biphasic NN O O
ph NN O O
curve NN O O
with NN O O
a NN O O
greatly NN O O
increased NN O O
activity NN O O
at NN O O
low NN O O
ph. NN O O
although NN O O
molecular NN O O
characteristics NN O O
of NN O O
this NN O O
variant NN O O
closely NN O O
resemble NN O O
those NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
bangkok NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
duarte, NN O O
it NN O O
can NN O O
be NN O O
distinguished NN O O
from NN O O
these NN O O
and NN O O
all NN O O
other NN O O
previously NN O O
reported NN O O
variants NN O O
by NN O O
virtue NN O O
of NN O O
its NN O O
unusual NN O O
ph NN O O
curve. NN O O
therefore NN O O
the NN O O
present NN O O
variant NN O O
has NN O O
been NN O O
designated NN O O
g NN O O
6 NN O O
pd NN O O
clinic NN O O
to NN O O
distinguish NN O O
it NN O O
from NN O O
other NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
previously NN O O
describe NN O O
. NN O O

regional NN O O
localization NN O O
of NN O O
polymorphic NN O O
dna NN O O
loci NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome NN O O
using NN O O
deletions NN O O
associated NN O O
with NN O O
choroideremia NN B-SpecificDisease B-MSH:D015794
. NN O O

in NN O O
two NN O O
unrelated NN O O
families, NN O O
males NN O O
have NN O O
been NN O O
identified NN O O
who NN O O
suffer NN O O
from NN O O
choroideremia NN B-SpecificDisease B-MSH:D015794
and NN O O
at NN O O
the NN O O
same NN O O
time NN O O
have NN O O
an NN O O
interstitial NN O O
deletion NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
the NN O O
x NN O O
chromosome. NN O O
by NN O O
high-resolution NN O O
banding NN O O
we NN O O
have NN O O
characterized NN O O
the NN O O
deletion NN O O
chromosomes NN O O
as NN O O
del NN O O
(x) NN O O
(q NN O O
21. NN O O
1-q NN O O
21 NN O O
1-q NN O O
21. NN O O
33) NN O O
and NN O O
del NN O O
(x) NN O O
(q NN O O
21. NN O O
2-q NN O O
21 NN O O
2-q NN O O
21. NN O O
31) NN O O
respectively. NN O O
by NN O O
southern NN O O
blot NN O O
analysis NN O O
we NN O O
have NN O O
mapped NN O O
ten NN O O
different NN O O
polymorphic NN O O
dna NN O O
loci NN O O
relative NN O O
to NN O O
the NN O O
position NN O O
of NN O O
the NN O O
deletion NN O O
and NN O O
the NN O O
choroideremia NN B-Modifier B-MSH:D015794
locus NN O O
tcd. NN O O
one NN O O
probe, NN O O
p NN O O
31, NN O O
was NN O O
shown NN O O
to NN O O
cover NN O O
one NN O O
of NN O O
the NN O O
breakpoints NN O O
of NN O O
the NN O O
smallest NN O O
deletion. NN O O
the NN O O
following NN O O
order NN O O
of NN O O
the NN O O
loci NN O O
was NN O O
suggested NN O O
by NN O O
deletion NN O O
mappin NN O O
. NN O O

cen-dxs NN O O
106-dxs NN O O
72-tcd- NN O O
(dxys NN O O
1/dxys NN O O
23/dxys NN O O
5) NN O O
- NN O O
dxys NN O O
2- NN O O
(dxys NN O O
12/dxs NN O O
3) NN O O
- NN O O
(dxs NN O O
17/dxs NN O O
101) NN O O
- NN O O
xqter NN O O
. NN O O

a NN O O
de NN O O
novo NN O O
unbalanced NN O O
reciprocal NN O O
translocation NN O O
identified NN O O
as NN O O
paternal NN O O
in NN O O
origin NN O O
in NN O O
the NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
. NN O O

interstitial NN O O
cytogenetic NN O O
deletions NN O O
involving NN O O
the NN O O
paternally NN O O
derived NN O O
chromosome NN O O
15 NN O O
q NN O O
11-13 NN O O
have NN O O
been NN O O
described NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
we NN O O
report NN O O
a NN O O
child NN O O
with NN O O
PWS NN B-SpecificDisease B-MSH:D011218
and NN O O
a NN O O
de NN O O
novo NN O O
unbalanced NN O O
karyotype NN O O
-45, NN O O
xy, NN O O
-9, NN O O
-15, NN O O
+ NN O O
der NN O O
(9) NN O O
t NN O O
(9; NN O O
15) NN O O
(q NN O O
34; NN O O
q NN O O
13). NN O O
molecular NN O O
studies NN O O
with NN O O
the NN O O
dna NN O O
probe NN O O
pml NN O O
34 NN O O
confirmed NN O O
that NN O O
only NN O O
a NN O O
single NN O O
Prader NN B-Modifier B-MSH:D011218
Willi NN I-Modifier I-MSH:D011218
critical NN O O
region NN O O
(pwcr NN O O
15 NN O O
q NN O O
11. NN O O
2-q NN O O
12) NN O O
copy NN O O
was NN O O
present. NN O O
hybridisation NN O O
of NN O O
patient NN O O
and NN O O
parental NN O O
dna NN O O
with NN O O
the NN O O
multi-allelic NN O O
probe NN O O
cmw NN O O
1, NN O O
which NN O O
maps NN O O
to NN O O
pter-15 NN O O
q NN O O
13, NN O O
showed NN O O
that NN O O
the NN O O
chromosome NN O O
involved NN O O
in NN O O
the NN O O
translocation NN O O
was NN O O
paternal NN O O
in NN O O
origin. NN O O
thi NN O O
. NN O O

is NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
paternally-derived NN O O
pwcr NN O O
allele NN O O
loss NN O O
caused NN O O
by NN O O
an NN O O
unbalanced NN O O
translocation NN O O
that NN O O
has NN O O
arisen NN O O
de NN O O
novo NN O O
. NN O O

clinicopathologic NN O O
features NN O O
of NN O O
BRCA-linked NN B-CompositeMention B-OMIM:604370
and NN I-CompositeMention I-OMIM:604370
sporadic NN I-CompositeMention I-OMIM:604370
ovarian NN I-CompositeMention I-OMIM:604370
cancer NN I-CompositeMention I-OMIM:604370
. NN O O

context NN O O
most NN O O
hereditary NN B-SpecificDisease B-MSH:D061325
ovarian NN I-SpecificDisease I-MSH:D061325
cancers NN I-SpecificDisease I-MSH:D061325
are NN O O
associated NN O O
with NN O O
germline NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
or NN O O
brca NN O O
2. NN O O
attempts NN O O
to NN O O
define NN O O
the NN O O
clinical NN O O
significance NN O O
of NN O O
brca NN O O
mutation NN O O
status NN O O
in NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
have NN O O
produced NN O O
conflicting NN O O
results, NN O O
especially NN O O
regarding NN O O
survival. NN O O
objective NN O O
to NN O O
determine NN O O
whether NN O O
hereditary NN B-SpecificDisease B-MSH:D061325
ovarian NN I-SpecificDisease I-MSH:D061325
cancers NN I-SpecificDisease I-MSH:D061325
have NN O O
distinct NN O O
clinical NN O O
and NN O O
pathological NN O O
features NN O O
compared NN O O
with NN O O
sporadic NN B-SpecificDisease B-MSH:D010051
(nonhereditary) NN I-SpecificDisease I-MSH:D010051
ovarian NN I-SpecificDisease I-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
. NN O O
design NN O O
and NN O O
setting NN O O
retrospective NN O O
cohort NN O O
study NN O O
of NN O O
a NN O O
consecutive NN O O
series NN O O
of NN O O
933 NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
diagnosed NN O O
and NN O O
treated NN O O
at NN O O
our NN O O
institution, NN O O
which NN O O
is NN O O
a NN O O
comprehensive NN O O
cancer NN B-Modifier B-MSH:D009369
center NN O O
as NN O O
designated NN O O
by NN O O
the NN O O
national NN O O
Cancer NN B-Modifier B-MSH:D009369
institute, NN O O
over NN O O
a NN O O
12-year NN O O
period NN O O
(december NN O O
1986 NN O O
to NN O O
august NN O O
1998). NN O O
patients NN O O
the NN O O
study NN O O
was NN O O
restricted NN O O
to NN O O
patients NN O O
of NN O O
jewish NN O O
origin NN O O
because NN O O
of NN O O
the NN O O
ease NN O O
of NN O O
brca NN O O
1 NN O O
and NN O O
brca NN O O
2 NN O O
genotyping NN O O
in NN O O
this NN O O
ethnic NN O O
group. NN O O
from NN O O
the NN O O
189 NN O O
patient NN O O
. NN O O

who NN O O
identified NN O O
themselves NN O O
as NN O O
jewish, NN O O
88 NN O O
hereditary NN O O
cases NN O O
were NN O O
identified NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
germline NN O O
founder NN O O
mutation NN O O
in NN O O
brca NN O O
1 NN O O
or NN O O
brca NN O O
2. NN O O
the NN O O
remaining NN O O
101 NN O O
cases NN O O
from NN O O
the NN O O
same NN O O
series NN O O
not NN O O
associated NN O O
with NN O O
a NN O O
brca NN O O
mutation NN O O
and NN O O
2 NN O O
additional NN O O
groups NN O O
(gynecologic NN O O
oncology NN O O
group NN O O
protocols NN O O
52 NN O O
and NN O O
111) NN O O
with NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancer NN I-SpecificDisease I-MSH:D010051
from NN O O
clinical NN O O
trials NN O O
(for NN O O
the NN O O
survival NN O O
analysis) NN O O
were NN O O
included NN O O
for NN O O
comparison. NN O O
main NN O O
outcome NN O O
measures NN O O
age NN O O
at NN O O
diagnosis, NN O O
surgical NN O O
stage, NN O O
histologic NN O O
cell NN O O
type NN O O
and NN O O
grade, NN O O
and NN O O
surgical NN O O
outcome; NN O O
and NN O O
response NN O O
to NN O O
chemotherapy NN O O
and NN O O
survival NN O O
for NN O O
advanced-stage NN O O
(ii NN O O
and NN O O
iv) NN O O
cases. NN O O
results NN O O
Hereditary NN B-DiseaseClass B-MSH:D009369
cancers NN I-DiseaseClass I-MSH:D009369
were NN O O
rarely NN O O
diagnosed NN O O
before NN O O
age NN O O
40 NN O O
years NN O O
and NN O O
were NN O O
common NN O O
after NN O O
age NN O O
60 NN O O
years, NN O O
with NN O O
mean NN O O
age NN O O
at NN O O
diagnosis NN O O
being NN O O
significantly NN O O
younger NN O O
for NN O O
brca NN O O
1- NN O O
vs NN O O
brca NN O O
. NN O O

-linked NN O O
patients NN O O
(54 NN O O
vs NN O O
62 NN O O
years; NN O O
p NN O O
=. NN O O
04). NN O O
histology, NN O O
grade, NN O O
stage, NN O O
and NN O O
success NN O O
of NN O O
cytoreductive NN O O
surgery NN O O
were NN O O
similar NN O O
for NN O O
hereditary NN O O
and NN O O
sporadic NN O O
cases. NN O O
the NN O O
hereditary NN O O
group NN O O
had NN O O
a NN O O
longer NN O O
disease-free NN O O
interval NN O O
following NN O O
primary NN O O
chemotherapy NN O O
in NN O O
comparison NN O O
with NN O O
the NN O O
nonhereditary NN O O
group, NN O O
with NN O O
a NN O O
median NN O O
time NN O O
to NN O O
recurrence NN O O
of NN O O
14 NN O O
months NN O O
and NN O O
7 NN O O
months, NN O O
respectively NN O O
(p NN O O
<. NN O O
001). NN O O
those NN O O
with NN O O
hereditary NN B-DiseaseClass B-MSH:D009369
cancers NN I-DiseaseClass I-MSH:D009369
had NN O O
improved NN O O
survival NN O O
compared NN O O
with NN O O
the NN O O
nonhereditary NN O O
group NN O O
(p NN O O
=. NN O O
004). NN O O
for NN O O
stage NN B-DiseaseClass B-MSH:D009369
III NN I-DiseaseClass I-MSH:D009369
cancers NN I-DiseaseClass I-MSH:D009369
, NN O O
brca NN O O
mutation NN O O
status NN O O
was NN O O
an NN O O
independent NN O O
prognostic NN O O
variable NN O O
(p NN O O
=. NN O O
03). NN O O
conclusions NN O O
although NN O O
BRCA-associated NN B-SpecificDisease B-OMIM:604370
hereditary NN I-SpecificDisease I-OMIM:604370
ovarian NN I-SpecificDisease I-OMIM:604370
cancers NN I-SpecificDisease I-OMIM:604370
in NN O O
this NN O O
population NN O O
have NN O O
surgical NN O O
and NN O O
pathological NN O O
characteristics NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
sporadic NN B-DiseaseClass B-MSH:D009369
cancers NN I-DiseaseClass I-MSH:D009369
, NN O O
advanced-stage NN B-Modifier B-MSH:D009386
hereditary NN I-Modifier I-MSH:D009386
cancer NN I-Modifier I-MSH:D009386

hereditary NN O O
cancer NN O O
patients NN O O
survive NN O O
longer NN O O
than NN O O
nonhereditary NN B-Modifier B-MSH:D009369
cancer NN I-Modifier I-MSH:D009369
patients. NN O O
age NN O O
penetrance NN O O
is NN O O
greater NN O O
for NN O O
BRCA1-linked NN B-CompositeMention B-OMIM:604370
than NN I-CompositeMention I-OMIM:604370
for NN I-CompositeMention I-OMIM:604370
BRCA2-linked NN I-CompositeMention I-OMIM:604370
cancers NN I-CompositeMention I-OMIM:604370
in NN O O
this NN O O
population NN O O
. NN O O

germline NN O O
intronic NN O O
and NN O O
exonic NN O O
mutations NN O O
in NN O O
the NN O O
Wilms' NN B-Modifier B-MSH:D009396
tumour NN I-Modifier I-MSH:D009396
gene NN O O
(wt NN O O
1) NN O O
affecting NN O O
urogenital NN O O
development NN O O
. NN O O

denys-drash NN O O
syndrome NN O O
is NN O O
a NN O O
rare NN O O
human NN O O
developmental NN B-DiseaseClass B-MSH:D002658
disorder NN I-DiseaseClass I-MSH:D002658
affecting NN O O
the NN O O
urogenital NN O O
system NN O O
and NN O O
leading NN O O
to NN O O
renal NN B-DiseaseClass B-MSH:D051437
failure NN I-DiseaseClass I-MSH:D051437
, NN O O
intersex NN B-DiseaseClass B-MSH:D012734
disorders NN I-DiseaseClass I-MSH:D012734
and NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumour NN I-SpecificDisease I-MSH:D009396
. NN O O
in NN O O
this NN O O
report, NN O O
four NN O O
individuals NN O O
with NN O O
this NN O O
syndrome NN O O
are NN O O
described NN O O
carrying NN O O
germline NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
Wilms NN B-Modifier B-MSH:D009396
tumour NN I-Modifier I-MSH:D009396
suppressor NN O O
gene, NN O O
wt NN O O
1. NN O O
three NN O O
of NN O O
these NN O O
mutations NN O O
were NN O O
in NN O O
the NN O O
zinc NN O O
finger NN O O
domains NN O O
of NN O O
wt NN O O
1. NN O O
the NN O O
fourth NN O O
occurred NN O O
within NN O O
intron NN O O
9, NN O O
preventing NN O O
splicing NN O O
at NN O O
one NN O O
of NN O O
the NN O O
alternatively NN O O
chosen NN O O
splice NN O O
donor NN O O
sites NN O O
of NN O O
exon NN O O
9 NN O O
when NN O O
assayed NN O O
in NN O O
vitro. NN O O
these NN O O
results NN O O
provide NN O O
genetic NN O O
evidence NN O O
for NN O O
distinct NN O O
functional NN O O
roles NN O O
of NN O O
the NN O O
wt NN O O
1 NN O O
isoforms NN O O
in NN O O
urogenital NN O O
development. NN O O
. NN O O

analysis NN O O
of NN O O
deletions NN O O
in NN O O
dna NN O O
from NN O O
patients NN O O
with NN O O
Becker NN B-CompositeMention B-MSH:D020388
and NN I-CompositeMention I-MSH:D020388
Duchenne NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
. NN O O

duchenne NN O O
muscular NN O O
dystrophy NN O O
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
recessive NN I-DiseaseClass I-MSH:D040181
genetic NN I-DiseaseClass I-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
for NN O O
which NN O O
the NN O O
biochemical NN O O
defect NN O O
is NN O O
as NN O O
yet NN O O
unknown. NN O O
recently, NN O O
two NN O O
cloned NN O O
segments NN O O
of NN O O
human NN O O
x-chromosome NN O O
dna NN O O
have NN O O
been NN O O
described NN O O
which NN O O
detect NN O O
structural NN O O
alterations NN O O
within NN O O
or NN O O
near NN O O
the NN O O
genetic NN O O
locus NN O O
responsible NN O O
for NN O O
the NN O O
disorder. NN O O
both NN O O
of NN O O
these NN O O
cloned NN O O
segments NN O O
were NN O O
described NN O O
as NN O O
tightly NN O O
linked NN O O
to NN O O
the NN O O
locus NN O O
and NN O O
were NN O O
capable NN O O
of NN O O
detecting NN O O
deletions NN O O
in NN O O
the NN O O
dna NN O O
of NN O O
boys NN O O
affected NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
in NN O O
an NN O O
attempt NN O O
to NN O O
determine NN O O
more NN O O
precisely NN O O
the NN O O
occurrence NN O O
of NN O O
these NN O O
deletions NN O O
within NN O O
a NN O O
large NN O O
population NN O O
of NN O O
DMD NN B-Modifier B-MSH:D020388
patients NN O O
and NN O O
the NN O O
accuracy NN O O
of NN O O
one NN O O
of NN O O
the NN O O
segments, NN O O
dxs NN O O
164 NN O O
(pert NN O O
87), NN O O
in NN O O
determining NN O O
the NN O O
inheritance NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
x NN O O
chromosome, NN O O
the NN O O
subclones NN O O
1, NN O O
8 NN O O
and NN O O
15 NN O O
were NN O O
made NN O O
available NN O O
to NN O O
many NN O O
investigators NN O O
throughou NN O O
. NN O O

the NN O O
world. NN O O
here NN O O
we NN O O
describe NN O O
the NN O O
combined NN O O
results NN O O
of NN O O
more NN O O
than NN O O
20 NN O O
research NN O O
laboratories NN O O
with NN O O
respect NN O O
to NN O O
the NN O O
occurrence NN O O
of NN O O
deletions NN O O
at NN O O
the NN O O
dxs NN O O
164 NN O O
locus NN O O
in NN O O
dna NN O O
samples NN O O
isolated NN O O
from NN O O
patients NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
and NN O O
Becker NN B-SpecificDisease B-MSH:C537666
muscular NN I-SpecificDisease I-MSH:C537666
dystrophy NN I-SpecificDisease I-MSH:C537666
( NN O O
BMD NN B-SpecificDisease B-MSH:C537666
). NN O O
the NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
dxs NN O O
164 NN O O
locus NN O O
apparently NN O O
recombines NN O O
with NN O O
DMD NN B-SpecificDisease B-MSH:D020388
5% NN O O
of NN O O
the NN O O
time, NN O O
but NN O O
is NN O O
probably NN O O
located NN O O
between NN O O
independent NN O O
sites NN O O
of NN O O
mutation NN O O
which NN O O
yield NN O O
DMD NN B-SpecificDisease B-MSH:D020388
. NN O O
the NN O O
breakpoints NN O O
of NN O O
some NN O O
deletions NN O O
are NN O O
delineated NN O O
within NN O O
the NN O O
dxs NN O O
164 NN O O
locus, NN O O
and NN O O
it NN O O
is NN O O
evident NN O O
that NN O O
the NN O O
deletions NN O O
at NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
locus NN O O
are NN O O
frequent NN O O
and NN O O
extremely NN O O
large. NN O O
. NN O O

additional NN O O
case NN O O
of NN O O
female NN O O
monozygotic NN O O
twins NN O O
discordant NN O O
for NN O O
the NN O O
clinical NN O O
manifestations NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
due NN O O
to NN O O
opposite NN O O
x-chromosome NN O O
inactivation NN O O
. NN O O

a NN O O
pair NN O O
of NN O O
female NN O O
monozygotic NN O O
(mz) NN O O
twins, NN O O
heterozygous NN O O
carriers NN O O
for NN O O
a NN O O
deletion NN O O
in NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
and NN O O
discordant NN O O
for NN O O
the NN O O
clinical NN O O
manifestations NN O O
of NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
, NN O O
were NN O O
analyzed NN O O
by NN O O
molecular NN O O
studies, NN O O
in NN O O
situ NN O O
hybridization, NN O O
and NN O O
methylation NN O O
pattern NN O O
of NN O O
x NN O O
chromosomes NN O O
to NN O O
search NN O O
for NN O O
opposite NN O O
x NN O O
inactivation NN O O
as NN O O
an NN O O
explanation NN O O
of NN O O
their NN O O
clinical NN O O
discordance. NN O O
results NN O O
in NN O O
lymphocytes NN O O
and NN O O
skin NN O O
fibroblast NN O O
cell NN O O
lines NN O O
suggest NN O O
a NN O O
partial NN O O
mirror NN O O
inactivation NN O O
with NN O O
the NN O O
normal NN O O
x NN O O
chromosome NN O O
preferentially NN O O
active NN O O
in NN O O
the NN O O
unaffected NN O O
twin, NN O O
and NN O O
the NN O O
maternal NN O O
deleted NN O O
x NN O O
chromosome NN O O
preferentially NN O O
active NN O O
in NN O O
the NN O O
affected NN O O
twin. NN O O
a NN O O
review NN O O
shows NN O O
that NN O O
mz NN O O
female NN O O
twins NN O O
discordant NN O O
for NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
diseases NN I-DiseaseClass I-MSH:D040181
are NN O O
not NN O O
uncommon. NN O O
twinning NN O O
and NN O O
x NN O O
inactivation NN O O
may NN O O
be NN O O
interrelated NN O O
and NN O O
could NN O O
explain NN O O
the NN O O
female NN O O
twins NN O O
discordant NN O O
for NN O O
x-linked NN O O
traits. NN O O
. NN O O

analbuminemia NN O O
in NN O O
a NN O O
neonate NN O O
. NN O O

a NN O O
small-for-gestational-age NN O O
infant, NN O O
found NN O O
to NN O O
have NN O O
analbuminemia NN B-SpecificDisease B-OMIM:103600
in NN O O
the NN O O
neonatal NN O O
period, NN O O
is NN O O
reported NN O O
and NN O O
the NN O O
twelve NN O O
cases NN O O
recorded NN O O
in NN O O
the NN O O
world NN O O
literature NN O O
are NN O O
reviewed. NN O O
patients NN O O
lacking NN O O
this NN O O
serum NN O O
protein NN O O
are NN O O
essentially NN O O
asymptomatic, NN O O
apart NN O O
from NN O O
minimal NN O O
ankle NN B-DiseaseClass B-MSH:D016512
edema NN I-DiseaseClass I-MSH:D016512
and NN O O
ease NN B-DiseaseClass B-MSH:D005221
of NN I-DiseaseClass I-MSH:D005221
fatigue NN I-DiseaseClass I-MSH:D005221
. NN O O
apparent NN O O
compensatory NN O O
mechanisms NN O O
which NN O O
come NN O O
into NN O O
play NN O O
when NN O O
serum NN O O
albumin NN O O
is NN O O
low NN O O
include NN O O
prolonged NN O O
half-life NN O O
of NN O O
albumin NN O O
and NN O O
transferrin, NN O O
an NN O O
increase NN O O
in NN O O
serum NN O O
globulins, NN O O
beta NN O O
lipoprotein, NN O O
and NN O O
glycoproteins, NN O O
arterial NN B-DiseaseClass B-MSH:D007022
hypotension NN I-DiseaseClass I-MSH:D007022
with NN O O
reduced NN O O
capillary NN O O
hydrostatic NN O O
pressure, NN O O
and NN O O
the NN O O
ability NN O O
to NN O O
respond NN O O
with NN O O
rapid NN O O
sodium NN O O
and NN O O
chloride NN O O
diuresis NN O O
in NN O O
response NN O O
to NN O O
small NN O O
volume NN O O
changes. NN O O
examination NN O O
of NN O O
plasma NN O O
amino NN O O
acids, NN O O
an NN O O
investigation NN O O
not NN O O
previously NN O O
reported, NN O O
revealed NN O O
an NN O O
extremely NN O O
low NN O O
plasma NN O O
tryptophan NN O O
level, NN O O
a NN O O
finding NN O O
which NN O O
may NN O O
be NN O O
important NN O O
in NN O O
vie NN O O
. NN O O

of NN O O
the NN O O
role NN O O
of NN O O
tryptophan NN O O
in NN O O
albumin NN O O
synthesis. NN O O
. NN O O

homozygous NN O O
presence NN O O
of NN O O
the NN O O
crossover NN O O
(fusion NN O O
gene) NN O O
mutation NN O O
identified NN O O
in NN O O
a NN O O
type NN B-Modifier B-MSH:D005776
II NN I-Modifier I-MSH:D005776
Gaucher NN I-Modifier I-MSH:D005776
disease NN I-Modifier I-MSH:D005776
fetus: NN O O
is NN O O
this NN O O
analogous NN O O
to NN O O
the NN O O
gaucher NN O O
knock-out NN O O
mouse NN O O
model? NN O O
Gaucher NN B-SpecificDisease B-MSH:D005776
disease NN I-SpecificDisease I-MSH:D005776
( NN O O
GD NN B-SpecificDisease B-MSH:D005776
) NN O O
is NN O O
an NN O O
inherited NN O O
deficiency NN B-SpecificDisease B-MSH:D005776
of NN I-SpecificDisease I-MSH:D005776
beta-glucocerebrosidase NN I-SpecificDisease I-MSH:D005776
(ec NN O O
3. NN O O
1. NN O O
2. NN O O
45, NN O O
gene NN O O
symbol NN O O
gba). NN O O
in NN O O
type NN B-SpecificDisease B-MSH:D005776
I NN I-SpecificDisease I-MSH:D005776
GD NN I-SpecificDisease I-MSH:D005776
, NN O O
the NN O O
cns NN O O
is NN O O
not NN O O
involved NN O O
(nonneuronopathic), NN O O
whereas NN O O
in NN O O
type NN B-SpecificDisease B-MSH:D005776
II NN I-SpecificDisease I-MSH:D005776
GD NN I-SpecificDisease I-MSH:D005776
(acute NN O O
neuronopathic) NN O O
cns NN O O
involvement NN O O
is NN O O
early NN O O
and NN O O
rapidly NN O O
progressive, NN O O
while NN O O
in NN O O
type NN B-SpecificDisease B-MSH:D005776
III NN I-SpecificDisease I-MSH:D005776
GD NN I-SpecificDisease I-MSH:D005776
(subacute NN O O
neuronopathic) NN O O
cns NN O O
involvement NN O O
occurs NN O O
later NN O O
and NN O O
is NN O O
slowly NN O O
progressive. NN O O
the NN O O
t NN O O
6433 NN O O
c NN O O
(l NN O O
444 NN O O
p) NN O O
substitution NN O O
is NN O O
prevalent NN O O
in NN O O
type NN B-SpecificDisease B-MSH:D005776
GD NN I-SpecificDisease I-MSH:D005776
II NN I-SpecificDisease I-MSH:D005776
. NN O O
it NN O O
may NN O O
occur NN O O
alone NN O O
as NN O O
a NN O O
single NN O O
base-pair NN O O
mutation NN O O
but NN O O
often NN O O
is NN O O
foun NN O O
. NN O O

as NN O O
part NN O O
of NN O O
a NN O O
complex NN O O
allele NN O O
containing NN O O
additional NN O O
gba NN O O
nucleotide NN O O
substitutions, NN O O
g NN O O
6468 NN O O
c NN O O
(a NN O O
456 NN O O
p) NN O O
and NN O O
g NN O O
6482 NN O O
c NN O O
(v NN O O
460 NN O O
v), NN O O
without NN O O
(recncii) NN O O
or NN O O
with NN O O
(rectl) NN O O
g NN O O
5957 NN O O
c NN O O
(d NN O O
409 NN O O
h). NN O O
this NN O O
complex NN O O
allele NN O O
is NN O O
presumed NN O O
to NN O O
have NN O O
formed NN O O
by NN O O
recombination NN O O
(crossover, NN O O
fusion) NN O O
of NN O O
the NN O O
structural NN O O
gene NN O O
with NN O O
the NN O O
pseudogene, NN O O
which NN O O
contains NN O O
the NN O O
mutated NN O O
sequences. NN O O
two NN O O
complex NN O O
alleles NN O O
have NN O O
never NN O O
been NN O O
demonstrated NN O O
to NN O O
coexist NN O O
in NN O O
any NN O O
individual. NN O O
we NN O O
devised NN O O
a NN O O
selective NN O O
pcr NN O O
method NN O O
for NN O O
the NN O O
specific NN O O
amplification NN O O
of NN O O
the NN O O
normal NN O O
and/or NN O O
fusion NN O O
gene. NN O O
using NN O O
this NN O O
procedure NN O O
we NN O O
demonstrated NN O O
the NN O O
fusion NN O O
gene NN O O
in NN O O
homozygous NN O O
form NN O O
for NN O O
the NN O O
first NN O O
time, NN O O
in NN O O
a NN O O
macedonian/ashkenazi NN O O
jewish NN O O
GD NN B-Modifier B-MSH:D005776
type NN I-Modifier I-MSH:D005776
II NN I-Modifier I-MSH:D005776
fetus. NN O O
both NN O O
parents NN O O
were NN O O
carrier NN O O
. NN O O

of NN O O
the NN O O
recombination. NN O O
this NN O O
was NN O O
confirmed NN O O
by NN O O
direct NN O O
sequence NN O O
analysis. NN O O
a NN O O
previous NN O O
conceptus NN O O
in NN O O
this NN O O
family NN O O
was NN O O
stillborn NN B-DiseaseClass B-MSH:D005313
at NN O O
36 NN O O
weeks, NN O O
with NN O O
features NN O O
of NN O O
severe NN O O
type NN B-SpecificDisease B-MSH:D005776
II NN I-SpecificDisease I-MSH:D005776
GD NN I-SpecificDisease I-MSH:D005776
. NN O O
neonates NN O O
showing NN O O
a NN O O
severe NN O O
clinical NN O O
phenotype, NN O O
analogous NN O O
to NN O O
the NN O O
early NN O O
neonatal NN O O
lethal NN O O
disease NN O O
occurring NN O O
in NN O O
mice NN O O
homozygous NN O O
for NN O O
a NN O O
null NN O O
allele NN O O
produced NN O O
by NN O O
targeted NN O O
disruption NN O O
of NN O O
gba, NN O O
have NN O O
been NN O O
described NN O O
elsewhere, NN O O
but NN O O
the NN O O
specific NN O O
mutations NN O O
in NN O O
these NN O O
cases NN O O
have NN O O
not NN O O
yet NN O O
been NN O O
characterized. NN O O
(abstract NN O O
truncated NN O O
at NN O O
250 NN O O
words NN O O
. NN O O

decrease NN O O
in NN O O
gtp NN O O
cyclohydrolase NN O O
i NN O O
gene NN O O
expression NN O O
caused NN O O
by NN O O
inactivation NN O O
of NN O O
one NN O O
allele NN O O
in NN O O
hereditary NN B-SpecificDisease B-MSH:D020821
progressive NN I-SpecificDisease I-MSH:D020821
dystonia NN I-SpecificDisease I-MSH:D020821
with NN O O
marked NN O O
diurnal NN O O
fluctuation NN O O
. NN O O

hereditary NN O O
progressive NN O O
dystonia NN O O
with NN O O
marked NN O O
diurnal NN O O
fluctuation NN O O
( NN O O
HPD NN B-SpecificDisease B-MSH:D020821
; NN O O
dopa-responsive NN B-SpecificDisease B-MSH:C538007
dystonia NN I-SpecificDisease I-MSH:C538007
, NN O O
DRD NN B-SpecificDisease B-MSH:C538007
) NN O O
have NN O O
been NN O O
recently NN O O
found NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
a NN O O
genetic NN B-DiseaseClass B-MSH:D030342
defect NN I-DiseaseClass I-MSH:D030342
in NN O O
the NN O O
gtp NN O O
cyclohydrolase NN O O
i NN O O
(gch NN O O
1) NN O O
gene. NN O O
in NN O O
this NN O O
study, NN O O
we NN O O
quantified NN O O
the NN O O
mrna NN O O
level NN O O
of NN O O
gch NN O O
1 NN O O
in NN O O
phytohemagglutinin NN O O
(pha) NN O O
-stimulated NN O O
mononuclear NN O O
blood NN O O
cells NN O O
from NN O O
one NN O O
japanese NN O O
family NN O O
that NN O O
do NN O O
not NN O O
have NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
or NN O O
splice NN O O
junctions NN O O
of NN O O
the NN O O
gene. NN O O
the NN O O
results NN O O
showed NN O O
that NN O O
the NN O O
amounts NN O O
of NN O O
the NN O O
gch NN O O
1 NN O O
mrna NN O O
were NN O O
decreased NN O O
to NN O O
about NN O O
40% NN O O
of NN O O
the NN O O
normal NN O O
level NN O O
in NN O O
both NN O O
patients NN O O
and NN O O
carriers. NN O O
in NN O O
addition, NN O O
we NN O O
found NN O O
that NN O O
the NN O O
gch NN O O
1 NN O O
mrna NN O O
was NN O O
transcribed NN O O
from NN O O
only NN O O
one NN O O
allele, NN O O
indicating NN O O
that NN O O
the NN O O
other NN O O
allele NN O O
was NN O O
in NN O O
an NN O O
inactive NN O O
state. NN O O
these NN O O
results NN O O
sugges NN O O
. NN O O

that NN O O
some NN O O
novel NN O O
mutations NN O O
should NN O O
exist NN O O
on NN O O
one NN O O
of NN O O
the NN O O
alleles NN O O
in NN O O
some NN O O
unknown NN O O
region NN O O
of NN O O
the NN O O
gch NN O O
1 NN O O
gene, NN O O
and NN O O
may NN O O
decrease NN O O
the NN O O
gch NN O O
1 NN O O
mrna NN O O
causing NN O O
the NN O O
HPD NN B-Modifier B-MSH:D020821
/ NN O O
DRD NN B-Modifier B-MSH:C538007
symptoms. NN O O
. NN O O

novel NN O O
mutations NN O O
in NN O O
the NN O O
Wiskott-Aldrich NN B-Modifier B-MSH:D014923
syndrome NN I-Modifier I-MSH:D014923
protein NN O O
gene NN O O
and NN O O
their NN O O
effects NN O O
on NN O O
transcriptional, NN O O
translational, NN O O
and NN O O
clinical NN O O
phenotypes NN O O
. NN O O

wiskott-aldrich NN O O
syndrome NN O O
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
) NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D053632
recessive NN I-DiseaseClass I-MSH:D053632
immunodeficiency NN I-DiseaseClass I-MSH:D053632
characterized NN O O
by NN O O
thrombocytopenia NN B-DiseaseClass B-MSH:D013921
, NN O O
eczema NN B-DiseaseClass B-MSH:D004485
, NN O O
and NN O O
recurrent NN O O
infections, NN O O
and NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
protein NN O O
(wasp) NN O O
gene. NN O O
wasp NN O O
contains NN O O
several NN O O
functional NN O O
domains NN O O
through NN O O
which NN O O
it NN O O
interacts NN O O
with NN O O
proteins NN O O
involved NN O O
in NN O O
intracellular NN O O
signaling NN O O
and NN O O
regulation NN O O
of NN O O
the NN O O
actin NN O O
cytoskeleton. NN O O
in NN O O
this NN O O
report, NN O O
17 NN O O
wasp NN O O
gene NN O O
mutations NN O O
were NN O O
identified, NN O O
12 NN O O
of NN O O
which NN O O
are NN O O
novel. NN O O
dna NN O O
of NN O O
affected NN O O
males NN O O
and NN O O
obligate NN O O
carriers NN O O
was NN O O
pcr NN O O
amplified NN O O
and NN O O
analyzed NN O O
by NN O O
ssca, NN O O
heteroduplex NN O O
analysis, NN O O
and NN O O
direct NN O O
sequencing. NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
mutations NN O O
at NN O O
the NN O O
mrna NN O O
and NN O O
protein NN O O
level NN O O
were NN O O
ascertained NN O O
by NN O O
rt-pcr NN O O
and NN O O
western NN O O
blot NN O O
analyses. NN O O
all NN O O
missense NN O O
mutations NN O O
were NN O O
located NN O O
in NN O O
exons NN O O
1-4. NN O O
most NN O O
of NN O O
the NN O O
nonsense, NN O O
frameshift NN O O
and NN O O
splice NN O O
sit NN O O
. NN O O

mutations NN O O
were NN O O
found NN O O
in NN O O
exons NN O O
6-11. NN O O
mutations NN O O
that NN O O
alter NN O O
splice NN O O
sites NN O O
led NN O O
to NN O O
the NN O O
synthesis NN O O
of NN O O
several NN O O
types NN O O
of NN O O
mrnas, NN O O
a NN O O
fraction NN O O
of NN O O
which NN O O
represented NN O O
the NN O O
normally NN O O
spliced NN O O
product. NN O O
the NN O O
presence NN O O
of NN O O
normally NN O O
spliced NN O O
transcripts NN O O
was NN O O
correlated NN O O
with NN O O
a NN O O
milder NN O O
phenotype. NN O O
when NN O O
one NN O O
such NN O O
case NN O O
was NN O O
studied NN O O
by NN O O
western NN O O
blotting, NN O O
reduced NN O O
amounts NN O O
of NN O O
normal-size NN O O
wasp NN O O
were NN O O
present. NN O O
in NN O O
other NN O O
cases NN O O
as NN O O
well, NN O O
a NN O O
correlation NN O O
was NN O O
found NN O O
between NN O O
the NN O O
amount NN O O
of NN O O
normal NN O O
or NN O O
mutant NN O O
wasp NN O O
present NN O O
and NN O O
the NN O O
phenotypes NN O O
of NN O O
the NN O O
affected NN O O
individuals. NN O O
no NN O O
protein NN O O
was NN O O
detected NN O O
in NN O O
two NN O O
individuals NN O O
with NN O O
severe NN O O
WAS NN B-SpecificDisease B-MSH:D014923
. NN O O
reduced NN O O
levels NN O O
of NN O O
a NN O O
normal-size NN O O
wasp NN O O
with NN O O
a NN O O
missense NN O O
mutation NN O O
were NN O O
seen NN O O
in NN O O
two NN O O
individuals NN O O
with NN O O
XLT NN B-SpecificDisease B-OMIM:313900
. NN O O
it NN O O
is NN O O
concluded NN O O
that NN O O
mutation NN O O
analysis NN O O
at NN O O
the NN O O
dna NN O O
level NN O O
is NN O O
not NN O O
sufficient NN O O
for NN O O
predictin NN O O
. NN O O

clinical NN O O
course. NN O O
studies NN O O
at NN O O
the NN O O
transcript NN O O
and NN O O
protein NN O O
level NN O O
are NN O O
needed NN O O
for NN O O
a NN O O
better NN O O
assessment. NN O O
. NN O O

incidence NN O O
and NN O O
characteristics NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
variants NN O O
in NN O O
japan NN O O
. NN O O

a NN O O
total NN O O
of NN O O
3000 NN O O
men NN O O
living NN O O
in NN O O
yamaguchi NN O O
were NN O O
screened NN O O
for NN O O
glucose-6-phosphate NN B-SpecificDisease B-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
using NN O O
beutlers NN O O
spot NN O O
test NN O O
and NN O O
three NN O O
types NN O O
of NN O O
starch NN O O
gel NN O O
electrophoresis. NN O O
these NN O O
electrophoresis NN O O
used NN O O
a NN O O
phosphate NN O O
buffer NN O O
system NN O O
at NN O O
ph NN O O
7. NN O O
0, NN O O
a NN O O
tris-edta-borate NN O O
buffer NN O O
system NN O O
at NN O O
ph NN O O
8. NN O O
6, NN O O
and NN O O
a NN O O
tris-hydrochloride NN O O
buffer NN O O
system NN O O
at NN O O
ph NN O O
8.. NN O O
fifteen NN O O
G6PD-deficient NN B-Modifier B-MSH:D005955
variants NN O O
were NN O O
found NN O O
at NN O O
the NN O O
rate NN O O
of NN O O
0. NN O O
5% NN O O
and NN O O
classified NN O O
into NN O O
four NN O O
groups. NN O O
as NN O O
new NN O O
variants, NN O O
g NN O O
6 NN O O
pd NN O O
konan, NN O O
kamiube, NN O O
and NN O O
kiwa NN O O
were NN O O
identified. NN O O
these NN O O
three NN O O
variants NN O O
had NN O O
a NN O O
mild NN O O
to NN O O
moderate NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
and NN O O
were NN O O
not NN O O
associated NN O O
with NN O O
any NN O O
clinical NN O O
signs. NN O O
g NN O O
6 NN O O
pd NN O O
konan NN O O
had NN O O
fas NN O O
. NN O O

electrophoretic NN O O
mobility NN O O
as NN O O
compared NN O O
with NN O O
normal NN O O
levels, NN O O
g NN O O
6 NN O O
pd NN O O
kiwa NN O O
had NN O O
slightly NN O O
elevated NN O O
electrophoretic NN O O
mobility, NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
kamiube NN O O
had NN O O
normal NN O O
electrophoretic NN O O
mobility. NN O O
these NN O O
three NN O O
variants NN O O
had NN O O
normal NN O O
levels NN O O
of NN O O
km NN O O
g NN O O
6 NN O O
p, NN O O
km NN O O
nadp, NN O O
and NN O O
ki NN O O
nadph, NN O O
normal NN O O
utilizations NN O O
of NN O O
both NN O O
2-deoxy-g NN O O
6 NN O O
p NN O O
and NN O O
deamino-napd, NN O O
normal NN O O
heat NN O O
stability, NN O O
and NN O O
a NN O O
normal NN O O
ph NN O O
curve. NN O O
the NN O O
other NN O O
variant NN O O
was NN O O
g NN O O
6 NN O O
pd NN O O
ube, NN O O
which NN O O
we NN O O
had NN O O
previously NN O O
found NN O O
in NN O O
yamaguchi NN O O
(nakashima NN O O
et NN O O
al., NN O O
1977). NN O O
one NN O O
boy NN O O
with NN O O
g NN O O
6 NN O O
pd NN O O
ube NN O O
was NN O O
korea NN O O
. NN O O

difference NN O O
in NN O O
methylation NN O O
patterns NN O O
within NN O O
the NN O O
d NN O O
15 NN O O
s NN O O
9 NN O O
region NN O O
of NN O O
chromosome NN O O
15 NN O O
q NN O O
11-13 NN O O
in NN O O
first NN O O
cousins NN O O
with NN O O
Angelman NN B-SpecificDisease B-MSH:D017204
syndrome NN I-SpecificDisease I-MSH:D017204
and NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
. NN O O

abnormalities NN O O
of NN O O
chromosome NN O O
region NN O O
15 NN O O
q NN O O
11-13 NN O O
are NN O O
associated NN O O
with NN O O
Angelman NN B-SpecificDisease B-MSH:D017204
syndrome NN I-SpecificDisease I-MSH:D017204
( NN O O
AS NN B-SpecificDisease B-MSH:D017204
) NN O O
and NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
differences NN O O
between NN O O
the NN O O
methylation NN O O
patterns NN O O
of NN O O
the NN O O
region NN O O
of NN O O
chromosome NN O O
15 NN O O
q NN O O
11-13 NN O O
which NN O O
hybridizes NN O O
to NN O O
the NN O O
highly NN O O
conserved NN O O
dna, NN O O
dn NN O O
34, NN O O
in NN O O
normal NN O O
individuals NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
AS NN B-SpecificDisease B-MSH:D017204
and NN O O
PWS NN B-SpecificDisease B-MSH:D011218
have NN O O
been NN O O
described. NN O O
we NN O O
report NN O O
on NN O O
a NN O O
family NN O O
in NN O O
which NN O O
first NN O O
cousins NN O O
are NN O O
affected NN O O
by NN O O
AS NN B-SpecificDisease B-MSH:D017204
and NN O O
PWS NN B-SpecificDisease B-MSH:D011218
as NN O O
a NN O O
result NN O O
of NN O O
a NN O O
familial NN O O
paracentric NN O O
inversion NN O O
of NN O O
15 NN O O
q NN O O
11-q NN O O
13. NN O O
the NN O O
results NN O O
of NN O O
the NN O O
studies NN O O
on NN O O
this NN O O
family NN O O
demonstrate NN O O
the NN O O
differences NN O O
in NN O O
the NN O O
methylation NN O O
patterns NN O O
in NN O O
the NN O O
2 NN O O
conditions NN O O
and NN O O
the NN O O
phenomenon NN O O
of NN O O
genomic NN O O
imprinting, NN O O
whereby NN O O
genetic NN O O
information NN O O
is NN O O
expressed NN O O
differently NN O O
dependent NN O O
on NN O O
the NN O O
parent NN O O
of NN O O
origin. NN O O
. NN O O

mutations NN O O
in NN O O
the NN O O
candidate NN O O
gene NN O O
for NN O O
Norrie NN B-SpecificDisease B-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
. NN O O

recently, NN O O
we NN O O
and NN O O
others NN O O
have NN O O
isolated NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
X NN B-SpecificDisease B-MSH:C537849
linked NN I-SpecificDisease I-MSH:C537849
Norrie NN I-SpecificDisease I-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
( NN O O
ND NN B-SpecificDisease B-MSH:C537849
) NN O O
which NN O O
was NN O O
found NN O O
to NN O O
be NN O O
deleted NN O O
or NN O O
disrupted NN O O
in NN O O
several NN O O
patients. NN O O
as NN O O
a NN O O
prerequisite NN O O
for NN O O
the NN O O
identification NN O O
of NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
ND NN B-Modifier B-MSH:C537849
gene NN O O
we NN O O
have NN O O
established NN O O
the NN O O
exon-intron NN O O
structure NN O O
of NN O O
this NN O O
gene. NN O O
in NN O O
17 NN O O
unrelated NN O O
patients NN O O
and NN O O
15 NN O O
controls, NN O O
pcr NN O O
products NN O O
derived NN O O
from NN O O
the NN O O
promoter NN O O
region, NN O O
exons NN O O
1 NN O O
and NN O O
2 NN O O
as NN O O
well NN O O
as NN O O
the NN O O
coding NN O O
part NN O O
of NN O O
exon NN O O
3 NN O O
were NN O O
analysed NN O O
with NN O O
the NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
technique. NN O O
in NN O O
12 NN O O
patients NN O O
altered NN O O
pcr NN O O
fragments NN O O
were NN O O
detected NN O O
which NN O O
were NN O O
studied NN O O
in NN O O
detail NN O O
by NN O O
direct NN O O
sequencing. NN O O
eleven NN O O
different NN O O
mutations NN O O
were NN O O
found, NN O O
and NN O O
all NN O O
but NN O O
one NN O O
are NN O O
likely NN O O
to NN O O
give NN O O
rise NN O O
to NN O O
significant NN O O
structural NN O O
changes NN O O
in NN O O
the NN O O
predicted NN O O
protein. NN O O
these NN O O
finding NN O O
. NN O O

, NN O O
and NN O O
the NN O O
absence NN O O
of NN O O
functionally NN O O
relevant NN O O
base NN O O
changes NN O O
in NN O O
healthy NN O O
controls, NN O O
emphasize NN O O
the NN O O
causal NN O O
role NN O O
of NN O O
this NN O O
candidate NN O O
gene NN O O
in NN O O
Norrie NN B-SpecificDisease B-MSH:C537849
disease NN I-SpecificDisease I-MSH:C537849
and NN O O
pave NN O O
the NN O O
way NN O O
for NN O O
reliable NN O O
diagnosis NN O O
and NN O O
carrier NN O O
detection. NN O O
. NN O O

a NN O O
single NN O O
amino NN O O
acid NN O O
substitution NN O O
(g NN O O
103 NN O O
d) NN O O
in NN O O
the NN O O
type NN O O
ii NN O O
collagen NN O O
triple NN O O
helix NN O O
produces NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
. NN O O

kniest NN O O
dysplasia NN O O
is NN O O
a NN O O
moderately NN O O
severe NN O O
chondrodysplasia NN B-Modifier B-MSH:D010009
phenotype NN O O
that NN O O
results NN O O
from NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
for NN O O
type NN O O
ii NN O O
collagen, NN O O
col NN O O
2 NN O O
a NN O O
1. NN O O
characteristics NN O O
of NN O O
the NN O O
disorder NN O O
include NN O O
a NN O O
short NN B-SpecificDisease B-MSH:D006130
trunk NN I-SpecificDisease I-MSH:D006130
and NN I-SpecificDisease I-MSH:D006130
extremities NN I-SpecificDisease I-MSH:D006130
, NN O O
mid-face NN B-DiseaseClass B-MSH:D019767
hypoplasia NN I-DiseaseClass I-MSH:D019767
, NN O O
cleft NN B-SpecificDisease B-MSH:D002972
palate NN I-SpecificDisease I-MSH:D002972
, NN O O
myopia NN B-DiseaseClass B-MSH:D009216
, NN O O
retinal NN B-SpecificDisease B-MSH:D012163
detachment NN I-SpecificDisease I-MSH:D012163
, NN O O
and NN O O
hearing NN B-DiseaseClass B-MSH:D034381
loss NN I-DiseaseClass I-MSH:D034381
. NN O O
recently, NN O O
deletions NN O O
of NN O O
all NN O O
or NN O O
part NN O O
of NN O O
exon NN O O
12 NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
individuals NN O O
with NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
, NN O O
suggesting NN O O
that NN O O
mutations NN O O
within NN O O
this NN O O
region NN O O
of NN O O
the NN O O
protein NN O O
may NN O O
primarily NN O O
result NN O O
in NN O O
the NN O O
Kniest NN B-Modifier B-MSH:C537207
dysplasia NN I-Modifier I-MSH:C537207
phenotype. NN O O
we NN O O
used NN O O
sscp NN O O
to NN O O
analyze NN O O
an NN O O
amplified NN O O
genomic NN O O
dna NN O O
fragment NN O O
containing NN O O
exon NN O O
12 NN O O
from NN O O
seven NN O O
individuals NN O O
with NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
. NN O O
an NN O O
abnormality NN O O
was NN O O
identified NN O O
in NN O O
one NN O O
patient. NN O O
dna NN O O
sequence NN O O
analysis NN O O
demonstrated NN O O
that NN O O
the NN O O
patient NN O O
was NN O O
heterozygous NN O O
for NN O O
a NN O O
g NN O O
to NN O O
a NN O O
transition NN O O
that NN O O
implied NN O O
substitution NN O O
of NN O O
glycine NN O O
103 NN O O
o NN O O
. NN O O

the NN O O
triple NN O O
helical NN O O
domain NN O O
by NN O O
aspartate. NN O O
the NN O O
mutation NN O O
was NN O O
not NN O O
observed NN O O
in NN O O
dna NN O O
from NN O O
either NN O O
of NN O O
the NN O O
clinically NN O O
unaffected NN O O
parents NN O O
of NN O O
the NN O O
proband. NN O O
protein NN O O
microsequencing NN O O
demonstrated NN O O
expression NN O O
of NN O O
the NN O O
abnormal NN O O
allele NN O O
in NN O O
cartilage. NN O O
these NN O O
data NN O O
demonstrate NN O O
that NN O O
point NN O O
mutations NN O O
which NN O O
result NN O O
in NN O O
single NN O O
amino NN O O
acid NN O O
substitutions NN O O
can NN O O
produce NN O O
Kniest NN B-SpecificDisease B-MSH:C537207
dysplasia NN I-SpecificDisease I-MSH:C537207
and NN O O
further NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
alteration NN O O
of NN O O
a NN O O
domain, NN O O
which NN O O
includes NN O O
the NN O O
region NN O O
encoded NN O O
by NN O O
exon NN O O
12, NN O O
in NN O O
the NN O O
type NN O O
ii NN O O
collagen NN O O
protein NN O O
leads NN O O
to NN O O
this NN O O
disorder. NN O O
. NN O O

linkage NN O O
analysis NN O O
of NN O O
5 NN O O
novel NN O O
van NN B-Modifier B-MSH:C536528
der NN I-Modifier I-MSH:C536528
Woude NN I-Modifier I-MSH:C536528
syndrome NN I-Modifier I-MSH:C536528
kindreds NN O O
to NN O O
1 NN O O
q NN O O
32-q NN O O
41 NN O O
markers NN O O
further NN O O
supports NN O O
locus NN O O
homogeneity NN O O
of NN O O
the NN O O
disease NN O O
trait NN O O
. NN O O

van NN O O
der NN O O
woude NN O O
syndrome NN O O
( NN O O
vWS NN B-SpecificDisease B-MSH:C536528
, NN O O
mim NN O O
119300) NN O O
is NN O O
a NN O O
rare NN O O
autosomal NN B-DiseaseClass B-MSH:C536528
dominant NN I-DiseaseClass I-MSH:C536528
clefting NN I-DiseaseClass I-MSH:C536528
condition NN I-DiseaseClass I-MSH:C536528
with NN O O
cardinal NN O O
features NN O O
of NN O O
mucous NN B-SpecificDisease B-MSH:D009078
cysts NN I-SpecificDisease I-MSH:D009078
( NN O O
lower-lip NN B-SpecificDisease B-MSH:C536528
pits NN I-SpecificDisease I-MSH:C536528
) NN O O
and NN O O
clefts NN B-CompositeMention B-MSH:D002971
to NN I-CompositeMention I-MSH:D002971
the NN I-CompositeMention I-MSH:D002971
lip NN I-CompositeMention I-MSH:D002971
and/or NN I-CompositeMention I-MSH:D002971
palate NN I-CompositeMention I-MSH:D002971
. NN O O
the NN O O
vWS NN B-Modifier B-MSH:C536528
gene NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
a NN O O
locus NN O O
in NN O O
1 NN O O
q NN O O
32-q NN O O
41 NN O O
by NN O O
linkage NN O O
analysis NN O O
and NN O O
physical NN O O
mapping. NN O O
we NN O O
have NN O O
investigated NN O O
5 NN O O
novel NN O O
vWS NN B-Modifier B-MSH:C536528
families NN O O
through NN O O
probands NN O O
attended NN O O
for NN O O
cleft NN B-Modifier B-MSH:D002971
lip NN I-Modifier I-MSH:D002971
and/or NN I-Modifier I-MSH:D002971
palate NN I-Modifier I-MSH:D002971
repair NN O O
at NN O O
the NN O O
department NN O O
of NN O O
maxillofacial NN O O
surgery NN O O
of NN O O
hopital NN O O
trousseau, NN O O
paris, NN O O
in NN O O
order NN O O
to NN O O
tentatively NN O O
refine NN O O
the NN O O
genetic NN O O
map NN O O
of NN O O
the NN O O
vWS NN B-Modifier B-MSH:C536528
region NN O O
in NN O O
1 NN O O
q NN O O
32-q NN O O
41 NN O O
and NN O O
possibly NN O O
identify NN O O
unlinked NN O O
pedigrees. NN O O
linkage NN O O
analysis NN O O
was NN O O
carried NN O O
out NN O O
to NN O O
6 NN O O
microsatellite NN O O
markers NN O O
(d NN O O
1 NN O O
s NN O O
249, NN O O
d NN O O
1 NN O O
s NN O O
425, NN O O
d NN O O
1 NN O O
. NN O O

491, NN O O
d NN O O
1 NN O O
s NN O O
205, NN O O
d NN O O
1 NN O O
s NN O O
414, NN O O
d NN O O
1 NN O O
s NN O O
425), NN O O
yielding NN O O
a NN O O
maximum NN O O
cumulative NN O O
lod NN O O
score NN O O
of NN O O
z NN O O
= NN O O
3. NN O O
27 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
00 NN O O
for NN O O
d NN O O
1 NN O O
s NN O O
245. NN O O
the NN O O
innermost NN O O
four NN O O
markers NN O O
were NN O O
found NN O O
to NN O O
be NN O O
tightly NN O O
linked NN O O
to NN O O
one NN O O
another, NN O O
with NN O O
no NN O O
evidence NN O O
for NN O O
recombination. NN O O
our NN O O
results NN O O
support NN O O
linkage NN O O
of NN O O
vWS NN B-SpecificDisease B-MSH:C536528
within NN O O
a NN O O
region NN O O
of NN O O
tightly NN O O
linked NN O O
markers NN O O
and NN O O
do NN O O
not NN O O
favour NN O O
locus NN O O
heterogeneity NN O O
of NN O O
the NN O O
disease NN O O
trait NN O O
. NN O O

hypopigmentation NN O O
in NN O O
the NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
. NN O O

cutaneous NN O O
and NN O O
ocular NN O O
pigmentation NN O O
were NN O O
evaluated NN O O
in NN O O
29 NN O O
individuals NN O O
with NN O O
the NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
criteria NN O O
for NN O O
hypopigmentation NN B-DiseaseClass B-MSH:D017496
included NN O O
the NN O O
presence NN O O
of NN O O
type NN O O
i NN O O
or NN O O
ii NN O O
skin, NN O O
the NN O O
lightest NN O O
skin NN O O
type NN O O
in NN O O
the NN O O
family NN O O
by NN O O
history, NN O O
and NN O O
iris NN O O
translucency NN O O
on NN O O
globe NN O O
transillumination. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
these NN O O
criteria, NN O O
48% NN O O
of NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
individuals NN O O
were NN O O
hypopigmented NN B-Modifier B-MSH:D017496
. NN O O
the NN O O
presence NN O O
of NN O O
hypopigmentation NN B-DiseaseClass B-MSH:D017496
correlated NN O O
with NN O O
a NN O O
small NN O O
interstitial NN O O
deletion NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
15; NN O O
however, NN O O
this NN O O
deletion NN O O
was NN O O
also NN O O
found NN O O
in NN O O
individuals NN O O
who NN O O
did NN O O
not NN O O
meet NN O O
the NN O O
full NN O O
criteria NN O O
for NN O O
hypopigmentation NN B-DiseaseClass B-MSH:D017496
. NN O O
hairbulb NN O O
tyrosinase NN O O
activity NN O O
and NN O O
glutathione NN O O
content, NN O O
as NN O O
well NN O O
as NN O O
urine NN O O
cysteinyldopa NN O O
excretion, NN O O
were NN O O
low NN O O
in NN O O
PWS NN B-Modifier B-MSH:D011218
individuals NN O O
with NN O O
and NN O O
without NN O O
hypopigmentation NN B-DiseaseClass B-MSH:D017496
and NN O O
did NN O O
not NN O O
separate NN O O
these NN O O
two NN O O
groups. NN O O
we NN O O
conclude NN O O
that NN O O
hypopigmentation NN B-DiseaseClass B-MSH:D017496
is NN O O
foun NN O O
. NN O O

in NN O O
a NN O O
significant NN O O
proportion NN O O
of NN O O
individuals NN O O
with NN O O
PWS NN B-SpecificDisease B-MSH:D011218
and NN O O
that NN O O
the NN O O
hypopigmentation NN B-DiseaseClass B-MSH:D017496
may NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
15. NN O O
the NN O O
mechanism NN O O
for NN O O
the NN O O
hypopigmentation NN B-DiseaseClass B-MSH:D017496
is NN O O
unknown. NN O O
. NN O O

deficiency NN O O
of NN O O
the NN O O
fifth NN O O
component NN O O
of NN O O
complement NN O O
in NN O O
human NN O O
subjects. NN O O
clinical, NN O O
genetic NN O O
and NN O O
immunologic NN O O
studies NN O O
in NN O O
a NN O O
large NN O O
kindred NN O O
. NN O O

the NN O O
discovery NN O O
of NN O O
a NN O O
large NN O O
kindred NN O O
with NN O O
a NN O O
heritable NN O O
deficiency NN B-SpecificDisease B-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
the NN I-SpecificDisease I-OMIM:609536
fifth NN I-SpecificDisease I-OMIM:609536
component NN I-SpecificDisease I-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
complement NN I-SpecificDisease I-OMIM:609536
(c NN O O
5) NN O O
has NN O O
permitted NN O O
the NN O O
accumulation NN O O
of NN O O
new NN O O
clinical, NN O O
genetic NN O O
and NN O O
immunologic NN O O
data NN O O
concerning NN O O
the NN O O
role NN O O
of NN O O
c NN O O
5 NN O O
in NN O O
human NN O O
subjects. NN O O
the NN O O
proband, NN O O
who NN O O
has NN O O
had NN O O
nine NN O O
episodes NN O O
of NN O O
disseminated NN O O
gonococcal NN B-SpecificDisease B-MSH:D006069
infection NN I-SpecificDisease I-MSH:D006069
, NN O O
has NN O O
a NN O O
hemolytic NN O O
c NN O O
5 NN O O
level NN O O
of NN O O
approximately NN O O
0. NN O O
5 NN O O
per NN O O
cent NN O O
of NN O O
normal. NN O O
no NN O O
c NN O O
5 NN O O
protein NN O O
was NN O O
detectable, NN O O
but NN O O
low NN O O
levels NN O O
of NN O O
functional NN O O
c NN O O
5 NN O O
activity NN O O
could NN O O
be NN O O
found NN O O
using NN O O
a NN O O
sensitive NN O O
bactericidal NN O O
assay. NN O O
the NN O O
probands NN O O
twin NN O O
as NN O O
well NN O O
as NN O O
another NN O O
sister NN O O
also NN O O
had NN O O
extremely NN O O
low NN O O
levels NN O O
of NN O O
hemolytic NN O O
c NN O O
5 NN O O
(approximately NN O O
0. NN O O
5 NN O O
per NN O O
cent NN O O
normal), NN O O
but NN O O
both NN O O
these NN O O
subjects NN O O
have NN O O
been NN O O
healthy. NN O O
hemolytic NN O O
complement NN O O
and NN O O
bacteriolytic NN O O
activity NN O O
could NN O O
be NN O O
restored NN O O
by NN O O
th NN O O
. NN O O

addition NN O O
of NN O O
purified NN O O
c NN O O
5. NN O O
no NN O O
chemotactic NN O O
activity NN O O
for NN O O
polymorphonuclear NN O O
leukocytes NN O O
could NN O O
be NN O O
generated NN O O
in NN O O
the NN O O
C5-deficient NN B-Modifier B-OMIM:609536
serums NN O O
upon NN O O
activation NN O O
of NN O O
either NN O O
the NN O O
classic NN O O
or NN O O
alternative NN O O
pathways, NN O O
again NN O O
demonstrating NN O O
the NN O O
importance NN O O
of NN O O
c NN O O
5 NN O O
in NN O O
human NN O O
subjects NN O O
for NN O O
the NN O O
production NN O O
of NN O O
chemotactic NN O O
factors. NN O O
the NN O O
chemotactic NN O O
responsiveness NN O O
of NN O O
the NN O O
patients NN O O
polymorphonuclear NN O O
leukocytes NN O O
and NN O O
monocytes NN O O
to NN O O
preformed NN O O
chemotactic NN O O
factors NN O O
was NN O O
not NN O O
depressed. NN O O
twenty-two NN O O
of NN O O
32 NN O O
other NN O O
family NN O O
members NN O O
from NN O O
three NN O O
generations NN O O
had NN O O
depressed NN O O
whole NN O O
hemolytic NN O O
complement NN O O
levels. NN O O
in NN O O
19 NN O O
of NN O O
30 NN O O
family NN O O
members, NN O O
levels NN O O
of NN O O
hemolytic NN O O
c NN O O
5 NN O O
ranged NN O O
from NN O O
13 NN O O
to NN O O
64 NN O O
per NN O O
cent NN O O
of NN O O
normal. NN O O
no NN O O
linkage NN O O
for NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
and NN O O
the NN O O
a NN O O
or NN O O
b NN O O
loci NN O O
of NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
could NN O O
be NN O O
found. NN O O
these NN O O
data NN O O
suggest NN O O
an NN O O
autosomal NN O O
codominant NN O O
mode NN O O
of NN O O
inheritance NN O O
of NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536

deficiency. NN O O
Deficiency NN B-SpecificDisease B-OMIM:609536
of NN I-SpecificDisease I-OMIM:609536
C5 NN I-SpecificDisease I-OMIM:609536
is NN O O
compatible NN O O
with NN O O
good NN O O
health, NN O O
but NN O O
it NN O O
can NN O O
be NN O O
associated NN O O
with NN O O
repeated NN O O
disseminated NN O O
gonococcal NN B-SpecificDisease B-MSH:D006069
infection NN I-SpecificDisease I-MSH:D006069
. NN O O

a NN O O
new NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
variant, NN O O
g NN O O
6 NN O O
pd NN O O
orissa NN O O
(44 NN O O
ala-->gly), NN O O
is NN O O
the NN O O
major NN O O
polymorphic NN O O
variant NN O O
in NN O O
tribal NN O O
populations NN O O
in NN O O
india NN O O
. NN O O
in NN O O
india NN O O
. NN O O

deficiency NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
is NN O O
usually NN O O
found NN O O
at NN O O
high NN O O
frequencies NN O O
in NN O O
areas NN O O
of NN O O
the NN O O
world NN O O
where NN O O
malaria NN B-SpecificDisease B-MSH:D008288
has NN O O
been NN O O
endemic. NN O O
the NN O O
frequency NN O O
and NN O O
genetic NN O O
basis NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
have NN O O
been NN O O
studied NN O O
in NN O O
africa, NN O O
around NN O O
the NN O O
mediterranean, NN O O
and NN O O
in NN O O
the NN O O
far NN O O
east, NN O O
but NN O O
little NN O O
such NN O O
information NN O O
is NN O O
available NN O O
about NN O O
the NN O O
situation NN O O
in NN O O
india. NN O O
to NN O O
determine NN O O
the NN O O
extent NN O O
of NN O O
heterogeneity NN O O
of NN O O
g NN O O
6 NN O O
pd, NN O O
we NN O O
have NN O O
studied NN O O
several NN O O
different NN O O
indian NN O O
populations NN O O
by NN O O
screening NN O O
for NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
, NN O O
followed NN O O
by NN O O
molecular NN O O
analysis NN O O
of NN O O
deficient NN O O
alleles. NN O O
the NN O O
frequency NN O O
of NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
varies NN O O
between NN O O
3% NN O O
and NN O O
15% NN O O
in NN O O
different NN O O
tribal NN O O
and NN O O
urban NN O O
groups. NN O O
remarkably, NN O O
a NN O O
previously NN O O
unreported NN O O
deficient NN O O
variant, NN O O
g NN O O
6 NN O O
pd NN O O
orissa NN O O
(44 NN O O
ala- NN O O
. NN O O

> NN O O
gly), NN O O
is NN O O
responsible NN O O
for NN O O
most NN O O
of NN O O
the NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
tribal NN O O
indian NN O O
populations NN O O
but NN O O
is NN O O
not NN O O
found NN O O
in NN O O
urban NN O O
populations, NN O O
where NN O O
most NN O O
of NN O O
the NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
is NN O O
due NN O O
to NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
mediterranean NN O O
(188 NN O O
ser-- NN O O
> NN O O
phe) NN O O
variant. NN O O
the NN O O
kmnadp NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
orissa NN O O
is NN O O
fivefold NN O O
higher NN O O
than NN O O
that NN O O
of NN O O
the NN O O
normal NN O O
enzyme. NN O O
this NN O O
may NN O O
be NN O O
due NN O O
to NN O O
the NN O O
fact NN O O
that NN O O
the NN O O
alanine NN O O
residue NN O O
that NN O O
is NN O O
replaced NN O O
by NN O O
glycine NN O O
is NN O O
part NN O O
of NN O O
a NN O O
putative NN O O
coenzyme-binding NN O O
site. NN O O
. NN O O

germline NN O O
mutations NN O O
in NN O O
the NN O O
Wilms' NN B-Modifier B-MSH:D009396
tumor NN I-Modifier I-MSH:D009396
suppressor NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
abnormal NN O O
urogenital NN O O
development NN O O
in NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
. NN O O

denys-drash NN O O
syndrome NN O O
is NN O O
a NN O O
rare NN O O
human NN O O
condition NN O O
in NN O O
which NN O O
severe NN O O
urogenital NN B-DiseaseClass B-MSH:D014564
aberrations NN I-DiseaseClass I-MSH:D014564
result NN O O
in NN O O
renal NN B-SpecificDisease B-MSH:D051437
failure NN I-SpecificDisease I-MSH:D051437
, NN O O
pseudohermaphroditism NN B-SpecificDisease B-MSH:D012734
, NN O O
and NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumor NN I-SpecificDisease I-MSH:D009396
( NN O O
nephroblastoma NN B-SpecificDisease B-MSH:D009396
). NN O O
to NN O O
investigate NN O O
its NN O O
possible NN O O
role, NN O O
we NN O O
have NN O O
analyzed NN O O
the NN O O
coding NN O O
exons NN O O
of NN O O
the NN O O
Wilms NN B-Modifier B-MSH:D009396
tumor NN I-Modifier I-MSH:D009396
suppressor NN O O
gene NN O O
(wt NN O O
1) NN O O
for NN O O
germline NN O O
mutations. NN O O
in NN O O
ten NN O O
independent NN O O
cases NN O O
of NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
, NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
zinc NN O O
finger NN O O
domains NN O O
of NN O O
one NN O O
wt NN O O
1 NN O O
gene NN O O
copy NN O O
were NN O O
found. NN O O
nine NN O O
of NN O O
these NN O O
mutations NN O O
are NN O O
found NN O O
within NN O O
exon NN O O
9 NN O O
(zinc NN O O
finger NN O O
iii); NN O O
the NN O O
remaining NN O O
mutation NN O O
is NN O O
in NN O O
exon NN O O
8 NN O O
(zinc NN O O
finger NN O O
ii). NN O O
these NN O O
mutations NN O O
directly NN O O
affect NN O O
dna NN O O
sequence NN O O
recognition. NN O O
in NN O O
two NN O O
families NN O O
analyzed, NN O O
the NN O O
mutations NN O O
were NN O O
shown NN O O
to NN O O
arise NN O O
de NN O O
novo. NN O O
Wilms NN B-SpecificDisease B-MSH:D009396
tumors NN I-SpecificDisease I-MSH:D009396
from NN O O
three NN O O
individuals NN O O
and NN O O
one NN O O
juvenile NN O O
granulosa NN O O
cel NN O O
. NN O O

tumor NN O O
demonstrate NN O O
reduction NN O O
to NN O O
homozygosity NN O O
for NN O O
the NN O O
mutated NN O O
wt NN O O
1 NN O O
allele. NN O O
our NN O O
results NN O O
provide NN O O
evidence NN O O
of NN O O
a NN O O
direct NN O O
role NN O O
for NN O O
wt NN O O
1 NN O O
in NN O O
Denys-Drash NN B-SpecificDisease B-MSH:D030321
syndrome NN I-SpecificDisease I-MSH:D030321
and NN O O
thus NN O O
urogenital NN O O
system NN O O
development. NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
feline NN O O
beta-glucuronidase NN B-SpecificDisease B-MSH:D016538
deficiency NN I-SpecificDisease I-MSH:D016538
: NN O O
an NN O O
animal NN O O
model NN O O
of NN O O
mucopolysaccharidosis NN B-SpecificDisease B-MSH:D016538
VII NN I-SpecificDisease I-MSH:D016538
. NN O O

a NN O O
family NN O O
of NN O O
domestic NN O O
cats NN O O
was NN O O
found NN O O
that NN O O
exhibited NN O O
clinical NN O O
and NN O O
biochemical NN O O
abnormalities NN O O
consistent NN O O
with NN O O
mucopolysaccharidosis NN B-SpecificDisease B-MSH:D016538
VII NN I-SpecificDisease I-MSH:D016538
, NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D016464
recessive NN I-DiseaseClass I-MSH:D016464
lysosomal NN I-DiseaseClass I-MSH:D016464
storage NN I-DiseaseClass I-MSH:D016464
disorder NN I-DiseaseClass I-MSH:D016464
caused NN O O
by NN O O
beta-glucuronidase NN B-SpecificDisease B-MSH:D016538
deficiency NN I-SpecificDisease I-MSH:D016538
. NN O O
beta-glucuronidase NN O O
activity NN O O
was NN O O
undetectable NN O O
in NN O O
affected NN O O
cat NN O O
fibroblasts NN O O
and NN O O
restored NN O O
by NN O O
retroviral NN O O
gene NN O O
transfer NN O O
of NN O O
rat NN O O
beta-glucuronidase NN O O
cdna. NN O O
beta-glucuronidase NN O O
mrna NN O O
was NN O O
normal NN O O
in NN O O
affected NN O O
cat NN O O
testis NN O O
by NN O O
northern NN O O
blot NN O O
analysis. NN O O
normal NN O O
feline NN O O
beta-glucuronidase NN O O
cdna NN O O
was NN O O
cloned NN O O
and NN O O
characterized, NN O O
and NN O O
amplified NN O O
from NN O O
affected NN O O
cat NN O O
fibroblasts NN O O
by NN O O
reverse NN O O
transcription NN O O
coupled NN O O
polymerase NN O O
chain NN O O
reaction. NN O O
there NN O O
was NN O O
a NN O O
g-to-a NN O O
transition NN O O
in NN O O
the NN O O
affected NN O O
cat NN O O
cdna NN O O
that NN O O
predicted NN O O
an NN O O
e NN O O
351 NN O O
k NN O O
substitution, NN O O
destroyed NN O O
a NN O O
bsssi NN O O
site, NN O O
and NN O O
eliminated NN O O
gusb NN O O
enzymatic NN O O
activity NN O O
in NN O O
expression NN O O
studies. NN O O
multiple NN O O
species NN O O
comparison NN O O
and NN O O
the NN O O
crystal NN O O
structure NN O O
of NN O O
human NN O O
bet NN O O
. NN O O

-glucuronidase NN O O
indicated NN O O
that NN O O
e NN O O
351 NN O O
is NN O O
a NN O O
highly NN O O
conserved NN O O
residue NN O O
most NN O O
likely NN O O
essential NN O O
in NN O O
maintenance NN O O
of NN O O
the NN O O
enzymes NN O O
conformation. NN O O
bsssi NN O O
digestion NN O O
of NN O O
polymerase NN O O
chain NN O O
reaction NN O O
products NN O O
amplified NN O O
from NN O O
genomic NN O O
dna NN O O
indicated NN O O
that NN O O
affected NN O O
cats NN O O
were NN O O
homozygous NN O O
and NN O O
cats NN O O
with NN O O
half-normal NN O O
beta-glucuronidase NN O O
activity NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
missense NN O O
mutation. NN O O
carriers NN O O
identified NN O O
in NN O O
this NN O O
manner NN O O
produced NN O O
affected NN O O
kittens NN O O
in NN O O
prospective NN O O
breedings, NN O O
and NN O O
a NN O O
feline NN O O
MPS NN B-Modifier B-MSH:D016538
VII NN I-Modifier I-MSH:D016538
breeding NN O O
colony NN O O
has NN O O
been NN O O
established. NN O O
. NN O O

loss-of-function NN O O
mutations NN O O
in NN O O
the NN O O
cathepsin NN O O
c NN O O
gene NN O O
result NN O O
in NN O O
periodontal NN B-SpecificDisease B-MSH:D010510
disease NN I-SpecificDisease I-MSH:D010510
and NN O O
palmoplantar NN B-DiseaseClass B-MSH:D007645
keratosis NN I-DiseaseClass I-MSH:D007645
. NN O O

papillon-lefevre NN O O
syndrome, NN O O
or NN O O
keratosis NN B-DiseaseClass B-MSH:D007645
palmoplantaris NN I-DiseaseClass I-MSH:D007645
with NN O O
periodontopathia NN B-SpecificDisease B-MSH:D010510
( NN O O
PLS NN B-SpecificDisease B-MSH:D010214
, NN O O
mim NN O O
245000), NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
that NN O O
is NN O O
mainly NN O O
ascertained NN O O
by NN O O
dentists NN O O
because NN O O
of NN O O
the NN O O
severe NN O O
periodontitis NN B-SpecificDisease B-MSH:D010518
that NN O O
afflicts NN O O
patients. NN O O
both NN O O
the NN O O
deciduous NN O O
and NN O O
permanent NN O O
dentitions NN O O
are NN O O
affected, NN O O
resulting NN O O
in NN O O
premature NN O O
tooth NN B-SpecificDisease B-MSH:D016388
loss NN I-SpecificDisease I-MSH:D016388
. NN O O
Palmoplantar NN B-DiseaseClass B-MSH:D007645
keratosis NN I-DiseaseClass I-MSH:D007645
, NN O O
varying NN O O
from NN O O
mild NN O O
psoriasiform NN O O
scaly NN O O
skin NN O O
to NN O O
overt NN O O
hyperkeratosis NN B-SpecificDisease B-MSH:D017488
, NN O O
typically NN O O
develops NN O O
within NN O O
the NN O O
first NN O O
three NN O O
years NN O O
of NN O O
life. NN O O
Keratosis NN B-SpecificDisease B-MSH:D007642
also NN O O
affects NN O O
other NN O O
sites NN O O
such NN O O
as NN O O
elbows NN O O
and NN O O
knees. NN O O
most NN O O
PLS NN B-Modifier B-MSH:D010214
patients NN O O
display NN O O
both NN O O
periodontitis NN B-SpecificDisease B-MSH:D010518
and NN O O
hyperkeratosis NN B-SpecificDisease B-MSH:D017488
. NN O O
some NN O O
patients NN O O
have NN O O
only NN O O
palmoplantar NN B-DiseaseClass B-MSH:D007645
keratosis NN I-DiseaseClass I-MSH:D007645
or NN O O
periodontitis NN B-SpecificDisease B-MSH:D010518
, NN O O
and NN O O
in NN O O
rare NN O O
individuals NN O O
the NN O O
periodontitis NN B-SpecificDisease B-MSH:D010518
is NN O O
mild NN O O
and NN O O
of NN O O
late NN O O
onset. NN O O
the NN O O
pls NN O O
locus NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
11 NN O O
q NN O O
14-q NN O O
21 NN O O
(refs NN O O
7, NN O O
. NN O O

, NN O O
9). NN O O
using NN O O
homozygosity NN O O
mapping NN O O
in NN O O
eight NN O O
small NN O O
consanguineous NN O O
families, NN O O
we NN O O
have NN O O
narrowed NN O O
the NN O O
candidate NN O O
region NN O O
to NN O O
a NN O O
1. NN O O
2-cm NN O O
interval NN O O
between NN O O
d NN O O
11 NN O O
s NN O O
4082 NN O O
and NN O O
d NN O O
11 NN O O
s NN O O
931. NN O O
the NN O O
gene NN O O
(ctsc) NN O O
encoding NN O O
the NN O O
lysosomal NN O O
protease NN O O
cathepsin NN O O
c NN O O
(or NN O O
dipeptidyl NN O O
aminopeptidase NN O O
i) NN O O
lies NN O O
within NN O O
this NN O O
interval. NN O O
we NN O O
defined NN O O
the NN O O
genomic NN O O
structure NN O O
of NN O O
ctsc NN O O
and NN O O
found NN O O
mutations NN O O
in NN O O
all NN O O
eight NN O O
families. NN O O
in NN O O
two NN O O
of NN O O
these NN O O
families NN O O
we NN O O
used NN O O
a NN O O
functional NN O O
assay NN O O
to NN O O
demonstrate NN O O
an NN O O
almost NN O O
total NN O O
loss NN O O
of NN O O
cathepsin NN O O
c NN O O
activity NN O O
in NN O O
PLS NN B-Modifier B-MSH:D010214
patients NN O O
and NN O O
reduced NN O O
activity NN O O
in NN O O
obligate NN O O
carriers NN O O
. NN O O

brca NN O O
1 NN O O
deficiency NN O O
results NN O O
in NN O O
early NN O O
embryonic NN B-DiseaseClass B-MSH:D020964
lethality NN I-DiseaseClass I-MSH:D020964
characterized NN O O
by NN O O
neuroepithelial NN B-DiseaseClass B-MSH:D018302
abnormalities NN I-DiseaseClass I-MSH:D018302
. NN O O

the NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
susceptibility NN O O
gene, NN O O
brca NN O O
1, NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
shown NN O O
to NN O O
encode NN O O
a NN O O
zinc-finger NN O O
protein NN O O
of NN O O
unknown NN O O
function. NN O O
mutations NN O O
in NN O O
brca NN O O
1 NN O O
account NN O O
for NN O O
at NN O O
least NN O O
80% NN O O
of NN O O
families NN O O
with NN O O
both NN O O
breast NN B-CompositeMention B-MSH:D061325
and NN I-CompositeMention I-MSH:D061325
ovarian NN I-CompositeMention I-MSH:D061325
cancer NN I-CompositeMention I-MSH:D061325
, NN O O
as NN O O
well NN O O
as NN O O
some NN O O
non-familial NN O O
sporadic NN O O
ovarian NN B-SpecificDisease B-MSH:D010051
cancers NN I-SpecificDisease I-MSH:D010051
. NN O O
the NN O O
loss NN O O
of NN O O
wild-type NN O O
brca NN O O
1 NN O O
in NN O O
tumours NN B-DiseaseClass B-MSH:D009369
of NN O O
individuals NN O O
carrying NN O O
one NN O O
nonfunctional NN O O
brca NN O O
1 NN O O
allele NN O O
suggests NN O O
that NN O O
brca NN O O
1 NN O O
encodes NN O O
a NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
that NN O O
may NN O O
inhibit NN O O
the NN O O
proliferation NN O O
of NN O O
mammary NN O O
epithelial NN O O
cells. NN O O
to NN O O
examine NN O O
the NN O O
role NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
normal NN O O
tissue NN O O
growth NN O O
and NN O O
differentiation, NN O O
and NN O O
to NN O O
generate NN O O
a NN O O
potential NN O O
model NN O O
for NN O O
the NN O O
cancer NN B-Modifier B-MSH:D009369
susceptibility NN O O
associated NN O O
with NN O O
loss NN O O
of NN O O
brca NN O O
1 NN O O
function, NN O O
we NN O O
have NN O O
created NN O O
a NN O O
mouse NN O O
line NN O O
carrying NN O O
a NN O O
mutation NN O O
in NN O O
one NN O O
brca NN O O
1 NN O O
allele NN O O
. NN O O

analysis NN O O
of NN O O
mice NN O O
homozygous NN O O
for NN O O
the NN O O
mutant NN O O
allele NN O O
indicate NN O O
that NN O O
brca NN O O
1 NN O O
is NN O O
critical NN O O
for NN O O
normal NN O O
development, NN O O
as NN O O
these NN O O
mice NN O O
died NN O O
in NN O O
utero NN O O
between NN O O
10 NN O O
and NN O O
13 NN O O
days NN O O
of NN O O
gestation NN O O
(e NN O O
10-e NN O O
13). NN O O
abnormalities NN O O
in NN O O
Brca1-deficient NN B-Modifier B-OMIM:604370
embryos NN O O
were NN O O
most NN O O
evident NN O O
in NN O O
the NN O O
neural NN O O
tube, NN O O
with NN O O
40% NN O O
of NN O O
the NN O O
embryos NN O O
presenting NN O O
with NN O O
varying NN O O
degrees NN O O
of NN O O
spina NN B-SpecificDisease B-MSH:D016135
bifida NN I-SpecificDisease I-MSH:D016135
and NN O O
anencephaly NN B-SpecificDisease B-MSH:D000757
. NN O O
in NN O O
addition, NN O O
the NN O O
neuroepithelium NN O O
in NN O O
Brca1-deficient NN B-Modifier B-OMIM:604370
embryos NN O O
appeared NN O O
disorganized, NN O O
with NN O O
signs NN O O
of NN O O
both NN O O
rapid NN O O
proliferation NN O O
and NN O O
excessive NN O O
cell NN O O
death. NN O O
. NN O O

x NN O O
linked NN O O
recessive NN O O
thrombocytopenia NN O O
. NN O O

a NN O O
saudi NN O O
arab NN O O
boy NN O O
presented NN O O
in NN O O
early NN O O
childhood NN O O
with NN O O
thrombocytopenia NN B-SpecificDisease B-MSH:D013921
, NN O O
morphologically NN O O
large NN O O
and NN O O
normal NN O O
sized NN O O
platelets, NN O O
increased NN O O
mean NN O O
platelet NN O O
volume, NN O O
and NN O O
a NN O O
hypermegakaryocytic NN O O
bone NN O O
marrow. NN O O
there NN O O
was NN O O
no NN O O
clinical NN O O
and NN O O
laboratory NN O O
evidence NN O O
of NN O O
any NN O O
significant NN O O
immunological NN B-DiseaseClass B-MSH:D007154
abnormalities NN I-DiseaseClass I-MSH:D007154
. NN O O
similar NN O O
findings NN O O
in NN O O
two NN O O
other NN O O
brothers NN O O
suggested NN O O
strongly NN O O
that NN O O
they NN O O
were NN O O
all NN O O
suffering NN O O
from NN O O
an NN O O
X NN B-SpecificDisease B-OMIM:313900
linked NN I-SpecificDisease I-OMIM:313900
recessive NN I-SpecificDisease I-OMIM:313900
thrombocytopenic NN I-SpecificDisease I-OMIM:313900
disorder NN I-SpecificDisease I-OMIM:313900
. NN O O
results NN O O
of NN O O
dna NN O O
analysis NN O O
with NN O O
the NN O O
probe NN O O
m NN O O
27 NN O O
beta NN O O
are NN O O
consistent NN O O
with NN O O
x NN O O
linkage NN O O
and NN O O
indicate NN O O
also NN O O
that NN O O
the NN O O
locus NN O O
of NN O O
the NN O O
relevant NN O O
gene NN O O
lies NN O O
close NN O O
to NN O O
or NN O O
is NN O O
identical NN O O
to NN O O
the NN O O
locus NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
Wiskott-Aldrich NN B-SpecificDisease B-MSH:D014923
syndrome NN I-SpecificDisease I-MSH:D014923
( NN O O
WAS NN B-SpecificDisease B-MSH:D014923
). NN O O
because NN O O
of NN O O
various NN O O
features NN O O
which NN O O
include NN O O
the NN O O
presence NN O O
of NN O O
large NN O O
and NN O O
normal NN O O
sized NN O O
platelets NN O O
(rather NN O O
than NN O O
small NN O O
platelets) NN O O
and NN O O
freedom NN O O
from NN O O
significant NN O O
immune NN B-DiseaseClass B-MSH:D007154
deficiencies NN I-DiseaseClass I-MSH:D007154
, NN O O
it NN O O
is NN O O
likel NN O O
. NN O O

that NN O O
the NN O O
X NN B-SpecificDisease B-OMIM:313900
linked NN I-SpecificDisease I-OMIM:313900
recessive NN I-SpecificDisease I-OMIM:313900
thrombocytopenia NN I-SpecificDisease I-OMIM:313900
in NN O O
this NN O O
family NN O O
is NN O O
an NN O O
isolated NN O O
entity NN O O
quite NN O O
distinct NN O O
from NN O O
the NN O O
classical NN O O
WAS NN B-Modifier B-MSH:D014923
phenotype. NN O O
however, NN O O
a NN O O
modified NN O O
expression NN O O
of NN O O
the NN O O
WAS NN B-Modifier B-MSH:D014923
gene NN O O
producing NN O O
a NN O O
mild NN O O
phenotypic NN O O
variant NN O O
cannot NN O O
be NN O O
excluded NN O O
entirely. NN O O
. NN O O

genetics NN O O
of NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
( NN O O
CTX NN B-SpecificDisease B-MSH:D019294
): NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
with NN O O
high NN O O
gene NN O O
frequency NN O O
in NN O O
sephardim NN O O
of NN O O
moroccan NN O O
origin NN O O
. NN O O

we NN O O
described NN O O
6 NN O O
patients NN O O
(from NN O O
3 NN O O
families) NN O O
affected NN O O
with NN O O
cerebrotendinous NN B-SpecificDisease B-MSH:D019294
xanthomatosis NN I-SpecificDisease I-MSH:D019294
( NN O O
CTX NN B-SpecificDisease B-MSH:D019294
). NN O O
all NN O O
are NN O O
sephardic NN O O
jews NN O O
of NN O O
moroccan NN O O
extraction. NN O O
in NN O O
view NN O O
of NN O O
the NN O O
small NN O O
number NN O O
of NN O O
CTX NN B-Modifier B-MSH:D019294
patients NN O O
diagnosed NN O O
in NN O O
the NN O O
world NN O O
(a NN O O
total NN O O
of NN O O
50 NN O O
including NN O O
our NN O O
6 NN O O
patients), NN O O
we NN O O
are NN O O
probably NN O O
dealing NN O O
with NN O O
an NN O O
ethnic NN O O
subgroup NN O O
with NN O O
a NN O O
high NN O O
ctx NN O O
gene NN O O
frequency, NN O O
which NN O O
we NN O O
have NN O O
estimated NN O O
to NN O O
be NN O O
1/108. NN O O
since NN O O
there NN O O
are NN O O
differences NN O O
in NN O O
expression NN O O
in NN O O
this NN O O
disease, NN O O
we NN O O
recommend NN O O
cholestanol NN O O
study NN O O
in NN O O
cases NN O O
of NN O O
undiagnosed NN O O
cataract NN B-SpecificDisease B-MSH:D002386
or NN O O
tendinous NN B-SpecificDisease B-MSH:D014973
xanthomas NN I-SpecificDisease I-MSH:D014973
in NN O O
childhood NN O O
or NN O O
early NN O O
adolescence. NN O O
the NN O O
diagnosis NN O O
in NN O O
CTX NN B-SpecificDisease B-MSH:D019294
is NN O O
important NN O O
not NN O O
only NN O O
for NN O O
genetic NN O O
counseling, NN O O
but NN O O
also NN O O
in NN O O
veiw NN O O
of NN O O
possible NN O O
treatment. NN O O
. NN O O

a NN O O
missense NN O O
mutation NN O O
in NN O O
the NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
gene NN O O
with NN O O
possible NN O O
dominant NN O O
effects NN O O
on NN O O
plasma NN O O
high NN O O
density NN O O
lipoproteins NN O O
. NN O O

plasma NN O O
hdl NN O O
are NN O O
a NN O O
negative NN O O
risk NN O O
factor NN O O
for NN O O
atherosclerosis NN B-SpecificDisease B-MSH:D050197
. NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
(cetp; NN O O
476 NN O O
amino NN O O
acids) NN O O
transfers NN O O
cholesteryl NN O O
ester NN O O
from NN O O
hdl NN O O
to NN O O
other NN O O
lipoproteins. NN O O
subjects NN O O
with NN O O
homozygous NN O O
CETP NN B-SpecificDisease B-OMIM:143470
deficiency NN I-SpecificDisease I-OMIM:143470
caused NN O O
by NN O O
a NN O O
gene NN O O
splicing NN O O
defect NN O O
have NN O O
markedly NN O O
elevated NN O O
hdl; NN O O
however, NN O O
heterozygotes NN O O
have NN O O
only NN O O
mild NN O O
increases NN O O
in NN O O
hdl. NN O O
we NN O O
describe NN O O
two NN O O
probands NN O O
with NN O O
a NN O O
cetp NN O O
missense NN O O
mutation NN O O
(442 NN O O
d NN O O
g). NN O O
although NN O O
heterozygous, NN O O
they NN O O
have NN O O
threefold NN O O
increases NN O O
in NN O O
hdl NN O O
concentration NN O O
and NN O O
markedly NN O O
decreased NN O O
plasma NN O O
cetp NN O O
mass NN O O
and NN O O
activity, NN O O
suggesting NN O O
that NN O O
the NN O O
mutation NN O O
has NN O O
dominant NN O O
effects NN O O
on NN O O
cetp NN O O
and NN O O
hdl NN O O
in NN O O
vivo. NN O O
cellular NN O O
expression NN O O
of NN O O
mutant NN O O
cdna NN O O
results NN O O
in NN O O
secretion NN O O
of NN O O
only NN O O
30% NN O O
of NN O O
wild NN O O
type NN O O
cetp NN O O
activity. NN O O
moreover, NN O O
coexpression NN O O
of NN O O
wild NN O O
type NN O O
and NN O O
mutant NN O O
cdnas NN O O
leads NN O O
to NN O O
inhibition NN O O
of NN O O
wild NN O O
type NN O O
secretion NN O O
and NN O O
activit NN O O
. NN O O

. NN O O
the NN O O
dominant NN O O
effects NN O O
of NN O O
the NN O O
cetp NN O O
missense NN O O
mutation NN O O
during NN O O
cellular NN O O
expression NN O O
probably NN O O
explains NN O O
why NN O O
the NN O O
probands NN O O
have NN O O
markedly NN O O
increased NN O O
hdl NN O O
in NN O O
the NN O O
heterozygous NN O O
state, NN O O
and NN O O
suggests NN O O
that NN O O
the NN O O
active NN O O
molecular NN O O
species NN O O
of NN O O
cetp NN O O
may NN O O
be NN O O
multimeric. NN O O
. NN O O
f NN O O
cetp NN O O
may NN O O
be NN O O
multimeric. NN O O
. NN O O

huntington NN O O
disease: NN O O
no NN O O
evidence NN O O
for NN O O
locus NN O O
heterogeneity NN O O
. NN O O

a NN O O
total NN O O
of NN O O
63 NN O O
families NN O O
with NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
were NN O O
examined NN O O
for NN O O
linkage NN O O
between NN O O
HD NN B-SpecificDisease B-MSH:D006816
and NN O O
g NN O O
8 NN O O
(d NN O O
4 NN O O
s NN O O
10). NN O O
the NN O O
families NN O O
included NN O O
57 NN O O
caucasian, NN O O
four NN O O
black NN O O
american, NN O O
and NN O O
two NN O O
japanese. NN O O
the NN O O
combined NN O O
maximum NN O O
lod NN O O
score NN O O
was NN O O
87. NN O O
69 NN O O
at NN O O
theta NN O O
= NN O O
0. NN O O
04 NN O O
(99% NN O O
confidence NN O O
interval NN O O
0. NN O O
018-0. NN O O
071). NN O O
the NN O O
maximum NN O O
frequency NN O O
of NN O O
recombination NN O O
was NN O O
0. NN O O
03 NN O O
in NN O O
males NN O O
and NN O O
0. NN O O
05 NN O O
in NN O O
females. NN O O
fifty-seven NN O O
families NN O O
gave NN O O
positive NN O O
lod NN O O
scores; NN O O
five NN O O
small NN O O
families NN O O
gave NN O O
mildly NN O O
negative NN O O
lod NN O O
scores. NN O O
the NN O O
maximum NN O O
likelihood NN O O
estimate NN O O
of NN O O
alpha, NN O O
the NN O O
proportion NN O O
of NN O O
linked NN O O
loci, NN O O
was NN O O
1. NN O O
0 NN O O
with NN O O
a NN O O
lower NN O O
99% NN O O
confidence NN O O
interval NN O O
of NN O O
0. NN O O
88. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
ther NN O O
. NN O O

is NN O O
only NN O O
one NN O O
HD NN B-Modifier B-MSH:D006816
locus, NN O O
although NN O O
a NN O O
second NN O O
rare NN O O
locus NN O O
cannot NN O O
be NN O O
ruled NN O O
out NN O O
. NN O O

homozygous NN O O
and NN O O
heterozygous NN O O
deletions NN O O
of NN O O
the NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
gene NN O O
in NN O O
patients NN O O
and NN O O
carriers NN O O
of NN O O
severe NN B-SpecificDisease B-MSH:D056729
von NN I-SpecificDisease I-MSH:D056729
Willebrand NN I-SpecificDisease I-MSH:D056729
disease NN I-SpecificDisease I-MSH:D056729
. NN O O

severe NN O O
von NN O O
willebrand NN O O
disease NN O O
is NN O O
characterized NN O O
by NN O O
undetectable NN O O
or NN O O
trace NN O O
quantities NN O O
of NN O O
von NN B-Modifier B-MSH:D014842
Willebrand NN I-Modifier I-MSH:D014842
factor NN O O
in NN O O
plasma NN O O
and NN O O
tissue NN O O
stores. NN O O
we NN O O
have NN O O
studied NN O O
the NN O O
genomic NN O O
dna NN O O
of NN O O
10 NN O O
affected NN O O
individuals NN O O
from NN O O
six NN O O
families NN O O
with NN O O
this NN O O
disorder NN O O
using NN O O
probes NN O O
from NN O O
the NN O O
5 NN O O
and NN O O
3 NN O O
ends NN O O
of NN O O
the NN O O
vwf NN O O
cdna NN O O
and NN O O
with NN O O
a NN O O
probe NN O O
extending NN O O
from NN O O
the NN O O
5 NN O O
end NN O O
into NN O O
the NN O O
central NN O O
region. NN O O
southern NN O O
blots NN O O
of NN O O
restriction NN O O
endonuclease NN O O
digests NN O O
and NN O O
gene NN O O
dosage NN O O
analysis NN O O
measurements NN O O
carried NN O O
out NN O O
with NN O O
quantitative NN O O
slot NN O O
blots NN O O
of NN O O
undigested NN O O
genomic NN O O
dna NN O O
separated NN O O
these NN O O
patients NN O O
into NN O O
three NN O O
groups. NN O O
the NN O O
first NN O O
group NN O O
consisted NN O O
of NN O O
a NN O O
family NN O O
with NN O O
complete NN O O
homozygous NN O O
deletions NN O O
of NN O O
the NN O O
vwf NN O O
gene NN O O
in NN O O
the NN O O
four NN O O
probands. NN O O
gene NN O O
dosage NN O O
analysis NN O O
was NN O O
consistent NN O O
with NN O O
heterozygous NN O O
deletions NN O O
in NN O O
both NN O O
of NN O O
the NN O O
asymptomatic NN O O
parents NN O O
and NN O O
four NN O O
asymptomatic NN O O
siblings NN O O
of NN O O
this NN O O
kindred NN O O
(p NN O O
less NN O O
than NN O O
0. NN O O
01 NN O O
. NN O O

. NN O O
the NN O O
second NN O O
group NN O O
was NN O O
comprised NN O O
of NN O O
a NN O O
family NN O O
in NN O O
which NN O O
there NN O O
was NN O O
a NN O O
complete NN O O
heterozygous NN O O
deletion NN O O
of NN O O
the NN O O
vwf NN O O
gene NN O O
in NN O O
the NN O O
proband NN O O
and NN O O
one NN O O
asymptomatic NN O O
parent, NN O O
suggesting NN O O
that NN O O
a NN O O
different NN O O
type NN O O
of NN O O
genetic NN B-DiseaseClass B-MSH:D030342
abnormality NN I-DiseaseClass I-MSH:D030342
was NN O O
inherited NN O O
from NN O O
the NN O O
other NN O O
parent. NN O O
thus, NN O O
the NN O O
patient NN O O
appeared NN O O
to NN O O
be NN O O
doubly NN O O
heterozygous NN O O
for NN O O
interacting NN O O
genetic NN B-DiseaseClass B-MSH:D030342
abnormalities NN I-DiseaseClass I-MSH:D030342
affecting NN O O
vwf NN O O
expression. NN O O
in NN O O
the NN O O
third NN O O
group, NN O O
no NN O O
gene NN O O
deletions NN O O
could NN O O
be NN O O
detected. NN O O
alloantibodies NN O O
developed NN O O
only NN O O
in NN O O
the NN O O
kindred NN O O
with NN O O
homozygous NN O O
deletions. NN O O
these NN O O
techniques NN O O
should NN O O
prove NN O O
useful NN O O
in NN O O
identifying NN O O
carriers NN O O
of NN O O
severe NN B-SpecificDisease B-MSH:D056729
von NN I-SpecificDisease I-MSH:D056729
Willebrand NN I-SpecificDisease I-MSH:D056729
disease NN I-SpecificDisease I-MSH:D056729
and NN O O
also NN O O
in NN O O
defining NN O O
patients NN O O
predictably NN O O
at NN O O
risk NN O O
of NN O O
developing NN O O
alloantibodies NN O O
to NN O O
vwf NN O O
. NN O O

spectrum NN O O
of NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
rb NN O O
1 NN O O
gene: NN O O
a NN O O
study NN O O
of NN O O
232 NN O O
patients NN O O
with NN O O
hereditary NN B-CompositeMention B-MSH:D012175
and NN I-CompositeMention I-MSH:D012175
non NN I-CompositeMention I-MSH:D012175
hereditary NN I-CompositeMention I-MSH:D012175
retinoblastoma NN I-CompositeMention I-MSH:D012175
. NN O O

germline NN O O
mutations NN O O
in NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
confer NN O O
hereditary NN O O
predisposition NN O O
to NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
. NN O O
we NN O O
have NN O O
performed NN O O
a NN O O
mutation NN O O
survey NN O O
of NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
in NN O O
232 NN O O
patients NN O O
with NN O O
hereditary NN B-CompositeMention B-MSH:D012175
or NN I-CompositeMention I-MSH:D012175
non NN I-CompositeMention I-MSH:D012175
hereditary NN I-CompositeMention I-MSH:D012175
retinoblastoma NN I-CompositeMention I-MSH:D012175
. NN O O
we NN O O
systematically NN O O
explored NN O O
all NN O O
27 NN O O
exons NN O O
and NN O O
flanking NN O O
sequences NN O O
as NN O O
well NN O O
as NN O O
the NN O O
promotor. NN O O
all NN O O
types NN O O
of NN O O
point NN O O
mutations NN O O
are NN O O
represented NN O O
and NN O O
are NN O O
found NN O O
unequally NN O O
distributed NN O O
along NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
sequence. NN O O
in NN O O
the NN O O
population NN O O
we NN O O
studied, NN O O
exons NN O O
3, NN O O
8, NN O O
18 NN O O
and NN O O
19 NN O O
are NN O O
preferentially NN O O
altered. NN O O
the NN O O
range NN O O
of NN O O
frequency NN O O
of NN O O
detection NN O O
of NN O O
germline NN O O
mutations NN O O
is NN O O
about NN O O
20%, NN O O
indicating NN O O
that NN O O
other NN O O
mechanisms NN O O
of NN O O
inactivation NN O O
of NN O O
rb NN O O
1 NN O O
should NN O O
be NN O O
involved. NN O O
the NN O O
spectrum NN O O
of NN O O
mutations NN O O
presented NN O O
here NN O O
should NN O O
help NN O O
to NN O O
improve NN O O
the NN O O
clinical NN O O
management NN O O
of NN O O
retinoblastoma NN B-SpecificDisease B-MSH:D012175
and NN O O
to NN O O
understand NN O O
the NN O O
molecular NN O O
mechanisms NN O O
leading NN O O
to NN O O
tumorigenesis. NN O O
. NN O O

pelizaeus-merzbacher NN O O
disease: NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D020279
neurologic NN I-DiseaseClass I-MSH:D020279
disorder NN I-DiseaseClass I-MSH:D020279
of NN I-DiseaseClass I-MSH:D020279
myelin NN I-DiseaseClass I-MSH:D020279
metabolism NN I-DiseaseClass I-MSH:D020279
with NN O O
a NN O O
novel NN O O
mutation NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
proteolipid NN O O
protein NN O O
. NN O O

the NN O O
nosology NN O O
of NN O O
the NN O O
inborn NN B-DiseaseClass B-MSH:D020279
errors NN I-DiseaseClass I-MSH:D020279
of NN I-DiseaseClass I-MSH:D020279
myelin NN I-DiseaseClass I-MSH:D020279
metabolism NN I-DiseaseClass I-MSH:D020279
has NN O O
been NN O O
stymied NN O O
by NN O O
the NN O O
lack NN O O
of NN O O
molecular NN O O
genetic NN O O
analysis. NN O O
historically, NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
has NN O O
encompassed NN O O
a NN O O
host NN O O
of NN O O
neurologic NN B-DiseaseClass B-MSH:D009422
disorders NN I-DiseaseClass I-MSH:D009422
that NN O O
present NN O O
with NN O O
a NN O O
deficit NN B-DiseaseClass B-MSH:D003711
of NN I-DiseaseClass I-MSH:D003711
myelin NN I-DiseaseClass I-MSH:D003711
, NN O O
the NN O O
membrane NN O O
elaborated NN O O
by NN O O
glial NN O O
cells NN O O
that NN O O
encircles NN O O
and NN O O
successively NN O O
enwraps NN O O
axons. NN O O
we NN O O
describe NN O O
here NN O O
a NN O O
Pelizaeus-Merzbacher NN B-Modifier B-OMIM:312080
pedigree NN O O
of NN O O
the NN O O
classical NN O O
type, NN O O
with NN O O
x-linked NN O O
inheritance, NN O O
a NN O O
typical NN O O
clinical NN O O
progression, NN O O
and NN O O
a NN O O
pathologic NN O O
loss NN O O
of NN O O
myelinating NN O O
cells NN O O
and NN O O
myelin NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system. NN O O
to NN O O
discriminate NN O O
variants NN O O
of NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
, NN O O
a NN O O
set NN O O
of NN O O
oligonucleotide NN O O
primers NN O O
was NN O O
constructed NN O O
to NN O O
polymerase-chain-reaction NN O O
(pcr) NN O O
amplify NN O O
and NN O O
sequence NN O O
the NN O O
gene NN O O
encoding NN O O
proteolipid NN O O
protein NN O O
(plp), NN O O
a NN O O
structural NN O O
protein NN O O
that NN O O
comprises NN O O
half NN O O
of NN O O
the NN O O
protein NN O O
o NN O O
. NN O O

the NN O O
myelin NN O O
sheath. NN O O
the NN O O
plp NN O O
gene NN O O
in NN O O
one NN O O
of NN O O
two NN O O
affected NN O O
males NN O O
and NN O O
the NN O O
carrier NN O O
mother NN O O
of NN O O
this NN O O
family NN O O
exhibited NN O O
a NN O O
single NN O O
base NN O O
difference NN O O
in NN O O
the NN O O
more NN O O
than NN O O
2 NN O O
kb NN O O
of NN O O
the NN O O
plp NN O O
gene NN O O
sequenced, NN O O
a NN O O
c----t NN O O
transition NN O O
that NN O O
would NN O O
create NN O O
a NN O O
serine NN O O
substitution NN O O
for NN O O
proline NN O O
at NN O O
the NN O O
carboxy NN O O
end NN O O
of NN O O
the NN O O
protein. NN O O
our NN O O
results NN O O
delineate NN O O
the NN O O
clinical NN O O
features NN O O
of NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
, NN O O
define NN O O
the NN O O
possible NN O O
molecular NN O O
pathology NN O O
of NN O O
this NN O O
dysmyelinating NN B-DiseaseClass B-MSH:D003711
disorder NN I-DiseaseClass I-MSH:D003711
, NN O O
and NN O O
address NN O O
the NN O O
molecular NN O O
classification NN O O
of NN O O
inborn NN B-DiseaseClass B-MSH:D020279
errors NN I-DiseaseClass I-MSH:D020279
of NN I-DiseaseClass I-MSH:D020279
myelin NN I-DiseaseClass I-MSH:D020279
metabolism NN I-DiseaseClass I-MSH:D020279
. NN O O
patients NN O O
with NN O O
the NN O O
classical NN O O
form NN O O
(type NN O O
i) NN O O
and NN O O
the NN O O
more NN O O
severely NN O O
affected, NN O O
connatal NN O O
variant NN O O
of NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
(type NN I-SpecificDisease I-OMIM:312080
II) NN I-SpecificDisease I-OMIM:312080
would NN O O
be NN O O
predicted NN O O
to NN O O
display NN O O
mutation NN O O
at NN O O
the NN O O
plp NN O O
locus. NN O O
the NN O O
other NN O O
variants NN O O
(types NN O O
iii-v NN O O
. NN O O

), NN O O
which NN O O
have NN O O
sometimes NN O O
been NN O O
categorized NN O O
as NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
, NN O O
may NN O O
represent NN O O
mutations NN O O
in NN O O
genes NN O O
encoding NN O O
other NN O O
structural NN O O
myelin NN O O
proteins NN O O
or NN O O
proteins NN O O
critical NN O O
to NN O O
myelination. NN O O
. NN O O

cag NN O O
expansions NN O O
in NN O O
a NN O O
novel NN O O
gene NN O O
for NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
at NN O O
chromosome NN O O
14 NN O O
q NN O O
32.1 NN O O
. NN O O

we NN O O
have NN O O
identified NN O O
a NN O O
novel NN O O
gene NN O O
containing NN O O
cag NN O O
repeats NN O O
and NN O O
mapped NN O O
it NN O O
to NN O O
chromosome NN O O
14 NN O O
q NN O O
32. NN O O
1, NN O O
the NN O O
genetic NN O O
locus NN O O
for NN O O
Machado-Joseph NN B-SpecificDisease B-MSH:D017827
disease NN I-SpecificDisease I-MSH:D017827
( NN O O
MJD NN B-SpecificDisease B-MSH:D017827
). NN O O
in NN O O
normal NN O O
individuals NN O O
the NN O O
gene NN O O
contains NN O O
between NN O O
13 NN O O
and NN O O
36 NN O O
cag NN O O
repeats, NN O O
whereas NN O O
most NN O O
of NN O O
the NN O O
clinically NN O O
diagnosed NN O O
patients NN O O
and NN O O
all NN O O
of NN O O
the NN O O
affected NN O O
members NN O O
of NN O O
a NN O O
family NN O O
with NN O O
the NN O O
clinical NN O O
and NN O O
pathological NN O O
diagnosis NN O O
of NN O O
MJD NN B-SpecificDisease B-MSH:D017827
show NN O O
expansion NN O O
of NN O O
the NN O O
repeat-number NN O O
(from NN O O
68-79). NN O O
southern NN O O
blot NN O O
analyses NN O O
and NN O O
genomic NN O O
cloning NN O O
demonstrates NN O O
the NN O O
existence NN O O
of NN O O
related NN O O
genes. NN O O
these NN O O
results NN O O
raise NN O O
the NN O O
possibility NN O O
that NN O O
similar NN O O
abnormalities NN O O
in NN O O
related NN O O
genes NN O O
may NN O O
give NN O O
rise NN O O
to NN O O
diseases NN O O
similar NN O O
to NN O O
MJD NN B-SpecificDisease B-MSH:D017827
. NN O O

conservation NN O O
of NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
gene NN O O
in NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O

a NN O O
portion NN O O
of NN O O
the NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
gene NN O O
transcript NN O O
from NN O O
human NN O O
fetal NN O O
skeletal NN O O
muscle NN O O
and NN O O
mouse NN O O
adult NN O O
heart NN O O
was NN O O
sequenced, NN O O
representing NN O O
approximately NN O O
25 NN O O
percent NN O O
of NN O O
the NN O O
total, NN O O
14-kb NN O O
DMD NN B-Modifier B-MSH:D020388
transcript. NN O O
the NN O O
nucleic NN O O
acid NN O O
and NN O O
predicted NN O O
amino NN O O
acid NN O O
sequences NN O O
from NN O O
the NN O O
two NN O O
species NN O O
are NN O O
nearly NN O O
90 NN O O
percent NN O O
homologous. NN O O
the NN O O
amino NN O O
acid NN O O
sequence NN O O
that NN O O
is NN O O
predicted NN O O
from NN O O
this NN O O
portion NN O O
of NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
gene NN O O
indicates NN O O
that NN O O
the NN O O
protein NN O O
product NN O O
might NN O O
serve NN O O
a NN O O
structural NN O O
role NN O O
in NN O O
muscle, NN O O
but NN O O
the NN O O
abundance NN O O
and NN O O
tissue NN O O
distribution NN O O
of NN O O
the NN O O
messenger NN O O
rna NN O O
suggests NN O O
that NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
protein NN O O
is NN O O
not NN O O
nebulin. NN O O
. NN O O

deficiency NN O O
of NN O O
the NN O O
murine NN O O
fifth NN O O
complement NN O O
component NN O O
(c NN O O
5). NN O O
a NN O O
2-base NN O O
pair NN O O
gene NN O O
deletion NN O O
in NN O O
a NN O O
5'-exon NN O O
. NN O O

to NN O O
ascertain NN O O
the NN O O
molecular NN O O
mechanism NN O O
that NN O O
causes NN O O
murine NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
, NN O O
genomic NN O O
and NN O O
cdna NN O O
libraries NN O O
were NN O O
constructed NN O O
from NN O O
mouse NN O O
liver NN O O
dna NN O O
and NN O O
mrna NN O O
employing NN O O
the NN O O
congenic NN O O
strains NN O O
b NN O O
10. NN O O
d NN O O
2/nsnj NN O O
and NN O O
b NN O O
10. NN O O
d NN O O
2/osnj NN O O
that NN O O
are NN O O
sufficient NN O O
and NN O O
deficient NN B-SpecificDisease B-OMIM:609536
for NN I-SpecificDisease I-OMIM:609536
C5 NN I-SpecificDisease I-OMIM:609536
, NN O O
respectively. NN O O
genomic NN O O
fragments NN O O
were NN O O
isolated NN O O
which NN O O
correspond NN O O
to NN O O
pvuii NN O O
and NN O O
hindiii NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
associated NN O O
with NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
. NN O O
sequence NN O O
analyses NN O O
demonstrated NN O O
that NN O O
each NN O O
of NN O O
these NN O O
polymorphisms NN O O
resulted NN O O
from NN O O
single NN O O
base NN O O
pair NN O O
substitutions NN O O
and NN O O
that NN O O
neither NN O O
substitution NN O O
would NN O O
probably NN O O
cause NN O O
or NN O O
contribute NN O O
to NN O O
the NN O O
C5 NN B-SpecificDisease B-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
. NN O O
sequence NN O O
analyses NN O O
of NN O O
c NN O O
5 NN O O
sufficient NN O O
and NN O O
deficient NN O O
cdnas NN O O
revealed NN O O
a NN O O
2 NN O O
base-pair NN O O
deletion NN O O
in NN O O
the NN O O
deficient NN O O
cdnas. NN O O
the NN O O
" NN O O
ta NN O O
" NN O O
deletion NN O O
was NN O O
located NN O O
near NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
cdna. NN O O
thi NN O O
. NN O O

deletion NN O O
shifts NN O O
the NN O O
reading NN O O
frame NN O O
of NN O O
the NN O O
c NN O O
5 NN O O
mrna NN O O
so NN O O
that NN O O
the NN O O
termination NN O O
codon NN O O
uga NN O O
is NN O O
present NN O O
4 NN O O
base NN O O
pairs NN O O
downstream NN O O
from NN O O
the NN O O
deletion. NN O O
genomic NN O O
dna NN O O
was NN O O
amplified NN O O
and NN O O
sequenced NN O O
corresponding NN O O
to NN O O
the NN O O
area NN O O
surrounding NN O O
the NN O O
2-base NN O O
pair NN O O
deletion. NN O O
six NN O O
C5-deficient NN B-Modifier B-OMIM:609536
strains, NN O O
a/hej, NN O O
akr/j, NN O O
dba/2 NN O O
j, NN O O
nzb/b NN O O
1 NN O O
nj, NN O O
swr/j, NN O O
and NN O O
b NN O O
10. NN O O
d NN O O
2/osnj, NN O O
and NN O O
four NN O O
c NN O O
5-sufficient NN O O
strains, NN O O
balb/cj, NN O O
c NN O O
57 NN O O
bl/6 NN O O
j, NN O O
dba/1 NN O O
j, NN O O
and NN O O
b NN O O
10. NN O O
d NN O O
2/nsnj, NN O O
were NN O O
analyzed. NN O O
the NN O O
sequencing NN O O
data NN O O
revealed NN O O
that NN O O
the NN O O
2 NN O O
base NN O O
pairs NN O O
were NN O O
deleted NN O O
from NN O O
the NN O O
c NN O O
5 NN O O
gene NN O O
of NN O O
each NN O O
deficient NN O O
mouse NN O O
teste NN O O
. NN O O

but NN O O
not NN O O
from NN O O
the NN O O
c NN O O
5 NN O O
gene NN O O
of NN O O
any NN O O
sufficient NN O O
mouse. NN O O
these NN O O
data NN O O
demonstrate NN O O
that NN O O
1) NN O O
there NN O O
is NN O O
an NN O O
identical NN O O
2-base NN O O
pair NN O O
deletion NN O O
in NN O O
an NN O O
exon NN O O
of NN O O
the NN O O
c NN O O
5 NN O O
gene NN O O
in NN O O
several NN O O
different NN O O
C5-deficient NN B-Modifier B-OMIM:609536
mouse NN O O
strains; NN O O
2) NN O O
the NN O O
mrna NN O O
transcribed NN O O
from NN O O
the NN O O
c NN O O
5 NN O O
d NN O O
gene NN O O
retains NN O O
this NN O O
deletion; NN O O
and NN O O
3) NN O O
this NN O O
mutation NN O O
should NN O O
result NN O O
in NN O O
C5 NN B-SpecificDisease B-OMIM:609536
protein NN I-SpecificDisease I-OMIM:609536
deficiency NN I-SpecificDisease I-OMIM:609536
. NN O O

recurrent NN O O
meningitis NN B-SpecificDisease B-MSH:D008581
in NN O O
a NN O O
patient NN O O
with NN O O
congenital NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
of NN I-SpecificDisease I-OMIM:613825
the NN I-SpecificDisease I-OMIM:613825
C9 NN I-SpecificDisease I-OMIM:613825
component NN I-SpecificDisease I-OMIM:613825
of NN I-SpecificDisease I-OMIM:613825
complement NN I-SpecificDisease I-OMIM:613825
. NN O O
first NN O O
case NN O O
of NN O O
C9 NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
in NN O O
europe NN O O
. NN O O

we NN O O
describe NN O O
the NN O O
first NN O O
cases, NN O O
to NN O O
our NN O O
knowledge, NN O O
of NN O O
C9 NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
in NN O O
europe NN O O
that NN O O
were NN O O
detected NN O O
in NN O O
a NN O O
swiss NN O O
family, NN O O
of NN O O
which NN O O
two NN O O
members--one NN O O
with NN O O
a NN O O
complete NN O O
deficiency NN O O
and NN O O
the NN O O
other NN O O
with NN O O
approximately NN O O
half-normal NN O O
c NN O O
9 NN O O
levels--experienced NN O O
bacterial NN B-SpecificDisease B-MSH:D016920
meningitis NN I-SpecificDisease I-MSH:D016920
. NN O O
the NN O O
index NN O O
patient, NN O O
a NN O O
56-year-old NN O O
white NN O O
man NN O O
with NN O O
a NN O O
history NN O O
of NN O O
purulent NN B-SpecificDisease B-MSH:D008586
meningitis NN I-SpecificDisease I-MSH:D008586
at NN O O
the NN O O
age NN O O
of NN O O
23 NN O O
years, NN O O
presented NN O O
with NN O O
an NN O O
acute NN B-SpecificDisease B-MSH:D008585
meningococcal NN I-SpecificDisease I-MSH:D008585
meningitis NN I-SpecificDisease I-MSH:D008585
. NN O O
no NN O O
impairment NN B-DiseaseClass B-MSH:D007153
of NN I-DiseaseClass I-MSH:D007153
cellular NN I-DiseaseClass I-MSH:D007153
immunity NN I-DiseaseClass I-MSH:D007153
or NN O O
immunoglobulin NN B-SpecificDisease B-MSH:D004406
deficiency NN I-SpecificDisease I-MSH:D004406
could NN O O
be NN O O
found. NN O O
complement NN O O
assays NN O O
showed NN O O
a NN O O
complete NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
of NN I-SpecificDisease I-OMIM:613825
the NN I-SpecificDisease I-OMIM:613825
C9 NN I-SpecificDisease I-OMIM:613825
component NN I-SpecificDisease I-OMIM:613825
, NN O O
while NN O O
the NN O O
other NN O O
individual NN O O
component NN O O
levels NN O O
were NN O O
normal NN O O
and NN O O
the NN O O
hemolytic NN O O
activity NN O O
(measured NN O O
using NN O O
the NN O O
ch NN O O
50 NN O O
assay) NN O O
was NN O O
only NN O O
slightly NN O O
reduced. NN O O
a NN O O
family NN O O
study NN O O
revealed NN O O
complete NN B-SpecificDisease B-OMIM:613825
C9 NN I-SpecificDisease I-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825

deficiency NN O O
in NN O O
the NN O O
patients NN O O
healthy NN O O
brother NN O O
and NN O O
half-normal NN O O
c NN O O
9 NN O O
concentrations NN O O
in NN O O
his NN O O
sister, NN O O
his NN O O
son NN O O
(who NN O O
also NN O O
had NN O O
experienced NN O O
an NN O O
episode NN O O
of NN O O
bacterial NN B-SpecificDisease B-MSH:D016920
meningitis NN I-SpecificDisease I-MSH:D016920
), NN O O
and NN O O
his NN O O
niece, NN O O
consistent NN O O
with NN O O
an NN O O
inherited NN O O
C9 NN B-SpecificDisease B-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
. NN O O
this NN O O
first NN O O
case NN O O
of NN O O
recurrent NN B-SpecificDisease B-MSH:D008581
meningitis NN I-SpecificDisease I-MSH:D008581
in NN O O
a NN O O
white NN O O
patient NN O O
with NN O O
complete NN B-SpecificDisease B-OMIM:613825
C9 NN I-SpecificDisease I-OMIM:613825
deficiency NN I-SpecificDisease I-OMIM:613825
suggests NN O O
that NN O O
this NN O O
complement NN B-DiseaseClass B-MSH:D007153
defect NN I-DiseaseClass I-MSH:D007153
may NN O O
also NN O O
be NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
bacterial, NN B-DiseaseClass B-MSH:D016870
especially NN I-DiseaseClass I-MSH:D016870
neisserial, NN I-DiseaseClass I-MSH:D016870
infections NN I-DiseaseClass I-MSH:D016870
. NN O O
. NN O O

bone NN O O
marrow NN O O
transplant NN O O
in NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
. NN O O

an NN O O
allogeneic NN O O
bone NN O O
marrow NN O O
transplant NN O O
(bmt) NN O O
from NN O O
a NN O O
normal NN O O
hla NN O O
identical NN O O
sibling NN O O
donor NN O O
was NN O O
performed NN O O
in NN O O
a NN O O
13-year-old NN O O
boy NN O O
with NN O O
rapidly NN O O
progressive NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
). NN O O
engraftment NN O O
and NN O O
complete NN O O
hematologic NN O O
recovery NN O O
occurred NN O O
within NN O O
4 NN O O
weeks, NN O O
but NN O O
neurologic NN B-DiseaseClass B-MSH:D019636
deterioration NN I-DiseaseClass I-MSH:D019636
continued. NN O O
the NN O O
patient NN O O
died NN O O
of NN O O
an NN O O
adenovirus NN B-SpecificDisease B-MSH:D000257
infection NN I-SpecificDisease I-MSH:D000257
141 NN O O
days NN O O
after NN O O
bmt. NN O O
ALD NN B-SpecificDisease B-MSH:D000326
is NN O O
characterized NN O O
by NN O O
abnormally NN O O
high NN O O
plasma NN O O
levels NN O O
of NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
(vlcfa) NN O O
as NN O O
a NN O O
result NN O O
of NN O O
impaired NN O O
capacity NN O O
to NN O O
degrade NN O O
them. NN O O
ten NN O O
days NN O O
after NN O O
bmt, NN O O
the NN O O
white NN O O
blood NN O O
cell NN O O
vlcfa NN O O
levels NN O O
and NN O O
enzyme NN O O
activity NN O O
became NN O O
normal; NN O O
after NN O O
3 NN O O
months, NN O O
there NN O O
was NN O O
progressive NN O O
reduction NN O O
of NN O O
plasma NN O O
vlcfa NN O O
to NN O O
levels NN O O
only NN O O
slightly NN O O
above NN O O
normal. NN O O
. NN O O

increased NN O O
incidence NN O O
of NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
in NN O O
male NN O O
subjects NN O O
deficient NN B-SpecificDisease B-MSH:D005955
in NN I-SpecificDisease I-MSH:D005955
glucose-6-phosphate NN I-SpecificDisease I-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
. NN O O

glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
deficiency NN O O
in NN O O
rbcs NN O O
was NN O O
found NN O O
significantly NN O O
more NN O O
frequently NN O O
in NN O O
210 NN O O
male NN O O
cataractous NN B-Modifier B-MSH:D002386
patients NN O O
than NN O O
in NN O O
672 NN O O
control NN O O
subjects NN O O
of NN O O
sardinian NN O O
origin. NN O O
the NN O O
frequency NN O O
of NN O O
the NN O O
deficiency NN O O
was NN O O
increasingly NN O O
higher NN O O
in NN O O
presenile NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
. NN O O
in NN O O
the NN O O
G6PD-deficient NN B-Modifier B-MSH:D005955
group, NN O O
the NN O O
incidence NN O O
of NN O O
cortical NN B-CompositeMention B-MSH:D002386
and NN I-CompositeMention I-MSH:D002386
total NN I-CompositeMention I-MSH:D002386
cataracts NN I-CompositeMention I-MSH:D002386
was NN O O
also NN O O
increased. NN O O
it NN O O
is NN O O
suggested NN O O
that NN O O
decrease NN O O
of NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
activity NN O O
in NN O O
the NN O O
lens, NN O O
which NN O O
accompanies NN O O
its NN O O
deficiency NN O O
in NN O O
the NN O O
erythrocyte, NN O O
might NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
cataracto-genesis NN O O
of NN O O
these NN O O
patients. NN O O
moreover, NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
should NN O O
be NN O O
added NN O O
to NN O O
other NN O O
conditions, NN O O
such NN O O
as NN O O
the NN O O
galactosemic NN B-Modifier B-OMIM:230400
states NN O O
and NN O O
riboflavin NN B-SpecificDisease B-MSH:D012257
deficiency NN I-SpecificDisease I-MSH:D012257
, NN O O
where NN O O
cataracts NN B-SpecificDisease B-MSH:D002386
represent NN O O
a NN O O
sensitive NN O O
indicator NN O O
of NN O O
metabolic NN B-DiseaseClass B-MSH:D008659
abnormalities NN I-DiseaseClass I-MSH:D008659
of NN O O
the NN O O
rbc. NN O O
. NN O O

von NN O O
hippel-lindau NN O O
disease NN O O
maps NN O O
to NN O O
the NN O O
region NN O O
of NN O O
chromosome NN O O
3 NN O O
associated NN O O
with NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
. NN O O

von NN O O
hippel-lindau NN O O
disease NN O O
( NN O O
VHL NN B-SpecificDisease B-MSH:D006623
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
dominant NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
with NN O O
inherited NN O O
susceptibility NN O O
to NN O O
various NN O O
forms NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
, NN O O
including NN O O
hemangioblastomas NN B-SpecificDisease B-MSH:D018325
of NN O O
the NN O O
central NN O O
nervous NN O O
system, NN O O
phaeochromocytomas NN B-SpecificDisease B-MSH:D010673
, NN O O
pancreatic NN B-SpecificDisease B-OMIM:260350
malignancies NN I-SpecificDisease I-OMIM:260350
, NN O O
and NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinomas NN I-SpecificDisease I-MSH:D002292
. NN O O
Renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinomas NN I-SpecificDisease I-MSH:D002292
constitute NN O O
a NN O O
particularly NN O O
frequent NN O O
cause NN O O
of NN O O
death NN O O
in NN O O
this NN O O
disorder, NN O O
occurring NN O O
as NN O O
bilateral NN B-CompositeMention B-MSH:D009369
and NN I-CompositeMention I-MSH:D009369
multifocal NN I-CompositeMention I-MSH:D009369
tumours NN I-CompositeMention I-MSH:D009369
, NN O O
and NN O O
presenting NN O O
at NN O O
an NN O O
earlier NN O O
age NN O O
than NN O O
in NN O O
sporadic, NN O O
non-familial NN O O
cases NN O O
of NN O O
this NN O O
tumour NN B-Modifier B-MSH:D009369
type. NN O O
we NN O O
report NN O O
here NN O O
that NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
gene NN O O
is NN O O
linked NN O O
to NN O O
the NN O O
locus NN O O
encoding NN O O
the NN O O
human NN O O
homologoue NN O O
of NN O O
the NN O O
raf NN O O
1 NN O O
oncogene, NN O O
which NN O O
maps NN O O
to NN O O
chromosome NN O O
3 NN O O
p NN O O
25 NN O O
(ref. NN O O
4). NN O O
crossovers NN O O
with NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
locus NN O O
suggest NN O O
that NN O O
the NN O O
defect NN O O
responsible NN O O
for NN O O
the NN O O
VHL NN B-Modifier B-MSH:D006623
phenotype NN O O
is NN O O
not NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
raf NN O O
1 NN O O
gene NN O O
itself NN O O
. NN O O

an NN O O
alternative NN O O
or NN O O
prior NN O O
event NN O O
to NN O O
oncogene NN O O
activation NN O O
in NN O O
tumour NN B-Modifier B-MSH:D009369
formation NN O O
may NN O O
be NN O O
the NN O O
inactivation NN O O
of NN O O
a NN O O
putative NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
which NN O O
can NN O O
be NN O O
associated NN O O
with NN O O
both NN O O
the NN O O
inherited NN B-CompositeMention B-MSH:D009369
and NN I-CompositeMention I-MSH:D009369
sporadic NN I-CompositeMention I-MSH:D009369
forms NN I-CompositeMention I-MSH:D009369
of NN I-CompositeMention I-MSH:D009369
the NN I-CompositeMention I-MSH:D009369
cancer NN I-CompositeMention I-MSH:D009369
. NN O O
Sporadic NN B-SpecificDisease B-MSH:D002292
renal NN I-SpecificDisease I-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinomas NN I-SpecificDisease I-MSH:D002292
have NN O O
previously NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
loss NN O O
of NN O O
regions NN O O
on NN O O
chromosome NN O O
3 NN O O
p NN O O
(refs NN O O
. NN O O

, NN O O
6). NN O O
consequently, NN O O
sporadic NN O O
and NN O O
vhl-associated NN O O
forms NN O O
of NN O O
renal NN B-SpecificDisease B-MSH:D002292
cell NN I-SpecificDisease I-MSH:D002292
carcinoma NN I-SpecificDisease I-MSH:D002292
might NN O O
both NN O O
result NN O O
from NN O O
alterations NN O O
causing NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
the NN O O
same NN O O
tumour NN B-Modifier B-MSH:D009369
suppressor NN O O
gene NN O O
on NN O O
this NN O O
chromosome. NN O O
. NN O O

tightly NN O O
linked NN O O
flanking NN O O
markers NN O O
for NN O O
the NN O O
Lowe NN B-SpecificDisease B-MSH:D009800
oculocerebrorenal NN I-SpecificDisease I-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
, NN O O
with NN O O
application NN O O
to NN O O
carrier NN O O
assessment NN O O
. NN O O

the NN O O
Lowe NN B-SpecificDisease B-MSH:D009800
oculocerebrorenal NN I-SpecificDisease I-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
( NN O O
OCRL NN B-SpecificDisease B-MSH:D009800
) NN O O
is NN O O
characterized NN O O
by NN O O
congenital NN O O
cataract NN B-SpecificDisease B-MSH:D002386
, NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
and NN O O
defective NN B-DiseaseClass B-MSH:D015499
renal NN I-DiseaseClass I-MSH:D015499
tubular NN I-DiseaseClass I-MSH:D015499
function NN I-DiseaseClass I-MSH:D015499
. NN O O
a NN O O
map NN O O
assignment NN O O
of NN O O
OCRL NN B-SpecificDisease B-MSH:D009800
to NN O O
xq NN O O
24-q NN O O
26 NN O O
has NN O O
been NN O O
made NN O O
previously NN O O
by NN O O
linkage NN O O
analysis NN O O
with NN O O
dxs NN O O
42 NN O O
at NN O O
xq NN O O
24-q NN O O
26 NN O O
(theta NN O O
= NN O O
0, NN O O
z NN O O
= NN O O
5. NN O O
09) NN O O
and NN O O
with NN O O
dxs NN O O
10 NN O O
at NN O O
xq NN O O
26 NN O O
(theta NN O O
= NN O O
0, NN O O
z NN O O
= NN O O
6. NN O O
45). NN O O
two NN O O
additional NN O O
families NN O O
were NN O O
studied NN O O
and NN O O
three NN O O
additional NN O O
polymorphisms NN O O
were NN O O
identified NN O O
at NN O O
dxs NN O O
42 NN O O
by NN O O
using NN O O
a NN O O
35-kb NN O O
sequence NN O O
isolated NN O O
with NN O O
the NN O O
probe NN O O
detecting NN O O
the NN O O
original NN O O
polymorphism NN O O
at NN O O
dxs NN O O
42. NN O O
with NN O O
additional NN O O
OCRL NN B-Modifier B-MSH:D009800
families NN O O
made NN O O
informative NN O O
for NN O O
dxs NN O O
42, NN O O
theta NN O O
remained NN O O
0 NN O O
with NN O O
z NN O O
= NN O O
6. NN O O
63; NN O O
and NN O O
for NN O O
dxs NN O O
10 NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

03 NN O O
and NN O O
z NN O O
= NN O O
7. NN O O
07. NN O O
evidence NN O O
for NN O O
placing NN O O
ocrl NN O O
at NN O O
xq NN O O
25 NN O O
also NN O O
comes NN O O
from NN O O
a NN O O
female NN O O
with NN O O
Lowe NN B-SpecificDisease B-MSH:D009800
syndrome NN I-SpecificDisease I-MSH:D009800
and NN O O
an NN O O
x; NN O O
3 NN O O
translocation. NN O O
we NN O O
have NN O O
used NN O O
the NN O O
xq NN O O
25 NN O O
breakpoint NN O O
in NN O O
this NN O O
patient NN O O
to NN O O
determine NN O O
the NN O O
position NN O O
of NN O O
ocrl NN O O
relative NN O O
to NN O O
the NN O O
two NN O O
linked NN O O
markers. NN O O
each NN O O
derivative NN O O
chromosome NN O O
was NN O O
isolated NN O O
away NN O O
from NN O O
its NN O O
normal NN O O
counterpart NN O O
in NN O O
somatic NN O O
cell NN O O
hybrids. NN O O
dxs NN O O
42 NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
derivative NN O O
chromosome NN O O
x NN O O
containing NN O O
xpterq NN O O
25, NN O O
and NN O O
dxs NN O O
10 NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
derivative NN O O
chromosome NN O O
3 NN O O
containing NN O O
xq NN O O
25-qter. NN O O
the NN O O
markers NN O O
dxs NN O O
10 NN O O
and NN O O
dxs NN O O
42 NN O O
therefore NN O O
show NN O O
tight NN O O
linkage NN O O
with NN O O
OCRL NN B-SpecificDisease B-MSH:D009800
in NN O O
six NN O O
families NN O O
and NN O O
flank NN O O
the NN O O
xq NN O O
25 NN O O
breakpoint NN O O
in NN O O
a NN O O
female NN O O
patient NN O O
with NN O O
an NN O O
x; NN O O
3 NN O O
translocation. NN O O
linkage NN O O
analysis NN O O
with NN O O
flanking NN O O
markers NN O O
was NN O O
used NN O O
to NN O O
assess NN O O
OCRL NN B-Modifier B-MSH:D009800
. NN O O

carrier NN O O
status NN O O
in NN O O
women NN O O
at NN O O
risk. NN O O
results, NN O O
when NN O O
compared NN O O
with NN O O
carrier NN O O
determination NN O O
by NN O O
ophthalmologic NN O O
examination, NN O O
indicated NN O O
that NN O O
the NN O O
slit-lamp NN O O
exam NN O O
can NN O O
be NN O O
a NN O O
sensitive NN O O
and NN O O
specific NN O O
method NN O O
of NN O O
carrier NN O O
determination NN O O
in NN O O
many NN O O
case NN O O
. NN O O

abnormal NN O O
development NN O O
of NN O O
purkinje NN O O
cells NN O O
and NN O O
lymphocytes NN O O
in NN O O
atm NN O O
mutant NN O O
mice NN O O
. NN O O

motor NN O O
incoordination, NN O O
immune NN B-DiseaseClass B-MSH:D007154
deficiencies NN I-DiseaseClass I-MSH:D007154
, NN O O
and NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
cancer NN B-DiseaseClass B-MSH:D009369
are NN O O
the NN O O
characteristic NN O O
features NN O O
of NN O O
the NN O O
hereditary NN B-DiseaseClass B-MSH:D030342
disease NN I-DiseaseClass I-MSH:D030342
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
( NN O O
A-T NN B-SpecificDisease B-MSH:D001260
), NN O O
which NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
atm NN O O
gene. NN O O
through NN O O
gene NN O O
targeting, NN O O
we NN O O
have NN O O
generated NN O O
a NN O O
line NN O O
of NN O O
atm NN O O
mutant NN O O
mice, NN O O
atm NN O O
(y/y) NN O O
mice. NN O O
in NN O O
contrast NN O O
to NN O O
other NN O O
atm NN O O
mutant NN O O
mice, NN O O
atm NN O O
(y/y) NN O O
mice NN O O
show NN O O
a NN O O
lower NN O O
incidence NN O O
of NN O O
thymic NN B-SpecificDisease B-MSH:D013953
lymphoma NN I-SpecificDisease I-MSH:D013953
and NN O O
survive NN O O
beyond NN O O
a NN O O
few NN O O
months NN O O
of NN O O
age. NN O O
atm NN O O
(y/y) NN O O
mice NN O O
exhibit NN O O
deficits NN O O
in NN O O
motor NN O O
learning NN O O
indicative NN O O
of NN O O
cerebellar NN B-DiseaseClass B-MSH:D002526
dysfunction NN I-DiseaseClass I-MSH:D002526
. NN O O
even NN O O
though NN O O
we NN O O
found NN O O
no NN O O
gross NN O O
cerebellar NN B-DiseaseClass B-MSH:D013132
degeneration NN I-DiseaseClass I-MSH:D013132
in NN O O
older NN O O
atm NN O O
(y/y) NN O O
animals, NN O O
ectopic NN O O
and NN O O
abnormally NN O O
differentiated NN O O
purkinje NN O O
cells NN O O
were NN O O
apparent NN O O
in NN O O
mutant NN O O
mice NN O O
of NN O O
al NN O O
. NN O O

ages. NN O O
these NN O O
findings NN O O
establish NN O O
that NN O O
some NN O O
neuropathological NN B-DiseaseClass B-MSH:D009422
abnormalities NN I-DiseaseClass I-MSH:D009422
seen NN O O
in NN O O
A-T NN B-Modifier B-MSH:D001260
patients NN O O
also NN O O
are NN O O
present NN O O
in NN O O
atm NN O O
mutant NN O O
mice. NN O O
in NN O O
addition, NN O O
we NN O O
report NN O O
a NN O O
previously NN O O
unrecognized NN O O
effect NN O O
of NN O O
Atm NN B-SpecificDisease B-OMIM:208900
deficiency NN I-SpecificDisease I-OMIM:208900
on NN O O
development NN O O
or NN O O
maintenance NN O O
of NN O O
cd NN O O
4 NN O O
(+) NN O O
8 NN O O
(+) NN O O
thymocytes. NN O O
we NN O O
discuss NN O O
these NN O O
findings NN O O
in NN O O
the NN O O
context NN O O
of NN O O
the NN O O
hypothesis NN O O
that NN O O
abnormal NN O O
development NN O O
of NN O O
purkinje NN O O
cells NN O O
and NN O O
lymphocytes NN O O
contributes NN O O
to NN O O
the NN O O
pathogenesis NN O O
of NN O O
A-T NN B-SpecificDisease B-MSH:D001260
. NN O O
. NN O O

both NN O O
mutations NN O O
in NN O O
g NN O O
6 NN O O
pd NN O O
a- NN O O
are NN O O
necessary NN O O
to NN O O
produce NN O O
the NN O O
G6PD NN B-Modifier B-MSH:D005955
deficient NN I-Modifier I-MSH:D005955
phenotype NN O O
. NN O O

the NN O O
high NN O O
prevalence NN O O
of NN O O
glucose NN B-SpecificDisease B-MSH:D005955
6-phosphate NN I-SpecificDisease I-MSH:D005955
dehydrogenase NN I-SpecificDisease I-MSH:D005955
(G6PD) NN I-SpecificDisease I-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN O O
african NN O O
populations NN O O
is NN O O
due NN O O
almost NN O O
entirely NN O O
to NN O O
the NN O O
enzyme NN O O
variant NN O O
a-, NN O O
which NN O O
differs NN O O
from NN O O
the NN O O
wild-type NN O O
g NN O O
6 NN O O
pd NN O O
b NN O O
by NN O O
two NN O O
amino NN O O
acid NN O O
replacements, NN O O
68 NN O O
val-- NN O O
> NN O O
met NN O O
and NN O O
126 NN O O
asn-- NN O O
> NN O O
asp. NN O O
the NN O O
non-deficient NN O O
polymorphic NN O O
variant NN O O
g NN O O
6 NN O O
pd NN O O
a NN O O
contains NN O O
only NN O O
the NN O O
mutation NN O O
126 NN O O
asn-- NN O O
> NN O O
asp. NN O O
the NN O O
frequencies NN O O
of NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
a NN O O
and NN O O
of NN O O
the NN O O
g NN O O
6 NN O O
pd NN O O
a- NN O O
genes NN O O
in NN O O
parts NN O O
of NN O O
africa NN O O
are NN O O
both NN O O
about NN O O
0. NN O O
2. NN O O
the NN O O
68 NN O O
val-- NN O O
> NN O O
met NN O O
mutation NN O O
has NN O O
not NN O O
been NN O O
found NN O O
in NN O O
a NN O O
b NN O O
background. NN O O
this NN O O
could NN O O
be NN O O
because NN O O
the NN O O
68 NN O O
val-- NN O O
> NN O O
met NN O O
mutation NN O O
happened NN O O
t NN O O
. NN O O

arise NN O O
in NN O O
an NN O O
a NN O O
gene NN O O
in NN O O
the NN O O
first NN O O
instance, NN O O
or NN O O
because NN O O
the NN O O
68 NN O O
val-- NN O O
> NN O O
met NN O O
mutation NN O O
alone NN O O
is NN O O
not NN O O
sufficient NN O O
to NN O O
cause NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
. NN O O
we NN O O
have NN O O
approached NN O O
this NN O O
question NN O O
by NN O O
producing NN O O
g NN O O
6 NN O O
pd NN O O
b, NN O O
a, NN O O
a-, NN O O
and NN O O
g NN O O
6 NN O O
pd NN O O
68 NN O O
val-- NN O O
> NN O O
met NN O O
in NN O O
a NN O O
bacterial NN O O
expression NN O O
system NN O O
and NN O O
analysing NN O O
their NN O O
biochemical NN O O
properties. NN O O
with NN O O
each NN O O
single NN O O
mutation NN O O
we NN O O
found NN O O
a NN O O
slight NN O O
decrease NN O O
in NN O O
both NN O O
the NN O O
specific NN O O
activity NN O O
and NN O O
the NN O O
yield NN O O
of NN O O
enzyme NN O O
when NN O O
compared NN O O
to NN O O
g NN O O
6 NN O O
pd NN O O
b. NN O O
when NN O O
both NN O O
mutations NN O O
were NN O O
introduced NN O O
together, NN O O
there NN O O
was NN O O
a NN O O
roughly NN O O
additive NN O O
effect NN O O
on NN O O
specific NN O O
activity, NN O O
but NN O O
a NN O O
much NN O O
more NN O O
drastic NN O O
effect NN O O
on NN O O
enzyme NN O O
yield NN O O
(4% NN O O
of NN O O
normal). NN O O
this NN O O
synergistic NN O O
effect NN O O
was NN O O
also NN O O
demonstrated NN O O
on NN O O
thermal NN O O
stability, NN O O
especiall NN O O
. NN O O

at NN O O
low NN O O
nadp NN O O
concentrations. NN O O
comparable NN O O
results NN O O
were NN O O
produced NN O O
when NN O O
the NN O O
replacement NN O O
119 NN O O
gln-- NN O O
> NN O O
glu NN O O
was NN O O
studied NN O O
instead NN O O
of NN O O
126 NN O O
asn-- NN O O
> NN O O
asp. NN O O
we NN O O
infer NN O O
that NN O O
the NN O O
coexistence NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
is NN O O
responsible NN O O
for NN O O
enzyme NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
in NN I-SpecificDisease I-MSH:D005955
G6PD NN I-SpecificDisease I-MSH:D005955
a- NN O O
because NN O O
they NN O O
act NN O O
synergistically NN O O
in NN O O
causing NN O O
instability NN O O
of NN O O
the NN O O
enzyme NN O O
. NN O O

detection NN O O
of NN O O
98% NN O O
of NN O O
DMD NN B-Modifier B-MSH:D020388
/ NN O O
BMD NN B-Modifier B-MSH:C537666
gene NN O O
deletions NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
. NN O O

we NN O O
describe NN O O
oligonucleotide NN O O
primer NN O O
sequences NN O O
that NN O O
can NN O O
be NN O O
used NN O O
to NN O O
amplify NN O O
eight NN O O
exons NN O O
plus NN O O
the NN O O
muscle NN O O
promoter NN O O
of NN O O
the NN O O
dystrophin NN O O
gene NN O O
in NN O O
a NN O O
single NN O O
multiplex NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr). NN O O
when NN O O
used NN O O
in NN O O
conjunction NN O O
with NN O O
an NN O O
existing NN O O
primer NN O O
set, NN O O
these NN O O
two NN O O
multiplex NN O O
reactions NN O O
detect NN O O
about NN O O
98% NN O O
of NN O O
deletions NN O O
in NN O O
patients NN O O
with NN O O
Duchenne NN B-CompositeMention B-MSH:D020388
or NN I-CompositeMention I-MSH:D020388
Becker NN I-CompositeMention I-MSH:D020388
muscular NN I-CompositeMention I-MSH:D020388
dystrophy NN I-CompositeMention I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
, NN O O
BMD NN B-SpecificDisease B-MSH:C537666
). NN O O
furthermore, NN O O
these NN O O
primers NN O O
amplify NN O O
most NN O O
of NN O O
the NN O O
exons NN O O
in NN O O
the NN O O
deletion NN O O
prone NN O O
" NN O O
hot NN O O
spot NN O O
" NN O O
region NN O O
around NN O O
exons NN O O
44 NN O O
to NN O O
53, NN O O
allowing NN O O
determination NN O O
of NN O O
deletion NN O O
endpoints NN O O
and NN O O
prediction NN O O
of NN O O
mutational NN O O
effects NN O O
on NN O O
the NN O O
translational NN O O
reading NN O O
frame. NN O O
thus, NN O O
use NN O O
of NN O O
these NN O O
pcr-based NN O O
assays NN O O
will NN O O
allow NN O O
deletion NN O O
detection NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
for NN O O
most NN O O
DMD NN B-Modifier B-MSH:D020388
/ NN O O
BMD NN B-Modifier B-MSH:C537666
patients NN O O
in NN O O
a NN O O
fraction NN O O
of NN O O
the NN O O
time NN O O
required NN O O
for NN O O
southern NN O O
blot NN O O
analysis NN O O
. NN O O

. NN O O

recombination NN O O
events NN O O
that NN O O
locate NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
distal NN O O
to NN O O
apoc NN O O
2 NN O O
on NN O O
19 NN O O
q NN O O
. NN O O

we NN O O
previously NN O O
reported NN O O
a NN O O
recombination NN O O
in NN O O
an NN O O
individual NN O O
with NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O O
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
which NN O O
placed NN O O
the NN O O
markers NN O O
d NN O O
19 NN O O
s NN O O
19 NN O O
and NN O O
apoc NN O O
2 NN O O
on NN O O
the NN O O
same NN O O
side NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
locus. NN O O
haplotyping NN O O
of NN O O
this NN O O
family NN O O
with NN O O
more NN O O
recently NN O O
characterized NN O O
probes NN O O
which NN O O
are NN O O
either NN O O
tightly NN O O
linked NN O O
to NN O O
DM NN B-SpecificDisease B-MSH:D009223
or NN O O
distal NN O O
to NN O O
the NN O O
linkage NN O O
group NN O O
at NN O O
q NN O O
13. NN O O
2 NN O O
shows NN O O
that NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
locus NN O O
is NN O O
distal NN O O
to NN O O
apoc NN O O
2. NN O O
this NN O O
is NN O O
confirmed NN O O
by NN O O
other NN O O
recombinants NN O O
where NN O O
DM NN B-SpecificDisease B-MSH:D009223
segregates NN O O
with NN O O
distal NN O O
probes. NN O O
additional NN O O
marker NN O O
to NN O O
marker NN O O
recombinations NN O O
in NN O O
unaffected NN O O
individuals NN O O
are NN O O
reported NN O O
and NN O O
support NN O O
the NN O O
order NN O O
and NN O O
orientation NN O O
of NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
linkage NN O O
group NN O O
as NN O O
pter- NN O O
(insr, NN O O
ldlr, NN O O
s NN O O
9) NN O O
- NN O O
(s NN O O
19, NN O O
bcl NN O O
3, NN O O
apoc NN O O
2) NN O O
- NN O O
(ckmm, NN O O
dm) NN O O
- NN O O
(s NN O O
22, NN O O
. NN O O

+ NN O O
+ NN O O
prkcg) NN O O
-qter. NN O O
the NN O O
data NN O O
presented NN O O
here NN O O
cannot NN O O
determine NN O O
whether NN O O
DM NN B-SpecificDisease B-MSH:D009223
is NN O O
proximal NN O O
or NN O O
distal NN O O
to NN O O
ckmm. NN O O
the NN O O
consequences NN O O
of NN O O
this NN O O
probe NN O O
order NN O O
for NN O O
antenatal NN O O
diagnosis NN O O
and NN O O
future NN O O
research NN O O
aiming NN O O
to NN O O
isolate NN O O
the NN O O
gene NN O O
which NN O O
is NN O O
affected NN O O
in NN O O
DM NN B-SpecificDisease B-MSH:D009223
are NN O O
discussed NN O O
. NN O O

new NN O O
mutations, NN O O
polymorphisms, NN O O
and NN O O
rare NN O O
variants NN O O
in NN O O
the NN O O
atm NN O O
gene NN O O
detected NN O O
by NN O O
a NN O O
novel NN O O
sscp NN O O
strategy NN O O
. NN O O

the NN O O
gene NN O O
for NN O O
ataxia-telangiectasia NN B-SpecificDisease B-MSH:D001260
, NN O O
atm, NN O O
spans NN O O
about NN O O
150 NN O O
kb NN O O
of NN O O
genomic NN O O
dna. NN O O
atm NN O O
mutations NN O O
are NN O O
found NN O O
along NN O O
the NN O O
entire NN O O
gene, NN O O
with NN O O
no NN O O
evidence NN O O
of NN O O
a NN O O
mutational NN O O
hot NN O O
spot. NN O O
using NN O O
dna NN O O
as NN O O
the NN O O
starting NN O O
material, NN O O
we NN O O
screened NN O O
the NN O O
atm NN O O
gene NN O O
in NN O O
92 NN O O
A-T NN B-Modifier B-MSH:D001260
patients, NN O O
using NN O O
an NN O O
optimized NN O O
single-strand NN O O
conformation NN O O
polymorphism NN O O
(sscp) NN O O
technique NN O O
that NN O O
detected NN O O
all NN O O
previously NN O O
known NN O O
mutations NN O O
in NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
(pcr) NN O O
segments NN O O
being NN O O
analyzed. NN O O
to NN O O
expedite NN O O
screening, NN O O
we NN O O
sequentially NN O O
loaded NN O O
the NN O O
sscp NN O O
gels NN O O
with NN O O
three NN O O
different NN O O
sets NN O O
of NN O O
pcr NN O O
products NN O O
that NN O O
were NN O O
pretested NN O O
to NN O O
avoid NN O O
overlapping NN O O
patterns. NN O O
many NN O O
of NN O O
the NN O O
dna NN O O
changes NN O O
we NN O O
detected NN O O
were NN O O
intragenic NN O O
polymorphisms. NN O O
of NN O O
an NN O O
expected NN O O
177 NN O O
unknown NN O O
mutations, NN O O
we NN O O
detected NN O O
approximately NN O O
70%, NN O O
mostly NN O O
protein NN O O
truncating NN O O
mutations NN O O
(that NN O O
woul NN O O
. NN O O

have NN O O
been NN O O
detectable NN O O
by NN O O
protein NN O O
truncation NN O O
testing NN O O
if NN O O
rna NN O O
starting NN O O
material NN O O
had NN O O
been NN O O
available). NN O O
mutations NN O O
have NN O O
now NN O O
been NN O O
defined NN O O
for NN O O
every NN O O
exon NN O O
of NN O O
the NN O O
atm NN O O
gene. NN O O
herein, NN O O
we NN O O
present NN O O
35 NN O O
new NN O O
mutations NN O O
and NN O O
34 NN O O
new NN O O
intragenic NN O O
polymorphisms NN O O
or NN O O
rare NN O O
variants NN O O
within NN O O
the NN O O
atm NN O O
gene. NN O O
this NN O O
is NN O O
the NN O O
most NN O O
comprehensive NN O O
compilation NN O O
of NN O O
atm NN O O
polymorphisms NN O O
assembled NN O O
to NN O O
date. NN O O
defining NN O O
polymorphic NN O O
sites NN O O
as NN O O
well NN O O
as NN O O
mutations NN O O
in NN O O
the NN O O
atm NN O O
gene NN O O
will NN O O
be NN O O
of NN O O
great NN O O
importance NN O O
in NN O O
designing NN O O
automated NN O O
methods NN O O
for NN O O
detecting NN O O
mutations. NN O O
. NN O O
rare NN O O
variants NN O O
within NN O O
the NN O O
atm NN O O
gene. NN O O
this NN O O
is NN O O
the NN O O
most NN O O
comprehensive NN O O
compilation NN O O
of NN O O
atm NN O O
polymorphisms NN O O
assembled NN O O
to NN O O
date. NN O O
defining NN O O
polymorphic NN O O
sites NN O O
as NN O O
well NN O O
as NN O O
mutations NN O O
in NN O O
the NN O O
atm NN O O
gene NN O O
will NN O O
be NN O O
of NN O O
great NN O O
importance NN O O
in NN O O
designing NN O O
automated NN O O
methods NN O O
for NN O O
detecting NN O O
mutations. NN O O
. NN O O

chromosome NN O O
breakage NN O O
in NN O O
the NN O O
Prader-Willi NN B-CompositeMention B-MSH:D011218
and NN I-CompositeMention I-MSH:D011218
Angelman NN I-CompositeMention I-MSH:D011218
syndromes NN I-CompositeMention I-MSH:D011218
involves NN O O
recombination NN O O
between NN O O
large, NN O O
transcribed NN O O
repeats NN O O
at NN O O
proximal NN O O
and NN O O
distal NN O O
breakpoints NN O O
. NN O O

prader-willi NN O O
syndrome NN O O
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
and NN O O
Angelman NN B-SpecificDisease B-MSH:D017204
syndrome NN I-SpecificDisease I-MSH:D017204
( NN O O
AS NN B-SpecificDisease B-MSH:D017204
) NN O O
are NN O O
distinct NN O O
neurobehavioral NN B-DiseaseClass B-MSH:D019954
disorders NN I-DiseaseClass I-MSH:D019954
that NN O O
most NN O O
often NN O O
arise NN O O
from NN O O
a NN O O
4-mb NN O O
deletion NN O O
of NN O O
chromosome NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
during NN O O
paternal NN O O
or NN O O
maternal NN O O
gametogenesis, NN O O
respectively. NN O O
at NN O O
a NN O O
de NN O O
novo NN O O
frequency NN O O
of NN O O
approximately. NN O O
67-1/10, NN O O
000 NN O O
births, NN O O
these NN O O
deletions NN O O
represent NN O O
a NN O O
common NN O O
structural NN O O
chromosome NN O O
change NN O O
in NN O O
the NN O O
human NN O O
genome. NN O O
to NN O O
elucidate NN O O
the NN O O
mechanism NN O O
underlying NN O O
these NN O O
events, NN O O
we NN O O
characterized NN O O
the NN O O
regions NN O O
that NN O O
contain NN O O
two NN O O
proximal NN O O
breakpoint NN O O
clusters NN O O
and NN O O
a NN O O
distal NN O O
cluster. NN O O
novel NN O O
dna NN O O
sequences NN O O
potentially NN O O
associated NN O O
with NN O O
the NN O O
breakpoints NN O O
were NN O O
positionally NN O O
cloned NN O O
from NN O O
yacs NN O O
within NN O O
or NN O O
near NN O O
these NN O O
regions. NN O O
analyses NN O O
of NN O O
rodent-human NN O O
somatic-cell NN O O
hybrids, NN O O
yac NN O O
contigs, NN O O
and NN O O
fish NN O O
of NN O O
normal NN O O
or NN O O
rearranged NN O O
chromosomes NN O O
15 NN O O
identified NN O O
duplicated NN O O
sequences NN O O
. NN O O

the NN O O
end NN O O
repeats) NN O O
at NN O O
or NN O O
near NN O O
the NN O O
breakpoints. NN O O
the NN O O
end-repeat NN O O
units NN O O
are NN O O
derived NN O O
from NN O O
large NN O O
genomic NN O O
duplications NN O O
of NN O O
a NN O O
novel NN O O
gene NN O O
(herc NN O O
2), NN O O
many NN O O
copies NN O O
of NN O O
which NN O O
are NN O O
transcriptionally NN O O
active NN O O
in NN O O
germline NN O O
tissues. NN O O
one NN O O
of NN O O
five NN O O
PWS NN B-Modifier B-MSH:D011218
/ NN O O
AS NN B-Modifier B-MSH:D017204
patients NN O O
analyzed NN O O
to NN O O
date NN O O
has NN O O
an NN O O
identifiable, NN O O
rearranged NN O O
herc NN O O
2 NN O O
transcript NN O O
derived NN O O
from NN O O
the NN O O
deletion NN O O
event. NN O O
we NN O O
postulate NN O O
that NN O O
the NN O O
end NN O O
repeats NN O O
flanking NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
mediate NN O O
homologous NN O O
recombination NN O O
resulting NN O O
in NN O O
deletion. NN O O
furthermore, NN O O
we NN O O
propose NN O O
that NN O O
active NN O O
transcription NN O O
of NN O O
these NN O O
repeats NN O O
in NN O O
male NN O O
and NN O O
female NN O O
germ NN O O
cells NN O O
may NN O O
facilitate NN O O
the NN O O
homologous NN O O
recombination NN O O
process NN O O
. NN O O

a NN O O
4-megabase NN O O
yac NN O O
contig NN O O
that NN O O
spans NN O O
the NN O O
Langer-Giedion NN B-Modifier B-MSH:D015826
syndrome NN I-Modifier I-MSH:D015826
region NN O O
on NN O O
human NN O O
chromosome NN O O
8 NN O O
q NN O O
24.1: NN O O
use NN O O
in NN O O
refining NN O O
the NN O O
location NN O O
of NN O O
the NN O O
trichorhinophalangeal NN B-SpecificDisease B-OMIM:190350
syndrome NN I-SpecificDisease I-OMIM:190350
and NN O O
multiple NN O O
exostoses NN O O
genes NN O O
(trps NN O O
1 NN O O
and NN O O
ext NN O O
1) NN O O
. NN O O

we NN O O
have NN O O
constructed NN O O
a NN O O
physical NN O O
map NN O O
covering NN O O
over NN O O
4 NN O O
mb NN O O
of NN O O
human NN O O
chromosome NN O O
8 NN O O
q NN O O
24. NN O O
1 NN O O
and NN O O
used NN O O
this NN O O
map NN O O
to NN O O
refine NN O O
the NN O O
locations NN O O
of NN O O
the NN O O
genes NN O O
responsible NN O O
for NN O O
Langer-Giedion NN B-SpecificDisease B-MSH:D015826
syndrome NN I-SpecificDisease I-MSH:D015826
. NN O O
the NN O O
map NN O O
is NN O O
composed NN O O
of NN O O
overlapping NN O O
yac NN O O
clones NN O O
that NN O O
were NN O O
identified NN O O
and NN O O
ordered NN O O
in NN O O
relation NN O O
to NN O O
sequence NN O O
tagged NN O O
sites NN O O
mapped NN O O
to NN O O
the NN O O
langer-giedion NN O O
chromosomal NN O O
region NN O O
on NN O O
somatic NN O O
cell NN O O
hybrids. NN O O
the NN O O
minimal NN O O
region NN O O
of NN O O
overlap NN O O
of NN O O
Langer-Giedion NN B-Modifier B-MSH:D015826
syndrome NN I-Modifier I-MSH:D015826
deletions, NN O O
previously NN O O
identified NN O O
by NN O O
analysis NN O O
of NN O O
15 NN O O
patients, NN O O
was NN O O
placed NN O O
on NN O O
the NN O O
map NN O O
by NN O O
analysis NN O O
of NN O O
2 NN O O
patients NN O O
whose NN O O
deletions NN O O
define NN O O
the NN O O
endpoints. NN O O
the NN O O
chromosome NN O O
8 NN O O
breakpoint NN O O
of NN O O
a NN O O
balanced NN O O
t NN O O
(8; NN O O
9) NN O O
(q NN O O
24. NN O O
11; NN O O
q NN O O
33. NN O O
3) NN O O
translocation NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
trichorhinophalangeal NN B-SpecificDisease B-OMIM:190350
syndrome NN I-SpecificDisease I-OMIM:190350
( NN O O
TRPS NN B-SpecificDisease B-OMIM:190350
i) NN O O
wa NN O O
. NN O O

found NN O O
to NN O O
be NN O O
located NN O O
just NN O O
within NN O O
the NN O O
proximal NN O O
end NN O O
of NN O O
the NN O O
minimal NN O O
deletion NN O O
region. NN O O
a NN O O
deletion NN O O
of NN O O
8 NN O O
q NN O O
24. NN O O
11-q NN O O
24. NN O O
3 NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
multiple NN O O
exostoses NN O O
was NN O O
found NN O O
to NN O O
overlap NN O O
the NN O O
distal NN O O
end NN O O
of NN O O
the NN O O
LGS NN B-Modifier B-MSH:D015826
deletion NN O O
region, NN O O
indicating NN O O
that NN O O
the NN O O
ext NN O O
1 NN O O
gene NN O O
is NN O O
distal NN O O
to NN O O
the NN O O
trps NN O O
1 NN O O
gene NN O O
and NN O O
supporting NN O O
the NN O O
hypothesis NN O O
that NN O O
Langer-Giedion NN B-SpecificDisease B-MSH:D015826
syndrome NN I-SpecificDisease I-MSH:D015826
is NN O O
due NN O O
to NN O O
loss NN O O
of NN O O
functional NN O O
copies NN O O
of NN O O
both NN O O
the NN O O
trps NN O O
1 NN O O
and NN O O
the NN O O
ext NN O O
1 NN O O
gene NN O O
. NN O O

genetic NN O O
mapping NN O O
of NN O O
the NN O O
breast-ovarian NN B-DiseaseClass B-MSH:D061325
cancer NN I-DiseaseClass I-MSH:D061325
syndrome NN I-DiseaseClass I-MSH:D061325
to NN O O
a NN O O
small NN O O
interval NN O O
on NN O O
chromosome NN O O
17 NN O O
q NN O O
12-21: NN O O
exclusion NN O O
of NN O O
candidate NN O O
genes NN O O
edh NN O O
17 NN O O
b NN O O
2 NN O O
and NN O O
rara NN O O
. NN O O

a NN O O
susceptibility NN O O
gene NN O O
for NN O O
hereditary NN B-DiseaseClass B-MSH:D061325
breast-ovarian NN I-DiseaseClass I-MSH:D061325
cancer NN I-DiseaseClass I-MSH:D061325
, NN O O
brca NN O O
1, NN O O
has NN O O
been NN O O
assigned NN O O
by NN O O
linkage NN O O
analysis NN O O
to NN O O
chromosome NN O O
17 NN O O
q NN O O
21. NN O O
candidate NN O O
genes NN O O
in NN O O
this NN O O
region NN O O
include NN O O
edh NN O O
17 NN O O
b NN O O
2, NN O O
which NN O O
encodes NN O O
estradiol NN O O
17 NN O O
beta-hydroxysteroid NN O O
dehydrogenase NN O O
ii NN O O
(17 NN O O
beta-hsd NN O O
ii), NN O O
and NN O O
rara, NN O O
the NN O O
gene NN O O
for NN O O
retinoic NN O O
acid NN O O
receptor NN O O
alpha. NN O O
we NN O O
have NN O O
typed NN O O
22 NN O O
breast NN B-Modifier B-MSH:D001943
and NN I-Modifier I-MSH:D001943
breast-ovarian NN I-Modifier I-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
families NN O O
with NN O O
eight NN O O
polymorphisms NN O O
from NN O O
the NN O O
chromosome NN O O
17 NN O O
q NN O O
12-21 NN O O
region, NN O O
including NN O O
two NN O O
in NN O O
the NN O O
edh NN O O
17 NN O O
b NN O O
2 NN O O
gene. NN O O
genetic NN O O
recombination NN O O
with NN O O
the NN O O
breast NN B-Modifier B-MSH:D001943
cancer NN I-Modifier I-MSH:D001943
trait NN O O
excludes NN O O
rara NN O O
from NN O O
further NN O O
consideration NN O O
as NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
brca NN O O
1. NN O O
both NN O O
brca NN O O
1 NN O O
and NN O O
edh NN O O
17 NN O O
b NN O O
2 NN O O
map NN O O
to NN O O
a NN O O
6 NN O O
cm NN O O
interval NN O O
(between NN O O
thra NN O O
1 NN O O
and NN O O
d NN O O
17 NN O O
. NN O O

579) NN O O
and NN O O
no NN O O
recombination NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
two NN O O
genes. NN O O
however, NN O O
direct NN O O
sequencing NN O O
of NN O O
overlapping NN O O
pcr NN O O
products NN O O
containing NN O O
the NN O O
entire NN O O
edh NN O O
17 NN O O
b NN O O
2 NN O O
gene NN O O
in NN O O
four NN O O
unrelated NN O O
affected NN O O
women NN O O
did NN O O
not NN O O
uncover NN O O
any NN O O
sequence NN O O
variation, NN O O
other NN O O
than NN O O
previously NN O O
described NN O O
polymorphisms. NN O O
mutations NN O O
in NN O O
the NN O O
edh NN O O
17 NN O O
b NN O O
2 NN O O
gene, NN O O
therefore NN O O
do NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
hereditary NN B-DiseaseClass B-MSH:D061325
breast-ovarian NN I-DiseaseClass I-MSH:D061325
cancer NN I-DiseaseClass I-MSH:D061325
syndrome NN I-DiseaseClass I-MSH:D061325
. NN O O
single NN O O
meiotic NN O O
crossovers NN O O
in NN O O
affected NN O O
women NN O O
suggest NN O O
that NN O O
brca NN O O
1 NN O O
is NN O O
flanked NN O O
by NN O O
the NN O O
loci NN O O
rara NN O O
and NN O O
d NN O O
17 NN O O
s NN O O
78. NN O O
. NN O O

hereditary NN O O
c NN O O
2 NN O O
deficiency NN O O
associated NN O O
with NN O O
common NN O O
variable NN O O
immunodeficiency NN B-DiseaseClass B-MSH:D007153
. NN O O

homozygous NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
in NN O O
a NN O O
19-year-old NN O O
boy NN O O
was NN O O
associated NN O O
with NN O O
variable NN O O
immunodeficiency NN B-DiseaseClass B-MSH:D007153
manifested NN O O
by NN O O
marked NN O O
hypoimmunoglobulinemia NN B-DiseaseClass B-MSH:D007153
and NN O O
impaired NN O O
antibody NN O O
responses, NN O O
normal NN O O
circulating NN O O
b NN O O
lymphocytes, NN O O
and NN O O
subnormal NN O O
t-cell NN O O
functions. NN O O
neither NN O O
antilymphocytic NN O O
autoantibodies NN O O
nor NN O O
chromosomal NN B-DiseaseClass B-MSH:D002869
abnormalities NN I-DiseaseClass I-MSH:D002869
were NN O O
found. NN O O
serum NN O O
immunoglobulin NN O O
levels NN O O
were NN O O
within NN O O
normal NN O O
limits NN O O
in NN O O
his NN O O
parents NN O O
and NN O O
brother NN O O
who NN O O
were NN O O
heterozygous NN O O
for NN O O
C2 NN B-SpecificDisease B-OMIM:217000
deficiency NN I-SpecificDisease I-OMIM:217000
. NN O O
the NN O O
patients NN O O
lymphocytes NN O O
were NN O O
homozygous NN O O
at NN O O
the NN O O
hla-d NN O O
locus NN O O
but NN O O
expressed NN O O
an NN O O
antigen NN O O
different NN O O
from NN O O
dw NN O O
2. NN O O
. NN O O

isolation NN O O
of NN O O
molecular NN O O
probes NN O O
associated NN O O
with NN O O
the NN O O
chromosome NN O O
15 NN O O
instability NN O O
in NN O O
the NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
. NN O O

flow NN O O
cytometry NN O O
and NN O O
recombinant NN O O
dna NN O O
techniques NN O O
have NN O O
been NN O O
used NN O O
to NN O O
obtain NN O O
reagents NN O O
for NN O O
a NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
Prader-Willi NN B-SpecificDisease B-MSH:D011218
syndrome NN I-SpecificDisease I-MSH:D011218
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
). NN O O
hindiii NN O O
total-digest NN O O
libraries NN O O
were NN O O
prepared NN O O
in NN O O
lambda NN O O
phage NN O O
charon NN O O
21 NN O O
a NN O O
from NN O O
flow-sorted NN O O
inverted NN O O
duplicated NN O O
no. NN O O
15 NN O O
human NN O O
chromosomes NN O O
and NN O O
propagated NN O O
on NN O O
recombination-proficient NN O O
(le NN O O
392) NN O O
and NN O O
recbc-, NN O O
sbcb- NN O O
(db NN O O
1257) NN O O
bacteria. NN O O
twelve NN O O
distinct NN O O
chromosome NN O O
15-specific NN O O
probes NN O O
have NN O O
been NN O O
isolated. NN O O
eight NN O O
localized NN O O
to NN O O
the NN O O
region NN O O
15 NN O O
q NN O O
11----13. NN O O
four NN O O
of NN O O
these NN O O
eight NN O O
sublocalized NN O O
to NN O O
band NN O O
15 NN O O
q NN O O
11. NN O O
2 NN O O
and NN O O
are NN O O
shown NN O O
to NN O O
be NN O O
deleted NN O O
in NN O O
dna NN O O
of NN O O
one NN O O
of NN O O
two NN O O
patients NN O O
examined NN O O
with NN O O
the NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
heteroduplex NN O O
analysis NN O O
of NN O O
two NN O O
of NN O O
these NN O O
clones, NN O O
which NN O O
grew NN O O
on NN O O
db NN O O
125 NN O O
. NN O O

but NN O O
not NN O O
on NN O O
le NN O O
392, NN O O
revealed NN O O
stem-loop NN O O
structures NN O O
in NN O O
the NN O O
inserts, NN O O
indicative NN O O
of NN O O
inverted, NN O O
repeated NN O O
dna NN O O
elements. NN O O
such NN O O
dna NN O O
repeats NN O O
might NN O O
account NN O O
for NN O O
some NN O O
of NN O O
the NN O O
cloning NN O O
instability NN O O
of NN O O
dna NN O O
segments NN O O
from NN O O
proximal NN O O
15 NN O O
q. NN O O
analysis NN O O
of NN O O
the NN O O
genetic NN O O
and NN O O
physical NN O O
instability NN O O
associated NN O O
with NN O O
the NN O O
repeated NN O O
sequences NN O O
we NN O O
have NN O O
isolated NN O O
from NN O O
band NN O O
15 NN O O
q NN O O
11. NN O O
2 NN O O
may NN O O
elucidate NN O O
the NN O O
molecular NN O O
basis NN O O
for NN O O
the NN O O
instability NN O O
of NN O O
this NN O O
chromosomal NN O O
region NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
PWS NN B-SpecificDisease B-MSH:D011218
or NN O O
other NN O O
diseases NN O O
associated NN O O
with NN O O
chromosomal NN B-DiseaseClass B-MSH:D002869
abnormalities NN I-DiseaseClass I-MSH:D002869
in NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
human NN O O
chromosome NN O O
1 NN O O
. NN O O

myotonic NN O O
dystrophy: NN O O
evidence NN O O
for NN O O
a NN O O
possible NN O O
dominant-negative NN O O
rna NN O O
mutation NN O O
. NN O O

the NN O O
trinucleotide NN O O
expansion NN O O
mutation NN O O
causing NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
is NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
a NN O O
protein NN O O
kinase NN O O
gene. NN O O
the NN O O
molecular NN O O
mechanisms NN O O
by NN O O
which NN O O
the NN O O
expanded NN O O
repeat NN O O
causes NN O O
the NN O O
clinically NN O O
variable NN O O
and NN O O
multisystemic NN B-DiseaseClass B-MSH:D004194
disease NN I-DiseaseClass I-MSH:D004194
, NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
, NN O O
are NN O O
not NN O O
understood. NN O O
it NN O O
has NN O O
been NN O O
particularly NN O O
difficult NN O O
to NN O O
rationalize NN O O
the NN O O
dominant NN O O
inheritance NN O O
with NN O O
the NN O O
fact NN O O
that NN O O
the NN O O
expansion NN O O
mutation NN O O
lies NN O O
outside NN O O
of NN O O
the NN O O
protein-encoding NN O O
gene NN O O
elements, NN O O
and NN O O
should NN O O
not NN O O
be NN O O
translated NN O O
into NN O O
protein. NN O O
here NN O O
we NN O O
use NN O O
muscle NN O O
biopsies NN O O
from NN O O
classical NN O O
adult-onset NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
patients NN O O
to NN O O
study NN O O
the NN O O
accumulation NN O O
of NN O O
transcripts NN O O
from NN O O
both NN O O
the NN O O
normal NN O O
and NN O O
expanded NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
genes NN O O
in NN O O
patient NN O O
muscle, NN O O
and NN O O
compare NN O O
the NN O O
results NN O O
to NN O O
normal NN O O
and NN O O
myopathic NN B-Modifier B-MSH:D009135
controls. NN O O
we NN O O
found NN O O
relatively NN O O
small NN O O
decreases NN O O
of NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
rna NN O O
in NN O O
the NN O O
total NN O O
rna NN O O
pool NN O O
from NN O O
muscle; NN O O
however, NN O O
these NN O O
reduction NN O O
. NN O O

were NN O O
not NN O O
disease NN O O
specific. NN O O
analysis NN O O
of NN O O
poly NN O O
(a) NN O O
+ NN O O
rna NN O O
showed NN O O
dramatic NN O O
decreases NN O O
of NN O O
both NN O O
the NN O O
mutant NN O O
and NN O O
normal NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
rnas, NN O O
and NN O O
these NN O O
changes NN O O
were NN O O
disease-specific. NN O O
our NN O O
findings NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
novel NN O O
molecular NN O O
pathogenetic NN O O
mechanism NN O O
for NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
both NN O O
the NN O O
normal NN O O
and NN O O
expanded NN O O
DM NN B-Modifier B-MSH:D009223
kinase NN O O
genes NN O O
are NN O O
transcribed NN O O
in NN O O
patient NN O O
muscle, NN O O
but NN O O
the NN O O
abnormal NN O O
expansion-containing NN O O
rna NN O O
has NN O O
a NN O O
dominant NN O O
effect NN O O
on NN O O
rna NN O O
metabolism NN O O
by NN O O
preventing NN O O
the NN O O
accumulation NN O O
of NN O O
poly NN O O
(a) NN O O
+ NN O O
rna. NN O O
the NN O O
ability NN O O
of NN O O
the NN O O
expansion NN O O
mutation NN O O
to NN O O
alter NN O O
accumulation NN O O
of NN O O
poly NN O O
(a) NN O O
+ NN O O
rna NN O O
in NN O O
trans NN O O
suggests NN O O
that NN O O
myotonic NN B-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
may NN O O
be NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
dominant-negative NN O O
mutation NN O O
manifested NN O O
at NN O O
the NN O O
rna NN O O
level. NN O O
. NN O O

isolation NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
McLeod NN B-SpecificDisease B-OMIM:300842
syndrome NN I-SpecificDisease I-OMIM:300842
that NN O O
encodes NN O O
a NN O O
novel NN O O
membrane NN O O
transport NN O O
protein NN O O
. NN O O

mcleod NN O O
syndrome NN O O
is NN O O
an NN O O
X-linked NN B-DiseaseClass B-MSH:D040181
multisystem NN I-DiseaseClass I-MSH:D040181
disorder NN I-DiseaseClass I-MSH:D040181
characterized NN O O
by NN O O
abnormalities NN O O
in NN O O
the NN O O
neuromuscular NN O O
and NN O O
hematopoietic NN O O
systems. NN O O
we NN O O
have NN O O
assembled NN O O
a NN O O
cosmid NN O O
contig NN O O
of NN O O
360 NN O O
kb NN O O
that NN O O
encompasses NN O O
the NN O O
McLeod NN B-Modifier B-OMIM:300842
gene NN O O
locus. NN O O
a NN O O
50 NN O O
kb NN O O
deletion NN O O
was NN O O
detected NN O O
by NN O O
screening NN O O
dna NN O O
from NN O O
patients NN O O
with NN O O
radiolabeled NN O O
whole NN O O
cosmids, NN O O
and NN O O
two NN O O
transcription NN O O
units NN O O
were NN O O
identified NN O O
within NN O O
this NN O O
deletion. NN O O
the NN O O
mrna NN O O
expression NN O O
pattern NN O O
of NN O O
one NN O O
of NN O O
them, NN O O
designated NN O O
as NN O O
xk, NN O O
correlates NN O O
closely NN O O
to NN O O
the NN O O
McLeod NN B-Modifier B-OMIM:300842
phenotype. NN O O
xk NN O O
encodes NN O O
a NN O O
novel NN O O
protein NN O O
with NN O O
structural NN O O
characteristics NN O O
of NN O O
prokaryotic NN O O
and NN O O
eukaryotic NN O O
membrane NN O O
transport NN O O
proteins. NN O O
nucleotide NN O O
sequence NN O O
analysis NN O O
of NN O O
xk NN O O
from NN O O
two NN O O
unrelated NN O O
McLeod NN B-Modifier B-OMIM:300842
patients NN O O
has NN O O
identified NN O O
point NN O O
mutations NN O O
at NN O O
conserved NN O O
splice NN O O
donor NN O O
and NN O O
acceptor NN O O
sites. NN O O
these NN O O
findings NN O O
provide NN O O
direct NN O O
evidence NN O O
that NN O O
xk NN O O
is NN O O
responsible NN O O
for NN O O
McLeod NN B-SpecificDisease B-OMIM:300842
syndrome NN I-SpecificDisease I-OMIM:300842
. NN O O
. NN O O

molecular NN O O
basis NN O O
of NN O O
very NN B-SpecificDisease B-MSH:C536353
long NN I-SpecificDisease I-MSH:C536353
chain NN I-SpecificDisease I-MSH:C536353
acyl-CoA NN I-SpecificDisease I-MSH:C536353
dehydrogenase NN I-SpecificDisease I-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
in NN O O
three NN O O
israeli NN O O
patients: NN O O
identification NN O O
of NN O O
a NN O O
complex NN O O
mutant NN O O
allele NN O O
with NN O O
p NN O O
65 NN O O
l NN O O
and NN O O
k NN O O
247 NN O O
q NN O O
mutations, NN O O
the NN O O
former NN O O
being NN O O
an NN O O
exonic NN O O
mutation NN O O
causing NN O O
exon NN O O
3 NN O O
skipping NN O O
. NN O O

very NN O O
long NN O O
chain NN O O
acyl-coa NN O O
dehydrogenase NN O O
(vlcad) NN O O
deficiency NN O O
is NN O O
a NN O O
life-threatening NN O O
disorder NN O O
of NN O O
mitochondrial NN O O
fatty NN O O
acid NN O O
beta-oxidation. NN O O
we NN O O
identified NN O O
four NN O O
novel NN O O
mutations NN O O
in NN O O
three NN O O
unrelated NN O O
patients. NN O O
all NN O O
patients NN O O
had NN O O
the NN O O
severe NN O O
childhood NN O O
form NN O O
of NN O O
VLCAD NN B-SpecificDisease B-MSH:C536353
deficiency NN I-SpecificDisease I-MSH:C536353
with NN O O
early NN O O
onset NN O O
and NN O O
high NN O O
mortality. NN O O
immunoblot NN O O
analysis NN O O
revealed NN O O
that NN O O
vlcad NN O O
protein NN O O
was NN O O
undetectable NN O O
in NN O O
patients NN O O
2 NN O O
and NN O O
3, NN O O
whereas NN O O
normal-size NN O O
vlcad NN O O
protein NN O O
and NN O O
an NN O O
aberrant NN O O
form NN O O
of NN O O
vlcad NN O O
(4 NN O O
kda NN O O
smaller) NN O O
were NN O O
detected NN O O
in NN O O
patient NN O O
1. NN O O
as NN O O
expected, NN O O
null NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
patients NN O O
2 NN O O
and NN O O
3 NN O O
patient NN O O
2 NN O O
is NN O O
homozygous NN O O
for NN O O
a NN O O
frameshift NN O O
mutation, NN O O
del NN O O
4 NN O O
bp NN O O
at NN O O
798-801, NN O O
and NN O O
patient NN O O
3 NN O O
is NN O O
homozygous NN O O
for NN O O
a NN O O
nonsense NN O O
mutation NN O O
65 NN O O
c NN O O
> NN O O
a NN O O
(s NN O O
22 NN O O
x). NN O O
patient NN O O
1 NN O O
wa NN O O
. NN O O

homozygous NN O O
for NN O O
a NN O O
complex NN O O
mutant NN O O
allele NN O O
containing NN O O
two NN O O
alterations, NN O O
including NN O O
a NN O O
194 NN O O
c NN O O
> NN O O
t NN O O
transition NN O O
(p NN O O
65 NN O O
l) NN O O
and NN O O
739 NN O O
a NN O O
> NN O O
c NN O O
transversion NN O O
(k NN O O
247 NN O O
q); NN O O
in NN O O
the NN O O
case NN O O
of NN O O
p NN O O
65 NN O O
l, NN O O
the NN O O
amino NN O O
acid NN O O
change NN O O
does NN O O
not NN O O
reduce NN O O
enzyme NN O O
activity. NN O O
however, NN O O
the NN O O
nucleotide NN O O
change NN O O
resulted NN O O
in NN O O
exon NN O O
3 NN O O
skipping, NN O O
whereas NN O O
the NN O O
latter NN O O
k NN O O
247 NN O O
q NN O O
mutation NN O O
had NN O O
a NN O O
drastic NN O O
effect NN O O
on NN O O
enzyme NN O O
activity. NN O O
we NN O O
verified NN O O
these NN O O
events NN O O
by NN O O
in NN O O
vivo NN O O
splicing NN O O
experiments NN O O
and NN O O
transient NN O O
expression NN O O
analysis NN O O
of NN O O
mutant NN O O
cdnas. NN O O
the NN O O
p NN O O
65 NN O O
l NN O O
mutation NN O O
locates NN O O
11 NN O O
bases NN O O
upstream NN O O
of NN O O
a NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
3. NN O O
this NN O O
is NN O O
an NN O O
example NN O O
of NN O O
an NN O O
exonic NN O O
mutation NN O O
which NN O O
affects NN O O
exon-splicing. NN O O
. NN O O
ulted NN O O
in NN O O
exon NN O O
3 NN O O
skipping, NN O O
whereas NN O O
the NN O O
latter NN O O
k NN O O
247 NN O O
q NN O O
mutation NN O O
had NN O O
a NN O O
drastic NN O O
effect NN O O
on NN O O
enzyme NN O O
activity. NN O O
we NN O O
verified NN O O
these NN O O
events NN O O
by NN O O
in NN O O
vivo NN O O
splicing NN O O
experiments NN O O
and NN O O
transient NN O O
expression NN O O
analysis NN O O
of NN O O
mutant NN O O
cdnas. NN O O
the NN O O
p NN O O
65 NN O O
l NN O O
mutation NN O O
locates NN O O
11 NN O O
bases NN O O
upstream NN O O
of NN O O
a NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
3. NN O O
this NN O O
is NN O O
an NN O O
example NN O O
of NN O O
an NN O O
exonic NN O O
mutation NN O O
which NN O O
affects NN O O
exon-splicing. NN O O
. NN O O

amino-terminal NN O O
fragments NN O O
of NN O O
mutant NN O O
huntingtin NN O O
show NN O O
selective NN O O
accumulation NN O O
in NN O O
striatal NN O O
neurons NN O O
and NN O O
synaptic NN O O
toxicity NN O O
. NN O O

huntington NN O O
disease NN O O
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
is NN O O
caused NN O O
by NN O O
expansion NN O O
of NN O O
a NN O O
glutamine NN O O
repeat NN O O
in NN O O
the NN O O
amino-terminal NN O O
region NN O O
of NN O O
huntingtin. NN O O
despite NN O O
its NN O O
widespread NN O O
expression, NN O O
mutant NN O O
huntingtin NN O O
induces NN O O
selective NN O O
neuronal NN O O
loss NN O O
in NN O O
striatal NN O O
neurons. NN O O
here NN O O
we NN O O
report NN O O
that, NN O O
in NN O O
mutant NN O O
mice NN O O
expressing NN O O
HD NN B-Modifier B-MSH:D006816
repeats, NN O O
the NN O O
production NN O O
and NN O O
aggregation NN O O
of NN O O
n-terminal NN O O
huntingtin NN O O
fragments NN O O
preferentially NN O O
occur NN O O
in NN O O
HD NN B-Modifier B-MSH:D006816
-affected NN O O
neurons NN O O
and NN O O
their NN O O
processes NN O O
and NN O O
axonal NN O O
terminals. NN O O
n-terminal NN O O
fragments NN O O
of NN O O
mutant NN O O
huntingtin NN O O
form NN O O
aggregates NN O O
and NN O O
induce NN O O
neuritic NN B-DiseaseClass B-MSH:D009410
degeneration NN I-DiseaseClass I-MSH:D009410
in NN O O
cultured NN O O
striatal NN O O
neurons. NN O O
n-terminal NN O O
mutant NN O O
huntingtin NN O O
also NN O O
binds NN O O
to NN O O
synaptic NN O O
vesicles NN O O
and NN O O
inhibits NN O O
their NN O O
glutamate NN O O
uptake NN O O
in NN O O
vitro. NN O O
the NN O O
specific NN O O
processing NN O O
and NN O O
accumulation NN O O
of NN O O
toxic NN O O
fragments NN O O
of NN O O
n-terminal NN O O
huntingtin NN O O
in NN O O
HD NN B-Modifier B-MSH:D006816
-affected NN O O
striatal NN O O
neurons, NN O O
especially NN O O
in NN O O
their NN O O
neuronal NN O O
processes NN O O
and NN O O
axonal NN O O
terminals, NN O O
may NN O O
contribut NN O O
. NN O O

to NN O O
the NN O O
selective NN O O
neuropathology NN O O
of NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
. NN O O

phenotypic NN O O
variation NN O O
including NN O O
retinitis NN B-SpecificDisease B-MSH:D012174
pigmentosa NN I-SpecificDisease I-MSH:D012174
, NN O O
pattern NN B-SpecificDisease B-MSH:D008268
dystrophy NN I-SpecificDisease I-MSH:D008268
, NN O O
and NN O O
fundus NN B-SpecificDisease B-MSH:C535804
flavimaculatus NN I-SpecificDisease I-MSH:C535804
in NN O O
a NN O O
single NN O O
family NN O O
with NN O O
a NN O O
deletion NN O O
of NN O O
codon NN O O
153 NN O O
or NN O O
154 NN O O
of NN O O
the NN O O
peripherin/rds NN O O
gene NN O O
. NN O O

background NN O O
and NN O O
objectives NN O O
mutations NN O O
of NN O O
the NN O O
peripherin/rds NN O O
gene NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
autosomal NN B-SpecificDisease B-MSH:D012174
dominant NN I-SpecificDisease I-MSH:D012174
retinitis NN I-SpecificDisease I-MSH:D012174
pigmentosa NN I-SpecificDisease I-MSH:D012174
, NN O O
pattern NN O O
macular NN B-SpecificDisease B-MSH:D008268
dystrophy NN I-SpecificDisease I-MSH:D008268
, NN O O
and NN O O
retinitis NN B-SpecificDisease B-OMIM:136880
punctata NN I-SpecificDisease I-OMIM:136880
albescens NN I-SpecificDisease I-OMIM:136880
. NN O O
we NN O O
report NN O O
herein NN O O
the NN O O
occurrence NN O O
of NN O O
three NN O O
separate NN O O
phenotypes NN O O
within NN O O
a NN O O
single NN O O
family NN O O
with NN O O
a NN O O
novel NN O O
3-base NN O O
pair NN O O
deletion NN O O
of NN O O
codon NN O O
153 NN O O
or NN O O
154 NN O O
of NN O O
the NN O O
peripherin/rds NN O O
gene. NN O O
design NN O O
case NN O O
reports NN O O
with NN O O
clinical NN O O
features, NN O O
fluorescein NN O O
angiography, NN O O
kinetic NN O O
perimetry, NN O O
electrophysiological NN O O
studies, NN O O
and NN O O
molecular NN O O
genetics. NN O O
setting NN O O
university NN O O
medical NN O O
centers. NN O O
patients NN O O
a NN O O
75-year-old NN O O
woman, NN O O
her NN O O
two NN O O
daughters NN O O
(aged NN O O
44 NN O O
and NN O O
50 NN O O
years), NN O O
and NN O O
her NN O O
49-year-old NN O O
son NN O O
were NN O O
screened NN O O
for NN O O
peripherin/rds NN O O
mutations NN O O
because NN O O
of NN O O
the NN O O
presence NN O O
of NN O O
multiple NN O O
phenotypes NN O O
within NN O O
the NN O O
same NN O O
family. NN O O
results NN O O
the NN O O
mother NN O O
presented NN O O
at NN O O
age NN O O
6 NN O O
. NN O O

years NN O O
with NN O O
a NN O O
profoundly NN O O
abnormal NN O O
electroretinogram NN O O
(erg) NN O O
and NN O O
adult-onset NN O O
retinitis NN B-SpecificDisease B-MSH:D012174
pigmentosa NN I-SpecificDisease I-MSH:D012174
that NN O O
progressed NN O O
dramatically NN O O
over NN O O
12 NN O O
years, NN O O
with NN O O
marked NN O O
loss NN O O
of NN O O
peripheral NN O O
visual NN O O
field. NN O O
one NN O O
daughter NN O O
developed NN O O
pattern NN B-SpecificDisease B-MSH:D008268
macular NN I-SpecificDisease I-MSH:D008268
dystrophy NN I-SpecificDisease I-MSH:D008268
at NN O O
age NN O O
31 NN O O
years. NN O O
at NN O O
age NN O O
44 NN O O
years, NN O O
her NN O O
erg NN O O
was NN O O
moderately NN O O
abnormal NN O O
but NN O O
her NN O O
clinical NN O O
disease NN O O
was NN O O
limited NN O O
to NN O O
the NN O O
macula. NN O O
another NN O O
daughter NN O O
presented NN O O
at NN O O
age NN O O
42 NN O O
years NN O O
with NN O O
macular NN B-SpecificDisease B-MSH:D008268
degeneration NN I-SpecificDisease I-MSH:D008268
and NN O O
over NN O O
10 NN O O
years NN O O
developed NN O O
the NN O O
clinical NN O O
picture NN O O
of NN O O
fundus NN B-SpecificDisease B-MSH:C535804
flavimaculatus NN I-SpecificDisease I-MSH:C535804
. NN O O
her NN O O
peripheral NN O O
visual NN O O
field NN O O
was NN O O
preserved NN O O
but NN O O
her NN O O
erg NN O O
was NN O O
moderately NN O O
abnormal. NN O O
the NN O O
son NN O O
had NN O O
onset NN O O
of NN O O
macular NN B-SpecificDisease B-MSH:D008268
degeneration NN I-SpecificDisease I-MSH:D008268
at NN O O
age NN O O
44 NN O O
years. NN O O
Pericentral NN B-SpecificDisease B-MSH:D012607
scotomas NN I-SpecificDisease I-MSH:D012607
were NN O O
present NN O O
and NN O O
the NN O O
erg NN O O
was NN O O
markedly NN O O
abnormal. NN O O
fluorescein NN O O
angiography NN O O
revealed NN O O
punctate NN O O
pigment NN O O
epithelial NN O O
transmission NN O O
defects. NN O O
conclusions NN O O
a NN O O
3-base NN O O
pair NN O O
deletion NN O O
of NN O O
codon NN O O
153 NN O O
or NN O O
15 NN O O
. NN O O

of NN O O
the NN O O
peripherin/rds NN O O
gene NN O O
can NN O O
produce NN O O
clinically NN O O
disparate NN O O
phenotypes NN O O
even NN O O
within NN O O
the NN O O
same NN O O
family. NN O O
. NN O O

missense NN O O
mutation NN O O
in NN O O
the NN O O
alternative NN O O
splice NN O O
region NN O O
of NN O O
the NN O O
pax NN O O
6 NN O O
gene NN O O
in NN O O
eye NN B-DiseaseClass B-MSH:D005124
anomalies NN I-DiseaseClass I-MSH:D005124
. NN O O

the NN O O
pax NN O O
6 NN O O
gene NN O O
is NN O O
involved NN O O
in NN O O
ocular NN O O
morphogenesis, NN O O
and NN O O
pax NN O O
6 NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
various NN O O
types NN O O
of NN O O
ocular NN B-DiseaseClass B-MSH:D005124
anomalies NN I-DiseaseClass I-MSH:D005124
, NN O O
including NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
, NN O O
Peters NN B-SpecificDisease B-MSH:C537884
anomaly NN I-SpecificDisease I-MSH:C537884
, NN O O
corneal NN B-SpecificDisease B-MSH:D003317
dystrophy NN I-SpecificDisease I-MSH:D003317
, NN O O
congenital NN B-SpecificDisease B-MSH:D002386
cataract NN I-SpecificDisease I-MSH:D002386
, NN O O
and NN O O
foveal NN B-SpecificDisease B-OMIM:136520
hypoplasia NN I-SpecificDisease I-OMIM:136520
. NN O O
the NN O O
gene NN O O
encodes NN O O
a NN O O
transcriptional NN O O
regulator NN O O
that NN O O
recognizes NN O O
target NN O O
genes NN O O
through NN O O
its NN O O
paired-type NN O O
dna-binding NN O O
domain. NN O O
the NN O O
paired NN O O
domain NN O O
is NN O O
composed NN O O
of NN O O
two NN O O
distinct NN O O
dna-binding NN O O
subdomains, NN O O
the NN O O
n-terminal NN O O
subdomain NN O O
(nts) NN O O
and NN O O
the NN O O
c-terminal NN O O
subdomain NN O O
(cts), NN O O
which NN O O
bind NN O O
respective NN O O
consensus NN O O
dna NN O O
sequences. NN O O
the NN O O
human NN O O
pax NN O O
6 NN O O
gene NN O O
produces NN O O
two NN O O
alternative NN O O
splice NN O O
isoforms NN O O
that NN O O
have NN O O
the NN O O
distinct NN O O
structure NN O O
of NN O O
the NN O O
paired NN O O
domain. NN O O
the NN O O
insertion, NN O O
into NN O O
the NN O O
nts, NN O O
of NN O O
14 NN O O
additional NN O O
amino NN O O
acids NN O O
encoded NN O O
by NN O O
exon NN O O
5 NN O O
a NN O O
abolishes NN O O
the NN O O
dna-bindin NN O O
. NN O O

activity NN O O
of NN O O
the NN O O
nts NN O O
and NN O O
unmasks NN O O
the NN O O
dna-binding NN O O
ability NN O O
of NN O O
the NN O O
cts. NN O O
thus, NN O O
exon NN O O
5 NN O O
a NN O O
appears NN O O
to NN O O
function NN O O
as NN O O
a NN O O
molecular NN O O
switch NN O O
that NN O O
specifies NN O O
target NN O O
genes. NN O O
we NN O O
ascertained NN O O
a NN O O
novel NN O O
missense NN O O
mutation NN O O
in NN O O
four NN O O
pedigrees NN O O
with NN O O
Peters NN B-SpecificDisease B-MSH:C537884
anomaly NN I-SpecificDisease I-MSH:C537884
, NN O O
congenital NN B-SpecificDisease B-MSH:D002386
cataract NN I-SpecificDisease I-MSH:D002386
, NN O O
Axenfeldt NN B-SpecificDisease B-MSH:C535679
anomaly NN I-SpecificDisease I-MSH:C535679
, NN O O
and/or NN O O
foveal NN B-SpecificDisease B-OMIM:136520
hypoplasia NN I-SpecificDisease I-OMIM:136520
, NN O O
which, NN O O
to NN O O
our NN O O
knowledge, NN O O
is NN O O
the NN O O
first NN O O
mutation NN O O
identified NN O O
in NN O O
the NN O O
splice-variant NN O O
region. NN O O
a NN O O
t-- NN O O
> NN O O
a NN O O
transition NN O O
at NN O O
the NN O O
20 NN O O
th NN O O
nucleotide NN O O
position NN O O
of NN O O
exon NN O O
5 NN O O
a NN O O
results NN O O
in NN O O
a NN O O
val-- NN O O
> NN O O
asp NN O O
(gtc-- NN O O
> NN O O
gac) NN O O
substitution NN O O
at NN O O
the NN O O
7 NN O O
th NN O O
codon NN O O
of NN O O
the NN O O
alternative NN O O
splice NN O O
region. NN O O
functional NN O O
analyses NN O O
demonstrated NN O O
that NN O O
the NN O O
v NN O O
54 NN O O
d NN O O
mutation NN O O
slightly NN O O
increased NN O O
nts NN O O
binding NN O O
and NN O O
decreased NN O O
cts NN O O
transactivation NN O O
activity NN O O
to NN O O
almost NN O O
hal NN O O
. NN O O

. NN O O
. NN O O

a NN O O
detailed NN O O
multipoint NN O O
map NN O O
of NN O O
human NN O O
chromosome NN O O
4 NN O O
provides NN O O
evidence NN O O
for NN O O
linkage NN O O
heterogeneity NN O O
and NN O O
position-specific NN O O
recombination NN O O
rates NN O O
. NN O O

utilizing NN O O
the NN O O
ceph NN O O
reference NN O O
panel NN O O
and NN O O
genotypic NN O O
data NN O O
for NN O O
53 NN O O
markers, NN O O
we NN O O
have NN O O
constructed NN O O
a NN O O
20-locus NN O O
multipoint NN O O
genetic NN O O
map NN O O
of NN O O
human NN O O
chromosome NN O O
4. NN O O
new NN O O
rflps NN O O
are NN O O
reported NN O O
for NN O O
four NN O O
loci. NN O O
the NN O O
map NN O O
integrates NN O O
a NN O O
high-resolution NN O O
genetic NN O O
map NN O O
of NN O O
4 NN O O
p NN O O
16 NN O O
into NN O O
a NN O O
continuous NN O O
map NN O O
extending NN O O
to NN O O
4 NN O O
q NN O O
31 NN O O
and NN O O
an NN O O
unlinked NN O O
cluster NN O O
of NN O O
three NN O O
loci NN O O
at NN O O
4 NN O O
q NN O O
35. NN O O
the NN O O
20 NN O O
linked NN O O
markers NN O O
form NN O O
a NN O O
continuous NN O O
linkage NN O O
group NN O O
of NN O O
152 NN O O
cm NN O O
in NN O O
males NN O O
and NN O O
202 NN O O
cm NN O O
in NN O O
females. NN O O
likely NN O O
genetic NN O O
locations NN O O
are NN O O
provided NN O O
for NN O O
25 NN O O
polymorphic NN O O
anonymous NN O O
sequences NN O O
and NN O O
28 NN O O
gene-specific NN O O
rflps. NN O O
the NN O O
map NN O O
was NN O O
constructed NN O O
employing NN O O
the NN O O
linkage NN O O
and NN O O
crimap NN O O
computational NN O O
methodologies NN O O
to NN O O
build NN O O
the NN O O
multipoint NN O O
map NN O O
via NN O O
a NN O O
stepwise NN O O
algorithm. NN O O
a NN O O
detailed NN O O
10-point NN O O
map NN O O
of NN O O
the NN O O
4 NN O O
p NN O O
16 NN O O
region NN O O
constructe NN O O
. NN O O
ked NN O O
cluster NN O O
of NN O O
three NN O O
loci NN O O
at NN O O
4 NN O O
q NN O O
35. NN O O
the NN O O
20 NN O O
linked NN O O
markers NN O O
form NN O O
a NN O O
continuous NN O O
linkage NN O O
group NN O O
of NN O O
152 NN O O
cm NN O O
in NN O O
males NN O O
and NN O O
202 NN O O
cm NN O O
in NN O O
females. NN O O
likely NN O O
genetic NN O O
locations NN O O
are NN O O
provided NN O O
for NN O O
25 NN O O
polymorphic NN O O
anonymous NN O O
sequences NN O O
and NN O O
28 NN O O
gene-specific NN O O
rflps. NN O O
the NN O O
map NN O O
was NN O O
constructed NN O O
employing NN O O
the NN O O
linkage NN O O
and NN O O
crimap NN O O
computational NN O O
methodologies NN O O
to NN O O
build NN O O
the NN O O
multipoint NN O O
map NN O O
via NN O O
a NN O O
stepwise NN O O
algorithm. NN O O
a NN O O
detailed NN O O
10-point NN O O
map NN O O
of NN O O
the NN O O
4 NN O O
p NN O O
16 NN O O
region NN O O
constructe NN O O
. NN O O

from NN O O
the NN O O
ceph NN O O
panel NN O O
provides NN O O
evidence NN O O
for NN O O
heterogeneity NN O O
in NN O O
the NN O O
linkage NN O O
maps NN O O
constructed NN O O
from NN O O
families NN O O
segregating NN O O
for NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
). NN O O
it NN O O
additionally NN O O
provides NN O O
evidence NN O O
for NN O O
position-specific NN O O
recombination NN O O
frequencies NN O O
in NN O O
the NN O O
telomeric NN O O
region NN O O
of NN O O
4 NN O O
p. NN O O
. NN O O

the NN O O
murine NN O O
homolog NN O O
of NN O O
the NN O O
human NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
susceptibility NN O O
gene NN O O
brca NN O O
1 NN O O
maps NN O O
to NN O O
mouse NN O O
chromosome NN O O
11 NN O O
d NN O O
. NN O O

the NN O O
recently NN O O
cloned NN O O
human NN O O
breast NN B-Modifier B-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier I-MSH:D061325
cancer NN I-Modifier I-MSH:D061325
susceptibility NN O O
gene, NN O O
brca NN O O
1, NN O O
is NN O O
located NN O O
on NN O O
human NN O O
chromosome NN O O
17 NN O O
q NN O O
21. NN O O
we NN O O
have NN O O
isolated NN O O
murine NN O O
genomic NN O O
clones NN O O
containing NN O O
brca NN O O
1 NN O O
as NN O O
a NN O O
first NN O O
step NN O O
in NN O O
generating NN O O
a NN O O
mouse NN O O
model NN O O
for NN O O
the NN O O
loss NN O O
of NN O O
brca NN O O
1 NN O O
function. NN O O
a NN O O
mouse NN O O
genomic NN O O
library NN O O
was NN O O
screened NN O O
using NN O O
probes NN O O
corresponding NN O O
to NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
human NN O O
brca NN O O
1 NN O O
gene. NN O O
two NN O O
overlapping NN O O
mouse NN O O
clones NN O O
were NN O O
identified NN O O
that NN O O
hybridized NN O O
to NN O O
human NN O O
brca NN O O
1 NN O O
exons NN O O
9-12. NN O O
sequence NN O O
analysis NN O O
of NN O O
1. NN O O
4 NN O O
kb NN O O
of NN O O
the NN O O
region NN O O
of NN O O
these NN O O
clones NN O O
corresponding NN O O
to NN O O
part NN O O
of NN O O
human NN O O
exon NN O O
11 NN O O
revealed NN O O
72% NN O O
nucleic NN O O
acid NN O O
identity NN O O
but NN O O
only NN O O
50% NN O O
amino NN O O
acid NN O O
identity NN O O
with NN O O
the NN O O
human NN O O
gene. NN O O
the NN O O
longest NN O O
of NN O O
the NN O O
mouse NN O O
brca NN O O
1 NN O O
genomic NN O O
clones NN O O
maps NN O O
to NN O O
chromosome NN O O
11 NN O O
d, NN O O
as NN O O
determine NN O O
. NN O O

by NN O O
two-color NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization. NN O O
the NN O O
synteny NN O O
to NN O O
human NN O O
chromosome NN O O
17 NN O O
was NN O O
confirmed NN O O
by NN O O
cohybridization NN O O
with NN O O
the NN O O
mouse NN O O
probe NN O O
for NN O O
the NN O O
nf NN O O
1-gene. NN O O
this NN O O
comparative NN O O
study NN O O
confirms NN O O
that NN O O
the NN O O
relative NN O O
location NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
has NN O O
been NN O O
conserved NN O O
between NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O
e NN O O
synteny NN O O
to NN O O
human NN O O
chromosome NN O O
17 NN O O
was NN O O
confirmed NN O O
by NN O O
cohybridization NN O O
with NN O O
the NN O O
mouse NN O O
probe NN O O
for NN O O
the NN O O
nf NN O O
1-gene. NN O O
this NN O O
comparative NN O O
study NN O O
confirms NN O O
that NN O O
the NN O O
relative NN O O
location NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
gene NN O O
has NN O O
been NN O O
conserved NN O O
between NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O

high NN O O
residual NN O O
arylsulfatase NN O O
a NN O O
(arsa) NN O O
activity NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
late-infantile NN B-SpecificDisease B-MSH:D007966
metachromatic NN I-SpecificDisease I-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
. NN O O

we NN O O
identified NN O O
a NN O O
patient NN O O
suffering NN O O
from NN O O
late-infantile NN B-SpecificDisease B-MSH:D007966
metachromatic NN I-SpecificDisease I-MSH:D007966
leukodystrophy NN I-SpecificDisease I-MSH:D007966
( NN O O
MLD NN B-SpecificDisease B-MSH:D007966
) NN O O
who NN O O
has NN O O
a NN O O
residual NN O O
arylsulfatase NN O O
a NN O O
(arsa) NN O O
activity NN O O
of NN O O
about NN O O
10%. NN O O
fibroblasts NN O O
of NN O O
the NN O O
patient NN O O
show NN O O
significant NN O O
sulfatide NN O O
degradation NN O O
activity NN O O
exceeding NN O O
that NN O O
of NN O O
adult NN B-Modifier B-MSH:D007966
MLD NN I-Modifier I-MSH:D007966
patients. NN O O
analysis NN O O
of NN O O
the NN O O
arsa NN O O
gene NN O O
in NN O O
this NN O O
patient NN O O
revealed NN O O
heterozygosity NN O O
for NN O O
two NN O O
new NN O O
mutant NN O O
alleles NN O O
in NN O O
one NN O O
allele, NN O O
deletion NN O O
of NN O O
c NN O O
447 NN O O
in NN O O
exon NN O O
2 NN O O
leads NN O O
to NN O O
a NN O O
frameshift NN O O
and NN O O
to NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
at NN O O
amino NN O O
acid NN O O
position NN O O
105; NN O O
in NN O O
the NN O O
second NN O O
allele, NN O O
a NN O O
g-- NN O O
> NN O O
a NN O O
transition NN O O
in NN O O
exon NN O O
5 NN O O
causes NN O O
a NN O O
gly NN O O
309-- NN O O
> NN O O
ser NN O O
substitution. NN O O
transient NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
ser NN O O
309-arsa NN O O
resulted NN O O
in NN O O
only NN O O
13% NN O O
enzyme NN O O
activity NN O O
of NN O O
that NN O O
observed NN O O
in NN O O
cells NN O O
expressing NN O O
normal NN O O
arsa. NN O O
the NN O O
mutant NN O O
ars NN O O
. NN O O

is NN O O
correctly NN O O
targeted NN O O
to NN O O
the NN O O
lysosomes NN O O
but NN O O
is NN O O
unstable. NN O O
these NN O O
findings NN O O
are NN O O
in NN O O
contrast NN O O
to NN O O
previous NN O O
results NN O O
showing NN O O
that NN O O
the NN O O
late-infantile NN B-SpecificDisease B-MSH:D007966
type NN I-SpecificDisease I-MSH:D007966
of NN I-SpecificDisease I-MSH:D007966
MLD NN I-SpecificDisease I-MSH:D007966
is NN O O
always NN O O
associated NN O O
with NN O O
the NN O O
complete NN O O
absence NN O O
of NN O O
arsa NN O O
activity. NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
arsa NN O O
protein NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
particular NN O O
features NN O O
of NN O O
oligodendrocytes, NN O O
such NN O O
that NN O O
the NN O O
level NN O O
of NN O O
mutant NN O O
enzyme NN O O
is NN O O
lower NN O O
in NN O O
these NN O O
cells NN O O
than NN O O
in NN O O
others. NN O O
. NN O O

de NN O O
novo NN O O
deletions NN O O
of NN O O
snrpn NN O O
exon NN O O
1 NN O O
in NN O O
early NN O O
human NN O O
and NN O O
mouse NN O O
embryos NN O O
result NN O O
in NN O O
a NN O O
paternal NN O O
to NN O O
maternal NN O O
imprint NN O O
switch NN O O
. NN O O

prader-willi NN O O
syndrome NN O O
( NN O O
PWS NN B-SpecificDisease B-MSH:D011218
) NN O O
is NN O O
a NN O O
neurogenetic NN B-DiseaseClass B-MSH:D020271
disease NN I-DiseaseClass I-MSH:D020271
characterized NN O O
by NN O O
infantile NN B-SpecificDisease B-MSH:D009123
hypotonia NN I-SpecificDisease I-MSH:D009123
, NN O O
gonadal NN B-SpecificDisease B-MSH:D006058
hypoplasia NN I-SpecificDisease I-MSH:D006058
, NN O O
obsessive NN O O
behaviour NN O O
and NN O O
neonatal NN O O
feeding NN O O
difficulties NN O O
followed NN O O
by NN O O
hyperphagia NN B-SpecificDisease B-MSH:D006963
, NN O O
leading NN O O
to NN O O
profound NN O O
obesity NN B-SpecificDisease B-MSH:D009765
. NN O O
PWS NN B-SpecificDisease B-MSH:D011218
is NN O O
due NN O O
to NN O O
a NN O O
lack NN O O
of NN O O
paternal NN O O
genetic NN O O
information NN O O
at NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
(ref. NN O O
2). NN O O
five NN O O
imprinted, NN O O
paternally NN O O
expressed NN O O
genes NN O O
map NN O O
to NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
region, NN O O
mkrn NN O O
3 NN O O
(ref. NN O O
3), NN O O
ndn NN O O
(ref. NN O O
4), NN O O
ndnl NN O O
1 NN O O
(ref. NN O O
5), NN O O
snrpn NN O O
(refs NN O O
6-8) NN O O
and NN O O
ipw NN O O
(ref. NN O O
9), NN O O
as NN O O
well NN O O
as NN O O
two NN O O
poorly NN O O
characterized NN O O
framents NN O O
designated NN O O
par-1 NN O O
and NN O O
par-5 NN O O
(ref. NN O O
10). NN O O
imprinting NN O O
of NN O O
this NN O O
region NN O O
involves NN O O
a NN O O
bipartite NN O O
imprinting NN O O
centre NN O O
(ic NN O O
. NN O O

, NN O O
which NN O O
overlaps NN O O
snrpn NN O O
(refs NN O O
10, NN O O
11). NN O O
deletion NN O O
of NN O O
the NN O O
snrpn NN O O
promoter/exon NN O O
1 NN O O
region NN O O
(the NN O O
PWS NN B-Modifier B-MSH:D011218
ic NN O O
element) NN O O
appears NN O O
to NN O O
impair NN O O
the NN O O
establishment NN O O
of NN O O
the NN O O
paternal NN O O
imprint NN O O
in NN O O
the NN O O
male NN O O
germ NN O O
line NN O O
and NN O O
leads NN O O
to NN O O
PWS NN B-SpecificDisease B-MSH:D011218
. NN O O
here NN O O
we NN O O
report NN O O
a NN O O
PWS NN B-Modifier B-MSH:D011218
family NN O O
in NN O O
which NN O O
the NN O O
father NN O O
is NN O O
mosaic NN O O
for NN O O
an NN O O
ic NN O O
deletion NN O O
on NN O O
his NN O O
paternal NN O O
chromosome. NN O O
the NN O O
deletion NN O O
chromosome NN O O
has NN O O
acquired NN O O
a NN O O
maternal NN O O
methylation NN O O
imprint NN O O
in NN O O
his NN O O
somatic NN O O
cells. NN O O
we NN O O
have NN O O
made NN O O
identical NN O O
findings NN O O
in NN O O
chimaeric NN O O
mice NN O O
generated NN O O
from NN O O
two NN O O
independent NN O O
embryonic NN O O
stem NN O O
(es) NN O O
cell NN O O
lines NN O O
harbouring NN O O
a NN O O
similar NN O O
deletion. NN O O
our NN O O
studies NN O O
demonstrate NN O O
that NN O O
the NN O O
PWS NN B-Modifier B-MSH:D011218
ic NN O O
element NN O O
is NN O O
not NN O O
only NN O O
required NN O O
for NN O O
the NN O O
establishment NN O O
of NN O O
the NN O O
paternal NN O O
imprint, NN O O
but NN O O
also NN O O
for NN O O
its NN O O
postzygotic NN O O
maintenance. NN O O
. NN O O

molecular NN O O
characterization NN O O
of NN O O
two NN O O
galactosemia NN B-Modifier B-MSH:D005693
mutations: NN O O
correlation NN O O
of NN O O
mutations NN O O
with NN O O
highly NN O O
conserved NN O O
domains NN O O
in NN O O
galactose-1-phosphate NN O O
uridyl NN O O
transferase NN O O
. NN O O

galactosemia NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D005693
recessive NN I-DiseaseClass I-MSH:D005693
disorder NN I-DiseaseClass I-MSH:D005693
of NN I-DiseaseClass I-MSH:D005693
human NN I-DiseaseClass I-MSH:D005693
galactose NN I-DiseaseClass I-MSH:D005693
metabolism NN I-DiseaseClass I-MSH:D005693
caused NN O O
by NN O O
deficiency NN B-SpecificDisease B-MSH:D005693
of NN I-SpecificDisease I-MSH:D005693
the NN I-SpecificDisease I-MSH:D005693
enzyme NN I-SpecificDisease I-MSH:D005693
galactose-1-phosphate NN I-SpecificDisease I-MSH:D005693
uridyl NN I-SpecificDisease I-MSH:D005693
transferase NN I-SpecificDisease I-MSH:D005693
(galt). NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
this NN O O
disorder NN O O
is NN O O
at NN O O
present NN O O
not NN O O
well NN O O
understood. NN O O
we NN O O
report NN O O
here NN O O
two NN O O
missense NN O O
mutations NN O O
which NN O O
result NN O O
in NN O O
low NN O O
or NN O O
undetectable NN O O
enzymatic NN O O
activity. NN O O
first, NN O O
we NN O O
identified NN O O
at NN O O
nucleotide NN O O
591 NN O O
a NN O O
transition NN O O
which NN O O
substitutes NN O O
glutamine NN O O
188 NN O O
by NN O O
arginine. NN O O
the NN O O
mutated NN O O
glutamine NN O O
is NN O O
not NN O O
only NN O O
highly NN O O
conserved NN O O
in NN O O
evolution NN O O
(conserved NN O O
also NN O O
in NN O O
escherichia NN O O
coli NN O O
and NN O O
saccharomyces NN O O
cerevisiae), NN O O
but NN O O
is NN O O
also NN O O
two NN O O
amino NN O O
acid NN O O
residues NN O O
downstream NN O O
from NN O O
the NN O O
active NN O O
site NN O O
histidine-proline-histidine NN O O
triad NN O O
and NN O O
results NN O O
in NN O O
about NN O O
10% NN O O
of NN O O
normal NN O O
enzymatic NN O O
activity. NN O O
the NN O O
arginine NN O O
188 NN O O
mutation NN O O
is NN O O
the NN O O
most NN O O
common NN O O
galactosemia NN B-Modifier B-MSH:D005693
mutation NN O O
characterized NN O O
to NN O O
date. NN O O
it NN O O
accounts NN O O
for NN O O
one NN O O
. NN O O

fourth NN O O
of NN O O
the NN O O
galactosemia NN B-Modifier B-MSH:D005693
alleles NN O O
studied. NN O O
second, NN O O
we NN O O
report NN O O
the NN O O
substitution NN O O
of NN O O
arginine NN O O
333 NN O O
by NN O O
tryptophan, NN O O
caused NN O O
by NN O O
a NN O O
transition NN O O
at NN O O
nucleotide NN O O
1025. NN O O
the NN O O
area NN O O
surrounding NN O O
this NN O O
missense NN O O
mutation NN O O
is NN O O
the NN O O
most NN O O
highly NN O O
conserved NN O O
domain NN O O
in NN O O
the NN O O
homologous NN O O
enzymes NN O O
from NN O O
e. NN O O
coli, NN O O
yeast, NN O O
and NN O O
humans, NN O O
and NN O O
this NN O O
mutation NN O O
results NN O O
in NN O O
undetectable NN O O
enzymatic NN O O
activity, NN O O
suggesting NN O O
that NN O O
this NN O O
is NN O O
a NN O O
severe NN O O
mutation. NN O O
this NN O O
second NN O O
mutation NN O O
appears NN O O
to NN O O
be NN O O
rare, NN O O
since NN O O
it NN O O
was NN O O
found NN O O
only NN O O
in NN O O
the NN O O
patient NN O O
we NN O O
sequenced. NN O O
our NN O O
data NN O O
provide NN O O
further NN O O
evidence NN O O
for NN O O
the NN O O
heterogeneity NN O O
of NN O O
galactosemia NN B-SpecificDisease B-MSH:D005693
at NN O O
the NN O O
molecular NN O O
level, NN O O
heterogeneity NN O O
which NN O O
might NN O O
be NN O O
related NN O O
to NN O O
the NN O O
variable NN O O
clinical NN O O
outcome NN O O
observed NN O O
in NN O O
this NN O O
disorder. NN O O
. NN O O

neurophysiologic NN O O
follow-up NN O O
of NN O O
long-term NN O O
dietary NN O O
treatment NN O O
in NN O O
adult-onset NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
. NN O O

objective NN O O
to NN O O
monitor NN O O
the NN O O
effects NN O O
of NN O O
dietary NN O O
treatment NN O O
in NN O O
adult-onset NN O O
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D000326
( NN O O
ALD NN B-SpecificDisease B-MSH:D000326
) NN O O
by NN O O
means NN O O
of NN O O
somatosensory NN O O
evoked NN O O
potentials NN O O
(seps) NN O O
and NN O O
motor NN O O
evoked NN O O
potentials NN O O
(meps). NN O O
background NN O O
seps NN O O
and NN O O
meps NN O O
have NN O O
proved NN O O
useful NN O O
in NN O O
revealing NN O O
signs NN O O
of NN O O
progressively NN O O
severe, NN O O
central NN O O
dying-back NN B-SpecificDisease B-MSH:D016472
axonopathy NN I-SpecificDisease I-MSH:D016472
in NN O O
early NN O O
stages NN O O
of NN O O
adult-onset NN O O
ALD NN B-SpecificDisease B-MSH:D000326
. NN O O
methods NN O O
eight NN O O
patients NN O O
with NN O O
adult-onset NN O O
ALD NN B-SpecificDisease B-MSH:D000326
underwent NN O O
clinical NN O O
examination, NN O O
brain NN O O
and NN O O
spine NN O O
mri, NN O O
and NN O O
sep NN O O
and NN O O
mep NN O O
studies NN O O
before NN O O
and NN O O
after NN O O
3 NN O O
years NN O O
of NN O O
lorenzos NN O O
oil NN O O
dietary NN O O
therapy. NN O O
results NN O O
before NN O O
treatment, NN O O
brain NN O O
mri NN O O
was NN O O
normal NN O O
in NN O O
five NN O O
patients. NN O O
three NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
pure NN O O
spinal NN B-DiseaseClass B-MSH:D016472
SEP NN I-DiseaseClass I-MSH:D016472
abnormalities NN I-DiseaseClass I-MSH:D016472
and NN O O
in NN O O
the NN O O
remaining NN O O
two NN O O
patients NN O O
seps NN O O
showed NN O O
signs NN O O
of NN O O
involvement NN O O
of NN O O
both NN O O
the NN O O
spinal NN O O
and NN O O
cerebral NN O O
somatosensory NN O O
tracts. NN O O
after NN O O
treatment, NN O O
the NN O O
thre NN O O
. NN O O

patients NN O O
with NN O O
pure NN O O
spinal NN B-DiseaseClass B-MSH:D016472
abnormalities NN I-DiseaseClass I-MSH:D016472
showed NN O O
clinical NN O O
and NN O O
neurophysiologic NN O O
worsening, NN O O
whereas NN O O
the NN O O
two NN O O
patients NN O O
with NN O O
a NN O O
more NN O O
advanced NN O O
stage NN O O
of NN O O
disease NN O O
(exhibited NN O O
by NN O O
seps) NN O O
showed NN O O
substantially NN O O
unchanged NN O O
clinical NN O O
and NN O O
neurophysiologic NN O O
features. NN O O
the NN O O
patients NN O O
with NN O O
abnormal NN O O
brain NN O O
mri NN O O
at NN O O
the NN O O
onset NN O O
of NN O O
treatment NN O O
showed NN O O
clinical NN O O
and NN O O
neurophysiologic NN O O
worsening. NN O O
conclusions NN O O
lorenzos NN O O
oil NN O O
therapy NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
patients NN O O
with NN O O
evidence NN O O
of NN O O
inflammatory NN B-DiseaseClass B-MSH:D004660
brain NN I-DiseaseClass I-MSH:D004660
lesions NN I-DiseaseClass I-MSH:D004660
. NN O O
moreover, NN O O
in NN O O
patients NN O O
without NN O O
clear NN O O
signs NN O O
of NN O O
inflammatory NN O O
damage, NN O O
this NN O O
treatment NN O O
does NN O O
not NN O O
modify NN O O
significantly NN O O
the NN O O
natural NN O O
course NN O O
of NN O O
the NN O O
disease. NN O O
however, NN O O
because NN O O
effective NN O O
treatments NN O O
should NN O O
begin NN O O
before NN O O
the NN O O
onset NN O O
of NN O O
severe NN O O
neurologic NN O O
symptoms, NN O O
seps NN O O
and NN O O
meps NN O O
should NN O O
be NN O O
considered NN O O
to NN O O
evaluate NN O O
the NN O O
effectiveness NN O O
of NN O O
other NN O O
experimental NN O O
treatments NN O O
in NN O O
the NN O O
patient NN O O
with NN O O
a NN O O
negative NN O O
brain NN O O
mri NN O O
. NN O O

the NN O O
molecular NN O O
basis NN O O
of NN O O
Sjogren-Larsson NN B-SpecificDisease B-MSH:D016111
syndrome NN I-SpecificDisease I-MSH:D016111
: NN O O
mutation NN O O
analysis NN O O
of NN O O
the NN O O
fatty NN O O
aldehyde NN O O
dehydrogenase NN O O
gene NN O O
. NN O O

sjogren-larsson NN O O
syndrome NN O O
( NN O O
SLS NN B-SpecificDisease B-MSH:D016111
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass B-MSH:D030342
recessive NN I-DiseaseClass I-MSH:D030342
disorder NN I-DiseaseClass I-MSH:D030342
characterized NN O O
by NN O O
ichthyosis NN B-DiseaseClass B-MSH:D007057
, NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
, NN O O
spasticity NN B-DiseaseClass B-MSH:D009128
, NN O O
and NN O O
deficient NN B-SpecificDisease B-MSH:D016111
activity NN I-SpecificDisease I-MSH:D016111
of NN I-SpecificDisease I-MSH:D016111
fatty NN I-SpecificDisease I-MSH:D016111
aldehyde NN I-SpecificDisease I-MSH:D016111
dehydrogenase NN I-SpecificDisease I-MSH:D016111
(faldh). NN O O
to NN O O
define NN O O
the NN O O
molecular NN O O
defects NN O O
causing NN O O
SLS NN B-SpecificDisease B-MSH:D016111
, NN O O
we NN O O
performed NN O O
mutation NN O O
analysis NN O O
of NN O O
the NN O O
faldh NN O O
gene NN O O
in NN O O
probands NN O O
from NN O O
63 NN O O
kindreds NN O O
with NN O O
SLS NN B-SpecificDisease B-MSH:D016111
. NN O O
among NN O O
these NN O O
patients, NN O O
49 NN O O
different NN O O
mutations-including NN O O
10 NN O O
deletions, NN O O
2 NN O O
insertions, NN O O
22 NN O O
amino NN O O
acid NN O O
substitutions, NN O O
3 NN O O
nonsense NN O O
mutations, NN O O
9 NN O O
splice-site NN O O
defects, NN O O
and NN O O
3 NN O O
complex NN O O
mutations-were NN O O
found. NN O O
all NN O O
of NN O O
the NN O O
patients NN O O
with NN O O
SLS NN B-SpecificDisease B-MSH:D016111
were NN O O
found NN O O
to NN O O
carry NN O O
mutations. NN O O
nineteen NN O O
of NN O O
the NN O O
missense NN O O
mutations NN O O
resulted NN O O
in NN O O
a NN O O
severe NN O O
reduction NN O O
of NN O O
faldh NN O O
enzyme NN O O
catalytic NN O O
activity NN O O
when NN O O
expressed NN O O
in NN O O
mammalian NN O O
cells, NN O O
but NN O O
one NN O O
mutation NN O O
(798 NN O O
g-- NN O O
> NN O O
c NN O O
[k NN O O
26 NN O O
. NN O O

n]) NN O O
seemed NN O O
to NN O O
have NN O O
a NN O O
greater NN O O
effect NN O O
on NN O O
mrna NN O O
stability. NN O O
the NN O O
splice-site NN O O
mutations NN O O
led NN O O
to NN O O
exon NN O O
skipping NN O O
or NN O O
utilization NN O O
of NN O O
cryptic NN O O
acceptor-splice NN O O
sites. NN O O
thirty-seven NN O O
mutations NN O O
were NN O O
private, NN O O
and NN O O
12 NN O O
mutations NN O O
were NN O O
seen NN O O
in NN O O
two NN O O
or NN O O
more NN O O
probands NN O O
of NN O O
european NN O O
or NN O O
middle NN O O
eastern NN O O
descent. NN O O
four NN O O
single-nucleotide NN O O
polymorphisms NN O O
(snps) NN O O
were NN O O
found NN O O
in NN O O
the NN O O
faldh NN O O
gene. NN O O
at NN O O
least NN O O
four NN O O
of NN O O
the NN O O
common NN O O
mutations NN O O
(551 NN O O
c-- NN O O
> NN O O
t, NN O O
682 NN O O
c-- NN O O
> NN O O
t, NN O O
733 NN O O
g-- NN O O
> NN O O
a, NN O O
and NN O O
798 NN O O
+ NN O O
1 NN O O
delg) NN O O
were NN O O
associated NN O O
with NN O O
multiple NN O O
snp NN O O
haplotypes, NN O O
suggesting NN O O
that NN O O
these NN O O
mutations NN O O
originated NN O O
independently NN O O
on NN O O
more NN O O
than NN O O
one NN O O
occasion NN O O
or NN O O
were NN O O
ancient NN O O
SLS NN B-Modifier B-MSH:D016111
genes NN O O
that NN O O
had NN O O
undergone NN O O
intragenic NN O O
recombination. NN O O
our NN O O
results NN O O
demonstrate NN O O
that NN O O
SLS NN B-SpecificDisease B-MSH:D016111
i NN O O
. NN O O

caused NN O O
by NN O O
a NN O O
strikingly NN O O
heterogeneous NN O O
group NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
faldh NN O O
gene NN O O
and NN O O
provide NN O O
a NN O O
framework NN O O
for NN O O
understanding NN O O
the NN O O
genetic NN O O
basis NN O O
of NN O O
SLS NN B-SpecificDisease B-MSH:D016111
and NN O O
the NN O O
development NN O O
of NN O O
dna-based NN O O
diagnostic NN O O
tests. NN O O
. NN O O

severe-glucose-6-phosphate NN O O
dehydrogenase NN O O
(g NN O O
6 NN O O
pd) NN O O
deficiency NN O O
associated NN O O
with NN O O
chronic NN O O
hemolytic NN B-SpecificDisease B-MSH:D000743
anemia NN I-SpecificDisease I-MSH:D000743
, NN O O
granulocyte NN B-DiseaseClass B-MSH:D007960
dysfunction NN I-DiseaseClass I-MSH:D007960
, NN O O
and NN O O
increased NN O O
susceptibility NN O O
to NN O O
infections: NN O O
description NN O O
of NN O O
a NN O O
new NN O O
molecular NN O O
variant NN O O
(g NN O O
6 NN O O
pd NN O O
barcelona) NN O O
. NN O O

molecular, NN O O
kinetic, NN O O
and NN O O
functional NN O O
studies NN O O
were NN O O
carried NN O O
out NN O O
on NN O O
erythrocytes NN O O
and NN O O
leukocytes NN O O
in NN O O
a NN O O
spanish NN O O
male NN O O
with NN O O
G6PD NN B-SpecificDisease B-MSH:D005955
deficiency NN I-SpecificDisease I-MSH:D005955
, NN O O
congenital NN B-SpecificDisease B-MSH:D000746
nonspherocytic NN I-SpecificDisease I-MSH:D000746
hemolytic NN I-SpecificDisease I-MSH:D000746
anemia NN I-SpecificDisease I-MSH:D000746
( NN O O
CNSHA NN B-SpecificDisease B-MSH:D000746
), NN O O
and NN O O
increased NN O O
susceptibility NN O O
to NN O O
infections. NN O O
g NN O O
6 NN O O
pd NN O O
activity NN O O
was NN O O
absent NN O O
in NN O O
patients NN O O
red NN O O
cells NN O O
and NN O O
was NN O O
about NN O O
2% NN O O
of NN O O
normal NN O O
in NN O O
leukocytes. NN O O
molecular NN O O
studies NN O O
using NN O O
standard NN O O
methods NN O O
(who, NN O O
1967) NN O O
showed NN O O
g NN O O
6 NN O O
pd NN O O
in NN O O
the NN O O
patient NN O O
to NN O O
have NN O O
a NN O O
slightly NN O O
fast NN O O
electrophoretic NN O O
mobility NN O O
at NN O O
ph NN O O
8. NN O O
0 NN O O
with NN O O
otherwise NN O O
normal NN O O
properties NN O O
(heat NN O O
stability NN O O
at NN O O
46 NN O O
degrees NN O O
c, NN O O
apparent NN O O
affinity NN O O
for NN O O
substrates, NN O O
optimum NN O O
ph, NN O O
and NN O O
utilization NN O O
of NN O O
substrate NN O O
analogues). NN O O
other NN O O
tests NN O O
showed NN O O
the NN O O
patients NN O O
granulocytes NN O O
to NN O O
engulf NN O O
latex NN O O
particles NN O O
normally, NN O O
but NN O O
to NN O O
have NN O O
impaired NN O O
reduction NN O O
of NN O O
nitroblue NN O O
tetrazolium NN O O
and NN O O
ferricytochrome-c NN O O
as NN O O
wel NN O O
. NN O O

as NN O O
reduced NN O O
iodination. NN O O
chemotaxis NN O O
and NN O O
random NN O O
migration NN O O
of NN O O
the NN O O
patients NN O O
granulocytes NN O O
were NN O O
normal NN O O
as NN O O
were NN O O
myeloperoxidase, NN O O
leukocyte NN O O
alkaline NN O O
phosphatase NN O O
(lap), NN O O
and NN O O
ultrastructural NN O O
features. NN O O
the NN O O
molecular NN O O
characteristics NN O O
of NN O O
g NN O O
6 NN O O
pd NN O O
in NN O O
the NN O O
patient NN O O
differed NN O O
from NN O O
those NN O O
of NN O O
all NN O O
previously NN O O
reported NN O O
variants NN O O
associated NN O O
with NN O O
CNSHA NN B-SpecificDisease B-MSH:D000746
, NN O O
so NN O O
the NN O O
present NN O O
variant NN O O
was NN O O
provisionally NN O O
called NN O O
g NN O O
6 NN O O
pd NN O O
barcelona NN O O
to NN O O
distinguish NN O O
it NN O O
from NN O O
other NN O O
g NN O O
6 NN O O
pd NN O O
variants NN O O
previously NN O O
described. NN O O
possible NN O O
mechanisms NN O O
for NN O O
the NN O O
severe NN O O
deficiency NN B-SpecificDisease B-MSH:D005955
of NN I-SpecificDisease I-MSH:D005955
G6PD NN I-SpecificDisease I-MSH:D005955
in NN O O
erythrocytes NN O O
and NN O O
granulocytes NN O O
was NN O O
investigated NN O O
by NN O O
studies NN O O
on NN O O
the NN O O
immunologic NN O O
specific NN O O
activity NN O O
of NN O O
the NN O O
mutant NN O O
enzyme NN O O
. NN O O

mutations NN O O
at NN O O
the NN O O
pax NN O O
6 NN O O
locus NN O O
are NN O O
found NN O O
in NN O O
heterogeneous NN O O
anterior NN B-DiseaseClass B-MSH:C537775
segment NN I-DiseaseClass I-MSH:C537775
malformations NN I-DiseaseClass I-MSH:C537775
including NN O O
Peters' NN B-SpecificDisease B-MSH:C537884
anomaly NN I-SpecificDisease I-MSH:C537884
. NN O O

mutation NN O O
or NN O O
deletion NN O O
of NN O O
the NN O O
pax NN O O
6 NN O O
gene NN O O
underlies NN O O
many NN O O
cases NN O O
of NN O O
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O O
three NN O O
lines NN O O
of NN O O
evidence NN O O
now NN O O
converge NN O O
to NN O O
implicate NN O O
pax NN O O
6 NN O O
more NN O O
widely NN O O
in NN O O
anterior NN B-DiseaseClass B-MSH:C537775
segment NN I-DiseaseClass I-MSH:C537775
malformations NN I-DiseaseClass I-MSH:C537775
including NN O O
Peters NN B-SpecificDisease B-MSH:C537884
anomaly NN I-SpecificDisease I-MSH:C537884
. NN O O
first, NN O O
a NN O O
child NN O O
with NN O O
Peters NN B-SpecificDisease B-MSH:C537884
anomaly NN I-SpecificDisease I-MSH:C537884
is NN O O
deleted NN O O
for NN O O
one NN O O
copy NN O O
of NN O O
pax NN O O
6. NN O O
second, NN O O
affected NN O O
members NN O O
of NN O O
a NN O O
family NN O O
with NN O O
dominantly NN O O
inherited NN O O
anterior NN B-DiseaseClass B-MSH:C537775
segment NN I-DiseaseClass I-MSH:C537775
malformations NN I-DiseaseClass I-MSH:C537775
, NN O O
including NN O O
Peters NN B-SpecificDisease B-MSH:C537884
anomaly NN I-SpecificDisease I-MSH:C537884
are NN O O
heterozygous NN O O
for NN O O
an NN O O
r NN O O
26 NN O O
g NN O O
mutation NN O O
in NN O O
the NN O O
pax NN O O
6 NN O O
paired NN O O
box. NN O O
third, NN O O
a NN O O
proportion NN O O
of NN O O
sey/+ NN O O
smalleye NN O O
mice, NN O O
heterozygous NN O O
for NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
murine NN O O
pax-6, NN O O
have NN O O
an NN O O
ocular NN O O
phenotype NN O O
resembling NN O O
Peters NN B-SpecificDisease B-MSH:C537884
anomaly NN I-SpecificDisease I-MSH:C537884
. NN O O
we NN O O
therefore NN O O
propose NN O O
that NN O O
a NN O O
variety NN O O
of NN O O
anterior NN B-DiseaseClass B-MSH:C537775
segment NN I-DiseaseClass I-MSH:C537775
anomalies NN I-DiseaseClass I-MSH:C537775
may NN O O
be NN O O
associated NN O O
with NN O O
pax NN O O
6 NN O O
mutations. NN O O
. NN O O

in NN O O
swedish NN O O
families NN O O
with NN O O
hereditary NN B-SpecificDisease B-MSH:C537243
prostate NN I-SpecificDisease I-MSH:C537243
cancer NN I-SpecificDisease I-MSH:C537243
, NN O O
linkage NN O O
to NN O O
the NN O O
hpc NN O O
1 NN O O
locus NN O O
on NN O O
chromosome NN O O
1 NN O O
q NN O O
24-25 NN O O
is NN O O
restricted NN O O
to NN O O
families NN O O
with NN O O
early-onset NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
. NN O O

prostate NN O O
cancer NN O O
clusters NN O O
in NN O O
some NN O O
families, NN O O
and NN O O
an NN O O
estimated NN O O
5% NN O O
-10% NN O O
of NN O O
all NN O O
cases NN O O
are NN O O
estimated NN O O
to NN O O
result NN O O
from NN O O
inheritance NN O O
of NN O O
prostate NN O O
cancer-susceptibility NN O O
genes. NN O O
we NN O O
previously NN O O
reported NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
the NN O O
1 NN O O
q NN O O
24-25 NN O O
region NN O O
(hpc NN O O
1) NN O O
in NN O O
91 NN O O
north NN O O
american NN O O
and NN O O
swedish NN O O
families NN O O
each NN O O
with NN O O
multiple NN O O
cases NN O O
of NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
(smith NN O O
et NN O O
al. NN O O
1996). NN O O
in NN O O
the NN O O
present NN O O
report NN O O
we NN O O
analyze NN O O
40 NN O O
(12 NN O O
original NN O O
and NN O O
28 NN O O
newly NN O O
identified) NN O O
swedish NN O O
families NN O O
with NN O O
hereditary NN B-SpecificDisease B-MSH:C537243
prostate NN I-SpecificDisease I-MSH:C537243
cancer NN I-SpecificDisease I-MSH:C537243
( NN O O
HPC NN B-SpecificDisease B-MSH:C537243
) NN O O
that, NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
40 NN O O
markers NN O O
spanning NN O O
a NN O O
25-cm NN O O
interval NN O O
within NN O O
1 NN O O
q NN O O
24-25, NN O O
have NN O O
evidence NN O O
of NN O O
linkage. NN O O
in NN O O
the NN O O
complete NN O O
set NN O O
of NN O O
families, NN O O
a NN O O
maximum NN O O
two-point NN O O
lod NN O O
score NN O O
of NN O O
1. NN O O
10 NN O O
wa NN O O
. NN O O

observed NN O O
at NN O O
d NN O O
1 NN O O
s NN O O
413 NN O O
(at NN O O
a NN O O
recombination NN O O
fraction NN O O
[theta] NN O O
of. NN O O
1), NN O O
with NN O O
a NN O O
maximum NN O O
npl NN O O
(nonparametric NN O O
linkage) NN O O
z NN O O
score NN O O
of NN O O
1. NN O O
64 NN O O
at NN O O
d NN O O
1 NN O O
s NN O O
202 NN O O
(p NN O O
=. NN O O
05). NN O O
the NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
this NN O O
region NN O O
originated NN O O
almost NN O O
exclusively NN O O
from NN O O
the NN O O
subset NN O O
of NN O O
12 NN O O
early-onset NN O O
(age NN O O
< NN O O
65 NN O O
years) NN O O
families, NN O O
which NN O O
yielded NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
2. NN O O
38 NN O O
at NN O O
d NN O O
1 NN O O
s NN O O
413 NN O O
(straight NN O O
theta NN O O
= NN O O
0) NN O O
and NN O O
an NN O O
npl NN O O
z NN O O
score NN O O
of NN O O
1. NN O O
95 NN O O
at NN O O
d NN O O
1 NN O O
s NN O O
422 NN O O
(p NN O O
=. NN O O
03). NN O O
estimates NN O O
from NN O O
heterogeneity NN O O
tests NN O O
suggest NN O O
that, NN O O
within NN O O
sweden, NN O O
as NN O O
many NN O O
as NN O O
50% NN O O
of NN O O
early-onset NN O O
families NN O O
had NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
the NN O O
hp NN O O
. NN O O
, NN O O
as NN O O
many NN O O
as NN O O
50% NN O O
of NN O O
early-onset NN O O
families NN O O
had NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
the NN O O
hp NN O O
. NN O O

1 NN O O
region. NN O O
these NN O O
results NN O O
are NN O O
consistent NN O O
with NN O O
the NN O O
hypothesis NN O O
of NN O O
linkage NN O O
to NN O O
hpc NN O O
1 NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
families NN O O
with NN O O
prostate NN B-SpecificDisease B-MSH:D011471
cancer NN I-SpecificDisease I-MSH:D011471
, NN O O
particularly NN O O
those NN O O
with NN O O
an NN O O
early NN O O
age NN O O
at NN O O
diagnosis NN O O
. NN O O

localisation NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
locus NN O O
to NN O O
19 NN O O
q NN O O
13.2-19 NN O O
q NN O O
13.3 NN O O
and NN O O
its NN O O
relationship NN O O
to NN O O
twelve NN O O
polymorphic NN O O
loci NN O O
on NN O O
19 NN O O
q NN O O
. NN O O

the NN O O
order NN O O
of NN O O
fourteen NN O O
polymorphic NN O O
markers NN O O
localised NN O O
to NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
human NN O O
chromosome NN O O
19 NN O O
has NN O O
been NN O O
established NN O O
by NN O O
multipoint NN O O
mapping NN O O
in NN O O
a NN O O
set NN O O
of NN O O
40 NN O O
ceph NN O O
(centre NN O O
detude NN O O
de NN O O
polymorphisme NN O O
humain, NN O O
paris) NN O O
reference NN O O
families. NN O O
we NN O O
report NN O O
here NN O O
the NN O O
linkage NN O O
relationship NN O O
of NN O O
the NN O O
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier I-MSH:D009223
( NN O O
DM NN B-Modifier B-MSH:D009223
) NN O O
locus NN O O
to NN O O
twelve NN O O
of NN O O
these NN O O
markers NN O O
as NN O O
studied NN O O
in NN O O
45 NN O O
families NN O O
with NN O O
DM NN B-SpecificDisease B-MSH:D009223
. NN O O
the NN O O
resulting NN O O
genetic NN O O
map NN O O
is NN O O
supported NN O O
by NN O O
the NN O O
localisation NN O O
of NN O O
the NN O O
dna NN O O
markers NN O O
in NN O O
a NN O O
panel NN O O
of NN O O
somatic NN O O
cell NN O O
hybrids. NN O O
ten NN O O
of NN O O
the NN O O
twelve NN O O
markers NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
proximal NN O O
to NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
gene NN O O
and NN O O
two, NN O O
prkcg NN O O
and NN O O
d NN O O
19 NN O O
s NN O O
22, NN O O
distal NN O O
but NN O O
at NN O O
distances NN O O
of NN O O
approximately NN O O
25 NN O O
cm NN O O
and NN O O
15 NN O O
cm, NN O O
respectively. NN O O
the NN O O
closest NN O O
proximal NN O O
markers NN O O
are NN O O
apoc NN O O
2 NN O O
(apolipoprotein NN O O
c-ii) NN O O
an NN O O
. NN O O

ckm NN O O
(creatine NN O O
kinase, NN O O
muscle) NN O O
approximately NN O O
3 NN O O
cm NN O O
and NN O O
2 NN O O
cm NN O O
from NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
gene NN O O
respectively, NN O O
in NN O O
the NN O O
order NN O O
apoc NN O O
2-ckm-dm. NN O O
the NN O O
distance NN O O
between NN O O
apoc NN O O
2, NN O O
ckm NN O O
and NN O O
DM NN B-SpecificDisease B-MSH:D009223
(of NN O O
the NN O O
order NN O O
of NN O O
2 NN O O
million NN O O
base NN O O
pairs) NN O O
and NN O O
their NN O O
known NN O O
orientation NN O O
should NN O O
permit NN O O
directional NN O O
chromosome NN O O
walking NN O O
and NN O O
jumping. NN O O
the NN O O
data NN O O
presented NN O O
here NN O O
should NN O O
enable NN O O
us NN O O
to NN O O
determine NN O O
whether NN O O
or NN O O
not NN O O
new NN O O
markers NN O O
are NN O O
distal NN O O
to NN O O
apoc NN O O
2/ckm NN O O
and NN O O
thus NN O O
potentially NN O O
flank NN O O
the NN O O
DM NN B-Modifier B-MSH:D009223
gene. NN O O
. NN O O

a NN O O
recurrent NN O O
expansion NN O O
of NN O O
a NN O O
maternal NN O O
allele NN O O
with NN O O
36 NN O O
cag NN O O
repeats NN O O
causes NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
in NN O O
two NN O O
sisters NN O O
. NN O O

large NN O O
intergenerational NN O O
repeat NN O O
expansions NN O O
of NN O O
the NN O O
cag NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
HD NN B-Modifier B-MSH:D006816
gene NN O O
have NN O O
been NN O O
well NN O O
documented NN O O
for NN O O
the NN O O
male NN O O
germline. NN O O
we NN O O
describe NN O O
a NN O O
recurrent NN O O
large NN O O
expansion NN O O
of NN O O
a NN O O
maternal NN O O
allele NN O O
with NN O O
36 NN O O
cag NN O O
repeats NN O O
(to NN O O
66 NN O O
and NN O O
57 NN O O
repeats, NN O O
respectively, NN O O
in NN O O
two NN O O
daughters) NN O O
associated NN O O
with NN O O
onset NN O O
of NN O O
Huntington NN B-SpecificDisease B-MSH:D006816
disease NN I-SpecificDisease I-MSH:D006816
( NN O O
HD NN B-SpecificDisease B-MSH:D006816
) NN O O
in NN O O
the NN O O
second NN O O
and NN O O
third NN O O
decade NN O O
in NN O O
a NN O O
family NN O O
without NN O O
history NN O O
of NN O O
HD NN B-SpecificDisease B-MSH:D006816
. NN O O
our NN O O
findings NN O O
give NN O O
evidence NN O O
of NN O O
a NN O O
gonadal NN O O
mosaicism NN O O
in NN O O
the NN O O
unaffected NN O O
mother. NN O O
we NN O O
hypothesize NN O O
that NN O O
large NN O O
expansions NN O O
also NN O O
occur NN O O
in NN O O
the NN O O
female NN O O
germline NN O O
and NN O O
that NN O O
a NN O O
negative NN O O
selection NN O O
of NN O O
oocytes NN O O
with NN O O
long NN O O
repeats NN O O
might NN O O
explain NN O O
the NN O O
different NN O O
instability NN O O
behavior NN O O
of NN O O
the NN O O
male NN O O
and NN O O
the NN O O
female NN O O
germlines. NN O O
. NN O O

germline NN O O
e-cadherin NN O O
gene NN O O
(cdh NN O O
1) NN O O
mutations NN O O
predispose NN O O
to NN O O
familial NN B-SpecificDisease B-MSH:D013274
gastric NN I-SpecificDisease I-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
and NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O

inherited NN O O
mutations NN O O
in NN O O
the NN O O
e-cadherin NN O O
gene NN O O
(cdh NN O O
1) NN O O
were NN O O
described NN O O
recently NN O O
in NN O O
three NN O O
maori NN O O
kindreds NN O O
with NN O O
familial NN B-SpecificDisease B-MSH:D013274
gastric NN I-SpecificDisease I-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
. NN O O
Familial NN B-SpecificDisease B-MSH:D013274
gastric NN I-SpecificDisease I-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
is NN O O
genetically NN O O
heterogeneous NN O O
and NN O O
it NN O O
is NN O O
not NN O O
clear NN O O
what NN O O
proportion NN O O
of NN O O
gastric NN B-Modifier B-MSH:D013274
cancer NN I-Modifier I-MSH:D013274
susceptibility NN O O
in NN O O
non-maori NN O O
populations NN O O
is NN O O
due NN O O
to NN O O
germline NN O O
cdh NN O O
1 NN O O
mutations. NN O O
therefore, NN O O
we NN O O
screened NN O O
eight NN O O
familial NN B-Modifier B-MSH:D013274
gastric NN I-Modifier I-MSH:D013274
cancer NN I-Modifier I-MSH:D013274
kindreds NN O O
of NN O O
british NN O O
and NN O O
irish NN O O
origin NN O O
for NN O O
germline NN O O
cdh NN O O
1 NN O O
mutations, NN O O
by NN O O
sscp NN O O
analysis NN O O
of NN O O
all NN O O
16 NN O O
exons NN O O
and NN O O
flanking NN O O
sequences. NN O O
each NN O O
family NN O O
contained NN O O
(i) NN O O
two NN O O
cases NN O O
of NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
in NN O O
first NN O O
degree NN O O
relatives NN O O
with NN O O
one NN O O
affected NN O O
before NN O O
age NN O O
50 NN O O
years; NN O O
or NN O O
(ii) NN O O
three NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
. NN O O
novel NN O O
germline NN O O
cdh NN O O
1 NN O O
mutations NN O O
(a NN O O
nonsense NN O O
and NN O O
a NN O O
splice NN O O
site) NN O O
were NN O O
detected NN O O
in NN O O
two NN O O
families NN O O
(2 NN O O
. NN O O

%). NN O O
both NN O O
mutations NN O O
were NN O O
predicted NN O O
to NN O O
truncate NN O O
the NN O O
e-cadherin NN O O
protein NN O O
in NN O O
the NN O O
signal NN O O
peptide NN O O
domain. NN O O
in NN O O
one NN O O
family NN O O
there NN O O
was NN O O
evidence NN O O
of NN O O
non-penetrance NN O O
and NN O O
susceptibility NN O O
to NN O O
both NN O O
gastric NN B-CompositeMention B-MSH:D015179
and NN I-CompositeMention I-MSH:D015179
colorectal NN I-CompositeMention I-MSH:D015179
cancer NN I-CompositeMention I-MSH:D015179
; NN O O
thus, NN O O
in NN O O
addition NN O O
to NN O O
six NN O O
cases NN O O
of NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
, NN O O
a NN O O
cdh NN O O
1 NN O O
mutation NN O O
carrier NN O O
developed NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
at NN O O
age NN O O
30 NN O O
years. NN O O
we NN O O
have NN O O
confirmed NN O O
that NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
cdh NN O O
1 NN O O
gene NN O O
cause NN O O
familial NN B-SpecificDisease B-MSH:D013274
gastric NN I-SpecificDisease I-MSH:D013274
cancer NN I-SpecificDisease I-MSH:D013274
in NN O O
non-maori NN O O
populations. NN O O
however, NN O O
only NN O O
a NN O O
minority NN O O
of NN O O
familial NN O O
gastric NN B-SpecificDisease B-MSH:D013274
cancers NN I-SpecificDisease I-MSH:D013274
can NN O O
be NN O O
accounted NN O O
for NN O O
by NN O O
cdh NN O O
1 NN O O
mutations. NN O O
loss NN O O
of NN O O
e-cadherin NN O O
function NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
sporadic NN O O
colorectal NN B-DiseaseClass B-MSH:D015179
and NN I-DiseaseClass I-MSH:D015179
other NN I-DiseaseClass I-MSH:D015179
cancers NN I-DiseaseClass I-MSH:D015179
, NN O O
and NN O O
our NN O O
findings NN O O
provide NN O O
evidence NN O O
that NN O O
germline NN O O
cdh NN O O
1 NN O O
mutations NN O O
predispose NN O O
to NN O O
early NN O O
onset NN O O
colorectal NN B-SpecificDisease B-MSH:D015179
cancer NN I-SpecificDisease I-MSH:D015179
. NN O O
thus NN O O
. NN O O

cdh NN O O
1 NN O O
should NN O O
be NN O O
investigated NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
inherited NN O O
susceptibility NN O O
to NN O O
both NN O O
gastric NN B-CompositeMention B-MSH:D015179
and NN I-CompositeMention I-MSH:D015179
colorectal NN I-CompositeMention I-MSH:D015179
cancers NN I-CompositeMention I-MSH:D015179
. NN O O

germinal NN O O
mosaicism NN O O
in NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
. NN O O

we NN O O
have NN O O
identified NN O O
a NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
( NN O O
DMD NN B-Modifier B-MSH:D020388
) NN O O
pedigree NN O O
where NN O O
the NN O O
disease NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
molecular NN O O
deletion NN O O
within NN O O
the NN O O
DMD NN B-Modifier B-MSH:D020388
locus. NN O O
we NN O O
have NN O O
examined NN O O
the NN O O
meiotic NN O O
segregation NN O O
products NN O O
of NN O O
the NN O O
common NN O O
female NN O O
ancestor NN O O
using NN O O
marker NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
(rflps) NN O O
detected NN O O
by NN O O
probes NN O O
that NN O O
lie NN O O
within NN O O
this NN O O
deletion. NN O O
these NN O O
studies NN O O
show NN O O
that NN O O
this NN O O
female NN O O
has NN O O
transmitted NN O O
three NN O O
distinct NN O O
types NN O O
of NN O O
x NN O O
chromosome NN O O
to NN O O
her NN O O
offspring. NN O O
this NN O O
observation NN O O
may NN O O
be NN O O
explained NN O O
by NN O O
postulating NN O O
that NN O O
the NN O O
mutation NN O O
arose NN O O
as NN O O
a NN O O
postzygotic NN O O
deletion NN O O
within NN O O
this NN O O
common NN O O
ancestor, NN O O
who NN O O
was NN O O
consequently NN O O
germinally NN O O
mosaic. NN O O
. NN O O

expression NN O O
of NN O O
the NN O O
murine NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
gene NN O O
in NN O O
muscle NN O O
and NN O O
brain NN O O
. NN O O

complementary NN O O
dna NN O O
clones NN O O
were NN O O
isolated NN O O
that NN O O
represent NN O O
the NN O O
5 NN O O
terminal NN O O
2. NN O O
5 NN O O
kilobases NN O O
of NN O O
the NN O O
murine NN O O
Duchenne NN B-Modifier B-MSH:D020388
muscular NN I-Modifier I-MSH:D020388
dystrophy NN I-Modifier I-MSH:D020388
(dmd) NN O O
messenger NN O O
rna NN O O
(mrna). NN O O
mouse NN O O
dmd NN O O
mrna NN O O
was NN O O
detectable NN O O
in NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle NN O O
and NN O O
at NN O O
a NN O O
level NN O O
approximately NN O O
90 NN O O
percent NN O O
lower NN O O
in NN O O
brain. NN O O
dmd NN O O
mrna NN O O
is NN O O
also NN O O
present, NN O O
but NN O O
at NN O O
much NN O O
lower NN O O
than NN O O
normal NN O O
levels, NN O O
in NN O O
both NN O O
the NN O O
muscle NN O O
and NN O O
brain NN O O
of NN O O
three NN O O
different NN O O
strains NN O O
of NN O O
dystrophic NN B-Modifier B-MSH:D020388
mdx NN O O
mice. NN O O
the NN O O
identification NN O O
of NN O O
dmd NN O O
mrna NN O O
in NN O O
brain NN O O
raises NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
relation NN O O
between NN O O
human NN O O
Duchenne NN B-SpecificDisease B-MSH:D020388
muscular NN I-SpecificDisease I-MSH:D020388
dystrophy NN I-SpecificDisease I-MSH:D020388
( NN O O
DMD NN B-SpecificDisease B-MSH:D020388
) NN O O
gene NN O O
expression NN O O
and NN O O
the NN O O
mental NN B-DiseaseClass B-MSH:D008607
retardation NN I-DiseaseClass I-MSH:D008607
found NN O O
in NN O O
some NN O O
DMD NN B-Modifier B-MSH:D020388
males. NN O O
these NN O O
results NN O O
also NN O O
provide NN O O
evidence NN O O
that NN O O
the NN O O
mdx NN O O
mutations NN O O
are NN O O
allelic NN O O
variants NN O O
of NN O O
mouse NN O O
dmd NN O O
gene NN O O
mutations NN O O
. NN O O

human NN O O
peroxisomal NN O O
targeting NN O O
signal-1 NN O O
receptor NN O O
restores NN O O
peroxisomal NN O O
protein NN O O
import NN O O
in NN O O
cells NN O O
from NN O O
patients NN O O
with NN O O
fatal NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
disorders NN I-DiseaseClass I-MSH:D018901
. NN O O

two NN O O
peroxisomal NN O O
targeting NN O O
signals, NN O O
pts NN O O
1 NN O O
and NN O O
pts NN O O
2, NN O O
are NN O O
involved NN O O
in NN O O
the NN O O
import NN O O
of NN O O
proteins NN O O
into NN O O
the NN O O
peroxisome NN O O
matrix. NN O O
human NN O O
patients NN O O
with NN O O
fatal NN O O
generalized NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
deficiency NN I-DiseaseClass I-MSH:D018901
disorders NN I-DiseaseClass I-MSH:D018901
fall NN O O
into NN O O
at NN O O
least NN O O
nine NN O O
genetic NN O O
complementation NN O O
groups. NN O O
cells NN O O
from NN O O
many NN O O
of NN O O
these NN O O
patients NN O O
are NN O O
deficient NN O O
in NN O O
the NN O O
import NN O O
of NN O O
pts NN O O
1-containing NN O O
proteins, NN O O
but NN O O
the NN O O
causes NN O O
of NN O O
the NN O O
protein-import NN O O
defect NN O O
in NN O O
these NN O O
patients NN O O
are NN O O
unknown. NN O O
we NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
the NN O O
human NN O O
cdna NN O O
homologue NN O O
(pts NN O O
1 NN O O
r) NN O O
of NN O O
the NN O O
pichia NN O O
pastoris NN O O
pas NN O O
8 NN O O
gene, NN O O
the NN O O
pts NN O O
1 NN O O
receptor NN O O
(mccollum, NN O O
d., NN O O
e. NN O O
monosov, NN O O
and NN O O
s. NN O O
subramani. NN O O
1993. NN O O
j. NN O O
cell NN O O
biol. NN O O
121 NN O O
761-774). NN O O
the NN O O
pts NN O O
1 NN O O
r NN O O
mrna NN O O
is NN O O
expressed NN O O
in NN O O
all NN O O
human NN O O
tissues NN O O
examined NN O O
. NN O O

antibodies NN O O
to NN O O
the NN O O
human NN O O
pts NN O O
1 NN O O
r NN O O
recognize NN O O
this NN O O
protein NN O O
in NN O O
human, NN O O
monkey, NN O O
rat, NN O O
and NN O O
hamster NN O O
cells. NN O O
the NN O O
protein NN O O
is NN O O
localized NN O O
mainly NN O O
in NN O O
the NN O O
cytosol NN O O
but NN O O
is NN O O
also NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
peroxisomes. NN O O
part NN O O
of NN O O
the NN O O
peroxisomal NN O O
pts NN O O
1 NN O O
r NN O O
protein NN O O
is NN O O
tightly NN O O
bound NN O O
to NN O O
the NN O O
peroxisomal NN O O
membrane. NN O O
antibodies NN O O
to NN O O
pts NN O O
1 NN O O
r NN O O
inhibit NN O O
peroxisomal NN O O
protein-import NN O O
of NN O O
pts NN O O
1-containing NN O O
proteins NN O O
in NN O O
a NN O O
permeabilized NN O O
cho NN O O
cell NN O O
system. NN O O
in NN O O
vitro-translated NN O O
pts NN O O
1 NN O O
r NN O O
protein NN O O
specifically NN O O
binds NN O O
a NN O O
serine-lysine-leucine-peptide. NN O O
a NN O O
pas NN O O
8-pts NN O O
1 NN O O
r NN O O
fusion NN O O
protein NN O O
complements NN O O
the NN O O
p. NN O O
pastoris NN O O
pas NN O O
8 NN O O
mutant. NN O O
the NN O O
pts NN O O
1 NN O O
r NN O O
cdna NN O O
also NN O O
complements NN O O
the NN O O
PTS1 NN B-SpecificDisease B-OMIM:202370
protein-import NN I-SpecificDisease I-OMIM:202370
defect NN I-SpecificDisease I-OMIM:202370
in NN O O
skin NN O O
fibroblasts NN O O
from NN O O
patients--belonging NN O O
to NN O O
complementation NN O O
grou NN O O
. NN O O

two--diagnosed NN O O
as NN O O
having NN O O
neonatal NN B-SpecificDisease B-OMIM:202370
adrenoleukodystrophy NN I-SpecificDisease I-OMIM:202370
or NN O O
Zellweger NN B-SpecificDisease B-MSH:D015211
syndrome NN I-SpecificDisease I-MSH:D015211
. NN O O
the NN O O
pts NN O O
1 NN O O
r NN O O
gene NN O O
has NN O O
been NN O O
localized NN O O
to NN O O
a NN O O
chromosomal NN O O
location NN O O
where NN O O
no NN O O
other NN O O
peroxisomal NN B-Modifier B-MSH:D018901
disorder NN I-Modifier I-MSH:D018901
genes NN O O
are NN O O
known NN O O
to NN O O
map. NN O O
our NN O O
findings NN O O
represent NN O O
the NN O O
only NN O O
case NN O O
in NN O O
which NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
the NN O O
protein-import NN B-DiseaseClass B-MSH:D008661
deficiency NN I-DiseaseClass I-MSH:D008661
in NN O O
human NN O O
peroxisomal NN B-DiseaseClass B-MSH:D018901
disorders NN I-DiseaseClass I-MSH:D018901
is NN O O
understood NN O O
. NN O O

x-linked NN O O
spastic NN O O
paraplegia NN O O
and NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
are NN O O
allelic NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
at NN O O
the NN O O
proteolipid NN O O
protein NN O O
locus NN O O
. NN O O

three NN O O
forms NN O O
of NN O O
X-linked NN B-SpecificDisease B-OMIM:312920
spastic NN I-SpecificDisease I-OMIM:312920
paraplegia NN I-SpecificDisease I-OMIM:312920
( NN O O
SPG NN B-SpecificDisease B-OMIM:312920
) NN O O
have NN O O
been NN O O
defined. NN O O
one NN O O
locus NN O O
(spg NN O O
1) NN O O
maps NN O O
to NN O O
xq NN O O
28 NN O O
while NN O O
two NN O O
clinically NN O O
distinct NN O O
forms NN O O
map NN O O
to NN O O
xq NN O O
22 NN O O
(spg NN O O
2). NN O O
a NN O O
rare NN O O
X-linked NN B-DiseaseClass B-MSH:D020279
dysmyelinating NN I-DiseaseClass I-MSH:D020279
disorder NN I-DiseaseClass I-MSH:D020279
of NN O O
the NN O O
central NN O O
nervous NN O O
system, NN O O
Pelizaeus-Merzbacher NN B-SpecificDisease B-OMIM:312080
disease NN I-SpecificDisease I-OMIM:312080
( NN O O
PMD NN B-SpecificDisease B-OMIM:312080
), NN O O
has NN O O
also NN O O
been NN O O
mapped NN O O
to NN O O
xq NN O O
21-q NN O O
22, NN O O
and NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
(plp) NN O O
which NN O O
encodes NN O O
two NN O O
myelin NN O O
proteins, NN O O
plp NN O O
and NN O O
dm NN O O
20. NN O O
while NN O O
narrowing NN O O
the NN O O
genetic NN O O
interval NN O O
containing NN O O
spg NN O O
2 NN O O
in NN O O
a NN O O
large NN O O
pedigree, NN O O
we NN O O
found NN O O
that NN O O
plp NN O O
was NN O O
the NN O O
closest NN O O
marker NN O O
to NN O O
the NN O O
disease NN O O
locus, NN O O
implicating NN O O
plp NN O O
as NN O O
a NN O O
possible NN O O
candidate NN O O
gene. NN O O
we NN O O
have NN O O
found NN O O
that NN O O
a NN O O
point NN O O
mutation NN O O
(his NN O O
139 NN O O
ty NN O O
. NN O O

) NN O O
in NN O O
exon NN O O
3 NN O O
b NN O O
of NN O O
an NN O O
affected NN O O
male NN O O
produces NN O O
a NN O O
mutant NN O O
plp NN O O
but NN O O
a NN O O
normal NN O O
dm NN O O
20, NN O O
and NN O O
segregates NN O O
with NN O O
the NN O O
disease NN O O
(zmax NN O O
= NN O O
6. NN O O
63, NN O O
theta NN O O
= NN O O
0. NN O O
00). NN O O
it NN O O
appears, NN O O
therefore, NN O O
that NN O O
spg NN O O
2 NN O O
and NN O O
PMD NN B-SpecificDisease B-OMIM:312080
are NN O O
allelic NN B-DiseaseClass B-MSH:D030342
disorders NN I-DiseaseClass I-MSH:D030342
. NN O O

